WO2002079492A2 - Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators - Google Patents

Abstract

Described herein are methods and compositions that can be used for diagnosis and treatment of angiogenic phenotypes and angiogenesis-associated diseases. Also described herein are methods that can be used to identify modulators of angiogenesis.

Description

METHODS OF DIAGNOSIS OF ANGIOGENESIS, COMPOSITIONS AND METHODS OF SCREENING FOR ANGIOGENESIS

MODULATORS

CROSS-REFERENCES TO RELATED APPLICATIONS This application claims priority to USSN 09/784,356, filed February 14 2001; USSN 09/791,390, filed February 22, 2001; USSN 60/285,475, filed April 19, 2001, USSN 60/310,025, filed August 3, 2001, and USSN 60/334,244, filed November 29, 2001, each of which is herein incoφorated by reference in its entirety.

FIELD OF THE INVENTION The invention relates to the identification of nucleic acid and protein expression profiles and nucleic acids, products, and antibodies thereto that are involved in angiogenesis; and to the use of such expression profiles and compositions in diagnosis and therapy of angiogenesis. The invention further relates to methods for identifying and using agents and/or targets that modulate angiogenesis.

BACKGROUND OF THE INVENTION Both vasculogenesis, the development of an interactive vascular system comprising arteries and veins, and angiogenesis, the generation of new blood vessels, play a role in embryonic development. In contrast, angiogenesis is limited in a normal adult to the placenta, ovary, endometrium and sites of wound healing. However, angiogenesis, or its absence, plays an important role in the maintenance of a variety of pathological states. Some of these states are characterized by neovascularization, e.g., cancer, diabetic retinopathy, glaucoma, and age related macular degeneration. Others, e.g., stroke, infertility, heart disease, ulcers, and scleroderma, are diseases of angiogenic insufficiency. Angiogenesis has a number of stages (see, e.g., Folkman, J.Natl Cancer Inst.

82:4-6, 1990; Firestein, J C/ /west.103:3-4, 1999; Koch, Arthritis Rheum .41:951-62, 1998; Carter, Oncologist 5(Suppl l):51-4, 2000; Browder et al, Cancer Res. 60:1878-86, 2000; and Zliu and Witte, Invest New Drugs 17:195-212, 1999). The early stages of angiogenesis include endothelial cell protease production, migration of cells, and proliferation. The early stages also appear to require some growth factors, with NEGF, TGF-α, angiostatin, and selected chemokines all putatively playing a role. Later stages of angiogenesis include population of the vessels with mural cells (pericytes or smooth muscle cells), basement membrane production, and the induction of vessel bed specializations. The final stages of vessel formation include what is known as "remodeling", wherein a forming vasculature becomes a stable, mature vessel bed. Thus, the process is highly dynamic, often requiring coordinated spatial and temporal waves of gene expression.

Conversely, the complex process may be subject to disruption by interfering with one or more critical steps. Thus, the lack of understanding of the dynamics of angiogenesis prevents therapeutic intervention in serious diseases such as those indicated. It is an object of the invention to provide methods that can be used to screen compounds for the ability to modulate angiogenesis. Additionally, it is an object to provide molecular targets for therapeutic intervention in disease states which either have an undesirable excess or a deficit in angiogenesis. The present invention provides solutions to both.

SUMMARY OF THE INVENTION The present invention provides compositions and methods for detecting or modulating angiogenesis associated sequences. In one aspect, the invention provides a method of detecting an angiogenesis- associated transcript in a cell in a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridized to a sequence at least 80% identical to a sequence as shown in Tables 1-8. In one embodiment, the biological sample is a tissue sample. In another embodiment, the biological sample comprises isolated nucleic acids, which are often mRNA.

In another embodiment, the method further comprises the step of amplifying nucleic acids before the step of contacting the biological sample with the polynucleotide. Often, the polynucleotide comprises a sequence as shown in Tables 1-8. The polynucleotide can be labeled, for example, with a fluorescent label and can be immobilized on a solid surface.

In other embodiments the patient is undergoing a therapeutic regimen to treat a disease associated with angiogenesis or the patient is suspected of having an angiogenesis- associated disorder. In another aspect, the invention comprises an isolated nucleic acid molecule consisting of a polynucleotide sequence as shown in Tables 1-8. The nucleic acid molecule can be labeled, for example, with a fluorescent label,

In other aspects, the invention provides an expression vector comprising an isolated nucleic acid molecule consisting of a polynucleotide sequence as shown in Tables 1- 8 or a host cell comprising the expression vector.

In another embodiment, the isolated nucleic acid molecule encodes a polypeptide having an amino acid sequence as shown in Table 8.

In another aspect, the invention provides an isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-8. In one embodiment, the isolated polypeptide has an amino acid sequence as shown in Table 8.

In another embodiment, the invention provides an antibody that specifically binds a polypeptide that has an amino acid sequence as shown in Table 8 or which is encoded by a nucleotide sequence of Tables 1-8 . The antibody can be conjugated or fused to an effector component such as a fluorescent label, a toxin, or a radioisotope. In some embodiments, the antibody is an antibody fragment or a humanized antibody.

In another aspect, the invention provides a method of detecting a cell undergoing angiogenesis in a biological sample from a patient, the method comprising contacting the biological sample with an antibody that specifically binds to a polypeptide that has an amino acid sequence as shown in Table 8 or which is encoded by a nucleotide sequence of Tables 1-8 . In some embodiments, the antibody is further conjugated or fused to an effector component, for example, a fluorescent label.

In another embodiment, the invention provides a method of detecting antibodies specific to angiogenesis in a patient, the method comprising contacting a biological sample from the patient with a polypeptide which is encoded by a nucleotide sequence of Tables 1-8.

The invention also provides a method of identifying a compound that modulates the activity of an angiogenesis-associated polypeptide, the method comprising the steps of: (i) contacting the compound with a polypeptide that comprises at least 80% identity to an amino acid sequence as shown in Table 8 or which is encoded by a nucleotide sequence of Tables 1-8; and (ii) detecting an increase or a decrease in the activity of the polypeptide. In one embodiment, the polypeptide has an amino acid sequence as shown in Table 8 or is a polypeptide encoded by a nucleotide sequence of Tables 1-8. In another embodiment, the polypeptide is expressed in a cell.

The invention also provides a method of identifying a compound that modulates angiogenesis, the method comprising steps of: (i) contacting the compound with a cell undergoing angiogenesis; and (ii) detecting an increase or a decrease in the expression of a polypeptide sequence as shown in Table 8 or a polypeptide which is encoded by a nucleotide sequence of Tables 1-8. In one embodiment, the detecting step comprises hybridizing a nucleic acid sample from the cell with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-8. In another embodiment, the method further comprises detecting an increase or decrease in the expression of a second sequence as shown in Table 8 or a polypeptide which is encoded by a nucleotide sequence of Tables 1-8 .

In another embodiment, the invention provides a method of inhibiting angiogenesis in a cell that expresses a polypeptide at least 80% identical to a sequence as shown in Table 8 or which is 80% identical to a polypeptide encoded by a nucleotide sequence of Tables 1-8 , the method comprising the step of contacting the cell with a therapeutically effective amount of an inhibitor of the polypeptide. In one embodiment, the polypeptide has an amino acid sequence shown in Table 8 or is a polypeptide which is encoded by a nucleotide sequence of Tables 1-8 . In another embodiment, the inhibitor is an antibody.

In other embodiments, the invention provides a method of activating angiogenesis in a cell that expresses a polypeptide at least 80% identical to a sequence as shown in Table 8 or at least 80%) identical to a polypeptide which is encoded by a nucleotide sequence of Tables 1-8 , the method comprising the step of contacting the cell with a therapeutically effective amount of an activator of the polypeptide. In one embodiment, the polypeptide has an amino acid sequence shown in Table 8 or is a polypeptide which is encoded by a nucleotide sequence of Tables 1-8.

Other aspects of the invention will become apparent to the skilled artisan by the following description of the invention.

Tables 1-8 provide nucleotide sequence of genes that exhibit changes in expression levels as a function of time in tissue undergoing angiogenesis compared to tissue that is not. DESCRIPTION OF THE SPECIFIC EMBODIMENTS In accordance with the objects outlined above, the present invention provides novel methods for diagnosis and treatment of disorders associated with angiogenesis (sometimes referred to herein as angiogenesis disorders or AD), as well as methods for screening for compositions which modulate angiogenesis. By "disorder associated with angiogenesis" or "disease associated with angiogenesis" herein is meant a disease state which is marked by either an excess or a deficit of blood vessel development. Angiogenesis disorders asociated with increased angiogenesis include, but are not limited to, cancer and proliferative diabetic retinopathy. Pathological states for which it may be desirable to increase angiogenesis include stroke, heart disease, infertility, ulcers, wound healing, ischemia, and scleradoma. Solid tumors typically require angiogenesis to support or sustain growth, e.g., breast, colon, lung, brain, bladder, and prostate tumors. Other AD include, e.g., arthritis, inflammatory bowel disease, diabetis retinopathy, macular degeneration, atherosclerosis, and psoriasis. Also provided are methods for treating AD. Definitions

The term "angiogenesis protein" or "angiogenesis polynucleotide" refers to nucleic acid and polypeptide polymorphic variants, alleles, mutants, and interspecies homologs that: (1) have an amino acid sequence that has greater than about 60% amino acid sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%o, 98% or 99% or greater amino acid sequence identity, preferably over a region of over a region of at least about 25, 50, 100, 200, 500, 1000, or more amino acids, to an angiogenesis protein sequence of Table 8; (2) bind to antibodies, e.g., polyclonal antibodies, raised against an immunogen comprising an amino acid sequence of Table 8, and conservatively modified variants thereof; (3) specifically hybridize under stringent hybridization conditions to an anti-sense strand corresponding to a nucleic acid sequence of Tables 1-8 and conservatively modified variants thereof; (4) have a nucleic acid sequence that has greater than about 95%, preferably greater than about 96%, 97%, 98%, 99%, or higher nucleotide sequence identity, preferably over a region of at least about 25, 50, 100, 200, 500, 1000, or more nucleotides, to a sense sequence corresponding to one set out in Tables 1-8 . A polynucleotide or polypeptide sequence is typically from a mammal including, but not limited to, primate, e.g., human; rodent, e.g., rat, mouse, hamster; cow, pig, horse, sheep, or any mammal. An "angiogenesis polypeptide" and an "angiogenesis polynucleotide," include both naturally occurring or recombinant. A "full length" angiogenesis protein or nucleic acid refers to an agiogenesis polypeptide or polynucleotide sequence, or a variant thereof, that contains all of the elements normally contained in one or more naturally occurring, wild type angiogenesis polynucleotide or polypeptide sequences. The "full length" may be prior to, or after, various stages of post- translation processing.

"Biological sample" as used herein is a sample of biological tissue or fluid that contains nucleic acids or polypeptides, e.g., of an angiogenic protein. Such samples include, but are not limited to, tissue isolated from primates, e.g., humans, or rodents, e.g., mice, and rats. Biological samples may also include sections of tissues such as biopsy and autopsy samples, and frozen sections taken for histologic purposes. A biological sample is typically obtained from a eukaryotic organism, most preferably a mammal such as a primate e.g., chimpanzee or human; cow; dog; cat; a rodent, e.g., guinea pig, rat, mouse; rabbit; or a bird; reptile; or fish.

"Providing a biological sample" means to obtain a biological sample for use in methods described in this invention. Most often, this will be done by removing a sample of cells from an animal, but can also be accomplished by using previously isolated cells (e.g., isolated by another person, at another time, and/or for another purpose), or by performing the methods of the invention in vivo. Archival tissues, having treatment or outcome histroy, will be particularly useful. The terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 70% identity, preferably 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region (e.g., SEQ ID NOS: 1-229), when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (see, e.g., NCBI web site http://www.ncbi.nlm.nih.gov/BLAST/ or the like). Such sequences are then said to be "substantially identical." This definition also refers to, or may be applied to, the compliment of a test sequence. The definition also includes sequences that have deletions and/or additions, as well as those that have substitutions. As described below, the preferred algorithms can account for gaps and the like. Preferably, identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 amino acids or nucleotides in length. For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Preferably, default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

A "comparison window", as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Natl. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, e.g., Current Protocols in Molecular Biology (Ausubel et al, eds. 1995 supplement)).

A preferred example of algorithm that is suitable for determimng percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al, Nuc. Acids Res. 25:3389-3402 (1977) and Altschul et al, J. Mol Biol. 215 :403-410 (1990), respectively. BLAST and BLAST 2.0 are used, with the parameters described herein, to determine percent sequence identity for the nucleic acids and proteins of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive- valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al, supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N—4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands. The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873- 5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001.

An indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions, as described below. Yet another indication that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequences.

A "host cell" is a naturally occurring cell or a transformed cell that contains an expression vector and supports the replication or expression of the expression vector. Host cells may be cultured cells, explants, cells in vivo, and the like. Host cells may be prokaryotic cells such as E. coli, or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells such as CHO, HeLa, and the like (see, e.g., the American Type Culture Collection catalog or web site, www.atcc.org).

The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer.

The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ- carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an α carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.

Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the UPAC-iUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes. "Conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in each described sequence with respect to the expression product, but not with respect to actual probe sequences.

As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention.

The following eight groups each contain amino acids that are conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)).

Macromolecular structures such as polypeptide structures can be described in terms of various levels of organization. For a general discussion of this organization, see, e.g., Alberts et al, Molecular Biology of the Cell (3^rd ed., 1994) and Cantor and Schimmel, Biophysical Chemistry Part I: Tlie Conformation of Biological Macromolecules (1980). "Primary structure" refers to the amino acid sequence of a particular peptide. "Secondary structure" refers to locally ordered, three dimensional structures within a polypeptide. These structures are commonly known as domains. Domains are portions of a polypeptide that form a compact unit of the polypeptide and are typically 25 to approximately 500 amino acids long. Typical domains are made up of sections of lesser organization such as stretches of β-sheet and α-helices. "Tertiary structure" refers to the complete three dimensional structure of a polypeptide monomer. "Quaternary structure" refers to the three dimensional structure formed, usually by the noncovalent association of independent tertiary units. Anisotropic terms are also known as energy terms.

A "label" or a "detectable moiety" is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means. For example, useful labels include ³²P, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins which can be made detectable, e.g., by incorporating a radiolabel into the peptide or used to detect antibodies specifically reactive with the peptide.

An "effector" or "effector moiety" or "effector component" is a molecule that is bound (or linked, or conjugated), either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds, to an antibody. The "effector" can be a variety of molecules including, for example, detection moieties including radioactive compounds, fluroescent compounds, an enzyme or substrate, tags such as epitope tags, a toxin; a chemotherapeutic agent; a lipase; an antibiotic; or a radioisotope emitting "hard" e.g., beta radiation.

A "labeled nucleic acid probe or oligonucleotide" is one that is bound, either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds to a label such that the presence of the probe may be detected by detecting the presence of the label bound to the probe. Alternatively, method using high affinity interactions may achieve the same results where one of a pair of binding partners binds to the other, e.g., biotin, streptavidin.

As used herein a "nucleic acid probe or oligonucleotide" is defined as a nucleic acid capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing, usually through hydrogen bond formation. As used herein, a probe may include natural (i.e., A, G, C, or T) or modified bases (7-deazaguanosine, inosine, etc.). In addition, the bases in a probe may be joined by a linkage other than a phosphodiester bond, so long as it does not interfere with hybridization. Thus, for example, probes may be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than phosphodiester linkages. It will be understood by one of skill in the art that probes may bind target sequences lacking complete complementarity with the probe sequence depending upon the stringency of the hybridization conditions. The probes are preferably directly labeled as with isotopes, chromophores, lumiphores, chromogens, or indirectly labeled such as with biotin to which a streptavidin complex may later bind. By assaying for the presence or absence of the probe, one can detect the presence or absence of the select sequence or subsequence.

The term "recombinant" when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (non- recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all. The term "heterologous" when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein indicates that the protein comprises two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).

A "promoter" is defined as an array of nucleic acid control sequences that direct transcription of a nucleic acid. As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription. A "constitutive" promoter is a promoter that is active under most environmental and developmental conditions. An "inducible" promoter is a promoter that is active under environmental or developmental regulation. The term "operably linked" refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence. An "expression vector" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a host cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the expression vector includes a nucleic acid to be transcribed operably linked to a promoter. The phrase "selectively (or specifically) hybridizes to" refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent hybridization conditions when that sequence is present in a complex mixture (e.g., total cellular or library DNA or RNA). The phrase "stringent hybridization conditions" refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acids, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Techniques in Biochemistry and Molecular Biology— Hybridization with Nucleic Probes, "Overview of principles of hybridization and the strategy of nucleic acid assays" (1993). Generally, stringent conditions are selected to be about 5-10°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength pH. The T_m is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at T_m, 50% of the probes are occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times background, preferably 10 times background hybridization. Exemplary stringent hybridization conditions can be as following: 50% formamide, 5x SSC, and 1% SDS, incubating at 42°C, or, 5x SSC, 1% SDS, incubating at 65°C, with wash in 0.2x SSC, and 0.1% SDS at 65°C. For PCR, a temperature of about 36°C is typical for low stringency amplification, although annealing temperatures may vary between about 32°C and 48°C depending on primer length. For high stringency PCR amplification, a temperature of about 62°C is typical, although high stringency annealing temperatures can range from about 50°C to about 65°C, depending on the primer length and specificity. Typical cycle conditions for both high and low stringency amplifications include a denaturation phase of 90°C - 95°C for 30 sec - 2 min., an annealing phase lasting 30 sec. - 2 min., and an extension phase of about 72°C for 1 - 2 min. Protocols and guidelines for low and high stringency amplification reactions are provided, e.g., in Innis et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, Inc. N.Y.).

Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, for example, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary "moderately stringent hybridization conditions" include a hybridization in a buffer of 40%> formamide, 1 M NaCl, % SDS at 37°C, and a wash in IX SSC at 45°C. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency. Additional guidelines for determining hybridization parameters are provided in numerous reference, e.g., and Current Protocols in Molecular Biology, ed. Ausubel, et al

The phrase "functional effects" in the context of assays for testing compounds that modulate activity of an angiogenesis protein includes the determination of a parameter that is indirectly or directly under the influence of the angiogenesis protein, e.g., a functional, physical, or chemical effect, such as the ability to increase or decrease angiogenesis. It includes binding activity, the ability of cells to proliferate, expression in cells undergoing angiogenesis, and other characteristics of angiogenic cells. "Functional effects" include in vz^'trø, in vivo, and ex vivo activities.

By "determining the functional effect" is meant assaying for a compound that increases or decreases a parameter that is indirectly or directly under the influence of an angiogenesis protein sequence, e.g., functional, physical and chemical effects. Such functional effects can be measured by any means known to those skilled in the art, e.g., changes in spectroscopic characteristics (e.g., fluorescence, absorbance, refractive index), hydrodynamic (e.g., shape), chromatographic, or solubility properties for the protein, measuring inducible markers or transcriptional activation of the angiogenesis protein; measuring binding activity or binding assays, e.g. binding to antibodies, and measuring cellular proliferation, particularly endothelial cell proliferation, cell viability, cell division especially of endothelial cells, lumen formation and capillary or vessel growth or formation. Determination of the functional effect of a compound on angiogenesis can also be performed using angiogenesis assays known to those of skill in the art such as an in vitro assays, e.g., in vitro endothelial cell tube formation assays, and other assays such as the chick CAM assay, the mouse corneal assay, and assays that assess vascularization of an implanted tumor. The functional effects can be evaluated by many means known to those skilled in the art, e.g., microscopy for quantitative or qualitative measures of alterations in morphological features, e.g., tube or blood vessel formation, measurement of changes in RNA or protein levels for angio genesis-associated sequences, measurement of RNA stability, identification of downstream or reporter gene expression (CAT, luciferase, β-gal, GFP and the like), e.g., via chemiluminescence, fluorescence, colorimetric reactions, antibody binding, inducible markers, and ligand binding assays.

"Inhibitors", "activators", and "modulators" of angiogenic polynucleotide and polypeptide sequences are used to refer to activating, inhibitory, or modulating molecules identified using in vitro and in vivo assays of angiogenic polynucleotide and polypeptide sequences. Inhibitors are compounds that, e.g., bind to, partially or totally block activity, decrease, prevent, delay activation, inactivate, desensitize, or down regulate the activity or expression of angiogenesis proteins, e.g., antagonists. "Activators" are compounds that increase, open, activate, facilitate, enhance activation, sensitize, agonize, or up regulate angiogenesis protein activity. Inhibitors, activators, or modulators also include genetically modified versions of angiogenesis proteins, e.g., versions with altered activity, as well as naturally occurring and synthetic ligands, antagonists, agonists, antibodies, small chemical molecules and the like. Such assays for inhibitors and activators include, e.g., expressing the angiogenic protein in vitro, in cells, or cell membranes, applying putative modulator compounds, and then determining the functional effects on activity, as described above. Activators and inhibitors of angiogenesis can also be identified by incubating angiogenic cells with the test compound and determining increases or decreases in the expression of 1 or more angiogenesis proteins, e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50 or more angiogenesis proteins, such as angiogenesis proteins comprising the sequences set out in Table 8. Samples or assays comprising angiogenesis proteins that are treated with a potential activator, inhibitor, or modulator are compared to control samples without the inhibitor, activator, or modulator to examine the extent of inhibition. Control samples (untreated with inhibitors) are assigned a relative protein activity value of 100%. Inhibition of a polypeptide is achieved when the activity value relative to the control is about 80%, preferably 50%_>, more preferably 25-0%. Activation of an angiogenesis polypeptide is achieved when the activity value relative to the control (untreated with activators) is 110%, more preferably 150%), more preferably 200-500% (i.e., two to five fold higher relative to the control), more preferably 1000-3000%) higher. "Antibody" refers to a polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes., as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively. Typically, the antigen-binding region of an antibody will be most critical in specificity and affinity of binding.

An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one "heavy" chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (V_L) and variable heavy chain (VH) refer to these light and heavy chains respectively. Antibodies exist, e.g., as intact immunoglobulins or as a number of well- characterized fragments produced by digestion with various peptidases. Thus, for example, pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab)⁵ ₂, a dimer of Fab which itself is a light chain joined to V_JJ-C_HI by a disulfide bond. The F(ab)'₂ may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the F(ab)'₂ dimer into an Fab' monomer. The Fab' monomer is essentially Fab with part of the hinge region (see Fundamental Immunology (Paul ed., 3d ed. 1993). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized de novo either chemically or by using recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies, or those synthesized de novo using recombinant DNA methodologies (e.g., single chain Fv) or those identified using phage display libraries (see, e.g., McCafferty et al, Nature 348:552-554 (1990))

For preparation of antibodies, e.g., recombinant, monoclonal, or polyclonal antibodies, many technique known in the art can be used (see, e.g., Kohler & Milstein,

Nature 256:495-497 (1975); Kozbor et al, Immunology Today 4: 72 (1983); Cole et al, pp. 77-96 in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. (1985); Coligan, Current Protocols in Immunology (1991); Harlow & Lane, Antibodies, A Laboratory Manual (1988); and Goding, Monoclonal Antibodies: Principles and Practice (2d ed. 1986)). Techniques for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies.

Alternatively, phage display technology can be used to identify antibodies and heteromeric Fab fragments that specifically bind to selected antigens (see, e.g. , McCafferty et al. , Nature

348:552-554 (1990); Marks et al, Biotechnology 10:779-783 (1992)).

A "chimeric antibody" is an antibody molecule in which (a) the constant region, or a portion thereof, is altered, replaced or exchanged so that the antigen binding site

(variable region) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region having a different or altered antigen specificity.

The detailed description of the invention includes discussion of the following aspects of the invention: Expression of angiogenesis-associated sequences

Informatics

Angiogenesis-associated sequences

Detection of angiogenesis sequence for diagnostic and therapeutic applications Modulators of angiogenesis

Methods of identifying variant angiogenesis-associated sequences

Administration of pharmaceutical and vaccine compositions

Kits for use in diagnostic and/or prognostic applications. Expression of angiogenesis-associated sequences

In one aspect, the expression levels of genes are determined in different patient samples for which diagnosis information is desired, to provide expression profiles. An expression profile of a particular sample is essentially a "fingerprint" of the state of the sample; while two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is unique to the state of the cell. That is, normal tissue may be distinguished from AD tissue. By comparing expression profiles of tissue in known different angiogenesis states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained. The identification of sequences that are differentially expressed in angiogenic versus non-angiogenic tissue allows the use of this information in a number of ways. For example, a particular treatment regime may be evaluated: does a chemotherapeutic drug act to down-regulate angiogenesis, and thus tumor growth or recurrence, in a particular patient. Similarly, diagnosis and treatment outcomes may be done or confirmed by comparing patient samples with the known expression profiles. Angiogenic tissue can also be analyzed to determine the stage of angiogenesis in the tissue. Furthermore, these gene expression profiles (or individual genes) allow screening of drug candidates with an eye to mimicking or altering a particular expression profile; for example, screening can be done for drugs that suppress the angiogenic expression profile. This may be done by making biochips comprising sets of the important angiogenesis genes, which can then be used in these screens. These methods can also be done on the protein basis; that is, protein expression levels of the angiogenic proteins can be evaluated for diagnostic purposes or to screen candidate agents. In addition, the angiogenic nucleic acid sequences can be administered for gene therapy purposes, including the administration of antisense nucleic acids, or the angiogenic proteins (including antibodies and other modulators thereof) administered as therapeutic drugs.

Thus the present invention provides nucleic acid and protein sequences that are differentially expressed in angiogenesis, herein termed "angiogenesis sequences". As outlined below, angiogenesis sequences include those that are up-regulated (i.e. expressed at a higher level) in disorders associated with angiogenesis, as well as those that are down- regulated (i.e. expressed at a lower level). In a preferred embodiment, the angiogenesis sequences are from humans; however, as will be appreciated by those in the art, angiogenesis sequences from other organisms may be useful in animal models of disease and drug evaluation; thus, other angiogenesis sequences are provided, from vertebrates, including mammals, including rodents (rats, mice, hamsters, guinea pigs, etc.), primates, farm animals (including sheep, goats, pigs, cows, horses, etc). Angiogenesis sequences from other organisms may be obtained using the techniques outlined below.

Angiogenesis sequences can include both nucleic acid and amino acid sequences. In a preferred embodiment, the angiogenesis sequences are recombinant nucleic acids. By the term "recombinant nucleic acid" herein is meant nucleic acid, originally formed in vitro, in general, by the manipulation of nucleic acid e.g., using polymerases and endonucleases, in a form not normally found in nature. Thus an isolated nucleic acid, in a linear form, or an expression vector formed in vitro by ligating DNA molecules that are not normally joined, are both considered recombinant for the purposes of this invention. It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell or organism, it will replicate non-recombinantly, i.e. using the in vivo cellular machinery of the host cell rather than in vitro manipulations; however, such nucleic acids, once produced recombinantly, although subsequently replicated non-recombinantly, are still considered recombinant for the purposes of the invention.

Similarly, a "recombinant protein" is a protein made using recombinant techniques, i. e. through the expression of a recombinant nucleic acid as depicted above. A recombinant protein is distinguished from naturally occurring protein by at least one or more characteristics. For example, the protein may be isolated or purified away from some or all of the proteins and compounds with which it is normally associated in its wild type host, and thus may be substantially pure. For example, an isolated protein is unaccompanied by at least some of the material with which it is normally associated in its natural state, preferably constituting at least about 0.5%, more preferably at least about 5% by weight of the total protein in a given sample. A substantially pure protein comprises at least about 75% by weight of the total protein, with at least about 80% being preferred, and at least about 90% being particularly preferred. The definition includes the production of an angiogenesis protein from one organism in a different organism or host cell. Alternatively, the protein may be made at a significantly higher concentration than is normally seen, through the use of an inducible promoter or high expression promoter, such that the protein is made at increased concentration levels. Alternatively, the protein may be in a form not normally found in nature, as in the addition of an epitope tag or amino acid substitutions, insertions and deletions, as discussed below.

In a preferred embodiment, the angiogenesis sequences are nucleic acids. As will be appreciated by those in the art and is more fully outlined below, angiogenesis sequences are useful in a variety of applications, including diagnostic applications, which will detect naturally occurring nucleic acids, as well as screening applications; for example, biochips comprising nucleic acid probes to the angiogenesis sequences can be generated. In the broadest sense, then, by "nucleic acid" or "oligonucleotide" or grammatical equivalents herein means at least two nucleotides covalently linked together. A nucleic acid of the present invention will generally contain phosphodiester bonds, although in some cases, nucleic acid analogs are included that may have alternate backbones, comprising, for example, phosphoramidate, phosphorothioate, phosphorodithioate, or O- methylphophoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press); and peptide nucleic acid backbones and linkages. Other analog nucleic acids include those with positive backbones; non-ionic backbones, and non- ribose backbones, including those described in U.S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y.S. Sanghui and P. Dan Cook. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids.

Modifications of the ribose-phosphate backbone may be done for a variety of reasons, for example to increase the stability and half-life of such molecules in physiological environments or as probes on a biochip.

As will be appreciated by those in the art, nucleic acid analogs may find use in the present invention. In addition, mixtures of naturally occurring nucleic acids and analogs can be made; alternatively, mixtures of different nucleic acid analogs, and mixtures of naturally occurring nucleic acids and analogs may be made.

Particularly preferred are peptide nucleic acids (PNA) which includes peptide nucleic acid analogs. These backbones are substantially non-ionic under neutral conditions, in contrast to the highly charged phosphodiester backbone of naturally occurring nucleic acids. This results in two advantages. First, the PNA backbone exhibits improved hybridization kinetics. PNAs have larger changes in the melting temperature (Tm) for mismatched versus perfectly matched basepairs. DNA and RNA typically exhibit a 2-4°C drop in T_m for an internal mismatch. With the non-ionic PNA backbone, the drop is closer to 7-9°C. Similarly, due to their non-ionic nature, hybridization of the bases attached to these backbones is relatively insensitive to salt concentration. In addition, PNAs are not degraded by cellular enzymes, and thus can be more stable.

The nucleic acids may be single stranded or double stranded, as specified, or contain portions of both double stranded or single stranded sequence. As will be appreciated by those in the art, the depiction of a single strand also defines the sequence of the complementary strand; thus the sequences described herein also provide the complement of the sequence. The nucleic acid may be DNA, both genomic and cDNA, RNA or a hybrid, where the nucleic acid may contain combinations of deoxyribo- and ribo-nucleotides, and combinations of bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine, isoguanine, etc. As used herein, the term "nucleoside" includes nucleotides and nucleoside and nucleotide analogs, and modified nucleosides such as amino modified nucleosides. In addition, "nucleoside" includes non-naturally occurring analog structures. Thus for example the individual units of a peptide nucleic acid, each containing a base, are referred to herein as a nucleoside. An angiogenesis sequence can be initially identified by substantial nucleic acid and/or amino acid sequence homology to the angiogenesis sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions.

For identifying angiogenesis-associated sequences, the angiogenesis screen typically includes comparing genes identified in a modification of an in vitro model of angiogenesis as described in Hiraoka, Cell 95:365 (1998) with genes identified in controls. Samples of normal tissue and tissue undergoing angiogenesis are applied to biochips comprising nucleic acid probes. The samples are first microdissected, if applicable, and treated as is known in the art for the preparation of mRNA. Suitable biochips are commercially available, for example from Affymetrix. Gene expression profiles as described herein are generated and the data analyzed.

In a preferred embodiment, the genes showing changes in expression as between normal and disease states are compared to genes expressed in other normal tissues, including, but not limited to lung, heart, brain, liver, breast, kidney, muscle, prostate, small intestine, large intestine, spleen, bone and placenta. In a preferred embodiment, those genes identified during the angiogenesis screen that are expressed in any significant amount in other tissues are removed from the profile, although in some embodiments, this is not necessary. That is, when screening for drugs, it is usually preferable that the target be disease specific, to minimize possible side effects.

In a preferred embodiment, angiogenesis sequences are those that are upregulated in angiogenesis disorders; that is, the expression of these genes is higher in the disease tissue as compared to normal tissue. "Up-regulation" as used herein means at least about a two-fold change, preferably at least about a three fold change, with at least about five-fold or higher being preferred. All accession numbers herein are for the GenBank sequence database and the sequences of the accession numbers are hereby expressly incorporated by reference. GenBank is known in the art, see, e.g., Benson, DA, et al., Nucleic Acids Research 26:1-7 (1998) and http://www.ncbi.nlm.nih.gov/. Sequences are also avialable in other databases, e.g., European Molecular Biology Laboratory (EMBL) and DNA Database of Japan (DDBJ). In addition, most preferred genes were found to be expressed in a limited amount or not at all in heart, brain, lung, liver, breast, kidney, prostate, small intestine and spleen. In another preferred embodiment, angiogenesis sequences are those that are down-regulated in the angiogenesis disorder; that is, the expression of these genes is lower in angiogenic tissue as compared to normal tissue. "Down-regulation" as used herein means at least about a two-fold change, preferably at least about a three fold change, with at least about five-fold or higher being preferred.

Angiogenesis sequences according to the invention may be classified into discrete clusters of sequences based on common expression profiles of the sequences. Expression levels of angiogenesis sequences may increase or decrease as a function of time in a manner that correlates with the induction of angiogenesis. Alternatively, expression levels of angiogenesis sequences may both increase and decrease as a function of time. For example, expression levels of some angiogenesis sequences are temporarily induced or diminished during the switch to the angiogenesis phenotype, followed by a return to baseline expression levels. Tables 1-8 provides genes, the mRNA expression of which varies as a function of time in angiogenesis tissue when compared to normal tissue. In a particularly preferred embodiment, angiogenesis sequences are those that are induced for a period of time, typically by positive angiogenic factors, followed by a return to the baseline levels. Sequences that are temporarily induced provide a means to target angiogenesis tissue, for example neovascularized tumors, at a particular stage of angiogenesis, while avoiding rapidly growing tissue that require perpetual vascularization. Such positive angiogenic factors include αFGF, βFGF, NEGF, angiogenin and the like.

Induced angiogenesis sequences also are further categorized with respect to the timing of induction. For example, some angiogenesis genes may be induced at an early time period, such as within 10 minutes of the induction of angiogenesis. Others may be induced later, such as between 5 and 60 minutes, while yet others may be induced for a time period of about two hours or more followed by a return to baseline expression levels.

In another preferred embodiment are angiogenesis sequences that are inhibited or reduced as a function of time followed by a return to "normal" expression levels. Inhibitors of angiogenesis are examples of molecules that have this expression profile. These sequences also can be further divided into groups depending on the timing of diminished expression. For example, some molecules may display reduced expression within 10 minutes of the induction of angiogenesis. Others may be diminished later, such as between 5 and 60 minutes, while others may be diminished for a time period of about two hours or more followed by a return to baseline. Examples of such negative angiogenic factors include thrombospondin and endostatin to name a few.

In yet another preferred embodiment are angiogenesis sequences that are induced for prolonged periods. These sequences are typically associated with induction of angiogenesis and may participate in induction and/or maintenance of the angiogenesis phenotype.

In another preferred embodiment are angiogenesis sequences, the expression of which is reduced or diminished for prolonged periods in angiogenic tissue. These sequences are typically angiogenesis inhibitors and their diminution is correlated with an increase in angiogenesis.

Informatics

The ability to identify genes that undergo changes in expression with time during angiogenesis can additionally provide high-resolution, high-sensitivity datasets which can be used in the areas of diagnostics, therapeutics, drug development, biosensor development, and other related areas. For example, the expression profiles can be used in diagnostic or prognostic evaluation of patients with angiogenesis-associated disease. Or as another example, subcellular toxicological information can be generated to better direct drug structure and activity correlation (see, Anderson, L., "Pharmaceutical Proteomics: Targets, Mechanism, and Function," paper presented at the IBC Proteomics conference, Coronado, CA (June 11-12, 1998)). Subcellular toxicological information can also be utilized in a biological sensor device to predict the likely toxicological effect of chemical exposures and likely tolerable exposure thresholds (see, U.S. Patent No. 5,811,231). Similar advantages accrue from datasets relevant to other biomolecules and bioactive agents (e.g., nucleic acids, saccharides, lipids, drugs, and the like).

Thus, in another embodiment, the present invention provides a database that includes at least one set of data assay data. The data contained in the database is acquired , e.g., using array analysis either singly or in a library format. The database can be in substantially any form in which data can be maintained and transmitted, but is preferably an electronic database. The electronic database of the invention can be maintained on any electronic device allowing for the storage of and access to the database, such as a personal computer, but is preferably distributed on a wide area network, such as the World Wide Web. The focus of the present section on databases that include peptide sequence data is for clarity of illustration only. It will be apparent to those of skill in the art that similar databases can be assembled for any assay data acquired using an assay of the invention.

The compositions and methods for identifying and/or quantitating the relative and/or absolute abundance of a variety of molecular and macromolecular species from a biological sample undergoing angiogenesis, i.e., the identification of angiogenesis-associated sequences described herein, provide an abundance of information, which can be correlated with pathological conditions, predisposition to disease, drug testing, therapeutic monitoring, gene-disease causal linkages, identification of correlates of immunity and physiological status, among others. Although the data generated from the assays of the invention is suited for manual review and analysis, in a preferred embodiment, prior data processing using highspeed computers is utilized.

An array of methods for indexing and retrieving biomolecular information is known in the art. For example, U.S. Patents 6,023,659 and 5,966,712 disclose a relational database system for storing biomolecular sequence information in a manner that allows sequences to be catalogued and searched according to one or more protein function hierarchies. U.S. Patent 5,953,727 discloses a relational database having sequence records containing information in a format that allows a collection of partial-length DNA sequences to be catalogued and searched according to association with one or more sequencing projects for obtaining full-length sequences from the collection of partial length sequences. U.S. Patent 5,706,498 discloses a gene database retrieval system for making a retrieval of a gene sequence similar to a sequence data item in a gene database based on the degree of similarity between a key sequence and a target sequence. U.S. Patent 5,538,897 discloses a method using mass spectroscopy fragmentation patterns of peptides to identify amino acid sequences in computer databases by comparison of predicted mass spectra with experimentally-derived mass spectra using a closeness-of-fit measure. U.S. Patent 5,926,818 discloses a multidimensional database comprising a functionality for multi-dimensional data analysis described as on-line analytical processing (OLAP), which entails the consolidation of projected and actual data according to more than one consolidation path or dimension. U.S. Patent 5,295,261 reports a hybrid database structure in which the fields of each database record are divided into two classes, navigational and informational data, with navigational fields stored in a hierarchical topological map which can be viewed as a tree structure or as the merger of two or more such tree structures. The present invention provides a computer database comprising a computer and software for storing in computer-retrievable form assay data records cross-tabulated, e.g., with data specifying the source of the target-containing sample from which each sequence specificity record was obtained. In an exemplary embodiment, at least one of the sources of target-containing sample is from a control tissue sample known to be free of pathological disorders. In a variation, at least one of the sources is a known pathological tissue specimen, e.g., a neoplastic lesion or another tissue specimen to be analyzed for angiogenesis. In another variation, the assay records cross-tabulate one or more of the following parameters for each target species in a sample: (1) a unique identification code, which can include, e.g., a target molecular structure and/or characteristic separation coordinate (e.g., electrophoretic coordinates); (2) sample source; and (3) absolute and/or relative quantity of the target species present in the sample.

The invention also provides for the storage and retrieval of a collection of target data in a computer data storage apparatus, which can include magnetic disks, optical disks, magneto-optical disks, DRAM, SRAM, SGRAM, SDRAM, RDRAM, DDR RAM, magnetic bubble memory devices, and other data storage devices, including CPU registers and on-CPU data storage arrays. Typically, the target data records are stored as a bit pattern in an array of magnetic domains on a magnetizable medium or as an array of charge states or transistor gate states, such as an array of cells in a DRAM device (e.g., each cell comprised of a transistor and a charge storage area, which may be on the transistor). In one embodiment, the invention provides such storage devices, and computer systems built therewith, comprising a bit pattern encoding a protein expression fingerprint record comprising unique identifiers for at least 10 target data records cross-tabulated with target source. When the target is a peptide or nucleic acid, the invention preferably provides a method for identifying related peptide or nucleic acid sequences, comprising performing a computerized comparison between a peptide or nucleic acid sequence assay record stored in or retrieved from a computer storage device or database and at least one other sequence. The comparison can include a sequence analysis or comparison algorithm or computer program embodiment thereof (e.g. , FASTA, TFASTA, GAP, BESTFIT) and/or the comparison may be of the relative amount of a peptide or nucleic acid sequence in a pool of sequences determined from a polypeptide or nucleic acid sample of a specimen.

The invention also preferably provides a magnetic disk, such as an IBM- compatible (DOS, Windows, Windows95/98/2000, Windows NT, OS/2) or other format (e.g., Linux, SunOS, Solaris, AIX, SCO Unix, VMS, MV, Macintosh, etc.). floppy diskette or hard (fixed, Winchester) disk drive, comprising a bit pattern encoding data from an assay of the invention in a file format suitable for retrieval and processing in a computerized sequence analysis, comparison, or relative quantitation method. The invention also provides a network, comprising a plurality of computing devices linked via a data link, such as an Ethernet cable (coax or lOBaseT), telephone line, ISDN line, wireless network, optical fiber, or other suitable signal tranmission medium, whereby at least one network device (e.g., computer, disk array, etc.) comprises a pattern of magnetic domains (e.g., magnetic disk) and/or charge domains (e.g., an array of DRAM cells) composing a bit pattern encoding data acquired from an assay of the invention.

The invention also provides a method for transmitting assay data that includes generating an electronic signal on an electronic communications device, such as a modem, ISDN terminal adapter, DSL, cable modem, ATM switch, or the like, wherein the signal includes (in native or encrypted format) a bit pattern encoding data from an assay or a database comprising a plurality of assay results obtained by the method of the invention. In a preferred embodiment, the invention provides a computer system for comparing a query target to a database containing an array of data structures, such as an assay result obtained by the method of the invention, and ranking database targets based on the degree of identity and gap weight to the target data. A central processor is preferably initialized to load and execute the computer program for alignment and/or comparison of the assay results. Data for a query target is entered into the central processor via an I/O device. Execution of the computer program results in the central processor retrieving the assay data from the data file, which comprises a binary description of an assay result.

The target data or record and the computer program can be transferred to secondary memory, which is typically random access memory (e.g., DRAM, SRAM, SGRAM, or SDRAM). Targets are ranked according to the degree of correspondence between a selected assay characteristic (e.g., binding to a selected affinity moiety) and the same characteristic of the query target and results are output via an I/O device. For example, a central processor can be a conventional computer (e.g., Intel Pentium, PowerPC, Alpha, PA-8000, SPARC, MIPS 4400, MIPS 10000, VAX, etc); a program can be a commercial or public domain molecular biology software package (e.g., UWGCG Sequence Analysis Software, Darwin); a data file can be an optical or magnetic disk, a data server, a memory device (e.g., DRAM, SRAM, SGRAM, SDRAM, EPROM, bubble memory, flash memory, etc.); an I/O device can be a terminal comprising a video display and a keyboard, a modem, an ISDN terminal adapter, an Ethernet port, a punched card reader, a magnetic strip reader, or other suitable I/O device.

The invention also preferably provides the use of a computer system, such as that described above, which comprises: (1) a computer; (2) a stored bit pattern encoding a collection of peptide sequence specificity records obtained by the methods of the invention, which may be stored in the computer; (3) a comparison target, such as a query target; and (4) a program for alignment and comparison, typically with rank-ordering of comparison results on the basis of computed similarity values.

Angiogenesis-associated sequences

Angiogenesis proteins of the present invention may be classified as secreted proteins, transmembrane proteins or intracellular proteins. In one embodiment,the angiogenesis protein is an intracellular protein. Intracellular proteins may be found in the cytoplasm and/or in the nucleus or associated with the intracellular side of the plasma membrane. Intracellular proteins are involved in all aspects of cellular function and replication (including, e.g., signaling pathways); aberrant expression of such proteins often results in unregulated or disregulated cellular processes (see, e.g., Molecular Biology of the Cell, 3rd Edition, Alberts, Ed., Garland Pub., 1994). For example, many intracellular proteins have enzymatic activity such as protein kinase activity, protein phosphatase activity, protease activity, nucleotide cyclase activity, polymerase activity and the like. Intracellular proteins also serve as docking proteins that are involved in organizing complexes of proteins, or targeting proteins to various subcellular localizations, and are involved in maintaining the structural integrity of organelles.

An increasingly appreciated concept in characterizing proteins is the presence in the proteins of one or more motifs for which defined functions have been attributed. In addition to the highly conserved sequences found in the enzymatic domain of proteins, highly conserved sequences have been identified in proteins that are involved in protein-protein interaction. For example, Src-homology-2 (SH2) domains bind tyrosine-phosphorylated targets in a sequence dependent manner. PTB domains, which are distinct from SH2 domains, also bind tyrosine phosphorylated targets. SH3 domains bind to proline-rich targets. In addition, PH domains, tetratricopeptide repeats and WD domains to name only a few, have been shown to mediate protein-protein interactions. Some of these may also be involved in binding to phospholipids or other second messengers. As will be appreciated by one of ordinary skill in the art, these motifs can be identified on the basis of primary sequence; thus, an analysis of the sequence of proteins may provide insight into both the enzymatic potential of the molecule and/or molecules with which the protein may associate.

In another embodiment, the angiogenesis sequences are transmembrane proteins. Transmembrane proteins are molecules that span a phospholipid bilayer of a cell. They may have an intracellular domain, an extracellular domain, or both. The intracellular domains of such proteins may have a number of functions including those already described for intracellular proteins. For example, the intracellular domain may have enzymatic activity and/or may serve as a binding site for additional proteins. Frequently the intracellular domain of transmembrane proteins serves both roles. For example certain receptor tyrosine kinases have both protein kinase activity and SH2 domains. In addition, autophosphorylation of tyrosines on the receptor molecule itself, creates binding sites for additional SH2 domain containing proteins.

Transmembrane proteins may contain from one to many transmembrane domains. For example, receptor tyrosine kinases, certain cytokine receptors, receptor guanylyl cyclases and receptor serine/threonine protein kinases contain a single transmembrane domain. However, various other proteins including channels and adenylyl cyclases contain numerous transmembrane domains. Many important cell surface receptors such as G protein coupled receptors (GPCRs) are classified as "seven transmembrane domain" proteins, as they contain 7 membrane spanning regions. Characteristics of transmembrane domains include approximately 20 consecutive hydrophobic amino acids that may be followed or flanked by charged amino acids. Therefore, upon analysis of the amino acid sequence of a particular protein, the localization and number of transmembrane domains within the protein may be predicted (see, e.g. PSORT web site http://psort.nibb.ac.jp/).

The extracellular domains of transmembrane proteins are diverse; however, conserved motifs are found repeatedly among various extracellular domains. Conserved structure and/or functions have been ascribed to different extracellular motifs. Many extracellular domains are involved in binding to other molecules. In one aspect, extracellular domains are found on receptors. Factors that bind the receptor domain include circulating ligands, which may be peptides, proteins, or small molecules such as adenosine and the like. For example, growth factors such as EGF, FGF and PDGF are circulating growth factors that bind to their cognate receptors to initiate a variety of cellular responses. Other factors include cytokines, mitogenic factors, neurotrophic factors and the like. Extracellular domains also bind to cell-associated molecules. In this respect, they mediate cell-cell interactions. Cell- associated ligands can be tethered to the cell for example via a glycosylphosphatidylinositol (GPI) anchor, or may themselves be transmembrane proteins. Extracellular domains also associate with the extracellular matrix and contribute to the maintenance of the cell structure. Angiogenesis proteins that are transmembrane are particularly preferred in the present invention as they are readily accessible targets for immunotherapeutics, as are described herein. In addition, as outlined below, transmembrane proteins can be also useful in imaging modalities. Antibodies may be used to label such readily accessible proteins in situ. Alternatively, antibodies can also label intracellular proteins, in which case samples are typically permeablized to provide acess to intracellular proteins.

It will also be appreciated by those in the art that a transmembrane protein can be made soluble by removing transmembrane sequences, for example through recombinant methods. Furthermore, transmembrane proteins that have been made soluble can be made to be secreted through recombinant means by adding an appropriate signal sequence.

In another embodiment, the angiogenesis proteins are secreted proteins; the secretion of which can be either constitutive or regulated. These proteins have a signal peptide or signal sequence that targets the molecule to the secretory pathway. Secreted proteins are involved in numerous physiological events; by virtue of their circulating nature, they serve to transmit signals to various other cell types. The secreted protein may function in an autocrine manner (acting on the cell that secreted the factor), a paracrine manner (acting on cells in close proximity to the cell that secreted the factor) or an endocrine manner (acting on cells at a distance). Thus secreted molecules find use in modulating or altering numerous aspects of physiology. Angiogenesis proteins that are secreted proteins are particularly preferred in the present invention as they serve as good targets for diagnostic markers, e.g., for blood or serum tests.

An angiogenesis sequence is typically initially identified by substantial nucleic acid and/or amino acid sequence homology or linkage to the angiogenesis sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions. Typically, linked sequences on a mRNA are found on the same molecule. As detailed in the definitions, percent identity can be determined using an algorithm such as BLAST. A preferred method utilizes the BLASTN module of WU- BLAST-2 set to the default parameters, with overlap span and overlap fraction set to 1 and 0.125, respectively. The alignment may include the introduction of gaps in the sequences to be aligned. In addition, for sequences which contain either more or fewer nucleotides than those of the nucleic acids of the figures, it is understood that the percentage of homology will be determined based on the number of homologous nucleosides in relation to the total number of nucleosides. Thus, for example, homology of sequences shorter than those of the sequences identified herein and as discussed below, will be determined using the number of nucleosides in the shorter sequence.

In one embodiment, the nucleic acid homology is determined through hybridization studies. Thus, e.g., nucleic acids which hybridize under high stringency to a nucleic acid of Tables 1-8 , or its complement, or is also found on naturally occurring mRNAs is considered an angiogenesis sequence. In another embodiment, less stringent hybridization conditions are used; for example, moderate or low stringency conditions may be used, as are known in the art; see Ausubel, supra, and Tijssen, supra.

In addition, the angiogenesis nucleic acid sequences of the invention, e.g, the sequence in Tables 1-8 , are fragments of larger genes, i.e. they are nucleic acid segments. "Genes" in this context includes coding regions, non-coding regions, and mixtures of coding and non-coding regions. Accordingly, as will be appreciated by those in the art, using the sequences provided herein, extended sequences, in either direction, of the angiogenesis genes can be obtained, using techniques well known in the art for cloning either longer sequences or the full length sequences; see Ausubel, et al, supra. Much can be done by informatics and many sequences can be clustered to include multiple sequences, e.g., systems such as UniGene (see, http://www.ncbi.nlm.nih.gov/UniGene/).

Once the angiogenesis nucleic acid is identified, it can be cloned and, if necessary, its constituent parts recombined to form the entire angiogenesis nucleic acid coding regions or the entire mRNA sequence. Once isolated from its natural source, e.g., contained within a plasmid or other vector or excised therefrom as a linear nucleic acid segment, the recombinant angiogenesis nucleic acid can be further-used as a probe to identify and isolate other angiogenesis nucleic acids, for example extended coding regions. It can also be used as a "precursor" nucleic acid to make modified or variant angiogenesis nucleic acids and proteins.

The angiogenesis nucleic acids of the present invention are used in several ways. In a first embodiment, nucleic acid probes to the angiogenesis nucleic acids are made and attached to biochips to be used in screening and diagnostic methods, as outlined below, or for administration, for example for gene therapy, vaccine, and/or antisense applications. Alternatively, the angiogenesis nucleic acids that include coding regions of angiogenesis proteins can be put into expression vectors for the expression of angiogenesis proteins, again for screening purposes or for administration to a patient.

In a preferred embodiment, nucleic acid probes to angiogenesis nucleic acids (both the nucleic acid sequences outlined in the figures and/or the complements thereof) are made. The nucleic acid probes attached to the biochip are designed to be substantially complementary to the angiogenesis nucleic acids, i.e. the target sequence (either the target sequence of the sample or to other probe sequences, for example in sandwich assays), such that hybridization of the target sequence and the probes of the present invention occurs. As outlined below, this complementarity need not be perfect; there may be any number of base pair mismatches which will interfere with hybridization between the target sequence and the single stranded nucleic acids of the present invention. However, if the number of mutations is so great that no hybridization can occur under even the least stringent of hybridization conditions, the sequence is not a complementary target sequence. Thus, by "substantially complementary" herein is meant that the probes are sufficiently complementary to the target sequences to hybridize under normal reaction conditions, particularly high stringency conditions, as outlined herein.

A nucleic acid probe is generally single stranded but can be partially single and partially double stranded. The strandedness of the probe is dictated by the structure, composition, and properties of the target sequence. In general, the nucleic acid probes range from about 8 to about 100 bases long, with from about 10 to about 80 bases being preferred, and from about 30 to about 50 bases being particularly preferred. That is, generally whole genes are not used. In some embodiments, much longer nucleic acids can be used, up to hundreds of bases.

In a preferred embodiment, more than one probe per sequence is used, with either overlapping probes or probes to different sections of the target being used. That is, two, three, four or more probes, with three being preferred, are used to build in a redundancy for a particular target. The probes can be overlapping (i.e. have some sequence in common), or separate. In some cases, PCR primers may be used to amplify signal for higher sensitivity. As will be appreciated by those in the art, nucleic acids can be attached or immobilized to a solid support in a wide variety of ways. By "immobilized" and grammatical equivalents herein is meant the association or binding between the nucleic acid probe and the solid support is sufficient to be stable under the conditions of binding, washing, analysis, and removal as outlined below. The binding can typically be covalent or non-covalent. By "non- covalent binding" and grammatical equivalents herein is meant one or more of electrostatic, hydrophilic, and hydrophobic interactions. Included in non-covalent binding is the covalent attachment of a molecule, such as, streptavidin to the support and the non-covalent binding of the biotinylated probe to the streptavidin. By "covalent binding" and grammatical equivalents herein is meant that the two moieties, the solid support and the probe, are attached by at least one bond, including sigma bonds, pi bonds and coordination bonds. Covalent bonds can be formed directly between the probe and the solid support or can be formed by a cross linker or by inclusion of a specific reactive group on either the solid support or the probe or both molecules. Immobilization may also involve a combination of covalent and non-covalent interactions. In general, the probes are attached to the biochip in a wide variety of ways, as will be appreciated by those in the art. As described herein, the nucleic acids can either be synthesized first, with subsequent attachment to the biochip, or can be directly synthesized on the biochip.

The biochip comprises a suitable solid substrate. By "substrate" or "solid support" or other grammatical equivalents herein is meant a material that can be modified to contain discrete individual sites appropriate for the attachment or association of the nucleic acid probes and is amenable to at least one detection method. As will be appreciated by those in the art, the number of possible substrates are very large, and include, but are not limited to, glass and modified or functionalized glass, plastics (including acrylics, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethanes, TeflonJ, etc.), polysaccharides, nylon or nitrocellulose, resins, silica or silica- based materials including silicon and modified silicon, carbon, metals, inorganic glasses, plastics, etc. In general, the substrates allow optical detection and do not appreciably fluorescese. A preferred substrate is described in copending application entitled Reusable Low Fluorescent Plastic Biochip, U.S. Application Serial No. 09/270,214, filed March 15, 1999, herein incorporated by reference in its entirety.

Generally the substrate is planar, although as will be appreciated by those in the art, other configurations of substrates may be used as well. For example, the probes may be placed on the inside surface of a tube, for flow-through sample analysis to minimize sample volume. Similarly, the substrate may be flexible, such as a flexible foam, including closed cell foams made of particular plastics.

In a preferred embodiment, the surface of the biochip and the probe may be derivatized with chemical functional groups for subsequent attachment of the two. Thus, for example, the biochip is derivatized with a chemical functional group including, but not limited to, amino groups, carboxy groups, oxo groups and thiol groups, with amino groups being particularly preferred. Using these functional groups, the probes can be attached using functional groups on the probes. For example, nucleic acids containing amino groups can be attached to surfaces comprising amino groups, for example using linkers as are known in the art; for example, homo-or hetero-bifunctional linkers as are well known (see 1994 Pierce Chemical Company catalog, technical section on cross-linkers, pages 155-200, incorporated herein by reference). In addition, in some cases, additional linkers, such as alkyl groups (including substituted and heteroalkyl groups) may be used.

In this embodiment, oligonucleotides are synthesized as is known in the art, and then attached to the surface of the solid support. As will be appreciated by those skilled in the art, either the 5 ' or 3' terminus may be attached to the solid support, or attachment may be via an internal nucleoside.

In another embodiment, the immobilization to the solid support may be very strong, yet non-covalent. For example, biotinylated oligonucleotides can be made, which bind to surfaces covalently coated with streptavidin, resulting in attachment.

Alternatively, the oligonucleotides may be synthesized on the surface, as is known in the art. For example, photoactivation techniques utilizing photopolymerization compounds and techniques are used. In a preferred embodiment, the nucleic acids can be synthesized in situ, using well known photolithographic techniques, such as those described in WO 95/25116; WO 95/35505; U.S. Patent Nos. 5,700,637 and 5,445,934; and references cited within, all of which are expressly incorporated by reference; these methods of attachment form the basis of the Affimetrix GeneChip™ technology.

Often, amplification-based assays are performed to measure the expression level of angiogenesis-associated sequences. These assays are typically performed in conjunction with reverse transcription. In such assays, an angiogenesis-associated nucleic acid sequence acts as a template in an amplification reaction (e.g., Polymerase Chain Reaction, or PCR). In a quantitative amplification, the amount of amplification product will be proportional to the amount of template in the original sample. Comparison to appropriate controls provides a measure of the amount of angiogenesis-associated RNA. Methods of quantitative amplification are well known to those of skill in the art. Detailed protocols for quantitative PCR are provided, e.g., in Innis et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, Inc. N.Y.).

In some embodiments, a TaqMan based assay is used to measure expression. TaqMan based assays use a fluorogenic oligonucleotide probe that contains a 5' fluorescent dye and a 3 ' quenching agent. The probe hybridizes to a PCR product, but cannot itself be extended due to a blocking agent at the 3' end. When the PCR product is amplified in subsequent cycles, the 5' nuclease activity of the polymerase, e.g., AmpliTaq, results in the cleavage of the TaqMan probe. This cleavage separates the 5' fluorescent dye and the 3' quenching agent, thereby resulting in an increase in fluorescence as a function of amplification (see, for example, literature provided by Perkin-Elmer, e.g., www2.perkin- elmer.com).

Other suitable amplification methods include, but are not limited to, ligase chain reaction (LCR) (see, Wu and Wallace (1989) Genomics 4: 560, Landegren et al. (1988) Science 241 : 1077, and Barringer et al. (1990) Gene 89: 117), transcription amplification

(Kwoh et al (1989) Proc. Natl. Acad. Sci. USA 86: 1173), self-sustained sequence replication (Guatelli et al. (1990) Proc. Nat Acad. Sci. USA 87: 1874), dot PCR, and linker adapter PCR, etc.

In a preferred embodiment, angiogenesis nucleic acids, e.g., encoding angiogenesis proteins are used to make a variety of expression vectors to express angiogenesis proteins which can then be used in screening assays, as described below. Expression vectors and recombinant DNA technology are well known to those of skill in the art (see, e.g., Ausubel, supra, and Gene Expression Systems, Fernandez & Hoeffler, Eds, Academic Press, 1999) and are used to express proteins. The expression vectors may be either self-replicating extrachromosomal vectors or vectors which integrate into a host genome. Generally, these expression vectors include transcriptional and translational regulatory nucleic acid operably linked to the nucleic acid encoding the angiogenesis protein. The term "control sequences" refers to DNA sequences used for the expression of an operably linked coding sequence in a particular host organism. Control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is typically accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice. Transcriptional and translational regulatory nucleic acid will generally be appropriate to the host cell used to express the angiogenesis protein; for example, transcriptional and translational regulatory nucleic acid sequences from Bacillus are preferably used to express the angiogenesis protein in Bacillus. Numerous types of appropriate expression vectors, and suitable regulatory sequences are known in the art for a variety of host cells. In general, transcriptional and translational regulatory sequences may include, but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. In a preferred embodiment, the regulatory sequences include a promoter and transcriptional start and stop sequences. Promoter sequences encode either constitutive or inducible promoters. The promoters may be either naturally occurring promoters or hybrid promoters. Hybrid promoters, which combine elements of more than one promoter, are also known in the art, and are useful in the present invention.

In addition, an expression vector may comprise additional elements. For example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, for example in mammalian or insect cells for expression and in a procaryotic host for cloning and amplification. Furthermore, for integrating expression vectors, the expression vector contains at least one sequence homologous to the host cell genome, and preferably two homologous sequences which flank the expression construct. The integrating vector may be directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector. Constructs for integrating vectors are well known in the art (e.g., Fernandez & Hoeffler, supra). See also Kitamura, et al. (1995) PNAS 92:9146-9150.

In addition, in a preferred embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known in the art and will vary with the host cell used.

The angiogenesis proteins of the present invention are produced by culturing a host cell transformed with an expression vector containing nucleic acid encoding an angiogenesis protein, under the appropriate conditions to induce or cause expression of the angiogenesis protein. Conditions appropriate for angiogenesis protein expression will vary with the choice of the expression vector and the host cell, and will be easily ascertained by one skilled in the art through routine experimentation or optimization. For example, the use of constitutive promoters in the expression vector will require optimizing the growth and proliferation of the host cell, while the use of an inducible promoter requires the appropriate growth conditions for induction. In addition, in some embodiments, the timing of the harvest is important. For example, the baculoviral systems used in insect cell expression are lytic viruses, and thus harvest time selection can be crucial for product yield.

Appropriate host cells include yeast, bacteria, archaebacteria, fungi, and insect and animal cells, including mammalian cells. Of particular interest are Saccharomyces cerevisiae and other yeasts, E. coli, Bacillus subtilis, Sf9 cells, C129 cells, 293 cells, Neurospora, BHK, CHO, COS, HeLa cells, HUVΕC (human umbilical vein endothelial cells), THPl cells (a macrophage cell line) and various other human cells and cell lines. In a preferred embodiment, the angiogenesis proteins are expressed in mammalian cells. Mammalian expression systems are also known in the art, and include retroviral and adenoviral systems. Of particular use as mammalian promoters are the promoters from mammalian viral genes, since the viral genes are often highly expressed and have a broad host range. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter, and the CMV promoter (see, e.g., Fernandez & Hoeffler, supra). Typically, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. Examples of transcription terminator and polyadenlytion signals include those derived form SV40. The methods of introducing exogenous nucleic acid into mammalian hosts, as well as other hosts, is well known in the art, and will vary with the host cell used. Techniques include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, viral infection, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

In a preferred embodiment, angiogenesis proteins are expressed in bacterial systems. Bacterial expression systems are well known in the art. Promoters from bacteriophage may also be used and are known in the art. In addition, synthetic promoters and hybrid promoters are also useful; for example, the tac promoter is a hybrid of the trp and lac promoter sequences. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. In addition to a functioning promoter sequence, an efficient ribosome binding site is desirable. The expression vector may also include a signal peptide sequence that provides for secretion of the angiogenesis protein in bacteria. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). The bacterial expression vector may also include a selectable marker gene to allow for the selection of bacterial strains that have been transformed. Suitable selection genes include genes which render the bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin, neomycin and tetracycline. Selectable markers also include biosynthetic genes, such as those in the histidine, tryptophan and leucine biosynthetic pathways. These components are assembled into expression vectors. Expression vectors for bacteria are well known in the art, and include vectors for Bacillus subtilis, E. coli, Streptococcus cremoris, and Streptococcus lividans, among others (e.g., Fernandez & Hoeffler, supra). The bacterial expression vectors are transformed into bacterial host cells using techniques well known in the art, such as calcium chloride treatment, electroporation, and others.

In one embodiment, angiogenesis proteins are produced in insect cells. Expression vectors for the transformation of insect cells, and in particular, baculovirus-based expression vectors, are well known in the art.

In a preferred embodiment, angiogenesis protein is produced in yeast cells. Yeast expression systems are well known in the art, and include expression vectors for Saccharomyces cerevisiae, Candida albicans and C. maltosa, Hansenula polymorpha, Kluyveromyces fragilis and K. lactis, Pichia guillerimondii and P. pastoris, Schizosaccharomyces pombe, and Yarrowia lipolytica.

The angiogenesis protein may also be made as a fusion protein, using techniques well known in the art. Thus, for example, for the creation of monoclonal antibodies, if the desired epitope is small, the angiogenesis protein may be fused to a carrier protein to form an immunogen. Alternatively, the angiogenesis protein may be made as a fusion protein to increase expression, or for other reasons. For example, when the angiogenesis protein is an angiogenesis peptide, the nucleic acid encoding the peptide may be linked to another nucleic acid for expression purposes. Fusion with detection epitope tags can be made, e.g., with FLAG, His 6, myc, HA, etc. In one embodiment, the angiogenesis nucleic acids, proteins and antibodies of the invention are labeled. By "labeled" herein is meant that a compound has at least one element, isotope or chemical compound attached to enable the detection of the compound. In general, labels fall into three classes: a) isotopic labels, which may be radioactive or heavy isotopes; b) immune labels, which may be antibodies, antigens, or epitope tags and c) colored or fluorescent dyes. The labels may be incorporated into the angiogenesis nucleic acids, proteins and antibodies at any position. For example, the label should be capable of producing, either directly or indirectly, a detectable signal. The detectable moiety may be a radioisotope, such as H, C, P, S, or I, a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin, or an enzyme, such as alkaline phosphatase, beta-galactosidase or horseradish peroxidase. Any method known in the art for conjugating the antibody to the label may be employed, including those methods described by Hunter et al, Nature, 144:945 (1962); David et al, Biochemistry, 13:1014 (1974); Pain et al., J. Immunol. Meth., 40:219 (1981); and Nygren, J. Histochem. and Cytochem., 30:407 (1982).

Accordingly, the present invention also provides angiogenesis protein sequences. An angiogenesis protein of the present invention may be identified in several ways. "Protein" in this sense includes proteins, polypeptides, and peptides. As will be appreciated by those in the art, the nucleic acid sequences of the invention can be used to generate protein sequences. There are a variety of ways to do this, including cloning the entire gene and verifying its frame and amino acid sequence, or by comparing it to known sequences to search for homology to provide a frame, assuming the angiogenesis protein has an identifiable motif or homology to some protein in the database being used. Generally, the nucleic acid sequences are input into a program that will search all three frames for homology. This is done in a preferred embodiment using the following NCBI Advanced

BLAST parameters. The program is blastx or blastn. The database is nr. The input data is as "Sequence in FASTA format". The organism list is "none". The "expect" is 10; the filter is default. The "descriptions" is 500, the "alignments" is 500, and the "alignment view" is pairwise. The "Query Genetic Codes" is standard (1). The matrix is BLOSUM62; gap existence cost is 11 , per residue gap cost is 1 ; and the lambda ratio is .85 default. This results in the generation of a putative protein sequence.

Also included within one embodiment of angiogenesis proteins are amino acid variants of the naturally occurring sequences, as determined herein. Preferably, the variants are preferably greater than about 75% homologous to the wild-type sequence, more preferably greater than about 80%, even more preferably greater than about 85% and most preferably greater than 90%. In some embodiments the homology will be as high as about 93 to 95 or 98%). As for nucleic acids, homology in this context means sequence similarity or identity, with identity being preferred. This homology will be determined using standard techniques well known in the art as are outlined above for the nucleic acid homologies.

Angiogenesis proteins of the present invention may be shorter or longer than the wild type amino acid sequences. Thus, in a preferred embodiment, included within the definition of angiogenesis proteins are portions or fragments of the wild type sequences, herein. In addition, as outlined above, the angiogenesis nucleic acids of the invention may be used to obtain additional coding regions, and thus additional protein sequence, using techniques known in the art.

In a preferred embodiment, the angiogenesis proteins are derivative or variant angiogenesis proteins as compared to the wild-type sequence. That is, as outlined more fully below, the derivative angiogenesis peptide will often contain at least one amino acid substitution, deletion or insertion, with amino acid substitutions being particularly preferred. The amino acid substitution, insertion or deletion may occur at any residue within the angiogenesis peptide.

Also included within one embodiment of angiogenesis proteins of the present invention are amino acid sequence variants. These variants typically fall into one or more of three classes: substitutional, insertional or deletional variants. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the angiogenesis protein, using cassette or PCR mutagenesis or other techniques well known in the art, to produce DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture as outlined above. However, variant angiogenesis protein fragments having up to about 100-150 residues may be prepared by in vitro synthesis using established techniques. Amino acid sequence variants are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the angiogenesis protein amino acid sequence. The variants typically exhibit the same qualitative biological activity as the naturally occurring analogue, although variants can also be selected which have modified characteristics as will be more fully outlined below.

While the site or region for introducing an amino acid sequence variation is predetermined, the mutation per se need not be predetermined. For example, in order to optimize the performance of a mutation at a given site, random mutagenesis may be conducted at the target codon or region and the expressed angiogenesis variants screened for the optimal combination of desired activity. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, for example, Ml 3 primer mutagenesis and PCR mutagenesis. Screening of the mutants is done using assays of angiogenesis protein activities. Amino acid substitutions are typically of single residues; insertions usually will be on the order of from about 1 to 20 amino acids, although considerably larger insertions may be tolerated. Deletions range from about 1 to about 20 residues, although in some cases deletions may be much larger.

Substitutions, deletions, insertions or any combination thereof may be used to arrive at a final derivative. Generally these changes are done on a few amino acids to minimize the alteration of the molecule. However, larger changes may be tolerated in certain circumstances. When small alterations in the characteristics of the angiogenesis protein are desired, substitutions are generally made in accordance with the amino acid substitution chart provided in the definition section. Substantial changes in function or immunological identity are made by selecting substitutions that are less conservative than those provided in the definition of "conservative substitution". For example, substitutions may be made which more significantly affect: the structure of the polypeptide backbone in the area of the alteration, for example the alpha-helical or beta-sheet structure; the charge or hydrophobicity of the molecule at the target site; or the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in the polypeptide's properties are those in which (a) a hydrophilic residue, e.g. seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, e.g. lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g. glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g. phenylalanine, is substituted for (or by) one not having a side chain, e.g. glycine.

The variants typically exhibit the same qualitative biological activity and will elicit the same immune response as the naturally-occurring analog, although variants also are selected to modify the characteristics of the angiogenesis proteins as needed. Alternatively, the variant may be designed such that the biological activity of the angiogenesis protein is altered. For example, glycosylation sites may be altered or removed.

Covalent modifications of angiogenesis polypeptides are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of an angiogenesis polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N-or C-terminal residues of an angiogenesis. polypeptide. Derivatization with bifunctional agents is useful, for instance, for crosslinking angiogenesis polypeptides to a water-insoluble support matrix or surface for use in the method for purifying anti-angiogenesis polypeptide antibodies or screening assays, as is more fully described below. Commonly used crosslinking agents include, e.g., 1,1- bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N- maleimido-l,8-octane and agents such as methyl-3-[(p-azidophenyl)dithio]propioimidate. Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl, threonyl or tyrosyl residues, methylation of the γ-amino groups of lysine, arginine, and histidine side chains [T.E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San

Francisco, pp. 79-86 (1983)], acetylation of the N-terminal amine, and amidation of any C- terminal carboxyl group.

Another type of covalent modification of the angiogenesis polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence angiogenesis polypeptide, and/or adding one or more glycosylation sites that are not present in the native sequence angiogenesis polypeptide. Glycosylation patterns can be altered in many ways. For example the use of different cell types to express angiogenesis-associated sequences can result in different glycosylation patterns.

Addition of glycosylation sites to angiogenesis polypeptides may also be accomplished by altering the amino acid sequence thereof. The alteration may be made, for example, by the addition of, or substitution by, one or more serine or threonine residues to the native sequence angiogenesis polypeptide (for O-linked glycosylation sites). The angiogenesis amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the angiogenesis polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids. Another means of increasing the number of carbohydrate moieties on the angiogenesis polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, CRC Grit. Rev. Biochem., pp. 259-306 (1981). Removal of carbohydrate moieties present on the angiogenesis polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo-and exo-glycosidases as described by Thotakura et al., Meth. Enzymol., 138:350 (1987).

Another type of covalent modification of angiogenesis comprises linking the angiogenesis polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

Angiogenesis polypeptides of the present invention may also be modified in a way to form chimeric molecules comprising an angiogenesis polypeptide fused to another, heterologous polypeptide or amino acid sequence. In one embodiment, such a chimeric molecule comprises a fusion of an angiogenesis polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino-or carboxyl-terminus of the angiogenesis polypeptide. The presence of such epitope-tagged forms of an angiogenesis polypeptide can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the angiogenesis polypeptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. In an alternative embodiment, the chimeric molecule may comprise a fusion of an angiogenesis polypeptide with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule, such a fusion could be to the Fc region of an IgG molecule. Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; HIS6 and metal chelation tags, the flu HA tag polypeptide and its antibody 12CA5 [Field et al, Mol Cell Biol, 8:2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto [Evan et al, Molecular and Cellular Biology, 5:3610-3616 (1985)]; and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody [Paborsky et al, Protein Engineering, 3(6):547-553 (1990)]. Other tag polypeptides include the Flag-peptide [Hopp et al, BioTechnology, 6:1204-1210 (1988)]; the KT3 epitope peptide [Martin et al, Science, 255:192-194 (1992)]; tubulin epitope peptide [Skinner et al, J. Biol. Chem., 266:15163-15166 (1991)]; and the T7 gene 10 protein peptide tag [Lutz-Freyermuth et al, Proc Natl. Acad. Sci. USA, 87:6393-6397 (1990)].

Also included with an embodiment of angiogenesis protein are other angiogenesis proteins of the angiogenesis family, and angiogenesis proteins from other organisms, which are cloned and expressed as outlined below. Thus, probe or degenerate polymerase chain reaction (PCR) primer sequences may be used to find other related angiogenesis proteins from humans or other organisms. As will be appreciated by those in the art, particularly useful probe and/or PCR primer sequences include the unique areas of the angiogenesis nucleic acid sequence. As is generally known in the art, preferred PCR primers are from about 15 to about 35 nucleotides in length, with from about 20 to about 30 being preferred, and may contain inosine as needed. The conditions for the PCR reaction are well known in the art (e.g., Innis, PCR Protocols, supra).

In addition, as is outlined herein, angiogenesis proteins can be made that are longer than those encoded by the nucleic acids of the figures, e.g., by the elucidation of extended sequences, the addition of epitope or purification tags, the addition of other fusion sequences, etc.

Angiogenesis proteins may also be identified as being encoded by angiogenesis nucleic acids. Thus, angiogenesis proteins are encoded by nucleic acids that will hybridize to the sequences of the sequence listings, or their complements, as outlined herein. In a preferred embodiment, when the angiogenesis protein is to be used to generate antibodies, e.g., for immunotherapy or immunodiagnosis, the angiogenesis protein should share at least one epitope or determinant with the full length protein. By "epitope" or "determinant" herein is typically meant a portion of a protein which will generate and/or bind an antibody or T-cell receptor in the context of MHC. Thus, in most instances, antibodies made to a smaller angiogenesis protein will be able to bind to the full-length protein, particularly linear epitopes. In a preferred embodiment, the epitope is unique; that is, antibodies generated to a unique epitope show little or no cross-reactivity. In a preferred embodiment, the epitope is selected from a protein sequence set out in Table 8. Methods of preparing polyclonal antibodies are known to the skilled artisan (e.g., Coligan, supra; and Harlow & Lane, supra). Polyclonal antibodies can be raised in a mammal, e.g., by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include a protein encoded by a nucleic acid of the figures or fragment thereof or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art without undue experimentation.

The antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized in vitro. The immunizing agent will typically include a polypeptide encoded by a nucleic acid of Tables 1- 8 , or fragment thereof, or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103]. Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells. In one embodiment, the antibodies are bispecific antibodies. Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens or that have binding specificities for two epitopes on the same antigen. In one embodiment, one of the binding specificities is for a protein encoded by a nucleic acid Tables 1-8 or a fragment thereof, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit, preferably one that is tumor specific. Alternatively, tetramer-type technology may create multivalent reagents.

In a preferred embodiment, the antibodies to angiogenesis protein are capable of reducing or eliminating a biological function of an angiogenesis protein, as is described below. That is, the addition of anti-angiogenesis protein antibodies (either polyclonal or preferably monoclonal) to angiogenic tissue (or cells containing angiogenesis) may reduce or eliminate the angiogenesis activity. Generally, at least a 25% decrease in activity is preferred, with at least about 50% being particularly preferred and about a 95-100% decrease being especially preferred.

In a preferred embodiment the antibodies to the angiogenesis proteins are humanized antibodies (e.g., Xenerex Biosciences, Mederex, Inc., Abgenix, Inc., Protein Design Labs,Inc.) Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues form a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non- human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework (FR) regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)].

Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as import residues, which are typically taken from an import variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non- human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)]. The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al., J. Immunol., 147(l):86-95 (1991)]. Similarly, human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al., Bio/Technology 10, 779-783 (1992); Lonberg et al., Nature 368 856-859 (1994); Morrison, Nature 368, 812-13 (1994); Fishwild et al., Nature Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology 14, 826 (1996); Lonberg and Huszar, Intern. Rev. Immunol. 13 65-93 (1995).

By immunotherapy is meant treatment of angiogenesis with an antibody raised against angiogenesis proteins. As used herein, immunotherapy can be passive or active. Passive immunotherapy as defined herein is the passive transfer of antibody to a recipient (patient). Active immunization is the induction of antibody and or T-cell responses in a recipient (patient). Induction of an immune response is the result of providing the recipient with an antigen to which antibodies are raised. As appreciated by one of ordinary skill in the art, the antigen may be provided by injecting a polypeptide against which antibodies are desired to be raised into a recipient, or contacting the recipient with a nucleic acid capable of expressing the antigen and under conditions for expression of the antigen, leading to an immune response.

In a preferred embodiment the angiogenesis proteins against which antibodies are raised are secreted proteins as described above. Without being bound by theory, antibodies used for treatment, bind and prevent the secreted protein from binding to its receptor, thereby inactivating the secreted angiogenesis protein.

In another preferred embodiment, the angiogenesis protein to which antibodies are raised is a transmembrane protein. Without being bound by theory, antibodies used for treatment, bind the extracellular domain of the angiogenesis protein and prevent it from binding to other proteins, such as circulating ligands or cell-associated molecules. The antibody may cause down-regulation of the transmembrane angiogenesis protein. As will be appreciated by one of ordinary skill in the art, the antibody may be a competitive, non- competitive or uncompetitive inhibitor of protein binding to the extracellular domain of the angiogenesis protein. The antibody is also an antagonist of the angiogenesis protein. Further, the antibody prevents activation of the transmembrane angiogenesis protein. In one aspect, when the antibody prevents the binding of other molecules to the angiogenesis protein, the antibody prevents growth of the cell. The antibody may also be used to target or sensitize the cell to cytotoxic agents, including, but not limited to TNF-α, TNF-β, IL-1, INF-γ and IL-2, or chemotherapeutic agents including 5FU, vinblastine, actinomycin D, cisplatin, methotrexate, and the like. In some instances the antibody belongs to a sub-type that activates serum complement when complexed with the transmembrane protein thereby mediating cytotoxicity or antigen-dependent cytotoxicity (ADCC). Thus, angiogenesis is treated by administering to a patient antibodies directed against the transmembrane angiogenesis protein. Antibody-labeling may activate a co-toxin, localize a toxin payload, or otherwise provide means to locally ablate cells.

In another preferred embodiment, the antibody is conjugated or fused to an effector moiety. The effector moiety can be any number of molecules, including labelling moieties such as radioactive labels or fluorescent labels, or can be a therapeutic moiety. In one aspect the therapeutic moiety is a small molecule that modulates the activity of the angiogenesis protein. In another aspect the therapeutic moiety modulates the activity of molecules associated with or in close proximity to the angiogenesis protein. The therapeutic moiety may inhibit enzymatic activity such as protease or coUagenase activity associated with angiogenesis, or be an attractant of other cells, such as NK cells.

In a preferred embodiment, the therapeutic moiety can also be a cytotoxic agent. In this method, targeting the cytotoxic agent to angiogenesis tissue or cells, results in a reduction in the number of afflicted cells, thereby reducing symptoms associated with angiogenesis. Cytotoxic agents are numerous and varied and include, but are not limited to, cytotoxic drugs or toxins or active fragments of such toxins. Suitable toxins and their corresponding fragments include diphtheria A chain, exotoxin A chain, ricin A chain, abrin A chain, curcin, crotin, phenomycin, enomycin and the like. Cytotoxic agents also include radiochemicals made by conjugating radioisotopes to antibodies raised against angiogenesis proteins, or binding of a radionuclide to a chelating agent that has been covalently attached to the antibody. Targeting the therapeutic moiety to transmembrane angiogenesis proteins not only serves to increase the local concentration of therapeutic moiety in the angiogenesis afflicted area, but also serves to reduce deleterious side effects that may be associated with the therapeutic moiety.

In another preferred embodiment, the angiogenesis protein against which the antibodies are raised is an intracellular protein. In this case, the antibody may be conjugated or fused to a protein which facilitates entry into the cell. In one case, the antibody enters the cell by endocytosis. In another embodiment, a nucleic acid encoding the antibody is administered to the individual or cell. Moreover, wherein the angiogenesis protein can be targeted within a cell, i.e., the nucleus, an antibody thereto contains a signal for that target localization, i.e., a nuclear localization signal.

The angiogenesis antibodies of the invention specifically bind to angiogenesis proteins. By "specifically bind" herein is meant that the antibodies bind to the protein with a K_d of at least about 0.1 mM, more usually at least about 1 μM, preferably at least about 0.1 μM or better, and most preferably, 0.01 μM or better. Selectivity of binding is also important.

In a preferred embodiment, the angiogenesis protein is purified or isolated after expression. Angiogenesis proteins may be isolated or purified in a variety of ways known to those skilled in the art depending on what other components are present in the sample. Standard purification methods include electrophoretic, molecular, immunological and chromato graphic techniques, including ion exchange, hydrophobic, affinity, and reverse- phase HPLC chromatography, and chromatofocusing. For example, the angiogenesis protein may be purified using a standard anti-angiogenesis protein antibody column. Ultrafiltration and diafiltration techniques, in conjunction with protein concentration, are also useful. For general guidance in suitable purification techniques, see Scopes, R., Protein Purification, Springer- Verlag, NY (1982). The degree of purification necessary will vary depending on the use of the angiogenesis protein. In some instances no purification will be necessary. Once expressed and purified if necessary, the angiogenesis proteins and nucleic acids are useful in a number of applications. They may be used as immunoselection reagents, as vaccine reagents, as screening agents, etc.

Detection of angiogenesis sequence for diagnostic and therapeutic applications

In one aspect, the RNAexpression levels of genes are determined for different cellular states in the angiogenesis phenotype. Expression levels of genes in normal tissue (i.e., not undergoing angiogenesis) and in angiogenesis tissue (and in some cases, for varying severities of angiogenesis that relate to prognosis, as outlined below) are evaluated to provide expression profiles. An expression profile of a particular cell state or point of development is essentially a "fingerprint" of the state. While two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is reflective of the state of the cell. By comparing expression profiles of cells in different states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained. Then, diagnosis may be performed or confirmed to determine whether a tissue sample has the gene expression profile of normal or angiogenesic tissue. This will provide for molecular diagnosis of related conditions.

"Differential expression," or grammatical equivalents as used herein, refers to qualitative or quantitative differences in the temporal and/or cellular gene expression patterns within and among cells and tissue. Thus, a differentially expressed gene can qualitatively have its expression altered, including an activation or inactivation, in, e.g., normal versus angiogenic tissue. Genes may be turned on or turned off in a particular state, relative to another state thus permitting comparison of two or more statese. A qualitatively regulated gene will exhibit an expression pattern within a state or cell type which is detectable by standard techniques. Some genes will be expressed in one state or cell type, but not in both. Alternatively, the difference in expression may be quantitative, e.g., in that expression is increased or decreased; i.e., gene expression is either upregulated, resulting in an increased amount of transcript, or downregulated, resulting in a decreased amount of transcript. The degree to which expression differs need only be large enough to quantify via standard characterization techniques as outlined below, such as by use of Affymetrix GeneChip™ expression arrays, Lockhart, Nature Biotechnology, 14: 1675- 1680 (1996), hereby expressly incorporated by reference. Other techniques include, but are not limited to, quantitative reverse transcriptase PCR, Northern analysis and RNase protection. As outlined above, preferably the change in expression (i.e., upregulation or downregulation) is at least about 50%, more preferably at least about 100%, more preferably at least about 150%, more preferably at least about 200%, with from 300 to at least 1000%) being especially preferred. Evaluation may be at the gene transcript, or the protein level. The amount of gene expression may be monitored using nucleic acid probes to the DNA or RNA equivalent of the gene transcript, and the quantification of gene expression levels, or, alternatively, the final gene product itself (protein) can be monitored, e.g., with antibodies to the angiogenesis protein and standard immunoassays (ELIS As, etc.) or other techniques, including mass spectroscopy assays, 2D gel electrophoresis assays, etc. Proteins corresponding to angiogenesis genes, i.e., those identified as being important in an angiogenesis phenotype, can be evaluated in an angiogenesis diagnostic test.

In a preferred embodiment, gene expression monitoring is performed simultaneously on a number of genes. Multiple protein expression monitoring can be performed as well. Similarly, these assays may be performed on an individual basis as well.

In this embodiment, the angiogenesis nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of angiogenesis sequences in a particular cell. The assays are further described below in the example. PCR techniques can be used to provide greater sensitivity.

In a preferred embodiment nucleic acids encoding the angiogenesis protein are detected. Although DNA or RNA encoding the angiogenesis protein may be detected, of particular interest are methods wherein an mRNA encoding an angiogenesis protein is detected. Probes to detect mRNA can be a nucleotide/deoxynucleotide probe that is complementary to and hybridizes with the mRNA and includes, but is not limited to, oligonucleotides, cDNA or RNA. Probes also should contain a detectable label, as defined herein. In one method the mRNA is detected after immobilizing the nucleic acid to be examined on a solid support such as nylon membranes and hybridizing the probe with the sample. Following washing to remove the non-specifically bound probe, the label is detected. In another method detection of the mRNA is performed in situ. In this method permeabilized cells or tissue samples are contacted with a detectably labeled nucleic acid probe for sufficient time to allow the probe to hybridize with the target mRNA. Following washing to remove the non-specifically bound probe, the label is detected. For example a digoxygenin labeled riboprobe (RNA probe) that is complementary to the mRNA encoding ^' an angiogenesis protein is detected by binding the digoxygenin with an anti-digoxygenin secondary antibody and developed with nitro blue tetrazolium and 5-bromo-4-chloro-3- indoyl phosphate.

In a preferred embodiment, various proteins from the three classes of proteins as described herein (secreted, transmembrane or intracellular proteins) are used in diagnostic assays. The angiogenesis proteins, antibodies, nucleic acids, modified proteins and cells containing angiogenesis sequences are used in diagnostic assays. This can be performed on an individual gene or corresponding polypeptide level. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow momtoring for expression profile genes and/or corresponding polypeptides.

As described and defined herein, angiogenesis proteins, including intracellular, transmembrane or secreted proteins, find use as markers of angiogenesis. Detection of these proteins in putative angiogenesis tissue allows for detection or diagnosis of angiogenesis. In one embodiment, antibodies are used to detect angiogenesis proteins. A preferred method separates proteins from a sample by electrophoresis on a gel (typically a denaturing and reducing protein gel, but may be another type of gel, including isoelectric focusing gels and the like). Following separation of proteins, the angiogenesis protein is detected, e.g., by immunoblotting with antibodies raised against the angiogenesis protein. Methods of immunoblotting are well known to those of ordinary skill in the art.

In another preferred method, antibodies to the angiogenesis protein find use in in situ imaging techniques, e.g., in histology (e.g., Methods in Cell Biology: Antibodies in Cell Biology, volume 37 (Asai, ed. 1993)). In this method cells are contacted with from one to many antibodies to the angiogenesis protein(s). Following washing to remove non-specific antibody binding, the presence of the antibody or antibodies is detected. In one embodiment the antibody is detected by incubating with a secondary antibody that contains a detectable label. In another method the primary antibody to the angiogenesis protein(s) contains a detectable label, for example an enzyme marker that can act on a substrate. In another preferred embodiment each one of multiple primary antibodies contains a distinct and detectable label. This method finds particular use in simultaneous screening for a plurality of angiogenesis proteins. As will be appreciated by one of ordinary skill in the art, many other histological imaging techniques are alsoprovided by the invention.

In a preferred embodiment the label is detected in a fluorometer which has the ability to detect and distinguish emissions of different wavelengths. In addition, a fluorescence activated cell sorter (FACS) can be used in the method.

In another preferred embodiment, antibodies find use in diagnosing angiogenesis from biological samples, such as blood, urine, sputum, or other bodily fluids. As previously described, certain angiogenesis proteins are secreted/circulating molecules. Blood samples, therefore, are useful as samples to be probed or tested for the presence of secreted angiogenesis proteins. Antibodies can be used to detect an angiogenesis protein by previously described immunoassay techniques including ELISA, immunoblotting (Western blotting), immunoprecipitation, BIACORE technology and the like. Conversely, the presence of antibodies may indicate an immune response against an endogenous angiogenesis protein. In a preferred embodiment, in situ hybridization of labeled angiogenesis nucleic acid probes to tissue arrays is done. For example, arrays of tissue samples, including angiogenesis tissue and/or normal tissue, are made. In situ hybridization (see, e.g., Ausubel, supra) is then performed. When comparing the fingerprints between an individual and a standard, the skilled artisan can make a diagnosis, a prognosis, or a prediction based on the findings. It is further understood that the genes which indicate the diagnosis may differ from those which indicate the prognosis and molecular profiling of the condition of the cells may lead to distinctions between responsive or refractory conditions or may be predictive of outcomes.

In a preferred embodiment, the angiogenesis proteins, antibodies, nucleic acids, modified proteins and cells containing angiogenesis sequences are used in prognosis assays. As above, gene expression profiles can be generated that correlate to angiogenesis severity, in terms of long term prognosis. Again, this may be done on either a protein or gene level, with the use of genes being preferred. As above, angiogenesis probes may be attached to biochips for the detection and quantification of angiogenesis sequences in a tissue or patient. The assays proceed as outlined above for diagnosis. PCR method may provide more sensitive and accurate quantification.

In a preferred embodiment members of the three classes of proteins as described herein are used in drug screening assays. The angiogenesis proteins, antibodies, nucleic acids, modified proteins and cells containing angiogenesis sequences are used in drug screening assays or by evaluating the effect of drug candidates on a "gene expression profile" or expression profile of polypeptides. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent (e.g., Zlokarnik, et al., Science 279, 84-8 (1998); Heid, Genome Res 6:986-94, 1996).

In a preferred embodiment, the angiogenesis proteins, antibodies, nucleic acids, modified proteins and cells containing the native or modified angiogenesis proteins are used in screening assays. That is, the present invention provides novel methods for screening for compositions which modulate the angiogenesis phenotype or an identified physiological function of an angiogenesis protein. As above, this can be done on an individual gene level or by evaluating the effect of drug candidates on a "gene expression profile". In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent, see Zlokarnik, supra. Having identified the differentially expressed genes herein, a variety of assays may be executed. In a preferred embodiment, assays may be run on an individual gene or protein level. That is, having identified a particular gene as up regulated in angiogenesis, test compounds can be screened for the ability to modulate gene expression or for binding to the angiogenic protein. "Modulation" thus includes both an increase and a decrease in gene expression. The preferred amount of modulation will depend on the original change of the gene expression in normal versus tissue undergoing angiogenesis, with changes of at least 10%, preferably 50%>, more preferably 100-300%, and in some embodiments 300-1000% or greater. Thus, if a gene exhibits a 4-fold increase in angiogenic tissue compared to normal tissue, a decrease of about four-fold is often desired; similarly, a 10-fold decrease in angiogenic tissue compared to normal tissue often provides a target value of a 10-fold increase in expression to be induced by the test compound.

The amount of gene expression may be monitored using nucleic acid probes and the quantification of gene expression levels, or, alternatively, the gene product itself can be monitored, e.g., through the use of antibodies to the angiogenesis protein and standard immunoassays. Proteomics and separation techniques may also allow quantification of expression.

In a preferred embodiment, gene expression or protein monitoring of a number of entitites, i.e., an expression profile, is monitored simultaneously. Such profiles will typically invove a plurality of those entitites described herein.. In this embodiment, the angiogenesis nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of angiogenesis sequences in a particular cell. Alternatively, PCR may be used. Thus, a series, e.g., of microtiter plate, may be used with dispensed primers in desired wells. A PCR reaction can then be performed and analyzed for each well.

Modulators of angiogenesis

Expression momtoring can be performed to identify compounds that modify the expression of one or more angiogenesis-associated sequences, e.g., a polynucleotide sequence set out in Tables 1-8 . Generally, in a preferred embodiment, a test modulator is added to the cells prior to analysis. Moreover, screens are also provided to identify agents that modulate angiogenesis, modulate angiogenesis proteins, bind to an angiogenesis protein, or interfere with the binding of an angiogenesis protein and an antibody or other binding partner. The term "test compound" or "drug candidate" or "modulator" or grammatical equivalents as used herein describes any molecule, e.g., protein, oligopeptide, small organic molecule, polysaccharide, polynucleotide, etc., to be tested for the capacity to directly or indirectly alter the angiogenesis phenotype or the expression of an angiogenesis sequence, e.g. , a nucleic acid or protein sequence. In preferred embodiments, modulators alter expression profiles, or expression profile nucleic acids or proteins provided herein. In one embodiment, the modulator suppresses an angiogenesis phenotype, for example to a normal tissue fingerprint. In another embodiment, a modulator induced an angiogenesis phenotype. Generally, a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration or below the level of detection.

In one aspect, a modulator will neutralize the effect of an angiogenesis protein. By "neutralize" is meant that activity of a protein is inhibited or blocked and thereby has substantially no effect on a cell. In certain embodiments, combinatorial libraries of potential modulators will be screened for an ability to bind to an angiogenesis polypeptide or to modulate activity. Conventionally, new chemical entities with useful properties are generated by identifying a chemical compound (called a "lead compound") with some desirable property or activity, e.g., inhibiting activity, creating variants of the lead compound, and evaluating the property and activity of those variant compounds. Often, high throughput screening (HTS) methods are employed for such an analysis.

In one preferred embodiment, high throughput screening methods involve providing a library containing a large number of potential therapeutic compounds (candidate compounds). Such "combinatorial chemical libraries" are then screened in one or more assays to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional "lead compounds" or can themselves be used as potential or actual therapeutics. A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis by combining a number of chemical "building blocks" such as reagents. For example, a linear combinatorial chemical library, such as a polypeptide (e.g., mutein) library, is formed by combining a set of chemical building blocks called amino acids in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks (Gallop et al (1994) J. Med. Chem. 37(9): 1233-1251).

Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Patent No. 5,010,175, Furka (1991) Int. J. Pept Prot Res., 37: 487-493, Houghton et al (1991) Nature, 354: 84-88), peptoids (PCT Publication No WO 91/19735, 26 Dec. 1991), encoded peptides (PCT Publication WO 93/20242, 14 Oct. 1993), random bio-oligomers (PCT Publication WO 92/00091, 9 Jan. 1992), benzodiazepines (U.S. Pat. No. 5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs et al, (1993) Proc. Nat. Acad. Sci. USA 90: 6909-6913), vinylogous polypeptides (Hagihara et al. (1992) J. Amer. Chem. Soc. 114: 6568), nonpeptidal peptidomimetics with a Beta-D- Glucose scaffolding (Hirschmann et al, (1992) J. Amer. Chem. Soc. 114: 9217-9218), analogous organic syntheses of small compound libraries (Chen et al. (1994) J. Amer. Chem. Soc. 116: 2661), oligocarbamates (Cho, et al., (1993) Science 261:1303), and/or peptidyl phosphonates (Campbell et al, (1994) J. Org. Chem. 59: 658). See, generally, Gordon et al, (1994) J. Med. Chem. 37:1385, nucleic acid libraries (see, e.g., Strategene, Corp.), peptide nucleic acid libraries (see, e.g., U.S. Patent 5,539,083), antibody libraries (see, e.g., Vaughn et al (1996) Nature Biotechnology, 14(3): 309-314), and PCT/US96/10287), carbohydrate libraries (see, e.g., Liang et al, (1996) Science, 27 A: 1520-1522, and U.S. Patent No. 5,593,853), and small organic molecule libraries (see, e.g., benzodiazepines, Baum (1993) C&EN, Jan 18, page 33; isoprenoids, U.S. Patent No. 5,569,588; thiazolidinones and metathiazanones, U.S. Patent No. 5,549,974; pyrrolidines, U.S. Patent Nos. 5,525,735 and 5,519,134; morpholino compounds, U.S. Patent No. 5,506,337; benzodiazepines, U.S. Patent No. 5,288,514; and the like). Devices for the preparation of combinatorial libraries are commercially available (see, e.g., 357 MPS, 390 MPS, Advanced Chem Tech, Louisville KY, Symphony, Rainin, Woburn, MA, 433A Applied Biosystems, Foster City, CA, 9050 Plus, Millipore, Bedford, MA).

A number of well known robotic systems have also been developed for solution phase chemistries. These systems include automated workstations like the automated synthesis apparatus developed by Takeda Chemical Industries, LTD. (Osaka, Japan) and many robotic systems utilizing robotic arms (Zymate II, Zymark Corporation, Hopkinton, Mass.; Orca, Hewlett-Packard, Palo Alto, Calif), which mimic the manual synthetic operations performed by a chemist. Any of the above devices are suitable for use with the present invention. The nature and implementation of modifications to these devices (if any) so that they can operate as discussed herein will be apparent to persons skilled in the relevant art. In addition, numerous combinatorial libraries are themselves commercially available (see, e.g., ComGenex, Princeton, N.J., Asinex, Moscow, Ru, Tripos, Inc., St. Louis, MO, ChemStar, Ltd, Moscow, RU, 3D Pharmaceuticals, Exton, PA, Martek Biosciences, Columbia, MD, etc.).

The assays to identify modulators are amenable to high throughput screening. Preferred assays thus detect enhancement or inhibition of angiogenesis gene transcription, inhibition or enhancement of polypeptide expression, and inhibition or enhancement of polypeptide activity. High throughput assays for the presence, absence, quantification, or other properties of particular nucleic acids or protein products are well known to those of skill in the art. Similarly, binding assays and reporter gene assays are similarly well known. Thus, for example, U.S. Patent No. 5,559,410 discloses high throughput screening methods for proteins, U.S. Patent No. 5,585,639 discloses high throughput screening methods for nucleic acid binding (i.e., in arrays), while U.S. Patent Nos. 5,576,220 and 5,541,061 disclose high throughput methods of screening for ligand/antibody binding.

In addition, high throughput screening systems are commercially available (see, e.g., Zymark Corp., Hopkinton, MA; Air Technical Industries, Mentor, OH; Beckman Instruments, Inc. Fullerton, CA; Precision Systems, Inc., Natick, MA, etc.). These systems typically automate entire procedures, including all sample and reagent pipetting, liquid dispensing, timed incubations, and final readings of the microplate in detector(s) appropriate for the assay. These configurable systems provide high throughput and rapid start up as well as a high degree of flexibility and customization. The manufacturers of such systems provide detailed protocols for various high throughput systems. Thus, for example, Zymark Corp. provides technical bulletins describing screening systems for detecting the modulation of gene transcription, ligand binding, and the like.

In one embodiment, modulators are proteins, often naturally occurring proteins or fragments of naturally occurring proteins. Thus, e.g., cellular extracts containing proteins, or random or directed digests of proteinaceous cellular extracts, may be used. In this way libraries of proteins may be made for screening in the methods of the invention. Particularly preferred in this embodiment are libraries of bacterial, fungal, viral, and mammalian proteins, with the latter being preferred, and human proteins being especially preferred. Paticularly useful test compound will be directed to the class of proteins to which the target belongs, e.g., substrates for enzymes or ligands and receptors.

In a preferred embodiment, modulators are peptides of from about 5 to about 30 amino acids, with from about 5 to about 20 amino acids being preferred, and from about 7 to about 15 being particularly preferred. The peptides may be digests of naturally occurring proteins as is outlined above, random peptides, or "biased" random peptides. By "randomized" or grammatical equivalents herein is meant that each nucleic acid and peptide consists of essentially random nucleotides and amino acids, respectively. Since generally these random peptides (or nucleic acids, discussed below) are chemically synthesized, they may incorporate any nucleotide or amino acid at any position. The synthetic process can be designed to generate randomized proteins or nucleic acids, to allow the formation of all or most of the possible combinations over the length of the sequence, thus forming a library of randomized candidate bioactive proteinaceous agents.

In one embodiment, the library is fully randomized, with no sequence preferences or constants at any position. In a preferred embodiment, the library is biased. That is, some positions within the sequence are either held constant, or are selected from a limited number of possibilities. For example, in a preferred embodiment, the nucleotides or amino acid residues are randomized within a defined class, for example, of hydrophobic amino acids, hydrophilic residues, sterically biased (either small or large) residues, towards the creation of nucleic acid binding domains, the creation of cysteines, for cross-linking, prolines for SH-3 domains, serines, threonines, tyrosines or histidines for phosphorylation sites, etc., or to purines, etc.

Modulators of angiogenesis can also be nucleic acids, as defined above.

As described above generally for proteins, nucleic acid modulating agents may be naturally occurring nucleic acids, random nucleic acids, or "biased" random nucleic acids. For example, digests of procaryotic or eucaryotic genomes may be used as is outlined above for proteins.

In a preferred embodiment, the candidate compounds are organic chemical moieties, a wide variety of which are available in the literature. After the candidate agent has been added and the cells allowed to incubate for some period of time, the sample containing a target sequence to be analyzed is added to the biochip. If required, the target sequence is prepared using known techniques. For example, the sample may be treated to lyse the cells, using known lysis buffers, electroporation, etc., with purification and/or amplification such as PCR performed as appropriate. For example, an in vitro transcription with labels covalently attached to the nucleotides is performed. Generally, the nucleic acids are labeled with biotin-FITC or PE, or with cy3 or cy5.

In a preferred embodiment, the target sequence is labeled with, for example, a fluorescent, a chemiluminescent, a chemical, or a radioactive signal, to provide a means of detecting the target sequence's specific binding to a probe. The label also can be an enzyme, such as, alkaline phosphatase or horseradish peroxidase, which when provided with an appropriate substrate produces a product that can be detected. Alternatively, the label can be a labeled compound or small molecule, such as an enzyme inhibitor, that binds but is not catalyzed or altered by the enzyme. The label also can be a moiety or compound, such as, an epitope tag or biotin which specifically binds to streptavidin. For the example of biotin, the streptavidin is labeled as described above, thereby, providing a detectable signal for the bound target sequence. Unbound labeled streptavidin is typically removed prior to analysis.

As will be appreciated by those in the art, these assays can be direct hybridization assays or can comprise "sandwich assays", which include the use of multiple probes, as is generally outlined in U.S. Patent Nos. 5,681,702, 5,597,909, 5,545,730, 5,594,117, 5,591,584, 5,571,670, 5,580,731, 5,571,670, 5,591,584, 5,624,802, 5,635,352, 5,594,118, 5,359,100, 5,124,246 and 5,681,697, all of which are hereby incorporated by reference. In this embodiment, in general, the target nucleic acid is prepared as outlined above, and then added to the biochip comprising a plurality of nucleic acid probes, under conditions that allow the formation of a hybridization complex. A variety of hybridization conditions may be used in the present invention, including high, moderate and low stringency conditions as outlined above. The assays are generally run under stringency conditions which allows formation of the label probe hybridization complex only in the presence of target. Stringency can be controlled by altering a step parameter that is a thermodynamic variable, including, but not limited to, temperature, formamide concentration, salt concentration, chaotropic salt concentration pH, organic solvent concentration, etc.

These parameters may also be used to control non-specific binding, as is generally outlined in U.S. Patent No. 5,681,697. Thus it may be desirable to perform certain steps at higher stringency conditions to reduce non-specific binding.

The reactions outlined herein may be accomplished in a variety of ways. Components of the reaction may be added simultaneously, or sequentially, in different orders, with preferred embodiments outlined below. In addition, the reaction may include a variety of other reagents. These include salts, buffers, neutral proteins, e.g. albumin, detergents, etc. which may be used to facilitate optimal hybridization and detection, and/or reduce nonspecific or background interactions. Reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may also be used as appropriate, depending on the sample preparation methods and purity of the target.

The assay data are analyzed to determine the expression levels, and changes in expression levels as between states, of individual genes, forming a gene expression profile.

Screens are performed to identify modulators of the angiogenesis phenotype. In one embodiment, screening is performed to identify modulators that can induce or suppress a particular expression profile, thus preferably generating the associated phenotype. In another embodiment, e.g., for diagnostic applications, having identified differentially expressed genes important in a particular state, screens can be performed to identify modulators that alter expression of individual genes. In an another embodiment, screening is performed to identify modulators that alter a biological function of the expression product of a differentially expressed gene. Again, having identified the importance of a gene in a particular state, screens are performed to identify agents that bind and/or modulate the biological activity of the gene product.

In addition screens can be done for genes that are induced in response to a candidate agent. After identifying a modulator based upon its ability to suppress an angiogenesis expression pattern leading to a normal expression pattern, or to modulate a single angiogenesis gene expression profile so as to mimic the expression of the gene from normal tissue, a screen as described above can be performed to identify genes that are specifically modulated in response to the agent. Comparing expression profiles between normal tissue and agent treated angiogenesis tissue reveals genes that are not expressed in normal tissue or angiogenesis tissue, but are expressed in agent treated tissue. These agent- specific sequences can be identified and used by methods described herein for angiogenesis genes or proteins. In particular these sequences and the proteins they encode find use in marking or identifying agent treated cells. In addition, antibodies can be raised against the agent induced proteins and used to target novel therapeutics to the treated angiogenesis tissue sample. Thus, in one embodiment, a test compound is administered to a population of angiogenic cells, that have an associated angiogenesis expression profile. By "administration" or "contacting" herein is meant that the candidate agent is added to the cells in such a manner as to allow the agent to act upon the cell, whether by uptake and intracellular action, or by action at the cell surface. In some embodiments, nucleic acid encoding a proteinaceous candidate agent (i. e. , a peptide) may be put into a viral construct such as an adenoviral or retroviral construct, and added to the cell, such that expression of the peptide agent is accomplished, e.g., PCT US97/01019. Regulatable gene therapy systems can also be used.

Once the test compound has been admimstered to the cells, the cells can be washed if desired and are allowed to incubate under preferably physiological conditions for some period of time. The cells are then harvested and a new gene expression profile is generated, as outlined herein.

Thus, for example, angiogenesis tissue may be screened for agents that modulate, e.g., induce or suppress the angiogenesis phenotype. A change in at least one gene, preferably many, of the expression profile indicates that the agent has an effect on angiogenesis activity. By defining such a signature for the angiogenesis phenotype, screens for new drugs that alter the phenotype can be devised. With this approach, the drug target need not be known and need not be represented in the original expression screening platform, nor does the level of transcript for the target protein need to change. Measure of angiogenesis polypeptide activity, or of angiogenesis or the angiogenic phenotype can be performed using a variety of assays. For example, the effects of the test compounds upon the function of the anagiogenesis polypeptides can be measured by examining parameters described above. A suitable physiological change that affects activity can be used to assess the influence of a test compound on the polypeptides of this invention. When the functional consequences are determined using intact cells or animals, one can also measure a variety of effects such as, in the case of angiogenesis associated with tumors, tumor growth, neovascularization, hormone release, transcriptional changes to both known and uncharacterized genetic markers (e.g., northern blots), changes in cell metabolism such as cell growth or pH changes, and changes in intracellular second messengers such as cGMP. In the assays of the invention, mammalian angiogenesis polypeptide is typically used, e.g., mouse, preferably human.

A variety of angiogenesis assays are known to those of skill in the art. Various models have been employed to evaluate angiogenesis (e.g., Croix et al, Science 289:1197- 1202, 2000 and Kahn et al, Amer. J. Pathol. 156:1887-1900). Assessement of angiogenesis in the presence of a potential modulator of angiogenesis can be performed using cell-cultre- based angiogenesis assays, e.g., endothelial cell tube formation assays, as well as other bioassays such as the chick CAM assay, the mouse corneal assay, and assays measuring the effect of administering potential modulators on implanted tumors. The chick CAM assay is described by O'Reilly, et al. Cell 79: 315-328, 1994. Briefly, 3 day old chicken embryos with intact yolks are separated from the egg and placed in a petri dish. After 3 days of incubation, a methylcellulose disc containing the protein to be tested is applied to the CAM of individual embryos. After about 48 hours of incubation, the embryos and CAMs are observed to determine whether endothelial growth has been inhibited. The mouse corneal assay involves implanting a growth factor-containing pellet, along with another pellet containing the suspected endothelial growth inhibitor, in the cornea of a mouse and observing the pattern of capillaries that are elaborated in the cornea. Angiogenesis can also be measured by determining the extent of neovascularization of a tumor. For example, carcinoma cells can be subcutaneously inoculated into athymic nude mice and tumor growth then monitored. The cancer cells are treated with an angiogenesis inhibitor, such as an antibody, or other compound that is exogenously administered, or can be transfected prior to inoculation with a polynucleotide inhibitor of angiogenesis. Immunoassays using endothelial cell-specific antibodies are typically used to stain for vascularization of tumor and the number of vessels in the tumor. Assays to identify compounds with modulating activity can be performed in vitro. For example, an angiogenesis polypeptide is first contacted with a potential modulator and incubated for a suitable amount of time, e.g., from 0.5 to 48 hours. In one embodiment, the angiogenesis polypeptide levels are determined in vitro by measuring the level of protein or mRNA. The level of protein is measured using immunoassays such as western blotting, ELISA and the like with an antibody that selectively binds to the angiogenesis polypeptide or a fragment thereof. For measurement of mRNA, amplification, e.g., using PCR, LCR, or hybridization assays, e.g., northern hybridization, RNAse protection, dot blotting, are preferred. The level of protein or mRNA is detected using directly or indirectly labeled detection agents, e.g., fluorescently or radioactively labeled nucleic acids, radioactively or enzymatically labeled antibodies, and the like, as described herein.

Alternatively, a reporter gene system can be devised using the angiogenesis protein promoter operably linked to a reporter gene such as luciferase, green fluorescent protein, CAT, or β-gal. The reporter construct is typically transfected into a cell. After treatment with a potential modulator, the amount of reporter gene transcription, translation, or activity is measured according to standard techniques known to those of skill in the art.

In a preferred embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of the expression of the gene or the gene product itself can be done. The gene products of differentially expressed genes are sometimes referred to herein as "angiogenesis proteins". In preferred embodiments the angiogenesis protein comprises a sequence shown in Table 8. The angiogenesis protein may be a fragment, or alternatively, be the full length protein to a fragment shown herein. Preferably, the angiogenesis protein is a fragment of approximately 14 to 24 amino acids long. More preferably the fragment is a soluble fragment. In one embodiment an angiogenesis protein is conjugated or fused to an immunogenic agent or BSA.

In one embodiment, screening for modulators of expression of specific genes is performed. Typically, the expression of only one or a few genes are evaluated. In another embodiment, screens are designed to first find compounds that bind to differentially expressed proteins. These compounds are then evaluated for the ability to modulate differentially expressed activity. Moreover, once initial candidate compounds are identified, variants can be further screened to better evaluate strucutre activity relationships.

In a preferred embodiment, binding assays are done. In general, purified or isolated gene product is used; that is, the gene products of one or more differentially expressed nucleic acids are made. For example, antibodies are generated to the protein gene products, and standard immunoassays are run to determine the amount of protein present. Alternatively, cells comprising the angiogenesis proteins can be used in the assays. Thus, in a preferred embodiment, the methods comprise combining an angiogenesis protein and a candidate compound, and determining the binding of the compound to the angiogenesis protein. Preferred embodiments utilize the human angiogenesis protein, although other mammalian proteins may also be used, for example for the development of animal models of human disease. In some embodiments, as outlined herein, variant or derivative angiogenesis proteins may be used.

Generally, in a preferred embodiment of the methods herein, the angiogenesis protein or the candidate agent is non-diffusably bound to an insoluble support having isolated sample receiving areas (e.g. a microtiter plate, an array, etc.). The insoluble supports may be made of any composition to which the compositions can be bound, is readily separated from soluble material, and is otherwise compatible with the overall method of screening. The surface of such supports may be solid or porous and of any convenient shape. Examples of suitable insoluble supports include microtiter plates, arrays, membranes and beads. These are typically made of glass, plastic (e.g., polystyrene), polysaccharides, nylon or nitrocellulose, teflon™, etc. Microtiter plates and arrays are especially convenient because a large number of assays can be carried out simultaneously, using small amounts of reagents and samples. The particular manner of binding of the composition is not crucial so long as it is compatible with the reagents and overall methods of the invention, maintains the activity of the composition and is nondiffusable. Preferred methods of binding include the use of antibodies (which do not sterically block either the ligand binding site or activation sequence when the protein is bound to the support), direct binding to "sticky" or ionic supports, chemical crosslinking, the synthesis of the protein or agent on the surface, etc. Following binding of the protein or agent, excess unbound material is removed by washing. The sample receiving areas may then be blocked through incubation with bovine serum albumin (BSA), casein or other innocuous protein or other moiety.

In a preferred embodiment, the angiogenesis protein is bound to the support, and a test compound is added to the assay. Alternatively, the candidate agent is bound to the support and the angiogenesis protein is added. Novel binding agents include specific antibodies, non-natural binding agents identified in screens of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like. The determination of the binding of the test modulating compound to the angiogenesis protein may be done in a number of ways. In a preferred embodiment, the compound is labelled, and binding determined directly, e.g., by attaching all or a portion of the angiogenesis protein to a solid support, adding a labelled candidate agent (e.g., a fluorescent label), washing off excess reagent, and determining whether the label is present on the solid support. Various blocking and washing steps may be utilized as appropriate.

By "labeled" herein is meant that the compound is either directly or indirectly labeled with a label which provides a detectable signal, e.g. radioisotope, fluorescers, enzyme, antibodies, particles such as magnetic particles, chemiluminescers, or specific binding molecules, etc. Specific binding molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin, etc. For the specific binding members, the complementary member would normally be labeled with a molecule which provides for detection, in accordance with known procedures, as outlined above. The label can directly or indirectly provide a detectable signal. In some embodiments, only one of the components is labeled, e.g., the proteins (or proteinaceous candidate compounds) can be labeled. Alternatively, more than one component can be labeled with different labels, e.g., ¹²⁵I for the proteinsand a fluorophor for the compound. Proximity reagents, e.g., quenching or energy transfer reagents are also useful. In one embodiment, the binding of the test compound is determined by competitive binding assay. The competitor is a binding moiety known to bind to the target molecule (i.e. an angiogenesis protein), such as an antibody, peptide, binding partner, ligand, etc. Under certain circumstances, there may be competitive binding between the compound and the binding moiety, with the binding moiety displacing the compound. In one embodiment, the test compound is labeled. Either the compound, or the competitor, or both, is added first to the protein for a time sufficient to allow binding, if present. Incubations may be performed at a temperature which facilitates optimal activity, typically between 4 and 40°C. Incubation periods are typically optimized, e.g., to facilitate rapid high throughput screening. Typically between 0.1 and 1 hour will be sufficient. Excess reagent is generally removed or washed away. The second component is then added, and the presence or absence of the labeled component is followed, to indicate binding.

In a preferred embodiment, the competitor is added first, followed by the test compound. Displacement of the competitor is an indication that the test compound is binding to the angiogenesis protein and thus is capable of binding to, and potentially modulating, the activity of the angiogenesis protein. In this embodiment, either component can be labeled. Thus, for example, if the competitor is labeled, the presence of label in the wash solution indicates displacement by the agent. Alternatively, if the test compound is labeled, the presence of the label on the support indicates displacement. In an alternative embodiment, the test compound is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor may indicate that the test compound is bound to the angiogenesis protein with a higher affinity. Thus, if the test compound is labeled, the presence of the label on the support, coupled with a lack of competitor binding, may indicate that the test compound is capable of binding to the angiogenesis protein.

In a preferred embodiment, the methods comprise differential screening to identity agents that are capable of modulating the activitity of the angiogenesis proteins. In this embodiment, the methods comprise combining an angiogenesis protein and a competitor in a first sample. A second sample comprises a test compound, an angiogenesis protein, and a competitor. The binding of the competitor is determined for both samples, and a change, or difference in binding between the two samples indicates the presence of an agent capable of binding to the angiogenesis protein and potentially modulating its activity. That is, if the binding of the competitor is different in the second sample relative to the first sample, the agent is capable of binding to the angiogenesis protein. Alternatively, differential screening is used to identify drug candidates that bind to the native angiogenesis protein, but cannot bind to modified angiogenesis proteins. The structure of the angiogenesis protein may be modeled, and used in rational drug design to synthesize agents that interact with that site. Drug candidates that affect the activity of an angiogenesis protein are also identified by screening drugs for the ability to either enhance or reduce the activity of the protein.

Positive controls and negative controls may be used in the assays. Preferably control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of all samples is for a time sufficient for the binding of the agent to the protein. Following incubation, samples are washed free of non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples may be counted in a scintillation counter to determine the amount of bound compound.

A variety of other reagents may be included in the screening assays. These include reagents like salts, neutral proteins, e.g. albumin, detergents, etc. which may be used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be used. The mixture of components may be added in an order that provides for the requisite binding. In a preferred embodiment, the invention provides methods for screening for a compound capable of modulating the activity of an angiogenesis protein. The methods comprise adding a test compound, as defined above, to a cell comprising angiogenesis proteins. Preferred cell types include almost any cell. The cells contain a recombinant nucleic acid that encodes an angiogenesis protein. In a preferred embodiment, a library of candidate agents are tested on a plurality of cells.

In one aspect, the assays are evaluated in the presence or absence or previous or subsequent exposure of physiological signals, for example hormones, antibodies, peptides, antigens, cytokines, growth factors, action potentials, pharmacological agents including chemotherapeutics, radiation, carcinogenics, or other cells (i.e. cell-cell contacts). In another example, the determinations are determined at different stages of the cell cycle process. In this way, compounds that modulate angiogenesis agents are identified. Compounds with pharmacological activity are able to enhance or interfere with the activity of the angiogenesis protein. Once identified, similar structures are evaluated to identify critical structural feature of the compound. In one embodiment, a method of inhibiting angiogenic cell division is provided. The method comprises administration of an angiogenesis inhibitor. In another embodiment, a method of inhibiting angiogenesis is provided. The method comprises administration of an angiogenesis inhibitor. In a further embodiment, methods of treating cells or individuals with angiogenesis are provided. The method comprises administration of an angiogenesis inhibitor.

In one embodiment, an angiogenesis inhibitor is an antibody as discussed above. In another embodiment, the angiogenesis inhibitor is an antisense molecule.

Polynucleotide modulators of angiogenesis Antisense Polynucleotides

In certain embodiments, the activity of an angiogenesis-associated protein is downregulated, or entirely inhibited, by the use of antisense polynucleotide, i.e., a nucleic acid complementary to, and which can preferably hybridize specifically to, a coding mRNA nucleic acid sequence, e.g., an angiogenesis protein mRNA, or a subsequence thereof. Binding of the antisense polynucleotide to the mRNA reduces the translation and or stability of the mRNA.

In the context of this invention, antisense polynucleotides can comprise naturally-occurring nucleotides, or synthetic species formed from naturally-occurring subunits or their close homologs. Antisense polynucleotides may also have altered sugar moieties or inter-sugar linkages. Exemplary among these are the phosphorothioate and other sulfur containing species which are known for use in the art. Analogs are comprehended by this invention so long as they function effectively to hybridize with the angiogenesis protein mRNA. See, e.g., Isis Pharmaceuticals, Carlsbad, CA; Sequitor, Inc., Natick, MA. Such antisense polynucleotides can readily be synthesized using recombinant means, or can be synthesized in vitro. Equipment for such synthesis is sold by several vendors, including Applied Biosystems. The preparation of other oligonucleotides such as phosphorothioates and alkylated derivatives is also well known to those of skill in the art. Antisense molecules as used herein include antisense or sense oligonucleotides. Sense oligonucleotides can, e.g., be employed to block trancription by binding to the anti-sense strand. The antisense and sense oligonucleotide comprise a single- stranded nucleic acid sequence (either RNA or DNA) capable of binding to target mRNA (sense) or DNA (antisense) sequences for angiogenesis molecules. A preferred antisense molecule is for an angiogenesis sequences in Tables 1-8 , or for a ligand or activator thereof. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment generally at least about 14 nucleotides, preferably from about 14 to 30 nucleotides. The ability to derive an antisense or a sense oligonucleotide, based upon a cDNA sequence encoding a given protein is described in, for example, Stein and Cohen (Cancer Res. 48:2659, 1988) and van der Krol et al. (BioTechniques 6:958, 1988).

Ribozymes

In addition to antisense polynucleotides, ribozymes can be used to target and inhibit transcription of angiogenesis-associated nucleotide sequences. A ribozyme is an RNA molecule that catalytically cleaves other RNA molecules. Different kinds of ribozymes have been described, including group I ribozymes, hammerhead ribozymes, hairpin ribozymes,

RNase P, and axhead ribozymes (see, e.g., Castanotto et al. (1994) Adv. in Pharmacology 25: 289-317 for a general review of the properties of different ribozymes).

The general features of hairpin ribozymes are described, e.g., in Hampel et al. (1990) Nucl. Acids Res. 18: 299-304; Hampel et al. (1990) European Patent Publication No. 0 360 257; U.S. Patent No. 5,254,678. Methods of preparing are well known to those of skill in the art (see, e.g., Wong-Staal et al, WO 94/26877; Ojwang et al. (1993) Proc. Natl. Acad. Sci. USA 90: 6340-6344; Yamada et al. (1994) Human Gene Therapy 1: 39-45; Leavitt et al. (1995) Proc Natl. Acad. Sci. USA 92: 699-703; Leavitt et al. (1994) Human Gene Therapy 5: 1151-120; and Yamada et al (1994) Virology 205: 121-126).

Polynucleotide modulators of angiogenesis may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell. Alternatively, a polynucleotide modulator of angiogenesis may be introduced into a cell containing the target nucleic acid sequence, e.g., by formation of an polynucleotide-lipid complex, as described in WO 90/10448. It is understood that the use of antisense molecules or knock out and knock in models may also be used in screening assays as discussed above, in addition to methods of treatment.

Thus, in one embodiment, methods of modulating angiogenesis in cells or organisms are provided. In one embodiment, the methods comprise administering to a cell an anti-angiogenesis antibody that reduces or eliminates the biological activity of an endogeneous angiogenesis protein. Alternatively, the methods comprise administering to a cell or organism a recombinant nucleic acid encoding an angiogenesis protein. This may be accomplished in any number of ways. In a preferred embodiment, for example when the angiogenesis sequence is down-regulated in angiogenesis, such state may be reversed by increasing the amount of angiogenesis gene product in the cell. This can be accomplished, e.g., by overexpressing the endogeneous angiogenesis gene or administering a gene encoding the angiogenesis sequence, using known gene-therapy techniques, for example. In a preferred embodiment, the gene therapy techniques include the incoφoration of the exogenous gene using enhanced homologous recombination (EHR), for example as described in PCT/US93/03868, hereby incoφorated by reference in its entireity. Alternatively, for example when the angiogenesis sequence is up-regulated in angiogenesis, the activity of the endogeneous angiogenesis gene is decreased, for example by the administration of a angiogenesis antisense nucleic acid or other inhibitor, such as RNAi. In one embodiment, the angiogenesis eproteins of the present invention may be used to generate polyclonal and monoclonal antibodies to angiogenesis proteins. Similarly, the angiogenesis proteins can be coupled, using standard technology, to affinity chromatography columns. These columns may then be used to purify angiogenesis antibodies useful for production, diagnostic, or therapeutic purposes. In a preferred embodiment, the antibodies are generated to epitopes unique to a angiogenesis protein; that is, the antibodies show little or no cross-reactivity to other proteins. The angiogenesis antibodies may be coupled to standard affinity chromatography columns and used to purify angiogenesis proteins. The antibodies may also be used as blocking polypeptides, as outlined above, since they will specifically bind to the angiogenesis protein.

Methods of identifying variant angiogenesis-associated sequences

Without being bound by theory, expression of various angiogenesis sequences is correlated with angiogenesis. Accordingly, disorders based on mutant or variant angiogenesis genes may be determined. In one embodiment, the invention provides methods for identifying cells containing variant angiogenesis genes, e.g., determining all or part of the sequence of at least one endogeneous angiogenesis genes in a cell. This may be accomplished using any number of sequencing techniques. In a preferred embodiment, the invention provides methods of identifying the angiogenesis genotype of an individual, e.g., determining all or part of the sequence of at least one angiogenesis gene of the individual. This is generally done in at least one tissue of the individual, and may include the evaluation of a number of tissues or different samples of the same tissue. The method may include comparing the sequence of the sequenced angiogenesis gene to a known angiogenesis gene, i.e., a wild-type gene. The sequence of all or part of the angiogenesis gene can then be compared to the sequence of a known angiogenesis gene to determine if any differences exist. This can be done using any number of known homology programs, such as Bestfit, etc. In a preferred embodiment, the presence of a a difference in the sequence between the angiogenesis gene of the patient and the known angiogenesis gene correlates with a disease state or a propensity for a disease state, as outlined herein.

In a preferred embodiment, the angiogenesis genes are used as probes to determine the number of copies of the angiogenesis gene in the genome.

In another preferred embodiment, the angiogenesis genes are used as probes to determine the chromosomal localization of the angiogenesis genes, information such as chromosomal localization finds use in providing a diagnosis or prognosis in particular when chromosomal abnormalities such as translocations, and the like are identified in the angiogenesis gene locus.

Administration of pharmaceutical and vaccine compositions

In one embodiment, a therapeutically effective dose of an angiogenesis protein or modulator thereof, is administered to a patient. By "therapeutically effective dose" herein is meant a dose that produces effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (e.g., Ansel et al, Pharmaceuitcal Dosage Forms and Drug Delivery, Lippincott, Williams & Wilkins Publishers, ISBN:0683305727; Lieberman (1992) Pharmaceutical Dosage Forms (vols. 1-3), Dekker, ISBN 0824770846, 082476918X, 0824712692, 0824716981; Lloyd (1999) The Art, Science and Technology of Pharmaceutical Compounding, Amer. Pharmacutical Assn, ISBN 0917330889; and Pickar (1999) Dosage Calculations, Delmar Pub, ISBN 0766805042). As is known in the art, adjustments for angiogenesis degradation, systemic versus localized delivery, and rate of new protease synthesis, as well as the age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those skilled in the art. A "patient" for the puφoses of the present invention includes both humans and other animals, particularly mammals. Thus the methods are applicable to both human therapy and veterinary applications. In the preferred embodiment the patient is a mammal, preferably a primate, and in the most preferred embodiment the patient is human.

The administration of the angiogenesis proteins and modulators thereof of the present invention can be done in a variety of ways as discussed above, including, but not limited to, orally, subcutaneously, intravenously, intranasally, transdermally, intraperitoneally, intramuscularly, intrapulmonary, vaginally, rectally, or intraocularly. In some instances, for example, in the treatment of wounds and inflammation, the angiogenesis proteins and modulators may be directly applied as a solution or spray. The pharmaceutical compositions of the present invention comprise an angiogenesis protein in a form suitable for administration to a patient. In the preferred embodiment, the pharmaceutical compositions are in a water soluble form, such as being present as pharmaceutically acceptable salts, which is meant to include both acid and base addition salts. "Pharmaceutically acceptable acid addition salt" refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. "Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. The pharmaceutical compositions may also include one or more of the following: carrier proteins such as serum albumin; buffers; fillers such as microcrystalline cellulose, lactose, corn and other starches; binding agents; sweeteners and other flavoring agents; coloring agents; and polyethylene glycol.

The pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration. For example, unit dosage forms suitable for oral administration include, but are not limited to, powder, tablets, pills, capsules and lozenges. It is recognized that angiogenesis protein modulators (e.g., antibodies, antisense constructs, ribozymes, small organic molecules, etc) when administered orally, should be protected from digestion. This is typically accomplished either by complexing the molecule(s) with a composition to render it resistant to acidic and enzymatic hydrolysis, or by packaging the molecule(s) in an appropriately resistant carrier, such as a liposome or a protection barrier. Means of protecting agents from digestion are well known in the art.

The compositions for administration will commonly comprise an angiogenesis protein modulator dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, e.g., buffered saline and the like. These solutions are sterile and generally free of undesirable matter. These compositions may be sterilized by conventional, well known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The concentration of active agent in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the patient's needs (e.g. , Remington 's Pharmaceutical Science, 15th ed., Mack Publishing Company, Easton, Pennsylvania (1980) and Goodman and Gillman, The Pharmacologial Basis of Therapeutics, (Rardman, J.G, Limbird, L.E, Molinoff, P.B., Ruddon, R.W, and Gilman, A.G.,eds) TheMcGraw-Hill Companies, Inc., 1996).

Thus, a typical pharmaceutical composition for intravenous administration would be about 0.1 to 10 mg per patient per day. Dosages from 0.1 up to about 100 mg per patient per day may be used, particularly when the drug is administered to a secluded site and not into the blood stream, such as into a body cavity or into a lumen of an organ. Substantially higher dosages are possible in topical administration. Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art, e.g., Remington 's Pharmaceutical Science and Goodman and Gillman, The Pharmacologial Basis of Therapeutics, supra.

The compositions containing modulators of angiogenesis proteins can be administered for therapeutic or prophylactic treatments. In therapeutic applications, compositions are administered to a patient suffering from a disease (e.g., a cancer) in an amount sufficient to cure or at least partially arrest the disease and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose." Amounts effective for this use will depend upon the severity of the disease and the general state of the patient's health. Single or multiple administrations of the compositions may be administered depending on the dosage and frequency as required and tolerated by the patient. In any event, the composition should provide a sufficient quantity of the agents of this invention to effectively treat the patient. An amount of modulator that is capable of preventing or slowing the development of cancer in a mammal is referred to as a "prophylactically effective dose." The particular dose required for a prophylactic treatment will depend upon the medical condition and history of the mammal, the particular cancer being prevented, as well as other factors such as age, weight, gender, administration route, efficiency, etc. Such prophylactic treatments may be used, e.g., in a mammal who has previously had cancer to prevent a recurrence of the cancer, or in a mammal who is suspected of having a significant likelihood of developing cancer. It will be appreciated that the present angiogenesis protein-modulating compounds can be administered alone or in combination with additional angiogenesis modulating compounds or with other therapeutic agent, e.g., other anti-cancer agents or treatments. In numerous embodiments, one or more nucleic acids, e.g., polynucleotides comprising nucleic acid sequences set forth in Tables 1-8 , such as antisense polynucleotides or ribozymes, will be introduced into cells, in vitro or in vivo. The present invention provides methods, reagents, vectors, and cells useful for expression of angiogenesis-associated polypeptides and nucleic acids using in vitro (cell-free), ex vivo or in vivo (cell or organism-based) recombinant expression systems.

The particular procedure used to introduce the nucleic acids into a host cell for expression of a protein or nucleic acid is application specific. Many procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use of calcium phosphate transfection, spheroplasts, electroporation, liposomes, microinjection, plasma vectors, viral vectors and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (see, e.g., Berger and Kimmel, Guide to Molecular Cloning Techniques, Methods in Enzymology volume 152 Academic Press, Inc., San Diego, CA (Berger), F.M. Ausubel et al, eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (supplemented through 1999), and Sambrook et al, Molecular Cloning - A Laboratory Manual (2nd Ed.), Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989.

In a preferred embodiment, angiogenesis proteins and modulators are administered as therapeutic agents, and can be formulated as outlined above. Similarly, angiogenesis genes (including both the full-length sequence, partial sequences, or regulatory sequences of the angiogenesis coding regions) can be administered in a gene therapy application. These angiogenesis genes can include antisense applications, either as gene therapy (i.e. for incoφoration into the genome) or as antisense compositions, as will be appreciated by those in the art. Angiogenesis polypeptides and polynucleotides can also be administered as vaccine compositions to stimulate HTL, CTL and antibody responses.. Such vaccine compositions can include, for example, lipidated peptides (e.g., Vitiello, A. et al, J. Clin. Invest. 95:341, 1995), peptide compositions encapsulated in poly(DL-lactide-co-glycolide) ("PLG") microspheres (see, e.g., Eldridge, et al., Molec. Immunol. 28:287-294, 1991: Alonso etal, Vaccine 12:299-306, 1994; Jones et al, Vaccine 13:675-681, 1995), peptide compositions contained in immune stimulating complexes (ISCOMS) (see, e.g., Takahashi et al, Nature 344:873-875, 1990; Hu et al, Clin Exp Immunol. 113:235-243, 1998), multiple antigen peptide systems (MAPs) (see e.g., Tarn, J. P., Proc. Natl. Acad. Sci. U.S.A. 85:5409- 5413, 1988; Tarn, J.P., J. Immunol. Methods 196:17-32, 1996), peptides formulated as multivalent peptides; peptides for use in ballistic delivery systems, typically crystallized peptides, viral delivery vectors (Perkus, M. E. et al, In: Concepts in vaccine development, Kaufmann, S. H. E., ed., p. 379, 1996; Chakrabarti, S. et al, Nature 320:535, 1986; Hu, S. L. et al, Nature 320:537, 1986; Kieny, M.-P. et al, AIDS Bio/Technology 4:790, 1986; Top, F. H. et al, J. Infect. Dis. 124:148, 1971; Chanda, P. K. et al, Virology 175:535, 1990), particles of viral or synthetic origin (e.g., Kofler, N. et al, J. Immunol. Methods. 192:25, 1996; Eldridge, J. H. et al, Sem. Hematol 30:16, 1993; Falo, L. D., Jr. et al, Nature Med. 7:649, 1995), adjuvants (Warren, H. S., Vogel, F. R., and Chedid, L. A. Annu. Rev. Immunol 4:369, 1986; Gupta, R. K. et al, Vaccine 11:293, 1993), liposomes (Reddy, R. et al, J. Immunol. 148:1585, 1992; Rock, K. L., Immunol. Today 17:131, 1996), or, naked or particle absorbed cDNA (Ulmer, J. B. et al, Science 259:1745, 1993; Robinson, H. L., Hunt, L. A, and Webster, R. G., Vaccine 11:957, 1993; Shiver, J. W. et al, In: Concepts in vaccine development, Kaufmann, S. H. E., ed., p. 423, 1996; Cease, K. B., and Berzofsky, J. A, Annu. Rev. Immunol 12:923, 1994 and Eldridge, J. H. et al, Sem. Hematol. 30:16, 1993). Toxin-targeted delivery technologies, also known as receptor mediated targeting, such as those of Avant Immunotherapeutics, Inc. (Needham, Massachusetts) may also be used.

Vaccine compositions often include adjuvants. Many adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, Bortadella pertussis or Mycobacterium tuberculosis derived proteins. Certain adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); AS-2 (SmithKline Beecham, Philadelphia, PA); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF, interleukin-2, -7, -12, and other like growth factors, may also be used as adjuvants. Vaccines can be administered as nucleic acid compositions wherein DNA or RNA encoding one or more of the polypeptides, or a fragment thereof, is administered to a patient. This approach is described, for instance, in Wolff et. al, Science 247:1465 (1990) as well as U.S. Patent Nos. 5,580,859; 5,589,466; 5,804,566; 5,739,118; 5,736,524; 5,679,647; WO 98/04720; and in more detail below. Examples of DNA-based delivery technologies include "naked DNA", facilitated (bupivicaine, polymers, peptide-mediated) delivery, cationic lipid complexes, and particle-mediated ("gene gun") or pressure-mediated delivery (see, e.g., U.S. Patent No. 5,922,687).

For therapeutic or prophylactic immunization pmposes, the peptides of the invention can be expressed by viral or bacterial vectors. Examples of expression vectors include attenuated viral hosts, such as vaccinia or fowlpox. This approach involves the use of vaccinia virus, for example, as a vector to express nucleotide sequences that encode angiogenic polypeptides or polypeptide fragments. Upon introduction into a host, the recombinant vaccinia virus expresses the immunogenic peptide, and thereby elicits an immune response. Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S. Patent No. 4,722,848. Another vector is BCG (Bacille Calmette Guerin). BCG vectors are described in Stover et al, Nature 351:456-460 (1991). A wide variety of other vectors useful for therapeutic administration or immunization e.g. adeno and adeno-associated virus vectors, retroviral vectors, Salmonella typhi vectors, detoxified anthrax toxin vectors, and the like, will be apparent to those skilled in the art from the description herein (see, e.g., Shata et al. (2000) Mol Med Today, 6: 66-71; Shedlock et al, J Leukoc Biol 68,:793-806, 2000; Hipp et al, In Vivo 14:571-85, 2000).

Methods for the use of genes as DNA vaccines are well known, and include placing an angiogenesis gene or portion of an angiogenesis gene under the control of a regulatable promoter or a tissue-specific promoter for expression in an angiogenesis patient. The angiogenesis gene used for DNA vaccines can encode full-length angiogenesis proteins, but more preferably encodes portions of the angiogenesis proteins including peptides derived from the angiogenesis protein. In one embodiment, a patient is immunized with a DNA vaccine comprising a plurality of nucleotide sequences derived from an angiogenesis gene. For example, angiogenesis-associated genes or sequence encoding subfragments of an angiogenesis protein are introduced into expression vectors and tested for their immunogenicity in the context of Class I MHC and an ability to generate cytotoxic T cell responses. This procedure provides for production of cytotoxic T cell responses against cells which present antigen, including intracellular epitopes. In a preferred embodiment, the DNA vaccines include a gene encoding an adjuvant molecule with the DNA vaccine. Such adjuvant molecules include cytokines that increase the immunogenic response to the angiogenesis polypeptide encoded by the DNA vaccine. Additional or alternative adjuvants are available. In another preferred embodiment angiogenesis genes find use in generating animal models of angiogenesis. When the angiogenesis gene identified is repressed or diminished in angiogenesic tissue, gene therapy technology, e.g., wherein antisense RNA directed to the angiogenesis gene will also diminish or repress expression of the gene. Animal models of angiogenesis find use in screening for modulators of an angiogenesis- associated sequence or modulators of angiogenesis. Similarly, transgenic animal technology including gene knockout technology, for example as a result of homologous recombination with an appropriate gene targeting vector, will result in the absence or increased expression of the angiogenesis protein. When desired, tissue-specific expression or knockout of the angiogenesis protein may be necessary. It is also possible that the angiogenesis protein is overexpressed in angiogenesis. As such, transgenic animals can be generated that overexpress the angiogenesis protein. Depending on the desired expression level, promoters of various strengths can be employed to express the transgene. Also, the number of copies of the integrated transgene can be determined and compared for a determination of the expression level of the transgene. Animals generated by such methods find use as animal models of angiogenesis and are additionally useful in screening for modulators to treat angiogenesis or to evaluate a therapeutic entity.

Kits for Use in Diagnostic and/or Prognostic Applications For use in diagnostic, research, and therapeutic applications suggested above, kits are also provided by the invention. In the diagnostic and research applications such kits may include any or all of the following: assay reagents, buffers, angiogenesis-specific nucleic acids or antibodies, hybridization probes and/or primers, antisense polynucleotides, ribozymes, dominant negative angiogenesis polypeptides or polynucleotides, small molecules inhibitors of angiogenesis-associated sequences etc. A therapeutic product may include sterile saline or another pharmaceutically acceptable emulsion and suspension base.

In addition, the kits may include instructional materials containing directions (i.e., protocols) for the practice of the methods of this invention. While the instructional materials typically comprise written or printed materials they are not limited to such. Any medium capable of storing such instructions and communicating them to an end user is contemplated by this invention. Such media include, but are not limited to electromc storage media (e.g., magnetic discs, tapes, cartridges, chips), optical media (e.g., CD ROM), and the like. Such media may include addresses to internet sites that provide such instructional materials.

The present invention also provides for kits for screening for modulators of angiogenesis-associated sequences. Such kits can be prepared from readily available materials and reagents. For example, such kits can comprise one or more of the following materials: an angiogenesis-associated polypeptide or polynucleotide, reaction tubes, and instructions for testing angiogenic-associated activity. Optionally, the kit contains biologically active angiogenesis protein. A wide variety of kits and components can be prepared according to the present invention, depending upon the intended user of the kit and the particular needs of the user. Diagnosis would typically involve evaluation of a plurality of genes or products. The genes will be selected based on correlations with important parameters in disease which may be identified in historical or outcome data.

It is understood that the examples described above in no way serve to limit the true scope of this invention, but rather are presented for illustrative puφoses. All publications, sequences of accession numbers, and patent applications cited in this specification are herein incoφorated by reference as if each individual publication or patent application were specifically and individually indicated to be incoφorated by reference.

EXAMPLES

Example 1: Tissue Preparation. Labeling Chips, and Fineeφrints Purify total RNA from tissue using TRIzol Reagent

Homogenize tissue samples in 1ml of TRIzol per 50mg of tissue using a Polytron 3100 homogenizer. The generator/probe used depends upon the tissue size. A generator that is too large for the amount of tissue to be homogenized will cause a loss of sample and lower RNA yield. TRIzol is added directly to frozen tissue, which is then homogenize. Following homogenization, insoluble material is removed by centrifugation at 7500 x g for 15 min in a Sorvall superspeed or 12,000 x g for 10 min. in an Eppendorf centrifuge at 4°C. The clear homogenate is transferred to a new tube for use. The samples may be frozen now at -60° to -70°C (and kept for at least one month). The homogenate is mixed with 0.2ml of chloroform per 1ml of TRIzol reagent used in the original homogenization and incubated at room temp, for 2-3 minutes. The aqueous phase is then separated by centrifugation and transferred to a fresh tube and the RNA precipitated using isopropyl alcohol. The pellet is isolated by centrifugation, washed, air-dried, resuspended in an appropriate volume of DEPC H₂0, and the absorbance measured.

Purification of poly A+ mRNA from total RNA is performed as follows. Heat an oligotex suspension to 37°C and mixing immediately before adding to RNA. The Elution Buffer is heated at 70°C. Warm up 2 x Binding Buffer at 65°C if there is precipitate in the buffer. Mix total RNA with DEPC-treated water, 2 x Binding Buffer, and Oligotex according to Table 2 on page 16 of the Oligotex Handbook. Incubate for 3 minutes at 65°C. Incubate for 10 minutes at room temperature. Centrifuge for 2 minutes at 14,000 to 18,000 g. Remove supernatant without disturbing Oligotex pellet. A little bit of solution can be left behind to reduce the loss of Oligotex. Gently resuspend in Wash Buffer OW2 and pipet onto spin column. Centrifuge the spin column at full speed for 1 minute. Transfer spin column to a new collection tube and gently resuspend in Wash Buffer OW2 and centrifuge as describe herein. Transfer spin column to a new tube and elute with 20 to 100 ul of preheated (70oC) Elution Buffer. Gently resuspend Oligotex resin by pipetting up and down. Centrifuge as above. Repeat elution with fresh elution buffer or use first eluate to keep the elution volume low. Read absorbance, using diluted Elution Buffer as the blank. Before proceeding with cDNA synthesis, precipitate the mRNA as follows: add 0.4 vol. of 7.5 M NH4OAc + 2.5 vol. of cold 100%) ethanol. Precipitate at -20oC 1 hour to overnight (or 20-30 min. at -70oC). Centrifuge at 14,000-16,000 x g for 30 minutes at 4oC. Wash pellet with 0.5ml of 80%ethanol (-20oC) then centrifuge at 14,000-16,000 x g for 5 minutes at room temperature.. Repeat 80%₀ ethanol wash. Air dry the ethanol from the pellet in the hood.. Suspend pellet in DEPC H₂0 at lug/ul concentration.

To further Clean up total RNA using Qiagen's RNeasy kit, add no more than lOOug to an RNeasy column. Adjust sample to a volume of lOOul with RNase-free water. Add 350ul Buffer RLT then 250ul ethanol (100%) to the sample. Mix by pipetting (do not centrifuge) then apply sample to an RNeasy mini spin column. Centrifuge for 15 sec at >10,000φm. Transfer column to a new 2-ml collection tube. Add 500ul Buffer RPE and centrifuge for 15 sec at >10,000φm. Discard flowthrough. Add 500ul Buffer RPE and centrifuge for 15 sec at >10,000φm. Discard flowthrough then centrifuge for 2 min at maximum speed to dry column membrane. Transfer column to a new 1.5-ml collection tube and apply 30-50ul of RNase-free water directly onto column membrane. Centrifuge 1 min at >10,000φm. Repeat elution. and read absorbance.

cDNA synthesis using Gibco's "Superscript Choice System for cDNA Synthesis" kit First Strand cDNA synthesis is performed as follows. Use 5ug of total RNA or lug of poly A+ mRNA as starting material. For total RNA, use 2ul of Superscript RT. For polyA+ mRNA, use lul of Superscript RT. Final volume of first strand synthesis mix is 20ul. RNA must be in a volume no greater than lOul. Incubate RNA with lul of lOOpmol T7-T24 oligo for 10 min at 70C. On ice, add 7 ul of: 4ul 5X 1 st Strand Buffer, 2ul of 0. IM DTT, and 1 ul of 1 OmM dNTP mix. Incubate at 37C for 2 min then add Superscript RT. Incubate at 37C for 1 hour.

For the second strand synthesis, place 1st strand reactions on ice and add: 9 lul DEPC H₂0; 30ul 5X 2nd Strand Buffer; 3ul lOmM dNTP mix; lul lOU/ul E.coli DNA Ligase; 4ul lOU/ul E.coli DNA Polymerase; and lul 2U/ul RNase H. Mix and incubate 2 hours at 16C. Add 2ul T4 DNA Polymerase. Incubate 5 min at 16C. Add lOul of 0.5M EDTA. A further clean-up of DNA is performed using phenol:chloroform:isoamyl Alcohol (25:24:1) purification.

In vitro Transcription (INT) and labeling with biotin is performed as follows: Pipet 1.5ul of cDΝA into a thin- wall PCR tube. Make ΝTP labeling mix by combining 2ul T7 lOxATP (75mM) (Ambion); 2ul T7 lOxGTP (75mM) (Ambion); 1.5ul T7 lOxCTP (75mM) (Ambion); 1.5ul T7 lOxUTP (75mM) (Ambion); 3.75ul lOmM Bio-11-UTP (Boehringer- Mannheim/Roche or Enzo); 3.75ul lOmM Bio-16-CTP (Enzo); 2ul lOx T7 transcription buffer (Ambion); and 2ul lOx T7 enzyme mix (Ambion). The final volume is 20ul. Incubate 6 hours at 37°C in a PCR machine. The RΝA can be furthered cleaned. Fragmentation is performed as follows. 15 ug of labeled RΝA is usually fragmented. Try to minimize the fragmentation reaction volume; a 10 ul volume is recommended but 20 ul is all right. Do not go higher than 20 ul because the magnesium in the fragmentation buffer contributes to precipitation in the hybridization buffer. Fragment RΝA by incubation at 94 C for 35 minutes in 1 x Fragmentation buffer (5 x Fragmentation buffer is 200 mM Tris-acetate, pH 8.1 ; 500 mM KOAc; 150 mM MgOAc). The labeled RΝA transcript can be analyzed before and after fragmentation. Samples can be heated to 65°C for 15 minutes and electrophoresed on 1% agarose/TBE gels to get an approximate idea of the transcript size range For hybridization, 200 ul (lOug cRNA) of a hybridization mix is put on the chip. If multiple hybridizations are to be done (such as cycling through a 5 chip set), then it is recommended that an initial hybridization mix of 300 ul or more be made. The hybridization mix is: fragment labeled RNA (50ng/ul final cone); 50 pM 948-b control oligo; 1.5 pM BioB; 5 pM BioC; 25 pM BioD; 100 pM CRE; 0. Img/ml herring sperm DNA; 0.5mg/ml acetylated BSA; and 300 ul with lxMES hyb buffer.

Labeling is performed as follows: The hybridization reaction includes non- biotinylated IVT (purified by RNeasy columns); INT antisense RΝA 4 μg:μl; random Hexamers (1 μg/μl) 4 μl and water to 14 ul. The reaciton is incubated at 70°C, 10 min. Reverse transcriptionis performed in the following reaction: 5X First Strand (BRL) buffer, 6 μl; 0.1 M DTT, 3 μl; 50X dΝTP mix, 0.6 μl; H₂O, 2.4 μl; Cy3 or Cy5 dUTP (lmM), 3 μl; SS RT II (BRL), 1 μl in a final volume of 16 μl. Add to hybridization reaction. Incubate 30 min., 42°C. Add 1 μl SSII and incubate another hour. Put on ice. 50X dΝTP mix (25mM of cold dATP, dCTP, and dGTP, lOmM of dTTP: 25 μl each of lOOmM dATP, dCTP, and dGTP; 10 μl of 1 OOmM dTTP to 15 μl H2O. dΝTPs from Pharmacia)

RΝA degradation is performed as follows. Add 86 μl H2O, 1.5 μl IM ΝaOH/ 2mM EDTA and incubate at 65°C, 10 min.. For U-Con 30, 500 μl TE/sample spin at 7000g for 10 min, save flow through for purification. For Qiagen purification, suspend u-con recovered material in 500μl buffer PB and proceed using Qiagen protocol. For DΝAse digestion, add 1 ul of 1/100 dil of DΝAse/30ul Rx and incubate at 37°C for 15 min. Incubate at 5 min 95 °C to denature the DNAse/

For sample preparation, add Cot-1 DNA, 10 μl; 50X dNTPs, 1 μl; 20X SSC, 2.3 μl; Na pyro phosphate, 7.5 μl; lOmg/ml Herring sperm DNA; lul of 1/10 dilution to 21.8 final vol. Dry in speed vac. Resuspend in 15 μl H20. Add 0.38 μl 10% SDS. Heat 95°C, 2 min and slow cool at room temp, for 20 min. Put on slide and hybridize overnight at 64°C. Washing after the hybridization: 3X SSC/0.03% SDS: 2 min., 37.5 mis 20X SSC+0.75mls 10% SDS in 250mls H2O; IX SSC: 5 min., 12.5 mis 20X SSC in 250mls H2O; 0.2X SSC: 5 min., 2.5 mis 20X SSC in 250mls H2O. Dry slides and scan at appropiate PMT's and channels.

Example 2. A model of angiogenesis is used to determine expression in angiogenesis

In the model of angiogenesis used to determine expression of angiogenesis- associated sequences, human umbilical vein endothelial cells (HUVEC) were obtained, e.g., as passage 1 (pl) frozen cells from Cascade Biologies (Oregon) and grown in maintenance medium: Medium 199 (Life Technologies) supplemented with 20% pooled human serum, 100 mg/ml heparin and 75 mg/ml endothelial cell growth supplements (Sigma) and gentamicin (Life Technologies). An in vitro cell system model was used in which 2x10 HUVECs were cultured in 0.5 ml 3 mgs/ml plasminogen-depleted fibrinogen (Calbiochem, San Diego, CA) that was polymerized by the addition of 1 unit of maintenance medium supplemented with 100 ng/ml NEGF and HGF and 10 ng/ml TGF-a (R&D Systems, Minneapolis,MΝ) added (growth medium). The growth medium was replaced every 2 days. Samples for RNA were collected, e.g., at 0, 2, 6, 15, 24, 48, and 96 hours of culture. The fibrin clots were placed in Trizol (Life Technologies) and disrupted using a Tissuemizer. Thereafter standard procedures were used for extracting the RNA (e.g., Example 1).

Angiogenesis associated sequences thus identified are shown in Tables 1-8 . As indicated, some of the Accession numbers include expression sequence tags (ESTs). Thus, in one embodiment herein, genes within an expression profile, also termed expression profile genes, include ESTs and are not necessarily full length.

TABLE 1:

Pkey: Unique Eos probeset identifier number

Accession: Accession number used for previous patent filings

ExAccn: Exemplar Accession number, Genbank accession number

UnigenelD: Unigene number

Unigene Title: Unigene gene title

Pkey Accession ExAccn UnigenelD UnigeneTitle

134404 AB000450 AB000450 Hs.82771 vaccinia related kinase 2

121443 AB002380 AF180681 Hs.6582 Rho guanine exchange factor (GEF) 12

100082 AB003103 AA130080 Hs.4295 proteasome (prosome, acropain) 26S subunit, non-ATPase, 12

132817 AB004884 N27852 Hs.57553 tousled-like kinase 2

130150 AF000573 ma1 BE094848 Hs.15113 homogentisate 1,2-dioxygenase (ho ogentisate oxidase)

100104 AF008937 AF008937 Hs.102178 syntaxin 16

130839 AF009301 AB011169 Hs.20141 similar to S. cerevisiae SSM4

427064 AF009368 AF029674 Hs.173422 KIAA1605 protein

100113 D00591 NMJ01269 Hs.84746 chromosome condensation 1

133980 D00760 AA294921 Hs.250811 v-ral simian leukemia viral oncogene homolog B (ras related; GTP binding protein)

100129 D11139 AA469369 Hs.5831 tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, coUagenase inhibitor)

100154 D14657 H60720 Hs.81892 KIAA0101 gene product

100169 D14878 AL037228 Hs.82043 D123 gene product

101956 D17716 NM 002410 Hs.121502 mannosyl (al pha-1 ,6-)-glycop rotein beta-1 ,6-N-acetyl-glucosaminyltransferase

100190 D21090 M91401 Hs.178658 RAD23 (S. cerevisiae) homolog B

134742 D26135 NM 001346 Hs.89462 diacylglycerol kinase, gamma (90kD)

100211 D26528 D26528 Hs.123058 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 7 (RNA helicase, 52kD)

100238 D30742 L24959 Hs.348 calcium/calmodulin-dependent protein kinase IV

130283 D31 62 NM 012288 Hs.153954 TRAM-like protein

134237 D31765 D31765 Hs.170114 KIAA0061 protein

100248 D31888 NM 015156 Hs.78398 KIAA0071 protein

100256 D38128 D25418 Hs.393 prostaglandin 12 (prostacyclin) receptor (IP)

100262 D38500 D38500 Hs.278468 postmeiotic segregation increased 2-like 4

134329 D38551 N92036 Hs.81848 RAD21 (S. pombe) homolog

100281 D42087 AF091035 Hs.184627 KIAA0118 protein

100294 D49396 AA331881 Hs.75454 peroxiredoxiπ 3

100327 D55640 D55640 gb:Human monocyte PABL (pseudoautosomal boundary-like sequence) mRNA, clone Mo2.

100335 D63391 AW247529 Hs.6793 platelet-activating factor acetylhydrolase, isoform lb, gamma subunit (29kD)

134495 D63477 D63477 Hs.84087 KIAA0143 protein

100338 D63483 D86864 Hs.57735 acetyl LDL receptor; SREC

135152 D64015 M96954 Hs.182741 TIA1 cytotoxic granule-associated RNA-binding protein-like 1

134269 D79990 NMJ14737 Hs.80905 Ras association (RalGDS/AF-6) domain family 2

100372 D79997 NM 014791 Hs.184339 KIAA0175 gene product

134304 D80010 BE613486 Hs.81412 lipin 1

100394 D84276 D84284 Hs.66052 CD38 antigen (p45)

100405 D86425 AW291587 Hs.82733 nidogen 2

100418 D86978 D86978 Hs.84790 KIAA0225 protein

133154 D87012 D87012 Hs.194685 topoisomerase (DNA) III beta

134347 D87075 AF164142 Hs.82042 solute earner family 23 (nucleobase transporters), member 1

128653 D87432 D87432 Hs.10315 solute carrier family 7 (cationic amino acid transporter, y+ system), member 6

100438 D87448 AA013051 Hs.91417 topoisomerase (DNA) II binding protein

134593 D87845 NM_000437 Hs.234392 platelet-activating factor acetylhydrolase 2 (40kD)

100481 HG1098-HT1098 X70377 Hs.121489 cystatin D

100552 HG2167-HT2237 AA019521 Hs.301946 lysosomal

100591 HG2415-HT2511 NMJ04091 Hs.231444 Homo sapiens, Similar to hypothetical protein PR01722, clone MGC:15692, mRNA, complete eds

100652 HG2825-HT2949 BE613608 Hs.142653 ret finger protein

100662 HG2887-HT3031 _r AI368680 Hs.816 SRY (sex determining region Y)-box 2

100899 HG4660-HT5073 AL039123 Hs.103042 microtubule-associated protein 1B

100905 HG4704-HT5146 L12260 Hs.172816 neuregulin 1

100945 HG884-HT884 AF002225 Hs.180686 ubiquitin protein ligase E3A (human papilloma virus E6-associated protein, Angelman syndrome)

100950 HG919-HT919 AF128542 Hs.166846 polymerase (DNA directed), epsilon

100964 J00212 f J00212 Empirically selected from AFFX single probeset

135407 J04029 J04029 Hs.99936 keratin 10 (epidermolytic hyperkeratosis; keratosis palmaris et plantaris)

130149 J04031 AW067805 Hs.172665 methylenetetrahydrofolate dehydrogenase (NADP+ dependent), methenyltetrahydrofoiate

131877 J04088 J04088 Hs.156346 topoisomerase (DNA) II alpha (170kD)

101016 J04543 J04543 Hs.78637 annexin A7

134786 L06139 T29618 Hs.89640 TEK tyrosine kinase, endothelial (venous malformations, multiple cutaneous and mucosal)

134100 L07540 AA460085 Hs.171075 replication factor C (activator 1) 5 (36.5kD)

134078 L08895 L08895 Hs.78995 MADS box transcription enhancer factor 2, polypeptide C (myocyte enhancer factor 2C)

101132 L11239 L11239 Hs.36993 gastrulation brain homeo box 1

134849 L11353 BE409525 Hs.902 neurofibromin 2 (bilateral acoustic neuroma)

106432 L13773 AK000310 Hs.17138 hypothetical protein FLJ20303 101152 L13800 AI984625 Hs.9884 spindle pole body protein

135397 L14922 L14922 Hs.166563 replication factor C (activator 1) 1 (145kD)

131687 L15189 BE297635 Hs.3069 heat shock 70kD protein 9B (mortalin-2)

101168 L15388 NM_005308 Hs.211569 G protein-coupled receptor kinase 5

421155 L16895 H87879 Hs.102267 lysyl oxidase

101226 L27476 AF083892 Hs.75608 tight junction protein 2 (zona occludens 2)

133975 L27624 C18356 Hs.295944 tissue factor pathway inhibitor 2

134739 L32976 NMJ02419 Hs.89449 mitogen-activated protein kinase kinase kinase 11

130155 L33404 AA101043 Hs.151254 kallikrein 7 (chymotryptic, stratum corneum)

440538 L35263 76332 Hs.79107 mitogen-activated protein kinase 14

132813 L37347 BE313625 Hs.57435 solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2

101294 L40371 AF168418 Hs.116784 thyroid hormone receptor interactor 4

101300 L40391 BE535511 Hs.74137 transmembrane trafficking protein

101310 L41607 L41607 Hs.934 glucosaminyl (N-acetyl) transferase 2, l-branching enzyme

130344 L77566 AW250122 Hs.154879 DiGeorge syndrome critical region gene DGSI; likely ortholog of mouse expressed sequence 2 embryonic lethal

101381 M13928 AW675039 Hs.1227 aminolevulinate, delta-, dehydratase

101668 M14016 AW005903 Hs.78601 uroporphyrinogeπ decarboxylase

133780 M14219 AA557660 Hs.76152 decorin

101396 M15796 BE267931 Hs.78996 proliferating cell nuclear antigen

101447 M21305 M21305 gb:Human alpha satellite and satellite 3 junction DNA sequence.

101458 M22092 M22092 gb:Human neural cell adhesion molecule (N-CAM) gene, exon SEC and partial eds.

101470 M22898 NM 000546 Hs.1846 tumor protein p53 (Li-Fraumeni syndrome)

134604 M22995 NM 002884 Hs.865 RAP1 A, member of RAS oncogene family

101478 M23379 NM_002890 Hs.758 RAS p21 protein activator (GTPase activating protein) 1

406698 M24364 X03068 Hs.73931 major histocompatibility complex, class II, DQ beta 1

133519 M24400 AW583062 Hs.74502 chymotrypsinogen B1

131185 M25753 BE280074 Hs.23960 cyclin B1

134116 M27691 R84694 Hs.79194 cAMP responsive element binding protein 1

133999 M28213 AA535244 Hs.78305 RAB2, member RAS oncogene family

130174 M29550 M29551 Hs.151531 protein phosphatase 3 (formerly 2B), catalytic subunit, beta isoform (calcineurin A beta)

129963 M29971 M29971 Hs.1384 O-6-methylguanine-DNA methyltransferase

132983 M30269 M30269 Hs.62041 nidogen (enactin)

133900 M31158 M31158 Hs.77439 protein kinase, cAMP-dependent, regulator/, type II, beta

101543 M31166 M31166 Hs.2050 pentaxin-related gene, rapidly induced by IL-1 beta

101545 M31210 BE246154 Hs.154210 endothelial differentiation, sphingolipid G-protein-coupled receptor, 1

101620 M55420 S55271 Hs.247930 Epsilon , IgE

134691 M59979 AW382987 Hs.88474 prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase)

133595 M62810 AA393273 Hs.75133 transcription factor 6-like 1 (mitochondrial transcription factor 1-like)

130425 M63838 AA243383 Hs.155530 interferon, gamma-inducible protein 16

101700 M64710 D90337 Hs.247916 natriuretic peptide precursor C

101714 M68874 M68874 Hs.211587 phospholipase A2, group IVA (cytosolic, calcium-dependent)

134246 M74524 D28459 Hs.80612 ubiquitin-conjugating enzyme E2A (RAD6 homolog)

101760 M80254 M80254 Hs.173125 peptidylprolyl isomerase F (cyclophilin F)

133948 M81780_cds3 X59960 Hs.77813 sphingomyelin phosphodiesterase 1, acid lysosomal (acid sphingomyelinase)

101791 M83822 M83822 Hs.62354 cell division cycle 4-iike

101812 M86934 BE439894 Hs.78991 DNA segment, numerous copies, expressed probes (GS1 gene)

101813 M87338 NM 002914 Hs.139226 replication factor C (activator 1) 2 (40kD)

133396 M96326_rna1 M96326 Hs.72885 azurocidin 1 (cationic antimicrobial protein 37)

135152 M96954 M96954 Hs.182741 TIA1 cytotoxic granule-associated RNA-binding protein-like 1

129026 M98833 AL120297 ^• Hs.108043 Friend leukemia virus integration 1

101901 S66793 H38026 Hs.308 arrestin 3, retinal (X-arrestin)

134831 S72370 AA853479 Hs.89890 pyruvate carboxylase

134039 S78569 NM 002290 Hs.78672 iaminin, alpha 4

134395 S79873 AA456539 Hs.8262 lysosomal

101975 S83325 AA079717 Hs.283664 aspartate beta-hydroxylase

101977 S83364 AF112213 Hs.184062 putative Rab5-interacting protein

101978 S83365 BE561610 Hs.5809 putative transmembrane protein; homolog of yeast Golgi membrane protein Yif1 p (Yip1 p- interacting factor)

101998 U01212 U01212 Hs.248153 olfactory marker protein

102003 U01922 U01922 Hs.125565 translocase of inner mitochondrial membrane 8 (yeast) homolog A

102007 U02556 U02556 Hs.75307 t-complex-associated-testis-expressed 1 -like

102009 U02680 BE245149 Hs.82643 protein tyrosine kinase 9

416658 U03272 U03272 Hs.79432 fibrillin 2 (congenital contractural arachnodactyly)

132951 U04209 AW821182 Hs.61418 microfibrillar-associated protein 1

135389 U05237 U05237 Hs.99872 fetal Alzheimer antigen

102048 U07225 U07225 Hs.339 purinergic receptor P2Y, G-protein coupled, 2

130145 U07620 U34820 Hs.151051 mitogen-activated protein kinase 10

303153 U09759 U09759 Hs.246857 mitogen-activated protein kinase 9

420269 U09820 U72937 Hs.96264 alpha thalassemia/mental retardation syndrome X-linked (RAD54 (S. cerevisiae) homolog)-

102095 U11313 U11313 Hs.75760 sterol carrier protein 2

102123 U14518 NM 01809 Hs.1594 centromere protein A (1 kD)

102126 U14575 AW950870 Hs.78961 protein phosphatase 1, regulatory (inhibitor) subunit 8

102133 U15173 AU076845 Hs.155596 BCL2/adenovirus E1B 19kD-interacting protein 2

102139 U15932 NM 004419 Hs.2128 dual specificity phosphatase 5

102162 U18291 AA450274 Hs.1592 CDC16 (cell division cycle 16, S. cerevisiae, homolog) 102164 U18300 NM_000107 Hs.77602 damage-specific DNA binding protein 2 (48kD)

427653 U18383 AA159001 Hs.180069 nuclear respiratory factor 1

131817 U20536 U20536 Hs.3280 caspase 6, apoptosis-related cysteine protease

102200 U21551 AA232362 Hs.157205 branched chain aminotransferase 1, cytosolic

102210 U23028 BE619413 Hs.2437 eukaryotic translation initiation factor 2B, subunit 5 (epsilon, 82kD)

102214 U23752 U23752 Hs.32964 SRY (sex determining region Y)-box 11

132811 U25435 U25435 Hs.57419 CCCTC-binding factor (zinc finger protein)

131319 U25997 NM 003155 Hs.25590 stanniocalcin 1

102256 U28251 cds2 U28251 Hs.53237 ESTs, Highly similar to Z169_HUMAN ZINC FINGER PROTEIN 169 [H.sapiens]

132316 U28831 U28831 Hs.44566 KIAA1641 protein

102269 U30245 U30245 gb:Human myelomonocytio specific protein (MNDA) gene, 5' flanking sequence and complete exon 1.

134365 U32315 AA568906 Hs.82240 syntaxin 3A

102293 U32439 AF090116 Hs.79348 regulator of G-protein signalling 7

102298 U32849 AA382169 Hs.54483 N-myc (and STAT) interactor

102325 U35139 AI815867 Hs.50130 necdin (mouse) homolog

302344 U36764 BE303044 Hs.192023 eukaryotic translation initiation factor 3, subunit 2 (beta, 36kD)

102361 U39400 AA223616 Hs.75859 chromosome 11 open reading frame 4

102367 U39657 U39656 Hs.118825 mitogen-activated protein kinase kinase 6

102388 U41344 AA362907 Hs.76494 proline arginine-rich end leucine-rich repeat protein

102394 U41766 NM_003816 Hs.2442 a disintegrin and metalloproteinase domain 9 (meltrin gamma)

129829 U41813 AF010258 Hs.127428 homeo boxA9

102251 U41815 NM_004398 Hs.41706 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 10 (RNA helicase)

102409 U43286 BE300330 Hs.118725 selenophosphate synthetase 2

133746 U44378 AW410035 Hs.75862 MAD (mothers against decapentaplegic, Drosophila) homolog 4

102423 U44754 Z47542 Hs.179312 small nuclear RNA activating complex, polypeptide 1, 43kD

132828 U47011 cdsl AB014615 Hs.57710 fibroblast growth factor 8 (androgen-induced)

130441 U47077 U63630 Hs.155637 protein kinase, DNA-activated, catalytic polypeptide

102450 U48251 U48251 Hs.75871 protein kinase C binding protein 1

129350 U50535 U50535 Hs.110630 Human BRCA2 region, mRNA sequence CG006

102534 U56833 U96759 Hs.198307 von Hippel-Lindau binding protein 1

130457 U58091 AB014595 Hs.155976 cullin 4B

135065 U58837 AA019401 Hs.93909 cyclic nucleotide gated channel beta 1

102560 U59289 R97457 Hs.63984 cadherin 13, H-cadherin (heart)

102567 U59863 U63830 Hs.146847 TRAF family member-associated NFKB activator

134305 U67122 U61397 Hs.81424 ubiquitin-like 1 (sentrin)

102638 U67319 U67319 Hs.9216 caspase 7, apoptosis-related cysteine protease

132736 U68019 A 081883 Hs.288261 Homo sapiens cDNA: FU23037 fis, clone LNG02036, highly similar to HSU68019 Homo sapiens mad protein homolog (hMAD-3) mRNA

133070 U69611 U92649 Hs.64311 a disintegrin and metalloproteinase domain 17 (tumor necrosis factor, alpha, converting enzyme)

102663 U70322 NM 002270 Hs.168075 karyopherin (importin) beta 2

134660 U73524 U73524 Hs.87465 ATP/GTP-binding protein

102735 U79267 AF111106 Hs.3382 protein phosphatase 4, regulatory subunit 1

102741 U79291 AW959829 Hs.83572 hypothetical protein MGC14433

101175 U82671 cds2 U82671 Hs.36980 melanoma antigen, family A, 2

132164 U84573 AI752235 Hs.41270 procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase) 2

102823 U90914 D85390 Hs.5057 carboxypeptidase D

102826 U91316 NM 007274 Hs.8679 cytosolic acyl coenzy e A thioester hydrolase

102831 U91932 AA262170 Hs.80917 adaptor-related protein complex 3, sigma 1 subunit

102846 U96131 BE264974 Hs.6566 thyroid hormone receptor interactor 13

129777 U97018 U97018 Hs.12451 echinoderm icrotubule-associated protein-like

134161 U97188 AA634543 Hs.79440 IGF-II mRNA-binding protein 3

134854 V00503 J03464 Hs.179573 collagen, type I, alpha 2

302363 X04327 AW163799 Hs.198365 2,3-bisphosphoglycerate mutase

133708 X06389 AI018666 Hs.75667 synaptophysin

125701 X07496 T72104 Hs.93194 apolipoprotein A-l

102915 X07820 X07820 Hs.2258 matrix metalloproteinase 10 (stromelysin 2)

134656 X14787 AI750878 Hs.87409 thrombospondin 1

413858 X15525 rna1 NM_001610 Hs.75589 acid phosphatase 2, lysosomal

102968 X16396 AU076611 Hs.154672 methylene tetrahydrofolate dehydrogenase (NAD+ dependent), methenyltetrahydrofoiate cyclohydrolase

102971 X16609 X16609 Hs.183805 ankyrin 1 , eryt rocytic

134037 X53586 rnal AI808780 Hs.227730 integrin, alpha 6

103023 X53793 AW500470 Hs.117950 multifunctional polypeptide similar to SAICAR synthetase and AIR carboxylase

103037 X54936 BE018302 Hs.2894 placental growth factor, vascular endothelial growth factor-related protein

130282 X55740 BE245380 Hs.153952 5' nucleotidase (CD73)

134542 X57025 M14156 Hs.85112 insulin-like growth factor 1 (somatomedin C)

128568 X60673 rnal H12912 Hs.274691 adenylate kinase 3

103093 X60708 S79876 Hs.44926 dipeptidylpeptidase IV (CD26, adenosine deaminase complexing protein 2)

133606 X62048 U10564 Hs.75188 wee1+(S. pombe) homolog

129063 X63097 X63094 Hs.283822 Rhesus blood group, D antigen

424460 X63563 BE275979 Hs.296014 polymerase (RNA) II (DNA directed) polypeptide B (140kD)

133227 X64037 A 977263 Hs.68257 general transcription factor IIF, polypeptide 1 (74kD subunit)

103181 X69636 X69636 Hs.334731 Homo sapiens, clone IMAGE:3448306, mRNA, partial eds

103184 X69878 U43143 Hs.74049 fms-related tyrosine kinase 4

103194 X70649 NMJ04939 Hs.78580 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 1 103208 X72841 AW411340 Hs.31314 retinoblastoma-binding protein 7

129698 X74987 BE242144 Hs.12013 ATP-binding cassette, sub-family E (OABP), member 1

131486 X83107 F06972 Hs.27372 BMX non-receptor tyrosine kinase

130729 X84194 AI963747 Hs.18573 acylphosphatase 1, erythrocyte (common) type

103334 X85753 NMJ01260 Hs.25283 cyclin-dependent kinase 8

132645 X87870 AI654712 Hs.54424 hepatocyte nuclear factor 4, alpha

135094 X89066 NM 003304 Hs.250687 transient receptor potential channel 1

103352 X89398 cds2 H09366 Hs.78853 uracil-DNA glycosylase

103353 X89399 X89399 Hs.119274 RAS p21 protein activator (GTPase activating protein) 3 (lns(1,3,4,5)P4-binding protein)

132173 X89426 X89426 Hs.41716 endothelial cell-specific molecule 1

103371 X91247 X91247 Hs.13046 thioredoxin reductase 1

131584 X91648 AA598509 Hs.29117 purine-rich element binding protein A

103376 X92098 AL036166 Hs.323378 coated vesicle membrane protein

103378 X92110 AL119690 Hs.153618 HCGVIII-1 protein

128510 X94703 X94703 Hs.296371 RAB28, member RAS oncogene family

103410 X96506 AA158294 Hs.334879 DR1 -associated protein 1 (negative cofactor 2 alpha)

133490 X97230 f AF022044 Hs.274601 killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1

103438 X98263 AW175781 Hs.152720 M-phase phosphoprotein 6

103440 X98296 X98296 Hs.77578 ubiquitin specific protease 9, X chromosome (Drosophila fat facets related)

103452 X99584 NM 006936 Hs.85119 SMT3 (suppressor of mif two 3, yeast) homolog 1

133536 Y00264 W25797.comp Hs.177486 amyloid beta (A4) precursor protein (protease nexin-ll, Alzheimer disease)

135185 Y07566 A 404908 Hs.96038 Ric (Drosophila)-like, expressed in many tissues

118523 Y07759 Y07759 Hs.170157 myosin VA (heavy polypeptide 12, myoxin)

134662 Y07827 NM 007048 Hs.284283 butyrophilin, subfamily 3, member A1

132083 Y07867 BE386490 Hs.279663 Pirin

103500 Y09443 AW408009 Hs.22580 alkylglycerone phosphate synthase

134389 Y09858 Y09858 Hs.82577 spindlin-like

132084 Y12394 NM 002267 Hs.3886 karyopherin alpha 3 (importin alpha 4)

103540 Z11559 NM 002197 Hs.154721 aconitase l, soluble

133152 Z11695 Z11695 Hs.324473 mitogen-activated protein kinase 1

103548 Z15005 Z15005 Hs.75573 centromere protein E (312kD)

103612 Z46261 BE336654 Hs.70937 H3 histone family, member A

129092 AA011243_s D56365 Hs.63525 poly(rC)-binding protein 2

103692 AA018418 AW137912 Hs.227583 Homo sapiens chromosome X map Xp11.23 L-type calcium channel alpha-1 subunit

(CACNA1F) gene, complete eds; HSP27 pseudogene, complete sequence; and JM1 protein, JM2 protein, and Hb2E genes, complete eds

103695 AA018758 AW207152 Hs.186600 ESTs

129796 AA018804 BE218319 Hs.5807 GTPase Rab14

132258 AA031993 AA306325 Hs.4311 SUMO-1 activating enzyme subunit 2

132683 AA044217 BE264633 Hs.143638 WD repeat domain 4

131887 AA046548 W17064 Hs.332848 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1

103723 AA057447_s BE274312 Hs.214783 Homo sapiens cDNA FLJ14041 fis, clone HEMBA1005780

453368 AA058376 W20296 Hs.288178 Homo sapiens cDNA FLJ11968 fis, clone HEMBB1001133

133260 AA083572 AA403045 Hs.6906 Homo sapiens cDNA: FLJ23197 fis, clone REC00917

103765 AA085696 AA085696 Hs.169600 KIAA0826 protein

103766 AA088744 AI920783 Hs.191435 ESTs

103767 AA089688 BE244667 Hs.296155 CGI-100 protein

132051 AA091284 AA393968 Hs.180145 HSPC030 protein

103773 AA092700 AI219323 Hs.101077 ESTs, Weakly similar to T22363 hypothetical protein F47G9.4 - Caenorhabditis elegans

[C.elegans]

135289 AA092968 AW372569 Hs.9788 hypothetical protein MGC10924 similar to Nedd4 WW-binding protein 5

132729 AA094800 AW970843 Hs.55682 eukaryotic translation initiation factor 3, subunit 7 (zeta, 66/67kD)

103794 AA100219 AF244135 Hs.30670 hepatocellular carcinoma-associated antigen 66

131471 AA114885 AA164842 Hs.192619 KIAA1600 protein

134319 AA129547 BE304999 Hs.75653 fumarate hydratase

103807 AA133016 AW958264 Hs.103832 similar to yeast Upf3, variant B

119159 AA149507 AF142419 Hs.15020 homolog of mouse quaking QKI (KH domain RNA binding protein)

129863 AA151005 BE379765 Hs.129872 sperm associated antigen 9

103850 AA187101 AA187101 Hs.213194 hypothetical protein MGC10895

103855 AA195179 s W02363 Hs.302267 hypothetical protein FLJ10330

322026 AA203138 AW024973 Hs.283675 NPD009 protein

135300 AA203645 AA142922 Hs.278626 Arg/Abl-interacting protein ArgBP2

103861 AA206236 AA206236 Hs.4944 hypothetical protein FLJ12783

130634 AA227621 AI769067 Hs.127824 ESTs, Weakly similar to T28770 hypothetical protein W03D2.1 - Caenorhabditis

[C.elegans]

447735 AA248283 AA775268 Hs.6127 Homo sapiens cDNA: FLJ23020 fis, clone LNG00943

103909 AA249611 AA249611 Hs.47438 SH3 domain binding glutamic acid-rich protein

131236 AA282640 AF043117 Hs.24594 ubiquitination factor E4B (homologous to yeast UFD2)

134060 AA287199 D42039 Hs.78871 mesoderm development candidate 2

129013 AA313990 AA371156 Hs.107942 DKFZP564M112 protein

129435 AA314256 AF151852 Hs.111449 CGI-94 protein

103988 AA314389 AA314389 Hs.42500 ADP-ribosylation factor-like 5

104000 AA324364 AI146527 Hs.80475 polymerase (RNA) II (DNA directed) polypeptide J (13.3kD)

425284 AA329211_s AF155568 Hs.155489 NS1 -associated protein 1

128629 AA399187 AL096748 Hs.102708 DKFZP434A043 protein

133281 AA421079 AK001601 Hs.69594 high-mobility group 20A 104104 AA422029 AA422029 Hs.143640 ESTs, Weakly similar to hyperpolarization-activated cyclic nucleotide-gated channel hHCN2

[H.sapiens]

108154 AA425230 NM_005754 Hs.220689 Ras-GTPase-activating protein SH3-domain-binding protein

132091 AA447052 AW954243 Hs.170218 KIAA0251 protein

135073 AA452000 W55956 Hs.94030 Homo sapiens mRNA; cDNA DKFZp586E1624 (from clone DKFZp586E1624)

131367 AA456687 AI750575 Hs.1 3933 nuclear factor l/A

129593 AA487015 s A1338247 Hs.98314 Homo sapiens mRNA; cDNA DKFZp586L0120 (from clone DKFZp586L0120)

135266 AB002326 R41179 Hs.97393 KIAA0328 protein

133505 C01527 AI630124 Hs.324504 Homo sapiens mRNA; cDNA DKFZp586J0720 (from clone DKFZp586J0720)

132064 C01714 AA121098 Hs.3838 serum-inducible kinase

134393 C01811 f W52642 Hs.8261 hypothetical protein FLJ22393

131427 C02352 s AF151879 Hs.26706 CGI-121 protein

133435 C02375 AI929357 Hs.323966 Homo sapiens clone H63 unknown mRNA

104282 C14448 C14448 Hs.332338 EST

134827 D16611 s BE314037 Hs.89866 coproporphyrinogen oxidase (coproporphyria, harderoporphyria)

130443 D25216 D25216 Hs.155650 KIAA0014 gene product

131742 D31352 AA961420 Hs.31433 ESTs

132837 D58024 s AA370362 Hs.57958 EGF-TM7-latrophilin-related protein

130377 D80897 NM 014909 Hs.155182 KIAA1036 protein

104334 D82614 D82614 Hs.78771 phosphoglycerate kinase 1

134593 D87845 NM 000437 Hs.234392 platelet-activating factor acetylhydrolase 2 (40kD)

134731 D89377 i D89377 Hs.89404 msh (Drosophila) homeo box homolog 2

129913 H06583 NM 001310 Hs.13313 cAMP responsive element binding protein-like 2

131670 H40732 H03514 Hs.10130 ESTs

104394 H46617 AA129551 Hs.172129 Homo sapiens cDNA: FLJ21409 fis, clone COL03924

104402 H56731 H56731 Hs.132956 ESTs

129781 H75570 AA306090 Hs.124707 ESTs

129077 H78886 N74724 Hs.108479 ESTs

104417 H81241 AI819448 Hs.320861 Kruppel-like factor 8

134927 L36531 L36531 Hs.91296 integrin, alpha 8

129280 M63154 M63154 Hs.110014 gastric intrinsic factor (vitamin B synthesis)

134498 M63180 AW246273 Hs.84131 threonyl-tRNA synthetase

104460 M91504 AW955705 Hs.62604 Homo sapiens, clone IMAGE:4299322, mRNA, partial eds

104488 N56191 N56191 Hs.106511 protocadherin 17

131248 N78483 AI038989 Hs.332633 Bardet-Biedl syndrome 2

129214 N79268 AL044335 Hs.109526 zinc finger protein 198

130017 R14652 AK000096 Hs.143198 inhibitor of growth family, member 3

104530 R20459 AK001676 Hs.12457 hypothetical protein FLJ10814

104534 R22303 R22303 gb:yh26b09.r1 Soares placenta Nb2HP Homo sapiens cDNA clone IMAGE:130841 5', mRNA sequence.

104544 R33779 AI091173 Hs.222362 ESTs, Weakly similar to p40 [H.sapiens]

133328 R36553 AW452738 Hs.265327 hypothetical protein DKFZp761H41

104567 R64534 AA040620 Hs.5672 hypothetical protein AF140225

128562 R66475 AA923382 Hs.101490 ESTs

129575 R70621 F08282 Hs.278428 progestin induced protein

130776 R79356 AF167706 Hs.19280 cysteine-rich motor neuron 1

104599 R84933 AW815036 Hs.151251 ESTs

104660 RC AA007160 BE298665 Hs.14846 Homo sapiens mRNA; cDNA DKFZp564D016 (from clone DKFZp564D016)

104667 RC AA007234 : 3 AI239923 Hs.30098 ESTs

104718 RC AA018409 AI143020 Hs.36250 ESTs, Weakly similar to 138022 hypothetical protein [H.sapiens]

104764 RC AA025351 AI039243 Hs.278585 ESTs

104786 RC AA027168 AA027167 Hs.10031 KIAA0955 protein

104787 RC_AA027317 AA027317 gb:ze97d11.s1 Soares_feta|_heart_NbHH19W Homo sapiens cDNA clone IMAGE:366933 3' similar to contains Alu repetitive element;, mRNA sequence.

134079 RC_AA029423 AK001751 Hs.171835 hypothetical protein FLJ10889

104804 RC_AA031357 AI858702 Hs.31803 ESTs, Weakly similar to N-WASP [H.sapiens]

104865 RC_AA045136 T79340 Hs.22575 B-cell CLL/lymphoma 6, member B (zinc finger protein)

130828 RC_AA053400 AW631469 Hs.203213 ESTs

104907 RC AA055829 AA055829 Hs.196701 ESTs, Weakly similar to ALULHUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION

WARNING ENTRY [H.sapiens]

104943 RC_AA065217 AF072873 Hs.114218 frizzled (Drosophila) homolog 6

105013 RC AA116054 H63789 Hs.296288 ESTs, Weakly similar to KIAA0638 protein [H.sapiens]

105024 RC AA126311 AA126311 Hs.9879 ESTs

132592 RC AA129390 AW803564 Hs.288850 Homo sapiens cDNA: FLJ22528 fis, clone HRC12825

105038 RC AA130273 AW503733 Hs.9414 KIAA1488 protein

105077 RC AA142919 W55946 Hs.234863 Homo sapiens cDNA FLJ12082 fis, clone HEMBB1002492

105096 RC AA150205 AL042506 Hs.21599 Kruppel-like factor 7 (ubiquitous)

129215 RC AA176867 AB040930 Hs.126085 KIAA1497 protein

105169 RC AA180321 BE245294 Hs.180789 S164 protein

132796 RC AA180487 NM 006283 Hs.173159 transforming, acidic coiled-coil containing protein 1

130401 RC AA187634 BE396283 Hs.173987 eukaiyotic translation initiation factor 3, subunit 1 (alpha, 35kD)

105200 RC AA195399 AA328102 Hs.24641 cytoskeleton associated protein 2

130114 RC AA234717 AA233393 Hs.14992 hypothetical protein FLJ11151

105330 RC AA234743 AW338625 Hs.22120 ESTs

105337 RC AA234957 AI468789 Hs.23200 myotubularin related protein 1

129385 RC AA235604 AA172106 Hs.110950 Rag C protein 105376 RC.AA236559 AW994032 Hs.8768 hypothetical protein FLJ10849 105397 RC_AA242868 AA814807 Hs.7395 hypothetical protein FLJ23182 131962 RC_AA251776 AK000046 Hs.267448 hypothetical protein FLJ20039 131991 RC_AA251909 AF053306 Hs.36708 budding uninhibited by benzimidazoles 1 (yeast homolog), beta 128658 RC_AA252672_ s BE397354 Hs.324830 diptheria toxin resistance protein required for diphthamide biosynthesis (Saccharomyces)-like 2 105489 RC_AA256157 AA256157 Hs.24115 Homo sapiens cDNA FLJ14178 fis, clone NT2RP2003339 105508 RC_AA256680 AA173942 Hs.326416 Homo sapiens mRNA; cDNA DKFZp564H1916 (from clone DKFZp564H1916) 105539 RC_AA258873 AB040884 Hs.109694 KIAA1451 protein 135172 RC_AA262727 AB028956 Hs.12144 KIAA1033 protein 131569 RC_AA281451 AL389951 Hs.271623 nucleoporin 50kD 132542 RC_AA281545 AL137751 Hs.263671 Homo sapiens mRNA; cDNA DKFZp434l0812 (from clone DKFZp434l0812); partial eds 105643 RC_AA282069 BE621719 Hs.173802 KIAA0603 gene product 105659 RC_AA283044 AA283044 Hs.25625 hypothetical protein FLJ11323 105666 RC_AA283930 AA426234 Hs.34906 ESTs, Weakly similar to T1 210 hypothetical protein DKFZp434N041.1 [H.sapiens] 105674 RC_AA284755 AI609530 Hs.279789 histone deacetylase 3 105709 RC_AA291268 A1928962 Hs.26761 DKFZP586L0724 protein 105722 RC_AA291927 AI922821 Hs.32433 ESTs 105765 RC_AA343514 AA299688 Hs.24183 ESTs 115951 RC_AA398109 BE546245 Hs.301048 see13-like protein 105962 RC_AA405737 AW880358 Hs.339808 hypothetical protein FLJ10120 105985 RC_AA406610 AA406610 gb:zv15b10.s1 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE 53691 3' similar to gb:X02067

106008 RC_AA411465 AB033888 Hs.8619 SRY (sex determining region Y)-box 18

131216 RC_AA416886 AI815486 Hs.243901 Homo sapiens cDNA FLJ20738 fis, clone HEP08257

134222 RC_AA424013 AW855861 Hs.8025 Homo sapiens clone 23767 and 23782 mRNA sequences

113689 RC_AA424148 AB037850 Hs.16621 DKFZP434I116 protein

106141 RC_AA424558 AF031463 Hs.9302 phosducin-like

130839 RC_AA424961_: s AB011169 Hs.20141 similar to S. cerevisiae SSM4

106157 RC.AA425367 W37943 Hs.34892 KIAA1323 protein

130777 RC_AA425921 A W135049 Hs.285418 Homo sapiens cDNA FLJ10643 fis, clone NT2RP2005753, highly similar to Homo sapiens 1-1 receptor

130561 RC_AA426220 AB011095 Hs.16032 KIAA0523 protein

106196 RC_AA427735 AA525993 Hs.173699 ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION

WARNING

131878 RC_AA430673 AA083764 Hs.6101 hypothetical protein MGC3178

133200 RC_AA432248 AB037715 Hs.183639 hypothetical protein FLJ10210 106302 RC_AA435896 AA398859 Hs.18397 hypothetical protein FLJ23221 106328 RC_AA436705 AL079559 Hs.28020 KIAA0766 gene product 450534 RC_AA446561 AI570189 Hs.25132 KIAA0470 gene product

106423 RC_AA448238 AB020722 Hs.16714 Rho guanine exchange factor (GEF) 15

133442 RC_AA448688 AL137663 Hs.7378 Homo sapiens mRNA; cDNA DKFZp434G227 (from clone DKFZp434G227)

439608 RC_AA449756 AW864696 Hs.301732 hypothetical protein MGC5306 106477 RC_AA450303 R23324 Hs.41693 DnaJ (Hsp40) homolog, subfamily B, member 4 106503 RC_AA452411 AB033042 Hs.29679 cofactor required for Sp1 transcriptional activation, subunit 3 (130kD) 446999 RC_AA454566 AA151520 Hs.334822 hypothetical protein MGC4485 106543 RC_AA454667 AA676939 Hs.69285 neuropilin 1 130010 RC_AA456437 AA301116 Hs.142838 πucleolarphosphoprotein Nopp34 106589 RC_AA456646 AK000933 Hs.28661 Homo sapiens cDNA FLJ10071 fis, clone HEMBA1001702 106593 RC_AA456826 AW296451 Hs.24605 ESTs 106596 RC_AA456981 AA452379 Hs.293552 ESTs, Moderately similar to ALU7_HUMAN ALU SUBFAMILY SQ SEQUENCE

CONTAMINATION

134655 RC_AA458959 AF265208 Hs.123090 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily f, member 1

106636 RC_AA459950 AW958037 Hs.286 ribosomal protein L4

106654 RC_AA460449 AW075485 Hs.286049 phosphoserine aminotransferase 131353 RC_AA463910 AW754182 gb:RC2-CT0321-131199-011-c01 CT0321 Homo sapiens cDNA, mRNA sequence 106707 RC_AA464603 AK000566 Hs.98135 hypothetical protein FLJ20559 131710 RC_AA464606 NM 015368 Hs.30985 pannexin 1 106717 RC_AA465093 AA600357 Hs.239489 TIA1 cytotoxic granule-associated RNA-binding protein

131775 RC_AA465692 AB014548 Hs.31921 KIAA0648 protein

106747 RC_AA476473 NMJ07118 Hs.171957 triple functional domain (PTPRF interacting)

106773 RC_AA478109 AA478109 Hs.188833 ESTs 106781 RC_AA478474 AA330310 Hs.24181 ESTs 106817 RC_AA480889 D61216 Hs.18672 ESTs 106846 RC_AA485223 AB037744 Hs.34892 KIAA1323 protein 106848 RC_AA485254 AA449014 Hs.121025 chromosome 11 open reading frame 5 106856 RC_AA486183 W58353 Hs.285123 Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 2005779 418699 RC_AA496936 BE539639 Hs.173030 ESTs, Weakly similar to ALU8_HUMAN ALU SUBFAMILY SX SEQUENCE CONTAMINATION

WARNING

107001 RC_AA598589 AI926520 Hs.31016 putative DNA binding protein

130638 RC_AA598831 f AW021276 Hs.17121 ESTs 107054 RC_AA600150 AI076459 Hs.15978 KIAA1272 protein 107059 RC_AA608545 BE614410 Hs.23044 RAD51 (S. cerevisiae) homolog (E coli RecA homolog) 107080 RC_AA609210 AL122043 Hs.19221 hypothetical protein DKFZp566G1424 107115 RC_AA610108 BE379623 Hs.27693 peptidylprolyl isomerase (cyclophilin)-like 1 107130 RC_AA620582 AB033106 Hs.12913 KIAA1280 protein 107156 RC_AA621239 AA137043 Hs.9663 programmed cell death 6-interacting protein 107174 RC_AA621714 BE122762 Hs.25338 ESTs 130621 RC_AA621718 AW513087 Hs.16803 LUC7 (S. cerevisiae)-like 107190 RC_D19673 AA836401 Hs.5103 ESTs 132626 RC_D25755_s AW504732 Hs.21275 hypothetical protein FLJ11011 107217 RC_D51095 AL080235 Hs.35861 DKFZP586E1621 protein 131610 RC_D60272_i AA357879 Hs.29423 scavenger receptor with C-type lectin 129604 T08879 AF088886 Hs.11590 cathepsin F 107295 T34527 AA186629 Hs.80120 UDP-N-acetyl-alpha-D^alactosamine:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-TI) 107299 T40327_s BE277457 Hs.30661 hypothetical protein MGC4606

107315 T62771_s AA316241 Hs.90691 nucleophosmin/nucleoplasmin 3 107316 T63174_s " T63174 Hs.193700 Homo sapiens mRNA; cDNA DKFZp586l0324 (from clone DKFZp586l0324) 107328 T83444 AW959891 Hs.76591 KIAA0887 protein 107334 T93641 T93597 Hs.187429 ESTs 134715 U48263 U48263 Hs.89040 prepronociceptin 128636 U49065 U49065 Hs.102865 interleukin 1 receptor-like 2 129938 U79300 AW003668 Hs.135587 Human clone 23629 mRNA sequence 107375 U88573 BE011845 Hs.251064 high-mobility group (nonhistone chromosomal) protein 14 130074 U93867 AL038596 Hs.250745 polymerase (RNA) III (DNA directed) (62kD) 107387 W01094 D86983 Hs.118893 Melanoma associated gene 132036 W01568 AL157433 Hs.37706 hypothetical protein DKFZp434E2220 107426 W26853 W26853 Hs.291003 hypothetical protein MGC4707 113857 W27179 AW243158 Hs.5297 DKFZP564A2416 protein 135388 W27965 W27965 Hs.99865 epimorphin 130419 W36280_s AF037448 Hs.155489 NS1-associated protein 1 107469 W47063 W47063 Hs.94668 ESTs 132616 W79060 BE262677 Hs.283558 hypothetical protein PR01855 107506 W88550 AB028981 Hs.8021 KIAA1058 protein 132358 X60486 NM 003542 Hs.46423 H4 histαπe family, member G 107522 X78931_s X78931 Hs.99971 zinc finger protein 272 125827 Z14077_S NM 003403 Hs.97496 YY1 transcription factor 107582 RC_AA002147 AA002147 Hs.59952 EST

107609 RC_AA004711 R75654 Hs.164797 hypothetical protein FLJ13693 107661 RC_AA010383 AA010383 Hs.60389 ESTs 107714 RC_AA015761 AA015761 Hs.60642 ESTs 107775 RC_AA018772 AW008846 Hs.60857 ESTs 107832 RC_AA021473_r AA021473 gb:ze66c11.s1 Soares retina N2b4HR Homo sapiens cDNA clone IMAGE:3639563', mRNA sequence.

107859 RC_AA024835 AW732573 Hs.47584 potassium voltage-gated channel, delayed-rectifier, subfamily S, member 3 124337 RC_AA025858 N23541 Hs.281561 Homo sapiens cDNA: FLJ23582 fis, clone LNG13759 107914 RC_AA027229 AA027229 Hs.61329 ESTs, Weakly similar to T16370 hypothetical protein F45E12.5 - Caenorhabditis elegans [C.elegans]

107935 RC_AA029428 AA029428 Hs.61555 ESTs

116262 RC_AA035143 AI936442 Hs.59838 hypothetical protein FLJ10808 131461 RC_AA035237 AA992841 Hs.27263 KIAA1458 protein 108007 RC_AA039347 AA039347 Hs.61916 EST 108029 RC. 040740 AA040740 Hs.62007 ESTs 108040 RC_AA041551 AL121031 Hs.159971 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1

108084 RC_AA045513 AA058944 Hs.116602 Homo sapiens, clone IMAGE:4154008, mRNA, partial eds 108088 RC_AA045745 AA045745 Hs.62886 ESTs 108168 RC_AA055348 AI453137 Hs.63176 ESTs 130719 RC_AA056582_s AA679262 Hs.14235 hypothetical protein FLJ20008; KIAA1839 protein 108189 RC_AA056697 AW376061 Hs.63335 ESTs, Moderately similar to A46010 X-linked retinopathy protein [H.sapiens]

108190 RC_AA056746 AA056746 Hs.63338 EST 108203 RC_AA057678 AW847814 Hs.289005 Homo sapiens cDNA: FLJ21532 fis, clone COL06049 108216 RC_AA058681 AA524743 Hs.44883 ESTs 108217 RC_AA058686 AA058686 Hs.62588 ESTs 108245 RC_AA062840 BE410285 Hs.89545 proteasome (prosome, macropain) subunit, beta type, 4 108277 RC_AA064859 AA064859 gb:zm50f03.s1 Stratagene fibroblast (937212) Homo sapiens cDNA clone IMAGE:5290853', mRNA

108280 RC_AA065069 AA065069 gb:zm12e11.s1 Stratagene pancreas (937208) Homo sapiens cDNA clone 3', mRNA sequence 108309 RC_AA069923 AA069818 gb:zm67e03.r1 Stratagene neuroepithelium (937231) Homo sapiens cDNA clone 5' similar to 133739 RC_AA070799_s BE536554 Hs.278270 unactive progesterone receptor, 23 kD 108340 RC_AA070815 AA069820 Hs.180909 peroxiredoxin 1 108403 RC_AA075374 AA075374 gb:zm87a01.s1 Stratagene ovarian cancer (937219) Homo sapiens cDNA clone IMAGE:544872 3', mRNA sequence, 108427 RC_AA076382 AA076382 gb:zm91g08.s1 Stratagene ovarian cancer (937219) Homo sapiens cDNA clone IMAGE:545342 3', mRNA sequence. 108435 RC_AA078787 T82427 Hs.194101 Homo sapiens cDNA: FLJ20869 fis, clone ADKA02377 108439 RC_AA078986 AA078986 gb:zm92h01.s1 Stratagene ovarian cancer (937219) Homo sapiens cDNA clone IMAGE:545425 3', mRNA sequence. 108465 RC_AA079393 AA079393 Hs.3462 cytochrome c oxidase subunit Vile 108469 RC_AA079487 AA079487 gb:zm97fi)8.s1 Stratagene colon HT29 (937221) Homo sapiens cDNA clone 3', mRNA sequence 108500 RC W083207 AA083207 Hs.68270 EST

108501 RC_AA083256 AA083256 gb:zn08g12.s1 Stratagene hNT neuron (937233) Homo sapiens cDNA clone 3' similar to gb:M33308

108533 RC_AA084415 AA084415 gb:zn06g09.s1 Stratagene hNT neuron (937233) Homo sapiens cDNA clone IMAGE:546688 3', mRNA

108562 RC_AA085274 AA100796 gb:zm26c06.s1 Stratagene pancreas (937208) Homo sapiens cDNA clone 3' similar to gb:X15341

108589 RC_AA088678 AI732404 Hs.68846 ESTs

130890 RC_AA100925 AI907537 Hs.76698 stress-associated endoplasmic reticulum protein 1; ribosome associated membrane protein 4 134585 RC_AA101255 D14041 Hs.278573 H-2K binding factor-2 130385 RC_AA126474 AW067800 Hs.155223 stanniocalcin 2 108749 RC_AA127017 AA127017 Hs.71052 ESTs 108807 RC_AA129968 AI652236 Hs.49376 hypothetical protein FLJ20644 108808 RC_AA130240 AA045088 Hs.62738 ESTs 108833 RC_AA131866 AF188527 Hs.61661 ESTs, Weakly similar to AF174605 1 F-box protein Fbx25 [H.sapiens] 107290 RC_AA132039 W27740 Hs.323780 ESTs 108846 RC_AA132983 AL117452 Hs.44155 DKFZP586G1517 protein 108857 RC_AA133250 AK001468 Hs.62180 anillin (Drosophila Scraps homolog), actin binding protein 131474 RC_AA133583 s L46353 Hs.2726 high-mobility group (nonhistone chromosomal) protein isoform l-C 108894 RC_AA135941 AK001431 Hs.5105 hypothetical protein FLJ10569 108941 RC AA148650 AA148650 gb:zo09e06.s1 Stratagene neuroepithelium NT2RAMI 937234 Homo sapiens cDNA clone

IMAGE:5672023',

108968 RC_AA151110 AI304870 Hs.188680 ESTs

108996 RC_AA155754 AW995610 Hs.332436 EST 109001 RC_AA156125 AI056548 Hs.72116 hypothetical protein FLJ20992 similar to hedgehog-interacting protein 131183 RC_AA156289 AI611807 Hs.285107 hypothetical protein FLJ13397 109019 RC_AA156997 AA156755 Hs.72150 ESTs 109022 RC_AA157291 AA157291 Hs.21479 ubinuclein 1 109023 RC_AA157293 AA157293 Hs.72168 ESTs 109068 RC AA164293 f AA164293 Hs.72545 ESTs 109072 RC_AA164676 AI732585 Hs.22394 hypothetical protein FLJ 10893 129021 RC_AA167375 AL044675 Hs.173081 KIAA0530 protein 130346 RC_AA167550 H05769 Hs.188757 Homo sapiens, clone MGC:5564, mRNA, complete eds 109146 RC_AA176589 AA176589 Hs.142078 EST 109172 RC_AA180448 AA180448 Hs.144300 EST 131080 RC_AA187144 s NM_001955 Hs.2271 endothelin 1 129208 RC_AA189170 f AI587376 Hs.109441 MSTP033 protein 109222 RC_AA192757 AA192833 Hs.333512 similar to rat myomegalin 109300 RC AA205650 AA418276 Hs.170142 ESTs 109481 RC_AA233342 AA878923 Hs.289069 hypothetical protein FLJ21016 109485 RC_AA233472 BE619092 Hs.28465 Homo sapiens cDNA: FLJ21869 fis, clone HEP02442 109516 RC_AA234110 AI471639 Hs.71913 ESTs 109537 RC_D80981 AI858695 Hs.34898 ESTs 109556 RC.F01660 AI925294 Hs.87385 ESTs 109577 RC_F02206 F02206 Hs.296639 Homo sapiens potassium channel subunit (HERG-3) mRNA, complete eds 109578 RC_F02208 F02208 Hs.27214 ESTs 109595 RC_F02544 AA078629 Hs.27301 ESTs 109625 RC_F03918 H29490 Hs.22697 ESTs 131983 RC_F04258_s AF119665 Hs.184011 pyrophosphatase (inorganic) 109648 RC_F04600 H17800 Hs.7154 ESTs 109671 RC_F08998 R59210 Hs.26634 ESTs 109699 RC F09605 H18013 Hs.167483 ESTs 109820 RC_F11115 AW016809 Hs.323795 ESTs 109933 RC_H06371 R52417 Hs.20945 Homo sapiens clone 24993 mRNA sequence 110014 RC_H10995 AL109666 Hs.7242 Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 35907 110039 RC H11938 H11938 Hs.21907 histone acetyltransferase 110099 RCJH16568 R44557 Hs.23748 ESTs 110107 RC_H16772 AW151660 Hs.31444 ESTs 110155 RC_H18951 AI559626 Hs.93522 Homo sapiens mRNA for KIAA1647 protein, partial eds 110197 RC_H20859 AW090386 Hs.112278 arrestin, beta 1 110223 RC_H23747 H19836 Hs.31697 ESTs 110306 RC_H38087 H38087 Hs.105509 CTL2 gene 110335 RC_H40331 H65490 Hs.18845 ESTs 110342 RC_H40567 H40961 Hs.33008 ESTs 110395 RC_H46966 AA025116 Hs.33333 ESTs 110511 RC_H56640_i H56640 Hs.221460 ESTs 110523 RCH57154 AI040384 Hs.19102 ESTs, Weakly similar to organic anion transporter 1 [H.sapiens] 110715 RC_H96712 H96712 Hs.269029 ESTs 110754 RC_N20814 AW302200 Hs.6336 KIAA0672 gene product 130132 RC_N25249 U55936 Hs.184376 synaptosomal-associated protein, 23kD 131135 RC_N27100 NMJ16569 Hs.267182 TBX3-iso protein 134263 RC_N39616 AW973443 Hs.8086 RNA (guanine-7-) methyltransferase 110938 RC_N48982 N48982 Hs.38034 Homo sapiens cDNA FLJ12924 fis, clone NT2RP2004709 110983 RC_N51957 NM.015367 Hs.10267 MIL1 protein 115062 RC.N52271 AA253314 Hs.154103 LIM protein (similar to rat protein kinase C-binding enigma) 111081 RC_N59435 A1146349 Hs.271614 CGI-112 protein 111128 RC N64139 AW505364 Hs.19074 LATS (large tumor suppressor, Drosophila) homolog 2

135244 RC N66981 AI834273 Hs.9711 novel protein

111216 RC N68640 AW139408 Hs.152940 ESTs

437562 RC N69352 AB001636 Hs.5683 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 15

131002 RC N95226 AL050295 Hs.22039 KIAA0758 protein

111399 RC R00138 AW270776 Hs.18857 ESTs

111514 RC_R07998 R07998 gb:yf16g11.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:127076 3' similarto

130182 RC R08929 BE267033 Hs.192853 ubiquitin-conjugating enzyme E2G 2 (homologous to yeast UBC7)

111574 RC_R10307 AI024145 Hs.188526 ESTs

111804 RC R33354 AA482478 Hs.181785 ESTs

111831 RC R36083 R36095 Hs.268695 ESTs

129675 RC R37938 f NM 015556 Hs.172180 KIAA0440 protein

111904 RC_R39330 Z41572 gb:HSCZYB122 normalized infant brain cDNA Homo sapiens cDNA clone c-∑yb12, mRNA sequence

133868 RC R40816 s AB012193 Hs.183874 cullin 4A

112033 RC R43162_s R49031 Hs.22627 ESTs

130987 RC R45698 BE613269 Hs.21893 hypothetical protein DKFZp761N0624

112300 RC R54554 H24334 Hs.26125 ESTs

112513 RC R68425 R68425 Hs.13809 hypothetical protein FLJ10648

112514 RC R68568 R68568 Hs.183373 src homology 3 domain-containing protein HIP-55

112522 RC_R68763 R68857 Hs.265499 ESTs

112540 RC_R70467 R69751 gb:yi40a10.s1 Soares placenta Nb2HP Homo sapiens cDNA clone 3', mRNA sequence

130346 RC R73565 H05769 Hs.188757 Homo sapiens, clone MGC:5564, mRNA, complete eds

129534^' RC R73640 AK002126 Hs.11260 hypothetical protein FLJ11264

112597 RC R78376 R78376 Hs.29733 EST

112732 RC R92453 R92453 Hs.34590 ESTs

131458 RC T03865 BE297567 Hs.27047 hypothetical protein FLJ20392

112888 RC T03872 AW195317 Hs.107716 hypothetical protein FLJ22344

131863 RC T10072 AI656378 Hs.33461 ESTs

112911 RC_T10080 AW732747 Hs.13493 like mouse brain protein E46

132215 RC T10132 AL035703 Hs.4236 KIAA0478 gene product

112931 RC T15343 T02966 Hs.167428 ESTs

112984 RC T23457 T16971 Hs.289014 ESTs, Weakly similarto A43932 mucin 2 precursor, intestinal [H.sapiens]

112998 RC T23555 H11257 Hs.22968 Homo sapiens clone IMAGE:451939, mRNA sequence

133376 RC T23670 BE618768 Hs.7232 acetyl-Coenzyme A carboxylase alpha

113026 RC T23948 AA376654 Hs.183684 eukaryotic translation initiation factor 4 gamma, 2

113070 RC T33464 AB032977 Hs.6298 KIAA1151 protein

128970 RC T34413 AI375672 Hs.165028 ESTs

113074 RC T34611 AK001335 Hs.31137 protein tyrosine phosphatase, receptor type, E

113095 RC T40920 AA828380 Hs.126733 ESTs

113179 RC T55182 BE622021 Hs.152571 ESTs, Highly similar to IGF-II mRNA-binding protein 2 [H.sapiens]

113337 RC T77453 T77453 Hs.302234 ESTs

113421 RC_T84039 AI769400 Hs.189729 ESTs

113454 RC_T86458 AI022166 Hs.16188 ESTs

113481 RC T87693 T87693 Hs.204327 EST

131441 RC T89350 s AA302862 Hs.90063 neurocalcin delta

113557 RCJ90945 H66470 Hs.16004 ESTs

113559 RC T90987 T79763 Hs.14514 ESTs

113589 RC_T91863 AI078554 Hs.15682 ESTs

113591 RC_T91881 T91881 Hs.200597 KIAA0563 gene product

113619 RC T93783_s R08665 Hs.1 244 hypothetical protein FLJ13605

113683 RC T96687 AB035335 Hs.144519 T-cell leukemia/lymphoma 6

113692 RC 96944 AL360143 Hs.17936 DKFZP434H132 protein

113702 ROJ97307 T97307 gb:ye53h05.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:121497 3' mRNA

113717 RC_T97764 T99513 Hs.187447 ESTs

113824 RC W48817 AI631964 Hs.34447 ESTs

113840 RC W58343 R72137 Hs.7949 DKFZP586B2420 protein

113844 RC W59949 AI369275 Hs.243010 Homo sapiens cDNA FLJ14445 fis, clone HEMBB1001294, highly similarto GTP-BINDING

PROTEIN TC10

113902 RC_W74644 AA340111 Hs.100009 acyl-Coenzyme A oxidase 1, palmitoyl

113904 RC_W74761 AF125044 Hs.19196 ubiquitin-conjugating enzyme HBUCE1

113905 RC W74802 R81733 Hs.33106 ESTs

113931 RC Λ/81205 BE255499 Hs.3496 hypothetical protein MGC15749

113932 RC W81237 AA256444 Hs.126485 hypothetical protein FLJ12604; KIAA1692 protein

131965 RC W90146 W79283 Hs.35962 ESTs

114035 RC W92798 W92798 Hs.269181 ESTs

114106 RC Z38412 AW602528 gb:RC5-BT0562-260100-011-A02 BT0562 Homo sapiens cDNA, mRNA sequence

133593 RC_Z38709 A1416988 Hs.238272 inositol 1,4,5-triphosphate receptor, type 2

114161 RC Z38904 BE548222 Hs.299883 hypothetical protein FLJ23399

424949 RC_Z39103 AF052212 Hs.153934 core-binding factor, runt domain, alpha subunit 2; translocated to, 2

129059 RC_Z39930_f AW069534 Hs.279583 CGI-81 protein

128937 RC_Z39939 AA251380 Hs.10726 ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION

WARNING

130983 RC_Z40012_i AI479813 Hs.278411 NCK-associated protein 1 114277 RC_Z40377_s AI052229 Hs.25373 ESTs, Weakly similar to T20410 hypothetical protein E02A10.2 - Caenorhabditis elegans [C.elegans] 114304 RC_Z40820 AI934204 Hs.16129 ESTs 114364 RC_Z41680 AL117427 Hs.172778 Homo sapiens mRNA; cDNA DKFZp566P013 (from clone DKFZp566P013) 132900 RC_AA005112 AA777749 Hs.5978 LIM domain only 7 129034 RC_AA005432 AA481157 Hs.108110 DKFZP547E2110 protein 131881 RC.AA010163 AW361018 Hs.3383 upstream regulatory element binding protein 1 452461 RC_AA026356 N78223 Hs.108106 transcription factor 114465 RC_AA026901 BE621056 Hs.131731 hypothetical protein FLJ11099 131376 RC_AA036867 AK001644 Hs.26156 hypothetical protein FLJ10782 101567 RC_AA044644 M33552 Hs.56729 lysosomal 431555 RC_AA046426 AI815470 Hs.260024 Cdc42 effector protein 3 132944 RC_AA054515 T96641 Hs.6127 Homo sapiens cDNA: FLJ23020 fis, clone LNG00943 114618 RC_AA084162 AW979261 Hs.291993 ESTs 130274 RC_AA085749 AA128376 Hs.153884 ATP binding protein associated with cell differentiation 110330 RC_AA098874 AI288666 Hs.16621 DKFZP434I116 protein 114648 RC_AA101056 AA101056 gb:zn25b03.s1 Stratagene neuroepithelium NT2RAMI 937234 Homo sapiens cDNA clone IMAGE:5484293' 114658 RC_AA102746 AA102383 Hs.249190 tumor necrosis factor receptor superfamily, member 10a 132456 RC_AA114250_s AB011084 Hs.48924 KIAA0512 gene product; ALEX2 131319 RC_AA126561_s NM 003155 Hs.25590 stanniocalcin 1 132225 RC_AA128980_i AA128980 gb:zo09a11.s1 Stratagene neuroepithelium NT2RAMI 937234 Homo sapiens cDNA clone IMAGE:5671643' 132669 RC .AA129757 W38586 Hs.293981 guanine nucleotide binding protein (G protein), gamma 3, linked

114709 RC_AA129921 AA397651 Hs.301959 proline synthetase co-transcribed (bacterial homolog) 131973 RC_AA133331 AB018284 Hs.158688 KIAA0741 gene product 114750 RC_AA135958 AA887211 Hs.129467 ESTs 115714 RC_AA136524_s T19228 Hs.172572 hypothetical protein FLJ20093 114763 RC_AA147044 AA810755 Hs.88977 hypothetical protein dJ511E16.2 114767 RC_AA148885 AI859865 Hs.154443 minichromosome maintenance deficient (S. cerevisiae) 4 114774 RC_AA150043 AV656017 Hs.184325 CGI-76 protein 129388 RC_AA151621 AA662477 Hs.110964 hypothetical protein FLJ23471 129183 RC_AA155743 BE561824 Hs.273369 uncharacterized hematopoietic stem/progenitor cells protein MDS027 128869 RC_AA156335 AA768242 Hs.80618 hypothetical protein 130207 RC_AA156336 AF044209 Hs.144904 nuclear receptor co-repressor 1 114798 RC_AA159181 AA159181 Hs.54900 serologically defined colon cancer antigen 1 114800 RC_AA159825 Z19448 Hs.131887 ESTs, Weakly similar to T24396 hypothetical protein T03F6.2 - Caenorhabditis elegans [C.elegans]

114828 RC_AA234185 AA252937 Hs.283522 Homo sapiens mRNA; cDNA DKFZp434J1912 (from clone DKFZp434J1912)

114846 RC_AA234929 BE018682 Hs.166196 ATPase, Class I, type 8B, member 1 114848 RC_AA234935 BE614347 Hs.169615 hypothetical protein FLJ20989 114902 RC_AA236359 AW275480 Hs.39504 hypothetical protein MGC4308 132271 RC_AA236466 AB030034 Hs.115175 sterile-alpha motif and leucine zipper containing kinase AZK 114907 RC_AA236535 N29390 Hs.13804 hypothetical protein dJ462023.2 135159 RC_AA236935_s U43374 Hs.95631 Human normal keratinocyte mRNA 132204 RC_AA236942 AA235827 Hs.42265 ESTs 114928 RC_AA237018 AA237018 Hs.94869 ESTs 132481 RC_AA237025 W93378 Hs.49614 ESTs 114932 RC_AA242751 AA971436 Hs.16218 KIAA0903 protein 314162 RC_AA242760 BE041820 Hs.38516 Homo sapiens, clone MGC:15887, mRNA, complete eds 131006 RC_AA242763 AF064104 Hs.22116 CDC 14 (cell division cycle 14, S. cerevisiae) homolog B 114935 RC_AA242809 H23329 Hs.290880 ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION WARNING

132454 RC_AA243133 BE296227 Hs.250822 serine/threonine kinase 15

437754 RC_AA243495 R60366 Hs.5822 Homo sapiens cDNA: FLJ22120 fis, clone HEP18874 114957 RC_AA243706 AW170425 Hs.87680 ESTs 114974 RC_AA250848 AW966931 Hs.179662 nucleoso e assembly protein 1-like 1 114977 RC_AA250868 AW296978 Hs.87787 ESTs 114995 RC_AA251152 AA769266 Hs.193657 ESTs 115005 RC_AA251544_s AI760825 Hs.111339 ESTs 417177 RC_AA251792 NM 04458 Hs.81452 fatty-acid-Coenzyme A ligase, long-chain 4 131889 RC_AA252063 NM.002589 Hs.34073 BH-protocadherin (brain-heart) 115026 RC_AA252144 AA251972 Hs.188718 ESTs 115045 RC_AA252524 AW014549 Hs.58373 ESTs 115068 RC_AA253461 AW512260 Hs.87767 ESTs 133138 RC_AA255522 AV657594 Hs.181161 Homo sapiens cDNA FLJ14643 fis, clone NT2RP2001597, weakly similarto RYANODINE RECEPTOR, 115114 RC_AA256468 AA527548 Hs.7527 small fragment nuclease 129584 RC_AA256528 AV656017 Hs.184325 CGI-76 protein 115137 RC_AA257976 AW968304 Hs.56156 ESTs 134312 RC_AA258296 AB011151 Hs.334659 hypothetical protein MGC14139

115166 RC_AA258409 AF095727 Hs.287832 myelin protein zero-like 1

115167 RC_AA258421 AA749209 Hs.43728 hypothetical protein 129807 RC_AA262077 Y11192 Hs.5299 aldehyde dehydrogenase 5 family, member A1 (succinate-se ialdehyde dehydrogenase) 115239 RC_AA278650 BE251328 Hs.73291 hypothetical protein FLJ10881 115243 RC_AA278766 AA806600 Hs.116665 KIAA1842 protein 100850 RC AA279667_s AA836472 Hs.297939 cathepsin B

126884 RC AA280791 U49436 Hs.286236 KIAA1856 protein

115322 RC AA280819 L08895 Hs.78995 MADS box transcription enhancer factor 2, polypeptide C (myocyte enhancer factor 2C)

133626 RC AA280828 AW836130 Hs.75277 hypothetical protein FLJ13910

115372 RC AA282195 AW014385 Hs.88678 ESTs, Weakly similar to Unknown [H.sapiens]

132825 RC AA283127_s U82671 Hs.57698 Empirically selected from AFFX single probeset

130269 RC AA284694 F05422 Hs.168352 nucleoporin-like protein 1

129192 RC AA291137 AA286914 Hs.183299 ESTs

452598 RC 291708 AI831594 Hs!θ8647 ESTs, Weakly similar to ALU7.HUMAN ALU SUBFAMILY SQ SEQUENCE CONTAMINATION WARNING

132131 RC AA293495 AF069291 Hs.40539 chromosome 8 open reading frame 1

115536 RC AA347193 AK001468 Hs.62180 anillin (Drosophila Scraps homolog), actin binding protein

132411 RC AA398474_s AA059412 Hs.47986 hypothetical protein MGC10940

115575 RC AA398512 AA393254 Hs.43619 ESTs

115601 RC AA400277 AA148984 Hs.48849 ESTs, Weakly similar to ALU4.HUMAN ALU SUBFAMILY SB2 SEQUENCE CONTAMINATION WARNING

103928 RC AA400896 D14540 Hs.199160 myeloid/lymphoid or mixed-lineage leukemia (trithorax (Drosophila) homolog)

125819 RC .AA404494 AA044840 Hs.251871 CTP synthase

115683 RC .AA410345 AF255910 Hs.54650 junctional adhesion molecule 2

115715 RC .AA416733 BE395161 Hs.1390 proteasome (prosome, macropain) subunit, beta type, 2

132952 RC AA425154 AI658580 Hs.61426 Homo sapiens mesenchymal stem cell protein DSC96 mRNA, partial eds

115819 RC AA426573 AA486620 Hs.41135 endomucin-2

132525 RC AA431418 AW292809 Hs.50727 N-acetylglucosaminidase, alpha- (Sanfllippo disease IIIB)

115895 RC AA436182 AB033035 Hs.51965 KIAA1209 protein

132333 RC AA437099 AA192669 Hs.45032 ESTs

115962 RC AA446585 AI636361 Hs.179520 hypothetical protein MGC10702

115967 RC AA446887 AI745379 Hs.42911 ESTs

115974 RC .AA447224 BE513442 Hs.238944 hypothetical protein FLJ10631

115985 RC AA447709 AA447709 Hs.268115 ESTs, Weakly similar to T08599 probable transcription factor CA150 [H.sapiens]

129254 RC .AA453624 AA252468 Hs.1098 DKFZp434J1813 protein

133071 RC AA455044 BE384932 Hs.64313 ESTs, Weakly similar to AF257182 1 G-protein-coupled receptor 48 [H.sapiens]

116095 RC AA456045 AA043429 Hs.62618 ESTs

122691 RC AA460454_s R19768 Hs.172788 ALEX3 protein

116210 RC AA476494 BE622792 Hs.172788 ALEX3 protein

116213 RC AA476738 AA292105 Hs.326740 hypothetical protein MGC10947

134585 RC .AA481422 D14041 Hs.278573 H-2K binding factor-2

134790 RC AA482269 BE002798 Hs.287850 integral membrane protein 1

116265 RC AA482595 BE297412 Hs.55189 hypothetical protein

129334 RC .AA485084_s AW157022 Hs.4947 hypothetical protein FLJ22584

116274 RC AA485431_s AI129767 Hs.182874 guanine nucleotide binding protein (G protein) alpha 12

303150 RC AA489057 AA887146 Hs.8217 stro al antigen 2

129945 RC AA489638 BE514376 Hs.165998 PAI-1 mRNA-binding protein

116331 RC. AA491000 N41300 Hs.71616 Homo sapiens mRNA; cDNA DKFZp586N1720 (from clone DKFZp586N1720)

116333 RC AA491250 AF155827 Hs.203963 hypothetical protein FLJ10339

132994 RC. .AA505133 AA112748 Hs.279905 clone HQ0310 P O0310p1

134577 RC .AA598447 BE244323 Hs.85951 exportin, tRNA (nuclear export receptor for tRNAs)

116391 RC AA599243 T86558 Hs.75113 general transcription factor IIIA

116394 RC. AA599574_i NMJ06033 Hs.65370 lipase, endothelial

134531 RC. .AA600153 AI742845 Hs.110713 DEK oncogene (DNA binding)

116417 RC. .AA609309 AW499664 Hs.12484 Human clone 23826 mRNA sequence

116429 RC. AA609710 AF191018 Hs.279923 putative nucleotide binding protein, estradiol-induced

116439 RC. AA610068 AA251594 Hs.43913 PIBF1 gene product

116459 RC. .AA621399 R80137 Hs.302738 Homo sapiens cDNA: FLJ21425 fis, clone COL04162

427505 RC. AA621752 AA361562 Hs.178761 26S proteasome-associated pad 1 homolog

132699 RC. C21523 AW449822 Hs.55200 ESTs

116541 RC. D12160 D12160 Hs.249212 polymerase (RNA) III (DNA directed) (155kD)

132557 RC. D19708 AA114926 Hs.5122 ESTs

112259 RC. D25801 AA337548 Hs.333402 hypothetical protein MGC12760

116571 RC. .D45652 D45652 gb:HUMGS02848 Human adult lung 3' directed Mbol cDNA Homo sapiens cDNA 3', mRNA sequence.

129815 RC. .D60208 BE565817 Hs.26498 hypothetical protein FLJ21657

421919 RC. D80504_s AJ224901 Hs.109526 zinc finger protein 198

116643 RC. .F03010 AI367044 Hs.153638 myeloid/lymphoid or mixed-lineage leukemia 2

116661 RC. .F04247 R61504 gb:yh16a03.s1 Soares infant brain 1NIB Homo sapiens cDNA clone 3' similar to contains Alu repetitive

116715 RC. .F10966 AL117440 Hs.170263 tumor protein p53-binding protein, 1

116729 RC. .F13700 BE549407 Hs.115823 ribonuclease P, 40kD subunit

318709 RC. .H05063 R52576 Hs.285280 Homo sapiens cDNA: FLJ22096 fis, clone HEP16953

134760 RC. .H16758 NM_000121 Hs.89548 erythropoietin receptor

116773 RC. .H17315_s AI823410 Hs.169149 karyopherin alpha 1 (importin alpha 5)

106425 RC. .H22556 H24201 Hs.247423 adducin 2 (beta)

116780 RC. H22566 H22566 Hs.30098 ESTs

131978 RC. H48459_s AA355925 Hs.36232 KIAA0186 gene product

116819 RC. H53073 H53073 Hs.93698 EST

111428 RC. .H56559_s AL031428 Hs.174174 KIAA0601 protein

133175 RC. H57957_s AW955632 Hs.66666 ESTs, Weakly similar to S19560 proline-rich protein MP4 - mouse [M.musculus] 116844 RC H64938 s H64938 Hs 337434 ESTs, Weakly similarto A46010 X-linked retinopathy protein [H sapiens]

116845 RC H64973 AA649530 gb ns44f05 s1 NCI_CGAP_Alv1 Homo sapiens cDNA clone, mRNA sequence

116892 RCH69535 AI573283 Hs 38458 ESTs

116925 RC H73110 H73110 Hs 260603 ESTs, Moderately similar to A47582 B-cell growth factor precursor [H sapiens]

116981 RC H81783 N29218 Hs 40290 ESTs

131768 RC H86259 AC005757 Hs 31809 hypothetical protein

117031 RC_H88353 H88353 gb yw21a02 s1 Morton Fetal Cochlea Homo sapiens cDNA clone IMAGE 2528423' similarto contains L1

117034 RC H88639 U72209 Hs 180324 YY1 -associated factor 2

132542 RC H88675 AL137751 Hs 263671 Homo sapiens mRNA, cDNA DKFZp434l0812 (from clone DKFZp434l0812), partial eds

134403 RC H93708 s AA334551 Hs 82767 sperm specific antigen 2

117280 RC_N22107 M18217 Hs 172129 Homo sapiens cDNA FLJ21409 fis, clone COL03924

117344 RC N24046 R19085 Hs 210706 Homo sapiens cDNA FLJ13182 fis, clone NT2RP3004070

117422 RC N27028 AI355562 Hs 43880 ESTs, Weakly similar to A46010 X-linked retinopathy protein [H,sapιens]

117475 RC N30205 N30205 Hs 93740 ESTs, Weakly similar to I38022 hypothetical protein [H sapiens]

117487 RC N30621 N30621 Hs 44203 ESTs

130207 RC N33258 AF044209 Hs 144904 nuclear receptor co repressor 1

117549 RC N33390 N33390 Hs 44483 EST

117683 RC N40180 N40180 gb yy44d02 s1 Soares_multιple_sclerosιs_2NbHMSP Homo sapiens cDNA clone

IMAGE 2763873' similarto

117710 RC N45198 N45198 Hs 47248 ESTs, Highly similarto similarto Cdc14B1 phosphatase [H sapiens]

104514 RC N45979 s AF164622 Hs 182982 golgιn-67

117791 RC N48325 N48325 Hs 93956 EST

117822 RC N48913 AA706282 Hs 93963 ESTs

129647 RC N49394 AB018259 Hs 118140 KIAA0716 gene product

117895 RC_N50656 AW450348 Hs 93996 ESTs, Highly similar to SORL_HUMAN SORTILIN-RELATED RECEPTOR PRECURSOR

[H sapiens]

131557 RC N50721 AA317439 Hs 28707 signal sequence receptor, gamma (translocon-associated protein gamma)

133057 RC N53143 AA465131 Hs 64001 Homo sapiens clone 25218 mRNA sequence

118103 RC N55326 AA401733 Hs 184134 ESTs

118111 RC N55493 N55493 gb yv50c02 s1 Soares fetal liver spleen 1 FLS Homo sapiens cDNA clone IMAGE 246146 3', mRNA

118129 RC_N57493 N57493 gb yy54c08 s1 Soares_multιple_sclerosιs_2NbHMSP Homo sapiens cDNA clone

IMAGE 2773583', mRNA

118278 RC N62955 N62955 Hs 316433 Homo sapiens cDNA FLJ11375 fis, clone HEMBA1000411, weakly similarto ANKYRIN

118329 RC N63520 N63520 gb yy62f01 s1 Soares_multιple_sclerosιs_2NbHMSP Homo sapiens cDNA clone IMAGE 278137

3', mRNA

118336 RC N63604 BE327311 Hs 47166 HT021

132457 RC N64166 AB017365 Hs 173859 fnzzled (Drosophila) homolog 7

118363 RC N64168 AI183838 Hs 48938 hypothetical protein FLJ21802

118364 RC N64191 N46114 Hs 29169 hypothetical protein FLJ22623

118475 RCN66845 N66845 gb za46d 1 s1 Soares fetal liver spleen 1 NFLS Homo sapiens cDNA clone IMAGE 2956043' similar to

118491 RC N67135 AV647908 Hs 90424 Homo sapiens cDNA FLJ23285 fis, clone HEP09071

118500 RC N67295 W32889 Hs 154329 ESTs

101663 RCN68399 NM 003528 Hs 2178 H2B histone family, member Q

118584 RCN68963 AW136928 gb UI-H-BH-adp-d-08-O-UI s1 NCI_CGAP_Sub3 Homo sapiens cDNA clone 3', mRNA sequence

421983 RC N69331 AI252640 Hs 110364 peptidylprolyl isomerase C (cyclophi n C)

118661 RC N70777 AL137554 Hs 49927 protein kinase NYD-SP15

118684 RC N71364 s N71313 Hs 163986 Homo sapiens cDNA FLJ22765 fis, Clone KAIA1180

118689 RC_N71545 s AW390601 Hs 184544 Homo sapiens, clone IMAGE 3355383, mRNA, partial eds

118690 RCN71571 N71571 Hs 269142 ESTs

118766 RC N74456 N74456 Hs 50499 EST

118793 RC N75594 N75594 Hs 285921 ESTs, Moderately similarto T47135 hypothetical protein DKFZp761L0812 1 [H sapiens]

118817 RC N79035 AI668658 Hs 50797 ESTs

118844 RC N80279 AL035364 Hs 50891 hypothetical protein

118919 RC_N91797 AW452696 Hs 130760 myosin phosphatase, target subunit 2

129558 RCN92454 AW580922 Hs 180446 karyopheπn (importin) beta 1

132692 RC N94581 AW191962 Hs 249239 collagen, type VIII, alpha 2

118996 RC N94746 N94746 Hs 274248 hypothetical protein FLJ20758

119021 RC_N98238 N98238 Hs 55185 ESTs

119039 RC_R02384 AI160570 Hs 252097 pregnancy specific beta-1-glycoproteιn 6

119063 RC R16833 R16833 Hs 53106 ESTs, Moderately similarto ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION

WARNING

118523 RC_R41828 s Y07759 Hs 170157 myosin VA (heavy polypeptide 12, myoxin)

119111 RC_R43203 T02865 Hs 328321 EST

133970 RC R46395 AA214228 Hs 127751 hypothetical protein

119146 RC_R58863 R58863 Hs 91815 ESTs

120296 RCR78248 AW995911 Hs 299883 hypothetical protein FLJ23399

119239 RC_T11483 T11483 gb CHR90049 Chromosome 9 exon Homo sapiens cDNA clone 111-1 5' and 3', mRNA sequence

119281 RC T16896 AI692322 Hs 65373 ESTs, Weakly similar to T02345 hypothetical protein KIAA0324 [H sapiens]

119298 ROJ23820 NM 001241 Hs 155478 cyclin T2

126502 RC_T30222 T10077 Hs 13453 hypothetical protein FLJ14753

135073 RC_W15275_s W55956 Hs 94030 Homo sapiens mRNA, cDNA DKFZp586E1624 (from clone DKFZp586E1624) 119558 RC W38194 W38194 Empirically selected from AFFX single probeset

132736 RC_W42414_s AW081883 Hs.288261 Homo sapiens cDNA: FLJ23037 fis, clone LNG02036, highly similar to HSU68019 Homo sapiens mad protein

132173 RC W46577_s X89426 Hs.41716 endothelial cell-specific molecule 1

134873 RC W49632 s AA884471 Hs.90449 Human clone 23908 mRNA sequence

119650 RC W57613 R82342 Hs.79856 ESTs, Weakly similar to S65657 alpha-1 C-adrenergic receptor splice form 2 [H.sapiens]

119654 RCW57759 W57759 gb:zd20g11.s1 Soares_fetal_heart_NbHH19W Homo sapiens cDNA clone IMAGE:3412523' similarto

119683 RC W61118 W65379 Hs.57835 ESTs

119694 RC W65344 AA041350 Hs.57847 ESTs, Moderately similar to ICE4 HUMAN CASPASE-4 PRECURSOR [H.sapiens]

119718 RC W69216 W69216 Hs.92848 ESTs

133010 RC W69379 AI287518 Hs.62669 Homo sapiens mRNA; cDNA DKFZp586D0923 (from clone DKFZp586D0923)

119938 RC W86728 AW014862 Hs.58885 ESTs

120128 RC Z38499 BE379320 Hs.91448 MKP-1 like protein tyrosine phosphatase

120130 RC Z38630 AA045767 Hs.5300 bladder cancer associated protein

120148 RC Z39494 F02806 Hs.65765 ESTs

120155 RC Z39623 Z39623 Hs.65783 ESTs

131486 RC Z40071 s F06972 Hs.27372 BMX non-receptor tyrosine kinase

120183 RC Z40174 AW082866 Hs.65882 ESTs

120184 RC Z40182 Z40182 Hs.65885 EST

120211 RC Z40904 Z40904 Hs.66012 EST

120245 RC AA166965 AW959615 Hs.111045 ESTs

120247 RC AA167500 AA167500 Hs.103939 EST

120254 RC AA169599 : s W90403 Hs.111054 ESTs

120259 RC AA171724 AW014786 Hs.192742 hypothetical protein FLJ 12785

120260 RC AA171739 AK000061 Hs.101590 hypothetical protein

120275 RC AA177105 AA177105 Hs.78457 solute carrier family 25 (mitochondrial carrier; ornithine transporter) member 15

120284 RC_AA182626 AA179656 gb:zp54e11.s1 Stratagene NT2 neuronal precursor 937230 Homo sapiens cDNA clone 3' similar to contains

114056 RC AA186324 AA188175 Hs.82506 KIAA1254 protein

129507 RC AA192099 AJ236885 Hs.112180 zinc finger protein 148 (pHZ-52)

120302 RC AA192173 AA837098 Hs.269933 ESTs

120303 RC AA192415 AI216292 Hs.96184 ESTs

120305 RC AA192553 AW295096 Hs.101337 uncoupling protein 3 (mitochondrial, proton carrier)

120319 RC AA194851 T57776 Hs.191094 ESTs

133389 RC AA195520 ! 3 AA195764 Hs.72639 ESTs

120326 RC AA196300 AA196300 Hs.21145 hypothetical protein RG083M05.2

134272 RC AA196517 X76040 Hs.278614 protease, serine, 15

133145 RC AA196549 H94227 Hs.6592 Homo sapiens, clone IMAGE:2961368, mRNA, partial eds

120327 RC AA196721 AK000292 Hs.278732 hypothetical protein FLJ20285

106686 RC AA196729J i N66397 Hs.334825 Homo sapiens cDNA FLJ14752 fis, clone NT2RP3003071

120328 RC AA196979 AA923278 Hs.290905 ESTs, Weakly similar to protease [H.sapiens]

120340 RC .AA206828 AA206828 gb:zq80b08.s1 Stratagene hNT neuron (937233) Homo sapiens cDNA clone IMAGE:6478953' similarto

134292 RC AA207123 A1906291 Hs.81234 immunoglobulin superfamily, member 3

131522 RC AA214539 i AI380040 Hs.239489 TIA1 cytotoxic granule-associated RNA-binding protein

129051 RC AA226914 ! 3 AA227068 Hs.108301 nuclear receptor subfamily 2, group C, member 1

120375 RC AA227260 AF028706 Hs.111227 Zic family member 3 (odd-paired Drosophila homolog, heterotaxy 1)

120376 RC .AA227469 AA227469 gb:zr18a07.s1 Stratagene NT2 neuronal precursor 937230 Homo sapiens cDNA clone

IMAGE:6637323', mRNA sequence.

120390 RC_AA233122 AA837093 Hs.111460 calcium/calmodulin-dependent protein kinase (CaM kinase) II delta

303876 RC_AA233334_! 3 U64820 Hs.66521 Machado-Joseph disease (spinocerebellar ataxia 3, olivopontocerebellar ataxia 3, autosomal dominant, ataxin 3)

132038 RC AA233347 AI825842 Hs.3776 zinc finger protein 216

104463 RC AA233519 T85825 Hs.246885 hypothetical protein FLJ20783

125750 RC AA233714 AA018515 Hs.264482 Homo sapiens mRNA; cDNA DKFZp761A0411 (from clone DKFZp761A0411)

120396 RC AA233796 AA134006 Hs.79306 eukaryotic translation initiation factor 4E

120409 RC AA235050 f AA235050 gb:zs38e04.s1 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE:6874863' similarto gb:L07077

120414 RC AA235704 AW137156 Hs.181202 hypothetical protein FLJ10038

120420 RC AA236031 AI128114 Hs.112885 spinal cord-derived growth factor-B

120422 RC AA236352 AL133097 Hs.301717 hypothetical protein DKFZp434N1928

132221 RC AA236390 i 3 W94915 Hs.42419 ESTs

120423 RC AA236453 AA236453 Hs.18978 Homo sapiens cDNA: FLJ22822 fis, clone KAIA3968

120435 RC AA243370 AA243370 Hs.96450 EST

120453 RC AA250947 AA250947 Hs.170263 tumor protein p53-binding protein, 1

120455 RC AA251083 AA251720 Hs.104347 ESTs, Weakly similar to ALUCHUMAN 111! ALU CLASS C WARNING ENTRY III [H.sapiens]

120456 RC AA251113 AA488750 Hs.88414 BTB and CNC homology 1 , basic leucine zipper transcription factor 2

120473 RC_AA251973 AA251973 Hs.269988 ESTs

128922 RC AA252023 AI244901 Hs.9589 ubiquilin 1

120477 RC AA252414 AA252414 Hs.43141 DKFZP727C091 protein

120479 RC AA252650 AF006689 Hs.110299 mitogen-activated protein kinase kinase 7

120488 RC AA255523 AW952916 Hs.63510 KIAA0141 gene product

120510 RC AA258128 AI796395 Hs.111377 ESTs

120527 RC AA262105 AA262105 Hs.4094 Homo sapiens cDNA FLJ14208 fis, clone NT2RP3003264

120528 RC AA262107 AI923511 Hs.104413 ESTs 120529 RC .AA262235 AI434823 Hs.104415 ESTs

120541 RC_AA278298 W07318 Hs.240 M-phase phosphoprotein 1

131445 RCAA278529 j NM_014264 Hs.172052 serine/threonine kinase 18

120544 RCAA278721 BE548277 Hs.103104 ESTs

120562 RC_AA280036 BE244580 Hs.302267 hypothetical protein FLJ10330

120569 RC_AA280648 AA807544 Hs.24970 ESTs, Weakly similar to B34323 GTP-binding protein Rab2 [H.sapiens]

120571 RC_AA280738 AB037744 Hs.34892 KIAA1323 protein

120572 RC_AA280794 H39599 Hs.294008 ESTs

129434 RC_AA280837 AW967495 Hs.186644 ESTs

130529 RC_AA280886 AA178953 gb:zp39e03.s1 Stratagene muscle 937209 Homo sapiens cDNA clone 3' similar to contains Alu repetitive

120575 RCAA280934 AW978022 Hs.238911 hypothetical protein DKFZp762E1511; KIAA1816 protein

132635 RCAA281535 AB020686 Hs.54037 ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative function) 120591 RC_AA281797 .s AF078847 Hs.191356 general transcription factor IIH, polypeptide 2 (44kD subunit) 120593 RC_AA282047 AA748355 Hs.193522 ESTs 430275 RC_AA283002 Z11773 Hs.237786 zinc finger protein 187 117729 RC_AA283709 AA306166 Hs.7145 calpain 7 120609 RCAA283902 AW978721 Hs.266076 ESTs, Weakly similar to A46010 X-linked retinopathy protein [H.sapiens]

132754 RC_AA284108 AI752244 Hs.75309 eukaryotic translation elongation factor 2

130315 RC_AA284109 AI241084 Hs.154353 nonselective sodium potassium/proton exchanger

132614 RC_AA284371 AA284371 Hs.118064 similar to rat nuclear ubiquitous casein kinase 2

447503 RC_AA284744. .f AA115496 Hs.336898 Homo sapiens, Similarto RIKEN cDNA 1810038N03 gene, clone MGC:9890, mRNA, complete eds

135376 RCAA284784 BE617856 Hs.99756 mitochondrial ribosome recycling factor

120621 RCAA284840 AW961294 Hs.143818 hypothetical protein FLJ23459

107868 RC_AA286844 AA286844 Hs.61260 hypothetical protein FLJ13164

129868 RC_AA287032 AW172431 Hs.13012 ESTs 120644 RC.AA287038 AI869129 Hs.96616 ESTs 120660 RC_AA287546 AA286785 Hs.99677 ESTs

135370 RC_AA287553 s BE622187 Hs.99670 ESTs, Weakly similarto I38022 hypothetical protein [H.sapiens] 120661 RC_AA287556 AA287556 Hs.263412 ESTs, Weakly similar to ALUB_HUMAN III! ALU CLASS B WARNING ENTRY 111 [H.sapiens] 129116 RC_AA287564 AB019494 Hs.225767 IDN3 protein 131567 RC_AA291015 s AF015592 Hs.28853 CDC7 (cell division cycle 7, S. cerevisiae, homolog)-like 1 120699 RCAA291 16 AI683243 Hs.97258 ESTs, Moderately similar to S29539 ribosomal protein L13a, cytosolic [H.sapiens] 100690 RC_AA291749 s AA383256 Hs.1657 estrogen receptor 1 120726 RC_AA293656 AA293655 Hs.97293 ESTs 120737 RC_AA302430 AL049176 Hs.82223 chordin-like 120745 RC_AA302809 AA302809 gb:EST10426 Adipose tissue, white I Homo sapiens cDNA 3' end, mRNA sequence, 135192 RC_AA302820 s U83993 Hs.321709 purinergic receptor P2X, ligand-gated ion channel, 4 120750 RC_AA310499 AI191410 Hs.96693 ESTs, Moderately similar to 2109260A B cell growth factor [H.sapiens] 120761 RCAA321890 AA321890 Hs.1265 branched chain keto acid dehydrogenase E1, beta polypeptide (maple syrup urine disease)

120768 RC_AA340589 AA340589 Hs.104560 EST

120769 RC_AA340622 AI769467 Hs.96769 ESTs 135232 RC_AA342457 j AL038812 Hs.96800 ESTs, Moderately similar to ALU7_HUMAN ALU SUBFAMILY SQ SEQUENCE CONTAMINATION 133439 RCAA342828 s Z23091 Hs.73734 glycoprotein V (platelet) 120793 RC_AA342864 AA342864 Hs.96812 ESTs 120796 RC_AA342973 AI247356 Hs.96820 ESTs 120809 RCAA346495 AA346495 gb:EST52657 Fetal heart II Homo sapiens cDNA 3' end similar to EST containing O family repeat, mRNA sequence. 132459 RC_AA347573 AL120071 Hs.48998 fibronectin leucine rich transmembrane protein 2 120825 RC_AA347614 AI280215 Hs.96885 ESTs 120827 RC_AA347717 AA382525 Hs.132967 Human EST clone 122887 mariner transposon Hsmarl sequence 120839 RC_AA348913 AA348913 gb:EST55442 Infant adrenal gland II Homo sapiens cDNA 3' end similar to EST containing Alu repeat, mRNA sequence. 120850 RC_AA349647 AA349647 Hs.96927 Homo sapiens cDNA FLJ12573 fis, clone NT2RM4000979

120852 RC_AA349773 AA349773 Hs.191564 ESTs 128852 RC_AA350541. s R40622 Hs.106601 ESTs 135240 RCAA357159 i AA357159 Hs.96986 EST 120870 RC_AA357172. j AA357172 Hs.292581 ESTs, Moderately similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION

WARNING

134637 RC_AA369856. .s U87309 Hs.180941 vacuolar protein sorting 41 (yeast homolog)

120894 RC_AA370132 AA370132 Hs.97063 ESTs 131854 RC_AA370472. .s AF229839 Hs.173202 l-kappa-B-interacting Ras-like protein 1 120897 RC_AA370867 AA370867 Hs.97079 ESTs, Moderately similar to AF174605 1 F-box protein Fbx25 [H.sapiens] 120915 RC_AA377296 AL135556 Hs.97104 ESTs 120935 RC_AA383902 AL048409 Hs.97177 ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION

WARNING

120936 RCAA385934 AA385934 Hs.97184 EST, Highly similar to (defline not available 7499603) [C.elegans]

120937 RC_AA386255 AA386255 Hs.97186 EST

120938 RC_AA386260 AA386260 Hs.104632 EST 129722 RC \A386266 R20855 Hs.5422 glycoprotein M6B 120960 RC_AA398014 AA398014 Hs.104684 EST 120985 RC.AA398222 AI219896 Hs.97592 ESTs 120988 RC_AA398235 AA398235 Hs.97631 ESTs 121008 RC_AA398348 AA398348 Hs.301720 Human DNA sequence from clone RP11-251 J8 on chromosome 13 Contains ESTs, STSs,

GSSs and a CpG

121029 RC AA398482 AA398482 Hs.97641 EST

121032 RC./AA398504 AA393037 Hs.161798 ESTs

121033 RC AA398505 AA398505 Hs.97360 ESTs

121034 RC AA398507 AL389951 Hs.271623 nucleoporin 50kD

121035 RC_AA398523 AA398523 Hs.210579 ESTs

121058 RC AA398625 AA398625 Hs.97391 ESTs

121060 RC AA398632 AA398632 Hs.97395 ESTs

121061 RC AA398633 AA393288 Hs.97396 ESTs

121091 RC_AA398894 AA398894 Hs.97657 ESTs, Moderately similar to ALU8_HUMAN ALU SUBFAMILY SX SEQUENCE

CONTAMINATION

121092 RC AA398895 AA398895 Hs.97658 EST

121094 RC AA398900 AA402505 gb:zt62h10.r1 Soares testis NHT Homo sapiens cDNA clone 5', mRNA sequence

121096 RC AA398904 AA398904 Hs.332690 ESTs

121115 RCAA399122 AA398187 Hs.104682 ESTs, Weakly similar to mitochondrial citrate transport protein [H.sapiens]

121121 RCAA399371 AA399371 Hs.189095 similarto SALL1 (sal (Drosophila)-like

121122 RC AA399373 AI126713 Hs.192233 ESTs, Highly similar to T00337 hypothetical protein KIAA0568 [H.sapiens]

121125 RC AA399441 AL042981 Hs.251278 KIAA1201 protein

121151 RC AA399636 AA399636 Hs.143629 ESTs

121153 RC AA399640 AA399640 Hs.97694 ESTs

121163 RC AA399680 AI676062 Hs.111902 ESTs

121176 RC AA400080 AL121523 Hs.97774 ESTs

121192 RC AA400262 AA400262 Hs.190093 ESTs

121223 RO.AA400725 AI002110 Hs.97169 ESTs, Weakly similar to dJ667H12.2.1 [H.sapiens]

121227 RC AA400748 AA400748 Hs.97823 Homo sapiens mRNA; cDNA DKFZp434D024 (from clone DKFZp434D024)

121231 RC AA400780 AA814948 Hs.96343 ESTs, Weakly similarto ALUC.HUMAN III! ALU CLASS C WARNING ENTRY II! [H.sapiens]

121278 RC AA401631 AA037121 Hs.98518 Homo sapiens cDNA FLJ11490 fis, clone HEMBA1001918

121279 RC AA401688 AA292873 Hs.177996 ESTs

121282 RC AA401695 AA401695 Hs.97334 ESTs

121299 RC AA402227 AA402227 Hs.22826 tropomodulin 3 (ubiquitous)

121301 RC AA402329 NMJ06202 Hs.89901 phosphodiesterase 4A, cAMP-specific (dunce (Drosophila)-homolog phosphodiesterase E2)

121302 RC AA402398 AA402587 Hs.325520 LAT1-3TM protein

121304 RC_AA402449 AA293863 Hs.97316 EST

121305 RC_AA402468 AA402468 Hs.291557 ESTs

134721 RC_AA403268 i 3 AK000112 Hs.89306 hypothetical protein FLJ20105

121323 RCAA403314 AA291411 Hs.97247 ESTs

121324 RC AA404229 AA404229 Hs.97842 EST

129047 RO.AA404260 AI768623 Hs.108264 ESTs

131074 RC_AA404271 U16125 Hs.181581 glutamate receptor, ionotropic, kainate 1

121344 RC AA405026 AA405026 Hs.193754 ESTs

121348 RC AA405182 AA405182 Hs.97973 ESTs

121350 RC .AA405237 AA405237 gb:zt06e10.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:7123623' similarto contains Alu

121400 RC AA406061 AA406061 Hs.98001 EST

121402 RC AA406063 AA406063 Hs.98003 ESTs

121403 ROAA406070 AA406070 Hs.98004 EST

121408 RO.AA406137 AA406137 Hs.98019 EST

121431 RO.AA406335 AA035279 Hs.176731 ESTs

132936 RC AA411801 AL120659 Hs.6111 aryl-hydrocarbon receptor nuclear translocator 2

121471 RO.AA411804 AA411804 Hs.261575 ESTs

121474 RC AA411833 AA402335 Hs.188760 ESTs, Highly similar to Trad [H.sapiens]

121526 RO.AA412219 AW665325 Hs.98120 ESTs

121530 RC_AA412259 AA778658 Hs.98122 ESTs

121558 RC_AA412497 AA412497 gb:zt95g12.s1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:7301503' similarto contains L1.0 L1

121559 RO.AA412498 AI192044 Hs.104778 ESTs

121584 RCAA416586 AI024471 Hs.98232 ESTs

121609 RCAA416867 AA416867 Hs.98185 EST

121612 RC_AA416874 AA416874 Hs.98168 ESTs

121737 RC_AA421133 AA421133 Hs.104671 erythrocyte transmembrane protein

121740 RC_AA421138 AA421138 Hs.98334 EST

129194 RC_AA422079 , AA150797 Hs.109276 latexin protein

121784 RC AA423837 T90789 Hs.94308 RAB35, member RAS oncogene family

121802 RC AA424328 AI251870 Hs.188898 ESTs

121803 RC_AA424339 AI338371 Hs.157173 ESTs

135286 RO AA424469 s ! AW023482 Hs.97849 ESTs

121806 RC AA424502 AA424313 Hs.98402 ESTs

129517 RC_AA425004 AW972853 Hs.112237 ESTs

121845 RC AA425734 AI732692 Hs.165066 ESTs, Moderately similar to ALU2_HUMAN ALU SUBFAMILY SB SEQUENCE

CONTAMINATION

121853 RC AA425887 AA425887 Hs.98502 hypothetical protein FLJ 14303

121891 RC AA426456 AA426456 Hs.98469 ESTs

121895 RC_AA427396 AA427396 gb:zw33a02.s1 Soares ovaiy tumor NbHOT Homo sapiens cDNA clone IMAGE:7710503' similarto contains

121899 RC_AA427555 R55341 Hs.50421 KIAA0203 gene product 121917 RC AA428218 AA406397 Hs.98038 ESTs

121918 RC AA428242 BE274689 Hs.184175 chromosome 2 open reading frame 3

121919 RC AA428281 AA428281 Hs.98560 EST

121941 RC AA428865 AA428865 Hs.98563 ESTs

121942 RC AA428994 AW452701 Hs.293237 ESTs

121970 RC AA429666 AA429666 Hs.98617 EST

121993 RC AA430181 AW297880 Hs.98661 ESTs

134660 RC AA430184 i 3 U73524 Hs.87465 ATP/GTP-binding protein

126753 RC AA431288 i s AA306478 Hs.95327 CD3D antigen, delta polypeptide (TiT3 complex)

122022 RC AA431293 AA431293 Hs.98716 ESTs, Moderately similar to T42650 hypothetical protein DKFZp434D0215.1 [H.sapiens]

122050 RC AA431478 AI453076 Hs.166109 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 2

122051 RC AA431492 AA431492 Hs.98742 EST

122055 RC_AA431732 AA431732 Hs.98747 EST

122105 RC AA432278 AW241685 Hs.98699 ESTs

122125 RC AA434411 AK000492 Hs.98806 hypothetical protein

135235 RC AA435512 i i AW298244 Hs.293507 ESTs

122162 ' RC AA435698 AA628233 Hs.79946 cytochrome P450, subfamily XIX (aromatization of androgens)

129406 RC AA435711 AB018255 Hs.111138 KIAA0712 gene product

318801 RC AA435815 i 3 U40763 Hs.77965 peptidyl-prolyl isomerase G (cyclophilin G)

122186 RC AA435842 AA398811 Hs.104673 ESTs

122235 RC AA436475 AA436475 Hs.112227 membrane-associated nucleic acid binding protein

129131 RC AA436489 AB026436 Hs.177534 dual specificity phosphatase 10

134664 RC AA442060 AA256106 Hs.87507 ESTs

122310 RC AA442079 AW192803 Hs.98974 ESTs, Weakly similar to S65824 reverse transcriptase homolog [H.sapiens]

122334 RC AA443151 BE465894 Hs.98365 ESTs, Weakly similar to LB4D HUMAN NADP-DEPENDENT LEUKOTRIENE B412-

122382 RCAA446133 AA446440 Hs.98643 ESTs

122425 RC AA447145 AB007859 Hs.100955 KIAA0399 protein

122431 RC AA447398 AA447398 Hs.99104 ESTs

122450 RC AA447643 AA447643 Hs.112095 hypothetical protein DKFZD434F1819

302653 RC AA447742 i 3 AJ404468 Hs.284259 dynein, axone al, heavy polypeptide 9

122477 RC_AA448226 AA448226 Hs.324123 ESTs

122500 RC AA448825 AA448825 Hs.99190 ESTs

122522 RC AA449444 AA299607 Hs.98969 ESTs

122536 RC AA450087 AF060877 Hs.99236 regulator of G-protein signalling 20

122538 RC AA450211 AA450211 Hs.99239 ESTs

122540 RC AA450244 AA476741 Hs.98279 ESTs, Weakly similarto A43932 mucin 2 precursor, intestinal [H.sapiens]

122560 RC AA452123 AW392342 Hs.283077 centrosomal P4.1-associated protein; uncharacterized bone marrow protein BM032

421919 RC AA452155 AJ224901 Hs.109526 zinc finger protein 198

122562 RC_AA452156 AA452156 gb:zx29c03.s1 Soares_tota|_fetus_Nb2HF8_9w Homo sapiens cDNA clone IMAGE:7878763' mRNA

122585 RC AA453036 AI681654 Hs.170737 hypothetical protein FLJ23251

122608 RC AA453526 AA453525 Hs.143077 ESTs

122635 RC_AA454085 AA454085 gb:zx33a08.s1 Soares_total_fetus_Nb2HF8_9w Homo sapiens cDNA clone IMAGE:7882463' similarto

122636 RC AA454103 AW651706 Hs.99519 hypothetical protein FLJ 14007

122653 RC AA454642 AW009166 Hs.99376 ESTs

122660 RC AA454935 AI816827 Hs.180069 nuclear respiratory factor 1

122703 RC AA456323 AA456323 Hs.269369 ESTs

122724 RCAA457395 AA457395 Hs.99457 ESTs

122749 RC AA458850 AA458850 Hs.293372 ESTs, Weakly similar to B34087 hypothetical protein [H.sapiens]

122772 RC_AA459662 AW117452 Hs.99489 ESTs

131098 RC AA459668 U66669 Hs.236642 3-hydroxyisobutyryl-Coenzyme A hydrolase

129045 RC_AA459679 i 3 AI082883 Hs.30732 hypothetical protein FLJ13409; KIAA1711 protein

122777 RC AA459702 AK001022 Hs.214397 hypothetical protein FLJ10160 similarto insulin related protein 2

135362 RC .AA460017 AA978128 Hs.99513 ESTs, Weakly similarto T17454 diaphanous-related formin - mouse [M.musculus]

122798 RC AA460324 AW366286 Hs.145696 splicing factor (CC1.3)

122837 RCAA461509 AA461509 Hs.293565 ESTs, Weakly similarto putative pl50 [H.sapiens]

122860 RC_AA464414_i AA464414 gb:zx78g01 ,s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:8099043', mRNA sequence.

122861 RC 164428 AA335721 Hs.119394 ESTs

122910 RCJ\A470084 AA470084 Hs.98358 ESTs

132899 RC_AA476606 ! 3 AA476606 Hs.59666 SMAD in the antisense orientation

122967 RC AA478521 AA806187 Hs.289101 glucose regulated protein, 58kD

129560 RC_AA478523 AA317841 Hs.7845 hypothetical protein MGC2752

123009 RC AA479949 AA535244 Hs.78305 RAB2, member RAS oncogene family

128917 RC_AA481252 AI365215 Hs.206097 oncogene TC21

123081 RC AA485351 AI815486 Hs.243901 Homo sapiens cDNA FLJ20738 fis, clone HEP08257

123133 RC_AA487264 AA487264 Hs.154974 Homo sapiens mRNA; cDNA DKFZp667N064 (from clone DKFZp667N064)

123184 RC_AA489072 BE247767 Hs.18166 KIAA0870 protein

129671 RC_AA489630 NM 014700 Hs.119004 KIAA0665 gene product

123233 RC_AA490225 AW974175 Hs.188751 ESTs, Weakly similarto MAPB_HUMAN MICROTUBULE-ASSOCIATED PROTEIN 1B

[H.sapiens]

123234 RC_AA490227 NM 01938 Hs.16697 down-regulator of transcription 1 , TBP-binding (negative cofactor 2)

123236 RC AA490255 AW968504 Hs.123073 CDC2-re!ated protein kinase 7

123255 RC_AA490890 AA830335 Hs.105273 ESTs

129503 RC_AA490916_ι 3 AW768399 Hs.112157 ESTs 131043 RC AA490925 AF084535 Hs.22464 epilepsy, progressive myoclonustype2, Lafora disease (laforin)

123259 RC. AA490955 AI744152 Hs.283374 ESTs, Weakly similar to CA15_HUMAN COLLAGEN ALPHA 1 (V) CHAIN PRECURSOR

[H.sapiens]

123284 RC AA495812 AA488988 Hs.293796 ESTs

123286 RC AA495824 AA495824 Hs.188822 ESTs, Weakly similarto A46010 X-linked retinopathy protein [H.sapiens]

123315 RC. AA496369 AA496369 gb:zv37d10.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:7558273' similar tocontains

129179 RC AA504125 i s AW969025 Hs.109154 ESTs

131612 AA521473 AU076668 Hs.334884 SEC10 (S. cerevisiae)-like 1

123421 AA598440 AA598440 Hs.291154 EST, Weakly similarto I38022 hypothetical protein [H.sapiens]

123449 .AA598899J i AL049325 Hs.112493 Homo sapiens mRNA; cDNA DKFZp564D036 (from clone DKFZp564D036)

129021 AA599244 AL044675 Hs.173081 KIAA0530 protein

132830 AA599694 i s NM 014777 Hs.57730 KIAA0133 gene product

123497 AA600037 AA765256 Hs.135191 ESTs, Weakly similar to unnamed protein product [H.sapiens]

123604 AA609135 AA609135 Hs.293076 ESTs

129539 AA609582 T47614 Hs.323022 ESTs, Highly similarto p60 katanin [H.sapiens]

123712 AA609684 AA609684 Hs.112748 Homo sapiens cDNA: FLJ21543 fis, clone COL06171

123731 AA609839 AA609839 gb:ae62f01.s1 Stratagene lung carcinoma 937218 Homo sapiens cDNA clone IMAGE:951481 3' similarto

130725 RC AA609862 T98807 Hs.80248 RNA-binding protein gene with multiple splicing

123800 AA620423 AA620423 Hs.112862 EST

123841 AA620747 AA620747 Hs.112896 ESTs

123929 AA621364 AA621364 Hs.112981 ESTs

123978 C20653 T89832 Hs.170278 ESTs

133184 .D20085 AA001021 Hs.6685 thyroid hormone receptor interactor 8

132835 D20749 Z83844 Hs.5790 hypothetical protein dJ37E16.5

132406 D51285 s AL133731 Hs.4774 Homo sapiens mRNA; cDNA DKFZp761C1712 (from clone DKFZp761C1712)

128695 D59972 i NM 003478 Hs.101299 cullin 5

124028 F04112J F04112 gb:HSC2JH062 normalized infant brain cDNA Homo sapiens cDNA clone c-2jh063', mRNA sequence.

124057 RC F13604 AA902384 Hs.73853 bone mo hogenetic protein 2

134899 H01662 AI609045 Hs.321775 hypothetical protein DKFZp434D1428

130973 H05135 i AI638418 Hs.78580 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 1

124106 H12245 H12245 gb:ym17a12.r1 Soares infant brain 1NIB Homo sapiens cDNA clone 3', mRNA sequence

124136 .H22842 H22842 Hs.101770 EST

124165 H30894 H30039 Hs.107674 ESTs

131229 H43442_s NM_015340 Hs.2450 leucyl-tRNA synthetase, mitochondrial

124178 .H45996 BE463721 Hs.97101 putative G protein-coupled receptor

129948 H69281 i AI537162 Hs.263988 ESTs >

134374 H69485 f N22687 Hs.8236 ESTs

124254 .H69899 H69899 gb:yu70c12.s1 Weizmann Olfactory Epithelium Homo sapiens cDNA clone IMAGE:2391583' similarto

129056 RC H70627 s AI769958 Hs.108336 ESTs, Weakly similar to ALUE_HUMAN 111! ALU CLASS E WARNING ENTRY 111 [H.sapiens]

100919 H73050 s X54534 Hs.278994 Rhesus blood group, CcEe antigens

130724 H73260 AK001507 Hs.306084 Homo sapiens clone FLB6914 PR01821 mRNA, complete eds

100716 .H77531 s X89887 Hs.172350 HIR (histone cell cycle regulation defective, S. cerevisiae) homolog A

124274 .H80552 H80552 Hs.102249 EST

129078 H80737 s AI351010 Hs.102267 lysosomal

124828 H93412 AW952124 Hs.13094 presenilins associated rhomboid-like protein

124315 H94892 s NM 005402 Hs.288757 v-ral simian leukemia viral oncogene homolog A (ras related)

100747 H95643 s X04588 Hs.85844 neurotrophic tyrosine kinase, receptor, type 1

124324 H96552 H96552 Hs.159472 Homo sapiens cDNA: FLJ22224 fis, clone HRC01703

452933 H97146 AW391423 Hs.288555 Homo sapiens cDNA: FLJ22425 fis, clone HRC08686

132231 H99131 s AA662910 Hs.42635 hypothetical protein DKFZp434K2435

129170 H99462 s AW250380 Hs.109059 mitochondrial ribosomal protein L12

133143 H99837_s AA094538 Hs.272808 putative transcription regulation nuclear protein; KIAA1689 protein

132963 N22140 AA099693 Hs.34851 epsilon-tubulin

135297 N22197 AL118782 Hs.300208 Sec23-interactiπg protein p125

134347 N23756 s AF164142 Hs.82042 solute carrier family 23 (nucleobase transporters), member 1

130365 .N24134 W56119 Hs.155103 eukaryotic translation initiation factor 1 A, Y chromosome

421642 N24195 AF172066 Hs.106346 retinoic acid repressible protein

439311 .N26739 BE270668 Hs.151945 mitochondrial ribosomal protein L43

124383 N27098 N27098 Hs.102463 EST

124387 .N27637 N27637 Hs.109019 ESTs

129341 N33090 AI193519 Hs.226396 hypothetical protein FLJ11126

129081 N35967 AI364933 Hs.168913 serine/threonine kinase 24 (Ste20, yeast homolog)

102827 N38959 f BE244588 Hs.6456 chaperonin containing TCP1, subunit 2 (beta)

124433 .N39069 AA280319 Hs.288840 PR01575 protein

124441 .N46441 AW450481 Hs.161333 ESTs

132338 N48270 f AA353868 Hs.182982 golgin-67

131403 N48365 s AI473114 Hs.26455 ESTs

124466 N51316 R10084 Hs.113319 kinesin heavy chain member 2

132210 N51499 s NM 007203 Hs.42322 A kinase (PRKA) anchor protein 2

124483 N53976 AI821780 Hs.179864 ESTs

124484 RC. N54157 H66118 Hs.285520 ESTs, Weakly similar to 2109260A B cell growth factor [H.sapiens]

124485 RC. N54300 AB040933 Hs.15420 KIAA1500 protein 124494 RCN54831 N54831 Hs.271381 ESTs, Weakly similarto I38022 hypothetical protein [H.sapiens] 129200 RC_N59849 N59849 Hs.13565 Sam68-like phosphotyrosine protein, T-STAR 124527 RCN62132 N79264 Hs.269104 ESTs 124532 RCJI62375 N62375 Hs.102731 EST 133213 RC N63138 AA903424 Hs.6786 ESTs 124539 RC.N63172 D54120 Hs.146409 cell division cycle 42 (GTP-binding protein, 25kD) 133651 RC_N63772 AI301740 Hs.173381 dihydropyrimidinase-like 2 129196 RC N63787 BE296313 Hs.265592 ESTs, Weakly similarto I38022 hypothetical protein [H.sapiens] 124575 RC_N68168 N68168 gb:za11 c01 ,s1 Soares fetal liver spleen 1 NFLS Homo sapiens cDNA clone 3', mRNA sequence

124576 RC_N68201 N68201 Hs.269124 ESTs, Weakly similarto I38022 hypothetical protein [H.sapiens]

124577 RC_N68300 N68300 gb:za12g07.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:2923803', mRNA

124578 RC N68321 N68321 Hs.231500 EST

124593 RC N69575 N69575 Hs.102788 ESTs

128501 RCJ175007 AL133572 Hs.199009 protein containing CXXC domain 2

105691 RC_N75542 AI680737 Hs.289068 Homo sapiens cDNA FLJ11918 fis, clone HEMBB1000272

128473 RC_N90066 T78277 Hs.100293 O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-acetylglucosamine:polypeptide-N-

128639 RC_N91246 AW582962 Hs.102897 CGI-47 protein

124652 RC_N92751 W19407 Hs.3862 regulator of nonsense transcripts 2; DKFZP434D222 protein

133137 RC_N93214_s AB002316 Hs.65746 KIAA0318 protein

124671 RC_N99148 AK001357 Hs.102951 Homo sapiens cDNA FLJ10495 fis, clone NT2RP2000297, moderately similarto ZINC FINGER

PROTEIN

133054 RC_R07876 AA464836 Hs.291079 ESTs, Weakly similar to T27173 hypothetical protein Y54G11 A.9 - Caenorhabditis elegans

[C.elegans]

130410 RC_R10865_f J00077 Hs.155421 alpha-fetoprotein

124720 RC_R11056 R05283 gb:ye91c08.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:1251023' similarto

124722 RC_R11488 T97733 Hs.185685 ESTs

129961 RC_R22947 R23053 gb:yh31a05.r1 Soares placenta Nb2HP Homo sapiens cDNA clone 5' similarto contains L1 repetitive element 128944 RC_R23930_s AL137586 Hs.52763 anaphase-promoting complex subunit 7

132965 RC_R26589J AI248173 Hs.191460 hypothetical protein MGC12936

133740 RC R37588_s AW162919 Hs.170160 RAB2, member RAS oncogene family-like

133074 RC_R37613 AL134275 Hs.6434 hypothetical protein DKFZp761F2014

124757 RC_R38398 H11368 Hs.141055 Homo sapiens clone 23758 mRNA sequence

124762 RC_R39179_f AA553722 Hs.92096 ESTs, Moderately similarto A46010 X-linked retinopathy protein [H.sapiens]

124773 RCR40923 R45154 Hs.106604 ESTs

135266 RC R41179 R41179 Hs.97393 KIAA0328 protein

131375 RC_R41294_s AW293165 Hs.143134 ESTs

133753 RC_R42307 NM_004427 Hs.165263 early development regulator 2 (homolog of polyhomeotic 2)

128540 RC_R43189J AW297929 Hs.328317 EST

124785 RCR43306 W38537 Hs.280740 hypothetical protein MGC3040

124792 RC R44357 R44357 Hs.48712 hypothetical protein FLJ20736

124793 RC_R44519 R44519 gb:yg24h04.s1 Soares infant brain 1NIB Homo sapiens cDNA clone IMAGE:333503', mRNA sequence.

124799 RC_R45088 R45088 gb:yg38g04.s1 Soares infant brain 1NIB Homo sapiens cDNA clone IMAGE:348963', mRNA sequence.

124812 RC_R47948_i R47948 Hs.188732 ESTs

124821 RC_R51524 H87832 Hs.7388 kelch (Drosophila)-like 3 127274 RC_R54950 AW966158 Hs.58582 Homo sapiens cDNA FLJ12789 fis, clone NT2RP2001947 124835 RC_R55241 R55241 Hs.101214 EST 124845 RC R59585 R59585 Hs.101255 ESTs 124847 RC_R60044 W07701 Hs.304177 Homo sapiens clone FLB8503 PR02286 mRNA, complete eds 440630 RC R60872 BE561430 Hs.239388 Human DNA sequence from clone RP1-304B14 on chromosome 6. Contains a gene for a novel protein and a part of a gene for a novel protein with two isoforms. Contains ESTs, STSs, GSSs and a CpG island

124861 RC_R66690 R67567 Hs.107110 ESTs

130141 RC_R67266_ NMJ04455 Hs.150956 exostoses (multiple)-like 1

124879 RC_R73588 R73588 Hs.101533 ESTs

124892 RC_R79403 AI970003 Hs.23756 hypothetical protein similarto swine acylneuraminate lyase

124906 RCR87647 H75964 Hs.107815 ESTs

124922 RC_R93622 R93622 Hs.12163 eukaryotic translation initiation factor 2, subunit 2 (beta, 38kD )

124940 RC_R99599_: AF068846 Hs.103804 heterogeneous nuclear ribonucleoprotein U (scaffold attachment factor A)

124941 RCR99612 AI766661 Hs.27774 ESTs, Highly similar to AF161349 1 HSPC086 [H.sapiens] 124943 RCJΪJ2888 AW963279 Hs.123373 ESTs, Weakly similarto ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION WARNING ENTRY [H.sapie 2nnss]] 124947 RCT03170 T03170 Hs.100165 ESTs 124954 RC_T10465 AW964237 Hs.6728 KIAA1548 protein 132924 RC_T15418_f U55184 Hs.154145 hypothetical protein FLJ11585 133113 RC_T15597J BE383768 Hs.65238 95 kDa retinoblastoma protein binding protein; KIAA0661 gene product 132975 RC_T15652 i R43504 Hs.6181 ESTs 133235 RC_T16898_s AW960782 Hs.6856 ash2 (absent, small, orhomeotic, Drosophila, homolog)-like 131082 RC_T26644_i AI091121 Hs.246218 Homo sapiens cDNA: FLJ21781 fis, clone HEP00223 124980 RC_T40841 T40841 Hs.98681 ESTs 124984 RC_T47566_i BE313210 Hs.223241 eukaryotic translation elongation factor 1 delta (guanine nucleotide exchange protein) 124991 ROT50116 T50116 gb:yb77c10.s1 Stratagene ovary (937217) Homo sapiens cDNA clone IMAGE.772023' similar to similar to SP:VE22 LAMBD P03756 EA22 GENE , mRNA sequence. 129475 RC_T50145_s NM 04477 Hs.203772 FSHD region gene 1 125000 RC T58615 T58615 Hs.110640 ESTs

132932 RC_T59940_f AW118826 Hs.6093 Homo sapiens cDNA: FLJ22783 fis, clone KAIA1993

129534 RC T63595 AK002126 Hs.11260 hypothetical protein FLJ11264

125008 RC T64891 T91251 gb:yd60a10.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone 3', mRNA sequence

125009 RC T64924 T64924 Hs.303046 ESTs 132940 RC_T64933_r T79136 Hs.127243 Homo sapiens mRNA for KIAA1724 protein, partial eds 125017 ROJ68875 T68875 gb:yc30f05.s1 Stratagene liver (937224) Homo sapiens cDNA clone IMAGE:822093', mRNA sequence.

125018 ROJ69027 T69027 Hs.57475 sex comb on midleg homolog 1 125020 RCJT69924 T69981 gb:yc19d03.r1 Stratagene lung (937210) Homo sapiens cDNA clone 5', mRNA sequence 129891 RC T70353 AI084813 Hs.13197 ESTs 134204 RC T79780_s AI873257 Hs.7994 hypothetical protein FLJ20551 125050 RC T79951 AW970209 Hs.111805 ESTs 125052 RC T80174_s T85104 Hs.222779 ESTs, Moderately similar to similar to NEDD-4 [H.sapiens] 125054 RC T80622 T80622 Hs.268601 ESTs, Weakly similar to envelope [H.sapiens]

125063 RC.T85352 T85352 gb:yd82d01.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:114721 3' similarto contains Alu repetitive element;' contains L1 repetitive element ;, mRNA sequence.

125064 RC.J85373 T85373 gb:yd82f07.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:1147573' similar to contains Alu repetitive element;! contains MER3 repetitive element ;, mRNA sequence. 125066 RC 86284 T86284 gb:yd77b07.s1 Soares fetal liver spleen 1 NFLS Homo sapiens cDNA clone 3' similar to contains Alu repetitive element;, mRNA sequence 112264 RC_T89579_s AL045364 Hs.79353 transcription factor Dp-1 125080 RC T90360 T90360 Hs.268620 ESTs, Highly similar to ALU6_HUMAN ALU SUBFAMILY SP SEQUENCE CONTAMINATION WARNING ENTRY [rf.sapiens] 125097 RC_T94328_i AW576389 Hs.335774 EST, Moderately similar to S65657 alpha-1 C-adrenergic receptor splice form 2 [H.sapiens] 125104 RC 95590 T95590 gb:ye40a03.s1 Soares fetal liver spleen 1 FLS Homo sapiens cDNA clone 3' similarto gb|M10817|IGURRAA Iguana iguana 5S (rRNA );, mRNA sequence 135107 RC_T97257_f T97257 Hs.337531 ESTs, Moderately similar to I38022 hypothetical protein [H.sapiens] 129550 RC_T97599_i AA845462 Hs.124024 deltex (Drosophila) homolog 1 125118 RC T97620 R10606 gb:yf35f11.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:128877 3' similarto contains Alu repetitive element;. , mRNA sequence.

125120 RC T97775 T97775 Hs.100717 EST 134160 RC T98152 T98152 Hs.79432 fibrillin 2 (congenital contractural arachnodactyly) 125136 RC_W31479 AW962364 Hs.129051 ESTs 125144 RC.W37999 AB037742 Hs.24336 KIAA1321 protein 125150 RC_W38240 W38240 Empirically selected from AFFX single probeset 104180 RC .W40150 AA247778 Hs.119155 Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 814975 131987 RC .W45435 AW453069 Hs.3657 activity-dependent neuroprotective protein 125178 RC .W58202 W93127 Hs.31845 ESTs 125180 RC W58344 W58469 Hs.103120 ESTs 125182 RC W58650 AA451755 Hs.263560 ESTs 130588 RC W68736 AL030996 Hs.16411 hypothetical protein LOC57187 125197 RC .W69106 AF086270 Hs.278554 heterochromatin-like protein 1 133497 RC.W69111 BE617303 Hs.74266 hypothetical protein MGC4251 100562 RC_W69385_s NM_006185 Hs.301512 nuclear mitotic apparatus protein 1 125639 RC W69399_s Z97630 Hs.226117 H1 histone family, member 0 129232 RC .W69459 R98881 Hs.109655 sex comb on midleg (Drosophila)-like 1 101495 RC_W72424 W72424 Hs.112405 S100 calcium-binding protein A9 (calgranulin B) 125209 RC_W72724 W72724 Hs.103174 ESTs, Weakly similarto TSP2_HUMAN THROMBOSPONDIN 2 PRECURSOR [H.sapiens] 125212 RC.W72834 AA746225 Hs.103173 ESTs 129132 RC_W73955 BE383436 Hs.108847 hypothetical protein MGC2749 125223 RC W74701 AI916269 Hs.109057 ESTs, Weakly similar to ALU5_HUMAN ALU SUBFAMILY SC SEQUENCE CONTAMINATION

WARNING ENTRY [H.sapiens]

125225 RC_W76540 W74169 Hs.16492 DKFZP564G2022 protein 125228 RCW79397 AA033982 Hs.110059 ESTs, Weakly similar to 138022 hypothetical protein [H.sapiens] 132393 RC_W85888 AL135094 Hs.47334 hypothetical protein FLJ14495 125238 RCJV86038 N99713 Hs.109514 ESTs 125247 RCW86881 AA694191 Hs.163914 ESTs 129296 RC_W87804 AI051967 Hs.110122 ESTs 125263 RCW88942 AA098878 gb:zn45g10.r1 Stratagene HeLa cell s3937216 Homo sapiens cDNA clone 5', mRNA sequence 125266 RC_W90022 W90022 Hs.186809 ESTs, Highly similar to LCT2_HUMAN LEUKOCYTE CELL-DERIVED CHEMOTAXIN 2 PRECURSOR [H.sapiens] 131321 RCW92272 U91543 Hs.25601 chromodomain helicase DNA binding protein 3 131601 RC_W92764_s NM_007115 Hs.29352 tumor necrosis factor, alpha-induced protein 6 131677 RC V93040 H05317 Hs.283549 ESTs 120837 RC_W93092 BE149656 Hs.306621 Homo sapiens CDNA FLJ11963 fis, clone HEMBB1001051

125277 RC_W93227 W93227 Hs.103245 EST

125278 RCW93523 AI218439 Hs.129998 enhancer of polycomb 1 125280 RC_W93659 AI123705 Hs.106932 ESTs 131856 RC_W94003_s W93949 Hs.33245 ESTs 131844 RC_W94401_s AI419294 Hs.324342 ESTs 125284 RC_W94688 NM_002666 Hs.103253 perilipin 313447 RC_W94787_s AW016321 Hs.82306 destrin (actin depolymerizing factor) 130799 RC_Z38294_s AB028945 Hs.12696 cortactin SH3 domain-binding protein 125289 RC_Z38311 T34530 Hs.4210 Homo sapiens cDNA FLJ13069 fis, clone NT2RP3001752 128874 RC_Z38465_s H06245 Hs.106801 ESTs, Weakly similar to PC4259 ferritin associated protein [H.sapiens] 130966 RC_Z38525 s AW971018 Hs.21659 ESTs

128875 RC Z38538 f AB040923 Hs.106808 kelch (Drosophila)-like 1

133200 RC Z38551 s AB037715 Hs.183639 hypothetical protein FLJ10210

130158 RC Z38783 s AB032947 Hs.151301 Ca2-*-dependent activator protein for secretion

125295 RC_Z39113 AB022317 Hs.25887 sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin)4F

125298 RC Z39255 f AW972542 Hs.289008 Homo sapiens cDNA: FLJ21814 fis, clone HEP01068

125300 RO.Z39591 Z39591 Hs.101376 EST

323122 RC Z39783 s BE622770 Hs.264915 Homo sapiens cDNA FLJ12908 fis, clone NT2RP2004399

311463 RO.Z39920 R55344 Hs.22142 cytochrome b5 redudase b5R.2

130882 RC_Z40166_f AA497044 Hs.20887 hypothetical protein FLJ10392

128888 RO.Z40388 s AI760853 Hs.241558 ariadne (Drosophila) homolog 2

125310 RO.Z40646 R59161 Hs.124953 ESTs

125315 RC Z41697 R38110 Hs.106296 ESTs

125317 RC Z99349 Z99348 Hs.112461 ESTs, Weakly similarto I38022 hypothetical protein [H.sapiens]

135096 RC Z99394 s AA081258 Hs.132390 zinc finger protein 36 (KOX 18)

104786 RC AA027168 AA027167 Hs.10031 KIAA0955 protein

132837 D58024 s AA370362 Hs.57958 EGF-TM7-latrophilin-related protein

120456 RO.AA251113 AA488750 Hs.88414 BTB and CNC homology 1, basic leucine zipper transcription factor 2

132459 RC AA347573 AL120071 Hs.48998 fibronectin leucine rich transmembrane protein 2

101545 M31210 BE246154 Hs.154210 endothelial differentiation, sphingolipid G-protein-coupled receptor, 1

133505 C01527 AI630124 Hs.324504 Homo sapiens mRNA; cDNA DKFZp586J0720 (from clone DKFZp586J0720)

132360 RC N62948 s AW893660 Hs.46440 solute carrier family 21 (organic anion transporter), member 3

132738 RC W42674 AK000738 Hs.264636 hypothetical protein FLJ20731

119586 RO.W43000 s AF088033 Hs.159225 ESTs

129914 RC N31750 s NMJ512421 Hs.13321 rearranged L-myc fusion sequence

130839 AF009301 AB011169 Hs.20141 similarto S. cerevisiae SSM4

132813 L37347 BE313625 Hs.57435 solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2

134342 M99564 NM_000275 Hs.82027 oculocutaneous albinism II (pink-eye dilution (murine) homolog)

131878 RC AA430673 AA083764 Hs.6101 hypothetical protein MGC3178

105426 RC AA251297 W20027 Hs.23439 ESTs

132968 RC AA620722 AF234532 Hs.61638 myosin X

132173 RC_W46577_s X89426 Hs.41716 endothelial cell-specific molecule 1

113932 RCJV81237 AA256444 Hs.126485 hypothetical protein FLJ12604; KIAA1692 protein

114452 RO.AA020825 AI369275 Hs.243010 Homo sapiens cDNA FLJ14445 fis, clone HEMBB1001294, highly similarto GTP-BINDING

PROTEIN TC10

115243 RCAA278766 AA806600 Hs.116665 KIAA1842 protein

134403 RC H93708 s AA334551 Hs.82767 sperm specific antigen 2

129647 RO.N49394 AB018259 Hs.118140 KIAA0716 gene product

111428 RC H56559 s AL031428 Hs.174174 KIAA0601 protein

115967 RC_AA446887 AI745379 Hs.42911 ESTs

120726 RC AA293656 AA293655 Hs.97293 ESTs

114995 RC AA251152 AA769266 Hs.193657 ESTs

303876 RC_AA233334_! 3 U64820 Hs.66521 Machado-Joseph disease (spinocerebellar ataxia 3, olivopontocerebellar ataxia 3, autosomal dominant, ataxin 3)

311463 RC Z39920 R55344 Hs.22142 cytochrome b5 reductase b5R.2

120302 RC_AA192173 AA837098 Hs.269933 ESTs

133071 RCAA455044 BE384932 Hs.64313 ESTs, Weakly similar to AF2571821 G-protein-coupled receptor 48 [H.sapiens]

121032 RCAA398504 AA393037 Hs.161798 ESTs

129829 U41813 AF010258 Hs.127428 ho eo box A9

120245 RCAA166965 AW959615 Hs.111045 ESTs

120985 RC_AA398222 AI219896 Hs.97592 ESTs

114184 RC_Z39095 R56434 Hs.21062 ESTs

447503 RC_AA284744_f AA115496 Hs.336898 Homo sapiens, Similar to RIKEN cDNA 1810038N03 gene, clone MGC:9890, mRNA, complete eds

132837 RC_AA428201 AA370362 Hs.57958 EGF-TM7-latrophilin-related protein

121034 RC_AA398507 AL389951 Hs.271623 nucleoporin 50kD

119718 RCW69216 W69216 Hs.92848 ESTs

120455 RC_AA251083 AA251720 Hs.104347 ESTs, Weakly similarto ALUCJHUMAN HI! ALU CLASS C WARNING ENTRY II! [H.sapiens]

125280 RCW93659 AI123705 Hs.106932 ESTs

132155 RC_AA227903 AK001607 Hs.41127 hypothetical protein FLJ13220

120609 RC AA283902 AW978721 Hs.266076 ESTs, Weakly similar to A46010 X-linked retinopathy protein [H.sapiens]

121278 RCAA401631 AA037121 Hs.98518 Homo sapiens cDNA FLJ11490 fis, clone HEMBA1001918

109023 RCJ\A157293 AA157293 Hs.72168 ESTs

129815 RCJD60208J BE565817 Hs.26498 hypothetical protein FLJ21657

108061 RC_AA043979 AA043979 Hs.62651 EST

113287 RC T66847 T66847 Hs.194040 ESTs, Weakly similarto I38022 hypothetical protein [H.sapiens]

114082 RC_Z38239 AK001612 Hs.26962 Homo sapiens cDNA FLJ10750 fis, clone NT2RP3001929

116334 RC_AA491457 AL038450 Hs.48948 ESTs

131486 RC_Z40071_s F06972 Hs.27372 BMX non-receptor tyrosine kinase

107860 RC_AA024961 AA024961 Hs.50730 ESTs

131263 RC_AA443826 AU077002 Hs.24950 regulator of G-protein signalling 5

132207 RC_AA443294 BE206939 Hs.42287 E2F transcription factor 6

129183 RC_AA155743 BE561824 Hs.273369 uncharacterized hematopoietic stem/progenitor cells protein MDS027

408431 RC 23708 AI338631 Hs.43266 Homo sapiens cDNA: FLJ22536 fis, clone HRC13155

120575 RC_AA280934 AW978022 Hs.238911 hypothetical protein DKFZp762E1511; KIAA1816 protein 132121 RC AA443284 : s NM 04529 Hs.404 ^" myeloid/lymphoid or mixed-lineage leukemia (trithorax (Drosophila) homolog); translocated to, 3

117657 RC N39074 N39074 Hs.44933 ESTs

134922 RC W04507 s AI718295 Hs.91161 prefoldin 4

118523 RC R41828 s Y07759 Hs.170157 myosin VA (heavy polypeptide 12, myoxin)

116845 RC H64973 AA649530 gb:ns44f05.s1 NCI_CGAP_Alv1 Homo sapiens cDNA clone, mRNA sequence

115291 RC AA279943 BE545072 Hs.122579 hypothetical protein FLJ10461

120326 RC AA196300 AA196300 Hs.21145 hypothetical protein RG083M05.2

130174 M29550 M29551 Hs.151531 protein phosphatase 3 (formerly 2B), catalytic subunit, beta isoform (calcineurin A beta)

129131 RC AA436489 AB026436 Hs.1 7534 dual specificity phosphatase 10

129868 RC AA287032 AW172431 Hs.13012 ESTs

118661 RC N70777 AL137554 Hs.49927 protein kinase NYD-SP15

129829 RC AA496921 AF010258 Hs.127428 homeo boxAΘ

115985 RC AA447709 AA447709 Hs.268115 ESTs, Weakly similar to T08599 probable transcription factor CA150 [H.sapiens]

^• 134637 RC AA369856 : 3 U87309 Hs.180941 vacuolar protein sorting 41 (yeast homolog)

132714 RC AA252598 W39388 Hs.55336 Homo sapiens, clone MGC:17421, mRNA, complete eds

129771 RC H73237 AL096748 Hs.102708 DKFZP434A043 protein

123360 RC AA504784 AA532718 Hs.178604 ESTs

132902 RC AA490969 AI936442 Hs.59838 hypothetical protein FLJ10808

113716 RC T97750 AA001356 Hs.18159 ESTs

113825 RC W48860 AW014486 Hs.22509 ESTs

130367 RC Z38501 AL135301 Hs.8768 hypothetical protein FLJ10849

120541 RC AA278298 W07318 Hs.240 M-phase phosphoprotein 1

116727 RC F13684 R76472 Hs.65646 ESTs

118219 RC N62231 AA862391 Hs.48494 ESTs, Moderately similar to A46010 X-linked retinopathy protein [H.sapiens]

119767 RC W72562 W72562 Hs.58119 ESTs

128917 RC AA481252 AI365215 Hs.206097 oncogene TC21

451553 RC AA020928 AA018454 Hs.269211 ESTs

132716 RC AA251288 BE379595 Hs.283738 casein kinase 1, alpha 1

118525 RC N67861 N67861 Hs.49390 ESTs

114618 RC AA084162 AW979261 Hs.291993 ESTs

119743 RC W70242 AA947552 Hs.58086 ESTs

108154 RC AA425151 : 3 NM 005754 Hs.220689 Ras-GTPase-activating protein SH3-domain-binding protein

122798 RC AA460324 AW366286 Hs.145696 splicing factor (CC1.3)

133746 U44378 AW410035 Hs.75862 MAD (mothers against decapentaplegic, Drosophila) homolog 4

119822 RC W74471 AF086409 Hs.301327 ESTs

122186 RC AA435842 AA398811 Hs.104673 ESTs

114941 RC AA243017 AA236512 Hs.87331 ESTs

118053 RC N53367 N53391 Hs.47629 ESTs

123234 RC AA490227 NM 001938 Hs.16697 down-regulator of transcription 1, TBP-bindiπg (negative cofactor 2)

129280 M63154 M63154 Hs.110014 gastric intrinsic factor (vitamin B synthesis)

118995 RC N94591 N94591 Hs.323056 ESTs

116750 RC H05960 AA760689 Hs.92418 ESTs

129026 M98833 AL120297 Hs.108043 Friend leukemia virus integration 1

105127 RC AA158132 AA045648 Hs.301957 nudix (nucleoside diphosphate linked moiety X)-type motif 5

114513 RC AA044825 AA044873 Hs.103446 ESTs

411856 RC T35697 H67899 Hs.4190 Homo sapiens cDNA: FLJ23269 fis, clone COL09533

132036 W01568 AL157433 Hs.37706 hypothetical protein DKFZp434E2220

130091 RC_W88999 W88999 gb:zh70h03.s1 Soares_fetaUiver_spleen_1NFLS_S1 Homo sapiens cDNA clone 3', mRNA sequence

414108 U09564 AI267592 Hs.75761 SFRS protein kinase 1

119881 RC W81456 W81486 Hs.58648 ESTs

117770 RC N47953 AW957372 Hs.46791 ESTs, Weakly similarto I38022 hypothetical protein [H.sapiens]

119850 RC W80447 AI247568 Hs.58452 ESTs

115439 RC AA284561 AI567972 Hs.193090 ESTs, Highly similar to AF161437 1 HSPC319 [H.sapiens]

123107 RC AA486071 AA225048 Hs.104207 ESTs

406698 M24364 X03068 Hs.73931 major histocompatibility complex, class II, DQ beta 1

121231 RC AA400780 AA814948 Hs.96343 ESTs, Weakly similar to ALUCJHUMA !!!! ALU CLASS C WARNING ENTRY III [H.sapiens]

132074 AB002366 AA478486 Hs.3852 KIAA0368 protein

413670 AB000115 AB000115 Hs.75470 hypothetical protein, expressed in osteoblast

125277 RC_W93227 W93227 Hs.103245 EST

114056 RC AA186324 AA188175 Hs.82506 KIAA1254 protein

121153 RC AA399640 AA399640 Hs.97694 ESTs

121609 RC AA416867 AA416867 Hs.98185 EST

120661 RC AA287556 AA287556 Hs.263412 ESTs, Weakly similar to ALUB_HUMAN !!!! ALU CLASS B WARNING ENTRY III [H.sapiens]

120850 RC AA349647 AA349647 Hs.96927 Homo sapiens cDNA FLJ 12573 fis, clone NT2RM4000979

124947 RC_T03170 T03170 Hs.100165 ESTs

130529 RC .AA280886 AA178953 gb:zp39e03.s1 Stratagene muscle 937209 Homo sapiens cDNA clone 3' similarto contains Alu repetitive element;, mRNA sequence

117683 RC_N40180 N40180 gb:yy44d02.s1 Soares_multiple_sclerosis_2NbHMSP Homo sapiens cDNA clone

IMAGE:2763873' similar to contains L1.t1 L1 repetitive element ;, mRNA sequence.

120745 RCAA302809 AA302809 gb:EST10426 Adipose tissue, white I Homo sapiens cDNA 3' end, mRNA sequence.

120936 RC AA385934 AA385934 Hs.97 84 EST, Highly similar to (defline not available 7499603) [C.elegans]

112597 RC R78376 R78376 Hs.29733 EST

120183 RC Z40174 AW082866 Hs.65882 ESTs

120644 RC A287038 AI869129 Hs.96616 ESTs 119023 RC_N98488 N98488 gb:zb82h01.s1 Soares_senescent_fibroblasts_NbHSF Homo sapiens cDNA clone IMAGE:3101293', mRNA sequence. 107582 RCAA002147 AA002147 Hs.59952 EST 118249 RC_N62580 N62580 Hs.322925 EST, Weakly similarto putative p150 [H.sapiens] 115022 RCAA252029 AA252029 Hs.87935 ESTs 117710 RC_N45198 N45198 Hs.47248 ESTs, Highly similar to similar to Cdc14B1 phosphatase [H.sapiens] 115341 RC_AA281452 AA281452 Hs.88840 EST, Weakly similar to granule cell marker protein [M.musculus] 118896 RCN90680 N46213 Hs.54642 methionine adenosyltransferase II, beta 121121 RC_AA399371 AA399371 Hs.189095 similar to SALL1 (sal (Drosophila)-like 118329 RCN63520 N63520 gb:yy62f01.s1 Soares_multiple_sclerosis_2NbHMSP Homo sapiens cDNA clone IMAGE:278137 3', mRNA sequence. 119496 RC_W35416 W35416 Hs.156861 ESTs, Moderately similarto A46010 X-linked retinopathy protein [H.sapiens] 118111 RC_N55493 N55493 gb:yv50c02.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:2461463', mRNA sequence. 119062 RC_R16698 AW444881 Hs.77829 ESTs 116710 RC_F10577_f F10577 Hs.306088 v-crk avian sarcoma virus CT10 oncogene homolog 119261 RCT15956 T15956 Hs.65289 EST 122723 RC_AA457380 AA457380 gb:aa86b10.s1 Stratagene fetal retina 937202 Homo sapiens cDNA clone IMAGE:838171 3' similarto contains L1.b3 L1 repetitive element ;, mRNA sequence.

117732 RC .N46452 N46452 gb:yy76h09.s1 Soares_multiple_sclerosis_2NbHMSP Homo sapiens cDNA clone

IMAGE:279521 3' similarto contains L1.t2 L1 repetitive element;, mRNA sequence.

104787 RC_AA027317 AA027317 gb:ze97d11.s1 Soares_feta|_heart_NbHH19W Homo sapiens cDNA clone IMAGE:3669333' similar to contains Alu repetitive element;, mRNA sequence.

100071 A28102 A28102 Human GABAa receptor alpha-3 subunit

115819 RC AA426573 AA486620 Hs.41135 endomucin-2

130882 RC Z40166J AA497044 Hs.20887 hypothetical protein FLJ10392

125225 RC W76540 W74169 Hs.16492 DKFZP564G2022 protein

108339 RC AA070801 AW151340 Hs.51615 ESTs, Weakly similarto ALU7_HUMAN ALU SUBFAMILY SQ SEQUENCE CONTAMINATION

WARNING ENTRY [H.sapiens]

100338 D63483 D86864 Hs.57735 acetyl LDL receptor; SREC

121636 RC_AA417027 AA379203 Hs.306654 Homo sapiens cDNA FLJ13574 fis, clone PLACE1008625

103875 RC AA418387 T26379 Hs.48802 Homo sapiens clone 23632 mRNA sequence

118716 RCN73460 AI658908 Hs.118722 fucosyltransferase 8 (alpha (1,6) fucosyltransferase)

119763 RC W72450 R54146 Hs.10450 Homo sapiens cDNA: FLJ22063 fis, clone HEP10326

121917 RC AA428218 AA406397 Hs.98038 ESTs

132806 M91488 AI699432 Hs.278619 hypothetical protein FLJ10099

130949 Y10659 AV656840 Hs.285115 interieukin 13 receptor, alpha 1

108806 RC AA129933 AF070578 Hs.71168 Homo sapiens clone 24674 mRNA sequence

133276 RC AA490478 AW978439 Hs.69504 ESTs

134760 RC H16758 NM 000121 Hs.89548 erythropoietin receptor

132867 AA121287 AF226667 Hs.58553 CTP synthase II

132051 AA091284 AA393968 Hs.180145 HSPC030 protein

114208 RC Z39301 AL049466 Hs.7859 ESTs

104094 AA418187 AA418187 Hs.330515 ESTs

128718 AA426361 NM 002959 Hs.281706 sortilin 1

302032 RC N20407 NM J01992 Hs.128087 coagulation factor II (thrombin) receptor

115501 RC AA291553 AA291553 Hs.190086 ESTs

101997 U01160 AU076536 Hs.50984 sarcoma amplified sequence

103708 AA037206 AA430591 Hs.72071 hypothetical protein FLJ20038

101899 S59184 S59184 Hs.79350 RYK receptor-like tyrosine kinase

115839 RC AA429038 BE300266 Hs.28935 transducin-like enhancer of split 1 , homolog of Drosophila E(sp1 )

409459 D50678 D86407 Hs.54481 low density lipoprotein receptor-related protein 8, apolipoprotein e receptor

103563 Z22534 L02911 Hs.150402 Activin A receptor, type I (ACVR1) (ALK-2)

123233 RC AA490225 AW974175 Hs.188751 ESTs, Weakly similarto MAPB_HUMAN MICROTUBULE-ASSOCIATED PROTEIN 1B

[H.sapiens]

121305 RC AA402468 AA402468 Hs.291557 ESTs

114798 RC AA159181 AA159181 Hs.54900 serologically defined colon cancer antigen 1

133145 RC AA196549 H94227 Hs.6592 Homo sapiens, clone IMAGE:2961368, mRNA, partial eds

131567 RC AA291015 i 5 AF015592 Hs.28853 CDC7 (cell division cycle 7, S. cerevisiae, homolog)-like 1

112300 RC R54554 H24334 Hs.26125 ESTs

129507 RC AA192099 AJ236885 Hs.112180 zinc finger protein 148 (pHZ-52)

121033 RC AA398505 AA398505 Hs.97360 ESTs

121151 RC AA399636 AA399636 Hs.143629 ESTs

121402 RC AA406063 AA406063 Hs.98003 ESTs

123203 RC AA489671 AA352335 Hs.65641 hypothetical protein FLJ20073

132271 RC AA236466 AB030034 Hs.115175 sterile-alpha motif and leucine zipper containing kinase AZK

125197 RC W69106 AF086270 Hs.278554 heterochromatin-like protein 1

114935 RC AA242809 H23329 Hs.290880 ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION

WARNIt* JG ENTRY [H.sapiens]

125279 RC W93640 AW401809 Hs.4779 KIAA1150 protein

108778 RC AA128548 AF133123 Hs.90847 general transcription factor IIIC, polypeptide 3 (102kD)

108087 RC AA045709 AA045708 Hs.40545 ESTs

132466 RC N66810 s AI597655 Hs.49265 ESTs

133328 R36553 AW452738 Hs.265327 hypothetical protein DKFZp761l141

124057 RC F13604 AA902384 Hs.73853 bone morphogenetic protein 2

124800 RC R45115 AW864086 Hs.138617 thyroid hormone receptor interactor 12 121029 RC AA398482 AA398482 Hs.97641 EST

120663 RC AA287627 AA827798 Hs.105089 ESTs

102133 U15173 AU076845 Hs.155596 BCL2/adenovirus E1B 19kD-interacting protein 2

108246 RC AA062855 AI423132 Hs.146343 ESTs

125226 RC W78134 AA782536 Hs.122647 N-myristoyltransferase 2

120260 RC AA171739 AK000061 Hs.101590 hypothetical protein

124906 RC R87647 H75964 Hs.107815 ESTs

109406 RC AA226877 AA199883 Hs.67624 ESTs

109271 RC AA195668 AW137422 Hs.86022 ESTs

125052 RC T80174 s T85104 Hs.222779 ESTs, Moderately similar to similarto NEDD-4 [H.sapiens]

109101 RC AA167708 AW608930 Hs.52184 hypothetical protein FLJ20618

115241 RC AA278723 AA648278 Hs.193859 ESTs

117163 RC H97909 N36861 Hs.42344 ESTs

113530 RC T90313 T90313 Hs.16732 ESTs

120375 RC AA227260 AF028706 Hs.111227 Zic family member 3 (odd-paired Drosophila homolog, heterotaxy 1)

129435 AA314256 AF151852 Hs.111449 CGI-94 protein

114864 RC AA235256 AA135332 Hs.71608 ESTs

103988 AA314389 AA314389 Hs.42500 ADP-ribosylation factor-like 5

131006 RC AA242763 AF064104 Hs.22116 CDC14 (cell division cycle 14, S. cerevisiae) homolog B

106781 RC AA478474 AA330310 Hs.24181 ESTs

106141 RC AA424558 AF031463 Hs.9302 phosducin-like

116213 RC AA476738 AA292105 Hs.326740 hypothetical protein MGC10947

135266 AB002326 R41179 Hs.97393 KIAA0328 protein

135058 RC AA430152 AI379720 Hs.93814 hypothetical protein

119908 RC W85844 AA524470 Hs.58753 ESTs

103695 AA018758 AW207152 Hs.186600 ESTs

103978 AA307443 NM 016940 Hs.34136 chromosome 21 open reading frame 6

109485 RC AA233472 BE619092 Hs.28465 Homo sapiens cDNA: FLJ21869 fis, clone HEP02442

129574 AA458603 AA026815 Hs.11463 UMP-CMP kinase

115347 RC AA281528 AA356792 Hs.334824 hypothetical protein FLJ14825

120765 RC AA338735 AW961026 Hs.96752 ESTs, Weakly similarto ALU8JHUMAN ALU SUBFAMILY SX SEQUENCE CONTAMINATION

WARNING ENTRY [H.sapiens]

121059 RC AA398628 AA393283 gb:zt74e03.r1 Soares_testis_NHT Homo sapiens cDNA clone 5', mRNA sequence

131887 AA046548 W17064 Hs.332848 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1

112064 RC R43812 AL049390 Hs.22689 Homo sapiens mRNA; cDNA DKFZp58601318 (from clone DKFZp58601318)

115606 RC AA400465 AI025829 Hs.86320 ESTs

131750 RC H94855 s NMJ04349 Hs.31551 core-binding factor, runt domain, alpha subunit 2; translocated to, 1; cyclin D-related

102123 U14518 NM 001809 Hs.1594 centromere protein A (17kD)

129847 RC W46767 N64025 Hs.296178 hypothetical protein FLJ22637

133809 RC AA235275 AV649326 Hs.76359 catalase

132210 RC N51499_s NM 007203 Hs.42322 A kinase (PRKA) anchor protein 2

122356 RC AA443794 AA443794 Hs.98390 ESTs

114958 RC AA243708 N20912 Hs.42369 ESTs

103951 AA287840 AL353944 Hs.50115 Homo sapiens mRNA; cDNA DKFZp761J1112 (from clone DKFZp761J1112)

134703 RC AA280704 AF117065 Hs.88764 male-specific lethal-3 (Drosophila)-like 1

128727 AA287864 AI223335 Hs.50651 Janus kinase 1 (a protein tyrosine kinase)

105743 RC_AA293300_! 3 BE246502 Hs.9598 sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4B

103744 AA076003 AA079267 gb:zm97e10.s1 Stratagene colon HT29 (937221) Homo sapiens cDNA clone 3', mRNA sequence

114348 N80402 AL050321 Hs.301532 CRP2 binding protein

114009 RC W90067 AI248544 Hs.103000 K1AA0831 protein

134704 RC AA280849 AA837124 Hs.88780 ESTs

1 12288662299 AA399187 AL096748 Hs.102708 DKFZP434A043 protein

110044441100 H65925 AI807519 Hs.104520 Homo sapiens cDNA FLJ13694 fis, clone PLACE2000115

111100220000 RC H21075 H21075 Hs.31802 ESTs, Highly similarto A59266 unconventional myosin-15 [H.sapiens]

112244448833 RC N53976 AI821780 Hs.179864 ESTs

110011339911 M14648 NM 002210 Hs.295726 integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51)

110099665577 RC F04826 R60900 Hs.26814 ESTs

111177114400 RC H96813 H96813 Hs.42241 ESTs 132937 RC_AA233706_f AW952912 Hs.300383 hypothetical protein MGC3032 129799 R36410 AW967473 Hs.239114 mannosidase, alpha, class 1 A, member 2 105077 RO.AA142919 W55946 Hs.234863 Homo sapiens cDNA FLJ12082 fis, clone HEMBB1002492 100850 RC_N58561_s AA836472 Hs.297939 cathepsin B 131043 RC_AA490925 AF084535 Hs.22464 epilepsy, progressive myodonus type 2, Lafora disease (laforin)

118417 RC_N66048_f AF080229 gb:Human endogenous retrovirus K clone 10.1 polymerase mRNA, partial eds 129254 RCAA243695 AA252468 Hs.1098 DKFZp434J1813 protein 119149 RCR58910 BE304701 Hs.65732 ESTs 133996 AA091367 AA380267 Hs.78277 DKFZP434F2021 protein 110223 RC_H23747 H19836 Hs.31697 ESTs 117626 RCN36090 AK001757 Hs.281348 hypothetical protein FLJ10895 135286 RC_AA424469 s AW023482 Hs.97849 ESTs 122967 RCAA478521 AA806187 Hs.289101 glucose regulated protein, 58kD 131236 AA282640 AF043117 Hs.24594 ubiquitination factor E4B (homologous to yeast UFD2)

128568 AA463380 H12912 Hs.274691 adenylate kinase 3 112888 RC T03872 AW195317 Hs.107716 hypothetical protein FLJ22344

115192 RC \A261920 AA741024 Hs.88378 ESTs

118688 RC N71484 AK000708 Hs.169764 hypothetical protein FLJ20701

122264 RC AA436837 AA436837 gb:zv57g07.s1 Soares_testis_NHT Homo sapiens cDNA clone 3', mRNA sequence

128981 AA135452 AA927177 Hs.86041 CGG triplet repeat binding protein 1

131042 RC R42457 AI826288 Hs.171637 hypothetical protein MGC2628

103704 AA028171 AA028171 Hs.151258 hypothetical protein FLJ21062

121341 AA233107 AF035528 Hs.153863 MAD (mothers against decapentaplegic, Drosophila) homolog 6

106593 RC AA456826 AW296451 Hs.24605 ESTs

115195 RC AA262156 AW968619 Hs.155849 ESTs

115425 RC AA284071 AA811895 Hs.180680 ESTs, Weakly similar to 154374 gene NF2 protein [H.sapiens]

117258 RC N21299 AF086041 Hs.42975 ESTs

120209 RC Z40892 F02951 gb:HSC1HB082 normalized infant brain cDNA Homo sapiens cDNA clone c-1hb083', mRNA sequence

134082 L16991 L L1166999911 Hs.79006 deoxythymidylate kinase (thymidylate kinase)

104774 RC AA026066 A AWW995599775555 Hs,288896 Homo sapiens cDNA FLJ12977 fis, clone NT2RP2006261

115625 RC AA401630 A AAA005599445599 Hs,62592 ESTs

104469 N28707 N N2288770077 Hs.154304 Homo sapiens chromosome 19, BAC 282485 (CIT-B-344H19)

107401 W20054 N N9911445533 Hs.102987 ESTs

111686 RC R21510 R R2222003399 Hs.23217 ESTs

115300 RC AA280026 A AAA228800009955 Hs.88689 ESTs

115378 RC AA282292 A AAA228822229922 Hs.279841 hypothetical protein FLJ10335

132224 RC H97819 N N4411554499 Hs.285410 ESTs

113791 M95767 A AII226699009966 Hs.135578 chitobiase, di-N-acetyl-

129144 AA004987 A ALL113377227755 Hs.20137 hypothetical protein DKFZp434P0116

104448 L44574 N NMMJ 000773333'1 Hs.110457 Wolf-Hirschhorn syndrome candidate 1

132084 RC T26981_s N NMM__0000222266i7 H Hss..33888866 karyopherin alpha 3 (importin alpha 4)

111831 RC R36083 R R3366009955 Hs.268695 ESTs

114765 RC AA252163 A AAA446633555500 Hs.337532 ESTs, Weakly similarto A47582 B-cell growth factor precursor [H.sapiens]

115029 RC AA252219 A ALL113377993399 Hs.40096 ESTs

100457 H81492 B BEE224466440000 Hs.285176 acetyl-Coenzyme A transporter

104536 R24011 R R2244002244 Hs.158101 Homo sapiens cDNA FLJ14673 fis, clone NT2RP2003714, moderately similarto ZINC FINGER

PROTEIN 91

116167 RC AA461562 A AII009911773311 Hs.87293 hypothetical protein FLJ20045

103889 AA236771 R R8855335500 Hs.101368 ESTs

131978 RC H48459 s A AAA335555992255 Hs.36232 KIAA0186 gene product

118843 RC N80181 N N8800118811 Hs.221498 ESTs

120837 RC W93092 B BEE114499665566 Hs.306621 Homo sapiens cDNA FLJ11963 fis, clone HEMBB1001051

133647 D21852 N NMM 11553366"1 Hs.268053 KIAA0029 protein

129521 U41815 A AFF007711007766 Hs.112255 nucleoporin 98kD

103746 AA081876 A AAA007755000000 gb:zm83c07.s1 Stratagene ovarian cancer (937219) Homo sapiens cDNA clone 3', mRNA sequence

132019 RC AA134965 i H56995 Hs.37372 Homo sapiens DNA binding peptide mRNA, partial eds

132310 RC AA284107 AA173223 Hs.289044 Homo sapiens cDNA FLJ12048 fis, clone HEMBB1001990

117367 RC N24954 AI041793 Hs.42502 ESTs

103743 AA075998 AA075998 gb:zm89b09.r1 Stratagene ovarian cancer (937219) Homo sapiens cDNA clone 5' similarto gb:M15887 ACYL-COA-BINDING PROTEIN (HUMAN);, mRNA sequence

103761 AA085138 AA765163 gb:nz79b10.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone 3' similarto gb:M34539 FK506-

BINDING PROTEIN (HUMAN);, mRNA sequence

130237 L39060 AA913909 Hs.153088 TATA box binding protein (TBP)-associated factor, RNA polymerase I, A, 48kD 128752 RC_N72879 AA504428 Hs.10487 Homo sapiens, clone IMAGE:3954132, mRNA, partial eds 135162 AA045930 AH 87925 Hs.95667 F-box protein 30 131386 AA096412 BE219898 Hs.173135 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 129021 RC AA599244 AL044675 Hs.173081 KIAA0530 protein 424274 AA293634 W73933 Hs.283738 casein kinase 1, alpha 1 129913 H06583 NMJ01310 Hs.13313 cAMP responsive element binding protein-like 2 131888 U79298 AW294659 Hs.34054 Homo sapiens cDNA: FLJ22488 fis, clone HRC10948, highly similarto HSU79298 Human clone 23803 mRNA 118612 RC_N69466 AB037788 Hs.224961 cleavage and polyadenylation specific factor 2, 100kD subunit 322026 AA203138 AW024973 Hs.283675 NPD009 protein 110892 RC N38882 AL035301 Hs.97375 H.sapiens gene from PAC 106H8 111429 RC..R01245 AI038052 Hs.19162 ESTs, Weakly similar to I54374 gene NF2 protein [H.sapiens] 113334 RC T76962 AW974666 Hs.293024 ESTs 104091 AA417310 BE465093 Hs.106101 hypothetical protein FLJ22557 105246 RC_AA226879 AA226879 gb:zr19c09.s1 Stratagene NT2 neuronal precursor 937230 Homo sapiens cDNA clone

IMAGE:6638563' similar to contains Alu repetitive element;, mRNA sequence.

113300 RC 67448 T67448 Hs.13101 ESTs

117147 RC_H97225_s AW901347 Hs.38592 hypothetical protein FLJ23342

121349 RC_AA405205 AA405205 Hs.97960 ESTs, Weakly similarto T51146 ring-box protein 1 [H.sapiens]

100294 D49396 AA331881 Hs.75454 peroxiredoxin 3

133999 M28213 AA535244 Hs.78305 RAB2, member RAS oncogene family

133259 AA278548 BE379646 Hs.6904 Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 2004403

129423 AA371418 AA204686 Hs.234149 hypothetical protein FLJ20647

131098 RC AA459668 U66669 Hs.236642 3-hydroxyisobutyryl-Coenzyme A hydrolase

135272 AA399391 AI828337 Hs.97591 ESTs

129155 AA046865 AI952677 Hs.108972 Homo sapiens mRNA; cDNA DKFZp434P228 (from clone DKFZp434P228) 311291 AA056319 AA782601 Hs.319817 ESTs 120750 RC_AA310499 AI191410 Hs.96693 ESTs, Moderately similarto 2109260A B cell growth factor [H.sapiens] 101002 J04058 AV655843 Hs.169919 electron-transfer-flavoprotein, alpha polypeptide (glutaric aciduria II) 133012 AA099241 AA847843 Hs.62711 Homo sapiens, clone IMAGE:3351295, mRNA 103879 AA228148_s BE543269 Hs.50252 mitochondrial ribosomal protein L32 131281 RC_AA443212 AA251716 Hs.25227 ESTs 115109 RCAA256383 AJ249977 Hs.88049 protein kinase, AMP-activated, gamma 3 non-catalytic subunit 118502 RCN67317 AL157488 Hs.50150 Homo sapiens mRNA; cDNA DKFZp564B182 (from clone DKFZp564B182) 134100 L07540 AA460085 Hs.171075 replication factor C (activator 1) 5 (36.5kD) 131869 AA484944 AW968547 Hs.33540 ESTs, Weakly similarto dJ309K20.4 [H.sapiens] 115396 RC_AA282985 AA810854 Hs.89081 ESTs 103860 AA203742 AW976877 Hs.38057 ESTs 135089 N75611_s AI918035 Hs.301198 roundabout (axon guidance receptor, Drosophila) homolog 1 129938 U79300 AW003668 Hs.135587 Human clone 23629 mRNA sequence 107508 W90095 N74925 Hs.38761 Homo sapiens cDNA: FLJ21564 fis, clone COL06452 103685 AA005190 AA158008 Hs.292444 ESTs 125170 AA203147 AL020996 Hs.8518 selenoprotein N 129179 RC_AA504125_s AW969025 Hs.109154 ESTs 116262 AA477046 AI936442 Hs.59838 hypothetical protein FLJ 10808 123009 RC_AA479949 AA535244 Hs.78305 RAB2, member RAS oncogene family 131004 D29833 D29833 Hs.2207 salivary proline-rich protein 103317 X83441 X83441 Hs.166091 ligase IV, DNA, ATP-dependent 132814 RC_C15251_f D60730 Hs.57471 ESTs 103992 U77718 BE018142 Hs.300954 Huntingtin interacting protein K 109258 X59710 AL044818 Hs.84928 nuclear transcription fadorY, beta 110754 RCN20814 AW302200 Hs.6336 KIAA0672 gene product 132727 AA136382_s N27495 Hs.5565 hypothetical protein FLJ22626 100341 D63506 AF032922 Hs.8813 syntaxin binding protein 3 134664 AA256106 AA256106 Hs.87507 ESTs 103826 AA165564 AW162998 Hs.24684 KIAA1376 protein 111678 RCR20628 R38487 Hs.169927 ESTs 101341 L76159 NM 04477 Hs.203772 FSHD region gene 1 115455 RC_AA285068 AA876002 Hs.120551 toll-like receptor 10 111192 RC_AA477748 AW021968 Hs.109438 Homo sapiens clone 24775 mRNA sequence 129385 RC_AA235604 AA172106 Hs.110950 Rag C protein 125050 RC_π9951 AW970209 Hs.111805 ESTs 122105 RC_AA432278 AW241685 Hs.98699 ESTs 121324 RC_AA404229 AA404229 Hs.97842 EST 120938 RC_AA386260 AA386260 Hs.104632 EST 115001 RO.AA251376 AA251376 gb:zs10a06.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:6847543', mRNA sequence.

124799 RC_R45088 R45088 gb:yg38g04.s1 Soares infant brain 1NIB Homo sapiens cDNA clone IMAGE:348963', mRNA sequence.

122724 RC_AA457395 AAAA445577339955 Hs.99457 ESTs 117791 RCN48325 NN4488332255 Hs.93956 EST

121895 RC_AA427396 AA427396 gb:zw33a02.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:7710503' similarto contains Alu repetitive element;contains MER12.t2 MER12 repetitive element ;, mRNA sequence.

108244 RC_AA062839 AA062839 gb:zm05c09.s1 Stratagene corneal stroma (937222) Homo sapiens cDNA clone IMAGE:513232 3', mRNA sequence. 117852 RC_N49408 AW877787 Hs.136102 KIAA0853 protein 109298 RC_AA205432 R77854 Hs.250693 Krueppel-related zinc finger protein 122432 RC_AA447400 AA447400 Hs.187684 ESTs, Weakly similarto B34087 hypothetical protein [H.sapiens] 124627 RC_N74625 N74625 gb:za55c03.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:2964523' similar to gb:M14338 VITAMIN K-DEPENDENT PROTEIN S PRECURSOR (HUMAN);contains OFR.b3 OFR repetitive element ;, mRNA sequence.

115141 RC AA258071 AA465131 Hs.64001 Homo sapiens clone 25218 mRNA sequence

128636 U49065 U49065 Hs.102865 interleukin 1 receptor-like 2

115373 RC AA282197 AA664862 Hs.181022 CGI-07 protein

114651 RC_AA101400 AA101400 Hs.189960 ESTs

132796 RC_AA180487 NM 006283 Hs.173159 transforming, acidic coiled-coil containing protein 1

103749 RC N35583 AL135301 Hs.8768 hypothetical protein FLJ10849

107328 T83444 AW959891 Hs.76591 KIAA0887 protein

115349 RC AA281563 AF121176 Hs.12797 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 16

111490 RC R06862 R06862 gb:yf11e09.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:126568 3' similarto contains L1 repetitive element ;, mRNA sequence.

103763 AA085354 AA085291 gb:zn01g06.s1 Stratagene colon HT29 (937221) Homo sapiens cDNA clone 3' similar to contains Alu repetitive element;, mRNA sequence

118791 RC N75520 N75520 Hs.261003 ESTs, Moderately similar to B34087 hypothetical protein [H.sapiens]

116644 RCF03032 F03032 Hs.290278 ESTs, Weakly similarto B34087 hypothetical protein [H.sapiens]

116823 RCH56485 AW204742 Hs.143542 ESTs, Highly similarto CSA_HUMAN COCKAYNE SYNDROME WD-REPEAT PROTEIN CSA

[H.sapiens]

108940 RC_AA148603 AA148603 gb:zo09e04.s1 Stratagene neuroepithelium NT2RAMI 937234 Homo sapiens cDNA clone

IMAGE:5671983', mRNA sequence.

112218 RC R50057 R50057 Hs.272251 Homo sapiens mRNA; cDNA DKFZp586M1418 (from clone DKFZp586M1418)

116557 RC_D20572 I D20572 Hs.90171 EST

133649 U25849 U25849 Hs.75393 acid phosphatase 1, soluble

131745 RC_C20746 AI828559 Hs.31447 ESTs, Moderately similar to A46010 X-linked retinopathy protein [H.sapiens] 116801 RC_H43879 H43879 gb:yo69h09.s1 Soares breast 3NbHBst Homo sapiens cDNA clone IMAGE:1832333', mRNA sequence.

115006 RC AA251548 AA251548 Hs.87886 EST

123424 RC AA598500 H29882 Hs.162614 ESTs

120831 RC AA347919 AA347919 Hs.96889 EST

103691 AA018298 AA018298 Hs.103332 ESTs

121555 RC AA412491 AF025771 Hs.50123 zinc finger protein 189

111193 RC N67946 N67946 Hs.117569 ESTs

132061 RC AA058946 AB020700 Hs.3830 KIAA0893 protein

134575 RC AA194568 i i AA194568 Hs.85938 EST

115050 RC AA252794 AA252794 Hs.88009 ESTs

420208 U31799 BE276055 Hs.95972 silver (mouse homolog) like

133735 AC002045 xptl R66740 Hs.110613 KIAA0220 protein

128546 Z21305 NM 003478 Hs.101299 cullin 5

111946 RC R40697 R40697 Hs.76666 C9orf10 protein

124879 RC R73588 R73588 Hs.101533 ESTs

115683 AA410345 AF255910 Hs.54650 junctional adhesion molecule 2

103692 AA018418 AW137912 Hs.227583 Homo sapiens chromosome X map Xp11.23 L-type calcium channel alpha-1 subunit

(CACNA1F) gene, complete eds; HSP27 pseudogene, complete sequence; and JM1 protein, JM2 protein, and Hb2E genes, complete eds

103767 AA089688 BE244667 Hs.296155 CGI-100 protein

125266 W90022 W90022 Hs.186809 ESTs, Highly similar to LCT2_HUMAN LEUKOCYTE CELL-DERIVED CHEMOTAXIN 2

PRECURSOR [H.sapiens^' I

135235 AA435512 AW298244 Hs.293507 ESTs

134497 RC AA404494 BE258532 Hs.251871 CTP synthase

426754 RC AA278529 i NM_014264 Hs.172052 serine/threonine kinase 18

412177 RC AA342828 : 3 Z23091 Hs.73734 glycoprotein V (platelet)

132000 RC AA044644 AW247017 Hs.36978 melanoma antigen, family A, 3

124738 RC AA044644 T07568 Hs.137158 ESTs

324000 RC AA196729 i AA604749 Hs.190213 ESTs

106896 RC AA196729 i AW073202 Hs.334825 Homo sapiens cDNA FLJ 14752 fis, clone NT2RP3003071

132000 RC AA025858 AW247017 Hs.36978 melanoma antigen, family A, 3

129577 RC AA025858 N75346 Hs.82906 CDC20 (cell division cycle 20, S. cerevisiae, homolog)

107091 RC AA233519 AI949109 Hs.246885 hypothetical protein FLJ20783

130296 RC N52271 D31139 Hs.154103 LIM protein (similarto rat protein kinase C-binding enigma)

102855 RC N68399 NM_003528 Hs.2178 H2B histone family, member Q

113689 RC AA098874 AB037850 Hs.16621 DKFZP434I116 protein

100939 RC AA279667_! 3 L04288 Hs.297939 cathepsin B

130430 RC H22556 W27893 Hs.150580 putative translation initiation factor

106734 RC_N45979_s BE296690 Hs.288173 Homo sapiens cDNA: FLJ21747 fis, clone COLF5160, highly similarto AF182198 Homo sapiens intersectin 2 long isoform (ITSN2) mRNA

135148 RC AA431288 ! 3 AA306478 Hs.95327 CD3D antigen, delta polypeptide (TiT3 complex)

134221 RC AA609862 BE280456 Hs.80248 RNA-binding protein gene with multiple splicing

105376 RC N35583 AW994032 Hs.8768 hypothetical protein FLJ10849

124541 U77718 AF112222 Hs.44499 pinin, desmosome associated protein

134546 AA203147 AL020996 Hs.8518 selenoprotein N

134000 RC W93092 AW175787 Hs.334841 selenium binding protein 1

125656 RC W93092 AW516428 Hs.78687 neutral sphingomyelinase (N-SMase) activation associated factor

100939 RC N58561_s L04288 Hs.297939 cathepsin B

125656 RC W93092 AW516428 Hs.78687 neutral sphingomyelinase (N-SMase) activation associated factor

101779 RC_W69385_s BE543412 Hs.250505 retinoic acid receptor, alpha

332489 RC R22947 R23053 NA Hu01 Chip Redos

133000 RC N38959 AL042444 Hs.62402 p21/Cdc42/Rad-activated kinase 1 (yeast Ste20-related)

125905 RC N38959J AI678638 Hs.6456 chaperonin containing TCP1, subunit 2 (beta)

129000 RC_H73050_s AA744902 Hs.107767 hypothetical protein PR01489

100920 RC H73050_s X54534 Hs.278994 Rhesus blood group, CcEe antigens

TABLE 1A

Table 1 A shows the accession numbers for those pkeys lacking unigenelD's for Tables 1. The pkeys in Table 7 lacking unigenelD's are represented within Tables 1 -6A. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey: Unique Eos probeset identifier number

CAT number: Gene cluster number Accession: Genbank accession numbers

Pkey CAT Number Accession

108469 116761J AA079487AA128547AA128291 AA079587AA079600 124106 125446J H12245AA094769 R14576 108501 13684_-12 AA083256 108562 36375J AA100796 AF020589 AA074629 AA075946 AA100849 AA085347 AA126309 AA079311 AA079323 AA085274 125008 1802095J T91251 T64891 T85665 125020 116017 T69981 T69924 AA078476 125066 1814993J T86284 T81933 116661 1532859J R61504 F04247 125104 413347J T95590 AA703278 H62764 124575 1666649 N68168 N69188 N90450 125263 1547_2 AA098878 W88942 116845 393481 1 AA649530 AA659316 H64973 118417 37186J AF080229 AF080231 AF080230 AF080232 AF080233 AF080234 BE550633 AI636743 AW614951 BE467547 AI680833

AI633818 N29986 U87592 U87593 U87590 U87591 S46404 U87587 AA463992 AW206802 AI970376 AI583718 AI672574 N25695 AW665466 AI818326 AA126128 AI480345 AW013827 AA248638 AI214968 AA204735 AA207155 AA206262 AA204833 AW003247 AW496808 A1080480 AI631703 AI651023 A1867418 AW818140 AA502500 AI206199 AI671282 AI352545 BE501030 AI652535 BE465762 AA206331 AW451866 AA471088 AA206342 AA204834 AA206100 AW021661 AA332922 N66048 AA703396 H92278 AW139734 H92683 U87589 U87595 H69001 U87594 BE466420 AI624817 BE466611 AI206344 AA574397 AA348354 AI493192

118584 532052 AW136928 AI685655 BE218584 BE465078 N68963 AA975338 BE147199 N76377 103743 112194J AA075998 AA075999 AA070986 AA070896 AA129207 AA078942 AA070783 AA078941 103744 114161J AA079267 AA076003 103746 113452J AA075000 AA081876 103761 114208J AA765163 AW298222 AA126126 AA085138 AA076068 103763 48290_6 AA085291 AA085354 120209 1531817 1 F02951 Z40892 F04711 120284 158963J AA179656 AA182626 AA182603 112540 1605263J R69751 R70467 H69771 H80879 H80878 111904 1719336J Z41572 R39330 121059 273450J AA393283 AA398628 121094 275729J AA402505 AA398900 114106 1182096J AW602528 BE073859 Z38412 130091 23961_-3 W88999 122264 296527J AA436837 AA442594 108280 110682 AA065069 AA085108 129961 1706092 R23053 R79884 R76271 130529 158447J AA1 8953 AA192740 108309 111495J AA069818 AA069971 AA069923 AA069908 107832 genbank_AA021473 AA021473 123731 genbank_AA609839 AA609839 116571 genbank_D45652 D45652 132225 genbank_AA128980 AA128980 125017 genbank_T68875 T68875 125063 genbank_T85352 T85352 125064 genbank_T85373 T85373 100964 entrez_J00212J00212 125118 149288J R10606T97620 AA576309 102269 entrez_U30245U30245 125150 NOT_FOUND_entrez_W38240 W38240 116801 genbank_H43879 H43879 118111 genbank_N55493 N55493 118129 genbank_N57493 N57493 118329 genbank_N63520 N63520 118475 genbank_N66845 N66845 111490 genbank_R06862 R06862 111514 genbank_R07998 R07998 104534 R22303_at R22303 120340 genbank_AA206828 AA206828 120376 genbank AA227469 AA227469

104787 genbank_AA02731 AA027317

120409 genbank_AA235050 AA235050

120745 genbank _AA302809 AA302809

120809 genbank AA346495 AA346495

120839 genbank_AA348913 AA348913

113702 genbank_T97307 T97307

115001 genbank_AA251376 AA251376

122562 genbank_AA452156 AA452156

122635 genbank AA454085 AA454085

108244 genbank_AA062839 AA062839

108277 genbank_AA064859 AA064859

122723 genbank AA457380 AA457380

124028 genbank F04112 F04112

108403 genbank AA075374 AA075374

122860 genbank AA464414 AA464414

108427 genbank AA076382 AA076382

108439 genbank AA078986 AA078986

131353 231290 1 AW411259 H23555 AW015049 AI684275 AW015886 AW068953 AW014085 AI027260 R52686 AA918278 AI129462

AA969360

N34869 AI948416 AA534205 AA702483 AA705292

108533 genbank AA084415 AA084415

117031 genbank H88353 H88353

124254 genbank_H69899 H69899

101447 entrez M21305 M21305

101458 entrez M22092 M22092

124577 genbank N68300 N68300

108940 genbank AA148603 AA148603

108941 genbank AA148650 AA148650

124627 genbank_N74625 N74625

124720 144582 1 R05283 R11056

124793 genbank R44519 R44519

124799 genbank_R45088 R45088

117683 genbank N40180 N40180

117732 genbank N46452 N46452

124991 genbank_T50116 T50116

119023 genbank_N98488 N98488

119239 95573 2 T11483 T11472

119558 NOT FOUND_entrez_W38194 W38194

119654 genbank W57759 W57759

105246 genbank AA226879 AA226879

121350 genbank AA405237 AA405237

121558 genbank_AA412497 AA412497

105985 genbank_AA406610 AA406610

100071 entrez_A28102A28102

114648 genbank AA101056 AA101056

121895 genbank_AA427396 AA427396

100327 entrez D55640D55640

123315 714071 1 AA496369 AA496646

TABLE 2:

Pkey: Unique Eos probeset identifier number

Accession: Accession number used for previous patent filings

ExAccn: Exemplar Accession number, Genbank accession number

UnigenelD: Unigene number

Unigene Title: Unigene gene title

Pkey Accession ExAccn UnigenelD UnigeneTitle

100420 100420 D86983 Hs.118893 Melanoma associated gene

100484 100484 NM 005402 Hs.288757 v-ral simian leukemia viral oncogene horn

100991 100991 J03836 Hs.82085 serine (or cysteine) proteinase inhibito

101168 101168 NM 005308 Hs.211569 G protein-coupled receptor kinase 5

101261 101261 D30857 Hs.82353 protein C receptor, endothelial (EPCR)

101447 101447 M21305 gb:Human alpha satellite and satellite 3

101543 101543 M31166 Hs.2050 pentaxin-related gene, rapidly induced b

101560 101560 AW958272 Hs.347326 intercellular adhesion molecule 2

101714 101714 M68874 Hs.211587 phospholipase A2, group IVA (cytosolic,

101838 101838 BE243845 Hs.75511 connective tissue growth factor

102012 102012 BE259035 Hs.118400 singed (Drosophila)-like (sea urchin fas

102164 102164 NM 000107 Hs.77602 damage-specific DNA binding protein 2 (4

102283 102283 AW161552 Hs.83381 guanine nucleotide binding protein 11

102564 102564 U59423 Hs.79067 MAD (mothers against decapentaplegic, Dr

102759 102759 NM 005100 Hs.788 A kinase (PRKA) anchor protein (gravin)

102804 102804 NM 002318 Hs.83354 lysyl oxidase-like 2

102898 102898 NM 002205 Hs.149609 integrin, alpha 5 (fibronectin receptor,

103036 103036 M13509 Hs.83169 matrix metalloproteinase 1 (interstitial

103095 103095 NM 005424 Hs.78824 tyrosine kinase with immunoglobulin and

103166 103166 AA159248 Hs.180909 peroxiredoxin 1

103280 103280 U84722 Hs.76206 cadherin 5, type 2, VE-cadherin (vascula

103850 103850 AA187101 Hs.213194 hypothetical protein MGC10895

104592 104592 AW630488 Hs.25338 protease, serine, 23

104786 104786 AA027167 Hs.10031 KIAA0955 protein

104865 104865 T79340 Hs.22575 B-cell CLL/lymphoma 6, member B (zinc fi

104952 104952 AW076098 Hs.345588 desmoplakin (DPI, DPII)

105178 105178 AA313825 Hs.21941 AD036 protein

105330 105330 AW338625 Hs.22120 ESTs

105729 105729 H46612 Hs.293815 Homo sapiens HSPC285 mRNA, partial eds

105977 105977 AK001972 Hs.30822 hypothetical protein FLJ11110

106031 106031 X64116 Hs.171844 Homo sapiens cDNA: FLJ22296 fis, clone H

106155 106155 AA425414 Hs.33287 nuclear factor l/B

106423 106423 AB020722 Hs.16714 Rho guanine exchange factor (GEF) 15

107174 107174 BE122762 Hs.25338 ESTs

107295 107295 AA186629 Hs.80120 UDP-N-acetyl-alpha-D-galactosamine:polyp

108756 108756 AA127221 Hs.117037 ESTs

108888 108888 AA135606 Hs.189384 gb:zl10a05.s1 Soares_pregnant_uterus_NbH

109166 109166 AA219691 Hs.73625 RAB6 interacting, kinesin-like (rabkines

109768 109768 F06838 Hs.14763 ESTs

110906 110906 AA035211 Hs.17404 ESTs

111006 111006 BE387014 Hs.166146 Homer, neuronal immediate early gene, 3

111133 111133 AW580939 Hs.97199 complement component C1q receptor

113073 113073 N39342 Hs.103042 microtubule-associated protein 1B

113923 113923 AW953484 Hs.3849 hypothetical protein FLJ22041 similarto

115061 115061 AI751438 Hs.41271 Homo sapiens mRNA full length insert cDN

115145 115145 AA740907 Hs.88297 ESTs

115947 115947 R47479 Hs.94761 KIAA1691 protein

116339 116339 AK000290 Hs.44033 dipeptidyl peptidase 8

116589 116589 AI557212 Hs.17132 ESTs, Moderately similar to I54374 gene

117023 117023 AW070211 Hs.102415 Homo sapiens mRNA; cDNA DKFZp586N0121 (f

117563 117563 AF055634 Hs.44553 uncδ (C.elegans homolog) c

118475 118475 N66845 gb:za46d 1.s1 Soares fetal liver spleen

119073 119073 BE245360 Hs.279477 ESTs

119174 119174 R71234 gb:yi54c08.s1 Soares placenta Nb2HP Homo

119416 119416 T97186 gb:ye50h09.s1 Soares fetal liver spleen

121335 121335 AA404418 gb:zw37e02.s1 Soaresjotaljetus Nb2HF8

123160 123160 AA488687 Hs.284235 ESTs, Weakly similar to I38022 hypotheti

123523 123523 AA608588 gb:ae54e06.s1 Stratagene lung carcinoma

123964 123964 C13961 gb:C13961 Clontech human aorta polyA+mR

124315 124315 NM_005402 Hs.288757 v-ral simian leukemia viral oncogene horn

124669 124669 AI571594 Hs.102943 hypothetical protein MGC12916

124875 124875 AI887664 Hs.285814 sprouty (Drosophila) homolog 4

125103 125103 AA570056 Hs.122730 ESTs, Moderately similarto KIAA1215 pro

125565 125565 R20840 gb:yg05c08.r1 Soares infant brain 1NIB H 126511 126511 T92143 Hs.57958 EGF-TM7-latrophilin-related protein

126649 126649 AA001860 Hs.279531 ESTs

449602 449602 AA001860 Hs.279531 ESTs

127402 127402 AA358869 Hs.227949 SEC13 (S. cerevisiae)-like 1

128992 128992 H04150 Hs.107708 ESTs

129188 129188 NM 01078 Hs.109225 vascular cell adhesion molecule 1

129371 129371 X06828 Hs.110802 von Willebrand factor

129765 129765 M86933 Hs.1238 amelogenin (Y chromosome)

129884 129884 AF055581 Hs.13131 lysosomal

130639 130639 AI557212 Hs.17132 ESTs, Moderately similarto I54374 gene

130828 130828 AW631469 Hs.203213 ESTs

131080 131080 NM 001955 Hs.2271 endothelin 1

131182 131182 AI824144 Hs.23912 ESTs

131573 131573 AA040311 Hs.28959 ESTs

131756 131756 AA443966 Hs.31595 ESTs

131881 131881 AW361018 Hs.3383 upstream regulatory element binding prot

132083 132083 BE386490 Hs.279663 Pirin

132358 132358 NM 003542 Hs.46423 H4 histone family, member G

132456 132456 AB011084 Hs.48924 KIAA0512 gene product; ALEX2

132676 132676 N92589 Hs.261038 ESTs, Weakly similar to I38022 hypotheti

132718 132718 NM_004600 Hs.554 SJogren syndrome antigen A2 (60kD, ribon

132760 132760 AA125985 Hs.56145 thymosin, beta, identified in neuroblast

132968 132968 AF234532 Hs.61638 myosin X

133061 133061 AH86431 Hs.296638 prostate differentiation factor

133161 133161 AW021103 Hs.6631 hypothetical protein FLJ20373

133260 133260 AA403045 Hs.6906 Homo sapiens cDNA: FLJ23197 fis, clone R

133491 133491 BE619053 Hs.170001 eukaryotic translation initiation factor

133550 133550 AI129903 Hs.74669 vesicle-associated membrane protein 5 (m

133614 133614 NM 003003 Hs.75232 SEC14 (S. cerevisiae)-like 1

133691 133691 M85289 Hs.211573 heparan sulfate proteoglycan 2 (periecan

133913 133913 AU076964 Hs.7753 calumenin

133985 133985 L34657 Hs.78146 platelet/endothelial cell adhesion molec

134088 134088 AI379954 Hs.79025 KIAA0096 protein

134299 134299 AW580939 Hs.97199 complement component C1q receptor

116470 116470 AI272141 Hs.83484 SRY (sex determining region Y)-box 4

134989 134989 AW968058 Hs.92381 nudix (nucleoside diphosphate linked moi

135073 135073 W55956 Hs.94030 Homo sapiens mRNA; cDNA DKFZp586E1624 (f

100114 100114 X02308 Hs.82962 thymidylate synthetase

100143 100143 AU076465 Hs.278441 KIAA0015 gene product

100208 100208 NM 002933 Hs.78224 ribonuclease, RNase A family, 1 (pancrea

100405 100405 AW291587 Hs.82733 nidogen 2

100455 100455 AW888941 Hs.75789 N-myc downstream regulated

100618 100618 AI752163 Hs.114599 collagen, type VIII, alpha 1

100658 100658 U56725 Hs.180414 heat shock 70kD protein 2

100718 100718 BE295928 Hs.75424 inhibitor of DNA binding 1, dominant neg

100828 100828 AL048753 Hs.303649 small inducible cytokine A2 (monocyte ch

100991 100991 J03836 Hs.82085 serine (or cysteine) proteinase inhibito

101110 101110 AI439011 Hs.86386 myeloid cell leukemia sequence 1 (BCL2-r

101156 101156 AA340987 Hs.75693 prolylcarboxypeptidase (angiotensinase C

101184 101184 NM.001674 Hs.460 activating transcription factor 3

101317 101317 L42176 Hs.8302 four and a half LIM domains 2

101345 101345 NM 005795 Hs.152175 calcitonin receptor-like

101475 101475 BE410405 Hs.76288 calpain 2, (m/ll) large subunit

101496 101496 X12784 Hs.119129 collagen, type IV, alpha 1

101543 101543 M31166 Hs.2050 pentaxin-related gene, rapidly induced b

101560 101560 AW958272 Hs.347326 intercellular adhesion molecule 2

101592 101592 AF064853 Hs.91299 guanine nucleotide binding protein (G pr

101634 101634 AV650262 Hs.75765 GR02 oncogene

101682 101682 AF043045 Hs.81008 filamin B, beta (actin-binding protein-2

101720 101720 M69043 Hs.81328 nuclear factor of kappa light polypeptid

101744 101744 AI879352 Hs.118625 hexokinase 1

101837 101837 M92843 Hs.343586 zinc finger protein homologous to Zfp-36

101840 101840 AA236291 Hs.183583 serine (or cysteine) proteinase inhibito

101864 101864 BE392588 Hs.75777 transgelin

101966 101966 X96438 Hs.76095 immediate early response 3

102013 102013 BE616287 Hs.178452 catenin (cadherin-associated protein), a

102059 102059 AI752666 Hs.76669 nicotinamide N-methyltransferase

102283 102283 AW161552 Hs.83381 guanine nucleotide binding protein 11

102378 102378 AU076887 Hs.28491 spermidine/spermine NI-acetyltransferase

102460 102460 U48959 Hs.211582 myosin, light polypeptide kinase

102499 102499 BE243877 Hs.76941 ATPase, Na K+ transporting, beta 3 poly

102560 102560 R97457 Hs.63984 cadherin 13, H-cadherin (heart)

102589 102589 AU076728 Hs.8867 cysteine-rich, angiogenic inducer, 61

102645 102645 AL119566 Hs.6721 lysosomal

102693 102693 AA532780 Hs.183684 eukaryotic translation initiation factor

102759 102759 NM_005100 Hs.788 A kinase (PRKA) anchor protein (gravin) 102882 102882 AI767736 Hs.290070 gelsolin (amyloidosis, Finnish type)

102915 102915 X07820 Hs.2258 matrix metalloproteinase 10 (stromelysin

102960 102960 AI904738 Hs.76053 DEAD/H (Asp-Glu-Ala-Asp/His) box polypep

103020 103020 X53416 Hs.195464 filamin A, alpha (actin-binding protein-

103036 103036 M13509 Hs.83169 matrix metalloproteinase 1 (interstitial

103080 103080 AU077231 Hs.82932 cyclin D1 (PRAD1: parathyroid adenomatos

103138 103138 X65965 gb:H.sapiens SOD-2 gene for manganese su

103195 103195 AA351647 Hs.2642 eukaryotic translation elongation factor

103371 103371 X91247 Hs.13046 thioredoxin reductase 1

103471 103471 Y00815 Hs.75216 protein tyrosine phosphatase, receptor t

104447 104447 AW204145 Hs.156044 ESTs

104783 104783 AA533513 Hs.93659 protein disulfide isomerase related prot

104865 104865 T79340 Hs.22575 B-cell CLUIymphoma 6, member B (zinc fi

104894 104894 AF065214 Hs.18858 phospholipase A2, group IVC (cytosolic,

105113 105113 AB037816 Hs.8982 Homo sapiens, clone IMAGE:3506202, mRNA,

105196 105196 W84893 Hs.9305 angiotensin receptor-like 1

105263 105263 AW388633 Hs.6682 solute carrier family 7, (cationic amino

105330 105330 AW338625 Hs.22120 ESTs

105492 105492 AI805717 Hs.289112 CGI-43 protein

105594 105594 AB024334 Hs.25001 tyrosine 3-monooxygenase/tryρtophan 5-mo

105732 105732 AW504170 Hs.274344 hypothetical protein MGC12942

105882 105882 W46802 Hs.81988 disabled (Drosophila) homolog 2 (mitogen

106031 106031 X64116 Hs.171844 Homo sapiens cDNA: FLJ22296 fis, clone H

106222 106222 AA356392 Hs.21321 Homo sapiens clone FLB9213 PR02474 mRNA,

106263 106263 W21493 Hs.28329 hypothetical protein FLJ14005

106366 106366 AA186715 Hs.336429 RIKEN CDNA 9130422N19 gene

106634 106634 W25491 Hs.288909 hypothetical protein FLJ22471

106793 106793 H94997 Hs.16450 ESTs

106842 106842 AF124251 Hs.26054 novel SH2-containing protein 3

106890 106890 AA489245 Hs.88500 mitogen-activated protein kinase 8 inter

106974 106974 AI817130 Hs.9195 Homo sapiens cDNA FLJ13698 fis, clone PL

107061 107061 BE147611 Hs.6354 stromal cell derived factor receptor 1

107216 107216 D51069 Hs.211579 melanoma cell adhesion molecule

107444 107444 W28391 Hs.343258 proliferation-associated 2G4, 38kD

108507 108507 AI554545 Hs.68301 ESTs

108931 108931 AA147186 gb:zo38d01.s1 Stratagene endothelial eel

109195 109195 AF047033 Hs.132904 solute carrier family 4, sodium bicarbon

109456 109456 AW956580 Hs.42699 ESTs

110411 110411 AW001579 Hs.9645 Homo sapiens mRNA for KIAA1741 protein,

110906 110906 AA035211 Hs.17404 ESTs

111091 111091 AA300067 Hs.33032 hypothetical protein DKFZp434N185

111378 111378 AW160993 Hs.326292 hypothetical gene DKFZp434A1114

111769 111769 AW629414 Hs.24230 ESTs

112951 112951 AA307634 Hs.6650 vacuolar protein sorting 45B (yeast homo

113195 113195 H83265 Hs.8881 ESTs, Weakly similarto S41044 chromosom

113542 113542 H43374 Hs.7890 Homo sapiens mRNA forKIAA1671 protein,

113847 113847 NM 005032 Hs.4114 plastin 3 (T isoform)

113947 113947 W84768 gb:zh53d03.s1 Soares_fetal_liver_spleen_

115061 115061 AI751438 Hs.41271 Homo sapiens mRNA full length insert cDN

115870 115870 NM 005985 Hs.48029 snail 1 (drosophila homolog), zinc tinge

116228 116228 AI767947 Hs.50841 ESTs

116314 116314 AI799104 Hs.178705 Homo sapiens cDNA FLJ11333 fis, clone PL

117023 117023 AW070211 Hs.102415 Homo sapiens mRNA; cDNA DKFZp586N0121 (f

117156 117156 W73853 ESTs

117280 117280 M18217 Hs.172129 Homo sapiens cDNA: FLJ21409 fis, clone C

119866 119866 AA496205 Hs.193700 Homo sapiens mRNA; cDNA DKFZp586l0324 (f

121314 121314 W07343 Hs.182538 phospholipid scramblase 4

121822 121822 AI743860 metallothionein 1E (fundional)

122331 122331 AL133437 Hs.110771 Homo sapiens cDNA: FLJ21904 fis, clone H

123160 123160 AA488687 Hs.284235 ESTs, Weakly similar to I38022 hypotheti

124059 124059 BE387335 Hs.283713 ESTs, Weakly similar to S64054 hypotheti

124358 124358 AW070211 Hs.102415 Homo sapiens mRNA; cDNA DKFZp586N0121 (f

124726 124726 NM_003654 Hs.104576 carbohydrate (keratan sulfate Gal-6) sul

125167 125167 AL137540 Hs.102541 netrin 4

125307 125307 AW580945 Hs.330466 ESTs

107985 107985 T40064 Hs.71968 Homo sapiens mRNA; cDNA DKFZp564F053 (fr

125598 125598 T40064 Hs.71968 Homo sapiens mRNA; cDNA DKFZp564F053 (fr

413731 413731 BE243845 Hs.75511 connective tissue growth factor

116024 116024 AA088767 Hs.83883 transmembrane, prostate androgen induced

418000 418000 AA932794 Hs.83147 guanine nucleotide binding protein-like

126399 126399 AA088767 Hs.83883 transmembrane, prostate androgen induced

127566 127566 AI051390 Hs.116731 ESTs

128453 128453 X02761 Hs.287820 fibronectin 1

128515 128515 BE395085 Hs.10086 type I transmembrane protein Fn14

128623 128623 BE076608 Hs.105509 CTL2gene

128669 128669 W28493 Hs.180414 heat shock 70kD protein 8 128914 128914 AW867491 Hs.107125 plasmalemma vesicle associated protein

129188 129188 NM 001078 Hs.109225 vascular cell adhesion molecule 1

129265 129265 AA530892 Hs.171695 dual specificity phosphatase 1

129468 129468 AW410538 Hs.111779 secreted protein, acidic, cysteine-rich

101838 101838 BE243845 Hs.75511 connective tissue growth factor

129619 129619 AA209534 Hs.284243 tetraspan NET-6 protein

129762 129762 AA453694 Hs.12372 tripartite motif protein TRIM2

130018 130018 AA353093 metallothionein 1L

130178 130178 U20982 Hs.1516 insulin-like growth factor-binding prate

130431 130431 AW505214 Hs.155560 calnexin

130553 130553 AF062649 Hs.252587 pituitary tumor-transforming 1

130639 130639 AI557212 Hs.17132 ESTs, Moderately similarto I54374 gene

130686 130686 BE548267 Hs.337986 Homo sapiens cDNA FLJ10934 fis, clone OV

130818 130818 AW190920 Hs.19928 hypothetical protein SP329

130899 130899 AI077288 Hs.296323 serum/glucocorticoid regulated kinase

131080 131080 NM 001955 Hs.2271 endothelin 1

131091 131091 AJ271216 Hs.22880 dipeptidylpeptidase III

131182 131182 AI824144 Hs.23912 ESTs

131319 131319 NM 003155 Hs.25590 stanniocalcin 1

131328 131328 AW939251 Hs.25647 v-fos FBJ murine osteosarcoma viral onco

131328 131328 AW939251 Hs.25647 v-fos FBJ murine osteosarcoma viral onco

131555 131555 T47364 Hs.278613 interferon, alpha-inducible protein 27

131573 131573 AA040311 Hs.28959 ESTs

131756 131756 AA443966 Hs.31595 ESTs

131909 131909 NM 016558 Hs.274411 SCAN domain-containing 1

132046 132046 AI359214 Hs.179260 chromosome 14 open reading frame 4

132151 132151 BE379499 Hs.173705 Homo sapiens cDNA: FLJ22050 fis, clone H

132187 132187 AA235709 Hs.4193 DKFZP58601624 protein

132314 132314 AF112222 Hs.323806 pinin, desmoso e associated protein

132398 132398 AA876616 Hs.16979 ESTs, Weakly similar to A43932 mucin 2 p

132490 132490 NM 001290 Hs.4980 LIM domain binding 2

132546 132546 M24283 Hs.168383 intercellular adhesion molecule 1 (CD54)

132716 132716 BE379595 Hs.283738 casein kinase 1, alpha 1

132883 132883 AA373314 Hs.5897 Homo sapiens mRNA; cDNA DKFZp586P1622 (f

132989 132989 AA480074 Hs.331328 hypothetical protein FLJ13213

133071 133071 BE384932 Hs.64313 ESTs, Weakly similarto AF257182 1 G-pro

133099 133099 W16518 Hs.279518 amyloid beta (A4) precursor-like protein

133149 133149 AA370045 Hs.6607 AX1N1 up-regulated

133200 133200 AB037715 Hs.183639 hypothetical protein FLJ10210

133260 133260 AA403045 Hs.6906 Homo sapiens cDNA: FLJ23197 fis, clone R

133349 133349 AW631255 Hs.8110 L-3-hydroxyacyl-Coenzyme A dehydrogenase

133398 133398 NM 000499 Hs.72912 cytochrome P450, subfamily I (aromatic c

133454 133454 BE547647 Hs.177781 hypothetical protein MGC5618

133491 133491 BE619053 Hs. 70001 eukaryotic translation initiation fador

133517 133517 NM_000165 Hs.74471 gap junction protein, alpha 1, 43kD (con

133538 133538 NM 003257 Hs.74614 tight junction protein 1 (zona occludens

133584 133584 D90209 Hs.181243 activating transcription factor 4 (tax-r

133617 133617 BE244334 Hs.75249 ADP-ribosylation factor-like 6 interacti

133671 133671 AW503116 Hs.301819 zinc finger protein 146

133681 133681 AI352558 tyrosine 3-monooxygenase/tryptophan 5-mo

133730 133730 BE242779 Hs.179526 upregulated by 1,25-dihydroxyvitamin D-3

133802 133802 AW239400 Hs.76297 G protein-coupled receptor kinase 6

133838 133838 BE222494 Hs.180919 inhibitor of DNA binding 2, dominant neg

133889 133889 U48959 Hs.211582 myosin, light polypeptide kinase

133975 133975 C18356 Hs.295944 tissue factor pathway inhibitor 2

134039 134039 NM 002290 Hs.78672 laminin, alpha 4

134081 134081 AL034349 Hs.79005 protein tyrosine phosphatase, receptor t

134203 134203 AA161219 Hs.799 diphtheria toxin receptor (heparin-bindi

134299 134299 AW580939 Hs.97199 complement component C1q receptor

134339 134339 R70429 Hs.81988 disabled (Drosophila) homolog 2 (mitogen

134381 134381 AI557280 Hs.184270 capping protein (actin filament) muscle

134416 134416 X68264 Hs.211579 melanoma cell adhesion molecule

134558 134558 NM_001773 Hs.85289 CD34 antigen

134983 134983 D28235 Hs.196384 prostaglandin-endoperoxide synthase 2 (p

135052 135052 AL136653 Hs.93675 decidual protein induced by progesterone

135069 135069 AA876372 Hs.93961 Homo sapiens mRNA; cDNA DKFZp667D095 (fr

135073 135073 W55956 Hs.94030 Homo sapiens mRNA; cDNA DKFZp586E1624 (f

135196 135196 C03577 Hs.9615 myosin regulatory light chain 2, smooth

134404 134404 AB000450 Hs.82771 vaccinia related kinase 2

100082 100082 AA130080 Hs.4295 proteasome (prosome, macropain) 26S subu

130150 130150 BE094848 Hs.15113 homogentisate 1,2-dioxygenase (homogenti

130839 130839 AB011169 Hs.20141 similarto S. cerevisiae SSM4

100113 100113 NM_001269 Hs.84746 chromosome condensation 1

100129 100129 AA469369 Hs.5831 tissue inhibitor of metalloproteinase 1

100169 100169 AL037228 Hs.82043 D123 gene product

100190 100190 M91401 Hs.178658 RAD23 (S. cerevisiae) homolog B 100211 100211 D26528 Hs.123058 DEAD/H (Asp-Glu-Ala-Asp/His) box polypep

130283 130283 NM 012288 Hs.153954 TRAM-like protein

100248 100248 NM_015156 Hs.78398 KIAA0071 protein

100262 100262 D38500 Hs.278468 postmeiotic segregation increased 2-like

100281 100281 AF091035 Hs.184627 KIAA0118 protein

100327 100327 D55640 gb:Human monocyte PABL (pseudoautosomal

134495 134495 D63477 Hs.84087 KIAA0143 protein

135152 135152 M96954 Hs.182741 TIA1 cytotoxic granule-associated RNA-bi

100372 100372 NM 014791 Hs.184339 KIAA0175 gene product

100394 100394 D84284 Hs.66052 CD38 antigen (p45)

100418 100418 D86978 Hs.84790 KIAA0225 protein

134347 134347 AF164142 Hs.82042 solute carrier family 23 (nucleobase tra

100438 100438 AA013051 Hs.91417 topoisomerase (DNA) II binding protein

100481 100481 X70377 Hs.121489 cystatin D

100591 100591 NM 004091 Hs.231444 Homo sapiens, Similarto hypothetical pr

100662 100662 A1368680 Hs.816 SRY (sex determining region Y)-box 2

100905 100905 L12260 Hs.172816 neuregulin 1

100950 100950 AF128542 Hs.166846 polymerase (DNA directed), epsilon

135407 135407 J04029 Hs.99936 keratin 10 (epidermolytic hyperkeratosis

131877 131877 J04088 Hs.156346 topoisomerase (DNA) II alpha (170kD)

134786 134786 T29618 Hs.89640 TEK tyrosine kinase, endothelial (venous

134078 134078 L08895 Hs.78995 MADS box transcription enhancer factor 2

134849 134849 BE409525 Hs.902 neurofibromin 2 (bilateral acoustic neur

101152 101152 AI984625 Hs.9884 spindle pole body protein

131687 131687 BE297635 Hs.3069 heat shock 70kD protein 9B (mortalin-2)

421155 421155 H87879 Hs.102267 lysyl oxidase

133975 133975 C18356 Hs.295944 tissue factor pathway inhibitor 2

130155 130155 AA101043 Hs.151254 kallikrein 7 (chymotryptic, stratum com

132813 132813 BE313625 Hs.57435 solute carrier family 11 (proton-coupled

101300 101300 BE535511 transmembrane trafficking protein

130344 130344 AW250122 Hs.154879 DiGeorge syndrome critical region gene D

101381 101381 AW675039 Hs.1227 aminolevulinate, delta-, dehydratase

133780 133780 AA557660 Hs.76152 decorin

101447 101447 M21305 gb:Human alpha satellite and satellite 3

101470 101470 NM 000546 Hs.1846 tumor protein p53 (Li-Fraumeni syndrome)

101478 101478 NM 002890 Hs.758 RAS p21 protein adivator (GTPase activa

133519 133519 AW583062 Hs.74502 chymotrypsinogen B1

134116 134116 R84694 Hs.79194 cAMP responsive element binding protein

130174 130174 M29551 Hs.151531 protein phosphatase 3 (formerly 2B), cat

132983 132983 M30269 nidogen (enactin)

101543 101543 M31166 Hs.2050 pentaxin-related gene, rapidly induced b

101620 101620 S55271 Hs.247930 Epsilon , IgE

133595 133595 AA393273 Hs.75133 transcription factor 6-like 1 (mitochond

101700 101700 D90337 Hs.247916 natriuretic peptide precursor C

134246 134246 D28459 Hs.80612 ubiquitin-conjugating enzyme E2A (RAD6 h

133948 133948 X59960 Hs.77813 sphingomyelin phosphodiesterase 1, acid

133948 133948 X59960 Hs.77813 sphingomyelin phosphodiesterase 1, acid

133948 133948 X59960 Hs.77813 sphingomyelin phosphodiesterase 1, acid

101812 101812 BE439894 Hs.78991 DNA segment, numerous copies, expressed

133396 133396 M96326 Hs.72885 azurocidin 1 (cationic antimicrobial pro

129026 129026 AL120297 Hs.108043 Friend leukemia virus integration 1

134831 134831 AA853479 Hs.89890 pyruvate carboxylase

134395 134395 AA456539 Hs.8262 lysosomal

101977 101977 AF112213 Hs.184062 putative Rab5-interacting protein

101998 101998 U01212 Hs.248153 olfactory marker protein

102007 102007 U02556 Hs.75307 t-complex-associated-testis-expressed 1 -

416658 416658 U03272 Hs.79432 fibrillin 2 (congenital contractural ara

135389 135389 U05237 Hs.99872 fetal Alzheimer antigen

130145 130145 U34820 Hs.151051 mitogen-activated, protein kinase 10

420269 420269 U72937 Hs.96264 alpha thalassemia/mental retardation syn

102123 102123 NM_001809 Hs.1594 centromere protein A (17kD)

102133 102133 AU076845 Hs.155596 BCL2/adenovirus E1B 19kD-interacting pro

102162 102162 AA450274 Hs.1592 CDC16 (cell division cycle 16, S. cerevi

427653 427653 AA159001 Hs.180069 nuclear respiratory factor 1

102200 102200 AA232362 Hs.157205 branched chain aminotransferase 1, cytos

102214 102214 U23752 Hs.32964 SRY (sex determining region Y)-box 11

131319 131319 NM_003155 Hs.25590 stanniocalcin 1

132316 132316 U28831 Hs.44566 KIAA1641 protein

134365 134365 AA568906 Hs.82240 syntaxin 3A

102298 102298 AA382169 Hs.54483 N-myc (and STAT) interactor

302344 302344 BE303044 Hs.192023 eukaryotic translation initiation factor

102367 102367 U39656 Hs.118825 mitogen-activated protein kinase kinase

102394 102394 NM 003816 Hs.2442 a disintegrin and metalloproteinase doma

129521 129521 AF071076 Hs.112255 nucleoporin 98kD

102251 102251 NM_004398 Hs.41706 DEAD/H (Asp-Glu-Ala-Asp/His) box polypep

133746 133746 ' AW410035 Hs.75862 MAD (mothers against decapentaplegic, Dr 132828 132828 AB014615 Hs.57710 fibroblast growth factor 8 (androgen-ind

132828 132828 AB014615 Hs.57710 fibroblast growth factor 8 (androgen-ind

130441 130441 U63630 Hs.155637 protein kinase, DNA-activated, catalytic

129350 129350 U50535 Hs.110630 Human BRCA2 region, mRNA sequence CG006

130457 130457 AB014595 Hs.155976 cullin 4B

102560 102560 R97457 Hs.63984 cadherin 13, H-cadherin (heart)

134305 134305 U61397 Hs.81424 ubiquitin-like 1 (sentrin)

132736 132736 AW081883 Hs.211578 Homo sapiens cDNA: FLJ23037 fis, clone L

102663 102663 NM 002270 Hs.168075 karyopherin (importin) beta 2

102735 102735 AF111106 Hs.3382 protein phosphatase 4, regulatory subuni

101175 101175 U82671 Hs.36980 melanoma antigen, family A, 2

132164 132164 A1752235 Hs.41270 procollagen-lysine, 2-oxoglutarate 5-dio

102826 102826 NM.007274 Hs.8679 cytosolic acyl coenzyme A thioester hydr

102846 102846 BE264974 Hs.6566 thyroid hormone receptor interactor 13

134161 134161 AA634543 Hs.79440 IGF-II mRNA-binding protein 3

302363 302363 AW163799 Hs. 98365 2,3-bisphosphoglycerate mutase

125701 125701 T72104 Hs.93194 apolipoprotein A-l

134656 134656 AI750878 Hs.87409 thrombospondin 1

102968 102968 AU076611 Hs.154672 methylene tetrahydrofolate dehydrogenase

134037 134037 AI808780 Hs.227730 integrin, alpha 6

103023 103023 AW500470 Hs.117950 multifunctional polypeptide similar to S

130282 130282 BE245380 Hs.153952 5' nucleotidase (CD73)

128568 128568 H12912 Hs.274691 adenylate kinase 3

103093 103093 S79876 Hs.44926 dipeptidylpeptidase IV (CD26, adenosine

129063 129063 X63094 Hs.283822 Rhesus blood group, D antigen

133227 133227 AW977263 Hs.68257 general transcription factor IIF, polype

103184 103184 U43143 Hs.74049 fms-related tyrosine kinase 4

103208 103208 AW411340 Hs.31314 retinoblastoma-binding protein 7

131486 131486 F06972 Hs.27372 BMX non-receptor tyrosine kinase

103334 103334 NM 001260 Hs.25283 cyclin-dependent kinase 8

135094 135094 NM 003304 Hs.250687 transient receptor potential channel 1

103352 103352 H09366 Hs.78853 uracil-DNA glycosylase

132173 132173 X89426 Hs.41716 endothelial cell-specific molecule 1

131584 131584 AA598509 Hs.29117 purine-rich element binding protein A

103378 103378 AL119690 Hs.153618 HCGVIII-1 protein

103410 103410 AA158294 Hs.295362 DR1 -associated protein 1 (negative cofac

103438 103438 AW175781 Hs.152720 M-phase phosphoprotein 6

103452 103452 NM 006936 Hs.85119 SMT3 (suppressor of mif two 3, yeast) ho

135185 135185 AW404908 Hs.96038 Ric (Drosophila)-like, expressed in many

134662 134662 NM_007048 Hs.284283 butyrophilin, subfamily 3, member A1

103500 103500 AW408009 Hs.22580 alkylglycerone phosphate synthase

132084 132084 NM_002267 Hs.3886 karyopherin alpha 3 (importin alpha 4)

133152 133152 Z11695 Hs.324473 mitogen-activated protein kinase 1

103612 103612 BE336654 Hs.70937 H3 histone family, member A

103692 103692 AW137912 Hs.227583 Homo sapiens chromosome X map Xp11.23 L-

129796 129796 BE218319 Hs.5807 GTPase Rab14

132683 132683 BE264633 Hs.143638 WD repeat domain 4

103723 103723 BE274312 Hs.214783 Homo sapiens cDNA FLJ14041 fis, clone HE

133260 133260 AA403045 Hs.6906 Homo sapiens cDNA: FLJ23197 fis, clone R

103766 103766 AI920783 Hs.191435 ESTs

132051 132051 AA393968 Hs.180145 HSPC030 protein

135289 135289 AW372569 Hs.9788 hypothetical protein MGC10924 similarto

103794 103794 AF244135 Hs.30670 hepatocellular carcinoma-associated anti

134319 134319 BE304999 Hs.285754 fumarate hydratase

119159 119159 AF142419 Hs.15020 homolog of mouse quaking QKI (KH domain

103850 103850 AA187101 Hs.213194 hypothetical protein MGC10895

322026 322026 AW024973 Hs.283675 NPD009 protein

103861 103861 AA206236 Hs.4944 hypothetical protein FLJ12783

447735 447735 AA775268 Hs.6127 Homo sapiens cDNA: FLJ23020 fis, clone L

131236 131236 AF043117 Hs.24594 ubiquitination factor E4B (homologous to

129013 129013 AA371156 Hs.107942 DKFZP564M112 protein

103988 103988 AA314389 Hs.342849 ADP-ribosylation factor-like 5

425284 425284 AF155568 Hs.348043 NS1-associated protein 1

133281 133281 AK001601 Hs.69594 high-mobility group 20A

108154 108154 NM 005754 Hs.220689 Ras-GTPase-activating protein SH3-domain

135073 135073 W55956 Hs.94030 Homo sapiens mRNA; cDNA DKFZp586E1624 (f

129593 129593 AI338247 Hs.98314 Homo sapiens mRNA; cDNA DKFZp586L0120 (f

132064 132064 AA121098 Hs.3838 serum-inducible kinase

131427 131427 AF151879 Hs.26706 CGI-121 protein

104282 104282 C14448 Hs.332338 EST

130443 130443 D25216 Hs.155650 KIAA0014 gene product

132837 132837 AA370362 Hs.57958 EGF-TM7-latrophilin-related protein

104334 104334 D82614 Hs.78771 phosphoglycerate kinase 1

134731 134731 D89377 Hs.89404 msh (Drosophila) homeo box homolog 2

131670 131670 H03514 Hs.15589 ESTs

104402 104402 H56731 Hs.132956 ESTs 129077 129077 N74724 Hs.108479 ESTs

134927 134927 L36531 Hs.91296 integrin, alpha 8

134498 134498 AW246273 Hs.84131 threonyl-tRNA synthetase

104488 104488 N56191 Hs.106511 protocadherin 17

129214 129214 AL044335 Hs.109526 zinc finger protein 198

104530 104530 AK001676 Hs.12457 hypothetical protein FLJ10814

104544 104544 AI091173 Hs.222362 ESTs, Weakly similarto p40 [H.sapiens]

104567 104567 AA040620 Hs.5672 hypothetical protein AF140225

129575 129575 F08282 Hs.278428 progestin induced protein

104599 104599 AW815036 Hs.151251 ESTs

104667 104667 AI239923 Hs.63931 ESTs

104764 104764 AI039243 Hs.278585 ESTs

104787 104787 AA027317 gb:ze97d11.s1 Soares_fetal_heart_NbHH19W

104804 104804 AI858702 Hs.31803 ESTs, Weakly similarto N-WASP [H.sapien

130828 130828 AW631469 Hs.203213 ESTs

104943 104943 AF072873 Hs.114218 frizzled (Drosophila) homolog 6

105024 105024 AA126311 Hs.9879 ESTs

105038 105038 AW503733 Hs.9414 KIAA1488 protein

105096 105096 AL042506 Hs.21599 Kruppel-like factor 7 (ubiquitous)

105169 105169 BE245294 Hs.180789 S164 protein

130401 130401 BE396283 Hs.173987 eukaryotic translation initiation factor

130114 130114 AA233393 Hs.14992 hypothetical protein FLJ11151

105337 105337 AI468789 Hs.347187 myotubularin related protein 1

105376 105376 AW994032 Hs.8768 hypothetical protein FLJ10849

131962 131962 AK000046 Hs.343877 hypothetical protein FLJ20039

128658 128658 BE397354 Hs.324830 diptheria toxin resistance protein requi

105508 105508 AA173942 Hs.326416 Homo sapiens mRNA; cDNA DKFZp564H1916 (f

135172 135172 AB028956 Hs.12144 KIAA1033 protein

132542 132542 AL137751 Hs.263671 Homo sapiens mRNA; cDNA DKFZp434l0812 (f

105659 105659 AA283044 Hs.25625 hypothetical protein FLJ11323

105674 105674 A1609530 Hs.279789 histone deacetylase 3

105722 105722 AI922821 Hs.32433 ESTs

115951 115951 BE546245 Hs.301048 sec13-like protein

105985 105985 AA406610 gb:zv15b10.s1 Soares_NhHMPu_S1 Homo sapi

131216 131216 AI815486 Hs.243901 Homo sapiens cDNA FLJ20738 fis, clone HE

113689 113689 AB037850 Hs.16621 DKFZP434I116 protein

130839 130839 AB011169 Hs.20141 similar to S. cerevisiae SSM4

130777 130777 AW135049 Hs.26285 Homo sapiens cDNA FLJ10643 fis, clone NT

106196 106196 AA525993 Hs.173699 ESTs, Weakly similarto ALU1JHUMAN ALU S

133200 133200 AB037715 Hs.183639 hypothetical protein FLJ10210

106328 106328 AL079559 Hs.28020 KIAA0766 gene product

106423 106423 AB020722 Hs.16714 Rho guanine exchange factor (GEF) 15

439608 439608 AW864696 Hs.301732 hypothetical protein MGC5306

106503 106503 AB033042 Hs.29679 cofador required for Sp1 transcriptiona

106543 106543 AA676939 Hs.69285 neuropilin 1

106589 106589 AK000933 Hs.28661 Homo sapiens cDNA FLJ10071 fis, clone HE

106596 106596 AA452379 ESTs, Moderately similar to ALU7_HUMAN A

106636 106636 AW958037 Hs.286 ribosomal protein L4

131353 131353 AW754182 gb:RC2-CT0321-131199-011 -c01 CT0321 Homo

131710 131710 NM 015368 Hs.30985 pannexin 1

131775 131775 AB014548 Hs.31921 KIAA0648 protein

106773 106773 AA478109 Hs.188833 ESTs

106817 106817 D61216 Hs.18672 ESTs

106848 106848 AA449014 Hs.121025 chromosome 11 open reading frame 5

418699 418699 BE539639 Hs.173030 ESTs, Weakly similarto ALU8JHUMAN ALU S

130638 130638 AW021276 Hs.17121 ESTs

107059 107059 BE614410 Hs.23044 RAD51 (S. cerevisiae) homolog (E coli Re

107115 107115 BE379623 Hs.27693 peptidylprolyl isomerase (cyclophilin)-l

107156 107156 AA137043 Hs.9663 programmed cell death 6-interacting prot

130621 130621 AW513087 Hs.16803 LUC7 (S. cerevisiae)-like

132626 132626 AW504732 Hs.21275 hypothetical protein FLJ11011

131610 131610 AA357879 Hs.29423 scavenger receptor with C-type lectin

107295 107295 AA186629 Hs.80120 UDP-N-acetyl-alpha-D-galactosamine:polyp

107315 107315 AA316241 Hs.90691 nucleophosmin/nucleoplasmin 3

107328 107328 AW959891 Hs.76591 KIAA0887 protein

134715 134715 U48263 Hs.89040 prepronociceptin

129938 129938 AW003668 Hs.135587 Human clone 23629 mRNA sequence

130074 130074 AL038596 Hs.250745 polymerase (RNA) III (DNA directed) (62k

132036 132036 AL157433 Hs.37706 hypothetical protein DKFZp434E2220

113857 113857 AW243158 Hs.5297 DKFZP564A2416 protein

130419 130419 AF037448 Hs.155489 NS1-associated protein 1

132616 132616 BE262677 Hs.283558 hypothetical protein PR01855

132358 132358 NM_003542 Hs.46423 H4 histone family, member G

125827 125827 NM 003403 Hs.97496 YY1 transcription factor

107609 107609 R75654 Hs.164797 hypothetical protein FLJ13693

107714 107714 AA015761 Hs.60642 ESTs 107832 107832 AA021473 gb:ze66c11.s1 Soares retina N2b4HR Homo

124337 124337 N23541 Hs.281561 Homo sapiens cDNA: FLJ23582 fis, clone L

129577 129577 N75346 Hs.306121 CDC20 (cell division cycle 20, S. cerevi

132000 132000 AW247017 Hs.36978 melanoma antigen, family A, 3

107935 107935 AA029428 Hs.61555 ESTs

131461 131461 AA992841 Hs.27263 KIAA1458 protein

108029 108029 AA040740 Hs.62007 ESTs

108084 108084 AA058944 Hs.116602 Homo sapiens, clone IMAGE:4154008, mRNA,

108168 108168 AI453137 Hs.63176 ESTs

108189 108189 AW376061 Hs.63335 ESTs, Moderately similar to A46010 X-lin

108203 108203 AW847814 Hs.289005 Homo sapiens cDNA: FLJ21532 fis, clone C

108217 108217 AA058686 Hs.62588 ESTs

108277 108277 AA064859 gb:zm50f03.s1 Stratagene fibroblast (937

108309 108309 AA069818 gb:zm67e03.r1 Stratagene neuroepithelium

108340 108340 AA069820 Hs.180909 peroxiredoxin 1

108427 108427 AA076382 gb:zm91g08.s1 Stratagene ovarian cancer

108439 108439 AA078986 gb:zm92h01.s1 Stratagene ovarian cancer

108469 108469 AA079487 gb:zm97f08.s1 Stratagene colon HT29 (937

108501 108501 AA083256 gb:zn08g12.s1 Stratagene hNT neuron (937

108562 108562 AA100796 gb:zm26c06.s1 Stratagene pancreas (93720

130890 130890 AI907537 Hs.76698 stress-associated endoplasmic reticulum

130385 130385 AW067800 Hs.155223 stanniocalcin 2

108807 108807 A1652236 Hs.49376 hypothetical protein FLJ20644

108833 108833 AF188527 Hs.61661 ESTs, Weakly similarto AF174605 1 F-box

108846 108846 AL117452 Hs.44155 DKFZP586G1517 protein

131474 131474 L46353 Hs.2726 high-mobility group (nonhistone chromoso

108941 108941 AA148650 gb:zo09e06.s1 Stratagene neuroepithelium

108996 108996 AW995610 Hs.332436 EST

131183 131183 AI611807 Hs.285107 hypothetical protein FLJ13397

109022 109022 AA157291 Hs.21479 ubinuclein 1

109068 109068 AA164293 Hs.72545 ESTs

129021 129021 AL044675 Hs.173081 KIAA0530 protein

109146 109146 AA176589 Hs.142078 EST

131080 131080 NM 001955 Hs.2271 endothelin 1

109222 109222 AA192833 Hs.333512 similar to rat myomegalin

109481 109481 AA878923 Hs.289069 hypothetical protein FLJ21016

109516 109516 AI471639 Hs.71913 ESTs

109556 109556 AI925294 Hs.87385 ESTs

109578 109578 F02208 Hs.27214 ESTs

109625 109625 H29490 Hs.22697 ESTs

109648 109648 H17800 Hs.7154 ESTs

109699 109699 H18013 Hs.167483 ESTs

109933 109933 R52417 Hs.20945 Homo sapiens clone 24993 mRNA sequence

110039 110039 H11938 Hs.21907 histone acetyltransferase

TABLE 2A

Table 2A shows the accession numbers for those pkeys lacking unigenelD's for Table 2. The pkeys in Table 7 lacking unigenelD's are represented within Tables 1 -6A. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and

Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey: Unique Eos probeset identifier number

CAT number: Gene cluster number Accession: Genbank accession numbers

Pkey CAT Number Accession

108469 116761J AA079487 AA128547 AA128291 AA079587 AA079600 108501 13684_-12 AA083256 108562 36375J AA100796 AF020589 AA074629 AA075946 AA100849 AA085347 AA126309 AA079311 AA079323 AA085274 101300 4669J BE535511 M62098 AA306787 AW891766 AA348998 AA338869 AA344013 AW956561 AW389343 AW403607 L40391 AW408435 AA121738 AI568978 H13317 R20373 AW948724 AW948744 AA335023 AA436722 AA448690 C21404 AW884390 AA345454 AA303292 AA174174 BE092290 T90614 AA035104 R76028 AA126924 AA741086 AW022056 AW118940 AA121666 AI832409 AA683475 AI140901 AI623576 AW519064 AW474125 AI953923 AI735349 AW150109 AI436154 AW118130 AW270782 AI804073 N27434 AA876543 AA937815 AI051166 AA505378 AI041975 AI335355 AI089540 AA662243 AI127912 AI925604 AI250880 AI366874 AI564386 AI815196 AI683526 AI435885 AI160934 H79030 AI801493 AA448691 AI673767 AI076042 AI804327 AA813438 AA680002 AI274492 T16177 AI287337 AI935050 AA907805 AA911493 AI589411 AI371358 AW576236 AI078866 AW516168 AA346372 AI560185 AA471009 R75857 AA296025 AA523155 AA853168 AI696593 AI658482 AI566601 AW072797 AA128047 AA035502 AW243274 AA992517 R43760 117156 145392 W73853 AA928112 W77887 AW889237 AA148524 AI749182 AI754442 AI338392 A1253102 AI079403 AI370541 AI697341 H97538 AW188021 AI927669 W72716 AI051402 A1188071 AI335900 N21488 AW770478 W92522 A1691028 AI913512 AI144448 W73819 AA604358 N28900 W95221 AI868132 H98465 AA148793

125565 1704098J R20840 R20839 132983 11922 M30269 NMJ02508 X82245 AI078760 AW957003 D78945 M27445 AA650439 AL048816 AV660256 AV660347 AA333052 BE295257 T60999 AA383049 AW369677 Z26985 AW175704 AA343326 AW747957 AI818389 W17308 W17302 H15591 AA371284 AA370412 W94966 BE384365 T28498 R80714 R16959 H21723 AW835154 D56097 D56381 W21232 AA190565 AW379755 AW067895

133681 13893J AI352558 Z82248 X78138 NM_003405 AU077248 AA223125 S80794 D78577 AI124697 AW403970 BE614089 BE296713 BE621334 L20422 X80536 D54224 D54950 X57345 N29226 AA127798 AA340253 F08031 AA192540 H67636 AA321827 AW950283 AA084159 BE538808 AW401377 AA256774 C03366 W46595 W47608 AA305009 H69431 H69456 AL120082 H11706 AA303717 AA361357 H22042 H78020 AW999584 AA134368 AA322911 AA322961 H60980 N85248 N31547 H79624 T11718 W85826 AW894663 AW894624 BE167441 BE170015 AA304626 AW602163 AW998929 AA156681 AA151067 BE002724 AA608688 H82692 BE155392 AW383636 BE155394 AA487004 AW383504 AI342365 R82553 W16498 BE155344 AI143938 R69901 AA322873 AW340648 R25364 AA367935 AI559406 AA033522 AA374252 AW835019 AI922133 AI697089 N99662 AW189078 AI199076 AW151598 W59944 AA662875 W94022 AA299055 AI039008 AI829449 AA583503 AI635674 AW131665 AI473820 AW273118 AW900930 AA908944 AI688035 AW170272 AI082545 AW468176 AI608761 AI082748 AI911682 AI248943 AI831016 AA192465 AI218477 AA938406 AA385288 AI809817 AA905196 AI191245 AI470204 AI188296 AI421367 A1125315 A1087141 AA629032 AA740589 AI554181 AA150830 AI248541 AI077943 AA775958 AA864930 AI261476 AI123121 AI310394 AA862331 AA872478 BE537084 AI205606 AA720684 A1872093 AW150042 AL120538 AA219627 AA988608 C21397 AI359337 H25337 AI089749 AA605146 AI359620 AA150478 AI359738 AW383642 AW995424 AI766457 R56892 AI089839 W61343 N69107 W46459 AA565955 N20527 AI279782 W46596 AA776573 H23204 AI866231 AI083995 N21530 AA126874 D82630 W65437 AI086917 AW382095 AI086877 H69844 AW340217 W85827 L08439 AA262704 AA505380 W47413 W94135 AA223241 AW089153 AA084101 BE538000 AA096126 T28031 AA491574 R84813 AA774536 AW383522 AA155615 AW383529 AA491520 AW028427 AA171496 AI469689 AW664539 AI811102 AI811116 BE464590 BE350791 H78021 T15405 H21979 AA219489 H13301 AA505883 AI864305 AI423963 AW084401 F04963 R69858 H67097 AI917740 AI655561 H69864 AA033631 AW383484 AI886261 H25293 AA513281 AW271187 H11617 N79982 AI174338 AI904207 AI904208 BE614558 W94127 W65436 AI272249 AA700018 AI579932 AI085941 AW152629

121335 279548J AA404418 AI217248 130018 18986 AA353093 AW957317 AW872498 AI560785 AI289110 AW135512 X97261 T68873 121822 244391 1 A1743860 N49543 AW027759 BE349467 AI656284 BE463975 R35022 AA370031 AW955302 AL042109 N53092 AI611424 AL079362 AI969290 A1928016 BE394912 BE504220 BE467505 AI611611 AI611407 AI611452 W56437 AI284566 AI583349 AW183058 AI308085 AI074952 AA437315 AA628161 AW301728 AI150224 AA400137 AA437279 AI223355 AA639462 AI261373 AI432414 AI984994 AI539335 AA401550 AA358757 AI609976 AA442357 AA359393 AA437046 AA370301 AA429328 AW272055 AI580502 AI832944 AI038530 AA425107 AI014986 AI148349 AW237721 AW779756 AW137877 A1125293 AA400404 R28554

108309 111495J AA069818 AA069971 AA069923 AA069908 107832 genbank_AA021473 AA021473 123523 genbank_AA608588 AA608588 123964 genbank_C13961 C13961 118475 genbank_N66845 N66845 104787 genbank_AA027317 AA027317 106596 304084J AI583948 AA578212 AW303715 AA653450 AA456981 AI400385 W88533 AI224133 AW272145 AA088686 R94698 113947 genbank V84768W84768 108277 genbank_AA064859 AA064859 108427 genbank_AA076382 AA076382

108439 genbank_AA078986 AA078986

131353 231290J AW411259 H23555 AW015049 AI684275AW015886 AW068953AW014085 AI027260 R52686 AA918278 AI129462

AA969360 N34869 AI948416 AA534205 AA702483 AA705292

101447 entrez_M21305 M21305

108931 genbank_AA147186 AA147186

108941 genbank_AA148650 AA148650

103138 entrez_X65965 X65965

119174 genbank_R71234 R71234

119416 genbank_T97186 T97186

105985 genbank_AA406610 AA406610

100327 entrez_D55640 D55640

TABLE 3:

Pkey: Unique Eos probeset identifier number

Accession: Accession number used for previous patent filings

ExAccn: Exemplar Accession number, Genbank accession number

UnigenelD: Unigene number

Unigene Title: Unigene gene title

Pkey Accession ExAccn UniGene UnigeneTitle

100405 D86425 AW291587 Hs.82733 nidogen 2

100420 D86983 D86983 Hs.118893 Melanoma associated gene

100481 HG1098-HT1098 X70377 Hs.121489 cystatin D

100484 HG1103-HT1103 NM 005402HS.288757 v-ral simian leukemia viral oncogene hom

100718 HG3342-HT3519 BE295928 Hs.75424 inhibitor of DNA binding 1 , dominant neg

100991 J03764 J03836 Hs.82085 serine (or cysteine) proteinase inhibito

101097 L06797 BE245301 Hs.89414 chemokine (C-X-C motif), receptor 4 (fus

101168 L15388 NM 005308HS.211569 G protein-coupled receptor kinase 5

101194 L20971 L20971 Hs.188 phosphodiesterase 4B, cAMP-specific (dun

101261 L35545 D30857 Hs.82353 protein C receptor, endothelial (EPCR)

101345 L76380 NM 005795Hs.152175 calcitonin receptor-like

101447 M21305 M21305 gb:Human alpha satellite and satellite 3

101485 M24736 AA296520 Hs.89546 selectin E (endothelial adhesion molecul

101543 M31166 M31166 Hs.2050 pentaxin-related gene, rapidly induced b

101550 M31551 Y00630 Hs.75716 serine (or cysteine) proteinase inhibito

101560 M32334 AW958272 Hs.347326 intercellular adhesion molecule 2

101674 M61916 NM 002291 Hs.82124 laminin, beta 1

101714 M68874 M68874 Hs.211587 phospholipase A2, group IVA (cytosolic,

101741 M74719 NM_003199Hs.326198 transcription factor 4

101838 M92934 BE243845 Hs.75511 connective tissue growth factor

101857 M94856 BE550723 Hs.153179 fatty acid binding protein 5 (psoriasis-

102012 U03057 BE259035 Hs.118400 singed (Drosophila)-like (sea urchin fas

102024 U03877 AA301867 Hs.76224 EGF-containing fibulin-like extracellula

102164 U18300 NM 000107HS.77602 damage-specific DNA binding protein 2 (4

102241 U27109 NM 007351Hs.268107 multimerin

102283 U31384 AW161552 Hs.83381 guanine nucleotide binding protein 11

102303 U33053 U33053 Hs.2499 protein kinase C-like 1

102564 U59423 U59423 Hs.79067 MAD (mothers against decapentaplegic, Dr

102663 U70322 NM_002270Hs.168075 karyopherin (importin) beta 2

102759 U81607 NM 005100HS.788 A kinase (PRKA) anchor protein (gravin)

102778 U83463 AF000652 Hs.8180 syndecan binding protein (syntenin)

102804 U89942 NM 002318HS.83354 lysyl oxldase-like 2

102887 X04729 J03836 Hs.82085 serine (or cysteine) proteinase inhibito

102898 X06256 NM 002205HS.149609 integrin, alpha 5 (fibronectin receptor,

102915 X07820 X07820 Hs.2258 matrix metalloproteinase 10 (stromelysin

103036 X54925 M13509 Hs.83169 matrix metalloproteinase 1 (interstitial

103037 X54936 BE018302 Hs.2894 placental growth fador, vascular endoth

103095 X60957 NM 005424Hs.78824 tyrosine kinase with immunoglobulin and

103158 X67235 BE242587 Hs.118651 hematopoietically expressed homeobox

103166 X67951 AA159248 Hs.180909 peroxiredoxin 1

103185 X69910 NM 006825HS.74368 transmembrane protein (63kD), endoplasmi

103280 X79981 U84722 Hs.76206 cadherin 5, type 2, VE-cadherin (vascula

103554 Z18951 AI878826 Hs.74034 caveolin 1, caveolae protein, 22kD

103850 AA187101 AA187101 Hs.213194 hypothetical protein MGC10895

104465 N24990 Z44203 Hs.26418 ESTs

104592 R81003 AW630488 Hs.25338 protease, serine, 23

104764 AA025351 AI039243 Hs.278585 ESTs

104786 AA027168 AA027167 Hs.10031 KIAA0955 protein

104850 AA040465 AL133035 Hs.8728 hypothetical protein DKFZp434G171

104865 AA045136 T79340 Hs.22575 B-cell CLUIymphoma 6, member B (zinc fi

104894 AA054087 AF065214 Hs.18858 phospholipase A2, group IVC (cytosolic,

104952 AA071089 AW076098 Hs.345588 desmopiakin (DPI, DPII)

104974 AA085918 Y12059 Hs.278675 bromodomain-containing 4

105178 AA187490 AA313825 Hs.21941 AD036 protein

105263 AA227926 AW388633 Hs.6682 solute carrier family 7, (cationic amino

105330 AA234743 AW338625 Hs.22120 ESTs

105376 AA236559 AW994032 Hs.8768 hypothetical protein FLJ 10849

105729 AA292694 H46612 Hs.293815 Homo sapiens HSPC285 mRNA, partial eds

105826 AA398243 AA478756 Hs.194477 E3 ubiquitin ligase SMURF2

105977 AA406363 AK001972 Hs.30822 hypothetical protein FLJ11110

106008 AA411465 AB033888 Hs.8619 SRY (sex determining region Y)-box 18

106031 AA412284 X64116 Hs.171844 Homo sapiens cDNA: FLJ22296 fis, clone H

106124 AA423987 H93366 Hs.7567 Homo sapiens cDNA: FLJ21962 fis, clone H 106155 AA425309 AA425414 Hs.33287 nuclear factor l/B

106302 AA435896 AA398859 Hs.18397 hypothetical protein FLJ23221

106423 AA448238 AB020722 Hs.16714 Rho guanine exchange factor (GEF) 15

106793 AA478778 H94997 Hs.16450 ESTs

107174 AA621714 BE122762 Hs.25338 ESTs

107216 D51069 D51069 Hs.211579 melanoma cell adhesion molecule

107295 T34527 AA186629 Hs.80120 UDP-N-acetyl-a',pha-D-galactosamine:polyp

107385 U97519 NM_005397Hs.16426 podocalyxin-like

108756 AA127221 AA127221 Hs.117037 ESTs

108846 AA132983 AL117452 Hs.44155 DKFZP586G1517 protein

108888 AA135606 AA135606 Hs.189384 gb:zl10a05.s1 Soares_pregnant_uterus_NbH

109001 AA156125 AI056548 Hs.72116 hypothetical protein FLJ20992 similarto

109166 AA179845 AA219691 Hs.73625 RAB6 interacting, kinesin-like (rabkines

109456 AA232645 AW956580 Hs.42699 ESTs

109768 F10399 F06838 Hs.14763 ESTs

110107 H16772 AW151660 Hs.31444 ESTs

110906 N39584 AA035211 Hs.17404 ESTs

110984 N52006 AW613287 Hs.80120 UDP-N-acetyl-alpha-D-galactosamine:polyp

111006 N53375 BE387014 Hs.166146 Homer, neuronal immediate early gene, 3

111018 N54067 AI287912 Hs.3628 mitogen-activated protein kinase kinase

111133 N64436 AW580939 Hs.97199 complement component C1q receptor .

111760 R26892 BE551929 Hs.268754 Homo sapiens cDNA FLJ11949 fis, clone HE

113073 T33637 N39342 Hs.103042 microtubule-associated protein 1B

113195 T57112 H83265 Hs.8881 ESTs, Weakly similar to S41044 chromosom

113923 W80763 AW953484 Hs.3849 hypothetical protein FLJ22041 similarto

114521 AA046808 AW139036 Hs.108957 40S ribosomal protein S27 isoform

115061 AA253217 AI751438 Hs.41271 Homo sapiens mRNA full length insert cDN

115096 AA255991 AI683069 Hs.175319 ESTs

115145 AA258138 AA740907 Hs.88297 ESTs

115819 AA426573 AA486620 Hs.41135 endomucin-2

115947 AA443793 R47479 Hs.94761 KIAA1691 protein

116314 AA490588 AI799104 Hs.178705 Homo sapiens cDNA FLJ11333 fis, clone PL

116339 AA496257 AK000290 Hs.44033 dlpeptidyl peptidase 8

116430 AA609717 AK001531 Hs.66048 hypothetical protein FLJ10669

116589 D59570 AI557212 Hs.17132 ESTs, Moderately similar to I54374 gene

116733 F13787 AL157424 Hs.61289 synaptojanin 2

117023 H88157 AW070211 Hs.102415 Homo sapiens mRNA; cDNA DKFZp586N0121 (f

117186 H98988 H98988 Hs.42612 ESTs, Weakly similar to ALU1_HUMAN ALU S

117563 N34287 AF055634 Hs.44553 unc5 (C.elegans homolog) c

117997 N52090 N52090 Hs.47420 EST

118475 N66845 N66845 gb:za46c11.s1 Soares fetal liver spleen

118581 N68905 N68905 gb:za69b09.s1 Soares etal lung_NbHL19W

119073 R32894 BE245360 Hs.279477 ESTs

119155 R61715 R61715 Hs.310598 ESTs, Moderately similarto ALU1_HUMAN A

119174 R71234 R71234 gb:yi54c08.s1 Soares placenta Nb2HP Homo

119221 R98105 C14322 Hs.250700 tryptase beta 1

119416 T97186 T97186 gb:ye50h09.s1 Soares fetal liver spleen

119866 W80814 AA496205 Hs.193700 Homo sapiens mRNA; cDNA DKFZp586l0324 (f

121335 AA404418 AA404418 gb:zw37e02.s1 Soares_total_fetus_Nb2HF8_

121381 AA405747 AW088642 Hs.97984 hypothetical protein FLJ22252 similarto

123160 AA488687 AA488687 Hs.284235 ESTs, Weakly similarto I38022 hypotheti

123473 AA599143 AA599143 gb:ae52d04.s1 Stratagene lung carcinoma

123523 AA608588 AA608588 gb:ae54e06.s1 Stratagene lung carcinoma

123533 AA608751 AA608751 gb:ae56h07.s1 Stratagene lung carcinoma

123964 C13961 C13961 gb:C13961 Clontech human aorta polyA+mR

124006 D60302 AI147155 Hs.270016 ESTs

124315 H94892 NM 005402HS.288757 v-ral simian leukemia viral oncogene hom

124659 N93521 AI680737 Hs.289068 Homo sapiens cDNA FLJ11918 fis, clone HE

124669 N95477 AI571594 Hs.102943 hypothetical protein MGC12916

124847 R60044 W07701 Hs.304177 Homo sapiens clone FLB8503 PR02286 mRNA,

124875 R70506 AI887664 Hs.285814 sprouty (Drosophila) homolog 4

125091 T91518 T91518 gb:ye20f05.s1 Stratagene lung (937210) H

125103 T95333 AA570056 Hs.122730 ESTs, Moderately similarto KIAA1215 pro

125355 R45630 R60547 Hs.170098 KIAA0372 gene product

125565 R20839 R20840 gb:yg05c08. Soares infant brain 1NIB H

125590 . R23858 R23858 Hs.143375 Homo sapiens, clone 1MAGE:3840937, mRNA,

126511 AI024874 T92143 Hs.57958 EGF-TM7-latrophilin-related protein

126563 W26247 AA516391 Hs.181368 U5 snRNP-specific protein (220 kD), orth

126649 AA856990 AA001860 Hs.279531 ESTs

126872 AA136653 AW450979 gb:UI-H-BI3-ala-a-12-0-Ul.s1 NCI_CGAP_Su

127402 AA358869 AA358869 Hs.227949 SEC13(S. cerevisiae)-like 1

127651 AI123976 AA382523 Hs.105689 MSTP031 protein

127759 AI369384 AI369384 Hs.292441 ESTs

128062 AA379500 AA379621 Hs.105547 neural proliferation, differentiation an

128992 R49693 H04150 Hs.107708 ESTs

129046 AA195678 AB029290 Hs.108258 actin binding protein; macrophin (microf 129188 M30257 NM_001078Hs.109225 vascular cell adhesion molecule 1

129314 AA028131 BE622768 Hs.290356 mesoderm development candidate 1

129371 M10321 X06828 Hs.110802 von Willebrand factor

129468 J03040 AW410538 Hs.111779 secreted protein, acidic, cysteine-rich

129765 M86933 M86933 Hs.1238 amelogenin (Y chromosome)

129805 AA012933 AA012848 Hs.12570 tubulin-specific chaperone d

129884 AA286710 AF055581 Hs.13131 lysosomal

130495 AA243278 AW250380 Hs.109059 mitochondrial ribosomal protein L12

130639 D59711 AI557212 Hs.17132 ESTs, Moderately similar to 154374 gene

130657 T94452 AW337575 Hs.201591 ESTs

130828 AA053400 AW631469 Hs.203213 ESTs

130972 AA370302 D81866 Hs.21739 Homo sapiens mRNA; cDNA DKFZp586H518 (f

131080 J05008 NM 001955HS.2271 endothelin 1

131137 U85193 W27392 Hs.33287 nuclear factor l/B

131182 AA256153 AI824144 Hs.23912 ESTs

131486 X83107 F06972 Hs.27372 BMX non-receptor tyrosine kinase

131573 AA046593 AA040311 Hs.28959 ESTs

131647 AA410480 AA359615 Hs.30089 ESTs

131756 D45304 AA443966 Hs.31595 ESTs

131859 M90657 AW960564 transmembrane 4 superfamily member 1

131881 AA010163 AW361018 Hs.3383 upstream regulatory element binding prat

132050 AA136353 AI267615 Hs.38022 ESTs

132083 Y07867 BE386490 Hs.279663 Pirin

132164 U84573 AI752235 Hs.41270 procollagen-lysine, 2-oxoglutarate 5-dio

132358 X60486 NM 003542HS.46423 H4 histone family, member G

132413 AA132969 AW361383 Hs.260116 metalloprotease 1 (pitrilysin family)

132456 AA114250 AB011084 Hs.48924 KIAA0512 gene product; ALEX2

132490 F13782 NM 001290HS.4980 LIM domain binding 2

132676 AA283035 N92589 Hs.261038 ESTs, Weakly similar to 138022 hypotheti

132687 AB002301 AB002301 Hs.54985 KIAA0303 protein

132718 AA056731 NM 004600HS.554 Sjogren syndrome antigen A2 (60kD, ribon

132736 U68019 AW081883 Hs.211578 Homo sapiens cDNA: FLJ23037 fis, clone L

132760 H99198 AA125985 Hs.56145 thymosin, beta, identified in neuroblast

132933 AA598702 BE263252 Hs.6101 hypothetical protein MGC3178

132968 N77151 AF234532 Hs.61638 myosin X

132994 AA505133 AA112748 Hs.279905 clone HQ0310 PRO0310p1

133061 AB000584 AI186431 Hs.296638 prostate differentiation factor

133147 D12763 AA026533 Hs.66 interleukin 1 receptor-like 1

133161 AA253193 AW021 03 Hs.6631 hypothetical protein FLJ20373

133200 AA432248 AB037715 Hs.183639 hypothetical protein FLJ10210

133260 AA083572 AA403045 Hs.6906 Homo sapiens cDNA: FLJ23197 fis, clone R

133363 AA479713 AI866286 Hs.71962 ESTs, Weakly similarto B36298 proline-r

133491 L40395 BE619053 Hs.170001 eukaryotic translation initiation factor

133517 X52947 NM 000165HS.74471 gap junction protein, alpha 1, 43kD (con

133550 W80846 AI129903 Hs.74669 vesicle-associated membrane protein 5 (m

133607 M34539 BE273749 FK506-binding protein 1A (12kD)

133614 D67029 NM 003003HS.75232 SEC14 (S. cerevisiae)-like 1

133627 U09587 NM_002047Hs.75280 glycyl-tRNA synthetase

133691 M85289 M85289 Hs.2 1573 heparan sulfate proteoglycan 2 (perlecan

133696 D10522 AI878921 Hs.75607 myristoylated alanine-rich protein kinas

133913 W84712 AU076964 Hs.7753 calumenin

133975 D29992 C18356 Hs.295944 tissue factor pathway inhibitor 2

133985 L34657 L34657 Hs.78146 platelet/endothelial cell adhesion molec

134039 S78569 NM 002290HS.78672 laminin, alpha 4

134088 D43636 AI379954 Hs.79025 KIAA0096 protein

134161 U97188 AA634543 Hs.79440 IGF-II mRNA-binding protein 3

134299 AA487558 AW580939 Hs.97199 complement component C1q receptor

134416 M28882 X68264 Hs.211579 melanoma cell adhesion molecule

134453 X70683 AI272141 Hs.83484 SRY (sex determining region Y)-box 4

134656 X14787 AI750878 Hs.87409 thrombospondin 1

134989 AA236324 AW968058 Hs.92381 nudix (nucleoside diphosphate linked moi

135051 C15324 AI272141 Hs.83484 SRY (sex determining region Y)-box 4

135073 AA452000 W55956 Hs.94030 Homo sapiens mRNA; cDNA DKFZp586E1624 (f

135349 D83174 AA114212 Hs.9930 serine (or cysteine) proteinase inhibito

100114 D00596 X02308 Hs.82962 thymidylate synthetase

100130 D11428 NM 000304HS.103724 peripheral myelin protein 22

100143 D13640 AU076465 Hs.278441 KIAA0015 gene product

100168 D14874 H73444 Hs.394 adrenomedullin

100208 D26129 NM_002933Hs.78224 ribonuclease, RNase A family, 1 (pancrea

100224 D28476 AL121516 Hs.138617 thyroid hormone receptor interactor 12

100405 D86425 AW291587 Hs.82733 nidogen 2

100420 D86983 D86983 Hs.118893 Melanoma associated gene

100455 D87953 AW888941 Hs.75789 N-myc downstream regulated

100529 HG1862-HT1897 BE313693 Hs.334330 calmodulin 2 (phosphorylase kinase, delt

100618 HG2614-HT2710 AI752163 Hs.114599 collagen, type VIII, alpha 1

100619 HG2639-HT2735 N24433 Hs.241567 RNA binding motif, single stranded inter 100658 HG2855-HT2995 U56725 Hs.180414 heat shock 70kD protein 2 100676 HG3044-HT3742 X02761 Hs.287820 fibronectin 1 100718 HG3342-HT3519 BE295928 Hs.75424 inhibitor of DNA binding 1 , dominant neg 100752 HG3543-HT3739 T81309 insulin-like growth factor 2 (somatomedi 100828 HG4069-HT4339 AL048753 Hs.303649 small inducible cytokine A2 (monocyte ch 100850 HG417-HT417 AA836472 Hs.297939 cathepsin B 100991 J03764 J03836 Hs.82085 serine (or cysteine) proteinase inhibito 101097 L06797 BE245301 Hs.89414 chemokine (C-X-C motif), receptor 4 (fus 101110 L08246 AI439011 Hs.86386 myeloid cell leukemia sequence 1 (BCL2-r 101142 L12711 L12711 Hs.89643 transketolase (Wemicke-Korsakoff syndro 101156 L13977 AA340987 Hs.75693 prolylcarboxypeptidase (angiotensinase C 101168 L15388 NM_005308Hs.211569 G protein-coupled receptor kinase 5 101184 L19871 NM_001674Hs.460 activating transcription factor 3 101192 L20859 BE247295 Hs.78452 solute carrier family 20 (phosphate tran 101317 L42176 L42176 Hs.8302 four and a half LIM domains 2 101336 L49169 NM 06732HS.75678 FBJ murine osteosarcoma viral oncogene h 101345 L76380 NM_005795Hs.152175 calcitonin receptor-like 101400 M15990 M15990 Hs.194148 v-yes-1 Yamaguchi sarcoma viral oncogene 101475 M23254 BE410405 Hs.76288 calpain 2, (m/ll) large subunit 101485 M24736 AA296520 Hs.89546 selectin E (endothelial adhesion molecul 101496 M26576 X12784 Hs.119129 collagen, type IV, alpha 1 101505 M27396 AA307680 Hs.75692 asparagine synthetase 101543 M31166 M31166 Hs.2050 pentaxin-related gene, rapidly induced b 101557 M31994 BE293116 Hs.76392 aldehyde dehydrogenase 1 family, member 101560 M32334 AW958272 Hs.347326 intercellular adhesion molecule 2 101587 M35878 AI752416 Hs.77326 insulin-like growth factor binding prate 101592 M36429 AF064853 Hs.91299 guanine nucleotide binding protein (G pr 101633 M57730 NM_004428Hs.1624 ephrin-A1 101634 M57731 AV650262 Hs.75765 GR02 oncogene 101667 M60858 NMJ05381 nucleolin 101682 M62994 AF043045 Hs.81008 filamin B, beta (actin-binding protein-2 101714 M68874 M68874 Hs.211587 phospholipase A2, group IVA (cytosolic, 101720 M69043 M69043 Hs.81328 nuclear fador of kappa light polypeptid 101741 M74719 NM_003199Hs.326198 transcription factor 4 101744 M75126 AI879352 Hs.118625 hexokinase 1 101793 M84349 W01076 Hs.278573 CD59 antigen p18-20 (antigen identified 101837 M92843 M92843 Hs.343586 zinc finger protein homologous to Zfp-36 101838 M92934 BE243845 Hs.75511 connective tissue growth factor 101840 M93056 AA236291 Hs.183583 serine (or cysteine) proteinase inhibito 101857 M94856 BE550723 Hs.153179 fatty acid binding protein 5 (psoriasis- 101864 M95787 BE392588 Hs.75777 transgelin 101931 S76965 NM 006823HS.75209 protein kinase (cAMP-dependent, catalyti 101966 S81914 X96438 Hs.76095 immediate early response 3 102012 U03057 BE259035 Hs.118400 singed (Drosophila)-like (sea urchin fas 102013 U03100 BE616287 Hs.178452 catenin (cadherin-associated protein), a 102024 U03877 AA301867 Hs.76224 EGF-containing fibulin-like extracellula 102059 U08021 AI752666 Hs.76669 nicotinamide N-methyltransferase 102121 U14391 NM_004998Hs.82251 myosin IE 102283 U31384 AW161552 Hs.83381 guanine nucleotide binding protein 11 102300 U32944 AI929721 Hs.5120 dynein, cytoplasmic, light polypeptide 102378 U40369 AU076887 Hs.28491 speιτnidine/spermine N1-acetyltransferase 102395 U41767 AU077005 Hs.92208 a disintegrin and metalloproteinase doma 102460 U48959 U48959 Hs.211582 myosin, light polypeptide kinase 102491 U51010 U51010 gb:Human nicotinamide N-methyltransferas 102499 U51478 BE243877 Hs.76941 ATPase, Na+/K+ transporting, beta 3 poly 102523 U53445 U53445 Hs.15432 downregulated in ovarian cancer 1 102560 U59289 R97457 Hs.63984 cadherin 13, H-cadherin (heart) 102564 U59423 U59423 Hs.79067 MAD (mothers against decapentaplegic, Dr 102589 U62015 AU076728 Hs.8867 cysteine-rich, angiogenic inducer, 61 102600 U63825 AI984144 Hs.66713 hepatitis delta antigen-interacting prot 102645 U67963 AL119566 Hs.6721 lysosomal 102687 U73379 NMJ07019HS.93002 ubiquitin carrier protein E2-C 102693 U73824 AA532780 Hs.183684 eukaryotic translation initiation factor 102709 U77604 AA122237 Hs.81874 microsomal glutathione S-transferase 2 102759 U81607 NM_005100Hs.788 A kinase (PRKA) anchor protein (gravin) 102804 U89942 NM_002318Hs.83354 lysyl oxidase-like 2 102882 X04412 AI767736 Hs.290070 gelsolin (amyloldosis, Finnish type) 102907 X06985 BE409861 Hs.202833 heme oxygenase (decycling) 1 102915 X07820 X07820 Hs.2258 matrix metalloproteinase 10 (stromelysin 102927 X12876 BE512730 Hs.65114 keratin 18 102960 X15729 AI904738 Hs.76053 DEAD/H (Asp-Glu-Ala-Asp/His) box polypep 103011 X52541 AJ243425 Hs.326035 early growth response 1 103020 X53416 X53416 Hs.195464 filamin A, alpha (actin-binding protein- 103029 X54489 AW800726 Hs.789 GR01 oncogene (melanoma growth stimulati 103036 X54925 M13509 Hs.83169 matrix metalloproteinase 1 (interstitial 103056 X57206 Y18024 Hs.78877 inositol 1,4,5-trisphosphate 3-kinase B 103080 X59798 AU077231 Hs.82932 cyclin D1 (PRAD1: parathyroid adenomatos

103095 X60957 NM 005424HS.78824 tyrosine kinase with immunoglobulin and

103138 X65965 X65965 gb:H.sapiens SOD-2 gene for manganese su

103176 X69111 AL021154 Hs.76884 inhibitor of DNA binding 3, dominant neg

103195 X70940 AA351647 Hs.2642 eukaryotic translation elongation factor

103347 X87838 AU077309 Hs.171271 catenin (cadherin-associated protein), b

103371 X91247 X91247 Hs.13046 thioredoxin reductase 1

103432 X97748 X97748 gb:H.sapiens PTX3 gene promotor region.

103471 Y00815 Y00815 Hs.75216 protein tyrosine phosphatase, receptor t

103967 AA303711 AL120051 Hs.144700 ephrin-B1

104447 L44538 AW204145 Hs.156044 ESTs

104764 AA025351 AI039243 Hs.278585 ESTs

104783 AA027050 AA533513 Hs.93659 protein disulfide isomerase related prat

104798 AA029462 AW952619 Hs.17235 Homo sapiens clone TCCCIA00176 mRNA sequ

104865 AA045136 T79340 Hs.22575 B-cell CLL/lymphoma 6, member B (zinc fi

104877 AA047437 AI138635 Hs.22968 Homo sapiens clone IMAGE:451939, mRNA se

104894 AA054087 AF065214 Hs.18858 phospholipase A2, group IVC (cytosolic,

104952 AA071089 AW076098 Hs.345588 desmoplakin (DPI, DPII)

105113 AA156450 AB037816 Hs.8982 Homo sapiens, clone IMAGE:3506202, mRNA,

105178 AA187490 AA313825 Hs.21941 AD036 protein

105196 AA195031 W84893 Hs.9305 angiotensin receptor-like 1

105215 AA205724 AA205759 Hs.10119 hypothetical protein FLJ 14957

105263 AA227926 AW388633 Hs.6682 solute carrier family 7, (cationic amino

105271 AA227986 AA807881 Hs.25329 ESTs

105330 AA234743 AW338625 Hs.22120 ESTs

105461 AA253216 BE539071 Hs.69388 hypothetical protein FLJ20505

105492 AA256210 AI805717 Hs.289112 CGI-43 protein

105493 AA256268 AL047586 Hs.10283 RNA binding motif protein 8B

105594 AA279397 AB024334 Hs.25001 tyrosine 3-monooxygenase/tryptophan 5-mo

105727 AA292379 AL135159 Hs.20340 KIAA1002 protein

105732 AA292717 AW504170 Hs.274344 hypothetical protein MGC12942

105767 AA346551 AW370946 Hs.23457 ESTs

105882 AA400292 W46802 Hs.81988 disabled (Drosophila) homolog 2 (mitogen

105936 AA404338 AI678765 Hs.21812 ESTs

106031 AA412284 X64116 Hs.171844 Homo sapiens cDNA: FLJ22296 fis, clone H

106124 AA423987 H93366 Hs.7567 Homo sapiens cDNA: FLJ21962 fis, clone H

106222 AA428594 AA356392 Hs.21321 Homo sapiens clone FLB9213 PR02474 mRNA,

106241 AA430108 BE019681 Hs.6019 Homo sapiens cDNA: FLJ21288 fis, clone C

106263 AA431462 W21493 Hs.28329 hypothetical protein FLJ14005

106264 AA431470 AL046859 Hs.3407 protein kinase (cAMP-dependent, catalyti

106366 AA443756 AA186715 Hs.336429 RIKEN CDNA 9130422N19 gene

106454 AA449479 NM 014038HS.5216 HSPC028 protein

106634 AA459916 W25491 Hs.288909 hypothetical protein FLJ22471

106724 AA465226 N48670 Hs.28631 Homo sapiens cDNA: FLJ22141 fis, clone H

106793 AA478778 H94997 Hs.16450 ESTs

106799 AA479037 BE313412 Hs.7961 Homo sapiens clone 25012 mRNA sequence

106842 AA482597 AF124251 Hs.26054 novel SH2-containing protein 3

106868 AA487561 BE185536 Hs.301183 molecule possessing ankyrin repeats indu

106890 AA489245 AA489245 Hs.88500 mitogen-activated protein kinase 8 inter

106961 AA504110 AW243614 Hs.18063 Homo sapiens cDNA FLJ10768 fis, clone NT

106974 AA520989 AI817130 Hs.9195 Homo sapiens cDNA FLJ13698 fis, clone PL

107030 AA599434 AL117424 Hs.25035 chloride intracellular channel 4

107061 AA608649 BE147611 Hs.6354 stromal cell derived factor receptor 1

107086 AA609519 NM 012331HS.26458 methionine sulfoxide reductase A

107216 D51069 D51069 Hs.211579 melanoma cell adhesion molecule

107385 U97519 NM 005397HS.16426 podocalyxin-like

107444 W28391 W28391 Hs.343258 proliferation-associated 2G4, 38kD

107985 AA035638 T40064 Hs.71968 Homo sapiens mRNA; cDNA DKFZp564F053 (fr

108507 AA083514 AI554545 Hs.68301 ESTs

108695 AA121315 AB029000 Hs.70823 KIAA1077 protein

108931 AA147186 AA147186 gb:zo38d01.s1 Stratagene endothelial eel

109001 AA156125 AI056548 Hs.72116 hypothetical protein FLJ20992 similarto

109195 AA188932 AF047033 Hs.132904 solute carrier family 4, sodium bicarbon

109390 AA219653 AW007485 Hs.87125 EH-domain containing 3

109456 AA232645 AW956580 Hs.42699 ESTs

109737 F10078 AA055415 Hs.13233 ESTs, Moderately similarto A47582 B-cel

110411 H48032 AW001579 Hs.9645 Homo sapiens mRNA for KIAA1741 protein,

110660 H82117 AA782114 Hs.28043 ESTs

110906 N39584 AA035211 Hs.17404 ESTs

111018 N54067 AI287912 Hs.3628 mitogen-activated protein kinase kinase

111091 N59858 AA300067 Hs.33032 hypothetical protein DKFZp434N185

111356 N90933 BE301871 Hs.4867 mannosyl (alpha-1 ,3-)-g]ycoprotein beta-

111378 N93764 AW160993 Hs.326292 hypothetical gene DKFZp434A1114

111741 R26124 AB020653 Hs.24024 KIAA0846 protein

111769 R27957 AW629414 Hs.24230 ESTs

112318 R55470 AW083384 Hs.11067 ESTs, Highly similar to T46395 hypotheti 112951 T16550 AA307634 Hs.6650 vacuolar protein sorting 45B (yeast homo

113057 T26674 AW194301 Hs.339283 Human DNA sequence from clone RP1-187J11

113195 T57112 H83265 Hs.8881 ESTs, Weakly similar to S41044 chromosom

113490 T88700 BE178110 Hs.173374 Homo sapiens cDNA FLJ10500 fis, clone NT

113542 T90527 H43374 Hs.7890 Homo sapiens mRNA for KIAA1671 protein,

113803 W42789 AW880709 Hs.283683 chromosome 8 open reading frame 4

113847 W60002 NM 005032HS.4114 plastin 3 (T isoform)

113910 W78175 AA113262 Hs.17901 Homo sapiens, clone IMAGE:3937015, mRNA,

113947 W84768 W84768 gb:zh53d03.s1 Soares_fetal_liver_spleen_

114047 W94427 AL035858 Hs.3807 FXYD domain-containing ion transport reg

115061 AA253217 AI751438 Hs.41271 Homo sapiens mRNA full length insert cDN

115819 AA426573 AA486620 Hs.41135 endomucin-2

115870 AA432374 NM_005985Hs.48029 snail 1 (drosophila homolog), zinc finge

115964 AA446622 AA987568 Hs.74313 KIAA1265 protein

116228 AA478771 AI767947 Hs.50841 ESTs

116264 AA482594 D51174 Hs.272239 lysosomal

116314 AA490588 AI799104 Hs.178705 Homo sapiens cDNA FLJ 11333 fis, clone PL

116589 D59570 AI557212 Hs.17132 ESTs, Moderately similar to I54374 gene

117023 H88157 AW070211 Hs.102415 Homo sapiens mRNA; cDNA DKFZp586N0121 (f

117112 H94648 AW969999 Hs.293658 ESTs

117156 H97538 W73853 ESTs

117176 H98670 H45100 Hs.49753 uveal autoantigen with coiled coil domai

117280 N22107 M18217 Hs.172129 Homo sapiens cDNA: FLJ21409 fis, clone C

119559 W38197 W38197 Empirically selected from AFFX single pr

119866 W80814 AA496205 Hs.193700 Homo sapiens mRNA; cDNA DKFZp586l0324 (f

120655 AA287347 AA305599 Hs.238205 hypothetical protein PRO2013

121314 AA402799 W07343 Hs.182538 phospholipid scramblase 4

121335 AA404418 AA404418 gb:zw37e02.s1 Soares_total_fetus_Nb2HF8_

121822 AA425107 AI743860 metallothionein 1E (functional)

121835 AA425435 AB033030 Hs.300670 KIAA1204 protein

122331 AA442872 AL133437 Hs.110771 Homo sapiens cDNA: FLJ21904 fis, clone H

122577 AA452860 AA829725 Hs.334437 hypothetical protein MGC4248

123160 AA488687 AA488687 Hs.284235 ESTs, Weakly similar to I38022 hypotheti

123486 AA599674 BE019072 Hs.334802 Homo sapiens cDNA FLJ14680 fis, clone NT

124059 F13673 BE387335 Hs.283713 ESTs, Weakly similar to S64054 hypotheti

124339 H99093 H99093 Hs.343411 DEAD/H (Asp-Glu-Ala-Asp/His) box polypep

124358 N22495 AW070211 Hs.102415 Homo sapiens mRNA; cDNA DKFZp586N0121 (f

124364 N23031 AF265555 Hs.250646 baculoviral IAP repeat-containing 6

124726 R15740 NM 003654HS.104576 carbohydrate (keratan sulfate Gal-6) sul

124763 R39610 BE410405 Hs.76288 calpain 2, (m/ll) large subunit

125167 W45560 AL137540 Hs.102541 netrin 4

125304 Z39833 AL359573 Hs.124940 GTP-binding protein

125307 Z40583 AW580945 Hs.330466 ESTs

125329 AA825437 AA825437 Hs.58875 ESTs

125598 R66613 T40064 Hs.71968 Homo sapiens mRNA; cDNA DKFZp564F053 (fr

125609 AA868063 AA868063 Hs.104576 carbohydrate (keratan sulfate Gal-6) sul

418245 AA128075 AA088767 Hs.83883 transmembrane, prostate androgen induced

127435 N66570 X69086 Hs.286161 Homo sapiens cDNA FLJ13613 fis, clone PL

127566 AI051390 AI051390 Hs.116731 ESTs

127619 AA627122 AA627122 Hs.163787 ESTs

128453 X02761 X02761 Hs.287820 fibronectin 1

128495 AF010193 NM_005904Hs.100602 MAD (mothers against decapentaplegic, Dr

128515 AA149044 BE395085 Hs.10086 type I transmembrane protein Fn14

128580 U82108 U82108 Hs.101813 solute carrier family 9 (sodium/hydrogen

128623 D78676 BE076608 Hs.105509 CTL2gene

128642 L35240 Z28913 Hs.102948 enigma (LIM domain protein)

128669 AA598737 W28493 Hs.180414 heat shock 70kD protein 8

128903 R69417 AW150717 Hs.345728 STAT induced STAT inhibitor 3

128914 AA232837 AW867491 Hs.107125 plasmalemma vesicle associated protein

129087 N72695 AI348027 Hs.108557 hypothetical protein PP1057

129188 M30257 NM 001078HS.109225 vascular cell adhesion molecule 1

129226 M96843 BE222494 Hs.180919 inhibitor of DNA binding 2, dominant neg

129265 X68277 AA530892 Hs.171695 dual specificity phosphatase 1

129345 AA292440 R22497 Hs.110571 growth arrest and DNA-damage-inducible,

129468 J03040 AW410538 Hs.111779 secreted protein, acidic, cysteine-rich

129488 AA228107 AW966728 Hs.54642 methionine adenosyltransferase II, beta

129498 AA449789 AA449789 Hs.75511 connective tissue growth factor

129557 W01367 AL045404 Hs.46366 KIAA0948 protein

129619 AA610116 AA209534 Hs.284243 tetraspan NET-6 protein

129627 AA258308 T40064 Hs.71968 Homo sapiens mRNA; cDNA DKFZp564F053 (fr

129762 AA460273 AA453694 Hs.12372 tripartite motif protein TRIM2

129884 AA286710 AF055581 Hs.13131 lysosomal

130018 T68873 AA353093 metallothionein 1L

130147 D63476 D63476 Hs.172813 PAK-interacting exchange factor beta

130178 M62403 U20982 Hs.1516 insulin-like growth fador-binding prate

130282 X55740 BE245380 Hs.153952 5' nucleotidase (CD73) 130431 L10284 AW505214 Hs.155560 calnexin

130495 AA243278 AW250380 Hs.109059 mitochondrial ribosomal protein L12

130553 AA430032 AF062649 Hs.252587 pituitary tumor-transforming 1

130638 H16402 AW021276 Hs.17121 ESTs

130639 D59711 AI557212 Hs.17132 ESTs, Moderately similar to I54374 gene

130657 T94452 AW337575 Hs.201591 ESTs

130686 AA431571 BE548267 Hs.337986 Homo sapiens cDNA FLJ10934 fis, clone OV

130776 R79356 AF167706 Hs.19280 cysteine-rich motor neuron 1

130818 AA280375 AW190920 Hs.19928 hypothetical protein SP329

130840 Z49269 BE048821 Hs.20144 small inducible cytokine subfamily A (Cy

130899 Z41740 AI077288 Hs.296323 serum/glucocorticoid regulated kinase

131002 AA121543 AL050295 Hs.22039 KIAA0758 protein

131080 J05008 NM 001955HS.2271 endofheliπ 1

131084 AA101878 NM_017413Hs.303084 apelin; peptide ligand for APJ receptor

131091 T35341 AJ271216 Hs.22880 dipeptidylpeptidase III

131107 N87590 BE620886 Hs.75354 GCN1 (general control of amino-acid synt

131182 AA256153 AI824144 Hs.23912 ESTs

131207 W74533 AF104266 Hs.24212 latrophilin

131319 U25997 NM 003155HS.25590 stanniocalcin 1

131328 V01512 AW939251 Hs.25647 v-fos FBJ murine osteosarcoma viral onco

131328 V01512 AW939251 Hs.25647 v-fos FBJ murine osteosarcoma viral onco

131328 V01512 AW939251 Hs.25647 v-fos FBJ murine osteosarcoma viral onco

131328 V01512 AW939251 Hs.25647 v-fos FBJ murine osteosarcoma viral onco

131509 X56681 X56681 Hs.2780 jun D proto-oncogene

131555 AA161292 T47364 Hs.278613 interferon, alpha-inducible protein 27

131564 AA491465 T93500 Hs.28792 Homo sapiens cDNA FLJ11041 fis, clone PL

131573 AA046593 AA040311 Hs.28959 ESTs

131692 D50914 BE559681 Hs.30736 KIAA0124 protein

131756 D45304 AA443966 Hs.31595 ESTs

131859 M90657 AW960564 transmembrane 4 superfamily member 1

131909 W69127 NM_016558Hs.274411 SCAN domain-containing 1

131915 AA316186 AI161383 Hs.34549 ESTs, Highly similar to S94541 1 clone 4

132046 AA384503 AI359214 Hs.179260 chromosome 14 open reading frame 4

132050 AA136353 AI267615 Hs.38022 ESTs

132151 AA044755 BE379499 Hs.173705 Homo sapiens cDNA: FLJ22050 fis, clone H

132164 U84573 AI752235 Hs.41270 procollagen-lysine, 2-oxoglutarate 5-dio

132187 AA058911 AA235709 Hs.4193 DKFZP58601624 protein

132303 AA620962 BE177330 Hs.325093 Homo sapiens cDNA: FLJ21210 fis, clone C

132314 AA285290 AF112222 Hs.323806 pinin, desmosome associated protein

132358 X60486 NM_003542Hs.46423 H4 histone family, member G

132398 R31641 AA876616 Hs.16979 ESTs, Weakly similarto A43932 mucin 2 p

132421 AA489190 AW163483 Hs.48320 double ring-finger protein, Dorfin

132490 F13782 NM 001290HS.4980 LIM domain binding 2

132520 AA257993 AA257992 Hs.50651 Janus kinase 1 (a protein tyrosine kinas

132546 M24283 M24283 Hs.168383 intercellular adhesion molecule 1 (CD54)

132610 AA443114 AA160511 Hs.5326 amino acid system N transporter 2; porcu

132716 T35289 BE379595 Hs.283738 casein kinase 1, alpha 1

132840 N23817 BE218319 Hs.5807 GTPase Rab14

132883 AA047151 AA373314 Hs.5897 Homo sapiens mRNA; cDNA DKFZp586P1622 (f

132968 N77151 AF234532 Hs.61638 myosin X

132989 AA480074 AA480074 Hs.331328 hypothetical protein FLJ13213

132999 Y00787 Y00787 Hs.624 interieukin 8

133071 T99789 BE384932 Hs.64313 ESTs, Weakly similar to AF2571821 G-pro

133076 W84341 AW946276 Hs.6441 Homo sapiens mRNA; cDNA DKFZp586J021 (fr

133099 L09209 W16518 Hs.279518 amyloid beta (A4) precursor-like protein

133147 D12763 AA026533 Hs.66 interieukin 1 receptor-like 1

133149 T16484 AA370045 Hs.6607 AXIN1 up-regulated

133161 AA253193 AW021103 Hs.6631 hypothetical protein FLJ20373

133200 AA432248 AB037715 Hs.183639 hypothetical protein FLJ10210

133220 X82200 NM_006074Hs.318501 Homo sapiens mRNA full length insert cDN

133260 AA083572 AA403045 Hs.6906 Homo sapiens cDNA: FLJ23197 fis, clone R

133295 L00352 AI147861 Hs.213289 low density lipoprotein receptor (famili

133349 N75791 AW631255 Hs.8110 L-3-hydroxyacyl-Coenzyme A dehydrogenase

133391 X57579 AW103364 Hs.727 inhibin, beta A (activin A, activin AB a

133398 X02612 NM_000499Hs.72912 cytochrome P450, subfamily I (aromatic c

133436 H44631 BE294068 Hs.737 immediate early protein

133454 AA090257 BE547647 Hs.177781 hypothetical protein MGC5618

133478 X83703 X83703 Hs.31432 cardiac ankyrin repeat protein

133491 L40395 BE619053 Hs.170001 eukaryotic translation initiation factor

133510 AA227913 AW880841 Hs.96908 p53-induced protein

133517 X52947 NM_000165Hs.74471 gap junction protein, alpha 1, 43kD (con

133526 M11313 AU077051 Hs.74561 alpha-2-macroglobulin

133538 L14837 NM 003257HS.74614 tight junction protein 1 (zona occludens

133562 M60721 M60721 Hs.74870 H2.0 (Drosophila)-like homeo box 1

133584 D90209 D90209 Hs.181243 activating transcription factor 4 (tax-r

133590 T67986 T70956 Hs.75106 clusterin (complement lysis inhibitor, S 133617 AA148318 BE244334 Hs.75249 ADP-ribosylation factor-like 6 interacti

133651 U97105 AI301740 Hs.173381 dihydropyrimidinase-like 2

133671 T25747 AW503116 Hs.301819 zinc finger protein 146

133678 K02574 AW247252 nucleoside phosphorylase

133681 D78577 AI352558 tyrosine 3-monooxygenase/tryptophan 5-mo

133722 X53331 AW969976 Hs.279009 matrix Gla protein

133730 S73591 BE242779 Hs.179526 upregulated by 1,25-dihydroxyvitamin D-3

133750 X95735 BE410769 Hs.75873 zyxin

133802 L16862 AW239400 Hs.76297 G protein-coupled receptor kinase 6

133825 U44975 BE616902 Hs.285313 core promoter element binding protein

133838 M97796 BE222494 Hs.180919 inhibitor of DNA binding 2, dominant neg

133859 U86782 U86782 Hs.178761 26S proteasome-associated padl homolog

133889 AA099391 U48959 Hs.211582 myosin, light polypeptide kinase

133960 M19267 M19267 Hs.77899 tropomyosin 1 (alpha)

133975 D29992 C18356 Hs.295944 tissue factor pathway inhibitor 2

133977 L19314 AI125639 Hs.250666 hairy (Drosophila)-homolog

134039 S78569 NM_002290Hs,78672 laminin, alpha 4

134075 U28811 NM 012201HS.78979 Golgi apparatus protein 1

134081 L77886 AL034349 Hs.79005 protein tyrosine phosphatase, receptor t

134164 C14407 AW245540 Hs.79516 brain abundant, membrane attached signal

134203 M60278 AA161219 Hs.799 diphtheria toxin receptor (heparin-bindi

134238 R81509 AA102179 Hs.160726 Homo sapiens cDNA FLJ11680 fis, clone HE

134299 AA487558 AW580939 Hs.97199 complement component C1q receptor

134332 D86962 D86962 Hs.81875 growth factor receptor-bound protein 10

134339 AA478971 R70429 Hs.81988 disabled (Drosophila) homolog 2 (mitogen

134343 D50683 D50683 Hs.82028 transforming growth factor, beta recepto

134381 U56637 AI557280 Hs.184270 capping protein (actin filament) muscle

134403 M61199 AA334551 sperm specific antigen 2

134416 M28882 X68264 Hs.211579 melanoma cell adhesion molecule

134493 X15183 M30627 Hs.289088 heat shock 90kD protein 1, alpha

134558 S53911 NM_001773Hs.85289 CD34 antigen

134817 U20734 AU076592 Hs.198951 jun B proto-oncogene

134983 D28235 D28235 Hs.196384 prostaglandin-endoperoxide synthase 2 (p

134989 AA236324 AW968058 Hs.92381 nudix (nucleoside diphosphate linked moi

135052 AA148923 AL136653 Hs.93675 decidual protein induced by progesterone

135062 AA174183 AK000967 Hs.93872 KIAA1682 protein

135069 AA456311 AA876372 Hs.93961 Homo sapiens mRNA; cDNA DKFZp667D095 (fr

135071 L08069 W27190 Hs.94 DnaJ (Hsp40) homolog, subfamily A, membe

135073 AA452000 W55956 Hs.94030 Homo sapiens mRNA; cDNA DKFZp586E1624 (f

135170 AA282140 T53169 Hs.9587 Homo sapiens cDNA: FLJ22290 fis, clone H

135196 J02854 C03577 Hs.9615 myosin regulatory light chain 2, smooth

135348 AA442054 U80983 Hs.268177 phospholipase C, gamma 1 (formerly subty

134404 AB000450 AB000450 Hs.82771 vaccinia related kinase 2

439561 AB002380 AF180681 Hs.6582 Rho guanine exchange factor (GEF) 12

100082 AB003103 AA130080 Hs.4295 proteasome (prosome, macropain) 26S subu

132817 AB004884 N27852 Hs.57553 tousled-like kinase 2

130150 AF000573 BE094848 Hs.15113 homogentisate 1,2-dioxygenase (homogenti

100104 AF008937 AF008937 syntaxin 16

447973 AF009301 AB011169 Hs.20141 similarto S. cerevisiae SSM4

332613 AF009368 AF029674 Hs.173422 KIAA1605 protein

100113 D00591 NM 001269HS.84746 chromosome condensation 1

133980 D00760 AA294921 Hs.348024 v-ral simian leukemia viral oncogene hom

100129 D11139 AA469369 Hs.5831 tissue inhibitor of metalloproteinase 1

100154 D14657 H60720 Hs.81892 KIAA0101 gene product

100169 D14878 AL037228 Hs.82043 D123 gene product

129718 D17716 NM 002410HS.121502 mannosyl (alpha-1 ,6-)-glycoprotein beta-

100190 D21090 M91401 Hs.178658 RAD23 (S. cerevisiae) homolog B

134742 D26135 NM_001346Hs.89462 diacylglycerol kinase, gamma (90kD)

100211 D26528 D26528 Hs.123058 DEAD/H (Asp-Glu-Ala-Asp/His) box polypep

100238 D30742 L24959 Hs.348 calcium/calmodulin-dependent protein kin

130283 D31762 NM 012288HS.153954 TRAM-like protein

134237 D31765 D31765 Hs.170114 KIAA0061 protein

100248 D31888 NM_015156Hs.78398 KIAA0071 protein

100256 D38128 D25418 Hs.393 prostaglandin 12 (prostacyclin) receptor

100262 D38500 D38500 Hs.278468 postmeiotic segregation increased 2-like

134329 D38551 N92036 Hs.81848 RAD21 (S. pombe) homolog

100281 D42087 AF091035 Hs.184627 KIAA0118 protein

100294 D49396 AA331881 Hs.75454 peroxiredoxin 3

100327 D55640 D55640 gb:Human monocyte PABL (pseudoautosomal

100335 D63391 AW247529 Hs.6793 platelet-activating factor acetylhydrola

134495 D63477 D63477 Hs.84087 KIAA0143 protein

100338 D63483 D86864 Hs.57735 acetyl LDL receptor; SREC

135152 D64015 M96954 Hs.182741 TIA1 cytotoxic granule-associated RNA-bi

134269 D79990 NM_014737Hs.80905 Ras association (RalGDS/AF-6) domain fam

100372 D79997 NM 014791HS.184339 KIAA0175 gene product

134304 D80010 BE613486 Hs.81412 lipin 1 100394 D84276 D84284 Hs.66052 CD38 antigen (p45) 100405 D86425 AW291587 Hs.82733 nidogen 2 100418 D86978 D86978 Hs.84790 KIAA0225 protein 133154 D87012 D87012 Hs.194685 topoisomerase (DNA) III beta 134347 D87075 AF164142 Hs.82042 solute carrier family 23 (nucleobase tra 444099 D87432 D87432 Hs.10315 solute carrier family 7 (cationic amino 100438 D87448 AA013051 Hs.91417 topoisomerase (DNA) II binding protein 134593 D87845 NM_000437Hs.234392 platelet-activating factor acetylhydrola 100481 HG1098-HT1098 X70377 Hs.121489 cystatin D 100552 HG2167-HT2237 AA019521 Hs.301946 lysosomal 100591 HG2415-HT2511 NM_004091Hs.231444 Homo sapiens, Similarto hypothetical pr 100652 HG2825-HT2949 BE613608 Hs.142653 ret finger protein 100662 HG2887-HT3031 AI368680 Hs.816 SRY (sex determining region Y)-box 2 100899 HG4660-HT5073 AL039123 Hs.103042 microtubule-associated protein 1B 100905 HG4704-HT5146 L12260 Hs.172816 neuregulin 1 100945 HG884-HT884 AF002225 Hs.180686 ubiquitin protein ligase E3A (human papi 100950 HG919-HT919 AF128542 Hs.166846 polymerase (DNA directed), epsilon 100964 J00212 J00212 Empirically selected from AFFX single pr 135407 J04029 J04029 Hs.99936 keratin 10 (epidermolytic hyperkeratosis 130149 J04031 AW067805 Hs.172665 methylenetetrahydrofolate dehydrogenase 131877 J04088 J04088 Hs.156346 topoisomerase (DNA) II alpha (170kD) 101016 J04543 J04543 Hs.78637 annexin A7 134786 L06139 T29618 Hs.89640 TEK tyrosine kinase, endothelial (venous 134100 L07540 AA460085 Hs.171075 replication factor C (activator 1) 5 (36 134078 L08895 L08895 Hs.78995 MADS box transcription enhancer factor 2 101132 L11239 L11239 Hs.36993 gastrulation brain homeo box 1 134849 L11353 BE409525 Hs.902 neurofibromin 2 (bilateral acoustic neur 332736 L13773 Z83689 Hs.114765 myeloid/lymphoid or mixed-lineage leukem 101152 L13800 AI984625 Hs.9884 spindle pole body protein 135397 L14922 L14922 Hs.166563 replication factor C (activator 1) 1 (14 432642 L15189 BE297635 Hs.3069 heat shock 70kD protein 9B (mortalin-2) 101168 L15388 NM_005308Hs.211569 G protein-coupled receptor kinase 5 421155 L16895 H87879 Hs.102267 lysyl oxidase 101226 L27476 AF083892 Hs.75608 tight junction protein 2 (zona occludens 415138 L27624 C18356 Hs.295944 tissue fador pathway inhibitor 2 134739 L32976 NMJ02419HS.89449 mitogen-activated protein kinase kinase 130155 L33404 AA101043 Hs.151254 kallikrein 7 (chymotryptic, stratum com 440538 L35263 W76332 Hs.79107 mitogen-activated protein kinase 14 409916 L37347 BE313625 Hs.57435 solute earner family 11 (proton-coupled 101294 L40371 AF168418 Hs.116784 thyroid hormone receptor interactor 4 101300 L40391 BE535511 transmembrane trafficking protein 101310 L41607 L41607 Hs.934 glucosaminyl (N-acetyl) transferase 2, 1 130344 L77566 AW250122 Hs.154879 DiGeorge syndrome critical region gene D 101381 M13928 AW675039 Hs.1227 aminolevulinate, delta-, dehydratase 101381 M13928 AW675039 Hs.1227 aminolevulinate, delta-, dehydratase 415678 M14016 AW005903 Hs.78601 uroporphyrinogen decarboxylase 133780 M14219 AA557660 Hs.76152 decorin 101396 M15796 BE267931 Hs.78996 proliferating cell nuclear antigen 101447 M21305 M21305 gb:Human alpha satellite and satellite 3 101458 M22092 M22092 gb:Human neural cell adhesion molecule ( 101470 M22898 NM_000546Hs.1846 tumor protein p53 (Li-Fraumeni syndrome) 134604 M22995 NM_002884Hs.865 RAP1 A, member of RAS oncogene family 101478 M23379 NM_002890Hs.758 RAS p21 protein activator (GTPase activa 133519 M24400 AW583062 Hs.74502 chymotrypsinogen B1 131185 M25753 BE280074 Hs.23960 cyclin B1 134116 M27691 R84694 Hs.79194 cAMP responsive element binding protein 133999 M28213 AA535244 Hs.78305 RAB2, member RAS oncogene family 130174 M29550 M29551 Hs.151531 protein phosphatase 3 (formerly 2B), cat 129963 M29971 M29971 Hs.1384 0-6-methylguanine-DNA methyltransferase 132983 M30269 M30269 nidogen (enactin) 133900 M31158 M31158 Hs.77439 protein kinase, cAMP-dependent, regulato 101543 M31166 M31166 Hs.2050 pentaxin-related gene, rapidly induced ^'b 101545 M31210 BE246154 Hs.154210 endothelial differentiation, sphingolipi 101620 M55420 S55271 Hs.247930 Epsilon , IgE 134691 M59979 AW382987 Hs.88474 prostaglandin-endoperoxide synthase 1 (p 133595 M62810 AA393273 Hs.75133 transcription factor 6-like 1 (mitochond 101700 M64710 D90337 Hs.247916 natriuretic peptide precursor C 101714 M68874 M68874 Hs.211587 phospholipase A2, group IVA (cytosolic, 134246 M74524 D28459 Hs.80612 ubiquitin-conjugating enzyme E2A (RAD6 h 101760 M80254 M80254 Hs.173125 peptidylprolyi isomerase F (cyclophilin 415022 M81780 X59960 Hs.77813 sphingomyelin phosphodiesterase 1, acid 415022 M81780 X59960 Hs.77813 sphingomyelin phosphodiesterase 1, acid 415022 M81780 X59960 Hs.77813 sphingomyelin phosphodiesterase 1, acid 415022 M81780 X59960 Hs.77813 sphingomyelin phosphodiesterase 1, acid 415022 M81780 X59960 Hs.77813 sphingomyelin phosphodiesterase 1, acid 101791 M83822 M83822 Hs.62354 cell division cycle 4-like 101812 M86934 BE439894 Hs.78991 DNA segment, numerous copies, expressed

101813 M87338 NM 002914HS.139226 replication factor C (adivator 1) 2 (40

133396 M96326 M96326 Hs.72885 azurocidin 1 (cationic antimicrobial pro

428161 M96954 M96954 Hs.182741 TIA1 cytotoxic granule-associated RNA-bi

129026 M98833 AL120297 Hs.108043 Friend leukemia virus integration 1

101901 S66793 H38026 Hs.308 arrestin 3, retinal (X-arrestin)

134831 S72370 AA853479 Hs.89890 pyruvate carboxylase

134039 S78569 NM 002290HS.78672 laminin, alpha 4

442355 S79873 AA456539 Hs.8262 lysosomal-associated membrane protein 2

101975 S83325 AA079717 Hs.283664 aspartate beta-hydroxylase

101977 S83364 AF112213 Hs.184062 putative Rab5-interacting protein

101978 S83365 BE561610 Hs.5809 putative transmembrane protein; homolog

101998 U01212 U01212 Hs.248153 olfactory marker protein

102003 U01922 U01922 Hs.125565 translocase of inner mitochondrial membr

102007 U02556 U02556 Hs.75307 t-complex-associated-testis-expressed 1-

102009 U02680 BE245149 Hs.82643 protein tyrosine kinase 9

416658 U03272 U03272 Hs.79432 fibrillin 2 (congenital contractural ara

132951 U04209 AW821182 Hs.61418 microfibrillar-associated protein 1

135389 U05237 U05237 Hs.99872 fetal Alzheimer antigen

102048 U07225 U07225 Hs.339 purinergic receptor P2Y, G-protein coupl

130145 U07620 U34820 Hs.151051 mitogen-activated protein kinase 10

303153 U09759 U09759 Hs.246857 mitogen-activated protein kinase 9

420269 U09820 U72937 Hs.96264 alpha thalassemia/mental retardation syn

102095 U11313 U11313 Hs.75760 sterol carrier protein 2

102123 U14518 NM_001809Hs.1594 centromere protein A (17kD)

102126 U14575 AW950870 Hs.78961 protein phosphatase 1, regulatory (inhib

102133 U15173 AU076845 Hs.155596 BCL2/adenovirus E1B 19kD-interacting pro

102139 U15932 NM 004419HS.2128 dual specificity phosphatase 5

102162 U18291 AA450274 Hs.1592 CDC16 (cell division cycle 16, S. cerevi

102164 U18300 NM 000107HS.77602 damage-specific DNA binding protein 2 (4

427653 U18383 AA159001 Hs.180069 nuclear respiratory factor 1

131817 U20536 U20536 Hs.3280 caspase 6, apoptosis-related cysteine pr

102200 U21551 AA232362 Hs.157205 branched chain aminotransferase 1, cytos

102210 U23028 BE619413 Hs.2437 eukaryotic translation initiation factor

102214 U23752 U23752 Hs.32964 SRY (sex determining region Y)-box 11

132811 U25435 U25435 Hs.57419 CCCTC-binding factor (zinc finger protei

131319 U25997 NM 003155HS.25590 stanniocalcin 1

102256 U28251 U28251 Hs.53237 ESTs, Highly similarto Z169JHUMAN ZINC

132316 U28831 U28831 Hs.44566 KIAA1641 protein

102269 U30245 U30245 gb:Human myelomonocytic specific protein

417526 U32315 AA568906 Hs.82240 syntaxin 3A

102293 U32439 AF090116 Hs.79348 regulator of G-protein signalling 7

102298 U32849 AA382169 Hs.54483 N-myc (and STAT) interactor

102325 U35139 AI815867 Hs.50130 necdin (mouse) homolog

428734 U36764 BE303044 Hs.192023 eukaryotic translation initiation factor

102361 U39400 AA223616 Hs.75859 chromosome 11 open reading frame 4

102367 U39657 U39656 Hs.118825 mitogen-activated protein kinase kinase

102388 U41344 AA362907 Hs.76494 proline arginine-rich end leucine-rich r

102394 U41766 NM 003816HS.2442 a disintegrin and metalloproteinase doma

129829 U41813 AF010258 Hs.127428 homeo boxA9

102409 U43286 BE300330 Hs.118725 selenophosphate synthetase 2

133746 U44378 AW410035 Hs.75862 MAD (mothers against decapentaplegic, Dr

102423 U44754 Z47542 Hs.179312 small nuclear RNA activating complex, po

132828 U47011 AB014615 Hs.57710 fibroblast growth factor 8 (androgen-ind

132828 U47011 AB014615 Hs.57710 fibroblast growth factor 8 (androgen-ind

132828 U47011 AB014615 Hs.57710 fibroblast growth factor 8 (androgen-ind

132828 U47011 AB014615 Hs.57710 fibroblast growth factor 8 (androgen-ind

425322 U47077 U63630 Hs.155637 protein kinase, DNA-activated, catalytic

102450 U48251 U48251 Hs.75871 protein kinase C binding protein 1

129350 U50535 U50535 Hs.110630 Human BRCA2 region, mRNA sequence CG006

102534 U56833 U96759 Hs.198307 von Hippel-Lindau binding protein 1

130457 U58091 AB014595 Hs.155976 cullin 4B

135065 U58837 AA019401 Hs.93909 cyclic nucleotide gated channel beta 1

102560 U59289 R97457 Hs.63984 cadherin 13, H-cadherin (heart)

102567 U59863 U63830 Hs.146847 TRAF family member-associated NFKB activ

417173 U67122 U61397 Hs.81424 ubiquitin-like 1 (sentrin)

102638 U67319 U67319 Hs.9216 caspase 7, apoptosis-related cysteine pr

132736 U68019 AW081883 Hs.211578 Homo sapiens cDNA: FLJ23037 fis, clone L

133070 U69611 U92649 Hs.64311 a disintegrin and metalloproteinase doma

102663 U70322 NM_002270Hs.168075 karyopherin (importin) beta 2

134660 U73524 U73524 Hs.87465 ATP/GTP-binding protein

102735 U79267 AF111106 Hs.3382 protein phosphatase 4, regulatory subuni

102741 U79291 AW959829 Hs.83572 hypothetical protein MGC14433

130564 U82671 U82671 Hs.36980 melanoma antigen, family A, 2

130564 U82671 U82671 Hs.36980 melanoma antigen, family A, 2

132164 U84573 AI752235 Hs.41270 procollagen-lysine, 2-oxoglutarate 5-dio 102823 U90914 D85390 Hs.5057 carboxypeptidase D

102826 U91316 NM 007274HS.8679 cytosolic acyl coenzyme A thioester hydr

102831 U91932 AA262170 Hs.80917 adaptor-related protein complex 3, sigma

102846 U96131 BE264974 Hs.6566 thyroid hormone receptor interactor 13

129777 U97018 U97018 Hs.12451 echinoderm microtubule-associated protei

134161 U97188 AA634543 Hs.79440 IGF-II mRNA-binding protein 3

134854 V00503 J03464 Hs.179573 collagen, type I, alpha 2

429257 X04327 AW163799 Hs.198365 2,3-bisphosphoglycerate mutase

413985 X06389 AI018666 Hs.75667 synaptophysin

419768 X07496 T72104 Hs.93194 apolipoprotein A-l

102915 X07820 X07820 Hs.2258 matrix metalloproteinase 10 (stromelysin

134656 X14787 AI750878 Hs.87409 thrombospondin 1

413858 X15525 NM 001610HS.75589 acid phosphatase 2, lysosomal

102968 X16396 AU076611 Hs.154672 methylene tetrahydrofolate dehydrogenase

102971 X16609 X16609 Hs.183805 ankyrin 1, erythrocytic

134037 X53586 AI808780 Hs.227730 integrin, alpha 6

134037 X53586 AI808780 Hs.227730 integrin, alpha 6

103023 X53793 AW500470 Hs.117950 multifunctional polypeptide similar to S

103037 X54936 BE018302 Hs.2894 placental growth factor, vascular endoth

130282 X55740 BE245380 Hs.153952 5' nucleotidase (CD73)

134542 X57025 M14156 Hs.85112 insulin-like growth factor 1 (somatomedi

128568 X60673 H12912 Hs.274691 adenylate kinase 3

128568 X60673 H12912 Hs.274691 adenylate kinase 3

103093 X60708 S79876 Hs.44926 dipeptidylpeptidase IV (CD26, adenosine

413076 X62048 U10564 Hs.75188 weel (S. pombe) homolog

129063 X63097 X63094 Hs.283822 Rhesus blood group, D antigen

424460 X63563 BE275979 Hs.296014 polymerase (RNA) II (DNA directed) polyp

411077 X64037 AW977263 Hs.68257 general transcription factor IIF, polype

103181 X69636 X69636 Hs.334731 Homo sapiens, clone !MAGE:3448306, mRNA,

103184 X69878 U43143 Hs.74049 fms-related tyrosine kinase 4

103194 X70649 NM_004939Hs.78580 DEAD/H (Asp-Glu-Ala-Asp/His) box polypep

103208 X72841 AW411340 Hs.31314 retinoblastoma-binding protein 7

129698 X74987 BE242144 Hs.12013 ATP-binding cassette, sub-family E (OABP

131486 X83107 F06972 Hs.27372 BMX non-receptor tyrosine kinase

130729 X84194 AI963747 Hs.18573 acylphosphatase 1, erythrocyte (common)

103334 X85753 NM_001260Hs.25283 cyclin-dependent kinase 8

132645 X87870 AI654712 Hs.54424 hepatocyte nuclear factor 4, alpha

135094 X89066 NM 003304HS.250687 transient receptor potential channel 1

103352 X89398 H09366 Hs.78853 uracil-DNA glycosylase

103352 X89398 H09366 Hs.78853 uracil-DNA glycosylase

103353 X89399 X89399 Hs.119274 RAS p21 protein activator (GTPase activa

132173 X89426 X89426 Hs.41716 endothelial cell-specific molecule 1

103371 X91247 X91247 Hs.13046 thioredoxin reductase 1

131584 X91648 AA598509 Hs.29117 purine-rich element binding protein A

103376 X92098 AL036166 Hs.323378 coated vesicle membrane protein

103378 X92110 AL119690 Hs.153618 HCGVIII-1 protein

128510 X94703 X94703 RAB28, member RAS oncogene family

103410 X96506 AA158294 Hs.295362 DR1 -associated protein 1 (negative cofac

133490 X97230 AF022044 Hs.274601 killer cell immunog lobulin-like receptor

332689 X97230 AF022044 Hs.274601 killer cell immunoglobulin-like receptor

103438 X98263 AW175781 Hs.152720 M-phase phosphoprotein 6

103440 X98296 X98296 Hs.77578 ubiquitin specific protease 9, X chromos

103452 X99584 NM_006936Hs.85119 SMT3 (suppressor of mif two 3, yeast) ho

133536 Y00264 W25797.comp Hs.177486 amyloid beta (A4) precursor protein (pro

420234 Y07566 AW404908 Hs.96038 Ric (Drosophila)-like, expressed in many

426502 Y07759 Y07759 Hs.170157 myosin VA (heavy polypeptide 12, myoxin)

134662 Y07827 NM 007048HS.284283 butyrophilin, subfamily 3, member A1

132083 Y07867 BE386490 Hs.279663 Pirin

103500 Y09443 AW408009 Hs.22580 alkylglycerone phosphate synthase

134389 Y09858 Y09858 Hs.82577 spindlin-like

132084 Y12394 NM 002267HS.3886 karyopherin alpha 3 (importin alpha 4)

103540 Z11559 NM 002197Hs.154721 aconitase l, soluble

133152 Z11695 Z11695 Hs.324473 mitogen-activated protein kinase 1

103548 Z15005 Z15005 Hs.75573 centromere protein E (312kD)

103612 Z46261 BE336654 Hs.70937 H3 histone family, member A

129092 AA011243 D56365 Hs.63525 poly(rC)-binding protein 2

103692 AA018418 AW137912 Hs.227583 Homo sapiens chromosome X map Xp11.23 L-

103695 AA018758 ^' AW207152 Hs.186600 ESTs

129796 AA018804 BE218319 Hs.5807 GTPase Rab14

434993 AA031993 AA306325 Hs.4311 SUMO-1 adivating enzyme subunit 2

132683 AA044217 BE264633 Hs.143638 WD repeat domain 4

131887 AA046548 W17064 Hs.332848 SWI/SNF related, matrix associated, acti

103723 AA057447 BE274312 Hs.214783 Homo sapiens cDNA FLJ14041 fis, clone HE

453368 AA058376 W20296 Hs.288178 Homo sapiens cDNA FLJ11968 fis, clone HE

133260 AA083572 AA403045 Hs.6906 Homo sapiens cDNA: FLJ23197 fis, clone R

103765 AA085696 AA085696 Hs.169600 KIAA0826 protein 103766 AA088744 AI920783 Hs.191435 ESTs

103767 AA089688 BE244667 CGI-100 protein

132051 AA091284 AA393968 Hs.180145 HSPC030 protein

103773 AA092700 AI219323 Hs.101077 ESTs, Weakly similar to T22363 hypotheti

135289 AA092968 AW372569 Hs.9788 hypothetical protein MGC10924 similarto

409659 AA094800 AW970843 Hs.55682 eukaryotic translation initiation factor

103794 AA100219 AF244135 Hs.30670 hepatocellular carcinoma-associated anti

131471 AA114885 AA164842 Hs.192619 KIAA1600 protein

134319 AA129547 BE304999 Hs.285754 fumarate hydratase

103807 AA133016 AW958264 Hs.103832 similar to yeast Upf3, variant B

446392 AA149507 AF142419 Hs.15020 homolog of mouse quaking QKI (KH domain

129863 AA151005 BE379765 Hs.129872 sperm associated antigen 9

103850 AA187101 AA187101 Hs.213194 hypothetical protein MGC10895

103855 AA195179 W02363 hypothetical protein FLJ10330

103861 AA206236 AA206236 Hs.4944 hypothetical protein FLJ 12783

130634 AA227621 AI769067 Hs.127824 ESTs, Weakly similar to T28770 hypotheti

447735 AA248283 AA775268 Hs.6127 Homo sapiens cDNA: FLJ23020 fis, clone L

103909 AA249611 AA249611 Hs.47438 SH3 domain binding glufamic acid-rich pr

458928 AA282640 AF043117 Hs.24594 ubiquitination factor E4B (homologous to

415824 AA287199 D42039 Hs.78871 mesoderm development candidate 2

129013 AA313990 AA371156 Hs.107942 DKFZP564M112 protein

129435 AA314256 AF151852 Hs.111449 CGI-94 protein

103988 AA314389 AA314389 Hs.342849 ADP-ribosylation factor-like 5

104000 AA324364 AI146527 Hs.80475 polymerase (RNA) II (DNA directed) polyp

425284 AA329211 AF155568 Hs.348043 NS1 -associated protein 1

128629 AA399187 AL096748 Hs.102708 DKFZP434A043 protein

133281 AA421079 AK001601 Hs.69594 high-mobility group 20A

104104 AA422029 AA422029 Hs.143640 ESTs, Weakly similar to hyperpolarizatio

332455 AA425230 NM_005754Hs.220689 Ras-GTPase-a ivating protein SH3-domain

132091 AA447052 AW954243 KIAA0251 protein

135073 AA452000 W55956 Hs.94030 Homo sapiens mRNA; cDNA DKFZp586E1624 (f

131367 AA456687 AI750575 Hs.173933 nuclear factor l/A

129593 AA487015 AI338247 Hs.98314 Homo sapiens mRNA; cDNA DKFZp586L0120 (f

133505 C01527 AI630124 Hs.324504 Homo sapiens mRNA; cDNA DKFZp586J0720 (f

132064 C01714 AA121098 Hs.3838 serum-inducible kinase

442351 C01811 W52642 Hs.8261 hypothetical protein FLJ22393

131427 C02352 AF151879 Hs.26706 CGI-121 protein

433892 C02375 AI929357 Hs.323966 Homo sapiens clone H63 unknown mRNA

104282 C14448 C14448 Hs.332338 EST

134827 D16611 BE314037 Hs.89866 coproporphyrinogen oxidase (coproporphyr

425330 D25216 D25216 Hs.155650 KIAA0014 gene product

131742 D31352 AA961420 Hs.31433 ESTs

456935 D58024 AA370362 Hs.57958 EGF-TM7-latrophilin-related protein

425218 D80897 NM 014909HS.155182 KIAA1036 protein

104334 D82614 D82614 Hs.78771 phosphoglycerate kinase 1

134593 D87845 NM 000437HS.234392 platelet-activating factor acetylhydrola

134731 D89377 D89377 Hs.89404 msh (Drosophila) homeo box homolog 2

445776 H06583 NM 001310HS.13313 cAMP responsive element binding protein-

131670 H40732 H03514 Hs.15589 ESTs

104394 H46617 AA129551 Hs.172129 Homo sapiens cDNA: FLJ21409 fis, clone C

104402 H56731 H56731 Hs.132956 ESTs

439130 H75570 AA306090 Hs.124707 ESTs

129077 H78886 N74724 Hs.108479 ESTs

104417 H81241 AI819448 Hs.320861 Kruppel-like factor 8

134927 L36531 L36531 Hs.91296 integrin, alpha 8

129280 M63154 M63154 Hs.110014 gastric intrinsic factor (vitamin B synt

134498 M63180 AW246273 Hs.84131 threonyl-tRNA synthetase

104460 M91504 AW955705 Hs.62604 Homo sapiens, clone 1MAGE:4299322, mRNA,

104488 N56191 N56191 Hs.106511 protocadherin 17

131248 N78483 AI038989 Hs.332633 Bardet-Biedl syndrome 2

130017 R14652 AK000096 Hs.143198 inhibitor of growth family, member 3

104530 R20459 AK001676 Hs.12457 hypothetical protein FLJ10814

104534 R22303 R22303 gb:yh26b09.r1 Soares placenta Nb2HP Homo

104544 R33779 AI091173 Hs.222362 ESTs, Weakly similar to p40 [H.sapiens]

133328 R36553 AW452738 Hs.265327 hypothetical protein DKFZp761M41

104567 R64534 AA040620 Hs.5672 hypothetical protein AF140225

129575 R70621 F08282 Hs.278428 progestin induced protein

130776 R79356 AF167706 Hs.19280 cysteine-rich motor neuron 1

104599 R84933 AW815036 Hs.151251 ESTs

104660 AA007160 BE298665 Hs.14846 Homo sapiens mRNA; cDNA DKFZp564D016 (fr

104667 AA007234 AI239923 Hs.63931 ESTs

104718 AA018409 AI143020 Hs.36250 ESTs, Weakly similar to I38022 hypotheti

104764 AA025351 AI039243 Hs.278585 ESTs

104786 AA027168 AA027167 Hs.10031 KIAA0955 protein

104787 AA027317 AA027317 gb:ze97d11.s1 Soares_fetaLheaιt_NbHH19W

134079 AA029423 AK001751 Hs.171835 hypothetical protein FLJ10889 104804 AA031357 AI858702 Hs.31803 ESTs, Weakly similarto N-WASP [H.sapien

104865 AA045136 T79340 Hs.22575 B-cell CLL/lymphoma 6, member B (zinc fi

130828 AA053400 AW631469 Hs.203213 ESTs

104907 AA055829 AA055829 Hs.196701 ESTs, Weakly similarto ALU1_HUMAN ALU S

104943 AA065217 AF072873 Hs.114218 frizzled (Drosophila) homolog 6

105013 AA116054 H63789 Hs.296288 ESTs, Weakly similar to KIAA0638 protein

105024 AA126311 AA126311 Hs.9879 ESTs

132592 AA129390 AW803564 Hs.288850 Homo sapiens cDNA: FLJ22528 fis, clone H

105038 AA130273 AW503733 Hs.9414 KIAA1488 protein

105077 AA142919 W55946 Hs.234863 Homo sapiens cDNA FLJ12082 fis, clone HE

105096 AA150205 AL042506 Hs.21599 Kruppel-like factor 7 (ubiquitous)

129215 AA176867 AB040930 Hs.126085 KIAA1497 protein

105169 AA180321 BE245294 Hs.180789 S164 protein

132796 AA180487 NM 006283HS.173159 transforming, acidic coiled-coil contain

427210 AA187634 BE396283 Hs.173987 eukaryotic translation initiation factor

105200 AA195399 AA328102 Hs.24641 cytoskeleton associated protein 2

130114 AA234717 AA233393 Hs.14992 hypothetical protein FLJ11151

105330 AA234743 AW338625 Hs.22120 ESTs

105337 AA234957 AI468789 Hs.347187 myotubularin related protein 1

422040 AA235604 AA172106 Hs.110950 Rag C protein

105376 AA236559 AW994032 Hs.8768 hypothetical protein FLJ10849

105397 AA242868 AA814807 Hs.7395 hypothetical protein FLJ23182

431679 AA251776 AK000046 Hs.343877 hypothetical protein FLJ20039

131991 AA251909 AF053306 Hs.36708 budding uninhibited by benzimidazoles 1

421305 AA252672 BE397354 Hs.324830 diptheria toxin resistance protein requi

105489 AA256157 AA256157 Hs.24115 Homo sapiens cDNA FLJ14178 fis, clone NT

105508 AA256680 AA173942 Hs.326416 Homo sapiens mRNA; cDNA DKFZp564H1916 (f

105539 AA258873 AB040884 Hs.109694 KIAA1451 protein

135172 AA262727 AB028956 Hs.12144 KIAA1033 protein

131569 AA281451 AL389951 Hs.271623 nucleoporin 50kD

431129 AA281545 AL137751 Hs.263671 Homo sapiens mRNA; cDNA DKFZp434l0812 (f

105643 AA282069 BE621719 Hs.173802 KIAA0603 gene product

105659 AA283044 AA283044 Hs.25625 hypothetical protein FLJ11323

105666 AA283930 AA426234 Hs.34906 ESTs, Weakly similarto T17210 hypotheti

105674 AA284755 AI609530 Hs.279789 histone deacetylase 3

105709 AA291268 AI928962 Hs.26761 DKFZP586L0724 protein

105722 AA291927 AI922821 Hs.32433 ESTs

105765 AA343514 AA299688 Hs.24183 ESTs

115951 AA398109 BE546245 Hs.301048 sec13-like protein

130884 AA398109 BE546245 Hs.301048 sec13-like protein

105962 AA405737 AW880358 Hs.339808 hypothetical protein FLJ10120

105985 AA406610 AA406610 gb:zv15b10.s1 Soares_NhHMPu_S1 Homo sapi

106008 AA411465 AB033888 Hs.8619 SRY (sex determining region Y)-box 18

457322 AA416886 AI815486 Hs.243901 Homo sapiens cDNA FLJ20738 fis, clone HE

134222 AA424013 AW855861 Hs.8025 Homo sapiens clone 23767 and 23782 mRNA

446954 AA424148 AB037850 Hs.16621 DKFZP434I116 protein

106141 AA424558 AF031463 Hs.9302 phosducin-like

447973 AA424961 AB011169 Hs.20141 similarto S. cerevisiae SSM4

106157 AA425367 W37943 Hs.34892 KIAA1323 protein

428314 AA425921 AW135049 Hs.26285 Homo sapiens cDNA FLJ10643 fis, clone NT

446727 AA426220 AB011095 Hs.16032 KIAA0523 protein

106196 AA427735 AA525993 Hs.173699 ESTs, Weakly similarto ALU1_HUMAN ALU S

457714 AA430673 AA083764 hypothetical protein MGC3178

133200 AA432248 AB037715 Hs.183639 hypothetical protein FLJ10210

106302 AA435896 AA398859 Hs.18397 hypothetical protein FLJ23221

106328 AA436705 AL079559 Hs.28020 KIAA0766 gene product

450534 AA446561 AI570189 Hs.25132 KIAA0470 gene product

106423 AA448238 AB020722 Hs.16714 Rho guanine exchange factor (GEF) 15

439608 AA449756 AW864696 Hs.301732 hypothetical protein MGC5306

106477 AA450303 R23324 Hs.41693 DnaJ (Hsp40) homolog, subfamily B, membe

106503 AA452411 AB033042 Hs.29679 cofactor required forSpl transcriptiona

446999 AA454566 AA151520 hypothetical protein MGC4485

106543 AA454667 AA676939 Hs.69285 neuropilin 1

442007 AA456437 AA301116 Hs.142838 nucleolarphosphoprotein Nopp34

106589 AA456646 AK000933 Hs.28661 Homo sapiens cDNA FLJ10071 fis, clone HE

106593 AA456826 AW296451 Hs.24605 ESTs

106596 AA456981 AA452379 ESTs, Moderately similar to ALU7_HUMAN A

423064 AA458959 AF265208 Hs.8740 SWI/SNF related, matrix associated, acti

106636 AA459950 AW958037 Hs.286 ribosomal protein L4

106654 AA460449 AW075485 Hs.286049 phosphoserine aminotransferase

131353 AA463910 AW754182 gb:RC2-CT0321-131199-011-c01 CT0321 Homo

106707 AA464603 AK000566 Hs.98135 hypothetical protein FLJ20559

452909 AA464606 NM 015368HS.30985 pannexin 1

106717 AA465093 AA600357 Hs.239489 TIA1 cytotoxic granule-associated RNA-bi

453141 AA465692 AB014548 Hs.31921 KIAA0648 protein

106747 AA476473 NM 007118HS.171957 triple functional domain (PTPRF interact 106773 AA478109 AA478109 Hs.188833 ESTs

106781 AA478474 AA330310 Hs.24181 ESTs

106817 AA480889 D61216 Hs.18672 ESTs

106846 AA485223 AB037744 Hs.34892 KIAA1323 protein

106848 AA485254 AA449014 Hs.121025 chromosome 11 open reading frame 5

106856 AA486183 W58353 Hs.285123 Homo sapiens mRNA full length insert cDN

418699 AA496936 BE539639 Hs.173030 ESTs, Weakly similar to ALU8_HUMAN ALU S

107001 AA598589 AI926520 Hs.31016 putative DNA binding protein

442853 AA598831 AW021276 Hs.17 21 ESTs

107054 AA600150 A1076459 Hs.15978 KIAA1272 protein

107059 AA608545 BE614410 Hs.23044 RAD51 (S. cerevisiae) homolog (E coli Re

107080 AA609210 AL122043 Hs.19221 hypothetical protein DKFZp566G1424

107115 AA610108 BE379623 Hs.27693 peptidylprolyl isomerase (cyclophilin)-l

107130 AA620582 AB033106 Hs.12913 KIAA1280 protein

107156 AA621239 AA137043 Hs.9663 programmed cell death 6-interading prat

107174 AA621714 BE122762 Hs.25338 ESTs

130621 AA621718 AW513087 Hs.16803 LUC7 (S. cerevisiae)-like

107190 D19673 AA836401 Hs.87860 ESTs

132626 D25755 AW504732 Hs.21275 hypothetical protein FLJ11011

107217 D51095 AL080235 Hs.35861 DKFZP586E1621 protein

332584 D60272 AA357879 Hs.29423 ESTs; Weakly similarto macrophage lecti

444655 T08879 AF088886 Hs.11590 cathepsin F

107295 T34527 AA186629 Hs.80120 UDP-N-acetyl-alpha-D-galactosamine:polyp

107299 T40327 BE277457 Hs.30661 hypothetical protein MGC4606

107315 T62771 AA316241 Hs.90691 nudeophosmin/nucleoplasmin 3

107316 T63174 T63174 Hs.193700 Homo sapiens mRNA; cDNA DKFZp586l0324 (f

107328 T83444 AW959891 Hs.76591 KIAA0887 protein

107334 T93641 T93597 Hs.187429 ESTs

456340 U48263 U48263 Hs.89040 prepronociceptin

128636 U49065 U49065 Hs.102865 interieukin 1 receptor-like 2

129938 U79300 AW003668 Hs.135587 Human clone 23629 mRNA sequence

107375 U88573 BE011845 Hs.251064 high-mobility group (nonhistone chromoso

130074 U93867 AL038596 Hs.250745 polymerase (RNA) III (DNA directed) (62k

107387 W01094 D86983 Hs.118893 Melanoma associated gene

132036 W01568 AL157433 Hs.37706 hypothetical protein DKFZp434E2220

107426 W26853 W26853 Hs.291003 hypothetical protein MGC4707

135388 W27965 W27965 Hs.99865 epimorphin

130419 W36280 AF037448 Hs.155489 NS1-associated protein 1

107469 W47063 W47063 Hs.94668 ESTs

434203 W79060 BE262677 Hs.283558 hypothetical protein PR01855

107506 W88550 AB028981 Hs.8021 KIAA1058 protein

132358 X60486 NM 003542HS.46423 H4 histone family, member G

107522 X78931 X78931 Hs.99971 zinc finger protein 272

456495 Z14077 NM 003403HS.97496 YY1 transcription factor

107582 AA002147 AA002147 Hs.59952 EST

107609 AA004711 R75654 Hs.164797 hypothetical protein FLJ13693

107661 AA010383 AA010383 Hs.60389 ESTs

107714 AA015761 AA015761 Hs.60642 ESTs

107775 AA018772 AW008846 Hs.60857 ESTs

107832 AA021473 AA021473 gb:ze66c11.s1 Soares retina N2b4HR Homo

107859 AA024835 AW732573 Hs.47584 potassium voltage-gated channel, delayed

107914 AA027229 AA027229 Hs.61329 ESTs, Weakly similar to T16370 hypotheti

107935 AA029428 AA029428 Hs.61555 ESTs

410196 AA035143 AI936442 Hs.59838 hypothetical protein FLJ10808

131461 AA035237 AA992841 Hs.27263 KIAA1458 protein

108007 AA039347 AA039347 Hs.61916 EST

108029 AA040740 AA040740 Hs.62007 ESTs

108040 AA041551 AL121031 Hs.159971 SWI/SNF related, matrix associated, acti

108084 AA045513 AA058944 Hs.116602 Homo sapiens, clone IMAGE:4154008, mRNA,

108088 AA045745 AA045745 Hs.62886 ESTs

108168 AA055348 AI453137 Hs.63176 ESTs

130719 AA056582 AA679262 Hs.14235 hypothetical protein FLJ20008; KIAA1839

108189 AA056697 AW376061 Hs.63335 ESTs, Moderately similar to A46010 X-lin

108190 AA056746 AA056746 Hs.63338 EST

108203 AA057678 AW847814 Hs.289005 Homo sapiens cDNA: FLJ21532 fis, clone C

108216 AA058681 AA524743 Hs.44883 ESTs

108217 AA058686 AA058686 Hs.62588 ESTs

108245 AA062840 BE410285 Hs.89545 proteasome (prosome, macropain) subunit,

108277 AA064859 AA064859 gb:zm50f03.s1 Stratagene fibroblast (937

108280 AA065069 AA065069 gb:zm12e11.s1 Stratagene pancreas (93720

108309 AA069923 AA069818 gb:zm67e03.r1 Stratagene neuroepithelium

108340 AA070815 AA069820 Hs.180909 peroxiredoxin 1

108403 AA075374 AA075374 gb:zm87a01.s1 Stratagene ovarian cancer

108427 AA076382 AA076382 gb:zm91g08.s1 Stratagene ovarian cancer

108435 AA078787 T82427 Hs.194101 Homo sapiens cDNA: FLJ20869 fis, clone A

108439 AA078986 AA078986 gb:zm92h01.s1 Stratagene ovarian cancer 108465 AA079393 AA079393 Hs.3462 cytochrome c oxidase subunit Vile

108469 AA079487 AA079487 gb:zm97f08.s1 Stratagene colon HT29 (937

108500 AA083207 AA083207 Hs.68270 EST

108501 AA083256 AA083256 gb:zn08g12.s1 Stratagene hNT neuron (937

108533 AA084415 AA084415 gb:zn06g09.s1 Stratagene hNT neuron (937

108562 AA085274 AA100796 gb:zm26c06.s1 Stratagene pancreas (93720

108589 AA088678 AI732404 Hs.68846 ESTs

130890 AA100925 AI907537 Hs.76698 stress-associated endoplasmic reticulum

432645 AA101255 D14041 Hs.347340 H-2K binding factor-2

130385 AA126474 AW067800 Hs.155223 stanniocalcin 2

108749 AA127017 AA127017 Hs.71052 ESTs

108807 AA129968 AI652236 Hs.49376 hypothetical protein FLJ20644

108808 AA130240 AA045088 Hs.62738 ESTs

108833 AA131866 AF188527 Hs.61661 ESTs, Weakly similarto AF174605 1 F-box

108846 AA132983 AL117452 Hs.44155 DKFZP586G1517 protein

108857 AA133250 AK001468 Hs.62180 anillin (Drosophila Scraps homolog), act

131474 AA133583 L46353 Hs.2726 high-mobility group (nonhistone chromoso

108894 AA135941 AK001431 Hs.5105 hypothetical protein FLJ10569

108941 AA148650 AA148650 gb:zo09e06.s1 Stratagene neuroepithelium

108968 AA151110 AI304870 Hs.188680 ESTs

108996 AA155754 AW995610 Hs.332436 EST

109001 AA156125 AI056548 Hs.72116 hypothetical protein FLJ20992 similarto

131183 AA156289 AI611807 Hs.285107 hypothetical protein FLJ13397

109019 AA156997 AA156755 Hs.72150 ESTs

109022 AA157291 AA157291 Hs.21479 ubinuclein 1

109023 AA157293 AA157293 Hs.72168 ESTs

109068 AA164293 AA164293 Hs.72545 ESTs

109072 AA164676 AI732585 Hs.22394 hypothetical protein FLJ10893

426981 AA167375 AL044675 Hs.173081 KIAA0530 protein

130346 AA167550 H05769 Hs.188757 Homo sapiens, clone MGC:5564, mRNA, comp

109146 AA176589 AA176589 Hs.142078 EST

109172 AA180448 AA180448 Hs.144300 EST

428438 AA187144 NM 001955HS.2271 endothelin 1

129208 AA189170 AI587376 Hs.109441 MSTP033 protein

109222 AA192757 AA192833 Hs.333512 similar to rat myomegalin

109300 AA205650 AA418276 Hs.170142 ESTs

109481 AA233342 AA878923 Hs.289069 hypothetical protein FLJ21016

109485 AA233472 BE619092 Hs.28465 Homo sapiens cDNA: FLJ21869 fis, clone H

109516 AA234110 AI471639 Hs.71913 ESTs

109537 D80981 AI858695 Hs.34898 ESTs

109556 F01660 AI925294 Hs.87385 ESTs

109577 F02206 F02206 Hs.296639 Homo sapiens potassium channel subunit (

109578 F02208 F02208 Hs.27214 ESTs

109595 F02544 AA078629 Hs.27301 ESTs

109625 F03918 H29490 Hs.22697 ESTs

428376 F04258 AF119665 Hs.184011 pyrophosphatase (inorganic)

109648 F04600 H17800 Hs.7154 ESTs

109671 F08998 R59210 Hs.26634 ESTs

109699 F09605 H18013 Hs.167483 ESTs

109820 F11115 AW016809 Hs.119021 ESTs

109933 H06371 R52417 Hs.20945 Homo sapiens clone 24993 mRNA sequence

110014 H10995 AL109666 Hs.7242 Homo sapiens mRNA full length insert cDN

110039 H11938 H11938 Hs.21907 histone acetyltransferase

110099 H16568 R44557 Hs.23748 ESTs

110107 H16772 AW151660 Hs.31444 ESTs

110155 H18951 AI559626 Hs.93522 Homo sapiens mRNA for KIAA1647 protein,

110197 H20859 AW090386 Hs.112278 arrestin, beta 1

110223 H23747 H19836 Hs.31697 ESTs

110306 H38087 H38087 Hs.105509 CTL2gene

110335 H40331 H65490 Hs.18845 ESTs

110342 H40567 H40961 Hs.33008 ESTs

110395 H46966 AA025116 Hs.33333 ESTs

110511 H56640 H56640 Hs.221460 ESTs

110523 H57154 AI040384 Hs.19102 ESTs, Weakly similar to organic anion tr

110715 H96712 H96712 Hs.269029 ESTs

110754 N20814 AW302200 Hs.6336 KIAA0672 gene product

428454 N25249 U55936 Hs.184376 synaptosomal-associated protein, 23kD

431663 N27100 NM_016569Hs.267182 TBX3-iso protein

134263 N39616 AW973443 Hs.8086 RNA (guanine-7-) methyltransferase

110938 N48982 N48982 Hs.38034 Homo sapiens cDNA FLJ12924 fis, clone NT

110983 N51957 NM 015367HS.10267 MIL1 protein

111081 N59435 AI146349 Hs.271614 CGI-112 protein

111128 N64139 AW505364 Hs.19074 LATS (large tumor suppressor, Drosophila

431548 N66981 AI834273 Hs.9711 novel protein

111216 N68640 AW139408 Hs.152940 ESTs

437562 N69352 AB001636 Hs.5683 DEAD/H (Asp-Glu-Ala-Asp/His) box polypep 111399 R00138 AW270776 Hs.18857 ESTs

111514 R07998 R07998 gb:yf16g11.s1 Soares fetal liver spleen

428744 R08929 BE267033 Hs.192853 ubiquitin-conjugating enzyme E2G 2 (homo

111574 R10307 AI024145 Hs.188526 ESTs

111804 R33354 AA482478 Hs.181785 ESTs

111831 R36083 R36095 Hs.268695 ESTs

426773 R37938 NM_015556Hs.172180 KIAA0440 protein

111904 R39330 Z41572 gb:HSCZYB122 normalized infant brain cDN

428371 R40816 AB012193 Hs.183874 cullin 4A

112033 R43162 R49031 Hs.22627 ESTs

130987 R45698 BE613269 Hs.21893 hypothetical protein DKFZp761N0624

112300 R54554 H24334 Hs.26125 ESTs

112513 R68425 R68425 Hs.13809 hypothetical protein FLJ10648

112514 R68568 R68568 Hs.183373 src homology 3 domain-containing protein

112522 R68763 R68857 Hs.265499 ESTs

112540 R70467 R69751 gb:yi40a10.s1 Soares placenta Nb2HP Homo

428655 R73565 H05769 Hs.188757 Homo sapiens, clone MGC:5564, mRNA, comp

129534 R73640 AK002126 Hs.11260 hypothetical protein FLJ11264

112597 R78376 R78376 Hs.29733 EST

112732 R92453 R92453 Hs.34590 ESTs

451798 T03865 BE297567 Hs.27047 hypothetical protein FLJ20392

112888 T03872 AW195317 Hs.107716 hypothetical protein FLJ22344

131863 T10072 AI656378 Hs.33461 ESTs

112911 T10080 AW732747 Hs.13493 like mouse brain protein E46

132215 T10132 AL035703 Hs.4236 KIAA0478 gene product

112931 T15343 T02966 Hs.167428 ESTs

112984 T23457 T16971 Hs.289014 ESTs, Weakly similarto A43932 mucin 2 p

112998 T23555 H11257 Hs.22968 Homo sapiens clone IMAGE:451939, mRNA se

133376 T23670 BE618768 Hs.7232 acetyl-Coenzyme A carboxylase alpha

113026 T23948 AA376654 eukaryotic translation initiation factor

113070 T33464 AB032977 Hs.6298 KIAA1151 protein

410781 T34413 AI375672 Hs.165028 ESTs

113074 T34611 AK001335 Hs.31137 protein tyrosine phosphatase, receptor t

113095 T40920 AA828380 Hs.126733 ESTs

113179 T55182 BE622021 Hs.152571 ESTs, Highly similarto IGF-II mRNA-bind

113337 T77453 T77453 Hs.302234 ESTs

113421 T84039 AI769400 Hs.189729 ESTs

113454 T86458 AI022166 Hs.16188 ESTs

113481 T87693 T87693 Hs.204327 EST

453345 T89350 AA302862 Hs.90063 neurocalcin delta

113557 T90945 H66470 Hs.16004 ESTs

113559 T90987 T79763 Hs.14514 ESTs

113589 T91863 AI078554 Hs.15682 ESTs

113591 T91881 T91881 Hs.200597 KIAA0563 gene product

113619 T93783 R08665 Hs.17244 hypothetical protein FLJ13605

113683 T96687 AB035335 Hs.144519 T-cell leukemia/lymphoma 6

113692 T96944 AL360143 Hs.17936 DKFZP434H132 protein

113702 T97307 T97307 gb:ye53h05.s1 Soares fetal liver spleen

113717 T97764 T99513 Hs.187447 ESTs

113824 W48817 AI631964 Hs.34447 ESTs

113840 W58343 R72137 Hs.7949 DKFZP586B2420 protein

113844 W59949 AI369275 Hs.243010 Homo sapiens cDNA FLJ14445 fis, clone HE

113902 W74644 AA340111 Hs.100009 acyl-Coenzyme A oxidase 1 , palmitoyl

113904 W74761 AF125044 Hs.19196 ubiquitin-conjugating enzyme HBUCE1

113905 W74802 R81733 Hs.33106 ESTs

113931 W81205 BE255499 Hs.3496 hypothetical protein MGC15749

113932 W81237 AA256444 Hs.126485 hypothetical protein FLJ12604; KIAA1692

131965 W90146 W79283 Hs.35962 ESTs

114035 W92798 W92798 Hs.269181 ESTs

114106 Z38412 AW602528 gb:RC5-BT0562-260100-011-A02 BT0562 Homo

457308 Z38709 AI416988 Hs.238272 inositol 1,4,5-triphosphate receptor, ty

114161 Z38904 BE548222 Hs.299883 hypothetical protein FLJ23399

424949 Z39103 AF052212 Hs.153934 core-binding factor, runt domain, alpha

457548 Z39930 AW069534 Hs.279583 CGI-81 protein

128937 Z39939 AA251380 Hs.10726 ESTs, Weakly similarto ALU1_HUMAN ALU S

432554 Z40012 AI479813 Hs.278411 NCK-associated protein 1

114277 Z40377 AI052229 Hs.25373 ESTs, Weakly similarto T20410 hypotheti

114304 Z40820 AI934204 Hs.16129 ESTs

114364 Z41680 AL117427 Hs.172778 Homo sapiens mRNA; cDNA DKFZp566P013 (fr

432620 AA005112 AA777749 Hs.5978 LIM domain only 7

129034 AA005432 AA481157 Hs.108110 DKFZP547E2110 protein

131881 AA010163 AW361018 Hs.3383 upstream regulatory element binding prot

332421 AA026356 AI909968 Hs.108106 transcription factor

114465 AA026901 BE621056 Hs.131731 hypothetical protein FLJ11099

451271 AA036867 AK001644 Hs.26156 hypothetical protein FLJ10782

332498 AA044644 AA303661 lymphocyte-specific protein 1 431555 AA046426 AI815470 Hs.260024 Cdc42 effector protein 3

132944 AA054515 T96641 Hs.6127 Homo sapiens cDNA: FLJ23020 fis, clone L

114618 AA084162 AW979261 Hs.291993 ESTs

332509 AA085749 AA128376 Hs.153884 ATP binding protein associated with cell

114648 AA101056 AA101056 gb:zn25b03.s1 Stratagene neuroepithelium

114658 AA102746 AA102383 Hs.249190 tumor necrosis factor receptor superfami

132456 AA114250 AB011084 Hs.48924 KIAA0512 gene product; ALEX2

450847 AA126561 NM 003155HS.25590 stanniocalcin 1

132225 AA128980 AA128980 gb:zo09a11.s1 Stratagene neuroepithelium

437197 AA129757 W38586 guanine nucleotide binding protein (G pr

114709 AA129921 AA397651 Hs.301959 proline synthetase co-transcribed (ba e

456926 AA133331 AB018284 Hs.158688 KIAA0741 gene product

114750 AA135958 AA887211 Hs.129467 ESTs

426806 AA136524 T19228 Hs.172572 hypothetical protein FLJ20093

114763 AA147044 AA810755 Hs.102500 hypothetical protein dJ511E16.2

114767 AA148885 AI859865 Hs.154443 minichromosome maintenance deficient (S.

114774 AA150043 AV656017 Hs.184325 CGI-76 protein

129388 AA151621 AA662477 Hs.110964 hypothetical protein FLJ23471

457742 AA155743 BE561824 Hs.273369 uncharaderized hematopoietic stem/proge

456200 AA156335 AA768242 Hs.80618 hypothetical protein

130207 AA156336 AF044209 Hs.144904 nuclear receptor co-repressor 1

114798 AA159181 AA159181 Hs.54900 serologically defined colon cancer antig

114800 AA159825 Z19448 Hs.131887 ESTs, Weakly similar to T24396 hypotheti

114828 AA234185 AA252937 Hs.283522 Homo sapiens mRNA; cDNA DKFZp434J1912 (f

114846 AA234929 BE018682 Hs.166196 ATPase, Class I, type 8B, member 1

114848 AA234935 BE614347 Hs.169615 hypothetical protein FLJ20989

114902 AA236359 AW275480 Hs.39504 hypothetical protein MGC4308

132271 AA236466 AB030034 Hs.115175 sterile-alpha motif and leucine zipper c

114907 AA236535 N29390 Hs.13804 hypothetical protein dJ462023.2

420170 AA236935 U43374 Hs.95631 Human normal keratinocyte mRNA

132204 AA236942 AA235827 Hs.42265 ESTs

114928 AA237018 AA237018 Hs.94869 ESTs

132481 AA237025 W93378 Hs.49614 ESTs

114932 AA242751 AA971436 Hs.16218 KIAA0903 protein

314162 AA242760 BE041820 Hs.38516 Homo sapiens, clone MGC:15887, mRNA, com

131006 AA242763 AF064104 Hs.22116 CDC14 (cell division cycle 14, S. cerevi

114935 AA242809 H23329 Hs.290880 ESTs, Weakly similar to ALU1JHUMAN ALU S

408908 AA243133 BE296227 Hs.250822 serine/threonine kinase 15

437754 AA243495 R60366 Hs.5822 Homo sapiens cDNA: FLJ22120 fis, clone H

114957 AA243706 AW170425 Hs.87680 ESTs

114974 AA250848 AW966931 Hs.302649 nucleosome assembly protein 1 -like 1

114977 AA250868 AW296978 Hs.87787 ESTs

114995 AA251152 AA769266 Hs.193657 ESTs

115005 AA251544 AI760825 Hs.153042 ESTs

417177 AA251792 NM 004458HS.81452 fatty-acid-Coenzyme A ligase, long-chain

115026 AA252144 AA251972 Hs.188718 ESTs

115045 AA252524 AW014549 Hs.58373 ESTs

115068 AA253461 AW512260 Hs.87767 ESTs

133138 AA255522 AV657594 Hs.181161 Homo sapiens cDNA FLJ14643 fis, clone NT

332668 AA255522 AV657594 Hs.181161 ESTs

115114 AA256468 AA527548 Hs.7527 small fragment nuclease

129584 AA256528 AV656017 Hs.184325 CGI-76 protein

115137 AA257976 AW968304 Hs.56156 ESTs

417187 AA258296 AB011151 Hs.334659 hypothetical protein MGC14139

115166 AA258409 AF095727 Hs.287832 myelin protein zero-like 1

115167 AA258421 AA749209 Hs.43728 hypothetical protein

436719 AA262077 Y11192 Hs.5299 aldehyde dehydrogenase 5 family, member

115239 AA278650 BE251328 Hs.73291 hypothetical protein FLJ10881

115243 AA278766 AA806600 Hs.116665 KIAA1842 protein

428419 AA280791 U49436 KIAA1856 protein

115322 AA280819 L08895 Hs.78995 MADS box transcription enhancer factor 2

413303 AA280828 AW836130 Hs.75277 hypothetical protein FLJ13910

115372 AA282195 AW014385 Hs.88678 ESTs, Weakly similar to Unknown [H.sapie

409962 AA283127 U82671 Hs.57698 Target CAT

130269 AA284694 F05422 Hs.168352 nucleoporin-like protein 1

456570 AA291137 AA286914 Hs.183299 ESTs

332675 AA291708 BE439944 ESTs

407864 AA293495 AF069291 Hs.40539 chromosome 8 open reading frame 1

115536 AA347193 AK001468 Hs.62180 anillin (Drosophila Scraps homolog), act

408799 AA398474 AA059412 Hs.47986 hypothetical protein MGC10940

115575 AA398512 AA393254 Hs.43619 ESTs

115601 AA400277 AA148984 Hs.48849 ESTs, Weakly similarto ALU4_HUMAN ALU S

434428 AA400896 D14540 Hs.199160 myeloid/lymphoid or mixed-lineage leukem

115683 AA410345 AF255910 Hs.54650 jun ional adhesion molecule 2

115715 AA416733 BE395161 Hs.1390 proteasome (prosome, macropain) subunit,

132952 AA425154 AI658580 Hs.61426 Homo sapiens mesenchymal stem cell prate 115819 AA426573 AA486620 Hs.41135 endomucin-2

409124 AA431418 AW292809 Hs.50727 N-acetylglucosaminidase, alpha- (Sanfili

115895 AA436182 AB033035 Hs.51965 KIAA1209 protein

458073 AA437099 AA192669 Hs.45032 ESTs

115962 AA446585 AI636361 Hs.179520 hypothetical protein MGC10702

115967 AA446887 AI745379 Hs.42911 ESTs

115974 AA447224 BE513442 Hs.238944 hypothetical protein FLJ10631

115985 AA447709 AA447709 Hs.268115 ESTs, Weakly similar to T0B599 probable

129254 AA453624 AA252468 Hs.1098 DKFZp434J1813 protein

446730 AA455044 BE384932 Hs.64313 ESTs, Weakly similarto AF2571821 G-pro

116095 AA456045 AA043429 Hs.62618 ESTs

426856 AA460454 R19768 Hs.172788 ALEX3 protein

116210 AA476494 BE622792 Hs.172788 ALEX3 protein

116213 AA476738 AA292105 Hs.326740 hypothetical protein MGC10947

432645 AA481422 D14041 Hs.347340 H-2K binding factor-2

116265 AA482595 BE297412 Hs.55189 hypothetical protein

129334 AA485084 AW157022 Hs.343551 hypothetical protein FLJ22584

116274 AA485431 AI129767 Hs.182874 guanine nucleotide binding protein (G pr

426002 AA489638 BE514376 Hs.165998 PAI-1 mRNA-binding protein

116331 AA491000 N41300 Hs.71616 Homo sapiens mRNA; cDNA DKFZp586N1720 (f

116333 AA491250 AF155827 Hs.203963 hypothetical protein FLJ10339

132994 AA505133 AA112748 Hs.279905 clone HQ0310 PRO0310p1

418538 AA598447 BE244323 Hs.85951 exportin, tRNA (nuclear export receptor

116391 AA599243 T86558 Hs.75113 general transcription factor IIIA

116394 AA599574 NM 006033HS.65370 lipase, endothelial

134531 AA600153 AI742845 Hs.110713 DEK oncogene (DNA binding)

116417 AA609309 AW499664 Human clone 23826 mRNA sequence

116429 AA609710 AF191018 Hs.279923 putative nucleotide binding protein, est

116439 AA610068 AA251594 Hs.43913 P1BF1 gene product

116459 AA621399 R80137 Hs.302738 Homo sapiens cDNA: FLJ21425 fis, clone C

427505 AA621752 AA361562 Hs.178761 26S proteasome-associated padl homolog

409633 C21523 AW449822 Hs.55200 ESTs

116541 D12160 D12160 Hs.249212 polymerase (RNA) III (DNA directed) (155

132557 D19708 AA114926 Hs.169531 ESTs

414964 D25801 AA337548 Hs.333402 hypothetical protein MGC12760

116571 D45652 D45652 Hs.211604 gb:HUMGS02848 Human adult lung 3' direct

451522 D60208 BE565817 Hs.26498 hypothetical protein FLJ21657

421919 D80504 AJ224901 Hs.109526 zinc finger protein 198

116643 F03010 A1367044 Hs.153638 myeloid/lymphoid or mixed-lineage leukem

116661 F04247 R61504 gb:yh16a03.s1 Soares infant brain 1NIB H

116715 F10966 AL117440 Hs.170263 tumor protein p53-binding protein, 1

116729 F13700 BE549407 Hs.115823 ribonuclease P, 40kD subunit

318709 H05063 R52576 Hs.285280 Homo sapiens cDNA: FLJ22096 fis, clone H

418999 H16758 NM 000121HS.89548 erythropoietin receptor

116773 H17315 AI823410 Hs.343581 karyopherin alpha 1 (importin alpha 5)

116780 H22566 H22566 Hs.63931 ESTs

453884 H48459 AA355925 Hs.36232 KIAA0186 gene product

116819 H53073 H53073 Hs.93698 EST

427278 H56559 AL031428 Hs.174174 KIAA0601 protein

407833 H57957 AW955632 Hs.66666 ESTs, Weakly similarto S19560 proline-r

116844 H64938 H64938 Hs.337434 ESTs, Weakly similar to A46010 X-linked

116845 H64973 AA649530 Hs.348148 gb:ns44f05.s1 NCI CGAP Alv1 Homo sapiens

116892 H69535 AI573283 Hs.38458 ESTs

116925 H73110 H73110 Hs.260603 ESTs, Moderately similarto A47582 B-cel

116981 H81783 N29218 Hs.40290 ESTs

453133 H86259 AC005757 Hs.31809 hypothetical protein

117031 H88353 H88353 Hs.347265 gb:yw21a02.s1 Morton Fetal Cochlea Homo

117034 H88639 U72209 YY1-associated factor 2

431129 H88675 AL137751 Hs.263671 Homo sapiens mRNA; cDNA DKFZp434l0812 (f

417861 H93708 AA334551 sperm specific antigen 2

117280 N22107 M18217 Hs.172129 Homo sapiens cDNA: FLJ21409 fis, clone C

117344 N24046 R19085 Hs.210706 Homo sapiens cDNA FLJ13182 fis, clone NT

117422 N27028 AI355562 Hs.43880 ESTs, Weakly similar to A46010 X-linked

117475 N30205 N30205 Hs.93740 ESTs, Weakly similarto I38022 hypotheti

117487 N30621 N30621 Hs.44203 ESTs

117937 N33258 AF044209 Hs.144904 nuclear receptor co-repressor 1

130207 N33258 AF044209 Hs.144904 nuclear receptor co-repressor 1

117549 N33390 N33390 Hs.44483 EST

117683 N40180 N40180 gb:yy44d02.s1 Soares_mulfiple_scierosis_

117710 N45198 N45198 Hs.47248 ESTs, Highly similar to similar to Cdc14

117791 N48325 N48325 Hs.93956 EST

117822 N48913 AA706282 Hs.93963 ESTs

422544 N49394 AB018259 Hs.118140 KIAA0716 gene product

117895 N50656 AW450348 Hs.9399δ ESTs, Highly similarto SORL_HUMAN SORTI

452259 N50721 AA317439 Hs.28707 signal sequence receptor, gamma (translo

133057 N53143 AA465131 Hs.64001 Homo sapiens clone 25218 mRNA sequence 118103 N55326 AA401733 Hs.184134 ESTs

118111 N55493 N55493 gb:yv50c02.s1 Soares fetal liver spleen

118129 N57493 N57493 gb:yy54c08.s1 Soares_multiple_sclerosis_

118278 N62955 N62955 Hs.316433 Homo sapiens cDNA FLJ11375 fis, clone HE

118329 N63520 N63520 gb:yy62f01.s1 Soares multiple sclerosis

118336 N63604 BE327311 Hs.47166 HT021

417098 N64166 AB017365 Hs.173859 frizzled (Drosophila) homolog 7

118363 N64168 AI183838 Hs.48938 hypothetical protein FLJ21802

118364 N64191 N46114 Hs.29169 hypothetical protein FLJ22623

118475 N66845 N66845 gb:za46c11.s1 Soares fetal liver spleen

118491 N67135 AV647908 Hs.90424 Homo sapiens cDNA: FLJ23285 fis, clone H

118500 N67295 W32889 Hs.154329 ESTs

118584 N68963 AW136928 gb:UI-H-BI1-adp-d-08-0-Ul.s1 NCl_CGAP_Su

456647 N69331 AI252640 Hs.110364 peptidylprolyl isomerase C (cyclophilin

118661 N70777 AL137554 Hs.49927 protein kinase NYD-SP15

118684 N71364 N71313 Hs.163986 Homo sapiens cDNA: FLJ22765 fis, clone K

118689 N71545 AW390601 Hs.184544 Homo sapiens, clone IMAGE:3355383, mRNA,

118690 N71571 N71571 Hs.269142 ESTs

118766 N74456 N74456 Hs.50499 EST

118793 N75594 N75594 Hs.285921 ESTs, Moderately similarto T47135 hypot

118817 N79035 AI668658 Hs.50797 ESTs

118844 N80279 AL035364 Hs.50891 hypothetical protein

118919 N91797 AW452696 Hs.130760 myosin phosphatase, target subunit 2

129558 N92454 AW580922 Hs.180446 kaiyopherin (importin) beta 1

407604 N94581 AW191962 Hs.288061 collagen, type VIII, alpha 2

118996 N94746 N94746 Hs.274248 hypothetical protein FLJ20758

119021 N98238 N98238 Hs.55185 ESTs

119039 R02384 AI160570 Hs.252097 pregnancy specific beta-1-glycoprotein 6

119063 R16833 R16833 Hs.53106 ESTs, Moderately similarto ALU1_HUMAN A

332622 R41828 R10674 CSR1 protein

119111 R43203 T02865 Hs.328321 EST

415115 R46395 AA214228 Hs.127751 hypothetical protein

119146 R58863 R58863 Hs.91815 ESTs

449224 R78248 AW995911 Hs.299883 hypothetical protein FLJ23399

119239 T11483 T11483 gb:CHR90049 Chromosome 9 exon Homo sapie

119281 T16896 AI692322 Hs.65373 ESTs, Weakly similarto T02345 hypotheti

119298 T23820 NM 001241HS.155478 cyclin T2

126502 T30222 T10077 Hs.13453 hypothetical protein FLJ14753

419983 W15275 W55956 Hs.94030 Homo sapiens mRNA; cDNA DKFZp586E1624 (f

119558 W38194 W38194 Empirically selected from AFFX single pr

429641 W42414 AW081883 Hs.211578 Homo sapiens cDNA: FLJ23037 fis, clone L

419445 W49632 AA884471 Hs.90449 Human clone 23908 mRNA sequence

119650 W57613 R82342 Hs.79856 ESTs, Weakly similarto S65657 alpha-1C-

119654 W57759 W57759 gb:zd20g11.s1 Soares fetal heart_NbHH19W

119683 W61118 W65379 Hs.57835 ESTs

119694 W65344 AA041350 Hs.57847 ESTs, Moderately similar to ICE4JHUMAN C

119718 W69216 W69216 Hs.92848 ESTs

410365 W69379 AI287518 Homo sapiens mRNA; cDNA DKFZp586D0923 (f

119938 W86728 AW014862 Hs.58885 ESTs

120128 Z38499 BE379320 Hs.91448 MKP-1 like protein tyrosine phosphatase

120130 Z38630 AA045767 Hs.5300 bladder cancer associated protein

120148 Z39494 F02806 Hs.65765 ESTs

120155 Z39623 Z39623 Hs.65783 ESTs

451979 Z40071 F06972 Hs.27372 BMX non-receptor tyrosine kinase

120183 Z40174 AW082866 Hs.65882 ESTs

120184 Z40182 Z40182 Hs.65885 EST

120211 Z40904 Z40904 Hs.66012 EST

120245 AA166965 AW959615 Hs.111045 ESTs

120247 AA167500 AA167500 Hs.103939 EST

120254 AA169599 W90403 Hs.111054 ESTs

120259 AA171724 AW014786 Hs.192742 hypothetical protein FLJ12785

120260 AA171739 AK000061 Hs.101590 hypothetical protein

120275 AA177105 AA177105 Hs.78457 solute carrier family 25 (mitochondrial

120284 AA182626 AA179656 gb:zp54e11.s1 Stratagene NT2 neuronal pr

417735 AA186324 AA188175 Hs.82506 KIAA1254 protein

422137 AA192099 AJ236885 zinc finger protein 148 (pHZ-52)

120302 AA192173 AA837098 Hs.269933 ESTs

120303 AA192415 AI216292 Hs.96184 ESTs

120305 AA192553 AW295096 Hs.101337 uncoupling protein 3 (mitochondrial, pro

120319 AA194851 T57776 Hs.191094 ESTs

408729 AA195520 AA195764 Hs.72639 ESTs

120326 AA196300 AA196300 Hs.21145 hypothetical protein RG083M05.2

133145 AA196549 H94227 Hs.6592 Homo sapiens, clone IMAGE:2961368, mRNA,

120327 AA196721 AK000292 Hs.130732 hypothetical protein FLJ20285

120328 AA196979 AA923278 Hs.290905 ESTs, Weakly similar to protease [H.sapi

120340 AA206828 AA206828 gb:zq80b08.s1 Stratagene hNT neuron (937 417122 AA207123 AI906291 Hs.81234 immunoglobulin superfamily, member 3

131522 AA214539 AI380040 Hs.239489 TIA1 cytotoxic granule-associated RNA-bi

421787 AA226914 AA227068 Hs.108301 nuclear receptor subfamily 2, group C, m

120375 AA227260 AF028706 Hs.111227 Zic family member 3 (odd-paired Drosophi

120376 AA227469 AA227469 gb:zr18a07.s1 Stratagene NT2 neuronal pr

120390 AA233122 AA837093 Hs.111460 calcium/calmodulin-dependent protein kin

410804 AA233334 U64820 Hs.66521 Machado-Joseph disease (spinocerebellar

434223 AA233347 AI825842 Hs.3776 zinc finger protein 216

312771 AA233714 AA018515 Hs.264482 Homo sapiens mRNA; cDNA DKFZp761 A0411 (f

120396 AA233796 AA134006 Hs.79306 eukaryotic translation initiation fador

120409 AA235050 AA235050 gb:zs38e04.s1 Soares_NhHMPu_S1 Homo sapi

120414 AA235704 AW137156 Hs.181202 hypothetical protein FLJ10038

120420 AA236031 AI128114 Hs.112885 spinal cord-derived growth factor-B

120422 AA236352 AL133097 Hs.301717 hypothetical protein DKFZp434N1928

419326 AA236390 W94915 Hs.42419 ESTs

120423 AA236453 AA236453 Hs.18978 Homo sapiens cDNA: FLJ22822 fis, clone K

120435 AA243370 AA243370 Hs.96450 EST

120453 AA250947 AA250947 Hs.170263 tumor protein p53-binding protein, 1

120455 AA251083 AA251720 Hs.104347 ESTs, Weakly similar to ALUC_HUMAN 111!

120456 AA251113 AA488750 Hs.88414 BTB and CNC homology 1, basic leucine zi

120473 AA251973 AA251973 Hs.269988 ESTs

128922 AA252023 AI244901 Hs.9589 ubiqui n 1

120477 AA252414 AA252414 Hs.43141 DKFZP727C091 protein

120479 AA252650 AF006689 Hs.110299 mitogen-activated protein kinase kinase

120488 AA255523 AW952916 Hs.63510 KIAA0141 gene product

120510 AA258128 AI796395 Hs.111377 ESTs

120527 AA262105 AA262105 Hs.4094 Homo sapiens cDNA FLJ 14208 fis, clone NT

120528 AA262107 AI923511 Hs.104413 ESTs

120529 AA262235 AI434823 Hs.104415 ESTs

120541 AA278298 W07318 Hs.240 M-phase phosphoprotein 1

120544 AA278721 BE548277 Hs.103104 ESTs

120562 AA280036 BE244580 Hs.342307 hypothetical protein FLJ10330

120569 AA280648 AA807544 Hs.24970 ESTs, Weakly similarto B34323 GTP-bindi

120571 AA280738 AB037744 Hs.34892 KIAA1323 protein

120572 AA280794 H39599 Hs.294008 ESTs

129434 AA280837 AW967495 Hs.186644 ESTs

130529 AA280886 AA178953 Hs.309648 gb:zp39e03.s1 Stratagene muscle 937209 H

120575 AA280934 AW978022 Hs.238911 hypothetical protein DKFZp762E1511; KIAA

409339 AA281535 AB020686 Hs.54037 ectonucleotide pyrophosphatase/phosphodi

120591 AA281797 AF078847 Hs.191356 general transcription factor IIH, polype

120593 AA282047 AA748355 Hs.193522 ESTs

430275 AA283002 Z11773 Hs.237786 zinc finger protein 187

440303 AA283709 AA306166 Hs.7145 calpain 7

120609 AA283902 AW978721 Hs.266076 ESTs, Weakly similar to A46010 X-linked

409702 AA284108 AI752244 eukaryotic translation elongation factor

456870 AA284109 AI241084 Hs.154353 nonselective sodium potassium/proton exc

132614 AA284371 AA284371 Hs.118064 similar to rat nuclear ubiquitous casein

458750 AA284744 AA115496 Hs.336898 Homo sapiens, Similarto RIKEN cDNA 1810

135376 AA2847S4 BE617856 Hs.99756 mitochondrial ribosome recycling factor

120621 AA284840 AW961294 Hs.143818 hypothetical protein FLJ23459

452279 AA286844 AA286844 Hs.61260 hypothetical protein FLJ13164

332484 AA287032 AW172431 Hs.13012 ESTs

120644 AA287038 AI869129 Hs.96616 ESTs

120660 AA287546 AA286785 Hs.99677 ESTs

135370 AA287553 BE622187 Hs.99670 ESTs, Weakly similar to I38022 hypotheti

120661 AA287556 AA287556 Hs.263412 ESTs, Weakly similar to ALUB_HUMAN 111!

429828 AA287564 AB019494 Hs.225767 IDN3 protein

452291 AA291015 AF015592 Hs.28853 CDC7 (cell division cycle 7, S. cerevisi

120699 AA291716 AI683243 Hs.97258 ESTs, Moderately similarto S29539 ribos

100690 AA291 49 AA383256 Hs.1657 estrogen receptor 1

120726 AA293656 AA293655 Hs.21198 ESTs

120737 AA302430 AL049176 Hs.82223 chordin-like

120745 AA302809 AA302809 gb:EST10426 Adipose tissue, white 1 Homo

443574 AA302820 U83993 Hs.321709 purinergic receptor P2X, ligand-gated io

120750 AA310499 AI191410 Hs.96693 ESTs, Moderately similar to 2109260A B c

120761 AA321890 AA321890 branched chain keto acid dehydrogenase E

120768 AA340589 AA340589 Hs.104560 EST

120769 AA340622 AI769467 Hs.9475 ESTs

135232 AA342457 AL038812 Hs.96800 ESTs, Moderately similarto ALU7JHUMAN A

120793 AA342864 AA342864 Hs.96812 ESTs

120796 AA342973 AI247356 Hs.96820 ESTs

120809 AA346495 AA346495 gb:EST52657 Fetal heart II Homo sapiens

332633 AA347573 AL120071 Hs.48998 fibronectin leucine rich transmembrane p

120825 AA347614 AI280215 Hs.96885 ESTs

120827 AA347717 AA382525 Hs.132967 Human EST clone 122887 mariner transposo

120839 AA348913 AA348913 gb:EST55442 Infant adrenal gland II Homo 120850 AA349647 AA349647 Hs.96927 Homo sapiens cDNA FLJ12573 fis, clone NT

120852 AA349773 AA349773 Hs.191564 ESTs

128852 AA350541 R40622 Hs.106601 ESTs

135240 AA357159 AA357159 Hs.96986 EST

120870 AA357172 AA357172 Hs.292581 ESTs, Moderately similar to ALU1 HUMAN A

120894 AA370132 AA370132 Hs.97063 ESTs

435737 AA370472 AF229839 Hs.173202 l-kappa-B-interacting Ras-like protein 1

120897 AA370867 AA370867 Hs.97079 ESTs, Moderately similar to AF174605 1 F

120915 AA377296 AL135556 Hs.97104 ESTs

120935 AA383902 AL048409 Hs.97177 ESTs, Weakly similar to ALU1_HUMAN ALU S

120936 AA385934 AA385934 Hs.97184 EST, Highly similar to (defline not aval

120937 AA386255 AA386255 Hs.97186 EST

120938 AA386260 AA386260 Hs.104632 EST

417632 AA386266 R20855 Hs.5422 glycoprotein M6B

120960 AA398014 AA398014 Hs.104684 EST

120985 AA398222 AI219896 Hs.97592 ESTs

120988 AA398235 AA398235 Hs.97631 ESTs

121008 AA398348 AA398348 Hs.130546 Human DNA sequence from clone RP11-251J8

121029 AA398482 AA398482 Hs.97641 EST

121032 AA398504 AA393037 Hs.161798 ESTs

121033 AA398505 AA398505 Hs.97360 ESTs

121034 AA398507 AL389951 Hs.271623 nucleoporin 50kD

121035 AA398523 AA398523 Hs.210579 ESTs

121058 AA398625 AA398625 Hs.97391 ESTs

121060 AA398632 AA398632 Hs.97395 ESTs

121061 AA398633 AA393288 Hs.97396 ESTs

121091 AA398894 AA398894 Hs.97657 ESTs, Moderately similar to ALU8 HUMA A

121092 AA398895 AA398895 Hs.97658 EST

121094 AA398900 AA402505 gb:zt62h10.r1 Soares testis NHT Homo sap

121096 AA398904 AA398904 Hs.332690 ESTs

121115 AA399122 AA398187 Hs.104682 ESTs, Weakly similar to mitochondrial ci

121121 AA399371 AA399371 Hs.189095 similarto SALL1 (sal (Drosophila)-like

121122 AA399373 AI126713 Hs.192233 ESTs, Highly similar to T00337 hypotheti

121125 AA399441 AL042981 Hs.251278 KIAA1201 protein

121151 AA399636 AA399636 Hs.143629 ESTs

121153 AA399640 AA399640 Hs.97694 ESTs

121163 AA399680 AI676062 Hs.111902 ESTs

121176 AA400080 AL121523 Hs.97774 ESTs

121192 AA400262 AA400262 Hs.190093 ESTs

121223 AA400725 AI002110 Hs.97169 ESTs, Weakly similar to dJ667H12.2.1 [H.

121227 AA400748 AA400748 Hs.97823 Homo sapiens mRNA; cDNA DKFZp434D024 (fr

121231 AA400780 AA814948 Hs.96343 ESTs, Weakly similar to ALUCHUMAN III!

121278 AA401631 AA037121 Hs.98518 Homo sapiens cDNA FLJ11490 fis, clone HE

121279 AA401688 AA292873 Hs.177996 ESTs

121282 AA401695 AA401695 Hs.97334 ESTs

121299 AA402227 AA402227 Hs.22826 tropomodulin 3 (ubiquitous)

121301 AA402329 NM 006202HS.89901 phosphodiesterase 4A, cAMP-specific (dun

121302 AA402398 AA402587 Hs.325520 LAT1-3TM protein

121304 AA402449 AA293863 Hs.97316 EST

121305 AA402468 AA402468 Hs.291557 ESTs

134721 AA403268 AK000112 Hs.89306 hypothetical protein FLJ20105

121323 AA403314 AA291411 Hs.97247 ESTs

121324 AA404229 AA404229 Hs.97842 EST

444422 AA404260 AI768623 Hs.108264 ESTs

131074 AA404271 U16125 Hs.181581 glutamate receptor, ionotropio, kainate

121344 AA405026 AA405026 Hs.193754 ESTs

121348 AA405182 AA405182 Hs.97973 ESTs

121350 AA405237 AA405237 gb:zt06e10.s1 NCI CGAP_GCB1 Homo sapiens

121400 AA406061 AA406061 Hs.98001 EST

121402 AA406063 AA406063 Hs.98003 ESTs

121403 AA406070 AA406070 Hs.98004 EST

121408 AA406137 AA406137 Hs.98019 EST

121431 AA406335 AA035279 Hs.176731 ESTs

121471 AA411804 AA411804 Hs.261575 ESTs

121474 AA411833 AA402335 Hs.188760 ESTs, Highly similarto Trad [H.sapiens]

121526 AA412219 AW665325 Hs.98120 ESTs

121530 AA412259 AA778658 Hs.98122 ESTs

121558 AA412497 AA412497 gb:zt95g12.s1 Soares testis NHT Homo sap

121559 AA412498 AI192044 Hs.104778 ESTs

121584 AA416586 AI024471 Hs.98232 ESTs

121609 AA416867 AA416867 Hs.98185 EST

121612 AA416874 AA416874 Hs.98168 ESTs

121737 AA421133 AA421133 Hs.104671 erythrocyte transmembrane protein

121740 AA421138 AA421138 Hs.143835 EST

436032 AA422079 AA150797 Hs.109276 latexin protein

121784 AA423837 T90789 Hs.94308 RAB35, member RAS oncogene family 121802 AA424328 AI251870 Hs.188898 ESTs

121803 AA424339 AI338371 Hs.157173 ESTs

135286 AA424469 AW023482 Hs.97849 ESTs

332778 AA424469 AW023482 Hs.97849 ESTs

121806 AA424502 AA424313 Hs.98402 ESTs

129517 AA425004 AW972853 Hs.112237 ESTs

121845 AA425734 AI732692 Hs.165066 ESTs, Moderately similarto ALU2_HUMAN A

121853 AA425887 AA425887 Hs.98502 hypothetical protein FLJ14303

121891 AA426456 AA426456 Hs.98469 ESTs

121895 AA427396 AA427396 gb:zw33a02.s1 Soares ovary tumor NbHOT H

121899 AA427555 R55341 Hs.50421 KIAA0203 gene product

121917 AA428218 AA406397 Hs.139425 ESTs

121918 AA428242 BE274689 Hs.184175 chromosome 2 open reading frame 3

121919 AA428281 AA428281 Hs.98560 EST

121941 AA428865 AA428865 Hs.98563 ESTs

121942 AA428994 AW452701 Hs.293237 ESTs

121970 AA429666 AA429666 Hs.98617 EST

121993 AA430181 AW297880 Hs.9866 ESTs

418706 AA430184 U73524 Hs.87465 ATP/GTP-binding protein

122022 AA431293 AA431293 Hs.98716 ESTs, Moderately similar to T42650 hypot

122050 AA431478 AI453076 ELAV (embryonic lethal, abnormal vision,

122051 AA431492 AA431492 Hs.98742 EST

122055 AA431732 AA431 32 Hs.98747 EST

122105 AA432278 AW241685 Hs.98699 ESTs

122125 AA434411 AK000492 Hs.98806 hypothetical protein

135235 AA435512 AW298244 Hs.266195 ESTs

122162 AA435698 AA628233 Hs.79946 cytochrome P450, subfamily XIX (aromatiz

422072 AA435711 AB018255 Hs.111138 KIAA0712 gene product

415106 AA435815 U40763 Hs.77965 peptidyl-prolyl isomerase G (cyclophilin

122186 AA435842 AA398811 Hs.104673 ESTs

122235 AA436475 AA436475 Hs.112227 membrane-associated nucleic acid binding

412970 AA436489 AB026436 Hs.177534 dual specificity phosphatase 10

419288 AA442060 AA256106 Hs.87507 ESTs

122310 AA442079 AW192803 Hs.98974 ESTs, Weakly similarto S65824 reverse t

122334 AA443151 BE465894 Hs.98365 ESTs, Weakly similarto LB4D HUMAN NADP-

122382 AA446133 AA446440 Hs.98643 ESTs

122425 AA447145 AB007859 Hs.100955 KIAA0399 protein

122431 AA447398 AA447398 Hs.99104 ESTs

122450 AA447643 AA447643 Hs.112095 hypothetical protein DKFZp434F1819

426284 AA447742 AJ404468 Hs.284259 dynein, axonemal, heavy polypeptide 9

122477 AA448226 AA448226 Hs.324123 ESTs

122500 AA448825 AA448825 Hs.99190 ESTs

122522 AA449444 AA299607 Hs.98969 ESTs

122536 AA450087 AF060877 Hs.99236 regulator of G-protein signalling 20

122538 AA450211 AA450211 Hs.99239 ESTs

122540 AA450244 AA476741 Hs.98279 ESTs, Weakly similar to A43932 mucin 2 p

122560 AA452123 AW392342 Hs.283077 centrosomal P4.1 -associated protein; unc

421919 AA452155 AJ224901 Hs.109526 zinc finger protein 198

122562 AA452156 AA452156 gb:zx29c03.s1 Soares_total_fetus_Nb2HF8_

122585 AA453036 AI681654 Hs.170737 hypothetical protein FLJ23251

122608 AA453526 AA453525 Hs.143077 ESTs

122635 AA454085 AA454085 gb:zx33a08.s1 Soares_total_fetus_Nb2HF8_

122636 AA454103 AW651706 Hs.99519 hypothetical protein FLJ14007

122653 AA454642 AW009166 Hs.99376 ESTs

122660 AA454935 AI816827 Hs.180069 nuclear respiratory factor 1

122703 AA456323 AA456323 Hs.269369 ESTs

122724 AA457395 AA457395 Hs.99457 ESTs

122749 AA458850 AA458850 Hs.293372 ESTs, Weakly similarto B34087 hypotheti

122772 AA459662 AW117452 Hs.99489 ESTs

430242 AA459668 U66669 Hs.236642 3-hydroxyisobutyryl-Coenzyme A hydrolase

429838 AA459679 AW904907 Hs.30732 hypothetical protein FLJ13409; KIAA1711

122777 AA459702 AK001022 Hs.214397 hypothetical protein FLJ10160 similarto

135362 AA460017 AA978128 Hs.99513 ESTs, Weakly similar to T17454 diaphanou

122798 AA460324 AW366286 Hs.145696 splicing factor (CC1.3)

122837 AA461509 AA461509 Hs.293565 ESTs, Weakly similarto putative p150 [H

122860 AA464414 AA464414 gb:zx7θg01.s1 Soares ovary tumor NbHOT H

122861 AA464428 AA335721 Hs.213628 ESTs

122910 AA470084 AA470084 Hs.98358 ESTs

132899 AA476606 AA476606 Hs.59666 SMAD in the antisense orientation

122967 AA478521 AA806187 Hs.289101 glucose regulated protein, 58kD

422845 AA478523 AA317841 Hs.7845 hypothetical protein MGC2752

123009 AA479949 AA535244 Hs.78305 RAB2, member RAS oncogene family

128917 AA481252 AI365215 Hs.206097 oncogene TC21

123081 AA485351 AI815486 Hs.243901 Homo sapiens cDNA FLJ20738 fis, clone HE

123133 AA487264 AA487264 Hs.154974 Homo sapiens mRNA; cDNA DKFZp667N064 (fr

123184 AA489072 BE247767 Hs.18166 KIAA0870 protein 332467 AA489630 NM_014700Hs.119004 KIAA0665 gene product

123233 AA490225 AW974175 Hs.151875 ESTs, Weakly similarto MAPB_HUMAN MICRO

123234 AA490227 NM_001938Hs.16697 down-regulator of transcription 1, TBP-b 123236 AA490255 AW968504 Hs.123073 CDC2-related protein kinase 7 123255 AA490890 AA830335 Hs.105273 ESTs 430015 AA490916 AW768399 Hs.106357 ESTs 448892 AA490925 AF084535 Hs.22464 epilepsy, progressive myodonus type 2, 123259 AA490955 AI744152 Hs.283374 ESTs, Weakly similar to CA15_HUMAN COLLA 123284 AA495812 AA488988 Hs.293796 ESTs 123286 AA495824 AA495824 Hs.188822 ESTs, Weakly similar to A46010 X-linked 123315 AA496369 AA496369 gb:zv37d10.s1 Soares ovary tumor NbHOT H 457397 AA504125 AW969025 Hs.109154 ESTs 433049 AA521473 AU076668 Hs.334884 SEC10 (S. cerevisiae)-like 1 123421 AA598440 AA598440 Hs.291154 EST, Weakly similarto 138022 hypothetic 123449 AA598899 AL049325 Hs.112493 Homo sapiens mRNA; cDNA DKFZp564D036 (fr 426981 AA599244 AL044675 Hs.173081 KIAA0530 protein 409986 AA599694 NM_014777Hs.57730 KIAA0133 gene product 123497 AA600037 AA765256 Hs.135191 ESTs, Weakly similarto unnamed protein 123604 AA609135 AA609135 Hs.293076 ESTs 123712 AA609684 AA609684 Homo sapiens cDNA: FLJ21543 fis, clone C 123731 AA609839 AA609839 Hs.334437 gb:ae62f01.s1 Stratagene lung carcinoma 123800 AA620423 AA620423 Hs.112862 EST 123841 AA620747 AA620747 Hs.112896 ESTs 123929 AA621364 AA621364 Hs.112981 ESTs 123978 C20653 T89832 Hs.170278 ESTs 133184 D20085 AA001021 Hs.6685 thyroid hormone receptor interactor 8 132835 D20749 Z83844 Hs.5790 hypothetical protein dJ37E16.5 435147 D51285 AL133731 Hs.4774 Homo sapiens mRNA; cDNA DKFZp761C1712 (f 128695 D59972 NM_003478Hs.101299 cullin 5 124029 F04112 F04112 Hs.312553 gb:HSC2JH062 normalized infant brain cDN 124057 F13604 AA902384 Hs.73853 bone morphogenetic protein 2 449316 H01662 AI609045 Hs.321775 hypothetical protein DKFZp434D1428 130973 H05135 AI638418 Hs.1440 DEAD/H (Asp-Glu-Ala-Asp/His) box polypep 124106 H12245 H 12245 gb:ym17a12.r1 Soares infant brain 1NIB H 124136 H22842 H22842 Hs.101770 EST 124165 H30894 H30039 Hs.107674 ESTs 429627 H43442 NM_015340Hs.2450 leucyl-tRNA synthetase, mitochondrial 124178 H45996 BE463721 Hs.97101 putative G protein-coupled receptor 129948 H69281 A1537162 Hs.263988 ESTs 452114 H69485 N22687 Hs.8236 ESTs 124-HD826254 H69899 H69899 gb:yu70c12.s1 Weizmann Olfactory Epithel 129056 H70627 AI769958 Hs.108336 ESTs, Weakly similarto ALUEJHUMAN HI! 427580 H73260 AK001507 Hs.44143 Homo sapiens clone FLB6914 PR01821 mRNA, 426793 H77531 X89887 Hs.172350 HIR (histone cell cycle regulation defec 124274 H80552 H80552 Hs.102249 EST 129078 H80737 AI351010 Hs.102267 lysosomal 457658 H93412 AW952124 Hs.13094 presenilins associated rhomboid-like pro 124315 H94892 NM_005402Hs.288757 v-ral simian leukemia viral oncogene hom 437712 H95643 X04588 Hs.85844 neurotrophic tyrosine kinase, receptor, 124324 H96552 H96552 Hs.159472 Homo sapiens cDNA: FLJ22224 fis, clone H 452933 H97146 AW391423 Hs.288555 Homo sapiens cDNA: FLJ22425 fis, clone H 132231 H99131 AA662910 Hs.42635 hypothetical protein DKFZp434K2435 421877 H99462 AW250380 Hs.109059 mitochondrial ribosomal protein L12 443123 H99837 AA094538 Hs.272808 putative transcription regulation nuclea 132963 N22140 AA099693 Hs.34851 epsilon-tubulin 420473 N22197 AL118782 Hs.300208 Sec23-interacting protein p125 417381 N23756 AF164142 Hs.82042 solute carrier family 23 (nucleobase tra 130365 N24134 W56119 Hs.155103 eukaryotic translation initiation factor 456610 N24195 AF172066 Hs.106346 retinoic acid repressible protein 439311 N26739 BE270668 Hs.151945 mitochondrial ribosomal protein L43 124383 N27098 N27098 Hs.102463 EST 124387 N27637 N27637 Hs.109019 ESTs 129341 N33090 AI193519 Hs.226396 hypothetical protein FLJ11126 419793 N35967 AI364933 Hs.168913 serine/threonine kinase 24 (Ste20, yeast 124433 N39069 AA280319 Hs.288840 PR01575 protein 124441 N46441 AW450481 Hs.161333 ESTs 132338 N48270 AA353868 Hs.182982 golgin-67 436575 N48365 AI473114 ESTs 124466 N51316 R10084 Hs.113319 kinesin heavy chain member 2 408048 N51499 NM_007203Hs.42322 A kinase (PRKA) anchor protein 2

124483 N53976 AI821780 Hs.179864 ESTs

124484 N54157 H66118 Hs.285520 ESTs, Weakly similarto 2109260A B cell

124485 N54300 AB040933 Hs.15420 KIAA1500 protein 124494 N54831 N54831 Hs.271381 ESTs, Weakly similarto I38022 hypotheti 129200 N59849 N59849 Hs.13565 Sam68-like phosphotyrosine protein, T-ST 124527 N62132 N79264 Hs.269104 ESTs 124532 N62375 N62375 Hs.102731 EST

133213 N63138 AA903424 Hs.6786 ESTs

124539 N63172 D54120 Hs.146409 cell division cycle 42 (GTP-binding prot

129196 N63787 BE296313 Hs.265592 ESTs, Weakly similarto I38022 hypotheti

124575 N68168 N68168 gb:za11c01.s1 Soares fetal liver spleen

124576 N68201 N68201 ESTs, Weakly similarto I38022 hypotheti

124577 N68300 N68300 Hs.138485 gb:za12g07.s1 Soares fetal liver spleen

124578 N68321 N68321 Hs.231500 EST

124593 N69575 N69575 Hs.102788 ESTs

128501 N75007 AL133572 Hs.199009 protein containing CXXC domain 2

332434 N75542 AI680737 Hs.289068 Homo sapiens cDNA FLJ11918 fis; clone HE

128473 N90066 T78277 Hs.100293 O-linked N-acetylglucosamine (GlcNAc) tr

128639 N91246 AW582962 Hs.102897 CGI-47 protein

124652 N92751 W19407 Hs.3862 regulator of nonsense transcripts 2; DKF

133137 N93214 AB002316 Hs.65746 KIAA0318 protein

124671 N99148 AK001357 Hs.102951 Homo sapiens cDNA FLJ10495 fis, clone NT

133054 R07876 AA464836 Hs.291079 ESTs, Weakly similar to T27173 hypotheti

425266 R10865 J00077 Hs.155421 alpha-fetoprotein

124720 R11056 R05283 gb:ye91c08.s1 Soares fetal liver spleen

124722 R11488 T97733 Hs.185685 ESTs

128944 R23930 AL137586 Hs.52763 anaphase-promoting complex subunit 7

132965 R26589 AI248173 Hs.191460 hypothetical protein MGC12936

426504 R37588 AW162919 Hs.170160 RAB2, member RAS oncogene family-like

438828 R37613 AL134275 Hs.6434 hypothetical protein DKFZp761F2014

124757 R38398 H11368 Hs.141055 Homo sapiens clone 23758 mRNA sequence

124762 R39179 AA553722 Hs.92096 ESTs, Moderately similar to A46010 X-lin

124773 R40923 R45154 Hs.338439 ESTs

135266 R41179 R41179 Hs.97393 KIAA0328 protein

427961 R41294 AW293165 Hs.143134 ESTs

414303 R42307 NM 004427HS.165263 early development regulator 2 (homolog o

128540 R43189 AW297929 Hs.328317 EST

124785 R43306 W38537 Hs.280740 hypothetical protein MGC3040

124792 R44357 R44357 Hs.48712 hypothetical protein FLJ20736

124793 R44519 R44519 gb:yg24h04.s1 Soares infant brain 1NIB H

124799 R45088 R45088 gb:yg38g04.s1 Soares infant brain 1NIB H

124812 R47948 R47948 Hs.188732 ESTs

124821 R51524 H87832 Hs.7388 kelch (Drosophila)-like 3

424123 R54950 AW966158 Hs.58582 Homo sapiens cDNA FLJ12789 fis, clone NT

124835 R55241 R55241 Hs.101214 EST

124845 R59585 R59585 Hs.101255. ESTs

124847 R60044 W07701 Hs.304177 Homo sapiens clone FLB8503 PR02286 mRNA,

440630 R60872 BE561430 Hs.239388 Human DNA sequence from clone RP1-304B14

124861 R66690 R67567 Hs.107110 ESTs

332503 R67266 NM_004455Hs.150956 exostoses (multiple)-like 1

124879 R73588 R73588 Hs.101533 ESTs

124892 R79403 AI970003 Hs.23756 hypothetical protein similarto swine ac

124906 R87647 H75964 Hs.107815 ESTs

124922 R93622 R93622 Hs.12163 eukaryotic translation initiation factor

124940 R99599 AF068846 Hs.103804 heterogeneous nuclear ribonucieoprotein

124941 R99612 AI766661 Hs.27774 ESTs, Highly similar to AF161349 1 HSPC0

124943 T02888 AW963279 Hs.123373 ESTs, Weakly similar to ALU1 HUMAN ALU S

124947 T03170 T03170 Hs.100165 ESTs

124954 T10465 AW964237 Hs.6728 KIAA1548 protein

456862 T15418 U55184 Hs.154145 hypothetical protein FLJ 11585

410653 T15597 BE383768 Hs.65238 . 95 kDa retinoblastoma protein binding pr

418133 T15652 R43504 Hs.6181 ESTs

440014 T16898 AW960782 Hs.6856 ash2 (absent, small, or homeotic, Drosop

131082 T26644 AI091121 Hs.246218 Homo sapiens cDNA: FLJ21781 fis, clone H

124980 T40841 T40841 Hs.98681 ESTs

124984 T47566 BE313210 Hs.334798 eukaryotic translation elongation factor

124991 T50116 T50116 gb:yb77c10.s1 Stratagene ovary (937217)

457222 T50145 NM 004477HS.203772 FSHD region gene 1

125000 T58615 T58615 Hs.235887 ESTs

132932 T59940 AW118826 Hs.6093 Homo sapiens cDNA: FLJ22783 fis, clone K

444484 T63595 AK002126 Hs.11260 hypothetical protein FLJ11264

125008 T64891 T91251 gb:yd60a10.s1 Soares fetal liver spleen

125009 T64924 T64924 Hs.303046 ESTs

445384 T64933 T79136 Hs.127243 Homo sapiens mRNA for KIAA1724 protein,

125017 T68875 T68875 gb:yc30f05.s1 Stratagene liver (937224)

125018 T69027 T69027 Hs.269481 sex comb on midleg homolog 1

125020 T69924 T69981 gb:yc19d03.r1 Stratagene lung (937210) H

437871 T70353 AI084813 Hs.114088 ESTs

134204 T79780 AI873257 Hs.7994 hypothetical protein FLJ20551

125050 T79951 AW970209 Hs.111805 ESTs

125052 T80174 T85104 Hs.222779 ESTs, Moderately similarto similarto N

125054 T80622 T80622 Hs.268601 ESTs, Weakly similar to envelope [H.sapi 125063 T85352 T85352 gb:yd82d01.s1 Soares fetal liver spleen

125064 T85373 T85373 gb:yd82f07.s1 Soares fetal liver spleen

125066 T86284 T86284 gb:yd77b07.s1 Soares fetal liver spleen

416507 T89579 AL045364 Hs.79353 transcription factor Dp-1

125080 T90360 T90360 Hs.268620 ESTs, Highly similar to ALU6_HUMAN ALU S

125097 T94328 AW576389 Hs.335774 EST, Moderately similarto S65657 alpha-

125104 T95590 T95590 gb:ye40a03.s1 Soares fetal liver spleen

135107 T97257 T97257 Hs.94560 ESTs, Moderately similarto I38022 hypot

423122 T97599 AA845462 Hs.124024 deltex (Drosophila) homolog 1

125118 T97620 R10606 Hs.269890 gb:yf35f11.s1 Soares fetal liver spleen

125120 T97775 T97775 Hs.100717 EST

134160 T98152 T98152 Hs.79432 fibrillin 2 (congenital contractural ara

125136 W31479 AW962364 Hs.129051 ESTs

125144 W37999 AB037742 Hs.24336 KIAA1321 protein

125150 W38240 W38240 Empirically selected from AFFX single pr

450142 W40150 AW207469 Hs.24485 chondroitin sulfate proteoglycan 6 (bama

131987 W45435 AW453069 Hs.3657 activity-dependent neuroprotective prate

125178 W58202 W93127 Hs.31845 ESTs

125180 W58344 W58469 Hs.103120 ESTs

125182 W58650 AA451755 Hs.263560 ESTs

446888 W68736 AL030996 Hs.16411 hypothetical protein L0C57187

125197 W69106 AF086270 Hs.278554 heterochromatin-like protein 1

133497 W69111 BE617303 Hs.74266 hypothetical protein MGC4251

429922 W69399 Z97630 Hs.226117 H1 histone family, member 0

129232 W69459 R98881 Hs.109655 sex comb on midleg (Drosophila)-like 1

422166 W72424 W72424 Hs.112405 S100 calcium-binding protein A9 (calgran

125209 W72724 W72724 Hs.103174 ESTs, Weakly similar to TSP2 HUMAN THROM

125212 W72834 AA746225 Hs.103173 ESTs

456631 W73955 BE383436 Hs.108847 hypothetical protein MGC2749

125223 W74701 AI916269 Hs.109057 ESTs, Weakly similarto ALU5 HUMAN ALU S

125225 W76540 W7 169 Hs.16492 DKFZP564G2022 protein

125228 W79397 AA033982 Hs.110059 ESTs, Weakly similar to I38022 hypotheti

132393 W85888 AL135094 Hs.47334 hypothetical protein FLJ14495

125238 W86038 N99713 Hs.109514 ESTs

125247 W86881 AA694191 Hs.163914 ESTs

129296 W87804 AI051967 Hs.110122 ESTs

125263 W88942 AA098878 gb:zn45g10.r1 Stratagene HeLa cell s393

125266 W90022 W90022 Hs.186809 ESTs, Highly similarto LCT2JHUMAN LEUKO

450862 W92272 U91543 Hs.25601 chromodomain helicase DNA binding protei

452401 W92764 NM 007115HS.29352 tumor necrosis factor, alpha-induced pro

428243 W93040 H05317 Hs.283549 ESTs

125277 W93227 W93227 Hs.103245 EST

125278 W93523 AI218439 Hs.129998 enhancer of polycomb l

125280 W93659 AI123705 Hs.106932 ESTs

448205 W94003 W93949 Hs.33245 ESTs

131844 W94401 AI419294 Hs.324342 ESTs

125284 W94688 NM_002666Hs.103253 perilipin

417111 W94787 AW016321 Hs.82306 destrin (actin depolymerizing factor)

445424 Z38294 AB028945 Hs.12696 cortactin SH3 domain-binding protein

125289 Z38311 T34530 Hs.4210 Homo sapiens cDNA FLJ13069 fis, clone NT

446313 Z38465 H06245 Hs.106801 ESTs, Weakly similar to PC4259 ferritin

431342 Z38525 AW971018 Hs.21659 ESTs

433227 Z38538 AB040923 Hs.106808 kelch (Drosophila)-like 1

428306 Z38551 AB037715 Hs.183639 hypothetical protein FLJ10210

424624 Z38783 AB032947 Hs.151301 Ca2+dependent activator protein for seer

125295 Z39113 AB022317 Hs.25887 sema domain, immunoglobulin domain (Ig),

125298 Z39255 AW972542 Hs.289008 Homo sapiens cDNA: FLJ21814 fis, clone H

125300 Z39591 Z39591 Hs.101376 EST

448378 Z39783 BE622770 Hs.264915 Homo sapiens cDNA FLJ12908 fis, clone NT

444582 Z39920 R55344 Hs.22142 cytochrome b5 reductase b5R.2

130882 Z40166 AA497044 Hs.20887 hypothetical protein FLJ10392

128888 Z40388 AI760853 Hs.241558 ariadne (Drosophila) homolog 2

125310 Z40646 R59161 Hs.124953 ESTs

125315 Z41697 R38110 Hs.106296 ESTs

125317 Z99349 Z99348 Hs.112461 ESTs, Weakly similarto I38022 hypotheti

135096 Z99394 AA081258 zinc finger protein 36 (KOX 18) TABLE 3A

Table 3A shows the accession numbers for those pkeys lacking unigenelD's for Table 3. The pkeys in Table 7 lacking unigenelD's are represented within Tables 1 -6A. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey: Unique Eos probeset identifier number

CAT number: Gene cluster number Accession: Genbank accession numbers

Pkey CAT Number Accession

108469 116761 1 AA079487 AA128547 AA128291 AA079587 AA079600

124106 125446 1 H12245 AA094769 R14576

108501 13684 -12 AA083256

108562 36375J AA100796 AF020589 AA074629 AA075946 AA100849 AA085347 AA126309 AA079311 AA079323 AA085274

101300 4669 1 BE535511 M62098 AA306787 AW891766 AA348998 AA338869 AA344013 AW956561 AW389343 AW403607 L40391 AW408435 AA121738 AI568978 H13317 R20373 AW948724 AW948744 AA335023 AA436722 AA448690 C21404 AW884390 AA345454 AA303292 AA174174 BE092290 T90614 AA035104 R76028 AA126924 AA741086 AW022056 AW118940 AA121666 AI832409 AA683475 AI140901 AI623576 AW519064 AW474125 AI953923 AI735349 AW150109 AI436154 AW118130 AW270782 AI804073 N27434 AA876543 AA937815 AI051166 AA505378 AI041975 AI335355 AI089540 AA662243 AI127912 AI925604 AI250880 AI366874 AI564386 AI815196 AI683526 AI435885 AI160934 H79030 AI801493 AA448691 AI673767 AI076042 AI804327 AA813438 AA680002 AI274492 T16177 AI287337 AI935050 AA907805 AA911493 AI589411 AI371358 AW576236 AI078866 AW516168 AA346372 AI560185 AA471009 R75857 AA296025 AA523155 AA853168 AI696593 AI658482 AI566601 AW072797 AA128047 AA035502 AW243274 AA992517 R43760

132091 94851J AW954243 AA829930 AA412478 AA828434 AA814538 AI927418 AI192435 W52897 AA443666 AA031913 AI683306 AA918481 AI183314 D83907 AI206832 AA876122 D83836 D83838 D82533 AI761290 AI191125 AI143749 AW771909 AI241436 AI767267 W56507 AA847787 AA568692 T10502 AI247870 AA715017 AA643304 AA890233 AA811387 AA897470 AA907729 AI708679 AI078010 AA452830 AW419160 AI783713 N80205 W56778 AA676899 AI888718 N69930 AI338935 AI217580 AA639508 AA575836 BE046852 AI312651 AI038406 AA628649 AA643838 AI493761 AA032024 W38849 AA340178 AA447052 AA452969 W19369 AA296364 H44229 W58767 C05751 C05835 AI741989 N98532 AW102617 AA412583 AI922246 W38495 AA355375 AA928571 C06275 AA352500 N93132

117034 20113_2 U72209 NM_005748 AI655607 AI052758 AA385199 AW956794 H88679 AL135153 AI765644 AA384399 AW966458 AA568443 AA804610 AI873513 H88639 Z25371 R63456 W44919 100752 33207_21 T81309 BE019033 R94181 BE019198 NM 00612 J03242 AW411299 BE300064 BE297544 R94182 AW630108 T53723 D58853 H78073 H80594 BE299560 T48899 H70196 M17426 N77077 S77035 H58384 H61664 H78540 T84527 C17198 H60255 H71980 R92644 W79050 X00910 M29645 R91055 M17863 M17862 T71815 BE299561 BE464561 X06260 R94741 T54216 C18594 BE262015 X06161 AW409889 AA378400 BE263228 BE313278 R88116 BE313457 H43500 T48617 BE313761 H77309 AI207601 X06159 H40413 X03425 T87663 R10627 X03562 M14118 W03982 R97520 H81229 T83157 H83168 H48762 AA669898 BE263054 H47289 AA022807 R11555 H74260 R76968 R28338 H72534 H72464 H62031 N72478 N45355 AW411300 R89113 R69135 H58454 T83281 R93476 H69645 H68015 T82229 H71089 T85121 H59939 W65299 N78176 H53909 N72373 R21788 H04660 H59639 H61874 BE262219 T53614 N73335 N50464 W00943 N77189 R89257 AA570502 R89432 R06366 AA553480 AA776271 AA551359 AA551050 H51670 AA601052 BE299081 H68198 H52276 BE207832 N91192 H70332 X07868 X07868 H69464 H53782 H73710 R80435 AA553384 AW884176 N53475 T71662 AW954036 AW954033 AA552931 H93206 AA430218 AA553476 AI918470 T54124 BE207982 BE300177 N73994 AW882625 N39549 N53838 AA722389 H71878 H58909 H37849 H78435 T47933 R77174 R83814 AA411890 H94199 AA663208 BE205778 AA490137 H70492 R98232 H37800 AA679294 H40341 H74238 H47290 H73231 T48618 AA025428 AI039521 H92969 N59389 H80538 H72933 T90630 AA411891 N55000 H74225 AA340290 AW957061 T54316 AA340437 H57125 H58908 H79027 H63450 N74623 R93425 H68714 H68758 N68396 H48763 N69256 H57320 H53831 H53589 N68833 N52453 H56048 H69870 H78074 R69253 R83375 T53615 H94330 H58455 H90864 T47934 H74261 R89258 R97997 R91056 R28339 R86760 H78235 R97521 H67692 H40358 AA022688 H52513 H59601 T88690 H65256 H63397 W65397 AA553588 R19280 N52645 W73930 R06367 R21743 H72372 N73921 AW883539 AW882639 T40616 H47084 R95723 AA634316AA862781 H77310 R91389 H93111 R92767 T54512 R89341 H70333 H57817 H82941 H62032 N52638 H58385 T91796 H51086 AA340292 T49918 H81230 R36121 N50411 T87664 N62436 N39340 AA665637 AA340446 H93377 H92973 BE296290 BE269788 H61665 AA340444 N54605 AA454101 R10628 R94200 AI200549 AA342640 BE298855 BE250229 T49916 H82008 N28278 AW880662 H71268 N76791 H47685 H65255 W05198 AW889144 N76677 H71702 H68036 H71915 R91612 R87807 H68059 AI133328 AI247866 AA621443 AW881050 AA700847 AA340413 AW878608 AW881181 AW878249 H71916 N54596 BE161581 AW878082 W04212 AW881040 AW885492 AW880519 AA334887 AW878715 W06882 AW630222 AW885381 H70869 AW381778 H47601 AW889982 H63868 AW884986 AW878713 AW878685 R36391 AW878694 AA368070 C03393 AW878695 AW878705 AW878665 AW878742 AW878620 AW878823 AW878688 R29048 AW878690 AW878686 AW878810 AW878827 AW878733 AW878659 AW878749 AW878681 AW883353 AW883277 AW883300 AW883565 AW883298 AW883143 AW883045 AW883482 AW883352 AW883417 AW883357 AW883231 AW883474 AW883355 AW882620 AW882533 AW883754 AW883139 AW882827 AW883641 AW883567 AW883481 AW882983 AW882982 AW882465 AW883419 AW882466 AW883639 AW883230 AW882981 AW882534 AW882874 AW882619 AW883480 AW882826 AW882831 AW882835 AW882830 AW883563 AW882456 AW627642

116417 5418J1 AW499664 AW500888 AL042095 AW576556 AW265424 AI521500 AA761333 AA761319 AW291137 AA649040 AA769094 AA489664 AA635311 AW070509 AA425658 AI381489 AA609309 AA134476 W74704 AI923640 AW084888 H45700 AI985564 AW629495 AW614573 AI859571 AI693486 AA913892 AI806164 AA909524 AW263513 AI356361 Z40708 AI332765 AI392620 AA181060 AW118719 AW968804 AW263502 AW505314 AA036967 W74741 R51139 H19364 H45751 Z44962 AW370823 H25650 T54007 AA453000 AL045739

123712 3744231 AA609684 AA758732

117156 145392J W73853 AA928112 W77887 AW889237 AA148524 AI749182 AI754442 AI338392 AI253102 AI079403 AI370541 AI697341 H97538 AW188021 AI927669 W72716 AI051402 A1188071 AI335900 N21488 AW770478 W92522 AI691028 AI913512 AI144448 W73819 AA604358 N28900 W95221 AI868132 H98465 AA148793

125008 18020951 T91251 T64891 T85665

125020 1160171 T69981 T69924 AA078476

125066 18149931 T86284 T81933

116661 15328591 R61504 F04247

125104 4133471 T95590 AA703278 H62764

124575 16666491 N68168 N69188 N90450

125263 15472 AA098878 W88942

131859 36721 AW960564 AA092457 T55890 D56120 T92525 AI815987 BE182608 BE182595 AW080238 M90657 AA347236 AW961686 AW176446 AA304671 AW583735 T61714 AA316968 AI446615 AA343532 AA083489 AA488005 W52095 W39480 N57402 D82638 W25540 W52847 D82729 D58990 BE619182 AA315188 AA308636 AA112474 W76162 AA088544 H52265 AA301631 H80982AA113786 BE620997 AW651691 AA343799 BE613669 BE547180 BE546656 F11933 AA376800 AW239185 AA376086 BE544387 BE619041 AA452515 AA001806 AA190873 AA180483 AA159546 F00242 AI940609 AI940602 AI189753 T97663 T66110 AW062896 AW062910 AW062902 AI051622 A1828930 AA102452 AI685095 AI819390 AA557597 AA383220 AI804422 AI633575 AW338147 AW603423 AW606800 AW750567 AW510672 AI250777 AA083510 AW629109 AW513200 AA921353 AI677934 AI148698 AI955858 AA173825 AA453027 AI027865 AW375542 AA454099 AA733014 AI591384 R79300 R80023 AA843108 AA626058 AA844898 AW375550 AA889018 AI474275 AW205937 AI052270 AW388117 AW388111 AA699452 AI242230 N47476 H38178 AA366621 AA113196 AA130023 H39740 T61629 AI885973 AW083671 AA179730 AA305757 AI285455 N83956 AA216013 AA336155 AW999959 T97525 AA345349 T91762 AA771981 AI285092 A1591386 BE392486 BE385852 AA682601 A1682884 AA345840 T85477 AA292949 AA932079 AA098791 D82607 T48574 AW752038 C06300

125565 1704098 R20840 R20839 132983 11922 1 M30269 NM J02508 X82245 AI078760 AW957003 D78945 M27445 AA650439 AL048816 AV660256 AV660347 AA333052 BE295257 T60999 AA383049 AW369677 Z26985 AW175704 AA343326 AW747957 AI818389 W17308 W17302 H15591 AA371284 AA370412 W94966 BE384365 T28498 R80714 R16959 H21723 AW835154 D56097 D56381 W21232 AA190565 AW379755 AW067895

118584 532052_ AW136928 AI685655 BE218584 BE465078 N68963 AA975338 BE147199 N76377 133607 1227 6 BE273749 BE397561 BE387189 AL037858 AL037878 AI963094 BE259216 AA011363 AL036189 BE562325 AA251169 BE617431 N98537 AA158093 AL047800 M34539 NMJ00801 AA312140 D16971 AA158904 AA307114 AA312803 T09203 AW629686 AL048504 BE388578 AA220957 AA158364 BE267385 AA294971 C18055 BE241757 AA115056 AI936769 BE378435 BE206971 AW674924 BE622060 AA604674 AA115273 AW402159 AA338608 BE568819 M80199 X55741 AA375111 AA376016 BE612671 AA805742 AW405588 N25850 N44580 H06031 AW403549 BE536552AA056726 BE543239 AA082517 AI201645 AI201642 AI192622 N40104 AA370921 BE547569 AI969602 AA302038 AI197890 AW268354 AI014938 W45448 AI541395 AA037272 BE538826 AL039613 BE536130 AA299355 AW805147 AW974624 H53220 AI471471 AA399303 AA007386 W35106 BE613277 R12739 R12738 AA304342 AA687802 BE409581 AI498844 AV662092 AW904105 AA011375 BE315214 H99302 BE537893 N32299 AW855829 AI291320 BE078322 AI301395 AA303362 N32719 AA358328 AA357877 AI952540 H56279 H02758 H02048 AW805233 R82224 AA410772 AA291352 BE171109 N69935 BE169248 AA361173 H44978 BE617887 D52560 AA084043 W03595 R67219 N36477 N42924 R67104 H44901 H79695 W21105 AA393988 W30899 AA316096 BE622896 W46872 AA442678 BE544893 BE540112 BE621873 AA338067 N55052 BE398154 BE621210 AA740760 C03739 C03206 BE396692 AA482370 AA031614 AA301575 AA304710 AA132153 AA029796 AA994960 H19567 AA442969 H49781 H46871 AA035395 AA056185 AA149378 AA643080 AL135479 AA292329 AA654337 AA041228 AA454888 AA025039 W58331 AA625981 T94941 AA302448 H19900 AA218956 AA513790 AA563962 AA398076 W44441 AA293276 W47373 AA625879 W30688 AA043029 T64284 R79151 AA304340 AA485186 AA604939 R82470 AA421425 AW771456 AI339329 AA304424 AA605236 AA936934 AA587673 AI209162 AI697301 AI479995 AI679814 A1361950 AW189125 AI955888 AI986019 BE301019 A1084792 AI310211 AW189307 AI022070 AW977204 AI146825 AW190163AW303281 AI828345 BE046043 AW029257 AA482268 AI246507 AI420729 AW084932 AW439514 AI890487 AW439692 AI523896 AI186612 AI659953 AI889773 AA687527 AW072694 AW262153 AW467371 AI613269 AI679238 D54404 AA158103 AW105527 AW149739 AW150361 AW268387 AW117708 AI951682 AI687440 AW674285 AA678365 AI587082 AA732095 AA019899 W45661 AA627300 BE613304 AA765891 AA612935 AI814658 AW316916 R66594 AA514640 AA025040 AA031472 AW732076 AA029797 AI244560 AI128734 AW381720 AI092360 AI263283 AW613175 AI890675 AI720156 AW631348 AI635106 AI278045 AA303979 AA703505 W45449 AW078661 AI292052 AW381707 AI147854 AW381743 AA158905 AA303258 AA888144 AW195967 AA428706 AA989559 AA617731 H19882 BE543418 AA830386 AA421302 W58652 T94995 AI869743 AI679145 AW085971 N98425 AA765136 AI347027 AI356955 AA928038 AI679717 AA458459 AA679281 AI367973 AI270041 AA765135 AA732793 AI798447 AA668646 AA251008 AI984538 AI401737 AA056186 BE043308 AW662375 AI302110 N50724 W96332 BE537047 N26983 AI567172 AA765296 AW673237 N29784 AA534275 AA084044 AW067973 AW300766 T63398 W46823 R39790 AI364185 AW298582 AA454814 AW069878 N67751 H05982 N23140 AI362647 AI302086 AI767772 N25755 H53114 AA706133 T93511 AA429291 AA935294 AA987647 W02803 R66595 AI680795 W23673 AW440794 AA722872 H49538 AW131042 AA531603 AA908665 AA040791 AA235312 W52205 N93444 R82180 H02759 H79696 AW088894 H56079 AA961143 AW067776 AW973745 AA016311 AW071227 AA017511 AI753994 W47374 T64155 AA296092 AI698626 AA558158 AA296088 AW794259 H01963 AA149267 AA485076 AA975856 H44938 AA035396 AI955555 H46289 AA486161 AI631222 AA359047 AW794253 AI806962 AW243930 AA526145 AW878734 AA018464 AA132031 R67220 R79152 AA296093 H54300 AI005160 BE242548 AW992803 AW878644 AW878666 T27742 R82471 AW517604 AW472738 AI282904 R39791 AA486098 AW467891 AW960520 AA551736 AA056621 AW945197 R66373 AA554236 BE242202 AI904376 AI832590 H19484 R00890 AI627677 AA302287 AI869451 AI734855 AI708073 AI832902 AA585184 AW204299 AA055565 D12417 D11975 T63543 AW664099 R54423 BE612712 T96340 T63985 AA598917 T40735 T64053 AA149284 AW272548 AA363445 AA042893 AW300697 BE261973 T53501 T53500 AW878729 AW878657 AW794391 AA069193 R01553 H44875 AA385406 AA533968 M93060 AL135600 W96331 AA017651 AA018849 AA017692 H85337 BE278690 AA731598 AA018512 AI076813 AI022644 R02585 X52220 AW296894 AA825671 AI699321 AI393601 AW592611 Al 146747 AA608921 AA158365 AW590007 AA354519 D20081 R02704 AW798339 M92422 AA094903 AA007676 133681 13893J AI352558 Z82248 X78138 NM 03405 AU077248 AA223125 S80794 D78577 AI124697 AW403970 BE614089 BE296713

BE621334 L20422 X80536 D54224 D54950 X57345 N29226 AA127798 AA340253 F08031 AA192540 H67636 AA321827 AW950283 AA084159 BE538808 AW401377 AA256774 C03366 W46595 W47608 AA305009 H69431 H69456 AL120082 H11706 AA303717 AA361357 H22042 H78020 AW999584 AA134368 AA322911 AA322961 H60980 N85248 N31547 H79624 T11718 W85826 AW894663 AW894624 BE167441 BE170015 AA304626 AW602163 AW998929 AA156681

AA151067 BE002724 AA608688 H82692 BE155392 AW383636 BE155394 AA487004 AW383504 AI342365 R82553 W16498 BE155344 AI143938 R69901 AA322873 AW340648 R25364 AA367935 AI559406 AA033522 AA374252 AW835019 AI922133 AI697089 N99662 AW189078 AI199076 AW151598 W59944 AA662875 W94022 AA299055 AI039008 AI829449 AA583503 AI635674 AW131665 AI473820 AW273118 AW900930 AA908944 AI688035 AW170272 AI082545 AW468176 AI608761 AI082748 AI911682 AI248943 AI831016 AA192465 AI218477 AA938406 AA385288

A1809817 AA905196 AI191245 AI470204 AI188296 AI421367 AI125315 AI087141 AA629032 AA740589 AI554181 AA150830 AI248541 AI077943 AA775958 AA864930 AI261476 AI123121 AI310394 AA862331 AA872478 BE537084 AI205606 AA720684 AI872093 AW150042 AL120538 AA219627 AA988608 C21397 AI359337 H25337 AI089749 AA605146 AI359620 AA150478 AI359738 AW383642 AW995424 AI766457 R56892 AI089839 W61343 N69107 W46459 AA565955 N20527 AI279782 W46596 AA776573 H23204 AI866231 AI083995 N21530 AA126874 D82630 W65437

AI086917 AW382095 AI086877 H69844 AW340217 W85827 L08439 AA262704 AA505380 W47413 W94135 AA223241 AW089153 AA084101 BE538000 AA096126 T28031 AA491574 R84813 AA774536 AW383522 AA155615 AW383529 AA491520 AW028427 AA171496 AI469689 AW664539 AI811102 AI8 1116 BE464590 BE350791 H78021 T15405 H21979 AA219489 H13301 AA505883 AI864305 AI423963 AW084401 F04963 R69858 H67097 AI917740 AI655561 H69864 AA033631 AW383484 AI886261 H25293 AA513281 AW271187 H11617 N79982 AH 74338 AI904207 AI904208 BE614558

W94127 W65436 AI272249 AA700018 AI579932 AI085941 AW152629 134403 17037J AA334551 BE008229AA307537AW961156AW995894AW995826 NM_006751 M61199 AA045603 AL036372 AV645606

AI688095 AW351901 AA101337 AA101345 N73342 BE018030 BE569044 AW841975 AA373388 BE090412 H95440 N53845 R67867 AA093441 AA363427 H93708 AW023134 AW994986 AW994989 BE090429 R23614 AI567932 H03726 H01101 H01867 AA548743 AI671806 AW872949 AW872941 AA742447 AI199788 AA045604 AI637465 AI741796

AW242217 AW131463 AI765302 AI683923 AA889762 AI804889 AI986437 C06049 BE502340 AI695651 AI491970 AA496804 AA281008 AA665699 AI473814 BE301445 AA707837 AA551925 AI017348 AI208185 AA775203 AA156296 AA557463 H95441 AA768547 AW769358 AA991197 AA181954 AI091389 AI147289 AW771837 AI638582 AA844411 AI374750 T29320 AW951272 AW085923 H02834 AA843259 AA814696 AW183290 AA158453 N68125 N69039 AA100423 AA101346 AI918720 H01102 R67868 H01868 N66438 R46580 A1858433 AA599560 AA187577 AA157481 AA361520

AL047827 AA158452 R21688 AW964874 AA325161 R40871 AW752395 AW375924 R13355 AA281174 AA428908 135096 33756_2 AA081258 AA160311 W17034 H83596 Z99393AI831206AW771108AW769214 N89775AW161495AW161522

AW160880 Z99394 AI814820 103767 34817J BE244667 BE241813 BE242271 AA381943 NM_016040 AF151858 AW967497 AW966873 AI824386 AW470133 AW015765 BE018650 AW503659 AI129838 AI632346 AA013099 AW770511 BE219482 AI824135 AI867379 AA019348

AA285143 AW087624 AI990100 AA251084 AI633962 AA287714 AA400773 AI292112 AW469095 AA743312 AW117423 AA694551 AA885657 AA112675 BE327333 AA082161 H03613 AA094735 AW500235 N28878 AA287713 AW300233 AA826249 N46921 BE348728 AW505056 AW966879 AI521202 AA393405 AI264668 AA910851 AA251721 AI470834 H03503 AA089688 R58562 BE004728 AA668793 H27167 R54717 103855 84277J W02363 N80298 AA304486 AW954799 AW805136 AW970817 AW373398 AW875459 AA136805 AA683501 N73299 AW341082 AI632954 AA493369 AI478433 AI037911 AW272169 AW043832 AA010683 AW629090 AW183622 N64510 AW079953 AI554533 AA563670 AA010682 AW237610 AW419057 AI470926 AI627833 AA195080 AA195179 AI471443 AW590266 AI168477 AW771214 AI767341 AW340086 AW748455 AI280079 AI244821 AI381283 AW300130 AW183374 AW195397 AA136706 AI824598 AW573004 Z98448 AA905255 AI497883

^— AW450979 AA136653 AA136656 AW419381 AA984358 AA492073 BE168945 AA809054 AW238038 BE011212 BE011359 BE011367 BE011368 BE011362 BE011215 BE011365 BE011363

113026 84431J AA376654 W76367 AA318232 AI694545 AI742403 AI887383 AW204731 AW874431 BE220997 AA114979 AA303838 AI002267 AW952031 W74801 AA011287 AA115112 AI306385 R37677 AW571707 R59986 W94102 AW197042 H10206 AW139819 AI686172 AI674165 R51633 AI367086 T23948 H10833 H23002 H11743 R37085 Z39208 H22794 H11820 R13817 Z43122 H10257 R88398 R18795 AA010848 R67191 H10875 R67170

120284 1589631 AA179656 AA182626 AA182603

112540 16052631 R69751 R70467 H69771 H80879 H80878

111904 17193361 Z41572R39330

121094 2757291 AA402505 AA398900

128510 198291 X94703 NM_004249 R52316 T87420 N46403 Z36855 BE076834

114106 11820961 AW602528 BE073859 Z38412

121335 2795481 AA404418AI217248

120761 2249031 AA321890 R18000

122050 2735072 AI453076 AI376075 AI014836 AA628633 AA961066 A1150282 AI028574 AI217182 AA732910 AA431478 AL041229

130018 189861 AA353093 AW957317 AW872498 AI560785 AI289110 AW135512 X97261 T68873

100104 19974 -3 AF008937

121822 2443911 AI743860 N49543 AW027759 BE349467 AI656284 BE463975 R35022 AA370031 AW955302 AL042109 N53092 A1611424 AL079362 A1969290 AI928016 BE394912 BE504220 BE467505 AI611611 AI611407 AI611452 W56437 AI284566 AI583349 AW183058 AI308085 AI074952 AA437315 AA628161 AW301728 AI150224 AA400137 AA437279 AI223355 AA639462 AI261373 A1432414 AI984994 AI539335 AA401550 AA358757 AI609976 AA442357 AA359393 AA437046 AA370301 AA429328 AW272055 A1580502 AI832944 AI038530 AA425107 AI014986 AI148349 AW237721 AW779756 AW137877 AI125293 AA400404 R28554

108280 110682J AA065069AA085108 108309 111495J AA069818 AA069971 AA069923 AA069908 107832 genbank_AA021473 AA021473 123523 genbank_AA608588 AA608588 123533 genbank_AA608751 AA608751 132225 genbank_AA128980 AA128980 125017 genbank_T68875 T68875 125063 genbank_T85352 T85352 125064 genbank_T85373 T85373 125091 genbank_T91518 T91518 100964 entrez_J00212 J00212 102269 entrez_U30245 U30245 125150 NOT_FOUND_en<rez_W38240 W38240 123964 genbank_C13961 C13961 118111 genbank_N55493 N55493 118129 genbank_N57493 N57493 102491 eπtrez_U51010 U51010 118329 genbank_N63520 N63520 118475 genbank_N66845 N66845 118581 genbank_N68905 N68905 111514 geπbank_R07998 R07998 104534 R22303_at R22303 120340 genbank_AA206828 AA206828 120376 genbank_AA227469 AA227469 104787 genbank_AA02731 AA027317 120409 genbank_AA235050 AA235050 120745 genbank_AA302809 AA302809 120809 genbank_AA346495 AA346495 120839 genbank_AA348913 AA348913 113702 genbank_T97307 T97307 106596 304084J AI583948 AA578212 AW303715 AA653450 AA456981 AI400385 W88533 AI224133 AW272145 AA088686 R94698 113947 genbank_W84768W84768 122562 genbank_AA452156 AA452156 122635 genbank_AA454085 AA454085 108277 genbank_AA064859 AA064859 108403 genbank_AA075374 AA075374 122860 genbank_AA464414 AA464414 108427 genbank_AA076382 AA076382 108439 genbank_AA078986 AA078986 131353 231290 1 AW411259 H23555 AW015049 AI684275 AW015886 AW068953 AW014085 AI027260 R52686 AA918278 AI129462 AA969360 N34869 AI948416 AA534205 AA702483 AA705292

108533 genbank_AA084415 AA084415 124254 genbank_H69899 H69899 101447 entrez M21305 M21305 101458 entrez M22092 M22092 101667 13349 J NM_005381 M60858 AW373732 AW373724 AW373689 AW373629 AW373609 AW373776 AA187806 AW386946 AW374207 T05235 AA216203 AW385556 AA306940 AA306526 AA315461 AL036757 AW373711 AW403124 AW403640 AW377084 T27360 H62638 F06957 AW377051 AA554779 AA378568 AA096007 AW352407 AW302637 F07929 H17433 AW382712 H05665 F07292 N39875 AA089729 H62556 N42842 R12952 AW373735 AW364155 AA056183 W39185 AW382708 N32488 AF114096 AW375993 AI133569 W52561 AA603040 AA133710 AI928796 AW176370 AA827519 AW338437 AA521142 T29341 AI800461 AW317002 AA703914 AA86083O AI859203 AI445772 AA714334 AI817066 A1832027 AW510442 AI635802 AW088306 AW068672 AW408555 AW467542 AA552657 AA152367 W32081 AA582124 AA074040 AA931657 AI051154 AW410203 AI921644 H17434 AI832330 AW404836 AI925038 AA088423 AA954166 AA580453 AW021292 AI267215 AW080082 AW383778 AI933053 AI919097 W31557 N90245 AA931591 AA563995 F36352 AA056184 AA476294 AA641327 AA533550 AI749630 W58323 AA569119 AA508573 AI809050 AI378996 AA411362 AW407505 AA938104 AA074041 AA632876 AW193748 AA507873 AI270128 AI472365 AA411363 AI523216 A1719965 AI816302 AA182681 AI707990 AA133588 AI758537 W60253 AI460308 AA135423 AI083904 F04188 N89693 AW408776 AI678595 AI270568 AA722059 W58234 F33650 AA090547 AA285108 AA425981 N85079 D20218 AI273980 AA159028 F03226 AW247914 N26918 AW272741 N90109 H05666 N23327 AW247953 R44748 AA962015 F03558 AI752394 AW409913 AW248396 AI816463 AI752393 AA325370 AA263089 AI570130 AI971951 AI160658 AI357360 AW168686 AL121075 AW050536 N21672 W67748 AA514242 AI127386 H14607 AI185752 W79364 AA088520 AA152476 AW351940 AW373683 AI940524 AW374953 T56500 N24329 AI940720 AW374933 AW374947 AW391913 AL138337 AW376241 AW062943 F26666 AW410202 AW062958 F34529 AW381807 AW393315 W17147 AW176359 AA664576 AW380424 AA306040 AI745674 AW300951 AI188579 AI438973 AI305271 AA433818 AA612807 AI831809 AI940409 AA158663 AI572988

124576 genbank_N68201 N68201 108931 genbank_AA147186 AA147186 108941 genbank_AA148650 AA148650 124720 144582 R05283 R11056 124793 genbank_R445 9 R44519 124799 genbank_R45088 R45088 103138 entrez_X65965 X65965 117683 genbank_N40180 N40180 124991 genbank_T50116 T50116 103432 entrez_X97748 X97748 119174 genbank_R71234 71234 119239 95573 2 T11483 T11472 133678 11235 AW247252 AA346143 NM_000270 AA381085 N91995 X00737 AA381079 AA296473 AA296110 AA315735 AA311617

AA326750 AA376804 AW403290 T95231 M13953 T47963 H82039 AA279899 AA627997 N76320 N99527 H37842 W20095 AA457308 AW469547 AA724143 H83220 AA319496 W86334 W30892 R89169 R99427 N41854 H47286 AA348094 AA045089 R63016 AI922219 AI024906 AI096488 AI885005 AA194872 N90489 AI452544 H72411 AA282427 AA430735 R68963 R22453 H70385 AW129369AW467320AW519082AA345018 AA582183 AI961789 R65918 N30611 AI979189 AI280889 AW273191 R66531 AI285845 AI675927 AI421990 AW190879 H37794 AA699667 H68427 AA954388 AI188757 AI140048 AA430382 AI204151 AW247864 AA559099 AI431420 AA548276 AI149466 AA772669 AA694388 AA724168 AA301651 AA281952 AA779925 AA234760 W86290 AA913603 AW511745 AI500697 AA814922 AA835040 T47964 H53998 AA975804 R98710 AI077604 N70252 R98084 AW250171 H69268 AI597614 AA970746 AA972548 AI377116 R62962 H16737 R89070 AA731329 R66532 N54354 AI818832 H81944 N71567 T95122 W86463 AA437095 AI431999 AI915724 N63851 A1674743 AA457307 AA211475 N64444 AI799146 H72853 R99335 H60413 AA770367 AA156105 AI269937 H64029 H89728 R65819 AW470496 AI873318 AI735713 H82987 C02447 AI478666 T27651 AI699770 AW025156 H69719 AI984717 N69225 AI459856 AA953577 AI424691 H13843 R22404 AI873796 A1336002

N70898 AI420854 AA541792 AA346142 AI000814 AI828348 AA045090 T51257 N90434 H13890 N73184 AI708083 AA781606 AA329050 AA339985 R68964 H64795 W04186 H16845

119416 genbank_T97186 T97186

119558 N0T_F0UND entrez_W38194 W38194 119559 NOT_FOUND_entrez_W38197 W38197

119654 genbank_W57759 W57759

121350 genbank_AA405237 AA405237

121558 genbank_AA4l2497 AA412497

105985 genbank_AA406610 AA406610 114648 genbank_AA101056 AA101056

121895 genbank_AA427396 AA427396

100327 entrez_D55640 D55640

123315 714071J AA496369 AA496646

123473 genbank_AA599143 AA599143

TABLE 4:

Pkey: Uniquε i Eos probeset identifier number

Accession: Accession number used for previous patent filings

ExAccn: Exemplar Accession number, Genbank accession number

UnigenelD: Uniger le number

Unigene Title: Unigene gene title

Pkey Accession ExAccn UniGene UnigeneTitle

100405 D86425 AW291587 Hs.82733 nidogen 2

100420 D86983 D86983 Hs.118893 Melanoma associated gene

100481 HG1098-HT1098 X70377 Hs.121489 cystatin D

100484 HG1103-HT1103 NM_005402Hs.288757 v-ral simian leukemia viral oncogene hom

100718 HG3342-HT3519 BE295928 Hs.75424 inhibitorof DNA binding 1, dominant neg

100991 J03764 J03836 Hs.82085 serine (or cysteine) proteinase inhibito

101097 L06797 BE245301 Hs.89414 chemokine (C-X-C motif), receptor 4 (fus

101168 L15388 NM_005308Hs.211569 G protein-coupled receptor kinase 5

101194 L20971 L20971 Hs.188 phosphodiesterase 4B, cAMP-specific (dun

101261 L35545 D30857 Hs.82353 protein C receptor, endothelial (EPCR)

101345 L76380 NM_005795Hs.152175 calcitonin receptor-like

101447 M21305 M21305 gb:Human alpha satellite and satellite 3

101485 M24736 AA296520 Hs.89546 sele in E (endothelial adhesion moiecul

101543 M31166 M31166 Hs.2050 pentaxin-related gene, rapidly induced b

101550 M31551 Y00630 Hs.75716 serine (or cysteine) proteinase inhibito

101560 M32334 AW958272 Hs.347326 intercellular adhesion molecule 2

101674 M61916 NM_002291Hs.82124 laminin, beta 1

101714 M68874 M68874 Hs.211587 phospholipase A2, group IVA (cytosolic,

101741 M74719 NM_003199Hs.326198 transcription factor 4

101838 M92934 BE243845 Hs.75511 connective tissue growth factor

101857 M94856 BE550723 Hs.153179 fatty acid binding protein 5 (psoriasis-

102012 U03057 BE259035 Hs.118400 singed (Drosophila)-like (sea urchin fas

102024 U03877 AA301867 Hs.76224 EGF-containiπg fibulin-like extracellula

102164 U18300 NM_000107Hs.77602 damage-specific DNA binding protein 2 (4

102241 U27109 NM_007351Hs.268107 multimerin

102283 U31384 AW161552 Hs.83381 guanine nucleotide binding protein 11

102303 U33053 U33053 Hs.2499 protein kinase C-like 1

102564 U59423 U59423 Hs.79067 MAD (mothers against decapentaplegic, Dr

102663 U70322 NM_002270Hs.168075 karyopherin (importin) beta 2

102759 U81607 NM_0051 OOHs.788 A kinase (PRKA) anchor protein (gravin)

102778 U83463 AF000652 Hs.8180 syndecan binding protein (syntenin)

102804 U89942 NM.002318HS.83354 lysyl oxidase-like 2

102887 X04729 J03836 Hs.82085 serine (or cysteine) proteinase inhibito

102898 X06256 NM_002205Hs.1496Q9 integrin, alpha 5 (fibronectin receptor,

102915 X07820 X07820 Hs.2258 matrix metalloproteinase 10 (stromelysin

103036 X54925 M13509 Hs.83169 matrix metalloproteinase 1 (interstitial

103037 X54936 BE018302 Hs.2894 placental growth factor, vascular endoth

103095 X60957 NM_005424Hs.78824 tyrosine kinase with immunoglobulin and

103158 X67235 BE242587 Hs.118651 hematopoietically expressed homeobox

103166 X67951 AA159248 Hs.180909 peroxiredoxin 1

103185 X69910 NM_006825Hs.74368 transmembrane protein (63kD), endoplasmi

103280 X79981 U84722 Hs.76206 cadherin 5, type 2, VE-cadherin (vascula

103554 Z18951 AI878826 Hs.74034 caveolin 1 , caveolae protein, 22kD

103850 AA187101 AA187101 Hs.213194 hypothetical protein MGC10895

104465 N24990 Z44203 Hs.26418 ESTs

104592 R81003 AW630488 Hs.25338 protease, serine, 23

104764 AA025351 AI039243 Hs.278585 ESTs

104786 AA027168 AA027167 Hs.10031 KIAA0955 protein

104850 AA040465 AL133035 Hs.8728 hypothetical protein DKFZp434G171

104865 AA045136 T79340 Hs.22575 B-cell CLUIymphoma 6, member B (zinc fi

104894 AA054087 AF065214 Hs.18858 phospholipase A2, group IVC (cytosolic,

104952 AA071089 AW076098 Hs.345588 desmoplakin (DPI, DPII)

104974 AA0859 8 Y12059 Hs.278675 bromodomain-containing 4

105178 AA187490 AA313825 Hs.21941 AD036 protein

105263 AA227926 AW388633 Hs.6682 solute carrier family 7, (cationic amino

105330 AA234743 AW338625 Hs.22120 ESTs

105376 AA236559 AW994032 Hs.8768 hypothetical protein FLJ10849

105729 AA292694 H46612 Hs.293815 Homo sapiens HSPC285 mRNA, partial eds

105826 AA398243 AA478756 Hs.194477 E3 ubiquitin ligase SMURF2

105977 AA406363 AK001972 Hs.30822 hypothetical protein FLJ11110

106008 AA411465 AB033888 Hs.8619 SRY (sex deteimining region Y)-box 18

106031 AA412284 X64116 Hs.171844 Homo sapiens cDNA: FLJ22296 fis, clone H

106124 AA423987 H93366 Hs.7567 Homo sapiens cDNA: FLJ21962 fis, clone H 106155 AA425309 AA425414 Hs.33287 nuclear factor l/B

106302 AA435896 AA398859 Hs.18397 hypothetical protein FLJ23221

106423 AA448238 AB020722 Hs.16714 Rho guanine exchange factor (GEF) 15

106793 AA478778 H94997 Hs.16450 ESTs

107174 AA621714 BE122762 Hs.25338 ESTs

107216 D51069 D51069 Hs.211579 melanoma cell adhesion molecule

107295 T34527 AA186629 Hs.80120 UDP-N-acetyl-a!pha-D-galactosamine:polyp

107385 U97519 NM 005397Hs.16426 podocalyxin-like

108756 AA127221 AA127221 Hs.117037 ESTs

108846 AA132983 AL117452 Hs.44155 DKFZP586G1517 protein

108888 AA135606 AA135606 Hs.189384 gb:zl10a05.s1 Soares_pregnant_uterus_NbH

109001 AA156125 AI056548 Hs.72116 hypothetical protein FLJ20992 similar to

109166 AA179845 AA219691 Hs.73625 RAB6 interacting, kinesin-like (rabkines

109456 AA232645 AW956580 Hs.42699 ESTs

109768 F10399 F06838 Hs.14763 ESTs

110107 H16772 AW151660 Hs.31444 ESTs

110906 N39584 AA035211 Hs.17404 ESTs

110984 N52006 AW613287 Hs.80120 UDP-N-acetyl-alpha-D-galactosamine:polyp

111006 N53375 BE387014 Hs.166146 Homer, neuronal immediate early gene, 3

111018 N54067 AI287912 Hs.3628 mitogen-activated protein kinase kinase

111133 N64436 AW580939 Hs.97199 complement component C1q receptor

111760 R26892 BE551929 Hs.268754 Homo sapiens cDNA FLJ11949 fis, clone HE

113073 T33637 N39342 Hs.103042 microtubule-associated protein 1B

113195 T57112 H83265 Hs.8881 ESTs, Weakly similar to S41044 chromosom

113923 W80763 AW953484 Hs.3849 hypothetical protein FLJ22041 similar to

114521 AA046808 AW139036 Hs.108957 40S ribosomal protein S27 isoform

115061 AA253217 AI751438 Hs.41271 Homo sapiens mRNA full length insert cDN

115096 AA255991 AI683069 Hs.175319 ESTs

115145 AA258138 AA740907 Hs.88297 ESTs

115819 AA426573 AA486620 Hs.41135 endomucin-2

115947 AA443793 R47479 Hs.94761 KIAA1691 protein

116314 AA490588 A1799104 Hs.178705 Homo sapiens cDNA FLH 1333 fis, clone PL

116339 AA496257 AK000290 Hs.44033 dipeptidyl peptidase 8

116430 AA609717 AK001531 Hs.66048 hypothetical protein FLJ10669

116589 D59570 AI557212 Hs.17132 ESTs, Moderately similarto I54374 gene

116733 F13787 AL157424 Hs.61289 synaptojanin 2

117023 H88157 AW070211 Hs.102415 Homo sapiens mRNA; cDNA DKFZp586N0121 (f

117186 H98988 H98988 Hs.42612 ESTs, Weakly similar to ALU1_HUMAN ALU S

117563 N34287 AF055634 Hs.44553 unc5 (C.elegans homolog) c

117997 N52090 N52090 Hs.47420 EST

118475 N66845 N66845 gb:za46d 1.s1 Soares fetal liver spleen

118581 N68905 N68905 gb:za69b09.s1 Soares fetaljung NbHL19W

119073 R32894 BE245360 Hs.279477 ESTs

119155 R61715 R61715 Hs.310598 ESTs, Moderately similar to ALU1_HUMAN A

119174 R71234 R71234 gb:yi54c08.s1 Soares placenta Nb2HP Homo

119221 R98105 C14322 Hs.250700 tryptase beta 1

119416 T97186 T97186 gb:ye50h09.s1 Soares fetal liver spleen

119866 W80814 AA496205 Hs.193700 Homo sapiens mRNA; cDNA DKFZp586l0324 (f

121335 AA404418 AA404418 gb:zw37e02.s1 Soares total fetus Nb2HF8

121381 AA405747 AW088642 Hs.97984 hypothetical protein FLJ22252 similar to

123160 AA488687 AA488687 Hs.284235 ESTs, Weakly similar to I38022 hypotheti

123473 AA599143 AA599143 gb:ae52d04.s1 Stratagene lung carcinoma

123523 AA608588 AA608588 gb:ae54e06.s1 Stratagene lung carcinoma

123533 AA608751 AA608751 gb:ae56h07.s1 Stratagene lung carcinoma

123964 C13961 C13961 gb:C13961 Clontech human aorta polyA÷ mR

124006 D60302 AI147155 Hs.270016 ESTs

124315 H94892 NM_005402Hs.288757 v-ral simian leukemia viral oncogene hom

124659 N93521 AI680737 Hs.289068 Homo sapiens cDNA FLJ11918 fis, clone HE

124669 N95477 AI571594 Hs.102943 hypothetical protein MGC12916

124847 R60044 W07701 Hs.304177 Homo sapiens clone FLB8503 PR02286 mRNA,

124875 R70506 AI887664 Hs.285814 sprouty (Drosophila) homolog 4

125091 T91518 T91518 gb:ye20f05.s1 Stratagene lung (937210) H

125103 T95333 AA570056 Hs.122730 ESTs, Moderately similar to KIAA1215 pro

125355 R45630 R60547 Hs.170098 KIAA0372 gene product

125565 R20839 R20840 gb:yg05c08.r1 Soares infant brain 1NIB H

125590 R23858 R23858 Hs.143375 Homo sapiens, clone IMAGE:3840937, mRNA,

423765 R23858 R23858 Hs.143375 Homo sapiens, clone IMAGE:3840937, mRNA,

126511 AI024874 T92143 Hs.57958 EGF-TM7-latrophilin-related protein

100286 W26247 BE247550 Hs.86859 growth factor receptor-bound protein 7

126563 W26247 AA516391 Hs.181368 U5 snRNP-specific protein (220 kD), orth

126649 AA856990 AA001860 Hs.279531 ESTs

449602 AA856990 AA001860 Hs.279531 ESTs

126872 AA136653 AW450979 gb:UI-H-BI3-ala-a-12-0-Ul.s1 NCI CGAP_Su

456000 AA136653 BE180876 Hs.11614 HSPC065 protein

414221 AA136653 AW450979 gb:UI-H-BI3-ala-a-12-0-Ul.s1 NCI_CGAP_Su

127402 AA358869 AA358869 Hs.227949 SEC13 (S. cerevisiae)-like 1 127651 AI123976 AA382523 Hs.105689 MSTP031 protein

424806 AI123976 AA382523 Hs.105689 MSTP031 protein

128062 AA379500 AA379621 Hs.105547 neural proliferation, differentiation an

128992 R49693 H04150 Hs.107708 ESTs

129046 AA195678 AB029290 Hs.108258 actin binding protein; macraphin (microf

129188 M30257 NM_001078Hs.109225 vascular cell adhesion molecule 1

129314 AA028131 BE622768 Hs.290356 mesoderm development candidate 1

129371 M10321 X06828 Hs.110802 von Willebrand factor

129468 J03040 AW410538 Hs.111779 secreted protein, acidic, cysteine-rich

129765 M86933 M86933 Hs.1238 amelogenin (Y chromosome)

129805 AA012933 AA012848 Hs.12570 tubuiin-specific chaperone d

129884 AA286710 AF055581 Hs.13131 lysosomal

130495 AA243278 AW250380 Hs.109059 mitochondrial ribosomal protein L12

130639 D59711 AI557212 Hs.17132 ESTs, Moderately similarto I54374 gene

130657 T94452 AW337575 Hs.201591 ESTs

130828 AA053400 AW631469 Hs.203213 ESTs

130972 AA370302 D81866 Hs.21739 Homo sapiens mRNA; cDNA DKFZp586l1518 (f

131080 J05008 NM 001955HS.2271 endothelin 1

131137 U85193 W27392 Hs.33287 nuclear factor l/B

131182 AA256153 AI824144 Hs.23912 ESTs

131486 X83107 F06972 Hs.27372 BMX non-receptor tyrosine kinase

131573 AA046593 AA040311 Hs.28959 ESTs

131647 AA410480 AA359615 Hs.30089 ESTs

131756 D45304 AA443966 Hs.31595 ESTs

131859 M90657 AW960564 transmembrane 4 superfamily member 1

131881 AA010163 AW361018 Hs.3383 upstream regulatory element binding prot

132050 AA136353 AI267615 Hs.38022 ESTs

132083 Y07867 BE386490 Hs.279663 Pirin

132164 U84573 AI752235 Hs.41270 procollagen-lysine, 2-oxoglutarate 5-dio

132358 X60486 NM_003542Hs.46423 H4 histone family, member G

132413 AA132969 AW361383 Hs.260116 metalloprotease 1 (pitrilysin family)

132456 AA114250 AB011084 Hs.48924 KIAA0512 gene product; ALEX2

132490 F13782 NM 001290HS.4980 LIM domain binding 2

132676 AA283035 N92589 Hs.261038 ESTs, Weakly similar to I38022 hypotheti

132687 AB002301 AB002301 Hs.54985 KIAA0303 protein

132718 AA056731 NM 004600Hs.554 Sjogren syndrome antigen A2 (60kD, ribon

132736 U68019 AW081883 Hs.211578 Homo sapiens cDNA: FLJ23037 fis, clone L

132760 H99198 AA125985 Hs.56145 thymosin, beta, identified in neuroblast

132933 AA598702 BE263252 Hs.6101 hypothetical protein MGC3178

132968 N77151 AF234532 Hs.61638 myosin X

132994 AA505133 AA112748 Hs.279905 clone HQ0310 PRO0310p1

133061 AB000584 AI186431 Hs.296638 prostate differentiation fador

133147 D12763 AA026533 Hs.66 interieukin 1 receptor-like 1

133161 AA253193 AW021103 Hs.6631 hypothetical protein FLJ20373

133200 AA432248 AB037715 Hs.183639 hypothetical protein FLJ10210

133260 AA083572 AA403045 Hs.6906 Homo sapiens cDNA: FLJ23197 fis, clone R

133363 AA479713 AI866286 Hs.71962 ESTs, Weakly similar to B36298 proline-r

133491 L40395 BE619053 Hs.170001 eukaryotic translation initiation factor

133517 X52947 NM_000165HS.74471 gap junction protein, alpha 1 , 43kD (con

133550 W80846 AI129903 Hs.74669 vesicle-associated membrane protein 5 (m

133607 M34539 BE273749 FK506-binding protein 1A (12kD)

133614 D67029 NM_003003Hs.75232 SEC14 (S. cerevisiae)-like 1

133627 U09587 NM_002047Hs.75280 glycyl-tRNA synthetase

133691 M85289 M85289 Hs.211573 heparan sulfate proteoglycan 2 (perlecan

133696 D10522 AI878921 Hs.75607 myristoylated alanine-rich protein kinas

133913 W84712 AU076964 Hs.7753 calumenin

133975 D29992 C18356 Hs.295944 tissue factor pathway inhibitor 2

133985 L34657 L34657 Hs.78146 platelet/endothelial cell adhesion molec

134039 S78569 NM_002290Hs.78672 laminin, alpha 4

134088 D43636 AI379954 Hs.79025 KIAA0096 protein

134161 U97188 AA634543 Hs.79440 IGF-II mRNA-binding protein 3

134299 AA487558 AW580939 Hs.97199 complement component C1 q receptor

134416 M28882 X68264 Hs.211579 melanoma cell adhesion molecule

116470 X70683 AI272141 Hs.83484 SRY (sex determining region Y)-box 4

134656 X14787 AI750878 Hs.87409 thrombospondin 1

134989 AA236324 AW968058 Hs.92381 nudix (nucleoside diphosphate linked moi

135051 C15324 AI272141 Hs.83484 SRY (sex determining region Y)-box 4

135073 AA452000 W55956 Hs.94030 Homo sapiens mRNA; cDNA DKFZp586E1624 (f

135349 D83174 AA114212 Hs.9930 serine (or cysteine) proteinase inhibito

100114 D00596 X02308 Hs.82962 thymidylate synthetase

100130 D11428 NM 000304HS.103724 peripheral myelin protein 22 -^'

100143 D13640 AU076465 Hs.278441 KIAA0015 gene product

100168 D14874 H73444 Hs.394 adrenomedullin

100208 D26129 NM_002933Hs.78224 ribonuclease, RNase A family, 1 (pancrea

100224 D28476 AL121516 Hs.138617 thyroid hormone receptor interactor 12

100405 D86425 AW291587 Hs.82733 nidogen 2 100420 D86983 D86983 Hs.118893 Melanoma associated gene 100455 D87953 AW888941 Hs.75789 N-myc downstream regulated 100529 HG1862-HT1897 BE313693 Hs.334330 calmodulin 2 (phosphorylase kinase, delt 100618 HG2614-HT2710 AI752163 Hs.114599 collagen, type VIII, alpha 1 100619 HG2639-HT2735 N24433 Hs.241567 RNA binding motif, single stranded inter 100658 HG2855-HT2995 U56725 Hs.180414 heat shock 70kD protein 2 100676 HG3044-HT3742 X02761 Hs.287820 fibronedin 1 100718 HG3342-HT3519 BE295928 Hs.75424 inhibltorof DNA binding 1, dominant neg 100752 HG3543-HT3739 T81309 insulin-like growth factor 2 (somatomedi 100828 HG4069-HT4339 AL048753 Hs.303649 small Inducible cytokine A2 (monocyte ch 100850 HG417-HT417 AA836472 Hs.297939 cathepsin B 100991 J03764 J03836 Hs.82085 serine (or cysteine) proteinase inhibito 101097 L06797 BE245301 Hs.89414 chemokine (C-X-C motif), receptor 4 (fus 101110 L08246 AI439011 Hs.86386 myeloid cell leukemia sequence 1 (BCL2-r 101142 L12711 L12711 Hs.89643 transketolase (Wernicke-Korsakoff syndro 101156 L13977 AA340987 Hs.75693 prolylcarboxypeptidase (angiotensinase C 101168 L15388 NM_005308Hs.211569 G protein-coupled receptor kinase 5 101184 L19871 NM_001674Hs.460 activating transcription factor 3 101192 L20859 BE247295 Hs.78452 solute carrier family 20 (phosphate tran 101317 L42176 L42176 Hs.8302 four and a half LIM domains 2 101336 L49169 NM_006732Hs.75678 FBJ murine osteosarcoma viral oncogene h 101345 L76380 NM_005795Hs.152175 calcitonin receptor-like 101400 M15990 M15990 Hs.194148 v-yes-1 Yamaguchi sarcoma viral oncogene 101475 M23254 BE410405 Hs.76288 calpain 2, (m/ll) large subunit 101485 M24736 AA296520 Hs.89546 selectin E (endothelial adhesion molecul 101496 M26576 X12784 Hs.119129 collagen, type IV, alpha 1 101505 M27396 AA307680 Hs.75692 asparagine synthetase 101543 M31166 M31166 Hs.2050 pentaxin-related gene, rapidly induced b 101557 M31994 BE293116 Hs.76392 aldehyde dehydrogenase 1 family, member 101560 M32334 AW958272 Hs.347326 intercellular adhesion molecule 2 101587 M35878 AI752416 Hs.77326 insulin-like growth factor binding prate 101592 M36429 AF064853 Hs.91299 guanine nucleotide binding protein (G pr 101633 M57730 NM_004428Hs.1624 ephrin-A1 101634 M57731 AV650262 Hs.75765 GR02 oncogene 101667 M60858 NM_005381 nucleolin 101682 M62994 AF043045 Hs.81008 filamin B, beta (actin-binding protein-2 101714 M68874 M68874 Hs.211587 phospholipase A2, group IVA (cytosolic, 101720 M69043 M69043 Hs.81328 nuclear factor of kappa light polypeptid 101741 M74719 NM_003199Hs.326198 transcription factor 4 101744 M75126 AI879352 Hs.118625 hexokinase 1 101793 M84349 W01076 Hs.278573 CD59 antigen p18-20 (antigen identified 101837 M92843 M92843 Hs.343586 zinc finger protein homologous to Zfp-36 101838 M92934 BE243845 Hs.75511 connective tissue growth factor 101840 M93056 AA236291 Hs.183583 serine (or cysteine) proteinase inhibito 101857 M94856 BE550723 Hs.153179 fatty acid binding protein 5 (psoriasis- 101864 M95787 BE392588 Hs.75777 transgelin 101931 S76965 NM_006823Hs.75209 protein kinase (cAMP-dependent, catalyti 101966 S81914 X96438 Hs.76095 immediate early response 3 102012 U03057 BE259035 Hs.118400 singed (Drosophila)-like (sea urchin fas 102013 U03100 BE616287 Hs.178452 catenin (cadherin-associated protein), a 102024 U03877 AA301867 Hs.76224 EGF-containing fibulin-like extracellula 102059 U08021 AI752666 Hs.76669 nicotinamide N-methyltransferase 102121 U14391 NM_004998Hs.82251 myosin IE 102283 U31384 AW161552 Hs.83381 guanine nucleotide binding protein 11 102300 U32944 AI929721 Hs.5120 dynein, cytoplasmic, light polypeptide 102378 U40369 AU076887 Hs.28491 spermidine/spermine NI-acetyltransferase 102395 U41 67 AU077005 Hs.92208 a disintegrin and metalloproteinase doma 102460 U48959 U48959 Hs.211582 myosin, light polypeptide kinase 102491 U51010 U51010 gb:Human nicotinamide N-methylfransferas 102499 U51478 BE243877 Hs.76941 ATPase, Na^K÷ transporting, beta 3 poly 102523 U53445 U53445 Hs.15432 downregulated in ovarian cancer 1 102560 U59289 R97457 Hs.63984 cadherin 13, H-cadherin (heart) 102564 U59423 U59423 Hs.79067 MAD (mothers against decapentaplegic, Dr 102589 U62015 AU076728 Hs.8867 cysteine-rich, angiogenic inducer, 61 102600 U63825 AI984144 Hs.66713 hepatitis delta antigen-interacting prot 102645 U67963 AL119566 Hs.6721 lysosomal 102687 U73379 NM_007019Hs.93002 ubiquitin carrier protein E2-C 102693 U73824 AA532780 Hs.183684 eukaryotic translation initiation factor 102709 U77604 AA122237 Hs.81874 microsomal glutathione S-transferase 2 102759 U81607 NM_005100Hs.788 A kinase (PRKA) anchor protein (gravin) 102804 U89942 NM_002318Hs.83354 lysyl oxidase-like 2 102882 X04412 AI767736 Hs.290070 gelsolin (amyloidosis, Finnish type) 102907 X06985 BE409861 Hs.202833 heme oxygenase (decycling) 1 102915 X07820 X07820 Hs.2258 matrix metalloproteinase 10 (stromelysin 102927 X12876 BE512730 Hs.65114 keratin 18 102960 X15729 AI904738 Hs.76053 DEAD/H (Asp-Glu-Ala-Asp/His) box polypep 103011 X52541 AJ243425 Hs.326035 early growth response 1

103020 X53416 X53416 Hs.195464 filamin A, alpha (actin-binding protein-

103029 X54489 AW800726 Hs.789 GR01 oncogene (melanoma growth stimulati

103036 X54925 M13509 Hs.83169 matrix metalloproteinase 1 (interstitial

103056 X57206 Y18024 Hs.78877 inositol 1 ,4,5-tϊisphosphate 3-kinase B

103080 X59798 AU077231 Hs.82932 cyclin D1 (PRAD1: parathyroid adenomatos

103095 X60957 NM_005424Hs.78824 tyrosine kinase with immunoglobulin and

103138 X65965 X65965 gb.Η.sapiens SOD-2 gene for manganese su

103176 X69111 AL021154 Hs.76884 inhibitor of DNA binding 3, dominant neg

103195 X70940 AA351647 Hs.2642 eukaryotic translation elongation factor

103347 X87838 AU077309 Hs.171271 catenin (cadherin-associated protein), b

103371 X91247 X91247 Hs.13046 thioredoxin reductase 1

103432 X97748 X97748 gb:H.sapiens PTX3 gene promoter region.

103471 Y00815 Y00815 Hs.75216 protein tyrosine phosphatase, receptor t

103967 AA303711 AL120051 Hs.144700 ephrin-B1

104447 L44538 AW204145 Hs.156044 ESTs

104764 AA025351 AI039243 Hs.278585 ESTs

104783 AA027050 AA533513 Hs.93659 protein disulfide isomerase related prat

104798 AA029462 AW952619 Hs.17235 Homo sapiens clone TCCCIA00176 mRNA sequ

104865 AA045136 T79340 Hs.22575 B-cell CLUIymphoma 6, member B (zinc fi

104877 AA047437 AI138635 Hs.22968 Homo sapiens clone IMAGE:451939, mRNA se

104894 AA054087 AF065214 Hs.18858 phospholipase A2, group IVC (cytosolic,

104952 AA071089 AW076098 Hs.345588 desmoplakin (DPI, DPII)

105113 AA156450 AB037816 Hs.8982 Homo sapiens, clone IMAGE:3506202, mRNA,

105178 AA187490 AA313825 Hs.21941 AD036 protein

105196 AA195031 W84893 Hs.9305 angiotensin receptor-like 1

105215 AA205724 AA205759 Hs.10119 hypothetical protein FLJ14957

105263 AA227926 AW388633 Hs.6682 solute carrier family 7, (cationic amino

105271 AA227986 AA807881 Hs.25329 ESTs

105330 AA234743 AW338625 Hs.22120 ESTs

105461 AA253216 BE539071 Hs.69388 hypothetical protein FLJ20505

105492 AA256210 AI805717 Hs.289112 CGl-43 protein

105493 AA256268 AL047586 Hs.10283 RNA binding motif protein 8B

105594 AA279397 AB024334 Hs.25001 tyrosine 3-monooxygenase/tryptophan 5-mo

105727 AA292379 AL135159 Hs.20340 KIAA1002 protein

105732 AA292717 AW504170 Hs.274344 hypothetical protein MGC12942

105767 AA346551 AW370946 Hs.23457 ESTs

105882 AA400292 W46802 Hs.81988 disabled (Drosophila) homolog 2 (mitogen

105936 AA404338 AI678765 Hs.21812 ESTs

106031 AA412284 X64116 Hs.171844 Homo sapiens cDNA: FLJ22296 fis, clone H

106124 AA423987 H93366 Hs.7567 Homo sapiens cDNA: FLJ21962 fis, clone H

106222 AA428594 AA356392 Hs.21321 Homo sapiens clone FLB9213 PR02474 mRNA,

106241 AA430108 BE019681 Hs.6019 Homo sapiens cDNA: FLJ21288 fis, clone C

106263 AA431462 W21493 Hs.28329 hypothetical protein FLJ 14005

106264 AA431470 AL046859 Hs.3407 protein kinase (cAMP-dependent, catalyti

106366 AA443756 AA186715 Hs.336429 RIKEN cDNA 9130422N19 gene

106454 AA449479 NM 014038Hs.5216 HSPC028 protein

106634 AA459916 W25491 Hs.288909 hypothetical protein FLJ22471

106724 AA465226 N48670 Hs.28631 Homo sapiens cDNA: FLJ22141 fis, clone H

106793 AA478778 H94997 Hs.16450 ESTs

106799 AA479037 BE313412 Hs.7961 Homo sapiens clone 25012 mRNA sequence

106842 AA482597 AF124251 Hs.26054 novel SH2-containing protein 3

106868 AA487561 BE185536 Hs.301183 molecule possessing ankyrin repeats indu

106890 AA489245 AA489245 Hs.88500 mitogen-activated protein kinase 8 inter

106961 AA504110 AW243614 Hs.18063 Homo sapiens cDNA FLJ10768 fis, clone NT

106974 AA520989 AI817130 Hs.9195 Homo sapiens CDNA FLJ13698 fis, clone PL

107030 AA599434 AL117424 Hs.25035 chloride intracellular channel 4

107061 AA608649 BE147611 Hs.6354 stromal cell derived factor receptor 1

107086 AA609519 NM_012331Hs.26458 methionine sulfoxide reductase A

107216 D51069 D51069 Hs.211579 melanoma cell adhesion molecule

107385 U97519 NM_005397Hs.16426 podocalyxin-like

107444 W28391 W28391 Hs.343258 proliferation-associated 2G4, 38kD

107985 AA035638 T40064 Hs.71968 Homo sapiens mRNA; cDNA DKFZp564F053 (fr

108507 AA083514 AI554545 Hs.68301 ESTs

108695 AA121315 AB029000 Hs.70823 KIAA1077 protein

108931 AA147186 AA147186 gb:zo38d01.s1 Stratagene endothelial eel

109001 AA156125 AI056548 Hs.72116 hypothetical protein FLJ20992 similar to

109195 AA188932 AF047033 Hs.132904 solute carrier family 4, sodium bicarbon

109390 AA219653 AW007485 Hs.87125 EH-domain containing 3

109456 AA232645 AW956580 Hs.42699 ESTs

109737 F10078 AA055415 Hs.13233 ESTs, Moderately similar to A47582 B-cel

110411 H48032 AW001579 Hs.9645 Homo sapiens mRNA for KIAA1741 protein,

110660 H82117 AA782114 Hs.28043 ESTs

110906 N39584 AA035211 Hs.17404 ESTs

111018 N54067 AI287912 Hs.3628 mitogen-activated protein kinase kinase

111091 N59858 AA300067 Hs.33032 hypothetical protein DKFZp434N185 111356 N90933 BE301871 Hs.4867 mannosyl (alpha-1 ,3-)-glycoprotein beta-

111378 N93764 AW160993 Hs.326292 hypothetical gene DKFZp434A1114

111741 R26124 AB020653 Hs.24024 KIAA0846 protein

111769 R27957 AW629414 Hs.24230 ESTs

112318 R55470 AW083384 Hs.11067 ESTs, Highly similar to T46395 hypotheti

112951 T16550 AA307634 Hs.6650 vacuolar protein sorting 45B (yeast homo

113057 T26674 AW194301 Hs.339283 Human DNA sequence from clone RP1-187J11

113195 T57112 H83265 Hs.8881 ESTs, Weakly similar to S41044 chromosom

113490 T88700 BE178110 Hs.173374 Homo sapiens cDNA FLJ10500 fis, clone NT

113542 T90527 H43374 Hs.7890 Homo sapiens mRNA for KIAA1671 protein,

113803 W42789 AW880709 Hs.283683 chromosome 8 open reading frame 4

113847 W60002 NM 005032HS.4114 plastin 3 (T isoform)

113910 W78175 AA113262 Hs.17901 Homo sapiens, clone IMAGE:3937015, mRNA,

113947 W84768 W84768 gb:zh53d03.s1 Soares_fetal_liver_spleen_

114047 W94427 AL035858 Hs.3807 FXYD domain-containing ion transport reg

115061 AA253217 AI751438 Hs.41271 Homo sapiens mRNA full length insert cDN

115819 AA426573 AA486620 Hs.41135 endomucin-2

115870 AA432374 NM 005985Hs.48029 snail 1 (drosophila homolog), zinc finge

115964 AA446622 AA987568 Hs.74313 KIAA1265 protein

116228 AA478771 AI767947 Hs.50841 ESTs

116264 AA482594 D51174 Hs.272239 lysosomal

116314 AA490588 AI799104 Hs.178705 Homo sapiens cDNA FLJ11333 fis, clone PL

116589 D59570 AI557212 Hs.17132 ESTs, Moderately similar to I54374 gene

117023 H88157 AW070211 Hs.102415 Homo sapiens mRNA; cDNA DKFZp586N0121 (f

117112 H94648 AW969999 Hs.293658 ESTs

117156 H97538 W73853 ESTs

117176 H98670 H45100 Hs.49753 uveal autoantigen with coiled coil domai

117280 N22107 M18217 Hs.172129 Homo sapiens cDNA: FLJ21409 fis, clone C

119559 W38197 W38197 Empirically selected from AFFX single pr

119866 W80814 AA496205 Hs.193700 Homo sapiens mRNA; cDNA DKFZp586l0324 (f

120655 AA287347 AA305599 Hs.238205 hypothetical protein PRO2013

121314 AA402799 W07343 Hs,182538 phospholipid scramblase 4

121335 AA404418 AA404418 gb:zw37e02.s1 Soares_total_fetus_Nb2HF8_

121822 AA425107 A1743860 metallothionein 1 E (functional)

121835 AA425435 AB033030 Hs.300670 KIAA1204 protein

122331 AA442872 AL133437 Hs.110771 Homo sapiens cDNA: FLJ21904 fis, clone H

122577 AA452860 AA829725 Hs.334437 hypothetical protein MGC4248

123160 AA488687 AA488687 Hs.284235 ESTs, Weakly similarto I38022 hypotheti

123486 AA599674 BE019072 Hs.334802 Homo sapiens cDNA FLJ14680 fis, clone NT

124059 F13673 BE387335 Hs.283713 ESTs, Weakly similar to S64054 hypotheti

124339 H99093 H99093 Hs.343411 DEAD/H (Asp-Glu-Ala-Asp/His) box polypep

124358 N22495 AW070211 Hs.102415 Homo sapiens mRNA; cDNA DKFZp586N0121 (f

124364 N23031 ^■ AF265555 Hs.250646 baculoviral IAP repeat-containing 6

124726 R15740 NM_003654Hs.104576 carbohydrate (keratan sulfate Gal-6) sul

124763 R39610 BE410405 Hs.76288 calpain 2, (m/ll) large subunit

125167 W45560 AL137540 Hs.102541 netrin 4

125304 Z39833 AL359573 Hs.124940 GTP-binding protein

125307 Z40583 AW580945 Hs.330466 ESTs

125329 AA825437 AA825437 Hs.58875 ESTs

107985 R66613 T40064 Hs.71968 Homo sapiens mRNA; cDNA DKFZp564F053 (fr

125598 R66613 T40064 Hs.71968 Homo sapiens mRNA; cDNA DKFZp564F053 (fr

125609 AA868063 AA868063 Hs.104576 carbohydrate (keratan sulfate Gal-6) sul

116024 AA128075 AA088767 Hs.83883 transmembrane, prostate androgen induced

418000 AA128075 AA932794 Hs.83147 guanine nucleotide binding protein-like

126399 AA128075 AA088767 Hs.83883 transmembrane, prostate androgen induced

127435 N66570 X69086 Hs.286161 Homo sapiens cDNA FLJ13613 fis, clone PL

127566 AI051390 AI051390 Hs.116731 ESTs

127619 AA627122 AA627122 Hs.163787 ESTs

434190 AA627122 AA627122 Hs.163787 ESTs

128453 X02761 X02761 Hs.287820 fibronectin 1

128495 AF010193 N M_005904Hs.100602 MAD (mothers against decapentaplegic, Dr

128515 AA149044 BE395085 Hs.10086 type I transmembrane protein Fn14

128580 U82108 U82108 Hs.101813 solute carrier family 9 (sodium/hydrogen

128623 D78676 BE076608 Hs.105509 CTL2 gene

128642 L35240 Z28913 Hs.102948 enigma (LIM domain protein)

128669 AA598737 W28493 Hs.180414 heat shock 70kD protein 8

128903 R69417 AW150717 Hs.345728 STAT induced STAT inhibitor 3

128914 AA232837 AW867491 Hs.107125 plasmalemma vesicle associated protein

129087 N72695 AI348027 Hs.108557 hypothetical protein PP1057

129188 M30257 NM_001078Hs.109225 vascular cell adhesion molecule 1

129226 M96843 BE222494 Hs.180919 inhibitor of DNA binding 2, dominant neg

129265 X68277 AA530892 Hs.171695 dual specificity phosphatase 1

129345 AA292440 R22497 Hs.110571 growth arrest and DNA-damage-inducible,

129468 J03040 AW410538 Hs.111779 secreted protein, acidic, cysteine-rich

129488 AA228107 AW966728 Hs.54642 methionine adenosyltransferase II, beta

101838 AA449789 BE243845 Hs.75511 connective tissue growth factor 413731 AA449789 BE243845 Hs.75511 connective tissue growth factor

129557 W01367 AL045404 Hs.46366 K1AA0948 protein

129619 AA610116 AA209534 Hs.284243 tetraspan NET-6 protein

129627 AA258308 T40064 Hs.71968 Homo sapiens mRNA; cDNA DKFZp564F053 (fr

129762 AA460273 AA453694 Hs.12372 tripartite motif protein TRIM2

129884 AA286710 AF055581 Hs.13131 lysosomal

130018 T68873 AA353093 metallothionein 1L

130147 D63476 D63476 Hs.172813 PAK-interacting exchange factor beta

130178 M62403 U20982 Hs.1516 insulin-like growth factor-binding prate

130282 X55740 BE245380 Hs.153952 5' nucleotidase (CD73)

130431 L10284 AW505214 Hs.155560 calnexin

130495 AA243278 AW250380 Hs.109059 mitochondrial ribosomal protein L12

130553 AA430032 AF062649 Hs.252587 pituitary tumor-transforming 1

130638 H16402 AW021276 Hs.17121 ESTs

130639 D59711 AI557212 Hs.17132 ESTs, Moderately similar to I54374 gene

130657 T94452 AW337575 Hs.201591 ESTs

130686 AA431571 BE548267 Hs.337986 Homo sapiens CDNA FLJ10934 fis, clone OV

130776 R79356 AF167706 Hs.19280 cysteine-rich motor neuron 1

130818 AA280375 AW190920 Hs.19928 hypothetical protein SP329

130840 Z49269 BE048821 Hs.20144 small inducible cytokine subfamily A (Cy

130899 Z41740 AI077288 Hs.296323 serum/glucocorticoid regulated kinase

131002 AA121543 AL050295 Hs.22039 KIAA0758 protein

131080 J05008 NM_001955Hs.2271 endothelin 1

131084 AA101878 NM_017413Hs.303084 apelin; peptide ligand for APJ receptor

131091 T35341 AJ271216 Hs.22880 dipeptidylpeptidase III

131107 N87590 BE620886 Hs.75354 GCN1 (general control of amino-acid synt

131182 AA256153 AI824144 Hs.23912 ESTs

131207 W74533 AF104266 Hs.24212 latrophilin

131319 U25997 NM_003155Hs.25590 stanniocalcin 1

131328 V01512 AW939251 Hs.25647 v-fos FBJ murine osteosarcoma viral onco

131509 X56681 X56681 Hs.2780 jun D proto-oncogene

131555 AA161292 T47364 Hs.278613 interferon, alpha-inducible protein 27

131564 AA491465 T93500 Hs.28792 Homo sapiens CDNA FLJ11041 fis, clone PL

131573 AA046593 AA040311 Hs.28959 ESTs

131692 D50914 BE559681 Hs.30736 KIAA0124 protein

131756 D45304 AA443966 Hs.31595 ESTs

131859 M90657 AW960564 transmembrane 4 superfamily member 1

131909 W69127 NM 016558Hs.274411 SCAN domain-containing 1

131915 AA316186 AI161383 Hs.34549 ESTs, Highly similar to S94541 1 clone 4

132046 AA384503 AI359214 Hs.179260 chromosome 14 open reading frame 4

132050 AA136353 AI267615 Hs.38022 ESTs

132151 AA044755 BE379499 Hs.173705 Homo sapiens cDNA: FLJ22050 fis, clone H

132164 U84573 A1752235 Hs.41270 procollagen-lysine, 2-oxoglutarate 5-dio

132187 AA058911 AA235709 Hs.4193 DKFZP58601624 protein

132303 AA620962 BE177330 Hs.325093 Homo sapiens cDNA: FLJ21210 fis, clone C

132314 AA285290 AF112222 Hs.323806 pinin, desmosome associated protein

132358 X60486 NM 003542HS.46423 H4 histone family, member G

132398 R31641 AA876616 Hs.16979 ESTs, Weakly similar to A43932 muc!n 2 p

132421 AA489190 AW163483 Hs.48320 double ring-finger protein, Dorfin

132490 F13782 NM 01290Hs.4980 LIM domain binding 2

132520 AA257993 AA257992 Hs.50651 Janus kinase 1 (a protein tyrosine kinas

132546 M24283 M24283 Hs.168383 intercellular adhesion molecule 1 (CD54)

132610 AA443114 AA160511 Hs.5326 amino acid system N transporter 2; porcu

132716 T35289 BE379595 Hs.283738 casein kinase 1, alpha 1

132840 N23817 BE218319 Hs.5807 GTPase Rab14

132883 AA047151 AA373314 Hs.5897 Homo sapiens mRNA; cDNA DKFZp586P1622 (f

132968 N77151 AF234532 Hs.61638 myosin X

132989 AA480074 AA480074 Hs.331328 hypothetical protein FLJ13213

132999 Y00787 Y00787 Hs.624 interieukin 8

133071 T99789 BE384932 Hs.64313 ESTs, Weakly similar to AF2571821 G-pro

133076 W84341 AW946276 Hs.6441 Homo sapiens mRNA; cDNA DKFZp586J021 (fr

133099 L09209 W16518 Hs.279518 amyloid beta (A4) precursor-like protein

133147 D12763 AA026533 Hs.66 interieukin 1 receptor-like 1

133149 T16484 AA370045 Hs.6607 AXIN1 up-regulated

133161 AA253193 AW021103 Hs.6631 hypothetical protein FLJ20373

133200 AA432248 AB037715 Hs.183639 hypothetical protein FLJ 10210

133220 X82200 NM 006074HS.318501 Homo sapiens mRNA full length insert cDN

133260 AA083572 AA403045 Hs.6906 Homo sapiens cDNA: FLJ23197 fis, clone R

133295 L00352 AI147861 Hs.213289 low density lipoprotein receptor (famili

133349 N75791 AW631255 Hs.8110 L-3-hydroxyacyl-Coenzyme A dehydrogenase

133391 X57579 AW103364 Hs.727 inhibin, beta A (activin A, activin AB a

133398 X02612 NM_000499Hs.72912 cytochrome P450, subfamily I (aromatic c

133436 H44631 BE294068 Hs.737 immediate early protein

133454 AA090257 BE547647 Hs.177781 hypothetical protein MGC5618

133478 X83703 X83703 Hs.31432 cardiac ankyrin repeat protein

133491 L40395 BE619053 Hs.170001 eukaryotic translation initiation factor 133510 AA227913 AW880841 Hs.96908 p53-induced protein

133517 X52947 NM 00165HS.74471 gap junction protein, alpha 1, 43kD (con

133526 M11313 AU077051 Hs.74561 alpha-2-macroglobulin

133538 L14837 NM_003257Hs.74614 tight junction protein 1 (zona occludens

133562 M60721 M60721 Hs.74870 H2.0 (Drosophila)-like homeo box 1

133584 D90209 D90209 Hs.181243 activating transcription factor 4 (tax-r

133590 T67986 T70956 Hs.75106 clusterin (complement lysis inhibitor, S

133617 AA148318 BE244334 Hs.75249 ADP-ribosylation factor-like 6 interacti

133651 U97105 AI301740 Hs.173381 dihydropyrimidinase-like 2

133671 T25747 AW503116 Hs.301819 zinc finger protein 146

133678 K02574 AW247252 nucleoside phosphorylase

133681 D78577 AI352558 tyrosine 3-monooxygenase/tryptophan 5-mo

133722 X53331 AW969976 Hs.279009 matrix Gla protein

133730 S73591 BE242779 Hs.179526 upregulated by 1,25-dihydroxyvitamin D-3

133750 X95735 BE410769 Hs.75873 zyxin

133802 L16862 AW239400 Hs.76297 G protein-coupled receptor kinase 6

133825 U44975 BE616902 Hs.285313 core promoter element binding protein

133838 M97796 BE222494 Hs.180919 inhibitor of DNA binding 2, dominant neg

133859 U86782 U86782 Hs.178761 26S proteasome-associated padl homolog

133889 AA099391 U48959 Hs.211582 myosin, light polypeptide kinase

133960 M19267 M19267 Hs.77899 tropomyosin 1 (alpha)

133975 D29992 C18356 Hs.295944 tissue factor pathway inhibitor 2

133977 L19314 AH 25639 Hs.250666 hairy (Drosophila)-homolog

134039 S78569 NM 002290HS.78672 laminin, alpha 4

134075 U28811 NM_012201Hs.78979 Golgi apparatus protein 1

134081 L77886 AL034349 Hs.79005 protein tyrosine phosphatase, receptor t

134164 C14407 AW245540 Hs.79516 brain abundant, membrane attached signal

134203 M60278 AA161219 Hs.799 diphtheria toxin receptor (heparin-bindi

134238 R81509 AA102179 Hs.160726 Homo sapiens cDNA FLJ11680 fis, clone HE

134299 AA487558 AW580939 Hs.97199 complement component C1q receptor

134332 D86962 D86962 Hs.81875 growth factor receptor-bound protein 10

134339 AA478971 R70429 Hs.81988 disabled (Drosophila) homolog 2 (mitogen

134343 D50683 D50683 Hs.82028 transforming growth factor, beta recepto

134381 U56637 AI557280 Hs.184270 capping protein (adin filament) muscle

134403 M61199 AA334551 sperm specific antigen 2

134416 M28882 X68264 Hs.211579 melanoma cell adhesion molecule

134493 X15183 M30627 Hs.289088 heat shock 90kD protein 1 , alpha

134558 S53911 NM 01773HS.85289 CD34 antigen

134817 U20734 AU076592 Hs.198951 jun B proto-oncogene

134983 D28235 D28235 Hs.196384 prostaglandin-endoperoxide synthase 2 (p

134989 AA236324 AW968058 Hs.92381 nudix (nucleoside diphosphate linked moi

135052 AA148923 AL136653 Hs.93675 decidual protein induced by progesterone

135062 AA174183 AK000967 Hs.93872 KIAA1682 protein

135069 AA456311 AA876372 Hs.93961 Homo sapiens mRNA; cDNA DKFZp667D095 (fr

135071 L08069 W27190 Hs.94 DnaJ (Hsp40) homolog, subfamily A, membe

135073 AA452000 W55956 Hs.94030 Homo sapiens mRNA; cDNA DKFZp586E1624 (f

135170 AA282140 T53169 Hs.9587 Homo sapiens cDNA: FLJ22290 fis, clone H

135196 J02854 C03577 Hs.9615 myosin regulatory light chain 2, smooth

135348 AA442054 U80983 Hs.268177 phospholipase C, gamma 1 (formerly subty

TABLE 4A

Table 4A shows the accession numbers for those pkeys lacking unigenelD's for Table 4. The pkeys in Table 7 lacking unigenelD's are represented within Tables 1-6A. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and

Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey: Unique Eos probeset identifier number

CAT number: Gene cluster number Accession: Genbank accession numbers

Pkey CAT Number Accession

100752 33207_21 T81309 BE019033 R94181 BE019198 NM_000612 J03242 AW411299 BE300064 BE297544 R94182 AW630108 T53723 D58853 H78073 H80594 BE299560 T48899 H70196 M17426 N77077 S77035 H58384 H61664 H78540 T84527 C17198 H60255 H71980 R92644 W79050 X00910 M29645 R91055 M17863 M17862 T71815 BE299561 BE464561 X06260 R94741 T54216 C18594 BE262015 X06161 AW409889 AA378400 BE263228 BE313278 R88116 BE313457 H43500 T48617 BE313761 H77309 AI207601 X06159 H40413 X03425 T87663 R10627 X03562 M14118 W03982 R97520 H81229 T83157 H83168 H48762 AA669898 BE263054 H47289 AA022807 R11555 H74260 R76968 R28338 H72534 H72464 H62031 N72478 N45355 AW411300 R89113 R69135 H58454T83281 R93476 H69645 H68015 T82229 H71089 T85121 H59939 W65299 N78176 H53909 N72373 R21788 H04660 H59639 H61874 BE262219 T53614 N73335 N50464 W00943 N77189 R89257 AA570502 R89432 R06366 AA553480 AA776271 AA551359 AA551050 H51670 AA601052 BE299081 H68198 H52276 BE207832 N91192 H70332 X07868 X07868 H69464 H53782 H73710 R80435 AA553384 AW884176 N53475 T71662 AW954036 AW954033 AA552931 H93206 AA430218 AA553476 AI918470 T54124 BE207982 BE300177 N73994 AW882625 N39549 N53838 AA722389 H71878 H58909 H37849 H78435 T47933 R77174 R83814 AA411890 H94199 AA663208 BE205778 AA490137 H70492 R98232 H37800 AA679294 H40341 H74238 H47290 H73231 T48618 AA025428 AI039521 H92969 N59389 H80538 H72933 T90630 AA411891 N55000 H74225 AA340290 AW957061 T54316 AA340437 H57125 H58908 H79027 H63450 N74623 R93425 H68714 H68758 N68396 H48763 N69256 H57320 H53831 H53589 N68833 N52453 H56048 H69870 H78074 R69253 R83375 T53615 H94330 H58455 H90864 T47934 H74261 R89258 R97997 R91056 R28339 R86760 H78235 R97521 H67692 H40358 AA022688 H52513 H59601 T88690 H65256 H63397 W65397 AA553588 R19280 N52645 W73930 R06367 R21743 H72372 N73921 AW883539 AW882639 T40616 H47084 R95723 AA634316AA862781 H77310 R91389 H93111 R92767 T54512 R89341 H70333 H5781 H82941 H62032 N52638 H58385 T91796 H51086 AA340292 T49918 H81230 R36121 N50411 T87664 N62436 N39340 AA665637 AA340446 H93377 H92973 BE296290 BE269788 H61665 AA340444 N54605 AA454101 R10628 R94200 AI200549 AA342640 BE298855 BE250229 T49916 H82008 N28278 AW880662 H71268 N76791 H47685 H65255 W05198 AW889144 N76677 H71702 H68036 H71915 R91612 R87807 H68059 AI133328 AI247866 AA621443 AW881050 AA700847 AA340413 AW878608AW881 81 AW878249 H71916 N54596 BE161581 AW878082 W04212 AW881040 AW885492 AW880519 AA334887 AW878715 W06882 AW630222 AW885381 H70869 AW381778 H47601 AW889982 H63868 AW884986 AW878713 AW878685 R36391 AW878694 AA368070 C03393 AW878695 AW878705 AW878665 AW878742 AW878620 AW878823 AW878688 R29048 AW878690 AW878686 AW878810 AW878827 AW878733 AW878659 AW878749 AW878681 AW883353 AW883277 AW883300 AW883565 AW883298 AW883143 AW883045 AW883482 AW883352 AW883417 AW883357 AW883231 AW883474 AW883355 AW882620 AW882533 AW883754 AW883139 AW882827 AW883641 AW883567 AW883481 AW882983 AW882982 AW882465 AW883419 AW882466 AW883639 AW883230 AW882981 AW882534 AW882874 AW882619 AW883480 AW882826 AW882831 AW882835 AW882830 AW883563 AW882456 AW627642

117156 145392J W73853 AA928112 W77887 AW889237 AA148524 AI749182 AI754442 AI338392 AI253102 AI079403 AI370541 AI697341 H97538 AW188021 AI927669 W72716 AI051402 AI188071 AI335900 N21488 AW770478 W92522 AI691028 AI913512 AH44448 W73819 AA604358 N28900 W95221 AI868132 H98465 AA148793

131859 3672J AW960564 AA092457 T55890 D56120 T92525 AI815987 BE182608 BE182595 AW080238 M90657 AA347236 AW961686 AW176446 AA304671 AW583735 T61714 AA316968 AI446615 AA343532 AA083489 AA488005 W52095 W39480 N57402 D82638 W25540 W52847 D82729 D58990 BE619182 AA315188 AA308636 AA112474 W76162 AA088544 H52265 AA301631 H80982 AA113786 BE620997 AW651691 AA343799 BE613669 BE547180 BE546656 F11933 AA376800 AW239185 AA376086 BE544387 BE619041 AA452515 AA001806 AA190873 AA180483 AA159546 F00242 AI940609 A1940602 AI189753 T97663 T66110 AW062896 AW062910 AW062902 AI051622 AI828930 AA102452 AI685095 AI819390 AA557597 AA383220 AI804422 AI633575 AW338147 AW603423 AW606800 AW750567 AW510672 AI250777 AA083510 AW629109 AW513200 AA921353 AI677934 AI148698 AI955858 AA173825 AA453027 AI027865 AW375542 AA454099 AA733014 AI591384 R79300 R80023 AA843108 AA626058 AA844898 AW375550 AA889018 AI474275 AW205937 AI052270AW388117 AW388111 AA699452 AI242230 N47476 H38178AA366621 AA113196 AA130023 H39740 T61629 AI885973 AW083671 AA179730 AA305757 AI285455 N83956 AA216013 AA336155 AW999959 T97525 AA345349 T91762 AA771981 AI285092 AI591386 BE392486 BE385852 AA682601 AI682884 AA345840 T85477 AA292949 AA932079 AA098791 D82607 T48574 AW752038 C06300

125565 1704098J R20840 R20839 133607 1227_6 BE273749 BE397561 BE387189 AL037858 AL037878 AI963094 BE259216 AA011363 AL036189 BE562325 AA251169 BE617431 N98537 AA158093 AL047800 M34539 NM_000801 AA312140 D16971 AA158904 AA307114 AA312803 T09203 AW629686 AL048504 BE388578 AA220957 AA158364 BE267385 AA294971 C18055 BE241757 AA115056 AI936769 BE378435 BE206971 AW674924 BE622060 AA604674 AA115273 AW402159 AA338608 BE568819 M80199 X55741 AA375111 AA376016 BE612671 AA805742AW405588 N25850 44580 H06031 AW403549 BE536552 AA056726 BE543239 AA082517 AI201645 AI201642 AI192622 N40104 AA370921 BE547569 AI969602 AA302038 AI197890 AW268354 AI014938 W45448 AI541395 AA037272 BE538826 AL039613 BE536130 AA299355 AW805147 AW974624 H53220 AI471471 AA399303 AA007386 W35106 BE613277 R12739 R12738 AA304342 AA687802 BE409581 AI498844 AV662092AW904105 AA011375 BE315214 H99302 BE537893 N32299 AW855829 AI291320 BE078322 AI301395 AA303362 N32719 AA358328 AA357877 AI952540 H56279 H02758 H02048 AW805233 R82224 AA410772 AA291352 BE171109 N69935 BE169248 AA361173 H44978 BE617887 D52560 AA084043 W03595 R67219 N36477 N42924 R67104 H44901 H79695 W21105 AA393988 W30899 AA316096 BE622896 W46872 AA442678 BE544893 BE540112 BE621873 AA338067 N55052 BE398154 BE621210 AA740760 C03739 C03206 BE396692 AA482370 AA031614 AA301575 AA304710 AA132153 AA029796 AA994960 H19567 AA442969 H49781 H46871 AA035395 AA056185 AA149378 AA643080 AL135479 AA292329 AA654337 AA041228 AA454888 AA025039 W58331 AA625981 T94941 AA302448 H19900 AA218956 AA513790 AA563962 AA398076 W44441 AA293276 W47373 AA625879 W30688 AA043029 T64284 R79151 AA304340 AA485186 AA604939 R82470 AA421425 AW771456 AI339329 AA304424 AA605236 AA936934 AA587673 AI209162 A1697301 AI479995 AI679814 AI361950 AW189125 AI955888 AI986019 BE301019 AI084792 AI310211 AW189307 AI022070 AW977204 AI146825 AW190163 AW303281 AI828345 BE046043 AW029257 AA482268 AI246507 AI420729 AW084932 AW439514 AI890487 AW439692 AI523896 AI186612 AI659953 AI889773 AA687527 AW072694 AW262153 AW467371 AI613269 AI679238 D54404 AA158103 AW105527 AW149739 AW150361 AW268387 AW117708 A1951682 AI687440 AW674285 AA678365 AI587082 AA732095 AA019899 W45661 AA627300 BE613304 AA765891 AA612935 AI814658 AW316916 R66594 AA514640 AA025040 AA031472 AW732076 AA029797 AI244560 AI128734 AW381720 AI092360 AI263283 AW613175 AI890675 AI720156 AW631348 AI635106 AI278045 AA303979 AA703505 W45449 AW078661 AI292052 AW381707 AI147854 AW381743 AA158905 AA303258 AA888144 AW195967 AA428706 AA989559 AA617731 H19882 BE543418 AA830386 AA421302 W58652 T94995 AI869743 AI679145 AW085971 N98425 AA765136 AI347027 AI356955 AA928038 AI679717 AA458459 AA679281 AI367973 AI270041 AA765135 AA732793 AI798447 AA668646 AA251008 AI984538 AI401737 AA056186 BE043308 AW662375 AI302110 N50724 W96332 BE537047 N26983 AI567172 AA765296 AW673237 N29784 AA534275 AA084044 AW067973 AW300766 T63398 W46823 R39790 AI364185 AW298582 AA454814 AW069878 N67751 H05982 N23140 AI362647 AI302086 AI767772 N25755 H53114 AA706133 T93511 AA429291 AA935294 AA987647 W02803 R66595 AI680795 W23673 AW440794 AA722872 H49538 AW131042 AA531603 AA908665 AA040791 AA235312 W52205 N93444 R82180 H02759 H79696 AW088894 H56079 AA961143 AW067776 AW973745 AA016311 AW071227 AA017511 AI753994 W47374 T64155 AA296092 AI698626 AA558158 AA296088 AW794259 H01963 AA149267 AA485076 AA975856 H44938 AA035396 AI955555 H46289 AA486161 AI631222 AA359047 AW794253 AI806962 AW243930 AA526145 AW878734 AA018464 AA132031 R67220 R79152 AA296093 H54300 AI005160 BE242548 AW992803 AW878644 AW878666 T27742 R82471 AW517604 AW472738 AI282904 R39791 AA486098 AW467891 AW960520 AA551736 AA056621 AW945197 R66373 AA554236 BE242202 AI904376 AI832590 H19484 R00890 AI627677 AA302287 AI869451 AI734855 AI708073 AI832902 AA585184 AW204299 AA055565 D12417 D11975 T63543 AW664099 R54423 BE612712T96340 T63985 AA598917 T40735 T64053 AA149284 AW272548 AA363445 AA042893 AW300697 BE261973 T53501 T53500 AW878729 AW878657 AW794391 AA069193 R01553 H44875 AA385406 AA533968 M93060 AL135600 W96331 AA017651 AA018849 AA017692 H85337 BE278690 AA731598 AA018512 AI076813 AI022644 R02585 X52220 AW296894 AA825671 AI699321 AI393601 AW592611 AI146747 AA608921 AA158365 AW590007 AA354519 D20081 R02704 AW798339 M92422 AA094903 AA007676

133681 13893J AI352558 Z82248 X78138 NM_003405 AU077248 AA223125 S80794 D78577 AI124697 AW403970 BE614089 BE296713

BE621334 L20422 X80536 D54224 D54950 X57345 N29226 AA127798 AA340253 F08031 AA192540 H67636 AA321827 AW950283 AA084159 BE538808 AW401377 AA256774 C03366 W46595 W47608 AA305009 H69431 H69456 AL120082 H11706 AA303717 AA361357 H22042 H78020 AW999584 AA134368 AA322911 AA322961 H60980 N85248 N31547 H79624 T11718 W85826 AW894663 AW894624 BE167441 BE170015 AA304626 AW602163 AW998929 AA156681 AA151067 BE002724 AA608688 H82692 BE155392 AW383636 BE155394 AA487004 AW383504 AI342365 R82553 W16498 BE155344 AI143938 R69901 AA322873 AW340648 R25364 AA367935 AI559406 AA033522 AA374252 AW835019 AI922133 AI697089 N99662 AW189078 AI199076 AW151598 W59944 AA662875 W94022 AA299055 AI039008 AI829449 AA583503 AI635674 AW131665 AI473820 AW273118 AW900930 AA908944 AI688035 AW170272 AI082545 AW468176 AI608761 AI082748 AI911682 AI248943 AI831016 AA192465 AI218477 AA938406 AA385288 AI809817 AA905196 AI191245 AI470204 AI188296 AI421367 AI125315 AI087141 AA629032 AA740589 AI554181 AA150830 AI248541 AI077943 AA775958 AA864930 AI261476 AI123121 AI310394 AA862331 AA872478 BE537084 AI205606 AA720684 AI872093 AW150042 AL120538 AA219627 AA988608 C21397 AI359337 H25337 A1089749 AA605146 AI359620 AA150478 AI359738 AW383642 AW995424 AI766457 R56892 AI089839 W61343 N69107 W46459 AA565955 N20527 AI279782 W46596 AA776573 H23204 AI866231 AI083995 N21530 AA126874 D82630 W65437 AI086917 AW382095 AI086877 H69844 AW340217 W85827 L08439 AA262704 AA505380 W47413 W94135 AA223241 AW089153 AA084101 BE538000 AA096126 T28031 AA491574 R84813 AA774536 AW383522 AA155615 AW383529 AA491520 AW028427 AA171496 AI469689 AW664539 AI811102 AI811116 BE464590 BE350791 H78021 T15405 H21979 AA219489 H13301 AA505883 AI864305 AI423963 AW084401 F04963 R69858 H67097 AI917740 AI655561 H69864 AA033631 AW383484 AI886261 H25293 AA513281 AW271187 H11617 N79982 AI174338 AI904207 AI904208 BE614558 W94127 W65436 AI272249 AA700018 AI579932 AI085941 AW152629

134403 17037J AA334551 BE008229AA307537AW961156AW995894AW995826 M_006751 M61199 AA045603 AL036372 AV645606

AI688095 AW351901 AA101337 AA101345 N73342 BE018030 BE569044 AW841975 AA373388 BE090412 H95440 N53845 R67867 AA093441 AA363427 H93708 AW023134 AW994986 AW994989 BE090429 R23614 A1567932 H03726 H01101 H01867 AA548743 AI671806 AW872949 AW872941 AA742447 AI199788 AA045604 AI637465 AI741796 AW242217 AW131463 AI765302 AI683923 AA889762 A1804889 AI986437 C06049 BE502340 AI695651 A1491970 AA496804 AA281008 AA665699 AI473814 BE301445 AA707837 AA551925 AI017348 AI208185 AA775203 AA156296 AA557463 H95441 AA768547 AW769358 AA991197 AA181954 AI091389 AI147289 AW771837 AI638582 AA844411 AI374750 T29320 AW951272 AW085923 H02834 AA843259 AA814696 AW183290 AA158453 N68125 N69039 AA100423 AA101346 AI918720 H01102 R67868 H01868 N66438 R46580 AI858433 AA599560 AA187577 AA157481 AA361520 AL047827 AA158452 R21688 AW964874 AA325161 R40871 AW752395 AW375924 R13355 AA281174 AA428908

126872 142696J AW450979 AA136653 AA136656 AW419381 AA984358 AA492073 BE168945 AA809054 AW238038 BE011212 BE011359

BE011367 BE011368 BE011362 BE011215 BE011365 BE011363

121335 279548J AA404418 AI217248

130018 18986J AA353093 AW957317 AW872498 AI560785 AI289110 AW135512 X97261 T68873

121822 244391J AI743860 N49543 AW027759 BE349467 AI656284 BE463975 R35022 AA370031 AW955302 AL042109 N53092 AI611424

AL079362 AI969290 AI928016 BE394912 BE504220 BE467505 AI611611 AI611407 AI611452 W56437 AI284566 AI583349 AW183058 AI308085 AI074952 AA437315 AA628161 AW301728 AI150224 AA400137 AA437279 AI223355 AA639462 AI261373 AI432414 AI984994 A1539335 AA401550 AA358757 AI609976 AA442357 AA359393 AA437046 AA370301 AA429328 AW272055 AI580502 AI832944 AI038530 AA425107 AI014986 AI148349 AW237721 AW779756 . AW137877 AI125293 AA400404 R28554

123523 genbank_AA608588 AA608588 123533 genbank_AA608751 AA608751

125091 genbank_T91518 T91518

123964 genbank_C13961 C13961

102491 entrez_U51010 U51010 118475 genbank_N66845 N66845

118581 genbank_N68905 N68905

113947 genbank_W84768W84768

101447 entrez_M21305 M21305

101667 13349 1 NM_005381 M60858 AW373732 AW373724 AW373689 AW373629 AW373609 AW373776 AA187806 AW386946 AW374207 T05235 AA216203 AW385556 AA306940 AA306526 AA315461 AL03675 AW373711 AW403124AW403640

AW377084 T27360 H62638 F06957 AW377051 AA554779 AA378568 AA096007 AW352407 AW302637 F07929 H17433 AW382712 H05665 F07292 N39875 AA089729 H62556 N42842 R12952 AW373735 AW364155 AA056183 W39185 AW382708 N32488 AF114096 AW375993 AI133569 W52561 AA603040 AA133710 AI928796 AW176370 AA827519 AW338437 AA521142 T29341 AI800461 AW317002 AA703914 AA860830 AI859203 AI445772 AA714334 AI817066 AI832027 AW510442 AI635802 AW088306 AW068672 AW408555 AW467542 AA552657 AA152367 W32081 AA582124

AA074040 AA931657 AI051154 AW410203 AI921644 H17434 AI832330 AW404836 AI925038 AA088423 AA954166 AA580453 AW021292 AI267215 AW080082 AW383778 AI933053 AI919097 W31557 N90245 AA931591 AA563995 F36352 AA056184 AA476294 AA641327 AA533550 AI749630 W58323 AA569119 AA508573 AI809050 AI378996 AA411362 AW407505 AA938104 AA074041 AA632876 AW193748 AA507873 AI270128 AI472365 AA411363 AI523216 AI719965 AI816302 AA182681 AI707990 AA133588 AI758537 W60253 AI460308 AA135423 AI083904 F04188 N89693

AW408776 AI678595 AI270568 AA722059 W58234 F33650 AA090547 AA285108 AA425981 N85079 D20218 AI273980 AA159028 F03226 AW247914 N26918 AW272741 N90109 H05666 N23327 AW247953 R44748 AA962015 F03558 AI752394 AW409913 AW248396 AI816463 AI752393 AA325370 AA263089 AI570130 AI971951 AI160658 AI357360 AW168686 AL121075 AW050536 N21672 W67748 AA514242 AI127386 H14607 AI185752 W79364 AA088520 AA152476 AW351940 AW373683 AI940524 AW374953 T56500 N24329 AI940720 AW374933 AW374947 AW391913 AL138337

AW376241 AW062943 F26666 AW410202 AW062958 F34529 AW381807 AW393315 W17147 AW176359 AA664576 AW380424 AA306040 AI745674 AW300951 AI188579 AI438973 AI305271 AA433818 AA612807 AI831809 AI940409 AA158663 AI572988

108931 genbank_AA147186 AA147186 103138 entrez_X65965 X65965

103432 entrez_X97748 X97748

119174 genbank_R71234 R71234

133678 11235 1 AW247252 AA346143 NM 000270 AA381085 N91995 X00737 AA381079 AA296473 AA296110 AA315735 AA311617

AA326750 AA376804 AW403290 T95231 M13953 T47963 H82039 AA279899 AA627997 N76320 N99527 H37842 W20095 AA457308 AW469547 AA724143 H83220 AA319496 W86334 W30892 R89169 R99427 N41854 H47286

AA348094 AA045089 R63016 AI922219 AI024906 AI096488 AI885005 AA194872 N90489 AI452544 H72411 AA282427 AA430735 R68963 R22453 H70385 AW129369 AW467320 AW519082 AA345018 AA582183 AI961789 R65918 N30611 AI979189 AI280889 AW273191 R66531 AI285845 AI675927 AI421990 AW190879 H37794 AA699667 H68427 AA954388 AI188757 AI140048 AA430382 AI204151 AW247864 AA559099 AI431420 AA548276 AI149466 AA772669 AA694388 AA724168 AA301651 AA281952 AA779925 AA234760 W86290 AA913603 AW511745 AI500697 AA814922 AA835040

T47964 H53998 AA975804 R98710 AI077604 N70252 R98084 AW250171 H69268 A1597614 AA970746 AA972548 AI377116 R62962 H16737 R89070 AA731329 R66532 N54354 AI818832 H81944 N71567 T95122 W86463 AA437095 AI431999 AI915724 N63851 AI674743 AA457307 AA211475 N64444 AI799146 H72853 R99335 H60413 AA770367 AA156105 AI269937 H64029 H89728 R65819 AW470496 AI873318 AI735713 H82987 C02447 AI478666 T27651 AI699770 AW025156 H69719 AI984717 N69225 AI459856 AA953577 A1424691 H13843 R22404 AI873796 AI336002

N70898 AI420854 AA541792 AA346142 AI000814 AI828348 AA045090 T51257 N90434 H13890 N73184 AI708083 AA781606 AA329050 AA339985 R68964 H64795 W04186 H16845

119416 genbank_T97186 T97186

119559 NOT_FOUND_entrez_W38197 W38197 123473 geπbaπk_AA599143 AA599143

TABLE 5:

Pkey: Unique Eos probeset identifier number

Accession: Accession number used for previous patent filings

ExAccn: Exemplar Accession number, Genbank accession number

UnigenelD: Unigene number

Unigene Title: Unigene gene title

Pkey Accession ExAccn UniGene UnigeneTifle

115819 AA426573 AA486620 Hs.41135 AA486620 132837 D58024 AA370362 Hs.57958 AA370362 101545 M31210 BE246154 Hs.154210 BE246154 102898 X06256 NM_002205Hs.149609 NM_002205 101192 L20859 BE247295 Hs.78452 BE247295 102915 X07820 X07820 Hs.2258 X07820 105330 AA234743 AW338625 Hs.22120 AW338625 107385 U97519 NM_005397Hs.16426 NM_005397 102024 U03877 AA301867 Hs.76224 AA301867 134416 M28882 X68264 Hs.211579 X68264 103036 X54925 M13509 Hs.83169 M13509 104865 AA045136 T79340 Hs.22575 T79340 106124 AA423987 H93366 Hs.7567 H93366 105330 AA234743 AW338625 Hs.22120 AW338625 109001 AA156125 AI056548 Hs.72116 AI056548 104764 AA025351 AI039243 Hs.278585 AI039243 133200 AA432248 AB037715 Hs.183639 AB037715 105263 AA227926 AW388633 Hs.6682 AW388633 105178 AA187490 AA313825 Hs.21941 AA313825 109456 AA232645 AW956580 Hs.42699 AW956580

TABLE 5A

Table 5A shows the accession numbers for those pkeys lacking unigenelD's for Table 5. The pkeys in Table 7 lacking unigenelD's are represented within Tables 1 -6A. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and

Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey: Unique Eos probeset identifier number

CAT number: Gene cluster number Accession: Genbank accession numbers

Pkey CAT Number Accession

115819 10241J AA486620 AF205940 AA297524 AB034695 AA081335 NM_016242 AA188323 AA297537 H88204 AW953081 W31695

AW582203 AA248250 AW681211 AA426230 AA464807 AA426155 N44141 AA347390 AA770661 AI333225 N36136 AW665724 AA431894 AI374976 AI400254 AI338446 AA186695 H88205 W04527 AA487066 AI051414 AA918383 AA426573 AA425620 AW438654 AA090513 BE167284 BE167291 AI301726

102024 14505J AA301867AW957981 R27614 AA155808 AI920990 AI740711 AA301026 AA301015 AI220981 AI857670 AI537140

AW015210 AA030000 W46890 H44021 AI355967 AI651735 AA058479 AA146932 T58265 R85890 AA047810 AA017387 AW026093 AA971133 AI827263 AI056416 AI355994 AI127691 H46603 U03877 NMJ04105 AA157357 H42844 AA146824 AA187709 AA187269 AA304348 AA147292 AA361687 AA156041 AA330636 R32929 AA321130 AW950260 AA082157 AA029129 AA303708 AA028155 D31561 T84689 AA302493 BE153057 BE153181 W39408 AA187200

BE153250 AW383337 AW382622 AW382647 AW750072 BE153060 AW382630 AW371865 AW392464 AW382664 AW382658 AW382650 H61647 AW365075 AW365049 AA373397 BE072779 BE072781 Z30254 W24381 BE153254 AA040442 BE072729 BE072731 N94740 AA146945 AW802737 AI826799 AI085395 R34034 H65140 AA082800 H88275 AA147824 R63882 W80899 AA296413 AI765300 AI862426 AW022055 AW300003 AI743784 AI862635 AI985428 AA147764 AW573245 AW190290 AI040898 D57613 N63457 AA148082 AI028458 AA148110 AW814489 N75105

AW629443 AA704122 AW582220 AA181240 AA057495 AI418224 AI261751 AW388595 AI472205 AW470672 AA102546 AA789046 AA182416 AA062668 AW300732 AI288220 AA181982 AA146825 AA028130 AI985522 AA303344 AA081313 N69082 AA182035 AI867128 AA100902 AA605087 N67178 AW020324 AW890446 AI472191 AI335691 AI597837 AI081143 AI335681 AA040443 AI128067 AI678244 AA018303 AA157260 W80792 AI934590 AI096430 T54343 AI446350 AA165196 AA780683 AA603631 AA047787 AA968580 AA912645 AW890504 AW026913 D56983 H52088 AA156121

R30848 AW023036 AI590960 N67345 AI753225 AI753283 AI183768 AA147818 H89101 AI362141 H89205 AI147711 AA321129 AA668622 AA343479 AW069438 A1422376 AW629270 AA013413 AI221948 AA970605 N52335 H38366 T91180 AA657841 AA017386 AA152227 AA187593 AI913340 A1719313 AI969943 AI701271 AI004328 AI868348 N93659 H65093 H25736 D57007 D56957 C00987 D61839 D56661 AI472137 AI971002 D56971 BE048830 D57972 AI589286 AI361055 AI361071 AI292223 AA155898 D57139 D57981 D57345 AI420034 D57332 D57959 AA875933 R33493 N67558

D58353 AA188394 AA147966 A1160640 A1363165 H40638 AA578137 AW950265 AA300943 AI128999 H46584 AA917355 N57820 AA320504 H51959 H25737 101545 24607J BE246154 M31210 NMJ01400 AA193392 NMJ16537 AF233365 AF022137 H27787 AA370448 F05373 T27666 W21494

AA036907 AI249966 N93476 F01623 AA304390 AA308808 109456 180633J AW956580 AA886361 A1147670 AI090115 AI168683 AA232645 H99504 AA374707 AA380875 AW139567 AI735132

BE439385 AW629780 N28322 AA232789 AA232790 N73285 103036 17145 M13509 X54925 NM_002421 M16567 X05231 M15996 W39354 AA186634 AA852324 AA187507 AA081149 AA186524

AA187264 AA187361 AA386155 AA186973 AA374217 U78045 AA081230 AA188049 AA186393 W56827 AA852602 AA157468 AA308204 AA186754 AA186808 AA082516 AA304334 AW376428 BE439384 AW376420 AA156273 T18504 AA186521 W49496 AW084608 AA083575 AA372360 AW963590 AA132297 W47445 AA186376 AA157628 AW003999

AI037890 AI858060 AI589010 AI743739 AI452673 AW304188 AW117854 BE439933 AA157416 AW778966 AI038497 AA081006 AA100829 AA181048 C02231 T27821 W23960 AW954802 A1471432 AW801296 AW801289 AW801603 AW801523 AW801292 AW801542 AW801601 AA181134 AI445147 AA191501 AA582862 N94407 AI147810 AA181880 W49497 W52714 AA188249 AI932881 AI082493 AA503656 AA182682 AW801393 AA182830 AA181882 AA182826 AI613182 N94510 W47343 AI085755 AI076956 AI918426 AA081208 AI282835 AA147528 AI081490 AI654536 AA181875

AA081282 AA186389 C06085 AA083542 AI800644 AA157642 AA101069 AA157752 AA158121 AA143331 AA081283 AA852603 AA188296 A1932880 AW449628 AA187348 C02091 AA514656 AA082736 AA308786 AA143201 M16567 133200 28960J AB037715 AI351347 AI375796 AI884765 AL121124 W01068 AI807275 T95240 R42807 AW515645 AI057314 AI033520

AA057671 N70215 AA054215 AW204183 AA552149 T95130 AW796310 AI866520 AW275564 AW796308 AI637901 AW197404 T78406 AA456232 AW206463 AA779800 AI052696 AA026744 AA454623 AW470729 R45490 AW770258

AI038393 AI290170 AA722734 AL121125 R41608 AI862414 AA838611 R45582 AI278083 BE466849 BE219944 AA418030 BE041555 AA578572 T16528 AW006344 Z39782 AI244848 AW137344 AA707400 AI032028 BE540464 A1094265 A1184281 AA931890 AW382744 AW382729 AW020448 AW827237 AA431226 A1672059 AW772345 N70172 AW022003 AI862704 H19344 R61511 AI080204 H16566 AA432248 AI767980 T16688 AI984342 AI217478 AI767095 Z38551 AI359566 AI361437 AI041000 R07033 H16608 H19054 R12874 R61567 N98368 BE221199 Z42320 AA094554

R07078 AW860886 AA418090 R41262 132837 256666J AA370362 AA364110 AW959554 AW371737 AW382068 AW604716 AW604713 AA487827 AW371674 AA429137

BE503321 T93570 W72803 AI093076 AA487977 AI241562 BE439445 AW204065 R51635 AI802994 T10362 W68553 AI866215 AW152154 AA700716 AI127443 R15824 AI537587 AA953110 D58024 AI520811 AA693670 AI453280 W76329 AW023955AW022563

102898 24023.1 NMJ02205 X06256 M13918 BE070866 AW239485 AW996127 BE273894 BE272590 BE410252 R25975 T11786 T11787

AA301142 AA301165 AW960506 BE272819 AA386086 T39391 AA285303 AA370580 D58585 T58668 AA156213 W24142 AA343323 AW796067 AA151197 AA376121 R94782 AA302363 H90357 R82621 AA301677 H55997 AW796059 W92358 AL046458 AA471198 AA301952 R46287 R82694 H03186 AA187706 R32562 R27094 R25947 R25320 AW949809 H13505 H79049 R32403 H11213 R39710 H49765 H21142 H21006 AA417664 W52075 N56771 AA284240 N98556 N30907 AA707335 AW603781 AI340367 AI814584 AA524182 AA370076 AA418785 AA704082 AI806851 H25513 T56388 AA419627 H03986 H20963 T56245 AI459715 AW973768 AI334096 AI693020 T63414 R82646 AW167251 H55998 AI274916 AA778367 AI755253 AI033667 AW083222 AA181979 R26865 AA661627 AA706329 AI798648 AA612799 AI160180 AI274973 AI039264 AA301880 AI042429 AA307632 AI085688 AI278366 AI498890 AA303865 AI954844 AA502380 AA156334 AA723480 AI803584 AI581026 AA304584 N51038 R94702 R69814 AW150962 AI570049 AA588807 AA151198 T53400 AI567709 AI185326 AA309205 AW338969 R53903 AA991891 AA301643 AI493337 AI026049 H25514 AI741075 R28632 AW166445 AI333068 H49978 H91267 AA558193 AW079663 AA627380 AA807401 AI199956 AA666118 AI718216 AW193228 AI077745 AI500496 AI266059 AW080383 R06468 R26757 R32404 AA716599 W92322 AI077734 AI270181 R46198 AI217540 AA304045 AA305421 AW074445 AI468256 AW089568 AW571605 BE162930 H41009 AA578313 AW874497 AA181284 AA861947 T29451 D20841 T58618 AA418731 AI282500 AW081407 AA604560 AA729855 AI262538 AI580225

102915 2903_2 X07820 NM J02425 BE271570 AI263526 AW296143 AI829878 AI973162 AI085155 AA857496 AA709305 C02220

134416 30694J X68264 NM 006500 AF089868 BE257461 BE275425 AW997154 AI902799 AI902803 M78206 AA085691 AW392972

AA325490 BE006161 AA349269 AA323568 AL042548 AA191148 AA187703 AA322791 AJ297452 T11625 AW366487 AA303513 AA186961 AA173480 N28330 N28379 W40320 AA187118 H03695 AA402709 BE407476 H06354 BE276589 AA351284 AA379921 AL138060 BE410587 AA113094 AA340481 BE277483 R21191 R79518 N86170 AA320505 AA296065 AW951900 AA658897 AA650052 AA654304 AA191691 N26649 AW080963 AI265800 N72019 AI453458 AA092563 AA402310 AI439450 AI061054 AA302358 T71566 AA302047 AA303432 N21289 H27357 AA303504 AI174583 AW151762 AA181958 AW880618 AA630773 AI889539 AW901058 AI373405 AA341941 AA086217 A1675590 AI653936 AA633570 AA987619 AI270656 N93847 N40689 AW517517 N20030 W95985 AA303955 H89170 AA309917 N21642 AA373132 W38517 AI687806 W76182 AA101065 AA036916 N45635 AI744510 AI669803 AI039157 AI126355 AA634607 AW131120 AW196838 AA190601 AA911130 BE221320 N92355 AA036752 H03696 AA588873 AI458868 AI041818 AA090477 AI093248 AA304755 AL137942 AL044688 AI083709 AI150965 N88891 AA635675 AA594898 W94657 AA182823 AW166205 F27886 R79246 F37329 AA565697 AI075739 AI088654 AI094287 AI204256 AA095203 T93020 AA688298 AA057324 N23442 AA075411 AA305046 AI031688 AI191503 AA111887 AA112264 N27929 AA187509 AI375522 AI474006 H06297 AI826177 N48880 H28333 AA075490 R22809 W79542 AI055934 AA042901 AA173481 AA301986 W74531 AI051747 AA187715 AI888888 AA993017 A1057530 T92954 N80227 AW273595 AI351260 AW170643 AW292979 AA302605 AA302330 BE349495 AA328602 AA302361 AI470984 AA155943 AA155914

105178 7792J AA313825 AW960347 AF223468 NM_016613 AA186345 AA186508 AA081195 AA147972 AA346943 AW961667

AA187222 AA187207 AW371052 AW449751 AW748803 AW391606 AW371047 AW371057 AW371085 AW362895 AW371092 AW377556 BE010930 AI016882 AA247878 C04398 C05158 F11398 AA188315 H23385 R55086 H15346 AA029106 AA228114 H17005 F08498 Z43376 AA095582 AA055186 AA463361 R15218 AA299132 AW103578 W21538 AA428131 AA187115 AA157197 AA157167 AW371371 AA363562 AW965995 N55663 Z17878 AA228023 AI140342 AA100927 AA496988 AA055917 AI089303 AW014967 AW090248 AW338371 AW131066 D62963 D79713 AI583950 AI336781 AI500705 AI471485 AW090239 D79784 D61847 D62789 D61842 AI086327 AI273381 D61815 D63043 AI913548 AI280560 AI510828 AA029996 C16343 C16513 AI075741 AW516308 AI804764 AA948068 A1356588 AW103452 AW573063 Z39445 C16489 AI949870 F04712 AA147823 AW026284 AI151538 AA081303 AA613890 AI251865 AW086499 AA992111 AI862091 AI373465 BE502094 AI922270 AA884288 AA157079 N56963 AW189145 AA428080 R55056 AA884068 AW771716 AA186662 C16364 H15723 AI921181 AA156888 H17006 AA187490 AI400994 AA346942 H28533 AW129047 R41656 H14636 AA995041 D58370 Z21131 D58186 AI383271 AA643977 D58044 A1934302 AW779425 F09065 H14930 AA890693 H23274

105263 178672_2 AW388633 AW378440 AW388283 AW388339 AW388333 AW388414 AW388413 AW388607 AW388453 AW388687 AW388480 AW388591 AW388711 AW388511 AW388438 AW388570 AW388449 AI694383 AW237145 AI652991 AI964041 AW366319 AW366321 AW961938 AW469211 AI634155 AI492186 AI624430 AI677965 N26502 AI963871 AW378431 AW378421 AI015391 AW352126 N59336 AI352317 AW197113 N67998 AW778935 AI476054 AI206626 R37116 R40211 AA227926 AA639698 R38073 A1001745 T32854 AI619649 AI423703 F10774 AW388615 T16595 H05894

105330 182497J AW338625 R43226 R51640 AI307645 AI308100 AI085787 AI420357 AI692610 AA877160 AI953366 AA234743

104764 90967J AI039243 R68234 AA025351 AA971063 AI537757 AA025362 R81636 T86650

104865 102037J T79340 AI742317 AW182676 AW451460 AI420964 R43284 AA088179 AW590886 AW269529 AA045187 AI521736 AI827455 AA045136 AW271709 AI004344 AA639631 AA744417 AA744218 AA045357 AA045351

106124 54542J H93366 AI653547 AA336265 AW966175 BE566451 R71178 AI630656 AA234331 N55039 AA305632 AW960431 R34044 R32254 AW020970 AW451281 AW275041 AI636933 AI655640 AA423986 AA642466 AI684063 AI633876 AI624897 AA814795 AW590328 AI889166 AW243541 AI439691 AW473445 AI475516 AA741228 AI127534 AA165143 AI074714 AI654076 AA400674 AI560249 N50709 AW438621 AI806810 AI434579 AI308184 AA423987 AI141272 AI565586 AI338440 AA219628 AI246643 AI985809 AA724260 AA633988 AI364172 AI798439 AI650801 R33503 AI435891 AA903649 T96161 AA665538 AA219620 AI309962 AA400707 BE247066 R32178 AI275962 AA661602 AW003197 BE466649 AA831198 AI620052 AI825387 AI634037 AI670978 AI670979 AI655092 R32304 AA828858 AI382428 AW023660 AA262892 T26891 AW089917 T26926 R32227

107385 6976J NM_005397 U97519 AW899329 A1902387 AA077792 AA078525 AW376607 AA077946 AA070415 BE208721 AW167958

BE293050 BE208240 AI648698 AA101314 BE393348 BE305122 AA077591 BE274036 AA313687 BE392220 BE378954 AA171461 AA464821 AW938242 AW938224 AW938243 AW938232 AA147953 N64294 AA205218 AW305065 AW517478 AA307983 AA377023 BE563629 R99976 N80294 T87719 T87928 AA496849 AA486344 AA204938 AW370448 AA318242 AW964384 H92423 W95317 BE378774 BE391156 AA349138 AA173095 AW513198 AA037672 AA148029 AA169726 W04791 AA075508 BE382937 BE395034 AF139793 AA961734 N48612 H64714 AW151251 A1565113 AI566881 AW087370 AA631168 AA622014 AW513098 AI857810 AW152287 AI052596 AI983246 AA024856 AI912456 AI677938 AW026403 AA972537 AI088497 AW999869 W94582 AI140166 AI160659 AI566868 AA101263 AW190390 AW166466 AI401207 AI418156 AI625265 AI146298 AW008592 BE223020 N58926 AI308797 AA037673 AI935992 AI304706 AA024939 AI216589 AI610423 AI354621 AI500677 AI679389 AI799310 N64508 AI128756 AI679897 AW589535 AA989333 AI500527 AA565479 AA913529 AI923295 F21691 AA989376 AI699064 AA902447 AI690910 AA772659 AA204983 AI337895 R99975 H65205 AA340766 AI339441 AI913855 AA450293 AW192010 AA070416 N72401 AI371481 AI247108 AI371261 AI364987 AI280171 AI269104 AI868756 AA909836 AA983640 AI973271 AA913092 AI868205 AI144112 AI190975 N58085 AI566638 N93405 AW150504 AW296846 AI687036 AA902984 AI824460 AI625047 AA653148 AI611228 AW131922 AA862687 AA902519 C01732 AW796045 AL044660

101192 15367J BE247295 AW068092 AL041313 AA159244 NM_005415 L20859 AL135570 W47073 AW516906 BE388271 BE408629

W46972 BE293646 BE256647 AI075010 AL041095 AA285300 AL039560 AA368740 W26602 AA399344 AA039235 W27631 AW834898 AW834914 R93390 AA378039 AV649660 T53674 N98824 AA399974 AW843378 AA368267 R08256 AV653575 R27900 N48215 AW366371 N45500 AV652967 AI889251 AI080457 N39021 AI738542 AW242849 AI857471 AI859775 A1582830 R75850 N66564 AW341636 AI499006 AI887217 AW026694 AW182840 AA039313 AA831346 AI393465 AW069210 AI743830 AA744243 AA401310 AW439758 AW088152 R93391 AA291379 AA225220 AW009358 AI192879 AA291202 AI565089 AA225089 AA807688 AI052058 AI341641 AI066625 AA333864 AA159147 AI923912 R75851 AI761143 AW768588 AA394195 AI288450 AW512564 AI452775 AI056520 AA468602 AA872566 AI434739 AA291838 AI948623 AW768614 AI374753 AW068174 AA884908 AI199346 AI199347 W94946 AI159995 AA877642 AI280646 AI307610 AA403310 R08205 AW182123 AI000999 R27808 AW026571 D20816 AI560350 T27667 AW960271 AI174628 AI432042 AI424528 AA909562 T17342 AI783866

AI056548 AW409843 AW263540 AA723669 AA909334 AA156120 AA157141 AA156125 AW409866 W19499 AA157229 AW887435

TABLE 6:

Pkey: Unique Eos probeset identifier number

ExAccn: Exemplar Accession number, Genbank accession number

UnigenelD: Unigene number

Unigene Title: Unigene gene title

AUC1 : 70^lh percentile of average intensity (Al) for probeset at each of 2,6,15,24,48, and 96 hour timepoints minus 70* percentile Al at 0 hrs, summed over 5 experiments.

AUC2: AUC1/90^lh percentile of Al for aorta, aortic valve, vein, and artery.

Pkey Ex.Accn UnigenelD UnigeneTitle AUC1 AUC2

314941 AA515902 Hs.130650 ESTs 1038 9

327414 predicted exon 303.2 30.3

321911 AF026944 Hs.293797 ESTs 429.2 42.9

331578 AI246482 Hs.249989 ESTs 677.4 10.3

332466 AB018259 Hs.118140 KIAA0716 gene product 395.2 39.5

313513 AW298600 Hs.141840 ESTs, Weakly similar to S59501 interfero 324 32.4

320635 N50617 Hs.80506 small nuclear ribonucleoprotein polypept 394.8 39.5

326230 predicted exon 357.2 35.7

313556 AA628517 Hs.118502 433.6 12

313665 AW751201 Hs.120932 ESTs -83 0.5

324852 AI380792 Hs.135104 ESTs 348.2 34.8

314372 AL040178 Hs.142003 ESTs, Weakly similarto The KIAA0149 gen 49.2 0.5

311877 AA084248 Hs.85339 G protein-coupled receptor 39 -1309 0.2

322262 AA632012 Hs.188746 ESTs -247.8 1

312173 AI821409 Hs.304471 ESTs, Highly similar to AF116865 1 hedge -1025.8 1

319795 AB037821 Hs.146858 protocadherin 10 203.6 5.2

313350 AW591949 Hs.57958 ETL protein 183.8 18.4

326759 predicted exon 1654.4 1.2

300318 AW444502 Hs.256982 ESTs, Highly similar to AF116865 1 hedge -346 1

313978 AI870175 Hs.13957 ESTs 576.6 2.3

306840 AI077477 Hs.307912 EST 56.4 0.4

310272 AF216389 Hs.148932 semaphorin Rs, short form -127.6 0

315044 BE547674 Hs.204169 ESTs -102.6 0

321325 AB033100 Hs.300646 KIAA protein (similarto mouse paladin) 1080.6 4.8

303251 AF240635 Hs.115897 protocadherin 12 1270.8 5.3

302378 AL109712 Hs.296506 Homo sapiens mRNA full length insert cDN 915.8 15.8

315060 AA551104 Hs.189048 ESTs, Moderately similar to ALUCJHUMAN ! 1236.8 4.9

332048 AW337575 Hs.201591 ESTs 522.6 4.7

337214 predicted exon 269 26.9

311598 AW023595 Hs.232048 ESTs 796.4 20.2

304782 AA582081 gb:nn32h08.s1 NCI CGAP Gas1 Homo sapiens 316.410.5

312802 AA644669 Hs.193042 ESTs 349.6 7.6

302680 AW192334 Hs.38218 ESTs 638.6 63.9

317452 AA972965 Hs.135568 ESTs 360.8 36.1

318558 AW402677 Hs.146381 RNA binding motif protein, X chromosome 700.2 6.6

312149 T90309 Hs.269651 ESTs 274.2 7.5

319267 F11802 Hs.6818 ESTs 238.2 23.8

321510 H75391 Hs.255748 ESTs 231.8 23.2

326198 predicted exon 581.6 8.2

315730 H25899 Hs.201591 ESTs 281.6 9.7

310442 AW072215 Hs.208470 ESTs -213 0.3

331237 W87874 Hs.25277 hypothetical protein FLJ21065 285 0.5

300469 BE301708 Hs.233955 hypothetical protein FLJ20401 26.6 0.3

338316 predicted exon 1494.2 34.7

330968 R44557 Hs.23748 ESTs 975.8 1.8

331019 NM_006033Hs.65370 lipase, endothelial 201.2 0.9

331261 BE539976 Hs.103305 Homo sapiens mRNA; cDNA DKFZp434B0425 (f 478.6 1.3

301822 X17033 Hs.271986 integrin, alpha 2 (CD49B, alpha 2 subuni 356.2 1.7

325544 predicted exon 1014.6 9.4

328700 predicted exon 627.4 62.7

322882 AW248508 Hs.279727 Homo sapiens CDNA FLJ14035 fis, clone HE 84.8 5.7

336034 predicted exon 782.6 78.3

316580 AA938198 Hs.146123 hypothetical protein FLJ 12972 746.4 13.8

309931 AW341683 gb:hd13d01.x1 Soares_NFL T GBC_S1 Homo s 134.813.5

330692 R39288 Hs.6702 ESTs 137 13.7

319962 H06350 Hs.135056 Human DNA sequence from clone RP5-850E9 14.6 0.5

338033 predicted exon 540.6 14

314943 Y00272 Hs.184572 cell division cycle 2, G1 to S and G2 to -494.8 1

332640 BE568452 Hs.5101 protein regulator of cytokinesis 1 -600 1

338158 predicted exon 311.2 31.1

327036 predicted exon 351.8 35.2 302655 AJ227892 Hs.146274 ESTs 180.2 18 327568 predicted exon 229 22.9 324801 AW770553 Hs.14553 sterol O-acyltransferase (acyl-Coenzyme 161.2 16.1 317850 AI681545 Hs.152982 hypothetical protein FLJ13117 -690 1 322818 AW043782 Hs.293616 ESTs 126.4 4.5 324626 AI685464 Hs.292638 ESTs 170.2 17 317224 X73608 Hs.93029 sparc/osteonectin, cwcv and kazal-like d -80 0 310955 AI476732 Hs.263912 ESTs 466.8 46.7 315240 R38772 Hs.172619 KIAA1106 protein 277 27.7 338388 predicted exon 267.6 26.8 338442 predicted exon 256 25.6 318617 AW247252 Hs.75514 nucleoside phosphorylase 1247.8 24.2 338645 predicted exon 206 20.6 313135 N58907 Hs.162430 ESTs 204.8 20.5 324716 BE169746 Hs.12504 hypothetical protein DKFZp761D081 203.6 20.4 330305 predicted exon 199.8 20 308248 AI560919 gb:tq41g10.x1 NCl_CGAP_Ut1 Homo sapiens 199.4 19.9 308886 AI833240 gb:at76d10.x1 Barstead colon HPLRB7 Homo 198.2 19.8 315622 AI796144 Hs.258188 Homo sapiens cDNA FLJ11674 fis, clone HE 191.2 19.1 323675 R43240 Hs.272168 tumor differentially expressed 1 189.2 18.9 312164 T91980 Hs.221074 ESTs 187.6 18.8 300378 Z45270 Hs.235873 hypothetical protein FLJ22672 271.6 18.7 317478 AI343569 Hs.107000 Homo sapiens mRNA for WDC146, complete c 187 18.7 317559 AW452344 Hs.129977 ESTs 184.2 18.4 317207 AI873346 Hs.214505 ESTs 182.8 18.3 334834 predicted exon 178.8 17.9 320925 D62892 gb:HUM337C07B Clontech human aorta polyA 177.2 17.7 303289 AL121460 Hs.272673 hypothetical protein FLJ20508 316.4 17.6 328548 predicted exon 174.6 17.5 317108 AA884000 Hs.8173 hypothetical protein FLJ10803 172.4 17.2 318013 AI188183 Hs.144078 ESTs 326 17.2 314299 AW382682 Hs.154840 ESTs 170.8 17.1 317702 AW173339 Hs.135665 ESTs 169.8 17 316094 AW975920 Hs.283361 ESTs 169.4 16.9 323706 AA377578 Hs.65234 hypothetical protein FLJ20596 169.2 16.9 325843 predicted exon 321.4 16.9 316012 AA764950 Hs.119898 ESTs 1047.2 16.9 309687 AW236154 Hs.77385 myosin,lightpolypeptide6,alkali,smoothmu 168.2 16.8 323329 AL134744 Hs.10852 ESTs 168 16.8 312853 W05086 Hs.114256 ESTs 167.4 16.7 313070 AI422023 Hs.161338 ESTs 298.6 16.6 314096 AW977642 Hs.291742 ESTs 165.6 16.6 338728 predicted exon 165.4 16.5 316609 AW292520 Hs.122082 ESTs 165 16.5 305989 AA888220 gb:oj15h01.s1 NCI_CGAP_Kid5 Homo sapiens 164.6 16.5 312642 AW052128 gb:wx26c02.x1 NCI_CGAP_Kid11 Homo sapien 164 16.4 339236 predicted exon 163.6 16.4 317058 AI217713 Hs.147586 ESTs 161.8 16.2 311137 AW207582 Hs.196042 ESTs 582.2 16.2 310178 AI936450 Hs.147482 ESTs 161.2 16.1 320745 H51696 Hs.89278 hypothetical protein FLJ11186 161 16.1 317336 AW014637 Hs.130212 ESTs 160 16 309871 AW300366 gb:xs63b05.x1 NCI_CGAP_Kid11 Homo sapien 159.8 16 302038 AC004076 Hs.129709 Homo sapiens chromosome 19, cosmid R3021 159 15.9 332237 N52883 Hs.102676 EST 159 15.9 312362 AW015994 gb:UI-H-BI0p-abh-g-09-0-Ul.s1 NCI CGAP S 158.6 15.9 331558 N62401 Hs.48531 EST 158.6 15.9 316215 A1684535 Hs.200811 ESTs 158.4 15.8 336059 predicted exon 157.4 15.7 302790 AJ245245 gb:Homo sapiens mRNA for immunoglobulin 155.8 15.6 328418 predicted exon 153.8 15.4 304229 AK000149 Hs.29493 hypothetical protein FLJ20142 153.6 15.4 331606 AW273285 Hs.50802 ESTs 153 15.3 338962 predicted exon 664.4 15.3 317959 AI204202 Hs.130264 ESTs 152.6 15.3 336228 predicted exon 152.4 15.2 313534 AW072916 Hs.78743 zinc finger protein 131 (clone pHZ-10) 152.2 15.2 317404 AI806867 Hs.126594 ESTs 152.2 15.2 311943 AI469911 Hs.26498 hypothetical protein FLJ21657 152 15.2 314680 AI247425 Hs.152182 ESTs 151.4 15.1 331484 N29696 Hs.44076 EST 151.2 15.1 338116 predicted exon 151.2 15.1 329863 predicted exon 150.6 15.1 315555 AW452886 Hs.239107 ESTs 149.6 15 317039 AA868583 Hs.126153 ESTs 149.6 15 331138 R63816 Hs.28445 ESTs 149.6 15 316561 AI917222 Hs.121655 ESTs 149.4 14.9

328695 predicted exon 149.2 14.9

302282 BE396283 Hs.173987 eukaryotic translation initiation factor 148.4 14.8

318781 F11802 Hs.6818 ESTs 148.2 14.8 323709 AW297246 Hs.288546 Homo sapiens cDNA FU14190 fis, clone NT 148 14.8

310790 AW192063 Hs.248865 ESTs 147.8 14.8

316833 AW292614 Hs.124367 ESTs 147.8 14.8

323176 NM 0O7350Hs.821O1 pleckstrin homology-like domain, family 229 14.8

324188 AW274439 Hs.252709 ESTs 147.6 14.8 317441 AA922798 Hs.196583 ESTs 147.4 14.7

317584 AI825890 Hs.220513 ESTs 146.8 14.7

321798 AI308206 Hs.181959 ESTs 146.8 14.7

304363 AA206045 gb:zq77f05.s1 Stratagene hNT neuron (937 146.6 14.7

313952 F20956 gb:HSPD05390 HM3 Homo sapiens cDNA clone 146.614.7 301909 AI702609 Hs.15713 ESTs 263.8 14.7

309196 AI904895 Hs.9614 nudeophosmin (nudeolar phosphoprotein 146.2 14.6

321860 N47474 Hs.212631 ESTs 146.2 14.6

330187 • predicted exon 146 14.6

323042 AA463571 Hs.172550 polypyrimidine tract binding protein (he 145.6 14.6 313636 AA262397 Hs.201366 ESTs 145.2 14.5

302437 AB024729 Hs.227473 UDP-N-acetylglucosamine:a-1,3-D-mannosid 145 14.5

318197 A1473096 Hs.133403 ESTs 144.8 14.5

302749 M16951 gkHuman Ig mu-chain mRNA VDJ4-region, 5 144.6 14.5

322357 AI734258 Hs.245367 ESTs, Weakly similar to ALU1JHUMAN ALU S 144.614.5 300391 AI927371 Hs.288839 hypothetical protein FLJ12178 144.4 14.4

326077 predicted exon 144.4 14.4

302004 Y18264 Hs.123094 sal (Drosophila)-like 1 ^' 144 14.4

320668 AA805666 Hs.146217 Homo sapiens cDNA: FLJ23077 fis, clone L 144 14.4

331212 T88693 Hs.226410 ESTs 144 14.4 311268 AI969727 Hs.231859 ESTs 143.2 14.3

305159 AA659166 Hs.275668 EST,WeaklyslmilartoEF1D_HUMANELONGATIONF 143 14.3

304510 AA457391 Hs.119122 ribosomalproteinL13a 142.8 14.3

320852 AA772920 Hs.303527 ESTs 142.8 14.3

330854 AW291944 Hs.122139 ESTs 142.8 14.3 318275 AW449952 Hs.190125 basic-helix-loop-helix-PAS protein 142.6 14.3

314992 AI824879 Hs.211286 ESTs, Weakly similarto 1207289A reverse 142.2 14.2

322631 AA001697 Hs.293565 ESTs, Weakly similar to putative p150 [H 142.2 14.2

332283 R40855 Hs.100839 EST 142 14.2

302894 AA719572 Hs.274441 Homo sapiens mRNA; cD A DKFZp434N011 (fr 141.214.1 301808 R35391 Hs.252831 reticulon 3 141 14.1

318608 AI204491 Hs.151502 ESTs 141 14.1

316499 AW292947 Hs.122872 ESTs 140.8 14.1

317011 AI248760 Hs.150276 ESTs 140.8 14.1

321840 N45600 Hs.46534 Homo sapiens mRNA; cDNA DKFZp434P0714 (f 140.814.1 327365 predicted exon 140.8 14.1

331264 AA278898 Hs.225979 hypothetical protein similar to small G 140.8 14.1

324545 AW501944 Hs.127243 Homo sapiens mRNA for KIAA1724 protein, 140.4 14

312986 AA211586 gb:zn56d05.s1 Stratagene muscle 937209 H 140.2 14

316053 AA825814 Hs.149065 ESTs 140.2 14 330723 BE247449 Hs.31082 hypothetical protein FLJ 10525 140.2 14

304876 AA595765 gb:nj28g06.s1 NCI_CGAP_AA1 Homo sapiens 139.814

311379 AW134766 Hs.202450 ESTs 139.8 14

318265 AW019873 Hs.146840 ESTs 139.8 14

324137 AA393127 Hs.222762 ESTs 139.8 14 328262 predicted exon 139.6 14

322349 AK001279 Hs.180171 Homo sapiens CDNA FLJ10417 fis, clone NT 139.4 13.9

323504 AA280223 Hs.130865 ESTs 139.4 13.9

304261 AA059387 gb:zf66d01.s1 Soares retina N2b4HR Homo 139.2 13.9

310489 AW451493 Hs.235516 hypothetical protein PR02955 139.2 13.9 335946 predided exon 139.2 13.9

318155 AI041546 Hs.132133 ESTs 138.8 13.9

313796 AI797169 Hs.208486 ESTs 138.6 13.9

333977 predicted exon 138.6 13.9

324845 AW969635 Hs.283718 ESTs 138.2 13.8 331139 R65706 gb:yi16g12.s1 Soares placenta Nb2HP Homo 138.2 13.8

331131 R54797 gb:yg87b07.s1 Soares infant brain 1NIB H 669.6 13.8

321250 H58539 Hs.151692 ESTs 138 13.8

312498 AA668782 Hs.191284 ESTs, Weakly similar to ALU1JHUMAN ALU S 137.813.8

331252 W52470 Hs.34578 alpha2,3-sialyltransferase 137.8 13.8 337407 predicted exon 137.8 13.8

303973 AW512014 gb:xx68a03.x1 NCI_CGAP_Lym12 Homo sapien 137.413.7

314582 AA412258 Hs.188817 ESTs 137.4 13.7

327373 predicted exon 137.2 13.7

323367 AA234591 Hs.304123 ESTs 136.6 13.7 316207 AA832065 Hs.120260 ESTs 136.4 13.6

315231 AA705809 Hs.119922 ESTs 136.2 13.6 318592 T39310 Hs.1139 cold shock domain protein A 136.2 13.6

320906 AW969706 Hs.293332 ESTs 136.2 13.6

328937 predicted exon 136.2 13.6

329073 predicted exon 136.2 13.6

318231 AV659082 Hs.134228 ESTs 136 13.6

311992 AL360200 Hs.114145 ESTs 135.8 13.6

316497 AA766457 Hs.136849 ESTs 135.8 13.6

317677 AA968594 Hs.127868 ESTs 135.8 13.6

321680 W02848 Hs.93704 ESTs 135.8 13.6

326080 predicted exon 135.8 13.6

330938 AF036943 Hs.172619 KIAA1106 protein 135.8 13.6

306573 AL134878 Hs.119500 ribosomal protein, large P2 135.6 13.6

307383 AI223207 Hs.147888 EST - 135.6 13.6

311114 AW449382 Hs.195297 ESTs 135.6 13.6

320579 R15138 Hs.165570 Homo sapiens clone 25052 mRNA sequence 135 13.5

301328 AA884104 Hs.125546 ESTs 134.8 13.5

312063 N58198 Hs.182898 ESTs 134.8 13.5

323036 H09604 Hs.13268 ESTs 134.6 13.5

332776 AF241850 Hs.151428 ret finger protein 2 134.4 13.4

332494 AA282330 Hs.145668 ESTs 134.2 13.4

334376 predicted exon 134.2 13.4

313264 N93416 Hs.118228 ESTs 133.6 13.4

313669 AA351109 Hs.5437 Taxi (human T-cell leukemia virus type I 133.2 13.3

312083 T87398 Hs.205816 ESTs 132.6 13.3

319354 AA993807 Hs.167367 ESTs 132.6 13.3

307414 AI242106 gb:qh92a02.x1 Soares_NFL_T_GBC_S1 Homo s 132.213.2

312771 AA018515 Hs.264482 Apg12 (autophagy 12, S. cerevisiae)-like 131.8 13.2

313004 AI274963 Hs.145900 ESTs 131.2 13.1

300995 AW510641 Hs.258018 ESTs 220.6 13

319323 F12650 Hs.13287 ESTs 125.4 12.5

329451 predicted exon 123.4 12.3

337603 predided exon 572 12.2

312480 R68651 Hs.144997 ESTs 121.4 12.1

324934 AW452051 Hs.147546 ESTs 119.4 11.9

320723 BE178025 Hs.7942 hypothetical protein FLJ20080 117 11.7

318188 AI792566 gb:qi74f02.y5 NCI_CGAP_Ov26 Homo sapiens 116.6 11.7

320873 AF238869 Hs.283955 Homo sapiens clone GLSH-2 similar to gli 112.8 11.3

331005 BE003191 Hs.119555 ESTs 112.6 11.3

304969 AA614406 gb:np46f05.s1 NCI_CGAP Br11 Homo sapiens 112.411.2

319799 AI139253 Hs.227767 zinc finger protein 41 111.2 11.1

302610 AA347945 Hs.256024 ESTs 111 11.1

309485 AW130320 Hs.108124 ribosomalproteinS4,X-iinked 111 11.1

311880 AW419225 Hs.256247 ESTs 110.2 11

313981 AW452334 Hs.128148 ESTs 110.2 11

322442 W49701 Hs.29667 ESTs 109.4 10.9

315099 AA806536 Hs.291841 ESTs 109 10.9

304793 AA583264 Hs.182979 ribosomalproteinL12 108.8 10.9

330815 AA019211 Hs.236463 KIAA1238 protein 108.8 10.9

304044 T81656 Hs.252259 ribosomal protein S3 714.8 10.8

325222 predicted exon 135 10.8

325889 predicted exon 814.6 10.8

321447 AW891130 Hs.38173 ESTs 107.8 10.8

302990 AA496212 Hs.180182 ESTs 106.2 10.6

308106 AI476803 gb:tj77e12.x1 Soares_NSF F8 9W OT_PA_P_S 270.610.6

310536 AI301041 Hs.150174 ESTs 106 10.6

315257 AW157431 Hs.248941 ESTs 233 10.6

318787 Z42313 Hs.22657 ESTs 105.8 10.6

312306 AI927226 Hs.175610 ESTs 105.2 10.5

326788 predicted exon 104.4 10.4

312234 AA830640 Hs.206934 ESTs 104 10.4

314482 AW085525 Hs.134182 ESTs 234 10.4

323597 AI185693 Hs.135119 ESTs 102.4 10.2

302623 AW836724 Hs.194110 hypothetical protein PRO2730 162.4 10.2

323594 AI791531 Hs.129993 ESTs 101 10.1

324315 N55761 Hs.194718 zinc finger protein 265 100.2 10

314217 AA256465 Hs.188725 ESTs 99.2 9.9

320932 AA554913 Hs.162297 ESTs 98.2 9.8

327876 predicted exon 98.2 9.8

319736 R17424 Hs.6650 vacuolar protein sorting 45B (yeast homo 98 9.8

327747 predicted exon 97.6 9.8

327844 predicted exon 97.4 9.7

318200 AI061192 Hs.166517 ESTs 97.2 9.7

329414 predicted exon 97.2 9.7

318296 AI089667 Hs.270713 ESTs 121.4 ^'. 9.7

307010 AI140014 gb:qa68f09.x1 Soares_fetal__heart_NbHH19W295 9.7

319792 AI138635 Hs.22968 ESTs 385.4 9.6 305671 AA811688 Hs.82113 dUTPpyrophosphatase 96 9.6 329440 predicted exon 93.8 9.4 310381 AI263059 Hs.145594 ESTs 93.4 9.3 318824 F06771 Hs.27226 ESTs 93.4 9.3 328957 predicted exon 92.2 9.2 318804 Z42549 Hs.160893 ESTs 92 9.2 330836 AA055611 Hs.226568 ESTs, Moderately similarto ALU4_HUMAN A 92 9.2 324592 AW752437 Hs.325708 ESTs 91.8 9.2 311820 AW274545 Hs.254333 ESTs 91.4 9.1 321614 H86161 gb:ys94b01.r1 Soares retina N2b5HR Homo 91 9.1 330306 predicted exon 91 9.1 303096 AL080276 Hs.268562 regulator of G-protein signalling 17 90 9 313275 A1027604 Hs.159650 ESTs 110.4 8.8 302593 H54855 Hs.36958 ESTs 88 8.8 321421 BE465115 Hs.171688 ESTs 86.2 8.6 330832 AI133530 Hs.62930 ESTs 456.4 8.6 311847 AW301807 Hs.297260 ESTs 86 8.6 322036 BE002723 Hs.301905 Homo sapiens cDNA FLJ14080 fis, clone HE : 145.8 8.6 328688 predicted exon 85.6 8.6 325251 predicted exon 85.4 8.5 329088 predicted exon 85.4 8.5 322524 W79027 Hs.271762 ESTs 84 8.4 337953 predicted exon 451 8.3 323529 AA284397 Hs.201 85 Homo sapiens clone FLC0664 PR02866 mRNA, 82.6 8.3 307041 AI144243 gb:qb85b12.x1 Soares fetal heart_NbHH19W 306.88.2 318285 AI332454 Hs.158412 ESTs 81.4 8.1 312021 AA759263 Hs.14041 ESTs 81 8.1 329350 predicted exon 81 8.1 326169 predicted exon 80.4 338038 predicted exon 1024.2 7.9 312549 AI214510 Hs.146304 ESTs 77.4 7.7 312542 D60076 gb:HUM084E10A Clontech human fetal brair i 76.8 7.7 320992 AB026891 Hs.225972 solute carrier family 7, (cationic amino 76 7.6 318596 AI470235 Hs.172698 EST 150.6 7.5 315650 AA649042 Hs.269615 ESTs 73.4 7.3 324328 AA447276 Hs.292020 ESTs 210.4 7.1 332622 R10674 Hs.128856 CSR1 protein 70.2 7 328229 predicted exon 69.4 6.9 319110 T75260 Hs.98321 hypothetical protein FLJ14103 68.6 6.9 316133 AH 87742 Hs.125562 ESTs 308.6 6.9 303992 AW515800 gb:hd88g01.x1 NCI_CGAP_GC6 Homo sapiens 67.8 6.8 322675 AA017656 Hs.146580 enolase 2, (gamma, neuronal) 377.2 6.7 325753 predicted exon 105.2 6.6 312539 AI004377 Hs.200360 Homo sapiens cDNA FLJ13027 fis, clone NT 92.2 6.4 302592 AA294921 Hs.250811 v-ral simian leukemia viral oncogene hom 361.6 6.3 314578 AA410183 Hs.137475 ESTs 201.6 6.1 335986 predicted exon 108.6 6 321478 AW402593 Hs.123253 hypothetical protein FLJ22009 528 305192 AA666019 gb:ag44a04.s1 Jia bone marrow stroma Hom 58.6 5.9 304275 AA070605 gb:zm53h09.s1 Stratagene fibroblast (937 78.6 5.6 302779 AJ235667 gb:Homo sapiens mRNA for immunoglobulin 278.8 5.5 301976 T97905 Hs.77256 enhancer of zeste (Drosophila) homolog 2 479.2 5.4 316021 AW293399 Hs.144904 nuclear receptor co-repressor 1 792.4 5.3 320802 BE336699 Hs.185055 BENE protein 2423.8 5.3 317282 AI733112 Hs.176101 ESTs 523.2 5.1 316827 AI380429 Hs.172445 ESTs 578 5.1 303190 BE280787 Hs.16079 hypothetical protein FLJ10233 223 5.1 315587 AI268399 Hs.140489 ESTs 136.2 5 333122 predicted exon 399 5 310214 AI220072 Hs.165893 ESTs 234.4 4.9 320089 D43945 Hs.113274 transcription factor EC 68 4.9 309328 AW024348 Hs.233191 EST, Weakly similar to A27217 glucose tr 258.8 4.8 318971 Z44067 Hs.10957 ESTs 376.6 4.8 327220 predicted exon 47.4 4.7 315757 AW014605 Hs.179872 ESTs 177.4 4.7 320730 R68869 Hs.151072 ESTs 205.2 4.6 313339 AI682536 Hs.163495 Homo sapiens cDNA FLJ13608 fis, clone PL 260 4.5 318634 T49598 Hs.156832 ESTs 475.2 4.5 320955 AW820035 Hs.278679 a disintegrin and metalloproteinase doma 388.6 4.4 306605 AI000497 Hs.119500 ribosomalprotein,largeP2 81.6 4.4 309349 AW051913 gb:wx24a09.x1 NCI_CGAP_Kid11 Homo sapien 102.44.3 306004 AA889992 Hs.2186 eukaryotictranslationelongationfactorlga 451.2 4.2 330020 predided exon 61.2 4.1 302308 AW327279 Hs.91379 ribosomal protein L26 342 3.9 314648 AW979268 gb:EST391378 MAGE resequences, MAGP Homo 56.4 3.8 315131 AI753709 Hs.152484 ESTs 130.4 3.7 313690 AI493591 Hs.78146 platelet/endothelial cell adhesion molec 3179.6 3.6 333585 predicted exon 175.4 3.5 312911 H93366 Hs.7567 Homo sapiens cDNA: FLJ21962 fis, clone H 219 3.5 322966 AA633669 Hs.235920 Homo sapiens cell recognition molecule C 350.2 3.4 312492 R71072 Hs.191269 ESTs 322.8 3 318988 Z44203 Hs.26418 ESTs 25 2.5 332363 AI123705 Hs.106932 ESTs 773.4 2.5 324181 AI025476 Hs.131628 ESTs 634.8 2.4 311717 AW205369 Hs.312830 ESTs 54.2 2.4 321342 AA127984 Hs.222024 transcription factor BMAL2 23.4 2.3 308852 AI829848 Hs.182937 peptidylprolylisomeraseA(cyclophilinA) 92 2.3 331466 AA373210 Hs.43047 Homo sapiens cDNA FLJ13585 fis, clone PL 494 2.3 320279 AB033062 Hs.134970 DKFZP434N178 protein 76.2 2.2 322221 N24236 Hs.179662 nucleosome assembly protein 1 -like 1 253.2 2.1 302925 AL137449 Hs.126666 homeo box B4 136.6 2.1 331384 AB041035 Hs.93847 NADPH oxidase 4 720 1.8 300938 AA514416 Hs.152320 ESTs, Weakly similar to 1605244A erythro 27 1.8 312695 AW196663 Hs.200242 ESTs 303.8 1.6 320223 W35132 Hs.267442 ESTs 189 1.5 332743 AW247977 Hs.87595 translocase of inner mitochondrial membr 14.4 1.4 331039 AW378685 Hs.18625 Mitochondrial Acyl-CoA Thioesterase 529.8 1.4 333123 predicted exon 396.2 1.4 328455 predicted exon 91.8 1.3 334458 predicted exon 406.4 1.3 313478 AA643008 Hs.192775 ESTs 413.4 1.1 309899 AW338564 Hs.217493 annexinA2 -30,8 1 311735 AW294416 Hs.144687 Homo sapiens cDNA FLJ12981 fis, clone NT -62.8 1 312953 NM_001992Hs.128087 coagulation factor II (thrombin) recepto -73.6 1 313055 AW367295 Hs.241175 ESTs -43.8 1 313291 AI267970 Hs.150614 ESTs, Weakly similar to ALU4_HUMAN ALU S •63 1 315059 AW275110 Hs.271106 ESTs -67 322284 AI792140 Hs.49265 ESTs -395.2 322450 AL121278 Hs.25144 ESTs -1.6 324803 AW975183 Hs.292663 ESTs 4.4 331495 AW970939 Hs.291039 ESTs -282.8 333610 predicted exon -152.6 335093 predicted exon -23.2 339403 predicted exon -331.2 302820 X04588 Hs.85844 neurotrophic tyrosine kinase, receptor, 591.2 302270 R56151 Hs.93589 Homo sapiens mRNA; cDNA DKFZp564B1162 (f 276.61 323755 AW300094 Hs.136252 ESTs 135 0.9 326946 predicted exon 727.4 0.9 315343 BE144306 Hs.179891 ESTs, Weakly similar to P4HA_HUMAN PROLY 122.80.9 311168 AK001270 Hs.196086 hypothetical protein FLJ10408 304 0.9 329732 predicted exon 109.2 0.9 321415 BE621807 Hs.3337 transmembrane 4 superfamily member 1 414.8 0.7 333121 predicted exon 87.8 0.7 333120 predicted exon 379.8 0.7 330392 AW797956 Hs.75748 proteasome (prosome, macropain) subunit, 589.2 0.7 314711 AA769365 Hs.126058 ESTs -87 0.6 330865 BE409857 Hs.69499 hypothetical protein 347.4 0.6 333169 predicted exon -1182 0.6 335095 predicted exon 106.4 0.6 335815 predicted exon -156 0.6 330232 predicted exon 102.6 0.6 330823 AA031565 Hs.221255 ESTs, Moderately similar to ALU5 HUMAN A -62 0.5 331704 F04225 Hs.66032 ESTs -14.6 0.5 302642 NM_016428Hs.130719 NESH protein 267.6 0.5 304484 AA432067 Hs.258373 ESTs 85 0.5 310230 AK000377 Hs.144840 homolog of mouse C2PA -70 0.4 301531 AI077462 Hs.134084 ESTs -195.4 0.4 306337 AA954221 Hs.73742 ribosomalproteinJarge.PO -33.4 0.4 331327 N46436 Hs.109221 ESTs -392 0.4 332961 predicted exon -5.6 0.4 322796 W31178 Hs.154140 Homo sapiens ovary-specific acidic prote -880.6 0.3 328857 predicted exon 55.2 0.3 316342 AA743935 Hs.202329 ESTs 43.4 0.3 331263 AW780192 Hs.267596 ESTs -180.4 0.3 335987 predicted exon -134 0.3 311923 T60843 Hs.189679 ESTs 12.2 0.3 310522 AW134529 Hs.244647 ESTs -187.8 0.3 315363 AA759190 Hs.121454 ESTs, Weakly similar to olfactory recept 80 0.3 302032 NM_001992Hs.128087 coagulation factor II (thrombin) recepto -877 0.3 313140 BE265133 Hs.217493 annexin A2 95.4 0.3 310860 AW015920 Hs.161359 ESTs -239 0.3 317899 AI952430 Hs.150614 ESTs, Weakly similar to ALU4_HUMAN ALU I S -715.2 0.3 328520 predicted exon -109.2 0.2 302406 NM_012099Hs.211956 CD3-epsilon-associated protein; antisens 10 0.2 311804 AI866921 Hs.203349 Homo sapiens cDNA FLJ12149 fis, clone MA -252.6 0.2 315065 AK001122 Hs.105859 hypothetical protein FLJ10260 -46.2 0.2 314129 AA228366 Hs.115122 ESTs -308.8 0.2 335697 predicted exon -47.2 0.2 335989 predicted exon 89 0.2 320606 AW867943 Hs.127216 hypothetical protein FLJ 13465 -205.6 0.2 329745 predicted exon 103 0.2 313628 AW419069 Hs.209670 ESTs -177.8 0.2 334616 predided exon -936.6 0.2 308820 AI821267 Hs.207243 EST -7.2 0.2 320416 AI026984 Hs.293662 ESTs -18.4 0.2 335211 predicted exon -142 0.2 323629 AA375957 Hs.6682 ESTs -100 0.1 331420 AW452904 gb:UI-H-BI3-aly-h-11-0-Ul.s1 NCI_CGAP_Su 83 0.1 315984 AI015862 Hs.131793 ESTs -250.6 0.1 332833 predicted exon -374.2 0.1 332607 NM_002314Hs.36566 LIM domain kinase 1 -27.6 0.1 313467 AA004879 Hs.187820 ESTs -288.2 0.1 323333 AV651680 Hs.208558 ESTs -735.6 0.1 330775 AW247020 Hs.250747 SUMO-1 activating enzyme subunit 1 53.6 0.1 333168 predicted exon -1041.8 0.1 332079 AI308876 Hs.103849 ESTs 19.4 0.1 322724 AF161442 Hs.191591 Homo sapiens HSPC324 mRNA, partial eds -123.6 0.1 303652 AI799111 Hs.64341 ESTs -46.4 0.1 303131 AW081061 Hs.103180 DC2 protein -156.4 0.1 320716 AI479439 Hs.171532 ESTs -146.6 0.1 300454 AA659037 Hs.163780 ESTs -304 0.1 312757 AI285970 Hs.183817 ESTs -445 0.1 312391 R43707 Hs.133159 ESTs, Weakly similar to PIHUSD salivary -111.8 0.1 308877 AI832519 gb:at69h03.x1 Barstead colon HPLRB7 Homo -149.6 0 311275 AI659166 Hs.207144 ESTs -62.6 0 302363 AW163799 Hs.198365 2,3-bisphosphoglycerate mutase -15 0 321717 AW956580 Hs.42699 ESTs -1059.6 0 302638 AA463798 Hs.102696 MCT-1 protein -332.2 0 306352 AA961367 gb:or52a05.s1 NCI_CGAP_GC3 Homo sapiens 21.8 313798 AI292148 Hs.71622 SWI/SNF related, matrix associated, acti -97.2 0 320807 AA135370 Hs.188536 Homo sapiens cDNA: FLJ21635 fis, clone C -2222 0 320931 AW262836 Hs.252844 ESTs -881.6 0 332450 AW288085 Hs.11156 hypothetical protein 28.4 0 332535 AF167706 Hs. 9280 cysteine-rich motor neuron 1 -722 0 335990 predicted exon 421 0 330746 AB033888 Hs.8619 SRY (sex determining region Y)-box 18 35.4 0 316820 AI627912 Hs.130783 Forssman synthetase -373.6 0 337429 predicted exon -257 0 331192 BE622021 Hs.152571 ESTs, Highly similar to IGF-II mRNA-bind -33 0 330609 AI346201 Hs.76118 ubiquitin carooxyl-terminal esterase L1 -280 0 323593 AI739435 Hs.39168 ESTs -3627.6 0 302704 AA531133 Hs.4253 hypothetical protein MGC2574 -278.6 0 330534 NM_004579Hs.82979 mitogen-activating protein kinase kinase -244 0 332374 X91195 Hs.100623 phospholipase C, beta 3, neighbor pseudo -1204.2 0 333221 predicted exon -189.6 0 335988 predicted exon -122.6 0 330574 AI984144 Hs.66713 hepatitis delta antigen-interacting prot -2257.4 0 312052 BE621697 Hs.14317 nudeolar protein family A, member 3 (H/ -359.2 0 319568 AF131781 Hs.84753 hypothetical protein FLJ12442 ' -874.6 0 337113 predicted exon -24.6 0 335149 predicted exon -191.8 0 TABLE 6A

Table 6A shows the accession numbers for those pkeys lacking unigenelD's for Table 6. The pkeys in Table 7 lacking unigenelD's are represented within Tables 1 -6A. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey: Unique Eos probeset identifier number

CAT number: Gene cluster number Accession: Genbank accession numbers

Pkey CAT Number Accession

320925 1525201J D62892 D79755 D62760 321614 87866J H86161 AA054308 AA018955

313952 136885J F20956 AA129374 AA133740AW819878

314648 293660J AW979268 AA878419 AA431342 AA431628

302749 458J07 M16951 M16952 M16948 M16949 M16950

312362 764066 AW015994 R39898 AW000978 AI598202 AI521706 312542 1522649J D60076 D60259 D61037

312642 1005225J AW052128 H51439 H51481

312986 171879J AA211586 F35799 AA211641 F29720 AW937387 AW937408

329350 c_x_hs

329414 c_y_hs 329440 c_y_hs

329451 c_y_hs

338033 CH22_6528FG_LINK_EM:AC00

338038 CH22_6535FG_LINK_EM:AC00

338116 CH22 6650FG_LINK_EM:AC00 338158 CH22_6700FG_LINK_EM:ACOO

329732 c14_p2

329745 c14_p2

308106 AI476803

329863 c14_p2 338316 CH22_6944FG_LINK_EM:AC0O

308248 AI560919

338388 CH22 7034FG_LlNK_EM:AC00

338442 CH22_7109FG_LINK_EM:ACOO

338645 CH22_7410FG_LINK_EM:ACOO 338728 CH22_7527FG_LINK_EM:AC00

308877 AI832519

338962 CH22_7838FG_LINK_DJ32I10

308886 AI833240

333120 CH22_349FG_81_3_LINK_EM:A 333121 CH22_350FG_81_4_LINK_EM:A

333122 CH22 351FG_81_6_UNK_EM:A

333123 CH22_352FG_81_7_UNK_EM:A

333168 CH22_400FG_94_1_LINK_EM:A

333169 CH22_401FG_94_2_LINK_EM:A 333221 CH22_458FG_105_1_LINK_EM:

326077 c17_hs

326080 c17_hs

326169 c17_hs

326198 c17_hs 326230 c17_hs

333585 CH22_846FG_203_4_LINK_EM:

333610 CH22_871FG_217_5_LINK_EM:

335093 CH22_2423FG_492_3_LINK_EM

335095 CH22_2425FG_492_5_LINK_EM 335149 CH22 2484FG_499_5_UNK_EM

326759 c20_hs

333977 CH22_1254FG_309_6_LINK_EM

326788 c20_hs

335211 CH22_2550FG_511_2_L1NK_EM 305192 AA666019

303973 AW512014

303992 AW515800

326946 c21_hs

328229 c_6_hs 328262 c_6_hs 328418 c_7_hs

328455 c_7_hs

335697 CH22_3058FG_596_12_LINK_E

328520 c_7_hs 328548 c_7_hs

335815 CH22_3187FG_618_3_LINK_EM

328688 c_7_hs

328695 c_7_hs

307010 AI140014 337113 CH22_5058FG_493_1_

307041 AI144243

328700 c_7_hs

335946 CH22_3324FG_646_20_LINK.D

335986 CH22_3366FG_654_10_LINK_D 335987 CH22_3367FG_654_11_LINK_D

335988 CH22_3368FG_654_12_LINK_D

335989 CH22_3369FG_655_2_LINK_DJ

335990 CH22_3370FG_655_4_LINK_DJ 337214 CH22_5288FG_613_7_ 330020 c16_p2

305989 AA888220

328857 c_7_hs

328937 c_8_hs

328957 c_8_hs 330187 c_4_p2

337407 CH22_5607FG_755_1_

337429 CH22_5633FG_762_3_

330232 c_5_p2

307414 AI242106 330305 c_7_p2

330306 c_7_p2

337603 CH22_5896FG_LINK_C20H12.

337953 CH22_6395FG_LINK_EM:AC00

339236 CH22_8181FG_LINK_BA354I1 339403 CH22_8384FG_LINK_BA232E1

309349 AW051913

325222 c10_hs

325251 c10_hs

318188 956161J AI792566 AI053836 AI054127 AI792489 A1288324 309871 AW300366

325544 c12_hs

309931 AW341683

332833 CH22_50FG_17_7_LINK_C20H1

302779 33837J AJ235667 AJ235666 AJ235664 AJ235665 AJ235668 AJ235669 AJ235670 302790 34168_1 AJ245245 AJ245247 AJ245257 AJ245248 AJ245254 AJ245256 AJ245253 AJ245203 AJ245250 AJ245252 AJ245243 AJ245204 AJ245201 AJ245206 AJ245246 AJ245255 AJ245205 AJ245202 AJ245251 AJ245249 AJ245207 AJ245244

332961 CH22J85FG 48_18_LINK_EM:

325753 c14_hs

327036 c21_hs 325843 c16_hs

325889 c16_hs

304261 AA059387

304275 AA070605

334376 CH22_1670FG_379 8_LINK_EM 327220 c_1_hs

304363 AA206045

334458 CH22_1757FG_391_2_LINK_EM

327365 c_1_hs

327373 c_2_hs 334616 CH22_1923FG_411_15_LINK E

327414 c_2_hs

327568 c_3_hs

336034 CH22_3419FG_678_5_LINK_DJ

336059 CH22_3445FG_684_2_LINK_DJ 334834 CH22_2148FG_439_3_LINK_EM

304782 AA582081

304876 AA595765

327747 c_5_hs

336228 CH22_3626FG_730_4_LINK_DA 329073 c_x_hs

329088 c_x_hs

304969 AA614406

327844 c_5_hs

327876 c_6_hs 306352 AA961367

331131 genbank_R54797 R54797 331139 genbank_R65706 R65706

331420 675963 1 AW452904 AW449414 BE467906 AI298565 BE549932 BE326357 F04362

TABLE 6B

Table 6B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 6. The pkeys in Table 7 lacking unigenelD's are represented within Tables 1-6B. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

Pkey: Unique number corresponding to an Eos probeset Ref: Sequence source. The 7 digit numbers in this column are Genbank Identifier (Gl) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489495.

Strand: Indicates DNA strand from which exons were predicted. N position: Indicates nucleotide positions of predicted exons.

Pkey Ref Strand NLposition

332961 Dunham, . etal. Plus 2521424-2521555

333221 Dunham, . etal. Plus 3978070-3978187

333585 Dunham, . etal. Plus 6234778-6234894

333610 Dunham, . etal. Plus 6547007-6547116

334376 Dunham, . etal. Plus 13902218-13902331

334458 Dunham, . etal. Plus 14353496-14353572

334616 Dunham, . etal. Plus 15176123-15176470

335149 Dunham, . etal. Plus 21497441-21497587

335211 Dunham, . etal. Plus 21774611-21774680

335697 Dunham, . etal. Plus 25481456-25481649

335986 Dunham, . etal. Plus 27967791-27967852

335987 Dunham, . etal. Plus 27971413-27971481

335988 Dunham, . etal. Plus 27977912-27978013

335989 Dunham, . etal. Plus 27983788-27983860

335990 Dunham, . etal. Plus 27988532-27988608

336034 Dunham, . et.al. Plus 29014404-29014590

337953 Dunham, . etal. Plus 6827029-6827125

338033 Dunham, . etal. Plus 8092128-8092271

338038 Dunham, . etal. Plus 8138219-8138392

338316 Dunham, . etal. Plus 17089711-17089988

338442 Dunham, . etal. Plus 19980640-19980698

338962 Dunham, . etal. Plus 29581892-29582020

332833 Dunham, . etal. Minus 1119848-1119705

333120 Dunham, . etal. Minus 3307508-3307427

333121 Dunham, . etal. Minus 3308446-3308358

333122 Dunham, . etal. Minus 3309596-3309531

333123 Dunham, . etal. Minus 3310817-3310749

333168 Dunham, . etal. Minus 3729896-3729788

333169 Dunham, . etal. Minus 3730864-3730767

333977 Dunham, . etal. Minus 8722928-8722725

334834 Dunham, . etal. Minus 17182681-17182535

335093 Dunham, . etal. Minus 21297367-21297214

335095 Dunham, . etal. Minus 21292546-21292381

335815 Dunham, . etal. Minus 26320518-26320421

335946 Dunham, . etal. Minus 27487203-27487035

336059 Dunham, . etal. Minus 29184079-29183969

336228 Dunham, . etal. Minus 30904602-30904497

337113 Dunham, . etal. Minus 21233344-21233237

337214 Dunham, . etal. Minus 26095902-26095502

337407 Dunham, . etal. Minus 31886652-31886567

337429 Dunham, . etal. Minus 32086238-32086079

337603 Dunham, . etal. Minus 1299296-1299194

338116 Dunham, . etal. Minus 10614071-10613814

338158 Dunham, . etal. Minus 11794465-11794343

338388 Dunham, . etal. Minus 18662403-18662305

338645 Dunham, . etal. Minus 24063839-24063775

338728 Dunham, . etal. Minus 25949039-25948927

339236 Dunham, . etal. Minus 32773355-32773202

339403 Dunham, . etal. Minus 34050728-34050625

325222 6525287 Minus 22332-22473

325251 6682448 Minus 411693411751

325544 6682452 Plus 171228-171286

325753 6682474 Plus 398512-398621

329745 6065779 Plus 174774-175142

329732 6065783 Plus 161252-161322

329863 6691797 Plus 196801-196971

325889 5867087 Plus 223829-223891 3258436552453 Minus 7126-7232

330020 6671887 Plus 172397-172491

326198 5867215 Minus 80295-80674

326230 5867230 Minus 301868-301972

326169 5867255 Minus 128321-128388

326077 6682495 Minus 312108-312168

326080 6682495 Plus 478644478847

326759 6249610 Plus 97216-97311

326788 6682503 Plus 277132-277335

326946 6004446 Minus 116677-116967

327036 6531965 Plus 319951-320040

327220 5867525 Minus 65701-65781

327365 6552412 Minus 118133-118198

327414 5867750 Plus 102461-102586

327373 5867792 Minus 8186-8742

327568 5867811 Minus 4615246287

330187 6706138 Plus 212923-213020

327747 5867947 Plus 115322-115498

327844 6249582 Minus 18895-18958

330232 6013526 Plus 113655-113830

328229 5868105 Minus 120936-121053

327876 5868140 Plus 103882-104034

328262 6381906 Plus 11867-12027

328688 5868262 Plus 626030-626094

328700 5868264 Plus 764089-764203

328695 5868264 Plus 318632-318695

328418 5868409 Minus 258811-258894

328455 5868431 Plus 385576-385633

328520 5868477 Plus 1942075-1942246

328548 5868487 Plus 72301-72397

328857 6381927 Minus 80557-81051

330305 4877982 Minus 52269-52365

330306 4877982 Plus 96161-96233

328937 5868500 Minus 1448241-1448333

328957 6456773 Plus 219195-219297

329073 5868596 Plus 37838-37956

329088 5868608 Plus 116738-116950

329350 6456785 Plus 98911-98969

329414 5868874 Plus 942555-942643

329440 5868885 Plus 21943-22063

329451 5868887 Plus 25974-26048

TABLE 7:

Table 7 depicts Seq ID No., UnigenelD, UnigeneTifle, Pkey, and ExAccn for all of the sequences in Table 8. Seq ID No links the nucleic acid and protein sequence information inTable 8 to Table 7.

Pkey: Unique Eos probeset identifier number

ExAccn: Exemplar Accession number, Genbank accession number

UnigenelD: Unigene number

Unigene Title: Unigene gene title

Seq.ID.No.: Sequence Identification Number found in Table 8

PKey ExAccn Unigene ID Unigene Tiltle SEQ ID NO

101545 BE246154 Hs.154210 endothelial differentiation, sphingolipi Seq ID 1 & 2

115819 AA486620 Hs.41135 endomucin-2 Seq lD 3 & 4

424503 NM 002205 Hs.149609 integrin, alpha 5 (fibronectin receptor, Seq ID 5 & 6

102917 A1016712 Hs.287797 integrin, beta 1 (fibronectin receptor, Seq ID 7 & 8

102915 X07820 Hs.2258 matrix metalloproteinase 10 (stromelysin Seq ID 9 & 10

105330 AW338625 Hs.22120 ESTs Seq ID 11 & 12

107385 NM 005397 Hs.16426 podocalyxin-like Seq ID 13 & 14

102024 AA301867 Hs.76224 EGF-containing fibulin-like extracellula Seq ID 15 & 16

102024 AA301867 Hs.76224 EGF-containing fibulin-like extracellula Seq ID 17 & 18

134416 X68264 Hs.211579 melanoma cell adhesion molecule Seq ID 19 & 20

103036 M13509 Hs.83169 matrix metalloproteinase 1 (interstitial Seq ID 21 & 22

104865 T79340 Hs.22575 B-cell CLL/lymphoma 6, member B (zinc fi Seq ID 23 & 24

106124 H93366 Hs.7567 Homo sapiens cDNA: FLJ21962 fis, clone H Seq ID 25 & 26

109001 AI056548 Hs.72116 hypothetical protein FLJ20992 similarto Seq ID 27 & 28

104764 AI039243 Hs.278585 ESTs Seq ID 29 & 30

133200 AB037715 Hs.183639 hypothetical protein FLJ10210 Seq ID 31 & 32

105263 AW388633 Hs.6682 solute carrier family 7, (cationic amino Seq ID 33 & 34

102892 BE440042 Hs.83326 matrix metalloproteinase 3 (stromelysin Seq ID 35 & 36

109456 AW956580 Hs.42699 ESTs Seq ID 37 & 38

110906 AA035211 Hs.17404 ESTs Seq ID 39 & 40

119073 BE245360 Hs.279477 ESTs Seq ID 41 & 42

132050 AI267615 Hs.38022 ESTs Seq ID 43 & 44

132490 NM 001290 Hs.4980 LIM domain binding 2 Seq ID 45 & 46

102283 AW161552 Hs.83381 guanine nucleotide binding protein 11 Seq ID 47 & 48

101714 M68874 Hs.211587 phospholipase A2, group IVA (cytosolic, Seq ID 49 & 50

133975 C18356 Hs.295944 tissue factor pathway inhibitor 2 Seq ID 51 & 52

106793 H94997 Hs.16450 ESTs Seq ID 53 & 54

118511 N75620 Hs.43157 ESTs Seq ID 54 & 55

101447 M21305 gb:Human alpha satellite and satellite 3 Seq ID 56 & 57

314941 AA515902 Hs.130650 ESTs Seq ID 58 & 59

332466 AB018259 Hs.118140 KIAA0716 gene product Seq ID 60 & 61

313513 AW298600 Hs.141840 ESTs, Weakly similar to S59501 interfero Seq ID 62 & 63

313556 AA628517 Hs.118502 ESTs Seq ID 64 & 65

313665 AW751201 Hs.51233 ESTs Seq ID 66 & 67

314372 AL040178 Hs.142003 ESTs Seq ID 68 & 69

429276 AF056085 Hs.198612 G protein-coupled receptor 51 Seq ID 70 & 71

101345 NMJ05795 Hs.152175 caicitonin receptor-like Seq ID 72 & 73

418994 AA296520 Hs.89546 selectin E (endothelial adhesion molecul Seq ID 74 & 75

103850 AA187101 Hs.213194 hypothetical protein MGC10895 Seq ID 76 & 77

133260 AA403045 Hs.6906 Homo sapiens cDNA: FLJ23197 fis, clone R Seq ID 78 & 79

101097 BE245301 Hs.89414 chemokine (C-X-C motif), receptor 4 (fus Seq ID 80 & 81

104786 AA027167 Hs.10031 KIAA0955 protein Seq ID 82 & 83

132173 X89426 Hs.41716 endothelial cell-specific molecule 1 Seq ID 84 & 85

100420 D86983 Hs.118893 Melanoma associated gene Seq ID 86 & 87

111018 AI287912 Hs.3628 mitogen-adivated protein kinase kinase Seq ID 88 & 89

108507 AI554545 Hs.68301 ESTs Seq ID 90 & 91

104894 AF065214 Hs.18858 phospholipase A2, group IVC (cytosolic, Seq ID 92 & 93

118511 N75620 Hs.43157 ESTs Seq ID 94 & 95

125609 AA868063 Hs.104576 carbohydrate (keratan sulfate Gal-6) sul Seq ID 96 & 97

101543 M31166 Hs.2050 pentaxin-related gene, rapidly induced b Seq ID 98 & 99

102241 NM 007351 Hs.268107 multimerin Seq ID 100 & 101

101560 AW958272 Hs.347326 intercellular adhesion molecule 2 Seq ID 102 & 103

103280 U84722 Hs.76206 cadherin 5, type 2, VE-cadherin (vascula Seq ID 104 & 105

105826 AA478756 Hs.194477 E3 ubiquitin ligase SMURF2 Seq ID 106 & 107

102804 NM 002318 Hs.83354 lysyl oxidase-like 2 Seq ID 108 & 109

131647 AA359615 Hs.30089 ESTs Seq ID 110 & 111

103095 NM 005424 Hs.78824 tyrosine kinase with immunoglobulin and Seq ID 112 & 113

103037 BE018302 Hs.2894 placental growth factor, vascular endoth Seq ID 114 & 115

100405 AW291587 Hs.82733 nidogen 2 Seq ID 116 & 117

102012 BE259035 Hs.118400 singed (Drosophila)-like (sea urchin fas Seq ID 118 & 119

TABLE 8

Seq ID NO: 1 DNA sequence

Nucleic Acid Accession #: NM_001 00

Coding sequence: 2 4-2 08 (underlined sequences correspond to start and stop codons))

11 21 31 41 51

GTCGGGGGCA GCAGCAAGAT GCGAAGCGAG CCGTACAGAT CCCGGGCTCT CCGAACGCAA 60

CTTCGCCCTG CTTGAGCGAG GCTGCGGTTT CCGAGGCCCT CTCCAGCCAA GGAAAAGCTA 120

CACAAAAAGC CTGGATCACT CATCGAACCA CCCCTGAAGC CAGTGAAGGC TCTCTCGCCT 180

CGCCCTCTAG CGTTCGTCTG GAGTAGCGCC ACCCCGGCTT CCTGGGGACA CAGGGTTGGC 240

ACCATGGGGC CCACCAGCGT CCCGCTGGTC AAGGCCCACC GCAGCTCGGT CTCTGACTAC 300

GTCAACTATG ATATCATCGT CCGGCATTAC AACTACACGG GAAAGCTGAA TATCAGCGCG 350

GACAAGGAGA ACAGCATTAA ACTGACCTCG GTGGTGTTCA TTCTCATCTG CTGCTTTATC 420

ATCCTGGAGA ACATCTTTGT CTTGCTGACC ATTTGGAAAA CCAAGAAATT CCACCGACCC 480

ATGTACTATT TTATTGGCAA TCTGGCCCTC TCAGACCTGT TGGCAGGAGT AGCCTACACA 540

GCTAACCTGC TCTTGTCTGG GGCCACCACC TACAAGCTCA CTCCCGCCCA GTGGTTTCTG 600

CGGGAAGGGA GTATGTTTGT GGCCCTGTCA GCCTCCGTGT TCAGTCTCCT CGCCATCGCC 660

ATTGAGCGCT ATATCACAAT GCTGAAAATG AAACTCCACA ACGGGAGCAA TAACTTCCGC 720

CTCTTCCTGC TAATCAGCGC CTGCTGGGTC ATCTCCCTCA TCCTGGGTGG CCTGCCTATC 780

ATGGGCTGGA ACTGCATCAG TGCGCTGTCC AGCTGCTCCA CCGTGCTGCC GCTCTACCAC 840

AAGCACTATA TCCTCTTCTG CACCACGGTC TTCACTCTGC TTCTGCTCTC CATCGTCATT 900

CTGTACTGCA GAATCTACTC CTTGGTCAGG ACTCGGAGCC GCCGCCTGAC GTTCCGCAAG 960

AACATTTCCA AGGCCAGCCG CAGCTCTGAG AAGTCGCTGG CGCTGCTCAA GACCGTAATT 1020

ATCGTCCTGA GCGTCTTCAT CGCCTGCTGG GCACCGCTCT TCATCCTGCT CCTGCTGGAT 1080

GTGGGCTGCA AGGTGAAGAC CTGTGACATC CTCTTCAGAG CGGAGTACTT CCTGGTGTTA 1140

GCTGTGCTCA ACTCCGGCAC CAACCCCATC ATTTACACTC TGACCAACAA GGAGATGCGT 1200

CGGGCCTTCA TCCGGATCAT GTCCTGCTGC AAGTGCCCGA GCGGAGACTC TGCTGGCAAA 1260

TTCAAGCGAC CCATCATCGC CGGCATGGAA TTCAGCCGCA GCAAATCGGA CAATTCCTCC 1320

CACCCCCAGA AAGAGGAAGG GGACAACCCA GAGACCATTA TGTCTTCTGG AAACGTCAAC 1380

TCTTCTTCCT AGAACTGGAA GCTGTCCACC CACCGGAAGC GCTCTTTACT TGGTCGCTGG 1440

CCACCCCAGT GTTTGGAAAA AAATCTCTGG GCTTCGACTG CTGCCAGGGA GGAGCTGCTG 1500

CAAGCCAGAG GGAGGAAGGG GGAGAATACG AACAGCCTGG TGGTGTCGGG TGTTGGTGGG 1560

TAGAGTTAGT TCCTGTGAAC AATGCACTGG GAAGGGTGGA GATCAGGTCC CGGCCTGGAA 1620

TATATATTCT ACCCCCCTGG AGCTTTGATT TTGCACTGAG CCAAAGGTCT AGCATTGTCA 1680

AGCTCCTAAA GGGTTCATTT GGCCCCTCCT CAAAGACTAA TGTCCCCATG TGAAAGCGTC 1740

TCTTTGTCTG GAGCTTTGAG GAGATGTTTT CCTTCACTTT AGTTTCAAAC CCAAGTGAGT 1800

GTGTGCACTT CTGCTTCTTT AGGGATGCCC TGTACATCCC ACACCCCACC CTCCCTTCCC 1860

TTCATACCCC TCCTCAACGT TCTTTTACTT TATACTTTAA CTACCTGAGA GTTATCAGAG 1920

CTGGGGTTGT GGAATGATCG ATCATCTATA GCAAATAGGC TATGTTGAGT ACGTAGGCTG 1980

TGGGAAGATG AAGATGGTTT GGAGGTGTAA AACAATGTCC TTCGCTGAGG CCAAAGTTTC 2040

CATGTAAGCG GGATCCGTTT TTTGGAATTT GGTTGAAGTC ACTTTGATTT CTTTAAAAAA 2100

CATCTTTTCA ATGAAATGTG TTACCATTTC ATATCCATTG AAGCCGAAAT CTGCATAAGG 2160

AAGCCCACTT TATCTAAATG ATATTAGCCA GGATCCTTGG TGTCCTAGGA GAAACAGACA 2220

AGCAAAACAA AGTGAAAACC GAATGGATTA ACTTTTGCAA ACCAAGGGAG ATTTCTTAGC 2280

AAATGAGTCT AACAAATATG ACATCCGTCT TTCCCACTTT TGTTGATGTT TATTTCAGAA 2340

TCTTGTGTGA TTCATTTCAA GCAACAACAT GTTGTATTTT GTTGTGTTAA AAGTACTTTT 2400

CTTGATTTTT GAATGTATTT GTTTCAGGAA GAAGTCATTT TATGGATTTT TCTAACCCGT 2460

GTTAACTTTT CTAGAATCCA CCCTCTTGTG CCCTTAAGCA TTACTTTAAC TGGTAGGGAA 2520

CGCCAGAACT TTTAAGTCCA GCTATTCATT AGATAGTAAT TGAAGATATG TATAAATATT 2580

ACAAAGAATA AAAATATATT ACTGTCTCTT TAGTATGGTT TTCAGTGCAA TTAAACCGAG 2640

AGATGTCTTG TTTTTTTAAA AAGAATAGTA TTTAATAGGT TTCTGACTTT TGTGGATCAT 2700

TTTGCACATA GCTTTATCAA CTTTTAAACA TTAATAAACT GATTTTTTTA AAG

Seq ID NO : 2 Protein sequence : Protein Accession # : NP 001391

11 21 31 41 51

MGPTSVPLVK AHRSSVSDYV NYDIIVRHYN YTGKLNISAD KENSIK TSV VFI ICCFII 60

LENIFV LTI KTKKFHRP YYFIGNLA S DL AGVAYTA NL SGATTY K TPAQWF R 120

EGSMFVALSA SVFSL AIAI ERYITM MK LHNGSNNFRL FLLISAC VI SLILGGLPIM 180

GWNCISAIiSS CSTVLP YHK HYI FCTTVF TL LLSIVIL, YCRIYSLVRT RSRR TFRKN 240

ISKASRSSEK SLALLKTVII V SVFIAC A PLFILL LDV GCKVKTCDIL FRAEYF VLA 300

VLNSGTNPII YTLTNKEMRR AFIRIMSCCK CPSGDSAGKF KRPIIAGMEF SRSKSDNSSH 360

PQKDEGDNPE TIMSSGNVNS SS Seq ID NO : 3 Nucleotide sequence : 10 Nucleic Acid Accession # : N _016242

Coding sequence : 79 - 864 (underlined sequences correspond to start and stop codons) )

11 21 31 41 51

15

AAGGCCCTGC CAGCTTGGGA GGGAATTGTC CCTGCCTGCT TCTGGAGAAA GAAGATATTG 60

ACACCATCTA CGGGCACCAT GGAACTGCTT CAAGTGACCA TTCTTTTTCT TCTGCCCAGT 120

ATTTGCAGCA GTAACAGCAC AGGTGTTTTA GAGGCAGCTA ATAATTCACT TGTTGTTACT 180

ACAACAAAAC CATCTATAAC AACACCAAAC ACAGAATCAT TACAGAAAAA TGTTGTCACA 240

20 CCAACAACTG GAACAACTCC TAAAGGAACA ATCACCAATG AATTACTTAA AATGTCTCTG 300

ATGTCAACAG CTACTTTTTT AACAAGTAAA GATGAAGGAT TGAAAGCCAC AACCACTGAT 360

GTCAGGAAGA ATGACTCCAT CATTTCAAAC GTAACAGTAA CAAGTGTTAC ACTTCCCAAT 420

GCTGTTTCAA CATTACAAAG TTCCAAACCC AAGACTGAAA CTCAGAGTTC AATTAAAACA 480

ACAGAAATAC CAGGTAGTGT TCTACAACCA GATGCATCAC CTTCTAAAAC TGGTACATTA 540

25 ACCTCAATAC CAGTTACAAT TCCAGAAAAC ACCTCACAGT CTCAAGTAAT AGACACTGAG 600

GGTGGAAAAA ATGCAAGCAC TTCAGCAACC AGCCGGTCTT ATTCCAGTAT TATTTTGCCG 660

GTGGTTATTG CTTTGATTGT AATAACACTT TCAGTATTTG TTCTGGTGGG TTTGTACCGA 720

ATGTGCTGGA AGGCAGATCC GGGCACACCA GAAAATGGAA ATGATCAACC TCAGTCTGAT 780

AAAGAGAGCG TGAAGCTTCT TACCGTTAAG ACAATTTCTC ATGAGTCTGG TGAGCACTCT 840

30 GCACAAGGAA AAACCAAGAA CTGACAGCTT GAGGAATTCT CTCCACACCT AGGCAATAAT 900

TACGCTTAAT CTTCAGCTTC TATGCACCAA GCGTGGAAAA GGAGAAAGTC CTGCAGAATC 960 AATCCCGACT TCCATACCTG CTGCTGG

35

Seq ID NO : 4 Protein sequence : Protein Accession # : NP 057326

11 21 31 41 51

40

MELLQVTILF LLPSICSSNS TGV EAANNS WTTTKPSI TTPNTESLQK NWTPTTGTT 60

PKGTITNELL KMSLMSTATF LTSKDEG KA TTTDVRKNDS IISNVTVTSV T PNAVSTLQ 120

SSKPKTETQS SIKTTEIPGS VLQPDASPSK TGTLTSIPVT IPENTSQSQV IDTEGG NAS 180

TSATSRSYSS IILPWIAIil VITLSVFVLV GLYRMCWKAD PGTPENGNDQ PQSDKESVKL 240 45 LTVKTISHES GEHSAQGKTK N

Seq ID NO : 5 Nucleotide sequence : Nucleic Acid Accession # : NM_002205

50 Coding sequence : 24 . . 3173 (underlined sequences correspond to start and stop codons )

1 11 21 31 41 51

„ I I I I I I

DD CAGGACAGGG AAGAGCGGGC GCTATGGGGA GCCGGACGCC AGAGTCCCCT CTCCACGCCG 60

TGCAGCTGCG CTGGGGCCCC CGGCGCCGAC CCCCGCTCGT GCCGCTGCTG TTGCTGCTCG 120

TGCCGCCGCC ACCCAGGGTC GGGGGCTTCA ACTTAGACGC GGAGGCCCCA GCAGTACTCT 180

CGGGGCCCCC GGGCTCCTTC TTCGGATTCT CAGTGGAGTT TTACCGGCCG GGAACAGACG 240

GGGTCAGTGT GCTGGTGGGA GCACCCAAGG CTAATACCAG CCAGCCAGGA GTGCTGCAGG 300

60 GTGGTGCTGT CTACCTCTGT CCTTGGGGTG CCAGCCCCAC ACAGTGCACC CCCATTGAAT 360

TTGACAGCAA AGGCTCTCGG CTCCTGGAGT CCTCACTGTC CAGCTCAGAG GGAGAGGAGC 420

CTGTGGAGTA CAAGTCCTTG CAGTGGTTCG GGGCAACAGT TCGAGCCCAT GGCTCCTCCA 480

TCTTGGCATG CGCTCCACTG TACAGCTGGC GCACAGAGAA GGAGCCACTG AGCGACCCCG 540

TGGGCACCTG CTACCTCTCC ACAGATAACT TCACCCGAAT TCTGGAGTAT GCACCCTGCC 600

65 GCTCAGATTT CAGCTGGGCA GCAGGACAGG GTTACTGCCA AGGAGGCTTC AGTGCCGAGT 660

TCACCAAGAC TGGCCGTGTG GTTTTAGGTG GACCAGGAAG CTATTTCTGG CAAGGCCAGA 720

TCCTGTCTGC CACTCAGGAG CAGATTGCAG AATCTTATTA CCCCGAGTAC CTGATCAACC 780

TGGTTCAGGG GCAGCTGCAG ACTCGCCAGG CCAGTTCCAT CTATGATGAC AGCTACCTAG 840

GATACTCTGT GGCTGTTGGT GAATTCAGTG GTGATGACAC AGAAGACTTT GTTGCTGGTG 900

70 TGCCCAAAGG GAACCTCACT TACGGCTATG TCACCATCCT TAATGGCTCA GACATTCGAT 960

CCCTCTACAA CTTCTCAGGG GAACAGATGG CCTCCTACTT TGGCTATGCA GTGGCCGCCA 1020

CAGACGTCAA TGGGGACGGG CTGGATGACT TGCTGGTGGG GGCACCCCTG CTCATGGATC 1080

GGACCCCTGA CGGGCGGCCT CAGGAGGTGG GCAGGGTCTA CGTCTACCTG CAGCACCCAG 1140

CCGGCATAGA GCCCACGCCC ACCCTTACCC TCACTGGCCA TGATGAGTTT GGCCGATTTG 1200

75 GCAGCTCCTT GACCCCCCTG GGGGACCTGG ACCAGGATGG CTACAATGAT GTGGCCATCG 1260

GGGCTCCCTT TGGTGGGGAG ACCCAGCAGG GAGTAGTGTT TGTATTTCCT GGGGGCCCAG 1320 GAGGGCTGGG CTCTAAGCCT TCCCAGGTTC TGCAGCCCCT GTGGGCAGCC AGCCACACCC 1380 CAGACTTCTT TGGCTCTGCC CTTCGAGGAG GCCGAGACCT GGATGGCAAT GGATATCCTG 1440 ATCTGATTGT GGGGTCCTTT GGTGTGGACA AGGCTGTGGT ATACAGGGGC CGCCCCATCG 1500 TGTCCGCTAG TGCCTCCCTC ACCATCTTCC CCGCCATGTT CAACCCAGAG GAGCGGAGCT 1560 GCAGCTTAGA GGGGAACCCT GTGGCCTGCA TCAACCTTAG CTTCTGCCTC AATGCTTCTG 1620 GAAAACACGT TGCTGACTCC ATTGGTTTCA CAGTGGAACT TCAGCTGGAC TGGCAGAAGC 1680 AGAAGGGAGG GGTACGGCGG GCACTGTTCC TGGCCTCCAG GCAGGCAACC CTGACCCAGA 1740 CCCTGCTCAT CCAGAATGGG GCTCGAGAGG ATTGCAGAGA GATGAAGATC TACCTCAGGA 1800 ACGAGTCAGA ATTTCGAGAC AAACTCTCGC CGATTCACAT CGCTCTCAAC TTCTCCTTGG 1860 ACCCCCAAGC CCCAGTGGAC AGCCACGGCC TCAGGCCAGC CCTACATTAT CAGAGCAAGA 1920 GCCGGATAGA GGACAAGGCT CAGATCTTGC TGGACTGTGG AGAAGACAAC ATCTGTGTGC 1980 CTGACCTGCA GCTGGAAGTG TTTGGGGAGC AGAACCATGT GTACCTGGGT GACAAGAATG 2040 CCCTGAACCT CACTTTCCAT GCCCAGAATG TGGGTGAGGG TGGCGCCTAT GAGGCTGAGC 2100 TTCGGGTCAC CGCCCCTCCA GAGGCTGAGT ACTCAGGACT CGTCAGACAC CCAGGGAACT 2160 TCTCCAGCCT GAGCTGTGAC TACTTTGCCG TGAACCAGAG CCGCCTGCTG GTGTGTGACC 2220 TGGGCAACCC CATGAAGGCA GGAGCCAGTC TGTGGGGTGG CCTTCGGTTT ACAGTCCCTC 2280 ATCTCCGGGA CACTAAGAAA ACCATCCAGT TTGACTTCCA GATCCTCAGC AAGAATCTCA 2340 ACAACTCGCA AAGCGACGTG GTTTCCTTTC GGCTCTCCGT GGAGGCTCAG GCCCAGGTCA 2400 CCCTGAACGG TGTCTCCAAG CCTGAGGCAG TGCTATTCCC AGTAAGCGAC TGGCATCCCC 2460 GAGAGGAGCC TCAGAAGGAG GAGGACCTGG GACCTGCTGT CCACCATGTC TATGAGCTCA 2520 TCAACCAAGG CCCCAGCTCC ATTAGCCAGG GTGTGCTGGA ACTCAGCTGT CCCCAGGCTC 2580 TGGAAGGTCA GCAGCTCCTA TATGTGACCA GAGTTACGGG ACTCAACTGC ACCACCAATC 2640 ACCCCATTAA CCCAAAGGGC CTGGAGTTGG ATCCCGAGGG TTCCCTGCAC CACCAGCAAA 2700 AACGGGAAGC TCCAAGCCGC AGCTCTGCTT CCTCGGGACC TCAGATCCTG AAATGCCCGG 2760 AGGCTGAGTG TTTCAGGCTG CGCTGTGAGC TCGGGCCCCT GCACCAACAA GAGAGCCAAA 2820 GTCTGCAGTT GCATTTCCGA GTCTGGGCCA AGACTTTCTT GCAGCGGGAG CACCAGCCAT 2880 TTAGCCTGCA GTGTGAGGCT GTGTACAAAG CCCTGAAGAT GCCCTACCGA ATCCTGCCTC 2940 GGCAGCTGCC CCAAAAAGAG CGTCAGGTGG CCACAGCTGT GCAATGGACC AAGGCAGAAG 3000 GCAGCTATGG CGTCCCACTG TGGATCATCA TCCTAGCCAT CCTGTTTGGC CTCCTGCTCC 3060 TAGGTCTACT CATCTACATC CTCTACAAGC TTGGATTCTT CAAACGCTCC CTCCCATATG 3120 GCACCGCCAT GGAAAAAGCT CAGCTCAAGC CTCCAGCCAC CTCTGATGCC TGAGTCCTCC 3180 CAATTTCAGA CTCCCATTCC TGAAGAACCA GTCCCCCCAC CCTCATTCTA CTGAAAAGGA 3240 GGGGTCTGGG TACTTCTTGA AGGTGCTGAC GGCCAGGGAG AAGCTCCTCT CCCCAGCCCA 3300 GAGACATACT TGAAGGGCCA GAGCCAGGGG GGTGAGGAGC TGGGGATCCC TCCCCCCCAT 3360 GCACTGTGAA GGACCCTTGT TTACACATAC CCTCTTCATG GATGGGGGAA CTCAGATCCA 3420 GGGACAGAGG CCCAGCCTCC CTGAAGCCTT TGCATTTTGG AGAGTTTCCT GAAACAACTG 3480 GAAAGATAAC TAGGAAATCC ATTCACAGTT CTTTGGGCCA GACATGCCAC AAGGACTTCC 3540 TGTCCAGCTC CAACCTGCAA AGATCTGTCC TCAGCCTTGC CAGAGATCCA AAAGAAGCCC 3600 CCAGTAAGAA CCTGGAACTT GGGGAGTTAA GACCTGGCAG CTCTGGACAG CCCCACCCTG 3660 GTGGGCCAAC AAAGAACACT AACTATGCAT GGTGCCCCAG GACCAGCTCA GGACAGATGC ₃720 CACAAGGATA GATGCTGGCC CAGGGCCAGA GCCCAGCTCC AAGGGGAATC AGAACTCAAA ₃780 TGGGGCCAGA TCCAGCCTGG GGTCTGGAGT TGATCTGGAA CCCAGACTCA GACATTGGCA 3840 CCAATCCAGG CAGATCCAGG ACTATATTTG GGCCTGCTCC AGACCTGATC CTGGAGGCCC 3900 AGTTCACCCT GATTTAGGAG AAGCCAGGAA TTTCCCAGGA CCTGAAGGGG CCATGATGGC 3960 AACAGATCTG GAACCTCAGC CTGGCCAGAC ACAGGCCCTC CCTGTTCCCC AGAGAAAGGG 4020 GAGCCCACTG TCCTGGGCCT GCAGAATTTG GGTTCTGCCT GCCAGCTGCA CTGATGCTGC 4080 CCCTCATCTC TCTGCCCAAC CCTTCCCTCA CCTTGGCACC AGACACCCAG GACTTATTTA 41₄0 AACTCTGTTG CAAGTGCAAT AAATCTGACC CAGTGCCCCC ACTGACCAGA ACTAGAAAAA ₄200 AAAA

Seq ID NO: 6 Protein sequence: Protein Accession #: NP 002196.1

11 21 31 41 51

MGSRTPESPL HAVQ RWGPR RRPPLVP L L VPPPPRVG GFNLDAEAPA V SGPPGSFF 60 GFSVEFYRPG TDGVSVLVGA PKANTSQPGV LQGGAVY CP GASPTQCTP IEFDSKGSRL 120 LESS SSSEG EEPVEYKSLQ FGATVRAHG SSIIACAPLY S RTEKEP S DPVGTCYLST 180 DNFTRI EYA PCRSDFS AA GQGYCQGGFS AEFTKTGRW LGGPGSYFWQ GQILSATQEQ 240 IAESYYPEY IN VQGQLQT RQASSIYDDS Y GYSVAVGE FSGDDTEDFV AGVPKGNLTY ₃00 GYV I NGSD IRS YNFSGE QMASYFGYAV AATDVNGDG DD LVGAPLL MDRTPDGRPQ 360 EVGRVYVYLQ HPAGIEPTPT T TGHDEFG RFGSS TPLG DLDQDGYNDV AIGAPFGGET 420 QQGWFVFPG GPGG GSKPS QV QP AAS HTPDFFGSAL RGGRDLDGNG YPD IVGSFG 480 VDKAWYRGR PIVSASASLT IFPAMFNPEE RSCSLEGNPV ACINLSFC N ASGKHVADSI 540 GFTVE Q DW QKQKGGVRRA LFLASRQAT TQTL IQNGA REDCREMKIY RNESEFRDK 600 LSPIHIA NF SLDPQAPVDS HGLRPA HYQ SKSRIEDKAQ ILLDCGEDNI CVPDLQLEVF 660 GEQNHVYLGD KNALNLTFHA QNVGEGGAYE AELRVTAPPE AEYSG VRHP GNFSS SCDY 720 FAVNQSR V CD GNPMKAG AS GG RFT VPH RDTKKT IQFDFQI SK NLNNSQSDW 780 SFR SVEAQA QVTLNGVSKP EAVLFPVSDW HPRDQPQKEE DLGPAVHHVY ELINQGPSSI 840 SQGV ELSCP QA EGQQLLY VTRVTG NCT TNHPINPKGL ELDPEGSLHH QQKREAPSRS 900 SASSGPQIL CPEAECFRLR CELGPLHQQE SQSLQIiHFRV AKTF QREH QPFS QCEAV 960 YKALKMPYRI PRQLPQKER QVATAVQ TK AEGSYGVPLW IIILAILFGL L LGLLIYIL 1020 YKLGFFKRSL PYGTAMEKAQ KPPATSDA Seq ID NO : 7 Nucleotide sequence :

Nucleic Acid Accession # : NM_002211

Coding sequence : 104 . . 500 (underlined sequences correspond to start and stop codons)

1 11 21 31 41 51

I I I I I I

GTCCGCCAAA ACCTGCGCGG ATAGGGAAGA ACAGCACCCC GGCGCCGATT GCCGTACCAA 60 ACAAGCCTAA CGTCCGCTGG GCCCCGGACG CCGCGCGGAA AAGATGAATT TACAACCAAT 120 TTTCTGGATT GGACTGATCA GTTCAGTTTG CTGTGTGTTT GCTCAAACAG ATGAAAATAG 180 ATGTTTAAAA GCAAATGCCA AATCATGTGG AGAATGTATA CAAGCAGGGC CAAATTGTGG 240 GTGGTGCACA AATTCAACAT TTTTACAGGA AGGAATGCCT ACTTCTGCAC GATGTGATGA 300 TTTAGAAGCC TTAAAAAAGA AGGGTTGCCC TCCAGATGAC ATAGAAAATC CCAGAGGCTC 360 CAAAGATATA AAGAAAAATA AAAATGTAAC CAACCGTAGC AAAGGAACAG CAGAGAAGCT 420 CAAGCCAGAG GATATTACTC AGATCCAACC ACAGCAGTTG GTTTTGCGAT TAAGATCAGG 480 GGAGCCACAG ACATTTACAT TAAAATTCAA GAGAGCTGAA GACTATCCCA TTGACCTCTA 540 CTACCTTATG GACCTGTCTT ATTCAATGAA AGACGATTTG GAGAATGTAA AAAGTGTTGG 600 AACAGATCTG ATGAATGAAA TGAGGAGGAT TACTTCGGAC TTCAGAATTG GATTTGGCTC 660 ATTTGTGGAA AAGACTGTGA TGCCTTACAT TAGCACAACA CCAGCTAAGC TCAGGAACCC 720 TTGCACAAGT GAACAGAACT GCACCACCCC ATTTAGCTAC AAAAATGTGC TCAGTCTTAC 780 TAATAAAGGA GAAGTATTTA ATGAACTTGT TGGAAAACAG CGCATATCTG GAAATTTGGA 840 TTCTCCAGAA GGTGGTTTCG ATGCCATCAT GCAAGTTGCA GTTTGTGGAT CACTGATTGG 900 CTGGAGGAAT GTTACACGGC TGCTGGTGTT TTCCACAGAT GCCGGGTTTC ACTTTGCTGG 960

AGATGGGAAA CTTGGTGGCA TTGTTTTACC AAATGATGGA CAATGTCACC TGGAAAATAA 1020 TATGTACACA ATGAGCCATT ATTATGATTA TCCTTCTATT GCTCACCTTG TCCAGAAACT 1080

GAGTGAAAAT AATATTCAGA CAATTTTTGC AGTTACTGAA GAATTTCAGC CTGTTTACAA 1140

GGAGCTGAAA AACTTGATCC CTAAGTCAGC AGTAGGAACA TTATCTGCAA ATTCTAGCAA 1200

TGTAATTCAG TTGATCATTG ATGCATACAA TTCCCTTTCC TCAGAAGTCA TTTTGGAAAA 1260

CGGCAAATTG TCAGAAGGAG TAACAATAAG TTACAAATCT TACTGCAAGA ACGGGGTGAA 1320 TGGAACAGGG GAAAATGGAA GAAAATGTTC CAATATTTCC ATTGGAGATG AGGTTCAATT 1380

TGAAATTAGC ATAACTTCAA ATAAGTGTCC AAAAAAGGAT TCTGACAGCT TTAAAATTAG 1440

GCCTCTGGGC TTTACGGAGG AAGTAGAGGT TATTCTTCAG TACATCTGTG AATGTGAATG 1500

CCAAAGCGAA GGCATCCCTG AAAGTCCCAA GTGTCATGAA GGAAATGGGA CATTTGAGTG 1560

TGGCGCGTGC AGGTGCAATG AAGGGCGTGT TGGTAGACAT TGTGAATGCA GCACAGATGA 1620 AGTTAACAGT GAAGACATGG ATGCTTACTG CAGGAAAGAA AACAGTTCAG AAATCTGCAG 1680

TAACAATGGA GAGTGCGTCT GCGGACAGTG TGTTTGTAGG AAGAGGGATA ATACAAATGA 1740

AATTTATTCT GGCAAATTCT GCGAGTGTGA TAATTTCAAC TGTGATAGAT CCAATGGCTT 1800

AATTTGTGGA GGAAATGGTG TTTGCAAGTG TCGTGTGTGT GAGTGCAACC CCAACTACAC 1860

TGGCAGTGCA TGTGACTGTT CTTTGGATAC TAGTACTTGT GAAGCCAGCA ACGGACAGAT 1920 CTGCAATGGC CGGGGCATCT GCGAGTGTGG TGTCTGTAAG TGTACAGATC CGAAGTTTCA 1980

AGGGCAAACG TGTGAGATGT GTCAGACCTG CCTTGGTGTC TGTGCTGAGC ATAAAGAATG 2040

TGTTCAGTGC AGAGCCTTCA ATAAAGGAGA AAAGAAAGAC ACATGCACAC AGGAATGTTC 2100

CTATTTTAAC ATTACCAAGG TAGAAAGTCG GGACAAATTA CCCCAGCCGG TCCAACCTGA 2160

TCCTGTGTCC CATTGTAAGG AGAAGGATGT TGACGACTGT TGGTTCTATT TTACGTATTC ₂220 AGTGAATGGG AACAACGAGG TCATGGTTCA TGTTGTGGAG AATCCAGAGT GTCCCACTGG 2280

TCCAGACATC ATTCCAATTG TAGCTGGTGT GGTTGCTGGA ATTGTTCTTA TTGGCCTTGC 2340

ATTACTGCTG ATATGGAAGC TTTTAATGAT AATTCATGAC AGAAGGGAGT TTGCTAAATT 2400

TGAAAAGGAG AAAATGAATG CCAAATGGGA CACGGGTGAA AATCCTATTT ATAAGAGTGC 2460

CGTAACAACT GTGGTCAATC CGAAGTATGA GGGAAAATGA GTACTGCCCG TGCAAATCCC 2520 ACAACACTGA ATGCAAAGTA GCAATTTCCA TAGTCACAGT TAGGTAGCTT TAGGGCAATA 2580

TTGCCATGGT TTTACTCATG TGCAGGTTTT GAAAATGTAC AATATGTATA ATTTTTAAAA 2640

TGTTTTATTA TTTTGAAAAT AATGTTGTAA TTCATGCCAG GGACTGACAA AAGACTTGAG 2700

ACAGGATGGT TATTCTTGTC AGCTAAGGTC ACATTGTGCC TTTTTGACCT TTTCTTCCTG 2760

GACTATTGAA ATCAAGCTTA TTGGATTAAG TGATATTTCT ATAGCGATTG AAAGGGCAAT 2820 AGTTAAAGTA ATGAGCATGA TGAGAGTTTC TGTTAATCAT GTATTAAAAC TGATTTTTAG 2880

CTTTACATAT GTCAGTTTGC AGTTATGCAG AATCCAAAGT AAATGTCCTG CTAGCTAGTT 29 0

AAGGATTGTT TTAAATCTGT TATTTTGCTA TTTGCCTGTT AGACATGACT GATGACATAT 3000

CTGAAAGACA AGTATGTTGA GAGTTGCTGG TGTAAAATAC GTTTGAAATA GTTGATCTAC 3060

AAAGGCCATG GGAAAAATTC AGAGAGTTAG GAAGGAAAAA CCAATAGCTT TAAAACCTGT 3120 GTGCCATTTT AAGAGTTACT TAATGTTTGG TAACTTTTAT GCCTTCACTT TACAAATTCA 3180

AGCCTTAGAT AAAAGAACCG AGCAATTTTC TGCTAAAAAG TCCTTGATTT AGCACTATTT 3240

ACATACAGGC CATACTTTAC AAAGTATTTG CTGAATGGGG ACCTTTTGAG TTGAATTTAT 3300

TTTATTATTT TTATTTTGTT TAATGTCTGG TGCTTTCTAT CACCTCTTCT AATCTTTTAA 3360

TGTATTTGTT TGCAATTTTG GGGTAAGACT TTTTTATGAG TACTTTTTCT TTGAAGTTTT 3420 AGCGGTCAAT TTGCCTTTTT AATGAACATG TGAAGTTATA CTGTGGCTAT GCAACAGCTC 3480

TCACCTACGC GAGTCTTACT TTGAGTTAGT GCCATAACAG ACCACTGTAT GTTTACTTCT 35₄0

CACCATTTGA GTTGCCCATC TTGTTTCACA CTAGTCACAT TCTTGTTTTA AGTGCCTTTA 3600 GTTTTAACAG TTCA Seq ID NO: 8 Protein sequence: Protein Accession #: NP 002202

1 11 21 31 41 51

I I I I I 1

MN QPIFWIG LISSVCCVFA QTDENRCLKA NAKSCGECIQ AGPNCGWCTN STFLQEGMPT 60 SARCDDLEAL KKKGCPPDDI ENPRGSKDIK KNKNVTNRSK GTAEK KPED ITQIQPQQLV 120 R RSGEPQT FTLKFKRAED YPID YY MD LSYSMKDDLE NVKSLGTDLM NEMRRITSDF 180 RIGFGSFVEK TVMPYISTTP AKLRNPCTSE QNCTSPFSYK NVLS TNKGE VFNE VGKQR 240 ISGNLDSPEG GFDAIMQVAV CGS IG RNV TRLLVFSTDA GFHFAGDGKL GGIV PNDGQ 300 CHLENNMYT SHYYDYPSIA H VQKLSENN IQTIFAVTEE FQPVYKELKN LIPKSAVGT 360 SANSSNVIQIJ IIDAYNSLSS EVI ENGKLS EGVTISYKSY CKNGVNGTGE NGRKCSNISI 420 GDEVQFEISI TSNKCPKKDS DSFKIRPLGF TEEVEVI QY ICECECQSEG IPESPKCHEG 480 NGTFECGACR CNEGRVGRHC ECSTDEVNSE DMDAYCRKEN SSEICSNNGE CVCGQCVCRK 540 RDNTNEIYSG KFCECDNFNC DRSNGLICGG NGVCKCRVCE CNPNYTGSAC DCSLDTSTCE 600 ASNGQICNGR GICECGVCKC TDPKFQGQTC EMCQTCLGVC AEHKECVQCR AFNKGEKKDT 660 CTQECSYFNI TKVESRDKLP QPVQPDPVSH C EKDVDDC FYFTYSVNGN NEVMVHWEN 720 PECPTGPDII PIVAGWAGI VLIG ALLLI K LMIIHDR REFAKFEKEK MNAK DTGEN 780 PIYKSAVTTV VNPKYEGK

Seq ID NO: 9 Nucleotide sequence:

Nucleic Acid Accession #:NM_002425

Coding sequence: 23..1453 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

AAAGAAGGTA AGGGCAGTGA GAATGATGCA TCTTGCATTC CTTGTGCTGT TGTGTCTGCC 60 AGTCTGCTCT GCCTATCCTC TGAGTGGGGC AGCAAAAGAG GAGGACTCCA ACAAGGATCT 120 TGCCCAGCAA TACCTAGAAA AGTACTACAA CCTCGAAAAG GATGTGAAAC AGTTTAGAAG 180 AAAGGACAGT AATCTCATTG TTAAAAAAAT CCAAGGAATG CAGAAGTTCC TTGGGTTGGA 240 GGTGACAGGG AAGCTAGACA CTGACACTCT GGAGGTGATG CGCAAGCCCA GGTGTGGAGT 300 TCCTGACGTT GGTCACTTCA GCTCCTTTCC TGGCATGCCG AAGTGGAGGA AAACCCACCT 360 TACATACAGG ATTGTGAATT ATACACCAGA TTTGCCAAGA GATGCTGTTG ATTCTGCCAT 420 TGAGAAAGCT CTGAAAGTCT GGGAAGAGGT GACTCCACTC ACATTCTCCA GGCTGTATGA 480 AGGAGAGGCT GATATAATGA TCTCTTTCGC AGTTAAAGAA CATGGAGACT TTTACTCTTT 540 TGATGGCCCA GGACACAGTT TGGCTCATGC CTACCCACCT GGACCTGGGC TTTATGGAGA 600 TATTCACTTT GATGATGATG AAAAATGGAC AGAAGATGCA TCAGGCACCA ATTTATTCCT 660 CGTTGCTGCT CATGAACTTG GCCACTCCCT GGGGCTCTTT CACTCAGCCA ACACTGAAGC 720 TTTGATGTAC CCACTCTACA ACTCATTCAC AGAGCTCGCC CAGTTCCGCC TTTCGCAAGA 780 TGATGTGAAT GGCATTCAGT CTCTCTACGG ACCTCCCCCT GCCTCTACTG AGGAACCCCT 840 GGTGCCCACA AAATCTGTTC CTTCGGGATC TGAGATGCCA GCCAAGTGTG ATCCTGCTTT 900 GTCCTTCGAT GCCATCAGCA CTCTGAGGGG AGAATATCTG TTCTTTAAAG ACAGATATTT 960 TTGGCGAAGA TCCCACTGGA ACCCTGAACC TGAATTTCAT TTGATTTCTG CATTTTGGCC 1020 CTCTCTTCCA TCATATTTGG ATGCTGCATA TGAAGTTAAC AGCAGGGACA CCGTTTTTAT 1080 TTTTAAAGGA AATGAGTTCT GGGCCATCAG AGGAAATGAG GTACAAGCAG GTTATCCAAG 1140 AGGCATCCAT ACCCTGGGTT TTCCTCCAAC CATAAGGAAA ATTGATGCAG CTGTTTCTGA 1200 CAAGGAAAAG AAGAAAACAT ACTTCTTTGC AGCGGACAAA TACTGGAGAT TTGATGAAAA 1260 TAGCCAGTCC ATGGAGCAAG GCTTCCCTAG ACTAATAGCT GATGACTTTC CAGGAGTTGA 1320 GCCTAAGGTT GATGCTGTAT TACAGGCATT TGGATTTTTC TACTTCTTCA GTGGATCATC 1380 ACAGTTTGAG TTTGACCCCA ATGCCAGGAT GGTGACACAC ATATTAAAGA GTAACAGCTG 1440 GTTACATTGC TAGGCGAGAT AGGGGGAAGA CAGATATGGG TGTTTTTAAT AAATCTAATA 1500 ATTATTCATC TAATGTATTA TGAGCCAAAA TGGTTAATTT TTCCTGCATG TTCTGTGACT 1560 GAAGAAGATG AGCCTTGCAG ATATCTGCAT GTGTCATGAA GAATGTTTCT GGAATTCTTC 1620 ACTTGCTTTT GAATTGCACT GAACAGAATT AAGAAATACT CATGTGCAAT AGGTGAGAGA 1680 ATGTATTTTC ATAGATGTGT TATTACTTCC TCAATAAAAA GTTTTATTTT GGGCCTGTTC 1740 CTT

Seq ID NO: 10 Protein sequence: Protein Accession #: NP 002416

11 21 31 41 51

MMHLAFLVLL CLPVCSAYP SGAAKEEDSN KDLAQQYLEK YYNLEKDVKQ FRRKDSN IV 60 KKIQGMQKF GLEVTGKLDT DTLEV RKPR CGVPDVGHFS SFPGMPKWRK THLTYRIVNY 120 TPD PRDAVD SAIEKA KVW EEVTPLTFSR YEGEADIMI SFAVKEHGDF YSFDGPGHSL 180 AHAYPPGPG YGDIHFDDDE K TEDASGTN LF VAAHELG HSLGLFHSAN TEA MYPLYN 240 SFTE AQFR SQDDVNGIQS YGPPPASTE EPLVPTKSVP SGSEMPAKCD PALSFDAIST 300 LRGEYLFFKD RYF RRSHWN PEPEFH ISA FWPS PSYLD AAYEVNSRDT VFIFKGNEF 360 AIRGNEVQAG YPRGIHTLGF PPTIRKIDAA VSDKEKKKTY FFAADKY RF DENSQSMEQG 420 FPR IADDFP GVEPKVDAVL QAFGFFYFFS GSSQFEFDPN ARMVTHILKS NS HC

Seq ID NO : 11 Nucleotide sequence :

Nucleic Acid Accession # : XM_058189

Coding sequence : 169. .774 (underlined sequences correspond to start and stop codons

1 11 21 31 41 51

I I I I I I

GAAGACCAGC TCAGCTCTTC AGTTGTTGAT CATTGTCTAT TGTTCTCCAA ACAGTAAACC 60 AGTATTTCAC ACTGAGATTG TCGGCTGCGG GTATATTCCA ATTCCCCGTC TCCTCATGAA 120 TATGAAGTGA AGGGCTCTGA CCCTGGAAGT GGTTCTAAGC AGGGCAAAAT ∞GGTCTCGG 180 AAGTGTGGAG GCTGCCTAAG TTGTTTGCTG ATTCCGCTTG CACTTTGGAG TATAATCGTG 240 AACATATTAT TGTATTTCCC GAATGGGCAA ACTTCCTATG CATCCAGCAA TAAACTCACC ₃00 AACTACGTGT GGTATTTTGA AGGAATCTGT TTCTCAGGCA TCATGATGCT TATAGTAACA 360 ACAGTTCTTC TGGTACTGGA GAATAATAAC AACTATAAAT GTTGCCAGAG TGAAAACTGC 420 AGCAAAAAAT ATGTGACACT GCTGTCAATT ATCTTTTCTT CCCTCGGAAT TGCTTTTTCT 480 GGATACTGCC TGGTCATCTC TGCCTTGGGT CTTGTCCAAG GGCCATATTG CCGCACCCTT 540 GATGGCTGGG AGTATGCTTT TGAAGGCACT GCTGGACGTT TCCTTACAGA TTCTAGCATA 600 TGGATTCAGT GCCTGGAACC TGCACATGTT GTGGAGTGGA ACATCATTTT ATTTTCCATT 660 CTCATAACCC TCAGTGGGCT TCAAGTGATC ATCTGCCTCA TCAGAGTAGT CATGCAACTA 720 TCCAAGATAC TGTGTGGAAG CTATTCAGTG ATCTTCCAGC CTGGAATCAT TTGAATAAGG 780 ACAAAATGTT TTCCATTATC AAGACATGGC CATCTATCTA AATATTATAT CAACTGTGTA 840 GACTTGAGGG CAATATTGAA ATGATGGTGC TTTCTGCATT TGGTGTTTAT TTGTAAAAAA 900 TTTGCAGTCC TCACTGCACA TGCAAGTATA CCACCCTTCC ATTTAGTATG TTTTTTAAGT 960 AATATGCATC AGAAACTTCA GAAATACTTC TGCCCTTTGA TCAAACAAAT CCATTTCCAA 1020 GAATCTGTAC TAGGGAAGTA AATAAGAATA TGAGAGAAAC CTTTATGCAA ATATGTATAT 1080 TGCAACATTA TTTAATATTC TGGAAAATTG GAAACACCCC AAAATTCTAA ACTCAGAGGA 1140 AGGATTAAGT AAAGAGTGGT ACATACTGTA AATGTTTTCT GATATTAAAA AAAAAATTAA 1200 ATAAAAAATA AAGAGTACTA CATGGTTGTA AAA

Seq ID NO: 12 Protein sequence: Protein Accession #: XP 058189

11 21 31 41 51

MGSRKCGGC SCLLIPLAL SIIVNILLYF PNGQTSYASS NK TNYV YF EGICFSGIMM 60

LIVTTVLLVL ENNNNYKCCQ SENCSKKYVT LLSIIFSSLG IAFSGYCLVI SALG VQGPY 120 CRT DG EYA FEGTAGRF T DSSI IQCLE PAHWEWNII LFSI ITLSG LQVIIC IRV 180 VMQLSKI CG SYSVIFQPGI I

Seq ID NO : 13 Nucleotide sequence : Nucleic Acid Accession # : NM_005397

Coding sequence : 251 . .1837 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

I I I I I

AAACGCCGCC CAGGACGCAG CCGCCGCCGC CGCCGCTCCT CTGCCACTGG CTCTGCGCCC 60 CAGCCCGGCT CTGCTGCAGC GGCAGGGAGG AAGAGCCGCC GCAGCGCGAC TCGGGAGCCC 120 CGGGCCACAG CCTGGCCTCC GGAGCCACCC ACAGGCCTCC CCGGGCGGCG CCCACGCTCC 180 TACCGCCCGG ACGCGCGGAT CCTCCGCCGG CACCGCAGCC ACCTGCTCCC GGCCCAGAGG 240 CGACGACACG ATGCGCTGCG CGCTGGCGCT CTCGGCGCTG CTGCTACTGT TGTCAACGCC 300 GCCGCTGCTG CCGTCGTCGC CGTCGCCGTC GCCGTCGCCG TCGCCCTCCC AGAATGCAAC 360 CCAGACTACT ACGGACTCAT CTAACAAAAC AGCACCGACT CCAGCATCCA GTGTCACCAT 420 CATGGCTACA GATACAGCCC AGCAGAGCAC AGTCCCCACT TCCAAGGCCA ACGAAATCTT 480 GGCCTCGGTC AAGGCGACCA CCCTTGGTGT ATCCAGTGAC TCACCGGGGA CTACAACCCT 540 GGCTCAGCAA GTCTCAGGCC CAGTCAACAC TACCGTGGCT AGAGGAGGCG GCTCAGGCAA 600 CCCTACTACC ACCATCGAGA GCCCCAAGAG CACAAAAAGT GCAGACACCA CTACAGTTGC 660 AACCTCCACA GCCACAGCTA AACCTAACAC CACAAGCAGC CAGAATGGAG CAGAAGATAC 720 AACAAACTCT GGGGGGAAAA GCAGCCACAG TGTGACCACA GACCTCACAT CCACTAAGGC 780 AGAACATCTG ACGACCCCTC ACCCTACAAG TCCACTTAGC CCCCGACAAC CCACTTTGAC 840 GCATCCTGTG GCCACCCCAA CAAGCTCGGG ACATGACCAT CTTATGAAAA TTTCAAGCAG 900 TTCAAGCACT GTGGCTATCC CTGGCTACAC CTTCACAAGC CCGGGGATGA CCACCACCCT 960 ACCGTCATCG GTTATCTCGC AAAGAACTCA ACAGACCTCC AGTCAGATGC CAGCCAGCTC 1020 TACGGCCCCT TCCTCCCAGG AGACAGTGCA GCCCACGAGC CCGGCAACGG CATTGAGAAC 1080 ACCTACCCTG CCAGAGACCA TGAGCTCCAG CCCCACAGCA GCATCAACTA CCCACCGATA 1140 CCCCAAAACA CCTTCTCCCA CTGTGGCTCA TGAGAGTAAC TGGGCAAAGT GTGAGGATCT 1200 TGAGACACAG ACACAGAGTG AGAAGCAGCT CGTCCTGAAC CTCACAGGAA ACACCCTCTG 1260 TGCAGGGGGC GCTTCGGATG AGAAATTGAT CTCACTGATA TGCCGAGCAG TCAAAGCCAC 1320 CTTCAACCCG GCCCAAGATA AGTGCGGCAT ACGGCTGGCA TCTGTTCCAG GAAGTCAGAC 1380 CGTGGTCGTC AAAGAAATCA CTATTCACAC TAAGCTCCCT GCCAAGGATG TGTACGAGCG 1440 GCTGAAGGAC AAATGGGATG AACTAAAGGA GGCAGGGGTC AGTGACATGA AGCTAGGGGA 1500 CCAGGGGCCA CCGGAGGAGG CCGAGGACCG CTTCAGCATG CCCCTCATCA TCACCATCGT 1560 CTGCATGGCG TCATTCCTGC TCCTCGTGGC GGCCCTCTAT GGCTGCTGCC ACCAGCGCCT 1620 CTCCCAGAGG AAGGACCAGC AGCGGCTAAC AGAGGAGCTG CAGACAGTGG AGAATGGTTA 1680 CCATGACAAC CCAACACTGG AAGTGATGGA GACCTCTTCT GAGATGCAGG AGAAGAAGGT 1740 GGTCAGCCTC AACGGGGAGC TGGGGGACAG CTGGATCGTC CCTCTGGACA ACCTGACCAA 1800 GGACGACCTG GATGAGGAGG AAGACACACA CCTCTAGTCC GGTCTGCCGG TGGCCTCCAG 1860 CAGCACCACA GAGCTCCAGA CCAACCACCC CAAGTGCCGT TTGGATGGGG AAGGGAAAGA 1920 CTGGGGAGGG AGAGTGAACT CCGAGGGGTG TCCCCTCCCA ATCCCCCCAG GGCCTTAATT 1980 TTTCCCTTTT CAACCTGAAC AAATCACATT CTGTCCAGAT TCCTCTTGTA AAATAACCCA 2040 CTAGTGCCTG AGCTCAGTGC TGCTGGATGA TGAGGGAGAT CAAGAAAAAG CCACGTAAGG 2100 GACTTTATAG ATGAACTAGT GGAATCCCTT CATTCTGCAG TGAGATTGCC GAGACCTGAA 2160 GAGGGTAAGT GACTTGCCCA AGGTCAGAGC CACTTGGTGA CAGAGCCAGG ATGAGAACAA 2220 AGATTCCATT TGCACCATGC CACACTGCTG TGTTCACATG TGCCTTCCGT CCAGAGCAGT 2280

CCCGGGCAGG GGTGAAACTC CAGGAGGTGG CTGGGCTGGA AAGGAGGGCA GGGCTACATC 2340

CTGGCTCGGT GGGATCTGAC GACCTGAAAG TCCAGCTCCC AAGTTTTCCT TCTCCTACCC 2400

CAGCCTCGTG TACCCATCTT CCCACCCTCT ATGTTCTTAC CCCTCCCTAC ACTCAGTGTT 2460 TGTTCCCACT TACTCTGTCC TGGGGCCTCT GGGATTAGCA CAGGTTATTC ATAACCTTGA 2520

ACCCCTTGTT CTGGATTCGG ATTTTCTCAC ATTTGCTTCG TGAGATGGGG GCTTAACCCA 2580

CACAGGTCTC CGTGCGTGAA CCAGGTCTGC TTAGGGGACC TGCGTGCAGG TGAGGAGAGA 2640

AGGGGACACT CGAGTCCAGG CTGGTATCTC AGGGCAGCTG ATGAGGGGTC AGCAGGAACA 2700

CTGGCCCATT GCCCCTGGCA CTCCTTGCAG AGGCCACCCA CGATCTTCTT TGGGCTTCCA 2760 TTTCCACCAG GGACTAAAAT CTGCTGTAGC TAGTGAGAGC AGCGTGTTCC TTTTGTTGTT 2820

CACTGCTCAG CTGATGGGAG TGATTCCCTG AGACCCAGTA TGAAAGAGCA GTGGCTGCAG 2880

GAGAGGCCTT CCCGGGGCCC CCCATCAGCG ATGTGTCTTC AGAGACAATC CATTAAAGCA ₂940

GCCAGGAAGG ACAGGCTTTC CCCTGTATAT CATAGGAAAC TCAGGGACAT TTCAAGTTGC 3000

TGAGAGTTTT GTTATAGTTG TTTTCTAACC CAGCCCTCCA CTGCCAAAGG CCAAAAGCTC 3060 AGACAGTTGG CAGACGTCCA GTTAGCTCAT CTCACTCACT CTGATTCTCC TGTGCCACAG 3120

GAAAAGAGGG CCTGGAAAGC GCAGTGCATG CTGGGTGCAT GAAGGGCAGC CTGGGGGACA 3180

GACTGTTGTG GGAACGTCCC ACTGTCCTGG CCTGGAGCTA GGCCTTGCTG TTCCTCTTCT 3240

CTGTGAGCCT AGTGGGGCTG CTGCGGTTCT CTTGCAGTTT CTGGTGGCAT CTCAGGGGAA 3300

CACAAAAGCT ATGTCTATTC CCCAATATAG GACTTTTATG GGCTCGGCAG TTAGCTGCCA 3360 TGTAGAAGGC TCCTAAGCAG TGGGCATGGT GAGGTTTCAT CTGATTGAGA AGGGGGAATC 3420

CTGTGTGGAA TGTTGAACTT TCGCCATGGT CTCCATCGTT CTGGGCGTAA ATTCCCTGGG 3480

ATCAAGTAGG AAAATGGGCA GAACTGCTTA GGGGAATGAA ATTGCCATTT TTCGGGTGAA 3540

ACGCCACACC TCCAGGGTCT TAAGAGTCAG GCTCCGGCTG TAGTAGCTCT GATGAAATAG 3600

GCTATCCACT CGGGATGGCT TACTTTTTAA AAGGGTAGGG GGAGGGGCTG GGGAAGATCT 3660 GTCCTGCACC ATCTGCCTAA TTCCTTCCTC ACAGTCTGTA GCCATCTGAT ATCCTAGGGG 3720

GAAAAGGAAG GCCAGGGGTT CACATAGGGC CCCAGCGAGT TTCCCAGGAG TTAGAGGGAT 3780

GCGAGGCTAA CAAGTTCCAA AAACATCTGC CCCGATGCTC TAGTGTTTGG AGGTGGGCAG 3840

GATGGAGAAC AGTGCCTGTT TGGGGGAAAA CAGGAAATCT TGTTAGGCTT GAGTGAGGTG 3900

TTTGCTTCCT TCTTGCCCAG CGCTGGGTTC TCTCCACCCA GTAGGTTTTC TGTTGTGGTC 3960 CCGTGGGAGA GGCCAGACTG GATTATTCCT CCTTTGCTGA TCCTGGGTCA CACTTCACCA 4020

GCCAGGGGTT TTGACGGAGA CAGCAAATAG GCCTCTGCAA ATCAATCAAA GGCTGCAACC 4080

CTATGGCCTC TTGGAGACAG ATGATGACTG GCAAGGACTA GAGAGCAGGA GTGCCTGGCC 4140

AGGTCGGTCC TGACTCTCCT GACTCTCCAT CGCTCTGTCC AAGGAGAACC CGGAGAGGCT 4200

CTGGGCTGAT TCAGAGGTTA CTGCTTTATA TTCGTCCAAA CTGTGTTAGT CTAGGCTTAG 4260 GACAGCTTCA GAATCTGACA CCTTGCCTTG CTCTTGCCAC CAGGACACCT ATGTCAACAG 4320

GCCAAACAGC CATGCATCTA TAAAGGTCAT CATCTTCTGC CACCTTTACT GGGTTCTAAA 4380

TGCTCTCTGA TAATTCAGAG AGCATTGGGT CTGGGAAGAG GTAAGAGGAA CACTAGAAGC 4440

TCAGCATGAC TTAAACAGGT TGTAGCAAAG ACAGTTTATC ATCAACTCTT TCAGTGGTAA 4500

ACTGTGGTTT CCCCAAGCTG CACAGGAGGC CAGAAACCAC AAGTATGATG ACTAGGAAGC 4560 CTACTGTCAT GAGAGTGGGG AGACAGGCAG CAAAGCTTAT GAAGGAGGTA CAGAATATTC 4620

TTTGCGTTGT AAGACAGAAT ACGGGTTTAA TCTAGTCTAG GCRCCAGATT TTTTTCCCGC 4680

TTGATAAGGA AAGCTAGCAG AAAGTTTATT TAAACCACTT CTTGAGCTTT ATCTTTTTTG 4740

ACAATATACT GGAGAAACTT TGAAGAACAA GTTCAAACTG ATACATATAC ACATATTTTT 4800

TTGATAATGT AAATACAGTG ACCATGTTAA CCTACCCTGC ACTGCTTTAA GTGAACATAC 4860 TTTGAAAAAG CATTATGTTA GCTGAGTGAT GGCCAAGTTT TTTCTCTGGA CAGGAATGTA 4920

AATGTCTTAC TGGAAATGAC AAGTTTTTGC TTGATTTTTT TTTTTAAACA AAAAATGAAA 4980

TATAACAAGA CAAACTTATG ATAAAGTATT TGTCTTGTAG ATCAGGTGTT TTGTTTTGTT 5040

TTTTTAATTT TAAAATGCAA CCCTGCCCCC TCCCCAGCAA AGTCACAGCT CCATTTCAGT 5100

AAAGGTTGGA GTCAATATGC TCTGGTTGGC AGGCAACCCT GTAGTCATGG AGAAAGGTAT 5160 TTCAAGATCT AGTCCAATCT TTTTCTAGAG AAAAAGATAA TCTGAAGCTC ACAAAGATGA 5220

AGTGACTTCC TCAAAATCAC ATGGTTCAGG ACAGAAACAA GATTAAAACC TGGATCCACA 5280

GACTGTGCGC CTCAGAAGGA ATAATCGGTA AATTAAGAAT TGCTACTCGA AGGTGCCAGA 5340

ATGACACAAA GGACAGAATT CCTTTCCCAG TTGTTACCCT AGCAAGGCTA GGGAGGGCAT 5 00

GAACACAAAC ATAAGAACTG GTCTTCTCAC ACTTTCTCTG AATCATTTAG GTTTAAGATG 5460 TAAGTGAACA ATTCTTTCTT TCTGCCAAGA AACAAAGTTT TGGATGAGCT TTTATATATG 5520

GAACTTACTC CAACAGGACT GAGGGACCAA GGAAACATGA TGGGGGAGGC AAGAGAGGGC 5580

AAAGAGTAAA ACTGTAGCAT AGCTTTTGTC ACGGTCACTA GCTGATCCCT CAGGTCTGCT 5640

GCAAACACAG CATGGAGGAC ACAGATGACT CTTTGGTGTT GGTCTTTTTG TCTGCAGTGA 5700

ATGTTCAACA GTTTGCCCAG GAACTGGGGG ATCATATATG TCTTAGTGGA CAGGGGTCTG 5760 AAGTACACTG GAATTTACTG AGAAACTTGT TTGTAAAAAC TATAGTTAAT AATTATTGCA 5820 TTTTCTTACA AAAATATATT TTGGAAAATT GTATACTGTC AATTAAAGT

Seq ID NO: 14 Protein sequence: Protein Accession #: NP_005388

11 21 31 41 51

MRCA ALSAL LLLSTPP PSSPSPSPSP SPSQNATQTT TDSSNKTAPT PASSVTIMAT 60

DTAQQSTVPT SKANEILASV KATTLGVSSD SPGTTT AQQ VSGPVNTTVA RGGGSGNPTT 120 TIESPKSTKS ADTTTVATST ATAKPNTTSS QNGAEDTTNS GGKSSHSVTT DLTSTKAEHL 180

TTPHPTSPLS PRQPT THPV ATPTSSGHDH LMKISSSSST VAIPGYTFTS PGMTTTLPSS 2 0

VISQRTQQTS SQMPASSTAP SSQETVQPTS PATA RTPTL PETMSSSPTA ASTTHRYPKT 300

PSPTVAHESN AKCED ETQ TQSEKQ VLN LTGNT CAGG ASDEKLIS I CRAVKATFNP 360

AQDKCGIRLA SVPGSQTVW KEITIHTKLP AKDVYERLKD K DELKEAGV SDMKLGDQGP 420 PEEAEDRFSM P IITIVCMA SFLLLVAA Y GCCHQRLSQR KDQQRLTEEL QTVENGYHDN 480 PTLEVMETSS EMQEKKWS NGE GDS IV P DNLTKDDL DEEEDTH Seq ID NO: 15 Nucleotide sequence:

Nucleic Acid Accession #: NM_004105

Coding sequence: 150..1631 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

CTAGTATTCT ACTAGAACTG GAAGATTGCT CTCCGAGTTT TTTTTTTGTT ATTTTGTTAA 60

AAAATAAAAA GCTTGAGCAG CAATTCATAT TACTGTCACA GGTATTTTTG CTGTGCTGTG 120

CAAGGTAACT CTGCTAGCTA AGATTCACAA TGTTGAAAGC CCTTTTCCTA ACTATGCTGA 180

CTCTGGCGCT GGTCAAGTCA CAGGACACCG AAGAAACCAT CACGTACACG CAATGCACTG 240

ACGGATATGA GTGGGATCCT GTGAGACAGC AATGCAAAGA TATTGATGAA TGTGACATTG 300

TCCCAGACGC TTGTAAAGGT GGAATGAAGT GTGTCAACCA CTATGGAGGA TACCTCTGCC 360

TTCCGAAAAC AGCCCAGATT ATTGTCAATA ATGAACAGCC TCAGCAGGAA ACACAACCAG 420

CAGAAGGAAC CTCAGGGGCA ACCACCGGGG TTGTAGCTGC CAGCAGCATG GCAACCAGTG 480

GAGTGTTGCC CGGGGGTGGT TTTGTGGCCA GTGCTGCTGC AGTCGCAGGC CCTGAAATGC 540

AGACTGGCCG AAATAACTTT GTCATCCGGC GGAACCCAGC TGACCCTCAG CGCATTCCCT 600

CCAACCCTTC CCACCGTATC CAGTGTGCAG CAGGCTACGA GCAAAGTGAA CACAACGTGT 660

GCCAAGACAT AGACGAGTGC ACTGCAGGGA CGCACAACTG TAGAGCAGAC CAAGTGTGCA 720

TCAATTTACG GGGATCCTTT GCATGTCAGT GCCCTCCTGG ATATCAGAAG CGAGGGGAGC 780

AGTGCGTAGA CATAGATGAA TGTACCATCC CTCCATATTG CCACCAAAGA TGCGTGAATA 840

CACCAGGCTC ATTTTATTGC CAGTGCAGTC CTGGGTTTCA ATTGGCAGCA AACAACTATA 900

CCTGCGTAGA TATAAATGAA TGTGATGCCA GCAATCAATG TGCTCAGCAG TGCTACAACA 960

TTCTTGGTTC ATTCATCTGT CAGTGCAATC AAGGATATGA GCTAAGCAGT GACAGGCTCA 1020

ACTGTGAAGA CATTGATGAA TGCAGAACCT CAAGCTACCT GTGTCAATAT CAATGTGTCA 1080

ATGAACCTGG GAAATTCTCA TGTATGTGCC CCCAGGGATA CCAAGTGGTG AGAAGTAGAA 1140

CATGTCAAGA TATAAATGAG TGTGAGACCA CAAATGAATG CCGGGAGGAT GAAATGTGTT 1200

GGAATTATCA TGGCGGCTTC CGTTGTTATC CACGAAATCC TTGTCAAGAT CCCTACATTC 1260

TAACACCAGA GAACCGATGT GTTTGCCCAG TCTCAAATGC CATGTGCCGA GAACTGCCCC 1320

AGTCAATAGT CTACAAATAC ATGAGCATCC GATCTGATAG GTCTGTGCCA TCAGACATCT 1380

TCCAGATACA GGCCACAACT ATTTATGCCA ACACCATCAA TACTTTTCGG ATTAAATCTG 1440

GAAATGAAAA TGGAGAGTTC TACCTACGAC AAACAAGTCC TGTAAGTGCA ATGCTTGTGC 1500

TCGTGAAGTC ATTATCAGGA CCAAGAGAAC ATATCGTGGA CCTGGAGATG CTGACAGTCA 1560

GCAGTATAGG GACCTTCCGC ACAAGCTCTG TGTTAAGATT GACAATAATA GTGGGGCCAT 1620

TTTCATTTTA GTCTTTTCTA AGAGTCAACC ACAGGCATTT AAGTCAGCCA AAGAATATTG 1680

TTACCTTAAA GCACTATTTT ATTTATAGAT ATATCTAGTG CATCTACATC TCTATACTGT 1740

ACACTCACCC ATAACAAACA ATTACACCAT GGTATAAAGT GGGCATTTAA TATGTAAAGA 1800

TTCAAAGTTT GTCTTTATTA CTATATGTAA ATTAGACATT AATCCACTAA ACTGGTCTTC 1860

TTCAAGAGAG CTAAGTATAC ACTATCTGGT GAAACTTGGA TTCTTTCCTA TAAAAGTGGG 1920

ACCAAGCAAT GATGATCTTC TGTGGTGCTT AAGGAAACTT ACTAGAGCTC CACTAACAGT 1980

CTCATAAGGA GGCAGCCATC ATAACCATTG AATAGCATGC AAGGGTAAGA ATGAGTTTTT 2040

AACTGCTTTG TAAGAAAATG GAAAAGGTCA ATAAAGATAT ATTTCTTTAG AAAATGGGGA 2100

TCTGCCATAT TTGTGTTGGT TTTTATTTTC ATATCCAGCC TAAAGGTGGT TGTTTATTAT 2160

ATAGTAATAA ATCATTGCTG TACAACATGC TGGTTTCTGT AGGGTATTTT TAATTTTGTC 2220

AGAAATTTTA GATTGTGAAT ATTTTGTAAA AAACAGTAAG CAAAATTTTC CAGAATTCCC 2280

AAAATGAACC AGATACCCCC TAGAAAATTA TACTATTGAG AAATCTATGG GGAGGATATG 2340

AGAAAATAAA TTCCTTCTAA ACCACATTGG AACTGACCTG AAGAAGCAAA CTCGGAAAAT 2400

ATAATAACAT CCCTGAATTC AGGCATTCAC AAGATGCAGA ACAAAATGGA TAAAAGGTAT 2460

TTCACTGGAG AAGTTTTAAT TTCTAAGTAA AATTTAAATC CTAACACTTC ACTAATTTAT 2520

AACTAAAATT TCTCATCTTC GTACTTGATG CTCACAGAGG AAGAAAATGA TGATGGTTTT 2580

TATTCCTGGC ATCCAGAGTG ACAGTGAACT TAAGCAAATT ACCCTCCTAC CCAATTCTAT 2640

GGAATATTTT ATACGTCTCC TTGTTTAAAA TCTGACTGCT TTACTTTGAT GTATCATATT 2700

TTTAAATAAA AATAAATATT CCTTTAGAAG •ATCACTCTAA AA

Seq ID NO: 16 Protein sequence: Protein Accession #: NP 004096

11 21 31 41 51

MLKALFLTM T A VKSQDT EETITYTQCT DGYE DPVRQ QCKDIDECDI VPDACKGGMK 60 CVNHYGGY C LPKTAQIIVN NEQPQQETQP AEGTSGATTG WAASSMATS GV PGGGFVA 120 SAAAVAGPEM QTGRNNFVIR RNPADPQRIP SNPSHRIQCA AGYEQSEHNV CQDIDECTAG 180 THNCRADQVC INLRGSFACQ CPPGYQKRGE QCVDIDECTI PPYCHQRCVN TPGSFYCQCS 240 PGFQLAANNY TCVDINECDA SNQCAQQCYN ILGSFICQCN QGYELSSDRL NCEDIDECRT 300 SSYLCQYQCV NEPGKFSCMC PQGYQWRSR TCQDINECET TNECREDEMC WNYHGGFRCY 360 PRNPCQDPYI LTPENRCVCP VSNAMCRELP QSIVYKYMSI RSDRSVPSDI FQIQATTIYA 420 NTINTFRIKS GNENGEFY R QTSPVSAMLV LVKSLSGPRE HIVDLEMLTV SSIGTFRTSS 480 VLR TIIVGP FSF

Seq ID NO: 17 Nucleotide sequence :

Nucleic Acid Accession #: NM_018894

Coding sequence: 27..1967 (underlined sequences correspond to start and stop codons) 11 21 31 41 51

AAAACATTCA ACAAATTAAT GGGTGTAAGG AACTGGAAAA CCTGGACTCC TACCACATGC 60 AGATAAAACC AATAGAGTGC AGAATAAGAC TCAAGTCAAG TAAGTAACGT TAAACACCAT 120 AAAGACACAT GGCCTTCTTT GTGTACATGA CATGCATTCT CAACAATGCA CTGACGGATA 180 TGAGTGGGAT CCTGTGAGAC AGCAATGCAA AGATATTGAT GAATGTGACA TTGTCCCAGA 240 CGCTTGTAAA GGTGGAATGA AGTGTGTCAA CCACTATGGA GGATACCTCT GCCTTCCGAA 300 AACAGCCCAG ATTATTGTCA ATAATGAACA GCCTCAGCAG GAAACACAAC CAGCAGAAGG 360 AACCTCAGGG GCAACCACCG GGGTTGTAGC TGCCAGCAGC ATGGCAACCA GTGGAGTGTT 420 GCCCGGGGGT GGTTTTGTGG CCAGTGCTGC TGCAGTCGCA GGCCCTGAAA TGCAGACTGG 480 CCGAAATAAC TTTGTCATCC GGCGGAACCC AGCTGACCCT CAGCGCATTC CCTCCAACCC 540 TTCCCACCGT ATCCAGTGTG CAGCAGGCTA CGAGCAAAGT GAACACAACG TGTGCCAAGA 600 CATAGACGAG TGCACTGCAG GGACGCACAA CTGTAGAGCA GACCAAGTGT GCATCAATTT 660 ACGGGGATCC TTTGCATGTC AGTGCCCTCC TGGATATCAG AAGCGAGGGG AGCAGTGCGT 720 AGACATAGAT GAATGTACCA TCCCTCCATA TTGCCACCAA AGATGCGTGA ATACACCAGG 780 CTCATTTTAT TGCCAGTGCA GTCCTGGGTT TCAATTGGCA GCAAACAACT ATACCTGCGT 840 AGATATAAAT GAATGTGATG CCAGCAATCA ATGTGCTCAG CAGTGCTACA ACATTCTTGG 900 TTCATTCATC TGTCAGTGCA ATCAAGGATA TGAGCTAAGC AGTGACAGGC TCAACTGTGA 960 AGACATTGAT GAATGCAGAA CCTCAAGCTA CCTGTGTCAA TATCAATGTG TCAATGAACC 1020 TGGGAAATTC TCATGTATGT GCCCCCAGGG ATACCAAGTG GTGAGAAGTA GAACATGTCA 1080 AGATATAAAT GAGTGTGAGA CCACAAATGA ATGCCGGGAG GATGAAATGT GTTGGAATTA 1140 TCATGGCGGC TTCCGTTGTT ATCCACGAAA TCCTTGTCAA GATCCCTACA TTCTAACACC 1200 AGAGAACCGA TGTGTTTGCC CAGTCTCAAA TGCCATGTGC CGAGAACTGC CCCAGTCAAT 1260 AGTCTACAAA TACATGAGCA TCCGATCTGA TAGGTCTGTG CCATCAGACA TCTTCCAGAT 1320 ACAGGCCACA ACTATTTATG CCAACACCAT CAATACTTTT CGGATTAAAT CTGGAAATGA 1380 AAATGGAGAG TTCTACCTAC GACAAACAAG TCCTGTAAGT GCAATGCTTG TGCTCGTGAA 1440 GTCATTATCA GGACCAAGAG AACATATCGT GGACCTGGAG ATGCTGACAG TCAGCAGTAT 1500 AGGGACCTTC CGCACAAGCT CTGTGTTAAG ATTGACAATA ATAGTGGGGC CATTTTCATT 1560 TTAGTCTTTT CTAAGAGTCA ACCACAGGCA TTTAAGTCAG CCAAAGAATA TTGTTACCTT 1620 AAAGCACTAT TTTATTTATA GATATATCTA GTGCATCTAC ATCTCTATAC TGTACACTCA 1680 CCCATAACAA ACAATTACAC CATGGTATAA AGTGGGCATT TAATATGTAA AGATTCAAAG 1740 TTTGTCTTTA TTACTATATG TAAATTAGAC ATTAATCCAC TAAACTGGTC TTCTTCAAGA 1800 GAGCTAAGTA TACACTATCT GGTGAAACTT GGATTCTTTC CTATAAAAGT GGGACCAAGC 1860 AATGATGATC TTCTGTGGTG CTTAAGGAAA CTTACTAGAG CTCCACTAAC AGTCTCATAA 1920 GGAGGCAGCC ATCATAACCA TTGAATAGCA TGCAAGGGTA AGAATGAGTT TTTAACTGCT 1980 TTGTAAGAAA ATGGAAAAGG TCAATAAAGA TATATTTCTT TAGAAAATGG GGATCTGCCA 2040 TATTTGTGTT GGTTTTTATT TTCATATCCA GCCTAAAGGT GGTTGTTTAT TATATAGTAA 2100 TAAATCATTG CTGTACAACA TGCTGGTTTC TGTAGGGTAT TTTTAATTTT GTCAGAAATT 2160 TTAGATTGTG AATATTTTGT AAAAAACAGT AAGCAAAATT TTCCAGAATT CCCAAAATGA 2220 ACCAGATACC CCCTAGAAAA TTATACTATT GAGAAATCTA TGGGGAGGAT ATGAGAAAAT 2280 AAATTCCTTC TAAACCACAT TGGAACTGAC CTGAAGAAGC AAACTCGGAA AATATAATAA 2340 CATCCCTGAA TTCAGGCATT CACAAGATGC AGAACAAAAT GGATAAAAGG TATTTCACTG 2400 GAGAAGTTTT AATTTCTAAG TAAAATTTAA ATCCTAACAC TTCACTAATT TATAACTAAA 2460 ATTTCTCATC TTCGTACTTG ATGCTCACAG AGGAAGAAAA TGATGATGGT TTTTATTCCT 2520 GGCATCCAGA GTGACAGTGA ACTTAAGCAA ATTACCCTCC TACCCAATTC TATGGAATAT 2580 TTTATACGTC TCCTTGTTTA AAATCTGACT GCTTTACTTT GATGTATCAT ATTTTTAAAT 2640 AAAAATAAAT ATTCCTTTAG AAGATCACTC TAAAA

Seq ID NO: 18 Protein sequence: Protein Accession #: NP 061489.1

11 21 31 41 51

I I I I I

MHSQQCTDGY EWDPVRQQCK DIDECDIVPD ACKGGMKCVN HYGGYLCLPK TAQIIVNNEQ 60 PQQETQPAEG TSGATTGWA ASSMATSGVL PGGGFVASAA AVAGPEMQTG RNNFVIRRNP 120 ADPQRIPSNP SHRIQCAAGY EQSEHNVCQD IDECTAGTHN CRADQVCINL RGSFACQCPP 180 GYQKRGEQCV DIDECTIPPY CHQRCVNTPG SFYCQCSPGF QLAANNYTCV DINECDASNQ 240 CAQQCYNI G SFICQCNQGY ELSSDRLNCE DIDECRTSSY CQYQCVNEP GKFSCMCPQG 300 YQWRSRTCQ DINECETTNE CREDEMC NY HGGFRCYPRN PCQDPYILTP ENRCVCPVSN 360 AMCRELPQSI VYKYMSIRSD RSVPSDIFQI QATTIYANTI NTFRIKSGNE NGEFY RQTS 420 PVSAMLVLVK S SGPREHIV DLEMLTVSSI GTFRTSSV R LTIIVGPFSF

Seq ID NO: 19 Nucleotide sequence:

Nucleic Acid Accession #: NM_006500

Coding sequence: 27..1967 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

ACTTGCGTCT CGCCCTCCGG CCAAGCATGG GGCTTCCCAG GCTGGTCTGC GCCTTCTTGC 60

TCGCCGCCTG CTGCTGCTGT CCTCGCGTCG CGGGTGTGCC CGGAGAGGCT GAGCAGCCTG 120

CGCCTGAGCT GGTGGAGGTG GAAGTGGGCA GCACAGCCCT TCTGAAGTGC GGCCTCTCCC 180

AGTCCCAAGG CAACCTCAGC CATGTCGACT GGTTTTCTGT CCACAAGGAG AAGCGGACGC 240

TCATCTTCCG TGTGCGCCAG GGCCAGGGCC AGAGCGAACC TGGGGAGTAC GAGCAGCGGC 300

TCAGCCTCCA GGACAGAGGG GCTACTCTGG CCCTGACTCA AGTCACCCCC CAAGACGAGC 360 GCATCTTCTT GTGCCAGGGC AAGCGCCCTC GGTCCCAGGA GTACCGCATC CAGCTCCGCG 420

TCTACAAAGC TCCGGAGGAG CCAAACATCC AGGTCAACCC CCTGGGCATC CCTGTGAACA 480

GTAAGGAGCC TGAGGAGGTC GCTACCTGTG TAGGGAGGAA CGGGTACCCC ATTCCTCAAG 540

TCATCTGGTA CAAGAATGGC CGGCCTCTGA AGGAGGAGAA GAACCGGGTC CACATTCAGT 600 CGTCCCAGAC TGTGGAGTCG AGTGGTTTGT ACACCTTGCA GAGTATTCTG AAGGCACAGC 660

TGGTTAAAGA AGACAAAGAT GCCCAGTTTT ACTGTGAGCT CAACTACCGG CTGCCCAGTG 720

GGAACCACAT GAAGGAGTCC AGGGAAGTCA CCGTCCCTGT TTTCTACCCG ACAGAAAAAG 780

TGTGGCTGGA AGTGGAGCCC GTGGGAATGC TGAAGGAAGG GGACCGCGTG GAAATCAGGT 840

GTTTGGCTGA TGGCAACCCT CCACCACACT TCAGCATCAG CAAGCAGAAC CCCAGCACCA 900 GGGAGGCAGA GGAAGAGACA ACCAACGACA ACGGGGTCCT GGTGCTGGAG CCTGCCCGGA 960

AGGAACACAG TGGGCGCTAT GAATGTCAGG CCTGGAACTT GGACACCATG ATATCGCTGC 10 0

TGAGTGAACC ACAGGAACTA CTGGTGAACT ATGTGTCTGA CGTCCGAGTG AGTCCCGCAG 1080

CCCCTGAGAG ACAGGAAGGC AGCAGCCTCA CCCTGACCTG TGAGGCAGAG AGTAGCCAGG 1140

ACCTCGAGTT CCAGTGGCTG AGAGAAGAGA CAGACCAGGT GCTGGAAAGG GGGCCTGTGC 1200 TTCAGTTGCA TGACCTGAAA CGGGAGGCAG GAGGCGGCTA TCGCTGCGTG GCGTCTGTGC 1260

CCAGCATACC CGGCCTGAAC CGCACACAGC TGGTCAAGCT GGCCATTTTT GGCCCCCCTT 1320

GGATGGCATT CAAGGAGAGG AAGGTGTGGG TGAAAGAGAA TATGGTGTTG AATCTGTCTT 1380

GTGAAGCGTC AGGGCACCCC CGGCCCACCA TCTCCTGGAA CGTCAACGGC ACGGCAAGTG 1440

AACAAGACCA AGATCCACAG CGAGTCCTGA GCACCCTGAA TGTCCTCGTG ACCCCGGAGC 1500 TGTTGGAGAC AGGTGTTGAA TGCACGGCCT CCAACGACCT GGGCAAAAAC ACCAGCATCC 1560

TCTTCCTGGA GCTGGTCAAT TTAACCACCC TCACACCAGA CTCCAACACA ACCACTGGCC 1620

TCAGCACTTC CACTGCCAGT CCTCATACCA GAGCCAACAG CACCTCCACA GAGAGAAAGC 1680

TGCCGGAGCC GGAGAGCCGG GGCGTGGTCA TCGTGGCTGT GATTGTGTGC ATCCTGGTCC 1740

TGGCGGTGCT GGGCGCTGTC CTCTATTTCC TCTATAAGAA GGGCAAGCTG CCGTGCAGGC 1800 GCTCAGGGAA GCAGGAGATC ACGCTGCCCC CGTCTCGTAA GACCGAACTT GTAGTTGAAG 1860

TTAAGTCAGA TAAGCTCCCA GAAGAGATGG GCCTCCTGCA GGGCAGCAGC GGTGACAAGA 1920

GGGCTCCGGG AGACCAGGGA GAGAAATACA TCGATCTGAG GCATTAGCCC CGAATCACTT 1980

CAGCTCCCTT CCCTGCCTGG ACCATTCCCA GCTCCCTGCT CACTCTTCTC TCAGCCAAAG 2040

CCTCCAAAGG GACTAGAGAG AAGCCTCCTG CTCCCCTCAC CTGCACACCC CCTTTCAGAG 2100 GGCCACTGGG TTAGGACCTG AGGACCTCAC TTGGCCCTGC AAGCCGCTTT TCAGGGACCA 2160

GTCCACCACC ATCTCCTCCA CGTTGAGTGA AGCTCATCCC AAGCAAGGAG CCCCAGTCTC 2220

CCGAGCGGGT AGGAGAGTTT CTTGCAGAAC GTGTTTTTTC TTTACACACA TTATGGCTGT 2280

AAATACCTGG CTCCTGCCAG CAGCTGAGCT GGGTAGCCTC TCTGAGCTGG TTTCCTGCCC 2340

CAAAGGCTGG CTTCCACCAT CCAGGTGCAC CACTGAAGTG AGGACACACC GGAGCCAGGC 2400 GCCTGCTCAT GTTGAAGTGC GCTGTTCACA CCCGCTCCGG AGAGCACCCC AGCGGCATCC 2460

AGAAGCAGCT GCAGTGTTGC TGCCACCACC CTCCTGCTCG CCTCTTCAAA GTCTCCTGTG 2520

ACATTTTTTC TTTGGTCAGA AGCCAGGAAC TGGTGTCATT CCTTAAAAGA TACGTGCCGG 2580

GGCCAGGTGT GGTGGCTCAC GCCTGTAATC CCAGCACTTT GGGAGGCCGA GGCGGGCGGA 2640

TCACAAAGTC AGGACGAGAC CATCCTGGCT AACACGGTGA AACCCTGTCT CTACTAAAAA 2700 TACAAAAAAA AATTAGCTAG GCGTAGTGGT TGGCACCTAT AGTCCCAGCT ACTCGGAAGG 2760

CTGAAGCAGG AGAATGGTAT GAATCCAGGA GGTGGAGCTT GCAGTGAGCC GAGACCGTGC 2820

CACTGCACTC CAGCCTGGGC AACACAGCGA GACTCCGTCT CGAGGAAAAA AAAAGAAAAG 2880

ACGCGTACCT GCGGTGAGGA AGCTGGGCGC TGTTTTCGAG TTCAGGTGAA TTAGCCTCAA 2940

TCCCCGTGTT CACTTGCTCC CATAGCCCTC TTGATGGATC ACGTAAAACT GAAAGGCAGC 3000 GGGGAGCAGA CAAAGATGAG GTCTACACTG TCCTTCATGG GGATTAAAGC TATGGTTATA 3060

TTAGCACCAA ACTTCTACAA ACCAAGCTCA GGGCCCCAAC CCTAGAAGGG CCCAAATGAG 3120

AGAATGGTAC TTAGGGATGG AAAACGGGGC CTGGCTAGAG CTTCGGGTGT GTGTGTCTGT 3180

CTGTGTGTAT GCATACATAT GTGTGTATAT ATGGTTTTGT CAGGTGTGTA AATTTGCAAA 3240

TTGTTTCCTT TATATATGTA TGTATATATA TATATGAAAA TATATATATA TATGAAAAAT 3300 AAAGCTTAAT TGTCCCAGAA AATCATACAT TGCTTTTTTA TTCTACATGG GTACCACAGG 3360

AACCTGGGGG CCTGTGAAAC TACAACCAAA AGGCACACAA AACCGTTTCC AGTTGGCAGC 3420

AGAGATCAGG GGTTACCTCT GCTTCTGAGC AAATGGCTCA AGCTCTACCA GAGCAGACAG 3480

CTACCCTACT TTTCAGCAGC AAAACGTCCC GTATGACGCA GCACGAAGGG CCTGGCAGGC 3540 TGTTAGCAGG AGCTATGTCC CTTCCTATCG TTTCCGTCCA CTT

Seq ID NO : 20 Protein sequence : Protein Accession # : NP 006491

11 21 31 41 51

MGLPRLVCAF LAACCCCPR VAGVPGEAEQ PAPELVEVEV GSTA LKCG SQSQGN SHV 60

DWFSVHKEKR T IFRVRQGQ GQSEPGEYEQ RLS QDRGAT ALTQVTPQD ERIFLCQGKR 120 PRSQEYRIQL RVYKAPEEPN IQVNP GIPV NSKEPEEVAT CVGRNGYPIP QVIWYKNGRP 180

LKEEKNRVHI QSSQTVESSG YTLQSI KA QLVKEDKDAQ FYCELNYRLP SGNHMKESRE 240

VTVPVFYPTE KVWLEVEPVG MLKEGDRVEI RCLADGNPPP HFSISKQNPS TREAEEETTN 300

DNGV VLEPA RKEHSGRYEC QA NLDT IS LLSEPQEL V NYVSDVRVSP AAPERQEGSS 360

LT TCEAESS QDLEFQWLRE ETDQV ERGP VLQLHDLKRE AGGGYRCVAS VPSIPG NRT 420 QLVKLAIFGP PWMAFKERKV WVKENMV N SCEASGHPRP TISWNVNGTA SEQDQDPQRV 480

LSTLNVLVTP EL ETGVECT ASNDLGKNTS ILF E VNLT T TPDSNTTT GLSTSTASPH 540

TRANSTSTER KLPEPESRGV VIVAVIVCIL V AV GAV Y FLYKKGKLPC RRSGKQEITL 600 PPSRKTELW EVKSDKLPEE MG LQGSSGD KRAPGDQGEK YID RH Seq ID NO : 21 Nucleotide sequence :

Nucleic Acid Accession # : NM_002421

Coding sequence : 72. .1481 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

GGGATATTGG AGTAGCAAGA GGCTGGGAAG CCATCACTTA CCTTGCACTG AGAAAGAAGA 60 CAAAGGCCAG TATGCACAGC TTTCCTCCAC TGCTGCTGCT GCTGTTCTGG GGTGTGGTGT 120 CTCACAGCTT CCCAGCGACT CTAGAAACAC AAGAGCAAGA TGTGGACTTA GTCCAGAAAT 180 ACCTGGAAAA ATACTACAAC CTGAAGAATG ATGGGAGGCA AGTTGAAAAG CGGAGAAATA 240 GTGGCCCAGT GGTTGAAAAA TTGAAGCAAA TGCAGGAATT CTTTGGGCTG AAAGTGACTG 300 GGAAACCAGA TGCTGAAACC CTGAAGGTGA TGAAGCAGCC CAGATGTGGA GTGCCTGATG 360 TGGCTCAGTT TGTCCTCACT GAGGGGAACC CTCGCTGGGA GCAAACACAT CTGACCTACA 420 GGATTGAAAA TTACACGCCA GATTTGCCAA GAGCAGATGT GGACCATGCC ATTGAGAAAG 480 CCTTCCAACT CTGGAGTAAT GTCACACCTC TGACATTCAC CAAGGTCTCT GAGGGTCAAG 540 CAGACATCAT GATATCTTTT GTCAGGGGAG ATCATCGGGA CAACTCTCCT TTTGATGGAC 600 CTGGAGGAAA TCTTGCTCAT GCTTTTCAAC CAGGCCCAGG TATTGGAGGG GATGCTCATT 660 TTGATGAAGA TGAAAGGTGG ACCAACAATT TCAGAGAGTA CAACTTACAT CGTGTTGCGG 720 CTCATGAACT CGGCCATTCT CTTGGACTCT CCCATTCTAC TGATATCGGG GCTTTGATGT 780 ACCCTAGCTA CACCTTCAGT GGTGATGTTC AGCTAGCTCA GGATGACATT GATGGCATCC 840 AAGCCATATA TGGACGTTCC CAAAATCCTG TCCAGCCCAT CGGCCCACAA ACCCCAAAAG 900 CGTGTGACAG TAAGCTAACC TTTGATGCTA TAACTACGAT TCGGGGAGAA GTGATGTTCT 960 TTAAAGACAG ATTCTACATG CGCACAAATC CCTTCTACCC GGAAGTTGAG CTCAATTTCA 1020 TTTCTGTTTT CTGGCCACAA CTGCCAAATG GGCTTGAAGC TGCTTACGAA TTTGCCGACA 1080 GAGATGAAGT CCGGTTTTTC AAAGGGAATA AGTACTGGGC TGTTCAGGGA CAGAATGTGC 1140 TACACGGATA CCCCAAGGAC ATCTACAGCT CCTTTGGCTT CCCTAGAACT GTGAAGCATA 1200 TCGATGCTGC TCTTTCTGAG GAAAACACTG GAAAAACCTA CTTCTTTGTT GCTAAGAAAT 1260 ACTGGAGGTA TGATGAATAT AAACGATCTA TGGATCCAGG TTATCCCAAA ATGATAGCAC 1320 ATGACTTTCC TGGAATTGGC CACAAAGTTG ATGCAGTTTT CATGAAAGAT GGATTTTTCT 1380 ATTTCTTTCA TGGAACAAGA CAATACAAAT TTGATCCTAA AACGAAGAGA ATTTTGACTC 1440 TCCAGAAAGC TAATAGCTGG TTCAACTGCA GGAAAAATTG AACATTACTA ATTTGAATGG 1500 AAAACACATG GTGTGAGTCC AAAGAAGGTG TTTTCCTGAA GAACTGTCTA TTTTCTCAGT 1560 CATTTTTAAC CTCTAGAGTC ACTGATACAC AGAATATAAT CTTATTTATA CCTCAGTTTG 1620 CATATTTTTT TACTATTTAG AATGTAGCCC TTTTTGTACT GATATAATTT AGTTCCACAA 1680 ATGGTGGGTA CAAAAAGTCA AGTTTGTGGC TTATGGATTC ATATAGGCCA GAGTTGCAAA 1740 GATCTTTTCC AGAGTATGCA ACTCTGACGT TGATCCCAGA GAGCAGCTTC AGTGACAAAC 1800 ATATCCTTTC AAGACAGAAA GAGACAGGAG ACATGAGTCT TTGCCGGAGG AAAAGCAGCT 1860 CAAGAACACA TGTGCAGTCA CTGGTGTCAC CCTGGATAGG CAAGGGATAA CTCTTCTAAC 1920 ACAAAATAAG TGTTTTATGT TTGGAATAAA GTCAACCTTG TTTCTACTGT TTT

Seq ID NO: 22 Protein sequence : Protein Accession #: NP_002412

11 21 31 41 51

MHSFPPLL L F GWSHSF PATLETQEQD VDLVQKYLEK YYN KNDGRQ VEKRRNSGPV 60 VEKLKQMQEF FGLKVTGKPD AETL VMKQP RCGVPDVAQF VLTEGNPR E QTHLTYRIEN 120 YTPD PRADV DHAIEKAFQL WSNVTPLTFT KVSEGQADIM ISFVRGDHRD NSPFDGPGGN 180 AHAFQPGPG IGGDAHFDED ER TNNFREY N HRVAAHE GHSLGLSHST DIGALMYPSY 240 TFSGDVQ AQ DDIDGIQAIY GRSQNPVQPI GPQTPKACDS K TFDAITTI RGEVMFFKDR 300 FYMRTNPFYP EVE NFISVF PQLPNGLEA AYEFADRDEV RFFKGNKY A VQGQNVLHGY 360 PKDIYSSFGF PRTVKHIDAA SEENTGKTY FFVANKY RY DEYKRSMDPG YPKMIAHDFP 420 GIGHKVDAVF MKDGFFYFFH GTRQYKFDP TKRILTLQKA NS FNCRKN

Seq ID NO: 23 Nucleotide sequence: Nucleic Acid Accession #: FGENESH predicted ORF

Coding sequence: 141-1580 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

I I I I I

TCTGCGTGTG CCGGGGCTAG GGGCTGGAAG TCCTGGCTCT AGTTGCACCT CGGAAGGAAA 60 AGGCAAACAG AGGAGGGAAG GCGTCTTAGG ACTGCCTGGA TCCAGAGCAC TTTCCTCGGC 120 CTCTACAGGC CTGTGTCGCT ATGGGTTCCC CCGCCGCCCC GGAGGGAGCG CTGGGCTACG 180 TCCGCGAGTT CACTCGCCAC TCCTCCGACG TGCTGGGCAA CCTCAACGAG CTGCGCCTGC 240 GCGGGATCCT CACTGACGTC ACGCTGCTGG TTGGCGGGCA ACCCCTCAGA GCACACAAGG 300 CAGTTCTCAT CGCCTGCAGT GGCTTCTTCT ATTCAATTTT CCGGGGCCGT GCGGGAGTCG 360 GGGTGGACGT GCTCTCTCTG CCCGGGGGTC CCGAAGCGAG AGGCTTCGCC CCTCTATTGG 420 ACTTCATGTA CACTTCGCGC CTGCGCCTCT CTCCAGCCAC TGCACCAGCA GTCCTAGCGG 480 CCGCCACCTA TTTGCAGATG GAGCACGTGG TCCAGGCATG CCACCGCTTC ATCCAGGCCA 540 GCTATGAACC TCTGGGCATC TCCCTGCGCC CCCTGGAAGC AGAACCCCCA ACACCCCCAA 600 CGGCCCCTCC ACCAGGTAGT CCCAGGCGCT CCGAAGGACA CCCAGACCCA CCTACTGAAT 660 CTCGAAGCTG CAGTCAAGGC CCCCCCAGTC CAGCCAGCCC TGACCCCAAG GCCTGCAACT 720 GGAAAAAGTA CAAGTACATC GTGCTAAACT CTCAGGCCTC CCAAGCAGGG AGCCTGGTCG 780 GGGAGAGAAG TTCTGGTCAA CCTTGCCCCC AAGCCAGGCT CCCCAGTGGA GACGAGGCCT 840 CCAGCAGCAG CAGCAGCAGC AGCAGCAGCA GTGAAGAAGG ACCCATTCCT GGTCCCCAGA 900 GCAGGCTCTC TCCAACTGCT GCCACTGTGC AGTTCAAATG TGGGGCTCCA GCCAGTACCC 960 CCTACCTCCT CACATCCCAG GCTCAAGACA CCTCTGGATC ACCCTCTGAA CGGGCTCGTC 1020 CACTACCGGG AAGTGAATTT TTCAGCTGCC AGAACTGTGA GGCTGTGGCA GGGTGCTCAT 1080 CGGGGCTGGA CTCCTTGGTT CCTGGGGACG AAGACAAACC CTATAAGTGT CAGCTGTGCC 1140 GGTCTTCGTT CCGCTACAAG GGCAACCTTG CCAGTCATCG TACAGTGCAC ACAGGGGAAA 1200 AGCCTTACCA CTGCTCAATC TGCGGAGCCC GTTTTAACCG GCCAGCAAAC CTGAAAACGC 1260 ACAGCCGCAT CCATTCGGGA GAGAAGCCGT ATAAGTGTGA GACGTGCGGC TCGCGCTTTG 1320 TACAGGTGGC ACATCTGCGG GCGCACGTGC TGATCCACAC CGGGGAGAAG CCCTACCCTT 1380 GCCCTACCTG CGGAACCCGC TTCCGCCACC TGCAGACCCT CAAGAGCCAC GTTCGCATCC 1440 ACACCGGAGA GAAGCCTTAC CACTGCGACC CCTGTGGCCT GCATTTCCGG CACAAGAGTC 1500 AACTGCGGCT GCATCTGCGC CAGAAACACG GAGCTGCTAC CAACACCAAA GTGCACTACC 1560 ACATTCTCGG GGGGCCCTAG CTGAGCGCAG GCCCAGGCCC CACTTGCTTC CTGCGGGTGG 1620 GAAAGCTGCA GGCCCAGGCC TTGCTTCCCT ATCAGGCTTG GGCATAGGGG TGTGCCAGGC 1680 CACTTTGGTA TCAGAAATTG CCACCCTCTT AATTTCTCAC TGGGGAGAGC AGGGGTGGCA 1740 GATCCTGGCT AGATCTGCCT CTGTTTTGCT GGTCAAAACC TCTTCCCCAC AAGCCAGATT 1800 GTTTCTGAGG AGAGAGCTAG CTAGGGGCTG GGAAAGGGGA GAGATTGGAG TCCTGGTCTC 1860 CCTAAGGGAA TAGCCCTCCA CCTGTGGCCC CCATTGCATT CAGTTTATCT GTAAATATAA 1920 TTTATTGAGG CCTTTGGGTG GCACCGGGGC CTTCATTCGA TTGCATTTCC CACTCCCCTC 1980 TTCCACAAGT GTGATTAAAA GTGACCAGAA ACACAGAAGG TGAGATCACA GCTCTGCTGG 2040 CAGAGATTAC TAGCCCTTGG CTCTCTCGTT TGGCTTGGGT ATTTTATATT ATTTCTGTCA 2100 TAACTTTTAT CTTTAGAATT GTTCTTTCTC CTGTTTGTTT GCTTGTTAGT TTGTTTAAAA 2160 TGGAAAAAGG GGTTCTCTGT GTTCTGCCCC TGTAATTCTA GGTCTGGAAC CTTTATTTGT 2220 TCTAGGGCAG CTCTGGGAAC ATGCGGGATT GTGGAAΓTGG GTCAGGAACC CTCTCTGGTA 2280 TTCTGGATGT TGTAGGTTCT CTAGCAGTCT AGAAATGGAT ACAGACATTT CTCTGTTCTT 2340 CAAGGGTGAT AGGAACCATT ATGTTGAGCC CAAAATGGAA GTAATAATAA ATGCCTCCTG 2400 GAGGCTGTGG GTGTGGGGGA TTCTGTATCT GGATTCCGTA TCACTCCAAC TGGAGGCTGT 2460 GGGTGTGGGG GATTCTGTAT CTGGATTCCG TATCACTCCA AGTGGAGGCT GGCAGGTTTT 2520 TCTGCAAGAT GGTCCAGAAT CTAAAATGTC CCATTAATCT GGTCACTTGG GTTTGGCTCT 2580 GCTGTATCCA TCTATAGTGG TAGAGACCCA CCAGGGCTCA AGTGGAGTCC ATCATCCTCC 2640 CACGGGGGCC TGTTCTTAGC ACTGAGTTGA TCGCTCCATG GGGGAGAGAT CAGACATTCC 2700 TTATCAGAGA TGATGTGACC TTTTCTGACT CTGCCCAGTC TCTATGAATG TTATGGCCTA 2760 GGGAAGAATC ATGAAACTCT TTAGCTTGAT TAGATGGTAA ACAGTGTTAA CCCATCCTTT 2820 ACTACAGAGG CATATGGGTT TGAATGTTAC CTGGGGTTCT CTCTATTGAG TTGAGCCCCT 2880 TCTTCCTTTA GTGGGTTTTG GACATCTTCT GGCAAGTGTC CAGATGCCAG AACCTTCTTT 2940 TCCTCTAGAA GGGATGGTGC TTGGTAACCT TACCTTTTAA AAGCTGGGTC TGTGACCTGG 3000 TCTTCCCATC CCTGCATTCC TGTCTGGAAC CAGTGAATGC ATTAGAACCT TCCATAGGAA 3060 AAGAAAAGGG GCTGAGTTCC ATTCTGGGTT TGCTGTAGTT TGGTTGGGAT TATTGTTGGC 3120 ATTACAGATG TAAAAGATTG ACTAGCCCAT AGGCCAAAGG CCTGTTCTAG TTGACCAAGT 3180 TTCAAGTAGG ATTAAGAGGT TGGTTGAGGG GTGCAGTTTC TGGTGTAGGC CAGGTAGGTA 3240 GAAAGTGAGG AACAGGGTTG CCTCTTGGCT GGGTGGAGTC TCTGAAATGT TAGAAGAAGC 3300 GCTGAAGCCT TGATTGATAG TTCTGCCCCT TGTTGCCCTG GGGCTTATCT GATTATGGGA 3360 CGAGGGTAGA AAGTAAGAAG CACTTTTGAA TTTGTGGGGT AGAACTTCAA CAATAAGTCA 3420 GTTCTAGTGG CTGTCGCCTG GGGACTAGTG AGAAAGCTAC TCTTCTCCCT CTTCCCTCTT 3480 TCTCCCCATG GCCCCACTGC AGAATTAAAG AAGGAAGAAG GGAAGGCGGA GGAGTCTATA 3540 AGAAGGAATC ATGATTTCTA TTTAGCAGAT TGGATGGGCA GGTGGAGAAT GCCTGGGGGT 3600 AGAAATGTTA GATCTTGCAA CATCAGATCC TTGGAATAAA GAAGCCTCTC TGYGCWRAAA 3660 AAAAAAAAAA AAAAAA

Seq ID NO: 4 Protein sequence: Protein Accession # : FGENESH predicted

11 21 31 41 51

MGSPAAPEGA LGYVREFTRH SSDVLGNLNE LR RGILTDV T VGGQPLR AHKAV IACS 60

GFFYSIFRGR AGVGVDVLSL PGGPEARGFA P LDFMYTSR R SPATAPA VLAAATY QM 120

EHWQACHRF IQASYEPLGI SLRP EAEPP TPPTAPPPGS PRRSEGHPDP PTESRSCSQG 180

PPSPASPDPK ACNWKKYKYI V NSQASQAG SLVGERSSGQ PCPQAR PSG DEASSSSSSS 240

SSSSEEGPIP GPQSR SPTA ATVQFKCGAP ASTPY LTSQ AQDTSGSPSE RARP PGSEF 300

FSCQNCEAVA GCSSGLDSLV PGDEDKPYKC QLCRSSFRYK GNLASHRTVH TGEKPYHCSI 360

CGARFNRPAN LKTHSRIHSG EKPYKCETCG SRFVQVAHIiR AHVLIHTGEK PYPCPTCGTR 420

FRH QT KSH VRIHTGEKPY HCDPCGLHFR HKSQLRLH R QKHGAATNTK VHYHILGGP

Seq ID NO : 25 Nucleotide sequence :

Nucleic Acid Accession # : U21551

Coding sequence : 1. .1155 (underlined sequences correspond to start and stop codons)

1 11 21 31 41 51

I 1 I I I I

ATGGATTGCA GTAACGGATC GGCAGAGTGT ACCGGAGAAG GAGGATCAAA AGAGGTGGTG 60 GGGACTTTTA AGGCTAAAGA CCTAATAGTC ACACCAGCTA CCATTTTAAA GGAAAAACCA 120

GACCCCAATA ATCTGGTTTT TGGAACTGTG TTCACGGATC ATATGCTGAC GGTGGAGTGG 180

TCCTCAGAGT TTGGATGGGA GAAACCTCAT ATCAAGCCTC TTCAGAACCT GTCATTGCAC 240

CCTGGCTCAT CAGCTTTGCA CTATGCAGTG GAATTATTTG AAGGATTGAA GGCATTTCGA 300 GGAGTAGATA ATAAAATTCG ACTGTTTCAG CCAAACCTCA ACATGGATAG AATGTATCGC 360

TCTGCTGTGA GGGCAACTCT GCCGGTATTT GACAAAGAAG AGCTCTTAGA GTGTATTCAA 420

CAGCTTGTGA AATTGGATCA AGAATGGGTC CCATATTCAA CATCTGCTAG TCTGTATATT 480

CGTCCTGCAT TCATTGGAAC TGAGCCTTCT CTTGGAGTCA AGAAGCCTAC CAAAGCCCTG 540

CTCTTTGTAC TCTTGAGCCC AGTGGGACCT TATTTTTCAA GTGGAACCTT TAATCCAGTG 600 TCCCTGTGGG CCAATCCCAA GTATGTAAGA GCCTGGAAAG GTGGAACTGG GGACTGCAAG 660

ATGGGAGGGA ATTACGGCTC ATCTCTTTTT GCCCAATGTG AAGACGTAGA TAATGGGTGT 720

CAGCAGGTCC TGTGGCTCTA TGGCAGAGAC CATCAGATCA CTGAAGTGGG AACTATGAAT 780

CTTTTTCTTT ACTGGATAAA TGAAGATGGA GAAGAAGAAC TGGCAACTCC TCCACTAGAT 840

GGCATCATTC TTCCAGGAGT GACAAGGCGG TGCATTCTGG ACCTGGCACA TCAGTGGGGT 900 GAATTTAAGG TGTCAGAGAG ATACCTCACC ATGGATGACT TGACAACAGC CCTGGAGGGG 960

AACAGAGTGA GAGAGATGTT TAGCTCTGGT ACAGCCTGTG TTGTTTGCCC AGTTTCTGAT 1020

ATACTGTACA AAGGCGAGAC AATACACATT CCAACTATGG AGAATGGTCC TAAGCTGGCA 1080

AGCCGCATCT TGAGCAAATT AACTGATATC CAGTATGGAA GAGAAGAGAG CGACTGGACA 1140 ATTGTGCTAT CCTGA

Seq ID NO: 26 Protein sequence : Protein Accession #: AAB08528 1 11 21 31 41 51

I I I I I I

MDCSNGSAEC TGEGGSKEW GTFKAKD IV TPATILKEKP DPNNLVFGTV FTDHM TVEW 60

SSEFGWEKPH IKP QN SLH PGSSA HYAV ELFEGLKAFR GVDNKIR FQ PN NMDRMYR 120

SAVRATLPVF DKEE LECIQ QLVKLDQEWV PYSTSASLYI RPAFIGTEPS LGVKKPTKAL 180 LFVLLSPVGP YFSSGTFNPV SLWANPKYVR AWKGGTGDCK MGGNYGSSLF AQCEDVDNGC 240

QQVLWLYGRD HQITEVGTMN LFLYWINEDG EEELATPPLD GIILPGVTRR CI DLAHQWG 300

EFKVSERYLT MDD TTA EG NRVREMFSSG TACWCPVSD ILYKGETIHI PTMENGPK A 360 SRI SKLTDI QYGREESDWT IVLS

Seq ID NO : 27 Nucleotide sequence :

Nucleic Acid Accession # : XM_039209

Coding sequence : 656 . . 2758 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

TCGCGCGGGG GCCGCCCCCT CCCCTTCCCT CCACCCTGGG CGGGGGCGCG CGAGAAGCGG 60

TGACGTCAAG GGGCGCGCTG TGGCAGCACC TCCCCGCGCG CTAGTTAAAA AGAAGAAGAA 120 AAGAGGGAAC GAAACATGAG AGGCTGTGTG AGAAGCTGCA GCCGCCGGCA GAGGAGACCT 180

CAGCATCATC TAGAGCCCAG CGCTGGCCCT GCCTCCGCCT GCCCCGCCGC CGCCGTCGCG 240

GTTTCTGTTC CTGCTACTGT CCCACCTAAA CAACTCCCGT TACACGGACA AGTGAACATC 300

TGTGGCTGTC CTCTCCTTTT CTTCCTCCTC TTCCAACTCC TTCTCCTCCT CCCACTTCCC 360

AGCCGCAGCA GAAAGCCCCC AACCCAACTG ACACTGGCAC AACTGCAAAC GGTGTCATCC 420 GCACAACTTT ATCTCGCTCC TCGGGCTCCC CTAAGGCATT GGACCCATCG CCGCGTCTTT 480

TATTTTTTGC AAAGTTGCAT CGCTGTACAT ATTTTTGTCC CCGCCACCTC CCTCTGTCTC 540

TGGAGTGCCC TACAGCCCCG CAAACTCCTC CTGGAGCTGC GCCCTAGTGC CCCTGCTGGG 600

CAGTGGCGTT CCCCCCCATC CTCCCGCGCC CAGCCCCTGC TGCTCTGGGC AGACGATGCT 660

GAAGATGCTC TCCTTTAAGC TGCTGCTGCT GGCCGTGGCT CTGGGCTTCT TTGAAGGAGA 720 TGCTAAGTTT GGGGAAAGAA ACGAAGGGAG CGGAGCAAGG AGGAGAAGGT GCCTGAATGG 780

GAACCCCCCG AAGCGCCTGA AAAGGAGAGA CAGGAGGATG ATGTCCCAGC TGGAGCTGCT 840

GAGTGGGGGA GAGATGCTGT GCGGTGGCTT CTACCCTCGG CTGTCCTGCT GCCTGCGGAG 900

TGACAGCCCG GGGCTAGGGC GCCTGGAGAA TAAGATATTT TCTGTTACCA ACAACACAGA 960

ATGTGGGAAG TTACTGGAGG AAATCAAATG TGCACTTTGC TCTCCACATT CTCAAAGCCT 1020 GTTCCACTCA CCTGAGAGAG AAGTCTTGGA AAGAGACCTA GTACTTCCTC TGCTCTGCAA 1080

AGACTATTGC AAAGAATTCT TTTACACTTG CCGAGGCCAT ATTCCAGGTT TCCTTCAAAC 1140

AACTGCGGAT GAGTTTTGCT TTTACTATGC AAGAAAAGAT GGTGGGTTGT GCTTTCCAGA 1200

TTTTCCAAGA AAACAAGTCA GAGGACCAGC ATCTAACTAC TTGGACCAGA TGGAAGAATA 1260

TGACAAAGTG GAAGAGATCA GCAGAAAGCA CAAACACAAC TGCTTCTGTA TTCAGGAGGT 1320 TGTGAGTGGG CTGCGGCAGC CCGTTGGTGC CCTGCATAGT GGGGATGGCT CGCAACGTCT 1380

CTTCATTCTG GAAAAAGAAG GTTATGTGAA GATACTTACC CCTGAAGGAG AAATTTTCAA 1440

GGAGCCTTAT TTGGACATTC ACAAACTTGT TCAAAGTGGA ATAAAGGGAG GAGATGAAAG 1500

AGGACTGCTA AGCCTCGCAT TCCATCCCAA TTACAAGAAA AATGGAAAGT TGTATGTGTC 1560

CTATACCACC AACCAAGAAC GGTGGGCTAT CGGGCCTCAT GACCACATTC TTAGGGTTGT 1620 GGAATACACA GTATCCAGAA AAAATCCACA CCAAGTTGAT TTGAGAACAG CCAGAGTCTT 1680

TCTTGAAGTT GCAGAACTCC ACAGAAAGCA TCTGGGAGGA CAACTGCTCT TTGGCCCTGA 1740

CGGCTTTTTG TACATCATTC TTGGTGATGG GATGATTACA CTGGATGATA TGGAAGAAAT 1800

GGATGGGTTA AGTGATTTCA CAGGCTCAGT GCTACGGCTG GATGTGGACA CAGACATGTG 1860

CAACGTGCCT TATTCCATAC CAAGGAGCAA CCCACACTTC AACAGCACCA ACCAGCCCCC 1920 CGAAGTGTTT GCTCATGGGC TCCACGATCC AGGCAGATGT GCTGTGGATA GACATCCCAC 1980

TGATATAAAC ATCAATTTAA CGATACTGTG TTCAGACTCC AATGGAAAAA ACAGATCATC 2040 AGCCAGAATT CTACAGATAA TAAAGGGGAA AGATTATGAA AGTGAGCCAT CACTTTTAGA 2100 ATTCAAGCCA TTCAGTAATG GTCCTTTGGT TGGTGGATTT GTATACCGGG GCTGCCAGTC 2160 AGAAAGATTG TATGGAAGCT ACGTGTTTGG AGATCGTAAT GGGAATTTCC TAACTCTCCA 2220 GCAAAGTCCT GTGACAAAGC AGTGGCAAGA AAAACCACTC TGTCTCGGCA CTAGTGGGTC 2280 CTGTAGAGGC TACTTTTCCG GTCACATCTT GGGATTTGGA GAAGATGAAC TAGGTGAAGT 2340 TTACATTTTA TCAAGCAGTA AAAGTATGAC CCAGACTCAC AATGGAAAAC TCTACAAAAT 2400 TGTAGATCCC AAAAGACCTT TAATGCCTGA GGAATGCAGA GCCACGGTAC AACCTGCACA 2460 GACACTGACT TCAGAGTGCT CCAGGCTCTG TCGAAACGGC TACTGCACCC CCACGGGAAA 2520 GTGCTGCTGC AGTCCAGGCT GGGAGGGGGA CTTCTGCAGA ACTGCAAAAT GTGAGCCAGC 2580 ATGTCGTCAT GGAGGTGTCT GTGTTAGACC GAACAAGTGC CTCTGTAAAA AAGGATATCT 2640 TGGTCCTCAA TGTGAACAAG TGGACAGAAA CATCCGCAGA GTGACCAGGG CAGGTATTCT 2700 TGATCAGATC ATTGACATGA CATCTTACTT GCTGGATCTA ACAAGTTACA TTGTATAGTT 2760 TCTGGGACTG TTTGAATATT CTATTCCAAT GGGCATTTAT TTTTTATCCT GTCATTAAAA 2820 AAAAAAGACT GTTATCCTGC TACACACTCC TGTGATTTCA TTCTCTTTTA TTAATTTAAA 2880 AATAATTTCC AGAAATGTGC AGATCCTCTG TGTGTATGTC AGCATGTTTG TTCACATATG 2940 CACATACACA TACTCATAAC CCCTATATGC GTTGTTGCAT AACAGATGAT TTTTTAAAAT 3000 ATATACTTCC TTATGCAAAG TAATTTACAC AGAAATTCCA TTGTAAATTG ATAATGGATT 3060 TTTTATGTTA CTAGAAGAGA TTATTTGACT TCCCAGGAAT TTTCTGTCTG TAATCACTAA 3120 AGTCAACTTT AATAGAGTTT TGAAACAGTA CTGTGCAATC CGATGGATCT AATTAAAAAA 3180 AAGGCAATAT TTTTATATTA AAGTACTATA CTAGGAGAGA ATGTTTCAGA ACTCCCTGAT 3240 GAATTTCTAA GTGAGCAACT TGATATAAAA TTGTAATCTT CATTTTTGTC AGTGTATCCA 3300 GTTACAGAAT GCTACACACT TACCTTTTTA TTGGCTGAGA AATCTGGTTA TTTCATCTTA 3360 ATCTCAAGAT TGTTTTCAAG TGTTTTATAA TTAAATCATA ATAGCATATT TTAAAATCAA 3420 TCTTCCTAAA AGGTCTGCTT TTATTGTATA TTTTATTTAA CAATAGGCAC TGGGTTTGTG 3480 TTACATATTT ATATATTTTA TTTTATTTTT ATAATATAGA CATCACCTAG

Seq ID NO : 28 Protein sequence : Protein Accession # : XP 039209

11 21 31 41 51

MLKMLSFK L LAVALGFFE GDAKFGERNE GSGARRRRCL NGNPPKRLKR RDRRMMSQLE 60 LLSGGEMLCG GFYPRLSCC RSDSPGLGRL ENKIFSVTNN TECGKL EEI KCA CSPHSQ 120 SLFHSPEREV LERD VLPLL CKDYCKEFFY TCRGHIPGFL QTTADEFCFY YARKDGGLCF 180 PDFPRKQVRG PASNYLDQME EYDKVEEISR KHKHNCFCIQ EWSG RQPV GA HSGDGSQ 240 RLFI EKEGY VKI TPEGEI FKEPYLDIHK LVQSGIKGGD ERGL S AFH PNYKKNGKLY 300 VSYTTNQERW AIGPHDHI R WEYTVSRKN PHQVDLRTAR VFLEVAELHR KHLGGQ LFG 360 PDGFLYIILG DGMIT DDME E DGLSDFTG SVLR DVDTD MCNVPYSIPR SNPHFNSTNQ 420 PPEVFAHG H DPGRCAVDRH PTDININ TI LCSDSNGKNR SSARI QIIK GKDYESEPS 480 LEFKPFSNGP VGGFVYRGC QSERLYGSYV FGDRNGNFLT LQQSPVTKQW QEKP C GTS 540 GSCRGYFSGH I GFGEDELG EVYILSSSKS MTQTHNG Y KIVDPKRP M PEECRATVQP 600 AQT TSECSR LCRNGYCTPT GKCCCSPGWE GDFCRTAKCE PACRHGGVCV RPNKC CKKG 660 YLGPQCEQVD RNIRRVTRAG ILDQIIDMTS Y LDLTSYIV

Seq ID NO: 29 Nucleotide sequence:

Nucleic Acid Accession #: NM_024756

Coding sequence: 75..2924 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

AAGACAACGT .CACTAGCAGT TTCTGGAGCT ACTTGCCAAG GCTGAGTGTG AGCTGAGCCT 60 GCCCCACCAC CAAGATGATC CTGAGCTTGC TGTTCAGCCT TGGGGGCCCC CTGGGCTGGG 120 GGCTGGTGGG GGCATGGGCC CAGGCTTCCA GTACTAGCCT CTCTGATCTG CAGAGCTCCA 180 GGACACCTGG GGTCTGGAAG GCAGAGGCTG AGGACACCAG CAAGGACCCC GTTGGACGTA 240 ACTGGTGCCC CTACCCAATG TCCAAGCTGG TCACCTTACT AGCTCTTTGC AAAACAGAGA 300 AATTCCTCAT CCACTCGCAG CAGCCGTGTC CGCAGGGAGC TCCAGACTGC CAGAAAGTCA 360 AAGTCATGTA CCGCATGGCC CACAAGCCAG TGTACCAGGT CAAGCAGAAG GTGCTGACCT 420 CTTTGGCCTG GAGGTGCTGC CCTGGCTACA CGGGCCCCAA CTGCGAGCAC CACGATTCCA 480 TGGCAATCCC TGAGCCTGCA GATCCTGGTG ACAGCCACCA GGAACCTCAG GATGGACCAG 540 TCAGCTTCAA ACCTGGCCAC CTTGCTGCAG TGATCAATGA GGTTGAGGTG CAACAGGAAC 600 AGCAGGAACA TCTGCTGGGA GATCTCCAGA ATGATGTGCA CCGGGTGGCA GACAGCCTGC 660 CAGGCCTGTG GAAAGCCCTG CCTGGTAACC TCACAGCTGC AGTGATGGAA GCAAATCAAA 720 CAGGGCACGA GTTCCCTGAT AGATCCTTGG AGCAGGTGCT GCTACCCCAC GTGGACACCT 780 TCCTACAAGT GCATTTCAGC CCCATCTGGA GGAGCTTTAA CCAAAGCCTG CACAGCCTTA 840 CCCAGGCCAT AAGAAACCTG TCTCTTGACG TGGAGGCCAA CCGCCAGGCC ATCTCCAGAG 900 TCCAGGACAG TGCCGTGGCC AGGGCTGACT TCCAGGAGCT TGGTGCCAAA TTTGAGGCCA 960 AGGTCCAGGA GAACACTCAG AGAGTGGGTC AGCTGCGACA GGACGTGGAG GACCGCCTGC 1020 ACGCCCAGCA CTTTACCCTG CACCGCTCGA TCTCAGAGCT CCAAGCCGAT GTGGACACCA 1080 AATTGAAGAG GCTGCACAAG GCTCAGGAGG CCCCAGGGAC CAATGGCAGT CTGGTGTTGG 1140 CAACGCCTGG GGCTGGGGCA AGGCCTGAGC CGGACAGCCT GCAGGCCAGG CTGGGCCAGC 1200 TGCAGAGGAA CCTCTCAGAG CTGCACATGA CCACGGCCCG CAGGGAGGAG GAGTTGCAGT 1260 ACACCCTGGA GGACATGAGG GCCACCCTGA CCCGGCACGT GGATGAGATC AAGGAACTGT 1320 ACTCCGAATC GGACGAGACT TTCGATCAGA TTAGCAAGGT GGAGCGGCAG GTGGAGGAGC 1380 TGCAGGTGAA CCACACGGCG CTCCGTGAGC TGCGCGTGAT CCTGATGGAG AAGTCTCTGA 1440 TCATGGAGGA GAACAAGGAG GAGGTGGAGC GGCAGCTCCT GGAGCTCAAC CTCACGCTGC 1500

AGCACCTGCA GGGTGGCCAT GCCGACCTCA TCAAGTACGT GAAGGACTGC AATTGCCAGA 1560

AGCTCTATTT AGACCTGGAC GTCATCCGGG AGGGCCAGAG GGACGCCACG CGTGCCCTGG 1620

AGGAGACCCA GGTGAGCCTG GACGAGCGGC GGCAGCTGGA CGGCTCCTCC CTGCAGGCCC 1680 TGCAGAACGC CGTGGACGCC GTGTCGCTGG CCGTGGACGC GCACAAAGCG GAGGGCGAGC 1740

GGGCGCGGGC GGCCACGTCG CGGCTCCGGA GCCAAGTGCA GGCGCTGGAT GACGAGGTGG 1800

GCGCGCTGAA GGCGGCCGCG GCCGAGGCCC GCCACGAGGT GCGCCAGCTG CACAGCGCCT 1860

TCGCCGCCCT GCTGGAGGAC GCGCTGCGGC ACGAGGCGGT GCTGGCCGCG CTCTTCGGGG 1920

AGGAGGTGCT GGAGGAGATG TCTGAGCAGA CGCCGGGACC GCTGCCCCTG AGCTACGAGC 1980 AGATCCGCGT GGCCCTGCAG GACGCCGCTA GCGGGCTGCA GGAGCAGGCG CTCGGCTGGG 2040

ACGAGCTGGC CGCCCGAGTG ACGGCCCTGG AGCAGGCCTC GGAGCCCCCG CGGCCGGCAG 2100

AGCACCTGGA GCCCAGCCAC GACGCGGGCC GCGAGGAGGC CGCCACCACC GCCCTGGCCG 2160

GGCTGGCGCG GGAGCTCCAG AGCCTGAGCA ACGACGTCAA GAATGTCGGG CGGTGCTGCG 2220

AGGCCGAGGC CGGGGCCGGG GCCGCCTCCC TCAACGCCTC CCTTGACGGC CTCCACAACG 2280 CACTCTTCGC CACTCAGCGC AGCTTGGAGC AGCACCAGCG GCTCTTCCAC AGCCTCTTTG 2340

GGAACTTCCA AGGGCTCATG GAAGCCAACG TCAGCCTGGA CCTGGGGAAG CTGCAGACCA 2400

TGCTGAGCAG GAAAGGGAAG AAGCAGCAGA AAGACCTGGA AGCTCCCCGG AAGAGGGACA 2460

AGAAGGAAGC GGAGCCTTTG GTGGACATAC GGGTCACAGG GCCTGTGCCA GGTGCCTTGG 2520

GCGCGGCGCT CTGGGAGGCA GGATCCCCTG TGGCCTTCTA TGCCAGCTTT TCAGAAGGGA 2580 CGGCTGCCCT GCAGACAGTG AAGTTCAACA CCACATACAT CAACATTGGC AGCAGCTACT 2640

TCCCTGAACA TGGCTACTTC CGAGCCCCTG AGCGTGGTGT CTACCTGTTT GCAGTGAGCG 2700

TTGAATTTGG CCCAGGGCCA GGCACCGGGC AGCTGGTGTT TGGAGGTCAC CATCGGACTC 2760

CAGTCTGTAC CACTGGGCAG GGGAGTGGAA GCACAGCAAC GGTCTTTGCC ATGGCTGAGC 2820

TGCAGAAGGG TGAGCGAGTA TGGTTTGAGT TAACCCAGGG ATCAATAACA AAGAGAAGCC 2880 TGTCGGGCAC TGCATTTGGG GGCTTCCTGA TGTTTAAGAC CTGAACCCCA GCCCCAATCT 2940

GATCAGACAT CATGGACTCG CCCAGCTCTC CTCGGCCTGG GGCTCTGGCC AAGGATGGGC 3000

TGGAGGTCAT TCAGTTGGTC TGTCTCTTCC CTGGAAACCT TCTGCAAAGA TGGTGTGGTG 3060

TACGTGGCTT CCCTGTAACC ACATGGGGCT TGGCCATTTC TCCATGATGA GAAGGACTGG 3120

AATGCTTCTC CGGGCAGGAC ATGGTCCTAG GAAGCCTGAA CCTTGGCTTG GCATGCCTTC 3180 TCAGACAGCA CGGCCTGGGC TCCAACTCTT CACCACACCC TGTATTCTAC AACTTCTTTG 3240

GTGTTTTGCT CCTCCTGTGG TTGGAAACTT CTGTACAACA CTTTAAACTT TTCTCTTGCT 3300

TCCTCTTCTC TTCTCCCTTA TCGTATGATA GAAAGACATT CTTCCCCAGG AGGAATGTTT 3360

AAAATGGAGG CAACATTTTG GCCAACATTG GAAAGCACTA GAGGGCAATG GGATTAAACC 3420

AACCTGCTTG GTCTCTATTA GTCAGTAATG AAGACGACAG CCTGGCCAAC CAAGGGAAAG 3480 GAAATTAGTA TCTTTAGTTT CAGTCATTCC TTGTAGGATA TGGTTTAGCT GTGCCCCCAC 3540

CTAAAATATC ATCTTGAATT GTAATCCCTA TAATCCCCAC ATCAAGGGAG AGATCAGGTG 3600

GAGGTAATTG GATCTTGGGG GCGGTTCCCC CATGCTGTTC TTGTGATAGT TCTCACGAGA 3660

TCTGATGATT TTATAAGTTT GATAGTTCCT CCTGTGTTCA TTCTCCTTCC TGCCACCTTG 3720

TGAAGATGCC TTGGTTCCTC TTCACTGTCT GCCATGATTG TAAGTTTCCT GAGGCCTCCC 3780 CAGCCATGTG GAACAGTGAG TCAATTAAAC CTCTTTCCTT TATAAATT

Seq ID NO: 30 Protein sequence: Protein Accession #: NP 079032

11 21 31 41 51

MI S LFSLG GP GWGL GA WAQASSTSLS DLQSSRTPGV WKAEAEDTSK DPVGRN CPY 60

PMSKLVTL A CKTEKFLIH SQQPCPQGAP DCQKVKVMYR MAHKPVYQVK QKVLTSLAWR 120 CCPGYTGPNC EHHDSMAIPE PADPGDSHQE PQDGPVSF P GHLAAVINEV EVQQEQQEHL 180

LGDLQNDVHR VADSLPGLWK A PGNLTAAV MEANQTGHEF PDRSLEQVLL PHVDTFLQVH 240

FSPIWRSFNQ SLHSLTQAIR NLSLDVEANR QAISRVQDSA VARADFQELG AKFEAKVQEN 300

TQRVGQLRQD VEDRLHAQHF T HRSISELQ ADVDTKLKRL HKAQEAPGTN GSLVLATPGA 360

GARPEPDSLQ ARLGQLQRNL SE HMTTARR EEE QYTLED MRATLTRHVD EIKELYSESD 420 ETFDQISKVE RQVEELQVNH TALRELRVIL MEKS IMEEN KEEVERQ LE LNLTLQH QG 480

GHADLIKYVK DCNCQKLYLD LDVIREGQRD ATRA EETQV SLDERRQLDG SS QALQNAV 540

DAVSLAVDAH KAEGERARAA TSR RSQVQA LDDEVGALKA AAAEARHEVR Q HSAFAAL 600

EDALRHEAVL AALFGEEVLE EMSEQTPGPL PLSYEQIRVA LQDAASG QE QA GWDELAA 660

RVTA EQASE PPRPAEHLEP SHDAGREEAA TTALAG ARE LQS SNDVKN VGRCCEAEAG 720 AGAAS NASL DGLHNALFAT QRSLEQHQRL FHSLFGNFQG MEANVSLDL GKLQTMLSRK 780

GKKQQKDLEA PRKRDKKEAE PLVDIRVTGP VPGALGAALW EAGSPVAFYA SFSEGTAALQ 840

TVKFNTTYIN IGSSYFPEHG YFRAPERGVY LFAVSVEFGP GPGTGQLVFG GHHRTPVCTT 900 GQGSGSTATV FAMAE QKGE RVWFELTQGS ITKRSLSGTA FGGF MFKT Seq ID NO : 31 Nucleotide sequence :

Nucleic Acid Accession # : AB037715 Coding sequence : 370 . . 3489 (underlined sequences correspond to start and stop codons)

1 11 21 31 41 51

I I I I I I

GAACGCTCAC AGAACAGGCA GTGCAATTCC ATGTTCCTCT TAAGTATGTT AGCCCTACCG 60

GGAGCTGAGC TGGCCAGTCT ACTTGGAGAG GAAAAGTAGA TCTGGGGAAG GTGGAAGGGT 120

CAGTTCCTAA GTGACTTCCT CCTCGGGGAT GGTAAGGGCA TTTGCTGATC TCCAGTGACT 180 GCCTGGTGCC TCATGGTCAG ACTCGGCTGT CTCACTCCCA GATATCTGAT TTTGCAAAAA 240

GGGACACACC TATCTGCAGC AAAGAAGACA CTGACCAGAT TGCGAGCGGT GCTTTTGGAT 300 GCTCTGTAGC CACCCGGGGC CCAGGAGGAC TGACTCGGCA GCAGGATTCG TGCATGGGAA 360

TCGGAGACCA TGGCAGTGCA GCTGGTGCCC GACTCAGCTC TCGGCCTGCT GATGATGACG 420

GAGGGCCGCC GATGTCAAGT ACATCTTCTT GATGACAGGA AGCTGGAACT CCTAGTACAG 480

CCCAAGCTGT TGGCCAAGGA GCTTCTTGAC CTTGTGGCTT CTCACTTCAA TCTGAAGGAA 540 AAGGAGTACT TTGGAATAGC ATTCACAGAT GAAACGGGAC ACTTAAACTG GCTTCAGCTA 600

GATCGAAGAG TATTGGAACA TGACTTCCCT AAAAAGTCAG GACCCGTGGT TTTATACTTT 660

TGTGTCAGGT TCTATATAGA AAGCATTTCA TACCTGAAGG ATAATGCTAC CATTGAGCTT 720

TTCTTTCTGA ACGCGAAGTC CTGCATCTAC AAGGAGCTTA TTGACGTTGA CAGCGAAGTG 780

GTGTTTGAAT TAGCTTCCTA TATTTTACAG GAGGCAAAGG GAGATTTTTC TAGCAATGAA 840 GTTGTGAGGA GTGACTTGAA GAAGCTGCCA GCCCTTCCCA CCCAAGCCCT GAAGGAGCAC 900

CCTTCCCTGG CCTACTGTGA AGACAGAGTC ATTGAGCACT ACAAGAAACT GAACGGTCAG 960

ACAAGAGGTC AAGCAATCGT AAACTACATG AGCATCGTGG AGTCTCTCCC AACCTACGGG 1020

GTTCACTATT ATGCAGTGAA GGACAAGCAG GGCATACCAT GGTGGCTGGG CCTGAGCTAC 1080

AAAGGGATCT TCCAGTATGA CTACCATGAT AAAGTGAAGC CAAGAAAGAT ATTCCAATGG 1140 AGACAGTTGG AAAACCTGTA CTTCAGAGAA AAGAAGTTTT CCGTGGAAGT TCATGACCCA 1200

CGCAGGGCTT CAGTGACAAG GAGGACGTTT GGGCACAGCG GCATTGCAGT GCACACGTGG 1260

TATGCATGTC CGGCATTGAT CAAGTCCATC TGGGCTATGG CCATAAGCCA ACACCAGTTC 1320

TATCTGGACA GAAAGCAGAG TAAGTCCAAA ATCCATGCAG CACGCAGCCT GAGTGAGATC 1380

GCCATCGACC TGACCGAGAC GGGGACGCTG AAGACCTCGA AGCTGGCCAA CATGGGTAGC 1440 AAGGGGAAGA TCATCAGCGG CAGCAGCGGC AGCCTGCTGT CTTCAGGTTC TCAGGAATCA 1500

GATAGCTCGC AGTCGGCCAA GAAGGACATG CTGGCTGCCT TGAAGTCCAG GCAGGAAGCT 1560

CTGGAGGAAA CCCTGCGTCA GAGGCTGGAG GAACTGAAGA AGCTGTGTCT CCGAGAAGCT 1620

GAGCTCACGG GCAAGCTGCC AGTAGAATAT CCCCTGGATC CAGGGGAGGA ACCACCCATT 1680

GTTCGGAGAA GAATAGGAAC AGCCTTCAAA CTGGATGAAC AGAAAATCCT GCCCAAAGGA 1740 GAGGAAGCTG AGCTGGAACG CCTGGAACGA GAGTTTGCCA TTCAGTCCCA GATTACGGAG 1800

GCCGCCCGCC GCCTAGCCAG TGACCCCAAC GTCAGCAAAA AACTGAAGAA ACAAAGGAAA 1860

ACCTCGTATC TGAATGCACT GAAGAAACTG CAGGAGATTG AAAATGCAAT CAATGAGAAC 1920

CGCATCAAGT CTGGGAAGAA ACCCACCCAG AGGGCTTCGC TGATCATAGA CGATGGAAAC 1980

ATTGCCAGTG AAGACAGCTC CCTCTCAGAT GCCCTTGTTC TTGAGGATGA AGACTCTCAG 2040 GTTACCAGCA CAATATCCCC CCTACATTCT CCTCACAAGG GACTCCCTCC TCGGCCACCG 2100

TCGCACAACA GGCCTCCTCC TCCCCAGTCC CTGGAGGGAC TCCGACAGAT GCACTATCAC 2160

CGCAACGACT ATGACAAGTC ACCCATCAAG CCCAAAATGT GGAGTGAGTC CTCTTTAGAT 2220

GAACCCTATG AGAAGGTCAA GAAGCGCTCC TCTCACAGCC ATTCCAGCAG CCACAAGCGC 2280

TTCCCCAGCA CAGGAAGCTG TGCGGAAGCC GGCGGAGGAA GCAACTCCTT GCAGAACAGC 2340 CCCATCCGCG GCCTCCCGCA CTGGAACTCC CAGTCCAGCA TGCCGTCCAC GCCAGACCTG 2400

CGGGTCCGGA GTCCCCACTA CGTCCATTCC ACGAGGTCGG TGGACATCAG CCCCACCCGA 2460

CTGCACAGCC TCGCACTGCA CTTTAGGCAC CGGAGCTCCA GCCTGGAGTC CCAGGGCAAG 2520

CTCCTGGGCT CGGAAAACGA CACCGGGAGC CCCGACTTCT ACACCCCGCG GACTCGTAGC 2580

AGCAACGGCT CAGACCCCAT GGACGACTGC TCGTCGTGCA CCAGCCACTC GAGCTCGGAG 2640 CACTACTACC CGGCGCAGAT GAACGCCAAC TACTCCACGC TGGCCGAGGA CTCGCCGTCC 2700

AAGGCGCGCC AGAGGCAGAG GCAGCGGCAG CGGGCGGCGG GCGCACTGGG CTCAGCCAGC 2760

TCGGGCAGCA TGCCCAACCT GGCGGCGCGC GGGGGTGCGG GGGGCGCGGG GGGCGCGGGG 2820

GGCGGTGTGT ACCTGCACAG CCAGAGCCAG CCCAGCTCGC AGTACCGCAT CAAGGAGTAC 2880

CCGCTGTACA TCGAGGGCGG CGCCACGCCC GTGGTGGTGC GCAGCCTGGA GAGCGACCAG 2940 GAGTGCCACT ACAGCGTCAA GGCTCAGTTC AAGACGTCCA ACTCCTACAC GGCGGGCGGC 3000

CTGTTCAAGG AGAGCTGGCG CGGCGGCGGC GGCGACGAGG GCGACACGGG CCGCCTGACG 3060

CCGTCGCGAT CGCAGATCCT GCGGACTCCG TCGCTGGGCC GCGAGGGCGC CCACGACAAG 3120

GGCGCGGGCC GTGCCGCCGT CTCAGACGAG CTGCGCCAGT GGTACCAGCG TTCCACCGCC 3180

TCGCACAAGG AGCACAGCCG CCTGTCGCAC ACCAGCTCCA CCTCCTCGGA CAGCGGCTCG 3240 CAGTACAGCA CCTCCTCCCA GAGCACCTTC GTGGCGCACA GCAGGGTCAC CAGGATGCCC 3300

CAGATGTGCA AGGCCACGTC AGCTGCCTTA CCTCAAAGCC AGAGAAGCTC GACACCGTCA 3360

AGTGAAATTG GAGCCACCCC CCCAAGCAGC CCCCACCACA TCCTAACCTG GCAGACTGGA 3420

GAAGCAACAG AAAACTCACC CATTCTGGAT GGGTCTGAGT CTCCACCTCA CCAAAGTACT 3480

GATGAATAGA GGAGCTACAA TGATAGCTGT TTCCTGGATT CCTCCCTCTA TCCAGAACTA 3540 GCTGATGTCC AGTGGTACGG GCAGGAAAAA GCCAAGCCCG GGACCCTCGT GTGAGCCAGC 3600

CCGGCCTAAT CTGACCGCCT CAACGCCATT CTGAGATCAC CTCACTGCCT CTCATTTGCC 3660

TTACCCAGAC GCACCGTCAC CCTGCACCAG CTTTGGCCCT CAGCACTTTT TTTCTCCTGT 3720

CTCCGCATTC CCTCCCCCTT GAAAACCTGA CTGAGGAGAC ATTCTGGAAG GTTCCGGTCC 3780

CACTGTGTGT CCCCTGGCGC TCTTGCCCAT AGAGAGCCAG ACACCAATCC TCAATGGCAC 3840 ^• CTTGGTGGCT TCCCTCTGCC ATGACAGCCC CTAGGCCAGG AACCATCAGG GGGGCCAGCC 3900

GGCATCCAAT TCCTGCGGAT AAGTAGCGTT GGGAGAGAAC GGGAAAGGGG ACTTGGGTTA 3960

CAGGGTGACC CAGAAAGACG ATTCAGCTGT GTCCAGCCTG CCACCCATAC GTAGGCCAAC 4020

CAAGCACTTC ATGAAGAGGA GGCCTCGTGG CATATTCAGT TTACACCTGA AATATTCCTT 4080

GATGGGACAG CTTGTGGGGA TGGCTATGGG GGAAGGGGAG GTTGAGAAAG GAAGTTCTCG 4140 ACACCAGAAA TGCATCGGAG GACCACAATC AGTTCTATGC TGCCAAAGAT TAAAAATAAA 4200

TAAAAACATA AAAAATTAAG AGGGGCCAAG AGGAAGACAT TCTTTCTGCA AGGAAATTTC 4260

TTTTAAATTC TGAACTGCTA CTACACACAA GTGAAAGTCA ACCCTATGTA AACTGGTGTC 4320

CTCTCTCTAG CCCTCTCCCT TACTGGCCCA CTTCTCTCTC CGTAGAGAGC CTGAAAAACT 4380

GCCCCAATGC CACGGTAAAG GCGAGGAAGT CTTGGCTGGC GTTGCTGACT CACAGTCGCC 4440 ATCCATCTGG ACACAAAGAG AGACCTGTGG GAGTCATAGA GGGTACTGTT AGCCCCGGTC 4500

CATGCAGGGG GTTCAGCCGA GCCCAAGACT CAAAGCTGCT TTCCTTTCAG GATTTGTAGT 4560

AACGTAAGGT GATAATGGCC AAAAGTGGTT CTCTCTCATT AAACCAACCA GTAAAAGCGT 4620

ATCCTATTTT TTTGCATAAG GTGTTTCATT TTCGTTTTTA TGGGAAACCA AGGGAAAAGC 4680

ACATTGCGAT CCATTCAGTG TTTAACTGTC GTGGCTCATT TTCTGTTCGT TAGCACTTGT 4740 GTGACAAAAG AGCTCAGATC CGACTTCTCC TATGTGTCAC TTATTCCAAG AACCCAACTA 4800

TGCCCTTAGG TAGAAAGATT TGACTCGTGT GTCTACTAGC CAACAGGCAG AGCAGGGTTG 4860 AAAAAAATAT CAGCTCCCAA AGGGCCCATG TGTCTACATC ATCAGTTACT GTCATGCACC 4920 ACATTTGTGT GCAGATACCA AAAGAGGAGG AAAGAAGAAA AAAATTAATG TGTGGGAGCT 4980 GCACGTTTAC ATGTTTTGAG CTATGCTTCA AACACAACTG GAAAGCCATC AATCTTCAAA 5040 GGCCTCAAAA ATACTTTTAT AGTAACAAGT GCACGACTTT AGTTGGGTTA TTCAAGATGG 5100 CACAAAAAGG TTTCCGCAGA GGTGGTATGC TGTGCTTTTG GCGCAAGTGG TGGGGGGATG 5160 GGGGTGGGGG TGGAATTTTT TTCTCACTCT AATGACTTCC TATTGGAAAG GCATTGACAG 5220 CCAGGGACAG GAGCCAGGGT GGGGGTAGTT TTGTGGGAAA GCAGAACTGA AGTTAGCTTA 5280 AGCATAAAAA CAAAGAAAAA TCTTCGCTTT TCATGTATGT GGAATCCAAG AATAACCATA 5340 GGCTCTACCA GACCAGGAGG GTAAGGATGG ACACTAAAAT GAAACAAATA CCAAGGTATT 5400 CCTTCTGCTG CAGCCTGGAG ACCACCGAGA GTCGAGCTGG GGCACACACA CACCTGGCCG 5460 GGACCCGGCA GGGACAAGGC GGGCCGTGGC CTCCTCCACC AAGTCTCTCT AGACAATTCA 5520 GGGCCTGCTT TCCCCAGCTC CATGCATGGC TGGACTGGTG ATTCCAGGGT GCAGAAGGGA 5580 TTCATATTCC CAGAACGCTT TAAGTGTACA CCTGCAGGAT AAAGAGATAC CGGTTACATT 5640 ATTAAATGAT TCTAGGGATT CACTGGGGGA TATTTTTGTT GCTTTTACTT TCATGGTTAG 5700 AGCTACAAAG AACAGTGATT TTTTTTTTTT CTCCCTTCCC CATTCAGAAA CATTATACAT 5760 TGGGCCATTT TTCTTTCTCC CAAAGAAGAT TCATGGATAG TCAGACTGAA CTGTGTGCAA 5820 CAGGAAAAGT CAAAAGGGAA AAGGCAGCTG ATGAGGTTAC ATGGTTACAT GTTCTACATC 5880 ATGCAGAGTA GCTTGAAATC TAGTCTGGAG AAAACTGGAT CAAGATTCTA GCCCACTGGA 5940 GTTGCAAGGA ATGAGAGGCA AAAATTCTAA AGATTTGGGT TATATTTTCA ACTTGGGGGA 6000 CAGAGAGAAA TGGAGAGCAG GAATTACAGT TCCAACAAAC ATCATGATAG TCTGGTAGTC 6060 AAGACAGAGA TTAAGTAAAA CAGGTTTTAC TGTTTAGCTG AGTTCAGTTA ATACAAAATG 6120 TACATAAAAC GTTAGTCCTT TGAGACTGAC ATGATTAATG ATCAGTGTGG TGGGAAATGA 6180 TGTAGTTATT GTACACAAGC ACTTGCAAAC TCTTTATCCC TATTTCTTTA AAACAAAATA 6240 AGGTGAAATA CGAAGTCCTT GGTCTGATAT AAAGCCCCTA TTGGATTCTT CGGATGCGTA 6300 AAAGAAATTG CCTGTTTCAG CCAGAAGACT GGTGAAAACA CATACATCAG ACTATGTTGT 6360 GAGCCAGGTT GATTTTTTAT TTTATTATAT GCAGGTGAGT GTTGAAACTG TTAAAATTCC 6420 AATTTGTTTT CATTCAGTAT TAGTTTAGTT CTAAATATAG CAAACCCCAT CCAGGTGCTA 6480 TCAGATGACC AGTTACTGCT TAGTTAACTA GGTGTAAAGT TTTACATATA CATTAATTTC 6540 AATAGTTTAT TACAAGTTGT GTAAAATGGA CTCTAGTTTA ATAATGGGGG AAAAAAGATT 6600 AGGTTGCTCC TGAAACTGAC TGTAGAGCAT GTAAAATGAT TTTACTGGAT TCTGTTCAAC 6660 TGTAATCAAT GAAAAAGATG TACGTTGTAG ACAAAGTTGC AGAATTAAAA AAAGAAATCT 6720 GCTTTTAATT TATTCTTTTT GTATTAAGAA TTTGTATAGT ATCTTTACAT TTTGCAAAAC 6780 AGTGTTGTCA ACACTTATTA AAGCATTTTC AAAATG

Seq ID NO: 32 Protein sequence: Protein Accession #: BAA92532

11 21 31 41 51

MAVQ VPDSA LGL MMTEGR RCQVH DDR K E VQPKL LAKEL DLVA SHFNLKEKEY 60 FGIAFTDETG HLNWLQLDRR VLEHDFPKKS GPW YFCVR FYIESISYL.K DNATIELFFL 120 NAKSCIYKEL IDVDSEWFE LASYILQEAK GDFSSNEWR SDLKKLPALiP TQALKEHPS 180 AYCEDRVIEH YKKLNGQTRG QAIVNYMSIV ESLPTYGVHY YAV DKQGIP WWLGLSYKGI 240 FQYDYHDKVK PRKIFQWRQL ENLYFREKKF SVEVHDPRRA SVTRRTFGHS GIAVHTWYAC 300 PA IKSIWA AISQHQFY D RKQSKSKIHA ARSLSEIAID LTETGT KTS KLANMGSKGK 360 IISGSSGSLL SSGSQESDSS QSAKKD AA LKSRQEA EE T RQR EELK KLCIiREAELT 420 GKLPVEYPLD PGEEPPIVRR RIGTAFKLDE QKILPKGEEA E ERLEREFA IQSQITEAAR 480 RLASDPNVSK KLKKQRKTSY LNALKK QEI ENAINENRIK SGKKPTQRAS LIIDDGNIAS 540 EDSS SDAV LEDEDSQVTS TISPLHSPHK G PPRPPSHN RPPPPQSLEG LRQMHYHRND 600 YDKSPIKPK WSESSLDEPY EKVKKRSSHS HSSSHKRFPS TGSCAEAGGG SNSLQNSPIR 660 GLPHWNSQSS PSTPDLRVR SPHYVHSTRS VDISPTRLHS LA HFRHRSS S ESQGKLLG 720 SENDTGSPDF YTPRTRSSNG SDPMDDCSSC TSHSSSEHYY PAQMNANYST LAEDSPS AR 780 QRQRQRQRAA GALGSASSGS MPNLAARGGA GGAGGAGGGV YLHSQSQPSS QYRIKEYPLY 840 IEGGATPVW RSLESDQECH YSVKAQFKTS NSYTAGGLFK ESWRGGGGDE GDTGRLTPSR 900 SQILRTPSLG REGAHDKGAG RAAVSDELRQ WYQRSTASHK EHSR SHTSS TSSDSGSQYS 960 TSSQSTFVAH SRVTRMPQMC KATSAALPQS QRSSTPSSEI GATPPSSPHH ILTWQTGEAT 1020 ENSPILDGSE SPPHQSTDE

Seq ID NO: 33 Nucleotide sequence:

Nucleic Acid Accession #: NM_014331

Coding sequence: 1..1506 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

ATGGTCAGAA AGCCTGTTGT GTCCACCATC TCCAAAGGAG GTTACCTGCA GGGAAATGTT 60 AACGGGAGGC TGCCTTCCCT GGGCAACAAG GAGCCACCTG GGCAGGAGAA AGTGCAGCTG 120 AAGAGGAAAG TCACTTTACT GAGGGGAGTC TCCATTATCA TTGGCACCAT CATTGGAGCA 180 GGAATCTTCA TCTCTCCTAA GGGCGTGCTC CAGAACACGG GCAGCGTGGG CATGTCTCTG 240 ACCATCTGGA CGGTGTGTGG GGTCCTGTCA CTATTTGGAG CTTTGTCTTA TGCTGAATTG 300 GGAACAACTA TAAAGAAATC TGGAGGTCAT TACACATATA TTTTGGAAGT CTTTGGTCCA 360 TTACCAGCTT TTGTACGAGT CTGGGTGGAA CTCCTCATAA TACGCCCTGC AGCTACTGCT 420 GTGATATCCC TGGCATTTGG ACGCTACATT CTGGAACCAT TTTTTATTCA ATGTGAAATC 480 CCTGAACTTG CGATCAAGCT CATTACAGCT GTGGGCATAA CTGTAGTGAT GGTCCTAAAT 540 AGCATGAGTG TCAGCTGGAG CGCCCGGATC CAGATTTTCT TAACCTTTTG CAAGCTCACA 600 GCAATTCTGA TAATTATAGT CCCTGGAGTT ATGCAGCTAA TTAAAGGTCA AACGCAGAAC 660 TTTAAAGACG CGTTTTCAGG AAGAGATTCA AGTATTACGC GGTTGCCACT GGCTTTTTAT 720 TATGGAATGT ATGCATATGC TGGCTGGTTT TACCTCAACT TTGTTACTGA AGAAGTAGAA 780 AACCCTGAAA AAACCATTCC CCTTGCAATA TGTATATCCA TGGCCATTGT CACCATTGGC 840 TATGTGCTGA CAAATGTGGC CTACTTTACG ACCATTAATG CTGAGGAGCT GCTGCTTTCA 900 AATGCAGTGG CAGTGACCTT TTCTGAGCGG CTACTGGGAA ATTTCTCATT AGCAGTTCCG 960 ATCTTTGTTG CCCTCTCCTG CTTTGGCTCC ATGAACGGTG GTGTGTTTGC TGTCTCCAGG 1020 TTATTCTATG TTGCGTCTCG AGAGGGTCAC CTTCCAGAAA TCCTCTCCAT GATTCATGTC 1080 CGCAAGCACA CTCCTCTACC AGCTGTTATT GTTTTGCACC CTTTGACAAT GATAATGCTC 1140 TTCTCTGGAG ACCTCGACAG TCTTTTGAAT TTCCTCAGTT TTGCCAGGTG GCTTTTTATT 1200 GGGCTGGCAG TTGCTGGGCT GATTTATCTT CGATACAAAT GCCCAGATAT GCATCGTCCT 1260 TTCAAGGTGC CACTGTTCAT CCCAGCTTTG TTTTCCTTCA CATGCCTCTT CATGGTTGCC 1320 CTTTCCCTCT ATTCGGACCC ATTTAGTACA GGGATTGGCT TCGTCATCAC TCTGACTGGA 1380 GTCCCTGCGT ATTATCTCTT TATTATATGG GACAAGAAAC CCAGGTGGTT TAGAATAATG 1440 TCAGAGAAAA TAACCAGAAC ATTACAAATA ATACTGGAAG TTGTACCAGA AGAAGATAAG 1500 TTATGAACTA ATGGACTTGA GATCTTGGCA ATCTGCCCAA GGGGAGACAC AAAATAGGGA 1560 TTTTTACTTC ATTTTCTGAA AGTCTAGAGA ATTACAACTT TGGTGATAAA CAAAAGGAGT 1620 CAGTTATTTT TATTCATATA TTTTAGCATA TTCGAACTAA TTTCTAAGAA ATTTAGTTAT 1680 AACTCTATGT AGTTATAGAA AGTGAATATG CAGTTATTCT ATGAGTCGCA CAATTCTTGA 1740 GTCTCTGATA CCTACCTATT GGGGTTAGGA GAAAAGACTA GACAATTACT ATGTGGTCAT 1800 TCTCTACAAC ATATGTTAGC ACGGCAAAGA ACCTTCAAAT TGAAGACTGA GATTTTTCTG 1860 TATATATGGG TTTTGTAAAG ATGGTTTTAC ACACTACAGA TGTCTATACT GTGAAAAGTG 1920 TTTTCAATTC TGAAAAAAAG CATACATCAT GATTATGGCA AAGAGGAGAG AAAGAAATTT 1980 ATTTTACATT GACATTGCAT TGCTTCCCCT TAGATACCAA TTTAGATAAC AAACACTCAT 2040 GCTTTAATGG ATTATACCCA GAGCACTTTG AACAAAGGTC AGTGGGGATT GTTGAATACA 2100 TTAAAGAAGA GTTTCTAGGG GCTACTGTTT ATGAGACACA TCCAGGAGTT ATGTTTAAGT 2160 AAAAATCCTT GAGAATTTAT TATGTCAGAT GTTTTTTCAT TCATTATCAG GAAGTTTTAG 2220 TTATCTGTCA TTTTTTTTTT TCACATCAGT TTGATCAGGA AAGTGTATAA CACATCTTAG 2280 AGCAAGAGTT AGTTTGGTAT TAAATCCTCA TTAGAACAAC CACCTGTTTC ACTAATAACT 2340 TACCCCTGAT GAGTCTATCT AAACATATGC ATTTTAAGCC TTCAAATTAC ATTATCAACA 2400 TGAGAGAAAT AACCAACAAA GAAGATGTTC AAAATAATAG TCCCATATCT GTAATCATAT 2460 CTACATGCAA TGTTAGTAAT TCTGAAGTTT TTTAAATTTA TGGCTATTTT TACACGATGA 2520 TGAATTTTGA CAGTTTGTGC ATTTTCTTTA TACATTTTAT ATTCTTCTGT TAAAATATCT 2580 CTTCAGATGA AACTGTCCAG ATTAATTAGG AAAAGGCATA TATTAACATA AAAATTGCAA 2640 AAGAAATGTC GCTGTAAATA AGATTTACAA CTGATGTTTC TAGAAAATTT CCACTTCTAT 2700 ATCTAGGCTT TGTCAGTAAT TTCCACACCT TAATTATCAT TCAACTTGCA AAAGAGACAA 2760 CTGATAAGAA GAAAATTGAA ATGAGAATCT GTGGATAAGT GTTTGTGTTC AGAAGATGTT 2820 GTTTTGCCAG TATTAGAAAA TACTGTGAGC CGGGCATGGT GGCTTACATC TGTAATCCCA 2880 GCACTTTGGG AGGCTGAGGG GGTGGATCAC GTGAGGTGGG GAGTTCTAGA CCAGCCTGAC 2940 CAACATGGAG AAACCCCATC TCTACTAAAA ATACAAAATT AGCTGGGCAT GGTGGCACAT 3000 GCTGGTAATC TCAGCTATTG AGGAGGCTGA GGCAGGAGAA TTGCTTGAAC CCGGGAGGCG 3060 GAGGTTGCAG TGAGCCAAGA TTGCACCACT GTACTCCAGC CTGGGTGACA AAGTCAGACT 3120 CCATCTCCAA AAAAAAAAAA AAAA

Seq ID NO: 34 Protein sequence: Protein Accession #: NP 055146

11 21 31 41 51

MVR PWSTI SKGGY QGNV NGRLPSLGNK EPPGQEKVQ KRKVTLLRGV SIIIGTIIGA 60 GIFISPKGVL QNTGSVGMSL TIWTVCGV S LFGALSYAEL GTTIKKSGGH YTYILEVFGP 120 PAFVRVWVE LIIRPAATA VIS AFGRYI EPFFIQCEI PE AIKLITA VGITW VLN 180 SMSVSWSARI QIFLTFCKLT AI IIIVPGV MQLIKGQTQN FKDAFSGRDS SITRLP AFY 240 YG YAYAGWF YLNFVTEEVE NPEKTIP AI CISMAIVTIG YVLTNVAYFT TINAEE S 300 NAVAVTFSER LGNFSLAVP IFVA SCFGS MNGGVFAVSR FYVASREGH LPEI SMIHV 360 RKHTPLPAVI VLHPLTMIML FSGDLDS N FLSFARWLFI GLAVAGLIYL RYKCPDMHRP 420 FKVPLFIPAL FSFTCLFMVA S YSDPFST GIGFVITLTG VPAYYLFII DKKPRWFRIM 480 SEKITRTLQI ILEWPEEDK L

Seq ID NO: 35 Nucleotide sequence: Nucleic Acid Accession #: NM_00242 Coding sequence: 64..1497 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

ACAAGGAGGC AGGCAAGACA GCAAGGCATA GAGACAACAT AGAGCTAAGT AAAGCCAGTG 60

GAAATGAAGA GTCTTCCAAT CCTACTGTTG CTGTGCGTGG CAGTTTGCTC AGCCTATCCA 120

TTGGATGGAG CTGCAAGGGG TGAGGACACC AGCATGAACC TTGTTCAGAA ATATCTAGAA 180

AACTACTACG ACCTCAAAAA AGATGTGAAA CAGTTTGTTA GGAGAAAGGA CAGTGGTCCT 240

GTTGTTAAAA AAATCCGAGA AATGCAGAAG TTCCTTGGAT TGGAGGTGAC GGGGAAGCTG 300 GACTCCGACA CTCTGGAGGT GATGCGCAAG CCCAGGTGTG GAGTTCCTGA TGTTGGTCAC 360

TTCAGAACCT TTCCTGGCAT CCCGAAGTGG AGGAAAACCC ACCTTACATA CAGGATTGTG 420

AATTATACAC CAGATTTGCC AAAAGATGCT GTTGATTCTG CTGTTGAGAA AGCTCTGAAA 480

GTCTGGGAAG AGGTGACTCC ACTCACATTC TCCAGGCTGT ATGAAGGAGA GGCTGATATA 540

5 ATGATCTCTT TTGCAGTTAG AGAACATGGA GACTTTTACC CTTTTGATGG ACCTGGAAAT 600

GTTTTGGCCC ATGCCTATGC CCCTGGGCCA GGGATTAATG GAGATGCCCA CTTTGATGAT 660

GATGAACAAT GGACAAAGGA TACAACAGGG ACCAATTTAT TTCTCGTTGC TGCTCATGAA 720

ATTGGCCACT CCCTGGGTCT CTTTCACTCA GCCAACACTG AAGCTTTGAT GTACCCACTC 780

TATCACTCAC TCACAGACCT GACTCGGTTC CGCCTGTCTC AAGATGATAT AAATGGCATT 840

10 CAGTCCCTCT ATGGACCTCC CCCTGACTCC CCTGAGACCC CCCTGGTACC CACGGAACCT 900

GTCCCTCCAG AACCTGGGAC GCCAGCCAAC TGTGATCCTG CTTTGTCCTT TGATGCTGTC 960

AGCACTCTGA GGGGAGAAAT CCTGATCTTT AAAGACAGGC ACTTTTGGCG CAAATCCCTC 1020

AGGAAGCTTG AACCTGAATT GCATTTGATC TCTTCATTTT GGCCATCTCT TCCTTCAGGC 1080

GTGGATGCCG CATATGAAGT TACTAGCAAG GACCTCGTTT TCATTTTTAA AGGAAATCAA 1140

15 TTCTGGGCCA TCAGAGGAAA TGAGGTACGA GCTGGATACC CAAGAGGCAT CCACACCCTA 1200

GGTTTCCCTC CAACCGTGAG GAAAATCGAT GCAGCCATTT CTGATAAGGA AAAGAACAAA 1260

ACATATTTCT TTGTAGAGGA CAAATACTGG AGATTTGATG AGAAGAGAAA TTCCATGGAG 1320

CCAGGCTTTC CCAAGCAAAT AGCTGAAGAC TTTCCAGGGA TTGACTCAAA GATTGATGCT 1380

GTTTTTGAAG AATTTGGGTT CTTTTATTTC TTTACTGGAT CTTCACAGTT GGAGTTTGAC 1440

20 CCAAATGCAA AGAAAGTGAC ACACACTTTG AAGAGTAACA GCTGGCTTAA TTGTTGAAAG 1500

AGATATGTAG AAGGCACAAT ATGGGCACTT TAAATGAAGC TAATAATTCT TCACCTAAGT 1560

CTCTGTGAAT TGAAATGTTC GTTTTCTCCT GCCTGTGCTG TGACTCGAGT CACACTCAAG 1620

GGAACTTGAG CGTGAATCTG TATCTTGCCG GTCATTTTTA TGTTATTACA GGGCATTCAA 1680

ATGGGCTGCT GCTTAGCTTG CACCTTGTCA CATAGAGTGA TCTTTCCCAA GAGAAGGGGA 1740

25 AGCACTCGTG TGCAACAGAC AAGTGACTGT ATCTGTGTAG ACTATTTGCT TATTTAATAA 1800 AGACGATTTG TCAGTTGTTT T

Seq ID NO : 36 Protein sequence : 30 Protein Accession # : NP_002413

1 11 21 31 41 51

,<. I I I I I I

JD MKSLPIIi L CVAVCSAYP DGAARGEDTS MNLVQKYLEN YYDLKKDVKQ FVRRKDSGPV 60

VKKIREMQKF LG EVTGK D SDT EVMRKP RCGVPDVGHF RTFPGIPKWR KTH TYRIVN 120

YTPD PKDAV DSAVEKALKV WEEVTP TFS RLYEGEADI ISFAVREHGD FYPFDGPGNV 180

LAHAYAPGPG INGDAHFDDD EQWTKDTTGT NLF VAAHEI GHSLGLFHSA NTEAL YP Y 240

HSLTDLTRFR SQDDINGIQ S YGPPPDSP ETP VPTEPV PPEPGTPANC DPA SFDAVS 300

40 TLRGEILIFK DRHFWRKSLR KLEPE H IS SFWPS PSGV DAAYEVTSKD LVFIFKGNQF 360

WAIRGNEVRA GYPRGIHTLG FPPTVR IDA AISDKEKNKT YFFVEDKYWR FDEKRNSMEP 420 GFPKQIAEDF PGIDSKIDAV FEEFGFFYFF TGSSQ EFDP NAKKVTHTL SNSWLNC

45 Seq ID NO : 37 Nucleotide sequence :

Nucleic Acid Accession # : N _003246 Coding sequence : 112 . . 36 4 (underlined sequences correspond to start and stop codons)

50 1 11 21 31 41 51

I I I I I I

GGACGCACAG GCATTCCCCG CGCCCCTCCA GCCCTGGCCG CCCTCGCCAC CGCTCCCGGC 60

CGCCGCGCTC CGGTACACAC AGGATCCCTG CTGGGCACCA ACAGCTCCAC CATGGGGCTG 120

GCCTGGGGAC TAGGCGTCCT GTTCCTGATG CATGTGTGTG GCACCAACCG CATTCCAGAG 180

55 TCTGGCGGAG ACAACAGCGT GTTTGACATC TTTGAACTCA CCGGGGCCGC CCGCAAGGGG 240

TCTGGGCGCC GACTGGTGAA GGGCCCCGAC CCTTCCAGCC CAGCTTTCCG CATCGAGGAT 300

GCCAACCTGA TCCCCCCTGT GCCTGATGAC AAGTTCCAAG ACCTGGTGGA TGCTGTGCGG 360

GCAGAAAAGG GTTTCCTCCT TCTGGCATCC CTGAGGCAGA TGAAGAAGAC CCGGGGCACG 420

CTGCTGGCCC TGGAGCGGAA AGACCACTCT GGCCAGGTCT TCAGCGTGGT GTCCAATGGC 480

60 AAGGCGGGCA CCCTGGACCT CAGCCTGACC GTCCAAGGAA AGCAGCACGT GGTGTCTGTG 540

GAAGAAGCTC TCCTGGCAAC CGGCCAGTGG AAGAGCATCA CCCTGTTTGT GCAGGAAGAC 600

AGGGCCCAGC TGTACATCGA CTGTGAAAAG ATGGAGAATG CTGAGTTGGA CGTCCCCATC 660

CAAAGCGTCT TCACCAGAGA CCTGGCCAGC ATCGCCAGAC TCCGCATCGC AAAGGGGGGC 720

GTCAATGACA ATTTCCAGGG GGTGCTGCAG AATGTGAGGT TTGTCTTTGG AACCACACCA 780

65 GAAGACATCC TCAGGAACAA AGGCTGCTCC AGCTCTACCA GTGTCCTCCT CACCCTTGAC 840

AACAACGTGG TGAATGGTTC CAGCCCTGCC ATCCGCACTA ACTACATTGG CCACAAGACA 900

AAGGACTTGC AAGCCATCTG CGGCATCTCC TGTGATGAGC TGTCCAGCAT GGTCCTGGAA 960

CTCAGGGGCC TGCGCACCAT TGTGACCACG CTGCAGGACA GCATCCGCAA AGTGACTGAA 1020

GAGAACAAAG AGTTGGCCAA TGAGCTGAGG CGGCCTCCCC TATGCTATCA CAACGGAGTT 1080

70 CAGTACAGAA ATAACGAGGA ATGGACTGTT GATAGCTGCA CTGAGTGTCA CTGTCAGAAC 1140

TCAGTTACCA TCTGCAAAAA GGTGTCCTGC CCCATCATGC CCTGCTCCAA TGCCACAGTT 1200

CCTGATGGAG AATGCTGTCC TCGCTGTTGG CCCAGCGACT CTGCGGACGA TGGCTGGTCT 1260

CCATGGTCCG AGTGGACCTC CTGTTCTACG AGCTGTGGCA ATGGAATTCA GCAGCGCGGC 1320

CGCTCCTGCG ATAGCCTCAA CAACCGATGT GAGGGCTCCT CGGTCCAGAC ACGGACCTGC 1380

75 CACATTCAGG AGTGTGACAA AAGATTTAAA CAGGATGGTG GCTGGAGCCA CTGGTCCCCG 1440

TGGTCATCTT GTTCTGTGAC ATGTGGTGAT GGTGTGATCA CAAGGATCCG GCTCTGCAAC 1500 TCTCCCAGCC CCCAGATGAA TGGGAAACCC TGTGAAGGCG AAGCGCGGGA GACCAAAGCC 1560 TGCAAGAAAG ACGCCTGCCC CATCAATGGA GGCTGGGGTC CTTGGTCACC ATGGGACATC 1620 TGTTCTGTCA CCTGTGGAGG AGGGGTACAG AAACGTAGTC GTCTCTGCAA CAACCCCGCA 1680 CCCCAGTTTG GAGGCAAGGA CTGCGTTGGT GATGTAACAG AAAACCAGAT CTGCAACAAG 1740 CAGGACTGTC CAATTGATGG ATGCCTGTCC AATCCCTGCT TTGCCGGCGT GAAGTGTACT 1800 AGCTACCCTG ATGGCAGCTG GAAATGTGGT GCTTGTCCCC CTGGTTACAG TGGAAATGGC 1860 ATCCAGTGCA CAGATGTTGA TGAGTGCAAA GAAGTGCCTG ATGCCTGCTT CAACCACAAT 1920 GGAGAGCACC GGTGTGAGAA CACGGACCCC GGCTACAACT GCCTGCCCTG CCCCCCACGC 1980 TTCACCGGCT CACAGCCCTT CGGCCAGGGT GTCGAACATG CCACGGCCAA CAAACAGGTG 2040 TGCAAGCCCC GTAACCCCTG CACGGATGGG ACCCACGACT GCAACAAGAA CGCCAAGTGC 2100 AACTACCTGG GCCACTATAG CGACCCCATG TACCGCTGCG AGTGCAAGCC TGGCTACGCT 2160 GGCAATGGCA TCATCTGCGG GGAGGACACA GACCTGGATG GCTGGCCCAA TGAGAACCTG 2220 GTGTGCGTGG CCAATGCGAC TTACCACTGC AAAAAGGATA ATTGCCCCAA CCTTCCCAAC 2280 TCAGGGCAGG AAGACTATGA CAAGGATGGA ATTGGTGATG CCTGTGATGA TGACGATGAC 2340 AATGATAAAA TTCCAGATGA CAGGGACAAC TGTCCATTCC ATTACAACCC AGCTCAGTAT 2400 GACTATGACA GAGATGATGT GGGAGACCGC TGTGACAACT GTCCCTACAA CCACAACCCA 2460 GATCAGGCAG ACACAGACAA CAATGGGGAA GGAGACGCCT GTGCTGCAGA CATTGATGGA 2520 GACGGTATCC TCAATGAACG GGACAACTGC CAGTACGTCT ACAATGTGGA CCAGAGAGAC 2580 ACTGATATGG ATGGGGTTGG AGATCAGTGT GACAATTGCC CCTTGGAACA CAATCCGGAT 2640 CAGCTGGACT CTGACTCAGA CCGCATTGGA GATACCTGTG ACAACAATCA GGATATTGAT 2700 GAAGATGGCC ACCAGAACAA TCTGGACAAC TGTCCCTATG TGCCCAATGC CAACCAGGCT 2760 GACCATGACA AAGATGGCAA GGGAGATGCC TGTGACCACG ATGATGACAA CGATGGCATT 2820 CCTGATGACA AGGACAACTG CAGACTCGTG CCCAATCCCG ACCAGAAGGA CTCTGACGGC 2880 GATGGTCGAG GTGATGCCTG CAAAGATGAT TTTGACCATG ACAGTGTGCC AGACATCGAT 2940 GACATCTGTC CTGAGAATGT TGACATCAGT GAGACCGATT TCCGCCGATT CCAGATGATT 3000 CCTCTGGACC CCAAAGGGAC ATCCCAAAAT GACCCTAACT GGGTTGTACG CCATCAGGGT 3060 AAAGAACTCG TCCAGACTGT CAACTGTGAT CCTGGACTCG CTGTAGGTTA TGATGAGTTT 3120 AATGCTGTGG ACTTCAGTGG CACCTTCTTC ATCAACACCG AAAGGGACGA TGACTATGCT 3180 GGATTTGTCT TTGGCTACCA GTCCAGCAGC CGCTTTTATG TTGTGATGTG GAAGCAAGTC 3240 ACCCAGTCCT ACTGGGACAC CAACCCCACG AGGGCTCAGG GATACTCGGG CCTTTCTGTG 3300 AAAGTTGTAA ACTCCACCAC AGGGCCTGGC GAGCACCTGC GGAACGCCCT GTGGCACACA 3360 GGAAACACCC CTGGCCAGGT GCGCACCCTG TGGCATGACC CTCGTCACAT AGGCTGGAAA 3420 GATTTCACCG CCTACAGATG GCGTCTCAGC CACAGGCCAA AGACGGGTTT CATTAGAGTG 3480 GTGATGTATG AAGGGAAGAA AATCATGGCT GACTCAGGAC CCATCTATGA TAAAACCTAT 3540 GCTGGTGGTA GACTAGGGTT GTTTGTCTTC TCTCAAGAAA TGGTGTTCTT CTCTGACCTG ₃600 AAATACGAAT GTAGAGATCC CTAATCATCA AATTGTTGAT TGAAAGACTG ATCATAAACC 3660 AATGCTGGTA TTGCACCTTC TGGAACTATG GGCTTGAGAA AACCCCCAGG ATCACTTCTC 3720 CTTGGCTTCC TTCTTTTCTG TGCTTGCATC AGTGTGGACT CCTAGAACGT GCGACCTGCC 3780 TCAAGAAAAT GCAGTTTTCA AAAACAGACT CATCAGCATT CAGCCTCCAA TGAATAAGAC 3840 ATCTTCCAAG CATATAAACA ATTGCTTTGG TTTCCTTTTG AAAAAGCATC TACTTGCTTC 3900 AGTTGGGAAG GTGCCCATTC CACTCTGCCT TTGTCACAGA GCAGGGTGCT ATTGTGAGGC 3960 CATCTCTGAG CAGTGGACTC AAAAGCATTT TCAGGCATGT CAGAGAAGGG AGGACTCACT 40 0 AGAATTAGCA AACAAAACCA CCCTGACATC CTCCTTCAGG AACACGGGGA GCAGAGGCCA 4080 AAGCACTAAG GGGAGGGCGC ATACCCGAGA CGATTGTATG AAGAAAATAT GGAGGAACTG 4140 TTACATGTTC GGTACTAAGT CATTTTCAGG GGATTGAAAG ACTATTGCTG GATTTCATGA 4200 TGCTGACTGG CGTTAGCTGA TTAACCCATG TAAATAGGCA CTTAAATAGA AGCAGGAAAG 4260 GGAGACAAAG ACTGGCTTCT GGACTTCCTC CCTGATCCCC ACCCTTACTC ATCACCTTGC 4320 AGTGGCCAGA ATTAGGGAAT CAGAATCAAA CCAGTGTAAG GCAGTGCTGG CTGCCATTGC 4380 CTGGTCACAT TGAAATTGGT GGCTTCATTC TAGATGTAGC TTGTGCAGAT GTAGCAGGAA 4440 AATAGGAAAA CCTACCATCT CAGTGAGCAC CAGCTGCCTC CCAAAGGAGG GGCAGCCGTG 4500 CTTATATTTT TATGGTTACA ATGGCACAAA ATTATTATCA ACCTAACTAA AACATTCCTT 4560 TTCTCTTTTT TCCGTAATTA CTAGGTAGTT TTCTAATTCT CTCTTTTGGA AGTATGATTT 4620 TTTTAAAGTC TTTACGATGT AAAATATTTA TTTTTTACTT ATTCTGGAAG ATCTGGCTGA 4680 AGGATTATTC ATGGAACAGG AAGAAGCGTA AAGACTATCC ATGTCATCTT TGTTGAGAGT 4740 CTTCGTGACT GTAAGATTGT AAATACAGAT TATTTATTAA CTCTGTTCTG CCTGGAAATT 4800 TAGGCTTCAT ACGGAAAGTG TTTGAGAGCA AGTAGTTGAC ATTTATCAGC AAATCTCTTG 4860 CAAGAACAGC ACAAGGAAAA TCAGTCTAAT AAGCTGCTCT GCCCCTTGTG CTCAGAGTGG 4920 ATGTTATGGG ATTCCTTTTT TCTCTGTTTT ATCTTTTCAA GTGGAATTAG TTGGTTATCC 4980 ATTTGCAAAT GTTTTAAATT GCAAAGAAAG CCATGAGGTC TTCAATACTG TTTTACCCCA 5040 TCCCTTGTGC ATATTTCCAG GGAGAAGGAA AGCATATACA CTTTTTTCTT TCATTTTTCC 5100 AAAAGAGAAA AAAATGACAA AAGGTGAAAC TTACATACAA ATATTACCTC ATTTGTTGTG 5160 TGACTGAGTA AAGAATTTTT GGATCAAGCG GAAAGAGTTT AAGTGTCTAA CAAACTTAAA 5220 GCTACTGTAG TACCTAAAAA GTCAGTGTTG TACATAGCAT AAAAACTCTG CAGAGAAGTA 5280 TTCCCAATAA GGAAATAGCA TTGAAATGTT AAATACAATT TCTGAAAGTT ATGTTTTTTT 5340 TCTATCATCT GGTATACCAT TGCTTTATTT TTATAAATTA TTTTCTCATT GCCATTGGAA 5400 TAGAATATTC AGATTGTGTA GATATGCTAT TTAAATAATT TATCAGGAAA TACTGCCTGT 5460 AGAGTTAGTA TTTCTATTTT TATATAATGT TTGCACACTG AATTGAAGAA TTGTTGGTTT 5520 TTTCTTTTTT TTGTTTTTTT TTTTTTTTTG CTTTTGACCT CCCATTTTTA 5580 CTATTTGCCA ATACCTTTTT CTAGGAATGT GCTTTTTTTT GTACACATTT TTATCCATTT 5640 TACATTCTAA AGCAGTGTAA GTTGTATATT ACTGTTTCTT ATGTACAAGG AACAACAATA 5700 AATCATATGG AAATTTATAT TT

Seq ID NO: 38 Protein sequence: Protein Accession #: NP_003237 11 21 31 41 51

MGLAWGLGVL FLMHVCGTNR IPESGGDNSV FDIFELTGAA RKGSGRRLVK GPDPSSPAFR 60 IEDANLIPPV PDDKFQD VD AVRAEKGFLL LASLRQMKKT RGTLLALERK DHSGQVFSW 120 SNGKAGTLDL S TVQGKQHV VSVEEALLAT GQWKSITLFV QEDRAQLYID CEKMENAELD 180 VPIQSVFTRD LASIARLRIA KGGVNDNFQG VLQNVRFVFG TTPEDILRNK GCSSSTSVLL 240 T DNNWNGS SPAIRTNYIG HKTKDLQAIC GISCDELSSM VLELRGLRTI VTTLQDSIRK 300 VTEENKE AN E RRPP CYH NGVQYRNNEE WTVDSCTECH CQNSVTICKK VSCPIMPCSN 360 ATVPDGECCP RCWPSDSADD GWSPWSEWTS CSTSCGNGIQ QRGRSCDSLN NRCEGSSVQT 420 RTCHIQECDK RFKQDGGWSH WSPWSSCSVT CGDGVITRIR LCNSPSPQMN GKPCEGEARE 480 TKACKKDACP INGGWGPWSP WDICSVTCGG GVQKRSRLCN NPAPQFGGKD CVGDVTENQI 540 CNKQDCPIDG CLSNPCFAGV KCTSYPDGSW KCGACPPGYS GNGIQCTDVD ECKEVPDACF 600 NHNGEHRCEN TDPGYNCLPC PPRFTGSQPF GQGVEHATAN KQVCKPRNPC TDGTHDCNKN 660 AKCNYLGHYS DPMYRCECKP GYAGNGIICG EDTDLDGWPN ENLVCVANAT YHCKKDNCPN 720 LPNSGQEDYD KDGIGDACDD DDDNDKIPDD RDNCPFHYNP AQYDYDRDDV GDRCDNCPYN 780 HNPDQADTDN NGEGDACAAD IDGDGILNER DNCQYVYNVD QRDTDMDGVG DQCDNCPLEH 840 NPDQLDSDSD RIGDTCDNNQ DIDEDGHQNN LDNCPYVPNA NQADHDKDGK GDACDHDDDN 900 DGIPDDKDNC R VPNPDQKD SDGDGRGDAC KDDFDHDSVP DIDDICPENV DISETDFRRF 960 QMIP DPKGT ΞQNDPNWWR HQGKELVQTV NCDPGLAVGY DEFNAVDFSG TFFINTERDD 1020 DYAGFVFGYQ SSSRFYWMW KQVTQSYWDT NPTRAQGYSG LSVKWNSTT GPGEHLRNAL 1080 WHTGNTPGQV RTLWHDPRHI GWKDFTAYRW RLSHRPKTGF IRWMYEGKK IMADSGPIYD 1140 KTYAGGRLGL FVFSQEMVFF SDLKYECRDP

Seq ID NO : 39 Nucleotide sequence : Nucleic Acid Accession # : BC004299 Coding sequence : 69. .1235 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

CCCGACCCGT GCGAGGGCCA GGTCCGCGCC TGCCCCGCCA GGCGAAGCGA GGCGACCCGC 60 GTGCGGCCAT GGCTTCGCTG CTGGGAGCCT ACCCTTGGCC CGAGGGTCTC GAGTGCCCGG 120 CCCTGGACGC CGAGCTGTCG GATGGACAAT CGCCGCCGGC CGTCCCCCGG CCCCCGGGGG 180 ACAAGGGCTC CGAGAGCCGT ATCCGGCGGC CCATGAACGC CTTCATGGTT TGGGCCAAGG 240 ACGAGAGGAA ACGGCTGGCA GTGCAGAACC CGGACCTGCA CAACGCCGAG CTCAGCAAGA 300 TGCTGGGAAA GTCGTGGAAG GCGCTGACGC TGTCCCAGAA GAGGCCGTAC GTGGACGAGG 360 CGGAGCGGCT GCGCCTGCAG CACATGCAGG ACTACCCCAA CTACAAGTAC CGGCCGCGCA 420 GGAAGAAGCA GGCCAAGCGG CTGTGCAAGC GCGTGGACCC GGGCTTCCTT CTGAGCTCCC 480 TCTCCCGGGA CCAGAACGCC CTGCCGGAGA AGAGAAGCGG CAGCCGGGGG GCGCTGGGGG 540 AGAAGGAGGA CAGGGGTGAG TACTCCCCCG GCACTGCCCT GCCCAGCCTC CGGGGCTGCT 600 ACCACGAGGG GCCGGCTGGT GGTGGCGGCG GCGGCACCCC GAGCAGTGTG GACACGTACC 660 CGTACGGGCT GCCCACACCT CCTGAAATGT CTCCCCTGGA CGTGCTGGAG CCGGAGCAGA 720 CCTTCTTCTC CTCCCCCTGC CAGGAGGAGC ATGGCCATCC CCGCCGCATC CCCCACCTGC 780 CAGGGCACCC GTACTCACCG GAGTACGCCC CAAGCCCTCT CCACTGTAGC CACCCCCTGG 840 GCTCCCTGGC CCTTGGCCAG TCCCCCGGCG TCTCCATGAT GTCCCCTGTA CCCGGCTGTC 900 CCCCATCTCC TGCCTATTAC TCCCCGGCCA CCTACCACCC ACTCCACTCC AACCTCCAAG 960 CCCACCTGGG CCAGCTTTCC CCGCCTCCTG AGCACCCTGG CTTCGACGCC CTGGATCAAC 1020 TGAGCCAGGT GGAACTCCTG GGGGACATGG ATCGCAATGA ATTCGACCAG TATTTGAACA 1080 CTCCTGGCCA CCCAGACTCC GCCACAGGGG CCATGGCCCT CAGTGGGCAT GTTCCGGTCT 1140 CCCAGGTGAC ACCAACGGGT CCCACAGAGA CCAGCCTCAT CTCCGTCCTG GCTGATGCCA 1200 CGGCCACGTA CTACAACAGC TACAGTGTGT CATAGAGCTG GAGGCGCCCC GTCCGGTCAG 1260 CCCTCGCGCC CTCTCCTTCT TGTGCCTTGA GTGGCAGAGG AGCCGTCCAG CCACACCAGC 1320 TTTCCTCCCA CCGCTCAGGG CAGGGAGGTC TGAACTGCGG CCCCAGAGCC TTTGGCCTAA 1380 GCTGGACTCT CCTTATCCGA GTGCCGCCTC TATCCCCTTC CCCACGTTCC AGCCCCTGCA 1440 GCCCACATTT TAAGTATATT CCTTCAAGTG AGTTTTCCTC CAGCCCCTGA GAGTTGCTGT 1500 CTCCCAGTGG AATGTTCACT GACGTCTTTT CTTGGTAGCC ATCATCGAAA CTAATGGGGG 1560 GACAGACTTG ATAGCCAAGG TCCCTTCTGG TCCAGTTTTC TGATTTAGGG TTCTCTCAAG 1620 ATTAATAAAG GAAGATGGGG AAATTTGACT CATTAATGAG CTCGCTAACC TACGATCTGG 1680 TGATAATTTT GTGTGCACAG CCCAAGGACC ACGAGGCTTT CTGCACTTTC TGCACCCCCT 1740 TCCAAAGTGA CCACAAAATT TCAAAGGGAC TCATACAATT TGAGAAAAAA CAGTCAACCT 1800 GATTTGAGAA ATTAACCAGT ATGGCTAACT ATATCACAGA AAATGGGATT GAGTTAAAAC 1860 TATTTTATTT TAAATATACA TTTTAAAGCA GTTCTTTTTT TTTGTTAATT TGTTTATTAT 1920 ACACACACTT CAAGAGCCAC CGCGCCCAGC CTACATTTAT AATTTTCATT CTCTTTTACC 1980 TATAAAATTC AGTGTATTAG TTTCATTACA TAGGAGAAAT TATATTTCTA AACATTTTAT 2040 GATGTTTAAA AACAAAACAG GCTGTTGTAA AAAAAAAAAA AAAAAAAAA

Seq ID NO: 40 Protein sequence: Protein Accession #: AAH04299

11 21 31 41 51

MASLLGAYPW PEGLECPALD AELSDGQSPP AVPRPPGDKG SESRIRRPMN AFMVWAKDER 60 KRLAVQNPDL HNAELSKMLG KSWKALTLSQ KRPYVDEAER LRLQHMQDYP NYKYRPRRKK 120

QAKRLCKRVD PGFLLSSLSR DQNALPEKRS GSRGALGEKE DRGEYSPGTA LPSLRGCYHE 180 GPAGGGGGGT PSSVDTYPYG LPTPPEMSPL DVLEPEQTFF SSPCQEEHGH PRRIPHLPGH 240

PYSPEYAPSP LHCSHPLGSL ALGQSPGVSM MSPVPGCPPS PAYYSPATYH PLHSNLQAHL 300

GQLSPPPEHP GFDALDQLSQ VELLGDMDRN EFDQYLNTPG HPDSATGAMA LSGHVPVSQV 360 TPTGPTETSL ISVLADATAT YYNSYSVS

Seq ID NO: 41 Nucleotide sequence:

Nucleic Acid Accession #: NM_004449

Coding sequence: 1..1389 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

I 1 1 I I

ATGATTCAGA CTGTCCCGGA CCCAGCAGCT CATATCAAGG AAGCCTTATC AGTTGTGAGT 60 GAGGACCAGT CGTTGTTTGA GTGTGCCTAC GGAACGCCAC ACCTGGCTAA GACAGAGATG 120 ACCGCGTCCT CCTCCAGCGA CTATGGACAG ACTTCCAAGA TGAGCCCACG CGTCCCTCAG 180 CAGGATTGGC TGTCTCAACC CCCAGCCAGG GTCACCATCA AAATGGAATG TAACCCTAGC 240 CAGGTGAATG GCTCAAGGAA CTCTCCTGAT GAATGCAGTG TGGCCAAAGG CGGGAAGATG 300 GTGGGCAGCC CAGACACCGT TGGGATGAAC TACGGCAGCT ACATGGAGGA GAAGCACATG 360 CCACCCCCAA ACATGACCAC GAACGAGCGC AGAGTTATCG TGCCAGCAGA TCCTACGCTA 420 TGGAGTACAG ACCATGTGCG GCAGTGGCTG GAGTGGGCGG TGAAAGAATA TGGCCTTCCA 480 GACGTCAACA TCTTGTTATT CCAGAACATC GATGGGAAGG AACTGTGCAA GATGACCAAG 540 GACGACTTCC AGAGGCTCAC CCCCAGCTAC AACGCCGACA TCCTTCTCTC ACATCTCCAC 600 TACCTCAGAG AGACTCCTCT TCCACATTTG ACTTCAGATG ATGTTGATAA AGCCTTACAA 660 AACTCTCCAC GGTTAATGCA TGCTAGAAAC ACAGATTTAC CATATGAGCC CCCCAGGAGA 720 TCAGCCTGGA CCGGTCACGG CCACCCCACG CCCCAGTCGA AAGCTGCTCA ACCATCTCCT 780 TCCACAGTGC CCAAAACTGA AGACCAGCGT CCTCAGTTAG ATCCTTATCA GATTCTTGGA 840 CCAACAAGTA GCCGCCTTGC AAATCCAGGC AGTGGCCAGA TCCAGCTTTG GCAGTTCCTC 900 CTGGAGCTCC TGTCGGACAG CTCCAACTCC AGCTGCATCA CCTGGGAAGG CACCAACGGG 960 GAGTTCAAGA TGACGGATCC CGACGAGGTG GCCCGGCGCT GGGGAGAGCG GAAGAGCAAA 1020 CCCAACATGA ACTACGATAA GCTCAGCCGC GCCCTCCGTT ACTACTATGA CAAGAACATC 1080 ATGACCAAGG TCCATGGGAA GCGCTACGCC TACAAGTTCG ACTTCCACGG GATCGCCCAG 1140 GCGCTCCAGC CCCACCCCCC GGAGTCATCT CTGTACAAGT ACCCCTCAGA CCTCCCGTAC 1200 ATGGGCTGCT ATCACGCCCA CCCACAGAAG ATGAACTTTG TGGCGCCCCA CCCTCCAGCC 1260 CTCCCCGTGA CATCTTCCAG TTTTTTTGCT GCCCCAAACC CATACTGGAA TTCACCAACT 1320 GGGGGTATAT ACCCCAACAC TAGGCTCCCC ACCAGCCATA TGCCTTCTCA TCTGGGCACT 1380 TACTACTAA

Seq ID NO: 42 Protein sequence : Protein Accession #: NP 004440

11 21 31 41 51

MIQTVPDPAA HIKEALSWS EDQSLFECAY GTPHLAKTEM TASSSSDYGQ TSKMSPRVPQ 60 QDWLSQPPAR VTIKMECNPS QVNGSRNSPD ECSVAKGGKM VGSPDTVGMN YGSYMEEKHM 120 PPPNMTTNER RVIVPADPTL WSTDHVRQWL EWAVKEYGLP DVNILLFQNI DGKELCKMTK 180 DDFQRLTPSY NADILLSHLH YLRETPLPHL TSDDVDKALQ NSPRLMHARN TDLPYEPPRR 240 SAWTGHGHPT PQSKAAQPSP STVPKTEDQR PQLDPYQILG PTSSRLANPG SGQIQLWQFL 300 LELLSDSSNS SCITWEGTNG EFKMTDPDEV ARRWGERKSK PNMNYDKLSR ALRYYYDKNI 360 MTKVHGKRYA YKFDFHGIAQ ALQPHPPESS LYKYPSDLPY MGSYHAHPQK MNFVAPHPPA 420 LPVTSSSFFA APNPYWNSPT GGIYPNTRLP TSHMPSHLGT YY

Seq ID NO: 43 Nucleotide sequence :

Nucleic Acid Accession # : NM_005100

Coding sequence : 192 . . 5537 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

CCTTCTTTTA AGGAGTTTGC CGCGAGCGCG TCTCCTTCAT TCGCAGGCTG GGCGCGTTCG 60 CAGTCGGCTG GCGGCGAAGG AAGGCGCTCT CGGGACCTCA CGGGCGCGCG TCTTTTGGCT 120 CTTGCCCCTG TCCCTGCGGC TTGGGGAAAG CGTAACCCGG CGGCTAGGCG CGGGAGAAGT 180 GCGGAGGAGC CATGGGCGCC GGGAGCTCCA CCGAGCAGCG CAGCCCGGAG CAGCCGCCCG 240 AGGGGAGCTC CACGCCGGCT GAGCCCGAGC CCAGCGGCGG CGGCCCCTCG GCCGAGGCGG 300 CGCCAGACAC CACCGCGGAC CCCGCCATCG CTGCCTCGGA CCCCGCCACC AAGCTCCTAC 360 AGAAGAATGG TCAGCTGTCC ACCATCAATG GCGTAGCTGA GCAAGATGAG CTCAGCCTCC 420 AGGAGGGTGA CCTAAATGGC CAGAAAGGAG CCCTGAACGG TCAAGGAGCC CTAAACAGCC 480 AGGAGGAAGA AGAAGTCATT GTCACGGAGG TTGGACAGAG AGACTCTGAA GATGTGAGCG 540 AAAGAGACTC CGATAAAGAG ATGGCTACTA AGTCAGCGGT TGTTCACGAC ATCACAGATG 600 ATGGGCAGGA GGAGAACCGA AATATCGAAC AGATTCCTTC TTCAGAAAGC AATTTAGAAG 660 AGCTAACACA ACCCACTGAG TCCCAGGCTA ATGATATTGG ATTTAAGAAG GTGTTTAAGT 720 TTGTTGGCTT TAAATTCACT GTGAAAAAGG ATAAGACAGA GAAGCCTGAC ACTGTCCAGC 780 TACTCACTGT GAAGAAAGAT GAAGGGGAGG GAGCAGCAGG GGCTGGCGAC CACCAGGACC 840

CCAGCCTTGG GGCTGGAGAA GCAGCATCCA AAGAAAGCGA ACCCAAACAA TCTACAGAGA 900

AACCCGAAGA GACCCTGAAG CGTGAGCAAA GCCACGCAGA AATTTCTCCC CCAGCCGAAT 960

CTGGCCAAGC AGTGGAGGAA TGCAAAGAGG AAGGAGAAGA GAAACAAGAA AAAGAACCTA 1020 GCAAGTCTGC AGAATCTCCG ACTAGTCCCG TGACCAGTGA AACAGGATCA ACCTTCAAAA 1080

AATTCTTCAC TCAAGGTTGG GCCGGCTGGC GCAAAAAGAC CAGTTTCAGG AAGCCGAAGG 1140

AGGATGAAGT GGAAGCTTCA GAGAAGAAAA AGGAACAAGA GCCAGAAAAA GTAGACACAG 1200

AAGAAGACGG AAAGGCAGAG GTTGCCTCCG AGAAACTGAC CGCCTCCGAG CAAGCCCACC 1260

CACAGGAGGC GGCAGAAAGT GCCCACGAGC CCCGGTTATC AGCTGAATAT GAGAAAGTTG 1320 AGCTGCCCTC AGAGGAGCAA GTCAGTGGCT CGCAGGGACC TTCTGAAGAG AAACCTGCTC 1380

CGTTGGCGAC AGAAGTGTTT GATGAGAAAA TAGAAGTCCA CCAAGAAGAG GTTGTGGCCG 1440

AAGTCCACGT CAGCACCGTG GAGGAGAGAA CCGAAGAGCA GAAAACGGAG GTGGAAGAAA 1500

CAGCAGGGTC TGTGCCAGCT GAAGAATTGG TTGGAATGGA TGCAGAACCT CAGGAAGCCG 1560

AACCTGCCAA GGAGCTGGTG AAGCTCAAAG AAACGTGTGT TTCCGGAGAG GACCCTACAC 1620 AGGGAGCTGA CCTCAGTCCT GATGAGAAGG TGCTGTCCAA ACCCCCCGAA GGCGTTGTGA 1680

GTGAGGTGGA AATGCTGTCA TCACAGGAGA GAATGAAGGT GCAGGGAAGT CCACTAAAGA 1740

AGCTTTTTAC CAGCACTGGC TTAAAAAAGC TTTCTGGAAA GAAACAGAAA GGGAAAAGAG 1800

GAGGAGGAGA CGAGGAATCA GGGGAGCACA CTCAGGTTCC AGCCGATTCT CCGGACAGCC 1860

AGGAGGAGCA AAAGGGCGAG AGCTCTGCCT CATCCCCTGA GGAGCCCGAG GAGATCACGT 1920 GTCTGGAAAA GGGCTTAGCC GAGGTGCAGC AGGATGGGGA AGCTGAAGAA GGAGCTACTT 1980

CCGATGGAGA GAAAAAAAGA GAAGGTGTCA CTCCCTGGGC ATCATTCAAA AAGATGGTGA 2040

CGCCCAAGAA GCGTGTTAGA CGGCCTTCGG AAAGTGATAA AGAAGATGAG CTGGACAAGG 2100

TCAAGAGCGC TACCTTGTCT TCCACCGAGA GCACAGCCTC TGAAATGCAA GAAGAAATGA 2160

AAGGGAGCGT GGAAGAGCCA AAGCCGGAAG AACCAAAGCG CAAGGTGGAT ACCTCAGTAT 2220 _ CTTGGGAAGC TTTAATTTGT GTGGGATCAT CCAAGAAAAG AGCAAGGAGA AGGTCCTCTT 2280

CTGATGAGGA AGGGGGACCA AAAGCAATGG GAGGAGACCA CCAGAAAGCT GATGAGGCCG 2340

GAAAAGACAA AGAGACGGGG ACAGACGGGA TCCTTGCTGG TTCCCAAGAA CATGATCCAG 2400

GGCAGGGAAG TTCCTCCCCG GAGCAAGCTG GAAGCCCTAC CGAAGGGGAG GGCGTTTCCA 2460

CCTGGGAGTC ATTTAAAAGG TTAGTCACGC CAAGAAAAAA ATCAAAGTCC AAGCTGGAAG 2520 AGAAAAGCGA AGACTCCATA GCTGGGTCTG GTGTAGAACA TTCCACTCCA GACACTGAAC 2580

CCGGTAAAGA AGAATCCTGG GTCTCAATCA AGAAGTTTAT TCCTGGACGA AGGAAGAAAA 2640

GGCCAGATGG GAAACAAGAA CAAGCCCCTG TTGAAGACGC AGGGCCAACA GGGGCCAACG 2700

AAGATGACTC TGATGTCCCG GCCGTGGTCC CTCTGTCTGA GTATGATGCT GTAGAAAGGG 2760

AGAAAATGGA GGCACAGCAA GCCCAAAAAG GCGCAGAGCA GCCCGAGCAG AAGGCAGCCA 2820 CTGAGGTGTC CAAGGAGCTC AGCGAGAGTC AGGTTCATAT GATGGCAGCA GCTGTCGCTG 2880

ACGGGACGAG GGCAGCTACC ATTATTGAAG AAAGGTCTCC TTCTTGGATA TCTGCTTCAG 2940

TGACAGAACC TCTTGAACAA GTAGAAGCTG AAGCCGCACT GTTAACTGAG GAGGTATTGG 3000

AAAGAGAAGT AATTGCAGAA GAAGAACCCC CCACGGTTAC TGAACCTCTG CCAGAGAACA 3060

GAGAGGCCCG GGGCGACACG GTCGTTAGTG AGGCGGAATT GACCCCCGAA GCTGTGACAG 3120 CTGCAGAAAC TGCAGGGCCA TTGGGTTCCG AAGAAGGAAC CGAAGCATCT GCTGCTGAAG 3180

AGACCACAGA AATGGTGTCA GCAGTCTCCC AGTTAACCGA CTCCCCAGAC ACCACAGAGG 3240

AGGCCACTCC GGTGCAGGAG GTGGAAGGTG GCGTACCTGA CATAGAAGAG CAAGAGAGGC 3300

GGACTCAAGA GGTCCTCCAG GCAGTGGCAG AAAAAGTGAA AGAGGAATCC CAGCTGCCTG 3360

GCACCGGTGG GCCAGAAGAT GTGCTTCAGC CTGTGCAGAG AGCAGAGGCA GAAAGACCAG 3420 AAGAGCAGGC TGAAGCGTCG GGTCTGAAGA AAGAGACGGA TGTAGTGTTG AAAGTAGATG 3480

CTCAGGAGGC AAAAACTGAG CCTTTTACAC AAGGGAAGGT GGTGGGGCAG ACCACCCCAG 3540

AAAGCTTTGA AAAAGCTCCT CAAGTCACAG AGAGCATAGA GTCCAGTGAG CTTGTAACCA 3600

CTTGTCAAGC CGAAACCTTA GGTGGGGTAA AATCACAGGA GATGGTGATG GAACAGGCTA 3660

TCCCCCCTGA CTCGGTGGAA ACCCCTACAG ACAGTGAGAC TGATGGAAGC ACCCCCGTAG 3720 CCGACTTTGA CGCACCAGGC ACAACCCAGA AAGACGAGAT TGTGGAAATC CATGAGGAGA 3780

ATGAGGTCGC ATCTGGTACC CAGTCAGGGG GCACAGAAGC AGAGGCAGTT CCTGCACAGA 3840

AAGAGAGGCC TCCAGCACCT TCCAGTTTTG TGTTCCAGGA AGAAACTAAA GAACAATCAA 3900

AGATGGAAGA CACTCTAGAG CATACAGATA AAGAGGTGTC AGTGGAAACT GTATCCATTC 3960

TGTCAAAGAC TGAGGGGACT CAAGAGGCTG ACCAGTATGC TGATGAGAAA ACCAAAGACG 4020 TACCATTTTT CGAAGGACTT GAGGGGTCTA TAGACACAGG CATAACAGTC AGTCGGGAAA 4080

AGGTCACTGA AGTTGCCCTT AAAGGTGAAG GGACAGAAGA AGCTGAATGT AAAAAGGATG 4140

ATGCTCTTGA ACTGCAGAGT CACGCTAAGT CTCCTCCATC CCCCGTGGAG AGAGAGATGG 4200

TAGTTCAAGT CGAAAGGGAG AAAACAGAAG CAGAGCCAAC CCATGTGAAT GAAGAGAAGC 4260

TTGAGCACGA AACAGCTGTT ACCGTATCTG AAGAGGTCAG TAAGCAGCTC CTCCAGACAG 4320 TGAATGTGCC CATCATAGAT GGGGCAAAGG AAGTCAGCAG TTTGGAAGGA AGCCCTCCTC 4380

CCTGCCTAGG TCAAGAGGAG GCAGTATGCA CCAAAATTCA AGTTCAGAGC TCTGAGGCAT 4440

CATTCACTCT AACAGCGGCT GCAGAGGAGG AAAAGGTCTT AGGAGAAACT GCCAACATTT 4500

TAGAAACAGG TGAAACGTTG GAGCCTGCAG GTGCACATTT AGTTCTGGAA GAGAAATCCT 4560

CTGAAAAAAA TGAAGACTTT GCCGCTCATC CAGGGGAAGA TGCTGTGCCC ACAGGGCCCG 4620 ACTGTCAGGC AAAATCGACA CCAGTGATAG TATCTGCTAC TACCAAGAAA GGCTTAAGTT 4680

CCGACCTGGA AGGAGAGAAA ACCACATCAC TGAAGTGGAA GTCAGATGAA GTCGATGAGC 4740

AGGTTGCTTG CCAGGAGGTC AAAGTGAGTG TAGCAATTGA GGATTTAGAG CCTGAAAATG 4800

GGATTTTGGA ACTTGAGACC AAAAGCAGTA AACTTGTCCA AAACATCATC CAGACAGCCG 4860

TTGACCAGTT TGTACGTACA GAAGAAACAG CCACCGAAAT GTTGACGTCT GAGTTACAGA 4920 CACAAGCTCA CGTGATAAAA GCTGACAGCC AGGACGCTGG ACAGGAAACG GAGAAAGAAG 4980

GAGAGGAACC TCAGGCCTCT GCACAGGATG AAACACCAAT TACTTCAGCC AAAGAGGAGT 5040

CAGAGTCAAC CGCAGTGGGA CAAGCACATT CTGATATTTC CAAAGACATG AGTGAAGCCT 5100

CAGAAAAGAC CATGACTGTT GAGGTAGAAG GTTCCACTGT AAATGATCAG CAGCTGGAAG 5160

AGGTCGTCCT CCCATCTGAG GAAGAGGGAG GTGGAGCTGG AACAAAGTCT GTGCCAGAAG 5220 ATGATGGTCA TGCCTTGTTA GCAGAAAGAA TAGAGAAGTC ACTAGTTGAA CCGAAAGAAG 5280

ATGAAAAAGG TGATGATGTT GATGACCCTG AAAACCAGAA CTCAGCCCTG GCTGATACTG 5340 ATGCCTCAGG AGGCTTAACC AAAGAGTCCC CAGATACAAA TGGACCAAAA CAAAAAGAGA 5400 AGGAGGATGC CCAGGAAGTA GAATTGCAGG AAGGAAAAGT GCACAGTGAA TCAGATAAAG 5460 CGATCACACC CCAAGCACAG GAGGAGTTAC AGAAACAAGA GAGAGAATCT GCAAAGTCAG 5520 AACTTACAGA ATCTTAAAAC ATCATGCAGT TAAACTCATT GTCTGTTTGG AAGACCAGAA 5580 TGTGAAGACA AGTAGTAGAA GAAAATGAAT GCTGCTGCTG AGACTGAAGA CCAGTATTTC 5640 AGAACTTTGA GAATTGGAGA GCAGGCACAT CAACTGATCT CATTTCTAGA GAGCCCCTGA 5700 CAATCCTGAG GCTTCATCAG GAGCTAGAGC CATTTAACAT TTCCTCTTTC CAAGACCAAC 5760 CTACAATTTT CCCTTGATAA CCATATAAAT TCTGATTTAA GGTCCTAAAT TCTTAACCTG 5820 GAACTGGAGT TGGCAATACC TAGTTCTGCT TCTGAAACTG GAGTATCATT CTTTACATAT 5880 TTATATGTAT GTTTTAAGTA GTCCTCCTGT ATCTATTGTA TATTTTTTTC TTAATGTTTA 5940 AGGAAATGTG CAGGATACTA CATGCTTTTT GTATCACACA GTATATGATG GGGCATGTGC 6000 CATAGTGCAG GCTTGGGGAG CTTTAAGCCT CAGTTATATA ACCCACAAAA AACAGAGCCT 6060 CCTAGATGTA ACATTCCTGA TCAAGGTACA ATTCTTTAAA ATTCACTAAT GATTGAGGTC 6120 CATATTTAGT GGTACTCTGA AATTGGTCAC TTTCCTATTA CACGGAGTGT GCCAAAACTA 6180 AAAAGCATTT TGAAACATAC AGAATGTTCT ATTGTCATTG GGAAATTTTG CTTTCTAACC 6240 CAGTGGAGGT TAGAAAGAAG TTATATTCTG GTAGCAAATT AACTTTACAT CCTTTTTCCT 6300 ACTTGTTATG GTTGTTTGGA CCGATAAGTG TGCTTAATCC TGAGGCAAAG TAGTGAATAT 6360 GTTTTATATG TTATGAAGAA AAGAATTGTT GTAAGTTTTT GATTCTACTC TTATATGCTG 6420 GACTGCATTC ACACATGGCA TGAAATAAGT CAGGTTCTTT ACAAATGGTA TTTTGATAGA 6480 TACTGGATTG TGTTTGTGCC ATATTTGTGC CATTCCTTTA AGAACAATGT TGCAACACAT 6540 TCATTTGGAT AAGTTGTGAT TTGACGACTG ATTTAAATAA AATATTTGCT TCACTTAAAA 6600 AAAAAAAA

Seq ID NO: 44 Protein sequence : Protein Accession #: NP 005091

11 21 31 41 51

I I I I I

MGAGSSTEQR SPEQPPEGSS TPAEPEPSGG GPSAEAAPDT TADPAIAASD PATKLLQKNG 60 QLSTINGVAE QDELSLQEGD LNGQKGALNG QGALNSQEEE EVIVTEVGQR DSEDVSERDS 120 DKEMATKSAV VHDITDDGQE ENRNIEQIPS SESNLEELTQ PTESQANDIG FKKVFKFVGF 180 KFTVKKDKTE KPDTVQLLTV KKDEGEGAAG AGDHQDPSLG AGEAASKESE PKQSTEKPEE 240 TLKREQSHAE ISPPAESGQA VEECKEEGEE KQEKEPSKSA ESPTSPVTSE TGSTFKKFFT 300 QGWAGWRKKT SFRKPKEDEV EASEKKKEQE PEKVDTEEDG KAEVASEKLT ASEQAHPQEP 360 AESAHEPRLS AEYEKVELPS EEQVSGSQGP SEEKPAPLAT EVFDEKIEVH QEEWAEVHV 420 STVEERTEEQ KTEVEETAGS VPAEELVGMD AEPQEAEPAK ELVKLKETCV SGEDPTQGAD 480 LSPDEKVLSK PPEGWSEVE MLSSQERMKV QGSPLKKLFT STGLKKLSGK KQKGKRGGGD 540 EESGEHTQVP ADSPDSQEEQ KGESSASSPE EPEEITCLEK GLAEVQQDGE AEEGATSDGE 600 KKREGVTPWA SFKKMVTPKK RVRRPSESDK EDELDKVKSA TLSSTESTAS EMQEEMKGSV 660 EEPKPEEPKR KVDTSVSWEA LICVGSSKKR ARRRSSSDEE GGPKAMGGDH QKADEAGKDK 720 ETGTDGILAG SQEHDPGQGS SSPEQAGSPT EGEGVSTWES FKRLVTPRKK SKSKLEEKSE 780 DSIAGSGVEH STPDTEPGKE ESWVSIKKFI PGRRKKRPDG KQEQAPVEDA GPTGANEDDS 840 DVPAWPLSE YDAVEREKME AQQAQKGAEQ PEQKAATEVS KELSESQVHM MAAAVADGTR 900 AATIIEERSP SWISASVTEP LEQVEAEAAL LTEEVLEREV IAEEEPPTVT EPLPENREAR 960 GDTWSEAEL TPEAVTAAET AGPLGSEEGT EASAAEETTE MVSAVSQLTD SPDTTEEATP 1020 VQEVEGGVPD IEEQERRTQE VLQAVAEKVK EESQLPGTGG PEDVLQPVQR AEAERPEEQA 1080 EASGLKKETD WLKVDAQEA KTEPFTQGKV VGQTTPESFE KAPQVTESIE SSELVTTCQA 1140 ETLAGVKSQE MVMEQAIPPD SVETPTDSET DGSTPVADFD APGTTQKDEI VEIHEENEVA 1200 SGTQSGGTEA EAVPAQKERP PAPSSFVFQE ETKEQSKMED TLEHTDKEVS VETVSILSKT 1260 EGTQEADQYA DEKTKDVPFF EGLEGSIDTG ITVSREKVTE VALKGEGTEE AECKKDDALE 1320 LQSHAKSPPS PVEREMWQV EREKTEAEPT HVNEEKLEHE TAVTVSEEVS KQLLQTVNVP 1380 IIDGAKEVSS LEGSPPPCLG QEEAVCTKIQ VQSSEASFTL TAAAEEEKVL GETANILETG 1440 ETLEPAGAHL VLEEKSSEKN EDFAAHPGED AVPTGPDCQA KSTPVIVSAT TKKGLSSDLE 1500 GEKTTSLKWK SDEVDEQVAC QEVKVSVAIE DLEPENGILE LETKSSKLVQ NIIQTAVDQF 1560 VRTEETATEM LTSELQTQAH VIKADSQDAG QETEKEGEEP QASAQDETPI TSAKEESEST 1620 AVGQAHSDIS KDMSEASEKT MTVEVEGSTV NDQQLEEWL PSEEEGGGAG TKSVPEDDGH 1680 ALLAERIEKS LVEPKEDEKG DDVDDPENQN SALADTDASG GLTKESPDTN GPKQKEKEDA 1740 QEVELQEGKV HSESDKAITP QAQEELQKQE RESAKSELTE S

Seq ID NO: 45 Nucleotide sequence:

Nucleic Acid Accession #: NM_001290

Coding sequence: 110..1231 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

GTGAGCGTGT GTGCGTGCGT CTACTTTGTA CTGGGAAGAA CACAGCCCAT GTGCTCTGCA 60 TGGACGTTAC TGATACTCTG TTTAGCTTGA TTTTCGAAAA GCAGGCAAGA TGTCCAGCAC 120 ACCACATGAC CCCTTCTATT CTTCTCCTTT CGGCCCATTT TATAGGAGGC ATACACCATA 180 CATGGTACAG CCAGAGTACC GAATCTATGA GATGAACAAG AGACTGCAGT CTCGCACAGA 240 GGATAGTGAC AACCTCTGGT GGGACGCCTT TGCCACTGAA TTTTTTGAAG ATGACGCCAC 300 ATTAACCCTT TCATTTTGTT TGGAAGATGG ACCAAAGCGA TACACTATCG GCAGGACCCT 360 CATCCCCCGT TACTTTAGCA CTGTGTTTGA AGGAGGGGTG ACCGACCTGT ATTACATTCT 420 CAAACACTCG AAAGAGTCAT ACCACAACTC ATCCATCACG GTGGACTGCG ACCAGTGTAC 480 CATGGTCACC CAGCACGGGA AGCCCATGTT TACCAAGGTA TGTACAGAAG GCAGACTGAT 540 CTTGGAGTTC ACCTTTGATG ATCTCATGAG AATCAAAACA TGGCACTTTA CCATTAGACA 600 ATACCGAGAG TTAGTCCCGA GAAGCATCCT AGCCATGCAT GCACAAGATC CTCAGGTCCT 660 GGATCAGCTG TCCAAAAACA TCACCAGGAT GGGGCTAACA AACTTCACCC TCAACTACCT 720 CAGGTTGTGT GTAATATTGG AGCCAATGCA GGAACTGATG TCGAGACATA AAACTTACAA 780 CCTCAGTCCC CGAGACTGCC TGAAGACCTG CTTGTTTCAG AAGTGGCAGA GGATGGTGGC 840 TCCGCCAGCA GAACCCACAA GGCAACCAAC AACCAAACGG AGAAAAAGGA AAAATTCCAC 900 CAGCAGCACT TCCAACAGCA GCGCTGGGAA CAATGCAAAC AGCACTGGCA GCAAGAAGAA 960 GACCACAGCT GCAAACCTGA GTCTGTCCAG TCAGGTACCT GATGTGATGG TGGTAGGAGA 1020 GCCAACTCTG ATGGGAGGTG AGTTTGGGGA CGAGGACGAA AGGCTAATCA CTAGATTAGA 1080 AAACACGCAA TATGATGCGG CCAACGGCAT GGACGACGAG GAGGACTTCA ACAATTCACC 1140 CGCGCTGGGG AACAACAGCC CGTGGAACAG TAAACCTCCC GCCACTCAAG AGACCAAATC 1200 AGAAAACCCC CCACCCCAGG CTTCCCAATA AGATGATCGG CACCAGAATC CACTGTCAAT 1260 AGGCCCGTGG GTGATCATTA CAATTGCAAA TCTTTACTTA CAGGAGAGGA AACAGAAGAG 1320 ATAAAAACTT TTCCATGCAA ATATCTATTT CTAAACCACA ATGATCTGAT TTTCTTTCTT 1380 CTTTCTTTTT TTCTAATTGA GAGGATTATT CCCAGTAAGC TTCCATGACC CTTTCTTGGA 1440 GGCCTTCACA GGTAATACAG ATACTGGCAC TGATTGTAAT TAAAATGAGA GAAAACTCTA 1500 GCGCATCTTC TGGCACGGTT TTAACAACGT GTTTGTGTTG AATTTCCTTT TTATGCATCA 1560 AACGAAGGCC ATATTGTCCA TAAATGCTCA GTGCTCAGGA TCTCATTAAT ATGCCGAACC 1620 TAACTACAGA TGACTTTTTA ATATTGTAAA ATATTTTCTG CTTTTTGACT TGCATCTGAG 1680 AGTTTCTTGT TTCAGTAAAA AAAGAAAAGA CAAAAAAATC AGCTTTGGAA AGTAATTTAA 1740 ATGTACCTTA CTTTATGTTT TCTTTCATTG GGCAACAGCT AAGAGGGCCC 1800 AGCAAGGTAA TTTATGGTTG AGCTGATGTC AATTGGTTCT TGTCTTGAGT CGACTCAATT 1860 TAGCCCAAGT GCTGAAACAA GAAATGTCAT TTTTTTCATC AAAGACACCA GGGCAGATTT 1920 TTAAGTAAAG AAAGACAATT GGACCCTTAA GAATTTATGC ATTTGTAAAG TTGCTGTTGA 1980 TCCAAATATT TTCAAGCCAT GTAATCCATT GGTTTTGTGG GCAGTTTAAT AAACCTGAAC 2040 CTTTGTGTGT TTTCTAATTG TACCTGAGTT GACCATCCTT TCTTTTTATA GTATATTTCT 2100 TGTATGATAT TTTGTAAAGC TCTCACCTGG TTCTTTTATG GGGACTTTTC GTTTTTGGGC 2160 AACTCCAGTG TATTTATGTG AAACTTTATA AGAGAATTAA TTTTTCCATT TGCATATTAA 2220 TATGTTCCTC CACACATGTA AAGGCACAGT GGCTCCGTGT GTTAAAAAAC AGCTGTATTT 2280 TATGTATGCT TTACTGATAA GTGTGCCAAT AATAAACTGT GTTAATGACC

Seq ID NO: 46 Protein sequence: Protein Accession #: NP 001281

11 21 31 41 51

MSSTPHDPFY SSPFGPFYRR HTPYMVQPEY RIYEMNKRLQ SRTEDSDNLW WDAFATEFFE 60

DDATLTLSFC LEDGPKRYTI GRTLIPRYFS TVFEGGVTDL YYILKHSKES YHNSSITVDC 120

DQCTMVTQHG KPMFTKVCTE GRLILEFTFD DLMRIKTWHF TIRQYRELVP RSILAMHAQD 180

PQVLDQLSKN ITRMGLTNFT LNYLRLCVIL EPMQELMSRH KTYNLSPRDC LKTCLFQKWQ 240

RMVAPPAEPT RQPTTKRRKR KNSTSSTSNS SAGNNANSTG SKKKTTAANL SLSSQVPDVM 300

WGEPTLMGG EFGDEDERLI TRLENTQYDA ANGMDDEEDF NNSPALGNNS PWNSKPPATQ 360

ETKSENPPPQ ASQ

Seq ID NO : 47 Nucleotide sequence :

Nucleic Acid Accession # : NM_004126

Coding sequence : 108 . .329 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

GGCACGAGCT CGTGCCGGCC TTCAGTTGTT TCGGGACGCG CCGAGCTTCG CCGCTCTTCC 60 AGCGGCTCCG CTGCCAGAGC TAGCCCGAGC CCGGTTCTGG GGCGAAAATG CCTGCCCTTC 120 ACATCGAAGA TTTGCCAGAG AAGGAAAAAC TGAAAATGGA AGTTGAGCAG CTTCGCAAAG 180 AAGTGAAGTT GCAGAGACAA CAAGTGTCTA AATGTTCTGA AGAAATAAAG AACTATATTG 240 AAGAACGTTC TGGAGAGGAT CCTCTAGTAA AGGGAATTCC AGAAGACAAG AACCCCTTTA 300 AAGAAAAAGG CAGCTGTGTT ATTTCATAAA TAACTTGGGA GAAACTGCAT CCTAAGTGGA 360 AGAACTAGTT TGTTTTAGTT TTCCCAGATA AAACCAACAT GCTTTTTAAG GAAGGAAGAA 420 TGAAATTAAA AGGAGACTTT CTTAAGCACC ATATAGATAG GGTTATGTAT AAAAGCATAT 480 GTGCTACTCA TCTTTGCTCA CTATGCAGTC TTTTTTAAGA GAGCAGAGAG TATCAGATGT 540 ACAATTATGG AAATAAGAAC ATTACTTGAG CATGACACTT CTTTCAGTAT ATTGCTTGAT 600 GCTTCAAATA AAGTTTTGTC TT

Seq ID NO: 48 Protein sequence: Protein Accession #: NP 004117

11 21 31 41 51

MPALHIEDLP EKEKLKMEVE QLRKEVKLQR QQVSKCSEEI KNYIEERSGE DPLVKGIPED 60 KNPFKEKGSC VIS

Seq ID NO: 49 Nucleotide sequence:

Nucleic Acid Accession #: XM_051896

Coding sequence: 139..2388 (underlined sequences correspond to start and stop codons) 11 21 31 41 51

GTTTTAAAGA CGCTAGAGTG CCAAAGAAGA CTTTGAAGTG TGAAAACATT TCCTGTAATT 60 GAAACCAAAA TGTCATTTAT AGATCCTTAC CAGCACATTA TAGTGGAGCA CCAGTATTCC 120 CACAAGTTTA CGGTAGTGGT GTTACGTGCC ACCAAAGTGA CAAAGGGGGC CTTTGGTGAC 180 ATGCTTGATA CTCCAGATCC CTATGTGGAA CTTTTTATCT CTACAACCCC TGACAGCAGG 240 AAGAGAACAA GACATTTCAA TAATGACATA AACCCTGTGT GGAATGAGAC CTTTGAATTT 300 ATTTTGGATC CTAATCAGGA AAATGTTTTG GAGATTACGT TAATGGATGC CAATTATGTC 360 ATGGATGAAA CTCTAGGGAC AGCAACATTT ACTGTATCTT CTATGAAGGT GGGAGAAAAG 420 AAAGAAGTTC CTTTTATTTT CAACCAAGTC ACTGAAATGG TTCTAGAAAT GTCTCTTGAA 480 GTTTGCTCAT GCCCAGACCT ACGATTTAGT ATGGCTCTGT GTGATCAGGA GAAGACTTTC 540 AGACAACAGA GAAAAGAACA CATAAGGGAG AGCATGAAGA AACTCTTGGG TCCAAAGAAT 600 AGTGAAGGAT TGCATTCTGC ACGTGATGTG CCTGTGGTAG CCATATTGGG TTCAGGTGGG 660 GGTTTCCGAG CCATGGTGGG ATTCTCTGGT GTGATGAAGG CATTATACGA ATCAGGAATT 720 CTGGATTGTG CTACCTACGT TGCTGGTCTT TCTGGCTCCA CCTGGTATAT GTCAACCTTG 780 TATTCTCACC CTGATTTTCC AGAGAAAGGG CCAGAGGAGA TTAATGAAGA ACTAATGAAA 840 AATGTTAGCC ACAATCCCCT TTTACTTCTC ACACCACAGA AAGTTAAAAG ATATGTTGAG 900 TCTTTATGGA AGAAGAAAAG CTCTGGACAA CCTGTCACCT TTACTGATAT CTTTGGGATG 960 TTAATAGGAG AAACACTAAT TCATAATAGA ATGAATACTA CTCTGAGCAG TTTGAAGGAA 1020 AAAGTTAATA CTGCACAATG CCCTTTACCT CTTTTCACCT GTCTTCATGT CAAACCTGAC 1080 GTTTCAGAGC TGATGTTTGC AGATTGGGTT GAATTTAGTC CATACGAAAT TGGCATGGCT 1140 AAATATGGTA CTTTTATGGC TCCCGACTTA TTTGGAAGCA AATTTTTTAT GGGAACAGTC 1200 GTTAAGAAGT ATGAAGAAAA CCCCTTGCAT TTCTTAATGG GTGTCTGGGG CAGTGCCTTT 1260 TCCATATTGT TCAACAGAGT TTTGGGCGTT TCTGGTTCAC AAAGCAGAGG CTGCACAATG 1320 GAGGAAGAAT TAGAAAATAT TACCACAAAG CATATTGTGA GTAATGATAG CTCGGACAGT 1380 GATGATGAAT CACACGAACC CAAAGGCACT GAAAATGAAG ATGCTGGAAG TGACTATCAA 1440 AGTGATAATC AAGCAAGTTG GATTCATCGT ATGATAATGG CCTTGGTGAG TGATTCAGCT 1500 TTATTCAATA CCAGAGAAGG ACGTGCTGGG AAGGTACACA ACTTCATGCT GGGCTTGAAT 1560 CTCAATACAT CTTATCCACT GTCTCCTTTG AGTGACTTTG CCACACAGGA CTCCTTTGAT 1620 GATGATGAAC TGGATGCAGC TGTAGCAGAT CCTGATGAAT TTGAGCGAAT ATATGAGCCT 1680 CTGGATGTCA AAAGTAAAAA GATTCATGTA GTGGACAGTG GGCTCACATT TAACCTGCCG 1740 TATCCCTTGA TACTGAGACC TCAGAGAGGG GTTGATCTCA TAATCTCCTT TGACTTTTCT 1800 GCAAGGCCAA GTGACTCTAG TCCTCCGTTC AAGGAACTTC TACTTGCAGA AAAGTGGGCT 1860 AAAATGAACA AGCTCCCCTT TCCAAAGATT GATCCTTATG TGTTTGATCG GGAAGGGCTG 1920 AAGGAGTGCT ATGTCTTTAA ACCCAAGAAT CCTGATATGG AGAAAGATTG CCCAACCATC 1980 ATCCACTTTG TTCTGGCCAA CATCAACTTC AGAAAGTACA GGGCTCCAGG TGTTCCAAGG 2040 GAAACTGAGG AAGAGAAAGA AATCGCTGAC TTTGATATTT TTGATGACCC AGAATCACCA 2100 TTTTCAACCT TCAATTTTCA ATATCCAAAT CAAGCATTCA AAAGACTACA TGATCTTATG 2160 CACTTCAATA CTCTGAACAA CATTGATGTG ATAAAAGAAG CCATGGTTGA AAGCATTGAA 2220 TATAGAAGAC AGAATCCATC TCGTTGCTCT GTTTCCCTTA GTAATGTTGA GGCAAGAAGA 2280 TTTTTCAACA AGGAGTTTCT AAGTAAACCC AAAGCATAGT TCATGTACTG GAAATGGCAG 2340 CAGTTTCTGA TGCTGAGGCA GTTTGCAATC CCATGACAAC TGGATTTAAA AGTACAGTAC 2400 AGATAGTCGT ACTGATCATG AGAGACTGGC TGATACTCAA AGTTGCAGTT ACTTAGCTGC 2460 ATGAGAATAA TACTATTATA AGTTAGGTTG ACAAATGATG TTGATTATGT AAGGATATAC 2520 TTAGCTACAT TTTCAGTCAG TATGAACTTC CTGATACAAA TGTAGGGATA TATACTGTAT 2580 TTTTAAACAT TTCTCACCAA CTTTCTTATG TGTGTTCTTT TTAAAAATTT TTTTTCTTTT 2640 AAAATATTTA ACAGTTCAAT CTCAATAAGA CCTCGCATTA TGTATGAATG TTATTCACTG 2700 ACTAGATTTA TTCATACCAT GAGACAACAC TATTTTTATT TATATATGCA TATATATACA 2760 TACATGAAAT AAATACATCA ATATAAAAAT

Seq ID NO: 50 Protein sequence: Protein Accession #: XP_051896

11 21 31 41 51

MSFIDPYQHI IVEHQYSHKF TVWLRATKV TKGAFGDMLD TPDPYVELFI STTPDSRKRT 60 RHFNNDINPV WNETFEFILD PNQENVLEIT LMDANYVMDE TLGTATFTVS SMKVGEKKEV 120 PFIFNQVTEM VLEMSLEVCS CPDLRFSMAL CDQEKTFRQQ RKEHIRESMK KLLGPKNSEG 180 LHSARDVPW AILGSGGGFR AMVGFSGVMK ALYESGILDC ATYVAGLSGS TWYMSTLYSH 240 PDFPEKGPEE INEELMKNVS HNPLLLLTPQ KVKRYVESLW KKKSSGQPVT FTDIFGMLIG 300 ETLIHNRMNT TLSSLKEKVN TAQCPLPLFT CLHVKPDVSE LMFADWVEFS PYEIGMAKYG 360 TFMAPDLFGS KFFMGTWKK YEENPLHFLM GVWGSAFSIL FNRVLGVSGS QSRGSTMEEE 420 LENITTKHIV SNDSSDSDDE SHEPKGTENE DAGSDYQSDN QASWIHRMIM ALVSDSALFN 480 TREGRAGKVH NFMLGLNLNT SYPLSPLSDF ATQDSFDDDE LDAAVADPDE FERIYEPLDV 540 KSKKIHWDS GLTFNLPYPL ILRPQRGVDL IISFDFSARP SDSSPPFKEL LLAEKWAKMN 600 KLPFPKIDPY VFDREGLKEC YVFKPKNPDM EKDCPTIIHF VLANINFRKY KAPGVPRETE 660 EEKEIADFDI FDDPESPFST FNFQYPNQAF KRLHDLMHFN TLNNIDVIKE AMVESIEYRR 720 QNPSRCSVSL SNVEARRFFN KEFLSKPKA

Seq ID NO : 51 Nucleotide sequence :

Nucleic Acid Accession # : NM_006528

Coding sequence : 57 . .764 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51

1 I I I I I

GCCGCCAGCG GCTTTCTCGG ACGCCTTGCC CAGCGGGCCG CCCGACCCCC TGCACCATGG 60

ACCCCGCTCG CCCCCTGGGG CTGTCGATTC TGCTGCTTTT CCTGACGGAG GCTGCACTGG 120 GCGATGCTGC TCAGGAGCCA ACAGGAAATA ACGCGGAGAT CTGTCTCCTG CCCCTAGACT 180

ACGGACCCTG CCGGGCCCTA CTTCTCCGTT ACTACTACGA CAGGTACACG CAGAGCTGCC 240

GCCAGTTCCT GTACGGGGGC TGCGAGGGCA ACGCCAACAA TTTCTACACC TGGGAGGCTT 300

GCGACGATGC TTGCTGGAGG ATAGAAAAAG TTCCCAAAGT TTGCCGGCTG CAAGTGAGTG 360

TGGACGACCA GTGTGAGGGG TCCACAGAAA AGTATTTCTT TAATCTAAGT TCCATGACAT 420 GTGAAAAATT CTTTTCCGGT GGGTGTCACC GGAACCGGAT TGAGAACAGG TTTCCAGATG 480

AAGCTACTTG TATGGGCTTC TGCGCACCAA AGAAAATTCC ATCATTTTGC TACAGTCCAA 540

AAGATGAGGG ACTGTGCTCT GCCAATGTGA CTCGCTATTA TTTTAATCCA AGATACAGAA 600

CCTGTGATGC TTTCACCTAT ACTGGCTGTG GAGGGAATGA CAATAACTTT GTTAGCAGGG 660

AGGATTGCAA ACGTGCATGT GCAAAAGCTT TGAAAAAGAA AAAGAAGATG CCAAAGCTTC 720 GCTTTGCCAG TAGAATCCGG AAAATTCGGA AGAAGCAATT TTAAACATTC TTAATATGTC 780

ATCTTGTTTG TCTTTATGGC TTATTTGGCT TTATGGTTGT ATCTGAAGAA TAATATGACA 840

GCATGAGGAA ACAAATCATT GGTGATTTAT TCACCAGTTT TTATTAATAC AAGTCACTTT 900

TTCAAAAATT TGGATTTTTT TATATATAAC TAGCTGCTAT TCAAATGTGA GTCTACCATT 960

TTTAATTTAT GGTTCAACTG TTTGTGAGAC GAATTCTTGC AATGCATAAG ATATAAAAGC 1020 AAATATGACT CACTCATTTC TTGGGGTCGT ATTCCTGATT TCAGAAGAGG ATCATAACTG 1080

AAACAACATA AGACAATATA ATCATGTGCT TTTAACATAT TTGAGAATAA AAAGGACTAG 1140 CC

Seq ID NO : 52 Protein sequence : Protein Accession # : NP_006519

1 11 21 31 41 51

I I I 1 I I

MDPARPLGLS ILLLFLTEAA LGDAAQEPTG NNAEICLLPL DYGPCRALLL RYYYDRYTQS 60 CRQFLYGGCE GNANNFYTWE ACDDACWRIE KVPKVCRLQV SVDDQCEGST EKYFFNLSSM 120

TCEKFFSGGC HRNRIENRFP DEATCMGFCA PKKIPSFCYS PKDEGLCSAN VTRYYFNPRY 180 RTCDAFTYTG CGGNDNNFVS REDCKRACAK ALKKKKKMPK LRFASRIRKI RKKQF

Seq ID NO : 53 Nucleotide sequence :

Nucleic Acid Accession # : AA478778 Coding sequence : no ORF found

1 11 21 31 41 51

TATTTTTGTA CGTAAAATGA TTCTATTATG ACTGCCTTTG CATGTAGTAA TATGACAAAG 60

TGATCCTTCA TTATCACGGT ACACTATTGT TTACTTTTCA TCTGTAAATG TTTTATTGTT 120

ACTTTTTTAA AATGAATTTT TTTAAAACAA TCTAGCCATC ATCAAGGTGC TATAAGAGTT 180 GTATAAAAGA TATTTTTGGC ATTTCTAGGC AAGTATCAGC CAATAAGTAT GTTAGTGATA 240

TCACAGATTG TACCAACTAT TAACTATGTT AAATAAGTAT TCAGTTTCAT GTGATCTCTG 300

GGAAAAAAAT ATGCTGCCTT GGTGCTAATA TTGTATGTAT TTAAATGATC ATCTGACTCA 360

GAAATATAAA CACTTTTAAT GAAAGGGAGG AACGGAAGGA CAATTTCCAG TGCACAGAAT 420

CACTTGGATG AAATAAGACC AGCTCTTTAC CCTTATTTTT GGATATGCCT TTTTTGGAAG 480 AGACTTAGAC TTTATCCTTA TTGTTGTTAG TGTTGTTAAT ATTCGTTGCT TCAGCCCACG 540

GTGCCTTGGT CTCTCCACAA TCAAATGGAG GATCCCCCAA GCAGCTTCAT TACAGAGTGA 600

TATTGGGAAA GTGAGATCCT CTCACCATTT TGCCAAGATA CTCTAAAATG ACATCCAAGT 660

TTACCAGTAG AAAGACACAG GATGCACAGA ATGGGCATGA CCTTCAGCTC ACGAGCACAC 720

CTGGAGAAAT TCAGAACCAG GTTCTGAATC ATCACGATTG CCTTTTGCAT GAAAACATCG 780 GCTGGTGATG TGACTTCTCT TCAGGCCATG AGCCTAACAY CCTGCCGGTT TTCATGCCCG 840

CTGCAGTAAT GGACGTTTGT GTGAAGAAAT GAACTGTGGA GTACAAAATG CTTTGAGTCT 900

TTCCGATTGC TCATTAATTC ACTTTTTTGT TACTTCTTTC CAAAATGGAA GTGCTGAAGC 960

CATGGTCTTT CTGCCCCTCC AAGCTGATGA AGGGAAGCCT TTGCCAATGG CCCATGGAAG 1020

ACACTTGGTT TGAGAAACCC TGCCCACTTC CAAAGACCAA AGAGATTAGG AAAAGCCTGG 1080 CAGTATTCTC CAACTCCAAA CAAGCTCTAG AGTGCTCCAG GAAAAGTTAT ATTCAGTATA 1140

TGAATAAGTG TTATTCTCCA TTATTAATGT GTTCTGAAAA TATATTATGA ATAAATACAT 1200 CACCACACCC AAAAAAAAAA AAAAAAAAAA AAAA

Seq ID NO : 54 Nucleotide sequence :

Nucleic Acid Accession # : NM_020663

Coding sequence : 1 . . 645 (underlined sequences correspond to start and stop codons )

11 21 31 41 51

ATGAACTGCA AAGAGGGAAC TGACAGCAGC TGCGGCTGCA GGGGCAACGA CGAGAAGAAG 60

ATGTTGAAGT GTGTGGTGGT GGGGGACGGT GCCGTGGGGA AAACCTGCCT GCTGATGAGC 120

TACGCCAACG ACGCCTTCCC AGAGGAATAC GTGCCCACTG TGTTTGACCA CTATGCAGTT 180 ACTGTGACTG TGGGAGGCAA GCAACACTTG CTCGGACTGT ATGACACCGC GGGACAGGAG 240

GACTACAACC AGCTGAGGCC ACTCTCCTAC CCCAACACGG ATGTGTTTTT GATCTGCTTC 300 TCTGTCGTAA ACCCTGCCTC TTACCACAAT GTCCAGGAGG AATGGGTCCC CGAGCTCAAG 360

GACTGCATGC CTCACGTGCC TTATGTCCTC ATAGGGACCC AGATTGATCT CCGTGATGAC 420

CCAAAAACCT TGGCCCGTTT GCTGTATATG AAAGAGAAAC CTCTCACTTA CGAGCATGGT 480

GTGAAGCTCG CAAAAGCGAT CGGAGCACAG TGCTACTTGG AATGTTCAGC TCTGACTCAG 540

AAAGGTCTCA AAGCGGTTTT TGATGAAGCA ATCCTCACCA TTTTCCACCC CAAGAAAAAG 600

AAGAAACGCT GTTCTGAGGG TCACAGCTGC TGTTCAATTA TCTGA

Seq ID NO: 55 Protein sequence: Protein Accession #: NP 065714

11 21 31 41 51

MNCKEGTDSS CGCRGNDEKK MLKCVWGDG AVGKTCLLMS YANDAFPEEY VPTVFDHYAV 60 TVTVGGKQHL LGLYDTAGQE DYNQLRPLSY PNTDVFLICF SWNPASYHN VQEEWVPELK 120

DCMPHVPYVL IGTQIDLRDD PKTIARLLYM KEKPLTYEHG VKLAKAIGAQ CYLECSALTQ 180 KGLKAVFDEA ILTIFHPKKK KKRCSEGHSC CSII

Seq ID NO : 56 Nucleotide sequence :

Nucleic Acid Accession # : fgenesh prediction

Coding sequence : 1- 546 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

ATGGCCTTGG GCAGCTCCGC CCCTGTGGCT TTGCAGGGTA ATGCCCACTT CCCTGCTGCT 60

TTCATGGCTG GCATTAAGTG TCTGTGGCTT TTCCAGGTAG TCCCCCTGGG GCTCCCCGAG 120

TTGGTGCAAA GGCTCCTGGG TGGAGCTCGA ACTGAAACTC GCTTTGTGCC CGCAGCCCTG 180

CAGCTCGCCG GTGCCCTCGA CCTGCCCGCT GGGTCCTGTG CCTTTGAAGA GAGCACTTGC 240

GGCTTTGACT CCGTGTTGGC CTCTCTGCCG TGGATTTTAA ATGAGGAAGG CCAGCAACCT 300

TTCTGGTCCT CAGGAGACAT GTCTGACTGG GACTACTGGG TTGGCTGGCG GAAGTTAATT 360

CATTCTCCTC TGAGCACTCC AGGGTGGAGC AGGCAGGTTA GGCTCCAGTT GTTCCAGCTT 420

CAGTTTGTCA AAGGCCAGAA CTTGGACGTA ACAGTGTACT GCAGGCTCCA GGGCAGTGAG 480

AAACCCTTTG AAACTGGTTC CATGGTTCCA TTCACCTTCA TGTACTGGAT CCACCATGGA 540

AAGTAG

Seq ID NO: 57 Protein sequence :

11 21 31 41 51

MALGSSAPVA LQGNAHFPAA FMAGIKCLWL FQWPLGLPE LVQRLLGGAR TETRFVPAAL 60

QLAGALDLPA GSCAFEESTC GFDSVLASLP WILNEEGQQP FWSSGDMSDW DYWVGWRKLI 120

HSPLSTPGWS RQVRLQLFQL QFVKGQNLDV TVYCRLQGSE KPFETGSMVP FTFMYWIHHG 180 K

Seq ID NO : 58 Nucleotide sequence :

Nucleic Acid Accession # : XM_050478

Coding sequence : 27 . .4508 (underlined sequences correspond to start and stop codons )

21 31 41 51

CGGGCGGCGG CTGAGCCCAG CCGAGGATGG AGAACCGGCC TGGGTCCTTC CAGTACGTCC 60 CTGTGCAGCT GCAAGGGGGG GCACCCTGGG GCTTCACCCT TAAGGGGGGT CTGGAACACT 120 GTGAGCCGCT CACAGTGTCT AAGATTGAAG ATGGAGGCAA GGCAGCTTTG TCCCAGAAGA 180 TGAGGACTGG TGATGAGCTG GTGAATATCA ATGGCACTCC ATTATATGGC TCCCGCCAAG 240 AGGCCCTCAT TCTCATCAAA GGCTCCTTCC GGATTCTCAA GCTGATTGTC AGGAGGAGGA 300 ACGCCCCTGT CAGTAGGCCG CACTCATGGC ATGTGGCCAA GCTGCTGGAG GGATGCCCTG 360 AAGCAGCCAC CACCATGCAT TTCCCTTCTG AAGCCTTCAG CTTGTCCTGG CATTCTGGCT 420 GCAACACAAG TGACGTGTGT GTGCAGTGGT GTCCACTCTC CCGGCATTGC AGCACCGAGA 480 AAAGCAGCTC CATTGGCAGC ATGGAGAGCC TGGAGCAACC AGGCCAAGCC ACCTATGAGA 540 GCCATCTGTT GCCTATTGAC CAGAACATGT ACCCTAACCA GCGTGACTCA GCCTACAGCT 600 CCTTCTCGGC CAGCTCAAAT GCTTCTGACT GTGCCCTTTC CCTCAGGCCA GAGGAGCCAG 660 CCTCTACAGA CTGCATCATG CAAGGCCCAG GGCCAACTAA GGCCCCCAGT GGCCGGCCTA 720 ATGTGGCTGA GACCTCAGGA GGTAGTCGGC GCACCAATGG GGGCCACCTG ACCCCCAGCT 780 CTCAGATGTC ATCCCGTCCA CAGGAGGGAT ACCAGTCAGG GCCCGCCAAA GCAGTCAGGG 840 GCCCACCACA ACCTCCAGTG AGGCGGGACA GCCTTCAGGC CTCCAGAGCC CAACTCCTCA 900 ATGGAGAGCA GCGCAGGGCA TCTGAGCCTG TGGTCCCCTT GCCACAGAAG GAGAAACTGA 960 GCTTAGAGCC TGTGCTACCC GCAAGGAACC CTAATAGGTT CTGTTGCCTC AGTGGGCATG 1020 ACCAAGTGAC AAGTGAGGGC CATCAGAACT GTGAGTTCAG TCAGCCTCCT GAATCCAGCC 1080 AACAGGGCTC TGAGCATCTA CTGATGCAGG CCTCAACCAA AGCTGTTGGA TCCCCAAAAG 1140 CCTGTGACAG AGCTTCCAGC GTGGATTCCA ACCCACTCAA TGAGGCTTCT GCAGAGCTAG 1200 CTAAGGCTTC TTTTGGCAGA CCTCCACATC TCATAGGACC CACAGGGCAT CGCCATAGTG 1260 CCCCTGAACA GCTGCTGGCA TCCCACCTGC AGCATGTGCA CCTTGATACC AGGGGCAGCA 1320 AAGGGATGGA GCTCCCACCC GTACAGGATG GGCACCAGTG GACTCTGTCC CCTTTGCACA 1380 GCAGCCACAA AGGGAAGAAA AGTCCATGCC CCCCTACAGG AGGAACCCAT GACCAGTCCA 1440

GCAAAGAAAG AAAGACCAGA CAAGTGGATG ACAGGTCTTT AGTTTTGGGA CACCAGAGCC 1500

AAAGCAGTCC CCCACATGGA GAGGCTGATG GACACCCCTC AGAAAAAGGT TTCCTGGACC 1560

CAAACAGAAC AAGCAGAGCA GCCAGTGAAT TGGCCAACCA GCAACCCTCT GCCTCTGGCT 1620 CCCTTGTTCA ACAAGCCACG GACTGTTCTT CAACCACTAA AGCAGCTAGT GGGAGAGAGG 1680

CAGGTGAAGA AGGGGACAGC GAGCCCAAGG AGTGCAGCCG GATGGGTGGT AGGCGAAGTG 1740

GAGGGACCCG GGGCCGCTCG ATCCAAAACC GGCGGAAGAG TGAGCGTTTT GCTACCAATC 1800

TGCGTAATGA AATTCAGAGG AGGAAGGCCC AGCTCCAGAA AAGCAAGGGT CCCTTGTCAC 1860

AGCTGTGTGA CACTAAGGAG CCAGTGGAAG AGACCCAGGA GCCCCCAGAA AGTCCTCCAC 1920 TCACTGCCTC TAACACATCT CTTCTATCTT CATGTAAAAA ACCTCCCAGC CCCAGAGACA 1980

AGCTCTTCAA CAAAAGCATG ATGCTCAGAG CTAGGTCTTC CGAGTGCCTC AGCCAAGCCC 2040

CTGAGAGCCA TGAATCTAGG ACAGGCTTAG AGGGACGAAT AAGCCCTGGC CAGAGGCCTG 2100

GCCAGTCCTC TTTGGGCCTG AACACCTGGT GGAAAGCACC TGACCCATCC TCCTCAGACC 2160

CTGAGAAAGC ACATGCTCAC TGTGGAGTCC GTGGAGGTCA TTGGAGATGG TCTCCAGAGC 2220 ATAATTCACA GCCACTTGTG GCAGCAGCCA TGGAAGGCCC TTCCAACCCA GGTGACAACA 2280

AGGAATTGAA GGCTTCTACT GCTCAAGCTG GGGAGGATGC CATCCTCTTG CCTTTTGCAG 2340

ACAGAAGAAA GTTCTTTGAA GAGAGTAGCA AATCCTTATC TACATCTCAT TTGCCAGGTT 2400

TAACCACTCA TAGCAACAAG ACTTTTACCC AGAGACCAAA ACCTATAGAC CAAAACTTCC 2460

AGCCAATGAG CTCCAGCTGT AGGGAATTGA GGCGCCATCC CATGGACCAA TCATATCATT 2520 CCGCAGACCA ACCATATCAT GCCACAGACC AATCATATCA TTCCATGTCA CCCCTTCAGT 2580

CAGAAACTCC CACTTACTCA GAATGTTTTG CAAGCAAAGG TCTAGAAAAT TCCATGTGTT 2640

GTAAGCCACT ACACTGTGGT GATTTTGATT ACCACAGGAC CTGCTCTTAC TCCTGCAGTG 2700

TTCAAGGAGC TCTAGTCCAT GATCCTTGCA TTTATTGTTC TGGGGAAATC TGCCCTGCCT 2760

TGCTAAAGAG AAATATGATG CCAAATTGCT ACAACTGCCG GTGCCACCAC CACCAATGCA 2820 TTCGGTGTTC AGTTTGCTAT CATAATCCTC AGCACAGTGC CCTCGAGGAC AGCAGCTTGG 2880

CACCTGGCAA CACTTGGAAA CCCAGGAAGC TGACAGTGCA GGAATTTCCT GGGGACAAAT 2940

GGAATCCAAT AACAGGAAAC AGGAAGACCA GCCAGTCAGG GAGGGAAATG GCTCATTCCA 3000

AGACTAGCTT TTCATGGGCA ACCCCTTTCC ATCCTTGCCT TGAGAACCCA GCACTGGACT 3060

TGTCAAGCTA CCGAGCAATT TCTTCTCTTG ACCTCCTTGG AGACTTCAAA CATGCTTTGA 3120 AAAAATCAGA GGAAACTTCA GTTTATGAGG AGGGGAGCTC CCTTGCCTCC ATGCCCCACC 3180

CACTGCGCAG CCGTGCCTTC TCAGAGAGTC ACATCAGCTT GGCGCCCCAA AGCACCCGGG 3240

CCTGGGGGCA GCATAGGAGG GAGCTCTTTA GCAAAGGTGA TGAGACCCAG TCGGATCTTC 3300

TCGGAGCCAG GAAGAAGGCC TTTCCTCCTC CTCGCCCTCC TCCTCCCAAC TGGGAGAAGT 3360

ACAGGCTCTT TCGTGCAGCC CAGCAGCAGA AGCAGCAACA GCAGCAGCAG AAGCAACAGG 3420 AGGAGGAGGA GGAGGAGGAA GAAGAAGAAG AAGAGGAAGA GGAAGAGGAG GAGGAGGAGG 3480

CAGAGGAGGA GGAAGAGGAG CTGCCACCCC AGTATTTCAG TTCAGAAACC TCTGGTTCCT 3540

GTGCTCTCAA TCCTGAGGAG GTCCTAGAGC AGCCACAACC CCTCAGCTTT GGCCACCTGG 3600

AGGGCTCGAG ACAGGGTTCA CAAAGTGTCC CAGCAGAGCA AGAATCCTTT GCACTCCATT 3660

CCAGTGATTT CTTGCCTCCA ATAAGGGGTC ACTTGGGATC TCAACCTGAG CAGGCTCAGC 3720 CCCCTTGCTA CTATGGCATT GGTGGGCTTT GGAGGACATC GGGACAGGAA GCCACTGAAT 3780

CCGCCAAACA AGAGTTTCAG CACTTTTCGC CTCCTTCAGG GGCCCCAGGA ATCCCTACCT 3840

CTTACTCAGC TTATTACAAT ATTTCTGTGG CCAAGGCAGA GCTGCTGAAC AAACTGAAAG 3900

ACCAACCTGA GATGGCAGAG ATTGGCCTAG GAGAGGAGGA AGTTGACCAT GAACTGGCTC 3960

AAAAAAAGAT ACAGCTTATC GAAAGCATCA GCAGAAAACT TTCTGTCTTG CGGGAGGCCC 4020 AGCGAGGGCT GCTAGAGGAC ATCAATGCCA ATTCTGCCCT TGGGGAGGAG GTGGAGGCCA 4080

ACTTAAAAGC CGTCTGCAAA TCCAATGAAT TTGAAAAGTA CCACTTGTTT GTTGGGGACC 4140

TGGACAAAGT GGTCAACCTG TTGCTGTCAC TCTCTGGACG ACTGGCCCGG GTGGAGAATG 4200

CTCTGAACAG CATCGATTCA GAGGCCAACC AGGAGAAGTT GGTACTGATA GAGAAGAAGC 4260

AGCAGCTGAC GGGGCAGTTG GCAGATGCCA AGGAGCTGAA GGAGCACGTG GACCGCCGGG 4320 AGAAGTTGGT GTTTGGCATG GTCTCCCGCT ACCTGCCTCA GGACCAGCTC CAAGATTACC 4380

AGCACTTTGT CAAGATGAAA TCTGCTCTCA TCATTGAACA GCGAGAGCTG GAGGAGAAGA 4440

TCAAGCTCGG GGAAGAGCAA CTCAAATGTC TCAGGGAGAG TCTACTCCTG GGGCCCAGCA 4500

ATTTCTAATT CTACCAGCAC TCTGCCACAG CATCCCTGCC CAGCCATGTG GGAAGTGCTT 4560

TCAATCTTCT TTGTTAGCAG TTTCTCAGCA AGTAGATAGC AATTAGCAGT TTGTTCCAGC 4620 CCTCTACCCT GGATGTCTCT CACTACCCCT TCCCTAGCAG TGGTCCTAAC CAGCTAGGAG 4680

ACCCTGGGGA AGCCACAAGC TTCTACCCAA GGGAGCTGCA GCAAGGTGTG ATCTTAGAAC 4740

CACACTCTCC TTCCCACAGT TGCCAAGGGC AAGTACTTGC TGCACAGAGA ACCAAGGAAG 4800

TGCCTTCATT CTGCTTTGTA CTAGGACACC AAAGACATCA AGTACTCATC ACCCACCCAT 4860

ATCATCAACA GCCTCTAAAG GCTCAGAGGG AATCTGCCTT GCAGCTCTAC TCTGCCCCAG 4920 GGCTTGTGGC CAGCCATTTC TCACAGAGAG CTGGCTGCCT TGAGGGCATT CACCTGGCAC 4980

CAGTTTCAGG GCCTCACCCA AGCTTTGCAG GGGAAAGCAC AGAGGGAGGA ATTACACTGA 5040

AAAAAATGCA AGCAAAGGTT GAGTACCCCC AGGTGCCCCT TAGGAAGGAA CCAGGTTTAA 5100

ATAGGCTCTA CCCTTACCTT TCCCAGCAGC AAGTTCAGGG GAAGAGGCCT ACTCTTAGCC 5160

CTGGCTAGTG TGACCCTCTT CCTGTCCTAA GACTTTGGTC CTACCACCTC TTGTTTCATC 5220 TTTCCTTTAC ATTGCTGGGG GTTACCGCAG GTGCCTACCC CAGGGCTTCA CCATATGGGC 5280

CATTAATAGC TCTACTAAAA CTGACTTCTA GATGTAGGTT TCATTATTGG GGGAGGGGGT 5340

TCTTATTGTT ATATTTTAAA TGGCCTTTTG ATTTTATTTA TTTTTATGTT TTGATTATTT 5400

TTTTCTTTTT TAACTAATAA GGCGAGAAGA GGGAAGTTGG AGAGGGAAAA GTTAGCCCAG 5460

AAGGAAAGCA TTTTCTGCAG ATCAGCCTGA ATCCACCGTG GCTAGGCATA TTCTTGCTCT 5520 TCTCGTGTTG CTCACAACTA CCTGCCTGGA TGAATTTAGG AAAGTTGCAG GATACAAGGT 5580

TAAAACACAA GATCAAATGA ACAATCCGAA AATGTTATTA AGAAAACAGT TCCGGCCGGG 5640

CATGGTGGCT CACGCCTGAA ATCCCAGCAC TTTGGGAGGC CGAGGCAGGT GGATCACGAG 5700

GTCAGGAGAT CAAGACCATC CTGGCTAACA CGGTGAAACC CTATCTCTAC TAAAAATACA 5760

AAAAATTAGC CAGGTGTGGT GGCACGCACC AGTAGTCCCA GCTACTCGGG AGGCTGAGGC 5820 AGGAGAATTG CTTGAACCTG GAAGGCAGAG ATTGCAGTGA GCTGAGACCA CACCACTGCA 5880

CTCCATCCTG GGCAACAGAG TGAGACTTTG TCTCAAAAAG AAAGAAAGAA AGAAAGAAAG 5940 AAAGAAAGAA AGAAAAGAAA GAAAGAAAGA AAGAAAGAAA ACAGTTCCAT TTACAATAGC 6000 ATC

Seq ID NO : 59 Protein sequence : Protein Accession # : XP__050478

11 21 31 41 51

MENRPGSFQY VPVQLQGGAP WGFTLKGGLE HCEPLTVSKI EDGGKAALSQ KMRTGDELVN 60 INGTPLYGSR QEALILIKGS FRILKLIVRR RNAPVSRPHS WHVAKLLEGC PEAATTMHFP 120 SEAFSLSWHS GCNTSDVCVQ WCPLSRHCST EKSSSIGSME SLEQPGQATY ESHLLPIDQN 180 MYPNQRDSAY SSFSASSNAS DCALSLRPEE PASTDCIMQG PGPTKAPSGR PNVAETSGGS 240 RRTNGGHLTP SSQMSSRPQE GYQSGPAKAV RGPPQPPVRR DSLQASRAQL LNGEQRRASE 300 PWPLPQKEK LSLEPVLPAR NPNRFCCLSG HDQVTSEGHQ NCEFSQPPES SQQGSEHLLM 360 QASTKAVGSP KACDRASSVD SNPLNEASAE LAKASFGRPP HLIGPTGHRH SAPEQLLASH 420 LQHVHLDTRG SKGMELPPVQ DGHQWTLSPL HSSHKGKKSP CPPTGGTHDQ SSKERKTRQV 480 DDRSLVLGHQ SQSSPPHGEA DGHPSEKGFL DPNRTSRAAS ELANQQPSAS GSLVQQATDC 540 SSTTKAASGT EAGEEGDSEP KECSRMGGRR SGGTRGRSIQ NRRKSERFAT NLRNEIQRRK 600 AQLQKSKGPL SQLCDTKEPV EETQEPPESP PLTASNTSLL SSCKKPPSPR DKLFNKSMML 660 RARSSECLSQ APESHESRTG LEGRISPGQR PGQSSLGLNT WWKAPDPSSS DPEKAHAHCG 720 VRGGHWRWSP EHNSQPLVAA AMEGPSNPGD NKELKASTAQ AGEDAILLPF ADRRKFFEES 780 SKSLSTSHLP GLTTHSNKTF TQRPKPIDQN FQPMSSSCRE LRRHPMDQSY HSADQPYHAT 840 DQSYHSMSPL QSETPTYSEC FASKGLENSM CCKPLHCGDF DYHRTCSYSC SVQGALVHDP 900 CIYCSGEICP ALLKRNMMPN CYNCRCHHHQ CIRCSVCYHN PQHSALEDSS LAPGNTWKPR 960 KLTVQEFPGD KWNPITGNRK TSQSGREMAH SKTSFSWATP FHPCLENPAL DLSSYRAISS 1020 LDLLGDFKHA LKKSEETSVY EEGSSLASMP HPLRSRAFSE SHISLAPQST RAWGQHRREL 1080 FSKGDETQSD LLGARKKAFP PPRPPPPNWE KYRLFRAAQQ Q QQQQQQKQ QEEEEEEEEE 1140 EEEEEEEEEE EAEEEEEELP PQYFSSETSG SCALNPEEVL EQPQPLSFGH LEGSRQGSQS 1200 VPAEQESFAL HSSDFLPPIR GHLGSQPEQA QPPCYYGIGG LWRTSGQEAT ESAKQEFQHF 1260 SPPSGAPGIP TSYSAYYNIS VAKAELLNKL KDQPEMAEIG LGEEEVDHEL AQKKIQLIES 1320 ISRKLSVLRE AQRGLLEDIN ANSALGEEVE ANLKAVCKSN EFEKYHLFVG DLDKWNLLL 1380 SLSGRLARVE NALNSIDSEA NQEKLVLIEK KQQLTGQLAD AKELKEHVDR REKLVFGMVS 1440 RYLPQDQLQD YQHFVKMKSA LIIEQRELEE KIKLGEEQLK CLRESLLLGP SNF

Seq ID NO: 60 Nucleotide sequence:

Nucleic Acid Accession #: NM_014705

Coding sequence: 192..2489 (underlined sequences correspond to start and stop codons)

1 11 21 31 41 51

GGGAGAAGCT AGGAAAAAAT GTCTTTGAGC TGTGAGATGC TTGTATATTT TGAAAATATG 60

ATTATATGCA TGTGTTTGTA TTTTATGACT TGGATAATCT GAAAATCAAT TTGCTTTGTC 120 AATGCTTCCT GGATTAGAAT TCCACTATTT GGTCCCTATC CTAGTCTACT AAAGAAAATT 180

GAGCGGGAAA CATGGCGGGA AAGTGGCGTT TCATTAATTG CTACTGTAAC TCGTCTAATG 240

GAGAGGTTGT TAGATTACAG AACTTCTATA AGACTGAACT GAACAAGGAG GAGATGTATA 300

TACGCTACAT TCACAAACTC TATGATCTGC ATCTCAAAGC ACAGAACTTT ACAGAAGCTG 360

CATATACCCT CCTCTTATAT GACGAGCTAC TGGAATGGTC TGATCGGCCC CTCAGGGAGT 420 TCCTGACCTA CCCCATGCAA ACAGAATGGC AGCGCAAAGA GCACCTGCAC CTCACCATCA 80

TCCAGAACTT TGACAGAGGC AAATGTTGGG AGAATGGCAT TATCTTGTGC CGGAAGATTG 540

CAGAGCAGTA TGAGAGTTAT TATGACTACA GAAACCTGAG CAAGATGCGG ATGATGGAAG 600

CCTCTTTGTA TGACAAAATT ATGGACCAGC AACGTCTTGA ACCAGAGTTC TTCAGAGTTG 660

GATTTTATGG AAAAAAATTT CCATTTTTCT TAAGAAATAA GGAGTTTGTG TGTCGAGGGC 720 ATGACTACGA GAGGCTGGAA GCCTTCCAAC AGAGAATGCT GAACGAGTTC CCCCATGCCA 780

TCGCCATGCA GCACGCCAAC CAGCCCGATG AGACCATCTT CCAGGCAGAA GCTCAGTATT 840

TGCAGATATA TGCTGTGACT CCCATTCCAG AGAGCCAGGA GGTCCTGCAG AGAGAGGGTG 900

TTCCGGACAA CATCAAAAGC TTCTATAAAG TGAATCACAT CTGGAAATTC CGCTATGACC 960

GACCATTTCA CAAAGGCACA AAAGATAAAG AGAATGAATT CAAGAGTCTC TGGGTGGAGA 1020 GAACGTCATT ATACTTGGTG CAGAGTTTGC CTGGCATCTC TCGCTGGTTT GAAGTGGAAA 1080

AGCGTGAAGT GGTAGAAATG AGTCCTCTGG AAAATGCAAT TGAAGTGCTA GAAAATAAGA 1140

ATCAGCAGCT GAAGACTCTG ATTAGTCAGT GTCAGACAAG ACAGATGCAG AATATTAATC 1200

CCCTGACTAT GTGCCTGAAT GGAGTTATAG ATGCTGCAGT TAATGGTGGC GTTTCCAGGT 1260

ATCAAGAGGC ATTCTTTGTC AAAGAATATA TCTTAAGTCA CCCTGAAGAT GGGGAGAAAA 1320 TTGCACGATT AAGAGAGCTG ATGCTTGAGC AGGCACAGAT TCTGGAATTT GGTTTGGCCG 1380

TGCATGAGAA GTTTGTACCT CAAGATATGA GACCCCTTCA CAAAAAGCTG GTTGACCAAT 1440

TCTTTGTGAT GAAGTCGAGC TTAGGGATAC AGGAGTTCTC TGCTTGTATG CAAGCCAGTC 1500

CTGTCCATTT TCCTAATGGA AGCCCTCGTG TGTGTAGAAA CTCAGCACCT GCTTCTGTGA 1560

GCCCAGATGG TACCAGGGTA ATTCCTAGAC GCAGCCCGTT AAGTTACCCA GCTGTCAACC 1620 GATATTCTTC CTCCTCACTG TCCTCACAAG CTTCTGCTGA AGTAAGCAAT ATTACAGGGC 1680

AATCAGAAAG CTCTGATGAA GTCTTTAACA TGCAGCCAAG TCCATCTACC TCAAGCTTGA 1740

GTTCTACTCA CTCGGCTTCA CCTAATGTGA CAAGTTCTGC TCCATCGAGT GCCAGAGCTT 1800

CTCCTTTGTT GTCTGACAAA CACAAACATT CCCGAGAAAA CTCTTGCCTG TCACCAAGAG 1860

AGAGACCATG CAGTGCCATC TATCCAACAC CTGTGGAGCC TTCGCAGAGG ATGCTGTTTA 1920 ATCATATTGG AGACGGGGCC TTGCCACGCA GTGACCCAAA TCTCTCTGCA CCTGAAAAAG 1980

CTTCACCAGC AAGACACACG ACATCAGTAT CCCCCTCGCC TGCCGGGCGA TCTCCATTGA 2040 AGGGCTCTGT GCAGTCTTTC ACCCCCTCTC CAGTGGAGTA CCACTCGCCA GGACTCATCT 2100 CCAACTCCCC TGTCTTGTCG GGCAGCTACA GCAGTGGGAT TTCTTCTCTC AGCCGGTGCA 2160 GCACGTCGGA AACCTCAGGC TTTGAAAATC AGGTGAATGA ACAGTCGGCC CCCCTGCCGG ₂220 TGCCAGTGCC GGTGCCCGTG CCGAGCTACG GCGGGGAGGA GCCAGTGCGC AAGGAGAGCA 2280 AGACTCCGCC CCCGTACAGC GTCTACGAGC GGACTCTGCG GCGCCCCGTC CCGCTACCTC 2340 ACAGCCTCTC CATCCCCGTC ACGTCGGAGC CGCCCGCGCT GCCCCCCAAG CCTCTGGCAG 2400 CGCGATCCAG CCACCTGGAG AATGGGGCCC GGAGGACTGA CCCCGGCCCG CGGCCCAGGC 2460 CCCTGCCCCG CAAGGTCTCT CAGTTATAAG TCACTTTTCT ATGTACCTGC GATGCATTCT 2520 TTGCCCGTTT ACAAAATAAG AAGTATGATG AGAAGACATT TAGTGTAGGC ACTTTAATAA 2580 CTTACTCAGC TCCTTCGATG AATGGAATTA AAACTTGCTT ATTAAATATC ATGTTGCACA 2640 ATATTAAAAG TTGCTGATCT AAAACGCCAG ATGTTAAATG AAGTATGGCT GAATTTCATT 2700 AAAACGTTTC TCATTTGGAA GTGGTAAATA GTGATAAAGA CTCCTTTTGT ACCTTTTTAT 2760 GTTCACTTTT TTTTATATAG TTTAATCTTA AAACCAATAC GATATTGTCA AACGATACAA 2820 TGTGTGACAA TGTTGTATCG TTTTTACTGA ATACTTGATA CTTGGAGAAA GCTTATTAAG 2880 TCAGTGCACA TCCTAACACA GTGGTCCTTA TTTTAGAAGA CTTCTGTAAA TAAGGCAAGG 2940 TTTATCAGTG CAGATCATCA GAATTAAAGT TCAAGCAGGC GAGCAAGACA GTATACTTAA 3000 GGGGTTGCAA AGCTTGGGAC TGGAAATTGT TTTGTTCTTG AAACAAAATA CTTCTTTAAG 3060 GTTGCTTTTG CTGTTTGACT GCTGTCTACA TTCGTAAAAT TCTATTTTGT GAATTGGTAG 3120 CTAAATCCCT TACTACCCTG ACACCGTGGT ATCTACTGTA TTTCTTTTCA AGGTGCAATT 3180 TGCTTCAGAG TTCCAATCAG CTAGATTAAG CAAGAGGCTC CAGAAGAAAT GTTTACTTGA 3240 ATTTTGCGCT TCCTTTCTTG ATAGTTTCCT ATATAAAATT TGTCATTGAA CAAGAGCAAA 3300 TGCTGAAGTA TTAATGAGGC ACAAATGACT GTGCCCCATT AGCAAGAATT CAGGAATCAA 3360 TACAGACAGT ATTAAATTAA TAGCTTAAGT GAAGAAAAAA AAAAACTTAG TGAAAATGTA 3420 TTAGCACGAT TAAATGGCAA AAGGACTTAT AAAAGGCAAG GGCATTAACT TTCAGTCCTG 3480 CACAAAATAA AAAATTCCTC ACGACTCTCC ACTTTTACCA GTGGAGTTTG TCTTAGCTGA 3540 CCTGTCGTCT TTCTCTTGAA GGAGGATTGC TGTAGACTTC TCTAGCTTGA ATATTGCAAC 3600 ATAGCATCTT AGGTCTAGAT AGGGATGCTA ATGCCAGTTG TAGAAGTGTG AAAAAAGCAC 3660 CTTGTATGTA GTAATGTATT TTATATCTTT GTTTTTTCTT TTACTGACTG TTTATAACAC 3720 TCAATTGACA ATAGATATGA ACTGTATTTT AAATCATACT GTTAAATATT TTCCCTCTTT 3780 TGTTGGGAAG CTCATTTTAG TTTAACCATG TTTGTTTTGT TGGTAGCTTA CCTGGAAGGC 3840 AGTGACCACT TTTTTATATT CTCTTAATGA AACCATTCAG CAGGTATATG CTGTTGAGGC 3900 TGGTTATAGA GGTTTTCTAT AATAAATGTT CAAGTATTTT TGTATATAAC TG0TTAATTT 3960 TAATAAGAGA TACCATTATG TGTAAAAAAA AGTAAAAATA AACGCAAACA GTTGTTGATG 4020 CAGTATGATT GTTATAATTA TGCCAAATAC TTTACGTATG GAAAAAGAAT ATTTGTACAT 4080 ATGTGCTTTT AACAATTCTG CCATATTGAC TTTACAATTT TGAATGTCGG AAAAATTAAT 4140 ATATGTTAAA TATTTATGTT TAGTGAAAGT GTTCATAATT GAGAAAAGGA ACATATGCAT 4200 TTTAGCTTTG TATCTTGCAA GTTTTGCAGT CAGAAATTTT TTGAACTAGC TTTTGCTTTT 4260 GATAACACTT CGTGTTTGTA ACCACATTCA TATATATATA CATATATATG TGAAGCTCCA 4320 TATTTCTGTT GCTTTAAAGA AGTAAAACCT TCCATTTAAA TAAGATGACA TGCATAAGAT 4380 AACAAAGCTT CCTTGATTTC CTTTTCCTGT GTAATTTAAT AGATTTGTTG ACTAGTGCTT 4440 GGGCACATTA TAAATCAGTG TTATTTGCTC TTGGAGCCAT TTTTTAAAAA AAATTTTGGC 4500 AGTGAGCAGT TGAATTTATC TTGAATTTAT CATGTGTGTG TATTTCTGAA GCAGCTACAT 4560 AGCAGAACAT TTTAAGAGAT TCTGTTAGCC CACATGTTCA TGTTGGTTGC TGCTGAATGG 4620 TAAATATTAA ATAAAATTAC CAGATTAATC TT

Seq ID NO: 61 Protein sequence: Protein Accession #: NP 055520

11 21 31 41 51

I I I I I

MAGKWRFINC YCNSSNGEW RLQNFYKTEL NKEEMYIRYI HKLYDLHLKA QNFTEAAYTL 60 LLYDELLEWS DRPLREFLTY PMQTEWQRKE HLHLTIIQNF DRGKCWENGI ILCRKIAEQY 120 ESYYDYRNLS KMRMMEASLY DKIMDQQRLE PEFFRVGFYG KKFPFFLRNK EFVCRGHDYE 180 RLEAFQQRML NEFPHAIAMQ HANQPDETIF QAEAQYLQIY AVTPIPESQE VLQREGVPDN 240 IKSFYKVNHI WKFRYDRPFH KGTKDKENEF KSLWVERTSL YLVQSLPGIS RWFEVEKREV 300 VEMSPLENAI EVLENKNQQL KTLISQCQTR QMQNINPLTM CLNGVIDAAV NGGVSRYQEA 360 FFVKEYILSH PEDGEKIARL RELMLEQAQI LEFGLAVHEK FVPQDMRPLH KKLVDQFFVM 420 KSSLGIQEFS ACMQASPVHF PNGSPRVCRN SAPASVSPDG TRVIPRRSPL SYPAVNRYSS 480 SSLSSQASAE VSNITGQSES SDEVFNMQPS PSTSSLSSTH SASPNVTSSA PSSARASPLL 540 SDKHKHSREN SCLSPRERPC SAIYPTPVEP SQRMLFNHIG DGALPRSDPN LSAPEKASPA 600 RHTTSVSPSP AGRSPLKGSV QSFTPSPVEY HSPGLISNSP VLSGSYSSGI SSLSRCSTSE 660 TSGFENQVNE QSAPLPVPVP VPVPSYGGEE PVRKESKTPP PYSVYERTLR RPVPLPHSLS 720 IPVTSEPPAL PPKPLAARSS HLENGARRTD PGPRPRPLPR KVSQL

Seq ID NO: 6 Nucleotide sequence:

Nucleic Acid Accession #: fgenesh prediction

Coding sequence: 1..2561 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

ATGGACCGAG GCCAGGGTAA GAGGGGCCGC GACGCCCGCA CTTGTTGCGG CGCCGGGCGG 60

GAAAGGGAGA CTGGACGATC TGAAGCCGGA GAGGAGGAGG GAGAGAGGCG GGCGGTGGGG 120

CGGGGGCTGA GGAACGCTCG GAGGGGACTG GGAGACGCGG CGCTTATGCA AAGGTGCCTT 180

CGGCTGCCGG GACAACCCGC CAGCAACCAG GTACAGCTCT CAGAGGTTCC ACAGAGGAAG 240

CTCAGGGTCC CTGAATCTCC CAGTGTGGCA GAGAAAGTGA AACTTGGTCA CCGATGCCTG 300 GAACTGCTGG AGCAGCTGCT CCCAGAGCTC ACCGGGCTGC TCAGCCTCCT GGACCACGAG 360 TACCTCAGCG ATACCACCCT GGAAAAGAAG ATGGCCGTGG CCTCCATCCT GCAGAGCCTG 420 CAGCCCCTTC CAGCAAAGGA GGTCTCCTAC CTGTATGTGA ACACAGCAGA CCTCCACTCG 480 GGGCCCAGCT TCGTGGAATC CCTCTTTGAA GAATTTGACT GTGACCTGAG TGACCTTCGG 540 GACATGCCAG AGGATGATGG GGAGCCCAGC AAAGGAGCCA GCCCTGAGCT AGCCAAGAGC 600 CCACGCCTGA GAAACGCGGC CGACCTGCCT CCACCGCTCC CCAACAAGCC TCCCCCTGAG 660 GACTACTATG AAGAGGCCCT TCCTCTGGGA CCCGGCAAGT CGCCTGAGTA CATCAGCTCC 720 CACAATGGCT GCAGCCCCTC ACACTCGATT GTGGATGGCT ACTATGAGGA CGCAGACAGC 780 AGCTACCCTG CAACCAGGGT GAACGGCGAG CTTAAGAGCT CCTATAATGA CTCTGACGCA 840 ATGAGCAGCT CCTATGAGTC CTACGATGAA GAGGAGGAGG AAGGGAAGAG CCCGCAGCCC 900 CGACACCAGT GGCCCTCAGA GGAGGCCTCC ATGCACCTGG TGAGGGAATG CAGGATATGT 960 GCCTTCCTGC TGCGGAAAAA GCGTTTCGGG CAGTGGGCCA AGCAGCTGAC GGTCATCAGG 1020 GAGGACCAGC TCCTGTGTTA CAAAAGCTCC AAGGATCGGC AGCCACATCT GAGGTTGGCA 1080 CTGGATACCT GCAGCATCAT CTACGTGCCC AAGGACAGCC GGCACAAGAG GCACGAGCTG 1140 CGTTTCACCC AGGGGGCTAC CGAGGTCTTG GTGCTGGCAC TGCAGAGCCG AGAGCAGGCC 1200 GAGGAGTGGC TGAAGGTCAT CCGAGAAGTG AGCAAGCCAG TTGGGGGAGC TGAGGGAGTG 1260 GAGGTCCCCA GATCCCCAGT CCTCCTGTGC AAGTTGGACC TGGACAAGAG GCTGTCCCAA 1320 GAGAAGCAGA CCTCAGATTC TGACAGCGTG GGTGTGGGTG ACAACTGTTC TACCCTTGGC 1380 CGCCGGGAGA CCTGTGATCA CGGCAAAGGG AAGAAGAGCA GCCTGGCAGA ACTGAAGGGC 1440 TCAATGAGCA GGGCTGCGGG CCGCAAGATC ACCCGTATCA TTGGCTTCTC CAAGAAGAAG 1500 ACACTGGCCG ATGACCTGCA GACGTCCTCC ACCGAGGAGG AGGTTCCCTG CTGTGGCTAC 1560 CTGAACGTGC TGGTGAACCA GGGCTGGAAG GAACGCTGGT GCCGCCTGAA GTGCAACACT 1620 CTGTATTTCC ACAAGGATCA CATGGACCTG CGAACCCATG TGAACGCCAT CGCCCTGCAA 1680 GGCTGTGAGG TGGCCCCGGG CTTTGGGCCC CGACACCCAT TTGCCTTCAG GATCCTGCGC 1740 AACCGGCAGG AGGTGGCCAT CTTGGAGGCA AGCTGTTCAG AGGACATGGG TCGCTGGCTC 1800 GGGCTGCTGC TGGTGGAGAT GGGCTCCAGA GTCACTCCGG AGGCGCTGCA CTATGACTAC 1860 GTGGATGTGG AGACCTTAAC CAGCATCGTC AGTGCTGGGC GCAACTCCTT CCTATATGCA 1920 AGATCCTGCC AGAATCAGTG GCCTGAGCCC CGAGTCTATG ATGATGTTCC TTATGAAAAG 1980 ATGCAGGACG AGGAGCCCGA GCGCCCCACA GGGGCCCAGG TGAAGCGTCA CGCCTCCTCC 2040 TGCAGTGAGA AGTCCCATCG TGTGGACCCG CAGGTCAAAG TCAAACGCCA CGCCTCCAGT 2100 GCCAATCAAT ACAAGTATGG CAAGAACCGA GCCGAGGAGG ATGCCCGGAG GTACTTGGTA 2160 GAAAAAGAGA AGCTGGAGAA AGAGAAAGAG ACGATTCGGA CAGAGCTGAT AGCACTGAGA 2220 CAGGAGAAGA GGGAACTGAA GGAAGCCATT CGGAGCAGCC CAGGAGCAAA ATTAAAGGCT 2280 CTGGAAGAAG CCGTGGCCAC CCTGGAAGCT CAGTGTCGGG CAAAGGAGGA GCGCCGGATT 2340 GACCTGGAGC TGAAGCTGGT GGCTGTGAAG GAGCGCTTGC AGCAGTCCCT GGCAGGAGGG 2400 CCAGCCCTGG GGCTCTCCGT GAGCAGCAAG CCCAAGAGTG GGCAACTCTC TGAGGAAGAT 2460 ACGCTCACCT CCAATGGTGC TCTCTCAGAG AGAACTTCTC TGACCTCATC TACACCAGGG 2520 CTTCTCAACC CCAACACTAC TGACATTTTG GACCAGTAA

Seq ID NO: 63 Protein sequence:

Protein Accession #: fgenesh prediction

11 21 31 41 51

MDRGQGKRGR DARTCCGAGR ERETGRSEAG EEEGERRAVG RGLRNARRGL GDAALMQRCL 60 RLPGQPASNQ VQLSEVPQRK LRVPESPSVA EKVKLGHRCL ELLEQLLPEL TGLLSLLDHE 120 YLSDTTLEKK MAVASILQSL QPLPAKEVSY LYVNTADLHS GPSFVESLFE EFDCDLSDLR 180 DMPEDDGEPS KGASPELAKS PRLRNAADLP PPLPNKPPPE DYYEEALPLG PGKSPEYISS 240 HNGCSPSHSI VDGYYEDADS SYPATRVNGE LKSSYNDSDA MSSSYESYDE EEEEGKSPQP 300 RHQWPSEEAS MHLVRECRIC AFLLRKKRFG QWAKQLTVIR EDQLLCYKSS KDRQPHLRLA 360 LDTCSIIYVP KDSRHKRHEL RFTQGATEVL VLALQSREQA EEWLKVIREV SKPVGGAEGV 420 EVPRSPVLLC KLDLDKRLSQ EKQTSDSDSV GVGDNCSTLG RRETCDHGKG KKSSLAELKG 480 SMSRAAGRKI TRIIGFSKKK TLADDLQTSS TEEEVPCCGY LNVLVNQGWK ERWCRLKCNT 540 LYFHKDHMDL RTHVNAIALQ GCEVAPGFGP RHPFAFRILR NRQEVAILEA SCSEDMGRWL 600 GLLLVEMGSR VTPEALHYDY VDVETLTSIV SAGRNSFLYA RSCQNQWPEP RVYDDVPYEK 660 MQDEEPERPT GAQVKRHASS CSEKSHRVDP QVKVKRHASS ANQYKYGKNR AEEDARRYLV 720 EKEKLEKEKE TIRTELIALR QEKRELKEAI RSSPGAKLKA LEEAVATLEA QCRAKEERRI 780 DLELKLVAVK ERLQQSLAGG PALGLSVSSK PKSGQLSEED TLTSNGALSE RTSLTSSTPG 840 LLNPNTTDIL DQ

Seq ID NO: 64 Nucleotide sequence: Nucleic Acid Accession #: NM_004126.1 Coding sequence: 108-129 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

I I I I

GGCACGAGCT C 1GTGCCGGCC TTCAGTTGTT TCGGGACGCG CCGAGCTTCG CCGCTCTTCC 60 AGCGGCTCCG CTGCCAGAGC TAGCCCGAGC CCGGTTCTGG GGCGAAAATG CCTGCCCTTC 120 ACATCGAAGA TTTGCCAGAG AAGGAAAAAC TGAAAATGGA AGTTGAGCAG CTTCGCAAAG 180 AAGTGAAGTT GCAGAGACAA CAAGTGTCTA AATGTTCTGA AGAAATAAAG AACTATATTG 240 AAGAACGTTC TGGAGAGGAT CCTCTAGTAA AGGGAATTCC AGAAGACAAG AACCCCTTTA 300 AAGAAAAAGG CAGCTGTGTT ATTTCATAAA TAACTTGGGA GAAACTGCAT CCTAAGTGGA 360 AGAACTAGTT TGTTTTAGTT TTCCCAGATA AAACCAACAT GCTTTTTAAG GAAGGAAGAA 420 TGAAATTAAA AGGAGACTTT CTTAAGCACC ATATAGATAG GGTTATGTAT AAAAGCATAT 480

GTGCTACTCA TCTTTGCTCA CTATGCAGTC TTTTTTAAGA GAGCAGAGAG TATCAGATGT 540

ACAATTATGG AAATAAGAAC ATTACTTGAG CATGACACTT CTTTCAGTAT ATTGCTTGAT 600 GCTTCAAATA AAGTTTTGTC TT

5

Seq ID NO : 65 Protein sequence : Protein Accession # : NP_004117

10 1 11 21 31 41 51

I I 1 I I I

MPALHIEDLP EKEKLKMEVE QLRKEVKLQR QQVSKCSEEI KNYIEERSGE DPLVKGIPED 60 KNPFKEKGSC VIS

15

Seq ID NO: 66 Nucleotide sequence:

Nucleic Acid Accession #: NM_003842.l

Coding sequence: 1-1236 (underlined sequences correspond to start and stop codons)

20

1 11 21 31 41 51

ATGGAACAAC GGGGACAGAA CGCCCCGGCC GCTTCGGGGG CCCGGAAAAG GCACGGCCCA 60

GGACCCAGGG AGGCGCGGGG AGCCAGGCCT GGGCCCCGGG TCCCCAAGAC CCTTGTGCTC 120

25 GTTGTCGCCG CGGTCCTGCT GTTGGTCTCA GCTGAGTCTG CTCTGATCAC CCAACAAGAC 180

CTAGCTCCCC AGCAGAGAGC GGCCCCACAA CAAAAGAGGT CCAGCCCCTC AGAGGGATTG 240

TGTCCACCTG GACACCATAT CTCAGAAGAC GGTAGAGATT GCATCTCCTG CAAATATGGA 300

CAGGACTATA GCACTCACTG GAATGACCTC CTTTTCTGCT TGCGCTGCAC CAGGTGTGAT 360

TCAGGTGAAG TGGAGCTAAG TCCCTGCACC ACGACCAGAA ACACAGTGTG TCAGTGCGAA 420

30 GAAGGCACCT TCCGGGAAGA AGATTCTCCT GAGATGTGCC GGAAGTGCCG CACAGGGTGT 480

CCCAGAGGGA TGGTCAAGGT CGGTGATTGT ACACCCTGGA GTGACATCGA ATGTGTCCAC 540

AAAGAATCAG GCATCATCAT AGGAGTCACA GTTGCAGCCG TAGTCTTGAT TGTGGCTGTG 600

TTTGTTTGCA AGTCTTTACT GTGGAAGAAA GTCCTTCCTT ACCTGAAAGG CATCTGCTCA 660

GGTGGTGGTG GGGACCCTGA GCGTGTGGAC AGAAGCTCAC AACGACCTGG GGCTGAGGAC 720

351 AATGTCCTCA ATGAGATCGT GAGTATCTTG CAGCCCACCC AGGTCCCTGA GCAGGAAATG 780

GAAGTCCAGG AGCCAGCAGA GCCAACAGGT GTCAACATGT TGTCCCCCGG GGAGTCAGAG 840

CATCTGCTGG AACCGGCAGA AGCTGAAAGG TCTCAGAGGA GGAGGCTGCT GGTTCCAGCA 900

AATGAAGGTG ATCCCACTGA GACTCTGAGA CAGTGCTTCG ATGACTTTGC AGACTTGGTG 960

CCCTTTGACT CCTGGGAGCC GCTCATGAGG AAGTTGGGCC TCATGGACAA TGAGATAAAG 1020

40 GTGGCTAAAG CTGAGGCAGC GGGCCACAGG GACACCTTGT ACACGATGCT GATAAAGTGG 1080

GTCAACAAAA CCGGGCGAGA TGCCTCTGTC CACACCCTGC TGGATGCCTT GGAGACGCTG 1140

GGAGAGAGAC TTGCCAAGCA GAAGATTGAG GACCACTTGT TGAGCTCTGG AAAGTTCATG 1200 TATCTAGAAG GTAATGCAGA CTCTGCCATG TCCTAA

45 Seq ID NO : 67 Protein sequence :

Protein Accession # : NP_003833 . 1

1 11 21 31 41 51

,„ I I I I I I

OU MEQRGQNAPA ASGARKRHGP GPREARGARP GPRVPKTLVL WAAVLLLVS AESALITQQD 60

LAPQQRAAPQ QKRSSPSEGL CPPGHHISED GRDCISCKYG QDYSTHWNDL LFCLRCTRCD 120

SGEVELSPCT TTRNTVCQCE EGTFREEDSP EMCRKCRTGC PRGMVKVGDC TPWSDIECVH 180

KESGIIIGVT VAAWLIVAV FVCKSLLWKK VLPYLKGICS GGGGDPERVD RSSQRPGAED 240

NVLNEIVSIL QPTQVPEQEM EVQEPAEPTG VNMLSPGESE HLLEPAEAER SQRRRLLVPA 300

55 NEGDPTETLR QCFDDFADLV PFDSWEPLMR KLGLMDNEIK VAKAEAAGHR DTLYTMLIKW 360 VNKTGRDASV HTLLDALETL GERLAKQKIE DHLLSSGKFM YLEGNADSAM S

Seq ID NO : 68 Nucleotide sequence : Nucleic Acid Accession # : FGENESH predicted ORF 60 Coding sequence : 361- 2220 (underlined sequences correspond to start and stop codons)

1 11 21 31 41 51

I I I I I I

GGCACCATCT GCTCCCTGCC CTGCCCAGAG GGCTTTCACG GACCCAACTG CTCCCAGGAA 60

65 TGTCGCTGCC ACAACGGCGG CCTCTGTGAC CGATTCACTG GGCAGTGCCG CTGCGCTCCG 120

GGTTACACTG GGGATCGGTG CCGGGAGGAG TGCCCGGTGG GCCGCTTTGG GCAGGACTGT 180

GCTGAGACGT GCGACTGCGC CCCGGACGCC CGTTGCTTCC CGGCCAACGG CGCATGTCTG 240

TGCGAACACG GCTTCACTGG GGACCGCTGC ACGGATCGCC TCTGCCCCGA CGGCTTCTAC 300

GGTCTCAGCT GCCAGGCCCC CTGCACCTGC GACCGGGAGC ACAGCCTCAG CTGCCACCCG 360

70 ATGAACGGGG AGTGCTCCTG CCTGCCGGGC TGGGCGGGCC TCCACTGCAA CGAGAGCTGC 420

CCGCAGGACA CGCATGGGCC AGGGTGCCAG GAGCACTGTC TCTGCCTGCA CGGTGGCGTC 480

TGCCAGGCTA CCAGCGGCCT CTGTCAGTGC GCGCCGGGTT ACACGGGCCC TCACTGTGCT 540

AGTCTTTGTC CTCCTGACAC CTACGGTGTC AACTGTTCTG CACGCTGCTC ATGTGAAAAT 600

GCCATCGCCT GCTCACCCAT CGACGGCGAG TGCGTCTGCA AGGAAGGTTG GCAGCGTGGT 660

75 AACTGCTCTG TGCCCTGCCC ACCCGGAACC TGGGGCTTCA GTTGCAATGC CAGCTGCCAG 720

TGTGCCCATG AGGCAGTCTG CAGCCCCCAA ACTGGAGCCT GTACCTGCAC CCCTGGGTGG 780 CATGGGGCCC ACTGCCAGCT GCCCTGTCCG AAGGGGCAGT TTGGAGAAGG TTGTGCCAGT 840 CGCTGTGACT GTGACCACTC TGATGGCTGT GACCCTGTTC ATGGACGCTG TCAGTGCCAG 900 GCTGGCTGGA TGGGTGCCCG CTGCCACCTG TCCTGCCCTG AGGGCTTATG GGGAGTCAAC 960 TGTAGCAACA CCTGCACCTG CAAGAATGGG GGCACCTGTC TCCCTGAGAA TGGCAACTGC 1020 GTGTGTGCAC CCGGATTCCG GGGCCCCTCC TGCCAGAGAT CCTGTCAGCC TGGCCGCTAT 1080 GGCAAACGCT GTGTGCCCTG CAAGTGCGCT AACCACTCCT TCTGCCACCC CTCGAACGGG 1140 ACCTGCTACT GCCTGGCTGG CTGGACAGGC CCCGACTGCT CCCAGCGCTG CCCTCTGGGG 1200 ACATTTGGTG CTAACTGCTC CCAGCCATGC CAGTGTGGTC CTGGAGAAAA GTGCCACCCA 1260 GAGACTGGGG CCTGTGTATG TCCCCCAGGG CACAGTGGTG CACCTTGCAG GATTGGAATC 1320 CAGGAGCCCT TTACTGTGAT GCCGACCACT CCAGTAGCGT ATAACTCGCT GGGTGCAGTG 1380 ATTGGCATTG CAGTGCTGGG GTCCCTTGTG GTAGCCCTGG TGGCACTGTT CATTGGCTAT 1440 CGGCACTGGC AAAAAGGCAA GGAGCACCAC CACCTGGCTG TGGCTTACAG CAGCGGGCGC 1500 CTGGACGGCT CCGAGTATGT CATGCCAGAT GTCCCTCCGA GCTACAGTCA CTACTACTCC 1560 AACCCCAGCT ACCACACCCT GTCGCAGTGC TCCCCAAACC CCCCACCCCC TAACAAGGTT 1620 CCAGGCCCGC TCTTTGCCAG CCTGCAGAAC CCTGAGCGGC CAGGTGGGGC CCAAGGGCAT 1680 GATAACCACA CCACCCTGCC TGCTGACTGG AAGCACCGCC GGGAGCCCCC TCCAGGGCCT 1740 CTGGACAGGG GGAGCAGCCG CCTGGACCGA AGCTACAGCT ATAGCTACAG CAATGGCCCA 1800 GGCCCATTCT ACAATAAAGG GCTCATCTCT GAAGAGGAGC TCGGGGCCAG TGTGGCTTCC 1860 GTGAGGAGTG AGAACCCATA TGCCACCATC CGGGACCTGC CCAGCTTGCC AGGGGGCCCC 1920 CGGGAGAGCA GCTACATGGA GATGAAAGGC CCTCCCTCAG GATCTCCCCC CAGGCAGCCT 1980 CCTCAGTTCT GGGACAGCCA GAGGCGGCGG CAACCCCAGC CACAGAGAGA CAGTGGCACC 2040 TACGAGCAGC CCAGCCCCCT GATCCATGAC CGAGACTCTG TGGGCTCCCA GCCCCCTCTG 2100 CCTCCGGGCC TACCCCCCGG CCACTATGAC TCACCCAAGA ACAGCCACAT CCCTGGACAT 2160 TATGACTTGC CTCCAGTACG GCATCCCCCA TCACCTCCAC TTCGACGCCA GGACCGTTGA

Seq ID NO: 69 Protein sequence:

Protein Accession # : FGENESH prediction

11 21 31 41 51

GTICSLPCPE GFHGPNCSQE CRCHNGGLCD RFTGQCRCAP GYTGDRCREE CPVGRFGQDC 60 AETCDCAPDA RCFPANGACL CEHGFTGDRC TDRLCPDGFY GLSCQAPCTC DREHSLSCHP 120 MNGECSCLPG WAGLHCNESC PQDTHGPGCQ EHCLCLHGGV CQATSGLCQC APGYTGPHCA 180 SLCPPDTYGV NCSARCSCEN AIACSPIDGE CVCKEGWQRG NCSVPCPPGT WGFSCNASCQ 240 CAHEAVCSPQ TGACTCTPGW HGAHCQLPCP KGQFGEGCAS RCDCDHSDGC DPVHGRCQCQ 300 AGWMGARCHL SCPEGLWGVN CSNTCTCKNG GTCLPENGNC VCAPGFRGPS CQRSCQPGRY 360 GKRCVPCKCA NHSFCHPSNG TCYCLAGWTG PDCSQRCPLG TFGANCSQPC QCGPGEKCHP 420 ETGACVCPPG HSGAPCRIGI QEPFTVMPTT PVAYNSLGAV IGIAVLGSLV VALVALFIGY 480 RHWQKGKEHH HLAVAYSSGR LDGSEYVMPD VPPSYSHYYS NPSYHTLSQC SPNPPPPNKV 540 PGPLFASLQN PERPGGAQGH DNHTTLPADW KHRREPPPGP LDRGSSRLDR SYSYSYSNGP 600 GPFYNKGLIS EEELGASVAS LSSENPYATI RDLPSLPGGP RESSYMEMKG PPSGSPPRQP 660 PQFWDSQRRR QPQPQRDSGT YEQPSPLIHD RDSVGSQPPL PPGLPPGHYD SPKNSHIPGH 720 YDLPPVRHPP SPPLRRQDR

Seq ID NO: 70 Nucleotide sequence:

Nucleic Acid Accession #: NM_005458

Coding sequence: 1..2826 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

ATGGCTTCCC CGCGGAGGTC CGGGCAGCCA GGGCGGCCGC CGCCGCCGCC ACCGCCGCCC 60 GCGCGCCTGC TACTGCTACT GCTGCTGCCG CTGCTGCTGC CTCTGGCGCC CGGGGCCTGG 120 GGCTGGGCGC GGGGCGCCCC CCGGCCGCCG CCCAGCAGCC CGCCGCTCTC CATCATGGGC 180 CTCATGCCGC TCACCAAGGA GGTGGCCAAG GGCAGCATCG GGCGCGGTGT GCTCCCCGCC 240 GTGGAACTGG CCATCGAGCA GATCCGCAAC GAGTCACTCC TGCGCCCCTA CTTCCTCGAC 300 CTGCGGCTCT ATGACACGGA GTGCGACAAC GCAAAAGGGT TGAAAGCCTT CTACGATGCA 360 ATAAAATACG GGCCGAACCA CTTGATGGTG TTTGGAGGCG TCTGTCCATC CGTCACATCC 420 ATCATTGCAG AGTCCCTCCA AGGCTGGAAT CTGGTGCAGC TTTCTTTTGC TGCAACCACG 480 CCTGTTCTAG CCGATAAGAA AAAATACCCT TATTTCTTTC GGACCGTCCC ATCAGACAAT 540 GCGGTGAATC CAGCCATTCT GAAGTTGCTC AAGCACTACC AGTGGAAGCG CGTGGGCACG 600 CTGACGCAAG ACGTTCAGAG GTTCTCTGAG GTGCGGAATG ACCTGACTGG AGTTCTGTAT 660 GGCGAGGACA TTGAGATTTC AGACACCGAG AGCTTCTCCA ACGATCCCTG TACCAGTGTC 720 AAAAAGCTGA AGGGGAATGA TGTGCGGATC ATCCTTGGCC AGTTTGACCA GAATATGGCA 780 GCAAAAGTGT TCTGTTGTGC ATACGAGGAG AACATGTATG GTAGTAAATA TCAGTGGATC 840 ATTCCGGGCT GGTACGAGCC TTCTTGGTGG GAGCAGGTGC ACACGGAAGC CAACTCATCC 900 CGCTGCCTCC GGAAGAATCT GCTTGCTGCC ATGGAGGGCT ACATTGGCGT GGATTTCGAG 960 CCCCTGAGCT CCAAGCAGAT CAAGACCATC TCAGGAAAGA CTCCACAGCA GTATGAGAGA 1020 GAGTACAACA ACAAGCGGTC AGGCGTGGGG CCCAGCAAGT TCCACGGGTA CGCCTACGAT 1080 GGCATCTGGG TCATCGCCAA GACACTGCAG AGGGCCATGG AGACACTGCA TGCCAGCAGC 1140 CGGCACCAGC GGATCCAGGA CTTCAACTAC ACGGACCACA CGCTGGGCAG GATCATCCTC 1200 AATGCCATGA ACGAGACCAA CTTCTTCGGG GTCACGGGTC AAGTTGTATT CCGGAATGGG 1260 GAGAGAATGG GGACCATTAA ATTTACTCAA TTTCAAGACA GCAGGGAGGT GAAGGTGGGA 1320 GAGTACAACG CTGTGGCCGA CACACTGGAG ATCATCAATG ACACCATCAG GTTCCAAGGA 1380 TCCGAACCAC CAAAAGACAA GACCATCATC CTGGAGCAGC TGCGGAAGAT CTCCCTACCT 1440 CTCTACAGCA TCCTCTCTGC CCTCACCATC CTCGGGATGA TCATGGCCAG TGCTTTTCTC 1500 TTCTTCAACA TCAAGAACCG GAATCAGAAG CTCATAAAGA TGTCGAGTCC ATACATGAAC 1560 AACCTTATCA TCCTTGGAGG GATGCTCTCC TATGCTTCCA TATTTCTCTT TGGCCTTGAT 1620 GGATCCTTTG TCTCTGAAAA GACCTTTGAA ACACTTTGCA CCGTCAGGAC CTGGATTCTC 1680 ACCGTGGGCT ACACGACCGC TTTTGGGGCC ATGTTTGCAA AGACCTGGAG AGTCCACGCC 1740 ATCTTCAAAA ATGTGAAAAT GAAGAAGAAG ATCATCAAGG ACCAGAAACT GCTTGTGATC 1800 GTGGGGGGCA TGCTGCTGAT CGACCTGTGT ATCCTGATCT GCTGGCAGGC TGTGGACCCC 1860 CTGCGAAGGA CAGTGGAGAA GTACAGCATG GAGCCGGACC CAGCAGGACG GGATATCTCC 1920 ATCCGCCCTC TCCTGGAGCA CTGTGAGAAC ACCCATATGA CCATCTGGCT TGGCATCGTC 1980 TATGCCTACA AGGGACTTCT CATGTTGTTC GGTTGTTTCT TAGCTTGGGA GACCCGCAAC 2040 GTCAGCATCC CCGCACTCAA CGACAGCAAG TACATCGGGA TGAGTGTCTA CAACGTGGGG 2100 ATCATGTGCA TCATCGGGGC CGCTGTCTCC TTCCTGACCC GGGACCAGCC CAATGTGCAG 2160 TTCTGCATCG TGGCTCTGGT CATCATCTTC TGCAGCACCA TCACCCTCTG CCTGGTATTC 2220 GTGCCGAAGC TCATCACCCT GAGAACAAAC CCAGATGCAG CAACGCAGAA CAGGCGATTC 2280 CAGTTCACTC AGAATCAGAA GAAAGAAGAT TCTAAAACGT CCACCTCGGT CACCAGTGTG 2340 AACCAAGCCA GCACATCCCG CCTGGAGGGC CTACAGTCAG AAAACCATCG CCTGCGAATG 2400 AAGATCACAG AGCTGGATAA AGACTTGGAA GAGGTCACCA TGCAGCTGCA GGACACACCA 2460 GAAAAGACCA CCTACATTAA ACAGAACCAC TACCAAGAGC TCAATGACAT CCTCAACCTG 2520 GGAAACTTCA CTGAGAGCAC AGATGGAGGA AAGGCCATTT TAAAAAATCA CCTCGATCAA 2580 AATCCCCAGC TACAGTGGAA CACAACAGAG CCCTCTCGAA CATGCAAAGA TCCTATAGAA 2640 GATATAAACT CTCCAGAACA CATCCAGCGT CGGCTGTCCC TCCAGCTCCC CATCCTCCAC 2700 CACGCCTACC TCCCATCCAT CGGAGGCGTG GACGCCAGCT GTGTCAGCCC CTGCGTCAGC 2760 CCCACCGCCA GCCCCCGCCA CAGACATGTG CCACCCTCCT TCCGAGTCAT GGTCTCGGGC 2820 CTGTAA

Seq ID NO : 71 Protein sequence : Protein Accession # : NP 005449

11 21 31 41 51

MASPRRSGQP GRPPPPPPPP ARLLLLLLLP LLLPLAPGAW GWARGAPRPP PSSPPLSIMG 60 LMPLTKEVAK GSIGRGVLPA VELAIEQIRN ESLLRPYFLD LRLYDTECDN AKGLKAFYDA 120 IKYGPNHLMV FGGVCPSVTS IIAESLQGWN LVQLSFAATT PVLADKKKYP YFFRTVPSDN 180 AVNPAILKLL KHYQWKRVGT LTQDVQRFSE VRNDLTGVLY GEDIEISDTE SFSNDPCTSV 240 KKLKGNDVRI ILGQFDQNMA AKVFCCAYEE NMYGSKYQWI IPGWYEPSWW EQVHTEANSS 300 RCLRKNLLAA MEGYIGVDFE PLSSKQIKTI SGKTPQQYER EYNNKRSGVG PSKFHGYAYD 360 GIWVIAKTLQ RAMETLHASS RHQRIQDFNY TDHTLGRIIL NAMNETNFFG VTGQWFRNG 420 ERMGTIKFTQ FQDSREVKVG EYNAVADTLE IINDTIRFQG SEPPKDKTII LEQLRKISLP 480 LYSILSALTI LGMIMASAFL FFNIKNRNQK LIKMSSPYMN NLIILGGMLS YASIFLFGLD 540 GSFVSEKTFE TLCTVRTWIL TVGYTTAFGA MFAKTWRVHA IFKNVKMKKK IIKDQKLLVI 600 VGGMLLIDLC ILICWQAVDP LRRTVEKYSM EPDPAGRDIS IRPLLEHCEN THMTIWLGIV 660 YAYKGLLMLF GCFLAWETRN VSIPALNDSK YIGMSVYNVG IMCIIGAAVS FLTRDQPNVQ 720 FCIVALVIIF CSTITLCLVF VPKLITLRTN PDAATQNRRF QFTQNQKKED SKTSTSVTSV 780 NQASTSRLEG LQSENHRLRM KITELDKDLE EVTMQLQDTP EKTTYIKQNH YQELNDILNL 840 GNFTESTDGG KAILKNHLDQ NPQLQWNTTE PSRTCKDPIE DINSPEHIQR RLSLQLPILH 900 HAYLPSIGGV DASCVSPCVS PTASPRHRHV PPSFRVMVSG L

Seq ID NO: 72 Nucleotide sequence : Nucleic Acid Accession #: NM_005795

Coding sequence: 522-1940 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

I I I I I

GCACGAGGGA ACAACCTCTC TCTCTSCAGC AGAGAGTGTC ACCTCCTGCT TTAGGACCAT 60 CAAGCTCTGC TAACTGAATC TCATCCTAAT TGCAGGATCA CATTGCAAAG CTTTCACTCT 120 TTCCCACCTT GCTTGTGGGT AAATCTCTTC TGCGGAATCT CAGAAAGTAA AGTTCCATCC 180 TGAGAATATT TCACAAAGAA TTTCCTTAAG AGCTGGACTG GGTCTTGACC CCTGGAATTT 240 AAGAAATTCT TAAAGACAAT GTCAAATATG ATCCAAGAGA AAATGTGATT TGAGTCTGGA 300 GACAATTGTG CATATCGTCT AATAATAAAA ACCCATACTA GCCTATAGAA AACAATATTT 360 GAATAATAAA AACCCATACT AGCCTATAGA AAACAATATT TGAAAGATTG CTACCACTAA 420 AAAGAAAACT ACTACAACTT GACAAGACTG CTGCAAACTT CAATTGGTCA CCACAACTTG 480 ACAAGGTTGC TATAAAACAA GATTGCTACA ACTTCTAGTT TATGTTATAC AGCATATTTC 540 ATTTGGGCTT AATGATGGAG AAAAAGTGTA CCCTGTATTT TCTGGTTCTC TTGCCTTTTT 600 TTATGATTCT TGTTACAGCA GAATTAGAAG AGAGTCCTGA GGACTCAATT CAGTTGGGAG 660 TTACTAGAAA TAAAATCATG ACAGCTCAAT ATGAATGTTA CCAAAAGATT ATGCAAGACC 720 CCATTCAACA AGCAGAAGGC GTTTACTGCA ACAGAACCTG GGATGGATGG CTCTGCTGGA 780 ACGATGTTGC AGCAGGAACT GAATCAATGC AGCTCTGCCC TGATTACTTT CAGGACTTTG 840 ATCCATCAGA AAAAGTTACA AAGATCTGTG ACCAAGATGG AAACTGGTTT AGACATCCAG 900 CAAGCAACAG AACATGGACA AATTATACCC AGTGTAATGT TAACACCCAC GAGAAAGTGA 960 AGACTGCACT AAATTTGTTT TACCTGACCA TAATTGGACA CGGATTGTCT ATTGCATCAC 1020 TGCTTATCTC GCTTGGCATA TTCTTTTATT TCAAGAGCCT AAGTTGCCAA AGGATTACCT 1080 TACACAAAAA TCTGTTCTTC TCATTTGTTT GTAACTCTGT TGTAACAATC ATTCACCTCA 1140 CTGCAGTGGC CAACAACCAG GCCTTAGTAG CCACAAATCC TGTTAGTTGC AAAGTGTCCC 1200 AGTTCATTCA TCTTTACCTG ATGGGCTGTA ATTACTTTTG GATGCTCTGT GAAGGCATTT 1260 ACCTACACAC ACTCATTGTG GTGGCCGTGT TTGCAGAGAA GCAACATTTA ATGTGGTATT 1320 ATTTTCTTGG CTGGGGATTT CCACTGATTC CTGCTTGTAT ACATGCCATT GCTAGAAGCT 1380 TATATTACAA TGACAATTGC TGGATCAGTT CTGATACCCA TCTCCTCTAC ATTATCCATG 1440 GCCCAATTTG TGCTGCTTTA CTGGTGAATC TTTTTTTCTT GTTAAATATT GTACGCGTTC 1500 TCATCACCAA GTTAAAAGTT ACACACCAAG CGGAATCCAA TCTGTACATG AAAGCTGTGA 1560 GAGCTACTCT TATCTTGGTG CCATTGCTTG GCATTGAATT TGTGCTGATT CCATGGCGAC 1620 CTGAAGGAAA GATTGCAGAG GAGGTATATG ACTACATCAT GCACATCCTT ATGCACTTCC 1680 AGGGTCTTTT GGTCTCTACC ATTTTCTGCT TCTTTAATGG AGAGGTTCAA GCAATTCTGA 1740 GAAGAAACTG GAATCAATAC AAAATCCAAT TTGGAAACAG CTTTTCCAAC TCAGAAGCTC 1800 TTCGTAGTGC GTCTTACACA GTGTCAACAA TCAGTGATGG TCCAGGTTAT AGTCATGACT 1860 GTCCTAGTGA ACACTTAAAT GGAAAAAGCA TCCATGATAT TGAAAATGTT CTCTTAAAAC 1920 CAGAAAATTT ATATAATTGA AAATAGAAGG ATGGTTGTCT CACTGTTTGG TGCTTCTCCT 1980 AACTCAAGGA CTTGGACCCA TGACTCTGTA GCCAGAAGAC TTCAATATTA AATGACTTTG 2040 GGGAATGTCA TAAAGAAGAG CCTTCACATG AAATTAGTAG TGTGTTGATA AGAGTGTAAC 2100 ATCCAGCTCT ATGTGGGAAA AAAGAAATCC TGGTTTGTAA TGTTTGTCAG TAAATACTCC 2160 CACTATGCCT GATGTGACGC TACTAACCTG ACATCACCAA GTGTGGAATT GGAGAAAAGC 2220 ACAATCAACT TTTCTGAGCT GGTGTAAGCC AGTTCCAGCA CACCATTGAT GAATTCAAAC 2280 AAATGGCTGT AAAACTAAAC ATACATGTTG GGCATGATTC TACCCTTATT CSCCCCAAGA 2340 GACCTAGCTA AGGTCTATAA ACATGAAGGG AAAATTAGCT TTTAGTTTTA AAACTCTTTA 2400 TCCCATCTTG ATTGGGGCAG TTGACTTTTT TTTTTTCCCA GAGTGCCGTA GTCCTTTTTG 2460 TAACTACCCT CTCAAATGGA CAATACCAGA AGTGAATTAT CCCTGCTGGC TTTCTTTTCT 2520 CTATGAAAAG CAACTGAGTA CAATTGTTAT GATCTACTCA TTTGCTGACA CATCAGTTAT 2580 ATCTTGTGGC ATATCCATTG TGGAAACTGG ATGAACAGGA TGTATAATAT GCAATCTTAC 2640 TTCTATATCA TTAGGAAAAC ATCTTAGTTG ATGCTACAAA ACACCTTGTC AACCTCTTCC 2700 TGTCTTACCA AACAGTGGGA GGGAATTCCT AGCTGTAAAT ATAAATTTTG TCCCTTCCAT 2760 TTCTACTGTA TAAACAAATT AGCAATCATT TTATATAAAG AAAATCAATG AAGGATTTCT 2820 TATTTTCTTG GAATTTTGTA AAAAGAAATT GTGAAAAATG AGCTTGTAAA TACTCCATTA 2880 TTTTATTTTA TAGTCTCAAA TCAAATACAT ACAACCTATG TAATTTTTAA AGCAAATATA 2940 TAATGCAACA ATGTGTGTAT GTTAATATCT GATACTGTAT CTGGGCTGAT TTTTTAAATA 3000 AAATAGAGTC TGGAATGCTA TATTTGGTAA ATATTTTAAA GACAACCAGA TGCCAGCATC 3060 AGAAGTCTGT TTGAGAACTA AGAGAACAGA AACATCTATC ATAAGATATA TTTATTTTAA 3120 AAACACAAGG TCACTATTTT ACTGAATATA TTTGTTTTGA TAACTCATAC CTTAATAATA 3180 GGTGTGTTTG ACATATTTCT TTTTTCATTT TGACAATGAA CTCACATTCT AATCCAGAAA 3240 TTTTAAACAA CTACTGTGAT AAATACCAAT CTGCTACTTT TATAGATTTT ACCCCATTAA 3300 AATATTACTT TACTGACTTT TACTATGTGA AGATATATAG CTTTGGAAAT GTCCCAGGCT 3360 ATTCAAGAAA TATAAAAAAC TAGAAGGATA CTATATATAC CATATACAAT GCTTTAATAT 3420 TTTAATAGAG CTACTGTATA TAATACAAAT TAGGGAAATA CTTGAATATA TCATTGAGAA 3480 AAAATTATTG TCAGATCTTA CTGAATTATT GTCAGACTTT ATTAAATAAA GATAGAAGAA 3540 AACCTTGCTA ATGAATTAAA GTGAAATTTG CATGGGATTC AGTTTCTCTA ATGTTATTTT 3600 CCGCTGAAAT CTCTAAAGAA CAAGAATGAC TTCAATTAGT AAAAGTCAAT TTTGGGAAAA 3660 GTCATGGGTA TCTGTTTTTT AAGTGTGTCA ATCTGATTAA AATGGATGAA ACAAATTACT 3720 CATCATAAGT TGTTTCTTAA GCTGTCAATA TGTCAATAGA TGGTGAGTTC AGAACTTATT 3780 TCAAATTGCT AAGACAAATT ATCTAAATTC GTAAGAATTA ACATATAGAA TGGTCTGGTC 3840 AGTACATTTA TAATTTATCT ATGCATGAAA AAGTATTGTT TTGTTTGAAA CATGAATTTC 3900 ATAGCAAGCT GCCATAGAAA GGA

Seq ID NO: 73 Protein sequence: Protein Accession #: NM 005795

11 21 31 41 51

MLYSIFHLGL MMEKKCTLYF LVLLPFFMIL VTAELEESPE DSIQLGVTRN KIMTAQYECY 60 QKIMQDPIQQ AEGVYCNRTW DGWLCWNDVA AGTESMQLCP DYFQDFDPSE KVTKICDQDG 120 NWFRHPASNR TWTNYTQCNV NTHEKVKTAL NLFYLTIIGH GLSIASLLIS LGIFFYFKSL 180 SCQRITLHKN LFFSFVCNSV VTIIHLTAVA NNQALVATNP VSCKVSQFIH LYLMGCNYFW 240 MLCEGIYLHT LIWAVFAEK QHLMWYYFLG WGFPLIPACI HAIARSLYYN DNCWISSDTH 300 LLYIIHGPIC AALLVNLFFL LNIVRVLITK LKVTHQAESN LYMKAVRATL ILVPLLGIEF 360 VLIPWRPEGK IAEEVYDYIM HILMHFQGLL VSTIFCFFNG EVQAILRRNW NQYKIQFGNS 420 FSNSEALRSA SYTVSTISDG PGYSHDCPSE HLNGKSIHDI ENVLLKPENL YN

Seq ID NO : 74 Nucleotide sequence :

Nucleic Acid Accession # : NM_000450 . 1

Coding sequence : 117 . . 1949 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

CCTGAGACAG AGGCAGCAGT GATACCCACC TGAGAGATCC TGTGTTTGAA CAACTGCTTC 60 CCAAAACGGA AAGTATTTCA AGCCTAAACC TTTGGGTGAA AAGAACTCTT GAAGTCATGA 120 TTGCTTCACA GTTTCTCTCA GCTCTCACTT TGGTGCTTCT CATTAAAGAG AGTGGAGCCT 180 GGTCTTACAA CACCTCCACG GAAGCTATGA CTTATGATGA GGCCAGTGCT TATTGTCAGC 240 AAAGGTACAC ACACCTGGTT GCAATTCAAA ACAAAGAAGA GATTGAGTAC CTAAACTCCA 300 TATTGAGCTA TTCACCAAGT TATTACTGGA TTGGAATCAG AAAAGTCAAC AATGTGTGGG 360 TCTGGGTAGG AACCCAGAAA CCTCTGACAG AAGAAGCCAA GAACTGGGCT CCAGGTGAAC 420 CCAACAATAG GCAAAAAGAT GAGGACTGCG TGGAGATCTA CATCAAGAGA GAAAAAGATG 480 TGGGCATGTG GAATGATGAG AGGTGCAGCA AGAAGAAGCT TGCCCTATGC TACACAGCTG 540 CCTGTACCAA TACATCCTGC AGTGGCCACG GTGAATGTGT AGAGACCATC AATAATTACA 600 CTTGCAAGTG TGACCCTGGC TTCAGTGGAC TCAAGTGTGA GCAAATTGTG AACTGTACAG 660 CCCTGGAATC CCCTGAGCAT GGAAGCCTGG TTTGCAGTCA CCCACTGGGA AACTTCAGCT 720 ACAATTCTTC CTGCTCTATC AGCTGTGATA GGGGTTACCT GCCAAGCAGC ATGGAGACCA 780 TGCAGTGTAT GTCCTCTGGA GAATGGAGTG CTCCTATTCC AGCCTGCAAT GTGGTTGAGT 840 GTGATGCTGT GACAAATCCA GCCAATGGGT TCGTGGAATG TTTCCAAAAC CCTGGAAGCT 900 TCCCATGGAA CACAACCTGT ACATTTGACT GTGAAGAAGG ATTTGAACTA ATGGGAGCCC 960 AGAGCCTTCA GTGTACCTCA TCTGGGAATT GGGACAACGA GAAGCCAACG TGTAAAGCTG 1020 TGACATGCAG GGCCGTCCGC CAGCCTCAGA ATGGCTCTGT GAGGTGCAGC CATTCCCCTG 1080 CTGGAGAGTT CACCTTCAAA TCATCCTGCA ACTTCACCTG TGAGGAAGGC TTCATGTTGC 1140 AGGGACCAGC CCAGGTTGAA TGCACCACTC AAGGGCAGTG GACACAGCAA ATCCCAGTTT 1200 GTGAAGCTTT CCAGTGCACA GCCTTGTCCA ACCCCGAGCG AGGCTACATG AATTGTCTTC 1260 CTAGTGCTTC TGGCAGTTTC CGTTATGGGT CCAGCTGTGA GTTCTCCTGT GAGCAGGGTT 1320 TTGTGTTGAA GGGATCCAAA AGGCTCCAAT GTGGCCCCAC AGGGGAGTGG GACAACGAGA 1380 AGCCCACATG TGAAGCTGTG AGATGCGATG CTGTCCACCA GCCCCCGAAG GGTTTGGTGA 1440 GGTGTGCTCA TTCCCCTATT GGAGAATTCA CCTACAAGTC CTCTTGTGCC TTCAGCTGTG 1500 AGGAGGGATT TGAATTATAT GGATCAACTC AACTTGAGTG CACATCTCAG GGACAATGGA 1560 CAGAAGAGGT TCCTTCCTGC CAAGTGGTAA AATGTTCAAG CCTGGCAGTT CCGGGAAAGA 1620 TCAACATGAG CTGCAGTGGG GAGCCCGTGT TTGGCACTGT GTGCAAGTTC GCCTGTCCTG 1680 AAGGATGGAC GCTCAATGGC TCTGCAGCTC GGACATGTGG AGCCACAGGA CACTGGTCTG 1740 GCCTGCTACC TACCTGTGAA GCTCCCACTG AGTCCAACAT TCCCTTGGTA GCTGGACTTT 1800 CTGCTGCTGG ACTCTCCCTC CTGACATTAG CACCATTTCT CCTCTGGCTT CGGAAATGCT 1860 TACGGAAAGC AAAGAAATTT GTTCCTGCCA GCAGCTGCCA AAGCCTTGAA TCAGACGGAA 1920 GCTACCAAAA GCCTTCTTAC ATCCTTTAAG TTCAAAAGAA TCAGAAACAG GTGCATCTGG 1980 GGAACTAGAG GGATACACTG AAGTTAACAG AGACAGATAA CTCTCCTCGG GTCTCTGGCC 2040 CTTCTTGCCT ACTATGCCAG ATGCCTTTAT GGCTGAAACC GCAACACCCA TCACCACTTC 2100 AATAGATCAA AGTCCAGCAG GCAAGGACGG CCTTCAACTG AAAAGACTCA GTGTTCCCTT 2160 TCCTACTCTC AGGATCAAGA AAGTGTTGGC TAATGAAGGG AAAGGATATT TTCTTCCAAG 2220 CAAAGGTGAA GAGACCAAGA CTCTGAAATC TCAGAATTCC TTTTCTAACT CTCCCTTGCT 2280 CGCTGTAAAA TCTTGGCACA GAAACACAAT ATTTTGTGGC TTTCTTTCTT TTGCCCTTCA 2340 CAGTGTTTCG ACAGCTGATT ACACAGTTGC TGTCATAAGA ATGAATAATA ATTATCCAGA ₂400 GTTTAGAGGA AAAAAATGAC TAAAAATATT ATAACTTAAA AAAATGACAG ATGTTGAATG 2460 CCCACAGGCA AATGCATGGA GGGTTGTTAA TGGTGCAAAT CCTACTGAAT GCTCTGTGCG 2520 AGGGTTACTA TGCACAATTT AATCACTTTC ATCCCTATGG GATTCAGTGC TTCTTAAAGA 2580 GTTCTTAAGG ATTGTGATAT TTTTACTTGC ATTGAATATA TTATAATCTT CCATACTTCT 2640 TCATTCAATA CAAGTGTGGT AGGGACTTAA AAAACTTGTA AATGCTGTCA ACTATGATAT 2700 GGTAAAAGTT ACTTATTCTA GATTACCCCC TCATTGTTTA TTAACAAATT ATGTTACATC 2760 TGTTTTAAAT TTATTTCAAA AAGGGAAACT ATTGTCCCCT AGCAAGGCAT GATGTTAACC 2820 AGAATAAAGT TCTGAGTGTT TTTACTACAG TTGTTTTTTG AAAACATGGT AGAATTGGAG 2880 AGTAAAAACT GAATGGAAGG TTTGTATATT GTCAGATATT TTTTCAGAAA TATGTGGTTT 2940 CCACGATGAA AAACTTCCAT GAGGCCAAAC GTTTTGAACT AATAAAAGCA TAAATGCAAA 3000 CACACAAAGG TATAATTTTA TGAATGTCTT TGTTGGAAAA GAATACAGAA AGATGGATGT 3060 GCTTTGCATT CCTACAAAGA TGTTTGTCAG ATGTGATATG TAAACATAAT TCTTGTATAT 3120 TATGGAAGAT TTTAAATTCA CAATAGAAAC TCACCATGTA AAAGAGTCAT CTGGTAGATT 3180 TTTAACGAAT GAAGATGTCT AATAGTTATT CCCTATTTGT TTTCTTCTGT ATGTTAGGGT 3240 GCTCTGGAAG AGAGGAATGC CTGTGTGAGC AAGCATTTAT GTTTATTTAT AAGCAGATTT 3300 AACAATTCCA AAGGAATCTC CAGTTTTCAG TTGATCACTG GCAATGAAAA ATTCTCAGTC 3360 AGTAATTGCC AAAGCTGCTC TAGCCTTGAG GAGTGTGAGA ATCAAAACTC TCCTACACTT 3420 CCATTAACTT AGCATGTGTT GAAAAAAAAA GTTTCAGAGA AGTTCTGGCT GAACACTGGC 3480 AACGACAAAG CCAACAGTCA AAACAGAGAT GTGATAAGGA TCAGAACAGC AGAGGTTCTT 3540 TTAAAGGGGC AGAAAAACTC TGGGAAATAA GAGAGAACAA CTACTGTGAT CAGGCTATGT 3600 ATGGAATACA GTGTTATTTT CTTTGAAATT GTTTAAGTGT TGTAAATATT TATGTAAACT 3660 GCATTAGAAA TTAGCTGTGT GAAATACCAG TGTGGTTTGT GTTTGAGTTT TATTGAGAAT 3720 TTTAAATTAT AACTTAAAAT ATTTTATAAT TTTTAAAGTA TATATTTATT TAAGCTTATG 3780 TCAGACCTAT TTGACATAAC ACTATAAAGG TTGAGAATAA ATGTGCTTAT GTTT

Seq ID NO: 75 Protein sequence: Protein Accession #: NP_000441

11 21 31 41 51

I 1 I I I

MIASQFLSAL TLVLLIKESG AWSYNTSTEA MTYDEASAYC QQRYTHLVAI QNKEEIEYLN 60 SILSYSPSYY WIGIRKVNNV WVWVGTQKPL TEEAKNWAPG EPNNRQKDED CVEIYIKREK 120 DVGMWNDERC SKKKLALCYT AACTNTSCSG HGECVETINN YTCKCDPGFS GLKCEQIVNC 180 TALESPEHGS LVCSHPLGNF SYNSSCSISC DRGYLPSSME TMQCMSSGEW SAPIPACNW 240 ECDAVTNPAN GFVECFQNPG SFPWNTTCTF DCEEGFELMG AQSLQCTSSG NWDNEKPTCK 300 AVTCRAVRQP QNGSVRCSHS PAGEFTFKSS CNFTCEEGFM LQGPAQVECT TQGQWTQQIP 360 VCEAFQCTAL SNPERGYMNC LPSASGSFRY GSSCEFSCEQ GFVLKGSKRL QCGPTGEWDN 420 EKPTCEAVRC DAVHQPPKGL VRCAHSPIGE FTYKSSCAFS CEEGFELYGS TQLECTΞQGQ 480 WTEEVPSCQV VKCSSLAVPG KINMSCSGEP VFGTVCKFAC PEGWTLNGSA ARTCGATGHW 540 SGLLPTCEAP TESNIPLVAG LSAAGLSLLT LAPFLLWLRK CLRKAKKFVP ASSCQSLESD 600 GSYQKPSYIL

Seq ID NO: 76 Nucleotide sequence: Nucleic Acid Accession #: NM_031439

Coding sequence: 69..1235 (underlined sequences correspond to start and stop codons) 11 21 31 41 51

CCCGACCCGT GCGAGGGCCA GGTCCGCGCC TGCCCCGCCA GGCGAAGCGA GGCGACCCGC 60

GTGCGGCCAT GGCTTCGCTG CTGGGAGCCT ACCCTTGGCC CGAGGGTCTC GAGTGCCCGG 120

CCCTGGACGC CGAGCTGTCG GATGGACAAT CGCCGCCGGC CGTCCCCCGG CCCCCGGGGG 180

ACAAGGGCTC CGAGAGCCGT ATCCGGCGGC CCATGAACGC CTTCATGGTT TGGGCCAAGG 240

ACGAGAGGAA ACGGCTGGCA GTGCAGAACC CGGACCTGCA CAACGCCGAG CTCAGCAAGA 300

TGCTGGGAAA GTCGTGGAAG GCGCTGACGC TGTCCCAGAA GAGGCCGTAC GTGGACGAGG 360

CGGAGCGGCT GCGCCTGCAG CACATGCAGG ACTACCCCAA CTACAAGTAC CGGCCGCGCA 420

GGAAGAAGCA GGCCAAGCGG CTGTGCAAGC GCGTGGACCC GGGCTTCCTT CTGAGCTCCC 480

TCTCCCGGGA CCAGAACGCC CTGCCGGAGA AGAGAAGCGG CAGCCGGGGG GCGCTGGGGG 540

AGAAGGAGGA CAGGGGTGAG TACTCCCCCG GCACTGCCCT GCCCAGCCTC CGGGGCTGCT 600

ACCACGAGGG GCCGGCTGGT GGTGGCGGCG GCGGCACCCC GAGCAGTGTG GACACGTACC 660

CGTACGGGCT GCCCACACCT CCTGAAATGT CTCCCCTGGA CGTGCTGGAG CCGGAGCAGA 720

CCTTCTTCTC CTCCCCCTGC CAGGAGGAGC ATGGCCATCC CCGCCGCATC CCCCACCTGC 780

CAGGGCACCC GTACTCACCG GAGTACGCCC CAAGCCCTCT CCACTGTAGC CACCCCCTGG 840

GCTCCCTGGC CCTTGGCCAG TCCCCCGGCG TCTCCATGAT GTCCCCTGTA CCCGGCTGTC 900

CCCCATCTCC TGCCTATTAC TCCCCGGCCA CCTACCACCC ACTCCACTCC AACCTCCAAG 960

CCCACCTGGG CCAGCTTTCC CCGCCTCCTG AGCACCCTGG CTTCGACGCC CTGGATCAAC 1020

TGAGCCAGGT GGAACTCCTG GGGGACATGG ATCGCAATGA ATTCGACCAG TATTTGAACA 1080

CTCCTGGCCA CCCAGACTCC GCCACAGGGG CCATGGCCCT CAGTGGGCAT GTTCCGGTCT 1140

CCCAGGTGAC ACCAACGGGT CCCACAGAGA CCAGCCTCAT CTCCGTCCTG GCTGATGCCA 1200

CGGCCACGTA CTACAACAGC TACAGTGTGT CATAGAGCTG GAGGCGCCCC GTCCGGTCAG 1260

CCCTCGCGCC CTCTCCTTCT TGTGCCTTGA GTGGCAGAGG AGCCGTCCAG CCACACCAGC 1320

TTTCCTCCCA CCGCTCAGGG CAGGGAGGTC TGAACTGCGG CCCCAGAGCC TTTGGCCTAA 1380

GCTGGACTCT CCTTATCCGA GTGCCGCCTC TATCCCCTTC CCCACGTTCC AGCCCCTGCA 1440

GCCCACATTT TAAGTATATT CCTTCAAGTG AGTTTTCCTC CAGCCCCTGA GAGTTGCTGT 1500

CTCCCAGTGG AATGTTCACT GACGTCTTTT CTTGGTAGCC ATCATCGAAA CTAATGGGGG 1560

GACAGACTTG ATAGCCAAGG TCCCTTCTGG TCCAGTTTTC TGATTTAGGG TTCTCTCAAG 1620.

ATTAATAAAG GAAGATGGGG AAATTTGACT, CATTAATGAG CTCGCTAACC TACGATCTGG 1680

TGATAATTTT GTGTGCACAG CCCAAGGACC ACGAGGCTTT CTGCACTTTC TGCACCCCCT 1740

TCCAAAGTGA CCACAAAATT TCAAAGGGAC TCATACAATT TGAGAAAAAA CAGTCAACCT 1800

GATTTGAGAA ATTAACCAGT ATGGCTAACT ATATCACAGA AAATGGGATT GAGTTAAAAC 1860

TATTTTATTT TAAATATACA TTTTAAAGCA GTTCTTTTTT TTTGTTAATT TGTTTATTAT 1920

ACACACACTT CAAGAGCCAC CGCGCCCAGC CTACATTTAT AATTTTCATT CTCTTTTACC 1980

TATAAAATTC AGTGTATTAG TTTCATTACA TAGGAGAAAT TATATTTCTA AACATTTTAT 2040

GATGTTTAAA AACAAAACAG GCTGTTGTAA AAAAAAAAAA AAAAAAAAA

Seq ID NO : 77 Protein sequence : Protein Accession # : NP 113627

11 21 31 41 51

MASLLGAYPW PEGLECPALD AELSDGQSPP AVPRPPGDKG SESRIRRPMN AFMVWAKDER 60 KRLAVQNPDL HNAELSKMLG KSWKALTLSQ KRPYVDEAER LRLQHMQDYP NYKYRPRRKK 120 QAKRLCKRVD PGFLLSSLSR DQNALPEKRS GSRGALGEKE DRGEYSPGTA LPSLRGCYHE 180 GPAGGGGGGT PSSVDTYPYG LPTPPEMSPL DVLEPEQTFF SSPCQEEHGH PRRIPHLPGH 240 PYSPEYAPSP LHCSHPLGSL ALGQSPGVSM MSPVPGCPPS PAYYSPATYH PLHSNLQAHL 300 GQLSPPPEHP GFDALDQLSQ VELLGDMDRN EFDQYLNTPG HPDSATGAMA LSGHVPVSQV 360 TPTGPTETSL ISVLADATAT YYNSYSVS

Seq ID NO: 78 Nucleotide sequence:

Nucleic Acid Accession #: XM_035787

Coding sequence: 329..949 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

TGCCCCGCCC CGCTCCCCAG CGCCCCGGAA GTGATCTGTG GCGGCTGCTG CAGAGCCGCC 60

AGGAGGAGGG TGGATCTCCC CAGAGCAAAG CGTCGGAGTC CTCCTCCTCC TTCTCCTCCT 120

CCTCCTCCTC CTCCTCCAGC CGCCCAGGCT CCCCCGCCAC CCGTCAGACT CCTCCTTCGA 180

CCGCTCCCGG CGCGGGGCCT TCCAGGCGAC AAGGACCGAG TACCCTCCGG CCGGAGCCAC 240

GCAGCCGCGG CTTCCGGAGC CCTCGGGGCG GCGGACTGGC TCGCGGTGCA GATTCTTCTT 300

AATCCTTTGG TGAAAACTGA GACACAAAAT GGCTGCAAAT AAGCCCAAGG GTCAGAATTC 360

TTTGGCTTTA CACAAAGTCA TCATGGTGGG CAGTGGTGGC GTGGGCAAGT CAGCTCTGAC 420

TCTACAGTTC ATGTACGATG AGTTTGTGGA GGACTATGAG CCTACCAAAG CAGACAGCTA 480

TCGGAAGAAG GTAGTGCTAG ATGGGGAGGA AGTCCAGATC GATATCTTAG ATACAGCTGG 540

GCAGGAGGAC TACGCTGCAA TTAGAGACAA CTACTTCCGA AGTGGGGAGG GGTTCCTCTG 600

TGTTTTCTCT ATTACAGAAA TGGAATCCTT TGCAGCTACA GCTGACTTCA GGGAGCAGAT 660

TTTAAGAGTA AAAGAAGATG AGAATGTTCC ATTTCTACTG GTTGGTAACA AATCAGATTT 720

AGAAGATAAA AGACAGGTTT CTGTAGAAGA GGCAAAAAAC AGAGCTGAGC AGTGGAATGT 780

TAACTACGTG GAAACATCTG CTAAAACACG AGCTAATGTT GACAAGGTAT TTTTTGATTT 840 AATGAGAGAA ATTCGAGCGA GAAAGATGGA AGACAGCAAA GAAAAGAATG GAAAAAAGAA 900 GAGGAAAAGT TTAGCCAAGA GAATCAGAGA AAGATGCTGC ATTTTATAAT CAAAGCCCAA 960 ACTCCTTTCT TATCTTGACC ATACTAATAA ATATAATTTA TAAGCATTGC CATTGAAGGC 1020 TTAATTGACT GAAATTACTT TAACATTTTG GAAATTGTTG TATATCACTA AAAGCATGAA 1080 TTGGAACTGC AATGAAAGTC AAATTTACTT TAAAAAGAAA TTAATATGGC TTCACCAAGA 1140 AGCAAAGTTC AACTTATTTC ATAATTGCCT ACATTTATCA TGGTCCTGAA TGTAGCGTGT 1200 AAGCTTGTGT TTCTTGGGCA GTCTTTCTTG AAATTGAAGA GGTGAAATGG GGGTGGGGAG 1260 TGGGAGGAAA GGTGACTTCC TCTGGTGTTT ATTATAAAGC TTAAATTTTA TATCATTTTA 1320 AAATGTCTTG GTCTTCTACT GCCTTGAAAA ATGACAATTG TGAACATGAT AGTTAAACTA 1380 CCACTTTTTT TAACCATTAT TATGCAAAAT TTAGAAGAAA AGTTATTGGC ATGGTTGTTG 1440 CATATAGTTA AACTGAGAGT AATTCATCTG TGAATCTGCT TTAATTACCT GGTGAGTAAC 1500 TTAGAAAAGT GGTGTAAACT TGTACATGGA ATTTTTTGAA TATGCCTTAA TTTAGAAACT 1560 GAAAAATATC TGGTTATATC ATTCTGGGTG TGTTCTTACT GACACCAGGG GTCCGCTGCC 1620 CCATGTGTCC TGGTGAGAAA ATATATGCCT GGCACAGCTT TTGTATAGAA AATTCTTGAG 1680 AAGTAACTGT CCGCTAGAAG TCTGTCCAAA TTTAAAATGT GTGCCATATT CTGGTTCTTG 1740 AAAATAAGAT TCCAGAGCTC TTTGATCGCT TTTAATAAAC TGCAAGTTCA TTTTAAATGA 1800 AGGGCCAGCA TATATACTTG CAAGATAATT TTCAGCTGCA AGGATTCAGC ACCAGTTATG 1860 TTTGAATGAA CCCTCCTTTT CTCTGAGATT CTGGTCCCTG GAAATCCCTT TCTGCTAGTG 1920 GTGAGCATGT AAGTGTTAAG TTTTTAATCT GGGAGCAGGG CATAGGAAGA AAATGTCAGT 1980 AGTGCTAATG CATTTTGCAC TAGAACGCTT CGGGAAAATA TTCATGCTTG CCATCTGTTC 2040 ATTTCTAAAT TTATATTCAT AAAGTTACAG TTTGATACAG GAATTATTAG GAGTAATTCT 2100 TTTCTGTTTC TGTTTATAAT GAAGAACACT GTAGCTACAT TTTCAGAAGT TAACATCAAG 2160 CCATCAAACC TGGGTATAGT GCAGAAAACG TGGCACACAC TGACCACACA TTAGGCTGTG 2220 TCACCATTGT GTGGTGTACC TGCTGGAAGA ATTCTAGCAT GCTACTTGGG GACATAATTT 2280 CAGTGGGAAA TATGCCACTG ACCGATTTTT TTTTTTTCCT CTTTGCAGTG GGGCTAGGAC 2340 AGTTGATTCA ACAAAGTATT TTTTTCTTTT TTCTCAGTCC TAATTTGAAC AGGTCAAAGA 2400 TGTGTTCAGG CATTCCAGGT AACAGGTGTG TATGTAAAGT TAAAAATAGG CTTTTTAGGA 2460 ACTCACTCTT TAGATATTTA CATCCAGCTT CTCATGTTAA ATATTTGTCC TTAAAGGGTT 2520 TGAGATGTAC ATCTTTCATT TCGTATTTCT CATAGGCTAT GCCATGTGCG GAATTCAAGT 2580 TACCAATGTA ACACTGGCCA GCGGGCCCAG CAATCTCCAT GTGTACTTAT TACAGTCTTA 2640 TTTAACCAGG GGTCCTAACC ACTAACATTG TGACTTTGCT TTGAGACCTT TCCTCTCCTG 2700 GGTACTGAGG TGCTATGAAG CCAACTGACA AAGATGCATC ACGTGTCTTA GGCTGATGCC 2760 ACTACCCGAT TTGTTTATTT GCAATTTGAG CCATTTAAAG ACCAATAAAC TTCCTTTTTT

Seq ID NO: 79 Protein sequence: Protein Accession #: XP 035787

11 21 31 41 51

MAANKPKGQN SLALHKVIMV GSGGVGKSAL TLQFMYDEFV EDYEPTKADS YRKKWLDGE 60

EVQIDILDTA GQEDYAAIRD NYFRSGEGFL CVFSITEMES FAATADFREQ ILRVKEDENV 120

PFLLVGNKSD LEDKRQVSVE EAKNRAEQWN VNYVETSAKT RANVDKVFFD LMREIRARKM 180

EDSKEKNGKK KRKSLAKRIR ERCCIL

Seq ID NO : 80 Nucleotide sequence :

Nucleic Acid Accession # : NM_003467

Coding sequence : 89 . . 1147 (underlined sequences correspond to start and stop codons )

11 21 31 41 51

GTTTGTTGGC TGCGGCAGCA GGTAGCAAAG TGACGCCGAG GGCCTGAGTG CTCCAGTAGC 60 CACCGCATCT GGAGAACCAG CGGTTACCAT GGAGGGGATC AGTATATACA CTTCAGATAA 120 CTACACCGAG GAAATGGGCT CAGGGGACTA TGACTCCATG AAGGAACCCT GTTTCCGTGA 180 AGAAAATGCT AATTTCAATA AAATCTTCCT GCCCACCATC TACTCCATCA TCTTCTTAAC 240 TGGCATTGTG GGCAATGGAT TGGTCATCCT GGTCATGGGT TACCAGAAGA AACTGAGAAG 300 CATGACGGAC AAGTACAGGC TGCACCTGTC AGTGGCCGAC CTCCTCTTTG TCATCACGCT 360 TCCCTTCTGG GCAGTTGATG CCGTGGCAAA CTGGTACTTT GGGAACTTCC TATGCAAGGC 420 AGTCCATGTC ATCTACACAG TCAACCTCTA CAGCAGTGTC CTCATCCTGG CCTTCATCAG 480 TCTGGACCGC TACCTGGCCA TCGTCCACGC CACCAACAGT CAGAGGCCAA GGAAGCTGTT 540 GGCTGAAAAG GTGGTCTATG TTGGCGTCTG GATCCCTGCC CTCCTGCTGA CTATTCCCGA 600 CTTCATCTTT GCCAACGTCA GTGAGGCAGA TGACAGATAT ATCTGTGACC GCTTCTACCC 660 CAATGACTTG TGGGTGGTTG TGTTCCAGTT TCAGCACATC ATGGTTGGCC TTATCCTGCC 720 TGGTATTGTC ATCCTGTCCT GCTATTGCAT TATCATCTCC AAGCTGTCAC ACTCCAAGGG 780 CCACCAGAAG CGCAAGGCCC TCAAGACCAC AGTCATCCTC ATCCTGGCTT TCTTCGCCTG 840 TTGGCTGCCT TACTACATTG GGATCAGCAT CGACTCCTTC ATCCTCCTGG AAATCATCAA 900 GCAAGGGTGT GAGTTTGAGA ACACTGTGCA CAAGTGGATT TCCATCACCG AGGCCCTAGC 960 TTTCTTCCAC TGTTGTCTGA ACCCCATCCT CTATGCTTTC CTTGGAGCCA AATTTAAAAC 1020 CTCTGCCCAG CACGCACTCA CCTCTGTGAG CAGAGGGTCC AGCCTCAAGA TCCTCTCCAA 1080 AGGAAAGCGA GGTGGACATT CATCTGTTTC CACTGAGTCT GAGTCTTCAA GTTTTCACTC 1140 CAGCTAACAC AGATGTAAAA GACTTTTTTT TATACGATAA ATAACTTTTT TTTAAGTTAC 1200 ACATTTTTCA GATATAAAAG ACTGACCAAT ATTGTACAGT TTTTATTGCT TGTTGGATTT 1260 TTGTCTTGTG TTTCTTTAGT TTTTGTGAAG TTTAATTGAC TTATTTATAT AAATTTTTTT 1320 TGTTTCATAT TGATGTGTGT CTAGGCAGGA CCTGTGGCCA AGTTCTTAGT TGCTGTATGT 1380 CTCGTGGTAG GACTGTAGAA AAGGGAACTG AACATTCCAG AGCGTGTAGT GAATCACGTA 1440 AAGCTAGAAA TGATCCCCAG CTGTTTATGC ATAGATAATC TCTCCATTCC CGTGGAACGT 1500 TTTTCCTGTT CTTAAGACGT GATTTTGCTG TAGAAGATGG CACTTATAAC CAAAGCCCAA 1560 AGTGGTATAG AAATGCTGGT TTTTCAGTTT TCAGGAGTGG GTTGATTTCA GCACCTACAG 1620 TGTACAGTCT TGTATTAAGT TGTTAATAAA AGTACATGTT AAACTTACTT AGTGTTATG

Seq ID NO : 81 Protein sequence : Protein Accession # : NP_003458

1 11 21 31 41 51

10

MEGISIYTSD NYTEEMGSGD YDSMKEPCFR EENANFNKIF LPTIYSIIFL TGIVGNGLVI 60

LVMGYQKKLR SMTDKYRLHL SVADLLFVIT LPFWAVDAVA NWYFGNFLCK AVHVIYTVNL 120 YSSVLILAFI SLDRYLAIVH ATNSQRPRKL LAEKWYVGV WIPALLLTIP DFIFANVSEA 180 DDRYICDRFY PNDLWVWFQ FQHIMVGLIL PGIVILSCYC IIISKLSHSK GHQKRKALKT 240 15 TVILILAFFA CWLPYYIGIS IDSFILLEII KQGCEFENTV HKWISITEAL AFFHCCLNPI 300

LYAFLGAKFK TSAQHALTSV SRGSSLKILS KGKRGGHSSV STESESSSFH SS

Seq ID NO : 82 Nucleotide sequence : 20 Nucleic Acid Accession # : NM_014959

Coding sequence : 314 . . 1609 (underlined sequences correspond to start and stop codons )

1 11 21 31 41 51 , I I I I I I

I CTGGTTCTCA ACTTCTTTTG AAATAATGTT CATAGAGAAG GAGGGCTGTC TGAGATTCGA 60

GGGAAACAAG CTCTCAGGAC TTCCGGTCGC CATGATGGCT GTGGGCGGTA AACGCGGTTA 120 GTGCAAGCAT CTGGGCCATC TTCAATGGTA AAAAAGATAC AGTAAAGACA TAAATACCAC 180 ATTTGACAAA TGGAAAAAAA GGAGTGTCCA GAAAAGAGTA GCAGCAGTGA GGAAGAGCTG 240 CCGAGACGGG TATACAGGGA GCTACCCTGT GTTTCTGAGA CCCTTTGTGA CATCTCACAT 300

30 TTTTTCCAAG AAGATGATGA GACAGAGGCA GAGCCATTAT TGTTCCGTGC TGTTCCTGAG 360

TGTCAACTAT CTGGGGGGGA CATTCCCAGG AGACATTTGC TCAGAAGAGA ATCAAATAGT 420 TTCCTCTTAT GCTTCTAAAG TCTGTTTTGA GATCGAAGAA GATTATAAAA ATCGTCAGTT 480 TCTGGGGCCT GAAGGAAATG TGGATGTTGA GTTGATTGAT AAGAGCACAA ACAGATACAG 540

CGTTTGGTTC CCCACTGCTG GCTGGTATCT GTGGTCAGCC ACAGGCCTCG GCTTCCTGGT 600

35 AAGGGATGAG GTCACAGTGA CGATTGCGTT TGGTTCCTGG AGTCAGCACC TGGCCCTGGA 660

CCTGCAGCAC CATGAACAGT GGCTGGTGGG CGGCCCCTTG TTTGATGTCA CTGCAGAGCC 720

AGAGGAGGCT GTCGCCGAAA TCCACCTCCC CCACTTCATC TCCCTCCAAG GTGAGGTGGA 780

CGTCTCCTGG TTTCTCGTTG CCCATTTTAA GAATGAAGGG ATGGTCCTGG AGCATCCAGC 840

CCGGGTGGAG CCTTTCTATG CTGTCCTGGA AAGCCCCAGC TTCTCTCTGA TGGGCATCCT 900

40 GCTGCGGATC GCCAGTGGGA CTCGCCTCTC CATCCCCATC ACTTCCAACA CATTGATCTA 960

TTATCACCCC CACCCCGAAG ATATTAAGTT CCACTTGTAC CTTGTCCCCA GCGACGCCTT 1020

GCTAACAAAG GCGATAGATG ATGAGGAAGA TCGCTTCCAT GGTGTGCGCC TGCAGACTTC 1080

GCCCCCAATG GAACCCCTGA ACTTTGGTTC CAGTTATATT GTGTCTAATT CTGCTAACCT 1140

GAAAGTAATG CCCAAGGAGT TGAAATTGTC CTACAGGAGC CCTGGAGAAA TTCAGCACTT 1200

45 CTCAAAATTC TATGCTGGGC AGATGAAGGA ACCCATTCAA CTTGAGATTA CTGAAAAAAG 1260

ACATGGGACT TTGGTGTGGG ATACTGAGGT GAAGCCAGTG GATCTCCAGC TTGTAGCTGC 1320

ATCAGCCCCT CCTCCTTTCT CAGGTGCAGC CTTTGTGAAG GAGAACCACC GGCAACTCCA 1380

AGCCAGGATG GGGGACCTGA AAGGGGTGCT CGATGATCTC CAGGACAATG AGGTTCTTAC 1440

TGAGAATGAG AAGGAGCTGG TGGAGCAGGA AAAGACACGG CAGAGCAAGA ATGAGGCCTT 1500

50 GCTGAGCATG GTGGAGAAGA AAGGGGACCT GGCCCTGGAC GTGCTCTTCA GAAGCATTAG 1560

TGAAAGGGAC CCTTACCTCG TGTCCTATCT TAGACAGCAG AATTTGTAAA ATGAGTCAGT 1620

TAGGTAGTCT GGAAGAGAGA ATCCAGCGTT CTCATTGGAA ATGGATAAAC AGAAATGTGA 1680

TCATTGATTT CAGTGTTCAA GACAGAAGAA GACTGGGTAA CATCTATCAC ACAGGCTTTC 1740

AGGACAGACT TGTAACCTGG CATGTACCTA TTGACTGTAT CCTCATGCAT TTTCCTCAAG 1800

55 AATGTCTGAA GAAGGTAGTA ATATTCCTTT TAAATTTTTT CCAACCATTG CTTGATATAT 1860

CACTATTTTA TCCATTGACA TGATTCTTGA AGACCCAGGA TAAAGGACAT CCGGATAGGT 1920

GTGTTTATGA AGGATGGGGC CTGGAAAGGC AACTTTTCCT GATTAATGTG AAAAATAATT 1980

CCTATGGACA CTCCGTTTGA AGTATCACCT TCTCATAACT AAAAGCAGAA AAGCTAACAA 2040

AAGCTTCTCA GCTGAGGACA CTCAAGGCAT ACATGATGAC AGTCTTTTTT TTTTTTGTAT 2100

60 GTTAGGACTT TAACACTTTA TCTATGGCTA CTGTTATTAG AACAATGTAA ATGTATTTGC 2160

TGAAAGAGAG CACAAAAATG GGAGAAAATG CAAACATGAG CAGAAAATAT TTTCCCACTG 2220

GTGTGTAGCC TGCTACAAGG AGTTGTTGGG TTAAATGTTC ATGGTCAACT CCAAGGAATA 2280

CTGAGATGAA ATGTGGTAAA TCAACTCCAC AGAACCACCA AAAAGAAAAT GAGGGTAATT 2340

CAGCTTATTC TGAGACAGAC ATTCCTGGCA ATGTACCATA CAAAAAATAA GCCAACTCTG 2400

65 ACATTTGGAT TCTACCATAG ACTCTGTCAT TTTGTAGCCA TTTCAGCTGT CTTTTGATTA 2460

ATGTTTTCGT GGCACACATA TTTCCATCCT TTTATGTTTA ATCTGTTTAA AACAAGTTCC 2520

TAGTAGACAC CATCTGGTTG AGTCAGTTTT TTTTATGGTG TATTTTGAAC CCATTCTGAT 2580

AGTCTCTTTT AACTGGAAGA TTTCAATTAC TTACGTTAAT GTAATTATTA ATATGTTAGG 2640

ATTTATCCTC AGTCAGCCAG TTTGTTATGT CTTTTCTATT CTACTGTTAT CACATTTGTA 2700

70 CCACTTAAAG TGGAATCTAG GCACTTTATC ACCATTTAGA TCCTATTACC TTTTCTCATC 2760

TAGGATATAG TTATCTTCTA CATAATCTTT CTGTATCTTA AAACCCATCA ATAAATTATT 2820

ATATATTTTC TACTTTTAAT CACTCAGAAG ATTTAAAAAA CTCATGAGAA GAGTAATCTG 2880

TTATGTTTTT CCAGATATTT ACCATTTCTG TTGCTCTTCC TTCATTATTT TCCAAATTTC 2940

GTTCTGCAAA TTTCCACTTC TTCTGATAGA CGTTTTTTAG TTCTTTTAGA GTGGTTGTGA 3000

75 TAGGTACAGA TTCTCTTATT TTTTGCTTCC TCTGAGGACA TCTTTTTCTC ACCTTCATTC 3060

TCAGTGATGT TTTTTGCTTG TAGTATTTTT AGTTGACATT GTTTTCTGTT CAGCAGTTTC 3120 CTTTTAGCTT CCGTATTTCC TGATGAGAAA TCTGCAGTCA TTCAAATTGT TGTTTCCCTG 3180

TATGTAGTGT GTCATTTTTC TGTCAGATTT CAAGGTATTT ATCTTTAGTT TTTAGCCATT 3240

TCATTATGTT GGGGATGAGT TTCCTTGTTT TATTCCCTTT GGAATTTGCT CCAATTCATA 3300

AATTTGCAGT TTTATGTCTT TTACCAAACT TAGAGGTTTT CAGCCTAATT TCTAAAAATA 3360 CTTTTTATTA GCCTGATTTT CATCTTTATA GGAAATAGTT TAAGTGATGA CAAGTTCCAA 3420

TAGCTTATAT GCCCAGAAGG CCTTCAAAAT AAGAATTTTG AAAGAATACA GAAAACAAAC 3480

TTTTATATCC TTCTCATGTC TTCTACTGTA AAATTCATAT GCTTTGCTAC TCTAAACCTA 3540

GTTTGAAATC AACAGTCTTG AGAATAGATG AAAATTTTGA TGAATAGTGG AATTCTTTTA 3600

AATGGAAACC TCTTACATGT GATTTTCCTT GCCATCTAGA AATAAACCAT AGTATTTATG 3660 TTGAATCAAT CAATATTATA TTTTGTTTTT TTCCTCCTCT TCTGAGACTC TTATTGTGGA 3720

AATGTTAGAC TTTTATGTTT TCCTAAATGT CCCTGATATT CTACTTATTT AGAACATCTT 3780

TTCATTTTTT CCATTATTCT GATTGGGTAA TTTTAATTTG TCTATTTTCA AATTTGCTGG 3840

AGTGTTCACC TGTTGTTGTC TGTGTCGTCC CACTGAGTGC ATTCACCACC TTTTAAATTT 3900

TGGTCACTGT ATGTATCAGT TCTAAAATTT CCATTTTGTT CTCTATATTT TAAATTTCTT 3960 GGCTTATATT CTATTTTCCT GCAAATGTGT CAGCATTTGC TTGTTTGAGC TTTTTTTTTT 4020

TCAAGACAGG GTCTCAACTC TGTTACCCAG GCTGGAGTGC AGTGGTGCGA TCTCAGCTCA 4080

CTGCAACCTC TGCCTCCTGG TTCAAGCGAT TATTGTGCCT CAGCCTCCTG AGTAGCTGGG 4140

ATTACAGGCA TGCACCACCA CAGCCCAGCT AATTTTTTGT ATTTTTAGTA GAGACAGAGT 4200

TTTGCTATGT TGGCCAGGCT GGTTTTGAAC TCCTGGCCTC AAGTGATCCA CCCACCTCAG 4260 CCTCCCAAAG TGCTGGGATT ACAGGCCACT ACACCTGGCA CATTTGAGTA TTTTTTTTTT 4320 _{ττττττττττ} TTGAGATGGA GTCTCGCTCT GTCATCTAGG CTGGAGTGCA GTGGTGTGAT 4380

CTCAGCTCAC TGCAGCCTCT GTCTCCCGGG CTCAAGCGAT TCTCTTGCCT CAGCCTCCTG 4440

AGTAGCTAGG ACTACAGGTG CATGCCAACA CGCCCGGCTA ATTTTTTTAA AAAATATTTT 4500

TAGTAGAGAC AGGGTTTCAC CATTTTGGCC AGGATGGTCT CGATCTCCTG ACCTCATGAT 560 CCACCCGCCT CGGCCTTCCA AAGTGCTGGG ATTACAGGCA TGAGCCACCG TGCCTGGCCT 4620

CATTTGAGTA TTTTTATAAT GTCTCTTTTA AAGTCTTTGT CAGATAATTC CACTGTACAT 4680

GTTATTCAGT GTTTGGTGTC CACTGAGTTG TCATTTGCCA GACAAGTGGA GATTTTTGCA 4740

GCTCATCCTT GTATTCTCAG TAGTTCCGAT ATGTACCCTC GACATGTGAA TGTTATCTTA 4800

TGAGACTCTG TTTTATTTGT ATCCAACAGA AGATGTTTAT TATTTATTTG GCTTTCTGTG 4860 AACTGAGGTC TTAATATCAG CTCATTTTAA AAGTCTTTGC AGTGGTATTC GGATCTATCC 4920

TGTGTGTGCC TATGAGATTG GGTGCAGTGT ATCCTGTTAG CTCCATTCTC AGGGCGTTTG 4980

AATGTGAATT AGGACCAGCG CAATGAATGC TCAAGTTGGG GTTGGGCGTT AGAATTCATA 5040 AAAGTCTTTA TATGCTCAG

Seq ID NO : 83 Protein sequence : Protein Accession # : NP 055774

11 21 31 41 51

MMRQRQSHYC SVLFLSVNYL GGTFPGDICS EENQIVSSYA SKVCFEIEED YKNRQFLGPE 60

GNVDVELIDK STNRYSVWFP TAGWYLWSAT GLGFLVRDEV TVTIAFGSWS QHLALDLQHH 120

EQWLVGGPLF DVTAEPEEAV AEIHLPHFIS LQGEVDVSWF LVAHFKNEGM VLEHPARVEP 180 FYAVLESPSF SLMGILLRIA SGTRLSIPIT SNTLIYYHPH PEDIKFHLYL VPSDALLTKA 240

IDDEEDRFHβ VRLQTSPPME PLNFGSSYIV SNSANLKVMP KELKLSYRSP GEIQHFSKFY 300

AGQMKEPIQL EITEKRHGTL VWDTEVKPVD LQLVAASAPP PFSGAAFVKE NHRQLQARMG 360

DLKGVLDDLQ DNEVLTENEK ELVEQEKTRQ SKNEALLSMV EKKGDLALDV LFRSISERDP 420 YLVSYLRQQN L

Seq ID NO : 84 Nucleotide sequence :

Nucleic Acid Accession # : NM_007036

Coding sequence : 56-610 (underlined sequences correspond to start and stop codons )

1 11 21 31 41 51

CTTCCCACCA GCAAAGACCA CGACTGGAGA GCCGAGCCGG AGGCAGCTGG GAAACATGAA 60

GAGCGTCTTG CTGCTGACCA CGCTCCTCGT GCCTGCACAC CTGGTGGCCG CCTGGAGCAA 120 TAATTATGCG GTGGACTGCC CTCAACACTG TGACAGCAGT GAGTGCAAAA GCAGCCCGCG 180

CTGCAAGAGG ACAGTGCTCG ACGACTGTGG CTGCTGCCGA GTGTGCGCTG CAGGGCGGGG 240

AGAAACTTGC TACCGCACAG TCTCAGGCAT GGATGGCATG AAGTGTGGCC CGGGGCTGAG 300

GTGTCAGCCT TCTAATGGGG AGGATCCTTT TGGTGAAGAG TTTGGTATCT GCAAAGACTG 360

TCCCTACGGC ACCTTCGGGA TGGATTGCAG AGAGACCTGC AACTGCCAGT CAGGCATCTG 420 TGACAGGGGG ACGGGAAAAT GCCTGAAATT CCCCTTCTTC CAATATTCAG TAACCAAGTC 480

TTCCAACAGA TTTGTTTCTC TCACGGAGCA TGACATGGCA TCTGGAGATG GCAATATTGT 540

GAGAGAAGAA GTTGTGAAAG AGAATGCTGC CGGGTCTCCC GTAATGAGGA AATGGTTAAA 600

TCCACGCTGA TCCCGGCTGT GATTTCTGAG AGAAGGCTCT ATTTTCGTGA TTGTTCAACA 660

CACAGCCAAC ATTTTAGGAA CTTTCTAGAT ATAGCATAAG TACATGTAAT TTTTGAAGAT 720 CCAAATTGTG ATGCATGGTG GATCCAGAAA ACAAAAAGTA GGATACTTAC AATCCATAAC 780

ATCCATATGA CTGAACACTT GTATGTGTTT GTTAAATATT CGAATGCATG TAGATTTGTT 840

AAATGTGTGT GTATAGTAAC ACTGAAGAAC TAAAAATGCA ATTTAGGTAA TCTTACATGG 900

AGACAGGTCA ACCAAAGAGG GAGCTAGGCA AAGCTGAAGA CCGCAGTGAG TCAAATTAGT 960

TCTTTGACTT TGATGTACAT TAATGTTGGG ATATGGAATG AAGACTTAAG AGCAGGAGAA 1020 GATGGGGAGG GGGTGGGAGT GGGAAATAAA ATATTTAGCC CTTCCTTGGT AGGTAGCTTC 1080

TCTAGAATTT AATTGTGCTT TTTTTTTTTT TTTGGCTTTG GGAAAAGTCA AAATAAAACA 1140 ACCAGAAAAC CCCTGAAGGA AGTAAGATGT TTGAAGCTTA TGGAAATTTG AGTAACAAAC 1200 AGCTTTGAAC TGAGAGCAAT TTCAAAAGGC TGCTGATGTA GTTCCCGGGT TACCTGTATC 1260 TGAAGGACGG TTCTGGGGCA TAGGAAACAC ATACACTTCC ATAAATAGCT TTAACGTATG 1320 CCACCTCAGA GATAAATCTA AGAAGTATTT TACCCACTGG TGGTTTGTGT GTGTATGAAG 1380 GTAAATATTT ATATATTTTT ATAAATAAAT GTGTTAGTGC AAGTCATCTT CCCTACCCAT 1440 ATTTATCATC CTCTTGAGGA AAGAAATCTA GTATTATTTG TTGAAAATGG TTAGAATAAA 1500 AACCTATGAC TCTATAAGGT TTTCAAACAT CTGAGGCATG ATAAATTTAT TATCCATAAT 1560 TATAGGAGTC ACTCTGGATT TCAAAAAATG TCAAAAAATG AGCAACAGAG GGACCTTATT 1620 TAAACATAAG TGCTGTGACT TCGGTGAATT TTCAATTTAA GGTATGAAAA TAAGTTTTTA 1680 GGAGGTTTGT AAAAGAAGAA TCAATTTTCA GCAGAAAACA TGTCAACTTT AAAATATAGG 1740 TGGAATTAGG AGTATATTTG AAAGAATCTT AGCACAAACA GGACTGTTGT ACTAGATGTT 1800 CTTAGGAAAT ATCTCAGAAG TATTTTATTT GAAGTGAAGA ACTTATTTAA GAATTATTTC 1860 AGTATTTACC TGTATTTTAT TCTTGAAGTT GGCCAACAGA GTTGTGAATG TGTGTGGAAG 1920 GCCTTTGAAT GTAAAGCTGC ATAAGCTGTT AGGTTTTGTT TTAAAAGGAC ATGTTTATTA 1980 TTGTTCAATA AAAAAGAACA AGATAC

Seq ID NO: 85 Protein sequence: Protein Accession #: NP 008967.1

11 21 31 41 51

MKSVLLLTTL LVPAHLVAAW SNNYAVDCPQ HCDSSECKSS PRCKRTVLDD CGCCRVCAAG 60

RGETCYRTVS GMDGMKCGPG LRCQPSNGED PFGEEFGICK DCPYGTFGMD CRETCNCQSG 120 ICDRGTGKCL KFPFFQYSVT KSSNRFVSLT EHDMASGDGN IVREEWKEN AAGSPVMRKW 180 LNPR

Seq ID NO : 86 Nucleotide sequence : Nucleic Acid Accession # : D86983

Coding sequence : 52 -4491 (underlined sequences correspond to start and stop codons )

11 21 31 41 51

I I I

AGCCGGCCGT GGTGGCTCCG TGCGTCCGAG CGTCCGTCCG CGCCGTCGGC CATGGCCAAG 60 CGCTCCAGGG GCCCCGGGCG CCGCTGCCTG TTGGCGCTCG TGCTGTTCTG CGCCTGGGGG 120 ACGCTGGCCG TGGTGGCCCA GAAGCCGGGC GCAGGGTGTC CGAGCCGCTG CCTGTGCTTC 180 CGCACCACCG TGCGCTGCAT GCATCTGCTG CTGGAGGCCG TGCCCGCCGT GGCGCCGCAG 240 ACCTCCATCC TAGATCTTCG CTTTAACAGA ATCAGAGAGA TCCAACCTGG GGCATTCAGG 300 CGGCTGAGGA ACTTGAACAC ATTGCTTCTC AATAATAATC AGATCAAGAG GATACCTAGT 360 GGAGCATTTG AAGACTTGGA AAATTTAAAA TATCTCTATC TGTACAAGAA TGAGATCCAG 420 TCAATTGACA GGCAAGCATT TAAGGGACTT GCCTCTCTAG AGCAACTATA CCTGCACTTT 480 AATCAGATAG AAACTTTGGA CCCAGATTCG TTCCAGCATC TCCCGAAGCT CGAGAGGCTA 540 TTTTTGCATA ACAACCGGAT TACACATTTA GTTCCAGGGA CATTTAATCA CTTGGAATCT 600 ATGAAGAGAT TGCGACTGGA CTCAAACACA CTTCACTGCG ACTGTGAAAT CCTGTGGTTG 660 GCGGATTTGC TGAAAACCTA CGCGGAGTCG GGGAACGCGC AGGCAGCGGC CATCTGTGAA 720 TATCCCAGAC GCATCCAGGG ACGCTCAGTG GCAACCATCA CCCCGGAAGA GCTGAACTGT 780 GAAAGGCCCC GGATCACCTC CGAGCCCCAG GACGCAGATG TGACCTCGGG GAACACCGTG 840 TACTTCACCT GCAGAGCCGA AGGCAACCCC AAGCCTGAGA TCATCTGGCT GCGAAACAAT 900 AATGAGCTGA GCATGAAGAC AGATTCCCGC CTAAACTTGC TGGACGATGG GACCCTGATG 960 ATCCAGAACA CACAGGAGAC AGACCAGGGT ATCTACCAGT GCATGGCAAA GAACGTGGCC 1020 GGAGAGGTGA AGACGCAAGA GGTGACCCTC AGGTACTTCG GGTCTCCAGC TCGACCCACT 1080 TTTGTAATCC AGCCACAGAA TACAGAGGTG CTGGTTGGGG AGAGCGTCAC GCTGGAGTGC 1140 AGCGCCACAG GCCACCCCCC GCCGCGGATC TCCTGGACGA GAGGTGACCG CACACCCTTG 1200 CCAGTTGACC CGCGGGTGAA CATCACGCCT TCTGGCGGGC TTTACATACA GAACGTCGTA 1260 CAGGGGGACA GCGGAGAGTA TGCGTGCTCT GCGACCAACA ACATTGACAG CGTCCATGCC 1320 ACCGCTTTCA TCATCGTCCA GGCTCTTCCT CAGTTCACTG TGACGCCTCA GGACAGAGTC 1380 GTTATTGAGG GCCAGACCGT GGATTTCCAG TGTGAAGCCA AGGGCAACCC GCCGCCCGTC 1440 ^' ATCGCCTGGA CCAAGGGAGG GAGCCAGCTC TCCGTGGACC GGCGGCACCT GGTCCTGTCA 1500 TCGGGAACAC TTAGAATCTC TGGTGTTGCC CTCCACGACC AGGGCCAGTA CGAATGCCAG 1560 GCTGTCAACA TCATCGGCTC CCAGAAGGTC GTGGCCCACC TGACTGTGCA GCCCAGAGTC 1620 ACCCCAGTGT TTGCCAGCAT TCCCAGCGAC ACAACAGTGG AGGTGGGCGC CAATGTGCAG 1680 CTCCCGTGCA GCTCCCAGGG CGAGCCCGAG CCAGCCATCA CCTGGAACAA GGATGGGGTT 1740 CAGGTGACAG AAAGTGGAAA ATTTCACATC AGCCCTGAAG GATTCTTGAC CATCAATGAC 1800 GTTGGCCCTG CAGACGCAGG TCGCTATGAG TGTGTGGCCC GGAACACCAT TGGGTCGGCC 1860 TCGGTGAGCA TGGTGCTCAG TGTGAACGTT CCTGACGTCA GTCGAAATGG AGATCCGTTT 1920 GTAGCTACCT CCATCGTGGA AGCGATTGCG ACTGTTGACA GAGCTATAAA CTCAACCCGA 1980 ACACATTTGT TTGACAGCCG TCCTCGTTCT CCAAATGATT TGCTGGCCTT GTTCCGGTAT 2040 CCGAGGGATC CTTACACAGT TGAACAGGCA CGGGCGGGAG AAATCTTTGA ACGGACATTG 2100 CAGCTCATTC AGGAGCATGT ACAGCATGGC TTGATGGTCG ACCTCAACGG AACAAGTTAC 2160 CACTACAACG ACCTGGTGTC TCCACAGTAC CTGAACCTCA TCGCAAACCT GTCGGGCTGT 2220 ACCGCCCACC GGCGCGTGAA CAACTGCTCG GACATGTGCT TCCACCAGAA GTACCGGACG 2280 CACGACGGCA CCTGTAACAA CCTGCAGCAC CCCATGTGGG GCGCCTCGCT GACCGCCTTC 2340 GAGCGCCTGC TGAAATCCGT GTACGAGAAT GGCTTCAACA CCCCTCGGGG CATCAACCCC 2400 CACCGACTGT ACAACGGGCA CGCCCTTCCC ATGCCGCGCC TGGTGTCCAC CACCCTGATC 2460 GGGACGGAGA CCGTCACACC CGACGAGCAG TTCACCCACA TGCTGATGCA GTGGGGCCAG 2520 TTCCTGGACC ACGACCTCGA CTCCACGGTG GTGGCCCTGA GCCAGGCACG CTTCTCCGAC 2580

GGACAGCACT GCAGCAACGT GTGCAGCAAC GACCCCCCCT GCTTCTCTGT CATGATCCCC 2640

CCCAATGACT CCCGGGCCAG GAGCGGGGCC CGCTGCATGT TCTTCGTGCG CTCCAGCCCT 2700

GTGTGCGGCA GCGGCATGAC TTCGCTGCTC ATGAACTCCG TGTACCCGCG GGAGCAGATC 2760 AACCAGCTCA CCTCCTACAT CGACGCATCC AACGTGTACG GGAGCACGGA GCATGAGGCC 2820

CGCAGCATCC GCGACCTGGC CAGCCACCGC GGCCTGCTGC GGCAGGGCAT CGTGCAGCGG 2880

TCCGGGAAGC CGCTGCTCCC CTTCGCCACC GGGCCGCCCA CGGAGTGCAT GCGGGACGAG 2940

AACGAGAGCC CCATCCCCTG CTTCCTGGCC GGGGACCACC GCGCCAACGA GCAGCTGGGC 3000

CTGACCAGCA TGCACACGCT GTGGTTCCGC GAGCACAACC GCATTGCCAC GGAGCTGCTC 3060 AAGCTGAACC CGCACTGGGA CGGCGACACC ATCTACTATG AGACCAGGAA GATCGTGGGT 3120

GCGGAGATCC AGCACATCAC CTACCAGCAC TGGCTCCCGA AGATCCTGGG GGAGGTGGGC 3180

ATGAGGACGC TGGGAGAGTA CCACGGCTAC GACCCCGGCA TCAATGCTGG CATCTTCAAC 3240

GCCTTCGCCA CCGCGGCCTT CAGGTTTGGC CACACGCTTG TCAACCCACT GCTTTACCGG 3300

CTGGACGAGA ACTTCCAGCC CATTGCACAA GATCACCTCC CCCTTCACAA AGCTTTCTTC 3360 TCTCCCTTCC GGATTGTGAA TGAGGGCGGC ATCGATCCGC TTCTCAGGGG GCTGTTCGGG 3420

GTGGCGGGGA AAATGCGTGT GCCCTCGCAG CTGCTGAACA CGGAGCTCAC GGAGCGGCTG 3480

TTCTCCATGG CACACACGGT GGCTCTGGAC CTGGCGGCCA TCAACATCCA GCGGGGCCGG 3540

GACCACGGGA TCCCACCCTA CCACGACTAC AGGGTCTACT GCAATCTATC GGCGGCACAC 3600

ACGTTCGAGG ACCTGAAAAA TGAGATTAAA AACCCTGAGA TCCGGGAGAA ACTGAAAAGG 3660 TTGTATGGCT CGACACTCAA CATCGACCTG TTTCCGGCGC TCGTGGTGGA GGACCTGGTG 3720

CCTGGCAGCC GGCTGGGCCC CACCCTGATG TGTCTTCTCA GCACACAGTT CAAGCGCCTG 3780

CGAGATGGGG ACAGGTTGTG GTATGAGAAC CCTGGGGTGT TCTCCCCGGC CCAGCTGACT 3840

CAGATCAAGC AGACGTCGCT GGCCAGGATC CTATGCGACA ACGCGGACAA CATCACCCGG 3900

GTGCAGAGCG ACGTGTTCAG GGTGGCGGAG TTCCCTCACG GCTACGGCAG CTGTGACGAG 3960 ATCCCCAGGG TGGACCTCCG GGTGTGGCAG GACTGCTGTG AAGACTGTAG GACCAGGGGG 4020

CAGTTCAATG CCTTTTCCTA TCATTTCCGA GGCAGACGGT CTCTTGAGTT CAGCTACCAG 4080

GAGGACAAGC CGACCAAGAA AACAAGACCA CGGAAAATAC CCAGTGTTGG GAGACAGGGG 4140

GAACATCTCA GCAACAGCAC CTCAGCCTTC AGCACACGCT CAGATGCATC TGGGACAAAT 4200

GACTTCAGAG AGTTTGTTCT GGAAATGCAG AAGACCATCA CAGACCTCAG AACACAGATA 4260 AAGAAACTTG AATCACGGCT CAGTACCACA GAGTGCGTGG ATGCCGGGGG CGAATCTCAC 4320

GCCAACAACA CCAAGTGGAA AAAAGATGCA TGCACCATTT GTGAATGCAA AGACGGGCAG 4380

GTCACCTGCT TCGTGGAAGC TTGCCCCCCT GCCACCTGTG CTGTCCCCGT GAACATCCCA 4440

GGGGCCTGCT GTCCAGTCTG CTTACAGAAG AGGGCGGAGG AAAAGCCCTA_GGCTCCTGGG 4500

AGGCTCCTCA GAGTTTGTCT GCTGTGCCAT CGTGAGATCG GGTGGCCGAT GGCAGGGAGC 4560 TGCGGACTGC AGACCAGGAA ACACCCAGAA CTCGTGACAT TTCATGACAA CGTCCAGCTG 4620

GTGCTGTTAC AGAAGGCAGT GCAGGAGGCT TCCAACCAGA GCATCTGCGG AGAAGGAGGC 4680

ACAGCAGGTG CCTGAAGGGA AGCAGGCAGG AGTCCTAGCT TCACGTTAGA CTTCTCAGGT 4740

TTTTATTTAA TTCTTTTAAA ATGAAAAATT GGTGCTACTA TTAAATTGCA CAGTTGAATC 4800

ATTTAGGCGC CTAAATTGGT TTTGCCTCCC AACACCATTT CTTTTTAAAT AAAGCAGGAT 4860 ACCTCTATAT GTCAGCCTTG CCTTGTTCAG ATGCCAGGAG CCGGCAGACC TGTCACCCGC 4920

AGGTGGGGTG AGTCTCGGAG CTGCCAGAGG GGCTCACCGA AATCGGGGTT CCATCACAAG 4980

CTATGTTTAA AAAGAAAATT GGTGTTTGGC AAACGGAACA GAACCTTTGA TGAGAGCGTT 5040

CACAGGGACA CTGTCTGGGG GTGCAGTGCA AGCCCCCGGC CTCTTCCCTG GGAACCTCTG 5100

AACTCCTCCT TCCTCTGGGC TCTCTGTAAC ATTTCACCAC ACGTCAGCAT CTAATCCCAA 5160 GACAAACATT CCCGCTGCTC GAAGCAGCTG TATAGCCTGT GACTCTCCGT GTGTCAGCTC 5220

CTTCCACACC TGATTAGAAC ATTCATAAGC CACATTTAGA AACAGATTTG CTTTCAGCTG 5280

TCACTTGCAC ACATACTGCC TAGTTGTGAA CCAAATGTGA AAAAACCTCC TTCATCCCAT 5340

TGTGTATCTG ATACCTGCCG AGGGCCAAGG GTGTGTGTTG ACAACGCCGC TCCCAGCCGG 5400

CCCTGGTTGC GTCCACGTCC TGAACAAGAG CCGCTTCCGG ATGGCTCTTC CCAAGGGAGG 5460 AGGAGCTCAA GTGTCGGGAA CTGTCTAACT TCAGGTTGTG TGAGTGCGTT

Seq ID NO: 87 Protein sequence:

Protein Accession #: BAA13219

1 11 21 31 41 51

SRPWWLRASE RPSAPSAMAK RSRGPGRRCL LALVLFCAWG TLAWAQKPG AGCPSRCLCF 60

RTTVRCMHLL LEAVPAVAPQ TSILDLRFNR IREIQPGAFR RLRNLNTLLL NNNQIKRIPS 120

GAFEDLENLK YLYLYKNEIQ SIDRQAFKGL ASLEQLYLHF NQIETLDPDS FQHLPKLERL 180

FLHNNRITHL VPGTFNHLES MKRLRLDSNT LHCDCEILWL ADLLKTYAES GNAQAAAICE 240 YPRRIQGRSV ATITPEELNC ERPRITSEPQ DADVTSGNTV YFTCRAEGNP KPEIIWLRNN 300

NELSMKTDSR LNLLDDGTLM IQNTQETDQG IYQCMAKNVA GEVKTQEVTL RYFGSPARPT 360

FVIQPQNTEV LVGESVTLEC SATGHPPPRI SWTRGDRTPL PVDPRVNITP SGGLYIQNW 420

QGDSGEYACS ATNNIDSVHA TAFIIVQALP QFTVTPQDRV VIEGQTVDFQ CEAKGNPPPV 480

IAWTKGGSQL SVDRRHLVLS SGTLRISGVA LHDQGQYECQ AVNIIGSQKV VAHLTVQPRV 540 TPVFASIPSD TTVEVGANVQ LPCSSQGEPE PAITWNKDGV QVTESGKFHI SPEGFLTIND 600

VGPADAGRYE CVARNTIGSA SVSMVLSVNV PDVSRNGDPF VATSIVEAIA TVDRAINSTR 660

THLFDSRPRS PNDLLALFRY PRDPYTVEQA RAGEIFERTL QLIQEHVQHG LMVDLNGTSY 720

HYNDLVSPQY LNLIANLSGC TAHRRVNNCS DMCFHQKYRT HDGTCNNLQH PMWGASLTAF 780

ERLLKSVYEN GFNTPRGINP HRLYNGHALP MPRLVSTTLI GTETVTPDEQ FTHMLMQWGQ 840 FLDHDLDSTV VALSQARFSD GQHCSNVCSN DPPCFSVMIP PNDSRARSGA RCMFFVRSSP 900

VCGSGMTSLL MNSVYPREQI NQLTSYIDAS NVYGSTEHEA RSIRDLASHR GLLRQGIVQR 960

SGKPLLPFAT GPPTECMRDE NESPIPCFLA GDHRANEQLG LTSMHTLWFR EHNRIATELL 1020

KLNPHWDGDT IYYETRKIVG AEIQHITYQH WLPKILGEVG MRTLGEYHGY DPGINAGIFN 1080

AFATAAFRFG HTLVNPLLYR LDENFQPIAQ DHLPLHKAFF SPFRIVNEGG IDPLLRGLFG 1140 VAGKMRVPSQ LLNTELTERL FSMAHTVALD LAAINIQRGR DHGIPPYHDY RVYCNLSAAH 1200

TFEDLKNEIK NPEIREKLKR LYGSTLNIDL FPALWEDLV PGSRLGPTLM CLLSTQFKRL 1260 RDGDRLWYEN PGVFSPAQLT QIKQTSLARI LCDNADNITR VQSDVFRVAE FPHGYGSCDE 1320

IPRVDLRVWQ DCCEDCRTRG QFNAFSYHFR GRRSLEFSYQ EDKPTKKTRP RKIPSVGRQG 1380

EHLSNSTSAF STRSDASGTN DFREFVLEMQ KTITDLRTQI KKLESRLSTT ECVDAGGESH 1440 ANNTKWKKDA CTICECKDGQ VTCFVEACPP ATCAVPVNIP GACCPVCLQK RAEEKP

Seq ID NO: 88 DNA sequence

Nucleic Acid Accession #: NM_004834.1

Coding sequence: 80-3577 (underlined sequences correspond to start and stop codons)

1 11 21 31 41 51

AATTCGAGGA TCCGGGTACC ATGGCACAGA GCGACAGAGA CATTTATTGT TATTTGTTTT 60 TTGGTGGCAA AAAGGGAAAA TGGCGAACGA CTCCCCTGCA AAAAGTCTGG TGGACATCGA 120

CCTCTCCTCC CTGCGGGATC CTGCTGGGAT TTTTGAGCTG GTGGAAGTGG TTGGAAATGG 180

CACCTATGGA CAAGTCTATA AGGGTCGACA TGTTAAAACG GGTCAGTTGG CAGCCATCAA 240

AGTTATGGAT GTCACTGAGG ATGAAGAGGA AGAAATCAAA CTGGAGATAA ATATGCTAAA 300

GAAATACTCT CATCACAGAA ACATTGCAAC ATATTATGGT GCTTTCATCA AAAAGAGCCC 360 TCCAGGACAT GATGACCAAC TCTGGCTTGT TATGGAGTTC TGTGGGGCTG GGTCCATTAC 420

AGACCTTGTG AAGAACACCA AAGGGAACAC ACTCAAAGAA GACTGGATCG CTTACATCTC 480

CAGAGAAATC CTGAGGGGAC TGGCACATCT TCACATTCAT CATGTGATTC ACCGGGATAT 540

CAAGGGCCAG AATGTGTTGC TGACTGAGAA TGCAGAGGTG AAACTTGTTG ACTTTGGTGT 600

GAGTGCTCAG CTGGACAGGA CTGTGGGGCG GAGAAATACG TTCATAGGCA CTCCCTACTG 660 GATGGCTCCT GAGGTCATCG CCTGTGATGA GAACCCAGAT GCCACCTATG ATTACAGAAG 720

TGATCTTTGG TCTTGTGGCA TTACAGCCAT TGAGATGGCA GAAGGTGCTC CCCCTCTCTG 780

TGACATGCAT CCAATGAGAG CACTGTTTCT CATTCCCAGA AACCCTCCTC CCCGGCTGAA 840

GTCAAAAAAA TGGTCGAAGA AGTTTTTTAG TTTTATAGAA GGGTGCCTGG TGAAGAATTA 900

CATGCAGCGG CCCTCTACAG AGCAGCTTTT GAAACATCCT TTTATAAGGG ATCAGCCAAA 960 TGAAAGGCAA GTTAGAATCC AGCTTAAGGA TCATATAGAT CGTACCAGGA AGAAGAGAGG 1020

CGAGAAAGAT GAAACTGAGT ATGAGTACAG TGGGAGTGAG GAAGAAGAGG AGGAAGTGCC 1080

TGAACAGGAA GGAGAGCCAA GTTCCATTGT GAACGTGCCT GGTGAGTCTA CTCTTCGCCG 1140

AGATTTCCTG AGACTGCAGC AGGAGAACAA GGAACGTTCC GAGGCTCTTC GGAGACAACA 1200

GTTACTACAG GAGCAACAGC TCCGGGAGCA GGAAGAATAT AAAAGGCAAC TGCTGGCAGA 1260 GAGACAGAAG CGGATTGAGC AGCAGAAAGA ACAGAGGCGA CGGCTAGAAG AGCAACAAAG 1320

GAGAGAGCGG GAGGCTAGAA GGCAGCAGGA ACGTGAACAG CGAAGGAGAG AACAAGAAGA 1380

AAAGAGGCGT CTAGAGGAGT TGGAGAGAAG GCGCAAAGAA GAAGAGGAGA GGAGACGGGC 1440

AGAAGAAGAA AAGAGGAGAG TTGAAAGAGA ACAGGAGTAT ATCAGGCGAC AGCTAGAAGA 1500

GGAGCAGCGG CACTTGGAAG TCCTTCAGCA GCAGCTGCTC CAGGAGCAGG CCATGTTACT 1560 GCATGACCAT AGGAGGCCGC ACCCGCAGCA CTCGCAGCAG CCGCCACCAC CGCAGCAGGA 1620

AAGGAGCAAG GCAAGCTTCC ATGCTCCCGA GCCCAAAGCC CACTACGAGC CTGCTGACCG 1680

AGCGCGAGAG GTTCCTGTGA GAACAACATC TCGCTCCCCT GTTCTGTCCC GTCGAGATTC 1740

CCCACTGCAG GGCAGTGGGC AGCAGAATAG CCAGGCAGGA CAGAGAAACT CCACCAGTAT 1800

TGAGCCCAGG CTTCTGTGGG AGAGAGTGGA GAAGCTGGTG CCCAGACCTG GCAGTGGCAG 1860 CTCCTCAGGG TCCAGCAACT CAGGATCCCA GCCCGGGTCT CACCCTGGGT CTCAGAGTGG 1920

CTCCGGGGAA CGCTTCAGAG TGAGATCATC ATCCAAGTCT GAAGGCTCTC CATCTCAGCG 1980

CCTGGAAAAT GCAGTGAAAA AACCTGAAGA TAAAAAGGAA GTTTTCAGAC CCCTCAAGCC 2040

TGCTGGCGAA GTGGATCTGA CCGCACTGGC CAAAGAGCTT CGAGCAGTGG AAGATGTACG 2100

GCCACCTCAC AAAGTAACGG ACTACTCCTC ATCCAGTGAG GAGTCGGGGA CGACGGATGA 2160 GGAGGACGAC GATGTGGAGC AGGAAGGGGC TGACGAGTCC ACCTCAGGAC CAGAGGACAC 2220

CAGAGCAGCG TCATCTCTGA ATTTGAGCAA TGGTGAAACG GAATCTGTGA AAACCATGAT 2280

TGTCCATGAT GATGTAGAAA GTGAGCCGGC CATGACCCCA TCCAAGGAGG GCACTCTAAT 2340

CGTCCGCCAG ACTCAGTCCG CTAGTAGCAC ACTCCAGAAA CACAAATCTT CCTCCTCCTT 2400

TACACCTTTT ATAGACCCCA GATTACTACA GATTTCTCCA TCTAGCGGAA CAACAGTGAC 2460 ATCTGTGGTG GGATTTTCCT GTGATGGGAT GAGACCAGAA GCCATAAGGC AAGATCCTAC 2520

CCGGAAAGGC TCAGTGGTCA ATGTGAATCC TACCAACACT AGGCCACAGA GTGACACCCC 2580

GGAGATTCGT AAATACAAGA AGAGGTTTAA CTCTGAGATT CTGTGTGCTG CCTTATGGGG 2640

AGTGAATTTG CTAGTGGGTA CAGAGAGTGG CCTGATGCTG CTGGACAGAA GTGGCCAAGG 2700

GAAGGTCTAT CCTCTTATCA ACCGAAGACG ATTTCAACAA ATGGACGTAC TTGAGGGCTT 2760 GAATGTCTTG GTGACAATAT CTGGCAAAAA GGATAAGTTA CGTGTCTACT ATTTGTCCTG 2820

GTTAAGAAAT AAAATACTTC ACAATGATCC AGAAGTTGAG AAGAAGCAGG GATGGACAAC 2880

CGTAGGGGAT TTGGAAGGAT GTGTACATTA TAAAGTTGTA AAATATGAAA GAATCAAATT 2940

TCTGGTGATT GCTTTGAAGA GTTCTGTGGA AGTCTATGCG TGGGCACCAA AGCCATATCA 3000

CAAATTTATG GCCTTTAAGT CATTTGGAGA ATTGGTACAT AAGCCATTAC TGGTGGATCT 3060 CACTGTTGAG GAAGGCCAGA GGTTGAAAGT GATCTATGGA TCCTGTGCTG GATTCCATGC 3120

TGTTGATGTG GATTCAGGAT CAGTCTATGA CATTTATCTA CCAACACATG TAAGAAAGAA 3180

CCCACACTCT ATGATCCAGT GTAGCATCAA ACCCCATGCA ATCATCATCC TCCCCAATAC 3240

AGATGGAATG GAGCTTCTGG TGTGCTATGA AGATGAGGGG GTTTATGTAA ACACATATGG 3300

AAGGATCACC AAGGATGTAG TTCTACAGTG GGGAGAGATG CCTACATCAG TAGCATATAT 3360 TCGATCCAAT CAGACAATGG GCTGGGGAGA GAAGGCCATA GAGATCCGAT CTGTGGAAAC 3420

TGGTCACTTG GATGGTGTGT TCATGCACAA AAGGGCTCAA AGACTAAAAT TCTTGTGTGA 3480

ACGCAATGAC AAGGTGTTCT TTGCCTCTGT TCGGTCTGGT GGCAGCAGTC AGGTTTATTT 3540

CATGACCTTA GGCAGGACTT CTCTTCTGAG CTGGTAGAAG CAGTGTGATC CAGGGATTAC 3600

TGGCCTCCAG AGTCTTCAAG ATCCTGAGAA CTTGGAATTC CTTGTAACTG GAGCTCGGAG 3660 CTGCACCGAG GGCAACCAGG ACAGCTGTGT GTGCAGACCT CATGTGTTGG GTTCTCTCCC 3720

CTCCTTCCTG TTCCTCTTAT ATACCAGTTT ATCCCCATTC TTTTTTTTTT TCTTACTCCA 3780 AAATAAATCA AGGCTGCAAT GCAGCTGGTG CTGTTCAGAT TCCAAAAAAA AAAAAAAACC 3840 ATGGTACCCG GATCCTCGAA TTCC

Seq ID No : 89 Protein sequence : Protein Accession # : NP_004825 . 1

1 11 21 31 41 51

10

MANDSPAKSL VDIDLSSLRD PAGIFELVEV VGNGTYGQVY KGRHVKTGQL AAIKVMDVTE 60

DEEEEIKLEI NMLKKYSHHR NIATYYGAFI KKSPPGHDDQ LWLVMEFCGA GSITDLVKNT 120

KGNTLKEDWI AYISREILRG LAHLHIHHVI HRDIKGQNVL LTENAEVKLV DFGVSAQLDR 180

TVGRRNTFIG TPYWMAPEVI ACDENPDATY DYRSDLWSCG ITAIEMAEGA PPLCDMHPMR 240

15 ALFLIPRNPP PRLKSKKWSK KFFSFIEGCL VKNYMQRPST EQLLKHPFIR DQPNERQVRI 300

QLKDHIDRTR KKRGEKDETE YEYSGSEEEE EEVPEQEGEP SSIVNVPGES TLRRDFLRLQ 360

QENKERSEAL RRQQLLQEQQ LREQEEYKRQ LLAERQKRIE QQKEQRRRLE EQQRREREAR 420

RQQEREQRRR EQEEKRRLEE LERRRKEEEE RRRAEEEKRR VEREQEYIRR QLEEEQRHLE 480

VLQQQLLQEQ AMLLHDHRRP HPQHSQQPPP PQQERSKPSF HAPEPKAHYE PADRAREVPV 540

20 RTTSRSPVLS RRDSPLQGSG QQNSQAGQRN STSIEPRLLW ERVEKLVPRP GSGSSSGSSN 600

SGSQPGSHPG SQSGSGERFR VRSSSKSEGS PSQRLENAVK KPEDKKEVFR PLKPAGEVDL 660

TALAKELRAV EDVRPPHKVT DYSSSSEESG TTDEEDDDVE QEGADESTSG PEDTRAASSL 720

NLSNGETESV KTMIVHDDVE SEPAMTPSKE GTLIVRQTQS ASSTLQKHKS SSSFTPFIDP 780

RLLQISPSSG TTVTSWGFS CDGMRPEAIR QDPTRKGSW NVNPTNTRPQ SDTPEIRKYK 840

25 KRFNSEILCA ALWGVNLLVG TESGLMLLDR SGQGKVYPLI NRRRFQQMDV LEGLNVLVTI 900

SGKKDKLRVY YLSWLRNKIL HNDPEVEKKQ GWTTVGDLEG CVHYKWKYE RIKFLVIALK 960

SSVEVYAWAP KPYHKFMAFK SFGELVHKPL LVDLTVEEGQ RLKVIYGSCA GFHAVDVDSG 1020

SVYDIYLPTH VRKNPHSMIQ CSIKPHAIII LPNTDGMELL VCYEDEGVYV NTYGRITKDV 1080

VLQWGEMPTS VAYIRSNQTM GWGEKAIEIR SVETGHLDGV FMHKRAQRLK FLCERNDKVF 1140

30 FASVRSGGSS QVYFMTLGRT SLLSW

Seq ID NO : 90 DNA sequence Nucleic Acid Accession # : none found 35 Coding sequence : 2 -71 (underlined sequences correspond to start and stop codons )

1 11 21 31 41 51

4 „n1) T ITACACTTCA A ITTCCTTACA C IGGTATTTCA A IACAAACAGT T ITTGCTGAGA G IGAGCTTTTG 60

TCTCTCCTTA AGAAAATGTT TATAAAGCTG AAAGGAAATC AAACAGTAAT CTTAAAAATG 120

AAAACAAAAC AACCCAACAA CCTAGATAAC TACAGTGATC AGGGAGCACA GTTCAACTCC 180

TTGTTATGTT TTAGTCATAT GGCCTACTCA AACAGCTAAA TAACAACACC AGTGGCAGAT 240

AAAAATCACC ATTTATCTTT CAGCTATTAA TCTTTTGAAT GAATAAACTG TGACAAACAA 300 5 ATTAACATTT TTGAACATGA AAGGCAACTT CTGCACAATG CTGTATCCAA GCAAACTTTA 360

AATTATCCAC TTAATTATTA CTTAATCTTA AAAAAAATTA GAACCCAGAA CTTTTCAATG 420

AAGCATTTGA AAGTTGAAGT GGAATTTAGG AAAGCCATAA AAATATAAAT ACTGTTATCA 480

CAGCACCAGC AAGCCATAAT CTTTATACCT ATCAGTTCTA TTTCTATTAA CAGTAAAAAC 540

ATTAAGCAAG ATATAAGACT ACCTGCCCAA GAATTCAGTC TTTTTTCATT TTTGTTTTTC 600

50 TCAGTTCTGA GGATGTTAAT CGTCAAATTT TCTTTGGACT GCATTCCTCA CTACTTTTTG 660

CACAATGGTC TCACGTTCTC ACATTTGTTC TCGCGAATAA ATTGATAAAA GGTGTTAAGT 720

TCTGTGAATG TCTTTTTAAT TATGGGCATA ATTGTGCTTG ACTGGATAAA AACTTAAGTC 780

CACCCTTATG TTTATAATAA TTTCTTGAGA ACAGCAAACT GCATTTACCA TCGTAAAACA 840

ACATCTGACT TACGGGAGCT GCAGGGAAGT GGTGAGACAG TTCGAACGGC TCCTCAGAAA 900

55 TCCAGTGACC CAATTCTAAA GACCATAGCA CCTGCAAGTG ACACAACAAG CAGATTTATT 960

ATACATTTAT TAGCCTTAGC AGGCAATAAA CCAAGAATCA CTTTGAAGAC ACAGCAAAAA 1020

GTGATACACT CCGCAGATCT GAAATAGATG TGTTCTCAGA CAACAAAGTC CCTTCAGAAT 1080 CTTCATGTTG CATAAATGTT ATGAATATTA ATAAAAAGTT GATTGAGA

60

Seq ID No: 91 Protein sequence: Protein Accession #: none found

1 11 21 31 41 51

65 I I I I I I

YTSIPYTVFQ TNSFAERSFC LSL

Seq ID NO: 92 DNA sequence 70 Nucleic Acid Accession #: NM_003706.1

Coding sequence: 310-1935 (underlined sequences correspond to start and stop codons)

1 11 21 31 41 51

75 I I I I I I

CACGAGGCAG GGGCCATTTT ACCTCCAGGT TGGCCCTGCT CAGGACCAGG AGGAAACACC 60 TCCAGCCCGC GACCTCCTCC CACAGGGGGA AAAGGAAAGC AGGAGGACCA CAGAAGCTTT 120

GGCACCGAGG ATCCCCGCAG TCTTCACCCG CGGAGATTCC GGCTGAAGGA GCTGTCCAGC 180

GACTACACCG CTAAGCGCAG GGAGCCCAAG CCTCCGCACC GGATTCCGGA GCACAAGCTC 240

CACCGCGCAT GCGCACACGC CCCAGACCCA GGCTCAGGAG GACTGAGAAT TTTCTGACCG 300

CAGTGCACCA. TGGGAAGCTC TGAAGTTTCC ATAATTCCTG GGCTCCAGAA AGAAGAAAAG 360

GCGGCCGTGG AGAGACGAAG ACTTCATGTG CTGAAAGCTC TGAAGAAGCT AAGGATTGAG 420

GCTGATGAGG CCCCAGTTGT TGCTGTGCTG GGCTCAGGCG GAGGACTGCG GGCTCACATT 480

GCCTGCCTTG GGGTCCTGAG TGAGATGAAA GAACAGGGCC TGTTGGATGC CGTCACGTAC 540

CTCGCAGGGG TCTCTGGATC CACTTGGGCA ATATCTTCTC TCTACACCAA TGATGGTGAC 600

ATGGAAGCTC TCGAGGCTGA CCTGAAACAT CGATTTACCC GACAGGAGTG GGACTTGGCT 660

AAGAGCCTAC AGAAAACCAT CCAAGCAGCG AGGTCTGAGA ATTACTCTCT GACCGACTTC 720

TGGGCCTACA TGGTTATCTC TAAGCAAACC AGAGAACTGC CGGAGTCTCA TTTGTCCAAT 780

ATGAAGAAGC CCGTGGAAGA AGGGACACTA CCCTACCCAA TATTTGCAGC CATTGACAAT 840

GACCTGCAAC CTTCCTGGCA GGAGGCAAGA GCACCAGAGA CCTGGTTCGA GTTCACCCCT 900

CACCACGCTG GCTTCTCTGC ACTGGGGGCC TTTGTTTCCA TAACCCACTT CGGAAGCAAA 960

TTCAAGAAGG GAAGACTGGT CAGAACTCAC CCTGAGAGAG ACCTGACTTT CCTGAGAGGT 1020

TTATGGGGAA GTGCTCTTGG TAACACTGAA GTCATTAGGG AATACATTTT TGACCAGTTA 1080

AGGAATCTGA CCCTGAAAGG TTTATGGAGA AGGGCTGTTG CTAATGCTAA AAGCATTGGA 1140

CACCTTATTT TTGCCCGATT ACTGAGGCTG CAAGAAAGTT CACAAGGGGA ACATCCTCCC 1200

CCAGAAGATG AAGGCGGTGA GCCTGAACAC ACCTGGCTGA CTGAGATGCT CGAGAATTGG 1260

ACCAGGACCT CCCTGGAAAA GCAGGAGCAG CCCCATGAGG ACCCCGAAAG GAAAGGCTCA 1320

CTCAGTAACT TGATGGATTT TGTGAAGAAA ACAGGCATTT GCGCTTCAAA GTGGGAATGG 1380

GGGACCACTC ACAACTTCCT GTACAAACAC GGTGGCATCC GGGACAAGAT AATGAGCAGC 1440

CGGAAGCACC TCCACCTGGT GGATGCTGGT TTAGCCATCA ACACTCCCTT CCCACTCGTG 1500

CTGCCCCCGA CGCGGGAGGT TGACCTCATC CTCTCCTTCG ACTTCAGTGC CGGAGATCCT 1560

TTCGAGACCA TCCGGGCTAC CACTGACTAC TGCCGCCGCC ACAAGATCCC CTTTCCCCAA 1620

GTAGAAGAGG CTGAGCTGGA TTTGTGGTCC AAGGCCCCCG CCAGCTGCTA CATCCTGAAA 1680

GGAGAAACTG GACCAGTGGT GATACATTTT CCCCTGTTCA ACATAGATGC CTGTGGAGGT 1740

GATATTGAGG CATGGAGTGA CACATACGAC ACATTCAAGC TTGCTGACAC CTACACTCTA 1800

GATGTGGTGG TGCTACTCTT GGCATTAGCC AAGAAGAATG TCAGGGAAAA CAAGAAGAAG 1860

ATCCTTAGAG AGTTGATGAA CGTGGCCGGG CTCTACTACC CGAAGGATAG TGCCCGAAGT 1920

TGCTGCTTGG CATAGATGAG CCTCAGCTTC CAGGGCACTG TGGGCCTGTT GGTCTACTAG 1980

GGCCCTGAAG TCCACCTGGC CTTCCTGTTC TTCACTCCCT TCAGCCACAC GCTTCATGGC 2040

CTTGAGTTCA CCTTGGCTGT CCTAACAGGG CCAATCACCA GTGACCAGCT AGACTGTGAT 2100

TTTGATAGCG TCATTCAGAA GAAGGTGTCC AAGGAGCTGA AGGTGGTGAA ATTTGTCCTG 2160

CAGGTCCCTC GGGAGATCCT GGAGCTGGAG CATGAGTGTC TGACAATCAG AAGCATCATG 2220

TCCAATGTCC AGATGGCCAG AATGAATGTG ATAGTTCAGA CCAATGCCTT CCACTGCTCC 2280

TTTATGACTG CACTTCTAGC CAGTAGCTCT GCACAAGTTA GCTCTGTAGA AGTAAGAACT 2340

TGGGCTTAAA TCATGGGCTA TCTCTCCACA GCCAAGTGGA GCTCTGAGAA TACAACAAGT 2400

GCTCAATAAA TGCTTGCTGA TTGACTGATG AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 2460

AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAA

Seq ID No: 93 Protein sequence: Protein Accession #: NP 003697.1

11 21 31 41 51

MGSSEVSIIP GLQKEEKAAV ERRRLHVLKA LKKLRIEADE APWAVLGSG GGLRAHIACL 60

GVLSEMKEQG LLDAVTYLAG VSGSTWAISS LYTNDGDMEA LEADLKHRFT RQEWDLAKSL 120

QKTIQAARSE NYSLTDFWAY MVISKQTREL PESHLSNMKK PVEEGTLPYP IFAAIDNDLQ 180

PSWQEARAPE TWFEFTPHHA GFSALGAFVS ITHFGSKFKK GRLVRTHPER DLTFLRGLWG 240

SALGNTEVIR EYIFDQLRNL TLKGLWRRAV ANAKSIGHLI FARLLRLQES SQGEHPPPED 300

EGGEPEHTWL TEMLENWTRT SLEKQEQPHE DPERKGSLSN LMDFVKKTGI CASKWEWGTT 360

HNFLYKHGGI RDKIMSSRKH LHLVDAGLAI NTPFPLVLPP TREVHLILSF DFSAGDPFET 420

IRATTDYCRR HKIPFPQVEE AELDLWSKAP ASCYILKGET GPWIHFPLF NIDACGGDIE 480

AWSDTYDTFK LADTYTLDW VLLLALAKKN VRENKKKILR ELMNVAGLYY PKDSARSCCL _, 540 A

Seq ID NO: 94 DNA sequence

Nucleic Acid Accession #: AK027351

Coding sequence: 1-642 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

AGGGAAAAAA ACTCCATTAA AAAGCCCAGC TTTCCTCCAT GTTAGATGTG ACTTGGAAAA 60

TGAGAAAGAT TTAGCAAAAT TCCACCGTAT CTTTTGCCAG GCTAGAGACA GGGAGAGCAG 120

AGTAAAACCC TCAGGCTGCT GAAATTTCTA GGCTGTTAGG AAGCCCCTCG AATTCTGTGA 180

AAATGAGGGT TTCTTAACTC ACACTGAGAG CGGAAAGGGG CAGACCCTTT TCATAACTCC 240

CTCAAGTGTG TGTTACCTTT CTTTACCAGC ATGGTAAGCA ACAGGACATA TCCCAGCCTC 300

GGACATGTCT GTATGATCCA AGGTACCCAA AGTCAGACAG AGTAAACTCA AGCCTGGCAC 360

TGGCTTTCTG CCGCTTCATG TGCTTTGGAA AAAGCAGGAG AAGCAATAGC AGCAGGAGTC 420

CCCAGCAGCT GGAGCCGCAA GAATGAACTG CAAAGAGGGA ACTGACAGCA GCTGCGGCTG 480

CAGGGGCAAC GACGAGAAGA AGATGTTGAA GTGTGTGGTG GTGGGGGACG GTGCCGTGGG 540 GAAAACCTGC CTGCTGATGA GCTACGCCAA CGACGCCTTC CCAGAGGAAT ACGTGCCCAC 600 TGTGTTTGAC CACTATGCAG TTACTGTGAC TGTGGGAGGC AAGCAACACT TGCTCGGACT 660 GTATGACACC GCGGGACAGG AGGACTACAA CCAGCTGAGG CCACTCTCCT ACCCCAACAC 720 GGATGTGTTT TTGATCTGCT TCTCTGTCGT AAACCCTGCC TCTTACCACA ATGTCCAGGA 780 GGAATGGGTC CCCGAGCTCA AGGACTGCAT GCCTCACGTG CCTTATGTCC TCATAGGGAC 840 CCAGATTGAT CTCCGTGATG ACCCAAAAAC CTTGGCCCGT TTGCTGTATA TGAAAGAGAA 900 ACCTCTCACT TACGAGCATG GTGTGAAGCT CGCAAAAGCG ATCGGAGCAC AGTGCTACTT 960 GGAATGTTCA GCTCTGACTC AGAAAGGTCT CAAAGCGGTT TTTGATGAAG CAATCCTCAC 1020 CATTTTCCAC CCCAAGAAAA AGAAGAAACG CTGTTCTGAG GGTCACAGCT GCTGTTCAAT 1080 TATCTGAGGT TGTCTGGGAC CTGCCTCCAC CCCATCCAGG GATGAGAATG GCAGCCAATC 1140 TCTGTGGCCA AGCTCCAGCC AAAAAGGAGG GCACGACCAG AAAGGAACTC CCTTTGCACG 1200 GAGGCTTGCC CCATCACCCT CTGAGCCCTC CCAACACAGC ACACTAGTCA GCCCACTGCC 1260 ACGACCTCCC TGCCAGCCAG AAGCATCCGT ACTGCACGCT GTCTGAGAAT GCTGGGCCTG 1320 GATTGCAGAC AGTGCCGCTG CTGATCGCAT CAAAAACAAA GTCAAAGGCC ATCTCACATT 1380 TTACAAATCC CCAGCTCATG AACGTGAAGC TGATAGGAAA TCACCCCAGG GAACCCGAAA 1440 AAGAAACTTG ATTCCTCTAT TGCTGGCCTT ACTTGATGTC TTTTATAAAA CTTGGGACTA 1500 CAATACTAAC CTTTTTTTCT GAATCTGCTG TTCTACCCAT GTGTCTCACA TTCATTTGTA 1560 TTATTTCAAG AAATGTACTA ATTTCCAGTT CACTCAGGCC TTACTAATCC ATACCAAATT 1620 AGCCTAAAGA CAAGGCATTT TATATTCATT TCTATTTTCA GCATGTTTCT ACCAAAGCTA 1680 TTAGAACCAA CACGTACCTC TGAATGCCCG ATTATAAGAA GACATGAGAA GACTTTAAAA 1740 GTTTTGGAAA TTTACAGAGC CATGATTTTT GAACCTAATT GAAAGAAAAC CATCTGAATT 1800 GTTGCAGGTC CACATTTTTG CCAAAGATAC ACTCTATAGA TGCTTAGTAG TGGCCTGATT 1860 TTTTTCCATG TATTGCCACG ACAAACTAAA AATGAACTGT GTTTAAGAAT GTAGTATTTC 1920 TGTTTTTCAT CCAAGTTGAT TGGGGGAAGA ATATGGCAGG ATCCATCTTT TACAGTATTT 1980 TGTATTCAGT AAAGTGGACA TTCCTGCTCC TCCCTTCCCC CATTGCATGC CCTCTTCCTC 2040 ' CCTTGATTTC ACTTTCTCTC ATGCCCGGAT CCTTTTATTC TCCCCAGTTA TAACCCAGTT 2100 ATAAAAGAAA GATCTGAGCA TAAAGATACG TGTTTAAAAA TAACTAAAAG TAAAGGAAAG 2160 TGCCTTAATT TTTCTATTTG CTTCAACTGA AAGTGCTTCT CAGCTCGCCC CATGTAAGTT 2220 CTCATTCCAT GTAAATGACA TTTTCCAGTT ACAACTGGTA CTGAGATTTT GCCTCTCTCT 2280 TTCCTTACTC ATCCTCCCAA ATGTCTTTGT GGGAGCCATA TCAGTGGATA CCAAGCTCTG 2340 TATCCATTTG TCCCCTGCCC TCCACAATGT GTGACATAGA ACAGGGACTT TGGCCCTGGG 2400 AAAGCAAAAG CTCCCAGTAA GGAATCCTGT GCCCAATGAT GTAAAACAAT TCCAAACATC 2460 CAGGAATTTT TGTATCATAG AGCGAATTAC TTCCTATCTT TTCATTAGAG GCTATGAGGA 2520 CTTCTAATTA GTCTTAGTTG CTTATAAGTG CCCTGGAATC ACCCAGGTAG GCACTTAATT 2580 TTTTTTTCAG TTGCATGAGC AAAGTGCTTC TTAGTAGTGT GAAATTACAA CAACTTTAAG 2640 ACTTTCCAGA TTCAAGCTCC CACTGTTGGA AAAAGCCAGC CTTTCTAATC TCTTCTGCTA 2700 CTGGAATAAG CACTTAAGAA TTGCGTGATA GCCAGGCACC GTGGCTCATG CCTGTAATCC 2760 CAACACTTAG GGAGGCTGAG GTGGGTGGGC CGCTTGAGCT CAGGAGTTCA AGACCAGCCT 2820 GGGTAATATA GTGAGATCCT GTGTCTCTAT AAAAAAATTA AAAATTAGTC AGTTGTAGTG 2880 ACACATACCT GTAGTCCCAG CTACTCAGGA GGCTGAGGTG GAAGGATCAC TTGAGCCCAG 2940 AAGGTAAGGC TGCAGTGAGC TGTGACTGTG CCACTACACT CCAGCCTGAG TGACAGAGAA 3000 AGAACCTGTC AAAAAAAAAA AAAAAACAAC CTACATTTCA AGTACTATTT CCCTTCTCTC 3060 CCATCTAATT GCTAAAGATT TTCTTTCATA CGCACACACT CCAGTGACTG GAAAAACGGG 3120 AGTTTTCAGT CAAAGCTTGA CATTTAGAGA AAACAAGGAC TTTCTGCCTT TATAAATGGA 3180 AATCAACTGT GTATGAACTA TAACTCTGCA GAGGTTATGA ATTCATCCTT TACAAACAAT 3240 AATGAACTTT TAGTCCTGTA ATAAATGAAA TGTTATTAGG CAGCTTTGTT GCATGATTGC 3300 ATAGTTATAT CTTGCTAACG GGCCACTCAT TTCTCACTGA TGTGGATGAA AAAATGAGAG 3360 CAGTATGTTT CCAGGTGTGT GCACTCAACA GGCAAATAGC TCCCGAGGTC ACCACTTCCC 3420 TAATGGGCCA CAGGAAGTAA GTTGATCTTG ATGGGGAGAT CACGTCACCC AGAACCAGCA 3480 ACTGGATAGA GACTGTTGTT AGTGTCTGGG TAGAGCACAG GCTCCCAGGG GTCTTAAGAG 3540 CTAATTACTG AATAAAACAA TCTAGAACAA AGCAA

Seq ID No : 95 Protein sequence : Protein Accession # : CAC06611 . 1

11 21 31 41 51

MNCKEGTDSS CGCRGNDEKK MLKCVWGDG AVGKTCLLMS YANDAFPEEY VPTVFDHYAV 60 TVTVGGKQHL LGLYDTAGQE DYNQLRPLSY PNTDVFLICF SWNPASYHN VQEEWVPELK 120

DCMPHVPYVL IGTQIDLRDD PKTLARLLYM KEKPLTYEHG VKLAKAIGAQ CYLECSALTQ 180 KGLKAVFDEA ILTIFHPKKK KKRCSEGHSC CSII

Seq ID NO : 96 DNA sequence

Nucleic Acid Accession # : NM_003654 .1

Coding sequence : 367-1602 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

I I 1 I I

GGGGAGGGCG CGGGAGGCGG AGGATGCCGC CGCGGCTGCT GCCGCCGCCG CCACCCGCGG 60 GTCCCCGGCG ACCCTACTCC AGACCCGAGG ATGGAGCCGG CGCTGGGCGC TGCAGCTGCT 120 CCCGGCGCGT CCCCGACCAG GTAGCTGGTG TCACTTCGGT GTGGTTGGAA GAAGACTTTC 180 TCCCCAGCTG CATTCCCGGA GGCGCCCTTT CGACCTGGAG GCCGGGTCTG CTGGCCACAG 240 GGCTGCCGCA CTGGCTGGGA CTGCCAGCTG GGCCTGGAGA CGCTGGTGGC TGTGGACTCC 300 CCAGCTTGGA GCAGTCCCTC TTTGACCTCA CCCCTTGGAG AAGCAGCCCC ATGAAGGTGC 360 CCAGCCATGC AATGTTCCTG GAAGGCCGTC CTCCTCCTTG CCCTGGCCTC CATTGCCATC 420 CAGTACACGG CCATCCGCAC CTTCACCGCC AAGTCCTTTC ACACCTGCCC CGGGCTGGCA 480 GAGGCCGGGC TGGCCGAGCG ACTGTGCGAG GAGAGCCCCA CCTTCGCCTA CAACCTCTCC 540 CGCAAGACCC ACATCCTCAT CCTGGCCACC ACGCGCAGCG GCTCCTCCTT CGTGGGCCAG 600 CTCTTCAACC AGCACCTGGA CGTCTTCTAC CTGTTTGAGC CCCTCTACCA CGTCCAGAAC 660 ACGCTCATCC CCCGCTTCAC CCAGGGCAAG AGCCCGGCCG ACCGGCGGGT CATGCTAGGC 720 GCCAGCCGCG ACCTCCTGCG GAGCCTCTAC GACTGCGACC TCTACTTCCT GGAGAACTAC 780 ATCAAGCCGC CGCCGGTCAA CCACACCACC GACAGGATCT TCCGCCGCGG GGCCAGCCGG 840 GTCCTCTGCT CCCGGCCTGT GTGCGACCCT CCGGGGCCAG CCGACCTGGT CCTGGAGGAG 900 GGGGACTGTG TGCGCAAGTG CGGGCTACTC AACCTGACCG TGGCGGCCGA GGCGTGCCGC 960 GAGCGCAGCC AGGTGGCCAT CAAGACGGTG CGCGTGCCCG AGGTGAACGA CCTGCGCGCC 1020 CTGGTGGAAG ACCCGCGATT AAACCTCAAG GTCATCCAGC TGGTCCGAGA CCCCCGCGGC 1080 ATTCTGGCTT CGCGCAGCGA GACCTTCCGC GACACGTACC GGCTCTGGCG GCTCTGGTAC 1140 GGCACCGGGA GGAAACCCTA CAACCTGGAC GTGACGCAGC TGACCACGGT GTGCGAGGAC 1200 TTCTCCAACT CCGTGTCCAC CGGCCTCATG CGGCCCCCGT GGCTCAAGGG CAAGTACATG 1260 TTGGTGCGCT ACGAGGACCT GGCTCGGAAC CCTATGAAGA AGACCGAGGA GATCTACGGG 1320 TTCCTGGGCA TCCCGCTGGA CAGCCACGTG GCCCGCTGGA TCCAGAACAA CACGCGGGGC 1380 GACCCCACCC TGGGCAAGCA CAAATACGGC ACCGTGCGAA ACTCGGCGGC CACGGCCGAG 1440 AAGTGGCGCT TCCGCCTCTC CTACGACATC GTGGCCTTTG CCCAGAACGC CTGCCAGCAG 1500 GTGCTGGCCC AGCTGGGCTA CAAGATCGCC GCCTCGGAGG AGGAGCTGAA GAACCCCTCG 1560 GTCAGCCTGG TGGAGGAGCG GGACTTCCGC CCCTTCTCGT. GACCCGGGCG GTGCGGGTGG 1620 GGGCGGGAGG CGCAAGGTGT CGGTTTTGAT AAAATGGACC GTTTTTAACT GTTGCCTTAT 1680 TAACCCCTCC CTCTCCCACC TCATCTTCGT GTCCTTCCTG CCCCCAGCTC ACCCCACTCC 1740 CTTCTGCCCC TTTTTTGTCT CTGAAATTTG CACTACGTCT TGGACGGGAA TCACTGGGGC 1800 AGAGGGCGCC TGAAGTAGGG TCCCGCCCCC CCCACCCCAT TCAGACACAT GGATGTTGGG 1860 TCTCTGTGCG GACGGTGACA ATGTTTACAA GCACCACATT TACACATCCA CACACGCACA 1920 CGGGCACTCG CGAGGCGACT TCTCAAGCTT TTGAATGGGT GAGTGGTCGG GTATCTAGTT 1980 TTTGCACTGT CTTACTATTC AAGGTAAGAG GATACAAACA AGAGGACCAC TTGTCTCTAA 2040 TTTATGAATG GTGTCCATCC TTTCCCCATC CCTGCCTCCT GCCCCTGACG CCCATTTCCC 2100 CCCTTAGAGC AGCGAAACTG CCCCCTCCTG CCCGCCCTTG CCTGTCGGTG AGGCAGGTTT 2160 TTACTGTGAG GTGAACGTGG ACCTGTTTCT GTTTCCAGTC TGTGGTGATG CTGTCTGTCT 2220 GTCTGAGTCT CGTGGCCGCC CCTGGACCAG TGATGACTGA TGAATCTTAT GAGCTTCTGA 2280 TTGATCTCGG GGTCCATCTG TGATATTTCT TTGTGCCAAA AAGAAAAAAA AAGAGTGGAT 2340 CAGTTTGCTA AATGAACATT GAAATTGAAA TGCTTTATCT GTGTTTTCTG TAAATAAAAG 2400 AGTGCAATAA TCACC

Seq ID No: 97 Protein sequence : Protein Accession #: NP 003645.1

11 21 31 41 51

MQCSWKAVLL LALASIAIQY TAIRTFTAKS FHTCPGLAEA GLAERLCEES PTFAYNLSRK 60

THILILATTR SGSSFVGQLF NQHLDVFYLF EPLYHVQNTL IPRFTQGKSP ADRRVMLGAS 120

RDLLRSLYDC DLYFLENYIK PPPVNHTTDR IFRRGASRVL CSRPVCDPPG PADLVLEEGD 180

CVRKCGLLNL TVAAEACRER SHVAIKTVRV PEVNDLRALV EDPRLNLKVI QLVRDPRGIL 240

ASRSETFRDT YRLWRLWYGT GRKPYNLDVT QLTTVCEDFS NSVSTGLMRP PWLKGKYMLV 300

RYEDLARNPM KKTEEIYGFL GIPLDSHVAR WIQNNTRGDP TLGKHKYGTV RNSAATAEKW 360

RFRLSYDIVA FAQNACQQVL AQDGYKIAAS EEELKNPSVS LVEERDFRPF S

Seq ID NO: 98 DNA sequence

Nucleic Acid Accession #: NM_002852.1

Coding sequence: 68-1213 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

CTCAAACTCA GCTCACTTGA GAGTCTCCTC CCGCCAGCTG TGGAAAGAAC TTTGCGTCTC 60 TCCAGCAATG CATCTCCTTG CGATTCTGTT TTGTGCTCTC TGGTCTGCAG TGTTGGCCGA 120 GAACTCGGAT GATTATGATC TCATGTATGT GAATTTGGAC AACGAAATAG ACAATGGACT 180 CCATCCCACT GAGGACCCCA CGCCGTGCGA CTGCGGTCAG GAGCACTCGG AATGGGACAA 240 GCTCTTCATC ATGCTGGAGA ACTCGCAGAT GAGAGAGCGC ATGCTGCTGC AAGCCACGGA 300 CGACGTCCTG CGGGGCGAGC TGCAGAGGCT GCGGGAGGAG CTGGGCCGGC TCGCGGAAAG 360 CCTGGCGAGG CCGTGCGCGC CGGGGGCTCC CGCAGAGGCC AGGCTGACCA GTGCTCTGGA 420 CGAGCTGCTG CAGGCGACCC GCGACGCGGG CCGCAGGCTG GCGCGTATGG AGGGCGCGGA 480 GGCGCAGCGC CCAGAGGAGG CGGGGCGCGC CCTGGCCGCG GTGCTAGAGG AGCTGCGGCA 540 GACGCGAGCC GACCTGCACG CGGTGCAGGG CTGGGCTGCC CGGAGCTGGC TGCCGGCAGG 600 TTGTGAAACA GCTATTTTAT TCCCAATGCG TTCCAAGAAG ATTTTTGGAA GCGTGCATCC 660 AGTGAGACCA ATGAGGCTTG AGTCTTTTAG TGCCTGCATT TGGGTCAAAG CCACAGATGT 720 ATTAAACAAA ACCATCCTGT TTTCCTATGG CACAAAGAGG AATCCATATG AAATCCAGCT 780 GTATCTCAGC TACCAATCCA TAGTGTTTGT GGTGGGTGGA GAGGAGAACA AACTGGTTGC 840 TGAAGCCATG GTTTCCCTGG GAAGGTGGAC CCACCTGTGC GGCACCTGGA ATTCAGAGGA 900 AGGGCTCACA TCCTTGTGGG TAAATGGTGA ACTGGCGGCT ACCACTGTTG AGATGGCCAC 960 AGGTCACATT GTTCCTGAGG GAGGAATCCT GCAGATTGGC CAAGAAAAGA ATGGCTGCTG 1020 TGTGGGTGGT GGCTTTGATG AAACATTAGC CTTCTCTGGG AGACTCACAG GCTTCAATAT 1080 CTGGGATAGT GTTCTTAGCA ATGAAGAGAT AAGAGAGACC GGAGGAGCAG AGTCTTGTCA 1140 CATCCGGGGG AATATTGTTG GGTGGGGAGT CACAGAGATC CAGCCACATG GAGGAGCTCA 1200 GTATGTTTCA TAAATGTTGT GAAACTCCAC TTGAAGCCAA AGAAAGAAAC TCACACTTAA 1260 AACACATGCC AGTTGGGAAG GTCTGAAAAC TCAGTGCATA ATAGGAACAC TTGAGACTAA 1320 TGAAAGAGAG AGTTGAGACC AATCTTTATT TGTACTGGCC AAATACTGAA TAAACAGTTG 1380 AAGGAAAGAC ATTGGAAAAA GCTTTTGAGG ATAATGTTAC TAGACTTTAT GCCATGGTGC 1440 TTTCAGTTTA ATGCTGTGTC TCTGTCAGAT AAACTCTCAA ATAATTAAAA AGGACTGTAT 1500 TGTTGAACAG AGGGACAATT GTTTTACTTT TCTTTGGTTA ATTTTGTTTT GGCCAGAGAT 1560 GAATTTTACA TTGGAAGAAT AACAAAATAA GATTTGTTGT CCATTGTTCA TTGTTATTGG 1620 TATGTACCTT ATTACAAAAA AAATGATGAA AACATATTTA TACTACAAGG TGACTTAACA 1680 ACTATAAATG TAGTTTATGT GTTATAATCG AATGTCACGT TTTTGAGAAG ATAGTCATAT 1740 AAGTTATATT GCAAAAGGGA TTTGTATTAA TTTAAGACTA TTTTTGTAAA GCTCTACTGT 1800 AAATAAAATA TTTTATAAAA CTAAAAAAAA AAAAAAA

Seq ID No: 99 Protein sequence: Protein Accession #: NP 002843.1

11 21 31 41 51

I I I I I

MHLLAILFCA LWSAVLAENS DDYDLMYVNL DNEIDNGLHP TEDPTPCDCG QEHSEWDKLF 60 IMLENSQMRE RMLLQATDDV LRGELQRLRE ELGRLAESLA RPCAPGAPAE ARLTSALDEL 120 LQATRDAGRR LARMEGAEAQ RPEEAGRALA AVLEELRQTR ADLHAVQGWA ARSWLPAGCE 180 TAILFPMRSK KIFGSVHPVR PMRLESFSAC IWVKATDVLN KTILFSYGTK RNPYEIQLYL 240 SYQSIVFWG GEENKLVAEA MVSLGRWTHL CGTWNSEEGL TSLWVNGELA ATTVEMATGH 300 IVPEGGILQI GQEKNGCCVG GGFDETLAFS GRLTGFNIWD SVLSNEEIRE TGGAESCHIR 360 GNIVGWGVTE IQPHGGAQYV S

Seq ID NO: 100 DNA sequence

Nucleic Acid Accession #: NM_007351.1

Coding sequence: 72-3758 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

I I I I I

CTGCTATCAA AAAGGCCATA AGGATTTTGT CCCCAAATTT CACATGAGCT ACCTTGCTTC 60 AAACTACTGA GATGAAGGGG GCAAGATTAT TTGTCCTTCT TTCTAGTTTA TGGAGTGGGG 120 GCATTGGGCT TAACAACAGT AAGCATTCTT GGACTATACC TGAGGATGGG AACTCTCAGA 180 AGACTATGCC TTCTGCTTCA GTTCCTCCAA ATAAAATACA AAGTTTGCAA ATACTGCCAA 240 CCACTCGGGT CATGTCGGCG GAGATAGCTA CAACTCCAGA GGCAAGAACT TCTGAAGACA 300 GTCTTCTTAA ATCAACACTG CCTCCCTCAG AAACAAGTGC ACCTGCTGAG GGTGTGAGAA 360 ATCAAACTCT CACATCCACA GAGAAAGCAG AAGGAGTGGT CAAGTTACAG AATCTTACCC 420 TCCCAACCAA CGCTAGCATC AAGTTCAATC CTGGAGCAGA ATCAGTGGTC CTTTCCAATT 480 CTACACTGAA ATTTCTTCAG AGCTTTGCCA GAAAGTCAAA TGAACAAGCA ACTTCTCTAA 540 ACACAGTTGG AGGCACTGGA GGCATTGGAG GCGTTGGAGG CACTGGAGGC GTGGGAAATC 600 GAGCCCCACG GGAAACATAC CTCAGCCGGG GTGACAGCAG TTCCAGCCAA AGAACTGACT 660 ACCAAAAATC AAATTTCGAA ACAACTAGAG GAAAGAATTG GTGTGCTTAT GTACATACCA 720 GGTTATCTCC CACAGTGACA TTGGACAACC AGGTCACTTA TGTCCCAGGT GGGAAAGGAC 780 CTTGTGGCTG GACCGGTGGA TCCTGTCCTC AGAGATCTCA GAAGATATCC AATCCTGTCT 840 ATAGGATGCA ACATAAAATT GTCACCTCAT TGGATTGGAG GTGCTGTCCT GGATACAGTG 900 GGCCGAAATG TCAACTAAGA GCCCAGGAAC AGCAAAGTTT GATACACACC AACCAGGCTG 960 AAAGTCATAC AGCTGTTGGC AGAGGAGTAG CTGAGCAGCA GCAGCAGCAA GGCTGTGGTG 1020 ACCCAGAAGT GATGCAAAAA ATGACTGATC AGGTGAACTA CCAGGCAATG AAACTGACTC 1080 TTCTGCAGAA GAAGATTGAC AATATTTCTT TGACTGTGAA TGATGTAAGG AACACTTACT 1140 CCTCCCTAGA AGGAAAAGTC AGCGAAGATA AAAGCAGAGA ATTTCAATCT CTTCTAAAAG 1200 GTCTAAAATC CAAAAGCATT AATGTACTGA TAAGAGACAT AGTAAGAGAA CAATTTAAAA 1260 TTTTTCAAAA TGACATGCAA GAGACTGTAG CACAGCTCTT CAAGACTGTA TCAAGTCTAT 1320 CAGAGGACCT CGAAAGCACC AGGCAAATAA TTCAAAAAGT TAATGAATCT GTGGTTTCAA 1380 TAGCAGCCCA GCAAAAGTTT GTTTTGGTGC AAGAGAATCG GCCCACTTTG ACTGATATAG 1440 TGGAACTAAG GAATCACATT GTGAATGTAA GGCAAGAAAT GACTCTTACA TGTGAGAAGC 1500 CTATTAAAGA ACTAGAAGTA AAGCAGACTC ATTTAGAAGG TGCTCTAGAA CAGGAACACT 1560 CAAGAAGCAT TCTGTATTAT GAATCCCTCA ATAAAACTCT TTCTAAATTG AAGGAAGTAC 1620 ATGAGCAGCT TTTATCAACT GAACAGGTAT CAGACCAGAA GAATGCTCCA GCTGCTGAGT 1680 CAGTTAGCAA TAATGTCACT GAGTACATGT CTACTTTACA TGAAAATATA AAGAAGCAGA 1740 GTTTGATGAT GCTGCAAATG TTTGAAGATT TGCACATTCA AGAAAGCAAG ATTAACAATC 1800 TCACCGTCTC TTTGGAGATG GAGAAAGAGT CTCTCAGAGG TGAATGTGAA GACATGTTAT 1860 CCAAATGCAG AAATGATTTT AAATTTCAAC TTAAGGACAC AGAAGAGAAT TTACATGTGT 1920 TAAATCAAAC ATTGGCTGAA GTTCTCTTTC CAATGGACAA TAAGATGGAC AAAATGAGTG 1980 AGCAACTAAA TGATTTGACT TATGATATGG AGATCCTTCA ACCCTTGCTT GAGCAGGGAG 2040 CATCACTCAG ACAGACAATG ACATATGAAC AACCAAAGGA AGCAATAGTG ATAAGGAAAA 2100 AGATAGAAAA TCTGACTAGT GCTGTCAATA GTCTAAATTT TATTATCAAA GAACTTACAA 2160 AAAGACACAA CTTACTTAGA AATGAAGTAC AGGGTCGTGA TGATGCCTTA GAAAGACGTA 2220 TCAATGAATA TGCCTTAGAA ATGGAAGATG GCCTCAATAA GACAATGACT ATTATAAATA 2280 ATGCTATTGA TTTCATTCAA GATAACTATG CCCTAAAAGA GACTTTAAGT ACTATTAAGG 2340 ATAATAGTGA GATCCATCAT AAATGTACCT CCGATATGGA AACTATTTTG ACATTTATTC 2400 CTCAGTTCCA CCGTCTGAAT GATTCTATTC AGACTTTGGT CAATGACAAT CAGAGATATA 2460 ACTTTGTTTT GCAAGTCGCC AAGACCCTTG CAGGTATTCC CAGAGATGAG AAACTAAATC 2520

AGTCCAACTT CCAAAAGATG TATCAAATGT TCAATGAAAC CACTTCCCAA GTGAGAAAAT 2580

ACCAGCAAAA TATGAGTCAT TTGGAAGAAA AACTACTCTT AACTACCAAG ATTTCCAAAA 2640

ATTTTGAGAC TCGGTTGCAA GACATTGAGT CTAAAGTTAC CCAGACGCTC ATACCTTATT 2700

5 ATATTTCAGT TAAAAAAGGC AGTGTAGTTA CAAATGAGAG AGATCAGGCT CTTCAACTGC 2760

AAGTATTAAA TTCCAGATTT AAGGCGTTGG AAGCAAAATC TATCCATCTT TCAATTAACT 2820

TCTTTTCGCT TAACAAAACT CTCCACGAAG TTTTAACAAT GTGTCACAAT GCTTCTACAA 2880

GTGTGTCAGA ACTGAATGCT ACCATCCCTA AGTGGATAAA ACATTCCCTG CCAGATATTC 2940

AACTTCTTCA GAAAGGTCTA ACAGAATTTG TGGAACCAAT AATTCAAATA AAAACTCAAG 3000

10 CTGCCCTATC TAATTCAACT TGTTGTATAG ATCGATCGTT GCCTGGTAGT CTGGCAAATG 3060

TTGTCAAGTC TCAGAAGCAA GTAAAATCAT TGCCAAAGAA AATTAACGCA CTTAAGAAAC 3120

CAACGGTAAA TCTTACCACA GTCCTGATAG GCCGGACTCA AAGAAACACG GACAACATAA 3180

TATATCCTGA GGAGTATTCA AGCTGTAGTC GGCATCCGTG CCAAAATGGG GGCACGTGCA 3240

TAAATGGAAG AACTAGCTTT ACCTGTGCCT GCAGACATCC TTTTACTGGT GACAACTGCA 3300

15 CTATCAAGCT TGTGGAAGAA AATGCTTTAG CTCCAGATTT TTCCAAAGGA TCTTACAGAT 3360

ATGCACCCAT GGTGGCATTT TTTGCATCTC ATACGTATGG AATGACTATA CCTGGTCCTA 3420

TCCTGTTTAA TAACTTGGAT GTCAATTATG GAGCTTCATA TACCCCAAGA ACTGGAAAAT 3480

TTAGAATTCC GTATCTTGGA GTATATGTTT TCAAGTACAC CATCGAGTCA TTTAGTGCTC 3540

ATATTTCTGG ATTTTTAGTG GTTGATGGAA TAGACAAGCT TGCATTTGAG TCTGAAAATA 3600 0 TTAACAGTGA AATACACTGT GATAGGGTTT TAACTGGGGA TGCCTTATTA GAATTAAATT 3660

ATGGGCAGGA AGTCTGGTTA CGACTTGCAA AAGGAACAAT TGCAGCCAAG TTTCCCCCTG 3720

TTACTACATT TAGTGGCTAT TTATTATATC GTACATAAGT TAGTATGAAA AACAGACTAT 3780

CACCTTTATT GAGAAACAGC CAGTGTTTTC ATTTATCTTT GCTTGCACAT CTGCTCTGTT 3840

TTGGTTTTTC TACAGGAAAT GAAAATCAAC TTGTTTTTTT AATATGAGTA AACTTGTATG 3900 5 TCTATTTTAT AAAATTATTT GAATATTGTT TAATGTCTGA ATATGAAAGA GTTCTTGATC 3960

CTAAAGAAAT TTAGTGGCAC AGAAAACAAA GTGAATTTGT TAGCATAATT ATTCCTATTC 4020

TTATTTCTTC ATTTTAAGTC ATTGCAATGG AAAGTAATAT TATAAAACGG TAATTACAAC 4080

ATATTATCAG TCACAGTTTT CTTTCCAATT AAACACTTAA CTTTTGTTAT TCCCTGTATA 4140 TAAATATATA ACACACATTT TCTAGATTCA CAAATTTAAA TAAATTACTC AAAAAATG

30

Seq ID No : 101 Protein sequence : Protein Accession # : NP 031377 . 1

11 21 31 41 51 5

MKGARLFVLL SSLWSGGIGL NNSKHSWTIP EDGNSQKTMP SASVPPNKIQ SLQILPTTRV 60

MSAEIATTPE ARTSEDSLLK STLPPSETSA PAEGVRNQTL TSTEKAEGW KLQNLTLPTN 120

ASIKFNPGAE SWLSNSTLK FLQSFARKSN EQATSLNTVG GTGGIGGVGG TGGVGNRAPR 180

ETYLSRGDSS SSQRTDYQKS NFETTRGKNW CAYVHTRLSP TVTLDNQVTY VPGGKGPCGW 240 0 TGGSCPQRSQ KISNPVYRMQ HKIVTSLDWR CCPGYSGPKC QLRAQEQQSL IHTNQAESHT 300

AVGRGVAEQQ QQQGCGDPEV MQKMTDQVNY QAMKLTLLQK KIDNISLTVN DVRNTYSSLE 36θ^'

GKVSEDKSRE FQSLLKGLKS KSINVLIRDI VREQFKIFQN DMQETVAQLF KTVSSLSEDL 420

ESTRQIIQKV NESWSIAAQ QKFVLVQENR PTLTDIVELR NHIVNVRQEM TLTCEKPIKE 480

LEVKQTHLEG ALEQEHSRSI LYYESLNKTL SKLKEVHEQL LSTEQVSDQK NAPAAESVSN 540 5 NVTEYMSTLH ENIKKQSLMM LQMFEDLHIQ ESKINNLTVS LEMEKESLRG ECEDMLSKCR 600

NDFKFQLKDT EENLHVLNQT LAEVLFPMDN KMDKMSEQLN DLTYDMEILQ PLLEQGASLR 660

QTMTYEQPKE AIVIRKKIEN LTSAVNSLNF IIKELTKRHN LLRNEVQGRD DALERRINEY 720

ALEMEDGLNK TMTIINNAID FIQDNYALKE TLSTIKDNSE IHHKCTSDME TILTFIPQFH 780

RLNDSIQTLV NDNQRYNFVL QVAKTLAGIP RDEKLNQSNF QKMYQMFNET TSQVRKYQQN 840 0 MSHLEEKLLL TTKISKNFET RLQDIESKVT QTLIPYYISV KKGSWTNER DQALQLQVLN 900

SRFKALEAKS IHLSINFFSL NKTLHEVLTM CHNASTSVSE LNATIPKWIK HSLPDIQLLQ 960

KGLTEFVEPI IQIKTQAALS NSTCCIDRSL PGSLANWKS QKQVKSLPKK INALKKPTVN 1020

LTTVLIGRTQ RNTDNIIYPE EYSSCSRHPC QNGGTCINGR TSFTCACRHP FTGDNCTIKL 1080

VEENALAPDF SKGSYRYAPM VAFFASHTYG MTIPGPILFN NLDVNYGASY TPRTGKFRIP 1140 5 YLGVYVFKYT IESFSAHISG FLWDGIDKL AFESENINSE IHCDRVLTGD ALLELNYGQE 1200 VWLRLAKGTI PAKFPPVTTF SGYLLYRT

Seq ID NO : 102 DNA sequence Nucleic Acid Accession # : NM_000873 . 2 0 Coding sequence : 57- 884 (underlined sequences correspond to start and stop codons)

1 11 21 31 41 51

„ I I I I I I J ATCTCCCTCC AGGCAGCCCT TGGCTGGTCC CTGCGAGCCC GTGGAGACTG CCAGAGATGT 60

CCTCTTTCGG TTACAGGACC CTGACTGTGG CCCTCTTCAC CCTGATCTGC TGTCCAGGAT 120

CGGATGAGAA GGTATTCGAG GTACACGTGA GGCCAAAGAA GCTGGCGGTT GAGCCCAAAG 180

GGTCCCTCGA GGTCAACTGC AGCACCACCT GTAACCAGCC TGAAGTGGGT GGTCTGGAGA 240

CCTCTCTAAA TAAGATTCTG CTGGACGAAC AGGCTCAGTG GAAACATTAC TTGGTCTCAA 300 0 ACATCTCCCA TGACACGGTC CTCCAATGCC ACTTCACCTG CTCCGGGAAG CAGGAGTCAA 360

TGAATTCCAA CGTCAGCGTG TACCAGCCTC CAAGGCAGGT CATCCTGACA CTGCAACCCA 420

CTTTGGTGGC TGTGGGCAAG TCCTTCACCA TTGAGTGCAG GGTGCCCACC GTGGAGCCCC 480

TGGACAGCCT CACCCTCTTC CTGTTCCGTG GCAATGAGAC TCTGCACTAT GAGACCTTCG 540

GGAAGGCAGC CCCTGCTCCG CAGGAGGCCA CAGCCACATT CAACAGCACG GCTGACAGAG 600 5 AGGATGGCCA CCGCAACTTC TCCTGCCTGG CTGTGCTGGA CTTGATGTCT CGCGGTGGCA 660

ACATCTTTCA CAAACACTCA GCCCCGAAGA TGTTGGAGAT CTATGAGCCT GTGTCGGACA 720 GCCAGATGGT CATCATAGTC ACGGTGGTGT CGGTGTTGCT GTCCCTGTTC GTGACATCTG 780

TCCTGCTCTG CTTCATCTTC GGCCAGCACT TGCGCCAGCA GCGGATGGGC ACCTACGGGG 840

TGCGAGCGGC TTGGAGGAGG CTGCCCCAGG CCTTCCGGCC ATAGCAACCA TGAGTGGCAT 900

GGCCACCACC ACGGTGGTCA CTGGAACTCA GTGTGACTCC TCAGGGTTGA GGTCCAGCCC 960

TGGCTGAAGG ACTGTGACAG GCAGCAGAGA CTTGGGACAT TGCCTTTTCT AGCCCGAATA 1020 CAAACACCTG GACTT

Seq ID No : 103 Protein sequence : Protein Accession # : NP 000864 . 1

11 21 31 41 51

MSSFGYRTLT VALFTLICCP GSDEKVFEVH VRPKKLAVEP KGSLEVNCST TCNQPEVGGL 60 ETSLNKILLD EQAQWKHYLV SNISHDTVLQ CHFTCSGKQE SMNSNVSVYQ PPRQVILTLQ 120

PTLVAVGKSF TIECRVPTVE PLDSLTLFLF RGNETLHYET FGKAAPAPQE ATATFNSTAD 180

REDGHRNFSC LAVLDLMSRG GNIFHKHSAP KMLEIYEPVS DSQMVIIVTV VSVLLSLFVT 240 SVLLCFIFGQ HLRQQRMGTY GVRAAWRRLP QAFRP Seq ID NO : 104 DNA sequence

Nucleic Acid Accession # : NM_001795 . 2

Coding sequence : 121-2475 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

GACGGTCGGC TGACAGGCTC CACAGAGCTC CACTCACGCT CAGGCCCTGG ACGGACAGGC 60 AGTCCAACGG AACAGAAACA TCCCTCAGCC CCACAGGCAC GATCTGTTCC TCCTGGGAAG 120 ATGCAGAGGC TCATGATGCT CCTCGCCACA TCGGGCGCCT GCCTGGGCCT GCTGGCAGTG 180 GCAGCAGTGG CAGCAGCAGG TGCTAACCCT GCCCAACGGG ACACCCACAG CCTGCTGCCC 240 ACCCACCGGC GCCAAAAGAG AGATTGGATT TGGAACCAGA TGCACATTGA TGAAGAGAAA 300 AACACCTCAC TTCCCCATCA TGTAGGCAAG ATCAAGTCAA GCGTGAGTCG CAAGAATGCC 360 AAGTACCTGC TCAAAGGAGA ATATGTGGGC AAGGTCTTCC GGGTCGATGC AGAGACAGGA 420 GACGTGTTCG CCATTGAGAG GCTGGACCGG GAGAATATCT CAGAGTACCA CCTCACTGCT 480 GTCATTGTGG ACAAGGACAC TGGTGAAAAC CTGGAGACTC CTTCCAGCTT CACCATCAAA 540 GTTCATGACG TGAACGACAA CTGGCCTGTG TTCACGCATC GGTTGTTCAA TGCGTCCGTG 600 CCTGAGTCGT CGGCTGTGGG GACCTCAGTC ATCTCTGTGA CAGCAGTGGA TGCAGACGAC 660 CCCACTGTGG GAGACCACGC CTCTGTCATG TACCAAATCC TGAAGGGGAA AGAGTATTTT 720 GCCATCGATA ATTCTGGACG TATTATCACA ATAACGAAAA GCTTGGACCG AGAGAAGCAG 780 GCCAGGTATG AGATCGTGGT GGAAGCGCGA GATGCCCAGG GCCTCCGGGG GGACTCGGGC 840 ACGGCCACCG TGCTGGTCAC TCTGCAAGAC ATCAATGACA ACTTCCCCTT CTTCACCCAG 900 ACCAAGTACA CATTTGTCGT GCCTGAAGAC ACCCGTGTGG GCACCTCTGT GGGCTCTCTG 960 TTTGTTGAGG ACCCAGATGA GCCCCAGAAC CGGATGACCA AGTACAGCAT CTTGCGGGGC 1020 GACTACCAGG ACGCTTTCAC CATTGAGACA AACCCCGCCC ACAACGAGGG CATCATCAAG 1080 CCCATGAAGC CTCTGGATTA TGAATACATC CAGCAATACA GCTTCATCGT CGAGGCCACA 1140 GACCCCACCA TCGACCTCCG ATACATGAGC CCTCCCGCGG GAAACAGAGC CCAGGTCATT 1200 ATCAACATCA CAGATGTGGA CGAGCCCCCC ATTTTCCAGC AGCCTTTCTA CCACTTCCAG 1260 CTGAAGGAAA ACCAGAAGAA GCCTCTGATT GGCACAGTGC TGGCCATGGA CCCTGATGCG 1320 GCTAGGCATA GCATTGGATA CTCCATCCGC AGGACCAGTG ACAAGGGCCA GTTCTTCCGA 1380 GTCACAAAAA AGGGGGACAT TTACAATGAG AAAGAACTGG ACAGAGAAGT CTACCCCTGG 1440 TATAACCTGA CTGTGGAGGC CAAAGAACTG GATTCCACTG GAACCCCCAC AGGAAAAGAA 1500 TCCATTGTGC AAGTCCACAT TGAAGTTTTG GATGAGAATG ACAATGCCCC GGAGTTTGCC 1560 AAGCCCTACC AGCCCAAAGT GTGTGAGAAC GCTGTCCATG GCCAGCTGGT CCTGCAGATC 1620 TCCGCAATAG ACAAGGACAT AACACCACGA AACGTGAAGT TCAAATTCAC CTTGAATACT 1680 GAGAACAACT TTACCCTCAC GGATAATCAC GATAACACGG CCAACATCAC AGTCAAGTAT 1740 GGGCAGTTTG ACCGGGAGCA TACCAAGGTC CACTTCCTAC CCGTGGTCAT CTCAGACAAT 1800 GGGATGCCAA GTCGCACGGG CACCAGCACG CTGACCGTGG CCGTGTGCAA GTGCAACGAG 1860 CAGGGCGAGT TCACCTTCTG CGAGGATATG GCCGCCCAGG TGGGCGTGAG CATCCAGGCA 1920 GTGGTAGCCA TCTTACTCTG CATCCTCACC ATCACAGTGA TCACCCTGCT CATCTTCCTG 1980 CGGCGGCGGC TCCGGAAGCA GGCCCGCGCG CACGGCAAGA GCGTGCCGGA GATCCACGAG 2040 CAGCTGGTCA CCTACGACGA GGAGGGCGGC GGCGAGATGG ACACCACCAG CTACGATGTG 2100 TCGGTGCTCA ACTCGGTGCG CCGCGGCGGG GCCAAGCCCC CGCGGCCCGC GCTGGACGCC 2160 CGGCCTTCCC TCTATGCGCA GGTGCAGAAG CCACCGAGGC ACGCGCCTGG GGCACACGGA 2220 GGGCCCGGGG AGATGGCAGC CATGATCGAG GTGAAGAAGG ACGAGGCGGA CCACGACGGC 2280 GACGGCCCCC CCTACGACAC GCTGCACATC TACGGCTACG AGGGCTCCGA GTCCATAGCC 2340 GAGTCCCTCA GCTCCCTGGG CACCGACTCA TCCGACTCTG ACGTGGATTA CGACTTCCTT 2400 AACGACTGGG GACCCAGGTT TAAGATGCTG GCTGAGCTGT ACGGCTCGGA CCCCCGGGAG 2460 GAGCTGCTGT ATTAGGCGGC CGAGGTCACT CTGGGCCTGG GGACCCAAAC CCCCTGCAGC 2520 CCAGGCCAGT CAGACGCCAG GCACCACAGC CTCCAAAAAT GGCAGTGACT CCCCAGCCCA 2580 GCACCCCTTC CTCGTGGGTC CCAGAGACCT CATCAGCCTT GGGATAGCAA ACTCCAGGTT 2640 CCTGAAATAT CCAGGAATAT ATGTCAGTGA TGACTATTCT CAAATGCTGG CAAATCCAGG 2700 CTGGTGTTCT- GTCTGGGCTC AGACATCCAC ATAACCCTGT CACCCACAGA CCGCCGTCTA 2760 ACTCAAAGAC TTCCTCTGGC TCCCCAAGGC TGCAAAGCAA AACAGACTGT GTTTAACTGC 2820 TGCAGGGTCT TTTTCTAGGG TCCCTGAACG CCCTGGTAAG GCTGGTGAGG TCCTGGTGCC 2880 TATCTGCCTG GAGGCAAAGG CCTGGACAGC TTGACTTGTG GGGCAGGATT CTCTGCAGCC 2940 CATTCCCAAG GGAGACTGAC CATCATGCCC TCTCTCGGGA GCCCTAGCCC TGCTCCAACT 3000 CCATACTCCA CTCCAAGTGC CCCACCACTC CCCAACCCCT CTCCAGGCCT GTCAAGAGGG 3060 AGGAAGGGGC CCCATGGCAG CTCCTGACCT TGGGTCCTGA AGTGACCTCA CTGGCCTGCC 3120 ATGCCAGTAA CTGTGCTGTA CTGAGCACTG AACCACATTC AGGGAAATGG CTTATTAAAC 3180 TTTGAAGCAA CTGTGAATTC ATTCTGGAGG GGCAGTGGAG ATCAGGAGTG ACAGATCACA 3240 GGGTGAGGGC CACCTCCACA CCCACCCCCT CTGGAGAAGG CCTGGAAGAG CTGAGACCTT 3300 GCTTTGAGAC TCCTCAGCAC CCCTCCAGTT TTGCCTGAGA AGGGGCAGAT GTTCCCGGAG 3360 CAGAAGACGT CTCCCCTTCT CTGCCTCACC TGGTCGCCAA TCCATGCTCT CTTTCTTTTC 3420 TCTGTCTACT CCTTATCCCT TGGTTTAGAG GAACCCAAGA TGTGGCCTTT AGCAAAACTG 3480 GACAATGTCC AAACCCACTC ATGACTGCAT GACGGAGCCG AGCCATGTGT CTTTACACCT 3540 CGCTGTTGTC ACATCTCAGG GAACTGACCC TCAGGCACAC CTTGCAGAAG GCAAGGCCCT 3600 GCCCTGCCCA ACCTCTGTGG TCACCCATGC ATCTTCCACT GGAACGTTTC ACTGCAAACA 3660 CACCTTGGAG AAGTGGCATC AGTCAACAGA GAGGGGCAGG GAAGGAGACA CCAAGCTCAC 3720 CCTTCGTCAT GGACCGAGGT TCCCACTCTG GGCAAAGCCC CTCACACTGC AAGGGATTGT 3780 AGATAACACT GACTTGTTTG TTTTAACCAA TAACTAGCTT CTTATAATGA TTTTTTTACT 3840 AATGATACTT ACAAGTTTCT AGCTCTCACA GACATATAGA ATAAGGGTTT TTGCATAATA 3900 AGCAGGTTGT TATTTAGGTT AACAATATTA ATTCAGGTTT TTTAGTTGGA AAAACAATTC 3960 CTGTAACCTT CTATTTTCTA TAATTGTAGT AATTGCTCTA CAGATAATGT CTATATATTG 4020 GCCAAACTGG TGCATGACAA GTACTGTATT TTTTTATACC TAAATAAAGA AAAATCTTTA ■4080 GCCTGGGCAA CAAAAAAA

Seq ID No: 105 Protein sequence : Protein Accession #: NP_001786.1

11 21 31 41 51

MQRLMMLLAT SGACLGLLAV AAVAAAGANP AQRDTHSLLP THRRQKRDWI WNQMHIDEEK 60 NTSLPHHVGK IKSSVSRKNA KYLLKGEYVG KVFRVDAETG DVFAIERLDR ENISEYHLTA 120 VIVDKDTGEN LETPSSFTIK VHDVNDNWPV FTHRLFNASV PESSAVGTSV ISVTAVDADD 180 PTVGDHASVM YQILKGKEYF AIDNSGRIIT ITKSLDREKQ ARYEIWEAR DAQGLRGDSG 240 TATVLVTLQD INDNFPFFTQ TKYTFWPED TRVGTSVGSL FVEDPDEPQN RMTKYSILRG 300 DYQDAFTIET NPAHNEGIIK PMKPLDYEYI QQYSFIVEAT DPTIDLRYMS PPAGNRAQVI 360 INITDVDEPP IFQQPFYHFQ LKENQKKPLI GTVLAMDPDA ARHSIGYSIR RTSDKGQFFR 420 VTKKGDIYNE KELDREVYPW YNLTVEAKEL DSTGTPTGKE SIVQVHIEVL DENDNAPEFA 480 KPYQPKVCEN AVHGQLVLQI SAIDKDITPR NVKFKFTLNT ENNFTLTDNH DNTANITVKY 540 GQFDREHTKV HFLPWISDN GMPSRTGTST LTVAVCKCNE QGEFTFCEDM AAQVGVSIQA 600 WAILLCILT ITVITLLIFL RRRLRKQARA HGKSVPEIHE QLVTYDEEGG GEMDTTSYDV 660 SVLNSVRRGG AKPPRPALDA RPSLYAQVQK PPRHAPGAHG GPGEMAAMIE VKKDEADHDG 720 DGPPYDTLHI YGYEGSESIA ESLSSLGTDS SDSDVDYDFL NDWGPRFKML AELYGSDPRE 780 ELLY

Seq ID NO: 106 DNA sequence

Nucleic Acid Accession # : none found

Coding sequence: 1-474 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

ACAGTACTCT GTGCAAAAAA CCTGGTGAAA AAGGATTTTT TCCGACTTCC TGATCCATTT 60 GCTAAGGTGG TGGTTGATGG ATCTGGGCAA TGCCATTCTA CAGATACTGT GAAGAATACG 120 CTTGATCCAA AGTGGAATCA GCATTATGAC CTGTATATTG GAAAGTCTGA TTCAGTTACG 180 ATCAGTGTAT GGAATCACAA GAAGATCCAT AAGAAACAAG GTGCTGGATT TCTCGGTTGT 240 GTTCGTCTTC TTTCCAATGC CATCAACCGC CTCAAAGACA CTGGTTATCA GAGGTTGGAT 300 TTATGCAAAC TCGGGCCAAA TGACAATGAT ACAGTTAGAG GACAGATAGT AGTAAGTCTT 360 CAGTCCAGAG ACCGAATAGG CACAGGAGGA CAAGTTGTGG ACTGCAGTCG TTTATTTGAT 420 AACGATTTAC CAGACGGAGC TCATTATTTG TGGACTTGGA AAGATAGATG TTAATGACTG 480 GAAGGTAAAC ACCCGGTTAA AACACTGTAC ACCAGACAGC AACATTGTCA AATGGTTCTG 540 GAAAGCTGTG GAGTTTTTTG ATGAAGAGCG ACGAGCAAGA TTGCTTCAGT TTGTGACAGG 600 ATCCTCTCGA GTGCCTCTGC AGGGCTTCAA AGCATTGCAA GGTGCTGCAG GCCCGAGACT 660 CTTTACCATA CACCAGATTG ATGCCTGCAC TAACAACCTG CCGAAAGCCC ACACTTGCTT 720 CAATCGAATA GACATTCCAC CCTATGAAAG CTATGAAAAG CTATATGAAA AGCTGCTAAC 780 AGCCATTGAA GAAACATGTG GATTTGCTGT GGAATGACAA GCTTCAAGGA TTTACCCAGG 840 AC

Seq ID No: 107 Protein sequence: Protein Accession #: none found

11 21 31 41 51

TVLCAKNLVK KDFFRLPDPF AKVWDGSGQ CHSTDTVKNT LDPKWNQHYD LYIGKSDSVT 60

ISVWNHKKIH KKQGAGFLGC VRLLSNAINR LKDTGYQRLD LCKLGPNDND TVRGQIWSL 120 QSRDRIGTGG QWDCSRLFD NDLPDGAHYL WTWKDRC

Seq ID NO : 108 DNA sequence

Nucleic Acid Accession # : NM_002318 .1

Coding sequence : 248-2572 (underlined sequences correspond to start and stop codons) 11 21 31 41 51

ACTCCAGCGC GCGGCTACCT ACGCTTGGTG CTTGCTTTCT CCAGCCATCG GAGACCAGAG 60 CCGCCCCCTC TGCTCGAGAA AGGGGCTCAG CGGCGGCGGA AGCGGAGGGG GACCACCGTG 120 GAGAGCGCGG TCCCAGCCCG GCCACTGCGG ATCCCTGAAA CCAAAAAGCT CCTGCTGCTT 180 CTGTACCCCG CCTGTCCCTC CCAGCTGCGC AGGGCCCCTT CGTGGGATCA TCAGCCCGAA 240 GACAGGGATG GAGAGGCCTC TGTGCTCCCA CCTCTGCAGC TGCCTGGCTA TGCTGGCCCT 300 CCTGTCCCCC CTGAGCCTGG CACAGTATGA CAGCTGGCCC CATTACCCCG AGTACTTCCA 360 GCAACCGGCT CCTGAGTATC ACCAGCCCCA GGCCCCCGCC AACGTGGCCA AGATTCAGCT 420 GCGCCTGGCT GGGCAGAAGA GGAAGCACAG CGAGGGCCGG GTGGAGGTGT ACTATGATGG 480 CCAGTGGGGC ACCGTGTGCG ATGACGACTT CTCCATCCAC GCTGCCCACG TCGTCTGCCG 540 GGAGCTGGGC TATGTGGAGG CCAAGTCCTG GACTGCCAGC TCCTCCTACG GCAAGGGAGA 600 AGGGCCCATC TGGTTAGACA ATCTCCACTG TACTGGCAAC GAGGCGACCC TTGCAGCATG 660 CACCTCCAAT GGGTGGGGCG TCACTGACTG CAAGCACACG GAGGATGTCG GTGTGGTGTG 720 CAGCGACAAA AGGATTCCTG GGTTCAAATT TGACAATTCG TTGATCAACC AGATAGAGAA 780 CCTGAATATC CAGGTGGAGG ACATTCGGAT TCGAGCCATC CTCTCAACCT ACCGCAAGCG 840 CACCCCAGTG ATGGAGGGCT ACGTGGAGGT GAAGGAGGGC AAGACCTGGA AGCAGATCTG 900 TGACAAGCAC TGGACGGCCA AGAATTCCCG CGTGGTCTGC GGCATGTTTG GCTTCCCTGG 960 GGAGAGGACA TACAATACCA AAGTGTACAA AATGTTTGCC TCACGGAGGA AGCAGCGCTA 1020 CTGGCCATTC TCCATGGACT GCACCGGCAC AGAGGCCCAC ATCTCCAGCT GCAAGCTGGG 1080 CCCCCAGGTG TCACTGGACC CCATGAAGAA TGTCACCTGC GAGAATGGGG TGCCGGCCGT 1140 GGTGAGTTGT GTGCCTGGGC AGGTCTTCAG CCCTGACGGA CCCTCGAGAT TCCGGAAAGC 1200 ATACAAGCCA GAGCAACCCC TGGTGCGACT GAGAGGCGGT GCCTACATCG GGGAGGGCCG 1260 CGTGGAGGTG CTCAAAAATG GAGAATGGGG GACCGTCTGC GACGACAAGT GGGACCTGGT 1320 GTCGGCCAGT GTGGTCTGCA GAGAGCTGGG CTTTGGGAGT GCCAAAGAGG CAGTCACTGG 1380 CTCCCGACTG GGGCAAGGGA TCGGACCCAT CCACCTCAAC GAGATCCAGT GCACAGGCAA 1440 TGAGAAGTCC ATTATAGACT GCAAGTTCAA TGCCGAGTCT CAGGGCTGCA ACCACGAGGA 1500 GGATGCTGGT GTGAGATGCA ACACCCCTGC CATGGGCTTG CAGAAGAAGC TGCGCCTGAA 1560 CGGCGGCCGC AATCCCTACG AGGGCCGAGT GGAGGTGCTG GTGGAGAGAA ACGGGTCCCT 1620 TGTGTGGGGG ATGGTGTGTG GCCAAAACTG GGGCATCGTG GAGGCCATGG TGGTCTGCCG 1680 CCAGCTGGGC CTGGGATTCG CCAGCAACGC CTTCCAGGAG ACCTGGTATT GGCACGGAGA 1740 TGTCAACAGC AACAAAGTGG TCATGAGTGG AGTGAAGTGC TCGGGAACGG AGCTGTCCCT 1800 GGCGCACTGC CGCCACGACG GGGAGGACGT GGCCTGCCCC CAGGGCGGAG TGCAGTACGG 1860 GGCCGGAGTT GCCTGCTCAG AAACCGCCCC TGACCTGGTC CTCAATGCGG AGATGGTGCA 1920 GCAGACCACC TACCTGGAGG ACCGGCCCAT GTTCATGCTG CAGTGTGCCA TGGAGGAGAA 1980 CTGCCTCTCG GCCTCAGCCG CGCAGACCGA CCCCACCACG GGCTACCGCC GGCTCCTGCG 2040 CTTCTCCTCC CAGATCCACA ACAATGGCCA GTCCGACTTC CGGCCCAAGA ACGGCCGCCA 2100 CGCGTGGATC TGGCACGACT GTCACAGGCA CTACCACAGC ATGGAGGTGT TCACCCACTA 2160 TGACCTGCTG AACCTCAATG GCACCAAGGT GGCAGAGGGC CACAAGGCCA GCTTCTGCTT 2220 GGAGGACACA GAATGTGAAG GAGACATCCA GAAGAATTAC GAGTGTGCCA ACTTCGGCGA 2280 TCAGGGCATC ACCATGGGCT GCTGGGACAT GTACCGCCAT GACATCGACT GCCAGTGGGT 2340 TGACATCACT GACGTGCCCC CTGGAGACTA CCTGTTCCAG GTTGTTATTA ACCCCAACTT 2400 CGAGGTTGCA GAATCCGATT ACTCCAACAA CATCATGAAA TGCAGGAGCC GCTATGACGG 2460 CCACCGCATC TGGATGTACA ACTGCCACAT AGGTGGTTCC TTCAGCGAAG AGACGGAAAA 2520 AAAGTTTGAG CACTTCAGCG GGCTCTTAAA CAACCAGCTG TCCCCGCAGT. AAAGAAGCCT 2580 GCGTGGTCAA CTCCTGTCTT CAGGCCACAC CACATCTTCC ATGGGACTTC CCCCCAACAA 2640 CTGAGTCTGA ACGAATGCCA CGTGCCCTCA CCCAGCCCGG CCCCCACCCT GTCCAGACCC 2700 CTACAGCTGT GTCTAAGCTC AGGAGGAAAG GGACCCTCCC ATCATTCATG GGGGGCTGCT 2760 ACCTGACCCT TGGGGCCTGA GAAGGCCTTG GGGGGGTGGG GTTTGTCCAC AGAGCTGCTG 2820 GAGCAGCACC AAGAGCCAGT CTTGACCGGG ATGAGGCCCA CAGACAGGTT GTCATCAGCT 2880 TGTCCCATTC AAGCCACCGA GCTCACCACA GACACAGTGG AGCCGCGCTC TTCTCCAGTG 2940 ACACGTGGAC AAATGCGGGC TCATCAGCCC CCCCAGAGAG GGTCAGGCCG AACCCCATTT 3000 CTCCTCCTCT TAGGTCATTT TCAGCAAACT TGAATATCTA GACCTCTCTT CCAATGAAAC 3060 CCTCCAGTCT ATTATAGTCA CATAGATAAT GGTGCCACGT GTTTTCTGAT TTGGTGAGCT 3120 CAGACTTGGT GCTTCCCTCT CCACAACCCC CACCCCTTGT TTTTCAAGAT ACTATTATTA 3180 TATTTTCACA GACTTTTGAA GCACAAATTT ATTGGCATTT AATATTGGAC ATCTGGGCCC 3240 TTGGAAGTAC AAATCTAAGG AAAAACCAAC CCACTGTGTA AGTGACTCAT CTTCCTGTTG 3300 TTCCAATTCT GTGGGTTTTT GATTCAACGG TGCTATAACC AGGGTCCTGG GTGACAGGGC 3360 GCTCACTGAG CACCATGTGT CATCACAGAC ACTTACACAT ACTTGAAACT TGGAATAAAA 3420 GAAAGATTTA TG

Seq ID No: 109 Protein sequence: Protein Accession #: NP_002309.1

11 21 31 41 51

I I 1 I I

MERPLCSHLC SCLAMLALLS PLSLAQYDSW PHYPEYFQQP APEYHQPQAP ANVAKIQLRL 60 AGQKRKHSEG RVEVYYDGQW GTVCDDDFSI HAAHWCREL GYVEAKSWTA SSSYGKGEGP 120 IWLDNLHCTG NEATLAACTS NGWGVTDCKH TEDVGWCSD KRIPGFKFDN SLINQIENLN 180 IQVEDIRIRA ILSTYRKRTP VMEGYVEVKE GKTWKQICDK HWTAKNSRW CGMFGFPGER 240 TYNTKVYKMF ASRRKQRYWP FSMDCTGTEA HISSCKLGPQ VSLDPMKNVT CENGLPAWS 300 CVPGQVFSPD GPSRFRKAYK PEQPLVRLRG GAYIGEGRVE VLKNGEWGTV CDDKWDLVSA 360 SWCRELGFG SAKEAVTGSR LGQGIGPIHL NEIQCTGNEK SIIDCKFNAE SQGCNHEEDA 420 GVRCNTPAMG LQKKLRBNGG RNPYEGRVEV LVERNGSLVW GMVCGQNWGI VEAMWCRQL 480

GLGFASNAFQ ETWYWHGDVN SNKWMSGVK CSGTELSLAH CRHDGEDVAC PQGGVQYGAG 540

VACSETAPDL VLNAEMVQQT TYLEDRPMFM LQCAMEENCL SASAAQTDPT TGYRRLLRFS 600

SQIHNNGQSD FRPKNGRHAW IWHDCHRHYH SMEVFTHYDL LNLNGTKVAE GHKASFCLED 660

TECEGDIQKN YECANFGDQG ITMGCWDMYR HDIDCQWVDI TDVPPGDYLF QWINPNFEV 720 AESDYSNNIM KCRSRYDGHR IWMYNCHIGG SFSEETEKKF EHFSGLLNNQ LSPQ

Seq ID NO: 110 DNA sequence

Nucleic Acid Accession #: none found, CAT_73007_3

Coding sequence: 1-495 (underlined sequences correspond to start and stop codons)

11 21 31 51

CGGACGCGTG GGTCGACCCA CGCGTCCGCC CACGCGTCCG TATGGACAGA GCCTCCACTG 60 GCTGCTGCCT GCCCGCCACA TACCCAGCTG ACATGGGCAC CGCAGGAGCC ATGCAGCTGT 120 CTGGGTGATC CTGGGCTTCC TCCTGTTCCG AGGCCACAAC TCCCAGCCCA CAATGACCCA 180 ACCTCTAGCT CTCAGGGAGG CCTTGGCGGT CTAAGTCTGA CCACAGAGCC AGTTTCTTCC 240 ACCCAGGATA CATCCCTTCC TCAGAGGCTA ACAGGCCAAG CCATCTGTCC AGCACTGGTA 300 CCCAGGCGCA GGTGTCCCCA GCAGTGGAAG AGACGGAGGC ACAAGCAGAG ACACATTTCA 360 ACTGTTCCCC CCAATTCAAC CACCATGAGC CTGAGCATGA GGGAAGATGC GACCATCCTG 420 CCAGCCCCAC GTCAGAGACT GTGCTCACTG TGGCTGCATT TGGGATGGAG TCGGGTGGAG 480 GCCCACTCTG GCTAGGGGGC GGCAGGCTGA GAGCTCACCT GTTCAGCAGA GAAGTGGAAC 540 CACTTTGCTC CTGGAGCCTG TCTACCACAG TGTTATCAGC TTCATTGTCA TCCTGGTGGT 600 GTGGTGATCA TCCTAGTTGG TGTGGTCAGC CTGAGGGTTC AGTGTCGGAA GAGCAAGGAG 660 TCTGAAGATC CCAGAACCTG GGAGTACAGG GCGTGTCTGA CAAGCTGGTC ACAGACCATG 720 GCGAGAACGA CAGCATCGCC CATTATCACA TGGAAGACAT CACACGACTT AGGGCAACAC 780 GCACTCAGCA GCGAGCATCA AAGGAGCCTA CGCATGGCCC AGACTGAGAG CAAGCACAAA 840 GGGC

Seq ID No: 111 Protein sequence:

Protein Accession #: none found, CAT 73007_3

11 21 31 41 51

RTRGSTHASA HASVWTEPPL AAACPPHTQL TWAPQEPCSC LGDPGLPPVP RPQLPAHNDP 60 TSSSQGGLGG LSLTTEPVSS TQDTSLPQRL TGQAICPALV PRRRCPQQWK RRRHKQRHIS 120 TVPPNSTTMS LSMREDATIL PAPRQRLCSL WLHLGWSRVE AHSG

Seq ID NO: 112 DNA sequence

Nucleic Acid Accession #: NM_005424.1

Coding sequence: 37-3453 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

CGCTCGTCCT GGCTGGCCTG GGTCGGCCTC TGGAGTATGG TCTGGCGGGT GCCCCCTTTC 60 TTGCTCCCCA TCCTCTTCTT GGCTTCTCAT GTGGGCGCGG CGGTGGACCT GACGCTGCTG 120 GCCAACCTGC GGCTCACGGA CCCCCAGCGC TTCTTCCTGA CTTGCGTGTC TGGGGAGGCC 180 GGGGCGGGGA GGGGCTCGGA CGCCTGGGGC CCGCCCCTGC TGCTGGAGAA GGACGACCGT 240 ATCGTGCGCA CCCCGCCCGG GCCACCCCTG CGCCTGGCGC GCAACGGTTC GCACCAGGTC 300 AGGCTTGGCG GCTTCTCCAA GCCCTCGGAC CTCGTGGGCG TCTTCTCCTG CGTGGGCGGT 360 GCTGGGGCGC GGCGCACGCG CGTCATCTAC GTGCACAACA GCCCTGGAGC CCACCTGCTT 420 CCAGACAAGG TCACACACAC TGTGAACAAA GGTGACACCG CTGTACTTTC TGCACGTGTG 480 CACAAGGAGA AGCAGACAGA CGTGATCTGG AAGAGCAACG GATCCTACTT CTACACCCTG 540 GACTGGCATG AAGCCCAGGA TGGGCGGTTC CTGCTGCAGC TCCCAAATGT GCAGCCACCA 600 TCGAGCGGCA TCTACAGTGC CACTTACCTG GAAGCCAGCC CCCTGGGCAG CGCCTTCTTT 660 CGGCTCATCG TGCGGGGTTG TGGGGCTGGG CGCTGGGGGC CAGGCTGTAC CAAGGAGTGC 720 CCAGGTTGCC TACATGGAGG TGTCTGCCAC GACCATGACG GCGAATGTGT ATGCCCCCCT 780 GGCTTCACTG GCACCCGCTG TGAACAGGCC TGCAGAGAGG GCCGTTTTGG GCAGAGCTGC 840 CAGGAGCAGT GCCCAGGCAT ATCAGGCTGC CGGGGCCTCA CCTTCTGCCT CCCAGACCCC 900 TATGGCTGCT CTTGTGGATC TGGCTGGAGA GGAAGCCAGT GCCAAGAAGC TTGTGCCCCT 960 GGTCATTTTG GGGCTGATTG CCGACTCCAG TGCCAGTGTC AGAATGGTGG CACTTGTGAC 1020 CGGTTCAGTG GTTGTGTCTG CCCCTCTGGG TGGCATGGAG TGCACTGTGA GAAGTCAGAC 1080 CGGATCCCCC AGATCCTCAA CATGGCCTCA GAACTGGAGT TCAACTTAGA GACGATGCCC 1140 CGGATCAACT GTGCAGCTGC AGGGAACCCC TTCCCCGTGC GGGGCAGCAT AGAGCTACGC 1200 AAGCCAGACG GCACTGTGCT CCTGTCCACC AAGGCCATTG TGGAGCCAGA GAAGACCACA 1260 GCTGAGTTCG AGGTGCCCCG CTTGGTTCTT GCGGACAGTG GGTTCTGGGA GTGCCGTGTG 1320 TCCACATCTG GCGGCCAAGA CAGCCGGCGC TTCAAGGTCA ATGTGAAAGT GCCCCCCGTG 1380 CCCCTGGCTG CACCTCGGCT CCTGACCAAG CAGAGCCGCC AGCTTGTGGT CTCCCCGCTG 1440 GTCTCGTTCT CTGGGGATGG ACCCATCTCC ACTGTCCGCC TGCACTACCG GCCCCAGGAC 1500 AGTACCATGG ACTGGTCGAC CATTGTGGTG GACCCCAGTG AGAACGTGAC GTTAATGAAC 1560 CTGAGGCCAA AGACAGGATA CAGTGTTCGT GTGCAGCTGA GCCGGCCAGG GGAAGGAGGA 1620 GAGGGGGCCT GGGGGCCTCC CACCCTCATG ACCACAGACT GTCCTGAGCC TTTGTTGCAG 1680 CCGTGGTTGG AGGGCTGGCA TGTGGAAGGC ACTGACCGGC TGCGAGTGAG CTGGTCCTTG 1740 CCCTTGGTGC CCGGGCCACT GGTGGGCGAC GGTTTCCTGC TGCGCCTGTG GGACGGGACA 1800 CGGGGGCAGG AGCGGCGGGA GAACGTCTCA TCCCCCCAGG CCCGCACTGC CCTCCTGACG 1860 GGACTCACGC CTGGCACCCA CTACCAGCTG GATGTGCAGC TCTACCACTG CAGCCTCCTG 1920 GGCCCGGCCT CGCCCCCTGC ACACGTGCTT CTGCCCCCCA GTGGGCCTCC AGCCCCCCGA 1980 CACCTCCACG CCCAGGCCCT CTCAGACTCC GAGATCCAGC TGACATGGAA GCACCCGGAG 2040 GCTCTGCCTG GGCCAATATC CAAGTACGTT GTGGAGGTGC AGGTGGCTGG GGGTGCAGGA 2100 GACCCACTGT GGATAGACGT GGACAGGCCT GAGGAGACAA GCACCATCAT CCGTGGCCTC 2160 AACGCCAGCA CGCGCTACCT CTTCCGCATG CGGGCCAGCA TTCAGGGGCT CGGGGACTGG 2220 AGCAACACAG TAGAAGAGTC CACCCTGGGC AACGGGCTGC AGGCTGAGGG CCCAGTCCAA 2280 GAGAGCCGGG CAGCTGAAGA GGGCCTGGAT CAGCAGCTGA TCCTGGCGGT GGTGGGCTCC 2340 GTGTCTGCCA CCTGCCTCAC CATCCTGGCC GCCCTTTTAA CCCTGGTGTG CATCCGCAGA 2400 AGCTGCCTGC ATCGGAGACG CACCTTCACC TACCAGTCAG GCTCGGGCGA GGAGACCATC 2460 CTGCAGTTCA GCTCAGGGAC CTTGACACTT ACCCGGCGGC CAAAACTGCA GCCCGAGCCC 2520 CTGAGCTACC CAGTGCTAGA GTGGGAGGAC ATCACCTTTG AGGACCTCAT CGGGGAGGGG 2580 AACTTCGGCC AGGTCATCCG GGCCATGATC AAGAAGGACG GGCTGAAGAT GAACGCAGCC 2640 ATCAAAATGC TGAAAGAGTA TGCCTCTGAA AATGACCATC GTGACTTTGC GGGAGAACTG 2700 GAAGTTCTGT GCAAATTGGG GCATCACCCC AACATCATCA ACCTCCTGGG GGCCTGTAAG 2760 AACCGAGGTT ACTTGTATAT CGCTATTGAA TATGCCCCCT ACGGGAACCT GCTAGATTTT 2820 CTGCGGAAAA GCCGGGTCCT AGAGACTGAC CCAGCTTTTG CTCGAGAGCA TGGGACAGCC 2880 TCTACCCTTA GCTCCCGGCA GCTGCTGCGT TTCGCCAGTG ATGCGGCCAA TGGCATGCAG 2940 TACCTGAGTG AGAAGCAGTT CATCCACAGG GACCTGGCTG CCCGGAATGT GCTGGTCGGA 3000 GAGAACCTAG CCTCCAAGAT TGCAGACTTC GGCCTTTCTC GGGGAGAGGA GGTTTATGTG 3060 AAGAAGACGA TGGGGCGTCT CCCTGTGCGC TGGATGGCCA TTGAGTCCCT GAACTACAGT 3120 GTCTATACCA CCAAGAGTGA TGTCTGGTCC TTTGGAGTCC TTCTTTGGGA GATAGTGAGC 3180 CTTGGAGGTA CACCCTACTG TGGCATGACC TGTGCCGAGC TCTATGAAAA GCTGCCCCAG 3₂40 GGCTACCGCA TGGAGCAGCC TCGAAACTGT GACGATGAAG TGTACGAGCT GATGCGTCAG 3300 TGCTGGCGGG ACCGTCCCTA TGAGCGACCC CCCTTTGCCC AGATTGCGCT ACAGCTAGGC 3360 CGCATGCTGG AAGCCAGGAA GGCCTATGTG AACATGTCGC TGTTTGAGAA CTTCACTTAC 34₂0 GCGGGCATTG ATGCCACAGC TGAGGAGGCC TGAGCTGCCA TCCAGCCAGA ACGTGGCTCT 3480 GCTGGCCGGA GCAAACTCTG CTGTCTAACC TGTGACCAGT CTGACCCTTA CAGCCTCTGA 3540 CTTAAGCTGC CTCAAGGAAT TTTTTTAACT TAAGGGAGAA AAAAAGGGAT CTGGGGATGG 3600 GGTGGGCTTA GGGGAACTGG GTTCCCATGC TTTGTAGGTG TCTCATAGCT ATCCTGGGCA 3660 TCCTTCTTTC TAGTTCAGCT GCCCCACAGG TGTGTTTCCC ATCCCACTGC TCCCCCAACA 3720 CAAACCCCCA CTCCAGCTCC TTCGCTTAAG CCAGCACTCA CACCACTAAC ATGCCCTGTT 3780 CAGCTACTCC CACTCCCGGC CTGTCATTCA GAAAAAAATA AATGTTCTAA TAAGCTCCAA 3840 AAAAA

Seq ID No : 113 Protein sequence : Protein Accession # : NP 005415 .1

11 21 31 41 51

MVWRVPPFLL PILFLASHVG AAVDLTLLAN LRLTDPQRFF LTCVSGEAGA GRGSDAWGPP 60 LLLEKDDRIV RTPPGPPLRL ARNGSHQVTL RGFSKPSDLV GVFSCVGGAG ARRTRVIYVH .120 NSPGAHLLPD KVTHTVNKGD TAVLSARVHK EKQTDVIWKS NGSYFYTLDW HEAQDGRFLL 180 QLPNVQPPSS GIYSATYLEA SPLGSAFFRL IVRGCGAGRW GPGCTKECPG CLHGGVCHDH 240 DGECVCPPGF TGTRCEQACR EGRFGQSCQE QCPGISGCRG LTFCLPDPYG CSCGSGWRGS 300 QCQEACAPGH FGADCRLQCQ CQNGGTCDRF SGCVCPSGWH GVHCEKSDRI PQILNMASEL 360 EFNLETMPRI NCAAAGNPFP VRGSIELRKP DGTVLLSTKA IVEPEKTTAE FEVPRLVLAD 420 SGFWECRVST SGGQDSRRFK VNVKVPPVPL AAPRLLTKQS RQLWSPLVS FSGDGPISTV 480 RLHYRPQDST MDWSTIWDP SENVTLMNLR PKTGYSVRVQ LSRPGEGGEG AWGPPTLMTT 540 DCPEPLLQPW LEGWHVEGTD RLRVSWSLPL VPGPLVGDGF LLRLWDGTRG QERRENVSSP 600 QARTALLTGL TPGTHYQLDV QLYHCTLLGP ASPPAHVLLP PSGPPAPRHL HAQALSDSEI 660 QLTWKHPEAL PGPISKYWE VQVAGGAGDP LWIDVDRPEE TSTIIRGLNA STRYLFRMRA 720 SIQGLGDWSN TVEESTLGNG LQAEGPVQES RAAEEGLDQQ LILAWGSVS ATCLTILAAL 780 LTLVCIRRSC LHRRRTFTYQ SGSGEETILQ FSSGTLTLTR RPKLQPEPLS YPVLEWEDIT 840 FEDLIGEGNF GQVIRAMIKK DGLKMNAAIK MLKEYASEND HRDFAGELEV LCKLGHHPNI 900 INLLGACKNR GYLYIAIEYA PYGNLLDFLR KSRVLETDPA FAREHGTAST LSSRQLLRFA 960 SDAANGMQYL SEKQFIHRDL AARNVLVGEN LASKIADFGL SRGEEVYVKK TMGRLPVRWM 1020 AIESLNYSVY TTKSDVWSFG VLLWEIVSLG GTPYCGMTCA ELYEKLPQGY RMEQPRNCDD 1080 EVYELMRQCW RDRPYERPPF AQIALQLGRM LEARKAYVNM SLFENFTYAG IDATAEEA

Seq ID NO: 114 DNA sequence

Nucleic Acid Accession #: NM_002632.1

Coding sequence: 322-771 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

GGGATTCGGG CCGCCCAGCT ACGGGAGGAC CTGGAGTGGC ACTGGGCGCC CGACGGACCA 60 TCCCCGGGAC CCGCCTGCCC CTCGGCGCCC CGCCCCGCCG GGCCGCTCCC CGTCGGGTTC 120 CCCAGCCACA GCCTTACCTA CGGGCTCCTG ACTCCGCAAG GCTTCCAGAA GATGCTCGAA 180 CCACCGGCCG GGGCCTCGGG GCAGCAGTGA GGGAGGCGTC CAGCCCCCCA CTCAGCTCTT 240 CTCCTCCTGT GCCAGGGGCT CCCCGGGGGA TGAGCATGGT GGTTTTCCCT CGGAGCCCCC 300 TGGCTCGGGA CGTCTGAGAA GATGCCGGTC ATGAGGCTGT TCCCTTGCTT CCTGCAGCTC 360 CTGGCCGGGC TGGCGCTGCC TGCTGTGCCC CCCCAGCAGT GGGCCTTGTC TGCTGGGAAC 420 GGCTCGTCAG AGGTGGAAGT GGTACCCTTC CAGGAAGTGT GGGGCCGCAG CTACTGCCGG 480 GCGCTGGAGA GGCTGGTGGA CGTCGTGTCC GAGTACCCCA GCGAGGTGGA GCACATGTTC 540

AGCCCATCCT GTGTCTCCCT GCTGCGCTGC ACCGGCTGCT GCGGCGATGA GAATCTGCAC 600

TGTGTGCCGG TGGAGACGGC CAATGTCACC ATGCAGCTCC TAAAGATCCG TTCTGGGGAC 660 CGGCCCTCCT ACGTGGAGCT GACGTTCTCT CAGCACGTTC GCTGCGAATG CCGGCCTCTG 720 CGGGAGAAGA TGAAGCCGGA AAGGTGCGGC GATGCTGTTC CCCGGAGGTA_ACCCACCCCT 780

TGGAGGAGAG AGACCCCGCA CCCGGCTCGT GTATTTATTA CCGTCACACT CTTCAGTGAC 840

TCCTGCTGGT ACCTGCCCTC TATTTATTAG CCAACTGTTT CCCTGCTGAA TGCCTCGCTC 900

CCTTCAAGAC GAGGGGCAGG GAAGGACAGG ACCCTCAGGA ATTCAGTGCC TTCAACAACG 960

TGAGAGAAAG AGAGAAGCCA GCCACAGACC CCTGGGAGCT TCCGCTTTGA AAGAAGCAAG 1020 ACACGTGGCC TCGTGAGGGG CAAGCTAGGC CCCAGAGGCC CTGGAGGTCT CCAGGGGCCT 1080

GCAGAAGGAA AGAAGGGGGC CCTGCTACCT GTTCTTGGGC CTCAGGCTCT GCACAGACAA 1140

GCAGCCCTTG CTTTCGGAGC TCCTGTCCAA AGTAGGGATG CGGATTCTGC TGGGGCCGCC 1200

ACGGCCTGGT GGTGGGAAGG CCGGCAGCGG GCGGAGGGGA TTCAGCCACT TCCCCCTCTT 1260

CTTCTGAAGA TCAGAACATT CAGCTCTGGA GAACAGTGGT TGCCTGGGGG CTTTTGCCAC 1320 TCCTTGTCCC CCGTGATCTC CCCTCACACT TTGCCATTTG CTTGTACTGG GACATTGTTC 1380

TTTCCGGCCG AGGTGCCACC ACCCTGCCCC CACTAAGAGA CACATACAGA GTGGGCCCCG 1440

GGCTGGAGAA AGAGCTGCCT GGATGAGAAA CAGCTCAGCC AGTGGGGATG AGGTCACCAG 1500

GGGAGGAGCC TGTGCGTCCC AGCTGAAGGC AGTGGCAGGG GAGCAGGTTC CCCAAGGGCC 1560

CTGGCACCCC CACAAGCTGT CCCTGCAGGG CCATCTGACT GCCAAGCCAG ATTCTCTTGA 1620 ATAAAGTATT CTAGTGTGGA AACGC ,

Seq ID No : 115 Protein sequence : Protein Accession # : NP_002623 . 1

1 11 21 31 41 51

I I I I I I

MPVMRLFPCF LQLLAGLALP AVPPQQWALS AGNGSSEVEV VPFQEVWGRS YCRALERLVD 60

WSEYPSEVE HMFSPSCVSL LRCTGCCGDE NLHCVPVETA NVTMQLLKIR SGDRPSYVEL 120 TFSQHVRCEC RPLREKMKPE RCGDAVPRR

Seq ID NO : 116 DNA sequence

Nucleic Acid Accession # : NM_007361 . 1

Coding sequence : 1-4131 (underlined sequences correspond to start and stop codons ) 1 11 21 31 41 51

I I I I I I

ATGGAGGGGG ACCGGGTGGC CGGGCGGCCG GTGCTGTCGT CGTTACCAGT GCTACTGCTG 60

CTGCAGTTGC TAATGTTGCG GGCCGCGGCG CTGCACCCAG ACGAGCTCTT CCCACACGGG 120

GAGTCGTGGT GGGACCAGCT CCTGCAGGAA GGCGACGACG TAAAGCTCAG CCGTGGTGAA 180 GCTGGCGAAT CCCCTGCACT TCTTACGAAG CCCGATTCAG CAACCTCTAC GTGGGCACCA 2 0

ACGGCATCAT CTCCACTCAG GACTTCCCCA GGGAAACGCA GTATGTGGAC TATGATTTCC 300

CCACCGACTT CCCGGCCATC GCCCCTTTTC TGGCGGACAT CGACACGAGC CACGGCAGAG 360

GCCGAGTCCT GTACCGAGAG GACACCTCCC CCGCAGTGCT GGGCCTGGCC GCCCGCTATG 420

TGCGCGCTGG CTTCCCGCGC TCTGCGCGCT TTTTACCCCC ACCCACGCCT TCCTGGCCAC 480 CTGGGAGCAG GTAGGCGCTT ACGAGGAGGT CAAACGCGGG CGCTGCCCTC GGGAGAGCTG 540

AACACTTTCC AGGCAGTTTT GGCATCTGAT GGGTCTGATA GCTACGCCCT CTTTCTTTAT 600

CCTGCCAACG GCCTGCAGTT CCTTGGAACC CGCCCCAAAG AGTCTTACAA TGTCCAGCTT 660

CAGCTTCCAG CTCGGGTGGG CTTCTGCCGA GGGGAGGCTG ATGATCTGAA GTCAGAAGGA 720

CCATATTTCA GCTTGACTAG CACTGAACAG TCTGTGAAAA ATCTCTATCA ACTAAGCAAC 780 CTGGGGATCC CTGGAGTGTG GGCTTTCCAT ATCGGCAGCA CTTCCCCGTT GGACAATGTC 840

AGGCCAGCTG CAGTTGGAGA CCTTTCCGCT GCCCACTCTT CTGTTCCCCT GGGACGTTCC 900

TTCAGCCATG CTACAGCCCT GGAAAGTGAC TATAATGAGG ACAATTTGGA TTACTACGAT 960

GTGAATGAGG AGGAAGCTGA ATACCTTCCG GGTGAACCAG AGGAGGCATT GAATGGCCAC 1020

AGCAGCATTG ATGTTTCCTT CCAATCCAAA GTGGATACAA AGCCTTTAGA GGAATCTTCC 1080 ACCTTGGATC CTCACACCAA AGAAGGAACA TCTCTGGGAG AGGTAGGGGG CCCAGATTTA 1140

AAAGGCCAAG TTGAGCCCTG GGATGAGAGA GAGACCAGAA GCCCAGCTCC ACCAGAGGTA 1200

GACAGAGATT CACTGGCTCC TTCCTGGGAA ACCCCACCAC CGTACCCCGA AAACGGAAGC 1260

ATCCAGCCCT ACCCAGATGG AGGGCCAGTG CCTTCGGAAA TGGATGTTCC CCCAGCTCAT 1320

CCTGAAGAAG AAATTGTTCT TCGAAGTTAC CCTGCTTCAG GTCACACTAC ACCCTTAAGT 1380 CGAGGGACGT ATGAGGTGGG ACTGGAAGAC AACATAGGTT CCAACACCGA GGTCTTCACG 1440

TATAATGCTG CCAACAAGGA AACCTGTGAA CACAACCACA GACAATGCTC CCGGCATGCC 1500

TTCTGCACGG ACTATGCCAC TGGCTTCTGC TGCCACTGCC AATCCAAGTT TTATGGAAAT 1560

GGGAAGCACT GTCTGCCTGA GGGGGCACCT CACCGAGTGA ATGGGAAAGT GAGTGGCCAC 1620

CTCCACGTGG GCCATACACC CGTGCACTTC ACTGATGTGG ACCTGCATGC GTATATCGTG 1680 GGCAATGATG GCAGAGCCTA CACGGCCATC AGCCACATCC CACAGCCAGC AGCCCAGGCC 1740

CTCCTCCCCC TCACACCAAT TGGAGGCCTG TTTGGCTGGC TCTTTGCTTT AGAAAAACCT 1800

GGCTCTGAGA ACGGCTTCAG CCTCGCAGGT GCTGCCTTTA CCCATGACAT GGAAGTTACA 1860

TTCTACCCGG GAGAGGAGAC GGTTCGTATC ACTCAAACTG CTGAGGGACT TGACCCAGAG 1920

AACTACCTGA GCATTAAGAC CAACATTCAA GGCCAGGTGC CTTACGTCCC AGCAAATTTC 1980 ACAGCCCACA TCTCTCCCTA CAAGGAGCTG TACCACTACT CCGACTCCAC TGTGACCTCT 2040

ACAAGTTCCA GAGACTACTC TCTGACTTTT GGTGCAATCA ACCAAACATG GTCCTACCGC 2100

ATCCACCAGA ACATCACTTA CCAGGTGTGC AGGCACGCCC CCAGACACCC GTCCTTCCCC 2160

ACCACCCAGC AGCTGAACGT GGACCGGGTC TTTGCCTTGT ATAATGATGA AGAAAGAGTG 2220

CTTAGATTTG CTGTGACCAA TCAAATTGGC CCGGTCAAAG AAGATTCAGA CCCCACTCCG 2280 GTGAATCCTT GCTATGATGG GAGCCACATG TGTGACACAA CAGCACGGTG CCATCCAGGG 2340

ACAGGTGTAG ATTACACCTG TGAGTGCGCA TCTGGGTACC AGGGAGATGG ACGGAACTGT 2400 GTGGATGAAA ATGAATGTGC AACTGGCTTT CATCGCTGTG GCCCCAACTC TGTATGTATC 2460 AACTTGCCTG GAAGCTACAG GTGTGAGTGC CGGAGTGGTT ATGAGTTTGC AGATGACCGG 2520 CATACTTGCA TCTTGATCAC CCCACCTGCC AACCCCTGTG AGGATGGCAG TCATACCTGT 2580 GCTCCTGCTG GGCAGGCCCG GTGTGTTCAC CATGGAGGCA GCACGTTCAG CTGTGCCTGC 2640 CTGCCTGGTT ATGCCGGCGA TGGGCACCAG TGCACTGATG TAGATGAATG CTCAGAAAAC 2700 AGATGTCACC CTGCAGCTAC CTGCTACAAT ACTCCTGGTT CCTTCTCCTG CCGTTGTCAA 2760 CCCGGATATT ATGGGGATGG ATTTCAGTGC ATACCTGACT CCACCTCAAG CCTGACACCC 2820 TGTGAACAAC AGCAGCGCCA TGCCCAGGCC CAGTATGCCT ACCCTGGGGC CCGGTTCCAC 2880 ATCCCCCAAT GCGACGAGCA GGGCAACTTC CTGCCCCTAC AGTGTCATGG CAGCACTGGT 2940 TTCTGCTGGT GCGTGGACCC TGATGGTCAT GAAGTTCCTG GTACCCAGAC TCCACCTGGC 3000 TCCACCCCGC CTCACTGTGG ACCATCACCA GAGCCCACCC AGAGGCCCCC GACCATCTGT 3060 GAGCGCTGGA GGGAAAACCT GCTGGAGCAC TACGGTGGCA CCCCCCGAGA TGACCAGTAC 3120 GTGCCCCAGT GCGATGACCT GGGCCACTTC ATCCCCCTGC AGTGCCACGG AAAGAGCGAC 3180 TTCTGCTGGT GTGTGGACAA AGATGGCAGA GAGGTGCAGG GCACCCGCTC CCAGCCAGGC 3240 ACCACCCCTG CGTGTATACC CACCGTCGCT CCACCCATGG TCCGGCCCAC GCCCCGGCCA 3300 GATGTGACCC CTCCATCTGT GGGCACCTTC CTGCTCTATA CTCAGGGCCA GCAGATTGGC 3360 TACTTACCCC TCAATGGCAC CAGGCTTCAG AAGGATGCAG CTAAGACCCT GCTGTCTCTG 3420 CATGGCTCCA TAATCGTGGG AATTGATTAC GACTGCCGGG AGAGGATGGT GTACTGGACA 3480 GATGTTGCTG GACGGACAAT CAGCCGTGCC GGTCTGGAAC TGGGAGCAGA GCCTGAGACG 3540 ATCGTGAATT CAGGTCTGAT AAGCCCTGAA GGACTTGCCA TAGACCACAT CCGCAGAACA 3600 ATGTACTGGA CGGACAGTGT CCTGGATAAG ATAGAGAGCG CCCTGCTGGA TGGCTCTGAG 3660 CGCAAGGTCC TCTTCTACAC AGATCTGGTG AATCCCCGTG CCATCGCTGT GGATCCAATC 3720 CGAGGCAACT TGTACTGGAC AGACTGGAAT AGAGAAGCTC CTAAAATTGA AACGTCATCT 3780 TTAGATGGAG AAAACAGAAG AATTCTGATC AATACAGACA TTGGATTGCC CAATGGCTTA 3840 ACCTTTGACC CTTTCTCTAA ACTGCTCTGC TGGGCAGATG CAGGAACCAA AAAACTGGAG 3900 TGTACACTAC CTGATGGAAC TGGACGGCGT GTCATTCAAA ACAACCTCAA GTACCCCTTC 3960 AGCATCGTAA GCTATGCAGA TCACTTCTAC CACACAGACT GGAGGAGGGA TGGTGTTGTA 4020 TCAGTAAATA AACATAGTGG CCAGTTTACT GATGAGTATC TCCCAGAACA ACGATCTCAC 4080 CTCTACGGGA TAACTGCAGT CTACCCCTAC TGCCCAACAG GAAGAAAGTA AGTACAGTAA 4140 TGTAAAGGAA GACTTGGAGT TTACAATCAG AACCTGGACC CTAAAGAACA GTGACTGCAA 4200 AGGCAAAGAA AGTAAAAAAG GAATTGGCCA TTAGACGTTC CTGAGCATCC AAGATGAACA 4260 TTTTGTAGTG CAAAAAGACT TTTGTGAAAA GCTGATACCT CAATCTTTAC TACTGTATTT 4320 TTAAAAATGA AGGTTGTTAT TGCAAGTTTA AAAAGGTAAC AGAATTTTAA CTGTTGCTTA 4380 TTAAAGCAAC TTCTTGTAAA CATTTATCAT TAATATTTAA AAGATCAAAT TCATTCAACT 4₄₄0 AAGAATTAGA GTTTAAGACT CTAAACCTGA TTTTTGCCAT GGATTCCTTC TGGCCAAGAA 4500 ATTAAAGCAC ATGTGATCAA TATAACAATA TAATCCTAAA CCTTGACAGT TGGAGAAGCC 4560 AATGCAGAAC TGATGGGAAA GGACCAATTA TTTATAGTTT CCCAACAAAA GTTCTAAGAT 4620 TTTTTACCTC TGCATCAGTG CATTTCTATT TATATCAAAA GGTGCTAAAA TGATTCAATT 4680 TGCATTTTCT GATCCTGTAG TGCCTCTATA GAAGTACCCA CAGAAAGTAA AGTATCACAT 4740 TTATAAATAC CAAAGATGTA ACAATTTTAA AATTTTCTAG ATTACTCCAA TAAAGTGTTT 4800 TAAGTTTAAA AAAAAAAAAA AAAAAAAAA

Seq ID No: 117 Protein sequence: Protein Accession #: NP 031387.1

11 21 31 41 51

MEGDRVAGRP VLSSLPVLLL LQLLMLRAAA LHPDELFPHG ESWWDQLLQE GDDVKLSRGE 60 AGESPALLTK PDSATSTWAP TASSPLRTSP GKRSMWTMIS PPTSRPSPLF WRTSTRATAE 120 AESCTERTPP PQCWAWPPAM CALASRALRA FYPHPRLPGH LGAGRRLRGG QTRALPSGEL 180 NTFQAVLASD GSDSYALFLY PANGLQFLGT RPKESYNVQL QLPARVGFCR GEADDLKSEG 240 PYFSLTSTEQ SVKNLYQLSN LGIPGVWAFH IGSTSPLDNV RPAAVGDLSA AHSSVPLGRS 300 FSHATALESD YNEDNLDYYD VNEEEAEYLP GEPEEALNGH SSIDVSFQSK VDTKPLEESS 360 TLDPHTKEGT SLGEVGGPDL KGQVEPWDER ETRSPAPPEV DRDSLAPSWE TPPPYPENGS 420 IQPYPDGGPV PSEMDVPPAH PEEEIVLRSY PASGHTTPLS RGTYEVGLED NIGSNTEVFT 480 YNAANKETCE HNHRQCSRHA FCTDYATGFC CHCQSKFYGN GKHCLPEGAP HRVNGKVSGH 5 0 LHVGHTPVHF TDVDLHAYIV GNDGRAYTAI SHIPQPAAQA LLPLTPIGGL FGWLFALEKP 600 GSENGFSLAG AAFTHDMEVT FYPGEETVRI TQTAEGLDPE NYLSIKTNIQ GQVPYVPANF 660 TAHISPYKEL YHYSDSTVTS TSSRDYSLTF GAINQTWSYR IHQNITYQVC RHAPRHPSFP 720 TTQQLNVDRV FALYNDEERV LRFAVTNQIG PVKEDSDPTP VNPCYDGSHM CDTTARCHPG 780 TGVDYTCECA SGYQGDGRNC VDENECATGF HRCGPNSVCI NLPGSYRCEC RSGYEFADDR 840 HTCILITPPA NPCEDGSHTC APAGQARCVH HGGSTFSCAC LPGYAGDGHQ CTDVDECSEN 900 RCHPAATCYN TPGSFSCRCQ PGYYGDGFQC IPDSTSSLTP CEQQQRHAQA QYAYPGARFH 960 IPQCDEQGNF LPLQCHGSTG FCWCVDPDGH EVPGTQTPPG STPPHCGPSP EPTQRPPTIC 1020 ERWRENLLEH YGGTPRDDQY VPQCDDLGHF IPLQCHGKSD FCWCVDKDGR EVQGTRSQPG 1080 TTPACIPTVA PPMVRPTPRP DVTPPSVGTF LLYTQGQQIG YLPLNGTRLQ KDAAKTLLSL 1140 HGSIIVGIDY DCRERMVYWT DVAGRTISRA GLELGAEPET IVNSGLISPE GLAIDHIRRT 1200 MYWTDSVLDK IESALLDGSE RKVLFYTDLV NPRAIAVDPI RGNLYWTDWN REAPKIETSS 1260 LDGENRRILI NTDIGLPNGL TFDPFSKLLC WADAGTKKLE CTLPDGTGRR VIQNNLKYPF 1320 SIVSYADHFY HTDWRRDGW SVNKHSGQFT DEYLPEQRSH LYGITAVYPY CPTGRK

Seq ID NO: 118 DNA sequence

Nucleic Acid Accession #: NM_003088.1

Coding sequence: 112-1593 (underlined sequences correspond to start and stop codons) 1 11 21 31 41 51

I I I I I I

GCGGAGGGTG CGTGCGGGCC GCGGCAGCCG AACAAAGGAG CAGGGGCGCC GCCGCAGGGA 60

CCCGCCACCC ACCTCCCGGG GCCGCGCAGC GGCCTCTCGT CTACTGCCAC CATGACCGCC 120 AACGGCACAG CCGAGGCGGT GCAGATCCAG TTCGGCCTCA TCAACTGCGG CAACAAGTAC 180

CTGACGGCCG AGGCGTTCGG GTTCAAGGTG AACGCGTCCG CCAGCAGCCT GAAGAAGAAG 240

CAGATCTGGA CGCTGGAGCA GCCCCCTGAC GAGGCGGGCA GCGCGGCCGT GTGCCTGCGC 300

AGCCACCTGG GCCGCTACCT GGCGGCGGAC AAGGACGGCA ACGTGACCTG CGAGCGCGAG 360

GTGCCCGGTC CCGACTGCCG TTTCCTCATC GTGGCGCACG ACGACGGTCG CTGGTCGCTG 420 CAGTCCGAGG CGCACCGGCG CTACTTCGGC GGCACCGAGG ACCGCCTGTC CTGCTTCGCG 480

CAGACGGTGT CCCCCGCCGA GAAGTGGAGC GTGCACATCG CCATGCACCC TCAGGTCAAC 540

ATCTACAGTG TCACCCGTAA GCGCTACGCG CACCTGAGCG CGCGGCCGGC CGACGAGATC 600

GCCGTGGACC GCGACGTGCC CTGGGGCGTC GACTCGCTCA TCACCCTCGC CTTCCAGGAC 660

CAGCGCTACA GCGTGCAGAC CGCCGACCAC CGCTTCCTGC GCCACGACGG GCGCCTGGTG 720 GCGCGCCCCG AGCCGGCCAC TGGCTACACG CTGGAGTTCC GCTCCGGCAA GGTGGCCTTC 780

CGCGACTGCG AGGGCCGTTA CCTGGCGCCG TCGGGGCCCA GCGGCACGCT CAAGGCGGGC 840

AAGGCCACCA AGGTGGGCAA GGACGAGCTC TTTGCTCTGG AGCAGAGCTG CGCCCAGGTC 900

GTGCTGCAGG CGGCCAACGA GAGGAACGTG TCCACGCGCC AGGGTATGGA CCTGTCTGCC 960

AATCAGGACG AGGAGACCGA CCAGGAGACC TTCCAGCTGG AGATCGACCG CGACACCAAA 1020 AAGTGTGCCT TCCGTACCCA CACGGGCAAG TACTGGACGC TGACGGCCAC CGGGGGCGTG 1080

CAGTCCACCG CCTCCAGCAA GAATGCCAGC TGCTACTTTG ACATCGAGTG GCGTGACCGG 1140

CGCATCACAC TGAGGGCGTC CAATGGCAAG TTTGTGACCT CCAAGAAGAA TGGGCAGCTG 1200

GCCGCCTCGG TGGAGACAGC AGGGGACTCA GAGCTCTTCC TCATGAAGCT CATCAACCGC 1260

CCCATCATCG TGTTCCGCGG GGAGCATGGC TTCATCGGCT GCCGCAAGGT CACGGGCACC 1320 CTGGACGCCA ACCGCTCCAG CTATGACGTC TTCCAGCTGG AGTTCAACGA TGGCGCCTAC 1380

AACATCAAAG ACTCCACAGG CAAATACTGG ACGGTGGGCA GTGACTCCGC GGTCACCAGC 1440

AGCGGCGACA CTCCTGTGGA CTTCTTCTTC GAGTTCTGCG ACTATAACAA GGTGGCCATC 1500

AAGGTGGGCG GGCGCTACCT GAAGGGCGAC CACGCAGGCG TCCTGAAGGC CTCGGCGGAA 1560

ACCGTGGACC CCGCCTCGCT CTGGGAGTAC TAGGGCCGGC CCGTCCTTCC CCGCCCCTGC 1620 CCACATGGCG GCTCCTGCCA ACCCTCCCTG CTAACCCCTT CTCCGCCAGG TGGGCTCCAG 1680

GGCGGGAGGC AAGCCCCCTT GCCTTTCAAA CTGGAAACCC CAGAGAAAAC GGTGCCCCCA 1740

CCTGTCGCCC CTATGGACTC CCCACTCTCC CCTCCGCCCG GGTTCCCTAC TCCCCTCGGG 1800

TCAGCGGCTG CGGCCTGGCC CTGGGAGGGA TTTCAGATGC CCCTGCCCTC TTGTCTGCCA 1860

CGGGGCGAGT CTGGCACCTC TTTCTTCTGA CCTCAGACGG CTCTGAGCCT TATTTCTCTG 1920 GAAGCGGCTA AGGGACGGTT GGGGGCTGGG AGCCCTGGGC GTGTAGTGTA ACTGGAATCT 1980

TTTGCCTCTC CCAGCCACCT CCTCCCAGCC CCCCAGGAGA GCTGGGCACA TGTCCCAAGC 2040

CTGTCAGTGG CCCTCCCTGG TGCACTGTCC CCGAAACCCC TGCTTGGGAA GGGAAGCTGT 2100

CGGGAGGGCT AGGACTGACC CTTGTGGTGT TTTTTTGGGT GGTGGCTGGA AACAGCCCCT 2160

CTCCCACGTG GGAGAGGCTC AGCCTGGCTC CCTTCCCTGG AGCGGCAGGG CGTGACGGCC 2220 ACAGGGTCTG CCCGCTGCAC GTTCTGCCAA GGTGGTGGTG GCGGGCGGGT AGGGGTGTGG 2280

GGGCCGTCTT CCTCCTGTCT CTTTCCTTTC ACCCTAGCCT GACTGGAAGC AGAAAATGAC 2340

CAAATCAGTA TTTTTTTTAA TGAAATATTA TTGCTGGAGG CGTCCCAGGC AAGCCTGGCT 2400

GTAGTAGCGA GTGATCTGGC GGGGGGCGTC TCAGCACCCT CCCCAGGGGG TGCATCTCAG 2460

CCCCCTCTTT CCGTCCTTCC CGTCCAGCCC CAGCCCTGGG CCTGGGCTGC CGACACCTGG 2520 GCCAGAGCCC CTGCTGTGAT TGGTGCTCCC TGGGCCTCCC GGGTGGATGA AGCCAGGCGT 2580

CGCCCCCTCC GGGAGCCCTG GGGTGAGCCG CCGGGGCCCC CCTGCTGCCA GCCTCCCCCG 2640

TCCCCAACAT GCATCTCACT CTGGGTGTCT TGGTCTTTTA TTTTTTGTAA GTGTCATTTG 2700

TATAACTCTA AACGCCCATG ATAGTAGCTT CAAACTGGAA ATAGCGAAAT AAAATAACTC 2760 AGTCTGC

Seq ID No: 119 Protein sequence: Protein Accession #: NP 003079.1 1 11 21 31 41 51

I I I I 1 I

MTANGTAEAV QIQFGLINCG NKYLTAEAFG FKVNASASSL KKKQIWTLEQ PPDEAGSAAV 60

CLRSHLGRYL AADKDGNVTC EREVPGPDCR FLIVAHDDGR WSLQSEAHRR YFGGTEDRLS 120

CFAQTVSPAE KWSVHIAMHP QVNIYSVTRK RYAHLSARPA DEIAVDRDVP WGVDSLITLA 180 FQDQRYSVQT ADHRFLRHDG RLVARPEPAT GYTLEFRSGK VAFRDCEGRY LAPSGPSGTL 240

KAGKATKVGK DELFALEQSC AQWLQAANE RNVSTRQGMD LSANQDEETD QETFQLEIDR 300

DTKKCAFRTH TGKYWTLTAT GGVQSTASSK NASCYFDIEW RDRRITLRAS NGKFVTSKKN 360

GQLAASVETA GDSELFLMKL INRPIIVFRG EHGFIGCRKV TGTLDANRSS YDVFQLEFND 420

GAYNIKDSTG KYWTVGSDSA VTSSGDTPVD FFFEFCDYNK VAIKVGGRYL KGDHAGVLKA 480 SAETVDPASL WEY

Seq ID NO : 120 DNA sequence

Nucleic Acid Accession # : NM_006₄04 . 1

Coding sequence : 25 -741 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

CAGGTCCGGA GCCTCAACTT CAGGATGTTG ACAACATTGC TGCCGATACT GCTGCTGTCT 60 GGCTGGGCCT TTTGTAGCCA AGACGCCTCA GATGGCCTCC AAAGACTTCA TATGCTCCAG 120

ATCTCCTACT TCCGCGACCC CTATCACGTG TGGTACCAGG GCAACGCGTC GCTGGGGGGA 180 CACCTAACGC ACGTGCTGGA AGGCCCAGAC ACCAACACCA CGATCATTCA GCTGCAGCCC 240

TTGCAGGAGC CCGAGAGCTG GGCGCGCACG CAGAGTGGCC TGCAGTCCTA CCTGCTCCAG 300

TTCCACGGCC TCGTGCGCCT GGTGCACCAG GAGCGGACCT TGGCCTTTCC TCTGACCATC 360

CGCTGCTTCC TGGGCTGTGA GCTGCCTCCC GAGGGCTCTA GAGCCCATGT CTTCTTCGAA 420 GTGGCTGTGA ATGGGAGCTC CTTTGTGAGT TTCCGGCCGG AGAGAGCCTT GTGGCAGGCA 480

GACACCCAGG TCACCTCCGG AGTGGTCACC TTCACCCTGC AGCAGCTCAA TGCCTACAAC 540

CGCACTCGGT ATGAACTGCG GGAATTCCTG GAGGACACCT GTGTGCAGTA TGTGCAGAAA 600

CATATTTCCG CGGAAAACAC GAAAGGGAGC CAAACAAGCC GCTCCTACAC TTCGCTGGTC 660

CTGGGCGTCC TGGTGGGCGG TTTCATCATT GCTGGTGTGG CTGTAGGCAT CTTCCTGTGC 720 ACAGGTGGAC GGCGATGTTA_ATTACTCTCC AGCCCCGTCA GAAGGGGCTG GATTGATGGA 780

GGCTGGCAAG GGAAAGTTTC AGCTCACTGT GAAGCCAGAC TCCCCAACTG AAACACCAGA 840

AGGTTTGGAG TGACAGCTCC TTTCTTCTCC CACATCTGCC CACTGAAGAT TTGAGGGAGG 900

GGAGATGGAG AGGAGAGGTG GACAAAGTAC TTGGTTTGCT AAGAACCTAA GAACGTGTAT 960

GCTTTGCTGA ATTAGTCTGA TAAGTGAATG TTTATCTATC TTTGTGGAAA ACAGATAATG 1020 GAGTTGGGGC AGGAAGCCTA TGCGCCATCC TCCAAAGACA GACAGAATCA CCTGAGGCGT 1080

TCAAAAGATA TAACCAAATA AACAAGTCAT CCACAATCAA AATACAACAT TCAATACTTC 1140

CAGGTGTGTC AGACTTGGGA TGGGACGCTG ATATAATAGG GTAGAAAGAA GTAACACGAA 1200

GAAGTGGTGG AAATGTAAAA TCCAAGTCAT ATGGCAGTGA TCAATTATTA ATCAATTAAT 1260 AATATTAATA AATTTCTTAT ATTT

Seq ID No : 121 Protein sequence : Protein Accession # : NP_006395 . 1

1 11 21 31 41 51

I I I I I I

MLTTLLPILL LSGWAFCSQD ASDGLQRLHM LQISYFRDPY HVWYQGNASL GGHLTHVLEG 60

PDTNTTIIQL QPLQEPESWA RTQSGLQSYL LQFHGLVRLV HQERTLAFPL TIRCFLGCEL 120

PPEGSRAHVF FEVAVNGSSF VSFRPERALW QADTQVTSGV VTFTLQQLNA YNRTRYELRE 180 FLEDTCVQYV QKHISAENTK GSQTSRSYTS LVLGVLVGGF IIAGVAVGIF LCTGGRRC

Seq ID NO : 122 DNA sequence

Nucleic Acid Accession # : none found

Coding sequence : 2 - 505 (underlined sequences correspond to start and stop codons)

1 11 21 31 41 51

CGAGAAGCTG GGAGAGACAC CACTTGTCCC TGAACAAGAC AATTCAGTAA CATCTATTCC 60

TGAGATTCCT CGATGGGGAT CACAGAGCAC GATGTCTACC CTTCAAATGT CCCTTCAAGC 120 CGAGTCAAAG GCCACTATCA CCCCATGAGG GAGCGTGATT TCCAAGTTTA ATTCTACGAC 180

TTCCTCTGCC ACTCCTCAGG CTTTCGACTC CTCCTCTGCC GTGGTCTTCA TATTTGTGAG 240

CACAGCAGTA GTAGTGTTGG TGATCTTGAC CATGACAGTA CTGGGGCTTG TCAAGCTCTG 300

CTTTCACGAA AGCCCCTCTT CCCAGCCAAG GAAGGAGTCT ATGGGCCCGC CGGGCCTGGA 360

GAGTGATCCT GAGCCCGCTG CTTTGGGCTC CAGTTCTGCA CATTGCACAA ACAATGGGGT 420 GAAAGTCGGG GACTGTGATC TGCGGGACAG AGCAGAGGGT GCCTTGCTGG CGGAGTCCCC 480

TCTTGGCTCT AGTGATGCAT AGGGAAACAG GGGACATGGG CACTCCTGTG AACAGTTTTT 540

CACTTTTGAT GAAACGGGGA ACCAAGAGGA ACTTACTTGT GTAACTGACA ATTTCTGCAG 600

AAATCCCCCT TCCTCTAAAT TCCCTTTACT CCACTGAGGA GCTAAATCAG AACTGCACAC 660

TCCTTCCCTG ATGATAGAGG AAGTGGAAGT GCCTTTAGGA TGGTGATACT GGGGGACCGG 720 GTAGTGCTGG GGAGAGATAT TTTCTTATGT TTATTCGGAG AATTTGGAGA AGTGATTGAA 780

CTTTTCAAGA CATTGGAAAC AAATAGAACA CAATATAATT TACATTAAAA AATAATTTCT 8 0

ACCAAAATGG AAAGGAAATG TTCTATGTTG TTCAGGCTAG GAGTATATTG GTTCGAAATC 900 CCAGGGAAAA AAATAAAAAT AAAAAATTAA AGGATTGTTG ATAAAA Seq ID No : 123 Protein sequence :

Protein Accession # : none found 1 11 21 31 41 51

I I I I I I

EKLGETPLVP EQDNSVTSIP EIPRWGSQST MSTLQMSLQA ESKATITPSG SVISKFNSTT 60 SSATPQAFDS SSAWFIFVS TAVWLVILT MTVLGLVKLC FHESPSSQPR KESMGPPGLE 120 SDPEPAALGS SSAHCTNNGV KVGDCDLRDR AEGALLAESP LGSSDA

Seq ID NO: 124 DNA sequence Nucleic Acid Accession #: NM_006500.1

Coding sequence: 27-1967 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

ACTTGCGTCT CGCCCTCCGG CCAAGCATGG GGCTTCCCAG GCTGGTCTGC GCCTTCTTGC 60

TCGCCGCCTG CTGCTGCTGT CCTCGCGTCG CGGGTGTGCC CGGAGAGGCT GAGCAGCCTG 120

CGCCTGAGCT GGTGGAGGTG GAAGTGGGCA GCACAGCCCT TCTGAAGTGC GGCCTCTCCC 180

AGTCCCAAGG CAACCTCAGC CATGTCGACT GGTTTTCTGT CCACAAGGAG AAGCGGACGC 240 TCATCTTCCG TGTGCGCCAG GGCCAGGGCC AGAGCGAACC TGGGGAGTAC GAGCAGCGGC 300

TCAGCCTCCA GGACAGAGGG GCTACTCTGG CCCTGACTCA AGTCACCCCC CAAGACGAGC 360 GCATCTTCTT GTGCCAGGGC AAGCGCCCTC GGTCCCAGGA GTACCGCATC CAGCTCCGCG 420

TCTACAAAGC TCCGGAGGAG CCAAACATCC AGGTCAACCC CCTGGGCATC CCTGTGAACA 480

GTAAGGAGCC TGAGGAGGTC GCTACCTGTG TAGGGAGGAA CGGGTACCCC ATTCCTCAAG 540

TCATCTGGTA CAAGAATGGC CGGCCTCTGA AGGAGGAGAA GAACCGGGTC CACATTCAGT 600 CGTCCCAGAC TGTGGAGTCG AGTGGTTTGT ACACCTTGCA GAGTATTCTG AAGGCACAGC 660

TGGTTAAAGA AGACAAAGAT GCCCAGTTTT ACTGTGAGCT CAACTACCGG CTGCCCAGTG 720

GGAACCACAT GAAGGAGTCC AGGGAAGTCA CCGTCCCTGT TTTCTACCCG ACAGAAAAAG 780

TGTGGCTGGA AGTGGAGCCC GTGGGAATGC TGAAGGAAGG GGACCGCGTG GAAATCAGGT 840

GTTTGGCTGA TGGCAACCCT CCACCACACT TCAGCATCAG CAAGCAGAAC CCCAGCACCA 900 GGGAGGCAGA GGAAGAGACA ACCAACGACA ACGGGGTCCT GGTGCTGGAG CCTGCCCGGA 960

AGGAACACAG TGGGCGCTAT GAATGTCAGG CCTGGAACTT GGACACCATG ATATCGCTGC 1020

TGAGTGAACC ACAGGAACTA CTGGTGAACT ATGTGTCTGA CGTCCGAGTG AGTCCCGCAG 1080

CCCCTGAGAG ACAGGAAGGC AGCAGCCTCA CCCTGACCTG TGAGGCAGAG AGTAGCCAGG 1140

ACCTCGAGTT CCAGTGGCTG AGAGAAGAGA CAGACCAGGT GCTGGAAAGG GGGCCTGTGC 1200 TTCAGTTGCA TGACCTGAAA CGGGAGGCAG GAGGCGGCTA TCGCTGCGTG GCGTCTGTGC 1260

CCAGCATACC CGGCCTGAAC CGCACACAGC TGGTCAAGCT GGCCATTTTT GGCCCCCCTT 1320

GGATGGCATT CAAGGAGAGG AAGGTGTGGG TGAAAGAGAA TATGGTGTTG AATCTGTCTT 1380

GTGAAGCGTC AGGGCACCCC CGGCCCACCA TCTCCTGGAA CGTCAACGGC ACGGCAAGTG 1440

AACAAGACCA AGATCCACAG CGAGTCCTGA GCACCCTGAA TGTCCTCGTG ACCCCGGAGC 1500 TGTTGGAGAC AGGTGTTGAA TGCACGGCCT CCAACGACCT GGGCAAAAAC ACCAGCATCC 1560

TCTTCCTGGA GCTGGTCAAT TTAACCACCC TCACACCAGA CTCCAACACA ACCACTGGCC 1620

TCAGCACTTC CACTGCCAGT CCTCATACCA GAGCCAACAG CACCTCCACA GAGAGAAAGC 1680

TGCCGGAGCC GGAGAGCCGG GGCGTGGTCA TCGTGGCTGT GATTGTGTGC ATCCTGGTCC 1740

TGGCGGTGCT GGGCGCTGTC CTCTATTTCC TCTATAAGAA GGGCAAGCTG CCGTGCAGGC 1800 GCTCAGGGAA GCAGGAGATC ACGCTGCCCC CGTCTCGTAA GACCGAACTT GTAGTTGAAG 1860

TTAAGTCAGA TAAGCTCCCA GAAGAGATGG GCCTCCTGCA GGGCAGCAGC GGTGACAAGA 1920

GGGCTCCGGG AGACCAGGGA GAGAAATACA TCGATCTGAG GCATTAGCCC CGAATCACTT 1980

CAGCTCCCTT CCCTGCCTGG ACCATTCCCA GCTCCCTGCT CACTCTTCTC TCAGCCAAAG 2040

CCTCCAAAGG GACTAGAGAG AAGCCTCCTG CTCCCCTCAC CTGCACACCC CCTTTCAGAG 2100 GGCCACTGGG TTAGGACCTG AGGACCTCAC TTGGCCCTGC AAGCCGCTTT TCAGGGACCA 2160

GTCCACCACC ATCTCCTCCA CGTTGAGTGA AGCTCATCCC AAGCAAGGAG CCCCAGTCTC 2220

CCGAGCGGGT AGGAGAGTTT CTTGCAGAAC GTGTTTTTTC TTTACACACA TTATGGCTGT 2280

AAATACCTGG CTCCTGCCAG CAGCTGAGCT GGGTAGCCTC TCTGAGCTGG TTTCCTGCCC 2340

CAAAGGCTGG CTTCCACCAT CCAGGTGCAC CACTGAAGTG AGGACACACC GGAGCCAGGC 2400 GCCTGCTCAT GTTGAAGTGC GCTGTTCACA CCCGCTCCGG AGAGCACCCC AGCGGCATCC 2460

AGAAGCAGCT GCAGTGTTGC TGCCACCACC CTCCTGCTCG CCTCTTCAAA GTCTCCTGTG 2520

ACATTTTTTC TTTGGTCAGA AGCCAGGAAC TGGTGTCATT CCTTAAAAGA TACGTGCCGG 2580

GGCCAGGTGT GGTGGCTCAC GCCTGTAATC CCAGCACTTT GGGAGGCCGA GGCGGGCGGA 2640

TCACAAAGTC AGGAGGAGAG CATCCTGGCT AACACGGTGA AACCCTGTCT CTACTAAAAA 2700 TACAAAAAAA AATTAGCTAG GCGTAGTGGT TGGCACCTAT AGTCCCAGCT ACTCGGAAGG 2760

CTGAAGCAGG AGAATGGTAT GAATCCAGGA GGTGGAGCTT GCAGTGAGCC GAGACCGTGC 2820

CACTGCACTC CAGCCTGGGC AACACAGCGA GACTCCGTCT CGAGGAAAAA AAAAGAAAAG 2880

ACGCGTACCT GCGGTGAGGA AGCTGGGCGC TGTTTTCGAG TTCAGGTGAA TTAGCCTCAA 2940

TCCCCGTGTT CACTTGCTCC CATAGCCCTC TTGATGGATC ACGTAAAACT GAAAGGCAGC 3000 GGGGAGCAGA CAAAGATGAG GTCTACACTG TCCTTCATGG GGATTAAAGC TATGGTTATA 3060

TTAGCACCAA ACTTCTACAA ACCAAGCTCA GGGCCCCAAC CCTAGAAGGG CCCAAATGAG 3120

AGAATGGTAC TTAGGGATGG AAAACGGGGC CTGGCTAGAG CTTCGGGTGT GTGTGTCTGT 3180

CTGTGTGTAT GCATACATAT GTGTGTATAT ATGGTTTTGT CAGGTGTGTA AATTTGCAAA 3240

TTGTTTCCTT TATATATGTA TGTATATATA TATATGAAAA TATATATATA TATGAAAAAT 3300 AAAGCTTAAT TGTCCCAGAA AATCATACAT TGCTTTTTTA TTCTACATGG GTACCACAGG 3360

AACCTGGGGG CCTGTGAAAC TACAACCAAA AGGCACACAA AACCGTTTCC AGTTGGCAGC 3420

AGAGATCAGG GGTTACCTCT GCTTCTGAGC AAATGGCTCA AGCTCTACCA GAGCAGACAG 3480

CTACCCTACT TTTCAGCAGC AAAACGTCCC GTATGACGCA GCACGAAGGG CCTGGCAGGC 3540 TGTTAGCAGG AGCTATGTCC CTTCCTATCG TTTCCGTCCA CTT

Seq ID No : 125 Protein sequence : Protein Accession # : NP 006491 . 1

1 11 21 31 41 51

I I I I I I

MGLPRLVCAF LLAACCCCPR VAGVPGEAEQ PAPELVEVEV GSTALLKCGL SQSQGNLSHV 60

DWFSVHKEKR TLIFRVRQGQ GQSEPGEYEQ RLSLQDRGAT LALTQVTPQD ERIFLCQGKR 120

PRSQEYRIQL RVYKAPEEPN IQVNPLGIPV NSKEPEEVAT CVGRNGYPIP QVIWYKNGRP 180 LKEEKNRVHI QSSQTVESSG LYTLQSILKA QLVKEDKDAQ FYCELNYRLP SGNHMKESRE 240

VTVPVFYPTE KVWLEVEPVG MLKEGDRVEI RCLADGNPPP HFSISKQNPS TREAEEETTN 300

DNGVLVLEPA RKEHSGRYEC QAWNLDTMIS LLSEPQELLV NYVSDVRVSP AAPERQEGSS 360

LTLTCEAESS QDLEFQWLRE ETDQVLERGP VLQLHDLKRE AGGGYRCVAS VPSIPGLNRT 420

QLVKLAIFGP PWMAFKERKV WVKENMVLNL SCEASGHPRP TISWNVNGTA SEQDQDPQRV 480 LSTLNVLVTP ELLETGVECT ASNDLGKNTS ILFLELVNLT TLTPDSNTTT GLSTSTASPH 540

TRANSTSTER KLPEPESRGV VIVAVIVCIL VLAVLGAVLY FLYKKGKLPC RRSGKQEITL 600 PPSRKTELW EVKSDKLPEE MGLLQGSSGD KRAPGDQGEK YIDLRH

Seq ID NO: 126 DNA sequence

Nucleic Acid Accession #: NM 001955.1 Coding sequence : 337-975 (underlined sequences correspond to start and stop ^' codons)

11 21 31 41 51

GGAGCTGTTT ACCCCCACTC TAATAGGGGT TCAATATAAA AAGCCGGCAG AGAGCTGTCC 60 AAGTCAGACG CGCCTCTGCA TCTGCGCCAG GCGAACGGGT CCTGCGCCTC CTGCAGTCCC 120 AGCTCTCCAC CACCGCCGCG TGCGCCTGCA GACGCTCCGC TCGCTGCCTT CTCTCCTGGC 180 AGGCGCTGCC TTTTCTCCCC GTTAAAGGGC ACTTGGGCTG AAGGATCGCT TTGAGATCTG 240 AGGAACCCGC AGCGCTTTGA GGGACCTGAA GCTGTTTTTC TTCGTTTTCC TTTGGGTTCA 300 GTTTGAACGG GAGGTTTTTG ATCCCTTTTT TTCAGAATGG ATTATTTGCT CATGATTTTC 360. TCTCTGCTGT TTGTGGCTTG CCAAGGAGCT CCAGAAACAG CAGTCTTAGG CGCTGAGCTC 420 AGCGCGGTGG GTGAGAACGG CGGGGAGAAA CCCACTCCCA GTCCACCCTG GCGGCTCCGC 480 CGGTCCAAGC GCTGCTCCTG CTCGTCCCTG ATGGATAAAG AGTGTGTCTA CTTCTGCCAC 540 CTGGACATCA TTTGGGTCAA CACTCCCGAG CACGTTGTTC CGTATGGACT TGGAAGCCCT 600 AGGTCCAAGA GAGCCTTGGA GAATTTACTT CCCACAAAGG CAACAGACCG TGAGAATAGA 660 TGCCAATGTG CTAGCCAAAA AGACAAGAAG TGCTGGAATT TTTGCCAAGC AGGAAAAGAA 720 CTCAGGGCTG AAGACATTAT GGAGAAAGAC TGGAATAATC ATAAGAAAGG AAAAGACTGT 780 TCCAAGCTTG GGAAAAAGTG TATTTATCAG CAGTTAGTGA GAGGAAGAAA AATCAGAAGA 840 AGTTCAGAGG AACACCTAAG ACAAACCAGG TCGGAGACCA TGAGAAACAG CGTCAAATCA 900 TCTTTTCATG ATCCCAAGCT GAAAGGCAAG CCCTCCAGAG AGCGTTATGT GACCCACAAC 960 CGAGCACATT GGTGACAGAC TTCGGGGCCT GTCTGAAGCC ATAGCCTCCA CGGAGAGCCC 1020 TGTGGCCGAC TCTGCACTCT CCACCCTGGC TGGGATCAGA GCAGGAGCAT CCTCTGCTGG 1080 TTCCTGACTG GCAAAGGACC AGCGTCCTCG TTCAAAACAT TCCAAGAAAG GTTAAGGAGT 1140 TCCCCCAACC ATCTTCACTG GCTTCCATCA GTGGTAACTG CTTTGGTCTC TTCTTTCATC 1200 TGGGGATGAC AATGGACCTC TCAGCAGAAA CACACAGTCA CATTCGAATT C

Seq ID No: 127 Protein sequence: Protein Accession #: NP 001946.1

11 21 31 41 51

MDYLLMIFSL LFVACQGAPE TAVLGAELSA VGENGGEKPT PSPPWRLRRS KRCSCSSLMD 60 KECVYFCHLD IIWVNTPEHV VPYGLGSPRS KRALENLLPT KATDRENRCQ CASQKDKKCW 120

NFCQAGKELR AEDIMEKDWN NHKKGKDCSK LGKKCIYQQL VRGRKIRRSS EEHLRQTRSE 180 TMRNSVKSSF HDPKLKGKPS RERYVTHNRA HW

Seq ID NO : 128 DNA sequence

Nucleic Acid Accession # : NM_001721 .1

Coding sequence : 34-2061 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

GCAAGCACGG AACAAGCTGA GACGGATGAT AATATGGATA CAAAATCTAT TCTAGAAGAA 60 CTTCTTCTCA AAAGATCACA GCAAAAGAAG AAAATGTCAC CAAATAATTA CAAAGAACGG 120 CTTTTTGTTT TGACCAAAAC AAACCTTTCC TACTATGAAT ATGACAAAAT GAAAAGGGGC 180 AGCAGAAAAG GATCCATTGA AATTAAGAAA ATCAGATGTG TGGAGAAAGT AAATCTCGAG 240 GAGCAGACGC CTGTAGAGAG ACAGTACCCA TTTCAGATTG TCTATAAAGA TGGGCTTCTC 300 TATGTCTATG CATCAAATGA AGAGAGCCGA AGTCAGTGGT TGAAAGCATT ACAAAAAGAG 360 ATAAGGGGTA ACCCCCACCT GCTGGTCAAG TACCATAGTG GGTTCTTCGT GGACGGGAAG 420 TTCCTGTGTT GCCAGCAGAG CTGTAAAGCA GCCCCAGGAT GTACCCTCTG GGAAGCATAT 480 GCTAATCTGC ATACTGCAGT CAATGAAGAG AAACACAGAG TTCCCACCTT CCCAGACAGA 540 GTGCTGAAGA TACCTCGGGC AGTTCCTGTT CTCAAAATGG ATGCACCATC TTCAAGTACC 600 ACTCTAGCCC AATATGACAA CGAATCAAAG AAAAACTATG GCTCCCAGCC ACCATCTTCA 660 AGTACCAGTC TAGCGCAATA TGACAGCAAC TCAAAGAAAA TCTATGGCTC CCAGCCAAAC 720 TTCAACATGC AGTATATTCC AAGGGAAGAC TTCCCTGACT GGTGGCAAGT AAGAAAACTG 780 AAAAGTAGCA GCAGCAGTGA AGATGTTGCA AGCAGTAACC AAAAAGAAAG AAATGTGAAT 840 CACACCACCT CAAAGATTTC ATGGGAATTC CCTGAGTCAA GTTCATCTGA AGAAGAGGAA 900 AACCTGGATG ATTATGACTG GTTTGCTGGT AACATCTCCA GATCACAATC TGAACAGTTA 960 CTCAGACAAA AGGGAAAAGA AGGAGCATTT ATGGTTAGAA ATTCGAGCCA AGTGGGAATG 1020 TACACAGTGT CCTTATTTAG TAAGGCTGTG AATGATAAAA AAGGAACTGT CAAACATTAC 1080 CACGTGCATA CAAATGCTGA GAACAAATTA TACCTGGCAG AAAACTACTG TTTTGATTCC 11₄0 ATTCCAAAGC TTATTCATTA TCATCAACAC AATTCAGCAG GCATGATCAC ACGGCTCCGC 1200 CACCCTGTGT CAACAAAGGC CAACAAGGTC CCCGACTCTG TGTCCCTGGG AAATGGAATC 1260 TGGGAACTGA AAAGAGAAGA GATTACCTTG TTGAAGGAGC TGGGAAGTGG CCAGTTTGGA 1320 GTGGTCCAGC TGGGCAAGTG GAAGGGGCAG TATGATGTTG CTGTTAAGAT GATCAAGGAG 1380 GGCTCCATGT CAGAAGATGA ATTCTTTCAG GAGGCCCAGA CTATGATGAA ACTCAGCCAT 1440 CCCAAGCTGG TTAAATTCTA TGGAGTGTGT TCAAAGGAAT ACCCCATATA CATAGTGACT 1500 GAATATATAA GCAATGGCTG CTTGCTGAAT TACCTGAGGA GTCACGGAAA AGGACTTGAA 1560 CCTTCCCAGC TCTTAGAAAT GTGCTACGAT GTCTGTGAAG GCATGGCCTT CTTGGAGAGT 1620 CACCAATTCA TACACCGGGA CTTGGCTGCT CGTAACTGCT TGGTGGACAG AGATCTCTGT 1680 GTGAAAGTAT CTGACTTTGG AATGACAAGG TATGTTCTTG ATGACCAGTA TGTCAGTTCA 1740 GTCGGAACAA AGTTTCCAGT CAAGTGGTCA GCTCCAGAGG TGTTTCATTA CTTCAAATAC 1800 AGCAGCAAGT CAGACGTATG GGCATTTGGG ATCCTGATGT GGGAGGTGTT CAGCCTGGGG 1860 AAGCAGCCCT ATGACTTGTA TGACAACTCC CAGGTGGTTC TGAAGGTCTC CCAGGGCCAC 1920 AGGCTTTACC GGCCCCACCT GGCATCGGAC ACCATCTACC AGATCATGTA CAGCTGCTGG 1980 CACGAGCTTC CAGAAAAGCG TCCCACATTT CAGCAACTCC TGTCTTCCAT TGAACCACTT 2040 CGGGAAAAAG ACAAGCATTG AAGAAGAAAT TAGGAGTGCT GATAAGAATG AATATAGATG 2100 CTGGCCAGCA TTTTCATTCA TTTTAAGGAA AGTAGGAAGG CATAAGTAAT TTTAGCTAGT 2160 TTTTAATAGT GTTCTCTGTA TTGTCTATTA TTTAGAAATG AACAAGGCAG GAAACAAAAG 2220 ATTCCCTTGA AATTTAGATC AAATTAGTAA TTTTGTTTTA TGCTGCTCCT GATATAACAC 2280 TTTCCAGCCT ATAGCAGAAG CACATTTTCA GACTGCAATA TAGAGACTGT GTTCATGTGT 2340 AAAGACTGAG CAGAACTGAA AAATTACTTA TTGGATATTC ATTCTTTTCT TTATATTGTC 2400 ATTGTCACAA CAATTAAATA TACTACCAAG TACAGAAATG TGGAAAAAAA AAACCG

Seq ID No: 129 Protein sequence: Protein Accession #: NP 001712.1

11 21 31 41 51

I I I I I

MDTKSILEEL LLKRSQQKKK MSPNNYKERL FVLTKTNLSY YEYDKMKRGS RKGSIEIKKI 60 RCVEKVNLEE QTPVERQYPF QIVYKDGLLY VYASNEESRS QWLKALQKEI RGNPHLLVKY 120 HSGFFVDGKF LCCQQSCKAA PGCTLWEAYA NLHTAVNEEK HRVPTFPDRV LKIPRAVPVL 180 KMDAPSSSTT LAQYDNESKK NYGSQPPSSS TSLAQYDSNS KKIYGSQPNF NMQYIPREDF 240 PDWWQVRKLK SSSSSEDVAS SNQKERNVNH TTSKISWEFP ESSSSEEEEN LDDYDWFAGN 300 ISRSQSEQLL RQKGKEGAFM VRNSSQVGMY TVSLFSKAVN DKKGTVKHYH VHTNAENKLY 360 LAENYCFDSI PKLIHYHQHN SAGMITRLRH PVSTKANKVP DSVSLGNGIW ELKREEITLL 420 KELGSGQFGV VQLGKWKGQY DVAVKMIKEG SMSEDEFFQE AQTMMKLSHP KLVKFYGVCS 480 KEYPIYIVTE YISNGCLLNY LRSHGKGLEP SQLLEMCYDV CEGMAFLESH QFIHRDLAAR 540 NCLVDRDLCV KVSDFGMTRY VLDDQYVSSV GTKFPVKWSA PEVFHYFKYS SKSDVWAFGI 600 LMWEVFSLGK QPYDLYDNSQ WLKVSQGHR LYRPHLASDT IYQIMYSCWH ELPEKRPTFQ 660 QLLSSIEPLR EKDKH

Seq ID NO: 130 DNA sequence Nucleic Acid Accession #: NM_012072.2

Coding sequence: 149-2107 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

I I I I

AAAGCCCTCA GCCTTTGTGT CCTTCTCTGC GCCGGAGTGG CTGCAGCTCA CCCCTCAGCT 60 CCCCTTGGGG CCCAGCTGGG AGCCGAGATA GAAGCTCCTG TCGCCGCTGG GCTTCTCGCC 120 TCCCGCAGAG GGCCACACAG AGACCGGGAT GGCCACCTCC ATGGGCCTGC TGCTGCTGCT 180 GCTGCTGCTC CTGACCCAGC CCGGGGCGGG GACGGGAGCT GACACGGAGG CGGTGGTCTG 240 CGTGGGGACC GCCTGCTACA CGGCCCACTC GGGCAAGCTG AGCGCTGCCG AGGCCCAGAA 300 CCACTGCAAC CAGAACGGGG GCAACCTGGC CACTGTGAAG AGCAAGGAGG AGGCCCAGCA 360 CGTCCAGCGA GTACTGGCCC AGCTCCTGAG GCGGGAGGCA GCCCTGACGG CGAGGATGAG 420 CAAGTTCTGG ATTGGGCTCC AGCGAGAGAA GGGCAAGTGC CTGGACCCTA GTCTGCCGCT 480 GAAGGGCTTC AGCTGGGTGG GCGGGGGGGA GGACACGCCT TACTCTAACT GGCACAAGGA 540 GCTCCGGAAC TCGTGCATCT CCAAGCGCTG TGTGTCTCTG CTGCTGGACC TGTCCCAGCC 600 GCTCCTTCCC AACCGCCTGC CCAAGTGGTC TGAGGGCCCC TGTGGGAGCC CAGGCTCCCC 660 CGGAAGTAAC ATTGAGGGCT TCGTGTGCAA GTTCAGCTTC AAAGGCATGT GCCGGCCTCT 720 GGCCCTGGGG GGCCCAGGTC AGGTGACCTA CACCACCCCC TTCCAGACCA CCAGTTCCTC 780 CTTGGAGGCT GTGCCCTTTG CCTCTGCGGC CAATGTAGCC TGTGGGGAAG GTGACAAGGA 840 CGAGACTCAG AGTCATTATT TCCTGTGCAA GGAGAAGGCC CCCGATGTGT TCGACTGGGG 900 CAGCTCGGGC CCCCTCTGTG TCAGCCCCAA GTATGGCTGC AACTTCAACA ATGGGGGCTG 960 CCACCAGGAC TGCTTTGAAG GGGGGGATGG CTCCTTCCTC TGCGGCTGCC GACCAGGATT 1020 CCGGCTGCTG GATGACCTGG TGACCTGTGC CTCTCGAAAC CCTTGCAGCT CCAGCCCATG 1080 TCGTGGGGGG GCCACGTGCG TCCTGGGACC CCATGGGAAA AACTACACGT GCCGCTGCCC 1140 CCAAGGGTAC CAGCTGGACT CGAGTCAGCT GGACTGTGTG GACGTGGATG AATGCCAGGA 1200 CTCCCCCTGT GCCCAGGAGT GTGTCAACAC CCCTGGGGGC TTCCGCTGCG AATGCTGGGT 1260 TGGCTATGAG CCGGGCGGTC CTGGAGAGGG GGCCTGTCAG GATGTGGATG AGTGTGCTCT 1320 GGGTCGCTCG CCTTGCGCCC AGGGCTGCAC CAACACAGAT GGCTCATTTC ACTGCTCCTG 1380 TGAGGAGGGC TACGTCCTGG CCGGGGAGGA CGGGACTCAG TGCCAGGACG TGGATGAGTG 1440 TGTGGGCCCG GGGGGCCCCC TCTGCGACAG CTTGTGCTTC AACACACAAG GGTCCTTCCA 1500 CTGTGGCTGC CTGCCAGGCT GGGTGCTGGC CCCAAATGGG GTCTCTTGCA CCATGGGGCC 1560 TGTGTCTCTG GGACCACCAT CTGGGCCCCC CGATGAGGAG GACAAAGGAG AGAAAGAAGG 1620 GAGCACCGTG CCCCGCGCTG CAACAGCCAG TCCCACAAGG GGCCCCGAGG GCACCCCCAA 1680 GGCTACACCC ACCACAAGTA GACCTTCGCT GTCATCTGAC GCCCCCATCA CATCTGCCCC 1740 ACTCAAGATG CTGGCCCCCA GTGGGTCCTC AGGCGTCTGG AGGGAGCCCA GCATCCATCA 1800 CGCCACAGCT GCCTCTGGCC CCCAGGAGCC TGCAGGTGGG GACTCCTCCG TGGCCACACA 1860 AAACAACGAT GGCACTGACG GGCAAAAGCT GCTTTTATTC TACATCCTAG GCACCGTGGT 1920 GGCCATCCTA CTCCTGCTGG CCCTGGCTCT GGGGCTACTG GTCTATCGCA AGCGGAGAGC 1980 GAAGAGGGAG GAGAAGAAGG AGAAGAAGCC CCAGAATGCG GCAGACAGTT ACTCCTGGGT 2040 TCCAGAGCGA GCTGAGAGCA GGGCCATGGA GAACCAGTAC AGTCCGACAC CTGGGACAGA 2100 CTGCTGAAAG TGAGGTGGCC CTAGAGACAC TAGAGTCACC AGCCACCATC CTCAGAGCTT 2160 TGAACTCCCC ATTCCAAAGG GGCACCCACA TTTTTTTGAA AGACTGGACT GGAATCTTAG _{2 2}0 CAAACAATTG TAAGTCTCCT CCTTAAAGGC CCCTTGGAAC ATGCAGGTAT TTTCTACGGG ₂ 80 TGTTTGATGT TCCTGAAGTG GAAGCTGTGT GTTGGCGTGC CACGGTGGGG ATTTCGTGAC 2340 TCTATAATGA TTGTTACTCC CCCTCCCTTT TCAAATTCCA ATGTGACCAA TTCCGGATCA 2400 GGGTGTGAGG AGGCTGGGGC TAAGGGGCTC CCCTGAATAT CTTCTCTGCT CACTTCCACC 2460 ATCTAAGAGG AAAAGGTGAG TTGCTCATGC TGATTAGGAT TGAAATGATT TGTTTCTCTT 2520 CCTAGGATGA AAACTAAATC AATTAATTAT TCAATTAGGT AAGAAGATCT GGTTTTTTGG 2580 TCAAAGGGAA CATGTTCGGA CTGGAAACAT TTCTTTACAT TTGCATTCCT CCATTTCGCC 2640 AGCACAAGTC TTGCTAAATG TGATACTGTT GACATCCTCC AGAATGGCCA GAAGTGCAAT 2700 TAACCTCTTA GGTGGCAAGG AGGCAGGAAG TGCCTCTTTA GTTCTTACAT TTCTAATAGC 2760 CTTGGGTTTA TTTGCAAAGG AAGCTTGAAA AATATGAGAA AAGTTGCTTG AAGTGCATTA 2820 CAGGTGTTTG TGAAGTCACA TAATCTACGG GGCTAGGGCG AGAGAGGCCA GGGATTTGTT 2880 CACAGATACT TGAATTAATT CATCCAAATG TACTGAGGTT ACCACACACT TGACTACGGA 29 0 TGTGATCAAC ACTAACAAGG AAACAAATTC AAGGACAACC TGTCTTTGAG CCAGGGCAGG 3000 CCTCAGACAC CCTGCCTGTG GCCCCGCCTC CACTTCATCC TGCCCGGAAT GCCAGTGCTC 3060 CGAGCTCAGA CAGAGGAAGC CCTGCAGAAA GTTCCATCAG GCTGTTTCCT AAAGGATGTG 3120 TGAACGGGAG ATGATGCACT GTGTTTTGAA AGTTGTCATT TTAAAGCATT TTAGCACAGT 3180 TCATAGTCCA CAGTTGATGC AGCATCCTGA GATTTTAAAT CCTGAAGTGT GGGTGGCGCA 3240 CACACCAAGT AGGGAGCTAG TCAGGCAGTT TGCTTAAGGA ACTTTTGTTC TCTGTCTCTT 3300 TTCCTTAAAA TTGGGGGTAA GGAGGGAAGG AAGAGGGAAA GAGATGACTA ACTAAAATCA 3360 TTTTTACAGC AAAAACTGCT CAAAGCCATT TAAATTATAT CCTCATTTTA AAAGTTACAT 3420 TTGCAAATAT TTCTCCCTAT GATAATGCAG TCGATAGTGT GCACTCTTTC TCTCTCTCTC 3480 TCTCTCTCAC ACACACACAC ACACACACAC ACACACACAC AGAGACACGG CACCATTCTG 3540 CCTGGGGCAC TGGAACACAT TCCTGGGGGT CACCGATGGT CAGAGTCACT AGAAGTTACC 3600 TGAGTATCTC TGGGAGGCCT CATGTCTGCT GTGGGCTTTT TACCACCACT GTGCAGGAGA 3660 ACAGACAGAG GAAATGTGTC TCCCTCCAAG GCCCCAAAGC CTCAGAGAAA GGGTGTTTCT 3720 GGTTTTGCCT TAGCAATGCA TCGGTCTCTG AGGTGACACT CTGGAGTGGT TGAAGGGCCA 3780 CAAGGTGCAG GGTTAATACT CTTGCCAGTT TTGAAATATA GATGCTATGG TTCAGATTGT 3840 TTTTAATAGA AAACTAAAGG GGCAGGGGAA GTGAAAGGAA AGATGGAGGT TTTGTGCGGC 3900 TCGATGGGGC ATTTGGAACT TCTTTTTAAA GTCATCTCAT GGTCTCCAGT TTTCAGTTGG 3960 AACTCTGGTG TTTAACACTT AAGGGAGACA AAGGCTGTGT CCATTTGGCA AAACTTCCTT 4020 GGCCACGAGA CTCTAGGTGA TGTGTGAAGC TGGGCAGTCT GTGGTGTGGA GAGCAGCCAT 4080 CTGTCTGGCC ATTCAGAGGA TTCTAAAGAC ATGGCTGGAT GCGCTGCTGA CCAACATCAG 4140 CACTTAAATA AATGCAAATG CAACATTTCT CCCTCTGGGG CTTGAAAATC CTTGCCCTTA 4200 TCATTTGGGG TGAAGGAGAC ATTTCTGTCC TTGGCTTCCC ACAGCCCCAA CGCAGTCTGT 4260 GTATGATTCC TGGGATCCAA CGAGCCCTCC TATTTTCACA GTGTTCTGAT TGCTCTCACA 4320 GCCCAGGCCC ATCGTCTGTT CTCTGAATGC AGCCCTGTTC TCAACAACAG GGAGGTCATG 4380 GAACCCCTCT GTGGAACCCA CAAGGGGAGA AATGGGTGAT AAAGAATCCA GTTCCTCAAA 4440 ACCTTCCCTG GCAGGCTGGG TCCCTCTCCT GCTGGGTGGT GCTTTCTCTT GCACACCACT 4500 CCCACCACGG GGGGAGAGCC AGCAACCCAA CCAGACAGCT CAGGTTGTGC ATCTGATGGA 4560 AACCACTGGG CTCAAACACG TGCTTTATTC TCCTGTTTAT TTTTGCTGTT ACTTTGAAGC 4620 ATGGAAATTC TTGTTTGGGG GATCTTGGGG CTACAGTAGT GGGTAAACAA ATGCCCACCG 4680 GCCAAGAGGC CATTAACAAA TCGTCCTTGT CCTGAGGGGC CCCAGCTTGC TCGGGCGTGG 4740 CACAGTGGGG AATCCAAGGG TCACAGTATG GGGAGAGGTG CACCCTGCCA CCTGCTAACT 4800 TCTCGCTAGA CACAGTGTTT CTGCCCAGGT GACCTGTTCA GCAGCAGAAC AAGCCAGGGC 4860 CATGGGGACG GGGGAAGTTT TCACTTGGAG ATGGACACCA AGACAATGAA GATTTGTTGT 4920 CCAAATAGGT CAATAATTCT GGGAGACTCT TGGAAAAAAC TGAATATATT CAGGACCAAC 4980 TCTCTCCCTC CCCTCATCCC ACATCTCAAA GCAGACAATG TAAAGAGAGA ACATCTCACA 5040 CACCCAGCTC GCCATGCCTA CTCATTCCTG AATTTCAGGT GCCATCACTG CTCTTTCTTT 5100 CTTCTTTGTC ATTTGAGAAA GGATGCAGGA GGACAATTCC CACAGATAAT CTGAGGAATG 5160 CAGAAAAACC AGGGCAGGAC AGTTATCGAC AATGCATTAG AACTTGGTGA GCATCCTCTG 5220 TAGAGGGACT CCACCCCTGC TCAACAGCTT GGCTTCCAGG CAAGACCAAC CACATCTGGT 5280 CTCTGCCTTC GGTGGCCCAC ACACCTAAGC GTCATCGTCA TTGCCATAGC ATCATGATGC 5340 AACACATCTA CGTGTAGCAC TACGACGTTA TGTTTGGGTA ATGTGGGGAT GAACTGCATG 5400 AGGCTCTGAT TAAGGATGTG GGGAAGTGGG CTGCGGTCAC TGTCGGCCTT GCAAGGCCAC 5460 CTGGAGGCCT GTCTGTTAGC CAGTGGTGGA GGAGCAAGGC TTCAGGAAGG GCCAGCCACA 5520 TGCCATCTTC CCTGCGATCA GGCAAAAAAG TGGAATTAAA AAGTCAAACC TTTATATGCA 5580 TGTGTTATGT CCATTTTGCA GGATGAACTG AGTTTAAAAG AATTTTTTTT TCTCTTCAAG 5640 TTGCTTTGTC TTTTCCATCC TCATCACAAG CCCTTGTTTG AGTGTCTTAT CCCTGAGCAA 5700 TCTTTCGATG GATGGAGATG ATCATTAGGT ACTTTTGTTT CAACCTTTAT TCCTGTAAAT 5760 ATTTCTGTGA AAACTAGGAG AACAGAGATG AGATTTGACA AAAAAAAATT GAATTAAAAA 5820 TAACACAGTC TTTTTAAAAC TAACATAGGA AAGCCTTTCC TATTATTTCT CTTCTTAGCT 5880 TCTCCATTGT CTAAATCAGG AAAACAGGAA AACACAGCTT TCTAGCAGCT GCAAAATGGT 5940 TTAATGCCCC CTACATATTT CCATCACCTT GAACAATAGC TTTAGCTTGG GAATCTGAGA 6000 TATGATCCCA GAAAACATCT GTCTCTACTT CGGCTGCAAA ACCCATGGTT TAAATCTATA 6060 TGGTTTGTGC ATTTTCTCAA CTAAAAATAG AGATGATAAT CCGAATTCTC CATATATTCA 6120 CTAATCAAAG ACACTATTTT CATACTAGAT TCCTGAGACA AATACTCACT GAAGGGCTTG 6180 TTTAAAAATA AATTGTGTTT TGGTCTGTTC TTGTAGATAA TGCCCTTCTA TTTTAGGTAG 6240 AAGCTCTGGA ATCCCTTTAT TGTGCTGTTG CTCTTATCTG CAAGGTGGCA AGCAGTTCTT 6300 TTCAGCAGAT TTTGCCCACT ATTCCTCTGA GCTGAAGTTC TTTGCATAGA TTTGGCTTAA 6360 GCTTGAATTA GATCCCTGCA AAGGCTTGCT CTGTGATGTC AGATGTAATT GTAAATGTCA 6420 GTAATCACTT CATGAATGCT AAATGAGAAT GTAAGTATTT TTAAATGTGT GTATTTCAAA 6480 TTTGTTTGAC TAATTCTGGA ATTACAAGAT TTCTATGCAG GATTTACCTT CATCCTGTGC 6540 ATGTTTCCCA AACTGTGAGG AGGGAAGGCT CAGAGATCGA GCTTCTCCTC TGAGTTCTAA 6600 CAAAATGGTG CTTTGAGGGT CAGCCTTTAG GAAGGTGCAG CTTTGTTGTC CTTTGAGCTT 6660 TCTGTTATGT GCCTATCCTA ATAAACTCTT AAACACATT Seq ID No: 131 Protein sequence: Protein Accession #: NP 036204.1

11 21 31 41 51

MATSMGLLLL LLLLLTQPGA GTGADTEAW CVGTACYTAH SGKLSAAEAQ NHCNQNGGNL 60

ATVKSKEEAQ HVQRVLAQLL RREAALTARM SKFWIGLQRE KGKCLDPSLP LKGFSWVGGG 120

EDTPYSNWHK ELRNSCISKR CVSLLLDLSQ PLLPNRLPKW SEGPCGSPGS PGSNIEGFVC 180

KFSFKGMCRP LALGGPGQVT YTTPFQTTSS SLEAVPFASA ANVACGEGDK DETQSHYFLC 240

KEKAPDVFDW GSSGPLCVSP KYGCNFNNGG CHQDCFEGGD GSFLCGCRPG FRLLDDLVTC 300

ASRNPCSSSP CRGGATCVLG PHGKNYTCRC PQGYQLDSSQ LDCVDVDECQ DSPCAQECVN 360

TPGGFRCECW VGYEPGGPGE GACQDVDECA LGRSPCAQGC TNTDGSFHCS CEEGYVLAGE 420

DGTQCQDVDE CVGPGGPLCD SLCFNTQGSF HCGCLPGWVL APNGVSCTMG PVSLGPPSGP 480

PDEEDKGEKE GSTVPRAATA SPTRGPEGTP KATPTTSRPS LSSDAPITSA PLKMLAPSGS 540

SGVWREPSIH HATAASGPQE PAGGDSSVAT QNNDGTDGQK LLLFYILGTV VAILLLLALA 600

LGLLVYRKRR AKREEKKEKK PQNAADSYSW VPERAESRAM ENQYSPTPGT DC

Seq ID NO : 132 DNA sequence

Nucleic Acid Accession #: NM_000963.1

Coding sequence: 135-1949 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

CAATTGTCAT ACGACTTGCA GTGAGCGTCA GGAGCACGTC CAGGAACTCC TCAGCAGCGC 60 CTCCTTCAGC TCCACAGCCA GACGCCCTCA GACAGCAAAG CCTACCCCCG CGCCGCGCCC 120 TGCCCGCCGC TCGGATGCTC GCCCGCGCCC TGCTGCTGTG CGCGGTCCTG GCGCTCAGCC 180 ATACAGCAAA TCCTTGCTGT TCCCACCCAT GTCAAAACCG AGGTGTATGT ATGAGTGTGG 240 GATTTGACCA GTATAAGTGC GATTGTACCC GGACAGGATT CTATGGAGAA AACTGCTCAA 300 CACCGGAATT TTTGACAAGA ATAAAATTAT TTCTGAAACC CACTCCAAAC ACAGTGCACT 360 ACATACTTAC CCACTTCAAG GGATTTTGGA ACGTTGTGAA TAACATTCCC TTCCTTCGAA 420 ATGCAATTAT GAGTTATGTC TTGACATCCA GATCACATTT GATTGACAGT CCACCAACTT 480 ACAATGCTGA CTATGGCTAC AAAAGCTGGG AAGCCTTCTC TAACCTCTCC TATTATACTA 540 GAGCCCTTCC TCCTGTGCCT GATGATTGCC CGACTCCCTT GGGTGTCAAA GGTAAAAAGC 600 AGCTTCCTGA TTCAAATGAG ATTGTGGAAA AATTGCTTCT AAGAAGAAAG TTCATCCCTG 660 ATCCCCAGGG CTCAAACATG ATGTTTGCAT TCTTTGCCCA GCACTTCACG CATCAGTTTT 720 TCAAGACAGA TCATAAGCGA GGGCCAGCTT TCACCAACGG GCTGGGCCAT GGGGTGGACT 780 TAAATCATAT TTACGGTGAA ACTCTGGCTA GACAGCGTAA ACTGCGCCTT TTCAAGGATG 840 GAAAAATGAA ATATCAGATA ATTGATGGAG AGATGTATCC TCCCACAGTC AAAGATACTC 900 AGGCAGAGAT GATCTACCCT CCTCAAGTCC CTGAGCATCT ACGGTTTGCT GTGGGGCAGG 960 AGGTCTTTGG TCTGGTGCCT GGTCTGATGA TGTATGCCAC AATCTGGCTG CGGGAACACA 1020 ACAGAGTATG CGATGTGCTT AAACAGGAGC ATCCTGAATG GGGTGATGAG CAGTTGTTCC 1080 AGACAAGCAG GCTAATACTG ATAGGAGAGA CTATTAAGAT TGTGATTGAA GATTATGTGC 1140 AACACTTGAG TGGCTATCAC TTCAAACTGA AATTTGACCC AGAACTACTT TTCAACAAAC 1200 AATTCCAGTA CCAAAATCGT ATTGCTGCTG AATTTAACAC CCTCTATCAC TGGCATCCCC 1260 TTCTGCCTGA CACCTTTCAA ATTCATGACC AGAAATACAA CTATCAACAG TTTATCTACA 1320 ACAACTCTAT ATTGCTGGAA CATGGAATTA CCCAGTTTGT TGAATCATTC ACCAGGCAAA 1380 TTGCTGGCAG GGTTGCTGGT GGTAGGAATG TTCCACCCGC AGTACAGAAA GTATCACAGG 1440 CTTCCATTGA CCAGAGCAGG CAGATGAAAT ACCAGTCTTT TAATGAGTAC CGCAAACGCT 1500 TTATGCTGAA GCCCTATGAA TCATTTGAAG AACTTACAGG AGAAAAGGAA ATGTCTGCAG 1560 AGTTGGAAGC ACTCTATGGT GACATCGATG CTGTGGAGCT GTATCCTGCC CTTCTGGTAG 1620 AAAAGCCTCG GCCAGATGCC ATCTTTGGTG AAACCATGGT AGAAGTTGGA GCACCATTCT 1680 CCTTGAAAGG ACTTATGGGT AATGTTATAT GTTCTCCTGC CTACTGGAAG CCAAGCACTT 1740 TTGGTGGAGA AGTGGGTTTT CAAATCATCA ACACTGCCTC AATTCAGTCT CTCATCTGCA 1800 ATAACGTGAA GGGCTGTCCC TTTACTTCAT TCAGTGTTCC AGATCCAGAG CTCATTAAAA 1860 CAGTCACCAT CAATGCAAGT TCTTCCCGCT CCGGACTAGA TGATATCAAT CCCACAGTAC 1920 TACTAAAAGA ACGTTCGACT GAACTGTAGA AGTCTAATGA TCATATTTAT TTATTTATAT 1980 GAACCATGTC TATTAATTTA ATTATTTAAT AATATTTATA TTAAACTCCT TATGTTACTT 2040 AACATCTTCT GTAACAGAAG TCAGTACTCC TGTTGCGGAG AAAGGAGTCA TACTTGTGAA 2100 GACTTTTATG TCACTACTCT AAAGATTTTG CTGTTGCTGT TAAGTTTGGA AAACAGTTTT 2160 TATTCTGTTT TATAAACCAG AGAGAAATGA GTTTTGACGT CTTTTTACTT GAATTTCAAC 2220 TTATATTATA AGAACGAAAG TAAAGATGTT TGAATACTTA AACACTATCA CAAGATGGCA 2280 AAATGCTGAA AGTTTTTACA CTGTCGATGT TTCCAATGCA TCTTCCATGA TGCATTAGAA 2340 GTAACTAATG TTTGAAATTT TAAAGTACTT TTGGTTATTT TTCTGTCATC AAACAAAAAC 2400 AGGTATCAGT GCATTATTAA ATGAATATTT AAATTAGACA TTACCAGTAA TTTCATGTCT 2460 ACTTTTTAAA ATCAGCAATG AAACAATAAT TTGAAATTTC TAAATTCATA GGGTAGAATC 2520 ACCTGTAAAA GCTTGTTTGA TTTCTTAAAG TTATTAAACT TGTACATATA CCAAAAAGAA 2580 GCTGTCTTGG ATTTAAATCT GTAAAATCAG ATGAAATTTT ACTACAATTG CTTGTTAAAA 2640 TATTTTATAA GTGATGTTCC TTTTTCACCA AGAGTATAAA CCTTTTTAGT GTGACTGTTA 2700 AAACTTCCTT TTAAATCAAA ATGCCAAATT TATTAAGGTG GTGGAGCCAC TGCAGTGTTA 2760 TCTCAAAATA AGAATATTTT GTTGAGATAT TCCAGAATTT GTTTATATGG CTGGTAACAT 2820 GTAAAATCTA TATCAGCAAA AGGGTCTACC TTTAAAATAA GCAATAACAA AGAAGAAAAC 2880 CAAATTATTG TTCAAATTTA GGTTTAAACT TTTGAAGCAA ACTTTTTTTT ATCCTTGTGC 2940 ACTGCAGGCC TGGTACTCAG ATTTTGCTAT GAGGTTAATG AAGTACCAAG CTGTGCTTGA 3000 ATAACGATAT GTTTTCTCAG ATTTTCTGTT GTACAGTTTA ATTTAGCAGT CCATATCACA 3060 TTGCAAAAGT AGCAATGACC TCATAAAATA CCTCTTCAAA ATGCTTAAAT TCATTTCACA 3120 CATTAATTTT ATCTCAGTCT TGAAGCCAAT TCAGTAGGTG CATTGGAATC AAGCCTGGCT 3180 ACCTGCATGC TGTTCCTTTT CTTTTCTTCT TTTAGCCATT TTGCTAAGAG ACACAGTCTT 3240 CTCATCACTT CGTTTCTCCT ATTTTGTTTT ACTAGTTTTA AGATCAGAGT TCACTTTCTT 3300 TGGACTCTGC CTATATTTTC TTACCTGAAC TTTTGCAAGT TTTCAGGTAA ACCTCAGCTC 3360 AGGACTGCTA TTTAGCTCCT CTTAAGAAGA TTAAAAGAGA AAAAAAAAGG CCCTTTTAAA 3420 AATAGTATAC ACTTATTTTA AGTGAAAAGC AGAGAATTTT ATTTATAGCT AATTTTAGCT 3480 ATCTGTAACC AAGATGGATG CAAAGAGGCT AGTGCCTCAG AGAGAACTGT ACGGGGTTTG 3540 TGACTGGAAA AAGTTACGTT CCCATTCTAA TTAATGCCCT TTCTTATTTA AAAACAAAAC 3600 CAAATGATAT CTAAGTAGTT CTCAGCAATA ATAATAATGA CGATAATACT TCTTTTCCAC 3660 ATCTCATTGT CACTGACATT TAATGGTACT GTATATTACT TAATTTATTG AAGATTATTA 3720 TTTATGTCTT ATTAGGACAC TATGGTTATA AACTGTGTTT AAGCCTACAA TCATTGATTT 3780 TTTTTTGTTA TGTCACAATC AGTATATTTT CTTTGGGGTT ACCTCTCTGA ATATTATGTA 3840 AACAATCCAA AGAAATGATT GTATTAAGAT TTGTGAATAA ATTTTTAGAA ATCTGATTGG 3900 CATATTGAGA TATTTAAGGT TGAATGTTTG TCCTTAGGAT AGGCCTATGT GCTAGCCCAC 3960 AAAGAATATT GTCTCATTAG CCTGAATGTG CCATAAGACT GACCTTTTAA AATGTTTTGA 4020 GGGATCTGTG GATGCTTCGT TAATTTGTTC AGCCACAATT TATTGAGAAA ATATTCTGTG 4080 TCAAGCACTG TGGGTTTTAA TATTTTTAAA TCAAACGCTG ATTACAGATA ATAGTATTTA 4140 TATAAATAAT TGAAAAAAAT TTTCTTTTGG GAAGAGGGAG AAAATGAAAT AAATATCATT 4200 AAAGATAACT CAGGAGAATC TTCTTTACAA TTTTACGTTT AGAATGTTTA AGGTTAAGAA 4260 AGAAATAGTC AATATGCTTG TATAAAACAC TGTTCACTGT TTTTTTTAAA AAAAAAACTT 4320 GATTTGTTAT TAACATTGAT CTGCTGACAA AACCTGGGAA TTTGGGTTGT GTATGCGAAT 4380 GTTTCAGTGC CTCAGACAAA TGTGTATTTA ACTTATGTAA AAGATAAGTC TGGAAATAAA 4440 TGTCTGTTTA TTTTTGTACT ATTTA

Seq ID No: 1₃₃ Protein sequence: Protein Accession #: NP 000954.1

11 21 31 41 51

MLARALLLCA VLALSHTANP CCSHPCQNRG VCMSVGFDQY KCDCTRTGFY GENCSTPEFL 60

TRIKLFLKPT PNTVHYILTH FKGFWNWNN IPFLRNAIMS YVLTSRSHLI DSPPTYNADY 120

GYKSWEAFSN LSYYTRALPP VPDDCPTPLG VKGKKQLPDS NEIVEKLLLR RKFIPDPQGS 180

NMMFAFFAQH FTHQFFKTDH KRGPAFTNGL GHGVDLNHIY GETLARQRKL RLFKDGKMKY 240

QIIDGEMYPP TVKDTQAEMI YPPQVPEHLR FAVGQEVFGL VPGLMMYATI WLREHNRVCD 300

VLKQEHPEWG DEQLFQTSRL ILIGETIKIV IEDYVQHLSG YHFKLKFDPE LLFNKQFQYQ 360

NRIAAEFNTL YHWHPLLPDT FQIHDQKYNY QQFIYNNSIL LEHGITQFVE SFTRQIAGRV 420

AGGRNVPPAV QKVSQASIDQ SRQMKYQSFN EYRKRFMLKP YESFEELTGE KEMSAELEAL 480

YGDIDAVELY PALLVEKPRP DAIFGETMVE VGAPFSLKGL MGNVICSPAY WKPSTFGGEV 540

GFQIINTASI QSLICNNVKG CPFTSFSVPD PELIKTVTIN ASSSRSGLDD INPTVLLKER 600 STEL

Seq ID NO: 134 DNA sequence

Nucleic Acid Accession #: XM_059648.1

Coding sequence: 35-664 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

AGGCTGCTGA GACTTCCCTC TAGAATCCTC CAACATGGAG CCTCTTGCAG CTTACCCGCT 60

AAAATGTTCC GGGCCCAGAG CAAAGGTATT TGCAGTTTTG CTGTCTATAG TTCTATGCAC 120

AGTAACGCTA TTTCTTCTAC AACTAAAATT CCTCAAACCT AAAATCAACA GCTTTTATGC 180

CTTTGAAGTG AAGGATGCAA AAGGAAGAAC TGTTTCTCTG GAAAAGTATA AAGGCAAAGT 240

TTCACTAGTT GTAAACGTGG CCAGTGACTG CCAACTCACA GACAGAAATT ACTTAGGGCT 300

GAAGGAACTG CACAAAGAGT TTGGACCATC CCACTTCAGC GTGTTGGCTT TTCCCTGCAA 360

TCAGTTTGGA GAATCGGAGC CCCGCCCAAG CAAGGAAGTA GAATCTTTTG CAAGAAAAAA 420

CTACGGAGTA ACTTTCCCCA TCTTCCACAA GATTAAGATT CTAGGATCTG AAGGAGAACC 480

TGCATTTAGA TTTCTTGTTG ATTCTTCAAA GAAGGAACCA AGGTGGAATT TTTGGAAGTA 540

TCTTGTCAAC CCTGAGGGTC AAGTTGTGAA GTTCTGGAAG CCAGAGGAGC CCATTGAAGT 600

CATCAGGCCT GACATAGCAG CTCTGGTTAG ACAAGTGATC ATAAAAAAGA AAGAGGATCT 660

ATGAGAATGC CATTGCGTTT CTAATAGAAC AGAGAAATGT CTCCATGAGG GTTTGGTCTC 720

ATTTTAAACA TTTTTTTTTT GGAGACAGTG TCTCACTCTG TCACCCAGGC TGGAGTGCAG 780

TAGTGCGTTC TCAGCTCATT GCAACCTCTG CCTTTTTAAA CATGCTATTA AATGTGGCAA 840

TGAAGGATTT TTTTTTAATG TTATCTTGCT ATTAAGTGGT AATGAATGTT CCCAGGATGA goo

GGATGTTACC CAAAGCAAAA ATCAAGAGTA GCCAAAGAAT CAACATGAAA TATATTAACT gεo

ACTTCCTCTG ACCATACTAA AGAATTCAGA ATACACAGTG ACCAATGTGC CTCAATATCT 1020

TATTGTTCAA CTTGACATTT TCTAGGACTG TACTTGATGA AAATGCCAAC ACACTAGACC 1080

ACTCTTTGGA TTCAAGAGCA CTGTGTATGA CTGAAATTTC TGGAATAACT GTAAATGGTT 1140

ATGTTAATGG AATAAAACAC AAATGTTGAA AAATGTAAAA TATATATACA TAGATTCAAA 1200

TCCTTATATA TGTATGCTTG TTTTGTGTAC AGGATTTTGT TTTTTCTTTT TAAGTACAGG 1260

TTCCTAGTGT TTTACTATAA CTGTCACTAT GTATGTAACT GACATATATA AATAGTCATT 1320

TATAAATGAC CGTATTATAA CA Seq ID No : 135 Protein sequence : Protein Accession # : XP_059648 . 1

11 21 31 41 51

MEPLAAYPLK CSGPRAKVFA VLLSIVLCTV TLFLLQLKFL KPKINSFYAF EVKDAKGRTV 60

SLEKYKGKVS LWNVASDCQ LTDRNYLGLK ELHKEFGPSH FSVLAFPCNQ FGESEPRPSK 120

EVESFARKNY GVTFPIFHKI KILGSEGEPA FRFLVDSSKK EPRWNFWKYL VNPEGQWKF 180 WKPEEPIEVI RPDIAALVRQ VIIKKKEDL

Seq ID NO: 136 DNA sequence

Nucleic Acid Accession #: NM_003003.1

Coding sequence: 304-2451 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

I I I I I

CAAGTGCCGT CGCCGCGCCC CTTCCCCCTC CCGCCTCCCC GGCCCCCTCC CCGGAACCGG 60 CGGTCGAGCT ACGGTCGCGG ACGAGTGGAA CCGAGACTGC CCCGCGGAGC CGCCGGTATG 120 AGCGCCCCTC GCCACCCCGT GTCCCAGGCC CGGCCTTTCT GACAAGAGCT AGACTTCGGG 180 CTCCTTGAGG ATATTCAGTT TTGTATGTTT GAATATCCTC TCACCATGTT CAGCATAAAG 240 TACCATTCTT AATGATTATC CTCAACAAGA CAGGTGTGAG AGGGTTGCTG TTGCATTGCA 300 ATCATGGTGC AAAAATACCA GTCCCCAGTG AGAGTGTACA AATACCCCTT TGAATTAATT 360 ATGGCTGCCT ATGAAAGGAG GTTCCCTACA TGTCCTTTGA TTCCGATGTT CGTGGGCAGT 420 GACACTGTGA GTGAATTCAA GAGCGAAGAT GGGGCTATTC ATGTCATTGA AAGGCGCTGC 480 AAGCTGGATG TAGATGCACC CAGACTGCTG AAGAAGATTG CAGGAGTTGA TTATGTTTAT 540 TTTGTCCAGA AAAACTCACT GAATTCTCGG GAACGTACTT TGCACATTGA GGCTTATAAT 600 GAAACGTTTT CCAATCGGGT CATCATTAAT GAGCATTGCT GCTACACCGT TCACCCTGAA 660 AATGAAGATT GGACCTGTTT TGAACAGTCT GCAAGTTTAG ATATTAAATC TTTCTTTGGT 720 TTTGAAAGTA CAGTGGAAAA AATTGCAATG AAACAATATA CCAGCAACAT TAAAAAAGGA 780 AAGGAAATCA TCGAATACTA CCTTCGCCAA TTAGAAGAAG AAGGCATAAC CTTTGTGCCC 840 CGTTGGAGTC CGCCTTCCAT CACGCCCTCT TCAGAGACAT CTTCATCATC CTCCAAGAAA 900 CAAGCAGCGT CCATGGCCGT CGTCATCCCA GAAGCTGCCC TCAAGGAGGG GCTGAGTGGT 960 GATGCCCTCA GCAGCCCCAG TGCACCTGAG CCCGTGGTGG GCACCCCTGA CGACAAACTA 1020 GATGCCGACC ACATCAAGAG ATACCTGGGC GATTTGACTC CGCTGCAGGA GAGCTGCCTC 1080 ATTAGACTTC GCCAGTGGCT CCAGGAGACC CACAAGGGCA AAATTCCAAA AGATGAGCAT 1140 ATTCTTCGGT TCCTCCGTGC ACGGGATTTT AATATTGACA AAGCCAGAGA GATCATGTGT 1200 CAGTCTTTGA CGTGGAGAAA GCAGCATCAG GTAGACTACA TTCTTGAAAC CTGGACCCCT 1260 CCTCAGGTCC TTCAGGATTA CTACGCGGGA GGCTGGCATC ATCACGACAA AGATGGGCGG 1320 CCCCTCTACG TGCTCAGGCT GGGGCAGATG GACACCAAAG GCTTGGTGAG AGCGCTCGGG 1380 GAGGAAGCCC TGCTGAGATA CGTTCTCTCC GTAAATGAAG AACGGCTAAG GCGATGCGAA 1440 GAGAATACAA AAGTCTTTGG TCGGCCTATC AGCTCATGGA CCTGCCTGGT GGACTTGGAA 1500 GGGCTGAACA TGCGCCACTT GTGGAGACCT GGTGTGAAAG CGCTGCTGCG GATCATCGAG 1560 GTGGTGGAGG CCAACTACCC TGAGACACTG GGCCGCCTTC TCATCCTGCG GGCGCCCAGG 1620 GTATTTCCTG TGCTCTGGAC GCTGGTTAGT CCGTTCATTG ATGACAACAC CAGAAGGAAG 1680 TTCCTCATTT ATGCAGGAAA TGACTACCAG GGTCCTGGAG GCCTGCTGGA TTACATCGAC 1740 AAAGAGATTA TTCCAGATTT CCTGAGTGGG GAGTGCATGT GCGAAGTGCC AGAGGGTGGA 1800 CTGGTCCCCA AATCTCTGTA CCGGACTGCA GAGGAGCTGG AGAACGAAGA CCTGAAGCTC 1860 TGGACTGAGA CCATCTACCA GTCTGCAAGC GTCTTCAAAG GAGCCCCACA TGAGATTCTC 1920 ATTCAGATTG TGGATGCCTC GTCAGTCATC ACTTGGGATT TCGACGTGTG CAAAGGGGAC 1980 ATTGTGTTTA ACATCTATCA CTCCAAGAGG TCGCCACAAC CACCCAAAAA GGACTCCCTG 2040 GGAGCCCACA GCATCACCTC TCCGGGTGGG AACAATGTGC AGCTCATAGA CAAAGTCTGG 2100 CAGCTGGGCC GCGACTACAG CATGGTGGAG TCGCCTCTGA TCTGCAAAGA AGGAGAAAGC 2160 GTGCAGGGTT CCCATGTGAC CAGGTGGCCG GGCTTCTACA TCCTGCAGTG GAAATTCCAC 2220 AGCATGCCTG CGTGCGCCGC CAGCAGCCTT CCCCGGGTGG ACGACGTGCT TGCGTCCCTG 2280 CAGGTCTCTT CGCACAAGTG TAAAGTGATG TACTACACCG AGGTGATCGG CTCGGAGGAT 2340 TTCAGAGGTT CCATGACGAG CCTGGAGTCC AGCCACAGCG GCTTCTCCCA GCTGAGTGCC 2400 GCCACCACCT CCTCCAGCCA GTCCCACTCC AGCTCCATGA TCTCCAGGTA .GTGCCGCGCT 2460 GCCTGCACCT AGTGTGCAGA GGGGACGGCC GCCCCTCCTC GGACAGCAGC TGCACCCGCC 2520 CACCCAGCGG CGACATTGTA CAGACTCCTC TCACCTCTAG ATAGCAAATA GCTCTCAGAT 2580 GGTAAACGTA GTCGTTTGAT CCCAAAACTA CCTTGGCAGG TAGTTTTAAC TCTGATCCTA 2640 ACTTAACTCA ATAGCCATAG ATTTTGTATA CGTTGTGCAC AAAATCCAAC CAGAGCGCAA 2700 GGGCTCTCTT GAAAGAAAAG TAGTTTCTGT ACCAATTAAA GGATTGACGT GGTCTCAGAT 2760 ATTGATGCAA AAAATTTTTC CAACGAACTC CGCATTGTCC ATTAGTGAAT GAATTCCTGT 2820 GACATCCTCC AGAGATGGCC CCTCCTCACC TGGGACGGAA GCTGCCAGCT CGCTTCCCCC 2880 AAGCTGCCTC ATGGCCCGCA CGCCGCCTCA CGGCCCCCAT GCTTCCCGCC AGTCAAGATG 2940 GTCTGTGGAC TTAGGGCCAG CCCTTGAGGT CCTTATCCTC TGAGGATTCA GAGGTTGCCT 3000 GCGGAGTACC TTGTCCCAGG GCCAGACACA CCCACACCAC CCACTGTCTG CAGTGGGGCC 3060 GGGGGCTCAG GAGGGGCTCT CAGGGACTCC TGGTGACTCC AGGAAAATGC TGCCATCGTT 3120 AAACATTACT TTCTCTTTCC TCCTTTTCAA ATCTTTTTGA TACTTTTTAG AGCAGGATTT 3180 TTCTGTATGT GAACTTGGGT GGGGGGGTTC TTCCCGTTTC CTTCCGTGCG TCGCCCCTCT 3240 CACCTGCAGT CAGCTCCCAG CCCAGTGTAG GCCATCTCCT CTGTGCCCTC TGGAGGCTCA 3300 TTGTCTCAGA GCCCAGACAG TTCCAGCCAC TAGGAGGCCG TCTTGGAACC AGCAAGTCGC 3360 ^' ATTTGCCACT TGACACTGTC CATGGGGTTT TATTAGTAGC TAAGCAGCAG CTCTCGCATC 3420 CACTTCAGGG TGGCGTGTGG CATGTAGGAG TCCTGCTTCT TTGTACATGG GAATTGTGGA 3480

CTCATGCGTG TGTGTGTGTG CATGTGCTGT GTGTGTGCAT GTGTGCATGA CGGTGGGGGT 3540

GCTGGGGGGA CGGGGTGAGT GGAAACTTAG TTTGAGTAAT GAAGGAATCT TCACAGAAGC 3600

AAATCAGAAT ATGGGATTTG TTTGCCTTTT ACATTTTGTT TAATTCCTGA TTTTAAAGCC 3660 TGCTCTATCT GGTACAGGCC CTTATTTTTT CAGCTTTTTA TGGGAAAAGC AGGTTATTTG 3720

AGAATCTGTC CAGAAGTTGC ATAGGGGATG GCCTCCACGA TAAGGACATG CAACACGTGT 3780

TTCTGTGTGC AGCAGAGGCC GTGTTTTTCA TGCCAAACCC CACGCGGCTG TCAACTGTGT 3840

GCGTGGTAGG CATGGAGATC CTGGTTGTGC CGTCTCAGCT CCGCTCTGAA GGCACTGTGT 3900

GGGTGCTGCG TGACTGGAGA GCTGTGTGGA GGCCATGTGT GCCCCGTGCA GGGATCAGGA 3960 GGGCGGGGGA GGGACCGAGC AGCCCTCTTG CCCGGTCGGG TCAGCCCTAG TGGCTGCCTG 4020

CACACTGTAG ACGTCCCAGG GCCTGTGCTG TGATCACCTG CCTTTGGACC ACATTTGTGT 4080

TTGCTCTTAG AGATCGAGCT CCTCAGTGGT ACCTGAAGCC TTTGCTTCCG GAAAGCGCGG 4140

TAGGGTTCGT AGGTAGGGCT AGTAGGTAGG GTTAGTAGGT AGGGCTAGTA GGTAGGGCTA 4200

GTAGGTAGGG TTAGTAGGTA GGGTTCGTAG GTAGGGCTGG TAGGTAGGGT TAGTAGGTAG 4260 GGCTAGTAGG TAGGGTTCGT AGGTAGGGCT AGTAGGTAGG GTTAGTAGGT AGGGCTAGTA 4320

GGTAGGGCTA GTAGGTAGGG TTAGTAGGTA GGGTTCGTAG GTAGGGCTGG TAGGTAGGGT 4380

TAGTAGGTAG GGCTAGTAGG TAGGGTTCGT AGGTAGGGCT AGTAGGTAGG GTTAGTAGGT 4440

AGGGCTAGTA GGTAGGGCTA GTAGGTAGGG TTAGTAGGTA GGGTTCGTAG GTAGGGCTGG 4500

TAGGTAGGGT TAGTAGGTAG GGCTAGTAGG TAGGGCTAGT AGGTAGGGCT AGTAGGTAGG 4560 GTTAGTAGGT AGGGCTAGTA GGTAGGGCTA GTAGGTAGGG TTAGTAGGTA GGGTTCGTAG 4620

GTAGGGCTGG TAGGTAGGGT TAGTAGGTAG GGCTAGTAGG TAGGGCTAGT AGGTAGGGCT 4680

AGTAGGTAGG GCTAGTAGGT AGGGCTAGTA GGTAGGGCTA GTAGGTAGGG CTAGTAGGTA 4740

GGGTTCGTAG GTAGGGTTCG TAGGTAGGGT TCGTAGGTAG GGTTAGTAGC GCGTCTGTGC 4800

TGCTTCCACC TGGTGCTTCC TGTTCCCAAA TCACAAGGGC CTGAAGGTGG TCCCTGCTTT 860 CTCTTTCTCT TTCTCTGTGT CTCAGATGGC GATTTTGCTG ACAGCTGCCA AGAAAATGCT 4920

TCACTCAACA GTCCTCATGT GCCCAGAGAT GTTTATAGAA CTGTTTGAAT TGCAGCCATC 4980

CCCTGCCCCC TCCCAGGCTG AAGATCTGTT CTTTTTAAGT TGATTCGGGA GTGGCATTCT 5040

TTTATACCCA AAGACTGTAG TGCATCTTGA AGAGCTCAAA GCACATGACC GCACAAATGC 5100

TTACAGGGTT TCCTCCCGAG TAATCCAATC TCACTCCCCT TGTAAGGGAA TTCTGGGGCA 5160 GCTATGGTTT GAGTATGCAG TTTGCATCGT GTTTCTACCT TTAGTACCTT GCCACTCTTT 5220

TAAAACGCTG CTGTCATTTC CCATTTCTTA GTACTAATGA TTCTTTGATT CTCCCTCTAT 5280

TATGTCTTAA TTCACTTTCC TTCCTAAATT TGTTATTTGC ATATCAAATT CTGTAAATGT 5340

TTTGTAAACA TATTACCTCA CTTGGTAATA CAATACTGAT AGTCTTTAAA AGATTTTTTT 5400 ATTGTTATCA ATAATAAATG TGAACTATTT AAAG

Seq ID No: 137 Protein sequence: Protein Accession #: NP 002994.1

11 21 31 41 51

MVQKYQSPVR VYKYPFELIM AAYERRFPTC PLIPMFVGSD TVSEFKSEDG AIHVIERRCK 60

LDVDAPRLLK KIAGVDYVYF VQKNSLNSRE RTLHIEAYNE TFSNRVIINE HCCYTVHPEN 120

EDWTCFEQSA SLDIKSFFGF ESTVEKIAMK QYTSNIKKGK EIIEYYLRQL EEEGITFVPR 180 WSPPSITPSS ETSSSSSKKQ AASMAWIPE AALKEGLSGD ALSSPSAPEP WGTPDDKLD 240

ADHIKRYLGD LTPLQESCLI RLRQWLQETH KGKIPKDEHI LRFLRARDFN IDKAREIMCQ 300

SLTWRKQHQV DYILETWTPP QVLQDYYAGG WHHHDKDGRP LYVLRLGQMD TKGLVRALGE 360

EALLRYVLSV NEERLRRCEE NTKVFGRPIS SWTCLVDLEG LNMRHLWRPG VKALLRIIEV 420

VEANYPETLG RLLILRAPRV FPVLWTLVSP FIDDNTRRKF LIYAGNDYQG PGGLLDYIDK 480 EIIPDFLSGE CMCEVPEGGL VPKSLYRTAE ELENEDLKLW TETIYQSASV FKGAPHEILI 540

QIVDASSVIT WDFDVCKGDI VFNIYHSKRS PQPPKKDSLG AHSITSPGGN NVQLIDKVWQ 600

LGRDYSMVES PLICKEGESV QGSHVTRWPG FYILQWKFHS MPACAASSLP RVDDVLASLQ 660 VSSHKCKVMY YTEVIGSEDF RGSMTSLESS HSGFSQLSAA TTSSSQSHSS SMISR Seq ID NO : 138 DNA sequence

Nucleic Acid Accession # : NM_004181 . 1

Coding sequence : 32 -670 (underlined sequences correspond to start and stop codons )

11 21 31 41 51

GCAGAAATAG CCTAGGGAGA TCAACCCCGA GATGCTGAAC AAAGTGCTGT CCCGGCTGGG 60

GGTCGCCGGC CAGTGGCGCT TCGTGGACGT GCTGGGGCTG GAAGAGGAGT CTCTGGGCTC 120

GGTGCCAGCG CCTGCCTGCG CGCTGCTGCT GCTGTTTCCC CTCACGGCCC AGCATGAGAA 180 CTTCAGGAAA AAGCAGATTG AAGAGCTGAA GGGACAAGAA GTTAGTCCTA AAGTGTACTT 240

CATGAAGCAG ACCATTGGGA ATTCCTGTGG CACAATCGGA CTTATTCACG CAGTGGCCAA 300

TAATCAAGAC AAACTGGGAT TTGAGGATGG ATCAGTTCTG AAACAGTTTC TTTCTGAAAC 360

AGAGAAAATG TCCCCTGAAG ACAGAGCAAA ATGCTTTGAA AAGAATGAGG CCATACAGGC 420

AGCCCATGAT GCCGTGGCAC AGGAAGGCCA ATGTCGGGTA GATGACAAGG TGAATTTCCA 480 TTTTATTCTG TTTAACAACG TGGATGGCCA CCTCTATGAA CTTGATGGAC GAATGCCTTT 540

TCCGGTGAAC CATGGCGCCA GTTCAGAGGA CACCCTGCTG AAGGACGCTG CCAAGGTGTG 600

CAGAGAATTC ACCGAGCGTG AGCAAGGAGA AGTCCGCTTC TCTGCCGTGG CTCTCTGCAA 660

GGCAGCCTAA TGCTCTGTGG GAGGGACTTT GCTGATTTCC CCTCTTCCCT TCAACATGAA 720

AATATATACC CCCCATGCAG TCTAAAATGC TTCAGTACTT GTGAAACACA GCTGTTCTTC 780 TGTTCTGCAG ACACGCCTTC CCCTCAGCCA CACCCAGGCA CTTAAGCACA AGCAGAGTGC 840

ACAGCTGTCC ACTGGGCCAT TGTGGTGTGA GCTTCAGATG GTGAAGCATT CTCCCCAGTG 900 TATGTCTTGT ATCCGATATC TAACGCTTTA AATGGCTACT TTGGTTTCTG TCTGTAAGTT 960 AAGACCTTGG ATGTGGTTAT GTTGTCCTAA AGAATAAATT TTGCTGATAG TAGC

Seq ID No: 139 Protein sequence: Protein Accession #: NP 004172.1

11 21 31 41 51

MLNKVLSRLG VAGQWRFVDV LGLEEESLGS VPAPACALLL LFPLTAQHEN FRKKQIEELK 60

GQEVSPKVYF MKQTIGNSCG TIGLIHAVAN NQDKLGFEDG SVLKQFLSET EKMSPEDRAK 120

CFEKNEAIQA AHDAVAQEGQ CRVDDKVNFH FILFNNVDGH LYELDGRMPF PVNHGASSED 180 TLLKDAAKVC REFTEREQGE VRFSAVALCK AA

Seq ID NO : 140 DNA sequence

Nucleic Acid Accession # : NM_000201 . 1

Coding sequence : 58 - 1656 (underlined sequences correspond to start and stop codons )

11 21 31 41 51

GCGCCCCAGT CGACGCTGAG CTCCTCTGCT ACTCAGAGTT GCAACCTCAG CCTCGCTATG 60 GCTCCCAGCA GCCCCCGGCC CGCGCTGCCC GCACTCCTGG TCCTGCTCGG GGCTCTGTTC 120 CCAGGACCTG GCAATGCCCA GACATCTGTG TCCCCCTCAA AAGTCATCCT GCCCCGGGGA 180 GGCTCCGTGC TGGTGACATG CAGCACCTCC TGTGACCAGC CCAAGTTGTT GGGCATAGAG 240 ACCCCGTTGC CTAAAAAGGA GTTGCTCCTG CCTGGGAACA ACCGGAAGGT GTATGAACTG 300 AGCAATGTGC AAGAAGATAG CCAACCAATG TGCTATTCAA ACTGCCCTGA TGGGCAGTCA 360 ACAGCTAAAA CCTTCCTCAC CGTGTACTGG ACTCCAGAAC GGGTGGAACT GGCACCCCTC 420 CCCTCTTGGC AGCCAGTGGG CAAGAACCTT ACCCTACGCT GCCAGGTGGA GGGTGGGGCA 480 CCCCGGGCCA ACCTCACCGT GGTGCTGCTC CGTGGGGAGA AGGAGCTGAA ACGGGAGCCA 540 GCTGTGGGGG AGCCCGCTGA GGTCACGACC ACGGTGCTGG TGAGGAGAGA TCACCATGGA 600 GCCAATTTCT CGTGCCGCAC TGAACTGGAC CTGCGGCCCC AAGGGCTGGA GCTGTTTGAG 660 AACACCTCGG CCCCCTACCA GCTCCAGACC TTTGTCCTGC CAGCGACTCC CCCACAACTT 720 GTCAGCCCCC GGGTCCTAGA GGTGGACACG CAGGGGACCG TGGTCTGTTC CCTGGACGGG 780 CTGTTCCCAG TCTCGGAGGC CCAGGTCCAC CTGGCACTGG GGGACCAGAG GTTGAACCCC 840 ACAGTCACCT ATGGCAACGA CTCCTTCTCG GCCAAGGCCT CAGTCAGTGT GACCGCAGAG 900 GACGAGGGCA CCCAGCGGCT GACGTGTGCA GTAATACTGG GGAACCAGAG CCAGGAGACA 960 CTGCAGACAG TGACCATCTA CAGCTTTCCG GCGCCCAACG TGATTCTGAC GAAGCCAGAG 1020 GTCTCAGAAG GGACCGAGGT GACAGTGAAG TGTGAGGCCC ACCCTAGAGC CAAGGTGACG 1080 CTGAATGGGG TTCCAGCCCA GCCACTGGGC CCGAGGGCCC AGCTCCTGCT GAAGGCCACC 1140 CCAGAGGACA ACGGGCGCAG CTTCTCCTGC TCTGCAACCC TGGAGGTGGC CGGCCAGCTT 1200 ATACACAAGA ACCAGACCCG GGAGCTTCGT GTCCTGTATG GCCCCCGACT GGACGAGAGG 1260 GATTGTCCGG GAAACTGGAC GTGGCCAGAA AATTCCCAGC AGACTCCAAT GTGCCAGGCT 1320 TGGGGGAACC CATTGCCCGA GCTCAAGTGT CTAAAGGATG GCACTTTCCC ACTGCCCATC 1380 GGGGAATCAG TGACTGTCAC TCGAGATCTT GAGGGCACCT ACCTCTGTCG GGCCAGGAGC 1440 ACTCAAGGGG AGGTCACCCG CGAGGTGACC GTGAATGTGC TCTCCCCCCG GTATGAGATT 1500 GTCATCATCA CTGTGGTAGC AGCCGCAGTC ATAATGGGCA CTGCAGGCCT CAGCACGTAC 1560 CTCTATAACC GCCAGCGGAA GATCAAGAAA TACAGACTAC AACAGGCCCA AAAAGGGACC 1620 CCCATGAAAC CGAACACACA AGCCACGCCT CCCTGAACCT ATCCCGGGAC AGGGCCTCTT 1680 CCTCGGCCTT CCCATATTGG TGGCAGTGGT GCCACACTGA ACAGAGTGGA AGACATATGC 1740 CATGCAGCTA CACCTACCGG CCCTGGGACG CCGGAGGACA GGGCATTGTC CTCAGTCAGA 1800 TACAACAGCA TTTGGGGCCA TGGTACCTGC ACACCTAAAA CACTAGGCCA CGCATCTGAT 1860 CTGTAGTCAC ATGACTAAGC CAAGAGGAAG GAGCAAGACT CAAGACATGA TTGATGGATG 1920 TTAAAGTCTA GCCTGATGAG AGGGGAAGTG GTGGGGGAGA CATAGCCCCA CCATGAGGAC 1980 ATACAACTGG GAAATACTGA AACTTGCTGC CTATTGGGTA TGCTGAGGCC CACAGACTTA 2040 CAGAAGAAGT GGCCCTCCAT AGACATGTGT AGCATCAAAA CACAAAGGCC CACACTTCCT 2100 GACGGATGCC AGCTTGGGCA CTGCTGTCTA CTGACCCCAA CCCTTGATGA TATGTATTTA 2160 TTCATTTGTT ATTTTACCAG CTATTTATTG AGTGTCTTTT ATGTAGGCTA AATGAACATA 2220 GGTCTCTGGC CTCACGGAGC TCCCAGTCCA TGTCACATTC AAGGTCACCA GGTACAGTTG 2280 TACAGGTTGT ACACTGCAGG AGAGTGCCTG GCAAAAAGAT CAAATGGGGC TGGGACTTCT 2340 CATTGGCCAA CCTGCCTTTC CCCAGAAGGA GTGATTTTTC TATCGGCACA AAAGCACTAT 2400 ATGGACTGGT AATGGTTCAC AGGTTCAGAG ATTACCCAGT GAGGCCTTAT TCCTCCCTTC 2460 CCCCCAAAAC TGACACCTTT GTTAGCCACC TCCCCACCCA CATACATTTC TGCCAGTGTT 2520 CACAATGACA CTCAGCGGTC ATGTCTGGAC ATGAGTGCCC AGGGAATATG CCCAAGCTAT 2580 GCCTTGTCCT CTTGTCCTGT TTGCATTTCA CTGGGAGCTT GCACTATTGC AGCTCCAGTT 2640 TCCTGCAGTG ATCAGGGTCC TGCAAGCAGT GGGGAAGGGG GCCAAGGTAT TGGAGGACTC 2700 CCTCCCAGCT TTGGAAGGGT CATCCGCGTG TGTGTGTGTG TGTATGTGTA GACAAGCTCT 2760 CGCTCTGTCA CCCAGGCTGG AGTGCAGTGG TGCAATCATG GTTCACTGCA GTCTTGACCT 2820 TTTGGGCTCA AGTGATCCTC CCACCTCAGC CTCCTGAGTA GCTGGGACCA TAGGCTCACA 2880 ACACCACACC TGGCAAATTT GATTTTTTTT TTTTTTTTCA GAGACGGGGT CTCGCAACAT 2940 TGCCCAGACT TCCTTTGTGT TAGTTAATAA AGCTTTCTCA ACTGCC

Seq ID No: 141 Protein sequence: Protein Accession #: NP 000192.1 11 21 31 41 51

MLQFVRAGAR AWLRPTGSQG LSSLAEEAAR ATENPEQVAS EGLPEPVLRK VELPVPTHRR 60 PVQAWVESLR GFEQERVGLA DLHPDVFATA PRLDILHQVA MWQKNFKRIS YAKTKTRAEV 120 RGGGGKPLAA ERHWAGPAWQ HPLSALARRR CCPWPPGPTS YYYMLPMKVR ALGLKVALTV 180 KLAQDDLHIM DSLELPTGDP QYLTELAHYR RWGDSVLLVD LTHEEMPQSI VEATSRLKTF 2 0 NLIPAVGLNV HSMLKHQTLV LTLPTVAFLE DKLLWQDSRY RPLYPFSLPY SDFPRPLPHA 300 TQGPAATPYH C

Seq ID NO: 142 DNA sequence

Nucleic Acid Accession #: NM_000270.1

Coding sequence: 110-g7g (underlined sequences correspond to start and stop codons)

11 21 31 41 51

AACTGTGCGA ACCAGACCCG GCAGCCTTGC TCAGTTCAGC ATAGCGGAGC GGATCCGATC 60 GGATCGGAGC ACACCGGAGC AGGCTCATCG AGAAGGCGTC TGCGAGACCA_ TGGAGAACGG 120 ATACACCTAT GAAGATTATA AGAACACTGC AGAATGGCTT CTGTCTCATA CTAAGCACCG 180 ACCTCAAGTT GCAATAATCT GTGGTTCTGG ATTAGGAGGT CTGACTGATA AATTAACTCA 240 GGCCCAGATC TTTGACTACA GTGAAATCCC CAACTTTCCT CGAAGTACAG TGCCAGGTCA 300 TGCTGGCCGA CTGGTGTTTG GGTTCCTGAA TGGCAGGGCC TGTGTGATGA TGCAGGGCAG 360 GTTCCACATG TATGAAGGGT ACCCACTCTG GAAGGTGACA TTCCCAGTGA GGGTTTTCCA 420 CCTTCTGGGT GTGGACACCC TGGTAGTCAC CAATGCAGCA GGAGGGCTGA ACCCCAAGTT 480 TGAGGTTGGA GATATCATGC TGATCCGTGA CCATATCAAC CTACCTGGTT TCAGTGGTCA 540 GAAGCCTCTC AGAGGGCCCA ATGATGAAAG GTTTGGAGAT CGTTTCCCTG CCATGTCTGA 600 TGCCTACGAC CGGACTATGA GGCAGAGGGC TCTCAGTACC TGGAAACAAA TGGGGGAGCA 660 ACGTGAGCTA CAGGAAGGCA CCTATGTGAT GGTGGCAGGC CCCAGCTTTG AGACTGTGGC 720 AGAATGTCGT GTGCTGCAGA AGCTGGGAGC AGACGCTGTT GGCATGAGTA CAGTACCAGA 780 AGTTATCGTT GCACGGCACT GTGGACTTCG AGTCTTTGGC TTCTCACTCA TCACTAACAA 840 GGTCATCATG GATTATGAAA GCCTGGAGAA GGCCAACCAT GAAGAAGTCT TAGCAGCTGG 900 CAAACAAGCT GCACAGAAAT TGGAACAGTT TGTCTCCATT CTTATGGCCA GCATTCCACT 960 CCCTGACAAA GCCAGTTGAC CTGCCTTGGA GTCGTCTGGC ATCTCCCACA CAAGACCCAA 1020 GTAGCTGCTA CCTTCTTTGG CCCCTTGCTG GAGTCATGTG CCTCTGTCCT TAGGTTGTAG 1080 CAGAAAGGAA AAGATTCCTG TCCTTCACCT TTCCCACTTT CTTCTACCAG ACCCTTCTGG 1140 TGCCAGATCC TCTTCTCAAA GCTGGGATTA CAGGTGTGAG CATAGTGAGA CCTTGGCGCT 1200 ACAAAATAAA GCTGTTCTCA TTCCTGTTCT TTCTTACACA AGAGCTGGAG CCCGTGCCCT 1260 ACCACACATC TGTGGAGATG CCCAGGATTT GACTCGGGCC TTAGAACTTT GCATAGCAGC 1320 TGCTACTAGC TCTTTGAGAT AATACATTCC GAGGGGCTCA GTTCTGCCTT ATCTAAATCA 1380 CCAGAGACCA AACAAGGACT AATCCAATAC CTCTTGGA

Seq ID No: 143 Protein sequence : Protein Accession #: NP 000261.1

11 21 31 41 51

MENGYTYEDY KNTAEWLLSH TKHRPQVAII CGSGLGGLTD KLTQAQIFDY SEIPNFPRST 60 VPGHAGRLVF GFLNGRACVM MQGRFHMYEG YPLWKVTFPV RVFHLLGVDT LWTNAAGGL 120

NPKFEVGDIM LIRDHINLPG FSGQNPLRGP NDERFGDRFP AMSDAYDRTM RQRALSTWKQ 180

MGEQRELQEG TYVMVAGPSF ETVAECRVLQ KLGADAVGMS TVPEVIVARH CGLRVFGFSL 240 ITNKVIMDYE SLEKANHEEV LAAGKQAAQK LEQFVSILMA SIPLPDKAS Seq ID NO : 144 DNA sequence

Nucleic Acid Accession # : NM_015577 . 1

Coding sequence : 112 -3054 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

GAAGCGGCGG GCGGGGTGGA GCAGCCAGCT GGGTCCGGGG AGCGCCGCCG CCGCCTCGAT 60 GGGGTGTTGA AAAGTCTCCT CTAGAGCTTT GGAAGGCTGA ATGCACTAAA CATGAAGAGC 120 TTGAAAGCGA AGTTCAGGAA GAGTGACACC AATGAGTGGA ACAAGAATGA TGACCGGCTA 180 CTGCAGGCCG TGGAGAATGG AGATGCGGAG AAGGTGGCCT CACTGCTCGG CAAGAAGGGG 240 GCCAGTGCCA CCAAACACGA CAGTGAGGGC AAGACCGCTT TCCATCTTGC TGCTGCAAAA 300 GGACACGTGG AATGCCTCAG GGTCATGATT ACACATGGTG TGGATGTGAC AGCCCAAGAT 360 ACTACCGGAC ACAGCGCCTT ACATCTCGCA GCCAAGAACA GCCACCATGA ATGCATCAGG 420 AGGCTGCTTC AGTCTAAATG CCCAGCCGAA AGTGTCGACA GCTCTGGGAA AACAGCTTTA 480 CATTATGCAG CGGCTCAGGG CTGCCTTCAA GCTGTGCAGA TTCTCTGCGA ACACAAGAGC 540 CCCATAAACC TCAAAGATTT GGATGGGAAT ATACCGCTGC TTCTTGCTGT ACAAAATGGT 600 CACAGTGAGA TCTGTCACTT TCTCCTGGAT CATGGAGCAG ATGTCAATTC CAGGAACAAA 660 AGTGGAAGAA CTGCTCTCAT GCTGGCCTGT GAGATTGGCA GCTCTAACGC TGTGGAAGCC 720 TTAATTAAAA AGGGTGCAGA CCTAAACCTT GTAGATTCTC TTGGATACAA TGCCTTACAT 780 TATTCCAAAC TCTCAGAAAA TGCAGGAATT CAAAGCCTTC TATTATCAAA AATCTCTCAG 840 GATGCTGATT TAAAGACCCC AACAAAACCA AAGCAGCATG ACCAAGTCTC TAAAATAAGC 900 TCAGAAAGAA GTGGAACTCC AAAAACACGC AAAGCTCCAC CACCTCCTAT CAGTCCTACC 960

CAGTTGAGTG ATGTCTCTTC CCCAAGATCA ATAACTTCGA CTCCACTATC GGGAAAGGAA 1020

TCGGTATTTT TTGCTGAACC ACCCTTCAAG GCTGAGATCA GTTCTATACG AGAAAACAAA 1080

GACAGACTAA GTGACAGTAC TACAGGTGCT GATAGCTTAT TGGATATAAG TTCTGAAGCT 1140 GACCAACAAG ATCTTCTCTC TCTATTGCAA GCAAAAGTTG CTTCCCTTAC CTTACACAAT 1200

AAGGAGTTAC AAGATAAATT ACAGGCCAAA TCACCCAAGG AGGCGGAAGC AGACCTAAGC 1260

TTTGACTCAT ACCATTCCAC CCAAACTGAC TTGGGCCCAT CCCTGGGAAA ACCTGGTGAA 1320

ACCTCTCCCC CAGACTCCAA ATCATCTCCA TCTGTCTTAA TACATTCTTT AGGTAAATCC 1380

ACTACTGACA ATGATGTCAG AATTCAGCAA CTGCAAGAGA TTTTGCAAGA TCTACAGAAG 1440 AGATTAGAGA GCTCTGAAGC AGAGAGAAAA CAGCTACAGG TCGAACTCCA ATCCCGAAGG 1500

GCAGAACTGG TATGCTTAAA CAACACTGAG ATTTCAGAGA ACAGCTCTGA CCTCAGCCAG 1560

AAACTTAAAG AAACTCAGAG CAAATACGAG GAGGCTATGA AAGAAGTCCT TAGTGTGCAG 1620

AAGCAGATGA AACTCGGTCT TGTCTCACCT GAAAGCATGG ATAATTATTC ACATTTCCAC 1680

GAGCTGAGGG TCACGGAAGA GGAAATAAAT GTGCTAAAGC AGGATCTGCA GAATGCATTA 1740 GAAGAAAGTG AAAGAAATAA AGAGAAAGTG AGAGAGTTAG AGGAAAAACT GGTAGAGAGG 1800

GAGAAAGGTA CAGTGATTAA GCCACCTGTG GAAGAGTACG AGGAAATGAA AAGTTCATAT 1860

TGCTCTGTTA TTGAGAATAT GAATAAGGAG AAAGCATTTT TGTTTGAGAA ATACCAAGAA 1920

GCCCAAGAAG AAATCATGAA ATTAAAAGAC ACACTAAAAA GTCAGATGAC ACAGGAAGCC 1980

AGTGATGAAG CTGAGGACAT GAAAGAAGCC ATGAATAGGA TGATAGATGA ACTCAATAAA 2040 CAGGTGAGCG AGCTGTCACA GCTGTACAAA GAAGCCCAGG CTGAGCTGGA GGATTACAGG 2100

AAGAGGAAAT CTCTAGAGGA TGTCACAGCT GAATATATCC ATAAAGCAGA GCATGAGAAA 2160

CTGATGCAAT TGACAAACGT GTCCAGGGCT AAAGCAGAAG ATGCACTGTC TGAAATGAAG 2220

TCTCAGTATT CAAAAGTGTT GAATGAGTTG ACCCAGCTCA AACAACTGGT GGATGCACAA 2280

AAAGAGAACT CTGTCTCTAT CACAGAACAT TTGCAAGTGA TAACCACGCT GCGGACTGCA 2340 GCAAAAGAGA TGGAAGAAAA AATAAGCAAT CTTAAGGAAC ACCTTGCAAG CAAGGAAGTG 2400

GAAGTAGCAA AGCTGGAGAA ACAACTCTTA GAAGAGAAAG CTGCTATGAC TGATGCAATG 2460

GTACCTCGGT CTTCCTATGA AAAACTCCAG TCATCCTTAG AGAGTGAAGT GAGTGTGTTG 2520

GCATCGAAAT TAAAGGAATC TGTGAAAGAG AAAGAGAAGG TCCATTCAGA GGTTGTCCAG 2580

ATTAGAAGTG AGGTCTCACA GGTGAAAAGA GAAAAGGAAA ATATTCAGAC TCTCTTGAAA 2640 TCCAAAGAGC AAGAAGTAAA TGAACTTCTG CAAAAATTCC AGCAAGCTCA GGAAGAACTT 2700

GCAGAAATGA AAAGATACGC TGAGAGCTCT TCAAAACTGG AGGAAGATAA AGATAAAAAG 2760

ATAAATGAGA TGTCGAAGGA AGTCACCAAA TTGAAGGAGG CCTTGAACAG CCTCTCCCAG 2820

CTCTCCTACT CAACAAGCTC ATCCAAAAGG CAGAGTCAGC AGCTGGAGGC GCTGCAGCAG 2880

CAAGTCAAAC AGCTCCAGAA CCAGCTGGCG GAATGCAAGA AACAACACCA GGAGGTCATA 2940 TCAGTTTACA GAATGCATCT TCTGTATGCT GTGCAGGGCC AGATGGATGA AGATGTCCAG 3000

AAAGTACTGA AGCAAATCCT TACCATGTGT AAAAACCAGT CTCAAAAGAA GTAAAGTGGA 3060

TTCCTTGGCA GGACACTGCC CCTTGTCATC TGTCTTTGTG TTAGATCCAG AGTTGTCGGC 3120

AGCCGCTGCC ATTGTTCTCA TTCGTGGTAT GCACTGTGGC CTAGCGTAGC TTCTTCCCTT 3180

TCCAAAGGTT TCTGAGGACT TCTCCCAGGA GAAGACTGCC CGCCTCAGAA CTGCTTAGAG 3240 ACTTCAAACC AGCAGAGGTG AAAGTCCCTG TCATCCCTTC AGATTCCAGA GCTGGGATCA 3300

GCCATGCCCA GAGGTCTGGT CCTGATGCTG GCAGGGGGGC CCCCTCCTCC ATCCCTGACT 3360

GGCTGAGTGG CTTTATCACC ACCGAGTGAT GTGCTGAGGC CTCCTGCAGT GAATGCTCCT 3420

TCCATTCCTG TACTCGGGCA GTGCCATTCA GCACAGGAGA GCTCTTTTTG CCTTTGGCTT 3480

TCAATTCCAA AACATGATTT AATTTCTAAC TAAATTAGTA TGGCACTAGT TATGAAGTAT 3540 CTGCTTAAAA CCCTTCATCA TGATATCCTG TGGATTTAAA AACTCTAATT CCATGTTTTC 3600

TTCCCATCTG CCTTATATAT CTCATCACCC TGCTTATCAA TATTCAGTTT GATGAGCACT 3660

ATTAACTAAA ATATGAAACT TAAAAACAAA AGCAAGTTGT CCTTAAAAGT TCTTTTTTTA 3720

AGTAAATTGT TGACATACTG CAAATTTTCT ATGCAAACTT GCCTCCTGCT GTTATCTGTG 3780

AAGCTCAGGA AATCCAAACA TTTGTGTTTC AACAAGGGAC AGTAAACTGT GTGTTTACAG 3840 CCAAAAGAAA TGCCTCATAG TTCTTAACCT CAACTTTTGT AGAAGTATTT TTTTCTCTGT 3900

AATATTTTTA TTGGCTCATA AAGATGTTTT CATATCTGAA CTCCTAAATA AGTGAAATTA 3960

CAGTAGATTA TATTAACAAA ATACTTTTTA GGTAGCCATG CTTGAGACTT TTTAAAAATA 020

TAACTTTTTC CTTAAAGTTT TCAGCTATAG CAAAAGGTAG TTATGTATGC CAGACCTAAT 4080

ATGAGCTGCC ACCAACACCC CTAGAACTTT CAGCCATGGT GTCTTCAGAA TTGTAGCGCA 4140 TTTCTGAATC TAGCAAATCC TCCTTTTACC CGTTGAATGT TTTGAATGCC CTGACTCTAC 4200

CAGCGCCCAT AAATGATCTC TAGAAGGACT GTTAGTACCA ATCTGTTTTT CAACTTTGAA 4260

GCTAAAAACC CTGATATGGT AATATTATGG TGCATAGCAG AGGTCTCGGA AAAAAAATAT 4320

TTCTGTTCAC TTTACTTTCA GGTTAAAAAT GTTTCTAACA CGCTTGCAAC TTCCCTTATG 4380

GCATTAATCT TGTTGAGGGA GAGAGACAGA ATCCTGGACT CTCCAAAGTA TTTAACTGAA ₄₄₄0 AGTAGGGCCT GCTCTGACAG GGCCCATGTC CCACAAGGCT GCTTGGCCTC AGTGGGTGCT ₄500

TGGCTGTGCT GGATGATATG TTGATCTGTA TTGGATAAGG ACCAATGACA GCAAAGCAAA 4560

AATGGCTTTA AAGCTTGGTG TTACTTTTCT TAAGTTGTTT AATTATAGTT AAGCAATTTC 4620

AAAAATGCTC CAAAGAAATG TGAAAGGACC TTTTGTCACA GCACTTCAGA AAATACACAA 4680

CAGCCCCTTC TGCCCCCGCA CAGAAATGCT GCAGAGTATA TAAAACTTGA GACATTTTTG 4740 TAGGATGCCT GACGAGGTGT AGCCTTTTAT CTTGTTTCCG GATGCATATT TATTACGAGT 4800

ACTCTGGTTA AATATTGAAA AGTTATATGC TGTAGTTTTT AGTATTTTGT CTTTGTAATT 4860

TACAGAAGTT ATTGGAGAAA ATAAACTTGT TTCATTTTGC AAAAAAAAAA AAAAAAAAAA 4920 AAAAA Seq ID No: 145 Protein sequence : Protein Accession #: NP 056392.1

1 11 21 31 41 51

I I I I I I

MKSLKAKFRK SDTNEWNKND DRLLQAVENG DAEKVASLLG KKGASATKHD SEGKTAFHLA 60 AAKGHVECLR VMITHGVDVT AQDTTGHSAL HLAAKNSHHE CIRRLLQSKC PAESVDSSGK 120 TALHYAAAQG CLQAVQILCE HKSPINLKDL DGNIPLLLAV QNGHSEICHF LLDHGADVNS 180 RNKSGRTALM LACEIGSSNA VEALIKKGAD LNLVDSLGYN ALHYSKLSEN AGIQSLLLSK 240 ISQDADLKTP TKPKQHDQVS KISSERSGTP KTRKAPPPPI SPTQLSDVSS PRSITSTPLS 300 GKESVFFAEP PFKAEISSIR ENKDRLSDST TGADSLLDIS SEADQQDLLS LLQAKVASLT 360 LHNKELQDKL QAKSPKEAEA DLSFDSYHST QTDLGPSLGK PGETSPPDSK SSPSVLIHSL 420 GKSTTDNDVR IQQLQEILQD LQKRLESSEA ERKQLQVELQ SRRAELVCLN NTEISENSSD 480 LSQKLKETQS KYEEAMKEVL SVQKQMKLGL VSPESMDNYS HFHELRVTEE EINVLKQDLQ 540 NALEESERNK EKVRELEEKL VEREKGTVIK PPVEEYEEMK SSYCSVIENM NKEKAFLFEK 600 YQEAQEEIMK LKDTLKSQMT QEASDEAEDM KEAMNRMIDE LNKQVSELSQ LYKEAQAELE 660 DYRKRKSLED VTAEYIHKAE HEKLMQLTNV SRAKAEDALS EMKSQYSKVL NELTQLKQLV 720 DAQKENSVSI TEHLQVITTL RTAAKEMEEK ISNLKEHLAS KEVEVAKLEK QLLEEKAAMT 780 DAMVPRSSYE KLQSSLESEV SVLASKLKES VKEKEKVHSE WQIRSEVSQ VKREKENIQT 840 LLKSKEQEVN ELLQKFQQAQ EELAEMKRYA ESSSKLEEDK DKKINEMSKE VTKLKEALNS 900 LSQLSYSTSS SKRQSQQLEA LQQQVKQLQN QLAECKKQHQ EVISVYRMHL LYAVQGQMDE 960 DVQKVLKQIL TMCKNQSQKK

Seq ID NO: 146 DNA sequence

Nucleic Acid Accession #: NM_000459.1

Coding sequence: 149-3523 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

I I I

CTTCTGTGCT GTTCCTTCTT GCCTCTAACT TGTAAACAAG ACGTACTAGG ACGATGCTAA 60 TGGAAAGTCA CAAACCGCTG GGTTTTTGAA AGGATCCTTG GGACCTCATG CACATTTGTG 120 GAAACTGGAT GGAGAGATTT GGGGAAGCAT GGACTCTTTA GCCAGCTTAG TTCTCTGTGG 180 AGTCAGCTTG CTCCTTTCTG GAACTGTGGA AGGTGCCATG GACTTGATCT TGATCAATTC 240 CCTACCTCTT GTATCTGATG CTGAAACATC TCTCACCTGC ATTGCCTCTG GGTGGCGCCC 300 CCATGAGCCC ATCACCATAG GAAGGGACTT TGAAGCCTTA ATGAACCAGC ACCAGGATCC 360 GCTGGAAGTT ACTCAAGATG TGACCAGAGA ATGGGCTAAA AAAGTTGTTT GGAAGAGAGA 420 AAAGGCTAGT AAGATCAATG GTGCTTATTT CTGTGAAGGG CGAGTTCGAG GAGAGGCAAT 480 CAGGATACGA ACCATGAAGA TGCGTCAACA AGCTTCCTTC CTACCAGCTA CTTTAACTAT 540 GACTGTGGAC AAGGGAGATA ACGTGAACAT ATCTTTCAAA AAGGTATTGA TTAAAGAAGA 600 AGATGCAGTG ATTTACAAAA ATGGTTCCTT CATCCATTCA GTGCCCCGGC ATGAAGTACC 660 TGATATTCTA GAAGTACACC TGCCTCATGC TCAGCCCCAG GATGCTGGAG TGTACTCGGC 720 CAGGTATATA "GGAGGAAACC TCTTCACCTC GGCCTTCACC AGGCTGATAG TCCGGAGATG 780 TGAAGCCCAG AAGTGGGGAC CTGAATGCAA CCATCTCTGT ACTGCTTGTA TGAACAATGG 840 TGTCTGCCAT GAAGATACTG GAGAATGCAT TTGCCCTCCT GGGTTTATGG GAAGGACGTG goo TGAGAAGGCT TGTGAACTGC ACACGTTTGG CAGAACTTGT AAAGAAAGGT GCAGTGGACA gεo AGAGGGATGC AAGTCTTATG TGTTCTGTCT CCCTGACCCC TATGGGTGTT CCTGTGCCAC 1020 AGGCTGGAAG GGTCTGCAGT GCAATGAAGC ATGCCACCCT GGTTTTTACG GGCCAGATTG 1080 TAAGCTTAGG TGCAGCTGCA ACAATGGGGA GATGTGTGAT CGCTTCCAAG GATGTCTCTG 1140 CTCTCCAGGA TGGCAGGGGC TCCAGTGTGA GAGAGAAGGC ATACCGAGGA TGACCCCAAA 1200 GATAGTGGAT TTGCCAGATC ATATAGAAGT AAAGAGTGGT AAATTTAATC CCATTTGCAA 1260 AGCTTCTGGC TGGCCGCTAC CTACTAATGA AGAAATGACC CTGGTGAAGC CGGATGGGAC 1320 AGTGCTCCAT CCAAAAGACT TTAACCATAC GGATCATTTC TCAGTAGCCA TATTCACCAT 1380 CCACCGGATC CTCCCCCCTG ACTCAGGAGT TTGGGTCTGC AGTGTGAACA CAGTGGCTGG 1440 GATGGTGGAA AAGCCCTTCA ACATTTCTGT TAAAGTTCTT CCAAAGCCCC TGAATGCCCC 1500 AAACGTGATT GACACTGGAC ATAACTTTGC TGTCATCAAC ATCAGCTCTG AGCCTTACTT 1560 TGGGGATGGA CCAATCAAAT CCAAGAAGCT TCTATACAAA CCCGTTAATC ACTATGAGGC 1620 TTGGCAACAT ATTCAAGTGA CAAATGAGAT TGTTACACTC AACTATTTGG AACCTCGGAC 1680 AGAATATGAA CTCTGTGTGC AACTGGTCCG TCGTGGAGAG GGTGGGGAAG GGCATCCTGG 1740 ACCTGTGAGA CGCTTCACAA CAGCTTCTAT CGGACTCCCT CCTCCAAGAG GTCTAAATCT 1800 CCTGCCTAAA AGTCAGACCA CTCTAAATTT GACCTGGCAA CCAATATTTC CAAGCTCGGA 1860 AGATGACTTT TATGTTGAAG TGGAGAGAAG GTCTGTGCAA AAAAGTGATC AGCAGAATAT ig20 TAAAGTTCCA GGCAACTTGA CTTCGGTGCT ACTTAACAAC TTACATCCCA GGGAGCAGTA ιgβo CGTGGTCCGA GCTAGAGTCA ACACCAAGGC CCAGGGGGAA TGGAGTGAAG ATCTCACTGC 2040 TTGGACCCTT AGTGACATTC TTCCTCCTCA ACCAGAAAAC ATCAAGATTT CCAACATTAC 2100 ACACTCCTCG GCTGTGATTT CTTGGACAAT ATTGGATGGC TATTCTATTT CTTCTATTAC 2160 TATCCGTTAC AAGGTTCAAG GCAAGAATGA AGACCAGCAC GTTGATGTGA AGATAAAGAA 2220 TGCCACCATC ATTCAGTATC AGCTCAAGGG CCTAGAGCCT GAAACAGCAT ACCAGGTGGA 2280 CATTTTTGCA GAGAACAACA TAGGGTCAAG CAACCCAGCC TTTTCTCATG AACTGGTGAC 2340 CCTCCCAGAA TCTCAAGCAC CAGCGGACCT CGGAGGGGGG AAGATGCTGC TTATAGCCAT 2400 CCTTGGCTCT" GCTGGAATGA CCTGCCTGAC TGTGCTGTTG GCCTTTCTGA TCATATTGCA 2460 ATTGAAGAGG GCAAATGTGC AAAGGAGAAT GGCCCAAGCC TTCCAAAACG TGAGGGAAGA 2520 ACCAGCTGTG CAGTTCAACT CAGGGACTCT GGCCCTAAAC AGGAAGGTCA AAAACAACCC 2580 AGATCCTACA ATTTATCCAG TGCTTGACTG GAATGACATC AAATTTCAAG ATGTGATTGG 2640 GGAGGGCAAT TTTGGCCAAG TTCTTAAGGC GCGCATCAAG AAGGATGGGT TACGGATGGA 2700 TGCTGCCATC AAAAGAATGA AAGAATATGC CTCCAAAGAT GATCACAGGG ACTTTGCAGG 2760 AGAACTGGAA GTTCTTTGTA AACTTGGACA CCATCCAAAC ATCATCAATC TCTTAGGAGC 2820 ATGTGAACAT CGAGGCTACT TGTACCTGGC CATTGAGTAC GCGCCCCATG GAAACCTTCT 2880 GGACTTCCTT CGCAAGAGCC GTGTGCTGGA GACGGACCCA GCATTTGCCA TTGCCAATAG 2g40 CACCGCGTCC ACACTGTCCT CCCAGCAGCT CCTTCACTTC GCTGCCGACG TGGCCCGGGG 3000 CATGGACTAC TTGAGCCAAA AACAGTTTAT CCACAGGGAT CTGGCTGCCA GAAACATTTT 3060 AGTTGGTGAA AACTATGTGG CAAAAATAGC AGATTTTGGA TTGTCCCGAG GTCAAGAGGT 3120 GTACGTGAAA AAGACAATGG GAAGGCTCCC AGTGCGCTGG ATGGCCATCG AGTCACTGAA 3180 TTACAGTGTG TACACAACCA ACAGTGATGT ATGGTCCTAT GGTGTGTTAC TATGGGAGAT 3240 TGTTAGCTTA GGAGGCACAC CCTACTGCGG GATGACTTGT GCAGAACTCT ACGAGAAGCT 3300 GCCCCAGGGC TACAGACTGG AGAAGCCCCT GAACTGTGAT GATGAGGTGT ATGATCTAAT 3360 GAGACAATGC TGGCGGGAGA AGCCTTATGA GAGGCCATCA TTTGCCCAGA TATTGGTGTC 3420 CTTAAACAGA ATGTTAGAGG AGCGAAAGAC CTACGTGAAT ACCACGCTTT ATGAGAAGTT 3480 TACTTATGCA GGAATTGACT GTTCTGCTGA AGAAGCGGCC TAGGACAGAA CATCTGTATA 3540 CCCTCTGTTT CCCTTTCACT GGCATGGGAG ACCCTTGACA ACTGCTGAGA AAACATGCCT 3600 CTGCCAAAGG ATGTGATATA TAAGTGTACA TATGTGCTGG AATTCTAACA AGTCATAGGT 3660 TAATATTTAA GACACTGAAA AATCTAAGTG ATATAAATCA GATTCTTCTC TCTCATTTTA 3720 TCCCTCACCT GTAGCATGCC AGTCCCGTTT CATTTAGTCA TGTGACCACT CTGTCTTGTG 3780 TTTCCACAGC CTGCAAGTTC AGTCCAGGAT GCTAACATCT AAAAATAGAC TTAAATCTCA 3840 TTGCTTACAA GCCTAAGAAT CTTTAGAGAA GTATACATAA GTTTAGGATA AAATAATGGG 3900 ATTTTCTTTT CTTTTCTCTG GTAATATTGA CTTGTATATT TTAAGAAATA ACAGAAAGCC 3960 TGGGTGACAT TTGGGAGACA TGTGACATTT ATATATTGAA TTAATATCCC TACATGTATT 4020 GCACATTGTA AAAAGTTTTA GTTTTGATGA GTTGTGAGTT TACCTTGTAT ACTGTAGGCA 4080 CACTTTGCAC TGATATATCA TGAGTGAATA AATGTCTTGC CTACTCAAAA AAAAAAAA

Seq ID No: 147 Protein sequence : Protein Accession #: NP 000450.1

11 21 31 41 51

I I I I I

MDSLASLVLC GVSLLLSGTV EGAMDLILIN SLPLVSDAET SLTCIASGWR PHEPITIGRD 60 FEALMNQHQD PLEVTQDVTR EWAKKWWKR EKASKINGAY FCEGRVRGEA IRIRTMKMRQ 120 QASFLPATLT MTVDKGDNVN ISFKKVLIKE EDAVIYKNGS FIHSVPRHEV PDILEVHLPH 180 AQPQDAGVYS ARYIGGNLFT SAFTRLIVRR CEAQKWGPEC NHLCTACMNN GVCHEDTGEC 240 ICPPGFMGRT CEKACELHTF GRTCKERCSG QEGCKSYVFC LPDPYGCSCA TGWKGLQCNE 300 ACHPGFYGPD CKLRCSCNNG EMCDRFQGCL CSPGWQGLQC EREGIPRMTP KIVDLPDHIE 360 VNSGKFNPIC KASGWPLPTN EEMTLVKPDG TVLHPKDFNH TDHFSVAIFT IHRILPPDSG 420 VWVCSVNTVA GMVEKPFNIS VKVLPKPLNA PNVIDTGHNF AVINISSEPY FGDGPIKSKK 480 LLYKPVNHYE AWQHIQVTNE IVTLNYLEPR TEYELCVQLV RRGEGGEGHP GPVRRFTTAS 540 IGLPPPRGLN LLPKSQTTLN LTWQPIFPSS EDDFYVEVER RSVQKSDQQN IKVPGNLTSV 600 LLNNLHPREQ YWRARVNTK AQGEWSEDLT AWTLSDILPP QPENIKISNI THSSAVISWT 660 ILDGYSISSI TIRYKVQGKN EDQHVDVKIK NATIIQYQLK GLEPETAYQV DIFAENNIGS 720 SNPAFSHELV TLPESQAPAD LGGGKMLLIA ILGSAGMTCL TVLLAFLIIL QLKRANVQRR 780 MAQAFQNVRE EPAVQFNSGT LALNRKVKNN PDPTIYPVLD WNDIKFQDVI GEGNFGQVLK 840 ARIKKDGLRM DAAIKRMKEY ASKDDHRDFA GELEVLCKLG HHPNIINLLG ACEHRGYLYL 900 AIEYAPHGNL LDFLRKSRVL ETDPAFAIAN STASTLSSQQ LLHFAADVAR GMDYLSQKQF 960 IHRDLAARNI LVGENYVAKI ADFGLSRGQE VYVKKTMGRL PVRWMAIESL NYSVYTTNSD 1020 VWSYGVLLWE IVSLGGTPYC GMTCAELYEK LPQGYRLEKP LNCDDEVYDL MRQCWREKPY 1080 ERPSFAQILV SLNRMLEERK TYVNTTLYEK FTYAGIDCSA EEAA

Seq ID NO: 148 DNA sequence

Nucleic Acid Accession #: NM_000552.2

Coding sequence: 311-8752 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

AGCTCACAGC TATTGTGGTG GGAAAGGGAG GGTGGTTGGT GGATGTCACA GCTTGGGCTT 60 TATCTCCCCC AGCAGTGGGG ACTCCACAGC CCCTGGGCTA CATAACAGCA AGACAGTCCG 120 GAGCTGTAGC AGACCTGATT GAGCCTTTGC AGCAGCTGAG AGCATGGCCT AGGGTGGGCG 180 GCACCATTGT CCAGCAGCTG AGTTTCCCAG GGACCTTGGA GATAGCCGCA GCCCTCATTT 240 GCAGGGGAAG GCACCATTGT CCAGCAGCTG AGTTTCCCAG GGACCTTGGA GATAGCCGCA 300 GCCCTCATTT ATGATTCCTG CCAGATTTGC CGGGGTGCTG CTTGCTCTGG CCCTCATTTT 360 GCCAGGGACC CTTTGTGCAG AAGGAACTCG CGGCAGGTCA TCCACGGCCC GATGCAGCCT 420 TTTCGGAAGT GACTTCGTCA ACACCTTTGA TGGGAGCATG TACAGCTTTG CGGGATACTG 480 CAGTTACCTC CTGGCAGGGG GCTGCCAGAA ACGCTCCTTC TCGATTATTG GGGACTTCCA 540 GAATGGCAAG AGAGTGAGCC TCTCCGTGTA TCTTGGGGAA TTTTTTGACA TCCATTTGTT 600 TGTCAATGGT ACCGTGACAC AGGGGGACCA AAGAGTCTCC ATGCCCTATG CCTCCAAAGG 660 GCTGTATCTA GAAACTGAGG CTGGGTACTA CAAGCTGTCC GGTGAGGCCT ATGGCTTTGT 720 GGCCAGGATC GATGGCAGCG GCAACTTTCA AGTCCTGCTG TCAGACAGAT ACTTCAACAA 780 GACCTGCGGG CTGTGTGGCA ACTTTAACAT CTTTGCTGAA GATGACTTTA TGACCCAAGA 840 AGGGACCTTG ACCTCGGACC CTTATGACTT TGCCAACTCA TGGGCTCTGA GCAGTGGAGA ^■ 900 ACAGTGGTGT GAACGGGCAT CTCCTCCCAG CAGCTCATGC AACATCTCCT CTGGGGAAAT 960 GCAGAAGGGC CTGTGGGAGC AGTGCCAGCT TCTGAAGAGC ACCTCGGTGT TTGCCCGCTG 1020 CCACCCTCTG GTGGACCCCG AGCCTTTTGT GGCCCTGTGT GAGAAGACTT TGTGTGAGTG 1080 TGCTGGGGGG CTGGAGTGCG CCTGCCCTGC CCTCCTGGAG TACGCCCGGA CCTGTGCCCA 1140 GGAGGGAATG GTGCTGTACG GCTGGACCGA CCACAGCGCG TGCAGCCCAG TGTGCCCTGC 1200 TGGTATGGAG TATAGGCAGT GTGTGTCCCC TTGCGCCAGG ACCTGCCAGA GCCTGCACAT 1260 CAATGAAATG TGTCAGGAGC GATGCGTGGA TGGCTGCAGC TGCCCTGAGG GACAGCTCCT 1320 GGATGAAGGC CTCTGCGTGG AGAGCACCGA GTGTCCCTGC GTGCATTCCG GAAAGCGCTA 1380 CCCTCCCGGC ACCTCCCTCT CTCGAGACTG CAACACCTGG ATTTGCCGAA ACAGCCAGTG 1440 GATCTGCAGC AATGAAGAAT GTCCAGGGGA GTGCCTTGTC ACTGGTCAAT CCCACTTCAA 1500 GAGCTTTGAC AACAGATACT TCACCTTCAG TGGGATCTGC CAGTACCTGC TGGCCCGGGA 1560 TTGCCAGGAC CACTCCTTCT CCATTGTCAT TGAGACTGTC CAGTGTGCTG ATGACCGCGA 1620 CGCTGTGTGC ACCCGCTCCG TCACCGTCCG GCTGCCTGGC CTGCACAACA GCCTTGTGAA 1680 ACTGAAGCAT GGGGCAGGAG TTGCCATGGA TGGCCAGGAC ATCCAGCTCC CCCTCCTGAA 1740 AGGTGACCTC CGCATCCAGC ATACAGTGAC GGCCTCCGTG CGCCTCAGCT ACGGGGAGGA 1800 CCTGCAGATG GACTGGGATG GCCGCGGGAG GCTGCTGGTG AAGCTGTCCC CCGTCTACGC 1860 CGGGAAGACC TGCGGCCTGT GTGGGAATTA CAATGGCAAC CAGGGCGACG ACTTCCTTAC ig20 CCCCTCTGGG CTGGCAGAGC CCCGGGTGGA GGACTTCGGG AACGCCTGGA AGCTGCACGG ιgβo GGACTGCCAG GACCTGCAGA AGCAGCACAG CGATCCCTGC GCCCTCAACC CGCGCATGAC 2040 CAGGTTCTCC GAGGAGGCGT GCGCGGTCCT GACGTCCCCC ACATTCGAGG CCTGCCATCG 2100 TGCCGTCAGC CCGCTGCCCT ACCTGCGGAA CTGCCGCTAC GACGTGTGCT CCTGCTCGGA 2160 CGGCCGCGAG TGCCTGTGCG GCGCCCTGGC CAGCTATGCC GCGGCCTGCG CGGGGAGAGG 2220 CGTGCGCGTC GCGTGGCGCG AGCCAGGCCG CTGTGAGCTG AACTGCCCGA AAGGCCAGGT 2280 GTACCTGCAG TGCGGGACCC CCTGCAACCT GACCTGCCGC TCTCTCTCTT ACCCGGATGA 2340 GGAATGCAAT GAGGCCTGCC TGGAGGGCTG CTTCTGCCCC CCAGGGCTCT ACATGGATGA 2400 GAGGGGGGAC TGCGTGCCCA AGGCCCAGTG CCCCTGTTAC TATGACGGTG AGATCTTCCA 2460 GCCAGAAGAC ATCTTCTCAG ACCATCACAC CATGTGCTAC TGTGAGGATG GCTTCATGCA 2520 CTGTACCATG AGTGGAGTCC CCGGAAGCTT GCTGCCTGAC GCTGTCCTCA GCAGTCCCCT 2580 GTCTCATCGC AGCAAAAGGA GCCTATCCTG TCGGCCCCCC ATGGTCAAGC TGGTGTGTCC 2640 CGCTGACAAC CTGCGGGCTG AAGGGCTCGA GTGTACCAAA ACGTGCCAGA ACTATGACCT 2700 GGAGTGCATG AGCATGGGCT GTGTCTCTGG CTGCCTCTGC CCCCCGGGCA TGGTCCGGCA 2760 GGAGTGCATG AGCATGGGCT GTGTCTCTGG CTGCCTCTGC CCCCCGGGCA TGGTCCGGCA 2760 TGAGAACAGA TGTGTGGCCC TGGAAAGGTG TCCCTGCTTC CATCAGGGCA AGGAGTATGC 2820 CCCTGGAGAA ACAGTGAAGA TTGGCTGCAA CACTTGTGTC TGTCGGGACC GGAAGTGGAA 2880 CTGCACAGAC CATGTGTGTG ATGCCACGTG CTCCACGATC GGCATGGCCC ACTACCTCAC 2 40 CTTCGACGGG CTCAAATACC TGTTCCCCGG GGAGTGCCAG TACGTTCTGG TGCAGGATTA 3000 CTGCGGCAGT AACCCTGGGA CCTTTCGGAT CCTAGTGGGG AATAAGGGAT GCAGCCACCC 3060 CTCAGTGAAA TGCAAGAAAC GGGTCACCAT CGTGGTGGAG GGAGGAGAGA TTGAGCTGTT 3120 TGACGGGGAG GTGAATGTGA AGAGGCCCAT GAAGGATGAG ACTCACTTTG AGGTGGTGGA 3180 GTCTGGCCGG TACATCATTC TGCTGCTGGG CAAAGCCCTC TCCGTGGTCT GGGACCGCCA 3240 CCTGAGCATC TCCGTGGTCC TGAAGCAGAC ATACCAGGAG AAAGTGTGTG GCCTGTGTGG 3300 GAATTTTGAT GGCATCCAGA ACAATGACCT CACCAGCAGC AACCTCCAAG TGGAGGAAGA 3360 CCCTGTGGAC TTTGGGAACT CCTGGAAAGT GAGCTCGCAG TGTGCTGACA CCAGAAAAGT 3420 GCCTCTGGAC TCATCCCCTG CCACCTGCCA TAACAACATC ATGAAGCAGA CGATGGTGGA 3480 TTCCTCCTGT AGAATCCTTA CCAGTGACGT CTTCCAGGAC TGCAACAAGC TGGTGGACCC 3540 CGAGCCATAT CTGGATGTCT GCATTTACGA CACCTGCTCC TGTGAGTCCA TTGGGGACTG 3600 CGCCTGCTTC TGCGACACCA TTGCTGCCTA TGCCCACGTG TGTGCCCAGC ATGGCAAGGT 3660 GGTGACCTGG AGGACGGCCA CATTGTGCCC CCAGAGCTGC GAGGAGAGGA ATCTCCGGGA 3720 GAACGGGTAT GAGTGTGAGT GGCGCTATAA CAGCTGTGCA CCTGCCTGTC AAGTCACGTG 3780 TCAGCACCCT GAGCCACTGG CCTGCCCTGT GCAGTGTGTG GAGGGCTGCC ATGCCCACTG 3840 CCCTCCAGGG AAAATCCTGG ATGAGCTTTT GCAGACCTGC GTTGACCCTG AAGACTGTCC 3goo AGTGTGTGAG GTGGCTGGCC GGCGTTTTGC CTCAGGAAAG AAAGTCACCT TGAATGCCAG 3g60 TGACCCTGAG CACTGCCAGA TTTGCCACTG TGATGTTGTC AACCTCACCT GTGAAGCCTG 4020 CCAGGAGCCG GGAGGCCTGG TGGTGCCTCC CACAGATGCC CCGGTGAGCC CCACCACTCT 4080 GTATGTGGAG GACATCTCGG AACCGCCGTT GCACGATTTC TACTGCAGCA GGCTACTGGA 4140 CCTGGTCTTC CTGCTGGATG GCTCCTCCAG GCTGTCCGAG GCTGAGTTTG AAGTGCTGAA 4200 GGCCTTTGTG GTGGACATGA TGGAGCGGCT GCGCATCTCC CAGAAGTGGG TCCGCGTGGC 4260 CGTGGTGGAG TACCACGACG GCTCCCACGC CTACATCGGG CTCAAGGACC GGAAGCGACC 4320 GTCAGAGCTG CGGCGCATTG CCAGCCAGGT GAAGTATGCG GGCAGCCAGG TGGCCTCCAC 4380 CAGCGAGGTC TTGAAATACA CACTGTTCCA AATCTTCAGC AAGATCGACC GCCCTGAAGC 4440 CTCCCGCATC GCCCTGCTCC TGATGGCCAG CCAGGAGCCC CAACGGATGT CCCGGAACTT 4500 TGTCCGCTAC GTCCAGGGCC TGAAGAAGAA GAAGGTCATT GTGATCCCGG TGGGCATTGG 4560 GCCCCATGCC AACCTCAAGC AGATCCGCCT CATCGAGAAG CAGGCCCCTG AGAACAAGGC 4620 CTTCGTGCTG AGCAGTGTGG ATGAGCTGGA GCAGCAAAGG GACGAGATCG TTAGCTACCT 4680 CTGTGACCTT GCCCCTGAAG CCCCTCCTCC TACTCTGCCC CCCCACATGG CACAAGTCAC 4740 TGTGGGCCCG GGGCTCTTGG GGGTTTCGAC CCTGGGGCCC AAGAGGAACT CCATGGTTCT 4800 GGATGTGGCG TTCGTCCTGG AAGGATCGGA CAAAATTGGT GAAGCCGACT TCAACAGGAG 4860 CAAGGAGTTC ATGGAGGAGG TGATTCAGCG GATGGATGTG GGCCAGGACA GCATCCACGT 4g20 CACGGTGCTG CAGTACTCCT ACATGGTGAC CGTGGAGTAC CCCTTCAGCG AGGCACAGTC 4g80 CAAAGGGGAC ATCCTGCAGC GGGTGCGAGA GATCCGCTAC CAGGGCGGCA ACAGGACCAA 5040 CACTGGGCTG GCCCTGCGGT ACCTCTCTGA CCACAGCTTC TTGGTCAGCC AGGGTGACCG 5100 GGAGCAGGCG CCCAACCTGG TCTACATGGT CACCGGAAAT CCTGCCTCTG ATGAGATCAA 5160 GAGGCTGCCT GGAGACATCC AGGTGGTGCC CATTGGAGTG GGCCCTAATG CCAACGTGCA 5220 GGAGCTGGAG AGGATTGGCT GGCCCAATGC CCCTATCCTC ATCCAGGACT TTGAGACGCT 5280 CCCCCGAGAG GCTCCTGACC TGGTGCTGCA GAGGTGCTGC TCCGGAGAGG GGCTGCAGAT 5340 CCCCACCCTC TCCCCTGCAC CTGACTGCAG CCAGCCCCTG GACGTGATCC TTCTCCTGGA 5400 TGGCTCCTCC AGTTTCCCAG CTTCTTATTT TGATGAAATG AAGAGTTTCG CCAAGGCTTT 5460 CATTTCAAAA GCCAATATAG GGCCTCGTCT CACTCAGGTG TCAGTGCTGC AGTATGGAAG 5520 CATCACCACC ATTGACGTGC CATGGAACGT GGTCCCGGAG AAAGCCCATT TGCTGAGCCT 5580 TGTGGACGTC ATGCAGCGGG AGGGAGGCCC CAGCCAAATC GGGGATGCCT TGGGCTTTGC 5640 TGTGCGATAC TTGACTTCAG AAATGCATGG TGCCAGGCCG GGAGCCTCAA AGGCGGTGGT 5700 CATCCTGGTC ACGGACGTCT CTGTGGATTC AGTGGATGCA GCAGCTGATG CCGCCAGGTC 5760 CAACAGAGTG ACAGTGTTCC CTATTGGAAT TGGAGATCGC TACGATGCAG CCCAGCTACG 5820 GATCTTGGCA GGCCCAGCAG GCGACTCCAA CGTGGTGAAG CTCCAGCGAA TCGAAGACCT 5880 CCCTACCATG GTCACCTTGG GCAATTCCTT CCTCCACAAA CTGTGCTCTG GATTTGTTAG 5940 GATTTGCATG GATGAGGATG GGAATGAGAA GAGGCCCGGG GACGTCTGGA CCTTGCCAGA 6000 CCAGTGCCAC ACCGTGACTT GCCAGCCAGA TGGCCAGACC TTGCTGAAGA GTCATCGGGT 6060

CAACTGTGAC CGGGGGCTGA GGCCTTCGTG CCCTAACAGC CAGTCCCCTG TTAAAGTGGA 6120

AGAGACCTGT GGCTGCCGCT GGACCTGCCC CTGCGTGTGC ACAGGCAGCT CCACTCGGCA 6180

CATCGTGACC TTTGATGGGC AGAATTTCAA GCTGACTGGC AGCTGTTCTT ATGTCCTATT 6240 TCAAAACAAG GAGCAGGACC TGGAGGTGAT TCTCCATAAT GGTGCCTGCA GCCCTGGAGC 6300

AAGGCAGGGC TGCATGAAAT CCATCGAGGT GAAGCACAGT GCCCTCTCCG TCGAGCTGCA 6360

CAGTGACATG GAGGTGACGG TGAATGGGAG ACTGGTCTCT GTTCCTTACG TGGGTGGGAA 6420

CATGGAAGTC AACGTTTATG GTGCCATCAT GCATGAGGTC AGATTCAATC ACCTTGGTCA 6480

CATCTTCACA TTCACTCCAC AAAACAATGA GTTCCAACTG CAGCTCAGCC CCAAGACTTT 6540 TGCTTCAAAG ACGTATGGTC TGTGTGGGAT CTGTGATGAG AACGGAGCCA ATGACTTCAT 6600

GCTGAGGGAT GGCACAGTCA CCACAGACTG GAAAACACTT GTTCAGGAAT GGACTGTGCA 6660

GCGGCCAGGG CAGACGTGCC AGCCCATCCT GGAGGAGCAG TGTCTTGTCC CCGACAGCTC 6720

CCACTGCCAG GTCCTCCTCT TACCACTGTT TGCTGAATGC CACAAGGTCC TGGCTCCAGC 6780

CACATTCTAT GCCATCTGCC AGCAGGACAG TTGCCACCAG GAGCAAGTGT GTGAGGTGAT 6840 CGCCTCTTAT GCCCACCTCT GTCGGACCAA CGGGGTCTGC GTTGACTGGA GGACACCTGA 6g00

TTTCTGTGCT ATGTCATGCC CACCATCTCT GGTCTACAAC CACTGTGAGC ATGGCTGTCC 6960

CCGGCACTGT GATGGCAACG TGAGCTCCTG TGGGGACCAT CCCTCCGAAG GCTGTTTCTG 7020

CCCTCCAGAT AAAGTCATGT TGGAAGGCAG CTGTGTCCCT GAAGAGGCCT GCACTCAGTG 7080

CATTGGTGAG GATGGAGTCC AGCACCAGTT CCTGGAAGCC TGGGTCCCGG ACCACCAGCC 7140 CTGTCAGATC TGCACATGCC TCAGCGGGCG GAAGGTCAAC TGCACAACGC AGCCCTGCCC 7200

CACGGCCAAA GCTCCCACGT GTGGCCTGTG TGAAGTAGCC CGCCTCCGCC AGAATGCAGA 7260

CCAGTGCTGC CCCGAGTATG AGTGTGTGTG TGACCCAGTG AGCTGTGACC TGCCCCCAGT 7320

GCCTCACTGT GAACGTGGCC TCCAGCCCAC ACTGACCAAC CCTGGCGAGT GCAGACCCAA 7380

CTTCACCTGC GCCTGCAGGA AGGAGGAGTG CAAAAGAGTG TCCCCACCCT CCTGCCCCCC 7440 GCACCGTTTG CCCACCCTTC GGAAGACCCA GTGCTGTGAT GAGTATGAGT GTGCCTGCAA 7500

CTGTGTCAAC TCCACAGTGA GCTGTCCCCT TGGGTACTTG GCCTCAACCG CCACCAATGA 7560

CTGTGGCTGT ACCACAACCA CCTGCCTTCC CGACAAGGTG TGTGTCCACC GAAGCACCAT 7620

CTACCCTGTG GGCCAGTTCT GGGAGGAGGG CTGCGATGTG TGCACCTGCA CCGACATGGA 7680

GGATGCCGTG ATGGGCCTCC GCGTGGCCCA GTGCTCCCAG AAGCCCTGTG AGGACAGCTG 7740 TCGGTCGGGC TTCACTTACG TTCTGCATGA AGGCGAGTGC TGTGGAAGGT GCCTGCCATC 7800

TGCCTGTGAG GTGGTGACTG GCTCACCGCG GGGGGACTCC CAGTCTTCCT GGAAGAGTGT 7860

CGGCTCCCAG TGGGCCTCCC CGGAGAACCC CTGCCTCATC AATGAGTGTG TCCGAGTGAA 7920

GGAGGAGGTC TTTATACAAC AAAGGAACGT CTCCTGCCCC CAGCTGGAGG TCCCTGTCTG 7980

CCCCTCGGGC TTTCAGCTGA GCTGTAAGAC CTCAGCGTGC TGCCCAAGCT GTCGCTGTGA 8040 GCGCATGGAG GCCTGCATGC TCAATGGCAC TGTCATTGGG CCCGGGAAGA CTGTGATGAT 8100

CGATGTGTGC ACGACCTGCC GCTGCATGGT GCAGGTGGGG GTCATCTCTG GATTCAAGCT 8160

GGAGTGCAGG AAGACCACCT GCAACCCCTG CCCCCTGGGT TACAAGGAAG AAAATAACAC 8220

AGGTGAATGT TGTGGGAGAT GTTTGCCTAC GGCTTGCACC ATTCAGCTAA GAGGAGGACA 8280

GATCATGACA CTGAAGCGTG ATGAGACGCT CCAGGATGGC TGTGATACTC ACTTCTGCAA 8340 GGTCAATGAG AGAGGAGAGT ACTTCTGGGA GAAGAGGGTC ACAGGCTGCC CACCCTTTGA 8400

TGAACACAAG TGTCTGGCTG AGGGAGGTAA AATTATGAAA ATTCCAGGCA CCTGCTGTGA 8460

CACATGTGAG GAGCCTGAGT GCAACGACAT CACTGCCAGG CTGCAGTATG TCAAGGTGGG 8520

AAGCTGTAAG TCTGAAGTAG AGGTGGATAT CCACTACTGC CAGGGCAAAT GTGCCAGCAA 8580

AGCCATGTAC TCCATTGACA TCAACGATGT GCAGGACCAG TGCTCCTGCT GCTCTCCGAC 8640 ACGGACGGAG CCCATGCAGG TGGCCCTGCA CTGCACCAAT GGCTCTGTTG TGTACCATGA 8700

GGTTCTCAAT GCCATGGAGT GCAAATGCTC CCCCAGGAAG TGCAGCAAGT GAGGCTGCTG 8760

CAGCTGCATG GGTGCCTGCT GCTGCCTGCC TTGGCCTGAT GGCCAGGCCA GAGTGCTGCC 8820

AGTCCTCTGC ATGTTCTGCT CTTGTGCCCT TCTGAGCCCA CAATAAAGGC TGAGCTCTTA 8880 TCTTGCTGCA TGTTCTGCTC TTGTGCCCTT CTGAGCCCAC AAT

Seq ID No : 149 Protein sequence : Protein Accession # : NP 000543 . 1

1 11 21 31 41 51

I I I I I I

MIPARFAGVL LALALILPGT LCAEGTRGRS STARCSLFGS DFVNTFDGSM YSFAGYCSYL 60

LAGGCQKRSF SIIGDFQNGK RVSLSVYLGE FFDIHLFVNG TVTQGDQRVS MPYASKGLYL 120

ETEAGYYKLS GEAYGFVARI DGSGNFQVLL SDRYFNKTCG LCGNFNIFAE DDFMTQEGTL 180 TSDPYDFANS WALSSGEQWC ERASPPSSSC NISSGEMQKG LWEQCQLLKS TSVFARCHPL 240

VDPEPFVALC EKTLCECAGG LECACPALLE YARTCAQEGM VLYGWTDHSA CSPVCPAGME 300

YRQCVSPCAR TCQSLHINEM CQERCVDGCS CPEGQLLDEG LCVESTECPC VHSGKRYPPG 360

TSLSRDCNTC ICRNSQWICS NEECPGECLV TGQSHFKSFD NRYFTFSGIC QYLLARDCQD 420

HSFSIVIETV QCADDRDAVC TRSVTVRLPG LHNSLVKLKH GAGVAMDGQD IQLPLLKGDL 480 RIQHTVTASV RLSYGEDLQM DWDGRGRLLV KLSPVYAGKT CGLCGNYNGN QGDDFLTPSG 540

LAEPRVEDFG NAWKLHGDCQ DLQKQHSDPC ALNPRMTRFS EEACAVLTSP TFEACHRAVS 600

PLPYLRNCRY DVCSCSDGRE CLCGALASYA AACAGRGVRV AWREPGRCEL NCPKGQVYLQ 660

CGTPCNLTCR SLSYPDEECN EACLEGCFCP PGLYMDERGD CVPKAQCPCY YDGEIFQPED 720

IFSDHHTMCY CEDGFMHCTM SGVPGSLLPD AVLSSPLSHR SKRSLSCRPP MVKLVCPADN 780 LRAEGLECTK TCQNYDLECM SMGCVSGCLC PPGMVRHENR CVALERCPCF HQGKEYAPGE 840

TVKIGCNTCV CRDRKWNCTD HVCDATCSTI GMAHYLTFDG LKYLFPGECQ YVLVQDYCGS 900

NPGTFRILVG NKGCSHPSVK CKKRVTILVE GGEIELFDGE VNVKRPMKDE THFEWESGR 960

YIILLLGKAL SWWDRHLSI SWLKQTYQE KVCGLCGNFD GIQNNDLTSS NLQVEEDPVD 1020

FGNSWKVSSQ CADTRKVPLD SSPATCHNNI MKQTMVDSSC RILTSDVFQD CNKLVDPEPY 1080 LDVCIYDTCS CESIGDCACF CDTIAAYAHV CAQHGKWTW RTATLCPQSC EERNLRENGY 1140

ECEWRYNSCA PACQVTCQHP EPLACPVQCV EGCHAHCPPG KILDELLQTC VDPEDCPVCE 1200 VAGRRFASGK KVTLNPSDPE HCQICHCDW NLTCEACQEP GGLWPPTDA PVSPTTLYVE 1260 DISEPPLHDF YCSRLLDLVF LLDGSSRLSE AEFEVLKAFV VDMMERLRIS QKWVRVAWE 1320 YHDGSHAYIG LKDRKRPSEL RRIASQVKYA GSQVASTSEV LKYTLFQIFS KIDRPEASRI 1380 ALLLMASQEP QRMSRNFVRY VQGLKKKKVI VIPVGIGPHA NLKQIRLIEK QAPENKAFVL 1440 SSVDELEQQR DEIVSYLCDL APEAPPPTLP PHMAQVTVGP GLLGVSTLGP KRNSMVLDVA 1500 FVLEGSDKIG EADFNRSKEF MEEVIQRMDV GQDSIHVTVL QYSYMVTVEY PFSEAQSKGD 1560 ILQRVREIRY QGGNRTNTGL ALRYLSDHSF LVSQGDREQA PNLVYMVTGN PASDEIKRLP 1620 GDIQWPIGV GPNANVQELE RIGWPNAPIL IQDFETLPRE APDLVLQRCC SGEGLQIPTL 1680 SPAPDCSQPL DVILLLDGSS SFPASYFDEM KSFAKAFISK ANIGPRLTQV SVLQYGSITT 1740 IDVPWNWPE KAHLLSLVDV MQREGGPSQI GDALGFAVRY LTSEMHGARP GASKAWILV 1800 TDVSVDSVDA AADAARSNRV TVFPIGIGDR YDAAQLRILA GPAGDSNWK LQRIEDLPTM 1860 VTLGNSFLHK LCSGFVRICM DEDGNEKRPG DVWTLPDQCH TVTCQPDGQT LLKSHRVNCD ig20 RGLRPSCPNS QSPVKVEETC GCRWTCPCVC TGSSTRHIVT FDGQNFKLTG SCSYVLFQNK lgso EQDLEVILHN GACSPGARQG CMKSIEVKHS ALSVELHSDM EVTVNGRLVS VPYVGGNMEV 2040 NVYGAIMHEV RFNHLGHIFT FTPQNNEFQL QLSPKTFASK TYGLCGICDE NGANDFMLRD 2100 GTVTTDWKTL VQEWTVQRPG QTCQPILEEQ CLVPDSSHCQ VLLLPLFAEC HKVLAPATFY 2160 AICQQDSCHQ EQVCEVIASY AHLCRTNGVC VDWRTPDFCA MSCPPSLVYN HCEHGCPRHC 2220 DGNVSSCGDH PSEGCFCPPD KVMLEGSCVP EEACTQCIGE DGVQHQFLEA WVPDHQPCQI 2280 CTCLSGRKVN CTTQPCPTAK APTCGLCEVA RLRQNADQCC PEYECVCDPV SCDLPPVPHC 2340 ERGLQPTLTN PGECRPNFTC ACRKEECKRV SPPSCPPHRL PTLRKTQCCD EYECACNCVN 2400 STVSCPLGYL ASTATNDCGC TTTTCLPDKV CVHRSTIYPV GQFWEEGCDV CTCTDMEDAV 2460 MGLRVAQCSQ KPCEDSCRSG FTYVLHEGEC CGRCLPSACE WTGSPRGDS QSSWKSVGSQ 2520 WASPENPCLI NECVRVKEEV FIQQRNVSCP QLEVPVCPSG FQLSCKTSAC CPSCRCERME 2580 ACMLNGTVIG PGKTVMIDVC TTCRCMVQVG VISGFKLECR KTTCNPCPLG YKEENNTGEC 2640 CGRCLPTACT IQLRGGQIMT LKRDETLQDG CDTHFCKVNE RGEYFWEKRV TGCPPFDEHK 2700 CLAEGGKIMK IPGTCCDTCE EPECNDITAR LQYVKVGSCK SEVEVDIHYC QGKCASKAMY 2760 SIDINDVQDQ CSCCSPTRTE PMQVALHCTN GSWYHEVLN AMECKCSPRK CSK

Seq ID NO : 150 DNA sequence

Nucleic Acid Accession # : NM_001508 .1

Coding sequence : 1-1362 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

ATGGCTTCAC CCAGCCTCCC GGGCAGTGAC TGCTCCCAAA TCATTGATCA CAGTCATGTC 60 CCCGAGTTTG AGGTGGCCAC CTGGATCAAA ATCACCCTTA TTCTGGTGTA CCTGATCATC 120 TTCGTGATGG GCCTTCTGGG GAACAGCGTC ACCATTCGGG TCACCCAGGT GCTGCAGAAG 180 AAAGGATACT TGCAGAAGGA GGTGACAGAC CACATGGTGA GTTTGGCTTG CTCGGACATC 240 TTGGTGTTCC TCATCGGCAT GCCCATGGAG TTCTACAGCA TCATCTGGAA TCCCCTGACC 300 ACGTCCAGCT ACACCCTGTC CTGCAAGCTG CACACTTTCC TCTTCGAGGC CTGCAGCTAC 360 GCTACGCTGC TGCACGTGCT GACGCTCAGC TTTGAGCGCT ACATCGCCAT CTGTCACCCC 20 TTCAGGTACA AGGCTGTGTC GGGACCTTGC CAGGTGAAGC TGCTGATTGG CTTCGTCTGG 480 GTCACCTCCG CCCTGGTGGC ACTGCCCTTG CTGTTTGCCA TGGGTACTGA GTACCCCCTG 540 GTGAACGTGC CCAGCCACCG GGGTCTCACT TGCAACCGCT CCAGCACCCG CCACCACGAG 600 CAGCCCGAGA CCTCCAATAT GTCCATCTGT ACCAACCTCT CCAGCCGCTG GACCGTGTTC 660 CAGTCCAGCA TCTTCGGCGC CTTCGTGGTC TACCTCGTGG TCCTGCTCTC CGTAGCCTTC 720 ATGTGCTGGA ACATGATGCA GGTGCTCATG AAAAGCCAGA AGGGCTCGCT GGCCGGGGGC 780 ACGCGGCCTC CGCAGCTGAG GAAGTCCGAG AGCGAAGAGA GCAGGACCGC CAGGAGGCAG 840 ACCATCATCT TCCTGAGGCT GATTGTTGTG ACATTGGCCG TATGCTGGAT GCCCAACCAG goo ATTCGGAGGA TCATGGCTGC GGCCAAACCC AAGCACGACT GGACGAGGTC CTACTTCCGG gεo GCGTACATGA TCCTCCTCCC CTTCTCGGAG ACGTTTTTCT ACCTCAGCTC GGTCATCAAC 1020 CCGCTCCTGT ACACGGTGTC CTCGCAGCAG TTTCGGCGGG TGTTCGTGCA GGTGCTGTGC 1080 TGCCGCCTGT CGCTGCAGCA CGCCAACCAC GAGAAGCGCC TGCGCGTACA TGCGCACTCC 1140 ACCACCGACA GCGCCCGCTT TGTGCAGCGC CCGTTGCTCT TCGCGTCCCG GCGCCAGTCC 1200 TCTGCAAGGA GAACTGAGAA GATTTTCTTA AGCACTTTTC AGAGCGAGGC CGAGCCCCAG 1260 TCTAAGTCCC AGTCATTGAG TCTCGAGTCA CTAGAGCCCA ACTCAGGCGC GAAACCAGCC 1320 AATTCTGCTG CAGAGAATGG TTTTCAGGAG CATGAAGTTT GA

Seq ID No: 151 Protein sequence: Protein Accession #: NP 0014gg.l

11 21 31 41 51

MASPSLPGSD CSQIIDHSHV PEFEVATWIK ITLILVYLII FVMGLLGNSV TIRVTQVLQK 60 KGYLQKEVTD HMVSLACSDI LVFLIGMPME FYSIIWNPLT TSSYTLSCKL HTFLFEACSY 120 ATLLHVLTLS FERYIAICHP FRYKAVSGPC QVKLLIGFVW VTSALVALPL LFAMGTEYPL 180 VNVPSHRGLT CNRSSTRHHE QPETSNMSIC TNLSSRWTVF QSSIFGAFW YLWLLSVAF 240 MCWNMMQVLM KSQKGSLAGG TRPPQLRKSE SEESRTARRQ TIIFLRLIW TLAVCWMPNQ 300 IRRIMAAAKP KHDWTRSYFR AYMILLPFSE TFFYLSSVIN PLLYTVSSQQ FRRVFVQVLC 360 CRLSLQHANH EKRLRVHAHS TTDSARFVQR PLLFASRRQS SARRTEKIFL STFQSEAEPQ 420 SKSQSLSLES LEPNSGAKPA NSAAENGFQE HEV

Seq ID NO: 152 DNA sequence Nucleic Acid Accession # : none found

Coding sequence : 3-65 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

TTATTATTTT GTGTAAACTA TATTCTGCTT ATAGAGAGTC TCTGAGACTA AAATTGACAA 60 CTTGAAAAGT ATTCCAAGGA ATATTATGAA AATAGGGCAA CATGGACTGT TTAAGATCTC 120 CATGTAATTG AAATTCATGC AAGGAAACAA CTCATAGAAA AGATAAATAT GGATGCCCTT 180 CACATGTTAT CAACCTCGTA ACTTTTGGTG CTTGCTGAAT CAGTCCATGA AAAGCTACAG 240 CCCGCTCTTT GGGAATGCTA CATACCCATT TCTGGTATTT AAAAAATATC TAGGAGGAGC 300 TAAATGACAA AACACAGCAG TGTTTTGAGG GAGAAAGGAC CATCATTTAT AATGCTCTGT 360 ACATACTACC AGAGCTGCTT GGAAAATTAA AGGCCACTTG TGGCTTTTTC CTACCAACTG 420 ATACGTTTAA ATTTGCCCTA GGATTSAGCT AACAGCAAAA AAAAAAAAAA AAAAAAAARA 480 GAGAGAAAGA AAGGAGKAAA CAGTGGTAAT AAAAAAATCC ATCTGTCTTC TTGCTATGTT 540 AATATTAATA AATCATAATA TGACAAGACC CTCACTGAAT AAGAGTATTT TCAGTCATCA 600 GAAGCCAGCT GTTGGTAGGC ATTAATGAGT TTAAAATTGT TCTCAATTGA AAAAACATCA 660 CACTATTTTG CCAAAACCAA AGTAATTATA ATACTGTGTC CTCCTGTAAT TTTTTGAGAA 720 GTGGTTATAA AGGGCATATT TACATAAATT CTACTTTATT CCTCAACTTC TTTGATGAAT 780 GTAACCCAAT TTTACTTCTT TAAAAAGTCT CAATTCAAGC TGGATTAGCC AGCTCAGCAT 840 AATCAACTAG ACAGTGGTTT GTTAAATTTA GCAGCATACT TCGTTCCCAT TCTAATTAAA 900 GTCATGAGTT CTTGAATCCC AGAGAAATAA TGCTTAGGAA CTTCTCTCAA TCTGGTTGGC 960 TTGGCCTAGA GAAGTGGCCA TTTTATCAAC AGGRAAAAAA AAAATTTTCT CTACTACAAC 1020 CCCGTTGCCT TCTGAAAAAC AGCAAGTTAT TTCTTTATAT AATTATCATT TTATTATTTT 1080 ATGGAAAATT AATTTATTAA TTAATAGCCT ATTATGTGTT CTCACTTGCT TCTCTAAGTA 1140 ATATTTTGAG ATAAAATGTT GAATAAAACC ATGGATTATA GAGAAAAGTC AAAATATATG 1200 TGTAATATTT AATTATTTTA TAAGTTTTAT AATAAAGTAT TCCATTTCTT TATCTT

Seq ID No: 153 Protein sequence: Protein Accession # : none found

1 11 21 31 41 51

I I I

IILCKLYSAY RESLRLKLTT

Seq ID NO : 154 DNA sequence

Nucleic Acid Accession # : none found

Coding sequence : 1-36 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

I I I I

CTGGATGATA TGGAAGAAAT GGATGGGTTA AGGTAAAAGG CTGATCACAG ATGGGTTCCT 60 CTCAAGGTTA AAATAGTTTA AGTGCCAGAA GAAAAGGTGG GCACCAGCGA ATTAAGAACC 120 ATCTTTGAAT GGTCCCCTTG GTTAAATACT TAACTTTTGT CATCAGTGTC TGCATTTATG 180 AAATGAAGAG GAATTCACTA ATATGCTACG TGATCTTTTG TTTGTCATGA AAAGAGTTAC 240 TGTTGTGTAG TTCTCTGTTC CAGGGCTGCC TTTGCTCCAC AAAGCACTGA GAAGCAGTGG 300 CCCTGTACAA CCATACTGCC TCTCAACACT GTGTAATAGG CTAACACCGC CCAGCGAACC 360 TTCCTGGGAG ATATAAAATA CATAGGTTTA GGCTGGCAAA AAAAAAAAAA AAA

Seq ID No : 155 Protein sequence : Protein Accession # : none found

1 11 21 31 41 51

I I

LDDMEEMDGL R

Seq ID NO : 156 DNA sequence

Nucleic Acid Accession # : NM_032961.1

Coding sequence : 827-3949 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

I ] AGGACTGGAA 1 I

CAGGCTCAGA G 1GCTGAAGCA GGAGGAAGGA GGAAAAAGAG ACAGGTTAGA 60 GGGAAAGAGG CTTGGGAAGA AAACAGCAGA AAAGAAACTG CTCATTACAC TTACAGAGAG 120 GCAAGTAACG GTGGAGATGA GGACAGAGGG AACCAAGACT CTGAAAGACA AAAAATACAA 180 ATAGAGCGAA AGAGGAAAAA AATGTCAAGA AGAACATCCA TCCGGAGAAA TGAAGAGAAT 240 GAAAGTTTTA AACTGCAGAG CCGTTCTGTG CTTTTCCGGC ACAAAATTAT ATCGCTGATT 300 TTAAGCCCTT TTGCATTTGC CAGCCGTTGA CATTAAGAGG CATGTTTAAC GGTGCCAACA 360 GCATCTCCTT TTCCTTCTCC TCTTCCTCTT CTTCTTCTTC CTCCTCCTCC TCCTCTTTTT 420 CCTCCTCCTC GTTCTCCTCC CATCAGCAAG AAGACAAACC GAGGACAGTC TTGAAATATC 480 GAAATTTCCT CTTTGGGATT TGCCAGCGCC AAGACTGTCG GAATAAAGGA CGCTGACTAT 540 TGTATTATTG TTATTTTATT AATTAGTCAG TGGAAAGATT ACAGATGAGG AAAGGGGACG 600 CCTGTCACCC TTCCTGTGCT AAGATTTAAA AAAAAATGAG GCTGGATTGC GGGAAGCTCT 660 AAAATGAAGC AAAAGGAGTA AGATTTTTAA AGACAGAAAG CCACAGGAGC CCCCACGTAG 720 CGCACTTTTA TTTGTATTTT TTCAGATTTT TTTTTGTTTC GTGGTGGTGG GGGAGGTGAT 780 TGGGTGGCTG ACTGGCTGCG GGAAGCTACT TCCTTTCCTT TTGGAGATGA TTGTGCTATT 840 ATTGTTTGCC TTGCTCTGGA TGGTGGAAGG AGTCTTTTCC CAGCTTCACT ACACGGTACA 900 GGAGGAGCAG GAACATGGCA CTTTCGTGGG GAATATCGCT GAAGATCTGG GTCTGGACAT 960 TACAAAACTT TCGGCTCGCG GGTTTCAGAC GGTGCCCAAC TCAAGGACCC CTTACTTAGA 1020 CCTCAACCTG GAGACAGGGG TGCTGTACGT GAACGAGAAA ATAGACCGCG AACAAATCTG 1080 CAAACAGAGC CCCTCCTGTG TCCTGCACCT GGAGGTCTTT CTGGAGAACC CCCTGGAGCT 1140 GTTCCAGGTG GAGATCGAGG TGCTGGACAT TAATGACAAC CCCCCCTCTT TCCCGGAGCC 1200 AGACCTGACG GTGGAAATCT CTGAGAGCGC CACGCCAGGC ACTCGCTTCC CCTTGGAGAG 1260 CGCATTCGAC CCAGACGTGG GCACCAACTC CTTGCGCGAC TACGAGATCA CCCCCAACAG 1320 CTACTTCTCC CTGGACGTGC AGACCCAGGG GGATGGCAAC CGATTCGCTG AGCTGGTGCT 1380 GGAGAAGCCA CTGGACCGAG AGCAGCAAGC GGTGCACCGC TACGTGCTGA CCGCGGTGGA 1440 CGGAGGAGGT GGGGGAGGAG TAGGAGAAGG AGGGGGAGGT GGCGGGGGAG CAGGCCTGCC 1500 CCCCCAGCAG CAGCGCACCG GCACGGCCCT ACTCACCATC CGAGTGCTGG ACTCCAATGA 1560 CAATGTGCCC GCTTTCGACC AACCCGTCTA CACTGTGTCC CTACCAGAGA ACTCTCCCCC 1620 AGGCACTCTC GTGATCCAGC TCAACGCCAC CGACCCGGAC GAGGGCCAGA ACGGTGAGGT 1680 CGTGTACTCC TTCAGCAGCC ACATTTCGCC CCGGGCGCGG GAGCTTTTCG GACTCTCGCC 1740 ^' GCGCACTGGC AGACTGGAGG TAAGCGGCGA GTTGGACTAT GAAGAGAGCC CAGTGTACCA 1800 AGTGTACGTG CAAGCCAAGG ACCTGGGCCC CAACGCCGTG CCTGCGCACT GCAAGGTGCT 1860 AGTGCGAGTA CTGGATGCTA ATGACAACGC GCCAGAGATC AGCTTCAGCA CCGTGAAGGA 1920 AGCGGTGAGT GAGGGCGCGG CGCCCGGCAC TGTGGTGGCC CTTTTCAGCG TGACTGACCG 1980 CGACTCAGAG GAGAATGGGC AGGTGCAGTG CGAGCTACTG GGAGACGTGC CTTTCCGCCT 2040 CAAGTCTTCC TTTAAGAATT ACTACACCAT CGTTACCGAA GCCCCCCTGG ACCGAGAGGC 2100 GGGGGACTCC TACACCCTGA CTGTAGTGGC TCGGGACCGG GGCGAGCCTG CGCTCTCCAC 2160 CAGTAAGTCG ATCCAGGTAC AAGTGTCGGA TGTGAACGAC AACGCGCCGC GTTTCAGCCA 2220 GCCGGTCTAC GACGTGTATG TGACTGAAAA CAACGTGCCT GGCGCCTACA TCTACGCGGT 2280 GAGCGCCACC GACCGGGATG AGGGCGCCAA CGCCCAGCTT GCCTACTCTA TCCTCGAGTG 2340 CCAGATCCAG GGCATGAGCG TCTTCACCTA CGTTTCTATC AACTCTGAGA ACGGCTACTT 2400 GTACGCCCTG CGCTCCTTCG ACTATGAGCA GCTGAAGGAC TTCAGTTTTC AGGTGGAAGC 2460 CCGGGACGCT GGCAGCCCCC AGGCGCTGGC TGGTAACGCC ACTGTCAACA TCCTCATAGT 2520 GGATCAAAAT GACAACGCCC CTGCCATCGT GGCGCCTCTA CCAGGGCGCA ACGGGACTCC 2580 AGCGCGTGAG GTGCTGCCCC GCTCGGCGGA GCCGGGTTAC CTGCTCACCC GCGTGGCCGC 2640 CGTGGACGCG GACGACGGCG AGAACGCCCG GCTCACTTAC AGCATCGTGC GTGGCAACGA 2700 AATGAACCTC TTTCGCATGG ACTGGCGCAC CGGGGAGCTG CGCACAGCAC GCCGAGTCCC 2760 GGCCAAGCGC GACCCCCAGC GGCCTTATGA GCTGGTGATC GAGGTGCGCG ACCATGGGCA 2820 GCCGCCCCTT TCCTCCACCG CCACCCTGGT GGTTCAGCTG GTGGATGGCG CCGTGGAGCC 2880 CCAGGGCGGG GGCGGGAGCG GAGGCGGAGG GTCAGGAGAG CACCAGCGCC CCAGTCGCTC 2940 TGGCGGCGGG GAAACCTCGC TAGACCTCAC CCTCATCCTC ATCATCGCGT TGGGCTCGGT 3000 GTCCTTCATC TTCCTGCTGG CCATGATCGT GCTGGCCGTG CGTTGCCAAA AAGAGAAGAA 3060 GCTCAACATC TATACTTGTC TGGCCAGCGA TTGCTGCCTC TGCTGCTGCT GCTGCGGTGG 3120 CGGAGGTTCG ACCTGCTGTG GCCGCCAAGC CCGGGCGCGC AAGAAGAAAC TCAGCAAGTC 3180 AGACATCATG CTGGTGCAGA GCTCCAATGT ACCCAGTAAC CCGGCCCAGG TGCCGATAGA 3240 GGAGTCCGGG GGCTTTGGCT CCCACCACCA CAACCAGAAT TACTGCTATC AGGTATGCCT 3300 GACCCCTGAG TCCGCCAAGA CCGACCTGAT GTTTCTTAAG CCCTGCAGCC CTTCGCGGAG 3360 TACGGACACT GAGCACAACC CCTGCGGGGC CATCGTCACC GGTTACACCG ACCAGCAGCC 3420 TGATATCATC TCCAACGGAA GCATTTTGTC CAACGAGACT AAACACCAGC GAGCAGAGCT 3480 CAGCTATCTA GTTGACAGAC CTCGCCGAGT TAACAGTTCT GCATTCCAGG AAGCCGACAT 3540 AGTAAGCTCT AAGGACAGTG GTCATGGAGA CAGTGAACAG GGAGATAGTG ATCATGATGC 3600 CACCAACCGT GCCCAGTCAG CTGGTATGGA TCTCTTCTCC AATTGCACTG AGGAATGTAA 3660 AGCTCTGGGC CACTCAGATC GGTGCTGGAT GCCTTCTTTT GTCCCTTCTG ATGGACGGGA 3720 GGCTGCTGAT TATCGCAGCA ATCTGCATGT TCCTGGCATG GACTCTGTTC CAGACACTGA 3780 GGTGTTTGAA ACTCCAGAAG CCCAGCCTGG GGCAGAGCGG TCCTTTTCCA CCTTTGGCAA 3840 AGAGAAGGCC CTTCACAGCA CTCTGGAGAG GAAGGAGCTG GATGGACTGC TGACTAATAC 3900 GCGAGCGCCT TACAAACCAC CATATTTGAC ACGGAAAAGG ATATGCTAGT CAATTCTACA 3960 GGACTTACCT GAAGCAGCAT GATTTGCACA AAGTCGACCA ACAAAAGCAT CAACTTTTCA 4020 ACTTCATTAT CTTGGCCATC CAGTTAGTCA TGTGTAACTG AGTATTAGAT TTCGGATGGA 4080 GTCATCATGG CCAATTATAG GACCTAATTG CTCTCAGCAG GCCTGAGAAA TGAGTTGAAA 4140 TGTGCAGAAC TGTAGAAACT TTAGAGGCAA CAGATTTTGC CTCCCCGATC AGTGTGTGCC 4200 TGTTTACAGC ACTATCTATC TTTCTCTCTC CAAATGTCAC TGAGCCCTTT AGATGTTTAT 4260 ATTCACCACG AGAAGCCAGT CATAAAGATA AAGGAAATTT GTGCATTATA AATGCAATAT 4320 CACTGTTTTA AACTTGACTG TTTTATATTA TTTTTGTGTG ATCAAGTGTT CCGCAAGCTA 4380 TTCCAACTTT ACAAGAGAAA TTGTGATTAT GTTCTTTTCA CCTGTGGGTT ATAAAAAATG 4440 TTGTATTCTG AAGACCCACA AAATATCAAA GACATTCTGT AGTTTATACA CCGTGTTGCA 4500 AAGTGTTTAC TGTACTATTT CAAAGCTTCT AAATAAATAT AAAATATATA TATTATATTA 4560 TATAATTTTC CTAAAATGTG GTACAACTCA GTTGGTTTTT AAATGGATGC ATACAGTCCA 4620 CATCATACAA TAAAATAAAA GGTAATTCAG GGTCCCAAAG ACAAACTTAC TAAGAAAAAA 4680 TCATTAATAG TTTTCTCCCA ATTTCCATAT CTTACTCAAC CGTGTTTTTC CTTGTTTAAA 4740 AGAAAATGAT GCTCTAAGCT ACAAAATTTT GTCAAAAACT CATATTGAAT TTTCAATGCC 4800 AAAGATGTAG CTATTGATGT TATCAGACAG AGCACTGACT ATGTACTATC AAACTATCTA 4860 ACAATCTGCA TAAGTCTGAT TCTATTTCTA TGACTTTGAA TTTAGAATCA CTTAAAGCTT 4920 TTATAAAGAA TCGATAAATT CACCTGTATT TGTTGTTAGA AAAAAACTGG GTGTCTGTAC 4980 ATTTTGTGGT GTAAAATATG TAATTGAAGA TTACTATTTT AAGAAGTCAT CAGTCATATC 5040 ACTCACACAG AATTTTATTT TACATAGTTT TGTGACTTAA TTACACATGA ATATAAAATC 5100 TATAATTCTA TATGAATATA TAGAGATATA GAAACATCTG AACTGGTAAA GAATAACTAT 5160 AAAATATGAA AGCTCTAAAT TTAAAATAAA TTTAGAGATA GAATCATGGT ACATTATTGT 5220 TTCAGTATTC CATGTAAAAA TTTTATAGCT TAAATGTAGT CAGTGTTTGA TTAATGAAAA 5280 AATTCTTCAT GAGTCAGCCT TCAAAAGTTA AGCTTGCCTT TTACTTTTAT GTCAACAATA 5340 TTAATTATTA AATTTAGTAA GACGCAAAAA AAAAAAAAAA AAAA

Seq ID No : 157 Protein sequence : Protein Accession # : NP_116586 .1

11 21 31 41 51

I I I I I

MIVLLLFALL WMVEGVFSQL HYTVQEEQEH GTFVGNIAED LGLDITKLSA RGFQTVPNSR 60 TPYLDLNLET GVLYVNEKID REQICKQSPS CVLHLEVFLE NPLELFQVEI EVLDINDNPP 120 SFPEPDLTVE ISESATPGTR FPLESAFDPD VGTNSLRDYE ITPNSYFSLD VQTQGDGNRF 180 AELVLEKPLD REQQAVHRYV LTAVDGGGGG GVGEGGGGGG GAGLPPQQQR TGTALLTIRV 240 LDSNDNVPAF DQPVYTVSLP ENSPPGTLVI QLNATDPDEG QNGEWYSFS SHISPRAREL 300 FGLSPRTGRL EVSGELDYEE SPVYQVYVQA KDLGPNAVPA HCKVLVRVLD ANDNAPEISF 360 STVKEAVSEG AAPGTWALF SVTDRDSEEN GQVQCELLGD VPFRLKSSFK NYYTIVTEAP 420 LDREAGDSYT LTWARDRGE PALSTSKSIQ VQVSDVNDNA PRFSQPVYDV YVTENNVPGA 480 YIYAVSATDR DEGANAQLAY SILECQIQGM SVFTYVSINS ENGYLYALRS FDYEQLKDFS 540 FQVEARDAGS PQALAGNATV NILIVDQNDN APAIVAPLPG RNGTPAREVL PRSAEPGYLL 600 TRVAAVDADD GENARLTYSI VRGNEMNLFR MDWRTGELRT ARRVPAKRDP QRPYELVIEV 660 RDHGQPPLSS TATLWQLVD GAVEPQGGGG SGGGGSGEHQ RPSRSGGGET SLDLTLILII 720 ALGSVSFIFL LAMIVLAVRC QKEKKLNIYT CLASDCCLCC CCCGGGGSTC CGRQARARKK 780 KLSKSDIMLV QSSNVPSNPA QVPIEESGGF GSHHHNQNYC YQVCLTPESA KTDLMFLKPC 840 SPSRSTDTEH NPCGAIVTGY TDQQPDIISN GSILSNETKH QRAELSYLVD RPRRVNSSAF 900 QEADIVSSKD SGHGDSEQGD SDHDATNRAQ SAGMDLFSNC TEECKALGHS DRCWMPSFVP 960 SDGRQAADYR SNLHVPGMDS VPDTEVFETP EAQPGAERSF STFGKEKALH STLERKELDG 1020 LLTNTRAPYK PPYLTRKRIC

Seq ID NO: 158 DNA sequence Nucleic Acid Accession #: NM_022159.1

Coding sequence: 70-18g0 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

I I I I I

GTGAAATTTA AACTCCAGTC CTGTGGCGAA AATGCTAATT GCACTAACAC AGAAGGAAGT 60 TATTATTGTA TGTGTGTACC TGGCTTCAGA TCCAGCAGTA ACCAAGACAG GTTTATCACT ^' 120 AATGATGGAA CCGTCTGTAT AGAAAATGTG AATGCAAACT GCCATTTAGA TAATGTCTGT 180 ATAGCTGCAA ATATTAATAA AACTTTAACA AAAATCAGAT CCATAAAAGA ACCTGTGGCT 240 TTGCTACAAG AAGTCTATAG AAATTCTGTG ACAGATCTTT CACCAACAGA TATAATTACA 300 TATATAGAAA TATTAGCTGA ATCATCTTCA TTACTAGGTT ACAAGAACAA CACTATCTCA 360 GCCAAGGACA CCCTTTCTAA CTCAACTCTT ACTGAATTTG TAAAAACCGT GAATAATTTT 420 GTTCAAAGGG ATACATTTGT AGTTTGGGAC AAGTTATCTG TGAATCATAG GAGAACACAT 480 CTTACAAAAC TCATGCACAC TGTTGAACAA GCTACTTTAA GGATATCCCA GAGCTTCCAA 540 AAGACCACAG AGTTTGATAC AAATTCAACG GATATAGCTC TCAAAGTTTT CTTTTTTGAT 600 TCATATAACA TGAAACATAT TCATCCTCAT ATGAATATGG ATGGAGACTA CATAAATATA 660 TTTCCAAAGA GAAAAGCTGC ATATGATTCA AATGGCAATG TTGCAGTTGC ATTTTTATAT 720 TATAAGAGTA TTGGTCCTTT GCTTTCATCA TCTGACAACT TCTTATTGAA ACCTCAAAAT 780 TATGATAATT CTGAAGAGGA GGAAAGAGTC ATATCTTCAG TAATTTCAGT CTCAATGAGC 840 TCAAACCCAC CCACATTATA TGAACTTGAA AAAATAACAT TTACATTAAG TCATCGAAAG 900 GTCACAGATA GGTATAGGAG TCTATGTGCA TTTTGGAATT ACTCACCTGA TACCATGAAT 960 GGCAGCTGGT CTTCAGAGGG CTGTGAGCTG ACATACTCAA ATGAGACCCA CACCTCATGC 1020 CGCTGTAATC ACCTGACACA TTTTGCAATT TTGATGTCCT CTGGTCCTTC CATTGGTATT 1080 AAAGATTATA ATATTCTTAC AAGGATCACT CAACTAGGAA TAATTATTTC ACTGATTTGT 1140 CTTGCCATAT GCATTTTTAC CTTCTGGTTC TTCAGTGAAA TTCAAAGCAC CAGGACAACA 1200 ATTCACAAAA ATCTTTGCTG TAGCCTATTT CTTGCTGAAC TTGTTTTTCT TGTTGGGATC 1260 AATACAAATA CTAATAAGCT CTTCTGTTCA ATCATTGCCG GACTGCTACA CTACTTCTTT 1320 TTAGCTGCTT TTGCATGGAT GTGCATTGAA GGCATACATC TCTATCTCAT TGTTGTGGGT 1380 GTCATCTACA ACAAGGGATT TTTGCACAAG AATTTTTATA TCTTTGGCTA TCTAAGCCCA 1440 GCCGTGGTAG TTGGATTTTC GGCAGCACTA GGATACAGAT ATTATGGCAC AACCAAAGTA 1500 TGTTGGCTTA GCACCGAAAA CAACTTTATT TGGAGTTTTA TAGGACCAGC ATGCCTAATC 1560 ATTCTTGTTA ATCTCTTGGC TTTTGGAGTC ATCATATACA AAGTTTTTCG TCACACTGCA 1620 GGGTTGAAAC CAGAAGTTAG TTGCTTTGAG AACATAAGGT CTTGTGCAAG AGGAGCCCTC 1680 GCTCTTCTGT TCCTTCTCGG CACCACCTGG ATCTTTGGGG TTCTCCATGT TGTGCACGCA 1740 TCAGTGGTTA CAGCTTACCT CTTCACAGTC AGCAATGCTT TCCAGGGGAT GTTCATTTTT 1800 TTATTCCTGT GTGTTTTATC TAGAAAGATT CAAGAAGAAT ATTACAGATT GTTGAAAAAT 1860 GTCCCCTGTT GTTTTGGATG TTTAAGGTAA ACATAGAGAA TGGTGGATAA TTACAACTGC i 20 ACAAAAATAA AAATTCCAAG CTGTGGATGA CCAATGTATA AAAATGACTC ATCAAATTAT 1980 CCAATTATTA ACTACTAGAC AAAAAGTATT TTAAATCAGT TTTTCTGTTT ATGCTATAGG 2040 AACTGTAGAT AATAAGGTAA AATTATGTAT CATATAGATA TACTATGTTT TTCTATGTGA 2100 AATAGTTCTG TCAAAAATAG TATTGCAGAT ATTTGGAAAG TAATTGGTTT CTCAGGAGTG 2160 ATATCACTGC ACCCAAGGAA AGATTTTCTT TCTAACACGA GAAGTATATG AATGTCCTGA 2220 AGGAAACCAC TGGCTTGATA TTTCTGTGAC TCGTGTTGCC TTTGAAACTA GTCCCCTACC 2280 ACCTCGGTAA TGAGCTCCAT TACAGAAAGT GGAACATAAG AGAATGAAGG GGCAGAATAT 2340 CAAACAGTGA AAAGGGAATG ATAAGATGTA TTTTGAATGA ACTGTTTTTT CTGTAGACTA 2400 GCTGAGAAAT TGTTGACATA AAATAAAGAA TTGAAGAAAC ACATTTTACC ATTTTGTGAA 2460 TTGTTCTGAA CTTAAATGTC CACTAAAACA ACTTAGACTT CTGTTTGCTA AATCTGTTTC 2520 TTTTTCTAAT ATTCTAAAA

Seq ID NO: 15g Protein sequence: Protein Accession #: NP 071442.1

11 21 31 41 51

MCVPGFRSSS NQDRFITNDG TVCIENVNAN CHLDNVCIAA NINKTLTKIR SIKEPVALLQ 60

EVYRNSVTDL SPTDIITYIE ILAESSSLLG YKNNTISAKD TLSNSTLTEF VKTVNNFVQR 120

DTFWWDKLS VNHRRTHLTK LMHTVEQATL RISQSFQKTT EFDTNSTDIA LKVFFFDSYN 180

MKHIHPHMNM DGDYINIFPK RKAAYDSNGN VAVAFLYYKS IGPLLSSSDN FLLKPQNYDN 240

SEEEERVISS VISVSMSSNP PTLYELEKIT FTLSHRKVTD RYRSLCAFWN YSPDTMNGSW 300

SSEGCELTYS NETHTSCRCN HLTHFAILMS SGPSIGIKDY NILTRITQLG IIISLICLAI 360

CIFTFWFFSE IQSTRTTIHK NLCCSLFLAE LVFLVGINTN TNKLFCSIIA GLLHYFFLAA 420

FAWMCIEGIH LYLIWGVIY NKGFLHKNFY IFGYLSPAW VGFSAALGYR YYGTTKVCWL 480

STENNFIWSF IGPACLIILV NLLAFGVIIY KVFRHTAGLK PEVSCFENIR SCARGALALL 540

FLLGTTWIFG VLHWHASW TAYLFTVSNA FQGMFIFLFL CVLSRKIQEE YYRLFKNVPC 600

CFGCLR

Seq ID NO: 160 DNA sequence

Nucleic Acid Accession # : none found

Coding sequence: 1-216 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

I I I I I

TGTCTGCTTA TGCGGTGGCT CGCTGCTCAG AACAGGATGG CAGAGATGAG CACCACCATC 60 AAAAACTCAA GGACCAGTGC TGTGGGTCCA GTCATCTGTT TCATGGAATT CACCAGTCTG 120 GTATCTTCAA AATCCAGAAG GATGATGGCA GATGGCAGGA AGGAGGAAGA GGGTAATCTG 180 GAAGAGTTTC CTGACCTACT CTGCTGCTGT GATTAAACAA CCACCAGGAA ATTTTGATGA 240 CACTGTTCTC CTGAGCTCCT CCCTTTCCTC GGGGAAGAAA AGCATTGAAA CTACAAAAAT 300 AAAGTGTTAT TTGGCTGGAG TGAGGTCTCA TGTCTGCTTA TGCGGTGGCT CGCTGCTCAG 360 AACAGGGAAC CATTGGAGAT ACTCATTACT CTTTGAAGGC TTACAGTGGA ATGAATTCAA 420 ATACGACTTA TTTGAGGAAT TGAAGTTGAC TTTATGGAGC TGATAAGAAT CTTCTTGGAG 480 AAAAAAAGAC TGGTACTTCT GAATTAACCA AAATCACAGT ATTCTGAAGA TGATTCTACA 540 AAGCCTGCTG TTTCTACAAA GGCTGCTGAT GATTTCTACA AAGCCTGCTG TAGTGTTGCT 600 GTGGCCTCTG CTTAAAAAAG TAGAAAACAC ATTGATGCAG CATGTTCACC CCAACCTCCC 660 TGCCTAAAGG CTCAGGGACC ATCTTGGAAG AGGAAGGCGC GTGAGATTGT AAGAGCCGAA 720 TTAGGGGGAT GGAGTGTGGA GAATAAGGAC ACTTCATCTT GGATGCTCAC CTGCCAAATT 780 GACTTCTGAT GAAAGCCAGC TCCAGAAATG TGCCTACAGT TACTACTTTC ACCTAAACCC 840 TGCCCTTAGT CAAATCCTTC TCTTCTTCTA AGCAATCAAC TTCAATTCCT TGTATAACCC goo ACAGTATAAA AGGGCTTTTA TACCATTCTA TCCTATTGCA TGTAAGCCTT GGGTCTGGGA gεo GGTAACAGTG TGGGATTCCA CCATCTCATC TCCCTGCCAC CCAAACATGC CTGCTCTTCT 1020 TTAAGCAATA TTAAATGTTT GTACTTCA

Seq ID No : 161 Protein sequence : Protein Accession # : none found

11 21 31 41 51

CLLMRWLAAQ NRMAEMSTTI KNSRTSAVGP VICFMEFTSL VSSKSRRMMA DGRKEEEGNL 60 EEFPDLLCCC D

Seq ID NO: 162 DNA sequence

Nucleic Acid Accession #: none found

Coding sequence: l-15 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

I I I I I

GAGACCCTCC AGAGGCAGGG CCCAGGATTG AAGAGGGAAG CCCTGCTCCA CACGTGTTCA 60 TCAGGAAGGA CCCACAGACT GCTGCTCCTG GAGGCCTCTC GGTTTATGGA TGTGTGTTTG 120 TTCCATAAAC CCTCAGAGGG TCACCTGGAG ACCCGCTAAA ATGCAGGTTC TTGGGCCACA 180 TCCTAGACCT TCTGACCGAC CCAGGGAGTG GGGCCCAGGA AGCTGCATTT GACAGATATC 240 CCCGTGTGAT CATCATGCAC ACAGGAGTGA GAGAACCAGT GTTCTCCCCG GGCAGAAGGG 300 AAGCTCGTGT GCAGGACACC TCACACCTCC TTTCCCATTC CCCTGCCAGG CTCTCCCTGC 360 TGACATTGTT TTTGCGGGAG AGCTGTGAAT TCTGAAGATT AGGTTGCTTC TCACCCCAAG 420 CTCCAGAAGT CCAGGCTGAG CCAAACCAAG CTTCAAGTTG TGCCTGGACT TGGAGAACCA 480

GGAGGTGAGG GGACTGACTA CTTGAAGATC ACATGGAGGA GGAGTCTGAT CCAGGCCCAG 540

GCACCAAGGA AAGGCCATGC AAGGACACAG GGAGAAGGGC AGCTGTCTGT AAGCCAGAAA 600

GAGCCTTCAC TAGAAACCAA ATCAGCCAGA ACCTTCATCT TGGACTTTCC AGCCTTCAGA 660 GATGTGAAAA AATAAATTTC TGTTGATTAA CCTAAAAAA

Seq ID No: 163 Protein sequence: Protein Accession #: none found

1 11 21 31 41 51

I I I I I I

ETLQRQGPGL KREALLHTCS SGRTHRLLLL EASRFMDVCL FHKPSEGHLE TR

Seq ID NO : 164 DNA sequence

Nucleic Acid Accession # : NM_020241 . 1

Coding sequence : 4 -1557 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

GCCATGCAGA CCCCGCGAGC GTCCCCTCCC CGCCCGGCCC TCCTGCTTCT GCTGCTGCTA 60 CTGGGGGGCG CCCACGGCCT CTTTCCTGAG GAGCCGCCGC CGCTTAGCGT GGCCCCCAGG 120 GACTACCTGA ACCACTATCC CGTGTTTGTG GGCAGCGGGC CCGGACGCCT GACCCCCGCA 180 GAAGGTGCTG ACGACCTCAA CATCCAGCGA GTCCTGCGGG TCAACAGGAC GCTGTTCATT 240 GGGGACAGGG ACAACCTCTA CCGCGTAGAG TTGGAGCCCC CCACGTCCAC GGAGCTGCGG 300 TACCAGAGGA AGCTGACCTG GAGATCTAAC CCCAGCGACA TAAACGTGTG TCGGATGAAG 360 GGCAAACAGG AGGGCGAGTG TCGAAACTTC GTAAAGGTGC TGCTCCTTCG GGACGAGTCC 420 ACGCTCTTTG TGTGCGGTTC CAACGCCTTC AACCCGGTGT GCGCCAACTA CAGCATAGAC 480 ACCCTGCAGC CCGTCGGAGA CAACATCAGC GGTATGGCCC GCTGCCCGTA CGACCCCAAG 540 CACGCCAATG TTGCCCTCTT CTCTGACGGG ATGCTCTTCA CAGCTACTGT TACCGACTTC 600 CTAGCCATTG ATGCTGTCAT CTACCGCAGC CTCGGGGACA GGCCCACCCT GCGCACCGTG 660 AAACATGACT CCAAGTGGTT CAAAGAGCCT TACTTTGTCC ATGCGGTGGA GTGGGGCAGC 720 CATGTCTACT TCTTCTTCCG GGAGATTGCG ATGGAGTTTA ACTACCTGGA GAAGGTGGTG 780 GTGTCCCGCG TGGCCCGAGT GTGCAAGAAC GACGTGGGAG GCTCCCCCCG CGTGCTGGAG 840 AAGCAGTGGA CGTCCTTCCT GAAGGCGCGG CTCAACTGCT CTGTACCCGG AGACTCCCAT 900 TTCTACTTCA ACGTGCTGCA GGCTGTCACG GGCGTGGTCA GCCTCGGGGG CCGGCCCGTG 960 GTCCTGGCCG TTTTTTCCAC GCCCAGCAAC AGCATCCCTG GCTCGGCTGT CTGCGCCTTT 1020 GACCTGACAC AGGTGGCAGC TGTGTTTGAA GGCCGCTTCC GAGAGCAGAA GTCCCCCGAG 1080 TCCATCTGGA CGCCGGTGCC GGAGGATCAG GTGCCTCGAC CCCGGCCCGG GTGCTGCGCA 1140 GCCCCCGGGA TGCAGTACAA TGCCTCCAGC GCCTTGCCGG ATGACATCCT CAACTTTGTC 1200 AAGACCCACC CTCTGATGGA CGAAGCGGTG CCCTCGCTGG GCCATGCGCC CTGGATCCTG 1260 CGGACCCTGA TGAGGCACCA GCTGACTCGA GTGGCTGTGG ACGTGGGAGC CGGCCCCTGG 1320 GGCAACCAGA CCGTTGTCTT CCTGGGTTCT GAGGCGGGGA CGGTCCTCAA GTTCCTCGTC 1380 CGGCCCAATG CCAGCACCTC AGGGACGTCT GGGCGTGTGT GTCAAGTGGG CCACGCGTGC 1440 AGGGTGTGTG TCCACGAGCG ACGATCGTGG TGGCCCCAGC GGCCTGGGCG TTGGCTGAGC 1500 CGACGCTGGG GCTTCCAGAA GGCCCGGGGG CCTCCGAGGT GCCGGTTAGG AGTTTGAACC 1560 CCCCCCACTC TGCAGAGGGA AGCGGGGACA ATGCCGGGGT TTCAGGCAGG AGACACGAGG 1620 AGGGCCTGCC CGGAAGTCAC ATCGGCAGCA GCTGTCTAAA GGGCTTGGGG GCCTGGGGGG 1680 CGGCGAAGGT GGGTGGGGCC CCTCTGTAAA TACGGCCCCA GGGTGGTGAG AGAGTCCCAT 1740 GCCACCCGTC CCCTTGTGAC CTCCCCCCTC TGACCTCCAG CTGAGCATGC ATGCCACGTG 1800 G

Seq ID No: 165 Protein sequence: Protein Accession #: NP 064626.1

11 21 31 41 51

MQTPRASPPR PALLLLLLLL GGAHGLFPEE PPPLSVAPRD YLNHYPVFVG SGPGRLTPAE 60 GADDLNIQRV LRVNRTLFIG DRDNLYRVEL EPPTSTELRY QRKLTWRSNP SDINVCRMKG 120 KQEGECRNFV KVLLLRDEST LFVCGSNAFN PVCANYSIDT LQPVGDNISG MARCPYDPKH 180 ANVALFSDGM LFTATVTDFL AIDAVIYRSL GDRPTLRTVK HDSKWFKEPY FVHAVEWGSH 240 VYFFFREIAM EFNYLEKVW SRVARVCKND VGGSPRVLEK QWTSFLKARL NCSVPGDSHF 300 YFNVLQAVTG WSLGGRPW LAVFSTPSNS IPGSAVCAFD LTQVAAVFEG RFREQKSPES 360 IWTPVPEDQV PRPRPGCCAA PGMQYNASSA LPDDILNFVK THPLMDEAVP SLGHAPWILR 420 TLMRHQLTRV AVDVGAGPWG NQTWFLGSE AGTVLKFLVR PNASTSGTSG RVCQVGHACR 480 VCVHERRSWW PQRPGRWLSR RWGFQKARGP PRCRLGV

Seq ID NO: 166 DNA sequence

Nucleic Acid Accession #: NM_032108.1

Coding sequence.- 39-2705 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

TCCGAGGCGT CACCTCCTCC TGTCGCCTGG CCCTCGCC T_GCAGACCCCG CGAGCGTCCC 60 CTCCCCGCCC GGCCCTGCTG CTTCTGCTGC TGCTACTGGG GGGCGCCCAC GGCCTCTTTC 120 CTGAGGACCC GCCGCCGCTT AGCGTGGCCC CCAGGGACTA CCTGAACCAC TATCCCGTGT 180

TTGTGGGCAG CGGGCCCGGA CGCCTGACCC CCGCAGAAGG TGCTGACGAC CTCAACATCC 240

AGCGAGTCCT GCGGGTCAAC AGGACGCTGT TCATTGGGGA CAGGGACAAC CTCTACCGCG 300

TAGAGCTGGA GCCCCCCACG TCCACGGAGC TGCGGTACCA GAGGAAGCTG ACCTGGAGAT 360 CTAACCCCAG CGACATAAAC GTGTGTCGGA TGAAGGGCAA ACAGGAGGGC GAGTGTCGAA 420

ACTTCGTAAA GGTGCTGCTC CTTCGGGACG AGTCCACGCT CTTTGTGTGC GGTTCCAACG 480

CCTTCAACCC GGTGTGCGCC AACTACAGCA TAGACACCCT GCAGCCCGTC GGAGACAACA 540

TCAGCGGTAT GGCCCGCTGC CCGTACGACC CCAAGCACGC CAATGTTGCC CTCTTCTCTG 600

ACGGGATGCT CTTCACAGCT ACTGTTACCG ACTTCCTAGC CATTGATGCT GTCATCTACC 660 GCAGCCTCGG GGACAGGCCC ACCCTGCGCA CCGTGAAACA TGACTCCAAG TGGTTCAAAG 720 '

AGCCTTACTT TGTCCATGCG GTGGAGTGGG GCAGCCATGT CTACTTCTTC TTCCGGGAGA 780

TTGCGATGGA GTTTAACTAC CTGGAGAAGG TGGTGGTGTC CCGCGTGGCC CGAGTGTGCA 8 0

AGAACGACGT GGGAGGCTCC CCCCGCGTGC TGGAGAAGCA GTGGACGTCC TTCCTGAAGG 900

CGCGGCTCAA CTGCTCTGTA CCCGGAGACT CCCATTTCTA CTTCAACGTG CTGCAGGCTG 960 TCACGGGCGT GGTCAGCCTC GGGGGCCGGC CCGTGGTCCT GGCCGTTTTT TCCACGCCCA 1020

GCAACAGCAT CCCTGGCTCG GCTGTCTGCG CCTTTGACCT GACACAGGTG GCAGCTGTGT 1080

TTGAAGGCCG CTTCCGAGAG CAGAAGTCCC CCGAGTCCAT CTGGACGCCG GTGCCGGAGG 1140

ATCAGGTGCC TCGACCCCGG CCCGGGTGCT GCGCAGCCCC CGGGATGCAG TACAATGCCT 1200

CCAGCGCCTT GCCGGATGAC ATCCTCAACT TTGTCAAGAC CCACCCTCTG ATGGACGAGG 1260 CGGTGCCCTC GCTGGGCCAT GCGCCCTGGA TCCTGCGGAC CCTGATGAGG CACCAGCTGA 1320

CTCGAGTGGC TGTGGACGTG GGAGCCGGCC CCTGGGGCAA CCAGACCGTT GTCTTCCTGG 1380

GTTCTGAGGC GGGGACGGTC CTCAAGTTCC TCGTCCGGCC CAATGCCAGC ACCTCAGGGA 1440

CGTCTGGGCT CAGTGTCTTC CTGGAGGAGT TTGAGACCTA CCGGCCGGAC AGGTGTGGAC 1500

GGCCCGGCGG TGGCGAGACA GGGCAGCGGC TGCTGAGCTT GGAGCTGGAC GCAGCTTCGG 1560 GGGGCCTGCT GGCTGCCTTC CCCCGCTGCG TGGTCCGAGT GCCTGTGGCT CGCTGCCAGC 1620

AGTACTCGGG GTGTATGAAG AACTGTATCG GCAGTCAGGA CCCCTACTGC GGGTGGGCCC 1680

CCGACGGCTC CTGCATCTTC CTCAGCCCGG GCACCAGAGC CGCCTTTGAG CAGGACGTGT 1740

CCGGGGCCAG CACCTCAGGC TTAGGGGACT GCACAGGACT CCTGCGGGCC AGCCTCTCCG 1800

AGGACCGCGC GGGGCTGGTG TCGGTGAACC TGCTGGTAAC GTCGTCGGTG GCGGCCTTCG 1860 TGGTGGGAGC CGTGGTGTCC GGCTTCAGCG TGGGCTGGTT CGTGGGCCTC CGTGAGCGGC ig20

GGGAGCTGGC CCGGCGCAAG GACAAGGAGG CCATCCTGGC GCACGGGGCG GGCGAGGCGG 1980

TGCTGAGCGT CAGCCGCCTG GGCGAGCGCA GGGCGCAGGG TCCCGGGGGC CGGGGCGGAG 2040

GCGGTGGCGG TGGCGCCGGG GTTCCCCCGG AGGCCCTGCT GGCGCCCCTG ATGCAGAACG 2100

GCTGGGCCAA GGCCACGCTG CTGCAGGGCG GGCCCCACGA CCTGGACTCG GGGCTGCTGC 2160 CCACGCCCGA GCAGACGCCG CTGCCGCAGA AGCGCCTGCC CACTCCGCAC CCGCACCCCC 2220

ACGCCCTGGG CCCCCGCGCC TGGGACCACG GCCACCCCCT GCTCCCGGCC TCCGCTTCAT 2280

CCTCCCTCCT GCTGCTGGCG CCCGCCCGGG CCCCCGAGCA GCCCCCCGCG CCTGGGGAGC 2340

CGACCCCCGA CGGCCGCCTC TATGCTGCCC GGCCCGGCCG CGCCTCCCAC GGCGACTTCC 2400

CGCTCACCCC CCACGCCAGC CCGGACCGCC GGCGGGTGGT GTCCGCGCCC ACGGGCCCCT 2460 TGGACCCAGC CTCAGCCGCC GATGGCCTCC CGCGGCCCTG GAGGCCGCCG CCGACGGGCA 2520

GCCTGAGGAG GCCACTGGGC CCCCACGCCC CTCCGGCCGC CACCCTGCGC CGCACCCACA 2580

CGTTCAACAG CGGCGAGGCC CGGCCTGGGG ACCGCCACCG CGGCTGCCAC GCCCGGCCGG 2640

GCACAGACTT GGCCCACCTC CTCCCCTATG GGGGGGCGGA CAGGACTGCG CCCCCCGTGC 2700

CCTAGGCCGG GGGCCCCCCG ATGCCTTGGC AGTGCCAGCC ACGGGAACCA GGAGCGAGAG 2760 ACGGTGCCAG AACGCCGGGG CCCGGGGCAA CTCCGAGTGG GTGCTCAAGT CCCCCCCGCG 2820

ACCCACCCGC GGAGTGGGGG GCCCCCTCCG CCACAAGGAA GCACAACCAG CTCGCCCTCC 2880

CCCTACCCGG GGCCGCAGGA CGCTGAGACG GTTTGGGGGT GGGTGGGCGG GAGGACTTTG 2940

CTATGGATTT GAGGTTGACC TTATGCGCGT AGGTTTTGGT TTTTTTTGCA GTTTTGGTTT 3000

CTTTTGCGGT TTTCTAACCA ATTGCACAAC TCCGTTCTCG GGGTGGCGGC AGGCAGGGGA 3060 GGCTTGGACG CCGGTGGGGA ATGGGGGGCC ACAGCTGCAG ACCTAAGCCC TCCCCCACCC 3120

CTGGAAAGGT CCCTCCCCAA CCCAGGCCCC TGGCGTGTGT GGGTGTGCGT GCGTGTGCGT 3180

GCCGTGTTCG TGTGCAAGGG GCCGGGGAGG TGGGCGTGTG TGTGCGTGCC AGCGAAGGCT 3240

GCTGTGGGCG TGTGTGTCAA GTGGGCCACG CGTGCAGGGT GTGTGTCCAC GAGCGACGAT 3300

CGTGGTGGCC CCAGCGGCCT GGGCGTTGGC TGAGCCGACG CTGGGGCTTC CAGAAGGCCC 3360 GGGGGTCTCC GAGGTGCCGG TTAGGAGTTT GAACCCCCCC CACTCTGCAG AGGGAAGCGG 3420

GGACAATGCC GGGGTTTCAG GCAGGAGACA CGAGGAGGGC CTGCCCGGAA GTCACATCGG 3480 CAGCAGCTGT CTAAAGGGCT TGGGGGCCTG GGGGGCGGCG AAAG

Seq ID No : 167 Protein sequence :

Protein Accession # : NP_115484 . 1

1 11 21 31 41 51 I I I I I I MQTPRASPPR PALLLLLLLL GGAHGLFPED PPPLSVAPRD YLNHYPVFVG SGPGRLTPAE 60

GADDLNIQRV LRVNRTLFIG DRDNLYRVEL EPPTSTELRY QRKLTWRSNP SDINVCRMKG 120

KQEGECRNFV KVLLLRDEST LFVCGSNAFN PVCANYSIDT LQPVGDNISG MARCPYDPKH 180

ANVALFSDGM LFTATVTDFL AIDAVIYRSL GDRPTLRTVK HDSKWFKEPY FVHAVEWGSH 240

VYFFFREIAM EFNYLEKVW SRVARVCKND VGGSPRVLEK QWTSFLKARL NCSVPGDSHF 300 YFNVLQAVTG WSLGGRPW LAVFSTPSNS IPGSAVCAFD LTQVAAVFEG RFREQKSPES 360

IWTPVPEDQV PRPRPGCCAA PGMQYNASSA LPDDILNFVK THPLMDEAVP SLGHAPWILR 420

TLMRHQLTRV AVDVGAGPWG NQTWFLGSE AGTVLKFLVR PNASTSGTSG LSVFLEEFET 480

YRPDRCGRPG GGETGQRLLS LELDAASGGL LAAFPRCWR VPVARCQQYS GCMKNCIGSQ 540

DPYCGWAPDG SCIFLSPGTR AAFEQDVSGA STSGLGDCTG LLRASLSEDR AGLVSVNLLV 600 TSSVAAFWG AWSGFSVGW FVGLRERREL ARRKDKEAIL AHGAGEAVLS VSRLGERRAQ 660

GPGGRGGGGG GGAGVPPEAL LAPLMQNGWA KATLLQGGPH DLDSGLLPTP EQTPLPQKRL 720 PTPHPHPHAL GPRAWDHGHP LLPASASSSL LLLAPARAPE QPPAPGEPTP DGRLYAARPG 780 RASHGDFPLT PHASPDRRRV VSAPTGPLDP ASAADGLPRP WSPPPTGSLR RPLGPHAPPA 840 ATLRRTHTFN SGEARPGDRH RGCHARPGTD LAHLLPYGGA DRTAPPVP

Seq ID NO : 168 DNA sequence

Nucleic Acid Accession # : AW205664

Coding sequence : 1 -135 (underlined sequences correspond to start and stop codons)

1 11 21 31 41 51

CGGCACGAGG AGAACAGGGG CCTCTGCCTC AGTTTGCCCG GGAGCCAGCC AGGGCCCATC 60

CTAATTTGGA GCACAGTCTT CCCGGTGCCT AGACATGCCA AGGCCCCTCC CACGTGGTAC 120 ACCCTCTCCG TTTAGTACCT GACCACCTGT TTCAAAACGC AGGTGTTTCT GGTTTAGAAA 180

CTTGGAAGGC GGAATGTGTT TTCGTGTCTT CTAGGAAGGG TCTGCTGAGG ACCAGACCAC 240

GTAAGCCTGA GTGGATCCTG ACTCAGCTGC AGCCCTTACC TGCCTCGTGC TGATGATCTA 300

TGCATGGCGT TATGTAGATC ACGTGCGGCA GAGACAGCCA CTGTCCTGTG TGCGGGTTTT 360 TAAAACAGCT GCCCTGGATG AAACGGAATA AACCAGTGAT GCTAAAAAAA AAAAAAAAAA

Seq ID No : 169 Protein sequence : Protein Accession # : AW205664

1 11 • 21 31 41 51

I I I I I I

RHEENRGLCL SLPGSQPGPI LIWSTVFPVP RHAKAPPTWY TLSV

Seq ID NO : 170 DNA sequence

Nucleic Acid Accession # : AB033100

Coding sequence : 32 -2623 (underlined sequences correspond to start and stop codons )

1 11 21 31 41 51

I I I I I I

AGGTCTGGGG TCCTGAGGCT GCTGGCAGAC TATGGGTACA ACGGCCAGCA CAGCCCAGCA 60

GACGGTCTCG GCAGGCACCC CATTTGAGGG CCTACAGGGC AGTGGCACGA TGGACAGTCG 120

GCACTCCGTC AGCATCCACT CCTTCCAGAG CACTAGCTTG CATAACAGCA AGGCCAAGTC 180 CATCATCCCC AACAAGGTGG CCCCTGTTGT GATCACGTAC AACTGCAAGG AGGAGTTCCA 240

GATCCATGAT GAGCTGCTCA AGGCTCATTA CACGTTGGGC CGGCTCTCGG ACAACACCCC 300

TGAGCACTAC CTGGTGCAAG GAGCTCAGGC CTTACCCCAG GGCCGCTACT TCCTGGTGCG 360

GGATGTCACT GAGAAGATGG ATGTGCTGGG CACCGTGGGA AGCTGTGGGG CCCCCAACTT 420

CCGGCAGGTG CAGGGTGGGC TCACTGTGTT CGGCATGGGA CAGCCCAGCC TCTTAGGGTT 480 CAGGCGGGTC CTCCAGAAAC TCCAGAAGGA CGGACATAGG GAGTGTGTCA TCTTCTGTGT 540

GCGGGAGGAA MCTGTGCTTT TCCTGCGTGC AGATGAGGAC TTTGTGTCCT ACACACCTCG 600

AGACAAGCAG AACCTTCATG AGAACCTCCA GGGCCTTGGA CCCGGGGTCC GGGTGGAGAG 660

CCTGGAGCTG GCCATCCGGA AAGAGATCCA CGACTTTGCC CAGCTGAGCG AGAACACATA 720

CCATGTGTAC CATAACACCG AGGACCTGTG GGGGGAGCCC CATGCTGTGG CCATCCATGG 780 TGAGGACGAC TTGCATGTGA CGGAGGAGGT GTACAAGCGG CCCCTCTTCC TGCAGCCCAC 840

CTACAGGTAC CACCGCCTGC CCCTGCCCGA GCAAGGGAGT CCCCTGGAGG CCCAGTTGGA 900

CGCCTTTGTC AGTGTTCTCC GGGAGACCCC CAGCCTGCTG CAGCTCCGTG ATGCCCACGG 960

GCCTCCCCCA GCCCTCGTCT TCAGCTGCCA GATGGGCGTG GGCAGGACCA ACCTGGGCAT 1020

GGTCCTGGGC ACCCTCATCC TGCTTCACCG CAGTGGGACC ACCTCCCAGC CAGAGGCTGC 1080 CCCCACGCAG GCCAAGCCCC TGCCTATGGA GCAGTTCCAG GTGATCCAGA GCTTTCTCCG 1140

CATGGTGCCC CAGGGAAGGA GGATGGTGGA AGAGGTGGAC AGAGCCATCA CTGCCTGTGC 1200

CGAGTTGCAT GACCTGAAAG AAGTGGTCTT GGAAAACCAG AAGAAGTTAG AAGGTATCCG 1260

ACCGGAGAGC CCAGCCCAGG GAAGCGGCAG CCGACACAGC GTCTGGCAGA GGGCGCTGTG 1320

GAGCCTGGAG CGATACTTCT ACCTGATCCT GTTTAACTAC TACCTTCATG AGCAGTACCC 1380 GCTGGCCTTT GCCCTCAGTT TCAGCCGCTG GCTGTGTGCC CACCCTGAGC TGTACCGCCT 1440

GCCCGTGACG CTGAGCTCAG CAGGCCCTGT GGCTCCGAGG GACCTCATCG CCAGGGGCTC 1500

CCTACGGGAG GACGATCTGG TCTCCCCGGA CGCGCTCAGC ACTGTCAGAG AGATGGATGT 1560

GGCCAACTTC CGGCGGGTGC CCCGCATGCC CATCTACGGC ACGGCCCAGC CCAGCGCCAA 1620

GGCCCTGGGG AGCATCCTGG CCTACCTGAC GGACGCCAAG AGGAGGCTGC GGAAGGTTGT 1680 CTGGGTGAGC CTTCGGGAGG AGGCCGTGTT GGAGTGTGAC GGGCACACCT ACAGCCTGCG 1740

GTGGCCTGGG CCCCCTGTGG CTCCTGACCA GCTGGAGACC CTGGAGGCCC AGCTGAAGGC 1800

CCATCTAAGC GAGCCTCCCC CAGGCAAGGA GGGCCCCCTG ACCTACAGGT TCCAGACCTG 1860

CCTTACCATG CAGGAGGTCT TCAGCCAGCA CCGCAGGGCC TGTCCTGGCC TCACCTACCA 1920

CCGCATCCCC ATGCCGGACT TCTGTGCCCC CCGAGAGGAG GACTTTGACC AGCTGCTGGA 1980 GGCCCTGCGG GCCGCCCTCT CCAAGGACCC AGGCACTGGC TTCGTGTTCA GCTGCCTCAG 2040

CGGCCAGGGC CGTACCACAA CTGCGATGGT GGTGGCTGTC CTGGCCTTCT GGCACATCCA 2100

AGGCTTCCCC GAGGTGGGTG AGGAGGAGCT CGTGAGTGTG CCTGATGCCA AGTTCACTAA 2160

GGGTGAATTT CAGGTAGTAA TGAAGGTGGT GCAGCTGCTA CCCGATGGGC ACCGTGTGAA 2220

GAAGGAGGTG GACGCAGCGC TGGACACTGT CAGCGAGACC ATGACGCCCA TGCACTACCA 2280 CCTGCGGGAG ATCATCATCT GCACCTACCG CCAGGCGAAG GCAGCGAAAG AGGCGCAGGA 2340

AATGCGGAGG CTGCAGCTGC GGAGCCTGCA GTACTTGGAG CGCTATGTCT GCCTGATTCT 2400 CTTCAACGCG TACCTCCACC TGGAGAAGGC CGACTCCTGG CAGAGGCCCT TCAGCACCTG 2460 GATGCAGGAG GTGGCATCGA AGGCTGGCAT CTACGAGATC CTTAACGAGC TGGGCTTCCC 2520 CGAGCTGGAG AGCGGGGAGG ACCAGCCCTT CTCCAGGCTG CGCTACCGGT GGCAGGAGCA 2580 GAGCTGCAGC CTCGAGCCCT CTGCCCCCGA GGACTTGCTG TAGGGGGCCT TACTCCCTGT 2640 CCCCCCACCC ACAGGGCCCC ACGCAGGCCT GGGGTGTCTG AGGTGCTCTT GGCTGGGAGC 2700 GGCCCTGAGG GGTGCTGGCC TTGAAATGAT TCCCCCACTT CCTGGAGAGA CTGAGCGGAG 2760 TTGGGAGCCT TTTTAGAAAG AACTTTTTAT AGGACAGGGA GACAGCACAG CCATCCCTTG 2820 CAAACCACCA AGGTGTGTGG CTGACCTCCA GGGAGGAGCA CTCACTGGAG TGCTCACAAG 2880 GTGCACACTG CTGTGTGTAC CTTGCAGACA GGCCGGCGTT CAGCCTCCAA GGGGCTCACT 2940 CCCCCAGTTG CCAAACACTG TGGATCTCTC TGTCCTCTTC TCCCCTCTCT CAGATTGGCC 3000 TGGCAGCCCC TGGCACAGAG CAGACCCGGC CACTGGTAGC TCCCCACTTC CTTACTCCTG 3060 CTGCTCTGCC ATTGCCGCTC CCCTTCTTGC TGCCCAAGCA CTGCCCTCGG GCGTCTGGCA 3120 GCCTGAGGTG GGTGGAGGGG ACAGTGTTCT GGATAGATCT ATTATGTGAA AGGCAGCTTC 3180 ACCCAGTTTT CTGGACTCTC ATGCCCCCAT CTCCGACCTG GGAGACTTCA GGAATGACAA 3240 CCTACCCAGC CTGGTGGGGC TGGCAGGATG GTGGAGGTTT CTCAAGGAGC TGGAGACTTC 3300 AGGGAGCCCC TCTCATGGGG AGGAAAGAGC TTCCAGGGGG CGAACGCAGC ACAGAGGAAG 3360 AGGCCTGCTC CACTTGTCTG GGAACCTGGG CAGGAGGCAC AGAGGAAGCC AAGGCCTGGA 3420 GCTGCAGGTC CCCCGGCATC TCTCTCTGTC CCGGCAGCCC AGGATGGCCT GGTGCCCCCA 3480 CCTGCTGCAG CAGGAGCCCC AAGGAGTGCT AGCTGAGGGT GGTTGCTGGG GTGGTCCTCA 3540 TGGACAGTGA GGTGTGCAAG GGTGCACTGA GGGTGGTGGG AGGGGATCAC CTGGGTTCCA 3600 GGCCATCCTT GCTGAGCATC TTTGAGCCTG CCTTCCGGTG GGAGCAGAAA AGGCCAGACC 3660 CTGCTGAGTT AGAGGCTGCT GGGATCCACT GTTTCCACAC AGCGGGAAGG CTGCTGGGAA 3720 CAGGTGGCAG AGAAGTGCCA TGTTTGCGTT GAGCCTTGCA GCTCTTCCAG CTGGGGACTG 3780 GTGCTTGCTG AAACCCAGGA GCTGAACAGT GAGGAGGCTG TCCACCTTGC TTGGCTCACT 3840 GGGACCAGSA AAGCCTGTCT TTGGTTAGGC TCGTGTACTT CTGCAGGAAA AAAAAAAAAG 3goo GATGTGTCAT TGGTCATGAT ATTTGAAAAG GGGAGGAGGC CGAAGTTGTT CCCATTTATC 3960 CAGTATTGGA AAATATTTGA CCCCCTTGGC TGAATTCTTT TGCAGAACTA CTGTGTGTCT 4020 GTTCACTACC TTTTCAGGTT TATTGTTTTT ATTTTTGCAT GAATTAAGAC GTTTTAATTT ₄080 CTTTGCAGAC AAGGTCTAGA TGCGGAGTCA GAGATGGGAC TGAATGGGGA GGGATCCTTT 4140 GTGTTCTCAT GGTTGGCTCT GACTTTCAGC TGTGTTGGGA CCACTGGCTG ATCACATCAC 4200 CTCTCTGCCT CAGTTTCCCC ATCTGTAAAA TGGGAGAATA ATACTTGCCT ACCTACCTCA 4260 CRGGGGTGTT GTGAGGATTC ATTTGTGATT TTTTTTTTTT TTTTTGTACA GAGCTTTTAA 4320 GCATTAAAAA CAGCTAAATG TG

Seq ID No: 171 Protein sequence: Protein Accession #: BAA86588.1

11 21 31 41 51

I I I I I

MGTTASTAQQ TVSAGTPFEG LQGSGTMDSR HSVSIHSFQS TSLHNSKAKS IIPNKVAPW 60 ITYNCKEEFQ IHDELLKAHY TLGRLSDNTP EHYLVQGAQA LPQGRYFLVR DVTEKMDVLG 120 TVGSCGAPNF RQVQGGLTVF GMGQPSLLGF RRVLQKLQKD GHRECVIFCV REEVLFLRAD 180 EDFVSYTPRD KQNLHENLQG LGPGVRVESL ELAIRKEIHD FAQLSENTYH VYHNTEDLWG 240 EPHAVAIHGE DDLHVTEEVY KRPLFLQPTY RYHRLPLPEQ GSPLEAQLDA FVSVLRETPS 300 LLQLRDAHGP PPALVFSCQM GVGRTNLGMV LGTLILLHRS GTTSQPEAAP TQAKPLPMEQ 360 FQVIQSFLRM VPQGRRMVEE VDRAITACAE LHDLKEWLE NQKKLEGIRP ESPAQGSGSR 420 HSVWQRALWS LERYFYLILF NYYLHEQYPL AFALSFSRWL CAHPELYRLP VTLSSAGPVA 480 PRDLIARGSL REDDLVSPDA LSTVREMDVA NFRRVPRMPI YGTAQPSAKA LGSILAYLTD 540 AKRRLRKWW VSLREEAVLE CDGHTYSLRW PGPPVAPDQL ETLEAQLKAH LSEPPPGKEG 600 PLTYRFQTCL TMQEVFSQHR RACPGLTYHR IPMPDFCAPR EEDFDQLLEA LRAALSKDPG 660 TGFVFSCLSG QGRTTTAMW AVLAFWHIQG FPEVGEEELV SVPDAKFTKG EFQWMKWQ 720 LLPDGHRVKK EVDAALDTVS ETMTPMHYHL REIIICTYRQ AKAAKEAQEM RRLQLRSLQY 780 LERYVCLILF NAYLHLEKAD SWQRPFSTWM QEVASKAGIY EILNELGFPE LESGEDQPFS 840 RLRYRWQEQS CSLEPSAPED LL

Seq ID NO: 172 DNA sequence

Nucleic Acid Accession #: AK021806.1

Coding sequence: 1-645 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

ACTGTGCTTT TCCTGCGTGC AGATGAGGAC TTTGTGTCCT ACACACCTCG AGACAAGCAG 60 AACCTTCATG AGAACCTCCA GGGCCTTGGA CCCGGGGTCC GGGTGGAGAG CCTGGAGCTG 120 GCCATCCGGA AAGAGATCCA CGACTTTGCC CAGCTGAGCG AGAACACATA CCATGTGTAC 180 CATAACACCG AGGACCTGTG GGGGGAGCCC CATGCTGTGG CCATCCATGG TGAGGACGAC 240 TTGCATGTGA CGGAGGAGGT GTACAAGCGG CCCCTCTTCC TGCAGCCCAC CTACAGGTAC 300 CACCGCCTGC CCCTGCCCGA GCAAGGGAGT CCCCTGGAGG CCCAGTTGGA CGCCTTTGTC 360 AGTGTTCTCC GGGAGACCCC CAGCCTGCTG CAGCTCCGTG ATGCCCACGG GCCTCCCCCA 420 GCCCTCGTCT TCAGCTGCCA GATGGGCGTG GGCAGGACCA ACCTGGGCAT GGTCCTGGGC 480 ACCCTCATCC TGCTTCACCG CAGTGGGACC ACCTCCCAGC CAGAGGCTGC CCCCACGCAG 540 GCCAAGCCCC TGCCTATGGA GCAGTTCCAG GTGATCCAGA GCTTTCTCCG CATGGTGCCC 600 CAGGGAAGGA GGATGGTGGA AGAGGTGGAT AGATCTATTA TGTGAAAGGC AGCTTCACCC 660 AGTTTTCTGG ACTCTCATGC CCCCATCTCC GACCTGGGAG ACTTCAGGAA TGACAACCTA 720 CCCAGCCTGG TGGGGCTGGC AGGATGGTGG AGGTTTCTCA AGGAGCTGGA GACTTCAGGG 780 AGCCCCTCTC ATGGGGAGGA AAGAGCTTCC AGGGGGCGAA CGCAGCACAG AGGAAGAGGC 840 CTGCTCCACT TGTCTGGGAA CCTGGGCAGG AGGCACAGAG GAAGCCAAGG CCTGGAGCTG 900 CAGGTCCCCC GGCATCTCTC TCTGTCCCGG CAGCCCAGGA TGGCCTGGTG CCCCCACCTG 960 CTGCAGCAGG AGCCCCAAGG AGTGCTAGCT GAGGGTGGTT GCTGGGGTGG TCCTCATGGA 1020 CAGTGAGGTG TGCAAGGGTG CACTGAGGGT GGTGGGAGGG GATCACCTGG GTTCCAGGCC 1080 ATCCTTGCTG AGCATCTTTG AGCCTGCCTT CCGGTGGGAG CAGAAAAGGC CAGACCCTGC 1140 TGAGTTAGAG GCTGCTGGGA TCCACTGTTT CCACACAGCG GGAAGGCTGC TGGGAACAGG 1200 TGGCAGAGAA GTGCCATGTT TGCGTTGAGC CTTGCAGCTC TTCCAGCTGG GGACTGGTGC 1260 TTGCTGAAAC CCAGGAGCTG AACAGTGAGG AGGCTGTCCA CCTTGCTTGG CTCACTGGGA 1320 CCAGGAAAGC CTGTCTTTGG TTAGGCTCGT GTACTTCTGC AGGAAAAAAA AAAAAGGATG 1380 TGTCATTGGT CATGATATTT GAAAAGGGGA GGAGGCCGAA GTTGTTCCCA TTTATCCAGT 1440 ATTGGAAAAT ATTTGACCCC CTTGGCTGAA TTCTTTTGCA GAACTACTGT GTGTCTGTTC 1500 ACTACCTTTT CAGGTTTATT GTTTTTATTT TTGCATGAAT TAAGACGTTT TAATTTCTTT 1560 GCAGACAAGG TCTAGATGCG GAGTCAGAGA TGGGACTGAA TGGGGAGGGA TCCTTTGTGT 1620 TCTCATGGTT GGCTCTGACT TTCAGCTGTG TTGGGACCAC TGGCTGATCA CATCACCTCT 1680 CTGCCTCAGT TTCCCCATCT GTAAAATGGG AGAATAATAC TTGCCTACCT ACCTCACGGG 1740 GGTGTTGTGA GGATTCATTT GTGATTTTTT TTTTTTTTTT TGTACAGAGC TTTTAAGCAT 1800 TAAAAACAGC TAAATGTG

Seq ID No: 173 Protein sequence : Protein Accession # : AK021806 .1

11 21 31 41 51

TVLFLRADED FVSYTPRDKQ NLHENLQGLG PGVRVESLEL AIRKEIHDFA QLSENTYHVY 60

HNTEDLWGEP HAVAIHGEDD LHVTEEVYKR PLFLQPTYRY HRLPLPEQGS PLEAQLDAFV 120

SVLRETPSLL QLRDAHGPPP ALVFSCQMGV GRTNLGMVLG TLILLHRSGT TSQPEAAPTQ 180 AKPLPMEQFQ VIQSFLRMVP QGRRMVEEVD RSIM

Seq ID- NO: 174 DNA sequence

Nucleic Acid Accession # : NM_016580 . 2

Coding sequence : 1212 -4766 (underlined sequences correspond to start and stop codons)

11 21 , 31 41 51

I I I I I

GGGAAGCGGG AGGAGAGCCA CACGGTCAAG TTGCACAGGT TCTTGCAGCT TCTGGAATCA 60 AGACCATGGG CACCCTCATA AGTCAGTGTG GGCAGGGACT GCCCCAGGGC CAATCCAAGA 120 TCCAGAGGTA GCCATAGGGT GTGACAAGTT GTGCAGATTA CAACACTCAC CCCTTGCAAT 180 AACGTCACTG CCTGTGACTC GGGGCCAGGC CCAGGCCAAA GCCCTTCCTA CATCATTTCG 240 TTTAATCCTC ACAGTTTCCT GCTGAAAGGG CTACTATTCT TACTCCCATC CCCACTCTAC 300 AGATGAGGTA ATGGAGGCCC AGGAAAGTTA AGTGACTTGT CCCAGATGAC AGCGCTGGTA 360 AGTTGCAAAG TCAGAATTTG AACTCAGGCA GTTTACCTCT GATGGCTGCT CTGTTAATCA 420 CAGCTGCTTT CCAGTGAGAC AAAAACGGGT GATCAGGGCA GAGTCAAGAC AGAGAGGTAA 480 ACAAGATTGG GAAAAAGACA GGAATGAGAG GGGAACAATG GGGGAAAAGA TAGGAACAAA 540 GAGAGTTGGG GAAGGGGAGA GAAACAGGAA ACATGACTTG CCCGGGAGGG GCATCAGTCC 600 ACGTGCAAGC AGGTGGAGGC TCAAGTTTTC TGCTCACTTG GTGATGCAGA GGCTCCCTTT 660 CCCTCAGCAG CCGCCTTGCT GCGTGGACAG CAGCTTCCCA TCTGGCCTGT CCCCGGAGCC 720 CCGGCCTCAT CCTCCTCAGC GGCAGGCCAC TTAGCTTCAC AGGAAATGCT CTTTCTCTAA 780 TTGGCATTGA AACTCACAGC CCTCCCTTTT CCTGTAGGTG GGGTTTCCAT AGGAAAAAGC 840 TGCTTCTCTG TTTCCCCAGC CTAGCAACTG TTTGGCAGTC AGAGTCCCAC ATCCTGCTCA 900 ACTGGGTCAG GTCCCTCTTA GACCAGCTCT TGTCCATCAT TTGCTGAAGT GGACCAACTA 960 GTTCCCCAGT AGGGGGTCTC CCCTGGCAAT TCTTGATCGG CGTTTGGACA TCTCAGATCG 1020 CTTCCAATGA AGATGGCCTT GCCTTGGGGT CCTGCTTGTT TCATAATCAT CTAACTATGG 1080 GACAAGGTTG TGCCGGCAGC TCTGGGGGAA GGAGCACGGG GCTGATCAAG CCATCCAGGA 1140 AACACTGGAG GACTTGTCCA GCCTTGAAAG AACTCTAGTG GTTTCTGAAT CTAGCCCACT 1200 TGGCGGTAAG CATGATGCAA CTTCTGCAAC TTCTGCTGGG GCTTTTGGGG CCAGGTGGCT 1260 ACTTATTTCT TTTAGGGGAT TGTCAGGAGG TGACCACTCT CACGGTGAAA TACCAAGTGT 1320 CAGAGGAAGT GCCATCTGGT ACAGTGATCG GGAAGCTGTC CCAGGAACTG GGCCGGGAGG 1380 AGAGGCGGAG GCAAGCTGGG GCTGCCTTCC AGGTGTTGCA GCTGCCTCAG GCGCTCCCCA 1440 TTCAGGTGGA CTCTGAGGAA GGCTTGCTCA GCACAGGCAG GCGGCTGGAT CGAGAGCAGC 1500 TGTGCCGACA GTGGGATCCC TGCCTGGTTT CCTTTGATGT GCTTGCCACA GGGGATTTGG 1560 CTCTGATCCA TGTGGAGATC CAAGTGCTGG' ACATCAATGA CCACCAGCCA CGGTTTCCCA 1620 AAGGCGAGCA GGAGCTGGAA ATCTCTGAGA GCGCCTCTCT GCGAACCCGG ATCCCCCTGG 1680 ACAGAGCTCT TGACCCAGAC ACAGGCCCTA ACACCCTGCA CACCTACACT CTGTCTCCCA 1740 GTGAGCACTT TGCCTTGGAT GTCATTGTGG GCCCTGATGA GACCAAACAT GCAGAACTCA 1800 TAGTGGTGAA GGAGCTGGAC AGGGAAATCC ATTCATTTTT TGATCTGGTG TTAACTGCCT 1860 ATGACAATGG GAACCCCCCC AAGTCAGGTA CCAGCTTGGT CAAGGTCAAC GTCTTGGACT 1920 CCAATGACAA TAGCCCTGCG TTTGCTGAGA GTTCACTGGC ACTGGAAATC CAAGAAGATG 1980 CTGCACCTGG TACGCTTCTC ATAAAACTGA CCGCCACAGA CCCTGACCAA GGCCCCAATG 2040 GGGAGGTGGA GTTCTTCCTC AGTAAGCACA TGCCTCCAGA GGTGCTGGAC ACCTTCAGTA 2100 TTGATGCCAA GACAGGCCAG GTCATTCTGC GTCGACCTCT AGACTATGAA AAGAACCCTG 2160 CCTACGAGGT GGATGTTCAG GCAAGGGACC TGGGTCCCAA TCCTATCCCA GCCCATTGCA 2220 AAGTTCTCAT CAAGGTTCTG GATGTCAATG ACAACATCCC AAGCATCCAC GTCACATGGG 2280

CCTCCCAGCC ATCACTGGTG TCAGAAGCTC TTCCCAAGGA CAGTTTTATT GCTCTTGTCA 2340

TGGCAGATGA CTTGGATTCA GGACACAATG GTTTGGTCCA CTGCTGGCTG AGCCAAGAGC 2400

TGGGCCACTT CAGGCTGAAA AGAACTAATG GCAACACATA CATGTTGCTA ACCAATGCCA 2460 CACTGGACAG AGAGCAGTGG CCCAAATATA CCCTCACTCT GTTAGCCCAA GACCAAGGAC 2520

TCCAGCCCTT ATCAGCCAAG AAACAGCTCA GCATTCAGAT CAGTGACATC AACGACAATG 2580

CACCTGTGTT TGAGAAAAGC AGGTATGAAG TCTCCACGCG GGAAAACAAC TTACCCTCTC 2640

TTCACCTCAT TACCATCAAG GCTCATGATG CAGACTTGGG CATTAATGGA AAAGTCTCAT 2700

ACCGCATCCA GGACTCCCCA GTTGCTCACT TAGTAGCTAT TGACTCCAAC ACAGGAGAGG 2760 TCACTGCTCA GAGGTCACTG AACTATGAAG AGATGGCCGG CTTTGAGTTC CAGGTGATCG 2820

CAGAGGACAG CGGGCAACCC ATGCTTGCAT CCAGTGTCTC TGTGTGGGTC AGCCTCTTGG 2880

ATGCCAATGA TAATGCCCCA GAGGTGGTCC AGCCTGTGCT CAGCGATGGA AAAGCCAGCC 2g40

TCTCCGTGCT TGTGAATGCC TCCACAGGCC ACCTGCTGGT GCCCATCGAG ACTCCCAATG 3000

GCTTGGGCCC AGCGGGCACT GACACACCTC CACTGGCCAC TCACAGCTCC CGGCCATTCC 3060 TTTTGACAAC CATTGTGGCA AGAGATGCAG ACTCGGGGGC AAATGGAGAG CCCCTCTACA 3120

GCATCCGCAG TGGAAATGAA GCCCACCTCT TCATCCTCAA CCCTCATACG GGGCAGCTGT 3180

TCGTCAATGT CACCAATGCC AGCAGCCTCA TTGGGAGTGA GTGGGAGCTG GAGATAGTAG 3240

TAGAGGACCA GGGAAGCCCC CCCTTACAGA CCCGAGCCCT GTTGAGGGTC ATGTTTGTCA 3300

CCAGTGTGGA CCACCTGAGG GACTCAGCCC GCAAGCCTGG GGCCTTGAGC ATGTCGATGC 3360 TGACGGTGAT CTGCCTGGCT GTACTGTTGG GCATCTTCGG GTTGATCCTG GCTTTGTTCA 3420

TGTCCATCTG CCGGACAGAA AAGAAGGACA ACAGGGCCTA CAACTGTCGG GAGGCCGAGT 3480

CCACCTACCG CCAGCAGCCC AAGAGGCCCC AGAAACACAT TCAGAAGGCA GACATCCACC 3540

TCGTGCCTGT GCTCAGGGGT CAGGCAGGTG AGCCTTGTGA AGTCGGGCAG TCCCACAAAG 3600

ATGTGGACAA GGAGGCGATG ATGGAAGCAG GCTGGGACCC CTGCCTGCAG GCCCCCTTCC 3660 ACCTCACCCC GACCCTGTAC AGGACGCTGC GTAATCAAGG CAACCAGGGA GCACCGGCGG 3720

AGAGCCGAGA GGTGCTGCAA GACACGGTCA ACCTCCTTTT CAACCATCCC AGGCAGAGGA 3780

ATGCCTCCCG GGAGAACCTG AACCTTCCCG AGCCCCAGCC TGCCACAGGC CAGCCACGTT 3840

CCAGGCCTCT GAAGGTTGCA GGCAGCCCCA CAGGGAGGCT GGCTGGAGAC CAGGGCAGTG 3900

AGGAAGCCCC ACAGAGGCCA CCAGCCTCCT CTGCAACCCT GAGACGGCAG CGACATCTCA 3960 ATGGCAAAGT GTCCCCTGAG AAAGAATCAG GGCCCCGTCA GATCCTGCGG AGCCTGGTCC 4020

GGCTGTCTGT GGCTGCCTTC GCCGAGCGGA ACCCCGTGGA GGAGCTCACT GTGGATTCTC 4080

CTCCTGTTCA GCAAATCTCC CAGCTGCTGT CCTTGCTGCA TCAGGGCCAA TTCCAGCCCA 4140

AACCAAACCA CCGAGGAAAT AAGTACTTGG CCAAGCCAGG AGGCAGCAGG AGTGCAATCC 4200

CAGACACAGA TGGCCCAAGT GCAAGGGCTG GAGGCCAGAC AGACCCAGAA CAGGAGGAAG 4260 GGCCTTTGGA TCCTGAAGAG GACCTCTCTG TGAAGCAACT GCTAGAAGAA GAGCTGTCAA 4320

GTCTGCTGGA CCCCAGCACA GGTCTGGCCC TGGACCGGCT GAGCGCCCCT GACCCGGCCT 4380

GGATGGCGAG ACTCTCTTTG CCCCTCACCA CCAACTACCG TGACAATGTG ATCTCCCCGG 4440

ATGCTGCAGC CACGGAGGAG CCAAGGACCT TCCAGACGTT CGGCAAGGCA GAGGCACCAG 4500

AGCTGAGCCC AACAGGCACG AGGCTGGCCA GCACCTTTGT CTCGGAGATG AGCTCACTGC 4560 TGGAGATGCT GCTGGAACAG CGCTCCAGCA TGCCCGTGGA GGCCGCCTCC GAGGCGCTGC 4620

GGCGGCTCTC GGTCTGCGGG AGGACCCTCA GTTTAGACTT GGCCACCAGT GCAGCCTCAG 4680

GCATGAAAGT GCAAGGGGAC CCAGGTGGAA AGACGGGGAC TGAGGGCAAG AGCAGAGGCA 4740

GCAGCAGCAG CAGCAGGTGC CTGTGAACAT ACCTCAGACG CCTCTGGATC CAAGAACCAG 4800

GGGCCTGAGG ATCTGTGGAC AAGAGCTGGT TTCTAAAATC TTGTAACTCA CTAGCTAGCG 4860 GCGGCCTGAG AACTTTAGGG TGACTGATGC TACCCCCACA GAGGAGGCAA GAGCCCCAGG 4920

ACTAACAGCT GACTGACCAA AGCAGCCCCT TGTAAGCAGC TCTGAGTGTT TTGGAGGACA 4980

GGGACGGTTT GTGGCTGAGA TAAGTGTTTC CTGGCAAAAC ATATGTGGAG CACAAAGGGT 5040

CAGTCCTCTG GCAGAACAGA TGCCACGGAG TATCACAGGC AGGAAAGGGT GGCCTTCTTG 5100

GGTAGCAGGA GTCAGGGGGC TGTACCCTGG GGGTGCCAGG AAATGCTCTC TGACCTATCA 5160 ATAAAGGAAA AGCAGTGATT CAAAAAAAAA AAAAAAAAAA AAAAAAAAAA

Seq ID No : 175 Protein sequence : Protein Accession # : NP 057664 . 1

11 21 31 41 51

MMQLLQLLLG LLGPGGYLFL LGDCQEVTTL TVKYQVSEEV PSGTVIGKLS QELGREERRR 60

QAGAAFQVLQ LPQALPIQVD SEEGLLSTGR RLDREQLCRQ WDPCLVSFDV LATGDLALIH 120 VEIQVLDIND HQPRFPKGEQ ELEISESASL RTRIPLDRAL DPDTGPNTLH TYTLSPSEHF 180

ALDVIVGPDE TKHAELIWK ELDREIHSFF DLVLTAYDNG NPPKSGTSLV KVNVLDSNDN 240

SPAFAESSLA LEIQEDAAPG TLLIKLTATD PDQGPNGEVE FFLSKHMPPE VLDTFSIDAK 300

TGQVILRRPL DYEKNPAYEV DVQARDLGPN PIPAHCKVLI KVLDVNDNIP SIHVTWASQP 360

SLVSEALPKD SFIALVMADD LDSGHNGLVH CWLSQELGHF RLKRTNGNTY MLLTNATLDR 420 EQWPKYTLTL LAQDQGLQPL SAKKQLSIQI SDINDNAPVF EKSRYEVSTR ENNLPSLHLI 480

TIKAHDADLG INGKVSYRIQ DSPVAHLVAI DSNTGEVTAQ RSLNYEEMAG FEFQVIAEDS 540

GQPMLASSVS VWVSLLDAND NAPEWQPVL SDGKASLSVL VNASTGHLLV PIETPNGLGP 600

AGTDTPPLAT HSSRPFLLTT IVARDADSGA NGEPLYSIRS GNEAHLFILN PHTGQLFVNV 660

TNASSLIGSE WELEIWEDQ GSPPLQTRAL LRVMFVTSVD HLRDSARKPG ALSMSMLTVI 720 CLAVLLGIFG LILALFMSIC RTEKKDNRAY NCREAESTYR QQPKRPQKHI QKADIHLVPV 780

LRGQAGEPCE VGQSHKDVDK EAMMEAGWDP CLQAPFHLTP TLYRTLRNQG NQGAPAESRE 840

VLQDTVNLLF NHPRQRNASR ENLNLPEPQP ATGQPRSRPL KVAGSPTGRL AGDQGSEEAP 900

QRPPASSATL RRQRHLNGKV SPEKESGPRQ ILRSLVRLSV AAFAERNPVE ELTVDSPPVQ 960

QISQLLSLLH QGQFQPKPNH RGNKYLAKPG GSRSAIPDTD GPSARAGGQT DPEQEEGPLD 1020 PEEDLSVKQL LEEELSSLLD PSTGLALDRL SAPDPAWMAR LSLPLTTNYR DNVISPDAAA 1080

TEEPRTFQTF GKAEAPELSP TGTRLASTFV SEMSSLLEML LEQRSSMPVE AASEALRRLS 1140 VCGRTLSLDL ATSAASGMKV QGDPGGKTGT EGKSRGSSSS SRCL

Seq ID NO: 176 DNA sequence

Nucleic Acid Accession #: AL109712.1

Coding sequence: 2-128 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

I I I I I

GAGTCTCTTT GGGCCAGCCG GGCTGCTGCA GACAGACAGG AAGCACGCCT GACGCTCCTC 60 TACCCTCGGG CAGCACAGCG GGGCTGGGAC TCACTCTAGC TTGCCCAGCA ACTTGCTTTC 120 CTGTGTGAAC TCTGGCAGGC TGCCCTCTCT GTGCAAAGCT GCCACTGGGG CCTGCTCAGG 180 GTGGCCTGGA ACTTGGAGGT GGGCAGTCAG GGCCTAGGAT GGGCCTGTGT CACCAGGGCA 240 TGTGCCCTTG GGCCAGTTAC TTCCTCTCAG AGCCTTGGGC TCCTCCTCTG AGGATGGGGC 300 TTGTTGGTGT GAAATGAGGT GAGCATGTTG AGTTGGGGAG CAGCAGGACA CGCACCTGCA 360 GGCAGCCGCC CTGGCCACGC TCCCTCCCTA CCTTCCGAGT CCTGGGACAG ACACAGTAGA 420 GCACAGCGGG CCAGCCTGCT CTCTTCTCTG TCTACTTTTT GCAGAAGAGT CAACAGATAC 480 AACAGGCCCA GGGAGGTGCC CCTGGGGGCC CCAGTCCCCA TCACTCCAAG GGGCAGTCCT 540 GCAAGTGACA AGGTGGGCCC AATCCCTGTG GAACAGGTCT CTGAGGACCA CAGAGTGGGG 600 CCCCAGGGAA AGCTGGGAGC CGAGCTAGAG GCAGGCAGCA AGTAAGGGCA AAGCTGTGCC 660 CCTGCCCGGA AGACCTTCCT GCCCCCAGAA CCCGACCCTC CGCAGATAGC CCTCCCTGGG 720 CAGCAGCCCC CCAGCTTCCA AGGCCCGTGC CTCACCAGAC GCCATGCTCT CACGGACTTG 780 TTTGCTGCTC TGTACCCTGC AGATCTGCCC CAGAGGAGCA GGTGAAAAGC CGCGCCTGCC 840 GAGGTGCTGT GGCGGTGGAG TTTTGGGCAG AGGAGTGGGG GGAAGAGTTT CTCACTTTTA 900 AGATTCTCCA AATCCAAGAT GAAGTCATGC TGTGCTTTGG AATGGTAGAT GCTCATTTAT 960 GTAAAATCAT AATAAATGTT ACACAAACTG TTAAAAAAAA AAAAAAAAAA AAAAAA

Seq ID No : 177 Protein sequence : Protein Accession # : AL109712 .1

11 21 31 41 51

VSLGQPGCCR QTGSTPDAPL PSGSTAGLGL TLACPATCFP V Seq ID NO : 178 DNA sequence

Nucleic Acid Accession # : none found

Coding sequence : 3 -107 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

AATGGAGCAC TCCAAAGAAC GATTTGACCA ATAGCATTTC TTCTCTGGGG GTTGTATTTC 60 AAAGCATGCA ACTCTCCAGG GAACCAGAAC TAAATTGCTT AAAATGAAGT CATTCCTCAG 120 ATTAACTTCC TCAGATAAAG TGTCAGCGGT CTGCAGAAAC GAAGAAGACA AAACTGAGAT 180 TATCACTCAT AATTCTCTTA CTTACTATGT CAGTGAAACA ATGAGTTTGC ATTTTTGCAA 240 TCCTAGAACA TTGTTCATTA GCCCTGGGTC ATGACCTCTT CCAGTTAATT CTCTTTCACA 300 CCTTTAGGAA AGATTTAAGA TGAACCTTCA ATAGGATATT AACATAACTC ATAGCCAATA 360 CCACAGCTGC CTTTCAAATT AATGAGGTTA ATTGTTCTCC AGCAAACATG AGTTTGTCTT 420 TGGCATTTTA AATGCTTCCC ATTGATCTGA CATTTTGCTG TTTCAAGTTT TAAAGGGCTC 480 AAATCAAAGA CTATTGATAA CTGAGCAAAG AGCGAAGATC CAGAAATACG AAAACATTGT 540 CTTTTTTTTT CCATGAAAAA CAATCATAGC CTTTTGAATT CAATCGAAGT TTCTACATTA 600 GCCATCTAAG ACTTATTTAA TTATTTCTGT TCTCAGTCAA GCTAATTCAA GTGAATGAAC 660 AGTATTGACT TTTAAAATGT TTTTTAAATT TTTTTAAATC TTTAGTTTAT TAAGTTTGTA 720 GAAAAGCTCT GGGGCCATGA CCACTTACGT AAATGTTTCA GTTTAAAAAC AAAAGATTCA 780 GGCCTCTAAT TTGAGCCAAA TCCAGGTGAT CTTGTTTGAA ATTTTTGATG AATTTGAAAA 840 GATGAAAGTG GAACTTTTAA CATTCATGTT CCCCAAATTT TTCACTGGGA AGGGATGCTA 900 ATTGCCTACT TAAGATATAA GTTCAAGAAT AACATTTTCA TAGAAAATTC AGAAAACTGC 960 TTGACACAGC AGTGACATAG TTAGATGTGG CTCAGATGCC TTCCAAACCT GAGGGTCCCC 1020 AAAGATTTCT TTACCAGTTG TTTTTAACTA TGAATCTTAA TCTTGTTCAT TCCCCTGCCA 1080 AAACAAATTT AAAAG

Seq ID No : 179 Protein sequence : Protein Accession # : none found

1 11 21 31 41 51 l l l l

WSTPKNDLTN SISSLGWFQ SMQLSREPEL NCLK

Seq ID NO : 180 DNA sequence

Nucleic Acid Accession # : none found

Coding sequence : 2-176 (underlined sequences correspond to start and stop codons)

11 21 31 41 51 CCGGGTGGGG CCTCGGGATG CAGGCGCCGG TGCCCGGGCC CCTGGGCCTG CTGGACCCCG 60 CAGAAGGGCT TTCGAGGAGG AAGAAGACGT CGCTCTGGTT TGTGGGGTCT CTGCTGCTGG 120 TGTCCGTCCT CATAGTCACC GTCGGGCTGG CTGCATCAGC AGGACGGAGA ATGTGACCGT 180 TGGGGGCTAC TACCCAGGGA TCATTCTCGG CTTTGGATCT TTCTTAGGAA TTATTGGCAT 240 CAACTTGGTG GAGAATAGAA GGCAAATGCT GGTGGCAGCG ATCGTGTTTA TCAGTTTTGG 300 CGTGGTGGCC GCCTTCTGCT GCGCCATCGT GGACGGCGTA TTTGCAGCAC AGCACATTGA 360 ACCGAGGCCC CTCACCACGG GAAGATGCCA GTTTTACTCC AGTGGGGTGG GGTACTTGTA 420 CGATGTCTAC CAGACAGAGG TGAGCAGGAG CACTGAGATT CATGTGGGTT TTGCTCAGCT 480 AACCCCGCCG ACCCCACGCG GTTTTCCCTG CACATAGGCG TGGTCTGAAT ATTTGGATTC 540 TAATAGTTCC TGGGGGTCAC CCCTGCAGCT GGTGAACCGT TGATGCCCCC TGTGTAAGGG 600 ACCTTGACAT TTCGATGTGC TGTATTTCAC TCTGGAGTCA GAGTTCTGGA CTTGCTTCAT 660 TAAATCACAA CAGTCTCAGA AAACAACCGC ACCACCCCGC AATCCCACCA AAGGGGCGCG 720 CCGTCCCTAA GAGTTATCCC

Seq ID No: 181 Protein sequence: Protein Accession # : none found

11 21 31 41 51

RVGPRDAGAG ARAPGPAGPR RRAFEEEEDV ALVCGVSAAG VRPHSHRRAG CISRTENV

Seq ID NO : 182 DNA sequence

Nucleic Acid Accession # : AK001579 .1

Coding sequence : 1150-2637 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

TTTTCTCTGC TTTTCGCTAC CCCGGTCACT CTCATTTCTC TCCCCTATTC CTTGTCTCTT 60 CCCCCATCCC CCTTTCTCCT GTCCTCCCCC TGCCTCTACA GTGGTTCTCC CCGCTGAGCT 120 GCCACCAGCT GCTGGGCCCC GGGCTGCTGC GGCTGGGCCG CCTATGGCTG CGGTCCCCCT 180 CCCATACAGC CCCGGCCCCT GGTCTCTGGC TGTCAGGGTT TGGCCTCCTT CGTGGTGACC 240 ACCTCTTCCT GTGCTCAGCG CCGGGCCCAG GCCCCCCAGC CCCTGAGGAC ATGGTGCATC 300 TGCGGCGGCT ACAGGAGATC AGTGTGGTTT CTGCAGCTGA CACCCCAGAT AAGAAAGAGC 360 ATTTGGTCCT GGTGGAGACA GGAAGGACCC TGTATCTGCA AGGAGAGGGC CGGCTGGACT 420 TCACGGCATG GAACGCAGCC ATTGGGGGCG CGGCTGGTGG GGGCGGCACA GGGCTGCAGG 480 AGCAGCAGAT GAGCCGGGGT GACATCCCCA TCATCGTGGA TGCCTGCATC AGTTTTGTTA 540 CCCAGCATGG GCTCCGGCTG GAAGGTGTAT ACCGGAAAGG GGGCGCTCGT GCCCGCAGCC 600 TGAGACTCCT GGCTGAGTTC CGTCGGGATG CCCGGTCGGT GAAGCTCCGA CCAGGGGAGC 660 ACTTTGTGGA GGATGTCACT GACACACTCA AACGCTTCTT TCGTGAGCTC GATGACCCTG 720 TGACCTCTGC ACGGTTGCTG CCTCGCTGGA GGGAGGCTGC TGGTATTCCT AAGATCCCTG 780 AGAGCCAAGG CCCAACCAGG ATCTCTGCCT TCCCCCACCA GAATCCATGG TTTGGCAGCC 840 CTCCGCCCCA TCACTTCCCA CCCTGGGGGA TCATCCAGAG ACTTGGCTCA GGGGGAGGTG goo GGAAGGGGGC AGAGACACAT CCATCCTGCA TTTGTGCCTA AAAATCCCTC CCTCTGTACC gεo AGCTGCCACT CTTTCTTCCC GGGTCCTCCC CAACCCTCCT CCATTCCATC CCCAGAGCTG 1020 CCCCAGAAGA ATCAGCGCCT GGAGAAATAT AAAGATGTGA TTGGCTGCCT GCCGCGGGTC 1080 AACCGCCGCA CACTGGCCAC CCTCATTGGG CATCTCTATC GGGTGCAGAA ATGTGCGGCT 1140 CTAAACCAGA TGTGCACGCG GAACTTGGCT CTGCTGTTTG CACCCAGCGT GTTCCAGACG 1200 GATGGGCGAG GGGAGCACGA GGTGCGAGTG CTGCAAGAGC TCATTGATGG CTACATCTCT 1260 GTCTTTGATA TCGATTCTGA CCAGGTAGCT CAGATTGACT TGGAGGTCAG TCTTATCACC 1320 ACCTGGAAGG ACGTGCAGCT GTCTCAGGCT GGAGACCTCA TCATGGAAGT TTATATAGAG 1380 CAGCAGCTCC CAGACAACTG TGTCACCCTG AAGGTGTCCC CAACCCTGAC TGCTGAGGAG 1440 CTGACTAACC AGGTACTGGA GATGCGGGGG ACAGCAGCTG GGATGGACTT GTGGGTGACT 1500 TTTGAGATTC GCGAGCATGG GGAGCTGGAG CGGCCACTGC ATCCCAAGGA AAAGGTCTTA 1560 GAGCAGGCTT TACAATGGTG CCAGCTCCCA GAGCCCTGCT CAGCTTCCCT GCTCTTGAAA 1620 AAAGTCCCCC TGGCCCAAGC TGGCTGCCTC TTCACAGGTA TCCGACGTGA GAGCCCACGG 1680 GTGGGGCTGT TGCGGTGTCG TGAGGAGCCA CCTCGCTTGC TGGGAAGCCG CTTCCAGGAG 1740 AGGTTCTTTC TGCTGCGTGG CCGCTGCCTG CTGCTGCTCA AGGAGAAGAA AAGCTCTAAA 1800 CCAGAACGGG AGTGGCCTTT GGAAGGTGCC AAGGTCTACC TGGGAATCCG CAAGAAGTTA 1860 AAGCCCCCAA CACCGTGGGG CTTCACATTG ATACTAGAGA AGATGCACCT CTACTTGTCC ig20 TGCACTGACG AGGATGAAAT GTGGGATTGG ACCACCAGCA TCCTTAAAGC CCAGCACGAT ιgso GACCAGCAGC CAGTGGTCTT ACGACGCCAT TCCTCCTCTG ACCTTGCCCG TCAGAAGTTT 2040 GGCACTATGC CTTTGCTGCC TATCCGTGGG GATGACAGTG GAGCCACCCT CCTCTCTGCC 2100 AATCAGACCC TGCGGCGACT ACACAACCGG AGGACCCTGT CCATGTTCTT TCCAATGAAG 2160 TCATCCCAGG GGTCTGTGGA GGAGCAAGAG GAGCTGGAGG AGCCTGTGTA CGAGGAGCCA 2220 GTGTATGAGG AAGTAGGGGC CTTCCCTGAG TTGATCCAGG ACACTTCTAC CTCCTTCTCC 2280 ACCACACGGG AGTGGACAGT GAAGCCAGAG AACCCCCTCA CCAGCCAGAA GTCATTGGAT 2340 CAACCCTTTC TCTCCAAGTC AAGCACCCTT GGCCAGGAGG AGAGGCCACC TGAGCCCCCT 2400 CCAGGCCCCC CTTCAAAGAG CAGTCCCCAG GCACGGGGGT CCCTAGAGGA ACAGCTGCTC 2460 CAGGAGCTCA GCAGCCTCAT CCTGAGGAAA GGAGAGACCA CTGCAGGCCT GGGAAGTCCT 2520 TCCCAGCCAT CCAGCCCCCA ATCCCCCAGC CCCACTGGCC TTCCAACACA GACACCTGGC 2580 TTCCCCACCC AACCCCCATG CACTTCCAGT CCACCCTCCA GCCAGCCCCT CACATGACCC 2640 TAGGACCAGC AGTCTGAGAG GGTAGGTACC AGAAGACCCA GAAACTCTTA TCGTGGCACT 2700 GTTGCAGCTT CCTCTGCCCT GGCTGGAAAG ACTCCAGAAT CCAGTGTGGT GCTGTGGAAG 2760 GAGCACTGGA CTAAAGGCTT CAGTGGCTGC GTGTCCCAGG ACAGGTCATG GCCCCTCTCT 2820 GGGCCCAGCC CATTTATCTA TACCATGAGG TAACTGAAGT AAGGAGAGCA GTGAATGTCA 2880 AACTGTGTTT CTTAGAGCCA TAAGCCCCAC ATATTATCCC TGAACAAGGG CAGCTCCTGC ₂g40

TTTATATATT TGATACGTAG GGGTTCCATG AGAGATTTTG GGTTTTAAAG GAATGGTTTT 3000

ACTGCATTAA AGAAAAAAAA TGCTTTGGAA ACCAGAGGCC TGGGTGATGT TAAAGTCTAT 3060

CCTGTCCCAC TTCCTACATT CTGGGACTAC CGTGAAGCCT GGAGTAGGGA GAGCGAGTTT 3120 GGGAGCTGGG ACTCGGGGAG TCAAAAATAG ATGAGTAATT GTCAATAAAC CTGGGAACC

Seq ID No : 183 Protein sequence : Protein Accession # : AK00157g . l

11 21 31 41 51

MSLTHSNASF VSSMTLPLHG CCLAGGRLLV FLRSLRAKAQ PGSLPSPTRI HGLAALRPIT 60 SHPGGSSRDL AQGEVGRGQR HIHPAFVPKN PSLCTSCHSF FPGPPQPSSI PSPELPQKNQ 120 RLEKYKDVIG CLPRVNRRTL ATLIGHLYRV QKCAALNQMC TRNLALLFAP SVFQTDGRGE 180 HEVRVLQELI DGYISVFDID SDQVAQIDLE VSLITTWKDV QLSQAGDLIM EVYIEQQLPD 240 NCVTLKVSPT LTAEELTNQV LEMRGTAAGM DLWVTFEIRE HGELERPLHP KEKVLEQALQ 300 WCQLPEPCSA SLLLKKVPLA QAGCLFTGIR RESPRVGLLR CREEPPRLLG SRFQERFFLL 360 RGRCLLLLKE KKSSKPEREW PLEGAKVYLG IRKKLKPPTP WGFTLILEKM HLYLSCTDED 420 EMWDWTTSIL KAQHDDQQPV VLRRHSSSDL ARQKFGTMPL LPIRGDDSGA TLLSANQTLR 480 RLHNRRTLSM FFPMKSSQGS VEEQEELEEP VYEEPVYEEV GAFPELIQDT STSFSTTREW 540 TVKPENPLTS QKSLDQPFLS KSSTLGQEER PPEPPPGPPS KSSPQARGSL EEQLLQELSS 600 LILRKGETTA GLGSPSQPSS PQSPSPTGLP TQTPGFPTQP PCTSSPPSSQ PLT

Seq ID NO: 184 DNA sequence

Nucleic Acid Accession #: none found

Coding sequence: 1-81 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

GTAGAGTTAG TGTCAATGTG CTTAGAATAT ACCAAATTCA TAAACATTTT CTCTAAAAAA 60 GTATTAAGCT TAAAAAGTTA ATTCAGTTTA AGGAATATAA ACCAAATTAT TTTATATTTG 120 AATCTCAACA TAAGAAGTCA AAATGTAATG CTGCCAGATA ACAATATCAA AGGTATTTTT 180 CTTTCTCTAT AATTTCATCA GTATGTCCTC TCCCTTTTCT CCTATTTGTC AAATTTTAGC 240 AACCCTAACT CTGCTAATTA TAAGCTAGGC AAGTAATCTT GGACAAGTTA TTTGACCTCT 300 CACTGCACCA GCTTTGTTAT CTGTAAAATG ATGATAATAC CAACACCTTC TTCTTGGGGT 360 ACTGAAGATG AGAGAACATG ATATGTGTAA AGTGCCTTCC ACAATACCCA GAACATAGCA 420 AACATGTAAT GAATGTAGTA ATAGTAATTA TTTTATTTTC TTTTGATTCA GTTGGGACTA 480 TGTTCAGCTG TAACAGAATA CCCAAAATAA CAGTTTTAAA CAAATTAAAG TTTTGTTGTG 540 AAGTTTTGTT ACGAATTCAG ACAATCCAGG GCTTTTATAG ATGCACCAGG ATCAGCAGGT 600 ACAAAGGCAT CTTTCCTGAT TTCTGCCAGT CTCAATGCAT GGGTTGCAAT CCAGAGTCCA 660 GGATGGCAGT TCCAGCCCTG GTTACGCCCA TATTAGCACA CAGAAAGAAA GAGAAAGGGA 720 TGTGCCTCTT CACTTTAATC ATAGCTCCCA CTAGATGCAC CCACTACTTC TGCTGATACT 780 CCATTAGCTA ATGCTTGCTT ACATGGTCAC ACTTAGTTTC CAGAGAGACA TGTCTGGACA 840 GTCATGTGCT CAATTAATAT CCAAGTGTCC AATTACTGAG AAAAAAAGAA ACTAGCACCT goo TTGCTTGGTT GCATTCTTCT TAGCATAAGC CACATTCTTT TTATGAAGTT GTCCTCAGTT geo ACTTGGATGC CTCAGTTGTC CTTTCATTTA GAAATGCTCC TTGGACATCC TGAATCTGAC 1020 TTCTTTTGTC ATCAGCACCA TCACTACCAC TGCCTTCTTC AAAGCCACCA CGTTCTGTCC 1080 CAGGATGGTT GCAACAACCA CCATAGGGAC TTTTTGCTTC TACTTCCACA CAATAGCCAG 1140 AGTAAGCTTT TGAAAATGTA GGTCAGATCA TGTCTCTCTC TTCTCTTCAA AACCCTCCGA 1200 TGGCTTTTCA TATTACTCAA AAGAAAACCT AAAACTTTGC TGTGAGATCT ATGTGACCCG 1260 GCTTATTCTT CCTCTTACTT TATCTCTGTA TTGCTCTTCC TCACTCTACT CCAGCCATCC 1320 CACCTCCTTG CTGCTTGTCC TATACTCCTA AAAGAAGTTC AGTCTTCCCT TATGATATTT 1380 GCACTTAAAA TAGAAAAAAA AAAAAAAAAA AGCTCAGAGA GGCTGAGTTG TCCAAGGTCA 1440 TGCAGGTTAG AAGTCATGGA GCTGGGATCT AAATCCATGT CAGTCTGACT ATGAGTTCTG 1500 CACCGTTCTA TTCAACCCCA TTGCCTAGAG GTGCTTGATT GCTCAATAAT AGATTCCATG 1560 GACACAGTCA GCTCTTTCTG AGAAAAGGCA GCTCAGCATT TCCATGAGAT CCGCACATCC 1620 TTTTGCAGAA GAAAAC

Seq ID No: 185 Protein sequence: Protein Accession #: none found

1 11 21 31 41 51

I I I

VELVSMCLEY TKFINIFSKK VLSLKS

Seq ID NO : 186 DNA sequence Nucleic Acid Accession # : NM_002203 .2

Coding sequence : 43 -3588 (underlined sequences correspond to start and stop codons)

11 21 31 41 51 CTGCAAACCC AGCGCAACTA CGGTCCCCCG GTCAGACCCA GGATGGGGCC AGAACGGACA 60

GGGGCCGCGC CGCTGCCGCT GCTGCTGGTG TTAGCGCTCA GTCAAGGCAT TTTAAATTGT 120 TGTTTGGCCT ACAATGTTGG TCTCCCAGAA GCAAAAATAT TTTCCGGTCC TTCAAGTGAA 180

CAGTTTGGGT ATGCAGTGCA GCAGTTTATA AATCCAAAAG GCAACTGGTT ACTGGTTGGT 240

TCACCCTGGA GTGGCTTTCC TGAGAACCGA ATGGGAGATG TGTATAAATG TCCTGTTGAC 300

CTATCCACTG CCACATGTGA AAAACTAAAT TTGCAAACTT CAACAAGCAT TCCAAATGTT 360 ACTGAGATGA AAACCAACAT GAGCCTCGGC TTGATCCTCA CCAGGAACAT GGGAACTGGA 420

GGTTTTCTCA CATGTGGTCC TCTGTGGGCA CAGCAATGTG GGAATCAGTA TTACACAACG 480

GGTGTGTGTT CTGACATCAG TCCTGATTTT CAGCTCTCAG CCAGCTTCTC ACCTGCAACT 540

CAGCCCTGCC CTTCCCTCAT AGATGTTGTG GTTGTGTGTG ATGAATCAAA TAGTATTTAT 600

CCTTGGGATG CAGTAAAGAA TTTTTTGGAA AAATTTGTAC AAGGCCTTGA TATAGGCCCC 660 ACAAAGACAC AGGTGGGGTT AATTCAGTAT GCCAATAATC CAAGAGTTGT GTTTAACTTG 720

AACACATATA AAACCAAAGA AGAAATGATT GTAGCAACAT CCCAGACATC CCAATATGGT 780

GGGGACCTCA CAAACACATT CGGAGCAATT CAATATGCAA GAAAATATGC CTATTCAGCA 840

GCTTCTGGTG GGCGACGAAG TGCTACGAAA GTAATGGTAG TTGTAACTGA CGGTGAATCA 900

CATGATGGTT CAATGTTGAA AGCTGTGATT GATCAATGCA ACCATGACAA TATACTGAGG 960 TTTGGCATAG CAGTTCTTGG GTACTTAAAC AGAAACGCCC TTGATACTAA AAATTTAATA 1020

AAAGAAATAA AAGCGATCGC TAGTATTCCA ACAGAAAGAT ACTTTTTCAA TGTGTCTGAT 1080

GAAGCAGCTC TACTAGAAAA GGCTGGGACA TTAGGAGAAC AAATTTTCAG CATTGAAGGT 1140

ACTGTTCAAG GAGGAGACAA CTTTCAGATG GAAATGTCAC AAGTGGGATT CAGTGCAGAT 1200

TACTCTTCTC AAAATGATAT TCTGATGCTG GGTGCAGTGG GAGCTTTTGG CTGGAGTGGG 1260 ACCATTGTCC AGAAGACATC TCATGGCCAT TTGATCTTTC CTAAACAAGC CTTTGACCAA 1320

ATTCTGCAGG ACAGAAATCA CAGTTCATAT TTAGGTTACT CTGTGGCTGC AATTTCTACT 1380

GGAGAAAGCA CTCACTTTGT TGCTGGTGCT CCTCGGGCAA ATTATACCGG CCAGATAGTG 1440

CTATATAGTG TGAATGAGAA TGGCAATATC ACGGTTATTC AGGCTCACCG AGGTGACCAG 1500

ATTGGCTCCT ATTTTGGTAG TGTGCTGTGT TCAGTTGATG TGGATAAAGA CACCATTACA 1560 GACGTGCTCT TGGTAGGTGC ACCAATGTAC ATGAGTGACC TAAAGAAAGA GGAAGGAAGA 1620

GTCTACCTGT TTACTATCAA AAAGGGCATT TTGGGTCAGC ACCAATTTCT TGAAGGCCCC 1680

GAGGGCATTG AAAACACTCG ATTTGGTTCA GCAATTGCAG CTCTTTCAGA CATCAACATG 17 0

GATGGCTTTA ATGATGTGAT TGTTGGTTCA CCACTAGAAA ATCAGAATTC TGGAGCTGTA 1800

TACATTTACA ATGGTCATCA GGGCACTATC CGCACAAAGT ATTCCCAGAA AATCTTGGGA 1860 TCCGATGGAG CCTTTAGGAG CCATCTCCAG TACTTTGGGA GGTCCTTGGA TGGCTATGGA 1920

GATTTAAATG GGGATTCCAT CACCGATGTG TCTATTGGTG CCTTTGGACA AGTGGTTCAA 1980

CTCTGGTCAC AAAGTATTGC TGATGTAGCT ATAGAAGCTT CATTCACACC AGAAAAAATC 2040

ACTTTGGTCA ACAAGAATGC TCAGATAATT CTCAAACTCT GCTTCAGTGC AAAGTTCAGA 2100

CCTACTAAGC AAAACAATCA AGTGGCCATT GTATATAACA TCACACTTGA TGCAGATGGA 2160 TTTTCATCCA GAGTAACCTC CAGGGGGTTA TTTAAAGAAA ACAATGAAAG GTGCCTGCAG 2220

AAGAATATGG TAGTAAATCA AGCACAGAGT TGCCCCGAGC ACATCATTTA TATACAGGAG 2280

CCCTCTGATG TTGTCAACTC TTTGGATTTG CGTGTGGACA TCAGTCTGGA AAACCCTGGC 2340

ACTAGCCCTG CCCTTGAAGC CTATTCTGAG ACTGCCAAGG TCTTCAGTAT TCCTTTCCAC 2400

AAAGACTGTG GTGAGGATGG ACTTTGCATT TCTGATCTAG TCCTAGATGT CCGACAAATA 2460 CCAGCTGCTC AAGAACAACC CTTTATTGTC AGCAACCAAA ACAAAAGGTT AACATTTTCA 2520

GTAACACTGA AAAATAAAAG GGAAAGTGCA TACAACACTG GAATTGTTGT TGATTTTTCA 2580

GAAAACTTGT TTTTTGCATC ATTCTCCCTA CCGGTTGATG GGACAGAAGT AACATGCCAG 2640

GTGGCTGCAT CTCAGAAGTC TGTTGCCTGC GATGTAGGCT ACCCTGCTTT AAAGAGAGAA 2700

CAACAGGTGA CTTTTACTAT TAACTTTGAC TTCAATCTTC AAAACCTTCA GAATCAGGCG 2760 TCTCTCAGTT TCCAAGCCTT AAGTGAAAGC CAAGAAGAAA ACAAGGCTGA TAATTTGGTC 2820

AACCTCAAAA TTCCTCTCCT GTATGATGCT GAAATTCACT TAACAAGATC TACCAACATA 2880

AATTTTTATG AAATCTCTTC GGATGGGAAT GTTCCTTCAA TCGTGCACAG TTTTGAAGAT 2940

GTTGGTCCAA AATTCATCTT CTCCCTGAAG GTAACAACAG GAAGTGTTCC AGTAAGCATG 3000

GCAACTGTAA TCATCCACAT CCCTCAGTAT ACCAAAGAAA AGAACCCACT GATGTACCTA 3060 ACTGGGGTGC AAACAGACAA GGCTGGTGAC ATCAGTTGTA ATGCAGATAT CAATCCACTG 3120

AAAATAGGAC AAACATCTTC TTCTGTATCT TTCAAAAGTG AAAATTTCAG GCACACCAAA 3180

GAATTGAACT GCAGAACTGC TTCCTGTAGT AATGTTACCT GCTGGTTGAA AGACGTTCAC 3240

ATGAAAGGAG AATACTTTGT TAATGTGACT ACCAGAATTT GGAACGGGAC TTTCGCATCA 3300

TCAACGTTCC AGACAGTACA GCTAACGGCA GCTGCAGAAA TCAACACCTA TAACCCTGAG 3360 ATATATGTGA TTGAAGATAA CACTGTTACG ATTCCCCTGA TGATAATGAA ACCTGATGAG 3420

AAAGCCGAAG TACCAACAGG AGTTATAATA GGAAGTATAA TTGCTGGAAT CCTTTTGCTG 3480

TTAGCTCTGG TTGCAATTTT ATGGAAGCTC GGCTTCTTCA AAAGAAAATA TGAAAAGATG 3540

ACCAAAAATC CAGATGAGAT TGATGAGACC ACAGAGCTCA GTAGCTGAAC CAGCAGACCT 3600

ACCTGCAGTG GGAACCGGCA GCATCCCAGC CAGGGTTTGC TGTTTGCGTG CATGGATTTC 3660 TTTTTAAATC CCATATTTTT TTTATCATGT CGTAGGTAAA CTAACCTGGT ATTTTAAGAG 3720

AAAACTGGAG GTCAGTTTGG ATGAAGAAAT TGTGGGGGGT GGGGGAGGTG CGGGGGGCAG 3780

GTAGGGAAAT AATAGGGAAA ATACCTATTT TATATGATGG GGGAAAAAAA GTAATCTTTA 3840

AACTGGCTGG CCCAGAGTTT ACATTCTAAT TTGCATTGTG TCAGAAACAT GAAATGCTTC 3900

CAAGCATGAC AACTTTTAAA GAAAAATATG ATACTCTCAG ATTTTAAGGG GGAAAACTGT 3960 TCTCTTTAAA ATATTTGTCT TTAAACAGCA ACTACAGAAG TGGAAGTGCT TGATATGTAA 4020

GTACTTCCAC TTGTGTATAT TTTAATGAAT ATTGATGTTA ACAAGAGGGG AAAACAAAAC 4080

ACAGGTTTTT TCAATTTATG CTGCTCATCC AAAGTTGCCA CAGATGATAC TTCCAAGTGA 4140

TAATTTTATT TATAAACTAG GTAAAATTTG TTGTTGGTTC CTTTTATACC ACGGCTGCCC 4200

CTTCCACACC CCATCTTGCT CTAATGATCA AAACATGCTT GAATAACTGA GCTTAGAGTA 4260 TACCTCCTAT ATGTCCATTT AAGTTAGGAG AGGGGGCGAT ATAGAGACTA AGGCACAAAA 4320

TTTTGTTTAA AACTCAGAAT ATAACATTTA TGTAAAATCC CATCTGCTAG AAGCCCATCC 4380

TGTGCCAGAG GAAGGAAAAG GAGGAAATTT CCTTTCTCTT TTAGGAGGCA CAACAGTTCT 4440

CTTCTAGGAT TTGTTTGGCT GACTGGCAGT AACCTAGTGA ATTTTTGAAA GATGAGTAAT 4500

TTCTTTGGCA ACCTTCCTCC TCCCTTACTG AACCACTCTC CCACCTCCTG GTGGTACCAT 4560 TATTATAGAA GCCCTCTACA GCCTGACTTT CTCTCCAGCG GTCCAAAGTT ATCCCCTCCT 4620

TTACCCCTCA TCCAAAGTTC CCACTCCTTC AGGACAGCTG CTGTGCATTA GATATTAGGG ₄680 GGGAAAGTCA TCTGTTTAAT TTACACACTT GCATGAATTA CTGTATATAA ACTCCTTAAC 4740 TTCAGGGAGC TATTTTCATT TAGTGCTAAA CAAGTAAGAA AAATAAGCTA GAGTGAATTT 4800 CTAAATGTTG GAATGTTATG GGATGTAAAC AATGTAAAGT AAAACACTCT CAGGATTTCA 4860 CCAGAAGTTA CAGATGAGGC ACTGGAAACC ACCACCAAAT TAGCAGGTGC ACCTTCTGTG 4g20 GCTGTCTTGT TTCTGAAGTA CTTTTTCTTC CACAAGAGTG AATTTGACCT AGGCAAGTTT 4g80 GTTCAAAAGG TAGATCCTGA GATGATTTGG TCAGATTGGG ATAAGGCCCA GCAATCTGCA 5040 TTTTAACAAG CACCCCAGTC ACTAGGATGC AGATGGACCA CACTTTGAGA AACACCACCC 5100 ATTTCTACTT TTTGCACCTT ATTTTCTCTG TTCCTGAGCC CCCACATTCT CTAGGAGAAA 5160 CTTAGATTAA AATTCACAGA CACTACATAT CTAAAGCTTT GACAAGTCCT TGACCTCTAT 5220 AAACTTCAGA GTCCTCATTA TAAAATGGGA AGACTGAGCT GGAGTTCAGC AGTGATGCTT 5280 TTTAGTTTTA AAAGTCTATG ATCTGATCTG GACTTCCTAT AATACAAATA CACAATCCTC 5340 CAAGAATTTG ACTTGGAAAA G

Seq ID NO: 187 Protein sequence: Protein Accession #: NP 002194.1

11 21 31 41 51

MGPERTGAAP LPLLLVLALS QGILNCCLAY NVGLPEAKIF SGPSSEQFGY AVQQFINPKG 60 NWLLVGSPWS GFPENRMGDV YKCPVDLSTA TCEKLNLQTS TSIPNVTEMK TNMSLGLILT 120 RNMGTGGFLT CGPLWAQQCG NQYYTTGVCS DISPDFQLSA SFSPATQPCP SLIDWWCD 180 ESNSIYPWDA VKNFLEKFVQ GLDIGPTKTQ VGLIQYANNP RWFNLNTYK TKEEMIVATS 240 QTSQYGGDLT NTFGAIQYAR KYAYSAASGG RRSATKVMW VTDGESHDGS MLKAVIDQCN 300 HDNILRFGIA VLGYLNRNAL DTKNLIKEIK AIASIPTERY FFNVSDEAAL LEKAGTLGEQ 360 IFSIEGTVQG GDNFQMEMSQ VGFSADYSSQ NDILMLGAVG AFGWSGTIVQ KTSHGHLIFP 420 KQAFDQILQD RNHSSYLGYS VAAISTGEST HFVAGAPRAN YTGQIVLYSV NENGNITVIQ 480 AHRGDQIGSY FGSVLCSVDV DKDTITDVLL VGAPMYMSDL KKEEGRVYLF TIKKGILGQH 540 QFLEGPEGIE NTRFGSAIAA LSDINMDGFN DVIVGSPLEN QNSGAVYIYN GHQGTIRTKY 600 SQKILGSDGA FRSHLQYFGR SLDGYGDLNG DSITDVSIGA FGQWQLWSQ SIADVAIEAS 660 FTPEKITLVN KNAQIILKLC FSAKFRPTKQ NNQVAIVYNI TLDADGFSSR VTSRGLFKEN 720 NERCLQKNMV VNQAQSCPEH IIYIQEPSDV VNSLDLRVDI SLENPGTSPA LEAYSETAKV 780 FSIPFHKDCG EDGLCISDLV LDVRQIPAAQ EQPFIVSNQN KRLTFSVTLK NKRESAYNTG 840 IWDFSENLF FASFSLPVDG TEVTCQVAAS QKSVACDVGY PALKREQQVT FTINFDFNLQ 900 NLQNQASLSF QALSESQEEN KADNLVNLKI PLLYDAEIHL TRSTNINFYE ISSDGNVPSI 960 VHSFEDVGPK FIFSLKVTTG SVPVSMATVI IHIPQYTKEK NPLMYLTGVQ TDKAGDISCN 1020 ADINPLKIGQ TSSSVSFKSE NFRHTKELNC RTASCSNVTC WLKDVHMKGE YFVNVTTRIW 1080 NGTFASSTFQ TVQLTAAAEI NTYNPEIYVI EDNTVTIPLM IMKPDEKAEV PTGVIIGSII 1140 AGILLLLALV AILWKLGFFK RKYEKMTKNP DEIDETTELS S

Seq ID NO: 188 DNA sequence

Nucleic Acid Accession #: NM_002210.1

Coding sequence: 42-3188 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

I I I I

GGCTACCGCT CCCGGCTTGG CGTCCCGCGC GCACTTCGGC GATGGCTTTT CCGCCGCGGC 60 GACGGCTGCG CCTCGGTCCC CGCGGCCTCC CGCTTCTTCT CTCGGGACTC CTGCTACCTC 120 TGTGCCGCGC CTTCAACCTA GACGTGGACA GTCCTGCCGA GTACTCTGGC CCCGAGGGAA 180 GTTACTTCGG CTTCGCCGTG GATTTCTTCG TGCCCAGCGC GTCTTCCCGG ATGTTTCTTC 240 TCGTGGGAGC TCCCAAAGCA AACACCACCC AGCCTGGGAT TGTGGAAGGA GGGCAGGTCC 300 TCAAATGTGA CTGGTCTTCT ACCCGCCGGT GCCAGCCAAT TGAATTTGAT GCAACAGGCA 360 ATAGAGATTA TGCCAAGGAT GATCCATTGG AATTTAAGTC CCATCAGTGG TTTGGAGCAT 420 CTGTGAGGTC GAAACAGGAT AAAATTTTGG CCTGTGCCCC ATTGTACCAT TGGAGAACTG 480 AGATGAAACA GGAGCGAGAG CCTGTTGGAA CATGCTTTCT TCAAGATGGA ACAAAGACTG 540 TTGAGTATGC TCCATGTAGA TCACAAGATA TTGATGCTGA TGGACAGGGA TTTTGTCAAG 600 GAGGATTCAG CATTGATTTT ACTAAAGCTG ACAGAGTACT TCTTGGTGGT CCTGGTAGCT 660 TTTATTGGCA AGGTCAGCTT ATTTCGGATC AAGTGGCAGA AATCGTATCT AAATACGACC 720 CCAATGTTTA CAGCATCAAG TATAATAACC AATTAGCAAC TCGGACTGCA CAAGCTATTT 780 TTGATGACAG CTATTTGGGT TATTCTGTGG CTGTCGGAGA TTTCAATGGT GATGGCATAG 840 ATGACTTTGT TTCAGGAGTT CCAAGAGCAG CAAGGACTTT GGGAATGGTT TATATTTATG 900 ATGGGAAGAA CATGTCCTCC TTATACAATT TTACTGGCGA GCAGATGGCT GCATATTTCG 960 GATTTTCTGT AGCTGCCACT GACATTAATG GAGATGATTA TGCAGATGTG TTTATTGGAG 1020 CACCTCTCTT CATGGATCGT GGCTCTGATG GCAAACTCCA AGAGGTGGGG CAGGTCTCAG 1080 TGTCTCTACA GAGAGCTTCA GGAGACTTCC AGACGACAAA GCTGAATGGA TTTGAGGTCT 1140 TTGCACGGTT TGGCAGTGCC ATAGCTCCTT TGGGAGATCT GGACCAGGAT GGTTTCAATG 1200 ATATTGCAAT TGCTGCTCCA TATGGGGGTG AAGATAAAAA AGGAATTGTT TATATCTTCA 1260 ATGGAAGATC AACAGGCTTG AACGCAGTCC CATCTCAAAT CCTTGAAGGG CAGTGGGCTG 1320 CTCGAAGCAT GCCACCAAGC TTTGGCTATT CAATGAAAGG AGCCACAGAT ATAGACAAAA 1380 ATGGATATCC AGACTTAATT GTAGGAGCTT TTGGTGTAGA TCGAGCTATC TTATACAGGG 1440 CCAGACCAGT TATCACTGTA AATGCTGGTC TTGAAGTGTA CCCTAGCATT TTAAATCAAG 1500 ACAATAAAAC CTGCTCACTG CCTGGAACAG CTCTCAAAGT TTCCTGTTTT AATGTTAGGT 1560 TCTGCTTAAA GGCAGATGGC AAAGGAGTAC TTCCCAGGAA ACTTAATTTC CAGGTGGAAC 1620 TTCTTTTGGA TAAACTCAAG CAAAAGGGAG CAATTCGACG AGCACTGTTT CTCTACAGCA 1680 GGTCCCCAAG TCACTCCAAG AACATGACTA TTTCAAGGGG GGGACTGATG CAGTGTGAGG 1740 AATTGATAGC GTATCTGCGG GATGAATCTG AATTTAGAGA CAAACTCACT CCAATTACTA 1800 TTTTTATGGA ATATCGGTTG GATTATAGAA CAGCTGCTGA TACAACAGGC TTGCAACCCA 1860 TTCTTAACCA GTTCACGCCT GCTAACATTA GTCGACAGGC TCACATTCTA CTTGACTGTG 1920 GTGAAGACAA TGTCTGTAAA CCCAAGCTGG AAGTTTCTGT AGATAGTGAT CAAAAGAAGA 1980 TCTATATTGG GGATGACAAC CCTCTGACAT TGATTGTTAA GGCTCAGAAT CAAGGAGAAG 2040 GTGCCTACGA AGCTGAGCTC ATCGTTTCCA TTCCACTGCA GGCTGATTTC ATCGGGGTTG 2100 TCCGAAACAA TGAAGCCTTA GCAAGACTTT CCTGTGCATT TAAGACAGAA AACCAAACTC 2160 GCCAGGTGGT ATGTGACCTT GGAAACCCAA TGAAGGCTGG AACTCAACTC TTAGCTGGTC 2220 TTCGTTTCAG TGTGCACCAG CAGTCAGAGA TGGATACTTC TGTGAAATTT GACTTACAAA 2280 TCCAAAGCTC AAATCTATTT GACAAAGTAA GCCCAGTTGT ATCTCACAAA GTTGATCTTG 2340 CTGTTTTAGC TGCAGTTGAG ATAAGAGGAG TCTCGAGTCC TGATCATATC TTTCTTCCGA 2400 TTCCAAACTG GGAGCACAAG GAGAACCCTG AGACTGAAGA AGATGTTGGG CCAGTTGTTC 2460 AGCACATCTA TGAGCTGAGA AACAATGGTC CAAGTTCATT CAGCAAGGCA ATGCTCCATC 2520 TTCAGTGGCC TTACAAATAT AATAATAACA CTCTGTTGTA TATCCTTCAT TATGATATTG 2580 ATGGACCAAT GAACTGCACT TCAGATATGG AGATCAACCC TTTGAGAATT AAGATCTCAT 2640 CTTTGCAAAC AACTGAAAAG AATGACACGG TTGCCGGGCA AGGTGAGCGG GACCATCTCA 2700 TCACTAAGCG GGATCTTGCC CTCAGTGAAG GAGATATTCA CACTTTGGGT TGTGGAGTTG 2760 CTCAGTGCTT GAAGATTGTC TGCCAAGTTG GGAGATTAGA CAGAGGAAAG AGTGCAATCT 2820 TGTACGTAAA GTCATTACTG TGGACTGAGA CTTTTATGAA TAAAGAAAAT CAGAATCATT 2880 CCTATTCTCT GAAGTCGTCT GCTTCATTTA ATGTCATAGA GTTTCCTTAT AAGAATCTTC 2940 CAATTGAGGA TATCACCAAC TCCACATTGG TTACCACTAA TGTCACCTGG GGCATTCAGC 3000 CAGCGCCCAT GCCTGTGCCT GTGTGGGTGA TCATTTTAGC AGTTCTAGCA GGATTGTTGC 3060 TACTGGCTGT TTTGGTATTT GTAATGTACA GGATGGGCTT TTTTAAACGG GTCCGGCCAC 3120 CTCAAGAAGA ACAAGAAAGG GAGCAGCTTC AACCTCATGA AAATGGTGAA GGAAACTCAG 3180 AAACTTAACT GCAGTTTTTA AGTTATGCTA CATCTTGACC CACTAGAATT AGCAACTTTA 3240 TTATAGATTT AAACTTTCTT CATGAGGAGT AAAAATCCAA GGCTTTACTG CTGATAGTGC 3300 TAATTGGCAT TAACCACAAA ATGAGAATTA TATTTGTCAA CCTTCTCCTT ATAAATAAGT 3360 TCAGACATAC ATTTAATAAC ATAGGGTGAC TTGTGTTTTT AGGTATTTAA ATAATAAAAT 3420 TTCAAGGGAT AGTTTTTATT CAATGTATAT AAGACAGGTA GTGCCTGATT TACTACTTTA 3480 TATAAAATAG TACCTCCTTC AGTTACTGTT TCTGATTTAA TGTACGGAAC TTTATTTGTT 3540 GTTGTTGTTG TTGTTGTTGT TGTTGTTTTA AAGCAGTCCA AATTTGGACC TTAGCAATCA 3600 TGTCTTTTGT ATAGGTACTT AATGTTAATA CATATTACAC TACAGTTTAC TTTTCAGAAT 3660 ACTAAAGACT TTATAACTGC ATGAACTTGG ATTTTTTTAA TCACTCATAT GGTAGAATTT 3720 TATAAACACA TACATGATAC CATCCAAATT CTTGCTTTTA ATAACAAAGG TACAATATTT 3780 TGTTTTAGTA TGAAAATCTG GTAGATCCTA TTACACTTCT GTTTATATTA AATCCACAAT 3840 ATTTTATTAC ATTTTTAACT TGTATAAATT TTAGGTCAAA TCCTTCAAGC CAACCTATAC 3900 TAAAAATTAG TTCCATAATC ACAAATGGCT CTTTTGTGTA ATTGTTTAAT TTCACCTGAA 3960 TATCATAATG CTTAAAGCCA TATGGAGTTG GAAATTATTT CCAAAGCATA TTTATTCCAT 4020 TGTTTTAGTC TGGCTATTTA CAGTATAAAA AAAGCATTTT ATTAAAATAC TGTGTAGTTC 4080 TTTGAGATAG TTGCTTATGC ATATAGTAAG TATTACATTC TTAGAGTAGA GCAGAGTTTT 4140 TAGTTAGTAT TAATTTATTT TCCTCCATTC ATGTACTTTT CCTTATATTT CCAAAACTGT 4200 TACTGAGAAT GGGTCAAGAT CAGTGAGAAA TCTTTACAGT TGACAGGAAC CTGGACCCCT 4260 TACCCCAACT TTATGAGTAA TGCTTGGAAT AAAAAACTCT TAAGGCAACT CACTGATTTA 4320 CTTCTAGCAA TAGCATGATG TTACAGGAAT ATTACCTCTG TTTAAGCAAG GTAATGTGTA 4380 AAATCAGTCT CGGCTGTCAG AATAACTTCT AAAAGGTATT TTTATAAGCA GTTCAAGTTA 4440 CTGAAAACCT TTTAAACCTT TCTGAAGTTC GTTAGTATAA ATTACTTTTC TAGGATTATT 4500 AATAAAAGCC ACATAGGTGG CAAGTTGTAG TTTTATATGG CTCTGTAGAG TGGTGAACCT 4560 TCTAGAGGAA TATATGATTT ATTCACAGTT CCTCAAGGCC TGGGGATGAT GATCAGTTAT 4620 ACCTATTTTT GTGCAATTAC ATCATGTTGT ACATTAGAAA TGGAGAGTTT AATAGCTCTT 4680 TAACTGCTGT CCTCATTAGG TAATGATAAA TATTTCCCTT AAATAATTGA CTATTTTGCT 4740 GTGTTTTAAA AATGATTGAA ATTTATCTTG CCATATCTCA TAATTTCATG CACAAGTTGA 4800 CTGAGCTAAT CTTGAGAATA TATTCGTAAA ATAGGAGCAC ATTTAGTTGA GGTATACAAG 4860 GTAGGACTCT AGACAAAACC TTCTATTTTA GCTTTAGTGA ATTTCAAAAG TAATGGGTCT 4920 TGGAGTATAG ATTTTTATTA GTAGCTTGAA AGAGCTTAAT CATATGCAGT AAGTATTTTT ₄980 ATTACCAATA AATTTAAAAT TTTTTAAGAA AAATATTTTT ATCCTAGGGC CAAGTGTTGC 50₄0 CTGCCACCAA TCAGTAAGTT AGTCTATAAC AAATTTTACC CTAACAGTTT TACCACCTAG 5100 CAACAGTCAT TTCTGAAAAT ATGTTGGATA GAAAGTCACT CTTTGGCAAA AGTGTTAGAA 5160 TTTGCTTTTG TGCCATCTAT TCCTTTTATG GCATCTATCT TGAAAGTAAT CTTGTATTGG 5220 AGATTGAAAG ATGCTGTAAT TTAGAAATTA ACATGATATC TTAAATTACC TTTATGAAAT 5280 ATAGTTTTGT ATAATAGCAT AGATTTTCCT TCAAAAAATG AACATTTATA TATCTACAAA 5340 AATATGGAGA AGAGCAATTT GAAAGCCTAC TTTCTGAAGA AAATGGTGGG ATTTTTTTTT 5400 ATCATGATTA AATATCAAAA AATTGCCCTA TGAAAACTTT AAATCTCTAA AACATTTGAA 5460 ATACTACCAT ATTTGTGATT TATTGAGAAT AAAAATCCAT TTTGAAATGT AAAATTTTTA 5520 TGATCTGATT CAGTTTTAAG AAAACATGAA TGAACTAGAA GATATTAAAA ACATTTGACA 5580 TTGGTAAGAA ATATTGATAC TGATATTGAT TTTTATATAG GTATTTATTT CAGAATTGAT 5640 ATTTTGAGAA AAATACATGT GAGTCATTTT TTCTGTTTCT CTTTTCTCTT AACGATTATC 5700 ACTGTAATTC TGAATCT

Seq ID NO : 189 Protein sequence : Protein Accession # : NP 002201.1

11 21 31 41 51

MAFPPRRRLR LGPRGLPLLL SGLLLPLCRA FNLDVDSPAE YSGPEGSYFG FAVDFFVPSA 60 SSRMFLLVGA PKANTTQPGI VEGGQVLKCD WSSTRRCQPI EFDATGNRDY AKDDPLEFKS 120 HQWFGASVRS KQDKILACAP LYHWRTEMKQ EREPVGTCFL QDGTKTVEYA PCRSQDIDAD 180 GQGFCQGGFS IDFTKADRVL LGGPGSFYWQ GQLISDQVAE IVSKYDPNVY SIKYNNQLAT 240 RTAQAIFDDS YLGYSVAVGD FNGDGIDDFV SGVPRAARTL GMVYIYDGKN MSSLYNFTGE 300 QMAAYFGFSV AATDINGDDY ADVFIGAPLF MDRGSDGKLQ EVGQVSVSLQ RASGDFQTTK 360

LNGFEVFARF GSAIAPLGDL DQDGFNDIAI AAPYGGEDKK GIVYIFNGRS TGLNAVPSQI 420

LEGQWAARSM PPSFGYSMKG ATDIDKNGYP DLIVGAFGVD RAILYRARPV ITVNAGLEVY 480

PSILNQDNKT CSLPGTALKV SCFNVRFCLK ADGKGVLPRK LNFQVELLLD KLKQKGAIRR 540 ALFLYSRSPS HSKNMTISRG GLMQCEELIA YLRDESEFRD KLTPITIFME YRLDYRTAAD 600

TTGLQPILNQ FTPANISRQA HILLDCGEDN VCKPKLEVSV DSDQKKIYIG DDNPLTLIVK 660

AQNQGEGAYE AELIVSIPLQ ADFIGWRNN EALARLSCAF KTENQTRQW CDLGNPMKAG 720

TQLLAGLRFS VHQQSEMDTS VKFDLQIQSS NLFDKVSPW SHKVDLAVLA AVEIRGVSSP 780

DHIFLPIPNW EHKENPETEE DVGPWQHIY ELRNNGPSSF SKAMLHLQWP YKYNNNTLLY 840 ILHYDIDGPM NCTSDMEINP LRIKISSLQT TEKNDTVAGQ GERDHLITKR DLALSEGDIH gOO

TLGCGVAQCL KIVCQVGRLD RGKSAILYVK SLLWTETFMN KENQNHSYSL KSSASFNVIE 60

FPYKNLPIED ITNSTLVTTN VTWGIQPAPM PVPVWVIILA VLAGLLLLAV LVFVMYRMGF 1020 FKRVRPPQEE QEREQLQPHE NGEGNSET Seq ID NO : 190 DNA sequence

Nucleic Acid Accession # : NM_004864

Coding sequence : 26-952 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

CGGAACGAGG GCAACCTGCA CAGCCATGCC CGGGCAAGAA CTCAGGACGG TGAATGGCTC 60

TCAGATGCTC CTGGTGTTGG TGGTGCTCTC GTGGCTGCCG CATGGGGGCG CCCTGTCTCT 120

GGCCGAGGCG AGCCGCGCAA GTTTCCCGGG ACCCTCAGAG TTGCACTCCG AAGACTCCAG 180

ATTCCGAGAG TTGCGGAAAC GCTACGAGGA CCTGCTAACC AGGCTGCGGG CCAACCAGAG 240 CTGGGAAGAT TCGAACACCG ACCTCGTCCC GGCCCCTGCA GTCCGGATAC TCACGCCAGA 300

AGTGCGGCTG GGATCCGGCG GCCACCTGCA CCTGCGTATC TCTCGGGCCG CCCTTCCCGA 360

GGGGCTCCCC GAGGCCTCCC GCCTTCACCG GGCTCTGTTC CGGCTGTCCC CGACGGCGTC 420

AAGGTCGTGG GACGTGACAC GACCGCTGCG GCGTCAGCTC AGCCTTGCAA GACCCCAAGC 480

GCCCGCGCTG CACCTGCGAC TGTCGCCGCC GCCGTCGCAG TCGGACCAAC TGCTGGCAGA 540 ATCTTCGTCC GCACGGCCCC AGCTGGAGTT GCACTTGCGG CCGCAAGCCG CCAGGGGGCG 600

CCGCAGAGCG CGTGCGCGCA ACGGGGACGA CTGTCCGCTC GGGCCCGGGC GTTGCTGCCG 660

TCTGCACACG GTCCGCGCGT CGCTGGAAGA CCTGGGCTGG GCCGATTGGG TGCTGTCGCC 720

ACGGGAGGTG CAAGTGACCA TGTGCATGGG CGCGTGCCCG AGCCAGTTCC GGGCGGCAAA 780

CATGCACGCG CAGATCAAGA CGAGCCTGCA CCGCCTGAAG CCCGACACGG AGCCAGCGCC 840 CTGCTGCGTG CCCGCCAGCT ACAATCCCAT GGTGCTCATT CAAAAGACCG ACACCGGGGT 900

GTCGCTCCAG ACCTATGATG ACTTGTTAGC CAAAGACTGC CACTGCATAT GAGCAGTCCT 960

GGTCCTTCCA CTGTGCACCT GCGCGGGGGA GGCGACCTCA GTTGTCCTGC CCTGTGGAAT 1020

GGGCTCAAGG TTCCTGAGAC ACCCGATTCC TGCCCAAACA GCTGTATTTA TATAAGTCTG 1080

TTATTTATTA TTAATTTATT GGGGTGACCT TCTTGGGGAC TCGGGGGCTG GTCTGATGGA 1140 ACTGTGTATT TATTTAAAAC TCTGGTGATA AAAATAAAGC TGTCTGAACT GTTAAAAAAA 1200 AAAA

Seq ID NO : 191 Protein sequence : Protein Accession # : NP 004855

11 21 31 41 51

MPGQELRTVN GSQMLLVLLV LSWLPHGGAL SLAEASRASF PGPSELHSED SRFRELRKRY 60

EDLLTRLRAN QSWEDSNTDL VPAPAVRILT PEVRLGSGGH LHLRISRAAL PEGLPEASRL 120 HRALFRLSPT ASRSWDVTRP LRRQLSLARP QAPALHLRLS PPPSQSDQLL AESSSARPQL 180

ELHLRPQAAR GRRRARARNG DDCPLGPGRC CRLHTVRASL EDLGWADWVL SPREVQVTMC 240

IGACPSQFRA ANMHAQIKTS LHRLKPDTEP APCCVPASYN PMVLIQKTDT GVSLQTYDDL 300 LAKDCHCI Seq ID NO: 192 DNA sequence

Nucleic Acid Accession #: XM_061731.1

Coding sequence: 1-567 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

ATGAGAAAAG GAAATGAGGG AGAGAACACA GAAGAGGGCA GGCTTGCTCA GCTTGCTCAA 60

AGAAAGTTTC TCAAAGAAGA TGGCATTACA TTGCACATCT CTCTGTGTCT CTCTATTGCT 120

GTAAAAGAAC CTTTCTCTCT GATTGGACTT GACACACAGA AGGATCTCAG TAAAGATTTG 180

CTGTTGTTGA TGTCCACAGA CACTGGCAAG GACAGGTTTA CCAACATACT GCTGTCACAC 240 TCCCCTCCAA TGTGCACCAA ATCACGTAAA AATGGGGATA ATGACTCCCC TGCCTTCACA 300

TGGGGTGGCA AAGACACCAG GAGCAATACT GATCTTCCTA TCAGAGACCC TGGGGGCAAG 360

AGTCTTTCAC TCACCAAACA TTCCCACAAG CCTGTCCCTG AGCATCAGTG TGACCAGAGA 420

GAGGTCTTCC AGCCACTTTC AGAGCCAGGT GTAGAAGCAG AGATGGAAGT GTTCGCTGAT 480

GCTGGATGGT GGATTTATCA GAGCTGTCAG GTTCCTTCCT CAACCCTTGC AAGAAAGAAG 540 ATGGTTTATT CTAAAGAAAC TGAGTGA

Seq ID NO : 193 Protein sequence : Protein Accession # : XP_061731 . 1 1 11 21 31 41 51 MRKGNEGENT EEGRLAQLAQ RKFLKEDGIT LHISLCLSIA VKEPFSLIGL DTQKDLSKDL 60

LLLMSTDTGK DRFTNILLSH SPPMCTKSRK NGDNDSPAFT WGGKDTRSNT DLPIRDPGGK 120

SLSLTKHSHK PVPEHQCDQR EVFQPLSEPG VEAEMEVFAD AGWWIYQSCQ VPSSTLARKK 180 MVYSKETE

Seq ID NO: 194 DNA sequence

Nucleic Acid Accession #: NM_005415.2

Coding sequence: 371-2410 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

GAGCTGTCCC CGGTGCCGCC GACCCGGGCC GTGCCGTGTG CCCGTGGCTC CAGCCGCTGC 60 CGCCTCGATC TCCTCGTCTC CCGCTCCGCC CTCCCTTTTC CCTGGATGAA CTTGCGTCCT 120 TTCTCTTCTC CGCCATGGAA TTCTGCTCCG TGCTTTTAGC CCTCCTGAGC CAAAGAAACC 180 CCAGACAACA GATGCCCATA CGCAGCGTAT AGCAGTAACT CCCCAGCTCG GTTTCTGTGC 240 CGTAGTTTAC AGTATTTAAT TTTATATAAT ATATATTATT TATTATAGCA TTTTTGATAC 300 CTCATATTCT GTTTACACAT CTTGAAAGGC GCTCAGTAGT TCTCTTACTA AACAACCACT 360 ACTCCAGAGA ATGGCAACGC TGATTACCAG TACTACAGCT GCTACCGCCG CTTCTGGTCC 420' TTTGGTGGAC TACCTATGGA TGCTCATCCT GGGCTTCATT ATTGCATTTG TCTTGGCATT 480 CTCCGTGGGA GCCAATGATG TAGCAAATTC TTTTGGTACA GCTGTGGGCT CAGGTGTAGT 540 GACCCTGAAG CAAGCCTGCA TCCTAGCTAG CATCTTTGAA ACAGTGGGCT CTGTCTTACT 600 GGGGGCCAAA GTGAGCGAAA CCATCCGGAA GGGCTTGATT GACGTGGAGA TGTACAACTC 660 GACTCAAGGG CTACTGATGG CCGGCTCAGT CAGTGCTATG TTTGGTTCTG CTGTGTGGCA 720 ACTCGTGGCT TCGTTTTTGA AGCTCCCTAT TTCTGGAACC CATTGTATTG TTGGTGCAAC 780 TATTGGTTTC TCCCTCGTGG CAAAGGGGCA GGAGGGTGTC AAGTGGTCTG AACTGATAAA 840 AATTGTGATG TCTTGGTTCG TGTCCCCACT GCTTTCTGGA ATTATGTCTG GAATTTTATT 900 CTTCCTGGTT CGTGCATTCA TCCTCCATAA GGCAGATCCA GTTCCTAATG GTTTGCGAGC 960 TTTGCCAGTT TTCTATGCCT GCACAGTTGG AATAAACCTC TTTTCCATCA TGTATACTGG 1020 AGCACCGTTG CTGGGCTTTG ACAAACTTCC TCTGTGGGGT ACCATCCTCA TCTCGGTGGG 1080 ATGTGCAGTT TTCTGTGCCC TTATCGTCTG GTTCTTTGTA TGTCCCAGGA TGAAGAGAAA 1140 AATTGAACGA GAAATAAAGT GTAGTCCTTC TGAAAGCCCC TTAATGGAAA AAAAGAATAG 1200 CTTGAAAGAA GACCATGAAG AAACAAAGTT GTCTGTTGGT GATATTGAAA ACAAGCATCC 1260 TGTTTCTGAG GTAGGGCCTG CCACTGTGCC CCTCCAGGCT GTGGTGGAGG AGAGAACAGT 1320 CTCATTCAAA CTTGGAGATT TGGAGGAAGC TCCAGAGAGA GAGAGGCTTC CCAGCGTGGA 1380 CTTGAAAGAG GAAACCAGCA TAGATAGCAC CGTGAATGGT GCAGTGCAGT TGCCTAATGG 1440 GAACCTTGTC CAGTTCAGTC AAGCCGTCAG CAACCAAATA AACTCCAGTG GCCACTCCCA 1500 GTATCACACC GTGCATAAGG ATTCCGGCCT GTACAAAGAG CTACTCCATA AATTACATCT 1560 TGCCAAGGTG GGAGATTGCA TGGGAGACTC CGGTGACAAA CCCTTAAGGC GCAATAATAG 1620 CTATACTTCC TATACCATGG CAATATGTGG CATGCCTCTG GATTCATTCC GTGCCAAAGA 1680 AGGTGAACAG AAGGGCGAAG AAATGGAGAA GCTGACATGG CCTAATGCAG ACTCCAAGAA 1740 GCGAATTCGA ATGGACAGTT ACACCAGTTA CTGCAATGCT GTGTCTGACC TTCACTCAGC 1800 ATCTGAGATA GACATGAGTG TCAAGGCAGC GATGGGTCTA GGTGACAGAA AAGGAAGTAA 1860 TGGCTCTCTA GAAGAATGGT ATGACCAGGA TAAGCCTGAA GTCTCTCTCC TCTTCCAGTT 1920 CCTGCAGATC CTTACAGCCT GCTTTGGGTC ATTCGCCCAT GGTGGCAATG ACGTAAGCAA 1980 TGCCATTGGG CCTCTGGTTG CTTTATATTT GGTTTATGAC ACAGGAGATG TTTCTTCAAA 2040 AGTGGCAACA CCAATATGGC TTCTACTCTA TGGTGGTGTT GGTATCTGTG TTGGTCTGTG 2100 GGTTTGGGGA AGAAGAGTTA TCCAGACCAT GGGGAAGGAT CTGACACCGA TCACACCCTC 2160 TAGTGGCTTC AGTATTGAAC TGGCATCTGC CCTCACTGTG GTGATTGCAT CAAATATTGG 2220 CCTTCCCATC AGTACAACAC ATTGTAAAGT GGGCTCTGTT GTGTCTGTTG GCTGGCTCCG 2280 GTCCAAGAAG GCTGTTGACT GGCGTCTCTT TCGTAACATT TTTATGGCCT GGTTTGTCAC 2340 AGTCCCCATT TCTGGAGTTA TCAGTGCTGC CATCATGGCA ATCTTCAGAT ATGTCATCCT 2400 CAGAATGTGA AGCTGTTTGA GATTAAAATT TGTGTCAATG TTTGGGACCA TCTTAGGTAT 2460 TCCTGCTCCC CTGAAGAATG ATTACAGTGT TAACAGAAGA CTGACAAGAG TCTTTTTATT 2520 TGGGAGCAGA GGAGGGAAGT GTTACTTGTG CTATAACTGC TTTTGTGCTA AATATGAATT 2580 GTCTCAAAAT TAGCTGTGTA AAATAGCCCG GGTTCCACTG GCTCCTGCTG AGGTCCCCTT 2640 TCCTTCTGGG CTGTGAATTC CTGTACATAT TTCTCTACTT TTTGTATCAG GCTTCAATTC 2700 CATTATGTTT TAATGTTGTC TCTGAAGATG ACTTGTGATT TTTTTTTCTT TTTTTTAAAC 2760 CATGAAGAGC CGTTTGACAG AGCATGCTCT GCGTTGTTGG TTTCACCAGC TTCTGCCCTC 2820 ACATGCACAG GGATTTAACA ACAAAAATAT AACTACAACT TCCCTTGTAG TCTCTTATAT 2880 AAGTAGAGTC CTTGGTACTC TGCCCTCCTG TCAGTAGTGG CAGGATCTAT TGGCATATTC 2940 GGGAGCTTCT TAGAGGGATG AGGTTCTTTG AACACAGTGA AAATTTAAAT TAGTAACTTT 3000 TTTGCAAGCA GTTTATTGAC TGTTATTGCT AAGAAGAAGT AAGAAAGAAA AAGCCTGTTG 3060 GCAATCTTGG TTATTTCTTT AAGATTTCTG GCAGTGTGGG ATGGATGAAT GAAGTGGAAT 3120 GTGAACTTTG GGCAAGTTAA ATGGGACAGC CTTCCATGTT CATTTGTCTA CCTCTTAACT 3180 GAATAAAAAA GCCTACAGTT TTTAGAAAAA ACCCGAATTC

Seq ID NO: 195 Protein sequence: Protein Accession #: NP 005406.2

11 21 31 41 51

MATLITSTTA ATAASGPLVD YLWMLILGFI IAFVLAFSVG ANDVANSFGT AVGSGWTLK 60 QACILASIFE TVGSVLLGAK VSETIRKGLI DVEMYNSTQG LLMAGSVSAM FGSAVWQLVA 120 SFLKLPISGT HCIVGATIGF SLVAKGQEGV KWSELI IVM SWFVSPLLSG IMSGILFFLV 180 RAFILHKADP VPNGLRALPV FYACTVGINL FSIMYTGAPL LGFDKLPLWG TILISVGCAV 240 FCALIVWFFV CPRMKRKIER EIKCSPSESP LMEKKNSLKE DHEETKLSVG DIENKHPVSE 300 VGPATVPLQA WEERTVSFK LGDLEEAPER ERLPSVDLKE ETSIDSTVNG AVQLPNGNLV 360 QFSQAVSNQI NSSGHSQYHT VHKDSGLYKE LLHKLHLAKV GDCMGDSGDK PLRRNNSYTS 420 YTMAICGMPL DSFRAKEGEQ KGEEMEKLTW PNADSKKRIR MDSYTSYCNA VSDLHSAΞEI 480 DMSVKAAMGL GDRKGSNGSL EEWYDQDKPE VSLLFQFLQI LTACFGSFAH GGNDVSNAIG 540 PLVALYLVYD TGDVSSKVAT PIWLLLYGGV GICVGLWVWG RRVIQTMGKD LTPITPSSGF 600 SIELASALTV VIASNIGLPI STTHCKVGSV VSVGWLRSKK AVDWRLFRNI FMAWFVTVPI 660 SGVISAAIMA IFRYVILRM

Seq ID NO: 196 DNA sequence

10 Nucleic Acid Accession #: NM_000020.1

Coding sequence: 283-1794 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

I I I I I

15 AGGAAACGGT TTATTAGGAG GGAGTGGTGG AGCTGGGCCA GGCAGGAAGA CGCTGGAATA 60 AGAAACATTT TTGCTCCAGC CCCCATCCCA GTCCCGGGAG GCTGCCGCGC CAGCTGCGCC 120 GAGCGAGCCC CTCCCCGGCT CCAGCCCGGT CCGGGGCCGC GCCGGACCCC AGCCCGCCGT 180 CCAGCGCTGG CGGTGCAACT GCGGCCGCGC GGTGGAGGGG AGGTGGCCCC GGTCCGCCGA 240 AGGCTAGCGC CCCGCCACCC GCAGAGCGGG CCCAGAGGGA CCATGACCTT GGGCTCCCCC 300

20 AGGAAAGGCC TTCTGATGCT GCTGATGGCC TTGGTGACCC AGGGAGACCC TGTGAAGCCG 360 TCTCGGGGCC CGCTGGTGAC CTGCACGTGT GAGAGCCCAC ATTGCAAGGG GCCTACCTGC 420 CGGGGGGCCT GGTGCACAGT AGTGCTGGTG CGGGAGGAGG GGAGGCACCC CCAGGAACAT 480 CGGGGCTGCG GGAACTTGCA CAGGGAGCTC TGCAGGGGGC GCCCCACCGA GTTCGTCAAC 540 CACTACTGCT GCGACAGCCA CCTCTGCAAC CACAACGTGT CCCTGGTGCT GGAGGCCACC 600

25 CAACCTCCTT CGGAGCAGCC GGGAACAGAT GGCCAGCTGG CCCTGATCCT GGGCCCCGTG 660 CTGGCCTTGC TGGCCCTGGT GGCCCTGGGT GTCCTGGGCC TGTGGCATGT CCGACGGAGG 720 CAGGAGAAGC AGCGTGGCCT GCACAGCGAG CTGGGAGAGT CCAGTCTCAT CCTGAAAGCA 780 TCTGAGCAGG GCGACACGAT GTTGGGGGAC CTCCTGGACA GTGACTGCAC CACAGGGAGT 840 GGCTCAGGGC TCCCCTTCCT GGTGCAGAGG ACAGTGGCAC GGCAGGTTGC CTTGGTGGAG 900

30 TGTGTGGGAA AAGGCCGCTA TGGCGAAGTG TGGCGGGGCT TGTGGCACGG TGAGAGTGTG 960 GCCGTCAAGA TCTTCTCCTC GAGGGATGAA CAGTCCTGGT TCCGGGAGAC TGAGATCTAT 1020 AACACAGTAT TGCTCAGACA CGACAACATC CTAGGCTTCA TCGCCTCAGA CATGACCTCC 1080 CGCAACTCGA GCACGCAGCT GTGGCTCATC ACGCACTACC ACGAGCACGG CTCCCTCTAC 1140 GACTTTCTGC AGAGAGAGAG GCTGGAGCCC CATCTGGCTC TGAGGCTAGC TGTGTCCGCG 1200

35 GCATGCGGCC TGGCGCACCT GCACGTGGAG ATCTTCGGTA CACAGGGCAA ACCAGCCATT 1260 GCCCACCGCG ACTTCAAGAG CCGCAATGTG CTGGTCAAGA GCAACCTGCA GTGTTGCATC 1320 GCCGACCTGG GCCTGGCTGT GATGCACTCA CAGGGCAGCG ATTACCTGGA CATCGGCAAC 1380 AACCCGAGAG TGGGCACCAA GCGGTACATG GCACCCGAGG TGCTGGACGA GCAGATCCGC 1440 ACGGACTGCT TTGAGTCCTA CAAGTGGACT GACATCTGGG CCTTTGGCCT GGTGCTGTGG 1500

40 GAGATTGCCC GCCGGACCAT CGTGAATGGC ATCGTGGAGG ACTATAGACC ACCCTTCTAT 1560 GATGTGGTGC CCAATGACCC CAGCTTTGAG GACATGAAGA AGGTGGTGTG TGTGGATCAG 1620 CAGACCCCCA CCATCCCTAA CCGGCTGGCT GCAGACCCGG TCCTCTCAGG CCTAGCTCAG 1680 ATGATGCGGG AGTGCTGGTA CCCAAACCCC TCTGCCCGAC TCACCGCGCT GCGGATCAAG 1740 AAGACACTAC AAAAAATTAG CAACAGTCCA GAGAAGCCTA AAGTGATTCA ATAGCCCAGG 1800

45 AGCACCTGAT TCCTTTCTGC CTGCAGGGGG CTGGGGGGGT GGGGGGCAGT GGATGGTGCC 1860 CTATCTGGGT AGAGGTAGTG TGAGTGTGGT GTGTGCTGGG GATGGGCAGC TGCGCCTGCC 1920 TGCTCGGCCC CCAGCCCACC CAGCCAAAAA TACAGCTGGG CTGAAACCTG

Seq ID NO: 197 Protein sequence:

50 Protein Accession #: NP 000011.1

11 21 31 41 51

MTLGSPRKGL LMLLMALVTQ GDPVKPSRGP LVTCTCESPH CKGPTCRGAW CTWLVREEG 60

55. RHPQEHRGCG NLHRELCRGR PTEFVNHYCC DSHLCNHNVS LVLEATQPPS EQPGTDGQLA 120 LILGPVLALL ALVALGVLGL WHVRRRQEKQ RGLHSELGES SLILKASEQG DTMLGDLLDS 180 DCTTGSGSGL PFLVQRTVAR QVALVECVGK GRYGEVWRGL WHGESVAVKI FSSRDEQSWF 240 RETEIYNTVL LRHDNILGFI ASDMTSRNSS TQLWLITHYH EHGSLYDFLQ RQTLEPHLAL 300 RLAVSAACGL AHLHVEIFGT QGKPAIAHRD FKSRNVLVKS NLQCCIADLG LAVMHSQGSD 360

60 YLDIGNNPRV GTKRYMAPEV LDEQIRTDCF ESYKWTDIWA FGLVLWEIAR RTIVNGIVED 420 YRPPFYDWP NDPSFEDMKK WCVDQQTPT IPNRLAADPV LSGLAQMMRE CWYPNPSARL 480 TALRIKKTLQ KISNSPEKPK VIQ

Seq ID NO: 198 DNA sequence

65 Nucleic Acid Accession #: NM_00319g.l

Coding sequence: 200-2203 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

I I I I I

70 CGGGGGGATC TTGGCTGTGT GTCTGCGGAT CTGTAGTGGC GGCGGCGGCG GCGGCGGCGG 60 GGAGGCAGCA GGCGCGGGAG CGGGCGCAGG AGCAGGCGGC GGCGGTGGCG GCGGCGGTTA 120 GACATGAACG CCGCCTCGGC GCCGGCGGTG CACGGAGAGC CCCTTCTCGC GCGCGGGCGG 180 TTTGTGTGAT TTTGCTAAAA. TGCATCACCA ACAGCGAATG GCTGCCTTAG GGACGGACAA 240 AGAGCTGAGT GATTTACTGG ATTTCAGTGC GATGTTTTCA CCTCCTGTGA GCAGTGGGAA 300

75 AAATGGACCA ACTTCTTTGG CAAGTGGACA TTTTACTGGC TCAAATGTAG AAGACAGAAG 360 TAGCTCAGGG TCCTGGGGGA ATGGAGGACA TCCAAGCCCG TCCAGGAACT ATGGAGATGG 420 GACTCCCTAT GACCACATGA CCAGCAGGGA CCTTGGGTCA CATGACAATC TCTCTCCACC 480 TTTTGTCAAT TCCAGAATAC AAAGTAAAAC AGAAAGGGGC TCATACTCAT CTTATGGGAG 540 AGAATCAAAC TTACAGGGTT GCCACCAGCA GAGTCTCCTT GGAGGTGACA TGGATATGGG 600 CAACCCAGGA ACCCTTTCGC CCACCAAACC TGGTTCCCAG TACTATCAGT ATTCTAGCAA 660 TAATCCCCGA AGGAGGCCTC TTCACAGTAG TGCCATGGAG GTACAGACAA AGAAAGTTCG 720 AAAAGTTCCT CCAGGTTTGC CATCTTCAGT CTATGCTCCA TCAGCAAGCA CTGCCGACTA 780 CAATAGGGAC TCGCCAGGCT ATCCTTCCTC CAAACCAGCA ACCAGCACTT TCCCTAGCTC 840 CTTCTTCATG CAAGATGGCC ATCACAGCAG TGACCCTTGG AGCTCCTCCA GTGGGATGAA 900 TCAGCCTGGC TATGCAGGAA TGTTGGGCAA CTCTTCTCAT ATTCCACAGT CCAGCAGCTA 960 CTGTAGCCTG CATCCACATG AACGTTTGAG CTATCCATCA CACTCCTCAG CAGACATCAA 1020 TTCCAGTCTT CCTCCGATGT CCACTTTCCA TCGTAGTGGT ACAAACCATT ACAGCACCTC 1080 TTCCTGTACG CCTCCTGCCA ACGGGACAGA CAGTATAATG GCAAATAGAG GAAGCGGGGC 1140 AGCCGGCAGC TCCCAGACTG GAGATGCTCT GGGGAAAGCA CTTGCTTCGA TCTATTCTCC 1200 AGATCACACT AACAACAGCT TTTCATCAAA CCCTTCAACT CCTGTTGGCT CTCCTCCATC 1260 TCTCTCAGCA GGCACAGCTG TTTGGTCTAG AAATGGAGGA CAGGCCTCAT CGTCTCCTAA 1320 TTATGAAGGA CCCTTACACT CTTTGCAAAG CCGAATTGAA GATCGTTTAG AAAGACTGGA 1380 TGATGCTATT CATGTTCTCC GGAACCATGC AGTGGGCCCA TCCACAGCTA TGCCTGGTGG 1440 TCATGGGGAC ATGCATGGAA TCATTGGACC TTCTCATAAT GGAGCCATGG GTGGTCTGGG 1500 CTCAGGGTAT GGAACCGGCC TTCTTTCAGC CAACAGACAT TCACTCATGG TGGGGACCCA 1560 TCGTGAAGAT GGCGTGGCCC TGAGAGGCAG CCATTCTCTT CTGCCAAACC AGGTTCCGGT 1620 TCCACAGCTT CCTGTCCAGT CTGCGACTTC CCCTGACCTG AACCCACCCC AGGACCCTTA 1680 CAGAGGCATG CCACCAGGAC TACAGGGGCA GAGTGTCTCC TCTGGCAGCT CTGAGATCAA 1740 ATCCGATGAC GAGGGTGATG AGAACCTGCA AGACACGAAA TCTTCGGAGG ACAAGAAATT 1800 AGATGACGAC AAGAAGGATA TCAAATCAAT TACTAGCAAT AATGACGATG AGGACCTGAC 1860 ACCAGAGCAG AAGGCAGAGC GTGAGAAGGA GCGGAGGATG GCCAACAATG CCCGAGAGCG 1920 TCTGCGGGTC CGTGACATCA ACGAGGCTTT CAAAGAGCTC GGCCGCATGG TGCAGCTCCA 1980 CCTCAAGAGT GACAAGCCCC AGACCAAGCT CCTGATCCTC CACCAGGCGG TGGCCGTCAT 2040 CCTCAGTCTG GAGCAGCAAG TCCGAGAAAG GAATCTGAAT CCGAAAGCTG CGTGTCTGAA 2100 AAGAAGGGAG GAAGAGAAGG TGTCCTCGGA GCCTCCCCCT CTCTCCTTGG CCGGCCCACA 2160 CCCTGGAATG GGAGACGCAT CGAATCACAT GGGACAGATG TAAAAGGGTC CAAGTTGCCA 2220 CATTGCTTCA TTAAAACAAG AGACCACTTC CTTAACAGCT GTATTATCTT AAACCCACAT 2280 AAACACTTCT CCTTAACCCC CATTTTTGTA ATATAAGACA AGTCTGAGTA GTTATGAATC 2340 GCAGACGCAA GAGGTTTCAG CATTCCCAAT TATCAAAAAA CAGAAAAACA AAAAAAAGAA 2400 AGAAAAAAGT GCAACTTGAG GGACGACTTT CTTTAACATA TCATTCAGAA TGTGCAAAGC 2460 AGTATGTACA GGCTGAGACA CAGCCCAGAG ACTGAACGGC

Seq ID NO: 199 Protein sequence: Protein Accession #: NP 003190.1

11 21 31 41 51

MHHQQRMAAL GTDKELSDLL DFSAMFSPPV SSGKNGPTSL ASGHFTGSNV EDRSSSGSWG 60 NGGHPSPSRN YGDGTPYDHM TSRDLGSHDN LSPPFVNSRI QSKTERGSYS SYGRESNLQG 120 CHQQSLLGGD MDMGNPGTLS PTKPGSQYYQ YSSNNPRRRP LHSSAMEVQT KKVRKVPPGL 180 PSSVYAPSAS TADYNRDSPG YPSSKPATST FPSSFFMQDG HHSSDPWSSS SGMNQPGYAG 240 MLGNSSHIPQ SSSYCSLHPH ERLSYPSHSS ADINSSLPPM STFHRSGTNH YSTSSCTPPA 300 NGTDSIMANR GSGAAGSSQT GDALGKALAS IYSPDHTNNS FSSNPSTPVG SPPSLSAGTA 360 VWSRNGGQAS SSPNYEGPLH SLQSRIEDRL ERLDDAIHVL RNHAVGPSTA MPGGHGDMHG 420 IIGPSHNGAM GGLGSGYGTG LLSANRHSLM VGTHREDGVA LRGSHSLLPN QVPVPQLPVQ 480 SATSPDLNPP QDPYRGMPPG LQGQSVSSGS SEIKSDDEGD ENLQDTKSSE DKKLDDDKKD 540 IKSITSNNDD EDLTPEQKAE REKERRMANN ARERLRVRDI NEAFKELGRM VQLHLKSDKP 600 QTKLLILHQA VAVILSLEQQ VRERNLNPKA ACLKRREEEK VSSEPPPLSL AGPHPGMGDA 660 SNHMGQM

Seq ID NO: 200 DNA sequence

Nucleic Acid Accession #: BC005987 (1-1286), BE8887₄ (1287-1756)

Coding sequence: 124-525 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

I I I I

GGCAGAAGAG GAAGATTTCT GAAGAGTGCA GCTGCCTGAA CCGAGCCCTG CCGAACAGCT 60 GAGAATTGCA CTGCAACCAT GAGTGAGAAC AATAAGAATT CCTTGGAGAG CAGCCTACGG 120 CAACTAAAAT GCCATTTCAC CTGGAACTTG ATGGAGGGAG AAAACTCCTT GGATGATTTT 180 GAAGACAAAG TATTTTACCG GACTGAGTTT CAGAATCGTG AATTCAAAGC CACAATGTGC 240 AACCTACTGG CCTATCTAAA GCACCTCAAA GGGCAAAACG AGGCAGCCCT GGAATGCTTA 300 CGTAAAGCTG AAGAGTTAAT CCAGCAAGAG CATGCTGACC AGGCAGAAAT CAGAAGTCTG 360 GTCACCTGGG GAAACTATGC CTGGGTCTAC TATCACATGG GCCGACTCTC AGACGTTCAG 420 ATTTATGTAG ACAAGGTGAA ACATGTCTGT GAGAAGTTTT CCAGTCCCTA TAGAATTGAG 480 AGTCCAGAGC TTGACTGTGA GGAAGGGTGG ACACGGTTAA AGTGTGGARG AAACCAAAAT 540 GAAAGAGCGA AGGTGTGCTT TGAGAAGGCT CTGGAAAAGA AGCCAAAGAA CCCAGAATTC 600 ACCTCTGGAC TGGCAATAGC AAGCTACCGT CTGGACAACT GGCCACCATC TCAGAACGCC 660 ATTGACCCTC TGAGGCAAGC CATTCGGCTG AATCCTGACA ACCAGTACCT TAAAGTCCTC 720 CTGGCTCTGA AGCTTCATAA GATGCGTGAA GAAGGTGAAG AGGAAGGTGA AGGAGAGAAG 780 TTAGTTGAAG AAGCCTTGGA GAAAGCCCCA GGTGTAACAG ATGTACTTCG CAGTGCAGCC 840 AAGTTTTATC GAAGAAAAGA TGAGCCAGAC AAAGCGATTG AACTGCTTAA AAAGGCTTTA 900 GAATACATAC CAAACAATGC CTACCTGCAT TGCCAAATTG GGTGCTGCTA TAGGGCAAAA 960 GTCTTCCAAG TAATGAATCT AAGAGAGAAT GGAATGTATG GGAAAAGAAA GTTACTGGAA 1020

CTAATAGGAC ACGCTGTGGC TCATCTGAAG AAAGCTGATG AGGCCAATGA TAATCTCTTC 1080

CGTGTCTGTT CCATTCTTGC CAGCCTCCAT GCTCTAGCAG ATCAGTATGA AGAAGCAGAG 1140

TATTACTTCC AAAAGGAATT CAGTAAAGAG CTTACTCCTG TAGCGAAACA ACTGCTCCAT 1200

5 CTGCGGTATG GCAACTTTCA GCTGTACCAA ATGAAGTGTG AAGACAAGGC CATCCACCAC 1260

TTTATAGAGG GTGTAAAAAT AAACCAGAAA TCAAGGGAGA AAGAAAAGAT GAAAGACAAA 1320

CTGCAAAAAA TTGCCAAAAT GCGACTTTCT AAAAATGGAG CAGATTCTGA GGCTTTGCAT 1380

GTCTTGGCAT TCCTTCAGGA GCTGAATGAA AAAATGCAAC AAGCAGATGA AGACTCTGAG 1440

AGGGGTTTGG AGTCTGGAAG CCTCATCCCT TCAGCATCAA GCTGGAATGG GGAATGAAGA 1500

10 ATAGAGATGT GGTGCCCACT AGGCTACTGC TGAAAGGGAG CTGAAATTCC TCCACAAGTT 1560

GGTATTCAAA ATATGTAATG ACTGGTATGG CAAAAGATTG GACTAAGACA CTGGCCATAC 1620

CACTGGACAG GGTTATGTTA AACCTGAATT GCTGGGTCTT AAAAGAGCCC AAGGAGTTCT 1680

GGGAGAGGGA CAGATTGGGG GGTCGTCCAG GGCTGCGCTA AATTATTCTC AATGATTTGT 1740 CTCTTTGCGG AACTTC

15

Seq ID NO: 201 Protein sequence: Protein Accession #: AAA59191

1 11 21 31 41 51

20

MSENNKNSLE SSLRQLKCHF TWNLMEGENS LDDFEDKVFY RTEFQNREFK ATMCNLLAYL 60

KHLKGQNEAA LECLRKAEEL IQQEHADQAE IRSLVTWGNY AWVYYHMGRL SDVQIYVDKV 120

KHVCEKFSSP YRIESPELDC EEGWTRLKCG GNQNERAKVC FEKALEKKPK NPEFTSGLAI 180

ASYRLDNWPP SQNAIDPLRQ AIRLNPDNQY LKVLLALKLH KMREEGEEEG EGEKLVEEAL 240

25 EKAPGVTDVL RSAAKFYRRK DEPDKAIELL KKALEYIPNN AYLHCQIGCC YRAKVFQVMN 300

LRENGMYGKR KLLELIGHAV AHLKKADEAN DNLFRVCSIL ASLHALADQY EDAEYYFQKE 360

FSKELTPVAK QLLHLRYGNF QLYQMKCEDK AIHHFIEGVK INQKSREKEK MKDKLQKIAK 420 MRLSKNGADS EALHVLAFLQ ELNEKMQQAD EDSERGLESG SLIPSASSWN GE

30

Seq ID NO : 202 DNA sequence

Nucleic Acid Accession # : NM_003090

Coding sequence : 57- 824 (underlined sequences correspond to start and stop codons)

35 1 11 21 31 41 51

I I I I I I

GAATTCCGCG GGAGGCCACG GGCTTTCCAC AGCGCGGGGG AACGGGAGGC TGCAGGATGG 60

TCAAGCTGAC GGCGGAGCTG ATCGAGCAGG CGGCGCAGTA CACCAACGCG GTGCGCGACC 120

GGGAGCTGGA CCTCCGGGGG TATAAAATTC CCGTCATTGA AAATCTAGGT GCTACGTTAG 180

40 ACCAGTTTGA TGCTATTGAT TTTTCTGACA ATGAGATCAG GAAACTGGAT GGTTTTCCTT 240

TGTTGAGAAG ACTGAAAACA TTGTTAGTGA ACAACAACAG AATATGCCGT ATAGGTGAGG 300

GACTTGATCA GGCTCTGCCC TGTCTGACAG AACTCATTCT CACCAATAAT AGTCTCGTGG 360

AACTGGGTGA TCTGGACCCT CTGGCATCTC TCAAATCGCT GACTTACCTA AGTATCCTAA 420

GAAATCCGGT AACCAATAAG AAGCATTACA GATTGTATGT GATTTATAAA GTTCCGCAAG 480

45 TCAGAGTACT GGATTTCCAG AAAGTGAAAC TAAAAGAGCG TCAGGAAGCA GAGAAAATGT 540

TCAAGGGCAA ACGGGGTGCA CAGCTTGCAA AGGATATTGC CAGGAGAAGC AAAACTTTTA 600

ATCCAGGTGC TGGTTTGCCA ACTGACAAAA AGAGAGGTGG GCCATCTCCA GGGGATGTAG 660

AAGCAATCAA GAATGCCATA GCAAATGCTT CAACTCTGGC TGAAGTGGAG AGGCTGAAGG 720

GGTTGCTGCA GTCTGGTCAG ATCCCTGGCA GAGAACGCAG ATCAGGGCCC ACTGATGATG 780

50 GTGAAGAAGA GATGGAAGAA GACACAGTCA CAAACGGGTC CTGAGCAGTG AGGCAGATGT 840

ATAATAATAG GCCCTCTTGG AACAAGTCTT GCTTTTCGAA CATGGTATAA TAGCCTTGTT g00

TGTGTTAGCA AAGTGGAATC TATCAGCATT GTTGAAATGC TTAAGACTGC TGCTGATAAT 960

TTTGTAATAT AAGTTTTGAA ATCTAAATGT CAATTTTCTA CAAATTATAA AAATAAACTC 1020 CACTCTCTAT GCTAAAAAAA AAAAAAAGGA ATTC

55

Seq ID NO : 203 Protein sequence : Protein Accession # : NP_003081 . 1

1 11 21 31 41 51

60.

MVKLTAELIE QAAQYTNAVR DRELDLRGYK IPVIENLGAT LDQFDAIDFS DNEIRKLDGF 60

PLLRRLKTLL VNNNRICRIG EGLDQALPCL TELILTNNSL VELGDLDPLA SLKSLTYLSI 120

LRNPVTNKKH YRLYVIYKVP QVRVLDFQKV KLKERQEAEK MFKGKRGAQL AKDIARRSKT 180

FNPGAGLPTD KKRGGPSPGD VEAIKNAIAN ASTLAEVERL KGLLQSGQIP GRERRSGPTD 240

65 DGEEEMEEDT VTNGS

Seq ID NO : 204 DNA sequence

Nucleic Acid Accession # : NM_017643 . 1

Coding sequence : 169 -1401 (underlined sequences correspond to start and stop codons )

70

11 21 31 41 51

AATAGCAATA GCTTTATAGC AGCTCCGGTT ACCTGTTTTA AACATGGAAG GAGAGTCGCT 60

CCCAGATAGC CCTCACGAGT GGCCCTGGAG CAGGGAGTGG TGGAGCAGAT CTTCCTTGTT 120

75 TGGGAGGAGC CTGAGGTGGA CCTCGCGTCC TGAGTCTGGA AGGCACCTAT GGGGACCTGC 180

TGGGGTGATA TCTCAGAAAA TGTGAGAGTA GAAGTTCCCA ATACAGACTG CAGCCTACCT 240 ACCAAAGTCT TCTGGATTGC TGGAATTGTA AAATTAGCAG GTTACAATGC CCTTTTAAGA 300 TATGAAGGAT TTGAAAATGA CTCTGGTCTG GACTTCTGGT GCAATATATG TGGTTCTGAT 360 ATCCATCCAG TTGGTTGGTG TGCAGCCAGC GGAAAACCTC TTGTTCCTCC TAGAACTATT 420 CAGCATAAAT ATACAAACTG GAAAGCTTTT CTAGTGAAAC GACTTACTGG TGCCAAAACA 480 CTGCCTCCTG ATTTCTCCCA AAAGGTTTCA GAGAGTATGC AGTATCCTTT CAAACCTTGC 5 0 ATGAGAGTAG AAGTGGTTGA CAAGAGGCAT TTGTGTCGAA CACGAGTAGC AGTGGTGGAA 600 AGTGTAATTG GAGGAAGATT AAGACTAGTG TATGAAGAAA GCGAAGATAG AACAGATGAC 660 TTCTGGTGCC ATATGCACAG CCCATTAATA CATCATATTG GTTGGTCTCG AAGCATAGGT 720 CATCGATTCA AAAGATCTGA TATTACAAAG AAACAGGATG GACATTTTGA TACACCACCA 780 CATTTATTTG CTAAGGTAAA AGAAGTAGAC CAGAGTGGGG AATGGTTCAA GGAAGGAATG 840 AAATTGGAAG CTATAGACCC ATTAAATCTT TCTACAATAT GTGTCGCAAC CATTAGAAAG 900 GTGCTAGCTG ACGGATTCCT GATGATTGGG ATCGATGGCT CAGAAGCAGC AGACGGATCT 960 GACTGGTTCT GTTACCATGC AACCTCTCCT TCTATTTTCC CTGTCGGTTT CTGTGAAATT 1020 AACATGATTG AACTTACTCC ACCCAGAGGT TACACAAAAC TTCCTTTTAA ATGGTTTGAC 1080 TACCTCAGGG AAACTGGCTC CATTGCAGCA CCAGTAAAAC TATTTAATAA GGATGTTCCA 1140 AATCACGGAT TTCGTGTAGG AATGAAATTA GAAGCAGTAG ATCTCATGGA GCCACGTTTA 1200 ATATGTGTAG CCACAGTAAC TCGAATTATT CATCGTCTCT TGAGGATACA TTTTGATGGA 1260 TGGGAAGAAG AGTATGATCA GTGGGTAGAC TGTGAGTCAC CTGACCTCTA TCCTGTAGGG 1320 TGGTGTCAGT TAACTGGATA TCAACTACAG CCTCCAGCAT CACAGTGTAA GTTGGTATAC 1380 AGAAAAGGTG TCCTTTTGTA. AAAATCAGCA ATTCTCCAGA GGACTATCTC ACATAAGTCA 1440 TCTTATGAGC TCACAGGACA AGAATATACC TATGTCTGAT TGGTTGCCAG GTAAGACATT 1500 AAGACTCAAC AACAATATCA CAGAATCAGA CCATGTGTCC CATGGCAATG TGAATCCAAT 1560 AGTCAATTAC ATAATGACTA TAGAAACACA ACAGTCACCA AATTAAACTA GACTTACTAT 1620 TTTAGTGAGT TAAAAATTAC ATACTAAAAG TTTATTGGTA GGTAATAAAT GCTTTTGAGT 1680 AAATAGTGGA AAATGTCTCA TGTTGAGGCT ATGGTTTTGT AGGAACAAGT ACCCTTATTT 1740 TCAGAGCATC ATGTACTTAA GTATAATGGT CTTGGTAAAG ATAGTTCATA TAAGTTGTAT 1800 CTAGACAACT GTATCGTCTA AATTGTAAAC AATTATCTAG TACCAATTTT CCCTTTTTAT 1860 TTTTCAGCAT CAAGAGAAAA CCAATCAGCT TCATCAAAAC AGAAGAAAAA GGCTAAGTCC 1920 CAGCAATACA AAGGACATAA GAAAAGTGGG TCACCACGTG GTGTTCACAT ACATTTTCTA 1980 ATTGTTAACT AATTGGAGTC ACAGTATTCT TGGACAGAAA ATGATATATC TTGTGAGAAC 2040 TGATGATTGT GCATTATGTA TTATGCTTAA AGGTGCAGTA TGCCATAAAA GGCAAACCCT 2100 TGCAATAATG AGAAACACTG ATATTTTACT AACAGGAGAA ATGATTACCA CAGTATTTAA 2160 AGTATACGTG GTAAAGAATA GAGTCTGTGA ATGATTCTTG AAATAATATG TAAAACCTAC 2220 TGAAAGTTAA TCCTTTTTAA AAACTTTATT TAAAAAGAAA AATTAGCAGC CAGGTGCAGT 2280 GGCTCACGCC TGTAATCCCA GCACTTTAGG AGGCCGAGGC TGGCAGATCA CAAGGTCAGG 2340 AGATCGAGAC CATCCTGGCT AACACGGTGA AACCCTGTCT CCACCAAAAA TACAAAAAAT 2400 CTGCCGGGCG TGGTGGCACA CGCCTGAAGT CCCAGCTACT CAGGAGGCTG AGGCAAGAGA 2460 ATCACTTGAA CCCAGGAGGC AGAGGTTGCA GTGGGCCAAG ATCACGCCAC TACATTCCAG 2520 CTGGGCAACA CAGCAAGACT CTGTCTCAAA AAAAAAAAAA AAAA

Seq ID NO: 205 Protein sequence: Protein Accession #: NP 060113.1

11 21 31 41 51

I I I I I

MGTCWGDISE NVRVEVPNTD CSLPTKVFWI AGIVKLAGYN ALLRYEGFEN DSGLDFWCNI 60 CGSDIHPVGW CAASGKPLVP PRTIQHKYTN WKAFLVKRLT GAKTLPPDFS QKVSESMQYP 120 FKPCMRVEW DKRHLCRTRV AWESVIGGR LRLVYEESED RTDDFWCHMH SPLIHHIGWS 180 RSIGHRFKRS DITKKQDGHF DTPPHLFAKV KEVDQSGEWF KEGMKLEAID PLNLSTICVA 240 TIRKVLADGF LMIGIDGSEA ADGSDWFCYH ATSPSIFPVG FCEINMIELT PPRGYTKLPF 300 KWFDYLRETG SIAAPVKLFN KDVPNHGFRV GMKLEAVDLM EPRLICVATV TRIIHRLLRI 360 HFDGWEEEYD QWVDCESPDL YPVGWCQLTG YQLQPPASQC KLVYRKGVLL

Seq ID NO : 206 DNA sequence

Nucleic Acid Accession # : NM_012334

Coding sequence : 223-6399 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

GAGACAAAGG CTGCCGTCGG GACGGGCGAG TTAGGGACTT GGGTTTGGGC GAACAAAAGG 60

TGAGAAGGAC AAGAAGGGAC CGGGCGATGG CAGCAGGGGA GCCCCGCGGG CGCGCGTCCT 120

CGGGAGTGGC GCCGTGACAC GCATGGTTTC CCCGGACCCG CGGCGGCGCT GACTTCCGCG 180

AGTCGGAGCG GCACTCGGCG AGTCCGGGAC TGCGCTGGAA CAATGGATAA CTTCTTCACC 240

GAGGGAACAC GGGTCTGGCT GAGAGAAAAT GGCCAGCATT TTCCAAGTAC TGTAAATTCC 300

TGTGCAGAAG GCATCGTCGT CTTCCGGACA GACTATGGTC AGGTATTCAC TTACAAGCAG 360

AGCACAATTA CCCACCAGAA GGTGACTGCT ATGCACCCCA CGAACGAGGA GGGCGTGGAT 420

GACATGGCGT CCTTGACAGA GCTCCATGGC GGCTCCATCA TGTATAACTT ATTCCAGCGG 480

TATAAGAGAA ATCAAATATA TACCTACATC GGCTCCATCC TGGCCTCCGT GAACCCCTAC 540

CAGCCCATCG CCGGGCTGTA CGAGCCTGCC ACCATGGAGC AGTACAGCCG GCGCCACCTG 600

GGCGAGCTGC CCCCGCACAT CTTCGCCATC GCCAACGAGT GCTACCGCTG CCTGTGGAAG 660

CGCTACGACA ACCAGTGCAT CCTCATCAGT GGTGAAAGTG GGGCAGGTAA AACCGAAAGC 720

ACTAAATTGA TCCTCAAGTT TCTGTCAGTC ATCAGTCAAC AGTCTTTGGA ATTGTCCTTA 780

AAGGAGAAGA CATCCTGTGT TGAACGAGCT ATTCTTGAAA GCAGCCCCAT CATGGAAGCT 840

TTCGGCAATG CGAAGACCGT GTACAACAAC AACTCTAGTC GCTTTGGGAA GTTTGTTCAG 900 CTGAACATCT GTCAGAAAGG AAATATTCAG GGCGGGAGAA TTGTAGATTA TTTATTAGAA 960

AAAAACCGAG TAGTAAGGCA AAATCCCGGG GAAAGGAATT ATCACATATT TTATGCACTG 1020

CTGGCAGGGC TGGAACATGA AGAAAGAGAA GAATTTTATT TATCTACGCC AGAAAACTAC 1080

CACTACTTGA ATCAGTCTGG ATGTGTAGAA GACAAGACAA TCAGTGACCA GGAATCCTTT 1140 AGGGAAGTTA TTACGGCAAT GGACGTGATG CAGTTCAGCA AGGAGGAAGT TCGGGAAGTG 1200

TCGAGGCTGC TTGCTGGTAT ACTGCATCTT GGGAACATAG AATTTATCAC TGCTGGTGGG 1260

GCACAGGTTT CCTTCAAAAC AGCTTTGGGC AGATCTGCGG AGTTACTTGG GCTGGACCCA 1320

ACACAGCTCA CAGATGCTTT GACCCAGAGA TCAATGTTCC TCAGGGGAGA AGAGATCCTC 1380

ACGCCTCTCA ATGTTCAACA GGCAGTAGAC AGCAGGGACT CCCTGGCCAT GGCTCTGTAT 1440 GCGTGCTGCT TTGAGTGGGT AATCAAGAAG ATCAACAGCA GGATCAAAGG CAATGAGGAC 1500

TTCAAGTCTA TTGGCATCCT CGACATCTTT GGATTTGAAA ACTTTGAGGT TAATCACTTT 1560

GAACAGTTCA ATATAAACTA TGCAAACGAG AAACTTCAGG AGTACTTCAA CAAGCATATT 1620

TTTTCTTTAG AACAACTAGA ATATAGCCGG GAAGGATTAG TGTGGGAAGA TATTGACTGG 1680

ATAGACAATG GAGAATGCCT GGACTTGATT GAGAAGAAAC TTGGCCTCCT AGCCCTTATC 1740 AATGAAGAAA GCCATTTTCC TCAAGCCACA GACAGCACCT TATTGGAGAA GCTACACAGT 1800

CAGCATGCGA ATAACCACTT TTATGTGAAG CCCAGAGTTG CAGTTAACAA TTTTGGAGTG 1860

AAGCACTATG CTGGAGAGGT GCAATATGAT GTCCGAGGTA TCTTGGAGAA GAACAGAGAT ig20

ACATTTCGAG ATGACCTTCT CAATTTGCTA AGAGAAAGCC GATTTGACTT TATCTACGAT 1980

CTTTTTGAAC ATGTTTCAAG CCGCAACAAC CAGGATACCT TGAAATGTGG AAGCAAACAT 2040 CGGCGGCCTA CAGTCAGCTC ACAGTTCAAG GACTCACTGC ATTCCTTAAT GGCAACGCTA 2100

AGCTCCTCTA ATCCTTTCTT TGTTCGCTGT ATCAAGCCAA ACATGCAGAA GATGCCAGAC 2160

CAGTTTGACC AGGCGGTTGT GCTGAACCAG CTGCGGTACT CAGGGATGCT GGAGACTGTG 2220

AGAATCCGCA AAGCTGGGTA TGCGGTCCGA AGACCCTTTC AGGACTTTTA CAAAAGGTAT 2280

AAAGTGCTGA TGAGGAATCT GGCTCTGCCT GAGGACGTCC GAGGGAAGTG CACGAGCCTG 2340 CTGCAGCTCT ATGATGCCTC CAACAGCGAG TGGCAGCTGG GGAAGACCAA GGTCTTTCTT 2400

CGAGAATCCT TGGAACAGAA ACTGGAGAAG CGGAGGGAAG AGGAAGTGAG CCACGCGGCC 2460

ATGGTGATTC GGGCCCATGT CTTGGGCTTC TTAGCACGAA AACAATACAG AAAGGTCCTT 2520

TATTGTGTGG TGATAATACA GAAGAATTAC AGAGCATTCC TTCTGAGGAG GAGATTTTTG 2580

CACCTGAAAA AGGCAGCCAT AGTTTTCCAG AAGCAACTCA GAGGTCAGAT TGCTCGGAGA 2640 GTTTACAGAC AATTGCTGGC AGAGAAAAGG GAGCAAGAAG AAAAGAAGAA ACAGGAAGAG 2700

GAAGAAAAGA AGAAACGGGA GGAAGAAGAA AGAGAAAGAG AGAGAGAGCG AAGAGAAGCC 2760

GAGCTCCGCG CCCAGCAGGA AGAAGAAACG AGGAAGCAGC AAGAACTCGA AGCCTTGCAG 2820

AAGAGCCAGA AGGAAGCTGA ACTGACCCGT GAACTGGAGA AACAGAAGGA AAATAAGCAG 2880

GTGGAAGAGA TCCTCCGTCT GGAGAAAGAA ATCGAGGACC TGCAGCGCAT GAAGGAGCAG 2940 CAGGAGCTGT CGCTGACCGA GGCTTCCCTG CAGAAGCTGC AGGAGCGGCG GGACCAGGAG 3000

CTCCGCAGGC TGGAGGAGGA AGCGTGCAGG GCGGCCCAGG AGTTCCTCGA GTCCCTCAAT 3060

TTCGACGAGA TCGACGAGTG TGTCCGGAAT ATCGAGCGGT CCCTGTCGGT GGGAAGCGAA 3120

TTTTCCAGCG AGCTGGCTGA GAGCGCATGC GAGGAGAAGC CCAACTTCAA CTTCAGCCAG 3180

CCCTACCCAG AGGAGGAGGT CGATGAGGGC TTCGAAGCCG ACGACGACGC CTTCAAGGAC 3240 TCCCCCAACC CCAGCGAGCA CGGCCACTCA GACCAGCGAA CAAGTGGCAT CCGGACCAGC 3300

GATGACTCTT CAGAGGAGGA CCCATACATG AACGACACGG TGGTGCCCAC CAGCCCCAGT 3360

GCGGACAGCA CGGTGCTGCT CGCCCCATCA GTGCAGGACT CCGGGAGCCT ACACAACTCC 3420

TCCAGCGGCG AGTCCACCTA CTGCATGCCC CAGAACGCTG GGGACTTGCC CTCCCCAGAC 3480

GGCGACTACG ACTACGACCA GGATGACTAT GAGGACGGTG CCATCACTTC CGGCAGCAGC 3540 GTGACCTTCT CCAACTCCTA CGGCAGCCAG TGGTCCCCCG ACTACCGCTG CTCTGTGGGG 3600

ACCTACAACA GCTCGGGTGC CTACCGGTTC AGCTCTGAGG GGGCGCAGTC CTCGTTTGAA 3660

GATAGTGAAG AGGACTTTGA TTCCAGGTTT GATACAGATG ATGAGCTTTC ATACCGGCGT 3720

GACTCTGTGT ACAGCTGTGT CACTCTGCCG TATTTCCACA GCTTTCTGTA - CATGAAAGGT ₃780

GGCCTGATGA ACTCTTGGAA ACGCCGCTGG TGCGTCCTCA AGGATGAAAC CTTCTTGTGG 3840 TTCCGCTCCA AGCAGGAGGC CCTCAAGCAA GGCTGGCTCC ACAAAAAAGG GGGGGGCTCC 3900

TCCACGCTGT CCAGGAGAAA TTGGAAGAAG CGCTGGTTTG TCCTCCGCCA GTCCAAGCTG 3960

ATGTACTTTG AAAACGACAG CGAGGAGAAG CTCAAGGGCA CCGTAGAAGT GCGAACGGCA 4020

AAAGAGATCA TAGATAACAC CACCAAGGAG AATGGGATCG ACATCATTAT GGCCGATAGG 4080

ACTTTCCACC TGATTGCAGA GTCCCCAGAA GATGCCAGCC AGTGGTTCAG CGTGCTGAGT 4140 CAGGTCCACG CGTCCACGGA CCAGGAGATC CAGGAGATGC ATGATGAGCA GGCAAACCCA 4200

CAGAATGCTG TGGGCACCTT GGATGTGGGG CTGATTGATT CTGTGTGTGC CTCTGACAGC 4260

CCTGATAGAC CCAACTCGTT TGTGATCATC ACGGCCAACC GGGTGCTGCA CTGCAACGCC 4320

GACACGCCGG AGGAGATGCA CCACTGGATA ACCCTGCTGC AGAGGTCCAA AGGGGACACC 4380

AGAGTGGAGG GCCAGGAATT CATCGTGAGA GGATGGTTGC ACAAAGAGGT GAAGAACAGT ₄ 0 CCGAAGATGT CTTCACTGAA ACTGAAGAAA CGGTGGTTTG TACTCACCCA CAATTCCCTG 4500

GATTACTACA AGAGTTCAGA GAAGAACGCG CTCAAACTGG GGACCCTGGT CCTCAACAGC 4560

CTCTGCTCTG TCGTCCCCCC AGATGAGAAG ATATTCAAAG AGACAGGCTA CTGGAACGTC 4620

ACCGTGTACG GGCGCAAGCA CTGTTACCGG CTCTACACCA AGCTGCTCAA CGAGGCCACC 4680 CGGTGGTCCA GTGCCATTCA AAACGTGACT GACACCAAGG CCCCGATCGA CACCCCCACC 4740 CAGCAGCTGA TTCAAGATAT CAAGGAGAAC TGCCTGAACT CGGATGTGGT GGAACAGATT 4800

TACAAGCGGA ACCCGATCCT TCGATACACC CATCACCCCT TGCACTCCCC GCTCCTGCCC 4860

CTTCCGTATG GGGACATAAA TCTCAACTTG CTCAAAGACA AAGGCTATAC CACCCTTCAG 4920

GATGAGGCCA TCAAGATATT CAATTCCCTG CAGCAACTGG AGTCCATGTC TGACCCAATT 4980

CCAATAATCC AGGGCATCCT ACAGACAGGG CATGACCTGC GACCTCTGCG GGACGAGCTG 5040 TACTGCCAGC TTATCAAACA GACCAACAAA GTGCCCCACC CCGGCAGTGT GGGCAACCTG 5100

TACAGCTGGC AGATCCTGAC ATGCCTGAGC TGCACCTTCC TGCCGAGTCG AGGGATTCTC 5160

AAGTATCTCA AGTTCCATCT GAAAAGGATA CGGGAACAGT TTCCAGGAAC CGAGATGGAA 5220

AAATACGCTC TCTTCACTTA CGAATCTCTT AAGAAAACCA AATGCCGAGA GTTTGTGCCT 5280

TCCCGAGATG AAATAGAAGC TCTGATCCAC AGGCAGGAAA TGACATCCAC GGTCTATTGC 5340 CATGGCGGCG GCTCCTGCAA GATCACCATC AACTCCCACA CCACTGCTGG GGAGGTGGTG 5400

GAGAAGCTGA TCCGAGGCCT GGCCATGGAG GACAGCAGGA ACATGTTTGC TTTGTTTGAA 5460 TACAACGGCC ACGTCGACAA AGCCATTGAA AGTCGAACCG TCGTAGCTGA TGTCTTAGCC 5520 AAGTTTGAAA AGCTGGCTGC CACATCCGAG GTTGGGGACC TGCCATGGAA ATTCTACTTC 5580 AAACTTTACT GCTTCCTGGA CACAGACAAC GTGCCAAAAG ACAGTGTGGA GTTTGCATTT 5640 ATGTTTGAAC AGGCCCACGA AGCGGTTATC CATGGCCACC ATCCAGCCCC GGAAGAAAAC 5700 CTCCAGGTTC TTGCTGCCCT GCGACTCCAG TATCTGCAGG GGGATTATAC TCTGCACGCT 5760 GCCATCCCAC CTCTCGAAGA GGTTTATTCC CTGCAGAGAC TCAAGGCCCG CATCAGCCAG 5820 TCAACCAAAA CCTTCACCCC TTGTGAACGG CTGGAGAAGA GGCGGACGAG CTTCCTAGAG 5880 GGGACCCTGA GGCGGAGCTT CCGGACAGGA TCCGTGGTCC GGCAGAAGGT CGAGGAGGAG 5 40 CAGATGCTGG ACATGTGGAT TAAGGAAGAA GTCTCCTCTG CTCGAGCCAG TATCATTGAC 6000 AAGTGGAGGA AATTTCAGGG AATGAACCAG GAACAGGCCA TGGCCAAGTA CATGGCCTTG 6060 ATCAAGGAGT GGCCTGGCTA TGGCTCGACG CTGTTTGATG TGGAGTGCAA GGAAGGTGGC 6120 TTCCCTCAGG AACTCTGGTT GGGTGTCAGC GCGGACGCCG TCTCCGTCTA CAAGCGTGGA 6180 GAGGGAAGAC CACTGGAAGT CTTCCAGTAT GAACACATCC TCTCTTTTGG GGCACCCCTG 6240 GCGAATACGT ATAAGATCGT GGTCGATGAG AGGGAGCTGC TCTTTGAAAC CAGTGAGGTG 6300 GTGGATGTGG CCAAGCTCAT GAAAGCCTAC ATCAGCATGA TCGTGAAGAA GCGCTACAGC 6360 ACGACACGCT CCGCCAGCAG CCAGGGCAGC TCCAGGTGAA GGCGGGACAG AGCCCACCTG 6420 TCTTTGCTAC CTGAACGCAC CACCCTCTGG CCTAGGCTGG CTCCAGTGTG CCATGCCCAG 6480 CCAAAACAAA CACAGAGCTG CCCAGGCTTT CTGGAAGCTT CTGGTCTGAG GGAGGTGTCT 6540 CCGAGGATCC TTTTGCCTGC CGCCTTCATT GATCCTGTAT TAAGCTGTCA ACTTTAACAG 6600 TCTGCACAGT TTCCAAAGCT TTACTACTCT TAGAGGACAC ATGCCTTAAA AAAGGAGGGG 6660 AGGAACCACG CTGCCACCAA AGCAGCCGGA AGTGCCTTAA CTTGTGGAAC CAACACTAAT 6720 CGACCGTAAC TGTGCTACTG AAGGGAACTG CCTTTCCCCC TTCTGGGGGA GACTTAACAG 6780 AGCGTGGAAG GGGGGCATTC TCTGTCAATG ATGCACTAAC CTCCCAACCT GATTTCCCCG 6840 AATCTGAGGG AAGGTGAGGG AGTGGGAAGG GGGATGGAGA GCTCGAGGGG ACAGTGTGTT εgoo TGAGCTGGAG TGCTGCGGGC AGCCTTTCTC ATGGAATGAC ATGAATCAAC TTTTTTCTTT 6g60 GTTTCATCTT TTAAGTGTAC GTGCTTGCCT GTTCGTGCAT GTGTTCATAA ACTCAACACT 7020 TTAATCATGG TTTCATGAGC ATTAAAAAGC AAAGGGAAAA AGGATGTGTA ATGGTGTACA 7080 CAGTCTGTAT ATTTTAATAA TGCAGAGCTA TAGTCTCAAT TGTTACTTTA TAAGGTGGTT 7140 TTATTAACAA ACCCAAATCC TGGATTTTCC TGTCTTTGCT GTATTTTGAA AAACACGTGT 7200 TGACTCCATT GTTTTACATG TAGCAAAGTC TGCCATCTGT GTCTGCTGTA TTATAAACAG 7260 ATAAGCAGCC TACAAGATAA CTGTATTTAT AAACCACTCT TCAACAGCTG GCTCCAGTGC 7320 TGGTTTTAGA ACAAGAATGA AGTCATTTTG GAGTCTTTCA TGTCTAAAAG ATTTAAGTTA 7380 AAAACAAAGT GTTACTTGGA AGGTTAGCTT CTATCATTCT GGATAGATTA CAGATATAAT 7440 AACCATGTTG ACTATGGGGG AGAGACGCTG CATTCCAGAA ACGTCTTAAC ACTTGAGTGA 7500 ATCTTCAAAG GACCCTGACA TTAAATGCTG AGGCTTTAAT ACACACATAT TTTATCCCAA 7560 GTTTATAATG GTGGTCTGAA CAAGGCACCT GTAAATAAAT CAGCATTTAT GACCAGAAGA 7620 AAAATAATCT GGTCTTGGAC TTTTTATTTT TATATGGAAA AGTTTTAAGG ACTTGGGCCA 7680 ACTAAGTCTA CCCACACGAA AAAAGAAATT TGCCTTGTCC CTTTGTGTAC AACCATGCAA 7740 AACTGTTTGT TGGCTCACAG AAGTTCTGAC AATAAAAGAT ACTAGCT

Seq ID NO: 207 Protein sequence : Protein Accession #: NP 036466

11 21 31 41 51

I I I I I

MDNFFTEGTR VWLRENGQHF PSTVNSCAEG IWFRTDYGQ VFTYKQSTIT HQKVTAMHPT 60 NEEGVDDMAS LTELHGGSIM YNLFQRYKRN QIYTYIGSIL ASVNPYQPIA GLYEPATMEQ 120 YSRRHLGELP PHIFAIANEC YRCLWKRYDN QCILISGESG AGKTESTKLI LKFLSVISQQ 180 SLELSLKEKT SCVERAILES SPIMEAFGNA KTVYNNNSSR FGKFVQLNIC QKGNIQGGRI 240 VDYLLEKNRV VRQNPGERNY HIFYALLAGL EHEEREEFYL STPENYHYLN QSGCVEDKTI 300 SDQESFREVI TAMDVMQFSK EEVREVSRLL AGILHLGNIE FITAGGAQVS FKTALGRSAE 360 LLGLDPTQLT DALTQRSMFL RGEEILTPLN VQQAVDSRDS LAMALYACCF EWVIKKINSR 420 IKGNEDFKSI GILDIFGFEN FEVNHFEQFN INYANEKLQE YFNKHIFSLE QLEYSREGLV 480 WEDIDWIDNG ECLDLIEKKL GLLALINEES HFPQATDSTL LEKLHSQHAN NHFYVKPRVA 540 VNNFGVKHYA GEVQYDVRGI LEKNRDTFRD DLLNLLRESR FDFIYDLFEH VSSRNNQDTL 600 KCGSKHRRPT VSSQFKDSLH SLMATLSSSN PFFVRCIKPN MQKMPDQFDQ AWLNQLRYS 660 GMLETVRIRK AGYAVRRPFQ DFYKRYKVLM RNLALPEDVR GKCTSLLQLY DASNSEWQLG 720 KTKVFLRESL EQKLEKRREE EVSHAAMVIR AHVLGFLARK QYRKVLYCW IIQKNYRAFL 780 LRRRFLHLKK AAIVFQKQLR GQIARRVYRQ LLAEKREQEE KKKQEEEEKK KREEEERERE 840 RERREAELRA QQEEETRKQQ ELEALQKSQK EAELTRELEK QKENKQVEEI LRLEKEIEDL 900 QRMKEQQELS LTEASLQKLQ ERRDQELRRL EEEACRAAQE FLESLNFDEI DECVRNIERS 960 LSVGSEFSSE LAESACEEKP NFNFSQPYPE EEVDEGFEAD DDAFKDSPNP SEHGHSDQRT 1020 SGIRTSDDSS EEDPYMNDTV VPTSPSADST VLLAPSVQDS GSLHNSSSGE STYCMPQNAG 1080 DLPSPDGDYD YDQDDYEDGA ITSGSSVTFS NSYGSQWSPD YRCSVGTYNS SGAYRFSSEG 1140 AQSSFEDSEE DFDSRFDTDD ELSYRRDSVY SCVTLPYFHS FLYMKGGLMN SWKRRWCVLK 1200 DETFLWFRSK QEALKQGWLH KKGGGSSTLS RRNWKKRWFV LRQSKLMYFE NDSEEKLKGT 1260 VEVRTAKEII DNTTKENGID IIMADRTFHL IAESPEDASQ WFSVLSQVHA STDQEIQEMH 1320 DEQANPQNAV GTLDVGLIDS VCASDSPDRP NSFVIITANR VLHCNADTPE EMHHWITLLQ 1380 RSKGDTRVEG QEFIVRGWLH KEVKNSPKMS SLKLKKRWFV LTHNSLDYYK SSEKNALKLG 1440 TLVLNSLCSV VPPDEKIFKE TGYWNVTVYG RKHCYRLYTK LLNEATRWSS AIQNVTDTKA 1500 PIDTPTQQLI QDIKENCLNS DWEQIYKRN PILRYTHHPL HSPLLPLPYG DINLNLLKDK 1560 GYTTLQDEAI KIFNSLQQLE SMSDPIPIIQ GILQTGHDLR PLRDELYCQL IKQTNKVPHP 1620 GSVGNLYSWQ ILTCLSCTFL PSRGILKYLK FHLKRIREQF PGTEMEKYAL FTYESLKKTK 1680 CREFVPSRDE IEALIHRQEM TSTVYCHGGG SCKITINSHT TAGEWEKLI RGLAMEDSRN 1740 MFALFEYNGH VDKAIESRTV VADVLAKFEK LAATSEVGDL PWKFYFKLYC FLDTDNVPKD 1800 SVEFAFMFEQ AHEAVIHGHH PAPEENLQVL AALRLQYLQG DYTLHAAIPP LEEVYSLQRL 1860 KARISQSTKT FTPCERLEKR RTSFLEGTLR RSFRTGSWR QKVEEEQMLD MWIKEEVSSA 1920

RASIIDKWRK FQGMNQEQAM AKYMALIKEW PGYGSTLFDV ECKEGGFPQE LWLGVSADAV 1980

SVYKRGEGRP LEVFQYEHIL SFGAPLANTY KIWDERELL FETSEWDVA KLMKAYISMI 2040 VKKRYSTTRS ASSQGSSR

Seq ID NO: 208 DNA sequence

Nucleic Acid Accession #: XM_05g761.1

Coding sequence: 124-525 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

CGAAGATCTA TCCAAAATCA AGAAGCCTTT GATTTAGATG TTGCTGTAAA AGAAAATAAA 60 GATGATCTCA ATCATGTGGA TTTGAATGTG TGTACAAGCT TTTCGGGCCC GGGTAGGAGT 120 GGCATGGCTC TTATGGAAGT TAACCTATTA AGTGGCTTTA TGGTGCCTTC AGAAGCAATT 180 TCTCTGAGCG AGACAGTGAA GAAAGTGGAA TATGATCATG GAAAACTCAA CCTCTATTTA 240 GATTCTGTAA ATGAAACCCA GTTTTGTGTT AATATTCCTG CTGTGAGAAA CTTTAAAGTT 300 TCAAATACCC AAGATGCTTC AGTGTCCATA GTGGATTACT ATGAGCCAAG GAGACAGGCG 360 GTGAGAAGTT ACAACTCTGA AGTGAAGCTG TCCTCCTGTG ACCTTTGCAG TGATGTCCAG 420 GGCTGCCGTC CTTGTGAGGA TGGAGCTTCA GGCTCCCATC ATCACTCTTC AGTCATTTTT 480 ATTTTCTGTT TCAAGCTTCT GTACTTTATG GAACTTTGGC TGTGATTTAT TTTTAAAGGA 540 CTCTGTGTAA CACTAACATT TCCAGTAGTC ACATGTGATT GTTTTGTTTT CGTAGAAGAA 600 TACTGCTTCT ATTTTGAAAA AAGAGTTTTT TTTCTTTCTA TGGGGTTGCA GGGATGGTGT 660 ACAACAGGTC CTAGCATGTA TAGCTGCATA GATTTCTTCA CCTGATCTTT GTGTGGAAGA 720 TCAGAATGAA TGCAGTTGTG TGTCTATATT TTCCCCTCTC AAAATCTTTT AGAATTTTTT 780 TGGAGGTGTT TGTTTTCTCC AGAATAAAGG TATTACTTTA G

Seq ID NO : 20g Protein sequence : Protein Accession # : XP 059761.1

11 21 31 41 51

MALMEVNLLS GFMVPSEAIS LSETVKKVEY DHGKLNLYLD SVNETQFCVN IPAVRNFKVS 60

NTQDASVSIV DYYEPRRQAV RSYNSEVKLS SCDLCSDVQG CRPCEDGASG SHHHSSVIFI 120 FCFKLLYFME LWL

Seq ID NO : 210 DNA sequence

Nucleic Acid Accession # : NM_015472

Coding sequence : 258-1460 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

GACACACTCC TCTACAACAC CAGAGACTCC CAAACACAAG GCCTTATATT GACTCATTTC 60 AGCTCACATC CTGGCGACTC TCAAGAGAGA AACCTCAGAG TGACTAAAAT CTCCATAATG 120 AGAAGACATG TACATTCAGT ATCTATTTTG GCATTTTCCC CAATACATCT CTGCTCATCT 180 GACTCTTATC TTGGCATCTG CTTCCTGGTG GATCTGAACT GACCCATAAG CCACGCTTAC 240 TGGTGATTTT CCAGAAGATG AATCCGGCCT CGGCGCCCCC TCCGCTCCCG CCGCCTGGGC 300 AGCAAGTGAT CCACGTCACG CAGGACCTAG ACACAGACCT CGAAGCCCTC TTCAACTCTG 360 TCATGAATCC GAAGCCTAGC TCGTGGCGGA AGAAGATCCT GCCGGAGTCT TTCTTTAAGG 420 AGCCTGATTC GGGCTCGCAC TCGCGCCAGT CCAGCACCGA CTCGTCGGGC GGCCACCCGG 480 GGCCTCGACT GGCTGGGGGT GCCCAGCATG TCCGCTCGCA CTCGTCGCCC GCGTCCCTGC 540 AGCTGGGCAC CGGCGCGGGT GCTGCGGGTA GCCCCGCGCA GCAGCACGCG CACCTCCGCC 600 AGCAGTCCTA CGACGTGACC GACGAGCTGC CACTGCCCCC GGGCTGGGAG ATGACCTTCA 660 CGGCCACTGG CCAGAGGTAC TTCCTCAATC ACATAGAAAA AATCACCACA TGGCAAGACC 720 CTAGGAAGGC GATGAATCAG CCTCTGAATC ATATGAACCT CCACCCTGCC GTCAGTTCCA 780 CACCAGTGCC TCAGAGGTCC ATGGCAGTAT CCCAGCCAAA TCTCGTGATG AATCACCAAC 840 ACCAGCAGCA GATGGCCCCC AGTACCCTGA GCCAGCAGAA CCACCCCACT CAGAACCCAC goo CCGCAGGGCT CATGAGTATG CCCAATGCGC TGACCACTCA GCAGGAGCAG CAGCAGAAAC gεo TGCGGCTTCA GAGAATCCAG ATGGAGAGAG AAAGGATTCG AATGCGCCAA GAGGAGCTCA 1020 TGAGGCAGGA AGCTGCCCTC TGTCGACAGC TCCCCATGGA AGCTGAGACT CTTGCCCCAG 1080 TTCAGGCTGC TGTCAACCCA CCCACGATGA CCCCAGACAT GAGATCCATC ACTAATAATA 1140 GCTCAGATCC TTTCCTCAAT GGAGGGCCAT ATCATTCGAG GGAGCAGAGC ACTGACAGTG 1200 GCCTGGGGTT AGGGTGCTAC AGTGTCCCCA CAACTCCGGA GGACTTCCTC AGCAATGTGG 1260 ATGAGATGGA TACAGGAGAA AACGCAGGAC AAACACCCAT GAACATCAAT CCCCAACAGA 1320 CCCGTTTCCC TGATTTCCTT GACTGTCTTC CAGGAACAAA CGTTGACTTA GGAACTTTGG 1380 AATCTGAAGA CCTGATCCCC CTCTTCAATG ATGTAGAGTC TGCTCTGAAC AAAAGTGAGC 1440 CCTTTCTAAC CTGGCTGTAA TCACTACCAT TGTAACTTGG ATGTAGCCAT GACCTTACAT 1500 TTCCTGGGCC TCTTGGAAAA AGTGATGGAG CAGAGCAAGT CTGCAGGTGC ACCACTTCCC 1560 GCCTCCATGA CTCGTGCTCC CTCCTTTTTA TGTTGCCAGT TTAATCATTG CCTGGTTTTG 1620 ATTGAGAGTA ACTTAAGTTA AACATAAATA AATATTCTAT TTTCATTTTC

Seq ID NO : 211 Protein sequence : Protein Accession # : NP 056287.1

11 21 31 41 51 MNPASAPPPL PPPGQQVIHV TQDLDTDLEA LFNSVMNPKP SSWRKKILPE SFFKEPDSGS 60 HSRQSSTDSS GGHPGPRLAG GAQHVRSHSS PASLQLGTGA GAAGSPAQQH AHLRQQSYDV 120 TDELPLPPGW EMTFTATGQR YFLNHIEKIT TWQDPRKAMN QPLNHMNLHP AVSSTPVPQR 180 SMAVSQPNLV MNHQHQQQMA PSTLSQQNHP TQNPPAGLMS MPNALTTQQQ QQQKLRLQRI 240 QMERERIRMR QEELMRQEAA LCRQLPMEAE TLAPVQAAVN PPTMTPDMRS ITNNSSDPFL 300 NGGPYHSREQ STDSGLGLGC YSVPTTPEDF LSNVDEMDTG ENAGQTPMNI NPQQTRFPDF 360 LDCLPGTNVD LGTLESEDLI PLFNDVESAL NKSEPFLTWL

Seq ID NO: 212 DNA sequence Nucleic Acid Accession #: NM_018174

Coding sequence: 176-2194 (underlined sequences correspond to start and stop codons)

CATCTCCCCC AACCTGGGGG TCGTGTTCTT CAACGCCTGC GAGGCCGCGT CGCGGCTGGC 60 GCGCGGCGAG GATGAGGCGG AGCTGGCGCT GAGCCTCCTG GCGCAGCTGG GCATCACGCC 120 TCTGCCACTC AGCCGCGGCC CCGTGCCAGC CAAACCCACC GTGCTCTTCG AGAAGATGGG 180 CGTGGGCCGG CTGGACATGT ATGTGCTGCA CCCGCCCTCC GCCGGCGCCG AGCGCACGCT 240 GGCCTCTGTG TGCGCCCTGC TGGTGTGGCA CCCCGCCGGC CCGGGCGAGA AGGTGGTGCG 300 CGTGCTGTTC CCCGGTTGCA CCCCGCCCGC CTGCCTCCTG GACGGCCTGG TCCGCCTGCA 360 GCACTTGAGG TTCCTGCGAG AGCCCGTGGT GACGCCCCAG GACCTGGAGG GGCCGGGGCG 420 AGCCGAGAGC AAAGAGAGCG TGGGCTCCCG GGACAGCTCG AAGAGAGAGG GCCTCCTGGC 480 CACCCACCCT AGACCTGGCC AGGAGCGCCC TGGGGTGGCC CGCAAGGAGC CAGCACGGGC 540 TGAGGCCCCA CGCAAGACTG AGAAAGAAGC CAAGACCCCC CGGGAGTTGA AGAAAGACCC 600 CAAACCGAGT GTCTCCCGGA CCCAGCCGCG GGAGGTGCGC CGGGCAGCCT CTTCTGTGCC 660 CAACCTCAAG AAGACGAATG CCCAGGCGGC ACCCAAGCCC CGCAAAGCGC CCAGCACGTC 720 CCACTCTGGC TTCCCGCCGG TGGGAAATGG ACCCCGCAGC CCGCCCAGCC TCCGATGTGG 780 AGAAGCCAGC CCCCCCAGTG CAGCCTGCGG CTCTCCGGCC TCCCAGCTGG TGGCCACGCC 840 CAGCCTGGAG CTGGGGCCGA TCCCAGCCGG GGAGGAGAAG GCACTGGAGC TGCCTTTGGC 900 CGCCAGCTCA ATCCCAAGGC CACGCACACC CTCCCCTGAG TCCCACCGGA GCCCCGCAGA 960 GGGCAGCGAG CGGCTGTCGC TGAGCCCACT GCGGGGCGGG GAGGCCGGGC CAGACGCCTC 1020 ACCCACAGTG ACCACACCCA CGGTGACCAC GCCCTCACTA CCCGCAGAGG TGGGCTCCCG 1080 GCACTCGACC GAGGTGGACG AGTCCCTGTC GGTGTCCTTT GAGCAGGTGC TGCCGCCATC 1140 CGCCCCCACC AGTGAGGCTG GGCTGAGCCT CCCGCTGCGT GGCCCCCGGG CGCGGCGCTC 1200 GGCTTCCCCA CACGATGTGG ACCTGTGCCT GGTGTCACCC TGTGAATTTG AGCATCGCAA 1260 GGCGGTGCCA ATGGCACCGG CACCTGCGTC CCCCGGCAGC TCGAATGACA GCAGTGCCCG 1320 GTCACAGGAA CGGGCAGGTG GGCTGGGGGC CGAGGAGACG CCACCCACAT CGGTCAGCGA 1380 GTCCCTGCCC ACCCTGTCTG AGTCGGATCC CGTGCCCCTG GCCCCCGGTG CGGCAGACTC 1440 AGACGAAGAC ACAGAGGGCT TTGGAGTCCC TCGCCACGAC CCTTTGCCTG ACCCCCTCAA 1500 GGTCCCCCCA CCACTGCCTG ACCCATCCAG CATCTGCATG GTGGACCCCG AGATGCTGCC 1560 CCCCAAGACA GCACGGCAAA CGGAGAACGT CAGCCGCACC CGGAAGCCCC TGGCCCGCCC 1620 CAACTCACGC GCTGCCGCCC CCAAAGCCAC TCCAGTGGCT GCTGCCAAAA CCAAGGGGCT 1680 TGCTGGTGGG GACCGTGCCA GCCGACCACT CAGTGCCCGG AGTGAGCCCA GTGAGAAGGG 1740 AGGCCGGGCA CCCCTGTCCA GAAAGTCCTC AACCCCCAAG ACTGCCACTC GAGGCCCGTC 1800 GGGGTCAGCC AGCAGCCGGC CCGGGGTGTC AGCCACCCCA CCCAAGTCCC CGGTCTACCT 1860 GGACCTGGCC TACCTGCCCA GCGGGAGCAG CGCCCACCTG GTGGATGAGG AGTTCTTCCA ig20 GCGCGTGCGC GCGCTCTGCT ACGTCATCAG TGGCCAGGAC CAGCGCAAGG AGGAAGGCAT 1980 GCGGGCCGTC CTGGACGCGC TACTGGCCAG CAAGCAGCAT TGGGACCGTG ACCTGCAGGT 2040 GACCCTGATC CCCACTTTCG ACTCGGTGGC CATGCATACG TGGTACGCAG AGACGCACGC 2100 CCGGCACCAG GCGCTGGGCA TCACGGTGTT GGGCAGCAAC GGCATGGTGT CCATGCAGGA 2160 TGACGCCTTC CCGGCCTGCA AGGTGGAGTT CTAGCCCCAT CGCCGACACG CCCCCCACTC 2220 AGCCCAGCCC GCCTGTCCCT AGATTCAGCC ACATCAGAAA TAAACTGTGA CTACACTTG

Seq ID NO: 213 Protein sequence: Protein Accession #: NP 060644.1

MGVGRLDMYV LHPPSAGAER TLASVCALLV WHPAGPGEKV VRVLFPGCTP PACLLDGLVR 60 LQHLRFLREP WTPQDLEGP GRAESKESVG SRDSSKREGL LATHPRPGQE RPGVARKEPA 120 RAEAPRKTEK EAKTPRELKK DPKPSVSRTQ PREVRRAASS VPNLKKTNAQ AAPKPRKAPS 180 TSHSGFPPVA NGPRSPPSLR CGEASPPSAA CGSPASQLVA TPSLELGPIP AGEEKALELP 240 LAASSIPRPR TPSPESHRSP AEGSERLSLS PLRGGEAGPD ASPTVTTPTV TTPSLPAEVG 300 SPHSTEVDES LSVSFEQVLP PSAPTSEAGL SLPLRGPRAR RSASPHDVDL CLVSPCEFEH 360 RKAVPMAPAP ASPGSSNDSS ARSQERAGGL GAEETPPTSV SESLPTLSDS DPVPLAPGAA 420 DSDEDTEGFG VPRHDPLPDP LKVPPPLPDP SSICMVDPEM LPPKTARQTE NVSRTRKPLA 480 RPNSRAAAPK ATPVAAAKTK GLAGGDRASR- PLSARSEPSE KGGRAPLSRK SSTPKTATRG 540 PSGSASSRPG VSATPPKSPV YLDLAYLPSG SSAHLVDEEF FQRVRALCYV ISGQDQRKEE 600 GMRAVLDALL ASKQHWDRDL QVTLIPTFDS VAMHTWYAET HARHQALGIT VLGSNGMVSM 660 QDDAFPACKV EF

Seq ID NO: 214 DNA sequence

Nucleic Acid Accession #: NM_002019.1

Coding sequence: 250-4266 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

GCGGACACTC CTCTCGGCTC CTCCCCGGCA GCGGCGGCGG CTCGGAGCGG GCTCCGGGGC 60 TCGGGTGCAG CGGCCAGCGG GCCTGGCGGC GAGGATTACC CGGGGAAGTG GTTGTCTCCT 120 GGCTGGAGCC GCGAGACGGG CGCTCAGGGC GCGGGGCCGG CGGCGGCGAA CGAGAGGACG 180

GACTCTGGCG GCCGGGTCGT TGGCCGGGGG AGCGCGGGCA CCGGGCGAGC AGGCCGCGTC 240

GCGCTCACCA TGGTCAGCTA CTGGGACACC GGGGTCCTGC TGTGCGCGCT GCTCAGCTGT 300

CTGCTTCTCA CAGGATCTAG TTCAGGTTCA AAATTAAAAG ATCCTGAACT GAGTTTAAAA 360 GGCACCCAGC ACATCATGCA AGCAGGCCAG ACACTGCATC TCCAATGCAG GGGGGAAGCA 420

GCCCATAAAT GGTCTTTGCC TGAAATGGTG AGTAAGGAAA GCGAAAGGCT GAGCATAACT 480

AAATCTGCCT GTGGAAGAAA TGGCAAACAA TTCTGCAGTA CTTTAACCTT GAACACAGCT 540

CAAGCAAACC ACACTGGCTT CTACAGCTGC AAATATCTAG CTGTACCTAC TTCAAAGAAG 600

AAGGAAACAG AATCTGCAAT CTATATATTT ATTAGTGATA CAGGTAGACC TTTCGTAGAG 660 ATGTACAGTG AAATCCCCGA AATTATACAC ATGACTGAAG GAAGGGAGCT CGTCATTCCC 720

TGCCGGGTTA CGTCACCTAA CATCACTGTT ACTTTAAAAA AGTTTCCACT TGACACTTTG 780

ATCCCTGATG GAAAACGCAT AATCTGGGAC AGTAGAAAGG GCTTCATCAT ATCAAATGCA 840

ACGTACAAAG AAATAGGGCT TCTGACCTGT GAAGCAACAG TCAATGGGCA TTTGTATAAG 900

ACAAACTATC TCACACATCG ACAAACCAAT ACAATCATAG ATGTCCAAAT AAGCACACCA 960 CGCCCAGTCA AATTACTTAG AGGCCATACT CTTGTCCTCA ATTGTACTGC TACCACTCCC 1020

TTGAACACGA GAGTTCAAAT GACCTGGAGT TACCCTGATG AAAAAAATAA GAGAGCTTCC 1080

GTAAGGCGAC GAATTGACCA AAGCAATTCC CATGCCAACA TATTCTACAG TGTTCTTACT 1140

ATTGACAAAA TGCAGAACAA AGACAAAGGA CTTTATACTT GTCGTGTAAG GAGTGGACCA 1200

TCATTCAAAT CTGTTAACAC CTCAGTGCAT ATATATGATA AAGCATTCAT CACTGTGAAA 1260 CATCGAAAAC AGCAGGTGCT TGAAACCGTA GCTGGCAAGC GGTCTTACCG GCTCTCTATG 1320

AAAGTGAAGG CATTTCCCTC GCCGGAAGTT GTATGGTTAA AAGATGGGTT ACCTGCGACT 1380

GAGAAATCTG CTCGCTATTT GACTCGTGGC TACTCGTTAA TTATCAAGGA CGTAACTGAA 1440

GAGGATGCAG GGAATTATAC AATCTTGCTG AGCATAAAAC AGTCAAATGT GTTTAAAAAC 1500

CTCACTGCCA CTCTAATTGT CAATGTGAAA CCCCAGATTT ACGAAAAGGC CGTGTCATCG 1560 TTTCCAGACC CGGCTCTCTA CCCACTGGGC AGCAGACAAA TCCTGACTTG TACCGCATAT 1620

GGTATCCCTC AACCTACAAT CAAGTGGTTC TGGCACCCCT GTAACCATAA TCATTCCGAA 1680

GCAAGGTGTG ACTTTTGTTC CAATAATGAA GAGTCCTTTA TCCTGGATGC TGACAGCAAC 1740

ATGGGAAACA GAATTGAGAG CATCACTCAG CGCATGGCAA TAATAGAAGG AAAGAATAAG 1800

ATGGCTAGCA CCTTGGTTGT GGCTGACTCT AGAATTTCTG GAATCTACAT TTGCATAGCT 1860 TCCAATAAAG TTGGGACTGT GGGAAGAAAC A AAGCTTTT ATATCACAGA TGTGCCAAAT 1920

GGGTTTCATG TTAACTTGGA AAAAATGCCG ACGGAAGGAG AGGACCTGAA ACTGTCTTGC 1980

ACAGTTAACA AGTTCTTATA CAGAGACGTT ACTTGGATTT TACTGCGGAC AGTTAATAAC 2040

AGAACAATGC ACTACAGTAT TAGCAAGCAA AAAATGGCCA TCACTAAGGA GCACTCCATC 2100

ACTCTTAATC TTACCATCAT GAATGTTTCC CTGCAAGATT CAGGCACCTA TGCCTGCAGA 2160 GCCAGGAATG TATACACAGG GGAAGAAATC CTCCAGAAGA AAGAAATTAC AATCAGAGAT 2220

CAGGAAGCAC CATACCTCCT GCGAAACCTC AGTGATCACA CAGTGGCCAT CAGCAGTTCC 2280

ACCACTTTAG ACTGTCATGC TAATGGTGTC CCCGAGCCTC AGATCACTTG GTTTAAAAAC 2340

AACCACAAAA TACAACAAGA GCCTGGAATT ATTTTAGGAC CAGGAAGCAG CACGCTGTTT 2400

ATTGAAAGAG TCACAGAAGA GGATGAAGGT GTCTATCACT GCAAAGCCAC CAACCAGAAG 2460 GGCTCTGTGG AAAGTTCAGC ATACCTCACT GTTCAAGGAA CCTCGGACAA GTCTAATCTG 2520

GAGCTGATCA CTCTAACATG CACCTGTGTG GCTGCGACTC TCTTCTGGCT CCTATTAACC 2580

CTCCTTATCC GAAAAATGAA AAGGTCTTCT TCTGAAATAA AGACTGACTA CCTATCAATT 2640

ATAATGGACC CAGATGAAGT TCCTTTGGAT GAGCAGTGTG AGCGGCTCCC TTATGATGCC 2700

AGCAAGTGGG AGTTTGCCCG GGAGAGACTT AAACTGGGCA AATCACTTGG AAGAGGGGCT 2760 TTTGGAAAAG TGGTTCAAGC ATCAGCATTT GGCATTAAGA AATCACCTAC GTGCCGGACT 2820

GTGGCTGTGA AAATGCTGAA AGAGGGGGCC ACGGCCAGCG AGTACAAAGC TCTGATGACT 2880

GAGCTAAAAA TCTTGACCCA CATTGGCCAC CATCTGAACG TGGTTAACCT GCTGGGAGCC 2940

TGCACCAAGC AAGGAGGGCC TCTGATGGTG ATTGTTGAAT ACTGCAAATA TGGAAATCTC 3000

TCCAACTACC TCAAGAGCAA ACGTGACTTA TTTTTTCTCA ACAAGGATGC AGCACTACAC 3060 ATGGAGCCTA AGAAAGAAAA AATGGAGCCA GGCCTGGAAC AAGGCAAGAA ACCAAGACTA 3120

GATAGCGTCA CCAGCAGCGA AAGCTTTGCG AGCTCCGGCT TTCAGGAAGA TAAAAGTCTG 3180

AGTGATGTTG AGGAAGAGGA GGATTCTGAC GGTTTCTACA AGGAGCCCAT CACTATGGAA 3240

GATCTGATTT CTTACAGTTT TCAAGTGGCC AGAGGCATGG AGTTCCTGTC TTCCAGAAAG 3300

TGCATTCATC GGGACCTGGC AGCGAGAAAC ATTCTTTTAT CTGAGAACAA CGTGGTGAAG 3360 ATTTGTGATT TTGGCCTTGC CCGGGATATT TATAAGAACC CCGATTATGT GAGAAAAGGA 3420

GATACTCGAC TTCCTCTGAA ATGGATGGCT CCCGAATCTA TCTTTGACAA AATCTACAGC 3480

ACCAAGAGCG ACGTGTGGTC TTACGGAGTA TTGCTGTGGG AAATCTTCTC CTTAGGTGGG 3540

TCTCCATACC CAGGAGTACA AATGGATGAG GACTTTTGCA GTCGCCTGAG GGAAGGCATG 3600

AGGATGAGAG CTCCTGAGTA CTCTACTCCT GAAATCTATC AGATCATGCT GGACTGCTGG 3660 CACAGAGACC CAAAAGAAAG GCCAAGATTT GCAGAACTTG TGGAAAAACT AGGTGATTTG 3720

CTTCAAGCAA ATGTACAACA GGATGGTAAA GACTACATCC CAATCAATGC CATACTGACA 3780

GGAAATAGTG GGTTTACATA CTCAACTCCT GCCTTCTCTG AGGACTTCTT CAAGGAAAGT 3840

ATTTCAGCTC CGAAGTTTAA TTCAGGAAGC TCTGATGATG TCAGATATGT AAATGCTTTC 3900

AAGTTCATGA GCCTGGAAAG AATCAAAACC TTTGAAGAAC TTTTACCGAA TGCCACCTCC 3960 ATGTTTGATG ACTACCAGGG CGACAGCAGC ACTCTGTTGG CCTCTCCCAT GCTGAAGCGC 4020

TTCACCTGGA CTGACAGCAA ACCCAAGGCC TCGCTCAAGA TTGACTTGAG AGTAACCAGT 4080

AAAAGTAAGG AGTCGGGGCT GTCTGATGTC AGCAGGCCCA GTTTCTGCCA TTCCAGCTGT 4140

GGGCACGTCA GCGAAGGCAA GCGCAGGTTC ACCTACGACC ACGCTGAGCT GGAAAGGAAA 4200

ATCGCGTGCT GCTCCCCGCC CCCAGACTAC AACTCGGTGG TCCTGTACTC CACCCCACCC 4260 ATCTAGAGTT TGACACGAAG CCTTATTTCT AGAAGCACAT GTGTATTTAT ACCCCCAGGA 4320

AACTAGCTTT TGCCAGTATT ATGCATATAT AAGTTTACAC CTTTATCTTT CCATGGGAGC 4380

CAGCTGCTTT TTGTGATTTT TTTAATAGTG CTTTTTTTTT TTGACTAACA AGAATGTAAC ₄ 40

TCCAGATAGA GAAATAGTGA CAAGTGAAGA ACACTACTGC TAAATCCTCA TGTTACTCAG 4500

TGTTAGAGAA ATCCTTCCTA AACCCAATGA CTTCCCTGCT CCAACCCCCG CCACCTCAGG 4560 GCACGCAGGA CCAGTTTGAT TGAGGAGCTG CACTGATCAC CCAATGCATC ACGTACCCCA 4620

CTGGGCCAGC CCTGCAGCCC AAAACCCAGG GCAACAAGCC CGTTAGCCCC AGGGGATCAC 4680 TGGCTGGCCT GAGCAACATC TCGGGAGTCC TCTAGCAGGC CTAAGACATG TGAGGAGGAA 4740 AAGGAAAAAA AGCAAAAAGC AAGGGAGAAA AGAGAAACCG GGAGAAGGCA TGAGAAAGAA 4800 TTTGAGACGC ACCATGTGGG CACGGAGGGG GACGGGGCTC AGCAATGCCA TTTCAGTGGC 4860 TTCCCAGCTC TGACCCTTCT ACATTTGAGG GCCCAGCCAG GAGCAGATGG ACAGCGATGA 4920 GGGGACATTT TCTGGATTCT GGGAGGCAAG AAAAGGACAA ATATCTTTTT TGGAACTAAA 980 GCAAATTTTA GACCTTTACC TATGGAAGTG GTTCTATGTC CATTCTCATT CGTGGCATGT 5040 TTTGATTTGT AGCACTGAGG GTGGCACTCA ACTCTGAGCC CATACTTTTG GCTCCTCTAG 5100 TAAGATGCAC TGAAAACTTA GCCAGAGTTA GGTTGTCTCC AGGCCATGAT GGCCTTACAC 5160 TGAAAATGTC ACATTCTATT TTGGGTATTA ATATATAGTC CAGACACTTA ACTCAATTTC 5220 TTGGTATTAT TCTGTTTTGC ACAGTTAGTT GTGAAAGAAA GCTGAGAAGA ATGAAAATGC 5280 AGTCCTGAGG AGAGTTTTCT CCATATCAAA ACGAGGGCTG ATGGAGGAAA AAGGTCAATA 5340 AGGTCAAGGG AAGACCCCGT CTCTATACCA ACCAAACCAA TTCACCAACA CAGTTGGGAC 5400 CCAAAACACA GGAAGTCAGT CACGTTTCCT TTTCATTTAA TGGGGATTCC ACTATCTCAC 5460 ACTAATCTGA AAGGATGTGG AAGAGCATTA GCTGGCGCAT ATTAAGCACT TTAAGCTCCT 5520 TGAGTAAAAA GGTGGTATGT AATTTATGCA AGGTATTTCT CCAGTTGGGA CTCAGGATAT 5580 TAGTTAATGA GCCATCACTA GAAGAAAAGC CCATTTTCAA CTGCTTTGAA ACTTGCCTGG 5640 GGTCTGAGCA TGATGGGAAT AGGGAGACAG GGTAGGAAAG GGCGCCTACT CTTCAGGGTC 5700 TAAAGATCAA GTGGGCCTTG GATCGCTAAG CTGGCTCTGT TTGATGCTAT TTATGCAAGT 5760 TAGGGTCTAT GTATTTAGGA TGCGCCTACT CTTCAGGGTC TAAAGATCAA GTGGGCCTTG 5820 GATCGCTAAG CTGGCTCTGT TTGATGCTAT TTATGCAAGT TAGGGTCTAT GTATTTAGGA 5880 TGTCTGCACC TTCTGCAGCC AGTCAGAAGC TGGAGAGGCA ACAGTGGATT GCTGCTTCTT 5940 GGGGAGAAGA GTATGCTTCC TTTTATCCAT GTAATTTAAC TGTAGAACCT GAGCTCTAAG 6000 TAACCGAAGA ATGTATGCCT CTGTTCTTAT GTGCCACATC CTTGTTTAAA GGCTCTCTGT 6060 ATGAAGAGAT GGGACCGTCA TCAGCACATT CCCTAGTGAG CCTACTGGCT CCTGGCAGCG 6120 GCTTTTGTGG AAGACTCACT AGCCAGAAGA GAGGAGTGGG ACAGTCCTCT CCACCAAGAT 6180 CTAAATCCAA ACAAAAGCAG GCTAGAGCCA GAAGAGAGGA CAAATCTTTG TTGTTCCTCT 6240 TCTTTACACA TACGCAAACC ACCTGTGACA GCTGGCAATT TTATAAATCA GGTAACTGGA 6300 AGGAGGTTAA ACTCAGAAAA AAGAAGACCT CAGTCAATTC TCTACTTTTT 6360 TCCAAATCAG ATAATAGCCC AGCAAATAGT GATAACAAAT AAAACCTTAG CTGTTCATGT 6420 CTTGATTTCA ATAATTAATT CTTAATCATT AAGAGACCAT AATAAATACT CCTTTTCAAG 6480 AGAAAAGCAA AACCATTAGA ATTGTTACTC AGCTCCTTCA AACTCAGGTT TGTAGCATAC 6540 ATGAGTCCAT CCATCAGTCA AAGAATGGTT CCATCTGGAG TCTTAATGTA GAAAGAAAAA 6600 TGGAGACTTG TAATAATGAG CTAGTTACAA AGTGCTTGTT CATTAAAATA GCACTGAAAA 6660 TTGAAACATG AATTAACTGA TAATATTCCA ATCATTTGCC ATTTATGACA AAAATGGTTG 6720 GCACTAACAA AGAACGAGCA CTTCCTTTCA GAGTTTCTGA GATAATGTAC GTGGAACAGT 6780 CTGGGTGGAA TGGGGCTGAA ACCATGTGCA AGTCTGTGTC TTGTCAGTCC AAGAAGTGAC 6840. ACCGAGATGT TAATTTTAGG GACCCGTGCC TTGTTTCCTA GCCCACAAGA ATGCAAACAT εgoo CAAACAGATA CTCGCTAGCC TCATTTAAAT TGATTAAAGG AGGAGTGCAT CTTTGGCCGA 6960 CAGTGGTGTA ACTGTGTGTG TGTGTGTGTG TGTGTGTGTG TGTGTGTGTG TGTGGGTGTG 7020 GGTGTATGTG TGTTTTGTGC ATAACTATTT AAGGAAACTG GAATTTTAAA GTTACTTTTA 7080 TACAAACCAA GAATATATGC TACAGATATA AGACAGACAT GGTTTGGTCC TATATTTCTA 7140 GTCATGATGA ATGTATTTTG TATACCATCT TCATATAATA TACTTAAAAA TATTTCTTAA 7200 TTGGGATTTG TAATCGTACC AACTTAATTG ATAAACTTGG CAACTGCTTT TATGTTCTGT 7260 CTCCTTCCAT AAATTTTTCA AAATACTAAT TCAACAAAGA AAAAGCTCTT TTTTTTCCTA 7320 AAATAAACTC AAATTTATCC TTGTTTAGAG CAGAGAAAAA TTAAGAAAAA CTTTGAAATG 7380 GTCTCAAAAA ATTGCTAAAT ATTTTCAATG GAAAACTAAA TGTTAGTTTA GCTGATTGTA 7440 TGGGGTTTTC GAACCTTTCA CTTTTTGTTT GTTTTACCTA TTTCACAACT GTGTAAATTG 7500 CCAATAATTC CTGTCCATGA AAATGCAAAT TATCCAGTGT AGATATATTT GACCATCACC 7560 CTATGGATAT TGGCTAGTTT TGCCTTTATT AAGCAAATTC ATTTCAGCCT GAATGTCTGC 7620 CTATATATTC TCTGCTCTTT GTATTCTCCT TTGAACCCGT TAAAACATCC TGTGGCACTC

Seq ID NO : 215 Protein sequence : Protein Accession # : NP 002010.1

11 21 31 41 51

MVSYWDTGVL LCALLSCLLL TGSSSGSKLK DPELSLKGTQ HIMQAGQTLH LQCRGEAAHK 60 WSLPEMVSKE SERLSITKSA CGRNGKQFCS TLTLNTAQAN HTGFYSCKYL AVPTSKKKET 120 ESAIYIFISD TGRPFVEMYS EIPEIIHMTE GRELVIPCRV TSPNITVTLK KFPLDTLIPD 180 GKRIIWDSRK GFIISNATYK EIGLLTCEAT VNGHLYKTNY LTHRQTNTII DVQISTPRPV 240 KLLRGHTLVL NCTATTPLNT RVQMTWSYPD EKNKRASVRR RIDQSNSHAN IFYSVLTIDK 300 MQNKDKGLYT CRVRSGPSFK SVNTSVHIYD KAFITVKHRK QQVLETVAGK RSYRLSMKVK 360 AFPSPEWWL KDGLPATEKS ARYLTRGYSL IIKDVTEEDA GNYTILLSIK QSNVFKNLTA 420 TLIVNVKPQI YEKAVSSFPD PALYPLGSRQ ILTCTAYGIP QPTIKWFWHP CNHNHSEARC 480 DFCSNNEESF ILDADSNMGN RIESITQRMA IIEGKNKMAS TLWADSRIS GIYICIASNK 540 VGTVGRNISF YITDVPNGFH VNLEKMPTEG EDLKLSCTVN KFLYRDVTWI LLRTVNNRTM 600 HYSISKQKMA ITKEHSITLN LTIMNVSLQD SGTYACRARN VYTGEEILQK KEITIRDQEA 660 PYLLRNLSDH TVAISSSTTL DCHANGVPEP QITWFKNNHK IQQEPGIILG PGSSTLFIER 720 VTEEDEGVYH CKATNQKGSV ESSAYLTVQG TSDKSNLELI TLTCTCVAAT LFWLLLTLLI 780 RKMKRSSSEI KTDYLSIIMD PDEVPLDEQC ERLPYDASKW EFARERLKLG KSLGRGAFGK 840 WQASAFGIK KSPTCRTVAV KMLKEGATAS EYKALMTELK ILTHIGHHLN WNLLGACTK 900 QGGPLMVIVE YCKYGNLSNY LKSKRDLFFL NKDAALHMEP KKEKMEPGLE QGKKPRLDSV 960 TSSESFASSG FQEDKSLSDV EEEEDSDGFY KEPITMEDLI SYSFQVARGM EFLSSRKCIH 1020 RDLAARNILL SENNWKICD FGLARDIYKN PDYVRKGDTR LPLKWMAPES IFDKIYSTKS 1080 DVWSYGVLLW EIFSLGGSPY PGVQMDEDFC SRLREGMRMR APEYSTPEIY QIMLDCWHRD 1140 PKERPRFAEL VEKLGDLLQA NVQQDGKDYI PINAILTGNS GFTYSTPAFS EDFFKESISA 1200

PKFNSGSSDD VRYVNAFKFM SLERIKTFEE LLPNATSMFD DYQGDSSTLL ASPMLKRFTW 1260

TDSKPKASLK IDLRVTSKSK ESGLSDVSRP SFCHSSCGHV SEGKRRFTYD HAELERKIAC 1320 CSPPPDYNSV VLYSTPPI

Seq ID NO: 216 DNA sequence

Nucleic Acid Accession #: NM_024689

Coding sequence: 76-624 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

CTCTTTGGCC AAGCCCTGCC TCTGTACAGC CTCGAGTGGA CAGCCAGAGG CTGCAGCTGG 60 AGCCCAGAGC CCAAGATGGA GCCCCAGCTG GGGCCTGAGG CTGCCGCCCT CCGCCCTGGC 120 TGGCTGGCCC TGCTGCTGTG GGTCTCAGCC CTGAGCTGTT CTTTCTCCTT GCCAGCTTCT 180 TCCCTTTCTT CTCTGGTGCC CCAAGTCAGA ACCAGCTACA ATTTTGGAAG GACTTTCCTC 240 GGTCTTGATA AATGCAATGC CTGCATCGGG ACATCTATTT GCAAGAAGTT CTTTAAAGAA 300 GAAATAAGAT CTGACAACTG GCTGGCTTCC CACCTTGGAC TGCCTCCCGA TTCCTTGCTT 360 TCTTATCCTG CAAATTACTC AGATGATTCC AAAATCTGGC GCCCTGTGGA GATCTTTAGA 420 CTGGTCAGCA AATATCAAAA CGAGATCTCA GACAGGAAAA TCTGTGCCTC TGCATCAGCC 480 CCAAAGACCT GCAGCATTGA GCGTGTCCTG CGGAAAACAG AGAGGTTCCA GAAATGGCTG 540 CAGGCCAAGC GCCTCACGCC GGACCTGGTG CAGGACTGTC ACCAGGGCCA GAGAGAACTA 600 AAGTTCCTGT GTATGCTGAG ATAACACCAG TGAAAAAGCC TGGCATGGAG CCCAGCACTG 660 AGAACTTCCA GAAAGTGTTA GCCTTCTCCC AACTGTGTTA TACCAACCAC ATTTTCAAAT 720 AGTAATCATT AAAGAGGCTT CTGCATCAAA CCTTCACATG CAGCTCCCAT GCCACCCTCC 780 AGAATTCACC AACACACAGG CCCACCAGCA ACAGGCTACC TTTGCACAAT ATTCTCTGAT 840 GACAACTCCA AAGCCCCGGC TCTTTCCACC ACACTGTGGT CCCCTAGATG GGGCTGTTGC goo TGAGCCCACC CCAATCCAGA TGTGATCCCC CTGTGATCTA CTTCTGGCAA GATTCTCAGT gεo CTGGACAGGT CTTCCCTATG AGATAGAACC TGATAAGGAG CTAGGGCAAT TCTGACAACA 1020 TTACCAAAGG CCCACATAAC TTCTAAATTT TGGTCTGGTC TGAAGGAAAA CCTGTTCTCG 1080 CCCTAGTGAT GGATGAACTC TCTTATCTCT GGCTTCTAGA GGGAAAAAAA AAGCATACCT 1140 CTTTTACTTT TTAAGTACCT CCATCAGAGT CATGAAATCA CCTGTCAAGA CTATCTATCT 1200 TTTATGTTTC CATTCTGGTA AGAACTCTTT AAATGAGGAC ACTGCTGATT GCTGGTGATG 1260 TTTTTTGAGC AAACACTCGG GGGTATGGAT GAAAGCCAAT CGCAGGTCAA ATGACTCCTT 1320 GGGGAAGCTA CTTCTCCTCT ATTCAGATTT CACTAAAATC TTCCAAGATG AAAGCAAATC 1380 TAGATTTCGG TCTTCATTGC TGTCCATTTT TGTAATGAAC GAGTGTTTTT CCTTTAGCTA 1440 GTGTATCAGG CAGGGTTCTA CCAGAGAAAC AGAACCAGTA GGAGATACAT ATACATGTCC 1500 AGATTTATTT CAAAGAATTG ATTTACATGA TTGTGGGGAT TGGCAAGTCG AAAATCCATA 1560 TGGTAGGCCT GCAATCTGTA AACCTTTGGG CAGGAGCTGA TGCTGTAGTT TGCAGATAGA 1620 ATTCCTTGTT CCTTAAAAAA ATCTGTTTTT GTTCTTAAGG GCTTTGAATG ATTGGATCAG 1680 GCCCACCCAG ATTACCTAGA TAATCTCTTT TACTTAAAGT AAACTGATTG TAGGTGCTAA 1740 TCACATCTAT GAAATGCCTT CACAGCAACA CCTAGATTAG CATTCAATTG AATAACTGGG 1800 GAATACAGCC TAGCCAAGTT GACACATAAA ATTAACCATC ACAGCAACAT GCCTGCTAAA 1860 TTTTATCGAC CGTCTTCAGA CTGTTAAGGA TTGTGGTAGA GAACTGTGAC AGCCACTCTC 1920 AGCATCACCC TGAACCAAAG GCCCCTATCA AGTAACAATA TAGCCAAGCA AAATTCCAGT 1980 CAATAGAGAC ATTGACTGGT TGGCTGGCTT CCCAAGGGAT AGCACCAGAC AAGAAATGCA 2040 AGGATGAGGA AACCAGGCAC GGGAGAGGGA GGGGCAACAG AGGTCCAGGG TTTGGTTATC 2100 TTTTTATTTT TCACTGGGAG GTGGTAAGTT AGCCCTGTTG CCCATGTATG CAGATGGGAG 2160 AAGTGATTTA GAAACTCCAA AGCAATTGGT AATCCCCAAA ATGGGTGTAT CTGGTTTGAA 2220 ATGAAACCTT ATTTTATTGG AAATGGTTGG TTTCCCAATT CTGTTTGCCA TTGGCCAATA 2280 TAATTGTGGG TTTGCACATG GCCAGCACAT GCCAAACAGA AGTAGACAAA GGTCTCACTC 2340 TGTAAGTGGG ACCTTGGGGA GGAGCTGCCT CCATCATAAA GGGAGGGGTT AGTAAAAATG 2400 GTCTCTTAAG CCTGTTCCTG CTACAGTTAT AGAGGTTGCT CAGAACCTTC TCAGCAAATA 2460 TAGCAGTTAT CTATTGTTGT GTATTAAACC ATTTCAACAC AT

Seq ID NO: 217 Protein sequence: Protein Accession #: NP 078965.1

11 21 31 41 51

MEPQLGPEAA ALRPGWLALL LWVSALSCSF SLPASSLSSL VPQVRTSYNF GRTFLGLDKC 60

NACIGTSICK KFFKEEIRSD NWLASHLGLP PDSLLSYPAN YSDDSKIWRP VEIFRLVSKY 120

QNEISDRKIC ASASAPKTCS IERVLRKTER FQKWLQAKRL TPDLVQDCHQ GQRELKFLCM 180 LR

Seq ID NO: 218 DNA sequence

Nucleic Acid Accession #: AF075027.1

Coding sequence: 3-269 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

I I I I I

GATTAATTAA GTGCTTTAAA CGGTCTTGGT AAATATTCCG CGGGAGCTGG GGAGGACCGT 60 TGGGATGGCT GTAGCTTGAG TTGAATTTTA ACTGTCCTCA TTCTGGGTTT TGTCGCTCTG 120 CTTTCTGTGC CAAGGTGCTG TGTTACGGGA GAGAGTGACT GGAAAGTAAC AAAGCTGAAT 180 CTTTCTCCCT GGAGTAAGGC CGAAGACTGG ATTACTACAC GCCTAGACGT GACACTACAC 240 CCATAGATCT CATGCATCAT TAATGCCATA TGACATTGCC ATTTTCTTTC TCAGTTCACG 300 GACAAAAGTG GTGGGTTTTC ATTGTCTTCA CTGATTGTCA ATGCATTAAT AAAGAAGATG 360 TGTGGT

Seq ID NO: 219 Protein sequence : Protein Accession #: AF075027

11 21 31 41 51

ERKWQCHMAL MMHEIYGCSV TSRRWIQSS ALLQGERFSF VTFQSLSPVT QHLGTESRAT 60 KPRMRTVKIQ LKLQPSQRSS PAPAEYLPRP FKALN

Seq ID NO : 220 DNA sequence

Nucleic Acid Accession # : AL133411.8

Coding sequence : 1-1395 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

ATGGGCAAGG ACTTCATGAC TAAAACACTA AAAGCAATGG CAACAAAAGC CAAAATTGAC 60 AAATGGGATC TAATCAAATT AAAGAGCTTC CGCACAGCAA AAGAAACTAT TATCAGAGTG 120 AACAGGCAAC CTACAGAATG GGAGAAAAAT TTTGCAATGT ATCCATCTGA CAAAGGGCTG 180 ACATCCAGAA^" TCTATAAGGA ACTTAAACAA TTTTACAAGA AAAAACCAAA CAACGCCATC 240 AAAAAGGACA TGGATGAAGC TGGAAACCGT CATTCTCAGA AAACTAACAC AGGAACAGAA 300 AACCAAACAC CACATGTTCT CACTCATAAG TGGGAGTTGA ACAATGAGAA CACATGGACA 360 CAGGGAGGGG AACATCACAC ACTGGGGCCT GTCAGAAGCC CCTCTGGCCT CCTGGCTGGC 420 CTTGAACATG CTGGGAGGAA ATTACAATTC. ATCCATGGGC TGTTTACCCT TGAAAATGAA 480 TGGGCCCAGG AACAATCCAT AATACAAAAG AAATATGCAT TATGGATTGG AACCAAGCAG 540 ATCTGGGTGG CACAAACTCC TGGTGAATCT ATCTCCAGTT CACCAGCATT GCCTAATGTG 600 CTACCTTTAA ATGAAGATGT TAATAAGCAG GAAGAAAAGA ATGAAGATCA TACTCCCAAT 660 TATGCTCCTG CTAATGAGAA AAATGGCAAT TATTATAAAG ATATAAAACA ATATGTGTTC 720 ACAACACAAA ATCCAAATGG CACTGAGTCT GAAATATCTG TGAGAGCCAC AACTGACCTG 780 AATTTTGCTC TAAAAAACGA TAAAACTGTC AATGCAACTA CATATGAAAA ATCCACCATT 840 GAAGAAGAAA CAACTACTAG CGAACCCTCT CATAAAAATA TTCAAAGATC AACCCCAAAC 900 GTGCCTGCAT TTTGGACAAT GTTAGCTAAA GCTATAAATG GAACAGCAGT GGTCATGGAT 960 GATAAAGATC AATTATTTCA CCCAATTCCA GAGTCTGATG TGAATGCTAC ACAGGGAGAA 1020 AATCAGCCAG ATCTAGAGGA TCTGAAGATC AAAATAATGC TGGGAATCTC GTTGATGACC 1080 CTCCTCCTCT TTGTGGTCCT CTTGGCATTC TGTAGTGCTA CACTGTACAA ACTGAGGCAT 1140 CTGAGTTATA AAAGTTGTGA GAGTCAGTAC TCTGTCAACC CAGAGCTGGC CACGATGTCT 1200 TACTTTCATC CATCAGAAGG TGTTTCAGAT ACATCCTTTT CCAAGAGTGC AGAGAGCAGC 1260 ACATTTTTGG GTACCACTTC TTCAGATATG AGAAGATCAG GCACAAGAAC ATCAGAATCT 1320 AAGATAATGA CGGATATCAT TTCCATAGGC TCAGATAATG AGATGCATGA AAACGATGAG 1380 TCGGTTACCC GGTGA

Seq ID NO: 221 Protein sequence : Protein Accession #: AL133411.8

11 21 31 41 51

MGKDFMTKTL KAMATKAKID KWDLIKLKSF RTAKETIIRV NRQPTEWEKN FAMYPSDKGL 60

TSRIYKELKQ FYKKKPNNAI KKDMDEAGNR HSQKTNTGTE NQTPHVLTHK WELNNENTWT 120

QGGEHHTLGP VRSPSGLLAG LEHAGRKLQF IHGLFTLENE WAQEQSIIQK KYALWIGTKQ 180

IWVAQTPGES ISSSPALPNV LPLNEDVNKQ EEKNEDHTPN YAPANEKNGN YYKDIKQYVF 240

TTQNPNGTES EISVRATTDL NFALKNDKTV NATTYEKSTI EEETTTSEPS HKNIQRSTPN 300

VPAFWTMLAK AINGTAWMD DKDQLFHPIP ESDVNATQGE NQPDLEDLKI KIMLGISLMT 360

LLLFWLLAF CSATLYKLRH LSYKSCESQY SVNPELATMS YFHPSEGVSD TSFSKSAESS 420

TFLGTTSSDM RRSGTRTSES KIMTDIISIG SDNEMHENDE SVTR

Seq ID NO : 222 DNA sequence

Nucleic Acid Accession #: AL050295.1

Coding sequence: 237-2073 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

I I I I I

GAAGGGGACA GAAGGCAGTT CACCTCTGCT CCCGACAGCC TGGGAACCCG CAAGAGCCCC 60 AGCATTTGAA GTCTGGTCTT GTGAAACCCC ACCCTCCTCT GGCTGTGTGA TTGAATGGGA 120 TGCCCTCGAG GTACACCTCA CCTGAGAGGG TTTTGGGCAG ATCAGCAGTA AGGTGTTAAA 180 TTTTAGAAGC CTGAAAACTC CAGAAGAGAA AGGCCAACCA ACTCAAACTT GAAGACATGA 240 AATCCCCAAG GAGAACCACT TTGTGCCTCA TGTTTATTGT GATTTATTCT TCCAAAGCTG 300 CACTGAACTG GAATTACGAG TCTACTATTC ATCCTTTGAG TCTTCATGAA CATGAACCAG 360 CTGGTGAAGA GGCACTGAGG CAAAAACGAG CCGTTGCCAC AAAAAGTCCT ACGGCTGAAG 420 AATACACTGT TAATATTGAG ATCAGTTTTG AAAATGCATC CTTCCTGGAT CCTATCAAAG 480 CCTACTTGAA CAGCCTCAGT TTTCCAATTC ATGGGAATAA CACTGACCAA ATTACTGACA 540 TTTTGAGCAT AAATGTGACA ACAGTCTGCA GACCTGCTGG AAATGAAATC TGGTGCTCCT 600 GCGAGACAGG T.TATGGGTGG CCTCGGGAAA GGTGTCTTCA CAATCTCATT TGTCAAGAGC 660 GTGAGGTCTT CCTCCCAGGG CACCATTGCA GTTGCCTTAA AGAACTGCCT CCCAATGGAC 720 CTTTTTGCCT GCTTCAGGAA GATGTTACCC TGAACATGAG AGTCAGACTA AATGTAGGCT 780 TTCAAGAAGA CCTCATGAAC ACTTCCTCCG CCCTCTATAG GTCCTACAAG ACCGACTTGG 840 AAACAGCGTT CCGGAAGGGT TACGGAATTT TACCAGGCTT CAAGGGCGTG ACTGTGACAG 900 GGTTCAAGTC TGGAAGTGTG GTTGTGACAT ATGAAGTCAA GACTACACCA CCATCACTTG 960 AGTTAATACA TAAAGCCAAT GAACAAGTTG TACAGAGCCT CAATCAGACC TACAAAATGG 1020 ACTACAACTC CTTTCAAGCA GTTACTATCA ATGAAAGCAA TTTCTTTGTC ACACCAGAAA 1080 TCATCTTTGA AGGGGACACA GTCAGTCTGG TGTGTGAAAA GGAAGTTTTG TCCTCCAATG 1140 TGTCTTGGCG CTATGAAGAA CAGCAGTTGG AAATCCAGAA CAGCAGCAGA TTCTCGATTT 1200 ACACCGCACT TTTCAACAAC ATGACTTCGG TGTCCAAGCT CACCATCCAC AACATCACTC 1260 CAGGTGATGC AGGTGAATAT GTTTGCAAAC TGATATTAGA CATTTTTGAA TATGAGTGCA 1320 AGAAGAAAAT AGATGTTATG CCCATCCAAA TTTTGGCAAA TGAAGAAATG AAGGTGATGT 1380 GCGACAACAA TCCTGTATCT TTGAACTGCT GCAGTCAGGG TAATGTTAAT TGGAGCAAAG 1440 TAGAATGGAA GCAGGAAGGA AAAATAAATA TTCCAGGAAC CCCTGAGACA GACATAGATT 1500 CTAGCTGCAG CAGATACACC CTCAAGGCTG ATGGAACCCA GTGCCCAAGC GGGTCGTCTG 1560 GAACAACAGT CATCTACACT TGTGAGTTCA TCAGTGCCTA TGGAGCCAGA GGCAGTGCAA 1620 ACATAAAAGT GACATTCATC TCTGTGGCCA ATCTAACAAT AACCCCGGAC CCAATTTCTG 1680 TTTCTGAGGG ACAAAACTTT TCTATAAAAT GCATCAGTGA TGTGAGTAAC TATGATGAGG 1740 TTTATTGGAA CACTTCTGCT GGAATTAAAA TATACCAAAG ATTTTATACC ACGAGGAGGT 1800 ATCTTGATGG AGCAGAATCA GTACTGACAG TCAAGACCTC GACCAGGGAG TGGAATGGAA 1860 CCTATCACTG CATATTTAGA TATAAGAATT CATACAGTAT TGCAACCAAA GACGTCATTG ig20 TTCACCCGCT GCCTCTAAAG CTGAACATCA TGATTGATCC TTTGGAAGCT ACTGTTTCAT 1980 GCAGTGGTTC CCATCACATC AAGTGCTGCA TAGAGGAGGA TGGAGACTAC AAAGTTACTT 2040 TCCATATGGG TTCCTCATCC CTTCCTGCTG TAAAAAAAAA AAAAAAAAAA A

Seq ID NO: 223 Protein sequence : Protein Accession #: CAB43394.1

11 21 31 41 51

I I I I

MKSPRRTTLC LMFIVIYSSK AALNWNYEST IHPLSLHEHE PAGEEALRQK RAVATKSPTA 60 EEYTVNIEIS FENASFLDPI KAYLNSLSFP IHGNNTDQIT DILSINVTTV CRPAGNEIWC 120 SCETGYGWPR ERCLHNLICQ ERDVFLPGHH CSCLKELPPN GPFCLLQEDV TLNMRVRLNV 180 GFQEDLMNTS SALYRSYKTD LETAFRKGYG ILPGFKGVTV TGFKSGSVW TYEVKTTPPS 240 LELIHKANEQ WQSLNQTYK MDYNSFQAVT INESNFFVTP EIIFEGDTVS LVCEKEVLSS 300 NVSWRYEEQQ LEIQNSSRFS IYTALFNNMT SVSKLTIHNI TPGDAGEYVC KLILDIFEYE 360 CKKKIDVMPI QILANEEMKV MCDNNPVSLN CCSQGNVNWS KVEWKQEGKI NIPGTPETDI 420 DSSCSRYTLK ADGTQCPSGS SGTTVIYTCE FISAYGARGS ANIKVTFISV ANLTITPDPI 480 SVSEGQNFSI KCISDVSNYD EVYWNTSAGI KIYQRFYTTR RYLDGAESVL TVKTSTREWN 540 GTYHCIFRYK NSYSIATKDV IVHPLPLKLN IMIDPLEATV SCSGSHHIKC CIEEDGDYKV 600 TFHMGSSSLP AVKKKKKK

Seq ID NO: 224 DNA sequence

N Nuucclleeiicc AAcciidd AAccccessio—n ^u#-: NM_007268

Coding sequence: 46-1245 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

GGTAGCAGGA GGCTGGAAGA AAGGACAGAA GTAGCTCTGG CTGTGATGGG GATCTTACTG 60 GGCCTGCTAC TCCTGGGGCA CCTAACAGTG GACACTTATG GCCGTCCCAT CCTGGAAGTG 120 CCAGAGAGTG TAACAGGACC TTGGAAAGGG GATGTGAATC TTCCCTGCAC CTATGACCCC 180 CTGCAAGGCT ACACCCAAGT CTTGGTGAAG TGGCTGGTAC AACGTGGCTC AGACCCTGTC 240 ACCATCTTTC TACGTGACTC TTCTGGAGAC CATATCCAGC AGGCAAAGTA CCAGGGCCGC 300 CTGCATGTGA GCCACAAGGT TCCAGGAGAT GTATCCCTCC AATTGAGCAC CCTGGAGATG 360 GATGACCGGA GCCACTACAC GTGTGAAGTC ACCTGGCAGA CTCCTGATGG CAACCAAGTC 420 GTGAGAGATA AGATTACTGA GCTCCGTGTC CAGAAACTCT CTGTCTCCAA GCCCACAGTG 480 ACAACTGGCA GCGGTTATGG CTTCACGGTG CCCCAGGGAA TGAGGATTAG CCTTCAATGC 540 CAGGCTCGGG GTTCTCCTCC CATCAGTTAT ATTTGGTATA AGCAACAGAC TAATAACCAG 600 GAACCCATCA AAGTAGCAAC CCTAAGTACC TTACTCTTCA AGCCTGCGGT GATAGCCGAC 660 TCAGGCTCCT ATTTCTGCAC TGCCAAGGGC CAGGTTGGCT CTGAGCAGCA CAGCGACATT 720 GTGAAGTTTG TGGTCAAAGA CTCCTCAAAG CTACTCAAGA CCAAGACTGA GGCACCTACA 780 ACCATGACAT ACCCCTTGAA AGCAACATCT ACAGTGAAGC AGTCCTGGGA CTGGACCACT 840 GACATGGATG GCTACCTTGG AGAGACCAGT GCTGGGCCAG GAAAGAGCCT GCCTGTCTTT goo GCCATCATCC TCATCATCTC CTTGTGCTGT ATGGTGGTTT TTACCATGGC CTATATCATG 960 CTCTGTCGGA AGACATCCCA ACAAGAGCAT GTCTACGAAG CAGCCAGGGC ACATGCCAGA 1020 GAGGCCAACG ACTCTGGAGA AACCATGAGG GTGGCCATCT TCGCAAGTGG CTGCTCCAGT 1080 GATGAGCCAA CTTCCCAGAA TCTGGGCAAC AACTACTCTG ATGAGCCCTG CATAGGACAG 1140 GAGTACCAGA TCATCGCCCA GATCAATGGC AACTACGCCC GCCTGCTGGA CACAGTTCCT 1200 CTGGATTATG AGTTTCTGGC CACTGAGGGC AAAAGTGTCT GTTAAAAATG CCCCATTAGG 1260 CCAGGATCTG CTGACATAAT TGCCTAGTCA GTCCTTGCCT TCTGCATGGC CTTCTTCCCT 1320 GCTACCTCTC TTCCTGGATA GCCCAAAGTG TCCGCCTACC AACACTGGAG CCGCTGGGAG 1380 TCACTGGCTT TGCCCTGGAA TTTGCCAGAT GCATCTCAAG TAAGCCAGCT GCTGGATTTG 1440 GCTCTGGGCC CTTCTAGTAT CTCTGCCGGG GGCTTCTGGT ACTCCTCTCT AAATACCAGA 1500 GGGAAGATGC CCATAGCACT AGGACTTGGT CATCATGCCT ACAGACACTA TTCAACTTTG 1560 GCATCTTGCC ACCAGAAGAC CCGAGGGAGG CTCAGCTCTG CCAGCTCAGA GGACCAGCTA 1620 TATCCAGGAT CATTTCTCTT TCTTCAGGGC CAGACAGCTT TTAATTGAAA TTGTTATTTC 1680 ACAGGCCAGG GTTCAGTTCT GCTCCTCCAC TATAAGTCTA ATGTTCTGAC TCTCTCCTGG 1740 TGCTCAATAA ATATCTAATC ATAACAGCAA AAAAAAAAAA AAAAAAA

Seq ID NO : 225 Protein sequence : Protein Accession # : NP 00gi99 . 1

11 21 31 41 51

MGILLGLLLL GHLTVDTYGR PILEVPESVT GPWKGDVNLP CTYDPLQGYT QVLVKWLVQR 60 GSDPVTIFLR DSSGDHIQQA KYQGRLHVSH KVPGDVSLQL STLEMDDRSH YTCEVTWQTP 120

10 DGNQWRDKI TELRVQKLSV SKPTVTTGSG YGFTVPQGMR ISLQCQARGS PPISYIWYKQ 180 QTNNQEPIKV ATLSTLLFKP AVIADSGSYF CTAKGQVGSE QHSDIVKFW KDSSKLLKTK 240 TEAPTTMTYP LKATSTVKQS WDWTTDMDGY LGETSAGPGK SLPVFAIILI ISLCCMWFT 300 MAYIMLCRKT SQQEHVYEAA RAHAREANDS GETMRVAIFA SGCSSDEPTS QNLGNNYSDE 360 PCIGQEYQII AQINGNYARL LDTVPLDYEF LATEGKSVC

15

Seq ID NO: 226 DNA sequence

Nucleic Acid Accession #: XM_64321

Coding sequence: 1-2079 (underlined sequences correspond to start and stop codons)

20

1 11 21 31 41 51

ATGGTCGCCA GTTCCGATCA AGACAGAGCC CCGTATCTTC CAGGGACACT AGACAAGATG 60

CCAGGACCAC GCCTCCGCTC TGCCCAGAGG CCAAAAGCAG CCCAACAAGA GCCCGGCATT 120

25 GAGCCTGGTA CTTACAGGGA GGGTGGTGGA GCCATCGTCC TCACGTATGC GCTGGGGATC 180

GGGGTTGGGA TCACGGGAAA CACAGTTCAA CAACCACCTC AACTCACTGA CTCCGCCAGC 240

ATCCGTCAGG AGGATGCCTT TGATAACAAA ATTGACATTG CTGAAGATGG TGGCCAGACA 300

CCATACGAAG CTACCTTGCA GCAAAGCTTT CAATACTCAC CTACAACAGA TCTTCCTCCA 360

CTCACAAATG GCTACCTGCC ATCAATCAGC ATGTATGAAA TTCAAACCAA ATACCAGTCG 420

30 CATAATCAAT ATCCTAATGG AAATTCTAAA CAGAAGACCA CATTAAATTC TAGAAAACCC 480

TTCCCCTCCA CAGCCACCAC TTCGGTACCA CAAACTGTGA TTCCAAAGAA GAGTGGCTCA 540

CCTGAAGTTA AACTAAAAAT AACCAAAACT ATCCAGAATG GCAGGGAATT GTTCAAGTCT 600

TCCCTTTGTG GAGACCTTTT AAATGAAGTA CAGGCAAGTG AGCACACGAA GTCAAAGCAT 660

GAAAGCAGAA AAGAAAAGAG GAAAAAACCC AAAAAGCATG ACTCATCAAG ATCTGAAGAG 720

35 CGCAAGTCAC ACAAAATCCC CAAATTAGAA CCAGAGGAAC AAAATAGACC AAATGAGAGG 780

GTTCACACCA TATCAGAAAA ACCAAGGGAA GATCCAGTAC TAAAAGAGGA AGCCCCAGTT 840

CAGCCAATAC TATCTTCTGT TCCAACAACA GAAGTGTCCA CTGGTGTTAA GTTTCAAGTT 900

GGTGATCTTG TGTGGTCCAA GGTGACGGTC ACACCCTGTT GGGTGCCCCG CCTGCGAGGA g60

CGGAGGAGCC ATCACTGTTC CAGCTGCCTG GAGATCTTGG TGCTGGTGCC AGCCCTCAGC 1020

40 CTCAAGAGGT CTTTCATGGT TTCTTCCTTG AAGTTCCTCA CCTCCACGGG CAAACAGAAG 1080

CCCACATTCA AGGGAACTGC CCAGATGGGC TGGTCACCTA TGGCCTCCAC GACCAATGTC 1140

TCCCTGCTCC TTGGTCATTG GGAAGGAACA GACCAGATGT CATCCAGGGG CCCGGAATTT 1200

GGGGGGCGCC GCTGGGTGTG GCAGCATCAG AAGCCTCAGA TCCGCATCTC CATCTGCCAC 1260

AGGCCAGGGA AGGAACCTCT GAGACTCAGT TTCCTACGAT GTGAAGTGGA GAGAAGAATC 1320

45 TCCTCTTTAG CCACCTCTCA GGGCTGCTGG TGTTCGCCCC CAGACCACGT CTGTGAGAAA 1380

TGCTTAGAAG ACTATGCAGG GCGCCGCCAT TTGACACTCA GAGCCCAGGA AGCCTTTCTT 1440

GGTCCAGACA GCAGGACTGG AAGCCTTAGA GCTGTCGGCA AGAGATACTG CAGGAACAGC 1500

CAGCACCAGA GATATCTCCT GCAAGGCCTC CTAGGTGGGT TCTTGGAAGA AAGGAATGCC 1560

AATGAATATG ATTGCAAGCT AGAGACGAGA GAAGCGGCGT CCTCAACTCC AAGAATCCCG 1620

50 TATTCCCCAA CCCACATCCT TCAGTCT.GAA AGTGCCCCTA ACCACTACTT TCCCTACCAC 1680

GTCTCCCTTT CCAAGTTCCT CAAACGCAAA GCAAACAGCC ATTTCCTGCA CCTGTGTGCA 1740

GTCGTAGCAG TACGTAGGAG ATCCAATATG CCTGGCACAA GGGGGTGGGG TGGCCACAAA 1800

CAGAAGCAGC CCTGTCCTGC CAAGTACACG CCTGCCTGCC ACGCACAATG GGAGACATTC 1860

CGCAAGTTCC ACGTGATGGC TCAGAAGAGG GGCCTGTCAG GAAGATGTAG GGGCCAGCAG 1920

55 CCCCCGGCCG CGCCCCGCAA GGTGGCTGAC AGACGCCAGC AGCTGCCGGG GGCTCCGGGC 1980

TGCTCCTGCT CCCAGGATGT GTATCTGACT GGAGTTTCTG GATTAAAGGC CAGTCGTGGC 2040 TTCATTCCAC ATCCCTGGGT GCCCTTCGGC TCCTCCTAG

60 Seq ID NO: 227 Protein sequence :

Protein Accession #: XP_064321.1

1 11 21 31 41 51

,. I I . I I I I

0J MVASSDQDRA PYLPGTLDKM PGPRLRSAQR PKAAQQEPGI EPGTYREGGG AIVLTYALGI 60

GVGITGNTVQ QPPQLTDSAS IRQEDAFDNK IDIAEDGGQT PYEATLQQSF QYSPTTDLPP 120

LTNGYLPSIS MYEIQTKYQS HNQYPNGNSK QKTTLNSRKP FPSTATTSVP QTVIPKKSGS 180

PEVKLKITKT IQNGRELFKS SLCGDLLNEV QASEHTKSKH ESRKEKRKKP KKHDSSRSEE 240

RKSHKIPKLE PEEQNRPNER VHTISEKPRE DPVLKEEAPV QPILSSVPTT EVSTGVKFQV 300

70 GDLVWSKVTV TPCWVPRLRG RRSHHCSSCL EILVLVPALS LKRSFMVSSL KFLTSTGKQK 360

PTFKGTAQMG WSPMASTTNV SLLLGHWEGT DQMSSRGPEF GGRRWVWQHQ KPQIRISICH 420

RPGKEPLRLS FLRCEVERRI SSLATSQGCW CSPPDHVCEK CLEDYAGRRH LTLRAQEAFL 480

GPDSRTGSLR AVGKRYCRNS QHQRYLLQGL LGGFLEERNA NEYDCKLETR EAASSTPRIP 540

YSPTHILQSE SAPNHYFPYH VSLSKFLKRK ANSHFLHLCA WAVRRRSNM PGTRGWGGHK 600

75 QKQPCPAKYT PACHAQWETF RKFHVMAQKR GLSGRCRGQQ PPAAPRKVAD RRQQLPGAPG 660 CSCSQDVYLT GVSGLKASRG FIPHPWVPFG SS Seq ID NO: 228 DNA sequence

Nucleic Acid Accession #: NM_006033

Coding sequence: 253-1752 (underlined sequences correspond to start and stop codons)

11 21 31 41 51

AGCAGCGAGT CCTTGCCTCC CGGCGGCTCA GGACGAGGGC AGATCTCGTT CTGGGGCAAG 60 CCGTTGACAC TCGCTCCCTG CCACCGCCCG GGCTCCGTGC CGCCAAGTTT TCATTTTCCA 120 CCTTCTCTGC CTCCAGTCCC CCAGCCCCTG GCCGAGAGAA GGGTCTTACC GGCCGGGATT 180 GCTGGAAACA CCAAGAGGTG GTTTTTGTTT TTTAAAACTT CTGTTTCTTG GGAGGGGGTG 240 TGGCGGGGCA GGATGAGCAA CTCCGTTCCT CTGCTCTGTT TCTGGAGCCT CTGCTATTGC 300 TTTGCTGCGG GGAGCCCCGT ACCTTTTGGT CCAGAGGGAC GGCTGGAAGA TAAGCTCCAC 360 AAACCCAAAG CTACACAGAC TGAGGTCAAA CCATCTGTGA GGTTTAACCT CCGCACCTCC 420 AAGGACCCAG AGCATGAAGG ATGCTACCTC TCCGTCGGCC ACAGCCAGCC CTTAGAAGAC 480 TGCAGTTTCA ACATGACAGC TAAAACCTTT TTCATCATTC ACGGATGGAC GATGAGCGGT 540 ATCTTTGAAA ACTGGCTGCA CAAACTCGTG TCAGCCCTGC ACACAAGAGA GAAAGACGCC 600 AATGTAGTTG TGGTTGACTG GCTCCCCCTG GCCCACCAGC TTTACACGGA TGCGGTCAAT 660 AATACCAGGG TGGTGGGACA CAGCATTGCC AGGATGCTCG ACTGGCTGCA GGAGAAGGAC 720 GATTTTTCTC TCGGGAATGT CCACTTGATC GGCTACAGCC TCGGAGCGCA CGTGGCCGGG 780 TATGCAGGCA ACTTCGTGAA AGGAACGGTG GGCCGAATCA CAGGTTTGGA TCCTGCCGGG 840 CCCATGTTTG AAGGGGCCGA CATCCACAAG AGGCTCTCTC CGGACGATGC AGATTTTGTG 900 GATGTCCTCC ACACCTACAC GCGTTCCTTC GGCTTGAGCA TTGGTATTCA GATGCCTGTG 960 GGCCACATTG ACATCTACCC CAATGGGGGT GACTTCCAGC CAGGCTGTGG ACTCAACGAT 1020 GTCTTGGGAT CAATTGCATA TGGAACAATC ACAGAGGTGG TAAAATGTGA GCATGAGCGA 1080 GCCGTCCACC TCTTTGTTGA CTCTCTGGTG AATCAGGACA AGCCGAGTTT TGCCTTCCAG 1140 TGCACTGACT CCAATCGCTT CAAAAAGGGG ATCTGTCTGA GCTGCCGCAA GAACCGTTGT 1200 AATAGCATTG GCTACAATGC CAAGAAAATG AGGAACAAGA GGAACAGCAA AATGTACCTA 1260 AAAACCCGGG CAGGCATGCC TTTCAGAGTT TACCATTATC AGATGAAAAT CCATGTCTTC 1320 AGTTACAAGA ACATGGGAGA AATTGAGCCC ACCTTTTACG TCACCCTTTA TGGCACTAAT 1380 GCAGATTCCC AGACTCTGCC ACTGGAAATA GTGGAGCGGA TCGAGCAGAA TGCCACCAAC 1440 ACCTTCCTGG TCTACACCGA GGAGGACTTG GGAGACCTCT TGAAGATCCA GCTCACCTGG 1500 GAGGGGGCCT CTCAGTCTTG GTACAACCTG TGGAAGGAGT TTCGCAGCTA CCTGTCTCAA 1560 CCCCGCAACC CCGGACGGGA GCTGAATATC AGGCGCATCC GGGTGAAGTC TGGGGAAACC 1620 CAGCGGAAAC TGACATTTTG TACAGAAGAC CCTGAGAACA CCAGCATATC CCCAGGCCGG 1680 GAGCTCTGGT TTCGCAAGTG TCGGGATGGC TGGAGGATGA AAAACGAAAC CAGTCCCACT 1740 GTGGAGCTTC CCTGAGGGTG CCCGGGCAAG TCTTGCCAGC AAGGCAGCAA GACTTCCTGC 1800 TATCCAAGCC CATGGAGGAA AGTTACTGCT GAGGACCCAC CCAATGGAAG GATTCTTCTC 1860 AGCCTTGACC CTGGAGCACT GGGAACAACT GGTCTCCTGT GATGGCTGGG ACTCCTCGCG 1920 GGAGGGGACT GCGCTGCTAT AGCTCTTGCT GCCTCTCTTG AATAGCTCTA ACTCCAAACC 1980 TCTGTCCACA CCTCCAGAGC ACCAAGTCCA GATTTGTGTG TAAGCAGCTG GGTGCCTGGG 2040 GCCTCTCGTG CACACTGGAT TGGTTTCTCA GTTGCTGGGC GAGCCTGTAC TCTGCCTGAC 2100 GAGGAACGCT GGCTCCGAAG AGGCCCTGTG TAGAAGGCTG TCAGCTGCTC AGCCTGCTTT 2160 GAGCCTCAGT GAGAAGTCCT TCCGACAGGA GCTGACTCAT GTCAGGATGG CAGGCCTGGT 2220 ATCTTGCTCG GGCCCTAGCT GTTGGGGTTC TCATGGGTTG CACTGACCAT ACTGCTTACG 2280 TCTTAGCCAT TCCGTCCTGC TCCCCAGCTC ACTCTCTGAA GCACACATCA TTGGCTTTCC 2340 TATTTTTCTG TTCATTTTTT AATTGAGCAA ATGTCTATTG AACACTTAAA ATTAATTAGA 2400 ATGTGGTAAT GGACATATTA CTGAGCCTCT CCATTTGGAA CCCAGTGGAG TTGGGATTTC 2460 TAGACCCTCT TTCTGTTTGG ATGGTGTATG TGTATATGCA TGGGGAAAGG CACCTGGGGC 2520 CTGGGGGAGG CTATAGGATA TAAGCATTAG GGACCCTGAG GCTTTAAGTG GTTTCTATTT 2580 CTTCTTAGTT ATTATGTGCC ACCTTCTTAG TTATTATGTG CCACCTCCCC TATGAGTGAC 2640 GTGTTTGATC ACTAGCAGAA TAGCAAGCAG AGTATCATTC ATGCTGGGGC CAGAATGATG 2700 GCCGGTTGCC AGATATAACT GCTTTGGAGC AAATCTCTTC TGTTTAGAGA GATAGAAGTT 2760 ATGACATATG TAATACACAT CTGTGTACAC AGAAACCGGC ACCTGCCAGA CAGAGCTGGT 2820 TCTAAGATTT AATACAGTGC TTTTTTTCCT CTTTGAAATA TTTTACTTTA ATACCAGTGC 2880 CTTTTCTTGT TGAACTTCTT GGAAAAGCCA CCAATTCTAG ATCTTGATTT GAATTAATAC 2940 ACACAATATC TGAGACACTT ACACTTTTCA AAAGATTTGT GTATGCATTG CCTAATTAGA 3000 GTAGGGGGAG AAGGGCAACT ATTATTATCC CTATTTTACA AAACTGAGGC TTAGTGAGGT 3060 TCAGCCACAT GCCTAGACTT ATATACTAGT TAGTGGTGCA GCCAGGGAGA GGACTCAGAT 3120 TTCCTGGAGG CAAAGTCTAT CTCTGAAACT CCATGAAGAC TTTTGCAGCC AGTTCCCACC 3180 AATATGCCCC AGACGTGAGA CAAACAAGGA CTTTTTTTTT TATATAGAGC CATCCATAAA 3240 ATCCTAAGCC CTTTTATTAA TGTATAACCA GGAGAACATC TGTGCCAACG GTTGGACTTT 3300 TTATGGCTGA GATTCGGGAG GAAGTGTGAC ACCAAGCAGG AGAGGAAGAA TGATTTTCTT 3360 TGTACTTAGG TTTTCTAAGG ACATTGTTTT AATCTGTATC GTGCCAAAGT TGTATCACTG 3420 TTAAACTTCT GAAGACATAA CCAGTTGAGT CTTATTTCAA GATATGTTCT CAAGCCAATT 3480 GTGTGCTTCT CTTGTTTCTG TGATTGCTTT CTAGCCAAAG CGAAGCTTGT ACAGGTTGAG 3540 TATCCCTTAT CCAAAATGCT TGGAACCAGA AGTGTTTCAA ATTTTAGATT ATTTTCAGAT 3600 TTTGGAATGT TTGCATATAC ATAATGAGAT ATTTTGGGAA TAGGACCCGA GCCTAAACAC 3660 AAAATTCATT GATGTGTCAG TTACACCTTA TCCACATAGC CTGAGGGTAA TTTTATACGA 3720 TATTTTAAAT AGTTGTGTAC ATGAAGCATG GTTTGTGGTA ACTTATGTGA GGGGTTTTCC 3780 CATTTTTTGT CTTGTTGGTG CTCAAAAAGT TTTGGATTTT GGAGCATTTC GGATTTTGGA 3840 TTTTTGGATT AGGGTTGCTC AACCCATATT ATTGGCTGTA CATCCTGGTC ACTTCTGACT 3900 TCTGTTTTTA CTAATGGAAG CTTTGCA

Seq ID NO: 229 Protein sequence: Protein Accession # : NP_006024.1

1 11 21 31 41 51

- I I I I I I MSNSVPLLCF WSLCYCFAAG SPVPFGPEGR LEDKLHKPKA TQTEVKPSVR FNLRTSKDPE 60

HEGCYLSVGH SQPLEDCSFN MTAKTFFIIH GWTMSGIFEN WLHKLVSALH TREKDANVW 120

VDWLPLAHQL YTDAVNNTRV VGHSIARMLD WLQEKDDFSL GNVHLIGYSL GAHVAGYAGN 180

FVKGTVGRIT GLDPAGPMFE GADIHKRLSP DDADFVDVLH TYTRSFGLSI GIQMPVGHID 240

IYPNGGDFQP GCGLNDVLGS IAYGTITEW KCEHERAVHL FVDSLVNQDK PSFAFQCTDS 300 0 NRFKKGICLS CRKNRCNSIG YNAKKMRNKR NSKMYLKTRA GMPFRVYHYQ MKIHVFSYKN 360

MGEIEPTFYV TLYGTNADSQ TLPLEIVERI EQNATNTFLV YTEEDLGDLL KIQLTWEGAS 420

QSWYNLWKEF RSYLSQPRNP GRELNIRRIR VKSGETQRKL TFCTEDPENT SISPGRELWF 480 RKCRDGWRMK NETSPTVELP 5

987 It is understood that the examples described above in no way serve to limit the true scope of this invention, but rather are presented for illustrative purposes. All publications, sequences of accession numbers, and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

Claims

HAT IS CLAIME IS; 1. A method of detecting an angiogenesis-associated transcript in a cell in a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridized to a sequence at least 80% identical to a sequence as shown in Tables 1-8.

2. The method of claim 1 , wherein the biological sample is a tissue sample.

3. The method of claim 1, wherein the biological sample comprises isolated nucleic acids.

4. The method of claim 3, wherein the nucleic acids are mRNA.

5. The method of claim 3, further comprising the step of amplifying nucleic acids before the step of contacting the biological sample with the polynucleotide.

6. The method of claim 1 , wherein the polynucleotide comprises a sequence as shown in Tables 1-8 .

7. The method of claim 1 , wherein the polynucleotide is labeled.

8. The method of claim 7, wherein the label is a fluorescent label.

9. The method of claim 1, wherein the polynucleotide is immobilized on a solid surface.

10. The method of claim 1, wherein the patient is undergoing a therapeutic regimen to treat a disease associated with angiongenesis.

11. The method of claim 1, wherein the patient is suspected of having cancer.

12. An isolated nucleic acid molecule consisting of a polynucleotide sequence as shown in Tables 1 -8.

13. The nucleic acid molecule of claim 12, which is labeled.

14. The nucleic acid of claim 13, wherein the label is a fluorescent label

15. An expression vector comprising the nucleic acid of claim 12.

16. A host cell comprising the expression vector of claim 15.

17. An isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-8

18. An antibody that specifically binds a polypeptide of claim 17.

19. The antibody of claim 18, further conjugated or fused to an effector component.

20. The antibody of claim 19, wherein the effector component is a fluorescent label.

21. The antibody of claim 19, wherein the effector component is a radioisotope.

22. The antibody of claim 19, which is an antibody fragment.

23. The antibody of claim 19, which is a humanized antibody

24. A method of detecting a cell undergoing angiogenesis in a biological sample from a patient, the method comprising contacting the biological sample with an antibody of claim 18.

25. The method of claim 24, wherein the antibody is further conjugated or fused to an effector component.

26. The method of claim 25, wherein the effector component is a fluorescent label.

27. The method of detecting antibodies specific to angiogenesis in a patient, the method comprising contacting a biological sample from the patient with a polypeptide which is encoded by a nucleotide sequence of Tables 1-8.